PN,TI,AU,AE,GA,AB,TF,EA,DC,MC,IP,PD,AD,FD,PI,DS,FS,CP,CR,DN,MN,RI,CI,RG
IN202041051045-A,New oligonucleotide sequence specific primer set comprising primers e.g. loop-mediated isothermal amplification /Inward and loop primer for amplifying open reading frame 1AB used to detect severe acute respiratory syndrome coronavirus,ARUNAGIRI K D M;  SAMSON M;  THANGARAJAN R,CANCER INST WIA (CANC-Non-standard),202276490R,"   NOVELTY - Oligonucleotide Sequence specific primer set comprising primers (i) to (ix) (i) loop-mediated isothermal amplification (LAMP)/Inward primers for amplification of ORF1AB gene (a) SEQ ID NO: 3 and SEQ ID NO: 4, (b) SEQ ID NO: 9 and SEQ ID NO: 10, (c) SEQ ID NO: 15 and SEQ ID NO: 16, (ii) Loop primers for amplification of ORF1AB gene (d) SEQ ID NO: 5, SEQ ID NO: 6 or (e) SEQ ID NO: 11 and SEQ ID NO: 12, (f) SEQ ID NO: 17 and SEQ ID NO: 18, (iii) Outward/Displacement primers for amplification of open reading frame (ORF)1AB gene (g) SEQ ID NO: 1 and SEQ ID NO: 2 or (h) SEQ ID NO: 7 and SEQ ID NO: 8 or (i) SEQ ID NO: 13 and SEQ ID NO: 14, (iv) LAMP/Inward primers for amplification of N gene, (v) Loop primers for amplification of N gene, (vi) Outward/Displacement primers for amplification of N gene, (vii) LAMP/Inward primers for amplification of M gene (viii) Loop primers for amplification of M gene and (ix) Outward/Dispacement primers for amplification of M gene 13, is new.    USE - The primer pair is useful for amplifying SARS-CoV2 ORF1AB, N and M genes, which is used to detect SARS-CoV2 (claimed).    ADVANTAGE - The primer pair ensures rapid and specific detection of severe acute respiratory syndrome coronavirus 2, and is economical.    DETAILED DESCRIPTION - Oligonucleotide Sequence specific primer set configured to amplify severe acute respiratory syndrome (SARS)-coronavirus (CoV)2 open reading frame (ORF)1AB, N and M genes for detecting SARS-CoV2 comprising primers (i) to (ix) (i) LAMP/Inward primers for amplification of ORF1AB gene (a) SEQ ID NO: 3 (comprising a fully defined sequence of 47 nucleotides as given in the specification) and SEQ ID NO: 4 (comprising a fully defined sequence of 43 nucleotides as given in the specification), (b) SEQ ID NO: 9 (comprising a fully defined sequence of 45 nucleotides as given in the specification) and SEQ ID NO: 10 (comprising a fully defined sequence of 47 nucleotides as given in the specification), (c) SEQ ID NO: 15 (comprising a fully defined sequence of 50 nucleotides as given in the specification) and SEQ ID NO: 16 (comprising a fully defined sequence of 52 nucleotides as given in the specification), (ii) loop primers for amplification of ORF1AB gene of (d) aggatcagtgccaagctcgt (SEQ ID NO: 5), aggatcagtgccaagctcgt (SEQ ID NO: 6) or (e) aggatcagtgccaagctcgt (SEQ ID NO: 11) and aggatcagtgccaagctcgt (SEQ ID NO: 12), (f) aggatcagtgccaagctcgt (SEQ ID NO: 17) and aggatcagtgccaagctcgt (SEQ ID NO: 18), (iii) Outward/Displacement primers for amplification of ORF1AB gene (g) aggatcagtgccaagctcgt (SEQ ID NO: 1) and aggatcagtgccaagctcgt (SEQ ID NO: 2) or (h) aggatcagtgccaagctcgt (SEQ ID NO: 7) and aggatcagtgccaagctcgt (SEQ ID NO: 8) or (i) aggatcagtgccaagctcgt (SEQ ID NO: 13) and aggatcagtgccaagctcgt (SEQ ID NO: 14), (iv) LAMP/Inward primers for amplification of N gene (j) SEQ ID NO: 21 (comprising a fully defined sequence of 37 nucleotides as given in the specification) and SEQ ID NO: 22 (comprising a fully defined sequence of 39 nucleotides as given in the specification), (v) Loop primers for amplification of N gene (k) SEQ ID NO: 23 (comprising a fully defined sequence of 32 nucleotides as given in the specification) and gagggagccttgaatacaccaa (SEQ ID NO: 24), (vi) Outward/Displacement primers for amplification of N gene (l) gagggagccttgaatacaccaa (SEQ ID NO: 19) and gagggagccttgaatacaccaa (SEQ ID NO: 20) (vii) LAMP/Inward primers for amplification of M gene (m) SEQ ID NO: 27 (comprising a fully defined sequence of 33 nucleotides as given in the specification) and SEQ ID NO: 28 (comprising a fully defined sequence of 36 nucleotides as given in the specification) (viii) Loop primers for amplification of M gene (n) gagggagccttgaatacaccaa (SEQ ID NO: 29) and gagggagccttgaatacaccaa (SEQ ID NO: 30) (ix) Outward/Dispacement primers for amplification of M gene 13 (o) gagggagccttgaatacaccaa (SEQ ID NO: 25) and aggatcagtgccaagctcgt (SEQ ID NO: 26), is new. An INDEPENDENT CLAIM is also included for detecting SARS-CoV2, comprising amplifying target gene ORF1AB, N and M genes of SARS-CoV2 employing oligonucleotide sequence specific primer set. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-B03C;  B04-E01;  B04-E02F;  B04-E03F;  B04-E05;  B04-E99;  B04-F11B2;  B11-C07B1;  B11-C08F8;  B11-C08N2A;  B12-K04F;  B12-K04G1B;  D05-H06A;  D05-H09;  D05-H12D1;  D05-H18B2;  D05-H99,C12Q-001/6804;  C12Q-001/6844;  C12Q-001/6888;  C12Q-001/689;  C12Q-001/70,IN202041051045-A   27 May 2022   C12Q-001/70   202248Pages: 16   English,IN202041051045-A    IN41051045    24 Nov 2020,,IN41051045    24 Nov 2020,,,,,,,,,
WO2020222149-A1,"Open-gate pseudo-conductive high-electron mobility            transistor used in microelectronic sensor, comprises            multilayer hetero-junction structure, conducting            channel, source and drain contacts, and bolometric or            pyroelectric detector",RAM A;  MUNIEF W,EPITRONIC HOLDINGS PTE LTD (EPIT-Non-standard),2020A7043F,"   NOVELTY - An open-gate pseudo-conductive high-electron                mobility transistor comprises a multilayer                hetero-junction structure made of gallium nitride                and aluminum gallium nitride single-crystalline or                polycrystalline semiconductor materials deposited                on a substrate layer or placed on a free-standing                membrane, and comprising buffer layer and barrier                layer, a conducting channel comprising a                two-dimensional electron gas (2DEG) or a two-                dimensional hole gas (2DHG) formed at the interface                between the buffer layer and the barrier layer, and                upon applying a bias to the transistor, providing                electron or hole current in the transistor between                source and drain contacts connected to the                conducting channel and to electrical metalization                for connecting the transistor to an electric                circuit, and a bolometric or pyroelectric detector                placed on a top layer between the source and drain                contacts in an open gate area of the transistor,                and capable of detecting electrical signals in the                frequency of 30-430 THz.    USE - Open-gate pseudo-conductive high-electron                mobility transistor used in microelectronic sensor                for chemical sensing and biomolecular diagnostics                of particular analyte chosen from toxic metals,                such as chromium, cadmium or lead, regulated                ozone-depleting chlorinated hydrocarbons, food                toxins, such as aflatoxin, and shellfish poisoning                toxins, such as saxitoxin or microcystin,                neurotoxic compounds, such as methanol, manganese                glutamate, nitric oxide, tetanus toxin or                tetrodotoxin, Botox (RTM: Onabotulinumtoxin A                injection), oxybenzone, bisphenol A, or butylated                hydroxyanisole, explosives, such as picrates,                nitrates, trinitro derivatives, such as                2,4,6-trinitrotoluene,                1,3,5-trinitro-1,3,5-triazinane, trinitroglycerine,                N-methyl-N-(2,4,6-trinitrophenyl)nitramide                (nitramine or tetryl), pentaerythritol tetranitrate                (PETN), nitric ester, azide, derivates of chloric                and perchloric acids, fulminate, acetylide, and                nitrogen rich compounds, such as tetrazene,                octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine                (HMX), peroxide, such as triacetone trioxide, C4                plastic explosive and ozonidesor, or an associated                compound of the explosives, such as a decomposition                gases or taggants, and biological pathogens, such                as a respiratory viral or bacterial pathogen, an                airborne pathogen, a plant pathogen, a pathogen                from infected animals or a human viral pathogen                such as severe acute respiratory syndrome                coronavirus 2 (all claimed).    ADVANTAGE - The open-gate pseudo-conductive high-electron                mobility transistor has excellent sensitivity of                the sensor.    DETAILED DESCRIPTION - An open-gate pseudo-conductive high-electron                mobility transistor comprises a multilayer                hetero-junction structure made of gallium nitride                and aluminum gallium nitride single -crystalline or                polycrystalline semi-conductor materials, deposited                on a substrate layer (10) or placed on a                free-standing membrane, the structure comprising                buffer layer (11) and barrier layer (12), the                layers are stacked alternately, a conducting                channel (13) comprising a two-dimensional electron                gas (2DEG) or a two- dimensional hole gas (2DHG)                formed at the interface between the buffer layer                and the barrier layer, and upon applying a bias to                the transistor, providing electron or hole current,                in the transistor between source and drain                contacts, the source and drain contacts connected                to the 2DEG or 2DHG conducting channel and to                electrical metalization (14) for connecting the                transistor to an electric circuit, and a bolometric                or pyroelectric detector placed on a top layer                between the source and drain contacts in an open                gate area of the transistor, and capable of                detecting electrical signals in the frequency of                30-430 THz. The thickness of the top layer of the                heterojunction structure in the open gate area is                5-9 nm and surface roughness of top layer is 0.2 nm                or less. The combination of the thickness and the                roughness of the top layer create a quantum                electronic effect of operating said 2DEG or 2DHG                channel simultaneously in both normally-on and                normally-off operation modes of the channel,                thereby making the transistor suitable for                conducting electric current through the channel in                a quantum well between normally-on and normally-off                operation modes of the transistor. INDEPENDENT                CLAIMS are included for the following:    (1) a microelectronic sensor; and    (2) chemical sensing and biomolecular                diagnostics of a particular analyte in a                sample.    DESCRIPTION OF DRAWING(S) - The drawing shows a cross-sectional view of                the transistor.    Substrate layer (10)    Buffer layer (11)    Barrier layer (12)    Conducting channels (13)    Metalization (14) ",,,"A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C07 (Apparatus, formulation, general. including veterinary syringes, general formulations where the active compound is not central to the invention (e.g. wettable powders) and analysis.);  L03 (Electro-(in)organic - chemical features of conductors, resistors, magnets, capacitors and switches, electric discharge lamps, semiconductor and other materials, batteries, accumulators and thermoelectric devices, including fuel cells, magnetic recording media, radiation emission devices, liquid crystals and basic electric elements. Growing of single crystals of semiconductors and their doping are included, but semiconductor devices, where the manufacture is not claimed are excluded. Electrography, electrophotography, magnetography, electrolysis, electrophoresis, power plant, X-ray and plasma-techniques, ion exchange resins, polyelectrolytes, electroplating, metal electrodeposition, electroforming, anodising, electrolytic cleaning, cathodic protection and electrolytic or electrothermic production or refining of metals are all covered elsewhere (Sections G, J, K and M).);  S03 (Scientific Instrumentation);  ",A09-B;  A12-E13;  A12-V03C2;  A12-W11L;  D03-K03;  D03-K04;  D05-H04;  D05-H05;  D05-H06;  D05-H09;  D05-H10;  B04-B04C;  B04-C02B1;  B04-C03;  B04-E01;  B04-E07F;  B04-F01;  B04-F10;  B04-F11;  B04-G01;  B04-G23;  B04-K01;  B04-L01;  B04-N04;  B05-A01B;  B05-A03A1;  B05-A03B;  B05-C03;  B05-C06;  B05-C08;  B06-A03;  B06-D17;  B06-D18;  B06-E05;  B07-D13;  B10-A05;  B10-B02J;  B10-E02;  B10-E04D;  B10-F02;  B10-G03;  B11-C07A6;  B11-C08B;  B11-C08K;  B11-C12;  B12-K04G;  C04-B04C;  C04-C02B1;  C04-C03;  C04-E01;  C04-E07F;  C04-F01;  C04-F10;  C04-G01;  C04-K01;  C11-C07A6;  C11-C08B;  C11-C08K;  C12-K04G;  L04-A02B1;  L04-C04;  L04-C06C;  L04-C10F;  L04-C11C1;  L04-C11C3;  L04-C13;  L04-C18A;  L04-E01;  S03-A02B;  S03-A03;  S03-E03C;  U11-C01J6;  U14-E01,G01J-003/42;  G01J-005/20;  G01J-005/34;  G01L-001/16;  G01N-027/414;  H01L-029/84,WO2020222149-A1   05 Nov 2020   202095Pages: 75   English,WO2020222149-A1    WOIB054060    30 Apr 2020,,US841955P    02 May 2019,WO2020222149-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2020222149-A1 -- CN108007566-A   NUCTECH CO LTD (TONG)   ZHAO Z,  HU H,  MA X,  WANG Y;  US20190021622-A1   ;  US8313968-B2   UNIV OKLAHOMA STATE (OKLA)   ELGAWADI A","WO2020222149-A1  SOKOLOVSKIJ R ET          AL: ""Precision Recess of AlGaN/GaN with Controllable          Etching Rate Using ICP-RIE Oxidation and Wet Etching"",          PROCEDIA ENGINEERING, ELSEVIER BV, NL, vol. 168, 4          January 2017 (2017-01-04), pages 1094 - 1097,          XP029874885, ISSN: 1877-7058, DOI:          10.1016/J.PROENG.2016.11.350,relevantClaims[1-21],relevantPassages[&lt;paral&gt;3&lt;/paral&gt;&lt;figure&gt;1&lt;/figure&gt;];            GLOBUS ET AL.: ""Terahertz Fourier transform          characterization of biological materials in a liquid          phase"", J. PHYSICS D: APPLIED PHYSICS, vol. 39, no. 15,          pages 3405 - 3413, XP020094644, DOI:          10.1088/0022-3727/39/15/028;            HEILWEIL ET AL.: ""Terahertz Spectroscopy"", 2008, TAYLOR          AND FRANCIS, article ""Terahertz Spectroscopy of          Biomolecules"", pages: 269 - 297;            SAFRAI ET AL.: ""The remote sensing of mental stress from          the electromagnetic reflection coefficient of human skin          in the sub-THz range"", BIOELECTROMAGNETICS, vol. 33, no.          5, 2012, pages 375 - 82;            SAFRAI ET AL.: ""Remote monitoring of phasic heart rate          changes from the palm"", IEEE TRANSACTIONS ON TERAHERTZ          SCIENCE AND TECHNOLOGY, vol. 4, 2014, pages 618 -          624;            SAFRAI ET AL.: ""The correlation of ECG parameters to the          sub-THz reflection coefficient of human skin"", IEEE          TRANSACTIONS ON TERAHERTZ SCIENCE AND TECHNOLOGY, vol. 4,          no. 5, 2014, pages 624 - 630, XP011557224, DOI:          10.1109/TTHZ.2014.2342499;            MARTIN EICKHOFF ET AL.: ""Piezoresistivity of Al Gai-xN          layers and Al Gai-xN/GaN heterostructures"", JOURNAL OF          APPLIED PHYSICS, vol. 90, 2001, pages 3383;            BHAN ET AL.: ""Uncooled Infrared Microbolometer Arrays and          their Characterisation Techniques (Review Paper)"",          DEFENCE SCIENCE JOURNAL, vol. 59, no. 6, 2009, pages 580          - 589, XP055195018, DOI: 10.14429/dsj.59.1562;            ROGALSKISIZOV: ""Terahertz detectors and focal plane          arrays"", OPTO-ELECTRONICS REVIEW, vol. 19, 2011, pages          346 - 404, XP019915721, DOI:          10.2478/s11772-011-0033-3;            MITIN ET AL.: ""Hot-electron micro and nanobolometers          based on low-mobility 2DEG for high resolution THz          spectroscopy"", JOURNAL OF PHYSICS: CONFERENCE SERIES,          vol. 486, 2014, pages 012028;            RAMASWAMY ET AL.: ""2DEG GaN hot electron micro-bolometers          and quantum cascade lasers for THz heterodyne sensing"",          PROCEEDINGS SPIE DEFENCE, SECURITY, AND SENSING, 2011,          pages 8031;            FATIMY ET AL.: ""Room temperature Terahertz hot electron          bolometric detector based on AlGaAs/GaAs two dimensional          electron gas"", 35TH INTERNATIONAL CONFERENCE ON INFRARED,          MILLIMETER, AND TERAHERTZ WAVES, 2010, pages 1 - 1,          XP031783008;            KAWANO ET AL.: ""Terahertz sensing with a carbon          nanotube/two-dimensional electron gas hybrid transistor"",          APPLIED PHYSICS LETTERS, vol. 95, 2009, pages          083123;            WANG ET AL.: ""Preparation of room temperature terahertz          detector with lithium tantalate crystal and thin film"",          AIP ADVANCES, vol. 4, no. 2, 2014, pages 027106",92005-0-0-0 K M; 184613-0-0-0 K M; 2809115-0-0-0 K M; 130320-0-0-0 K M; 92-0-0-0 K M; 669752-0-0-0 K M;  K M; 111995-0-0-0 A K; 89597-0-0-0 A K; 15-0-0-0 A K; 102084-0-0-0 A K; 108666-1-0-0 A K; 62350-0-0-0 A K; 2973920-0-0-0 A K; 131246-0-0-0 A K; 131922-0-0-0 A K; 86664-0-0-0 A K; 106581-1-0-0 A K; 895522-0-0-0 A K; 9523-0-0-0 A K; 109476-0-0-0 A K; 92040-0-0-0 A K; 102110-0-0-0 A K; 132601-0-0-0 A K; 103536-0-0-0 A K; 132559-0-0-0 A K; 129892-0-0-0 A K; 3192247-0-0-0 A K; 135402-0-0-0 ; 107779-0-0-0 ; 2809115-0-0-0 CL USE; 2973920-0-0-0 CL DET; 3192247-0-0-0 CL DET,,42995; 90002; 07541; 40690; 49856; 00212; 00061; 00373,RA061R K M; RA00I9 K M; RBIV3I K M; R06079 K M; R01544 K M; RA9NXU K M; RCWR1Q K M; RA18H5 A K; RA01Q7 A K; R00270 A K; R01901 A K; R18707 A K; R05228 A K; RBMEGI A K; R10325 A K; R11233 A K; RA10NQ A K; R21860 A K; RAE4VR A K; R00470 A K; R00989 A K; R01022 A K; R00096 A K; R12911 A K; R00422 A K; R12803 A K; R03550 A K; RBR37G A K; R24032 ; R01863 ,1544-S; 0270-S; 1901-S; 0470-S; 0989-S; 1022-S; 0096-S; 0422-S
WO2023092089-A1;  US2024043846-A1;  EP4340893-A1;  US2024150771-A1;  US12006502-B2;  US2024191237-A1,"New therapeutic compound being capable of            delivering red blood cell-mediated in human to target            cell expressing cluster of differentiation-47,            comprising cluster of differentiation-47-binding            protein conjugated to active pharmaceutical ingredient            form conjugate, used for treating e.g. cancer",KIM H J;  KIM I;  KIM J S;  KIM S H;  KWON I C;  LEE J W;  YANG Y S;  YOON H Y,KIST KOREA INST SCI & TECHNOLOGY (KSCT-C);  K2B THERAPEUTICS INC (KTWO-Non-standard);  K2B THERAPEUTICS INC (KTWO-Non-standard);  KIST KOREA INST SCI & TECHNOLOGY (KSCT-C);  K2B THERAPEUTICS INC (KTWO-Non-standard);  KIST KOREA INST SCI & TECHNOLOGY (KSCT-C);  KIST KOREA INST SCI & TECHNOLOGY (KSCT-C),202356449E,"   NOVELTY - A therapeutic compound being capable of                performing red blood cell-mediated delivery in a                mammalian subject to a target cell expressing                cluster of differentiation (CD)47, comprising a                CD47-binding protein conjugated to an active                pharmaceutical ingredient (API) so as to form a                conjugate, is new. The CD47-binding protein is                chosen from wild type thrombospondin-1 (TSP-1) (SEQ                ID NO: 7), wild type signal-regulatory protein                (SIRP)&#947; (SEQ ID NO: 4), vSIRP&#947; -1                (SEQ ID NO: 5), vSIRP&#947; -2 (SEQ ID NO: 6),                evorpacept (ALX148) (SEQ ID NO: 962),                SIRP&#945; fragment crystallizable (Fc)                (TTI-661) (SEQ ID NO: 963), TTI-662 (SEQ ID NO:                964), their homologs, and their combinations, and                is configured to bind the conjugate to CD47 of a                red blood cell of the subject so as to enable                transport of the conjugate, through the circulatory                system of subject, to the target cell.    USE - The therapeutic compound is useful in                pharmaceutical composition for treating cancer,                viral infection, fibrotic disease in mammalian                subject, preferably a human by performing red blood                cell-mediated delivery to a target cell expressing                CD47 (all claimed), and enhancing innate and                adaptive immune responses. The fibrotic diseases                are cystic fibrosis. The cancer includes brain                tumor, spinal cord tumor, retinoblastoma, oral                cancer, nasal cavity cancer, paranasal sinus                cancer, pharyngeal cancer, laryngeal cancer, neck                cancer, head and neck cancer, melanoma, skin                cancer, breast cancer, thyroid cancer, malignant                adrenal tumor, endocrine cancer, lung cancer,                pleural tumor, respiratory tract cancer, esophageal                cancer, stomach cancer, small intestine cancer,                colon cancer, anal cancer, liver cancer, biliary                tract cancer, pancreatic cancer, kidney cancer,                bladder cancer and prostate cancer.    ADVANTAGE - The therapeutic compound has improved binding                affinity, stability, and target modulation                effects.    DETAILED DESCRIPTION - A therapeutic compound being capable of                performing red blood cell-mediated delivery in a                mammalian subject to a target cell expressing                cluster of differentiation (CD)47, comprising a                CD47-binding protein conjugated to an active                pharmaceutical ingredient (API) so as to form a                conjugate, is new. The CD47-binding protein is                chosen from wild type thrombospondin-1 (TSP-1) (SEQ                ID NO: 7), wild type signal-regulatory protein                (SIRP)&#947; (SEQ ID NO: 4), vSIRP&#947; -1                (SEQ ID NO: 5), vSIRP&#947; -2 (SEQ ID NO: 6),                evorpacept (ALX148) (SEQ ID NO: 962),                SIRP&#945; fragment crystallizable (Fc)                (TTI-661) (SEQ ID NO: 963), TTI-662 (SEQ ID NO:                964), their homologs, and their combinations, and                is configured to bind the conjugate to CD47 of a                red blood cell of the subject so as to enable                transport of the conjugate, through the circulatory                system of subject, to the target cell, so that (i)                the CD47-binding protein, being configured to bind                the conjugate to the CD47 of the red blood cell,                binds the CD47 of the target cell, thus                transferring the conjugate from the red blood cell                to the target cell so as to form a conjugate-CD47                complex on the target cell for blocking CD47 and                inhibiting CD47 activity as an immune escape                mechanism of the target cell, and (ii) the                conjugate is taken up by the target cell through                endocytosis of the conjugate-CD47 complex for                inhibiting the immune escape mechanism of the                target cell and delivering the API into the target                cell. The CD47-binding protein is chosen from wild                type SIRP-&#945; (SEQ ID NO: 1),                vSIRP&#945; (SEQ ID NO: 3), wild type                thrombospondin-1 (TSP-1) (SEQ ID NO: 7), wild type                SIRP&#947; (SEQ ID NO: 4), vSIRP&#947; -1                (SEQ ID NO: 5), vSIRP&#947; -2 (SEQ ID NO: 6),                ALX148 (SEQ ID NO: 962), TTI-661 (SEQ ID NO: 963),                TTI-662 (SEQ ID NO: 964), their homologs, and heir                combinations, and is configured to bind the                conjugate to CD47 of a red blood cell of the                subject so as to enable transport of the conjugate,                through the circulatory system of subject, to the                target cell, so that (i) the CD47-binding protein,                being configured to bind the conjugate to the CD47                of the red blood cell, binds the CD47 of the target                cell, thus transferring the conjugate from the red                blood cell to the target cell so as to form a                conjugate-CD47 complex on the target cell for                blocking CD47 and inhibiting CD47 activity as an                immune escape mechanism of the target cell, and                (ii) the conjugate is taken up by the target cell                via endocytosis of the conjugate-CD47 complex for                further inhibiting the immune escape mechanism of                the target cell and delivering the API into the                target cell. The CD47-binding protein is an                anti-CD47 antibody comprising (a) a heavy chain                variable region including complementarity                determining regions (CDR)1, CDR2, and CDR3                comprising amino acid sequences of SEQ ID NOs: 932,                933, and 934, respectively, and a light chain                variable region including CDR1, CDR2, and CDR3                comprising amino acid sequences of SEQ ID NOs: 935,                936, and 937, respectively, (b) a heavy chain                variable region including CDR1, CDR2, and CDR3                comprising amino acid sequences of SEQ ID NO: 940,                SEQ ID NO: 941, and SEQ ID NO: 942, respectively,                and a light chain variable region including CDR1,                CDR2, and CDR3 comprising amino acid sequences of                SEQ ID NO: 943, SEQ ID NO: 944, and SEQ ID NO: 945,                respectively, (c) a heavy chain variable region                including CDR1, CDR2, and CDR3 comprising amino                acid sequences of SEQ ID NO: 948, SEQ ID NO: 949,                and SEQ ID NO: 950, respectively, and a light chain                variable region including CDR1, CDR2, and CDR3                comprising amino acid sequences of SEQ ID NO: 951,                SEQ ID NO: 952, and SEQ ID NO: 953, respectively,                or (d) a heavy chain variable region including                CDR1, CDR2, and CDR3 comprising amino acid                sequences of SEQ ID NO: 956, SEQ ID NO: 957, and                SEQ ID NO: 958, respectively, and a light chain                variable region including CDR1, CDR2, and CDR3                comprising amino acid sequences of SEQ ID NO: 959,                SEQ ID NO: 960, and SEQ ID NO: 961, respectively,                and is configured to bind the conjugate to CD47 of                a red blood cell of the subject so as to enable                transport of the conjugate, through the circulatory                system of subject, to the target cell, so that (i)                the CD47-binding protein, being configured to bind                the conjugate to the CD47 of the red blood cell,                binds the CD47 of the target cell, thus                transferring the conjugate from the red blood cell                to the target cell so as to form a conjugate-CD47                complex on the target cell for blocking CD47 and                inhibiting CD47 activity as an immune escape                mechanism of the target cell, and (ii) the                conjugate is taken up by the target cell through                endocytosis of the conjugate-CD47 complex for                further inhibiting the immune escape mechanism of                the target cell and delivering the API into the                target cell. Sequences not defined here may be                found at                ftp://ftp.wipo.int/pub/publishedpctsequences/publication. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E01;  B04-E06;  B04-E07;  B04-E99;  B04-F02A;  B04-F04A;  B04-L01;  B04-N04;  B11-C11;  B14-A02;  B14-H01;  B14-K01;  B14-L06;  D05-A02;  D05-H99,A61K-047/68;  A61P-035/00;  C12N-015/113;  C12Q-001/68,WO2023092089-A1   25 May 2023   A61K-047/68   202346Pages: 114   English;  US2024043846-A1   08 Feb 2024   C12N-015/113   202413   English;  EP4340893-A1   27 Mar 2024   A61K-047/68   202427   English;  US2024150771-A1   09 May 2024   C12N-015/113   202440   English;  US12006502-B2   11 Jun 2024   C12N-015/113   202448   English;  US2024191237-A1   13 Jun 2024   C12N-015/113   202449   English,WO2023092089-A1    WOUS080167    18 Nov 2022;   US2024043846-A1    US057050    18 Nov 2022;   EP4340893-A1    EP844608    18 Nov 2022;   US2024150771-A1    US407815    09 Jan 2024;   US12006502-B2    US407815    09 Jan 2024;   US2024191237-A1    US407780    09 Jan 2024,US2024043846-A1 Provisional Application US392323P;   US2024043846-A1 Provisional Application US281370P;   EP4340893-A1 PCT application Application WOUS080167;   EP4340893-A1 Based on Patent WO2023092089;   US2024150771-A1 Cont of Application US057050;   US2024150771-A1 Provisional Application US281370P;   US2024150771-A1 Provisional Application US392323P;   US12006502-B2 Cont of Application US057050;   US12006502-B2 Provisional Application US281370P;   US12006502-B2 Provisional Application US392323P;   US12006502-B2 Previous Publ. Patent US2024150771;   US2024191237-A1 Cont of Application US057050;   US2024191237-A1 Provisional Application US281370P;   US2024191237-A1 Provisional Application US392323P,US281370P    19 Nov 2021;  US392323P    26 Jul 2022;  US057050    18 Nov 2022;  US407780    09 Jan 2024;  US407815    09 Jan 2024,WO2023092089-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP4340893-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  KH;  MA;  MD;  TN        ,,"WO2023092089-A1 -- EP3575326-A1   TRILLIUM THERAPEUTICS INC (TRIL-Non-standard)   UGER R A,  SLAVOVA-PETROVA P S,  PANG X;  WO2014149477-A1   UNIV LELAND STANFORD JUNIOR (STRD)   WILLINGHAM S,  HOWARD M,  LIU J,  MAJETI R,  PROHASKA S,  VOLKMER A K,  WEISSMAN I L;  WO2020163721-A1   INTEGRITY BIOVENTURES INC (INTE-Non-standard)   KAHANA J,  LIPPINCOTT J;  WO2021174127-A1   APEXIGEN INC (APEX-Non-standard)   SRIVASTAVA M K,  JALGAONKAR S,  TAN C,  HUANG G,  BAHJAT R,  YANG X,  FILBERT E L,  ALVARADO R,  KRISHNAN S;  US20210015931-A1   ;  US7056704-B2   WHITEHEAD INST BIOMEDICAL RES (WHED);  MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN (PLAC);  MASSACHUSETTS INST TECHNOLOGY (MASI);  UNIV MASSACHUSETTS MEDICAL CENT (UMAC)   TUSCHL T,  SHARP P A,  ZAMORE P D,  BARTEL D P;  US7078196-B2   WHITEHEAD INST BIOMEDICAL RES (WHED);  MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN (PLAC);  MASSACHUSETTS INST TECHNOLOGY (MASI);  UNIV MASSACHUSETTS MEDICAL CENT (UMAC)   TUSCHL T,  SHARP P A,  ZAMORE P D,  BARTEL D P;  US8372968-B2   MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN (PLAC);  EMBL EURO LAB MOLEKULARBIOLOGIE (EMEU)   TUSCHL T,  ELBASHIR S,  LENDECKEL W;  US9017675-B2   UNIV LELAND STANFORD JUNIOR (STRD)   LIU J,  WEISSMAN I L,  MAJETI R;  US9623079-B2   UNIV LELAND STANFORD JUNIOR (STRD)   WILLINGHAM S,  HOWARD M,  LIU J,  MAJETI R,  PROHASKA S,  VOLKMER A K,  WEISSMAN I L;  US9969789-B2   TRILLIUM THERAPEUTICS INC (TRIL-Non-standard)   UGER R A,  SLAVOVA-PETROVA P S,  PANG X;  US10696730-B2   ALEXO THERAPEUTICS INC (ALEX-Non-standard)   PONS J,  DEMING L,  GOODMAN C,  SIM B J,  KAUDER S E,  WAN H,  KUO T C;  US12006502-B2 -- EP3575326-A1   TRILLIUM THERAPEUTICS INC (TRIL-Non-standard)   UGER R A,  SLAVOVA-PETROVA P S,  PANG X;  US20210015931-A1   ;  US20220257729-A1   ;  WO2014149477-A1   UNIV LELAND STANFORD JUNIOR (STRD)   WILLINGHAM S,  HOWARD M,  LIU J,  MAJETI R,  PROHASKA S,  VOLKMER A K,  WEISSMAN I L;  WO2020163721-A1   INTEGRITY BIOVENTURES INC (INTE-Non-standard)   KAHANA J,  LIPPINCOTT J;  WO2021174127-A1   APEXIGEN INC (APEX-Non-standard)   SRIVASTAVA M K,  JALGAONKAR S,  TAN C,  HUANG G,  BAHJAT R,  YANG X,  FILBERT E L,  ALVARADO R,  KRISHNAN S","WO2023092089-A1  RATNIKOVA N M ET          AL: ""CD47 receptor as a primary target for cancer          therapy"", MOLECULAR BIOLOGY : COVER-TO-COVER TRANSLATION          = MOLEKULYARNAYA BIOLOGIYA, ACADEMY OF SCIENCES OF THE          USSR, RU, vol. 51, no. 2, 9 May 2017 (2017-05-09), pages          216 - 225, XP036230611, ISSN: 0026-8933, [retrieved on          20170509], DOI:          10.1134/S0026893317010150,relevantClaims[1-15,46-51|16-45],relevantPassages[&lt;pp&gt;220&lt;/pp&gt;&lt;ppl&gt;221&lt;/ppl&gt;];            WILLINGHAM ET AL., PNAS, vol. 109, no. 17, 2012, pages          6662 - 6667;            WEISKOPF, EUR. J. CANCER, vol. 76, 2017, pages 100 -          109;            WEISKOPF ET AL., J CLIN INVEST, vol. 126, no. 7, 2016,          pages 2610 - 2620;            CHAM ET AL., CELL REP, vol. 31, no. 2, 2020, pages          107494;            MCLAUGHLIN ET AL., BIORXIV 2021.03.01.433404,          2021;            CUI ET AL., NAT COMMUN, vol. 11, 2020, pages          2795;            WERNIG ET AL., PNAS, vol. 114, no. 18, 2017, pages 4757 -          62;            BOYD, JCYST FIBROS, 2020, pages S54 - S59;            LERBS ET AL., JCIINSIGHT, vol. 5, no. 16, 2020, pages          e140458;  KO          ET AL., CONTROL RELEASE, vol. 323, 2020, pages 376 -          386;            GUPTA ET AL., CANCER DRUG RESIST, vol. 3, 2020, pages 550          - 62;  SU          ET AL., ACTA PHARMACEUTICA SINICA B, 2021, ISSN:          2211-3835;            PAN ET AL., MED RES REV, vol. 40, 2020, pages 2682 -          2713;            KHONGORZULET, MOL CANCER RES, vol. 18, 2020, pages 3 -          19;            BARGH ET AL., CHEM SOC REV, vol. 48, 2019, pages 4361 -          4374;            SMITH ET AL., PHARM RES, vol. 32, 2015, pages 3526 -          3540;            KONG ET AL., J BIOL CHEM, vol. 290, 2015, pages 7160 -          7168;            POREBA, FEBSJ, vol. 287, 2020, pages 1936 -          1969;            SINGH ET AL., CURRENT MEDICINAL CHEMISTRY, vol. 15, no.          18, 2008;            SALOMON ET AL., MOL PHARM, vol. 16, no. 12, 2019, pages          4817 - 4825;            DRAGO ET AL., NAT REV CLIN ONCOL, vol. 18, 2021, pages          327 - 344;            RAO ET AL., ADV DRUG DELIV REV, vol. 61, no. 9, 2009,          pages 746 - 59;            QUEMENER ET AL., WILEY INTERDISCIP REV RNA, no. 5, 2020,          pages e1594;            LENNOX ET AL., GENE THERAPY, vol. 18, 2011, pages 1111 -          20;            WAHLESTEDT ET AL., PNAS, vol. 97, 2000, pages 5633 -          5638;            ELAYADI ET AL., CURR OPIN INVESTIGDRUGS, vol. 2, 2001,          pages 558 - 61;            LARSEN ET AL., BIOCHIM BIOPHYS ACTA, vol. 1489, 1999,          pages 159 - 166;            BRAASCH ET AL., BIOCHEMISTRY, vol. 41, 2002, pages 4503 -          4510;            SUMMERTON ET AL., ANTISENSE NUCLEIC ACID DRUG DEV, vol.          7, 1997, pages 187 - 195;            LIU ET AL., J BIOL CHEM, vol. 276, no. 43, 2001, pages          40156 - 66;            KALE ET AL., INT J MOL SCI, vol. 22, no. 8,          2021;            KAUR ET AL., J BIOL CHEM, vol. 285, no. 50, 2010, pages          38923 - 38932US12006502-B2            Ratnikova et al., CD47 Receptor as a Primary Target for          Cancer Therapy, Molecular Biology, vol. 51, No. 2, pp.          216-225, May 9, 2017.;            International Searching AuthorityInternational Search          Report, pertaining to International Application No.          PCT/US2023/080167 dated May 8, 2023, together with the          Written Opinion of the International Searching Authority,          14 pages.;            Tatiparti et al., siRNA Delivery Strategies: A          Comprehensive Review of Recent Developments,          Nanomaterials, vol. 7, 77, 17 pages, 2017.;            Singh et al., Advances in siRNA delivery in cancer          therapy, Artificial Cells, Nanomedicine, and          Biotechnology, 46:2, 274-283, 2018.;            Resnier et al., A review of the current status of siRNA          nanomedicines in the treatment of cancer, Biomaterials,          vol. 34, pp. 6429-6443, 2013.;            Boyd et al., New approaches to genetic therapies for          cystic fibrosis, Journal of Cystic Fibrosis, vol. 19, pp.          S54-S56, 2020.;            Wang et al., Strategies for short hairpin RNA delivery in          cancer gene therapy, Expert Opinion on Biological          Therapy, 9:11. pp. 1357-1369, 2009.;  Ho          et al., Biomaterials in siRNA Delivery: A Comprehensive          Review, Advanced Healthcare Materials, vol. 5, pp.          2715-2731, 2016.;            Qureshi et al., A review on current status of antiviral          siRNA, Rev. Med. Virol., vol. 28, 11 pages,          2018.;            Kim et al., Recent progress in development of siRNA          delivery vehicles for cancer therapy, Advanced Drug          Delivery Reviews, vol. 104, pp. 61-77, 2016.;            Yonezawa et al., Recent advances in siRNA delivery          mediated by lipid-based nanoparticles, Advanced Drug          Delivery Reviews, vols. 154-155, pp. 64-78,          2020.;            Gondi et al., Concepts in In Vivo siRNA Delivery for          Cancer Therapy, Journal of Cellular Physiology, vol. 220,          pp. 285-291, 2009.;  Ko          et al., Versatile activatable vSIRP-probe for          cancer-targeted imaging and macrophage-medicated          phagocytosis of cancer cells:, Journal of Controlled          Release, vol. 323, pp. 376-386, 2020.;            Acharya, The recent progresses in shRNA-nanoparticle          conjugate as a therapeutic approach, Materials Science          & Engineering C, vol. 104, 109928, 8 pages,          2019.;            Rao et al., siRNA vs. shRNA: Similarities and          differences, Advanced Drug Delivery Reviews, vol. 61, pp.          746-759, 2009.;            McLaughlin et al., CD47 as a potential biomarker for the          early diagnosis of severe COVID-19, bioRxiv, 35 pages,          2021.;            Cham et al., Immunotherapeutic Blockade of CD47          Inhibitory Signaling Enhances Innate and Adaptive Immute          Responses to Viral Infection, Cell Reports, vol. 31,          107494, 14 pages, Apr. 14, 2020.;            Khongorzul et al., Antibody-Drug Conjugates: A          Comprehensive Review, Molecular Cancer Research, American          Association for Cancer Research Journals, 18 pages, Oct.          28, 2019.;            Tan et al., MicroRNAs and cancer: Key paradigms in          molecular therapy (Review), Oncology Letters, vol. 15,          pp. 2735-2742, 2018.;            Gupta et al., Therapeutic modulation of the CD47-SIRP          axis in the pediatric tumor microenvironment: working up          an appetite, Cancer Drug Resist, vol. 3, pp. 550-562,          2020.;            Wernig et al., Unifying mechanism for different fibrotic          diseases, PNAS, vol. 14, No. 18, pp. 4757-4762, May 2,          2017.;            Cui et al., Activation of JUN in fibroblasts promotes          pro-fibrotic programme and modulates protective immunity,          Nature Communications, vol. 11, 2795, 14 pages,          2020.;            Wang et al., Intravenous delivery of siRNA targeting CD47          effectively inhibits melanoma tumor growth and lung          metastasis, Molecular Therapy, vol. 21, No. 10, pp.          1919-1929, Oct. 2013.",,,,,
WO2022226201-A1;  US2022372080-A1,"Immunogenic protein comprises amino acid identity            to amino acid sequence of antigenic peptide comprising            coronavirus receptor binding domain, coronavirus a            receptor binding motif of coronavirus spike            protein",KIPP P;  BERQUIST B;  PALLE S,IBIO INC (IBIO-Non-standard);  IBIO INC (IBIO-Non-standard),2022D3051W,"   NOVELTY - Immunogenic protein comprises at least 90%                amino acid identity to an amino acid sequence of at                least one antigenic peptide comprising a                coronavirus receptor binding domain (RBD),                coronavirus a receptor binding motif (RBM) of a                coronavirus spike protein, a coronavirus spike                protein N-terminus, a nucleocapsid protein, at                least one T cell epitope from a coronavirus spike                protein, and/or at least one T cell epitope from a                coronavirus nucleocapsid protein.    USE - Used as immunogenic protein.    ADVANTAGE - The immunogenic protein exhibits enhanced                immune response, and can be produced rapidly and                effectively.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    timulating (M1) an immune response in an                animal comprising administering to the animal a                composition comprising an immunogenic protein that                has at least 90% amino acid identity to at least                one antigenic peptide comprising a coronavirus RBD,                coronavirus a RBM of a coronavirus spike protein, a                coronavirus spike protein N-terminus, a                nucleocapsid protein, T cell epitopes from a                coronavirus spike protein, and/or T cell epitopes                from a coronavirus nucleocapsid protein;    producing (M2) a carrier protein in a plant                comprising (a) providing a plant containing an                expression cassette having a nucleic acid encoding                an immunogenic protein that has at least 90% amino                acid identity to at least one antigenic peptide,                and (b) growing the plant under conditions in which                the nucleic acid is expressed and the immunogenic                protein is produced;    nucleic acid encoding a protein comprising an                immunogenic protein that has at least 90% amino                acid identity to at least one antigenic                peptide;    vector that comprises a nucleic acid that                encodes an immunogenic protein that has at least                90% amino acid identity to at least one antigenic                peptide; and    pan-coronavirus booster comprising an                immunogenic protein comprising at least 90% amino                acid identity to an amino acid sequence of a                coronavirus nucleocapsid protein and adjuvant that                triggers a type 1 T helper (Th1) immune                response. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-C01G;  B04-E02F;  B04-E03F;  B04-E08;  B04-E99;  B04-N01;  B04-N03K1;  B11-C04;  C04-C01G;  C04-E02F;  C04-E03F;  C04-E08;  C04-E99;  C04-N01;  C04-N03K1;  C11-C04;  D05-H12A;  D05-H12E;  D05-H99,C07K-014/005;  A61K-039/215;  C12N-015/82,WO2022226201-A1   27 Oct 2022   C07K-014/005   202294Pages: 99   English;  US2022372080-A1   24 Nov 2022   C07K-014/005   202295   English,WO2022226201-A1    WOUS025768    21 Apr 2022;   US2022372080-A1    US726110    21 Apr 2022,US2022372080-A1 Provisional Application US178443P;   US2022372080-A1 Provisional Application US217364P;   US2022372080-A1 Provisional Application US222358P,US178443P    22 Apr 2021;  US217364P    01 Jul 2021;  US222358P    15 Jul 2021;  US726110    21 Apr 2022,WO2022226201-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,"WO2022226201-A1 -- CN111620952-A   SUZHOU MIDI BIOTECHNOLOGY CO LTD (SUZH-Non-standard)   SUN X,  CAO W,  KONG D,  TENG X,  ZHANG D,  YI X;  CN111944837-A   UNIV HENAN NORMAL (UYNR);  XINXIANG YIMAN BIOTECHNOLOGY CO LTD (XINX-Non-standard)   JIANG Y,  LI W,  ZHAO J,  XU G,  MA C;  WO2015080973-A1   BAYLOR COLLEGE MEDICINE (BAYU)   HOTEZ P J,  BOTTAZZI M E,  ZHAN B,  CHEN W,  CHAG S",,,,,,
WO2021168312-A1,"Affinity molecule for detecting presence or measuring amount of coronavirus, comprises amino acid sequence with 0, 1, 2, 3 amino acid substitutions, deletions, additions, where amino acid sequence comprises first and second binding domain",SUN R;  ZHANG T;  DU Y;  SHI Y;  MENG X;  HU M,UNIV CALIFORNIA (REGC-C);  UNIV HONG KONG (UYHK-C),202198974S,"   NOVELTY - Affinity molecule comprises an amino acid sequence, which comprises 88 amino acids (SEQ ID NO: 526), given in the specification with 0, 1, 2, or 3 amino acid substitutions, deletions, or additions. The amino acid sequence comprising a first binding domain, which comprises 7 amino acids each (SEQ ID NO: 2, 5), given in the specification, having at least 90 % identity, and a second binding domain comprising sequences, which comprises 10 amino acids each (SEQ ID NO: 3, 6), given in the specification, having 40 % sequence identity, or a first binding domain comprising the sequence, which comprises 10 amino acids each (SEQ ID NO: 3, 6), given in the specification, having 90 % sequence identity and a second binding domain comprising sequences, which comprises 7 amino acids each (SEQ ID NO: 2, 5), given in the specification, having 40 % sequence identity, where the amino acid sequence is not the sequence, which comprises 88 amino acids each (SEQ ID NO: 7, 8), given in the specification.    USE - Affinity molecules are used for detecting the presence or measuring the amount of a coronavirus.    DETAILED DESCRIPTION - Affinity molecule which comprises an amino acid sequence, which comprises 88 amino acids (SEQ ID NO: 526), given in the specification with 0, 1, 2, or 3 amino acid substitutions, deletions, or additions. The amino acid sequence comprising a first binding domain, which comprises 7 amino acids each (SEQ ID NO: 2, 5), that are Pro-Ala-Asn-Tyr-Tyr-Asn-Ile, Pro-Asn-Leu-Trp-Tyr-Lys-Val, given in the specification, having at least 90 % identity, and a second binding domain comprising sequences, which comprises 10 amino acids each (SEQ ID NO: 3, 6), that are Thr-Arg-Trp-Arg-Leu-Tyr-Gln-Met-Trp-Gln, Lys-Arg-Ser-Phe-Trp-Ser-Asn-Ser-Ala-Gly, given in the specification, having 40 % sequence identity, or a first binding domain comprising the sequence, which comprises 10 amino acids each (SEQ ID NO: 3, 6), that are Thr-Arg-Trp-Arg-Leu-Tyr-Gln-Met-Trp-Gln, Lys-Arg-Ser-Phe-Trp-Ser-Asn-Ser-Ala-Gly, given in the specification, having 90 % sequence identity and a second binding domain comprising sequences, which comprises 7 amino acids each (SEQ ID NO: 2, 5), that are Pro-Ala-Asn-Tyr-Tyr-Asn-Ile, Pro-Asn-Leu-Trp-Tyr-Lys-Val, given in the specification, having 40 % sequence identity, where the amino acid sequence is not the sequence, which comprises 88 amino acids each (SEQ ID NO: 7, 8), given in the specification. INDEPENDENT CLAIMS are included for the following:    (1) a composition, which comprises one or more affinity molecules and a carrier, e.g., a carrier;    (2) a kit, which comprises one or more affinity molecules and/or a composition packaged together with reagents for detecting a coronavirus using the one or more affinity molecules as a capture reagent and/or a detection reagent, or a drug delivery device for administering the one or more affinity molecules or composition to a subject; and    (3) a method for detecting the presence or measuring the amount of a coronavirus, which involves using one or more affinity molecules as a capture reagent and/or a detection reagent. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-C01G;  B04-E99;  B04-F11B2;  B04-N04A;  B11-C08E;  B12-K04;  D05-H06A;  D05-H99,A61K-039/12;  A61K-038/16;  C07K-014/00;  A61K-038/39,WO2021168312-A1   26 Aug 2021   A61K-039/12   202176Pages: 80   English,WO2021168312-A1    WOUS018862    19 Feb 2021,,US980016P    21 Feb 2020;  US016088P    27 Apr 2020,WO2021168312-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,,,184611-0-0-0 A K,,,RA00H1 A K,
CN111172325-A;  WO2021164050-A1,"Quickly detecting isothermal amplification useful            for detecting sample contains target nucleic acid and            applying to pathogenic pathogens comprises e.g.            collecting biological sample, extracting target nucleic            acid and determining sample",XU D,BEIJING TIANDZ GENE TECHNOLOGY CO LTD (BEIJ-Non-standard);  TIANDZ INC (TIAN-Non-standard),202049906Q,"   NOVELTY - Quickly detecting isothermal amplification                comprises e.g. collecting the biological sample                containing the target nucleic acid, extracting the                target nucleic acid, adding the target nucleic                acid, positive control and negative control to the                isothermal amplification reaction system and the                mixing tube of the primer composition for                isothermal amplification reaction, determining                whether the target sample contains the target                nucleic acid by visually observing the color change                in the reaction tube and the fluorescence scan                reading at room temperature, where the isothermal                amplification reaction system comprises a buffer                composition, a visualization composition, and a                polymerase that catalyzes the amplification                reaction under isothermal conditions, the room                temperature visualization composition comprises a                visible light coloring dye and a fluorescent signal                generating compound, adding visible light                chromogenic dye and fluorescent signal generating                compound to amplification system.    USE - The quickly detecting of isothermal                amplification/kit is useful for detecting a sample                contains a target nucleic acid and applying to                pathogenic pathogens comprising aquatic organisms                e.g. human pathogenic pathogens, fish and                shellfish, specific genes in the fields of                pathogens, plant pathogenic microorganisms, animal                and plant transgenics, and food safety in                agriculture and animal husbandry, the test samples                comprises clinical specimens of medical tests,                transgenic animal tissues, animal husbandry and                veterinary animal specimens and transgenic plant                tissues, crop plants, rice flour, flour, soy                products, rice products, infant food supplements,                canned foods, potatoes and puffed foods and                phytophagous feed, identifying the nucleic acid to                be tested is the target nucleic acid and                identifying the biological sample to be tested                contains the source of infection to be test.    ADVANTAGE - The method: is simple; can be adapted to                high-concentration and low-concentration virus                sample scenarios; has high sensitivity, strong                specificity, and the result can be judged by the                naked eye; detects at the basic level and on-site;                and is economical.    DETAILED DESCRIPTION - Quickly detecting isothermal amplification                comprises collecting the biological sample                containing the target nucleic acid, extracting the                target nucleic acid, adding the target nucleic                acid, positive control and negative control to the                isothermal amplification reaction system and the                mixing tube of the primer composition for                isothermal amplification reaction, determining                whether the target sample contains the target                nucleic acid by visually observing the color change                in the reaction tube and the fluorescence scan                reading at room temperature alone or in                combination, where the isothermal amplification                reaction system comprises a buffer composition, a                visualization composition, and a polymerase that                catalyzes the amplification reaction under                isothermal conditions, the room temperature                visualization composition comprises a visible light                coloring dye and a fluorescent signal generating                compound, simultaneously adding the visible light                chromogenic dye and the fluorescent signal                generating compound to the amplification system                before the isothermal amplification reaction, using                the visible light chromogenic dye and the                fluorescent signal generating compound alone or in                combination to detect the target nucleic acid                containing the specimen to be tested, where the                fluorescent signal generating compound comprises a                fluorescent color dye and a fluorescent probe, the                positive control is a synthetic target nucleic acid                of known concentration, which can be amplified by                LAMP primers, selecting the rapid detection method                of isothermal amplification from loop-mediated                isothermal amplification, nucleic acid                sequence-dependent amplification, rolling circle                amplification, single primer isothermal                amplification, helicase-dependent isothermal DNA                amplification, recombinase polymerase amplification                and/or strand displacement amplification or the                rapid detection method of isothermal amplification                is loop-mediated isothermal amplification.                INDEPENDENT CLAIM are also included for:    (1) kit comprising an isothermal amplification                reaction system, a primer composition, a positive                control and a negative control, where the                isothermal amplification reaction system comprises                an isothermal amplification polymerase, a                visualization composition, and a buffer                composition, the visualization composition                comprises a visible light coloring dye and a                fluorescent signal generating compound, the                fluorescent signal generating compound comprises                fluorescent chromogenic dyes and/or fluorescent                probes and the positive control solution is the                target nucleic acid extract to be tested; and    (2) preparing kit. ",,,"A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",A10-E08B;  A12-L04B;  A12-W11L;  B04-E01;  B04-E05;  B04-E99;  B04-L04A;  B11-C07B1;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B11-C08J;  B12-K04F;  C04-E01;  C04-E05;  C04-E99;  C04-L04A;  C11-C07B1;  C11-C08E3;  C11-C08F8;  C11-C08J;  C12-K04;  D05-A02B;  D05-H09;  D05-H18B;  D05-H99,C12Q-001/6844;  C12Q-001/70,CN111172325-A   19 May 2020   C12Q-001/70   202051Pages: 35   Chinese;  WO2021164050-A1   26 Aug 2021   C12Q-001/70   202172   Chinese,CN111172325-A    CN10108428    21 Feb 2020;   WO2021164050-A1    WOCN077400    02 Mar 2020,,CN10108428    21 Feb 2020,  WO2021164050-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW  ,,";  WO2021164050-A1 -- CN101368204-A   CHINA METROLOGY COLLEGE (UYJA)   CHEN Z,  FANG M,  FU X,  HU H,  LIU J,  ZHANG M;  CN101671745-A   BEIJING ENTRY EXIT INSPECTION &                  QUARANTI (BEIJ-Non-standard)   WANG J,  WEI H,  ZENG J,  ZHANG X,  ZHOU Q;  CN102344974-A   ZHANG X (ZHAN-Individual);  WANG X (WANG-Individual)   GONG Z,  WANG J,  WANG X,  ZHANG X,  ZHAO L;  CN110564822-A   CHINESE ACAD SCI CHENGDU BIOLOGY INST (CACB)   TANG Z,  DONG J,  WANG J,  CHEN G;  CN110760569-A   SHANGHAI IND TECHNOLOGY INST (SHAN-Non-standard);  SHANGHAI WANT WANT FOODS GROUP CO LTD (SHAN-Non-standard)   LI X,  LIU W,  LI Y,  WEI C,  LU C,  JIA B,  CAO Y;  WO2009098789-A1   UNIV MIYAZAKI (ZAKI);  KYUSHU MEDICAL CO LTD (KYUS-Non-standard)   ITAMI T,  SAKAI M,  KOUNO T,  MEKATA T",,204644-0-0-0 K M; 444-0-0-0 ,,,RA031J K M; R00351 ,
WO2022189976-A1,"New Euglena organism comprising non-transgenic,            human-induced alteration in glucan synthase-like 2            gene, used e.g. to produce proteins, lipids, amino            acids and/or fatty acids including saturated and/or            long chain unsaturated fatty acids",ZHANG Z;  FARROW S;  NOBLE A J,NOBLEGEN INC (NOBL-Non-standard),2022B6695Q,"   NOVELTY - Euglenaorganism comprising a non-transgenic,                human-induced alteration in the glucan                synthase-like 2 (GSL2) gene, is new, where the                Euglenaorganism comprises a property comprising (i)                reduced carbohydrate content, (ii) reduced size of                paramylon granules, (iii) increased protein                content, (iv) increased lipid content, (v) altered                amino acid profile, and/or (vi) altered fatty acid                profile, as compared to a wild type Euglenaorganism                of a same species comprising a GSL2 gene.    USE - The Euglena organism is useful for: altering a                trait; expressing a heterologous nucleic acid                molecule in a target genome insertion site;                expressing a heterologous nucleic acid molecule in                Euglena gracilis strain Z, line B2 organism;                producing proteins, lipids, amino acids and/or                fatty acids, where the fatty acids are saturated                fatty acids, and/or long chain unsaturated fatty                acids (all claimed); and producing severe acute                respiratory syndrome coronavirus 2 spike protein                subunit 1 domain.    ADVANTAGE - The Euglenaorganism: has reduced carbohydrate                content (i.e. less than 5 wt.%, or &#8804; 3                wt.%), reduced size of paramylon granules,                increased protein content (i.e. at least 60 wt.%,                preferably at least 65 wt.%), increased lipid                content (i.e. greater than 15 wt.%), altered amino                acid profile, and/or altered fatty acid profile, as                compared to a wild type Euglenaorganism of a same                species comprising a GSL2 gene; does not express                biologically functional paramylon; has                underdeveloped chloroplasts or no chloroplasts, as                compared to a wild-type Euglenaorganism of a same                species; does not comprise a chloroplast genome or                comprises a chloroplasts genome; provides an amino                acid profile with increased amounts of aspartic                acid, glutamic acid, serine, histidine, glycine,                threonine, tyrosine, methionine, phenylalanine,                leucine, lysine, and/or total amino acids, as                compared to a wild type Euglenaorganism of a same                species; provides a fatty acid profile with                increased amounts of myristic acid, palmitic acid,                stearic acid, oleic acid, and/or linolenic acid, as                compared to a wild-type Euglenaorganism of a same                species; and is non-transgenic, and is resistant to                hygromycin.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1)                altering (M1) a trait in a Euglenaorganism,                comprising (a) providing a ribonucleoprotein (RNP)                complex comprising a guide RNA having                complementarity to an endogenous gene of a                Euglenaorganism and a clustered regularly                interspaced short palindromic repeat                (CRISPR)-CRISPR-associated protein (Cas)-related                nuclease, (b) introducing the RNP complex into a                Euglenaorganism to effect a genetic alteration, and                (c) selecting for the genetic alteration in the                organism, where the organism comprises the genetic                alteration and a property comprising reduced                carbohydrate content, increased protein content,                increased lipid content, altered amino acid                profile, altered fatty acid profile and/or reduced                or underdeveloped chloroplasts, as compared to a                wild-type Euglenaorganism of a same species; (2)                expressing (M2) a heterologous nucleic acid                molecule in a target genome insertion site of a                Euglena organism, comprising the step (a) as per                se, providing a single-stranded                oligodeoxynucleotide (ssODN), where the ssODN                comprises a first homology arm, a heterologous                nucleic acid molecule, and a second homology arm,                where the first and second homology arms have                complementarity to regions flanking the target                genome insertion site, and introducing the RNP                complex and the ssODN into a Euglenaorganism, where                the heterologous nucleic acid molecule is inserted                into the target genome insertion site and is                expressed; (3) a composition comprising an ssODN                comprising a first homology arm, a heterologous                nucleic acid molecule and a second homology arm,                where the first and second homology arms have                complementarity to regions flanking the target                genome insertion site, and a guide RNA having                complementarity to an endogenous gene of a                Euglenaorganism, and a CRISPR Cas-related nuclease,                where the Cas-related nuclease cleaves the target                genome insertion site, and the nucleic acid                molecule encoding the heterologous nucleic acid                molecule is inserted into the target genome                insertion site; (4) expressing (M3) a heterologous                nucleic acid molecule in a Euglena gracilisstrain                Z, line B2 organism, comprising transforming a                Euglena gracilisstrain Z, line B2 organism with a                DNA vector comprising a heterologous nucleic acid                molecule, a promoter operably linked to the                heterologous nucleic acid molecule, and a                selectable marker, where the transforming expresses                the heterologous nucleic acid molecule in the                organism; and (5) producing (M4) proteins, lipids,                amino acids and/or fatty acids, comprising                culturing an Euglenaorganism that does not express                a biologically functional GSL2 protein in a medium                and harvesting the proteins, lipids, amino acids,                and/or fatty acids. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  D23 (Oils, fats and waxes - including fatty acids, essential oils, but excluding butter (substitutes) and montan wax (C11B, C).)",B04-E02E;  B04-E03E;  B04-E08;  B04-E12;  B04-E13;  B04-E99;  B04-F08A;  B04-L05A2;  B10-B02;  B10-C04E;  D05-H12A;  D05-H19C;  D05-H99,C12N-001/12;  C12N-001/13;  C12N-015/09;  C12N-015/10;  C12N-015/113;  C12N-015/31;  C12N-015/63;  C12N-015/90;  C12N-009/22;  C12P-021/00,WO2022189976-A1   15 Sep 2022   C12N-001/12   202279Pages: 145   English,WO2022189976-A1    WOIB052064    08 Mar 2022,,US158033P    08 Mar 2021,WO2022189976-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2022189976-A1 -- JP2021010344-A   EUGLENA CO LTD (EUGL-Non-standard);  RIKEN (RIKE)   YAMADA Y,  IWATA O,  SUZUKI K,  NOMURA T,  INOUE K,  UEHARA Y,  MOCHIDA K","WO2022189976-A1  NOMURA TOSHIHISA,          INOUE KOMAKI, UEHARAYAMAGUCHI YUKIKO, YAMADA KOJI, IWATA          OSAMU, SUZUKI KENGO, MOCHIDA KEIICHI: ""Highly efficient          transgenefree targeted mutagenesis and singlestranded          oligodeoxynucleotidemediated precise knockin in the          industrial microalga Euglena gracilis using Cas9          ribonucleoproteins"", PLANT BIOTECHNOLOGY JOURNAL,          BLACKWELL PUB., GB, vol. 17, no. 11, 1 November 2019          (2019-11-01), GB , pages 2032 - 2034, XP055970242, ISSN:          1467-7644, DOI:          10.1111/pbi.13174,relevantClaims[1-23,26-38,          56(2)-66],relevantPassages[* the whole document          *];  TANAKA, Y ET AL.:          ""Glucan synthase-like 2 is indispensable for paramylon          synthesis in Euglena gracilis"", FEBS LETT., vol. 591, no.          10, 7 May 2017 (2017-05-07), pages 1360 - 1370,          XP071256084, ISSN: 1873-3468,relevantClaims[1-23, 26-38,          56(2)-66];  GISSIBL, A ET AL.:          ""Bioproducts From Euglena gracilis: Synthesis and          Applications"", FRONT BIOENG BIOTECHNOL., vol. 7, no. 108,          15 May 2019 (2019-05-15), XP055779735, ISSN: 2296- 4185,          Retrieved from the Internet          &lt;URL:https://www.frontiersin.org/articles/10.3389/fbioe.2019.00108/full&gt;          [retrieved on 20220527], DOI:          10.3389/fbioe.2019.00108,relevantClaims[56(2)-66]",2418795-0-0-0 M N; 96195-1-0-0 M N; 184599-0-0-0 K P; 184624-0-0-0 K P; 1013819-0-0-0 K P; 2418795-0-0-0 CL NEW USE; 96195-1-0-0 CL NEW USE; 1013819-0-0-0 CL PRD,,,RBAAY7 M N; RA01SW M N; RA01IK K P; RA04V6 K P; R90209 K P,
WO2023274340-A1;  TW202317642-A;  CA3225629-A1;  AU2022303977-A1;  CN117616042-A;  KR2024038716-A;  EP4363445-A1,"New isolated antibody or an antigen binding            fragment thereof that specifically binds to MASP-2,            comprising specified sequence useful for treating e.g.            autoimmune disease, ischemia-reperfusion injury, and            atherosclerosis",QIAN X;  LI H;  GU Y;  TENG F;  SUN D;  XUEMING Q;  ROAST;  SUNDAE,SUZHOU TRANSCENTA THERAPEUTICS CO LTD (SUZH-Non-standard);  SUZHOU TRANSCENTA THERAPEUTICS CO LTD (SUZH-Non-standard);  SUZHOU TRANSCENTA THERAPEUTICS CO LTD (SUZH-Non-standard);  SUZHOU TRANSCENTA THERAPEUTICS CO LTD (SUZH-Non-standard);  SUZHOU TRANSCENTA THERAPEUTICS CO LTD (SUZH-Non-standard),2023027232,"   NOVELTY - Isolated antibody or an antigen binding                fragment of it that specifically binds to MASP-2,                comprising (a) a heavy chain CDR1 comprising the                amino acid sequence of Asp-Tyr-Tyr-Ile-Asn (SEQ ID                NO: 1), a heavy chain CDR2 comprising the amino                acid sequence of SEQ ID NO: 2 (comprising a fully                defined sequence of 17 amino acids as given in the                specification), and a heavy chain CDR3 comprising                the amino acid sequence of                Gly-Asp-Arg-Ser-Gly-Pro-Phe-Xaa-Tyr (SEQ ID NO: 3);                and/or b) a light chain CDR1 comprising the amino                acid sequence of SEQ ID NO: 4 (comprising a fully                defined sequence of 16 amino acids as given in the                specification), a light chain CDR2 comprising the                amino acid sequence of Leu-Val-Ser-Lys-Leu-Asp-Ser                (SEQ ID NO: 5), and a light chain CDR3 comprising                the amino acid sequence of                Val-Gln-Xaa-Thr-His-Phe-Pro-Phe-Thr (SEQ ID NO: 6)                is new.    USE - The antibody is used for treating disease or                condition i.e. autoimmune disease, vascular                condition, ischemia-reperfusion injury,                atherosclerosis, inflammation, pulmonary condition,                extracorporeal reperfusion procedure,                musculoskeletal condition, renal condition, skin                condition, organ or tissue transplant procedure,                nervous system disorder or injury, blood disorder,                urogenital condition, nonobese diabetes or a                complication associated with Type 1 or Type 2                diabetes, cancer, endocrine disorder, or                ophthalmologic condition, thrombotic                microangiopathies (TMAs), atypical hemolytic uremic                syndrome (aHUS), hematopoietic                transplant-associated thrombotic microangiopathy                (TA-TMA), lupus nephritis, systemic lupus                erythematosus (SLE) and IgA nephropathy, the                vascular condition includes a cardiovascular                condition, a cerebrovascular condition, a                peripheral (e.g. musculoskeletal) vascular                condition, a renovascular condition, a                mesenteric/enteric vascular condition,                revascularization to transplants and/or replants,                vasculitis, Henoch-Schonlein purpura nephritis,                systemic lupus erythematosus-associated vasculitis,                vasculitis associated with rheumatoid arthritis,                immune complex vasculitis, Takayasu's disease,                dilated cardiomyopathy, diabetic angiopathy,                Kawasaki's disease (arteritis),venous gas embolus                (VGE) , and restenosis following stent placement,                rotational atherectomy and percutaneous                transluminal coronary angioplasty (PTCA), the                ischemia-reperfusion injury included an                ischemia-reperfusion injury associated with aortic                aneurysm repair, cardiopulmonary bypass, vascular                reanastomosis in connection with organ transplants                and/or extremity/digit replantation, stroke,                myocardial infarction, and hemodynamic                resuscitation following shock and/or surgical                procedures (all claimed). No biological data                given.    ADVANTAGE - The antibody shows improved efficacy against                disease and condition.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    an isolated antibody or an antigen binding                fragment that specifically binds to MASP-2,                comprising: a) a heavy chain CDR1 comprising the                amino acid sequence of SEQ ID NO: 1, a heavy chain                CDR2 comprising the amino acid sequence of SEQ ID                NO : 7, and a heavy chain CDR3 comprising the amino                acid sequence of SEQ ID NO: 11, or (b) a heavy                chain CDR1 comprising the amino acid sequence of                SEQ ID NO: 1, a heavy chain CDR2 comprising the                amino acid sequence of SEQ ID NO: 9, and a heavy                chain CDR3 comprising the amino acid sequence of                SEQ ID NO: 12, or (c) a heavy chain CDR1 comprising                the amino acid sequence of SEQ ID NO: 1, a heavy                chain CDR2 comprising the amino acid sequence of                SEQ ID NO: 10, and a heavy chain CDR3 comprising                the amino acid sequence of SEQ ID NO: 11, or (d) a                heavy chain CDR1 comprising the amino acid sequence                of SEQ ID NO: 1;    antibody or antigen binding fragment                comprising (a) a heavy chain CDR1 comprising the                amino acid sequence of SEQ ID NO: 1, a heavy chain                CDR2 comprising the amino acid sequence of SEQ ID                NO: 7, and a heavy chain CDR3 comprising the amino                acid sequence of SEQ ID NO: 11, a light chain CDR1                comprising the amino acid sequence of SEQ ID NO: 4,                a light chain CDR2 comprising the amino acid                sequence of SEQ ID NO: 5, and a light chain CDR3                comprising the amino acid sequence of SEQ ID NO:                13, or b) a heavy chain CDR1 comprising the amino                acid sequence of SEQ ID NO: 1, a heavy chain CDR2                comprising the amino acid sequence of SEQ ID NO: 9,                and a heavy chain CDR3 comprising the amino acid                sequence of SEQ ID NO: 12, a light chain CDR1                comprising the amino acid sequence of SEQ ID NO: 4,                a light chain CDR2 comprising the amino acid                sequence of SEQ ID NO: 5, and a light chain CDR3                comprising the amino acid sequence of SEQ ID NO:                13, or (c) a heavy chain CDR1 comprising the amino                acid sequence of SEQ ID NO: 1, a heavy chain CDR2                comprising the amino acid sequence of SEQ ID NO:                10, and a heavy chain CDR3 comprising the amino                acid sequence of SEQ ID NO: 11, a light chain CDR1                comprising the amino acid sequence of SEQ ID NO: 4,                a light chain CDR2 comprising the amino acid                sequence of SEQ ID NO: 5, and a light chain CDR3                comprising the amino acid sequence of SEQ ID NO:                14, or (d) a heavy chain CDR1 comprising the amino                acid sequence of SEQ ID NO: 1, a heavy chain CDR2                comprising the amino acid sequence of SEQ ID NO: 8,                and a heavy chain CDR3 comprising the amino acid                sequence of SEQ ID NO: 11;    a monoclonal antibody or an antigen binding                fragment which competes for binding to MASP-2 with                the antibody or antigen binding fragment;    composition comprising the antibody or antigen                binding fragment and a carrier;    an isolated polynucleotide encoding the                antibody or antigen binding fragment;    a vector comprising the isolated                polynucleotide;    a host cell comprising the vector;    expressing the antibody or antigen binding                fragment, comprising culturing the host cell under                the condition at which the polynucleotide is                expressed;    inhibiting MASP-2 dependent complement                activation in a subject, comprising administering                to the subject a antibody or antigen binding or the                composition, thus inhibiting MASP-2 dependent                complement activation in the subject;    treating a disease or condition in a subject                that would benefit from inhibition of MASP-2                dependent complement activation, comprising                administering an antibody or antigen binding                fragment or the composition;    reducing level of serum C4 in a subject,                comprising administering an antibody or antigen                binding fragment or the composition;    treating a disease or condition in a subject                that would benefit from reduction of serum C4                level, or treating or preventing a condition or a                disease associated with abnormal serum C4 level,                comprising administering to the subject the                antibody or the composition; and    a kit comprising the antibody or antigen                binding fragment ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).);  A96 (Medical, dental, veterinary, cosmetic.)",B04-C01D;  B04-C01G;  B04-E08;  B04-E99;  B04-G01;  B14-C03;  B14-D01;  B14-F01;  B14-F02;  B14-F04;  B14-F05;  B14-F07;  B14-F08;  B14-G02D;  B14-G03;  B14-H01D;  B14-J01;  B14-N01;  B14-N07;  B14-N10;  B14-N16;  B14-N17;  B14-S04;  B14-S05;  C04-C01D;  C04-C01G;  C04-E08;  C04-E99;  C04-G01;  C14-C03;  C14-D01;  C14-F01;  C14-F02;  C14-F04;  C14-F05;  C14-F07;  C14-F08;  C14-G02D;  C14-G03;  C14-H01D;  C14-J01;  C14-N01;  C14-N07;  C14-N10;  C14-N16;  C14-N17;  C14-S04;  C14-S05;  D05-H11;  D05-H99;  D09-C01;  A12-V01,A61K-039/395;  A61P-037/00;  C07K-016/18;  C07K-016/40;  C12N-015/13;  A61K-039/00,WO2023274340-A1   05 Jan 2023   C07K-016/18   202308Pages: 101   English;  TW202317642-A   01 May 2023   C07K-016/40   202353   Chinese;  CA3225629-A1   05 Jan 2023   C07K-016/18   202406   English;  AU2022303977-A1   15 Feb 2024   C07K-016/18   202416   English;  CN117616042-A   27 Feb 2024   C07K-016/18   202419   Chinese;  KR2024038716-A   25 Mar 2024   C07K-016/40   202431   ;  EP4363445-A1   08 May 2024   C07K-016/18   202439   English,WO2023274340-A1    WOCN102611    30 Jun 2022;   TW202317642-A    TW124618    30 Jun 2022;   CA3225629-A1    CA3225629    30 Jun 2022;   AU2022303977-A1    AU303977    30 Jun 2022;   CN117616042-A    CN80046509    30 Jun 2022;   KR2024038716-A    KR703229    30 Jun 2022;   EP4363445-A1    EP832152    30 Jun 2022,CA3225629-A1 PCT application Application WOCN102611;   AU2022303977-A1 PCT application Application WOCN102611;   AU2022303977-A1 Based on Patent WO2023274340;   CN117616042-A PCT application Application WOCN102611;   CN117616042-A Based on Patent WO2023274340;   KR2024038716-A PCT application Application WOCN102611;   KR2024038716-A Based on Patent WO2023274340;   EP4363445-A1 PCT application Application WOCN102611;   EP4363445-A1 Based on Patent WO2023274340,WOCN103715    30 Jun 2021;  CA3225629    28 Dec 2023;  CN80046509    28 Dec 2023;  KR703229    26 Jan 2024,WO2023274340-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA            EP4363445-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN  ,,"WO2023274340-A1 -- AU2011218753-A1   MADISON E L (MADI-Individual);  NGUYEN J (NGUY-Individual);  RUGGLES S W (RUGG-Individual);  THANOS C (THAN-Individual)   MADISON E L,  NGUYEN J,  RUGGLES S W,  THANOS C;  AU2013201565-A1   OMEROS CORP (OMRS);  UNIV LEICESTER (CEST)   SCHWAEBLE H,  STOVER C M,  TEDFORD C E,  PARENT J B,  FUJITA T;  AU2015271989-A1   OMEROS CORP (OMRS);  UNIV LEICESTER (CEST)   DEMOPULOS G A,  DUDLER T,  SCHWAEBLE H;  CN1878862-A   NATLMMUNE AS (NATL-Non-standard)   HARMAT V,  GAL P,  ZAVODSKY P,  AMBRUS G;  CN111171147-A   BEIJING KANGPUMEITE INNOVATIVE PHARM (BEIJ-Non-standard)   TANG X,  DU L;  WO2004106384-A1   NATLMMUNE AS (NATL-Non-standard)   LARSEN F,  WAHLERS U","WO2023274340-A1  LAFAYETTE RICHARD          A., ROVIN BRAD H., REICH HEATHER N., TUMLIN JAMES A.,          FLOEGE JUeRGEN, BARRATT JONATHAN: ""Safety, Tolerability          and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for          the Treatment of IgA Nephropathy"", KIDNEY INTERNATIONAL          REPORTS, ELSEVIER INC., US, vol. 5, no. 11, 1 November          2020 (2020-11-01), US , pages 2032 - 2041, XP093013054,          ISSN: 2468-0249, DOI:          10.1016/j.ekir.2020.08.003,relevantClaims[1-38],relevantPassages[pages          2032-2041];  CLARKJ.E.ET AL.:          ""Cardioprotection by an anti-MASP-2 antibody in a murine          model of myocardial infarction"", OPEN HEART, vol. 5, 9          January 2018 (2018-01-09), XP055774335, DOI:          10.1136/openhrt-2017-000652,relevantClaims[1-38],relevantPassages[article          No. e000652]",184587-0-0-0 N,,,RA00C8 N,
WO2021216954-A1,"Inhibiting uptake of RGD and/or RLD-dependent virus into cell, comprises contacting cell with integrin antagonist that binds integrin and inhibits uptake of RGD and/or RLD-dependent virus into cell",CHERESH D;  WEIS S;  MCCORMACK S;  ROGERS T;  VON SCHALCHA T,ALPHA BETA HOLDINGS LLC (ALPH-Non-standard),2021C12146,"   NOVELTY - Inhibiting (M1) uptake of RGD and/or RLD-dependent virus into a cell, comprises contacting the cell with an integrin antagonist that binds integrin and inhibits uptake of RGD and/or RLD-dependent virus into a cell.    USE - The methods are useful for: inhibiting uptake of RGD and/or RLD-dependent virus into a cell; and treating, inhibiting the severity of, or preventing RGD and/or RLD dependent virus infection in a subject, where the subject has a condition that increases integrin expression, has tissue injury or tissue inflammation, has systemic or local inflammation, preferably lung inflammation, has tested positive for an RGD and/or RLD-dependent virus infection, has or may have been exposed to RGD and/or RLD-dependent virus or will potentially be exposed to RGD and/or RLD-dependent virus and the subject is human. The RGD and/or RLD-dependent virus is a coronavirus, adenovirus, human cytomegalovirus, Kaposi's sarcoma-associated herpesvirus, Epstein-Barr virus, HIV-1, foot and mouth disease virus, coxsackievirus A9, vaccinia virus, West Nile virus, Japanese encephalitis virus, Tick-borne encephalitis virus, Yellow fever virus, Dengue fever virus, simian virus 40, Ross River virus, human papillomavirus, Zika virus, or Ebola virus. The coronavirus is severe acute respiratory syndrome (SARS) coronavirus (CoV)-2, SARS-CoV, or Middle east respiratory syndrome (MERS)-CoV (all claimed). Test details are described but no results given.    ADVANTAGE - The method inhibits uptake of virus by at least 50%, preferably 99%.    DETAILED DESCRIPTION - Inhibiting (M1) uptake of Arg-Gly-Asp (RGD) and/or Arg-Leu-Asp (RLD) dependent virus into a cell, comprises contacting the cell with an integrin antagonist that binds integrin and inhibits uptake of Arg-Gly-Asp and/or Arg-Leu-Asp dependent virus into a cell. INDEPENDENT CLAIMS are also included for:    (1) treating (M2), inhibiting the severity of, or preventing RGD and/or RLD dependent virus infection in a subject, comprising administering the integrin antagonist;    (2) treating (M3), inhibiting the severity of, or preventing an RGD and/or RLD dependent virus infection in a subject, comprising (a) identifying a subject that has a condition that increases integrin expression, and (b) if the subject has a condition that increases integrin expression, administering the integrin antagonist;    (3) an integrin antagonist that binds integrin and inhibits uptake of RGD and/or RLD dependent virus into a cell;    (4) a polynucleotide encoding the integrin antagonist;    (5) a vector comprising the polynucleotide;    (6) a host cell comprising the polynucleotide or the vector;    (7) a composition comprising the integrin antagonist and a carrier; and    (8) a kit comprising the integrin antagonist. ",,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  C02 (Heterocyclic.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B02-P02;  B02-P03;  B04-A05;  B04-B03D;  B04-B03E;  B04-C01;  B04-E02A;  B04-E02F;  B04-E03A;  B04-E03F;  B04-E08;  B04-E99;  B04-F0100E;  B04-G01A;  B04-G01B;  B04-G01C;  B04-G04;  B04-G21;  B04-G23;  B04-G24;  B04-G27G;  B06-H;  B06-S;  B07-H;  B10-A17;  B10-B02F;  B10-E02;  B10-G02;  B14-A02B;  B14-C03;  B14-K01;  B14-L06;  B14-N17B;  B14-S11A;  B14-S18;  C02-P02;  C02-P03;  C04-A05;  C04-B03D;  C04-B03E;  C04-C01;  C04-E02A;  C04-E02F;  C04-E03A;  C04-E03F;  C04-E08;  C04-E99;  C04-F01;  C04-G01;  C04-G01B;  C04-G01C;  C04-G04;  C04-G21;  C04-G23;  C04-G24;  C04-G27G;  C06-H;  C06-S;  C07-H;  C10-A17;  C10-B02F;  C10-E02;  C10-G02;  C14-A02B;  C14-C03;  C14-K01;  C14-L06;  C14-N17B;  C14-S11A;  C14-S18;  D05-H12A;  D05-H12E;  D05-H14;  D05-H99,C07K-016/28;  C07K-016/40;  A61P-031/14;  A61K-039/00,WO2021216954-A1   28 Oct 2021   202193Pages: 78   English,WO2021216954-A1    WOUS028772    23 Apr 2021,,US014658P    23 Apr 2020;  US023140P    11 May 2020,WO2021216954-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,WO2021216954-A1 -- WO2007048127-A2   SCRIPPS RES INST (SCRI)   BARBAS C F,"WO2021216954-A1  HUSSEIN HOSNI A. M.; WALKER LIA R.; ABDEL-RAOUF USAMA M.; DESOUKY SAYED A.; MONTASSER ABDEL KHALEK M.; AKULA SHAW M.: ""Beyond RGD: virus interactions with integrins"", ARCHIVES OF VIROLOGY, SPRINGER WIEN, AT, vol. 160, no. 11, 1 September 2015 (2015-09-01), AT , pages 2669 - 2681, XP037066974, ISSN: 0304-8608, DOI: 10.1007/s00705-015-2579-8,relevantClaims[1-2,59-68],relevantPassages[page 2671, 2673-2675, table 2];  SIGRIST CHRISTIAN JA; BRIDGE ALAN; LE MERCIER PHILIPPE: ""A potential role for integrins in host cell entry by SARS-CoV-2"", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 177, 1 March 2020 (2020-03-01), NL , XP086133689, ISSN: 0166-3542, DOI: 10.1016/j.antiviral.2020.104759,relevantClaims[1-2,59-68],relevantPassages[the whole document];  WILLIAMS CIGDEM H., KAJANDER TOMMI, HYYPIA TIMO, JACKSON TERRY, SHEPPARD DEAN, STANWAY GLYN: ""Integrin v 6 Is an RGD-Dependent Receptor for Coxsackievirus A9"", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 78, no. 13, 1 July 2004 (2004-07-01), US , pages 6967 - 6973, XP055860781, ISSN: 0022-538X, DOI: 10.1128/JVI.78.13.6967-6973.2004,relevantClaims[1-2,59-68],relevantPassages[the whole document]",184611-0-0-0 K M;  K M;  K M; 821770-0-0-0 K M; 729624-0-0-0 K M; 2629613-1-0-0 K M;  K M; 324656-0-0-0 K M; 1182837-0-0-0 K M; 161989-1-0-0 K M; 86228-1-0-0 K M; 1372378-0-0-0 K M; 241868-1-0-0 K M; 160569-1-0-0 K M; 95660-1-0-0 K M; 182803-1-0-0 K M; 96855-1-0-0 K M; 82569-2-0-0 K M; 89192-0-0-0 K M; 95827-0-0-0 K M; 101574-0-0-0 K M; 91887-1-0-0 K M; 108335-0-0-0 K M; 96854-1-0-0 K M; 102185-0-0-0 K M; 6763-0-0-0 K M; 86344-1-0-0 K M; 85145-2-0-0 K M; 93420-1-0-0 K M; 87595-1-0-0 K M; 142011-0-0-0 K M; 105478-1-0-0 K M; 97700-1-0-0 K M; 12572-0-0-0 K M; 125313-1-0-0 K M; 98405-1-0-0 K M; 108041-0-0-0 K M; 88183-0-0-0 K M; 88707-2-0-0 K M; 90334-1-0-0 K M; 451479-13-0-0 K M; 1771662-0-0-0 K M; 87594-1-0-0 K M; 101791-1-0-0 K M; 100070-0-0-0 K M;  K M; 94825-1-0-0 K M;  K M; 103980-1-0-0 K M;  K M;  K M,,61435; 01260; 00133; 00998; 04757; 00096; 53817; 57428,RA00H1 K M; RD4BIG K M; RD4BIH K M; RAEA5Y K M; RAPAME K M; RBEZ9W K M; RCY57N K M; RAWGDO K M; RAX90F K M; RB7QK5 K M; RA17MV K M; RA02DL K M; RAUJEG K M; RAV3CA K M; RBFWMG K M; RBFXKS K M; RA01FU K M; RA1HN4 K M; RA1C6R K M; R01318 K M; R10974 K M; R04483 K M; R08508 K M; RA1YQP K M; R21736 K M; RA03DJ K M; R01319 K M; RA1DKG K M; R03812 K M; RANQ6B K M; R01179 K M; R07001 K M; RA393S K M; RAE1RB K M; R02034 K M; R06894 K M; R02011 K M; RA0RN6 K M; R12629 K M; R12996 K M; R09259 K M; R00222 K M; R09263 K M; R09524 K M; RAFZ5K K M; RAWPAL K M; R18372 K M; RBHX0C K M; RA0A97 K M; RA2PQU K M; RD4BII K M; RB9HI6 K M; RD4BIJ K M; RA0VGS K M; RD4BIE K M; RD4BIF K M,1318-S; 1319-S; 1179-S; 2034-S; 2011-S; 0222-S
WO2021188166-A1;  US2023276793-A1,"Removing and inactivating bacteria in a            cell-suspension, liquid, biofilm, and/or on a surface,            comprises applying nanobubbles to the surface to            deliver antimicrobial compounds to the bacteria",OVISSIPOUR R;  SHIROODI S;  SCHWARZ M H,VIRGINIA TECH INTELLECTUAL PROPERTIES (VIRG-C);  OVISSIPOUR R (OVIS-Individual);  SHIROODI S (SHIR-Individual);  SCHWARZ M H (SCHW-Individual);  VIRGINIA TECH INTELLECTUAL PROPERTIES (VIRG-C),2021B5990W,"   NOVELTY - Developing of engineered nanobubbles involves                exposing a substrate to a composition comprising                gas bubbles at a concentration and for a length of                time sufficient to reduce, interfere with,                alleviate, remove, and/or prevent growth and/or                presence of one or microbe(s) or biofilm on the                substrate.    USE - Developing engineered nanobubbles. Uses                include but are not limited to medical device                sanitation, wound cleaning, dental hygiene, food                and agriculture industry, food facilities,                aquaculture farms, aquaponics, hydroponics, and                organic foods industry.    ADVANTAGE - The nanobubbles have negative surface charges                which can reduce surface tension, release reactive                oxygen species, and facilitate surface modification                to carry antimicrobial compounds. The bubbles                attack and disrupt microbial biofilms, induce                oxidative stress, and reduces surface tension which                enhance biofilm removal from surfaces.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) disinfecting one or more microbe(s);    (2) bacterial reduction;    (3) substrate treated with nanobubbles/nanogas                and/or ultrafine bubbles;    (4) substrate resistant to one or more                microbe(s); and    (5) substrate containing reduced amount of one                or more microbe(s). ",,,"D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).);  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  ;  A96 (Medical, dental, veterinary, cosmetic.);  P34 (Sterilising, syringes, electrotherapy (A61L, M, N).)",D05-A03A;  A04-C02E;  A04-C03;  A04-E02E;  A04-E08;  A04-G03E;  A05-E04E;  A05-E06B;  A05-F01E;  A05-F01E3;  A05-G01E;  A10-E09;  A12-V03A;  A12-V03C1;  A12-V03D;  A12-W04;  A12-W14;  P34-A01,A61L-015/24;  A61L-015/34;  A61L-015/42;  A01N-025/22;  A01N-025/34;  A01N-059/00,WO2021188166-A1   23 Sep 2021   A61L-015/24   202184Pages: 76   English;  US2023276793-A1   07 Sep 2023   A01N-025/34   202374   English,WO2021188166-A1    WOUS063059    03 Dec 2020;   US2023276793-A1    US17912460    16 Sep 2022,US2023276793-A1 Provisional Application US027164P;   US2023276793-A1 Provisional Application US991539P;   US2023276793-A1 PCT application Application WOUS063059,US991539P    18 Mar 2020;  US027164P    19 May 2020;  US17912460    16 Sep 2022,WO2021188166-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,WO2021188166-A1 -- US20030164306-A1   ;  US20090233839-A1   ;  US20120270177-A1   ;  US20190059420-A1   ;  US20190232238-A1   ,,92818-0-0-0 ; 107779-0-0-0 ; 129503-0-0-0 ; 8781-0-0-0 ; 1911-0-0-0 ; 3112-0-0-0 ; 129474-0-0-0 ; 131134-0-0-0 ; 104328-1-0-0 ; 444-0-0-0 ; 368-0-0-0 ; 395-0-0-0 ; 129411-0-0-0 ; 1013-0-0-0 ; 621-0-0-0 ; 1145-0-0-0 ; 104333-0-0-0 ,,,R01857 ; R01863 ; R00114 ; R00444 ; R00446 ; R00901 ; R00709 ; R08306 ; R03882 ; R00351 ; R00708 ; R00817 ; R00806 ; R00326 ; R00338 ; R00964 ; R00975 ,
WO2023160672-A1;  US2023322675-A1;  TW202342017-A;  US11884627-B2,"New bicyclyl heterocyclic carboxylic acid            derivatives are lysophosphatidic acid antagonists used            to treat e.g. fibrosis e.g. pulmonary fibrosis,            transplant rejection, cancer e.g. bone cancer,            osteoporosis and inflammatory disorder",HUANG W;  LEI H;  XU Z;  ZHANG H;  ZHANG Q,LHOTSE BIO INC (LHOT-Non-standard);  HUANG W (HUAN-Individual);  LHOTSE BIO INC (LHOT-Non-standard),202390624J,"   NOVELTY - Bicyclyl heterocyclic carboxylic acid                derivatives (I) are new.    USE - (I) are useful for treating LPA associated                disease, disorder, or condition, where the                LPA-associated disease, disorder, or condition is a                LPA1-associated disease, fibrosis, transplant                rejection, cancer, osteoporosis, or an inflammatory                disorder, the fibrosis is pulmonary fibrosis, liver                fibrosis, renal fibrosis, cardiac fibrosis, dermal                fibrosis, ocular fibrosis, or pancreatic fibrosis,                the cancer is of the bladder, blood, bone, brain,                breast, central nervous system, cervix, colon,                endometrium, esophagus, gall bladder, genitalia,                genitourinary tract, head, kidney, larynx, liver,                lung, muscle tissue, neck, oral mucosa, nasal                mucosa, ovary, pancreas, prostate, skin, spleen,                small intestine, large intestine, stomach,                testicle, or thyroid and the LPA-associated                disease, disorder, or condition, is idiopathic                pulmonary fibrosis (IPF), non-alcoholic                steatohepatitis (NASH), non-alcoholic fatty liver                disease (NAFLD), chronic kidney disease, diabetic                kidney disease, systemic sclerosis, coronavirus                disease (COVID-19), chronic obstructive pulmonary                disease (COPD), neuroinflammation, or multiple                sclerosis (all claimed).    ADVANTAGE - (I): are safety or tolerance dosage in human                or non-human subjects; and exhibit improved drug                metabolism and pharmacokinetics properties.    DETAILED DESCRIPTION - Bicyclyl heterocyclic carboxylic acid                derivatives of formula (I) and their salts,                stereoisomers, mixture of stereoisomers, tautomers,                isotopically enriched analogs, or solvates are                new.    A1=1-6C alkyl, 3-10C cycloalkyl, heterocyclyl,                aryl, or heteroaryl (all optionally substituted by                1-5 Z1;    L1=bond, -O-, -S-, -S(O)-, -S(O) -, -NR10-,                1-3C alkylene, 2-3C alkenylene, 2-3C alkynylene, or                1-3C heteroalkylene (all optionally substituted by                1-5 1-9C alkyl, halo, OH or CN);    L2=bond, 1-3C alkylene, 2-3C alkenylene, 2-3C                alkynylene, or 1-3C heteroalkylene (all optionally                substituted by 1-5 1-9C alkyl, halo, OH or                CN);    X1=N or CR3;    X2=N or CR5;    X3=N or CR7;    X4=O or CHR11;    X6=N or CR6;    n=0-2;    m=0-3; either    R1, R2=H, 1-9C alkyl, 2-9C alkenyl, 2-9C                alkynyl, 3-10C cycloalkyl, or heterocyclyl (all                optionally substituted by 1-5 Z1); or    R1R2=3-10C cycloalkyl or heterocyclyl (all                optionally substituted by 1-5 Z1); either    R3=H, halo, CN, nitro, -OH, -SH, -NH 2,                -NH-1-5C alkyl, -N(1-5C alkyl) , -S-1-5C alkyl,                1-5C alkoxy, 1-5C alkyl, 2-5C alkenyl, 2-5C                alkynyl, 3-5C cycloalkyl, or 3-5 membered                heterocyclyl (all optionally substituted by 1-5                halo, OH or CN);    R4=1-5C alkyl, 2-5C alkenyl, 2-5C alkynyl,                3-5C cycloalkyl, or 3-5 membered heterocyclyl (all                optionally substituted by 1-5 halo, OH, 1-5C alkoxy                or CN), halo, CN, nitro, -OR14, -N(R14) or -SR14;                or    R3R4=cycloalkyl, aryl, heterocyclyl or                heteroaryl (all optionally substituted by 1-5 halo,                OH or CN);    R5=1-5C alkyl, 2-5C alkenyl, 2-5C alkynyl,                3-5C cycloalkyl, 3-5 membered heterocyclyl or 5                membered heteroaryl (all optionally substituted by                1-5 Z1), H, halo, CN, nitro, -OR15, -N(R15) ,                -SR15, -C(O)R15 or -C(O)OR15; either    R6=1-5C alkyl, 2-5C alkenyl, 2-5C alkynyl,                3-5C cycloalkyl, or 3-5 membered heterocyclyl (all                optionally substituted by 1-5 halo, OH or CN), H,                halo, CN, nitro, -OR16, -N(R16) or -SR16;    R7=-NH-1-5C alkyl, -N(1-5C alkyl) , -S-1-5C                alkyl, 1-5C alkoxy, 1-5C alkyl, 2-5C alkenyl, 2-5C                alkynyl, 3-5C cycloalkyl or 3-5 membered                heterocyclyl (all optionally substituted by 1-5                halo, OH or CN), H, halo, CN, nitro, -OH, -SH, -NH                ; or    R6R 7=cycloalkyl, aryl, heterocyclyl, or                heteroaryl (all optionally substituted by 1-5 halo,                OH or CN);    R8=H, 1-9C alkyl, oxo, halo, OH or CN;    R9=H, 1-9C alkyl, oxo, halo, OH or CN;    R10=H or 1-5C alkyl, 2-5C alkenyl, 2-5C                alkynyl, 3-5C cycloalkyl, or 3-5 membered                heterocyclyl (all optionally substituted by 1-5                halo, OH or CN);    R11=H, 1-9C alkyl, oxo, halo, OH or CN;    R13=H, halo, CN, nitro, -OH, -SH, -NH ,                -NH-1-9C alkyl, -N(1-9C alkyl) , -S-1-9C alkyl,                1-9C alkoxy, 1-9C alkyl, 2-9C alkenyl, 2-9C                alkynyl, 3-6C cycloalkyl, or 3 to 6-membered                heterocyclyl (all optionally substituted by 1-5                halo, OH or CN);    R14=H, 1-5C alkyl, 2-5C alkenyl, 2-5C alkynyl,                3-5C cycloalkyl, or 3-5 membered heterocyclyl (all                optionally substituted by 1-5 halo, OH or                CN);    R15=H, 1-5C alkyl, 2-5C alkenyl, 2-5C alkynyl,                3-5C cycloalkyl, or 3-5 membered heterocyclyl (all                optionally substituted by 1-5 halo, OH or                CN);    R16=H, 1-5C alkyl, 2-5C alkenyl, 2-5C alkynyl,                3-5C cycloalkyl, or 3-5 membered heterocyclyl (all                optionally substituted by 1-5 halo, OH or                CN);    Z1=halo, CN, nitro, oxo, 1-9C alkyl, 2-9C                alkenyl, 2-9C alkynyl, 3-10C cycloalkyl,                heterocyclyl, aryl, heteroaryl, -L1-H, -L1-1-9C                alkyl, -L1-2-9C alkenyl, -L1-2-9C alkynyl,                -L1-3-10C cycloalkyl, -L1-heterocyclyl, -L1-aryl or                -L1-heteroaryl (all optionally substituted by 1-5                Z1a);    L1=-O-, -S-, -NR20-, -C(O)-, -C(O)O-, -OC(O)-,                -OC(O)O-, -C(O)NR20-, -NR20C(O)-, -OC(O)NR20-,                -NR20C(O)O-, -NR20C(O)NR21-, -S(O)-, -S(O) -,                -S(O)NR20-, -S(O) NR20-, -NR20S(O)-, -NR20S(O) -,                -NR20S(O)NR21- or -NR20S(O) NR21-;    R20, R21=H, 1-9C alkyl, 2-9C alkenyl, 2-9C                alkynyl, 3-10C cycloalkyl, heterocyclyl, aryl, or                heteroaryl (all optionally substituted by 1-5 Z1a);                or    R20R21=heterocyclyl optionally substituted by                1-5 Z1a; and    Z1a=halo, OH, CN, nitro, oxo, -SH, -NH ,                -NH-1-9C alkyl, -N(1-9C alkyl) , -S-1-9C alkyl,                1-9C alkoxy, 1-9C alkyl, 2-9C alkenyl, 2-9C                alkynyl, 3-10C cycloalkyl, heterocyclyl, aryl or                heteroaryl (all optionally substituted by 1-5 1-9C                alkyl, oxo, halo, OH or CN.    Provided that when A1 is 1-6C alkyl, then X4                is O.     ",,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  B03 (Other heterocyclics.);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).)",B06-H;  B07-H;  B10-A08;  B10-A10;  B10-A11B;  B10-A12B;  B10-A12C;  B10-A13D;  B10-A15;  B10-B01;  B10-B01B;  B10-B02A;  B10-B02F;  B10-B02H;  B10-B02J;  B10-B03B;  B10-C04B;  B10-C04C;  B14-C03;  B14-G02C;  B14-K01;  B14-N01A;  B14-N10;  B14-N12;  B14-N17;  B14-S01;  D08-B09A,A61K-031/192;  A61K-031/196;  A61K-031/351;  A61K-031/36;  A61K-031/397;  A61K-031/4433;  A61P-011/00;  A61P-035/00;  A61P-037/00;  C07C-059/13;  C07D-205/04;  C07D-211/66;  C07D-213/65;  C07D-309/14;  C07D-317/50;  C07D-401/12;  C07D-405/12;  C07D-407/12;  C07C-229/18;  C07C-229/28;  C07C-061/39;  C07D-317/54;  C07D-317/58;  A61K-031/435;  A61K-031/495;  A61K-031/53,WO2023160672-A1   31 Aug 2023   A61P-011/00   202376Pages: 331   English;  US2023322675-A1   12 Oct 2023   C07D-211/66   202383   English;  TW202342017-A   01 Nov 2023   A61K-031/435   202402   Chinese;  US11884627-B2   30 Jan 2024   C07D-211/66   202410   English,WO2023160672-A1    WOCN078288    25 Feb 2023;   US2023322675-A1    US322492    23 May 2023;   TW202342017-A    TW107013    24 Feb 2023;   US11884627-B2    US322492    23 May 2023,US2023322675-A1 Cont of Application WOCN078288;   US11884627-B2 Cont of Application WOCN078288;   US11884627-B2 Previous Publ. Patent US2023322675,WOCN077844    25 Feb 2022;  WOCN094839    25 May 2022;  WOCN117690    08 Sep 2022,WO2023160672-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        ,,"WO2023160672-A1 -- EP3912975-A1   WUHAN LL SCI & TECHNOLOGY DEV CO LTD (WUHA-Non-standard);  WUHAN QR PHARM CO LTD (WUHA-Non-standard)   LOU J,  CHEN Y,  PENG W,  ZHANG Y,  GUO X,  LIU L,  LIU J,  QIAN L,  WANG C;  WO2019246109-A1   EPIGEN BIOSCI INC (EPIG-Non-standard)   BEATON G,  TUCCI F C,  RAVULA S B,  SHAH C R,  LEE S J;  WO2003026587-A2   BRISTOL-MYERS SQUIBB CO (BRIM)   PRIESTLEY E S,  DECICCO C P,  HUDYMA T W,  ZHENG X","WO2023160672-A1            FOSTER: ""Deuterium Isotope Effects in Studies of Drug          Metabolism"", TRENDS PHARMACOL. SCI., vol. 5, no. 12,          1984, pages 524 - 527, XP025943358, DOI:          10.1016/0165-6147(84)90534-0;            ""Remington: The Science and Practice of Pharmacy"", 2012,          LIPPINCOTT WILLIAMS & WILKINS;            ""Pharmaceutical Preformulation and Formulation"", 2009,          THE PHARMACEUTICAL PRESS AND THE AMERICAN PHARMACEUTICAL          ASSOCIATION;            ""Handbook of Pharmaceutical Additives"", 2007, GOWER          PUBLISHING COMPANY;            YAMADA, CANCER SCI., vol. 99, no. 8, 2008, pages 1603 -          1610;            BOUCHARABA ET AL., J CLIN. INVEST., vol. 114, no. 12,          2004, pages 1714 - 1725;            BOUCHARABA ET AL., PROC. NATL. ACAD. SCI., vol. 103, no.          25, 2006, pages 9643 - 9648;  T.          W. GREENEG. M. WUTS: ""Pharmaceutical Dosage Forms:          Parenteral Medications"", vol. 1-2, 1999, AMERICAN          PHARMACEUTICAL ASSOCIATION;            ""Fieser and Fieser's Reagents for Organic Synthesis"",          vol. 1-40, 1991, JOHN WILEY, AND SONS;            ""Larock's Comprehensive Organic Transformations"", vol.          1-5, 1989, ELSEVIER SCIENCE PUBLISHERS;            ""March's Advanced Organic Chemistry"", 2001, JOHN WILEY,          AND SONS", N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N,229894701 N,00210; 00211; 00212; 41247; 00695,RDGZRE N; RDGZRF N; RDGZRG N; RDGZRH N; RDGZRI N; RDGZRJ N; RDGZRK N; RDGZRL N; RDGZRM N; RDGZRN N; RDGZRO N; RDGZRP N; RDGZRQ N; RDGZRR N; RDGZRS N; RDGZRT N; RDGZRU N; RDGZRV N; RDGZRW N; RDGZRX N; RDGZRY N; RDGZRZ N; RDGZS0 N; RDGZS1 N; RDGZS2 N; RDGZS3 N; RDGZS4 N; RDGZS5 N; RDGZS6 N; RDGZS7 N; RDGZS8 N; RDGZS9 N; RDGZSA N; RDGZSB N; RDGZSC N; RDGZSD N; RDGZSE N; RDGZSF N; RDGZSG N; RDGZSH N; RDGZSI N; RDGZSJ N; RDGZSK N; RDGZSL N; RDGZSM N; RDGZSN N; RDGZSO N; RDGZSP N; RDGZSQ N; RDGZSR N; RDGZSS N; RDGZST N; RDGZSU N; RDGZSV N; RDGZSW N; RDGZSX N; RDGZSY N; RDGZSZ N; RDGZT0 N; RDGZT1 N; RDGZT2 N; RDGZT3 N; RDGZT4 N; RDGZT5 N; RDGZT6 N; RDGZT7 N; RDGZT8 N; RDGZT9 N; RDGZTA N; RDGZTB N; RDGZTC N; RDGZTD N; RDGZTE N; RDGZTF N; RDGZTG N; RDGZTH N; RDGZTI N; RDGZTJ N; RDGZTK N; RDGZTL N; RDGZTM N; RDGZTN N; RDGZTO N; RDGZTP N; RDGZTQ N; RDGZTR N; RDGZTS N; RDGZTT N; RDGZTU N; RDGZTV N; RDGZTW N; RDGZTX N; RDGZTY N; RDGZTZ N; RDGZU0 N; RDGZU1 N; RDGZU2 N; RDGZU3 N,
US2023241025-A1,"Treating viral disease in subject for use in            prophylaxis of viral disorders, e.g., common cold,            coronavirus by acting on fatty acid binding protein,            involves administering compounds, e.g.,            5-((3-cyanophenyl)methyl)-2-fluoro-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta(b)indole-4-carboxylic            acid, its salts",HOTAMISLIGIL G;  KIM H;  KOYUNCU E,CRESCENTA BIOSCI (CRES-Non-standard),202381137H,"   NOVELTY - Treating viral disease in subject involves                administering cyclohepta[b]indole-4-carboxylic acid                derivative of (I)-(VII), their salts or                stereoisomers, preferably compounds selected from,                e.g.,                5-[(3-cyanophenyl)methyl]-2-fluoro-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                5-[(6-cyanopyridin-2-yl)methyl]-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                5-[(6-carbamoylpyridin-2-yl)methyl]-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                6-({4-carboxy-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indol-5-yl}methyl)pyridine-2-carboxylic                acid,                5-[(3-cyano-2-fluorophenyl)methyl]-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                5-[(1,3-benzoxazol-6-yl)methyl]-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid.    USE - Method for treating viral disease in subject                for use in prophylaxis of viral disorders by acting                on fatty acid binding protein FABP4, where viral                disorders are selected from common cold, severe                acute respiratory syndrome (SARS), and                coronavirus-2019 (COVID-19) (all claimed).    ADVANTAGE - The composition has increased in-vivo                half-life or reduce dosage requirements.    DETAILED DESCRIPTION - Treating viral disease in subject involves                administering cyclohepta[b]indole-4-carboxylic acid                derivative of formula (I)-(VII), their salts or                stereoisomers, preferably compounds selected from,                e.g.,                5-[(3-cyanophenyl)methyl]-2-fluoro-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                5-[(6-cyanopyridin-2-yl)methyl]-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                5-[(6-carbamoylpyridin-2-yl)methyl]-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                6-({4-carboxy-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indol-5-yl}methyl)pyridine-2-carboxylic                acid,                5-[(3-cyano-2-fluorophenyl)methyl]-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                5-[(1,3-benzoxazol-6-yl)methyl]-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                5-[(1,3-benzoxazol-5-yl)methyl]-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                5-[(6-fluoropyridin-2-yl)methyl]-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                5-[(2-fluoropyridin-4-yl)methyl]-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                7-hexyl-5-{[6-(trifluoromethyl)pyridin-2-yl]methyl}-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,7-hexyl-5-{[2-(trifluoromethyl)pyridin-4-yl]methyl}-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                7-hexyl-5-[(pyridin-3-yl)methyl]-5H,6H,7H,8H,9H,                10H-cyclohepta[b]indole-4-carboxylic acid,                7-hexyl-5-[(3-methylphenyl)methyl]-5H,6H,7H,8H,9H,                10H-cyclohepta[b]indole-4-carboxylic acid,                7-hexyl-5-[(3-methoxyphenyl)methyl]-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                5-[(3-chlorophenyl)methyl]-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                7-hexyl-5-[(2-methoxypyridin-4-yl)methyl]-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                5-[(3-carboxyphenyl)methyl]-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                5-[(4-carbamoylphenyl)methyl]-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                5-[(2-carbamoylphenyl)methyl]-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                7-hexyl-5-[(4-methylphenyl)methyl]-5H,6H,7H,8H,9H,                10H-cyclohepta[b]indole-4-carboxylic acid,                5-[(4-cyanophenyl)methyl]-7-hexyl-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                2-hexyl-9-[(pyridin-3-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazole-8-carboxylic                acid,                2-hexyl-9-[(3-methylphenyl)methyl]-2,3,4,9-tetrahydro-1H-carbazole-8-carboxylic                acid,                2-hexyl-9-[(3-methoxyphenyl)methyl]-2,3,4,9-tetrahydro-1H-carbazole-8-carboxylic                acid,                7-butyl-5-[(3-fluorophenyl)methyl]-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                7-butyl-5-[(3-carboxyphenyl)methyl]-5H,6H,7H,8H,9H,10H-cyclohepta[b]indole-4-carboxylic                acid,                2-((2'-(5-Ethyl-3,4-diphenyl-1H-pyrazol-1-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic                acid,                6-chloro-4-phenyl-2-(piperidin-1-yl)-3-(1H-tetrazol-5-yl)quinoline,                5-((3-chloro-2-methylphenoxy)methyl)-2-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one,                and                3-(5-cyclopropyl-3-(3,5-dimethyl-1H-pyrazol-4-yl)-2-(3-isopropoxyphenyl)-1H-indol-1-yl)propanoic                acid.    W1-W4, Z1-Z5=-C, -CH, CH2, oxygen (O), sulfur                (S), or nitrogen (N); X=CH2, N or CHR4; Y'=CH2, or                CHR5; n=0-3; R1's on the ring Z=CN, OH, COOH, OCH3,                CF3, CONH2, B(OH)2, B(OR)2, acid isostere,                substituted amine, ethers, and halogen, substituted                or unsubstituted alkyl, substituted or                unsubstituted cyclic or heterocyclic, substituted                or unsubstituted cycloaryl or cychloheteroaryl,                where substituted cycloaryl or cychloheteroaryl are                substituted with hydrogen, CN, OH, COOH, OCH3, CF3,                CONH2, B(OH)2, B(OR)2, acid isostere, substituted                amine, ethers, and halogen, substituted or                unsubstituted alkyl, substituted or unsubstituted                cyclic or heterocyclic, substituted or                unsubstituted cycloaryl or cychloheteroaryl, and                SO2NH2. Full definitions are given in the                DEFINITIONS (Full Definitions) Field.     ",,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.)",B07-B01;  B06-A01;  B06-D02;  B10-B01A;  B10-C04A;  B06-D05;  B10-A09B;  B10-C04C;  B07-D08;  B07-E02;  B14-S18;  B07-D05;  B07-D12;  B06-D01;  B06-D13;  B14-K01D;  B14-A02,A61K-031/404;  A61K-045/06,US2023241025-A1   03 Aug 2023   A61K-031/404   202368   English,US2023241025-A1    US566695    31 Dec 2021,,US566695    31 Dec 2021,,,,, M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE; 3208112-1-0-0 CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE; 104047-0-0-0 CL NEW USE; 261145-0-0-0 CL NEW USE; 2989462-0-0-0 CL NEW USE; 2427742-0-0-0 CL NEW USE;  CL NEW USE; 3959990-0-0-0 CL NEW USE;  CL NEW USE; 276615-0-0-0 CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE;  CL NEW USE; 3050143-0-0-0 CL NEW USE;  CL NEW USE,,,,
WO2023028591-A1;  TW202328177-A;  AU2022332303-A1;  CA3228359-A1;  KR2024049296-A;  RU2024107311-A,"Slowing memory decline in cognitive, language,            praxis, and capacity, maintaining memory and treating            mild-to-moderate Alzheimer's disease without increased            risk of adverse event comprises administering humanized            monoclonal anti-tau antibody",TENG E H;  TOTH B;  MANSER P;  KEELEY M;  TOTE B;  DEN E KH;  TOT B;  KILI M,GENENTECH INC (GETH-C);  GENENTECH INC (GETH-C);  GENENTECH INC (GETH-C),202323686Y,"   NOVELTY - Slowing memory decline in cognitive, language,                praxis, capacity, diagnosed with mild-to-moderate                Alzheimer's disease (AD), maintaining cognitive                capacity within 5 points of the AD assessment                scale, cognitive subscale, 11-item version                (ADAS-Cog11) score of a patient diagnosed with                mild-to-moderate AD, maintaining memory within 2.5                points of the ADAS-Cog11 memory domain score of                diagnosed with mild-to-moderate AD and treating                diagnosed with mild-to-moderate AD without                increased risk of adverse event, comprising                administering 4500 mg dose of humanized monoclonal                anti-tau antibody to patient, where the antibody                comprises: an hypervariable region (HVR-H1)                comprising amino acid sequence of SEQ ID NO:2                (comprising a fully defined sequence of 23 amino                acids as given in specification); an HVR-H2                comprising the amino acid sequence of SEQ ID NO:3                (comprising a fully defined sequence of 17 amino                acids as given in specification); and an HVR-H3                comprising amino acid sequence of SEQ ID                NO:4.    USE - The methods are useful for slowing memory                decline in cognitive, language, praxis, and                capacity, maintaining memory and treating e.g.                mild-to-moderate Alzheimer's disease without                increased risk of adverse event, where the adverse                event comprises infusion-related reaction,                neuroimaging abnormality, immunogenicity, suicide                ideation, headache, worsening cognitive function,                alteration of consciousness, seizures,                unsteadiness, vomiting, fall, urinary tract                infection, anxiety, agitation, depression,                dizziness, dermatological;, hypertension,                nasopharyngitis, arthralgia, constipation,                coronavirus disease 19 (COVID-19), insomnia, upper                respiratory tract infection, abdominal pain, back                pain and cough (all claimed). Test details are                described but no results given.    ADVANTAGE - The methods administer tau PET tracer to the                patient before and/or after administration of the                antibody does not increase the risk of an adverse                event.    DETAILED DESCRIPTION - Slowing memory decline in cognitive, language,                praxis, capacity, diagnosed with mild-to-moderate                Alzheimer's disease (AD), maintaining cognitive                capacity within 5 points of the AD assessment                scale, cognitive subscale, 11-item version                (ADAS-Cog11) score of a patient diagnosed with                mild-to-moderate AD, maintaining memory within 2.5                points of the ADAS-Cog11 memory domain score of                diagnosed with mild-to-moderate AD and treating                diagnosed with mild-to-moderate AD without                increased risk of an adverse event, comprising                administering 4500 mg dose of humanized monoclonal                anti-tau antibody to the patient, where the                antibody comprises: an hypervariable region                (HVR-H1) comprising the amino acid sequence of SEQ                ID NO:2 (comprising a fully defined sequence of 23                amino acids as given in specification); an HVR-H2                comprising the amino acid sequence of SEQ ID NO:3                (comprising a fully defined sequence of 17 amino                acids as given in specification); an HVR-H3                comprising the amino acid sequence of SEQ ID NO:4                (comprising a fully defined sequence of 18 amino                acids as given in specification); an HVR-L1                comprising the amino acid sequence of SEQ ID NO:6                (comprising a fully defined sequence of 16 amino                acids as given in specification); an HVR-L2                comprising the amino acid sequence of SEQ ID NO:7                (comprising a fully defined sequence of 17 amino                acids as given in specification); and an                hypervariable region (HVR-L3 comprising the amino                acid sequence of SEQ ID NO:8 (comprising a fully                defined sequence of 19 amino acids as given in                specification). INDEPENDENT CLAIMS are also                included for:    humanized monoclonal anti-tau antibody                provided at a dose of 4500 mg for use in slowing or                treating memory decline in cognitive, language or                praxis capacity in a patient diagnosed with                mild-to-moderate AD, maintaining cognitive capacity                &#8815; 5 points higher than or maintaining                memory within 2.5 points of the (ADAS-Cog11) score                of a patient diagnosed with mild-to-moderate AD,                after administration of 12-17 doses;    use of the humanized monoclonal anti-tau                antibody for the manufacture of a medicament for                slowing decline in cognitive capacity in a patient                diagnosed with mild-to-moderate AD, maintaining or                slowing memory decline in cognitive, language or                praxis capacity &#8815; 5 points higher than or                within 2.5 points of the ADAS-Cog11 score of, or                treating a patient diagnosed with mild-to-moderate                AD, following administration of 12 to 17 doses;                and    lowing memory decline in cognitive, language                or praxis capacity in a patient diagnosed with                mild-to-moderate AD, maintaining cognitive capacity                within 5 points of or within 2.5 points the                ADAS-Cog11 score of a patient diagnosed with                mild-to-moderate AD, treating a patient diagnosed                with mild-to-moderate AD without increased risk of                an adverse event, comprising intravenously                administering to the patient a 4500 mg dose of                semorinemab at a frequency of once weekly (QW),                once every 2 weeks (Q2W) for 3 doses and                subsequently at a frequency of Q4W; and    emorinemab at a dose of 4500 mg for use in                slowing memory decline in cognitive, language, or                praxis capacity, maintaining cognitive capacity                &#8815; 5 points or &#8815; 2.5 points                higher than the ADAS-Cog11 score of or treating                patient without increased (or without significantly                increased) risk of an adverse event in a patient                diagnosed with mild-to-moderate AD, where the                semorinemab is intravenously administered at a                frequency of Q2W for 3 doses and subsequently at a                frequency of Q4W; and    use of semorinemab for the manufacture of                medicament for slowing memory decline or in                cognitive, language, or praxis capacity in a                patient diagnosed with mild-to-moderate AD,                maintaining cognitive capacity \5 points,                preferably &#8815; 2.5 points higher than an                ADAS-Cog11 score of a patient diagnosed with                mild-to-moderate AD, and treating a patient                diagnosed with mild-to-moderate AD without                increased (or without significantly increased) risk                of an adverse event, where the semorinemab is                formulated for intravenous administration at a dose                of 4500 mg, where the medicament is administered at                a frequency of Q2W for 3 doses and subsequently at                a frequency of Q4W. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B01-A01;  B01-C04;  B04-A01;  B04-C01B;  B04-C01H;  B04-E99;  B04-G01;  B04-G21;  B04-H05;  B04-L05C;  B06-H;  B07-H;  B09-D01;  B10-A09B;  B10-A12C;  B10-A15;  B10-A19;  B10-B02E;  B10-B03B;  B10-B04B;  B10-E02;  B12-M12F;  B14-A01;  B14-A02;  B14-A04;  B14-C01;  B14-D07A;  B14-D07C;  B14-E05;  B14-E09;  B14-F02B;  B14-J01A1;  B14-J01A4;  B14-J01B1;  B14-J01B4;  B14-K01;  B14-N02A;  B14-N07;  B14-S16;  B14-S18;  D05-H11A;  D05-H99,A61K-039/00;  A61K-039/395;  A61P-025/28;  C07K-016/18;  A61K-045/06,WO2023028591-A1   02 Mar 2023   A61K-039/395   202323Pages: 242   English;  TW202328177-A   16 Jul 2023   C07K-016/18   202372   Chinese;  AU2022332303-A1   01 Feb 2024   A61K-039/395   202411   English;  CA3228359-A1   02 Mar 2023   A61K-039/395   202416   English;  KR2024049296-A   16 Apr 2024   C07K-016/18   202434   ;  RU2024107311-A   19 Apr 2024   A61K-039/395   202446   Russian,WO2023028591-A1    WOUS075528    26 Aug 2022;   TW202328177-A    TW132373    26 Aug 2022;   AU2022332303-A1    AU332303    26 Aug 2022;   CA3228359-A1    CA3228359    26 Aug 2022;   KR2024049296-A    KR707389    26 Aug 2022;   RU2024107311-A    RU107311    26 Aug 2022,AU2022332303-A1 PCT application Application WOUS075528;   AU2022332303-A1 Based on Patent WO2023028591;   CA3228359-A1 PCT application Application WOUS075528;   KR2024049296-A PCT application Application WOUS075528;   KR2024049296-A Based on Patent WO2023028591;   RU2024107311-A PCT application Application WOUS075528;   RU2024107311-A Based on Patent WO2023028591,US238052P    27 Aug 2021;  US238737P    30 Aug 2021;  US275884P    04 Nov 2021;  US389269P    14 Jul 2022;  CA3228359    06 Feb 2024;  KR707389    05 Mar 2024;  RU107311    27 Mar 2024,WO2023028591-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA            ,,"WO2023028591-A1 -- WO2016196726-A1   GENENTECH INC (GETH);  AC IMMUNE SA (ACIM)   ADOLFSSON O,  AYALON G,  DI CARA D M,  HOTZEL I;  WO2018183175-A1   GENENTECH INC (GETH)   KERCHNER G,  TENG E;  EP404097-A   BEHRINGWERKE AG (BEHW)   BOSSLET K,  HERMENTIN P,  SEEMANN G,  KUHLMANN L,  STEINSTRAS A;  US4676980-A   US DEPT HEALTH & HUMAN SERVICE (USSH)   SEGAL D;  US4737456-A   SYNTEX (USA) (SYNT)   WENG L,  GIBBONS I;  US4816567-A   GENENTECH INC (GETH);  CITY OF HOPE (CITY)   CABILLY S,  HOLMES W E,  WETZEL R B,  HEYNEKER H L,  RIGGS A D;  US5208020-A   IMMUNOGEN INC (IMMG)   CHARI R J,  GOLDMACHER V S,  LAMBERT J M,  BLATTLER W A;  US5500362-A   INT GENETIC ENG INC (ITGE-Non-standard);  ONCOGEN (ONCO);  XOMA CORP (XOMA)   ROBINSON R R,  LIU A Y,  HELLSTROM K E,  HELLSTROM I,  LEDBETTER J A;  US5571894-A   CIBA GEIGY AG (CIBA)   WELS W S,  HYNES N E,  HARWERTH I,  GRONER B,  HARDMAN N,  ZWICKL M;  US5587458-A   ARONEX PHARM INC (ARON-Non-standard)   BIRD R E,  KING C R,  KASPRZYK P G;  US5624821-A   MEDICAL RES COUNCIL (MRCX)   WINTER G P,  DUNCAN A R,  BURTON D R;  US5648237-A   GENENTECH INC (GETH)   CARTER P J;  US5648260-A   MEDICAL RES COUNCIL (MRCX)   WINTER G P,  DUNCAN A R,  BURTON D R;  US5731168-A   GENENTECH INC (GETH)   CARTER P J,  PRESTA L G,  RIDGWAY J B;  US5789199-A   GENENTECH INC (GETH)   JOLY J C,  SWARTZ J R;  US5821337-A   GENENTECH INC (GETH)   CARTER P J,  PRESTA L G;  US5840523-A   GENENTECH INC (GETH)   SIMMONS L C,  YANSURA D G;  US5869046-A   GENENTECH INC (GETH)   PRESTA L G,  SNEDECOR B R;  US5959177-A   SCRIPPS RES INST (SCRI)   HEIN M B,  HIATT A,  JULIAN K M;  US6040498-A   UNIV NORTH CAROLINA STATE (UYNC)   STOMP A,  RAJBHANDARI N;  US20020164328-A1   ;  US20030115614-A1   ;  US20030157108-A1   ;  US20040093621-A1   ;  US20040109865-A1   ;  US20040110282-A1   ;  US20040110704-A1   ;  US20040132140-A1   ;  US20050014934-A1   ;  US20050123546-A1   ;  US20050260186-A1   ;  US20060025576-A1   ;  US20080069820-A1   ;  US6171586-B1   GENENTECH INC (GETH)   LAM X M,  OESWEIN J Q,  ONGPIPATTANAKUL B,  SHAHROKH Z,  WANG S X,  WEISSBURG R P,  WONG R L;  US6194551-B1   GENENTECH INC (GETH)   IDUSOGIE E E,  PRESTA L G,  MULKERRIN M G;  US6248516-B1   MEDICAL RES COUNCIL (MRCX)   WINTER G P,  GUSSOW D,  WARD E S;  US6267958-B1   GENENTECH INC (GETH)   ANDYA J,  CLELAND J L,  HSU C C,  LAM X M,  OVERCASHIER D E,  SHIRE S J,  YANG J Y,  WU S S;  US6417429-B1   SCRIPPS RES INST (SCRI)   HEIN M B,  HIATT A,  JULIAN K M;  US6420548-B1   MEDICAGO INC (MEGO)   VEZINA L,  D'AOUST M;  US6602684-B1   UMANA P (UMAN-Individual);  JEAN-MAIRET J (JEAN-Individual);  BAILEY J E (BAIL-Individual)   UMANA P,  JEAN-MAIRET J,  BAILEY J E;  US6737056-B1   GENENTECH INC (GETH)   PRESTA L G;  US7125978-B1   MEDICAGO INC (MEGO)   VEZINA L,  D'AOUST M;  US6982321-B2   WINTER G P (WINT-Individual)   WINTER G P;  US7087409-B2   SCRIPPS RES INST (SCRI)   BARBAS C F,  RADER C;  US7332581-B2   GENENTECH INC (GETH)   PRESTA L G;  US7371826-B2   GENENTECH INC (GETH)   PRESTA L G;  US7521541-B2   GENENTECH INC (GETH)   EIGENBROT C W,  JUNUTULA J R,  LOWMAN H,  RAAB H E,  VANDLEN R;  US7527791-B2   GENENTECH INC (GETH)   ADAMS C W,  FERRARA N,  FILVAROFF E,  MAO W,  PRESTA L G,  TEJADA M L;  US8980270-B2   IPIERIAN INC (IPIE-Non-standard)   GRISWOLD-PRENNER I,  STAGLIANO N E,  DANG V;  US8980271-B2   IPIERIAN INC (IPIE-Non-standard)   GRISWOLD-PRENNER I,  STAGLIANO N E,  DANG V;  US10076581-B2   HOFFMANN LA ROCHE & CO AG F (HOFF);  GENENTECH INC (GETH)   MARIK J,  LYSSIKATOS J P,  WILLIAMS S;  WO1993001161-A1   ;  WO1993008829-A1   ;  WO1997030087-A1   ;  WO1998058964-A1   ;  WO1999022764-A1   ;  WO1999051642-A1   ;  WO2000061739-A1   ;  WO2001029246-A1   ;  WO2002031140-A1   ;  WO2003084570-A1   KYOWA HAKKO KOGYO KK (KYOW)   NAKAMURA K,  SHITARA K,  HATANAKA S,  NIWA R,  OKAZAKI A;  WO2003085107-A1   KYOWA HAKKO KOGYO KK (KYOW)   YAMANE N,  SATOH M,  MORI K,  YAMANO K;  WO2003085119-A1   KYOWA HAKKO KOGYO KK (KYOW)   NAKAMURA K,  SHITARA K;  WO2004058258-A1   NEUROCHEM INT LTD (NEUR-Non-standard)   GERVAIS F,  BELLINI F;  WO2005035586-A1   KYOWA HAKKO KOGYO KK (KYOW)   SHITARA K,  HOSAKA E,  NATSUME A,  WAKITANI M,  UCHIDA K,  SATOH M,  OHNUKI N,  NAKAMURA K;  WO2005035778-A1   KYOWA HAKKO KOGYO KK (KYOW)   IMAI H,  SATOH M,  MORI K;  WO2005053742-A1   KYOWA HAKKO KOGYO KK (KYOW)   SHITARA K,  NIWA R;  WO2005100402-A1   GRAUS Y (GRAU-Individual);  HIMBER J (HIMB-Individual);  JANSEN-MOLENAAR M (JANS-Individual);  KLING D (KLIN-Individual);  KOPETZKI E (KOPE-Individual);  PARREN P (PARR-Individual);  REBERS F (REBE-Individual);  STEINER B (STEI-Individual);  STERN A (STER-Individual);  STREIN P (STRE-Individual);  STUBENRAUCH K (STUB-Individual);  VAN DE WINKEL J (VWIN-Individual);  VAN VUGT M (VVUG-Individual)   GRAUS Y,  HIMBER J,  JANSEN-MOLENAAR M,  KLING D,  KOPETZKI E,  PARREN P,  REBERS F,  STEINER B,  STERN A,  STREIN P,  STUBENRAUCH K,  VAN DE WINKEL J,  VAN VUGT M;  WO2008077546-A1   HOFFMANN LA ROCHE & CO AG F (HOFF)   KOLL H,  KUENKELE K,  MOSER S,  POEHLING S;  WO2009089004-A1   AMGEN INC (AMGE)   KANNAN G,  PENTONY M,  WITTEKIND M,  YAN W;  WO2012049570-A1   NITSCH R (NITS-Individual);  CHEN F (CHEN-Individual);  GRIMM J (GRIM-Individual);  BAERISWYL J (BAER-Individual);  HOCK C (HOCK-Individual)   NITSCH R,  CHEN F,  GRIMM J,  BAERISWYL J,  HOCK C;  WO1993016185-A2   ;  WO1994011026-A2   ;  WO1994029351-A2   ;  WO2003011878-A2   GLYCART BIOTECHNOLOGY AG (HOFF);  BAILEY S (BAIL-Individual)   JEAN-MAIRET J,  UMANA P,  BAILEY J E;  WO2004056312-A2   GENENTECH INC (GETH)   ADAMS C W,  CHAN A C,  CROWLEY C W,  LOWMAN H B,  NAKAMURA G R,  PRESTA L G;  WO2006029879-A2   HOFFMANN LA ROCHE & CO AG F (HOFF)   ENDL J,  EUGUI E,  FUENTES M,  GRAUS Y,  LABRIJN A,  LANZENDOERFER M,  PARREN P,  REBERS F,  SCHUMACHER R,  SEEBER S,  VAN DE WINKEL J,  VAN VUGT M;  WO2006044908-A2   GENENTECH INC (GETH)   ANDYA J D,  GWEE S C,  LIU J,  SHEN Y;  WO2014028777-A2   IPIERIAN INC (IPIE-Non-standard)   GRISWOLD-PRENNER I,  STAGLIANO N E,  DANG V;  WO2014100600-A2   BIOGEN IDEC MA INC (BIOJ);  BIOGEN IDEC INT NEUROSCIENCE GMBH (BIOJ)   WEINREB P H,  CHEN F,  GARBER E A,  GRIMM J,  MONTRASIO F;  WO2014165271-A2   NEOTOPE BIOSCI CO LTD (NEOT-Non-standard);  SEUBERT P (SEUB-Individual);  DOLAN P J (DOLA-Individual);  LIU Y (LIUY-Individual);  BARBOUR R (BARB-Individual)   SEUBERT P,  DOLAN P J,  LIU Y,  BARBOUR R;  WO2015200806-A2   C2N DIAGNOSTICS LLC (CTWO-Non-standard)   ATHWAL D S,  CARR F J,  HOLGATE R G E,  JONES T D,  WEST T","WO2023028591-A1  MONTEIRO CECILIA ET          AL: ""Phase 2 trial of Semorinemab in mild-to-moderate          Alzheimer's disease (LAURIET): Topline results"", JOURNAL          OF PREVENTION OF ALZHEIMER'S DISEASE, vol. 8 SUPP.1, 13          November 2021 (2021-11-13), pages S11 - S12,          XP093016121,relevantClaims[1-159],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  KUEPER JACQUELINE          K. ET AL: ""The Alzheimer's Disease Assessment          Scale-Cognitive Subscale (ADAS-Cog): Modifications and          Responsiveness in Pre-Dementia Populations. A Narrative          Review"", JOURNAL OF ALZHEIMER`S DISEASE, vol. 63, no. 2,          24 April 2018 (2018-04-24), NL, pages 423 - 444,          XP093016247, ISSN: 1387-2877, Retrieved from the Internet          &lt;URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929311/pdf/jad-63-jad170991.pdf&gt;          DOI:          10.3233/JAD-170991,relevantClaims[1-159],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            PRINCE ET AL.: ""World Alzheimer Report 2015: The Global          Impact of Dementia"", ALZHEIMER'S DISEASE INTERNATIONAL,          2015;            SAUNDERS ET AL., NEUROLOGY, vol. 43, 1993, pages 1467 -          72;            FOLSTEIN ET AL., J PSYCHIATR RES, vol. 12, 1975, pages          189 - 98;            CUMMINGS, N. ENGL. J. MED., vol. 351, 2004, pages 56 -          67;            WANGMANDELKOW, NAT. REV. NEUROSCI., vol. 17, no. 1,          January 2016 (2016-01-01), pages 5 - 21;            BRAAK ET AL., BRAIN, vol. 138, 2015, pages 2814 -          33;            OSSENKOPPELE ET AL., BRAIN, vol. 139, 2016, pages 1551 -          67;            ROBERSON ET AL., SCIENCE, vol. 316, 2007, pages 750 -          4;            SANDUSKY-BELTRAN ET AL., NEUROPHARMACOLOGY, vol. 175,          2020, pages 108104;            ALZHEIMER'S ASSOCIATION: ""2013 Alzheimer's Disease Facts          and Figures"", ALZHEIMER'S AND DEMENTIA, vol. 9, 2013,          pages 208 - 245;            ROBBIE ET AL., ANTIMICROB AGENTS CHEMOTHER, vol. 57,          2013, pages 6147 - 53;            JACK ET AL., LANCET NEUROL, vol. 12, 2013, pages 207 -          16;            DOODY ET AL., N ENGL J MED, 2013;            SALLOWAY ET AL., N ENGL J MED, vol. 370, 2014, pages 322          - 21369;            EGAN ET AL., N ENGL J MED, vol. 378, 2018, pages 1691 -          1703;            NELSON ET AL., J NEUROPATHOL EXP NEUROL., vol. 71, 2012,          pages 362 - 81;            KANAI ET AL., ANN NEUROL, vol. 44, 1998, pages 17 -          26;            ISHIKI ET AL., PLOS ONE, vol. 10, 2015, pages          e0140311;            BRAAK ET AL., ACTA NEUROPATHOL, vol. 112, 2006, pages 389          - 404;            BLENNOWZETTERBERG, J ALZHEIMERS DIS, vol. 18, 2009, pages          413 - 7;            SALLOWAY ET AL., NEUROLOGY, vol. 73, 2009, pages 1193 -          70;            SPERLING ET AL., LANCET NEUROL, vol. 11, 2012, pages 241          - 9;            HURLEGROSS, CURR. OP. BIOTECH., vol. 5, 1994, pages 428 -          433;            PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593          - 596;            QUEEN ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 86, 1989,          pages 10029 - 10033;            JONSSON ET AL., BIOTECHNIQUES, vol. 11, 1991, pages 620 -          627;            JEFFERIS ET AL., IMMUNOL LETT, vol. 82, 2002, pages 57 -          65;            JONSSON ET AL., ANN. BIOL. CLIN., vol. 51, 1993, pages 19          - 26;            JONSSON ET AL., J. MOL. RECOGNIT., vol. 8, 1995, pages          125 - 131;            JOHNSSON ET AL., ANAL. BIOCHEM., vol. 198, 1991, pages          268 - 277;            HEARTY S ET AL., METHODS MOL BIOL., vol. 907, 2012, pages          411 - 42;            MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81,          1984, pages 6851 - 6855;            JONES ET AL., NATURE, vol. 321, 1986, pages 522 -          525;            RIECHMANN ET AL., NATURE, vol. 322, 1988, pages 738 -          329;            VASWANIHAMILTON, ANN. ALLERGY, ASTHMA & IMMUNOL.,          vol. 1, 1998, pages 105 - 115;            HARRIS, BIOCHEM. SOC. TRANSACTIONS, vol. 23, 1995, pages          1035 - 1038;            MARKS ET AL., J. MOL. BIOL, vol. 222, 1991, pages 581 -          597;            HOOGENBOOM ET AL., NUCL ACIDS RES., vol. 19, 1991, pages          4133 - 4137;            KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001;            CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 -          917;            BOERNER ET AL., J. IMMUNOL., vol. 147, 1991, pages          60;            JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI USA, vol. 90,          1993, pages 2551;            JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages          255;            BRUGGERMANN ET AL., YEAR IN IMMUNOL, vol. 7, 1993, pages          33;            FLATMAN ET AL., CHROMATOGR. B, vol. 848, 2007, pages 79 -          87;            PORTOLANO ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623          - 887;            CLARKSON ET AL., NATURE, vol. 352, 1991, pages 624 -          628;            MACCALLUM ET AL., J. MOL. BIOL., vol. 262, 1996, pages          732 - 745;            PADLAN, MOL. IMMUNOL., vol. 1-3, 1991, pages 489 -          498;            MCKHANN ET AL., ALZHEIMERS DEMENT, vol. 7, 2011, pages          396 - 401;            DUBOIS ET AL., LANCET NEUROL., vol. 13, 2014, pages 614 -          29;            SHAW ET AL., ANN NEUROL, vol. 65, 2009, pages 403 -          13;            CLARK ET AL., JAMA, vol. 305, 2011, pages 275 -          83;  LE          BASTARD ET AL., J ALZHEIMER'S DIS, vol. 33, 2013, pages          117 - 31;            FAGAN ET AL., ANN NEUROL, vol. 59, 2006, pages 512 -          9;            FORSBERG ET AL., NEUROBIOL AGING, vol. 29, 2008, pages          1456 - 65;            TOLBOOM ET AL., J NUCL MED, vol. 50, 2009, pages 1464 -          70;            FAGAN ET AL., ARCH NEUROL, vol. 68, 2011, pages 1137 -          44;            LANDAU ET AL., ANN NEUROL, vol. 74, 2013, pages 826 -          36;            ZWAN ET AL., J ALZHEIMER'S DIS, vol. 41, 2014, pages 801          - 7;  S.          SANABRIA BOHORQUEZ ET AL., J. NUCL. MED., vol. 58, no. 1,          2017;            MORRIS NEUROLOGY, vol. 43, 1993, pages 2412 - 4;            O'BRYANT ET AL., ARCH NEUROL, vol. 65, 2008, pages 1091 -          1095;            ROZZINI ET AL., INT J GERIATR PSYCHIATRY, vol. 22, 2007,          pages 1217 - 22;            CONNORSABBAGH, J ALZHEIMERS DIS., vol. 15, 2008, pages          461 - 4;            IHL ET AL., INT J GERIATR PSYCHIATRY, vol. 27, 2012,          pages 15 - 21;            ROSEN ET AL., AM J PSYCHIATR, vol. 141, 1984, pages 1356          - 64;            GALASKO ET AL., ALZHEIMER DIS ASSOC DISORD, vol. 11, no.          S2, 1997, pages S13 - S21;            MANI, STAT MED, vol. 23, 2004, pages 305 - 14;            VERMA ET AL., ALZHEIMER'S RESEARCH & THERAPY,          2015;            VELLAS ET AL., LANCET NEUROL, vol. 7, 2008, pages 436 -          50;            GALASKO ET AL., ALZHEIMER DISEASE AND ASSOCIATED          DISORDERS, 1997, pages S33 - S39;            CUMMINGS ET AL., NEUROLOGY, vol. 44, 1994, pages 2308 -          14;            LAWTON, M.P.BRODY, EM, GERONTOLOGIST, vol. 9, 1969, pages          179 - 186;            PREKUMAR ET AL., AM. J PATHOL., vol. 148, 1996, pages          2083 - 95;            CHEN ET AL., J. MOL. BIOL., vol. 293, 1999, pages 865 -          881;            PRESTA ET AL., CANCER RES., vol. 57, 1997, pages 4593 -          4599;            HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 -          134;            GRUBER ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368 -          315;            HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90,          1993, pages 6444 - 6448;            ALMAGROFRANSSON, FRONT. BIOSCI., vol. 13, 2008, pages          1619 - 1633;            DALL'ACQUA ET AL., METHODS, vol. 36, 2005, pages 61 -          68;            KLIMKA ET AL., BR. J. CANCER, vol. 83, 2000, pages 252 -          260;            CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992,          pages 4285;            BACA ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 10678          - 10684;            ROSOK ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 22611          - 22618;            MILSTEINCUELLO, NATURE, vol. 305, 1983, pages          537;            TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages          3655;            BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages          81;            KOSTELNY ET AL., J. IMMUNOL., vol. 148, no. 5, 1992,          pages 1547 - 1553;            CHOWDHURY, METHODS MOL. BIOL., vol. 207, 2008, pages 179          - 196;            SHIELDS ET AL., J. BIOL. CHEM., vol. 178, no. 2, 2001,          pages 6591 - 6604;            CUNNINGHAMWELLS, SCIENCE, vol. 244, 1989, pages 1081 -          1085;            WRIGHT ET AL., TIBTECH, vol. 15, 1997, pages 26 -          32;            OKAZAKI ET AL., J. MOL. BIOL., vol. 336, 2004, pages 1239          - 1249;            YAMANE-OHNUKI ET AL., BIOTECH. BIOENG., vol. 87, 2004,          pages 614;            RIPKA ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 249, 1986,          pages 533 - 545;            KANDA, Y. ET AL., BIOTECHNOL. BIOENG., vol. 94, no. 4,          2006, pages 680 - 688;            RAVETCHKINET, ANNU. REV. IMMUNOL., vol. 9, 1991, pages          457 - 492;            HELLSTROM, I. ET AL., PROC. NAT'L ACAD. SCI. USA, vol.          83, 1986, pages 7059 - 7063;            HELLSTROM, I ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 82,          1985, pages 1499 - 1502;            BRUGGEMANN, M. ET AL., J. EXP. MED., vol. 166, 1987,          pages 1351 - 1361;            CLYNES ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 95, 1998,          pages 652 - 656;            GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, vol. 202,          1996, pages 163;            CRAGG, M.S. ET AL., BLOOD, vol. 101, 2003, pages 1045 -          1052;            CRAGG, M.S.M.J. GLENNIE, BLOOD, vol. 103, 2004, pages          2738 - 2743;            PETKOVA, S.B. ET AL., INT'L. IMMUNOL., vol. 18, no. 12,          2006, pages 1759 - 1769;            IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178          - 4184;            GUYER ET AL., J. IMMUNOL., vol. 117, 1976, pages          587;            KAM ET AL., PROC. NATL. ACAD. SCI. USA, vol. 102, 2005,          pages 11600 - 11605;            CHARLTON: ""Methods in Molecular Biology"", vol. 248, 1996,          HUMANA PRESS, article ""Epitope Mapping Protocols"", pages:          245 - 254;            GERNGROSS, NAT. BIOTECH., vol. 22, 2004, pages 1409 -          1414;  LI          ET AL., NAT. BIOTECH., vol. 24, 2006, pages 210 -          215;            GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages          59;            MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 -          251;            MATHER ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, pages 44          - 68;            URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980,          pages 4216;            HARLOWLANE: ""Antibodies: A Laboratory Manual"", vol. 248,          1988, COLD SPRING HARBOR LABORATORY, pages: 255 -          268;            VITETTA ET AL., SCIENCE, vol. 238, 1987, pages          1098;            CHARI ET AL., CANCER RES., vol. 52, 1992, pages 127 -          131;            ""Remington's Pharmaceutical Sciences"", 1980;            MCKHANN ET AL., NEUROLOGY, vol. 34, 1984, pages 939 -          44;            PREKUMAR ET AL., AM. J. PATHOL., vol. 148, 1996, pages          2083 - 95;            SHAW ET AL., ANN NEUROL., vol. 65, 2009, pages 403 -          13;  DE          OLIVIERA ET AL., J. OF NEUROL. SCI., vol. 359, no. 1-2,          2015, pages 127 - 132;            KENNEDY ET AL., ALZHEIMERS DEMENT (NY, vol. 1, 2015,          pages 46 - 52;            CAUNCA ET AL., J AM HEART ASSOC [SERIAL ON THE INTERNET,          14 April 2020 (2020-04-14);            VERMA ET AL., ALZHEIMER'S RESEARCH AND THERAPY,          2015", K M; 97854-0-0-0 K M;  K M;  K M;  K M; 1640321-0-0-0 K M;  K M;  K M; 487460-0-0-0 K M;  K M; 99316-1-0-0 K M; 108587-0-0-0 K M; 93289-0-0-0 K M; 73384-0-0-0 K M; 94305-2-0-0 K M; 169502-1-0-0 K M; 93856-0-0-0 K M; 100413-1-0-0 K M; 104722-0-0-0 K M; 93450-0-0-0 K M; 109424-0-0-0 K M; 88634-1-0-0 K M; 88872-0-0-0 K M; 94245-3-0-0 K M; 106854-1-0-0 K M; 134454-1-0-0 K M; 10414-1-0-0 K M; 101531-2-0-0 K M; 25857-0-0-0 K M; 152427-1-0-0 K M; 87611-1-0-0 K M; 90013-1-0-0 K M; 93655-1-0-0 K M; 103642-1-0-0 K M; 109129-0-0-0 K M; 87119-0-0-0 K M; 50639-0-0-0 K M; 95503-1-0-0 K M; 2358-0-0-0 K M; 97041-0-0-0 K M; 182443-0-0-0 K M; 94538-0-0-0 K M; 6478-1-0-0 K M; 1640321-0-0-0 CL USE,,03487; 02889; 13240; 03624; 02319; 05171,RD2G0L K M; RA022K K M; RCBOJ5 K M; RD2G0F K M; RCGIQW K M; RBF61X K M; RD029L K M; RCKFOL K M; RA5XYI K M; RCBKLG K M; R11749 K M; RA0I05 K M; RAGS75 K M; RAIBAI K M; R00828 K M; R09652 K M; RA0GLQ K M; R23222 K M; RA0GVN K M; R21227 K M; R00170 K M; R22027 K M; R08394 K M; R01315 K M; RA0QSI K M; R04236 K M; RA0GX0 K M; R03044 K M; RA0SUX K M; R22470 K M; RA0GRX K M; R00151 K M; R06863 K M; R00192 K M; R06856 K M; R10873 K M; RA1KYQ K M; R01452 K M; R00076 K M; R00183 K M; R00678 K M; RA0GVF K M; RAOE8N K M; RA5KUL K M; RA0JDO K M; R00145 K M,0828-S; 0170-S; 1315-S; 0151-S; 0192-S; 1452-S; 0076-S; 0183-S; 0678-S; 0145-S
WO2022177716-A1;  EP4288132-A1;  US2024042145-A1,"Capsule inhaler useful for delivering dry powder            agent containing pharmaceutical or nutraceutical to            subject useful for e.g. treating asthma or lung cancer,            comprises main portion, opening section, actuator,            nozzles and cover",DENNY J W;  WARDEN J,KNIGHTPOINT LLC (KNIG-Non-standard);  KNIGHTPOINT LLC (KNIG-Non-standard);  KNIGHTPOINT LLC (KNIG-Non-standard),2022A86152,"   NOVELTY - Capsule inhaler (100) comprises (a) (i) a main                portion (102) comprising an inner cavity, a                back-wall, and at least one air intake port, where                the inner cavity is sized and configured to receive                a capsule containing a dry powder formulation, (ii)                a opening section coupled to or integral with the                main portion and in fluid communication with the                inner cavity, (iii) an actuator (104) coupled to                the main portion, (iv) at least four longitudinally                spaced apart nozzles residing within the main                portion and in fluid communication with the inner                cavity, where each of the nozzles extends between                the inner cavity and back-wall of the main portion                and opposite the opening section terminating                adjacent to and spaced part from, the back-wall                leaving a gap between the nozzles and the                back-wall, and (v) a cover (106) coupled to the                main portion.    USE - The capsule inhaler is useful for delivering                dry powder agent containing pharmaceutical or                nutraceutical to subject, which is useful for (i)                treating a disease chosen from a respiratory                disease i.e. asthma, chronic obstructive pulmonary                disease (COPD), lung cancer, and COVID-19, (ii)                treating eosinophilic esophagitis (EoE) when                directly delivered into throat and/or esophagus of                the subject, (iii) providing a hormone treatment                through stomach or lungs of the subject, (iv)                treating an infection in the subject's lungs, and                (v) promoting health (all claimed).    ADVANTAGE - The capsule inhaler directly delivers dry                powder agent to the subject.    DETAILED DESCRIPTION - Capsule inhaler (100) comprises (a) (i) a main                portion (102) comprising an inner cavity, a                back-wall, and at least one air intake port, where                the inner cavity is sized and configured to receive                a capsule containing a dry powder formulation, (ii)                a opening section coupled to or integral with the                main portion and in fluid communication with the                inner cavity, (iii) an actuator (104) coupled to                the main portion, where the actuator comprises an                elongate member attachable to an end portion of the                capsule, and the actuator is configured to move                between first and second positions to separate the                capsule within the inner cavity, (iv) at least four                longitudinally spaced apart nozzles residing within                the main portion and in fluid communication with                the inner cavity, where each of the nozzles extends                between the inner cavity and back-wall of the main                portion and opposite the opening section                terminating adjacent to and spaced part from, the                back-wall leaving a gap between the nozzles and the                back-wall, and (v) a cover (106) coupled to the                main portion, where one or more of the inner                cavity, elongate member and cover each are                configured to engage with a capsule when inserted                into the inner cavity and assist in separating the                capsule to release the dry powder formulation into                the inner cavity of the inhaler for inhalation by a                subject, and at least two of the nozzles are                positioned and configured to direct airflow                received from the at least one air intake port into                separated segments of the capsule and at least                another two of the nozzles are positioned and                configured to direct bypass airflow received from                the at least one air intake port into the inner                cavity, or (b) (i) a main portion having an inner                cavity formed in it, where the inner cavity is                sized and configured to receive a capsule                containing a dry powder formulation, (ii) a opening                section coupled to or integral with the main                portion and in fluid communication with the inner                cavity, (iii) an actuator coupled to the main                portion, (iv) a first pair of nozzles and a second                pair of nozzles, each pair of nozzles residing                longitudinally spaced apart within the main portion                and in fluid communication with the inner cavity,                where the first and second pair of nozzles extend                between the inner cavity and a back-wall of the                main portion and opposite the opening section                terminating adjacent to, and spaced part from, the                back-wall leaving a gap between the pairs of                nozzles and the back-wall, and (v) a cover coupled                to the main portion, where the first pair of the                nozzles are sized and configured to direct airflow                into a first one of the capsule segments, and the                second pair of the nozzles are sized and configured                to direct bypass air into and/or across the inner                cavity. An INDEPENDENT CLAIM is included for a                method for delivering a dry powder agent to a                subject, which involves (a) providing the capsule                inhaler, (b) removing the cap from the opening                section, (c) opening the cover, (d) inserting a                capsule having two releasably coupled cylindrical                segments with opposing closed and open end portions                and containing the dry powder agent into the inner                cavity, where one segment of the capsule contacts                the inner cavity and the other segment contacts the                elongate member, (e) pivoting the cover to a closed                position to secure one segment of the capsule                between the inner cavity and the cover, (f) placing                the subject's opening over the opening section of                the inhaler, (g) pulling the actuator                longitudinally outwardly from the main portion of                the inhaler to an opened position which                simultaneously causes the elongate member to grip                and pull one segment of the capsule as the other                segment remains held in place between the inner                cavity and the cover, for separating the capsule                and releasing the dry powder agent contained in it,                and (h) inhaling by the subject to create an                airflow stream from the at least one air intake                port through the at least four nozzles into the                inner cavity and separated capsule segments to                receive the released the dry powder agent through                the aperture of the opening section.    DESCRIPTION OF DRAWING(S) - The drawing shows a top perspective view of a                capsule inhaler.    100Inhaler    102Main portion    104Actuator    106Cover    114Cap ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  ;  C02 (Heterocyclic.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  P34 (Sterilising, syringes, electrotherapy (A61L, M, N).)",B01-B03;  B01-B04;  B02-E;  B02-T;  B04-B03E;  B05-A03A4;  B06-D04;  B07-A02B;  B07-D05;  B10-A07B;  B10-B02E;  B10-B02J;  B10-B03B;  B10-C04E5;  B12-M11C;  B14-C03;  B14-E10A;  B14-H01K3;  B14-K01;  B14-S18;  B15-D00;  C01-B03;  C01-B04;  C02-E;  C02-T;  C04-B03B;  C05-A03A4;  C06-D04;  C07-A02B;  C07-D05;  C10-A07B;  C10-B02E;  C10-B02J;  C10-B03B;  C10-C04E5;  C12-M11C;  C14-C03;  C14-E10A;  C14-H01K3;  C14-K01;  C14-S18;  C15-D00;  P34-A02,A61M-015/00,WO2022177716-A1   25 Aug 2022   A61M-015/00   202273Pages: 54   English;  EP4288132-A1   13 Dec 2023   A61M-015/00   202301   English;  US2024042145-A1   08 Feb 2024   A61M-015/00   202413   English,WO2022177716-A1    WOUS013976    27 Jan 2022;   EP4288132-A1    EP756683    27 Jan 2022;   US2024042145-A1    US361220    28 Jul 2023,EP4288132-A1 PCT application Application WOUS013976;   EP4288132-A1 Based on Patent WO2022177716;   US2024042145-A1 Cont of Application WOUS013976;   US2024042145-A1 Provisional Application US149811P,US149811P    16 Feb 2021;  US361220    28 Jul 2023,WO2022177716-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP4288132-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    ,,WO2022177716-A1 -- US20150283338-A1   ;  US20170113008-A1   ;  US20180140789-A1   ;  US20190134323-A1   ;  WO2019215767-A9   PHARMADEVICES SRL (PHAR-Non-standard)   MERCANDELLI A,,88182-1-0-0 K M; 20225-2-0-0 K M; 2535423-1-0-0 K M; 95048-0-0-0 K M; 93655-1-0-0 K M; 106444-0-0-0 K M; 106472-0-0-0 K M; 109093-1-0-0 K M; 2629613-1-0-0 K M; 2021-0-1-0 K M; 100051-1-0-0 K M; 129498-0-0-0 K M; 949-1-0-0 K M; 56978-2-0-0 K M; 110856-0-0-0 K M; 89459-1-0-0 K M; 95479-1-0-0 K M; 140642-1-0-0 K M; 148587-1-0-0 K M; 2535423-1-0-0 CL USE; 2629613-1-0-0 CL USE,,54107; 01391; 61435; 05595,RA00N3 K M; RA09C1 K M; RBOIJP K M; R01254 K M; R00192 K M; R06856 K M; R02007 K M; R18850 K M; R02067 K M; RBEZ9W K M; R01376 K M; RBXMP2 K M; R00292 K M; R01221 K M; R00290 K M; R07423 K M; R00241 K M; RA05XZ K M; R06391 K M; R21762 K M; RA0Q87 K M; RA03HU K M,1254-S; 0192-S; 2007-S; 2067-S; 0292-S; 1221-S; 0290-S; 0241-S
WO2023031397-A1;  CA3230723-A1;  AU2022336665-A1;  IN202427014974-A;  KR2024050375-A;  SG11202401186-A,"New Fc silenced anti-oxidized macrophage migration            inhibitory factor antibody comprising variant Fc region            of wild-type human immunoglobulin G with            substitutions/glycosylation modifications, used to            treat e.g. ovarian cancer",SCHINAGL A;  KERSCHBAUMER R;  THIELE M R,ONCOONE RES & DEV GMBH (ONCO-Non-standard);  ONCOONE RES & DEV GMBH (ONCO-Non-standard);  ONCOONE RES & DEV GMBH (ONCO-Non-standard),2023261393,"   NOVELTY - Fc silenced anti-oxidized macrophage migration                inhibitory factor (oxMlF) antibody comprising a                variant Fc region of a wild-type human                immunoglobulin (Ig)G comprising SEQ ID NO: 1                (having a fully defined sequence of 216 amino acids                as given in the specification) with at least one                amino acid substitutions or glycosylation                modifications, and the following variable domains                e.g. (a1) a light chain variable domain comprising                SEQ ID NO: 2 (having a fully defined sequence of                216 amino acids as given in the specification)                having at least one of amino acid substitutions                Met30Leu, Phe49Tyr, Ala51Gly, Pro80Ser, Trp93Phe or                (a2) a light chain variable domain comprising SEQ                ID NO: 2 (having a fully defined sequence of 107                amino acids as given in the specification) with 1-5                amino acid substitutions further comprising a                conserved tyrosine at position 36, and at least one                of amino acid substitutions Met30Leu, Phe49Tyr,                Ala51Gly, Pro80Ser, Trp93Phe, is new.    USE - The Fc-silenced anti-oxMlF antibody is useful                in for preparation of a medicament for treatment or                detection of solid tumors, treatment of a patient                suffering from inflammatory disease, infectious                disease, preferably treatment of asthma,                vasculitis, arthritis, sepsis, septic shock,                endotoxic shock, toxic shock syndrome, acquired                respiratory distress syndrome, glomerulonephritis,                inflammatory bowel disease, Crohn's disease,                ulcerative colitis, peritonitis, nephritis, NASH                (nonalcoholic steatosis hepatitis), multiple                sclerosis, acute and chronic pancreatitis, Type 1                diabetes, IgA nephropathy, interstitial cystitis,                post COVID syndrome and psoriasis, and treatment of                a patient suffering from hyperproliferative                disorder or cancer, specifically in the treatment                of colorectal cancer, ovarian cancer, breast                cancer, prostate cancer, pancreas cancer, gastric                cancer, and lung cancer (all claimed).    ADVANTAGE - The antibody and the composition: provide the                combination of reduced aggregation potential,                reduced hydrophobicity and Fc silencing which would                render the antibody properties; provide Fc silenced                and aggregation-resistant antibodies against oxMlF                with reduced hydrophobicity; have improved                biochemical properties, preferably reduced                hydrophobicity, and aggregation propensity compared                to the control anti-oxMlF antibody C0008; strongly                reduce antibody-dependentcell-mediated cytotoxicity                (ADCC) and antibody dependent cellular phagocytosis                (ADCP) effector functions; and strongly reduce                complement dependent cytotoxicity (CDC) activity.                Test details are described but no results                given.    DETAILED DESCRIPTION - Fc silenced anti-oxidized macrophage migration                inhibitory factor (oxMlF) antibody, comprising a                variant Fc region of a wild-type human                immunoglobulin (Ig)G comprising SEQ ID NO: 1                (having a fully defined sequence of 216 amino acids                as given in the specification) with at least one                amino acid substitutions or glycosylation                modifications, and the following variable domains:                (a1) a light chain variable domain comprising SEQ                ID NO: 2 (having a fully defined sequence of 216                amino acids as given in the specification) having                at least one of amino acid substitutions Met30Leu,                Phe49Tyr, Ala51Gly, Pro80Ser, Trp93Phe or (a2) a                light chain variable domain comprising SEQ ID NO: 2                (having a fully defined sequence of 107 amino acids                as given in the specification) with 1-5 amino acid                substitutions further comprising a conserved                tyrosine at position 36, and at least one of amino                acid substitutions Met30Leu, Phe49Tyr, Ala51Gly,                Pro80Ser, Trp93Phe, and (b1) a heavy chain variable                domain comprising SEQ ID NO: 3 (having a fully                defined sequence of 118 amino acids as given in the                specification), or (b2) a heavy chain variable                domain comprising SEQ ID NO: 3 and the amino acid                substitutions Leu5Gln and/or Trp97Tyr, or (b3) a                heavy chain variable domain comprising SEQ ID NO: 3                (having a fully defined sequence of 118 amino acids                as given in the specification) having at least one                of amino acid substitutions Leu5Gln or Trp97Tyr,                and 1-5 further amino acid substitutions, where                amino acid positions are numbered according to                Kabat, where the variant Fc region exhibits                decreased Fc&#947; R binding compared to the                wildtype IgG1 Fc region, the antibody or its                antigen binding fragment has reduced aggregation                potential and reduced hydrophobicity compared to an                antibody or its antigen binding fragment comprising                SEQ ID NO: 2 and SEQ ID NO: 3 lacking the amino                acid substitutions. INDEPENDENT CLAIMS are also                included for:    Fc silenced anti-oxMlF antibody comprising a                variant Fc region of a wild-type human IgG having                SEQ ID NO: 1 with at least one amino acid                substitutions or glycosylation modifications,                comprising a light chain CDR1 sequence including                SEQ ID NOs: 72 or 78 (respectively having a fully                defined sequence of 13 amino acids as given in the                specification), and a light chain CDR2 sequence                including SEQ ID NOs: 73, 79, 80, or 81                (respectively having a fully defined sequence of 11                amino acids as given in the specification), and a                light chain CDR3 sequence including SEQ ID NOs: 74                (Gln-Gln-Ser-Phe-Trp-Thr-Pro-Leu-Thr) or 82                (Gln-Gln-Ser-Phe-Phe-Thr-Pro-Leu-Thr), and a heavy                chain CDR1 sequence including SEQ ID NOs: 75                (Ser-Ile-Tyr-Ser-Met-Asn) and a heavy chain CDR2                sequence including SEQ ID NOs: 76 or 83                (respectively having a fully defined sequence of 20                amino acids as given in the specification), and a                heavy chain CDR3 sequence including SEQ ID NOs: 77                or 84 (respectively having a fully defined sequence                of 11 amino acids as given in the specification),                with the provision that SEQ ID NO: 74 and SEQ ID                NO: 77 are not comprised together;    use of Fc-silenced anti-oxMlF antibody in the                treatment or detection of solid tumors, where the                antibody is administered to a subject in a first                step and a HSG hapten is administered in a second                step, where the HSG hapten binds to the antibody                and is labeled with a radionuclide;    isolated nucleic acid encoding the antibody;                and    an expression vector comprising the nucleic                acid. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-C01G;  B04-E01;  B04-E02A;  B04-E03A;  B04-E08;  B04-E99;  B04-G01;  B04-G24;  B04-G27G;  B14-A01;  B14-A02;  B14-A04;  B14-C03;  B14-C09;  B14-E08;  B14-E10C1;  B14-F02;  B14-H01;  B14-K01A;  B14-K01F;  B14-L06;  B14-N07B;  B14-N10;  B14-N12;  B14-N13;  B14-N17C;  B14-S01;  B14-S04;  B14-S06;  D05-H11;  D05-H12A;  D05-H12D;  D05-H12E;  D05-H99,A61K-031/00;  A61K-039/395;  A61K-049/00;  A61K-051/04;  A61P-013/12;  A61P-035/00;  A61P-037/06;  C07K-016/24;  C07K-016/44;  C07K-016/46;  A61K-039/00;  A61K-045/06;  A61K-047/68,WO2023031397-A1   09 Mar 2023   C07K-016/24   202326Pages: 121   English;  CA3230723-A1   09 Mar 2023   C07K-016/24   202420   English;  AU2022336665-A1   21 Mar 2024   C07K-016/24   202424   English;  IN202427014974-A   05 Apr 2024   C07K-016/24   202432   English;  KR2024050375-A   18 Apr 2024   C07K-016/24   202434   ;  SG11202401186-A   28 Mar 2024   C07K-016/24   202448   English,WO2023031397-A1    WOEP074449    02 Sep 2022;   CA3230723-A1    CA3230723    02 Sep 2022;   AU2022336665-A1    AU336665    02 Sep 2022;   IN202427014974-A    IN27014974    29 Feb 2024;   KR2024050375-A    KR708656    02 Sep 2022;   SG11202401186-A    SG11001186    02 Sep 2022,CA3230723-A1 PCT application Application WOEP074449;   AU2022336665-A1 PCT application Application WOEP074449;   AU2022336665-A1 Based on Patent WO2023031397;   IN202427014974-A PCT application Application WOEP074449;   IN202427014974-A Based on Patent WO2023031397;   KR2024050375-A PCT application Application WOEP074449;   KR2024050375-A Based on Patent WO2023031397;   SG11202401186-A PCT application Application WOEP074449;   SG11202401186-A Based on Patent WO2023031397,EP194701    03 Sep 2021;  EP204108    22 Oct 2021;  EP155394    07 Feb 2022;  SG11001186    22 Feb 2024;  CA3230723    29 Feb 2024;  KR708656    14 Mar 2024,WO2023031397-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA            ,,"WO2023031397-A1 -- US20160287732-A1   ;  WO2009086920-A1   BAXTER INT INC (BAXT);  BAXTER HEALTHCARE SA (BAXT);  DYAX CORP (DYAX)   HOET R,  KERSCHBAUMER R,  MUDDE C G,  MUELLBERG J,  RIEGER M,  SCHEIFLINGER F,  THIELE M;  WO2017178493-A1   SYMPHOGEN AS (SYPG)   LINDSTED T,  GJETTING T,  GALLER G R,  GAD M,  GRANDAL M M,  KOEFOED K,  KRAGH M,  HORAK I D,  BOUQUIN T,  PEDERSEN M W;  WO2019234241-A1   ONCOONE RES & DEV GMBH (ONCO-Non-standard)   THIELE M R,  SCHINAGL A,  KERSCHBAUMER R;  WO2022167474-A1   ONCOONE RES & DEV GMBH (ONCO-Non-standard)   SCHINAGL A,  KERSCHBAUMER R,  THIELE R M;  US20050025709-A1   ;  US20090240037-A1   ","WO2023031397-A1  MOHAMED ALTAI ET          AL: ""Pretargeted Imaging and Therapy"", THE JOURNAL OF          NUCLEAR MEDICINE, vol. 58, no. 10, 7 July 2017          (2017-07-07), US, pages 1553 - 1559, XP055764118, ISSN:          0161-5505, DOI:          10.2967/jnumed.117.189944,relevantClaims[10,11],relevantPassages[whole          document, especially Figures 1, 3; pages 1555-1556,          ""Approach 2: Bispecific antibodies""];  H. KARACAY ET AL:          ""Pretargeted Radioimmunotherapy of Pancreatic Cancer          Xenografts: TF10-90Y-IMP-288 Alone and Combined with          Gemcitabine"", THE JOURNAL OF NUCLEAR MEDICINE, vol. 50,          no. 12, 30 November 2009 (2009-11-30), pages 2008 - 2016,          XP055186129, ISSN: 0161-5505, DOI:          10.2967/jnumed.109.067686,relevantClaims[10,11],relevantPassages[whole          document, especially Figures 1-2; page 2015,          ""Conclusion""];  RIJ CATHARINA M VAN          ET AL: ""Pretargeted immuno-PET and radioimmunotherapy of          prostate cancer with an anti-TROP-2 x anti-HSG bispecific          antibody"", EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND          MOLECULAR IMAGING, SPRINGER BERLIN HEIDELBERG,          BERLIN/HEIDELBERG, vol. 40, no. 9, 15 May 2013          (2013-05-15), pages 1377 - 1383, XP035341747, ISSN:          1619-7070, [retrieved on 20130515], DOI:          10.1007/S00259-013-2434-7,relevantClaims[10,11],relevantPassages[whole          document, especially Figures 5-6; page 1383, left-hand          column, second paragraph];  ""CHAPTER 10:          Antibody Fc engineering for optimal antibody performance          ED - William R Strohl; Lila M Strohl"", 1 January 2012,          THERAPEUTIC ANTIBODY ENGINEERING (IN: WOODHEAD PUBLISHING          SERIES IN BIOMEDICINE), WP, WOODHEAD PUBLISHING, PAGE(S)          225 - 249, ISBN: 978-1-908818-09-6,          XP009181736,relevantClaims[1-18],relevantPassages[Section          10.5; Table 10.4];            SAMBROOK ET AL.: ""In Journal of Liquid Chromatography and          Related Technologies"", vol. 1 -3, 2012, COLD SPRING          HARBOR LABORATORY PRESS, article ""A review size-exclusion          chromatography for the analysis of protein          biotherapeutics and their aggregates"", pages: 2923 -          2950;            BRINKMANN UKONTERMANN R.E.: ""The making of bispecific          antibodies"", MABS, vol. 9, no. 2, 2017, pages 182 - 212,          XP055531122, DOI: 10.1080/19420862.2016.1268307;            WHO DRUG INFORMATION, vol. 28, no. 2, 2014;            KABAT ET AL.: ""Sequence of Proteins of Immunological          Interest"", 1983, U.S. DEPT. OF HEALTH AND HUMAN          SERVICES;            SCHINAGL, A. ET AL.: ""Role of the Cysteine 81 Residue of          Macrophage Migration Inhibitory Factor as a Molecular          Redox Switch"", BIOCHEMISTRY, vol. 57, no. 9, 2018, pages          1523 - 1532, XP055529991, Retrieved from the Internet          &lt;URL:https://doi.org/10.1021/acs.biochem.7b01156&gt;          DOI: 10.1021/acs.biochem.7b01156;            AEBERLI D ET AL.: ""Endogenous macrophage migration          inhibitory factor modulates glucocorticoid sensitivity in          macrophages via effects on MAP kinase phosphatase-1 and          p38 MAP kinase"", FEBS LETT., vol. 580, no. 3, 2006, pages          974 - 981, XP028030448, DOI:          10.1016/j.febslet.2006.01.027;            BACHER M ET AL.: ""An essential regulatory role for          macrophage migration inhibitory factor in T-cell          activation"", PROC NATL ACAD SCI USA., vol. 93, no. 15,          1996, pages 7849 - 7854, XP001119066, DOI:          10.1073/pnas.93.15.7849;            BACHER M ET AL.: ""Migration inhibitory factor expression          in experimentally induced endotoxemia"", AM J PATHOL.,          vol. 150, no. 1, 1997, pages 235 - 246,          XP001062227;            BANDO, H. ET AL.: ""Expression of macrophage migration          inhibitory factor in human breast cancer: association          with nodal spread"", JPN J CANCER RES, vol. 93, 2002,          pages 389 - 396;            BARNES PJADCOCK IM: ""How do corticosteroids work in          asthma?"", ANN INTERN MED, vol. 139, no. 5, 2003, pages          359 - 370;            BERNHAGEN, J. ET AL.: ""MIF is a pituitary-derived          cytokine that potentiates lethal endotoxaemia"", NATURE,          vol. 365, 1993, pages 756 - 759;            BERNHAGEN, J.: "" Purification, bioactivity, and secondary          structure analysis of mouse and human macrophage          migration inhibitory factor (MIF)"", BIOCHEMISTRY, vol.          33, pages 14144 - 14155;            BERNHAGEN, J. ET AL.: ""MIF is a noncognate ligand of CXC          chemokine receptors in inflammatory and atherogenic cell          recruitment"", NAT MED, vol. 13, 2007, pages 587 - 596,          XP008140753, DOI: 10.1038/nm1567;            BLOOM B.R.BENNET, B.: ""Mechanism of a reaction in vitro          associated with delayed-type hypersensitivity"", SCIENCE,          vol. 153, 1966, pages 80 - 82;            BOZZA FA ET AL.: ""Macrophage migration inhibitory factor          levels correlate with fatal outcome in sepsis"", SHOCK,          vol. 22, no. 4, 2004, pages 309 - 313;            BUCALA, R.DONNELLY, S. C: ""Macrophage migration          inhibitory factor: a probable link between inflammation          and cancer"", IMMUNITY, vol. 26, 2007, pages 281 -          285;            CALANDRA T ET AL.: ""The macrophage is an important and          previously unrecognized source of macrophage migration          inhibitory factor"", J EXP MED., vol. 179, no. 6, 1994,          pages 1895 - 1902, XP000615270, DOI:          10.1084/jem.179.6.1895;            CALANDRA T ET AL.: ""MIF as a glucocorticoid-induced          modulator of cytokine production"", NATURE, vol. 377, no.          6544, 1995, pages 68 - 71;            CHEN, R. ET AL.: ""Pilot study of blood biomarker          candidates for detection of pancreatic cancer"", PANCREAS,          vol. 39, 2010, pages 981 - 988;            CHOTHIA C. ET AL.: ""Canonical structures for the          hypervariable regions of immunoglobulins"", J.MOL.BIOL.,          vol. 196, 1987, pages 901 - 17, XP024010426, DOI:          10.1016/0022-2836(87)90412-8;            COLEMAN, A. M ET AL.: ""Cooperative regulation of          non-small cell lung carcinoma angiogenic potential by          macrophage migration inhibitory factor and its homolog,          D-dopachrome tautomerase"", J IMMUNOL, vol. 181, 2008,          pages 2330 - 2337, XP002664500;            CONROY, H. ET AL.: ""Inflammation and cancer: macrophage          migration inhibitory factor (MIF)--the potential missing          link"", QJM, vol. 103, 2010, pages 831 - 836;            COUSSENS, L. MWERB, Z.: ""Inflammation and cancer"",          NATURE, vol. 420, 2002, pages 860 - 867, XP002356258,          DOI: 10.1038/nature01322;            DAVID, J.R.: ""Delayed hypersensitivity in vitro: its          mediation by cell-free substances formed by lymphoid          cell-antigen interaction"", PROC. NATL. ACAD. SCI. U.S.A.,          vol. 56, 1966, pages 72 - 77, XP055098165;  DE          JONG ET AL.: ""Development of chronic colitis is dependent          on the cytokine MIF"", NAT. IMMUNOL., vol. 1061, no. 11,          2001, pages 6;            DEL RINCON ID ET AL.: ""High incidence of cardiovascular          events in a rheumatoid arthritis cohort not explained by          traditional cardiac risk factors"", ARTHRITIS RHEUM, vol.          44, no. 12, 2001, pages 2737 - 2745;            EHRENMANN F. ET AL.: ""MGT/3Dstructure-DB and          IMGT/DomainGapAlign: a database and a tool for          immunoglobulins or antibodies, T cell receptors, MHC,          IgSF and MhcSF"", NUCLEIC ACIDS RES., vol. 38, 2010, pages          D301 - 307, XP055247165, DOI:          10.1093/nar/gkp946;            EL-MAGADMI M ET AL.: ""Systemic lupus erythematosus: an          independent risk factor for endothelial dysfunction in          women"", CIRCULATION, vol. 110, no. 4, 2004, pages 399 -          404;            EMONTS M ET AL.: ""Association between high levels of          blood macrophage migration inhibitory factor,          inappropriate adrenal response, and early death in          patients with severe sepsis"", CLIN INFECT DIS., vol. 44,          no. 10, 2007, pages 1321 - 1328;            ESTEP P. ET AL.: ""An alternative assay to hydrophobic          interaction chromatography for high-throughput          characterization of monoclonal antibodies"", MABS, vol. 7,          no. 3, 2015, pages 553 - 561, XP055407802, DOI:          10.1080/19420862.2015.1016694;            EWERT S. ET AL.: ""Structure-based improvement of the          biophysical properties of immunoglobulin VH domains with          a generalizable approach"", BIOCHEMISTRY, vol. 42, no. 6,          2003, pages 1517 - 28, XP008052212, DOI:          10.1021/bi026448p;            FINGERLE-ROWSON G ET AL.: ""Regulation of macrophage          migration inhibitory factor expression by glucocorticoids          in vivo"", AM J PATHOL, vol. 162, no. 1, 2003, pages 47 -          56;  HA          J-H. ET AL.: ""Immunoglobulin Fc heterodimer platform          technology: From design to applications in therapeutic          antibodies and proteins"", FRONTIERS IMMUNOL., vol. 7,          2016;            HAGEMANN, T.BALKWILL, F.: ""MIFed about cancer?"",          GASTROENTEROLOGY, vol. 129, 2005, pages 1785 - 1787,          XP005155794, DOI: 10.1053/j.gastro.2005.09.039;            HAGEMANN, T. ET AL.: ""Ovarian cancer cell-derived          migration inhibitory factor enhances tumor growth,          progression, and angiogenesis"", MOL CANCER THER, vol. 6,          2007, pages 1993 - 2002, XP055168609, DOI:          10.1158/1535-7163.MCT-07-0118;            HUDSON, J. D. ET AL.: ""A proinflammatory cytokine          inhibits p53 tumor suppressor activity"", J EXP MED, vol.          190, 1999, pages 1375 - 1382, XP000882506, DOI:          10.1084/jem.190.10.1375;            HUSSAIN F ET AL.: ""Human anti-macrophage migration          inhibitory factor antibodies inhibit growth of human          prostate cancer cells in vitro and in vivo"", MOL CANCER          THER., vol. 12, no. 7, 2013, pages 1223 - 34,          XP055199203, DOI: 10.1158/1535-7163.MCT-12-0988;            LANELLO AAHMAD A.: ""Role of antibody-dependent          cell-mediated cytotoxicity in the efficacy of therapeutic          anti-cancer monoclonal antibodies"", CANCER AND METASTASIS          REVIEW, vol. 24, 2005, pages 487 - 499, XP019205202, DOI:          10.1007/s10555-005-6192-2;            KABAT ET AL.: ""Sequences of Proteins of Immunological          Interest"", vol. 1-3, 1991, NIH PUBLICATION;            KAMIMURA, A.: "" Intracellular distribution of macrophage          migration inhibitory factor predicts the prognosis of          patients with adenocarcinoma of the lung"", CANCER, vol.          89, 2000, pages 334 - 341, XP071125347, DOI:          10.1002/1097-0142(20000715)89:2&lt;334::AID-CNCR18&gt;3.0.CO;2-N;            KARACAY H. ET AL.: ""Pretargeting with bispecifics aCEA x          aHSG"", CLIN CANCER RES, vol. 11, no. 21, 2005;            KARIN, M.: ""NF-kappaB as a critical link between          inflammation and cancer"", COLD SPRING HARB PERSPECT BIOL,          vol. 1, 2009, pages a000141;            KENANOVA V. ET AL.: ""Tailoring the Pharmacokinetics and          Positron Emission Tomography Imaging Properties of          Anti-Carcinoembryonic Antigen Single-Chain Fv-Fc Antibody          Fragments"", CANCER RES., vol. 65, 2005, pages 622 -          633;            KESSENBROCK, K. ET AL.: ""Matrix metalloproteinases:          regulators of the tumor microenvironment"", CELL, vol.          141, 2010, pages 52 - 67, XP055388819, DOI:          10.1016/j.cell.2010.03.015;            LEFRANC MP: ""Unique database numbering system for          immunogenetic analysis"", IMMUNOL TODAY, vol. 18, 1997,          pages 509, XP004093509, DOI:          10.1016/S0167-5699(97)01163-8;            LIU R. ET AL.: ""Fc-Engineering for modulated effector          functions-improving antibodies for cancer treatment"",          ANTIBODIES, vol. 9, 2020, pages 64, XP055918764, DOI:          10.3390/antib9040064;            LUE, H ET AL.: ""Macrophage migration inhibitory factor          (MIF) promotes cell survival by activation of the Akt          pathway and role for CSN5/JAB1 in the control of          autocrine MIF activity"", ONCOGENE, vol. 26, 2007, pages          5046 - 5059, XP037745272, DOI:          10.1038/sj.onc.1210318;            MACCALLUM R.M ET AL.: ""Antibody-antigen Interactions:          Contact Analysis and Binding Site Topography"",          J.MOL.BIOL., vol. 262, no. 5, 1996, pages 732 - 745,          XP002242391, DOI: 10.1006/jmbi.1996.0548;            MAHALINGAM D. ET AL., ASCO, 2015;            MAHALINGAM ET AL.: ""Phase I study of Imalumab (BAX69), a          fully human recombinant antioxidized macrophage migration          inhibitory factor antibody in advanced solid tumours"", BR          J CLIN PHARMACOL., vol. 86, no. 9, 2020, pages 1836 -          1848, XP071603245, DOI: 10.1111/bcp.14289;            MANZI S ET AL.: ""Prevalence and risk factors of carotid          plaque in women with systemic lupus erythematosus"",          ARTHRITIS RHEUM., vol. 42, no. 1, 1999, pages 51 -          60;            MEYER-SIEGLER, K.HUDSON, P. B: ""Enhanced expression of          macrophage migration inhibitory factor in prostatic          adenocarcinoma metastases"", UROLOGY, vol. 48, 1996, pages          448 - 452;            MITCHELL RA ET AL.: ""Sustained mitogen-activated protein          kinase (MAPK) and cytoplasmic phospholipase A2 activation          by macrophage migration inhibitory factor (MIF).          Regulatory role in cell proliferation and glucocorticoid          action"", J BIOL CHEM., vol. 274, no. 25, 1999, pages          18100 - 18106, XP002555742, DOI:          10.1074/jbc.274.25.18100;            MITCHELL RA ET AL.: ""Macrophage migration inhibitory          factor (MIF) sustains macrophage proinflammatory function          by inhibiting p53: regulatory role in the innate immune          response"", PROC NATL ACAD SCI USA., vol. 99, no. 1, 2002,          pages 345 - 350, XP003021865, DOI:          10.1073/pnas.012511599;            MITCHELL, R. A.BUCALA, R.: ""Tumor growth-promoting          properties of macrophage migration inhibitory factor          (MIF"", SEMIN CANCER BIOL, vol. 10, 2000, pages 359 - 366,          XP002220300, DOI: 10.1006/scbi.2000.0328;            MORAND EF ET AL.: ""Macrophage migration inhibitory factor          in rheumatoid arthritis: clinical correlations"",          RHEUMATOLOGY (OXFORD, vol. 41, no. 5, 2002, pages 558 -          562;            MORRISON, S.L. ET AL.: ""Chimeric human antibody          molecules: mouse antigen-binding domains with human          constant region domains"", PROC. NATL. ACAD. SCI., vol.          81, 1984, pages 6851 - 6855, XP002014405, DOI:          10.1073/pnas.81.21.6851;            NATSUME A. ET AL.: ""Improving effector functions of          antibodies for cancer treatment: Enhancing ADCC and CDC"",          DRUG, DESIGN, DEVELOPMENT AND THERAPY, vol. 3, 2009,          pages 7 - 16, XP002727883, DOI:          10.2147/DDDT.S4378;            NIINO M. ET AL.: ""Macrophage migration inhibitory factor          in the cerebrospinal fluid of patients with conventional          and optic-spinal forms of multiple sclerosis and          neuro-Behget's disease"", J NEUROL SCI, vol. 179, no. 1-2,          2000, pages 127 - 131;            ONODERA S. ET AL.: ""High expression of macrophage          migration inhibitory factor in the synovial tissues of          rheumatoid joints"", CYTOKINE, vol. 11, no. 2, 1999, pages          163 - 167, XP002276324, DOI:          10.1006/cyto.1998.0402;            PETKOVA, S.B. ET AL.: ""Enhanced half-life of genetically          engineered human IgG1 antibodies in a humanized FcRn          mouse model: potential application in humorally mediated          autoimmune disease"", INT'L. IMMUNOL., vol. 18, no. 12,          2006, pages 1759 - 1769, XP002539987, DOI:          10.1093/intimm/dxl110;            PISU M. ET AL.: ""The cost of glucocorticoid-associated          adverse events in rheumatoid arthritis"", RHEUMATOLOGY          (OXFORD, vol. 44, no. 6, 2005, pages 781 - 788,          XP008055216, DOI: 10.1093/rheumatology/keh594;            PYZIK M ET AL.: ""The Neonatal Fc Receptor (FcRn): A          Misnomer?"", FRONTIERS IN IMMUNOL., vol. 10, no. 1540,          2019, pages 1 - 24;            RAMSEY-GOLDMAN R: ""Missed opportunities in physician          management of glucocorticoid-induced osteoporosis?"",          ARTHRITIS RHEUM., vol. 46, no. 12, 2002, pages 3115 -          3120;            REN, Y. ET AL.: ""Upregulation of macrophage migration          inhibitory factor contributes to induced N-Myc expression          by the activation of ERK signaling pathway and increased          expression of interleukin-8 and VEGF in neuroblastoma"",          ONCOGENE, vol. 23, 2004, pages 4146 - 4154, XP037738125,          DOI: 10.1038/sj.onc.1207490;            RENDON, B. E ET AL.: ""Regulation of human lung          adenocarcinoma cell migration and invasion by macrophage          migration inhibitory factor"", J BIOL CHEM, vol. 282,          2007, pages 29910 - 29918;            RENDON, B. E. ET AL.: ""Mechanisms of macrophage migration          inhibitory factor (MIF)-dependent tumor          microenvironmental adaptation"", EXP MOL PATHOL, vol. 86,          2009, pages 180 - 185, XP026096502, DOI:          10.1016/j.yexmp.2009.01.001;            RINTA S. ET AL.: ""Apoptosis-related molecules in blood in          multiple sclerosis"", J NEUROIMMUNOL., vol. 205, no. 1-2,          2008, pages 135 - 141, XP025743400, DOI:          10.1016/j.jneuroim.2008.09.002;            ROSSI EA ET AL.: ""Stably tethered multifunctional          structures of defined composition made by the dock and          lock method for use in cancer targeting"", PNAS, vol. 103,          no. 18, 2006, pages 6841 - 6846, XP008123542, DOI:          10.1073/PNAS.0600982103;            SAMPEY AV ET AL.: ""Regulation of synoviocyte          phospholipase A2 and cyclooxygenase 2 by macrophage          migration inhibitory factor"", ARTHRITIS RHEUM, vol. 44,          no. 6, 2001, pages 1273 - 1280;            SAUNDERS K.O: ""Conceptual approaches to modulating          antibody effector functions and circulation half-life"",          FRONTIERS IMMUNOL., vol. 10, 2019, pages 1 - 20;            SHARKEY RM ET AL.: ""Pretargeting with bispecific aCD20 x          aHSG"", LEUKEMIA, vol. 15, 2005, pages 1064 -          1069;            SCHACKE H. ET AL.: ""Mechanisms involved in the side          effects of glucocorticoids"", PHARMACOL THER, vol. 96, no.          1, 2002, pages 23 - 43, XP002715366, DOI:          10.1016/S0163-7258(02)00297-8;            SCHINAGL. A. ET AL.: ""Oxidized macrophage migration          inhibitory factor is a potential new tissue marker and          drug target in cancer"", ONCOTARGET, vol. 7, no. 45, 8          November 2016 (2016-11-08), pages 73486 - 73496,          XP055528463, DOI: 10.18632/oncotarget.11970;            SHIMIZU, T: ""High expression of macrophage migration          inhibitory factor in human melanoma cells and its role in          tumor cell growth and angiogenesis"", BIOCHEM BIOPHYS RES          COMMUN, vol. 264, 1999, pages 751 - 758, XP001008703,          DOI: 10.1006/bbrc.1999.1584;            SHIMIZU T. ET AL.: ""High macrophage migration inhibitory          factor (MIF) serum levels associated with extended          psoriasis"", J INVEST DERMATOL, vol. 116, no. 6, 2001,          pages 989 - 990;            SOLOMON DH ET AL.: ""Cardiovascular morbidity and          mortality in women diagnosed with rheumatoid arthritis"",          CIRCULATION, vol. 107, no. 9, 2003, pages 1303 -          1307;            SPIESS C. ET AL.: ""Alternative molecular formats and          therapeutic applications for bispecific antibodies"",          MOL.IMMUNOL., vol. 67, 2015, pages 95 - 106, XP029246892,          DOI: 10.1016/j.molimm.2015.01.003;            SPRONG T ET AL.: ""Macrophage migration inhibitory factor          (MIF) in meningococcal septic shock and experimental          human endotoxemia"", SHOCK, vol. 27, no. 5, 2007, pages          482 - 487;            STROHL W.R. ET AL.: ""Therapeutic Antibody Engineering"",          vol. 11, 2012, WOODHEAD PUBLISHING SERIES IN BIOMEDICINE,          article ""Antibody Fc engineering for optimal antibody          performance"", pages: 225 - 249;            TAKAHASHI, N ET AL.: ""Involvement of macrophage migration          inhibitory factor (MIF) in the mechanism of tumor cell          growth"", MOL MED, vol. 4, 1998, pages 707 - 714,          XP009022114;            TAM FWK ET AL.: ""Development of scarring and renal          failure in a rat model of crescentic glomerulonephritis"",          NEPHROL DIAL TRANSPLANT, vol. 14, 1999, pages 1658 -          1666, XP000960567, DOI: 10.1093/ndt/14.7.1658;            TANG J ET AL.: ""Comprehensive analysis of the clinical          immuno-oncology landscape"", ANN ONCOL., vol. 29, no. 1,          2018, pages 84 - 91;            THIELE, M. ET AL.: ""Selective Targeting of a          Disease-Related Conformational Isoform of Macrophage          Migration Inhibitory Factor Ameliorates Inflammatory          Conditions"", JOURNAL OF IMMUNOLOGY, vol. 195, no. 5,          2017, pages 2343 - 2352, XP055528478, Retrieved from the          Internet          &lt;URL:https://doi.org/10.4049/jimmunol.1500572&gt;          DOI: 10.4049/jimmunol.1500572;            VAN DER KANT, R. ET AL.: ""Prediction and Reduction of the          Aggregation of Monoclonal Antibodies"", J.MOL.BIOL., vol.          429, no. 8, 2017, pages 1244 - 1261;            VERJANS, E. ET AL.: ""Dual role of macrophage migration          inhibitory factor (MIF) in human breast cancer"", BMC          CANCER, vol. 9, 2009, pages 230, XP021057608, DOI:          10.1186/1471-2407-9-230;            WALSH LJ ET AL.: ""Use of oral corticosteroids in the          community and the prevention of secondary osteoporosis: a          cross sectional study"", BMJ, vol. 313, no. 7053, 1996,          pages 344 - 346;            WANG P ET AL.: ""A systematic assessment of MHC class II          peptide binding predictions and evaluation of a consensus          approach"", PLOS COMPUT BIOL, vol. 4, no. 4, 2008, pages          e1000048, XP002598739, DOI:          10.1371/journal.pcbi.1000048;            WANG P ET AL.: ""Peptide binding predictions for HLA DR,          DP and DQ molecules"", BMC BIOINFORMATICS, vol. 11, 2010,          pages 568, XP021085842, DOI:          10.1186/1471-2105-11-568;            WEI LI ET AL.: ""Antibody Aggregation: Insights from          Sequence and Structure"", ANTIBODIES, vol. 5, no. 3, 2016,          pages 19, XP055467473, DOI:          10.3390/antib5030019;            WILLUDA J. ET AL.: ""High thermal stability is essential          for tumor targeting of antibody fragments: engineering of          a humanized anti-epithelial glycoprotein-2 (epithelial          cell adhesion molecule) single-chain Fv fragment"", CANCER          RES., vol. 59, no. 22, 1999, pages 5758 - 67,          XP002249463;            WINNER, M ET AL.: ""Amplification of Tumor Hypoxic          Responses by Macrophage Migration Inhibitory          Factor-Dependent Hypoxia-Inducible Factor Stabilization"",          CANCER RESEARCH, vol. 67, 2007, pages 186 - 193",184587-0-0-0 K M,,,RA00C8 K M,
WO2022192162-A1,"New substituted amide compound used in composition            for treating fungal infection e.g. candidemia, oral            candidiasis, vulvovaginal candidiasis and aspergillosis            in human, plants and animals",BAUGH S D P;  FREEMAN K B;  PELLETIER J C;  REITZ A B;  SCOTT R W;  WEAVER D G;  WHITMAN D B,FOX CHASE CHEM DIVERSITY CENT INC (FOXC-Non-standard),2022B6728W,"   NOVELTY - A substituted amide compound (I), is                new.    USE - New substituted amide compound used in                composition for treating fungal infection e.g.                candidemia, oral candidiasis, vulvovaginal                candidiasis, aspergillosis, allergic                bronchopulmonary aspergillosis, allergic                aspergillus sinusitis, invasive aspergillosis,                disseminated aspergillosis, cryptococcosis,                pulmonary cryptococcosis, meningeal cryptococcosis,                skin keratitis, athlete's foot, ringworm, ocular                keratitis, onychomycosis, sinusitis,                endophthalmitis, otitis, endocarditism pneumonia,                osteomyelitis, meningitis, ventriculitis, COVID-19                associated pulmonary aspergillosis (CAPA) and                influenza associated pulmonary aspergillosis (IAPA)                in human, plants and animals e.g. cattle, sheep,                pigs, goats, horses, donkeys, mules, buffalo, oxen,                llamas, camels, dogs, cats, horses, rabbits,                ferrets, and guinea pigs. The fungal infection in                plant or plants includes wilt disease in tomato,                wilt disease cotton, wilt disease banana, wilt of                gram, downy mildew of cereals, damping of seedling,                rot of ginger, late blight of potato, early blight                of potato, blast disease of rice, powdery mildews,                tikka disease of groundnut, leaf rust of coffee,                red rot of sugarcane, brown rot in pear, brown rot                in plum, brown rot in peach, leaf spot of oats,                black wart disease of potato, yellow rust of wheat,                white rust of crucifers, maize smut, loose smut of                wheat, flag smut of wheat, covered smut of barley,                black rust of wheat, bakanese disease, foot rot of                rice and ergot disease of rye (all claimed).    ADVANTAGE - None given.    DETAILED DESCRIPTION - A substituted amide compound of formula (I) or                its enantiomers, diastereomers, hydrates, solvates,                salts, prodrugs or complexes, is new.    A =group chosen from 20 groups e.g. groups of                formulae (1)-(5);    X =N or CR ;    X =N or CR ;    X =O or S;    X =O, S or NR ;    A =group chosen from 23 groups e.g. groups of                formulae (6)-(10);    X =N or CR ;    X =N or CR ;    A =group chosen from 20 groups e.g. groups of                formulae (11)-(15);    m=0, 1 or 2;    n=1, 2 or 3;    A =group chosen from 23 groups e.g. groups                (11)-(15);    q=0, 1, 2, or 3;    t=1, 2, or 3;    R =H, 1-4C alkyl or 3-5C branched alkyl;    R =H, 1-4C alkyl, 3-5C branched alkyl, 1-4C                alkoxy, 3-5C branched alkoxy, F, Cl, CN, OCF , CHF                , CF , N(R )(R ) or group of formula (21) or (22),                SR or SO R ;    Y -Y =O or NR ;    R ,R =H, 1-4C alkyl, 3-5C branched alkyl, 1-4C                alkoxy, 3-5C branched alkoxy, F, Cl, CN, OCF , CHF                , CF , N(R )(R ) or group of formula (21) or (24),                SR or SO R ;and    R =H, 1-4C alkyl, 3-5C branched alkyl, 1-4C                alkoxy, 3-5C branched alkoxy, F, Cl, CN, OCF , CHF                , CF , N(R )(R ) or group of formula (21) or (26),                SR or SO R .    INDEPENDENT CLAIMS are included for the                following: (i) composition, which comprises the                compound (I), (ii) treating or preventing disease                or conditions associated with fungal infection in a                subject, which involves selecting a subject, and                administering the compound (I) to the subject,                (iii) treating or preventing fungal infection in a                plant or plants including wilt disease in tomato,                wilt disease cotton, wilt disease banana, wilt of                gram, downy mildew of cereals, damping of seedling,                rot of ginger, late blight of potato, early blight                of potato, blast disease of rice, powdery mildews,                tikka disease of groundnut, leaf rust of coffee,                red rot of sugarcane, brown rot in pear, brown rot                in plum, brown rot in peach, leaf spot of oats,                black wart disease of potato, yellow rust of wheat,                white rust of crucifers, maize smut, loose smut of                wheat, flag smut of wheat, covered smut of barley,                black rust of wheat, bakanese disease, foot rot of                rice, and ergot disease of rye, which involves                selecting a plant or plants, and administering the                compound (I) to the plant or plants, (iv) treating                or preventing fungal infections in an animal chosen                from domesticated animals, livestock, and companion                animals, which involves selecting the domesticated                animal, livestock, or companion animal, and                administering the compound (I) to the domesticated                animal, livestock, or companion animal, (v)                treating or preventing aspergillosis infections in                an animal chosen from the group consisting of                horses, cattle, sheep, goats, dogs and cats, which                involves selecting the animal, administering the                compound (I) to the animal, (vi) treating or                preventing mucormycosis infections in an animal                chosen from horses, cattle, sheep, goats, dogs and                cats, which involves selecting the animal, and                administering the compound (I) to the animal, (vii)                treating or preventing coccidioidomycosis in an                animal chosen from dogs and cats, the                coccidioidomycosis infection is caused by infection                with an organism chosen from Coccidioides                immitisand C.posadasii, which involves selecting an                animal, and administering the compound (I) to the                animal, (viii) treating or preventing blastomycosis                in an animal chosen from dogs and cats, in which                the blastomycosis is caused by infection with                Blastomyces dermatitidis, which involves selecting                the animal, and administering the compound (I) to                the animal, (ix) treating or preventing                Paracoccidioidomycosis in dogs caused by infection                with Paracoccidioides brasiliensis, which involves                selecting a dog, and administering the compound (I)                to the dog, (x) treating or preventing                dermatophytosis (ringworm) in an animal chosen from                cats and dogs, in which the dermatophytosis                (ringworm) is caused by infection with an organism                chosen from Microsporumcanis, M.gypseum, and                Trichophyton mentagrophytes, which involves                selecting a dog or cat, and administering the                compound (I) to the dog or cat, (xi) treating or                preventing cryptococcosis in an animal chosen from                dogs and cats, in which the cryptococcosis is                caused by infection with an organism chosen from                Cryptococcus neoformansand C.gattii, which involves                selecting a dog or cat, and administering the                compound (I) to the dog or cat, and (xii) treating                or preventing histoplasmosis in dogs, in which the                histoplasmosis is caused by infection with                Histoplasma capsulatum, which involves selecting a                dog, and administering the compound (I) to the dog.                Full definitions are given in the DEFINITIONS (Full                Definitions) Field         ",,,B03 (Other heterocyclics.);  C02 (Heterocyclic.),B07-H;  B10-A10;  B10-A15;  B10-A17;  B14-A01;  B14-A02B2;  B14-A04;  B14-C03;  B14-K01;  B14-N01;  B14-N03;  B14-N04;  B14-N16;  B14-N17;  C07-H;  C10-A10;  C10-A15;  C10-A17;  C14-A01;  C14-A02B2;  C14-A04;  C14-A06;  C14-C03;  C14-K01;  C14-N01;  C14-N03;  C14-N04;  C14-N16;  C14-N17,A61K-031/167;  A61K-031/341;  A61K-031/445;  A61K-031/4545;  C07D-211/70;  C07D-295/13;  C07D-307/30;  C07D-333/24;  C07D-401/12,WO2022192162-A1   15 Sep 2022   C07D-401/12   202283Pages: 774   English,WO2022192162-A1    WOUS019220    08 Mar 2022,,US158811P    09 Mar 2021,WO2022192162-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2022192162-A1 -- US20130252964-A1   ;  WO2004002430-A2   COMBINATORX INC (COBM)   JOHANSEN L M,  SERBEDZIJA G N,  AUSPITZ B A,  ZIMMERMANN G R,  KEITH C,  NICHOLS J M,  GAW D A;  WO2004026264-A2   BOTYANSZKI J (BOTY-Individual);  SHI D (SHID-Individual);  ROBERTS C D (ROBE-Individual);  GEZGINCI M H (GEZG-Individual);  VALDEZ S C (VALD-Individual);  SATTARZADEH S (SATT-Individual)   BOTYANSZKI J,  SHI D,  ROBERTS C D,  GEZGINCI M H,  VALDEZ S C,  SATTARZADEH S","WO2022192162-A1  BAUGH SIMON D.P.;          CHALY ANNA; WEAVER DAMIAN G.; PELLETIER JEFFREY C.;          THANNA SANDEEP; FREEMAN KATIE B.; REITZ ALLEN B.; SCOTT          RICH: ""Highly potent, broadly active antifungal agents          for the treatment of invasive fungal infections"",          BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER,          AMSTERDAM NL, vol. 33, 13 December 2020 (2020-12-13),          Amsterdam NL , XP086476659, ISSN: 0960-894X, DOI:          10.1016/j.bmcl.2020.127727,relevantClaims[1-14,23-42],relevantPassages[the          whole document];  ANTHONY NAHOUM G.,          BREEN DAVID, CLARKE JOANNA, DONOGHUE GAVIN, DRUMMOND          ALLAN J., ELLIS ELIZABETH M., GEMMELL CURTIS G.,          HELESBEUX: ""Antimicrobial Lexitropsins Containing Amide,          Amidine, and Alkene Linking Groups"", JOURNAL OF MEDICINAL          CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 50, no.          24, 1 November 2007 (2007-11-01), US , pages 6116 - 6125,          XP055966421, ISSN: 0022-2623, DOI:          10.1021/jm070831g,relevantClaims[1-14,23-42],relevantPassages[the          whole document]", N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N,227866401 N,00090; 00096; 00211; 00347,RD8S5L N; RD8S5M N; RD8S5N N; RD8S5O N; RD8S5P N; RD8S5Q N; RD8S5R N; RD8S5S N; RD8S5T N; RD8S5U N; RD8S5V N; RD8S5W N; RD8S5X N; RD8S5Y N; RD8S5Z N; RD8S60 N; RD8S61 N; RD8S62 N; RD8S63 N; RD8S64 N; RD8S65 N; RD8S66 N; RD8S67 N; RD8S68 N; RD8S69 N; RD8S6A N; RD8S6B N; RD8S6C N; RD8S6D N; RD8S6E N; RD8S6F N; RD8S6G N; RD8S6H N; RD8S6I N; RD8S6J N; RD8S6K N; RD8S6L N; RD8S6M N; RD8S6N N; RD8S6O N; RD8S6P N; RD8S6Q N; RD8S6R N; RD8S6S N; RD8S6T N; RD8S6U N; RD8S6V N; RD8S6W N; RD8S6X N; RD8S6Y N; RD8S6Z N; RD8S70 N; RD8S71 N; RD8S72 N; RD8S73 N; RD8S74 N; RD8S75 N; RD8S76 N; RD8S77 N; RD8S78 N; RD8S79 N; RD8S7A N; RD8S7B N; RD8S7C N; RD8S7D N; RD8S7E N; RD8S7F N; RD8S7G N; RD8S7H N; RD8S7I N; RD8S7J N; RD8S7K N; RD8S7L N; RD8S7M N; RD8S7N N; RD8S7O N; RD8S7P N; RD8S7Q N; RD8S7R N; RD8S7S N; RD8S7T N; RD8S7U N; RD8S7V N; RD8S7W N; RD8S7X N; RD8S7Y N; RD8S7Z N; RD8S80 N; RD8S81 N; RD8S82 N; RD8S83 N; RD8S84 N; RD8S85 N; RD8S86 N; RD8S87 N; RD8S88 N; RD8S89 N; RD8S8A N,
WO2024100663-A1,"Use of composition having anti-carcinoembryonic            antigen-related cell adhesion molecule 1 monoclonal            antibody for preventing, inhibiting, or delaying            pathological process, condition or disorder e.g.            melanoma, carcinoma, lymphoma and sarcoma",REUVENI H;  MEIRSON T;  SCHICKLER M,FAMEWAVE LTD (FAME-Non-standard),202450741H,"   NOVELTY - Use of composition comprising an                anti-carcinoembryonic antigen-related cell adhesion                molecule 1 (CEACAM1) monoclonal antibody (mAb), or                its active fragments, for: preventing, inhibiting,                or delaying a pathological process, condition or                disorder that involves neutrophil extracellular                trap (NET)-mediated activity in a subject, where                the mAb or active fragment comprises a set of six                complementarity determining region (CDR) sequences                comprising SEQ ID Nos. 1-6, and a salt, carrier or                diluent.    USE - The composition is useful for: preventing,                inhibiting, or delaying a pathological process,                condition or disorder that involves a NET-mediated                activity in a subject, where the pathological                process or condition that involves a NET-mediated                activity is a cancer or a tumor, or non-malignant                condition, the cancer comprises a solid tumor,                metastatic cancer or tumor, and the cancer                comprises melanoma, lung cancer, colorectal cancer,                pancreatic cancer (preferred), carcinoma, lymphoma,                blastoma, sarcoma, unknown primary, skin, thyroid,                parathyroid, breast, cardiac, thymic, bone,                soft-tissue, brain, retinal, ophthalmologic, head                and neck, esophageal, gastric, prostate, biliary,                hepatic, bladder, adrenal, renal, genito-urinal,                testicular, cervical , fallopian, ovarian, uterine,                vulvar, or endometrial cancers, the non-malignant                condition is a disease or disorder comprising                thrombotic diseases, thrombosis, disease-associated                thrombosis , pro-thrombosis condition,                thromboinflammatory condition, venous                thromboembolism, arterial thromboembolism,                cardiovascular condition, autoimmune disease,                autoinflammatory disease or disorder,                immune-mediated disease, systemic inflammatory                condition, the non-malignant condition is a                non-malignant thrombotic disease or disorder, the                non-malignant thrombotic disease is a thrombotic                cardiovascular disease, a hematological disease, an                autoimmune disease, or systemic inflammatory                response syndrome, the thrombotic cardiovascular                disease comprises myocardial infarction, carotid                atherosclerosis, cerebrovascular stroke, deep vein                thrombosis, portal vein thrombosis, marantic                endocarditis, pulmonary embolism, and chronic                thromboembolic pulmonary hypertension, the                hematological disease is thrombotic                thrombocytopenic purpura, or heparin-induced                thrombocytopenia or thrombosis, the autoimmune                disease comprises systemic lupus erythematosus,                antiphospholipid syndrome, rheumatoid arthritis,                psoriasis, ulcerative colitis, gout, systemic                sclerosis, antineutrophilic cytoplasmic                antibody-associated vasculitis, dermatomyositis,                and polymyositis, and the systemic inflammatory                response syndrome is coronavirus disease (COVID)-19                infection, sepsis or septic shock; treating a                NET-related disease, disorder, or complication in a                subject in need of the treatment, where the                NET-related disease is cancer, the subject is                diagnosed with cancer or is suspected to have                cancer and the NET-related disease, disorder or                complication is a non-malignant condition; and                treating a subject diagnosed with cancer or                suspected to have cancer (all claimed). The ability                of CM24 to treat cancer was tested in human NSCIAC                4549 using in vitro assay. The result showed that                CM24 exhibited 82.7% of inhibition of NET-induced                migration (versus isotype control).    ADVANTAGE - The composition utilizes anti-CEACAM1 mAb or                antibody fragment which administered to subject                which results in prevention, inhibition, or delay                of at least one of formation of metastases,                migration or spread of metastases, adhesion of                metastases, progression or growth of metastases,                intravasation of cancerous cells into the                vasculature, cancer cells' invasiveness into the                surrounding extra cellular matrix, cancer cells'                survival within the bloodstream, extravasation of                cancer cells into the organ parenchyma, formation                of dormant cells or multicellular metastases, and                seeding and exponential growth of distant                metastatic colonies, where formation, migration or                spread of metastases following tumor resection                surgery is prevented or inhibited, and results                significantly higher MPO level that is equivalent                to at least 100%, at least 200%, or at least 300%                increase relative to the reference value or to the                control sample value.    DETAILED DESCRIPTION - Use of composition comprising an                anti-carcinoembryonic antigen-related cell adhesion                molecule 1 (CEACAM1) monoclonal antibody (mAb), or                its active fragments, for: preventing, inhibiting,                or delaying a pathological process, condition or                disorder that involves a neutrophil extracellular                trap (NET)-mediated activity in a subject, where                the mAb or active fragment comprises a set of six                complementarity determining region (CDR) sequences                comprising Gly-Tyr-Ala-Phe-Thr-Asn-Asn-Leu-Ile-Glu                (SEQ ID NO: 1), SEQ ID NO: 2 (comprising a fully                defined sequence of 17 amino acids as given in                specification), SEQ ID NO: 3 (comprising a fully                defined sequence of 11 amino acids as given in                specification), SEQ ID NO: 4 (comprising a fully                defined sequence of 11 amino acids as given in                specification), Tyr-Thr-Ser-Arg-Leu-His-Ser (SEQ ID                NO: 5), and Gln-Gln-ly-Lys-Ser-Leu-Pro-Arg-Thr (SEQ                ID NO: 6), and a salt, carrier or diluent; treating                a NET-related disease, disorder, or complication in                a subject in need of the treatment; and treating a                subject diagnosed with cancer or suspected to have                cancer, where the use comprises selection of cancer                patient amenable to an anti-CEACAM1 antibody, the                selection comprises (ia)-(iiia). INDEPENDENT CLAIMS                are also included for:    preventing, inhibiting, or delaying (M1) a                pathological process, condition or disorder that                involves a NET-mediated activity in a subject,                comprising administering dose of an anti-CEACAM1                mAb, or its active fragments to the subject, where                the mAb or antibody fragment comprises a set of CDR                sequences comprising SEQ ID Nos. 1-6;    treating (M2) a NET-related disease, disorder,                or complication in a subject in need of                treatment;    electing (M3) a cancer patient amenable to a                treatment with an anti-CEACAM1 mAb of active                fragment of its;    preventing, delaying or inhibition (M4) of a                thrombosis in a subject, comprising administering                an anti-CEACAM1 mAb, or an active fragment of its                to a subject in need of its; and    a kit for predicting the response of a subject                to an anti-CEACAM1 antibody treatment, comprising                means for determining the level of at least one                NET-biomarker in a biological sample, means for                comparing the expression level of the NET-biomarker                to a reference value or to a control sample value                and instruction material directing the correlation                between the ratio of the NET-biomarker to the                reference or control levels. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).)",B04-C01;  B04-E99;  B04-G01;  B04-G21;  B04-G27G;  B11-C04;  B11-C07A;  B11-C10;  B12-K04E3;  B14-A02B5;  B14-C03;  B14-E08;  B14-E10C1;  B14-F01;  B14-F02;  B14-F03;  B14-F04;  B14-F07;  B14-F08;  B14-G02D;  B14-H01;  B14-J05;  B14-K01;  B14-N17;  B14-S06;  D05-H09;  D05-H99,A61P-035/00;  A61P-007/02;  C07K-016/28,WO2024100663-A1   16 May 2024   C07K-016/28   202452Pages: 85   English,WO2024100663-A1    WOIL051153    09 Nov 2023,,US424144P    10 Nov 2022;  US584181P    21 Sep 2023,WO2024100663-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,,,,,,,
WO2021214472-A1;  AU2021258539-A1;  CA3174360-A1;  KR2023004722-A;  CN115667242-A;  IL297440-A;  BR112022021370-A2;  EP4139295-A1;  AR121913-A1;  US2023159511-A1;  JP2023524207-W;  IN202217061512-A;  MX2022013396-A1;  HK40088671-A0,"New substituted tetrahydroisoquinoline compounds            are nuclear factor erythroid 2-related factor 2            inhibitors used to treat e.g. chronic obstructive            pulmonary disease, chronic and severe asthma,            Alzheimer's disease and pulmonary fibrosis",LUCAS C L;  BLANEY E L;  MARTIN B P;  NOWAK T;  RAY N C;  CRUMPLER S R;  SEWARD E M;  HYND G;  SWORDS E M,C4X DISCOVERY LTD (CFOU-Non-standard);  C4X DISCOVERY LTD (CFOU-Non-standard);  C4X DISCOVERY LTD (CFOU-Non-standard);  C4X DISCOVERY LTD (CFOU-Non-standard),2021C0952L,"   NOVELTY - Substituted tetrahydroisoquinoline compounds                (Q) are new.    USE - (Q) are useful: in therapy; for treating                diseases or disorders mediated by Nrf2 activation;                and for treating chronic obstructive pulmonary                disease, acute, chronic and severe asthma, acute                lung injury/acute respiratory distress syndrome                with or without accompanying multi organ                dysfunction syndrome, pulmonary fibrosis including                idiopathic pulmonary fibrosis, cystic fibrosis,                COVID-19, diabetes, atherosclerosis, hypertension,                heart failure, myocardial infarction and repair,                cardiac remodelling, cardiac arrhythmias, cardiac                hypertrophy, heart failure with preserved ejection                fraction, diabetic cardiomyopathy, sarcopenia,                obesity, metabolic syndrome, diabetes mellitus,                insulin resistance, pulmonary arterial                hypertension, subarachnoid haemorrhage,                intracerebral haemorrhage, ischemic stroke, beta                -thalassemia, sickle cell disease, rheumatoid                arthritis, irritable bowel disorder, ulcerative                colitis, Crohn's disease, psoriasis,                radiation-induced dermatitis, atopic dermatitis,                non-alcoholic fatty liver disease, non-alcoholic                steatohepatitis, toxin-induced liver disease, viral                hepatitis and cirrhosis, chronic kidney disease,                diabetic nephropathy, autosomal dominant polycystic                kidney disease, CKD associated with type 1                diabetes, IgA nephropathy (IgAN), Alport Syndrome,                focal segmental glomerulosclerosis, Huntington's                disease, Parkinson's disease, Alzheimer's disease,                amyotrophic lateral sclerosis, frontotemporal                dementia, multiple sclerosis, Friedreich's ataxia,                chronic pain, schizophrenia, lung cancer, breast                cancer, colon cancer, age related macular                degeneration, Fuchs Endothelial Corneal Dystrophy,                uveitis or preeclampsia (all claimed).    ADVANTAGE - (Q): is non-toxic; and exhibits                pharmacokinetic properties.    DETAILED DESCRIPTION - Substituted tetrahydroisoquinoline compounds                (Q) of formulae (IC) or (IF) and their salts are                new.    R1 = 1-4C alkylene-R11, heterocyclyl and 8-10                membered bicyclic heteroaryl, where heterocyclyl is                optionally substituted by at least one 1-4C alkyl,                -C(O)-R12, SO2- R13, 1-3C alkylene-OR14 and                heteroaryl optionally substituted by at least one                1-4C alkyl, 3-7C cycloalkyl, halo, OH, 1-3C alkoxy                and cyano, and 8-10 membered bicyclic heteroaryl is                optionally substituted by at least one 1-4C alkyl,                3-7C cycloalkyl, halo, OH and 1-3C alkoxy;    R2 = H, F, Cl or 1-3C alkyl;    R3 = H, F, Cl, Br, 1-3C alkoxy, 1-3C alkyl,                1-3C haloalkyl or cyano; either    R4 = H or 1-4C alkyl; or    R5 = -C(O)-1-4C alkyl, -C(O)-3-7C cycloalkyl,                -C(O)-heteroaryl or -C(O)-aryl, where heteroaryl                and aryl are optionally substituted by at least one                1-4C alkyl, halo, hydroxy, 1-3C alkoxy, CO2R15 or                cyano; or    NR4R5 = 4-6 membered heterocyclyl ring, where                heterocyclyl ring comprising at least one                -C(O)-moieties attached to the nitrogen atom,                optionally contains at least one additional                heteroatoms comprising O, N or S, optionally is                fused to aryl or heteroaryl ring, optionally is                spiro-attached to 3-7C cycloalkyl or 3-6 membered                heterocyclyl ring, and optionally is substituted by                at least one 1-4C alkyl, halo, OH, 1-3C alkoxy,                1-3C haloalkyl, cyano, NR16R17, C(O)R18, S(O)R19 or                SO2R20;    R6 = H, 1-4C alkyl or 3-7C cycloalkyl;    R8 = C(=O)NR8aR8b or -C(=O)R8c; either    R8a = H or 1-6C alkyl;    R8b = 1-6C alkyl or 3-7C cycloalkyl (both                optionally substituted by at least one 1-4C alkyl,                3-7C cycloalkyl, halo, OH, 1-3C alkoxy, 1-3C                haloalkyl, cyano, NR16R17, C(O)R18, S(O)R19 or                SO2R20; or    NR8aR8b = 3-7 membered heterocyclyl ring,                where the heterocyclyl ring optionally contains at                least one additional heteroatoms comprising O, N or                S, and is optionally substituted by at least one                1-4C alkyl, 3-7C cycloalkyl, halo, OH, 1-3C alkoxy,                1-3C haloalkyl, cyano, NR16R17, C(O)R18, S(O)r19                and SO2R20;    R8c = 1-3C alkyl or 1-3C haloalkyl;    R9 = methyl;    R11 = aryl or heteroaryl (both optionally                substituted by at least one 1-4C alkyl, 1-3C                haloalkyl, 3-7C cycloalkyl, 1-4C alkylene-R30,                halo, OH, 1-3C alkoxy, heterocyclyl and cyano),                heterocyclyl (optionally substituted by at least                one 1-4C alkyl, 1-3C haloalkyl, 3-7C cycloalkyl,                1-4C alkylene-R30, halo, OH, 1-3C alkoxy, oxo or                cyano), -C(O)-R24, -SO2-R25, -NR26C(O)-R27,                -NR28SO2-R29, heterocyclyl;    R12 = 1-4C alkyl, 3-7C cycloalkyl, OR31,                NR32R33, aryl and heteroaryl, where aryl and                heteroaryl are optionally substituted by at least                one 1-4C alkyl, halo, OH, 1-3C alkoxy and                cyano;    R13 = heteroaryl, heterocyclyl (both                optionally substituted by 1-4C alkyl, halo, OH,                1-3C alkoxy or cyano), 1-4C alkyl, 3-7C cycloalkyl,                or NR34R35;    R17 = H, 1-4C alkyl, C(O)1-3C alkyl or                C(O)NR36R37;    R18-R20 = 1-4C alkyl, OH, 1-3C alkoxy or                NR38R39;    R24 = 1-4C alkyl, NR40R41 or OR42;    R25 = 1-4C alkyl or NR43R44;    R27 = aryl, heteroaryl (both optionally                substituted by 1-4C alkyl, 1-3C haloalkyl, 3-7C                cycloalkyl, 1-4C alkylene-R45, halo, OH, 1-3C                alkoxy and cyano), 1-4C alkyl, 3-7C cycloalkyl,                1-3C haloalkyl or heterocyclyl;    R29 = aryl, heteroaryl (both optionally                substituted by 1-4C alkyl, 1-3C haloalkyl, 3-7C                cycloalkyl, 1-4C alkylene-R46, halo, OH, 1-3C                alkoxy or cyano-1-4C alkyl, 3-7C cycloalkyl, 1-3C                haloalkyl;    R30 = hydroxy, 1-3C alkoxy, 3-7C cycloalkyl,                cyano or NR47R48;    R40 = H or 1-4C alkyl;    R41 = H, 1-4C alkyl, 3-7C cycloalkyl, 1-3C                alkoxy, aryl or heteroaryl; or    NR40R41 = 4-6 membered heteroaryl or                heterocyclyl ring, (both optionally substituted by                1-4C alkyl, halo, OH, 1-3C alkoxy, 3-7C cycloalkyl                or cyano);    R45, R46 = hydroxy, 1-3C alkoxy or 3-7C                cycloalkyl; and    R14-R16, R26, R28, R31-R39, R42-R44, R47, R48                = H, 1-4C alkyl and 3-7C cycloalkyl.    Provided that the compound is not (1                S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxamide. ",,,B02 (Fused ring heterocyclics.),B06-D03;  B14-A02;  B14-C01;  B14-C03;  B14-C09B;  B14-D01C;  B14-E08;  B14-E10C;  B14-E12;  B14-F01;  B14-F02D1;  B14-F03;  B14-F07;  B14-F08;  B14-H01D1;  B14-H01E1;  B14-H01K3;  B14-J01;  B14-J05;  B14-K01;  B14-L06;  B14-N03;  B14-N10;  B14-N12;  B14-N14;  B14-N16;  B14-N17;  B14-S01;  B14-S04;  B14-S13;  B14-S16,A61K-031/4725;  A61P-001/16;  A61P-011/00;  A61P-011/06;  A61P-013/12;  A61P-017/00;  A61P-025/00;  A61P-003/10;  A61P-035/00;  A61P-009/00;  C07D-401/14;  C07D-413/14;  C07D-417/14;  C07D-471/04;  A61K-031/501;  A61K-031/506;  A61K-031/5377;  C07D-405/14;  C07D-487/04;  C07D-498/04;  C07D-401/06;  A61K-031/497;  A61P-001/00;  A61P-013/00;  A61P-019/00;  A61P-021/00;  A61P-003/00;  A61P-037/00;  A61P-043/00;  A61P-007/00,WO2021214472-A1   28 Oct 2021   C07D-401/14   202192Pages: 167   English;  AU2021258539-A1   10 Nov 2022   C07D-401/14   202291   English;  CA3174360-A1   28 Oct 2021   C07D-401/14   202204   English;  KR2023004722-A   06 Jan 2023   C07D-401/14   202304   ;  CN115667242-A   31 Jan 2023   C07D-401/14   202313   Chinese;  IL297440-A   01 Dec 2022   A61P-001/16   202318   English;  BR112022021370-A2   06 Dec 2022   C07D-401/14   202318   ;  EP4139295-A1   01 Mar 2023   C07D-401/14   202319   English;  AR121913-A1   20 Jul 2022   C07D-401/14   202320   Spanish;  US2023159511-A1   25 May 2023   C07D-413/14   202344   English;  JP2023524207-W   09 Jun 2023   C07D-401/06   202347   Japanese;  IN202217061512-A   15 Sep 2023   C07D-401/14   202378   English;  MX2022013396-A1   13 Dec 2022   A61P-035/00   202410   Spanish;  HK40088671-A0   29 Sep 2023   C07D-401/14   202427   English,WO2021214472-A1    WOGB050975    22 Apr 2021;   AU2021258539-A1    AU258539    22 Apr 2021;   CA3174360-A1    CA3174360    22 Apr 2021;   KR2023004722-A    KR740564    22 Apr 2021;   CN115667242-A    CN80030434    22 Apr 2021;   IL297440-A    IL297440    22 Apr 2021;   BR112022021370-A2    BR11021370    22 Apr 2021;   EP4139295-A1    EP724005    22 Apr 2021;   AR121913-A1    AR101081    22 Apr 2021;   US2023159511-A1    US17920244    20 Oct 2022;   JP2023524207-W    JP564532    22 Apr 2021;   IN202217061512-A    IN17061512    28 Oct 2022;   MX2022013396-A1    MX013396    24 Oct 2022;   HK40088671-A0    HK6077584    14 Aug 2023,AU2021258539-A1 PCT application Application WOGB050975;   AU2021258539-A1 Based on Patent WO2021214472;   CA3174360-A1 PCT application Application WOGB050975;   CA3174360-A1 Based on Patent WO2021214472;   KR2023004722-A PCT application Application WOGB050975;   KR2023004722-A Based on Patent WO2021214472;   CN115667242-A PCT application Application WOGB050975;   CN115667242-A Based on Patent WO2021214472;   IL297440-A Based on Patent WO2021214472;   BR112022021370-A2 PCT application Application WOGB050975;   BR112022021370-A2 Based on Patent WO2021214472;   EP4139295-A1 PCT application Application WOGB050975;   EP4139295-A1 Based on Patent WO2021214472;   US2023159511-A1 PCT application Application WOGB050975;   JP2023524207-W PCT application Application WOGB050975;   JP2023524207-W Based on Patent WO2021214472;   IN202217061512-A PCT application Application WOGB050975;   IN202217061512-A Based on Patent WO2021214472;   MX2022013396-A1 PCT application Application WOGB050975;   MX2022013396-A1 Based on Patent WO2021214472;   HK40088671-A0 PCT application Application WOGB050975;   HK40088671-A0 Based on Patent WO2021214472;   HK40088671-A0 Previous Publ. Patent EP4139295,GB005852    22 Apr 2020;  EP724005    22 Apr 2021;  CA3174360    30 Sep 2022;  BR11021370    20 Oct 2022;  CN80030434    21 Oct 2022;  KR740564    18 Nov 2022,WO2021214472-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA              EP4139295-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN              ,,";  CN115667242-A -- CN107709306-A   ASTEX THERAPEUTICS LTD (ASTX);  GLAXOSMITHKLINE INTELLECTUAL PROPERTY (GLAX)   GRIFFITHS-JONES C M,  HEIGHTMAN T D,  KERNS J K,  LI T,  WILLEMS H M G,  WOOLFORD A J,  YAN H;  WO2013067036-A1   UNIV RUTGERS STATE NEW JERSEY (RUTF);  BROAD INST INC (BROD)   HU L,  MAGESH S,  CHEN L,  LEWIS T,  MUNOZ B,  WANG L;  WO2018181345-A1   TAKEDA PHARM CO LTD (TAKE);  SCOHIA PHARMA INC (SCOH-Non-standard)   KITAZAKI T,  NISHIKAWA Y,  FUJIMOTO T,  KUBO O,  SASAKI M,  KINA A,  MORIMOTO S,  KIKUCHI F,  TAKADA H,  ISHICHI Y,  TAKAKURA N,  IKOMA M,  SATO K,  YAMASHITA T,  YAMASAKI T,  WATANABE K,  MATSUMOTO S,  FUKUSHI H,  NOGUCHI N,  HARA R,  KOBAYASHI T,  MAEKAWA T;  WO2020084300-A1   C4X DISCOVERY LTD (CFOU-Non-standard)   BLANEY E L,  CRICK D J,  CRUMPLER S R,  HYND G,  LUCAS C L,  MARTIN B P,  RAY N C,  SEWARD E M,  EVANS D G,  LE BOZEC L,  NOWAK T,  RUSSELL M G N,  YEAP S K,  ROUSSEL F J G,  SEHMI S S","CN115667242-A  HONGBIN DAI:          ""Development of Novel Nrf2/ARE Inducers Bearing          Pyrazino[2, 1-a]isoquinolin Scaffold with Potent In Vitro          Efficacy and Enhanced Physicochemical Properties"",          MOLECULES, vol. 22, no. 9, 1 September 2017 (2017-09-01),          pages 1541, XP055649795, DOI:          10.3390/molecules22091541,relevantClaims[1-32];  BENJAMIN G.          RICHARDSON: ""Replacement of a Naphthalene Scaffold in          Kelch like ECH-Associated Protein 1 (KEAP1)/ Nuclear          factor (erythroid-derived 2)-like 2 (NRF2) Inhibitors"",          JOURNAL OF MEDICINAL CHEMISTRY, vol. 61, no. 17, 20          August 2018 (2018-08-20), pages 8029 - 8047, XP055642376,          DOI:          10.1021/acs.jmedchem.8b01133,relevantClaims[1-32]", N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N,226260401 N; 226260402 N,00094; 00691,RD49H4 N; RD49H5 N; RD49H6 N; RD49H7 N; RD49H8 N; RD49H9 N; RD49HA N; RD49HB N; RD49HC N; RD49HD N; RD49HE N; RD49HF N; RD49HG N,
WO2021188804-A1;  US2021290760-A1;  CA3176130-A1;  EP4118202-A1;  US11826421-B2,"New engineered bacteriophage useful for forming            vaccine for preventing infection with targeted            pathogen(s) or enhancing individual's immune response            to existing infection, comprises first and second            fusion coat proteins comprising first and second            exogenous polypeptides",GHANBARI H A;  LEBOWITZ P M S;  LEBOWITZ M S,ATHANOR BIOSCI INC (ATHA-Non-standard);  ATHANOR BIOSCI INC (ATHA-Non-standard);  ATHANOR BIOSCI INC (ATHA-Non-standard),2021B0275K,"   NOVELTY - An engineered bacteriophage comprising a first                fusion coat protein comprising a first exogenous                polypeptide directly or indirectly fused to a first                coat protein of the bacteriophage, and a second                fusion coat protein comprising a second exogenous                polypeptide directly or indirectly fused to a                second coat protein of the bacteriophage is new,                where the engineered bacteriophage is free of                nucleic acid sequences encoding the first exogenous                polypeptide and the second exogenous polypeptide,                where the first exogenous polypeptide differs from                the second exogenous polypeptide and/or the first                coat protein differs from the second coat                protein.    USE - The engineered bacteriophage is useful for                forming vaccine (claimed) for preventing infection                with targeted pathogen(s) or enhancing an                individual's immune response to an existing                infection.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a method (M1) for forming an engineered                multivalent bacteriophage;    (2) a vaccine comprising an immunogenic                engineered bacteriophage, where the immunogenic                engineered bacteriophage includes a first fusion                coat protein, where the first fusion coat protein                includes a first exogenous polypeptide directly or                indirectly fused to a first bacteriophage coat                protein, where the first exogenous polypeptide                comprises a sequence that corresponds to or is                derived from a first immunogenic protein of a first                pathogen, where the immunogenic engineered                bacteriophage is free of a nucleic acid sequence                encoding the first exogenous peptide;    (3) a vaccination protocol involves                administering a vaccine to an individual, where the                protocol is a prophylactic protocol or a                therapeutic protocol, and administrating one or                more booster vaccinations; and    (4) a method (M2) of forming vaccine involves                transfecting a bacterial cell with a first                expression plasmid, where the first expression                plasmid includes a first nucleic acid sequence that                encodes the first fusion coat protein, where the                first expression plasmid comprises regulatory                sequences such that the first fusion coat protein                is transiently expressed by the bacterial cell                following the transfection, and infecting the                bacterial cell with a bacteriophage, where the                immunogenic engineered bacteriophage is produced by                the bacterial cell upon the transfection and the                infection. ",,,"A96 (Medical, dental, veterinary, cosmetic.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",A12-V01;  B04-E99;  B04-F1100E;  B04-N0400E;  B14-A01;  B14-A02;  B14-A04;  B14-G01;  B14-S11D3;  D05-H07;  D05-H12F;  D05-H99,C12N-015/10;  C12N-015/87;  C07K-014/005;  C12N-007/00;  A61K-039/295;  A61K-035/76;  A61K-039/00;  A61K-039/215;  C12N-015/11;  C12N-007/01,WO2021188804-A1   23 Sep 2021   C12N-015/10   202184Pages: 64   English;  US2021290760-A1   23 Sep 2021   A61K-039/295   202184   English;  CA3176130-A1   23 Sep 2021   202286   English;  EP4118202-A1   18 Jan 2023   C12N-015/10   202309   English;  US11826421-B2   28 Nov 2023   C12N-015/11   202396   English,WO2021188804-A1    WOUS022981    18 Mar 2021;   US2021290760-A1    US205671    18 Mar 2021;   CA3176130-A1    CA3176130    18 Mar 2021;   EP4118202-A1    EP722596    18 Mar 2021;   US11826421-B2    US205671    18 Mar 2021,US2021290760-A1 Provisional Application US992394P;   US2021290760-A1 Provisional Application US073908P;   CA3176130-A1 PCT application Application WOUS022981;   CA3176130-A1 Based on Patent WO2021188804;   EP4118202-A1 PCT application Application WOUS022981;   EP4118202-A1 Based on Patent WO2021188804;   US11826421-B2 Provisional Application US992394P;   US11826421-B2 Provisional Application US073908P;   US11826421-B2 Previous Publ. Patent US2021290760,US992394P    20 Mar 2020;  US073908P    02 Sep 2020;  US205671    18 Mar 2021;  CA3176130    20 Sep 2022,WO2021188804-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      EP4118202-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    ,,"WO2021188804-A1 -- US20050226892-A1   ;  WO2008109398-A1   UNIV CATHOLIC AMERICA (UYCA-Non-standard)   ALVING C R,  RAO V;  WO2018050871-A1   NOVIMMUNE SA (NOMM)   FAGETE S,  HARTLEY O,  FISCHER N;  US4863457-A   LEE D A (LEED-Individual)   LEE D A;  US5378475-A   UNIV KENTUCKY RES FOUND (KENT)   SMITH T J,  ASHTON P,  PEARSON P A;  US5443505-A   OCULEX PHARM INC (ALLR)   WONG V G,  KOCHINKE F;  US11826421-B2 -- US20050226892-A1   ;  US20060240456-A1   ;  US20210309973-A1   ;  US8685694-B2   RAO V B (RAOV-Individual)   RAO V B;  US9328149-B2   RAO V B (RAOV-Individual);  TAO P (TAOP-Individual)   RAO V B,  TAO P;  WO2008109398-A1   UNIV CATHOLIC AMERICA (UYCA-Non-standard)   ALVING C R,  RAO V;  WO2018050871-A1   NOVIMMUNE SA (NOMM)   FAGETE S,  HARTLEY O,  FISCHER N;  WO2005058006-A3   RAO V B (RAOV-Individual)   RAO V B","WO2021188804-A1  TAO PAN ET AL:          ""Bacteriophage T4 nanoparticles for vaccine delivery          against infectious diseases"", ADVANCED DRUG DELIVERY          REVIEWS, ELSEVIER, AMSTERDAM , NL, vol. 145, 6 July 2018          (2018-07-06), pages 57 - 72, XP085895281, ISSN:          0169-409X, [retrieved on 20180706], DOI:          10.1016/J.ADDR.2018.06.025,relevantClaims[1-4,9-14],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  EMILIANO PAVONI ET          AL: ""Simultaneous display of two large proteins on the          head and tail of bacteriophage lambda"", BMC          BIOTECHNOLOGY, BIOMED CENTRAL LTD, vol. 13, no. 1, 30          September 2013 (2013-09-30), pages 79, XP021163896, ISSN:          1472-6750, DOI:          10.1186/1472-6750-13-79,relevantClaims[1-17],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  AHMED SYED FARAZ ET          AL: ""Preliminary Identification of Potential Vaccine          Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based          on SARS-CoV Immunological Studies"", VIRUSES, vol. 12, no.          3, 25 February 2020 (2020-02-25), CH, pages 254,          XP055823903, ISSN: 1999-4915, DOI:          10.3390/v12030254,relevantClaims[1-17];  STAQUICINI DANIELA          I ET AL: ""Preliminary Identification of Potential Vaccine          Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based          on SARS-CoV Immunological Studies"", BIORXIV : THE          PREPRINT SERVER FOR BIOLOGY, 16 March 2021 (2021-03-16),          United States, pages 1 - 38, XP055823836, Retrieved from          the Internet          &lt;URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987025/pdf/nihpp-2021.03.15.435496.pdf&gt;          [retrieved on 20210713], DOI:          10.1101/2021.03.15.435496,relevantClaims[1-17],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  MALIK AND R N          PERHAM P: ""Simultaneous display of different peptides on          the surface of filamentous bacteriophages"", NUCLEIC ACIDS          RESEARCH, OXFORD UNIVERSITY PRESS, GB, vol. 25, no. 4, 1          January 1997 (1997-01-01), pages 915/916, XP002132956,          ISSN: 0305-1048, DOI:          10.1093/NAR/25.4.915,relevantClaims[1-17]US11826421-B2            Ahmed, et al. Preliminary Identification of Potential          Vaccine Targets for the COVID-19 Coronavirus (SARS-COV-2)          Based on SARS-COV Immunological Studies &lt;xhtml:i          &gt;Viruses&lt;/xhtml:i&gt;12:254 (2020) pp.          1-15.;            Malik, et al. Simultaneous display of different peptides          on the surface of filamentous bacteriophages          &lt;xhtml:i &gt;Nucl. Acids          Res&lt;/xhtml:i&gt;. 25 (1997) pp.          915-916.;            Pavoni, et al. Simultaneous display of two large proteins          on the head and tail of bacteriophage lambda          &lt;xhtml:i &gt;BMC          Biotech&lt;/xhtml:i&gt;. 13:79 (2013) pp.          1-16.;            Staquicini, et al. Design and proof-of-concept for          targeted phage-based COVID-19 vaccination strategies with          a streamlined cold-free supply chain &lt;xhtml:i          &gt;bioRxiv&lt;/xhtml:i&gt;(2021) pp.          1-38.;            Tao, et al. Bacteriophage T4 nanoparticles for vaccine          delivery against infectious diseases &lt;xhtml:i          &gt;Adv. Drug Del. Rev&lt;/xhtml:i&gt;. 145          (2018) pp. 57-72.;            ISA. International Search Report & Written Opinion          PCT/US2021/022981 (dated Aug. 5, 2021) pp.          1-17.",200757-0-0-0 M N P; 200757-0-0-0 CL NEW PRD USE,,,RA00GT M N P,
IN202021039765-A,"Topical antimicrobial formulation used to treat            bacterial and viral infections e.g. SARS-CoV2,            comprises organic acid, surfactant, humectant,            glycyrrhizin extract encapsulated with other natural            extracts, and excipients or additives",REDDY M P V N,UCUBE SCI RES PVT LTD (UCUB-Non-standard);  REDDY M P V N (REDD-Individual),202249547Y,"   NOVELTY - Topical antimicrobial formulation comprises:                (a) 0.1-10 wt.% an organic acid; (b) 0.1-10 wt.% a                surfactant; (c) 2-10 wt.% a humectant; (d) 0.1-3                wt.% glycyrrhizin extract encapsulated with other                natural extracts; and (e) excipients or                additives.    USE - The formulation is useful for treating                bacterial and viral infections (claimed),                preferably coronavirus e.g. SARS-CoV2, rhinovirus,                adenovirus and influenza virus.    ADVANTAGE - The formulation: reduces microbial                populations, is consumer acceptable i.e. mild to                the skin, phase stable, and generates copious,                stable foam; and is safe, non-irritating, has broad                spectrum antiviral activity, and exhibits long                lasting antimicrobial/antiviral effect. ",,,"A96 (Medical, dental, veterinary, cosmetic.);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).);  D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).);  B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  ",A12-V01;  A12-V04;  A12-W05;  D08-B09A1B;  D08-B13;  D09-A01;  B01-D02;  B04-A08F;  B04-A08G;  B04-A10;  B04-A98;  B04-B01C1;  B04-C02B;  B04-C02D;  B04-C03A;  B04-C03B;  B05-A01B;  B06-A02;  B07-D04C;  B10-A07B;  B10-A09B;  B10-B02J;  B10-C02;  B10-C04D;  B10-C04E6;  B10-D01;  B10-E02;  B10-E04A;  B10-E04C;  B10-E04D;  B10-F02;  B10-J02A;  B12-M12B;  B12-M18;  B14-A01;  B14-A02;  B14-S18;  B15-E00,A61K-008/34;  A61K-009/00;  A61Q-017/00;  A61Q-019/00;  A61Q-019/10,IN202021039765-A   18 Mar 2022   A61K-009/00   202234Pages: 24   English,IN202021039765-A    IN21039765    15 Sep 2020,,IN21039765    15 Sep 2020,,,,,2358-0-0-0 K M; 490-0-0-0 K M; 8489-3-0-0 K M; 109110-0-0-0 K M; 109111-0-0-0 K M; 4015-0-0-0 K M; 109113-0-0-0 K M; 109114-0-0-0 K M; 96212-1-0-0 K M; 2006-0-0-0 K M; 129503-0-0-0 K M; 7447-0-0-0 K M; 7560-0-0-0 K M; 7628-0-0-0 K M; 620-0-0-0 K M; 849-0-0-0 K M; 4073-0-0-0 K M; 1705-0-0-0 K M; 896-0-0-0 K M; 129629-0-2-0 K M; 1448-0-0-0 K M; 2117-0-1-0 K M; 94727-0-0-0 K M; 7435-0-0-0 K M; 7692-0-0-0 K M; 8332-0-0-0 K M; 129448-1-0-0 K M; 861-0-0-0 K M; 84325-1-0-0 K M; 60506-0-0-0 K M; 61641-0-0-0 K M; 2113-0-0-0 K M; 4336-3-0-0 K M;  K M; 8349-1-0-0 K M; 1062-0-0-0 K M; 133912-0-0-0 ; 444-0-0-0 ; 1911-0-0-0 ; 107779-0-0-0 ,,01735,R00678 K M; R00113 K M; RAQPAA K M; R01163 K M; R00990 K M; R00179 K M; R14756 K M; RA0CPW K M; R01693 K M; R01327 K M; R00104 K M; R04091 K M; R00114 K M; R00009 K M; R00448 K M; R00920 K M; R00873 K M; R00419 K M; R01656 K M; R00946 K M; R01061 K M; R05324 K M; RA1438 K M; RA1HEQ K M; R05325 K M; R05327 K M; R04115 K M; R00427 K M; R00651 K M; R00780 K M; R15871 K M; R00137 K M; RA006H K M; R00558 K M; RA08XN K M; R01119 K M; R01307 K M; RCK3UY K M; R00148 K M; RA00D5 K M; R01835 ; R00351 ; R00446 ; R01863 ,0678-S; 0113-S; 1163-S; 0990-S; 0179-S; 1693-S; 1327-S; 0104-S; 0114-S; 0009-S; 0448-S; 0920-S; 0873-S; 0419-S; 1656-S; 0946-S; 1061-S; 2057-S; 0427-S; 0651-S; 0780-S; 0401-S; 0137-S; 0558-S; 1119-S; 1307-S; 0148-S
WO2022164863-A1;  EP4284548-A1;  US2024110914-A1,"Sensor used in detector, has doped silicon layer,            graphene layer on doped silicon layer, molecularly            imprinted polymer layer derived from molecularly            imprinted polymer monomer and functional monomer on            graphene layer and electrodes in operative arrangement            with molecularly imprinted polymer layer",EMAM S;  SUN N,UNIV NORTHEASTERN (UNEN-C);  UNIV NORTHEASTERN (UNEN-C);  UNIV NORTHEASTERN (UNEN-C),202298211K,"   NOVELTY - Sensor comprises a doped silicon layer, a                graphene layer on the doped silicon layer, a                molecularly imprinted polymer (MIP) layer derived                from a MIP monomer and functional monomer on the                graphene layer, and electrodes in operative                arrangement with the MIP layer and configured to                provide a signal indicative of a resistance, or                sensor comprises a doped silicon layer having an                etched surface, a graphene layer on the etched                surface, where the graphene layer comprises                graphene and potassium ferrocyanide, a MIP layer of                poly(pyrrole-co-ethylene glycol                dimethacrylate-co-methacrylic acid) or                poly(pyrrole-co-dopamine) on the graphene layer,                and electrodes in operative arrangement with the                MIP layer and configured to provide a signal                indicative of a resistance.    USE - The sensor is useful in detector and detecting                viral infection, and used in used in hospitals, and                airports.    ADVANTAGE - The sensor is selective for analyte associated                with the viral infection, accurate, consistent, and                selective, and the measured resistance is                indicative of presence or absence of the viral                infection in the subject, and detects virus in                about 10 seconds.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a detector comprising the sensor, and a                voltage source configured to apply a voltage to the                MIP layer;    (2) a method for detecting an analyte in a                sample, involving measuring the resistance of the                sensor that is in contact with the sample to obtain                a measured resistance, where the sensor is                selective for the analyte, and the measured                resistance is indicative of presence or absence of                the analyte in the sample;    (3) a method for detecting a viral infection                in a subject, involving measuring the resistance of                the sensor that is in contact with a sample from a                subject to obtain a measured resistance, where the                sensor is selective for an analyte associated with                the viral infection, and the measured resistance is                indicative of presence or absence of the viral                infection in the subject; and    (4) a method for fabricating the sensor,                involving forming a graphene layer on a doped                silicon layer, and forming a MIP layer derived from                a MIP monomer and functional monomer on the                graphene layer. ",,,"D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  A14 (Polymers of other substituted monoolefins; including PVC, PTFE.);  S03 (Scientific Instrumentation)",D05-H09;  D05-H10;  A04-B09;  A04-F04;  A05-J02;  A05-J12;  A12-E13;  A12-E14;  A12-V03C2;  S03-E02A;  S03-E09F,B01J-020/26;  G01N-027/12;  G01N-033/543;  B01J-020/28;  G01N-033/569,WO2022164863-A1   04 Aug 2022   B01J-020/26   202266   English;  EP4284548-A1   06 Dec 2023   B01J-020/26   202399   English;  US2024110914-A1   04 Apr 2024   G01N-033/569   202429   English,WO2022164863-A1    WOUS013850    26 Jan 2022;   EP4284548-A1    EP704172    26 Jan 2022;   US2024110914-A1    US18260881    10 Jul 2023,EP4284548-A1 PCT application Application WOUS013850;   EP4284548-A1 Based on Patent WO2022164863;   US2024110914-A1 Provisional Application US143763P;   US2024110914-A1 PCT application Application WOUS013850,US143763P    29 Jan 2021;  US18260881    10 Jul 2023,WO2022164863-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW  EP4284548-A1:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  KH;  LI;  LT;  LU;  LV;  MA;  MC;  MD;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TN;  TR    ,,,,690-0-0-0 ; 114219-0-0-0 ; 10151-0-0-0 ,,,R00894 ; R00658 ; R00460 ,
WO2005010032-A2;  US2005202415-A1;  EP1636254-A2;  AU2004259640-A1;  JP2007526222-W;  US7442761-B2;  US2009053257-A1;  SG153065-A1;  AU2004259640-B2;  AU2010200602-A1;  EP1636254-B1;  DE602004029034-E;  EP2292643-A1;  EP2338901-A1;  SG163553-A1;  EP2390804-A2;  EP2390805-A2;  EP2390806-A2;  EP2390807-A2;  EP2390808-A2;  EP2390804-A3;  EP2390805-A3;  EP2390807-A3;  EP2390808-A3;  WO2005010032-A3;  EP2390806-A3;  SG182000-A1;  AU2010200602-B2;  IL204266-A;  IL172396-A;  IL199527-A;  NZ593774-A;  AU2013201657-A1;  US2013195916-A1;  SG117801-A1;  SG117801-B;  US2014206556-A1;  SG196773-A1;  EP2292643-B1;  IL224496-A;  IL224497-A;  IL224498-A;  US9388234-B2,"Novel coronavirus peptide and histidine residue, useful in preparing vaccine for preventing or treating severe acute respiratory syndrome",BOGOCH S;  BOGOCH E S;  BOGOCH E;  BOGOCH S W;  BORSANYI A E;  BORSANYI A B;  BOGOCH BORSANYI A,BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual);  BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual);  BOGOCH E (BOGO-Individual);  BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual);  BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual);  BOGOCH S W (BOGO-Individual);  BORSANYI A E (BORS-Individual);  BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual);  BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual);  BOGOCH S W (BOGO-Individual);  BORSANYI A E (BORS-Individual);  BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual);  BORSANYI A B (BORS-Individual);  BOGOCH S W (BOGO-Individual);  BORSANYI A E (BORS-Individual);  BORSANYI A B (BORS-Individual);  BORSANYI A B (BORS-Individual);  BORSANYI A B (BORS-Individual);  BOGOCH S W (BOGO-Individual);  BOGOCH S W (BOGO-Individual),2005123118,"   NOVELTY - An isolated or synthesized coronavirus peptide (I) comprising 7-50 amino acids comprising a lysine residue located 6-10 residues from a second lysine residue, a histidine residue and 6% lysine residues, or a synthesized replikin peptide having 7-10 amino acids comprising all lysine except for one histidine, a lysine located 7-10 residues from a second lysine residue, a histidine residue and 6% lysine resides, is new.    USE - (III) is useful for preventing or treating SARS, which involves administering (III) to a patient. (I) and (III) are useful for inducing an immune response against SARS, by administering a synthetic replikin peptide of (I). (M3) is useful for inducing an immune response against SARS. (M4) is useful for treating SARS (all claimed). (I) is useful for preparing a vaccine for SARS. The replikin of (I) are useful for detecting disease caused by viruses, bacteria, fungus, cancer associated proteins, to foster growth of algal and plant foods, for detecting pathogens qualitatively and quantitatively, for controlling broad range of diseases and for diagnosing diatom plankton, foot and mouth disease virus, tomato leaf curl gemini virus, hepatitis B and C, HIV, influenza virus and malignant.    ADVANTAGE - Replikin concentration and composition provide new quantitative method to detect and control the process of replication.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:    (1) antibody (II) which recognizes (I) having the amino acid sequence of Lys-His-Leu-Asp-Ala-Tyr-Lys-Thr-Phe-Pro-Pro-Thr-Glu-Pro-Lys-Lys-Asp-Lys-Lys-Lys-Lys (S1), Lys-His-Arg-Glu-Phe-Val-Phe-Lys-Asn-Lys-Asp-Gly-Phe-Leu-Tyr-Val-Tyr-Lys (S2), Lys-Glu-Glu-Leu-Asp-Lys-Tyr-Phe-Lys-Asn-His (S3), Lys-Tyr-Arg-Tyr-Leu-Arg-His-Gly-Lys (S4), and Lys-Lys-Gly-Ala-Lys-Leu-Leu-His-Lys (S5);    (2) a coronavirus vaccine (III) comprising at least one isolated replikin present in the nucleocapsid, or spike or envelope or other protein of an emerging strain of coronavirus and a carrier;    (3) providing (M1) passive immunity, by administering a composition comprising a universal synthetic epitope (UTOPE) and a carrier;    (4) providing (M2) passive immunity, by administering a composition comprising a universal synthetic epitope (UTOPE), adjuvant and carrier;    (5) inducing (M3) an immune response against severe acute respiratory syndrome (SARS), by administering a UTOPE;    (6) treating (M4) SARS by administering a UTOPE;    (7) a synthetic peptide (IV) encoding a UTOPE;    (8) an anti-replikin vaccine (UVAX) (V1) comprising at least one UTOPE and a carrier;    (9) an anti-UTOPE antibody (V) specific for a UTOPE has one of the sequence (S6-S16) of Lys-Lys-Lys-Lys-His-Lys, Lys-Lys-Lys-His-Lys-Lys, Lys-Lys-His-Lys-Lys-Lys, Lys-His-Lys-Lys-Lys-Lys, Lys-Lys-Lys-Lys-Lys-Lys-His, Lys-Lys-Lys-Lys-Lys-His-Lys, Lys-Lys-Lys-Lys-His-Lys-Lys, Lys-Lys-Lys-His-Lys-Lys-Lys, Lys-Lys-His-Lys-Lys-Lys-Lys, Lys-His-Lys-Lys-Lys-Lys-Lys and His-Lys-Lys-Lys-Lys-Lys-Lys;    (10) an antibody specific for a UTOPE is encoded by (S6-S16);    (11) identifying (M5) an emerging strain of a virus for diagnostic, preventive or therapeutic purposes, involves:    (a) obtaining at least one isolate of each strain of several strains of the virus, analyzing the amino acid sequence of the individual proteins of at least one isolate of each strain of the several strains of the virus for the presence and concentration of replikin sequences (number of replikin sequences per 100 amino acids), comparing the concentration of replikin sequences in the amino acid sequence of the individual proteins of at least one isolate of each strain of the several strains of individual protein of the virus to the concentration of replikin sequences observed in the amino acid sequence of each of the strains that individual protein at least one earlier time period to provide the concentration of replikins for at least two time periods, at least one earlier time period being within about 6 month to 3 yeas prior to obtaining step, and identifying the strain of the virus having the highest increase in concentration of replikin sequences during two time periods;    (b) obtaining at least one isolate of each strain of several strains of the virus, analyzing the amino acid sequence of the individual proteins of at least one isolate of each strain of the several strains of the virus for the presence and concentration of replikin sequences, comparing the concentration of replikin sequences in the amino acid sequence of the individual proteins of at least one isolate of each strain of the several strains of the virus to the concentration of replikin sequences observed in the amino acid sequence of each of the strains at least one earlier time to provide the concentration of replikins for at least two time periods, at least one earlier time period being within 6 month to 3 years prior to obtaining step, and identifying the strain of the virus having the highest increase in concentration of replikin sequences of the individual proteins during two time periods; or    (c) obtaining at least one isolate of each strain of several strains of the virus, analyzing the amino acid sequence of at least one isolate of each strain of several strains of the virus for the presence and concentration of replikin sequences, determining the replikin count, or number of replikins per 100 amino acid length sequence, comparing the replikin count in the amino acid sequence of at least one isolate of each strain of several strains of the virus to the replikin count observed in the amino acid sequence of each of the strains at least one earlier time period to provide the replikin count for at least two time periods, the at least one earlier time period being about 6 month to about 3 years prior to obtaining step, and identifying the strain of the virus having the highest increase in replikin count during two time periods; and    (12) identifying an non-emerging strain of the virus for diagnostic, preventive or therapeutic purposes, involves obtaining at least one isolate of each strain of several strains of the virus, analyzing the amino acid sequence of at least one isolate of each strain of several strains of the virus for the presence and concentration of replikin sequences, comparing the concentration of the replikin sequences in the amino acid sequence of at least one isolate of each strain of several strains of the virus to the concentration of replikin sequences observed in the amino acid sequence of each of the strains at least one earlier time period to provide the concentration of replikin for at least two time periods, at least one earlier time period being within 6 month to about 3 years prior to obtaining step, and identifying the strain of the virus having the lowest increase in concentration of the replikin sequences during two time periods. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).)",B04-C01;  B04-G01;  B04-N03A;  B04-N04A;  B11-C08F;  B12-K04A4A;  B14-A02B5;  B14-S11A;  C04-C01;  C04-G01;  C04-N03A;  C04-N04A;  C11-C08F;  C12-K04A4A;  C14-A02B5;  C14-S11A;  D05-H06A;  D05-H07;  D05-H11,C07K-014/005;  C12Q-001/70;  C07K-014/165;  C07K-016/10;  A61K-039/00;  A61K-039/215;  A61K-039/39;  A61P-031/12;  A61P-031/16;  A61P-031/18;  A61P-035/00;  C07K-016/08;  C07K-007/08;  C12N-007/00;  A61K-031/00;  A61K-039/12;  C07K-014/00;  C07K-007/06;  G01N-033/50;  G06F-017/00;  G06F-019/00;  G06F-019/16;  C07K-007/00;  A61K-039/395;  C07K-016/00;  C40B-030/02;  A61K-039/42;  G01N-033/569;  G06F-019/22;  A61K-039/015;  A61K-039/145,WO2005010032-A2   03 Feb 2005   C07K-014/005   200513Pages: 150   English;  US2005202415-A1   15 Sep 2005   C12Q-001/70   200561   English;  EP1636254-A2   22 Mar 2006   C07K-014/165   200621   English;  AU2004259640-A1   03 Feb 2005   C07K-014/165   200654   English;  JP2007526222-W   13 Sep 2007   C07K-014/165   200762Pages: 120   Japanese;  US7442761-B2   28 Oct 2008   A61K-031/00   200901   English;  US2009053257-A1   26 Feb 2009   A61K-039/12   200921   English;  SG153065-A1   29 Jun 2009   201011   English;  AU2004259640-B2   01 Apr 2010   A61K-039/215   201024   English;  AU2010200602-A1   11 Mar 2010   A61K-039/215   201028   English;  EP1636254-B1   08 Sep 2010   C07K-014/165   201059   English;  DE602004029034-E   21 Oct 2010   C07K-014/165   201070   German;  EP2292643-A1   09 Mar 2011   C07K-014/165   201118   English;  EP2338901-A1   29 Jun 2011   C07K-014/165   201143   English;  SG163553-A1   30 Aug 2010   201149   English;  EP2390804-A2   30 Nov 2011   G06F-019/00   201179   English;  EP2390805-A2   30 Nov 2011   G06F-019/00   201179   English;  EP2390806-A2   30 Nov 2011   G06F-019/00   201179   English;  EP2390804-A3   29 Feb 2012   G06F-019/00   201216   English;  EP2390805-A3   29 Feb 2012   G06F-019/00   201216   English;  EP2390807-A3   29 Feb 2012   G06F-019/00   201216   English;  EP2390808-A3   29 Feb 2012   G06F-019/00   201216   English;  WO2005010032-A3   09 Jun 2005   C07K-014/165   201217   English;  EP2390806-A3   07 Mar 2012   G06F-019/00   201218   English;  SG182000-A1   30 Jul 2012   C07K-014/165   201252   English;  AU2010200602-B2   20 Dec 2012   C07K-014/165   201310   English;  IL204266-A   31 Dec 2012   C07K-007/00   201311   English;  IL172396-A   31 Jan 2013   A61K-039/215   201312   English;  IL199527-A   28 Feb 2013   A61K-039/395   201344   English;  NZ593774-A   25 Jan 2013   C07K-014/005   201345   English;  AU2013201657-A1   11 Apr 2013   C07K-014/165   201351   English;  US2013195916-A1   01 Aug 2013   G06F-019/16   201351   English;  SG117801-A1   27 Jan 2006   C07K-014/165   201413   English;  SG117801-B   31 Dec 2007   C07K-014/165   201413   English;  US2014206556-A1   24 Jul 2014   C07K-016/10   201449   English;  SG196773-A1   13 Feb 2014   201458   English;  EP2292643-B1   18 Feb 2015   C07K-014/165   201516   English;  IL224496-A   24 Mar 2013   A61K-039/215   201527   English;  US9388234-B2   12 Jul 2016   G01N-033/50   201646   English,WO2005010032-A2    WOUS017936    07 Jun 2004;   US2005202415-A1    US860050    04 Jun 2004;   EP1636254-A2    EP785929    07 Jun 2004;   AU2004259640-A1    AU259640    07 Jun 2004;   JP2007526222-W    JP515241    07 Jun 2004;   US7442761-B2    US860050    04 Jun 2004;   US2009053257-A1    US170763    10 Jul 2008;   SG153065-A1    SG003296    28 Apr 2005;   AU2004259640-B2    AU259640    07 Jun 2004;   AU2010200602-A1    AU200602    18 Feb 2010;   AU2010200602-A1    AU200602    18 Feb 2010;   EP1636254-B1    EP785929    07 Jun 2004;   DE602004029034-E    DE60029034    07 Jun 2004;   EP2292643-A1    EP166675    07 Jun 2004;   EP2338901-A1    EP175477    07 Jun 2004;   SG163553-A1    SG004731    28 Apr 2005;   EP2390804-A2    EP158038    28 Apr 2005;   EP2390805-A2    EP158084    28 Apr 2005;   EP2390806-A2    EP158093    28 Apr 2005;   EP2390807-A2    EP158097    28 Apr 2005;   EP2390808-A2    EP158102    28 Apr 2005;   EP2390804-A3    EP158038    28 Apr 2005;   EP2390805-A3    EP158084    28 Apr 2005;   EP2390807-A3    EP158097    28 Apr 2005;   EP2390808-A3    EP158102    28 Apr 2005;   WO2005010032-A3    WOUS017936    07 Jun 2004;   EP2390806-A3    EP158093    28 Apr 2005;   SG182000-A1    SG018463    07 Jun 2004;   AU2010200602-B2    AU200602    18 Feb 2010;   AU2010200602-B2    AU200602    18 Feb 2010;   IL204266-A    IL204266    07 Jun 2004;   IL172396-A    IL172396    07 Jun 2004;   IL199527-A    IL199527    07 Jun 2004;   NZ593774-A    NZ593774    28 Jun 2011;   AU2013201657-A1    AU201657    19 Mar 2013;   AU2013201657-A1    AU201657    19 Mar 2013;   US2013195916-A1    US787450    06 Mar 2013;   SG117801-A1    SG007743    07 Jun 2004;   SG117801-B    SG007743    07 Jun 2004;   US2014206556-A1    US921981    19 Jun 2013;   SG196773-A1    SG009551    28 Apr 2005;   EP2292643-B1    EP166675    07 Jun 2004;   IL224496-A    IL224496    07 Jun 2004;   IL224497-A    IL224497    07 Jun 2004;   IL224498-A    IL224498    07 Jun 2004;   US9388234-B2    US921981    19 Jun 2013,US2005202415-A1 Provisional Application US476186P;   US2005202415-A1 Provisional Application US504958P;   US2005202415-A1 Provisional Application US531686P;   EP1636254-A2 PCT application Application WOUS017936;   EP1636254-A2 Based on Patent WO2005010032;   AU2004259640-A1 Based on Patent WO2005010032;   JP2007526222-W PCT application Application WOUS017936;   JP2007526222-W Based on Patent WO2005010032;   US7442761-B2 Provisional Application US476186P;   US7442761-B2 Provisional Application US504958P;   US7442761-B2 Provisional Application US531686P;   US2009053257-A1 Provisional Application US531686P;   US2009053257-A1 Provisional Application US504958P;   US2009053257-A1 Provisional Application US476186P;   US2009053257-A1 Cont of Application US860050;   US2009053257-A1 Cont of Patent US7442761;   AU2004259640-B2 Based on Patent WO2005010032;   AU2010200602-A1 Div ex Application AU259640;   EP1636254-B1 PCT application Application WOUS017936;   EP1636254-B1 Related to Application EP166675;   EP1636254-B1 Based on Patent WO2005010032;   DE602004029034-E PCT application Application WOUS017936;   DE602004029034-E EP application Application EP785929;   DE602004029034-E Based on Patent EP1636254;   DE602004029034-E Based on Patent WO2005010032;   EP2292643-A1 Div ex Application EP785929;   EP2292643-A1 Div ex Patent EP1636254;   EP2338901-A1 Div ex Application EP785929;   EP2338901-A1 Div ex Patent EP1636254;   EP2390804-A2 Div ex Application EP743059;   EP2390804-A2 Div ex Patent EP1745401;   EP2390805-A2 Div ex Application EP743059;   EP2390805-A2 Div ex Patent EP1745401;   EP2390806-A2 Div ex Application EP743059;   EP2390806-A2 Div ex Patent EP1745401;   EP2390807-A2 Div ex Application EP743059;   EP2390807-A2 Div ex Patent EP1745401;   EP2390808-A2 Div ex Application EP743059;   EP2390808-A2 Div ex Patent EP1745401;   EP2390804-A3 Div ex Application EP743059;   EP2390804-A3 Div ex Patent EP1745401;   EP2390805-A3 Div ex Application EP743059;   EP2390805-A3 Div ex Patent EP1745401;   EP2390807-A3 Div ex Application EP743059;   EP2390807-A3 Div ex Patent EP1745401;   EP2390808-A3 Div ex Application EP743059;   EP2390808-A3 Div ex Patent EP1745401;   EP2390806-A3 Div ex Application EP743059;   EP2390806-A3 Div ex Patent EP1745401;   AU2010200602-B2 Div ex Application AU259640;   IL204266-A Div ex Application IL172396;   IL204266-A Based on Patent WO2005010032;   IL204266-A Div ex Patent IL172396;   IL172396-A Based on Patent WO2005010032;   IL199527-A Div ex Application IL172396;   IL199527-A Based on Patent WO2005010032;   IL199527-A Div ex Patent IL172396;   AU2013201657-A1 Div ex Application AU200602;   US2013195916-A1 Provisional Application US565847P;   US2013195916-A1 Provisional Application US653083P;   US2013195916-A1 Cont of Application US349955;   US2013195916-A1 Cont of Application US116203;   US2013195916-A1 CIP of Application US860050;   US2013195916-A1 CIP of Application US189437;   US2013195916-A1 CIP of Application US105232;   US2013195916-A1 CIP of Application US984057;   US2013195916-A1 Cont of Patent US7774144;   US2013195916-A1 Cont of Patent US8417462;   US2013195916-A1 CIP of Patent US7420028;   US2013195916-A1 CIP of Patent US7442761;   US2013195916-A1 CIP of Patent US7189800;   US2013195916-A1 CIP of Patent US7452963;   SG117801-A1 PCT application Application WOUS017936;   SG117801-A1 Based on Patent WO2005010032;   SG117801-B PCT application Application WOUS017936;   SG117801-B Based on Patent WO2005010032;   US2014206556-A1 Provisional Application US653083P;   US2014206556-A1 Provisional Application US565847P;   US2014206556-A1 Provisional Application US531686P;   US2014206556-A1 Provisional Application US504958P;   US2014206556-A1 Provisional Application US476186P;   US2014206556-A1 Cont of Application US965365;   US2014206556-A1 CIP of Application US170763;   US2014206556-A1 Cont of Application US355120;   US2014206556-A1 CIP of Application US116203;   US2014206556-A1 Cont of Application US860050;   US2014206556-A1 CIP of Application US860050;   US2014206556-A1 Cont of Patent US7894999;   US2014206556-A1 Cont of Patent US8494781;   US2014206556-A1 Cont of Patent US7442761;   US2014206556-A1 CIP of Patent US7442761;   US2014206556-A1 CIP of Patent US7774144;   EP2292643-B1 Div ex Application EP785929;   EP2292643-B1 Div ex Patent EP1636254;   IL224496-A Div ex Application IL172396;   IL224496-A Based on Patent WO2005010032;   IL224496-A Div ex Patent IL172396;   IL224497-A Div ex Application IL172396;   IL224497-A Based on Patent WO2005010032;   IL224497-A Div ex Patent IL172396;   IL224498-A Div ex Application IL172396;   IL224498-A Based on Patent WO2005010032;   IL224498-A Div ex Patent IL172396;   US9388234-B2 Provisional Application US653083P;   US9388234-B2 Provisional Application US565847P;   US9388234-B2 Provisional Application US531686P;   US9388234-B2 Provisional Application US504958P;   US9388234-B2 Provisional Application US476186P;   US9388234-B2 Cont of Application US965365;   US9388234-B2 CIP of Application US170763;   US9388234-B2 Cont of Application US355120;   US9388234-B2 CIP of Application US116203;   US9388234-B2 CIP of Application US860050;   US9388234-B2 Cont of Patent US7894999;   US9388234-B2 Cont of Patent US8494781;   US9388234-B2 CIP of Patent US7442761;   US9388234-B2 CIP of Patent US7774144,US984057    26 Oct 2001;  US476186P    06 Jun 2003;  US504958P    23 Sep 2003;  US531686P    23 Dec 2003;  US565847P    28 Apr 2004;  US860050    04 Jun 2004;  AU259640    07 Jun 2004;  US653083P    16 Feb 2005;  WOUS014443    28 Apr 2005;  US170763    10 Jul 2008;  AU200602    18 Feb 2010;  US787450    06 Mar 2013;  AU201657    19 Mar 2013;  US921981    19 Jun 2013,WO2005010032-A2:      (National): AE;  AG;  AL;  AM;  AT;  AU;  AZ;  BA;  BB;  BG;  BR;  BW;  BY;  BZ;  CA;  CH;  CN;  CO;  CR;  CU;  CZ;  DE;  DK;  DM;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  HR;  HU;  ID;  IL;  IN;  IS;  JP;  KE;  KG;  KP;  KR;  KZ;  LC;  LK;  LR;  LS;  LT;  LU;  LV;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MZ;  NA;  NI;  NO;  NZ;  OM;  PG;  PH;  PL;  PT;  RO;  RU;  SC;  SD;  SE;  SG;  SK;  SL;  SY;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  YU;  ZA;  ZM;  ZW    (Regional): AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HU;  IE;  IT;  KE;  LS;  LU;  MC;  MW;  MZ;  NA;  NL;  OA;  PL;  PT;  RO;  SD;  SE;  SI;  SK;  SL;  SZ;  TR;  TZ;  UG;  ZM;  ZW    EP1636254-A2:      (Regional): AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HU;  IE;  IT;  LI;  LU;  MC;  NL;  PL;  PT;  RO;  SE;  SI;  SK;  TR                EP1636254-B1:      (Regional): AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HU;  IE;  IT;  LI;  LU;  MC;  NL;  PL;  PT;  RO;  SE;  SI;  SK;  TR    EP2292643-A1:      (Regional): AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HU;  IE;  IT;  LI;  LU;  MC;  NL;  PL;  PT;  RO;  SE;  SI;  SK;  TR  EP2338901-A1:      (Regional): AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HU;  IE;  IT;  LI;  LU;  MC;  NL;  PL;  PT;  RO;  SE;  SI;  SK;  TR    EP2390804-A2:      (Regional): AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  MC;  NL;  PL;  PT;  RO;  SE;  SI;  SK;  TR  EP2390805-A2:      (Regional): AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  MC;  NL;  PL;  PT;  RO;  SE;  SI;  SK;  TR  EP2390806-A2:      (Regional): AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  MC;  NL;  PL;  PT;  RO;  SE;  SI;  SK;  TR  EP2390804-A3:      (Regional): AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  MC;  NL;  PL;  PT;  RO;  SE;  SI;  SK;  TR  EP2390805-A3:      (Regional): AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  MC;  NL;  PL;  PT;  RO;  SE;  SI;  SK;  TR  EP2390807-A3:      (Regional): AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  MC;  NL;  PL;  PT;  RO;  SE;  SI;  SK;  TR  EP2390808-A3:      (Regional): AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  MC;  NL;  PL;  PT;  RO;  SE;  SI;  SK;  TR  WO2005010032-A3:      (National): AE;  AG;  AL;  AM;  AT;  AU;  AZ;  BA;  BB;  BG;  BR;  BW;  BY;  BZ;  CA;  CH;  CN;  CO;  CR;  CU;  CZ;  DE;  DK;  DM;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  HR;  HU;  ID;  IL;  IN;  IS;  JP;  KE;  KG;  KP;  KR;  KZ;  LC;  LK;  LR;  LS;  LT;  LU;  LV;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MZ;  NA;  NI;  NO;  NZ;  OM;  PG;  PH;  PL;  PT;  RO;  RU;  SC;  SD;  SE;  SG;  SK;  SL;  SY;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  YU;  ZA;  ZM;  ZW    (Regional): AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HU;  IE;  IT;  KE;  LS;  LU;  MC;  MW;  MZ;  NA;  NL;  OA;  PL;  PT;  RO;  SD;  SE;  SI;  SK;  SL;  SZ;  TR;  TZ;  UG;  ZM;  ZW  EP2390806-A3:      (Regional): AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  MC;  NL;  PL;  PT;  RO;  SE;  SI;  SK;  TR                          EP2292643-B1:      (Regional): AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HU;  IE;  IT;  LI;  LU;  MC;  NL;  PL;  PT;  RO;  SE;  SI;  SK;  TR      ,,"WO2005010032-A2 -- EP108564-A   UNIV CALIFORNIA (REGC)   CLINE M J,  SLAMON D J;  EP108564-B   UNIV CALIFORNIA (REGC)   CLINE M J,  SLAMON D J;  WO2001004135-A2   ;  US2005202415-A1 -- US5104854-A   UNIV WASHINGTON ST LOUIS (UNWL)   SCHLESINGE M J,  COLLIER N C,  ADAMS S P;  US20020120106-A1   ;  US20020151677-A1   ;  US20050271676-A1   ;  US7267942-B2   UNIV HONG KONG (UYHK)   CHAN K,  GUAN Y,  NICHOLLS J M,  PEIRIS J S M,  POON L,  YUEN K;  US7442761-B2 -- US7267942-B2   UNIV HONG KONG (UYHK)   CHAN K,  GUAN Y,  NICHOLLS J M,  PEIRIS J S M,  POON L,  YUEN K;  EP108564-A   UNIV CALIFORNIA (REGC)   CLINE M J,  SLAMON D J;  IT980874-A1   ;  US5104854-A   UNIV WASHINGTON ST LOUIS (UNWL)   SCHLESINGE M J,  COLLIER N C,  ADAMS S P;  US5231167-A   UNIV CALIFORNIA (REGC);  ORTHO PHARM CORP (ORTH)   LENERT P,  GOLUB E,  KROON D;  US5280113-A   MONSANTO CO (MONS);  OXFORD GLYCOSYSTEMS LTD (OXFO-Non-standard)   DWEK R A,  MANGER I D,  RADEMACHER T W,  WONG S Y C;  US5679352-A   CONNAUGHT LAB LTD (SNFI)   CHONG P,  KANDIL A,  SIA C,  KLEIN M H;  US5866690-A   BOGOCH S (BOGO-Individual)   BOGOCH S;  US6023659-A   INCYTE PHARM INC (INYT)   SEILHAMER J J,  AKERBLOM I E,  ALTUS C M,  RUSSO F,  AU-YOUNG J,  HILLMAN J L,  MASLYN T J,  KLINGLER T M;  US6070126-A   KOKOLUS W J (KOKO-Individual)   KOKOLUS W J,  JOHNSTON D A,  FRITSCHE H A;  US20020120106-A1   ;  US20020151677-A1   ;  US20030180328-A1   ;  US20030194414-A1   ;  US20050271676-A1   ;  US6242578-B1   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  US6256647-B1   BIOMOLECULAR ENG RES INST (BIOM-Non-standard)   TOH H;  US6470277-B1   AGY THERAPEUTICS INC (AGYT-Non-standard)   CHIN D J,  HENDRIX D,  ZHAO O;  US6484166-B1   EVRESEARCH LTD (EVRE-Non-standard)   MAYNARD G;  US6638505-B2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  WO1996032106-A1   ;  WO2000018351-A2   ;  WO2001004135-A2   ;  WO2002085093-A2   ;  WO2003005880-A2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  WO2003083058-A2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  US2009053257-A1 -- US4132769-A   OSTHER K B (OSTH-Individual);  BENZON AS ALFRED (BENA);  BENZ & HILGERS GMBH (BENZ);  US5104854-A   UNIV WASHINGTON ST LOUIS (UNWL)   SCHLESINGE M J,  COLLIER N C,  ADAMS S P;  US5231167-A   UNIV CALIFORNIA (REGC);  ORTHO PHARM CORP (ORTH)   LENERT P,  GOLUB E,  KROON D;  US5280113-A   MONSANTO CO (MONS);  OXFORD GLYCOSYSTEMS LTD (OXFO-Non-standard)   DWEK R A,  MANGER I D,  RADEMACHER T W,  WONG S Y C;  US5679352-A   CONNAUGHT LAB LTD (SNFI)   CHONG P,  KANDIL A,  SIA C,  KLEIN M H;  US5866690-A   BOGOCH S (BOGO-Individual)   BOGOCH S;  US6023659-A   INCYTE PHARM INC (INYT)   SEILHAMER J J,  AKERBLOM I E,  ALTUS C M,  RUSSO F,  AU-YOUNG J,  HILLMAN J L,  MASLYN T J,  KLINGLER T M;  US6070126-A   KOKOLUS W J (KOKO-Individual)   KOKOLUS W J,  JOHNSTON D A,  FRITSCHE H A;  US6090406-A   LIPOSOME CO INC (LIPO)   POPESCU M C,  RECINE M S,  JANOFF A S,  ESTIS L,  KEYES L D,  ALVING C R,  WEINER A L;  US20020120106-A1   ;  US20020151677-A1   ;  US20030180328-A1   ;  US20030194414-A1   ;  US20050202415-A1   ;  US20050271676-A1   ;  US20060024669-A1   ;  US20070026009-A1   ;  US6242578-B1   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  US6256647-B1   BIOMOLECULAR ENG RES INST (BIOM-Non-standard)   TOH H;  US6470277-B1   AGY THERAPEUTICS INC (AGYT-Non-standard)   CHIN D J,  HENDRIX D,  ZHAO O;  US6484166-B1   EVRESEARCH LTD (EVRE-Non-standard)   MAYNARD G;  US6638505-B2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  US7176275-B2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  US7189800-B2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  US7214786-B2   KOVALIC D K (KOVA-Individual);  ANDERSEN S E (ANDE-Individual);  BYRUM J R (BYRU-Individual);  CONNER T W (CONN-Individual);  MASUCCI J D (MASU-Individual);  ZHOU Y (ZHOU-Individual)   KOVALIC D K,  ANDERSEN S E,  BYRUM J R,  CONNER T W,  MASUCCI J D,  ZHOU Y;  US7267942-B2   UNIV HONG KONG (UYHK)   CHAN K,  GUAN Y,  NICHOLLS J M,  PEIRIS J S M,  POON L,  YUEN K;  US7420028-B2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  US7442761-B2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  US7452963-B2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  US7674888-B2   BIOMERIEUX SA (INMR)   PERRON H,  BESEME F,  BEDIN F,  PARANHOS-BACCALA G,  KOMURIAN-PRADEL F,  JOLIVET-REYNAUD C,  MANDRAND B,  GARSON J A,  TUKE P W;  US7705129-B2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  US7758863-B2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH E S,  BOGOCH S;  US7763705-B2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  US7774144-B2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  US7894999-B2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual);  BOGOCH S W (BOGO-Individual);  BORSANYI A B (BORS-Individual)   BOGOCH S,  BOGOCH E S,  BOGOCH S W,  BORSANYI A B;  US8050871-B2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual);  BOGOCH S W (BOGO-Individual);  BORSANYI A E (BORS-Individual)   BOGOCH S,  BOGOCH E S,  BOGOCH S W,  BORSANYI A E;  EP1636254-B1 -- EP108564-A   UNIV CALIFORNIA (REGC)   CLINE M J,  SLAMON D J;  WO2001004135-A2   ;  EP2292643-A1 -- US4946778-A   GENEX CORP (GEMX)   LADNER R C,  BIRD R E,  HARDMAN K;  US5866690-A   BOGOCH S (BOGO-Individual)   BOGOCH S;  US6242578-B1   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  US7189800-B2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  EP2338901-A1 -- EP108564-A   UNIV CALIFORNIA (REGC)   CLINE M J,  SLAMON D J;  US4946778-A   GENEX CORP (GEMX)   LADNER R C,  BIRD R E,  HARDMAN K;  US5866690-A   BOGOCH S (BOGO-Individual)   BOGOCH S;  US10523202-A   OLSSON M S (OLSS-Individual);  RUTLEDGE A (RUTL-Individual);  HEYENBRUCH L M (CANE-Individual);  WARREN A L (WARR-Individual);  TURGEON M E (TURG-Individual);  MEREWETHER R (MERE-Individual);  MARTIN M J (MART-Individual)   OLSSON M S,  RUTLEDGE A,  HEYENBRUCH L M,  WARREN A L,  TURGEON M E,  MEREWETHER R,  MARTIN M J;  US2011171236-A1   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  US6242578-B1   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  EP2390806-A2 -- US7189800-B2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  US7420028-B2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  US7442761-B2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  US7452963-B2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  EP2390804-A3 -- US20020151677-A1   ;  WO2003083058-A2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  EP2390805-A3 -- US20020151677-A1   ;  WO2003083058-A2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  EP2390807-A3 -- US20020151677-A1   ;  WO2003083058-A2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  EP2390808-A3 -- US20020151677-A1   ;  WO2005010032-A3 -- EP108564-A   UNIV CALIFORNIA (REGC)   CLINE M J,  SLAMON D J;  WO2001004135-A2   ;  EP2390806-A3 -- US20020151677-A1   ;  WO2003083058-A2   BOGOCH S (BOGO-Individual);  BOGOCH E S (BOGO-Individual)   BOGOCH S,  BOGOCH E S;  AU2010200602-B2 -- WO2002085093-A2   ","WO2005010032-A2  BOGOCH S ET AL: ""A checklist for suitability of biomarkers as surrogate endpoints in chemoprevention of breast cancer."" JOURNAL OF CELLULAR BIOCHEMISTRY. SUPPLEMENT. 1994, vol. 19, 1994, pages 173-185, XP009046492 ISSN: 0733-1959;  MARRA M A ET AL: ""The genome sequence of the SARS-associated coronavirus"" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1399-1404, XP002269483 ISSN: 0036-8075;  QIN E'DE ET AL: ""A genome sequence of novel SARS-CoV isolates: The genotype, GD-Ins29, leads to a hypothesis of viral transmission in South China."" GENOMICS PROTEOMICS & BIOINFORMATICS, vol. 1, no. 2, May 2003 (2003-05), pages 101-107, XP001206098 ISSN: 1672-0229;  ROTA P A ET AL: ""Characterization of a novel coronavirus associated with severe acute respiratory syndrome"" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1394-1399, XP002269482 ISSN: 0036-8075;  TANAKA T ET AL: ""EFFICIENT GENERATION OF ANTIBODIES TO ONCOPROTEINS BY USING SYNTHETIC PEPTIDE ANTIGENS"" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 82, no. 10, 1 May 1985 (1985-05-01), pages 3400-3404, XP000113798 ISSN: 0027-8424US2009053257-A1  Kucinskaite-Kodze et al., Virus Research Vol 211 (year 2016) pages 209221EP1636254-B1  TANAKA T ET AL: ""EFFICIENT GENERATION OF ANTIBODIES TO ONCOPROTEINS BY USING SYNTHETIC PEPTIDE ANTIGENS"" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 82, no. 10, 1 May 1985 (1985-05-01), pages 3400-3404, XP000113798 ISSN: 0027-8424;  MARRA M A ET AL: ""The genome sequence of the SARS-associated coronavirus"" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1399-1404, XP002269483 ISSN: 0036-8075;  ROTA P A ET AL: ""Characterization of a novel coronavirus associated with severe acute respiratory syndrome"" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1394-1399, XP002269482 ISSN: 0036-8075;  QIN E'DE ET AL: ""A genome sequence of novel SARS-CoV isolates: The genotype, GD-Ins29, leads to a hypothesis of viral transmission in South China."" GENOMICS PROTEOMICS&BIOINFORMATICS, vol. 1, no. 2, May 2003 (2003-05), pages 101-107, XP001206098 ISSN: 1672-0229;  BOGOCH S ET AL: ""A checklist for suitability of biomarkers as surrogate endpoints in chemoprevention of breast cancer."" JOURNAL OF CELLULAR BIOCHEMISTRY. SUPPLEMENT. 1994, vol. 19, 1994, pages 173-185, XP009046492 ISSN: 0733-1959EP2292643-A1  TANAKA T ET AL: ""EFFICIENT GENERATION OF ANTIBODIES TO ONCOPROTEINS BY USING SYNTHETIC PEPTIDE ANTIGENS"" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 82, no. 10, 1 May 1985 (1985-05-01), pages 3400-3404, XP000113798 ISSN: 0027-8424;  MARRA M A ET AL: ""The genome sequence of the SARS-associated coronavirus"" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1399-1404, XP002269483 ISSN: 0036-8075;  ROTA P A ET AL: ""Characterization of a novel coronavirus associated with severe acute respiratory syndrome"" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1394-1399, XP002269482 ISSN: 0036-8075;  BOGOCH ET AL. CANCER DETECTION AND PREVENTION vol. 26, no. 1, 20 February 0001, page 402;  BOGOCH ET AL. PROTIDES OF BIOLOGICAL FLUIDS vol. 31, 19 December 0006, pages 739 - 747;  AILING ET AL. AM J. EPIDEMIOL. vol. 113, no. 1, 19 September 0006, pages 30 - 43;  MORBIDITY AND MORTALITY WEEKLY REPORTS (MMWR), CENTER FOR DISEASE CONTROL vol. 50, no. 48, 20 January 1207, pages 1084 - 68;  WENZEL, J. EUR. J. DENNATOL. vol. 12, no. 3, 20 February 0500, pages 296 - 300;  KOHLERMILSTEIN NATURE vol. 256, 19 March 0006, pages 495 - 497;  KOSBOR ET AL. IMMUNOLOGY TODAY vol. 4, 19 November 0006, page 72;  MORRISON ET AL. PROC. NAT. ACAD. SCI USA vol. 81, 19 December 0006, pages 6851 - 6855;  HUSE ET AL. SCIENCE vol. 246, 19 May 0007, pages 1275 - 1281;  WEBSTER, R.G. J. IMMUNOL. vol. 97, no. 2, 19 June 0005, pages 177 - 183;  WEBSTER ET AL. J. INFECT. DIS. vol. 134, 19 April 0006, pages 48 - 58;  KLENERMAN ET AL. NATURE vol. 394, 19 February 0008, pages 421 - 422EP2338901-A1  TANAKA T ET AL: ""EFFICIENT GENERATION OF ANTIBODIES TO ONCOPROTEINS BY USING SYNTHETIC PEPTIDE ANTIGENS"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 82, no. 10, 1 May 1985 (1985-05-01), pages 3400 - 3404, XP000113798, ISSN: 0027-8424,relevantClaims[1-3,21|4-20],relevantPassages[&lt;table&gt;1,Peptide21&lt;/table&gt;];  MARRA M A ET AL: ""The genome sequence of the SARS-associated coronavirus"", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1399 - 1404, XP002269483, ISSN: 0036-8075,relevantClaims[6,9|1-5,7,8,10-21],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  ROTA P A ET AL: ""Characterization of a novel coronavirus associated with severe acute respiratory syndrome"", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1394 - 1399, XP002269482, ISSN: 0036-8075,relevantClaims[6,9|1-5,7,8,10-21],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  QIN E'DE ET AL: ""A genome sequence of novel SARS-CoV isolates: The genotype, GD-Ins29, leads to a hypothesis of viral transmission in South China."", GENOMICS PROTEOMICS & BIOINFORMATICS, vol. 1, no. 2, May 2003 (2003-05-01), pages 101 - 107, XP001206098, ISSN: 1672-0229,relevantClaims[6,9|1-5,7,8,10-21],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  BOGOCH S ET AL: ""A checklist for suitability of biomarkers as surrogate endpoints in chemoprevention of breast cancer."", JOURNAL OF CELLULAR BIOCHEMISTRY. SUPPLEMENT. 1994, vol. 19, 1994, pages 173 - 185, XP009046492, ISSN: 0733-1959,relevantClaims[1-21],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  BOGOCH ET AL., CANCER DETECTION AND PREVENTION, vol. 26, no. 1, 2002, pages 402;  BOGOCH ET AL., PROTIDES OF BIOLOGICAL FLUIDS, vol. 31, 1984, pages 739 - 747;  AILING ET AL., AM J. EPIDEMIOL., vol. 113, no. L, pages 30 - 43;  ""Morbidity and Mortality Weekly Reports"", vol. 50, 7 December 2001, CENTER FOR DISEASE CONTROL, pages: 1084 - 68;  WENZEL, J. EUR. J. DERMATOL., vol. 12, no. 3, May 2002 (2002-05-01), pages 296 - 300;  KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497;  KOSBOR ET AL., IMMUNOLOGY TODAY, vol. 4, 1983, pages 72;  COLE ET AL.: ""Monoclonal Antibodies and Cancer Therapy"", ALAN R. LISS, INC., pages: 77 - 96;  MORRISON ET AL., PROC. NAT. ACAD. SCI USA, vol. 81, 1984, pages 6851 - 6855;  HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281;  WEBSTER, R.G., J. IMMUNOL., vol. 97, no. 2, 1966, pages 177 - 183;  WEBSTER ET AL., J. INFECT. DIS., vol. 134, 1976, pages 48 - 58;  KLENENNAN ET AL., NATURE, vol. 394, 1998, pages 421 - 422EP2390804-A3  BOGOCH S, BOGOCH ES: ""Rapid replication and Replikintm structures: basis of the AMASRTest and CAVAXR."", CANCER DETECTION AND PREVENTION ONLINE, 9 February 2002 (2002-02-09), XP002350483,relevantClaims[1-10,16,17],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;]EP2390805-A3  BOGOCH S, BOGOCH ES: ""Rapid replication and Replikintm structures: basis of the AMASRTest and CAVAXR."", CANCER DETECTION AND PREVENTION ONLINE, 9 February 2002 (2002-02-09), XP002350483,relevantClaims[1-8],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; February 2000 (2000-02-01), MELVILLE M W ET AL: ""P58IPK, a novel cochaperone containing tetratricopeptide repeats and a J-domain with oncogenic potential"", XP055007716, Database accession no. PREV200000253165,relevantClaims[1-8],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;]EP2390807-A3  BOGOCH S, BOGOCH ES: ""Rapid replication and Replikintm structures: basis of the AMASRTest and CAVAXR."", CANCER DETECTION AND PREVENTION ONLINE, 9 February 2002 (2002-02-09), XP002350483,relevantClaims[1-5],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;]EP2390808-A3  BOGOCH S, BOGOCH ES: ""Rapid replication and Replikintm structures: basis of the AMASRTest and CAVAXR."", CANCER DETECTION AND PREVENTION ONLINE, 9 February 2002 (2002-02-09), XP002350483,relevantClaims[1-10],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;]WO2005010032-A3  TANAKA T ET AL: ""EFFICIENT GENERATION OF ANTIBODIES TO ONCOPROTEINS BY USING SYNTHETIC PEPTIDE ANTIGENS"" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 82, no. 10, 1 May 1985 (1985-05-01), pages 3400-3404, XP000113798 ISSN: 0027-8424;  MARRA M A ET AL: ""The genome sequence of the SARS-associated coronavirus"" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1399-1404, XP002269483 ISSN: 0036-8075;  ROTA P A ET AL: ""Characterization of a novel coronavirus associated with severe acute respiratory syndrome"" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1394-1399, XP002269482 ISSN: 0036-8075;  QIN E'DE ET AL: ""A genome sequence of novel SARS-CoV isolates: The genotype, GD-Ins29, leads to a hypothesis of viral transmission in South China."" GENOMICS PROTEOMICS & BIOINFORMATICS, vol. 1, no. 2, May 2003 (2003-05), pages 101-107, XP001206098 ISSN: 1672-0229;  BOGOCH S ET AL: ""A checklist for suitability of biomarkers as surrogate endpoints in chemoprevention of breast cancer."" JOURNAL OF CELLULAR BIOCHEMISTRY. SUPPLEMENT. 1994, vol. 19, 1994, pages 173-185, XP009046492 ISSN: 0733-1959;  TANAKA T ET AL: ""EFFICIENT GENERATION OF ANTIBODIES TO ONCOPROTEINS BY USING SYNTHETIC PEPTIDE ANTIGENS"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 82, no. 10, 1 May 1985 (1985-05-01), pages 3400 - 3404, XP000113798, ISSN: 0027-8424,relevantClaims[1-3,22],relevantPassages[&lt;table&gt;1,Peptide21&lt;/table&gt;];  MARRA M A ET AL: ""The genome sequence of the SARS-associated coronavirus"", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1399 - 1404, XP002269483, ISSN: 0036-8075,relevantClaims[8,10,12,16-20],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  ROTA P A ET AL: ""Characterization of a novel coronavirus associated with severe acute respiratory syndrome"", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1394 - 1399, XP002269482, ISSN: 0036-8075,relevantClaims[8,10,12,16-20],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  QIN E'DE ET AL: ""A genome sequence of novel SARS-CoV isolates: The genotype, GD-Ins29, leads to a hypothesis of viral transmission in South China."", GENOMICS PROTEOMICS & BIOINFORMATICS, vol. 1, no. 2, May 2003 (2003-05-01), pages 101 - 107, XP001206098, ISSN: 1672-0229,relevantClaims[8,10,12,16-20],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  BOGOCH S ET AL: ""A checklist for suitability of biomarkers as surrogate endpoints in chemoprevention of breast cancer."", JOURNAL OF CELLULAR BIOCHEMISTRY. SUPPLEMENT. 1994, vol. 19, 1994, pages 173 - 185, XP009046492, ISSN: 0733-1959,relevantClaims[1-13,16-20,22,31-54],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;]EP2390806-A3  BOGOCH S, BOGOCH ES: ""Rapid replication and Replikintm structures: basis of the AMASRTest and CAVAXR."", CANCER DETECTION AND PREVENTION ONLINE, 9 February 2002 (2002-02-09), XP002350483,relevantClaims[1-4],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  BUSCAGLIA CARLOS A ET AL: ""The repetitive domain of Trypanosoma cruzi trans-sialidase enhances the immune response against the catalytic domain"", JOURNAL OF INFECTIOUS DISEASES, UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, vol. 177, no. 2, 1 February 1998 (1998-02-01), pages 431 - 436, XP002529162, ISSN: 0022-1899, DOI: 10.1086/514199,relevantClaims[1-4],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  FERRO ET AL: ""The androgen receptor CAG repeat: a modifier of carcinogenesis"", CATALANO, 1 January 2002 (2002-01-01), pages 109 - 120, XP055008308,relevantClaims[1-4],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;]",1025529-1-0-0 A N T; 1025533-1-0-0 A N T; 1025593-1-0-0 A N T; 1025601-1-0-0 A N T; 1025614-1-0-0 A N T; 1025615-1-0-0 A N T; 1025616-1-0-0 A N T; 1025617-1-0-0 A N T; 1025618-1-0-0 A N T; 1025621-1-0-0 A N T; 1025622-1-0-0 A N T; 1025625-1-0-0 A N T; 1025626-1-0-0 A N T,,,RAGT30 A N T; RAGT34 A N T; RAGT4M A N T; RAGT4U A N T; RAGT57 A N T; RAGT58 A N T; RAGT59 A N T; RAGT5A A N T; RAGT5B A N T; RAGT5C A N T; RAGT5D A N T; RAGT5F A N T; RAGT5G A N T,
WO2020257356-A2;  WO2020257356-A3;  WO2020257356-A4;  AU2020296016-A1;  CA3143685-A1;  KR2022035376-A;  BR112021025669-A2;  EP3986614-A2;  IN202217002543-A;  SG11202114050-A;  CN114650883-A;  JP2022538046-W;  US2022325363-A1;  IL289050-A;  HK40070600-A0;  MX2021016027-A1;  CN114650883-B,"Microfluidic cartridge useful for e.g. detecting            target nucleic acid in sample, comprises amplification            chamber connected to valve, detection chamber connected            to valve, and detection reagent chamber connected to            detection chamber",BROUGHTON J P;  SINGH J;  FASCHING C L;  TSALOGLOU M;  GALARZO P P D;  CHEN J S;  MIAO X;  HARRINGTON L;  DRZAL D T;  SHAPIRO S J;  PAUL B J;  JASMIT S;  LOUIS P C;  MARIA-NEFELI S;  DRAPER G P P;  SHA G;  MIAOSIN;  LUCAS H;  THOMAS D D;  JANE S;  GALARZA P P D;  TSALOGLOU M N,MAMMOTH BIOSCI INC (MAMM-Non-standard);  BROUGHTON J P (BROU-Individual);  SINGH J (SING-Individual);  FASCHING C L (FASC-Individual);  TSALOGLOU M (TSAL-Individual);  GALARZO P P D (GALA-Individual);  CHEN J S (CHEN-Individual);  MIAO X (MIAO-Individual);  HARRINGTON L (HARR-Individual);  DRZAL D T (DRZA-Individual);  SHAPIRO S J (SHAP-Individual);  MAMMOTH BIOSCI INC (MAMM-Non-standard);  MAMMOTH BIOSCI INC (MAMM-Non-standard);  MAMMOTH BIOSCI INC (MAMM-Non-standard),2020C9805H,"   NOVELTY - Microfluidic cartridge comprises (a) an                amplification chamber connected to a valve, (b) a                detection chamber connected to the valve, where the                valve is connected to a sample metering channel,                and (c) a detection reagent chamber connected to                the detection chamber through a resistance channel.                The detection reagent chamber comprises a                programmable nuclease, a guide nucleic acid, and a                labeled detector nucleic acid, where the labeled                detector nucleic acid is capable of being cleaved                upon binding of the guide nucleic acid to a segment                of a target nucleic acid.    USE - The microfluidic cartridge is useful for                detecting target nucleic acid in sample, and                assaying target deoxyribonucleic acid and target                ribonucleic acid from virus in sample. The virus is                influenza virus comprising influenza A virus,                influenza B virus, or their combination (all                claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a manifold configured to accept the                microfluidic cartridge;    (2) a method for detecting a target nucleic                acid;    (3) use of a system in a method for detecting                a targeting nucleic acid;    (4) use of a programmable nuclease in a method                for detecting a target nucleic acid in a                sample;    (5) use of a composition in a method for                detecting a target a nucleic acid; and    (6) use of a DNA-activated programmable RNA                nuclease in a method for assaying a target                deoxyribonucleic acid from a virus in a sample, or                assaying a target ribonucleic acid from a virus in                a sample. ",,,"A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  J04 (Chemical/physical processes/apparatus - including catalysis, catalysts (excluding specific e.g. enzymatic or polymerisation catalysts), colloid chemistry, laboratory apparatus and methods, testing, controlling, general encapsulation, detection and sampling (excluding clinical testing) (B01J, L).);  T01 (Digital Computers)",A04-E08;  A12-H07;  A12-V03C2;  A12-W11L;  B04-E99;  B04-B03B;  B04-C03B;  B04-E01;  B04-E05;  B04-E13;  B04-L04A;  B04-L04B;  B04-L05A;  B11-C07B1;  B11-C07B3;  B11-C08B;  B11-C08C1;  B11-C08E3;  B11-C08F8;  B12-K04F;  D05-H99;  D05-A02B;  D05-A02C;  D05-H09;  D05-H18B;  D05-H19C;  J04-B03;  J04-B04;  J04-F;  J04-X04;  T01-C07C2;  T01-J05A2G;  T01-M02,B01L-003/00;  B01L-007/00;  C12Q-001/70;  A61K-035/14;  C12M-001/12;  F16K-099/00;  C12M-001/00;  C12N-015/09;  C12N-009/22;  C12Q-001/6844;  C12Q-001/686;  C12Q-001/6862;  C12Q-001/6865;  C12Q-001/6888,WO2020257356-A2   24 Dec 2020   B01L-003/00   202105Pages: 569   English;  WO2020257356-A3   25 Feb 2021   202119   English;  WO2020257356-A4   03 Jun 2021   202146   English;  AU2020296016-A1   10 Feb 2022   B01L-003/00   202213   English;  CA3143685-A1   24 Dec 2020   202213   English;  KR2022035376-A   22 Mar 2022   B01L-003/00   202227   ;  BR112021025669-A2   22 Feb 2022   B01L-003/00   202230   ;  EP3986614-A2   27 Apr 2022   B01L-003/00   202236   English;  IN202217002543-A   25 Mar 2022   B01L-003/00   202240   English;  SG11202114050-A   28 Jan 2022   B01L-003/00   202256   English;  CN114650883-A   21 Jun 2022   B01L-003/00   202259   Chinese;  JP2022538046-W   31 Aug 2022   C12M-001/00   202271   Japanese;  US2022325363-A1   13 Oct 2022   C12Q-001/70   202284   English;  IL289050-A   01 Feb 2022   B01L-003/00   202312   English;  HK40070600-A0   28 Oct 2022   B01L-003/00   202315   English;  MX2021016027-A1   07 Apr 2022   B01L-003/00   202385   Spanish;  CN114650883-B   27 Oct 2023   B01L-003/00   202391   Chinese,WO2020257356-A2    WOUS038242    17 Jun 2020;   WO2020257356-A3    WOUS038242    17 Jun 2020;   WO2020257356-A4    WOUS038242    17 Jun 2020;   AU2020296016-A1    AU296016    17 Jun 2020;   CA3143685-A1    CA3143685    17 Jun 2020;   KR2022035376-A    KR701075    17 Jun 2020;   BR112021025669-A2    BR11025669    17 Jun 2020;   EP3986614-A2    EP737671    17 Jun 2020;   IN202217002543-A    IN17002543    17 Jan 2022;   SG11202114050-A    SG11014050    17 Jun 2020;   CN114650883-A    CN80058836    17 Jun 2020;   JP2022538046-W    JP575939    17 Jun 2020;   US2022325363-A1    US555236    17 Dec 2021;   IL289050-A    IL289050    17 Jun 2020;   HK40070600-A0    HK6059696    07 Sep 2022;   MX2021016027-A1    MX016027    17 Dec 2021;   CN114650883-B    CN80058836    17 Jun 2020,AU2020296016-A1 PCT application Application WOUS038242;   AU2020296016-A1 Based on Patent WO2020257356;   CA3143685-A1 PCT application Application WOUS038242;   CA3143685-A1 Based on Patent WO2020257356;   KR2022035376-A PCT application Application WOUS038242;   KR2022035376-A Based on Patent WO2020257356;   BR112021025669-A2 PCT application Application WOUS038242;   BR112021025669-A2 Based on Patent WO2020257356;   EP3986614-A2 PCT application Application WOUS038242;   EP3986614-A2 Based on Patent WO2020257356;   IN202217002543-A PCT application Application WOUS038242;   IN202217002543-A Based on Patent WO2020257356;   SG11202114050-A PCT application Application WOUS038242;   SG11202114050-A Based on Patent WO2020257356;   CN114650883-A PCT application Application WOUS038242;   CN114650883-A Based on Patent WO2020257356;   JP2022538046-W PCT application Application WOUS038242;   JP2022538046-W Based on Patent WO2020257356;   US2022325363-A1 Provisional Application US985850P;   US2022325363-A1 Provisional Application US944926P;   US2022325363-A1 Provisional Application US881809P;   US2022325363-A1 Provisional Application US879325P;   US2022325363-A1 Provisional Application US863178P;   US2022325363-A1 Cont of Application WOUS038242;   IL289050-A Based on Patent WO2020257356;   HK40070600-A0 PCT application Application WOUS038242;   HK40070600-A0 Based on Patent WO2020257356;   HK40070600-A0 Previous Publ. Patent EP3986614;   MX2021016027-A1 PCT application Application WOUS038242;   MX2021016027-A1 Based on Patent WO2020257356;   CN114650883-B PCT application Application WOUS038242;   CN114650883-B Previous Publ. Patent CN114650883;   CN114650883-B Based on Patent WO2020257356,US863178P    18 Jun 2019;  US879325P    26 Jul 2019;  US881809P    01 Aug 2019;  US944926P    06 Dec 2019;  US985850P    05 Mar 2020;  EP737671    17 Jun 2020;  CA3143685    15 Dec 2021;  BR11025669    17 Dec 2021;  US555236    17 Dec 2021;  KR701075    12 Jan 2022;  CN80058836    18 Feb 2022,WO2020257356-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW  WO2020257356-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW  WO2020257356-A4:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW          EP3986614-A2:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  KH;  LI;  LT;  LU;  LV;  MA;  MC;  MD;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TN;  TR                    ,,";  WO2020257356-A3 -- WO2018107129-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S;  WO2019079787-A1   UNIV CALIFORNIA (REGC);  PIONEER HI-BRED INT INC (DUPO)   LEE A,  LI X,  YUN Y;  WO2020028729-A1   MAMMOTH BIOSCI INC (MAMM-Non-standard);  CHEN J S (CHEN-Individual);  TEHRANCHI A (TEHR-Individual);  LANE A B (LANE-Individual);  BROUGHTON J P (BROU-Individual);  HARRINGTON L B (HARR-Individual);  TSALOGLOU M (TSAL-Individual);  MIAO X (MIAO-Individual);  FASCHING C L (FASC-Individual);  SINGH J (SING-Individual);  GALARZA P P D (GALA-Individual)   CHEN J S,  TEHRANCHI A,  LANE A B,  BROUGHTON J P,  HARRINGTON L B,  TSALOGLOU M,  MIAO X,  FASCHING C L,  SINGH J,  GALARZA P P D;  CN114650883-A -- CN104040238-A   HANDYLAB INC (HAND-Non-standard)   HANDIQUE K;  EP3066218-A1   HTG MOLECULAR DIAGNOSTICS INC (HTGM-Non-standard)   ROUNSEVILLE M,  MODUR V;  US20080131870-A1   ;  US20090186344-A1   ;  US20180302300-A1   ;  WO2018107129-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S;  WO2019079787-A1   UNIV CALIFORNIA (REGC);  PIONEER HI-BRED INT INC (DUPO)   LEE A,  LI X,  YUN Y;  CN114650883-B -- CN1333465-A   WANG X B (WANG-Individual);  MORISAWA S (MORI-Individual)   WANG X B;  CN1764729-A   HUMAN GENETIC SIGNATURES PTY LTD (HUMA-Non-standard)   MILLAR D S,  MELKI J R,  GRIGG G W,  MIKLOS G L G;  CN103436608-A   GUANGZHOU BIOLOGICAL MEDICINE & HEALTH                  R (GIBH)   ZENG L,  WU W,  FANG Z;  CN104040238-A   HANDYLAB INC (HAND-Non-standard)   HANDIQUE K;  EP3066218-A1   HTG MOLECULAR DIAGNOSTICS INC (HTGM-Non-standard)   ROUNSEVILLE M,  MODUR V;  US20080131870-A1   ;  US20090186344-A1   ;  US20180302300-A1   ;  WO2018107129-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S;  WO2019079787-A1   UNIV CALIFORNIA (REGC);  PIONEER HI-BRED INT INC (DUPO)   LEE A,  LI X,  YUN Y",,201562-0-0-0 D K M; 218588-0-0-0 D K M; 2418795-0-0-0 D K M; 104333-0-0-0 K M; 2418795-0-0-0 CL USE,,,RA0124 D K M; RA0DQN D K M; RBAAY7 D K M; R00975 K M,0975-S
WO2022049220-A2;  WO2022049220-A3;  BR112023003868-A2;  IL300835-A;  EP4208200-A2;  CN116472060-A;  JP2023539525-W;  US2023310599-A1;  HK40096895-A0,"Preventing or reducing growth of tumor to treat            cancer e.g. breast cancer comprises providing binding            agent including antigen-binding region that binds to            cluster of differentiation and target antigen, and            immunogenic composition",BENONISSON H;  MIDDELBURG J;  VAN HALL T;  ALTINTAS I;  KEMPER K;  SCHUURMAN J;  LLOYD K A;  OVCINNIKOVS V;  ZOM G;  HALL T V,GENMAB AS (GNMB-C);  GENMAB AS (GNMB-C);  GENMAB AS (GNMB-C);  GENMAB AS (GNMB-C),2022367733,"   NOVELTY - Preventing or reducing growth of tumor for                treating cancer in a subject comprises providing                (i) a binding agent comprising an antigen-binding                region that binds to cluster of differentiation 3                (CD)3, e.g. human CD3, and an antigen-binding                region that binds to a target antigen on cells of                tumor or cancer to the subject, and (ii)                immunogenic composition comprising at least one                vaccine antigen.    USE - The method is useful for preventing or                reducing growth of tumor for treating cancer, and                treating infection, where the infectious disease or                infection includes cholera e.g. WC/rBS, diphtheria,                haemophilus influenzae type b (Hib), hepatitis A,                and hepatitis B, the tumor is a solid tumor                including e.g. breast cancer, prostate cancer,                non-small cell lung cancer, bladder cancer, ovarian                cancer, gastric cancer, colorectal cancer,                esophageal cancer and squamous cell carcinoma of                the head and neck, cervical cancer, pancreatic                cancer, testis cancer, malignant melanoma, a                soft-tissue cancer; e.g. synovial sarcoma, where                the tumor is devoid of any immune infiltrate, e.g.                as devoid of any functional immune filtrate, and                the tumor is characterized by the presence of                suppressive immune cells e.g. as immune cells                including regulatory T cells (Tregs),                myeloid-derived suppressor cells (MDSCs) and                M2-type macrophages (all claimed) Test details are                described but no results given.    ADVANTAGE - The method utilizes binding agent which has                high binding specificity to CD3, e.g. human CD3,                and an antigen ensures good treatment.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) preventing or reducing growth of a tumor                in a subject, comprising providing an immunogenic                composition comprising at least one vaccine antigen                to the subject, increasing the relative amount of                immune cells within the live cell population in the                tumor, and increasing the activation of immune                cells, and providing a binding agent comprising an                antigen-binding region that binds to CD3, e.g.                human CD3, and an antigen-binding region that binds                to a target antigen on cells of tumor or cancer to                the subject;    (2) binding agent for preventing or reducing                tumor outgrowth or treatment of cancer in a                subject, where the binding agent comprising a                binding region that binds to CD3 and a binding                region that binds to a target on cells of tumor or                cancer, and providing the antibody to the subject                in combination with an immunogenic composition                comprising at least one vaccine antigen;    (3) immunogenic composition comprising at                least one vaccine antigen; and    (4) kit of parts, comprising a binding agent                comprising a binding region that binds to CD3 and a                binding region that binds to a target on cells of a                tumor or cancer, and an immunogenic composition                comprising at least one vaccine antigen    . ",,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  C02 (Heterocyclic.);  ;  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.)",B04-A08G2;  B04-A10;  B04-B01B;  B04-B03C;  B04-B04C;  B04-C01;  B04-C02;  B04-C03C;  B04-E01;  B04-E99;  B04-F04B1A;  B04-G01;  B04-G21;  B04-H02B;  B04-H02Q;  B04-N04;  B04-N08;  B05-A01A;  B05-A01B;  B05-B01M;  B05-B01P;  B05-C01;  B05-C05;  B05-C08;  B06-D17;  B07-A02;  B10-A07B;  B10-B02A;  B10-J02;  B14-A01;  B14-A02;  B14-A04;  B14-C03;  B14-H01;  B14-L01;  B14-S11;  B14-S11D1;  B14-S11D2;  B14-S18;  B14-S21;  B15-E00;  C04-B03C;  C04-C03C;  C04-E99;  C04-G01;  C04-N04;  C04-N08;  C05-A01;  C06-D17;  C07-A02;  C10-J02;  C14-A01;  C14-A02;  C14-A04;  C14-C03;  C14-H01;  C14-S11;  C14-S11D1;  C14-S11D2;  C14-S21;  D05-H07;  D05-H99;  A03-A01;  A12-V01,A61K-039/00;  A61K-039/395;  A61P-035/00;  A61P-035/02;  C07K-016/28;  C07K-016/30;  A61K-035/17;  A61K-038/20;  A61K-039/02;  A61K-039/12;  A61K-039/155;  A61K-039/215;  A61K-039/39;  A61P-031/04;  A61P-031/12;  A61P-031/14;  A61P-031/16;  A61P-043/00;  A61K-039/42;  A61P-037/04,WO2022049220-A2   10 Mar 2022   A61K-039/00   202225Pages: 138   English;  WO2022049220-A3   21 Apr 2022   202233   English;  BR112023003868-A2   04 Apr 2023   A61K-039/395   202334   ;  IL300835-A   01 Apr 2023   A61P-035/00   202350   English;  EP4208200-A2   12 Jul 2023   A61K-039/395   202358   English;  CN116472060-A   21 Jul 2023   A61K-039/395   202362   Chinese;  JP2023539525-W   14 Sep 2023   A61K-039/395   202375   Japanese;  US2023310599-A1   05 Oct 2023   A61K-039/42   202381   English;  HK40096895-A0   01 Mar 2024   A61K-039/395   202447   English,WO2022049220-A2    WOEP074314    02 Sep 2021;   WO2022049220-A3    WOEP074314    02 Sep 2021;   BR112023003868-A2    BR11003868    02 Sep 2021;   IL300835-A    IL300835    02 Sep 2021;   EP4208200-A2    EP769045    02 Sep 2021;   CN116472060-A    CN80071121    02 Sep 2021;   JP2023539525-W    JP514116    02 Sep 2021;   US2023310599-A1    US18023808    28 Feb 2023;   HK40096895-A0    HK6085092    09 Jan 2024,BR112023003868-A2 PCT application Application WOEP074314;   BR112023003868-A2 Based on Patent WO2022049220;   IL300835-A Based on Patent WO2022049220;   EP4208200-A2 PCT application Application WOEP074314;   EP4208200-A2 Based on Patent WO2022049220;   CN116472060-A PCT application Application WOEP074314;   CN116472060-A Based on Patent WO2022049220;   JP2023539525-W PCT application Application WOEP074314;   JP2023539525-W Based on Patent WO2022049220;   US2023310599-A1 PCT application Application WOEP074314;   HK40096895-A0 PCT application Application WOEP074314;   HK40096895-A0 Based on Patent WO2022049220;   HK40096895-A0 Previous Publ. Patent EP4208200,EP194018    02 Sep 2020;  EP769045    02 Sep 2021;  BR11003868    01 Mar 2023;  CN80071121    18 Apr 2023,WO2022049220-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2022049220-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      EP4208200-A2:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN          ,,";  WO2022049220-A3 -- WO2014163684-A1   IBC PHARM INC (IBCP-Non-standard)   CHANG C,  GOLDENBERG D M,  ROSSI E A,  ROSSI D;  WO2009117616-A2   UNIV YALE (UYYA)   FAHMY T M,  HALLER G,  PFEFFERLE L D","WO2022049220-A3  CHORNOGUZ OLESYA ET          AL: ""Characterization of a Novel Bispecific Antibody That          Activates T Cells In Vitro and Slows Tumor Growth In          Vivo"", MONOCLONAL ANTIBODIES IN IMMUNODIAGNOSIS AND          IMMUNOTHERAPY, vol. 38, no. 6, 6 December 2019          (2019-12-06), US, pages 242 - 254, XP055898987, ISSN:          2167-9436, DOI:          10.1089/mab.2019.0035,relevantClaims[153-158|1-152],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;figure&gt;1-6&lt;/figure&gt;pages          243, 244, 250 and 252];  A.F. CARPENTIER ET          AL: ""The adjuvant effect of melanin is superior to          Incomplete Freund adjuvant in a tumor subunit vaccine          model"", EUROPEAN JOURNAL OF CANCER, vol. 92, 1 March 2018          (2018-03-01), Amsterdam NL, pages S2 - S3, XP055694878,          ISSN: 0959-8049, DOI:          10.1016/j.ejca.2018.01.008,relevantClaims[1-158],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  GROENEVELDT          CHRISTIANNE ET AL: ""Preconditioning of the tumor          microenvironment with oncolytic reovirus converts          CD3-bispecific antibody treatment into effective          immunotherapy"", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol.          8, no. 2, 1 October 2020 (2020-10-01), pages e001191,          XP055874040, Retrieved from the Internet          &lt;URL:https://jitc.bmj.com/content/jitc/8/2/e001191.full.pdf?with-ds=yes&gt;          DOI:          10.1136/jitc-2020-001191,relevantPassages[&lt;pp&gt;W&lt;/pp&gt;]",184587-0-0-0 K M; 184611-0-0-0 K M; 184614-0-0-0 K M; 184616-0-0-0 K M; 2254966-0-0-0 K M; 105181-0-0-0 K M; 184610-0-0-0 K M;  K M;  K M; 104370-0-0-0 K M; 485836-0-0-0 K M; 97946-0-0-0 K M; 137571-0-0-0 K M; 104479-0-0-0 K M; 154284-1-0-0 K M; 607047-0-0-0 K M; 2325937-0-0-0 K M; 772291-0-0-0 K M; 133254-0-0-0 K M; 4015-0-0-0 K M; 900-0-0-0 K M; 51640-0-0-0 K M; 949-1-0-0 K M; 107450-1-0-0 K M; 184612-0-0-0 K M; 87080-0-0-0 K M; 97733-0-0-0 K M; 116849-0-0-0 K M; 2038035-0-0-0 K M;  K M; 444-0-0-0 ; 2254966-0-0-0 CL USE; 2325937-0-0-0 CL USE; 2038035-0-0-0 CL USE,226876701 K M; 226876702 K M; 226876703 K M; 226876704 K M; 226876705 K M; 226876706 K M,06384; 02763,RA00C8 K M; RA00H1 K M; RA0121 K M; RA00H3 K M; RB6TPI K M; RA0LZS K M; RA013I K M; RBWXFU K M; RAFWOH K M; RARBZ9 K M; RA5WRV K M; R06364 K M; R16207 K M; RA1M7P K M; R01870 K M; RA0PH3 K M; RAHSJT K M; RBEFD1 K M; RABKVZ K M; R15561 K M; R00179 K M; R14756 K M; R02044 K M; RA0GM6 K M; R03875 K M; R00290 K M; R07423 K M; R01540 K M; RA01PM K M; R02020 K M; R19961 K M; RA65YP K M; RB2LDK K M; RD637M K M; R00351 ,1870-S; 0179-S; 2044-S; 0290-S; 1540-S; 2020-S
WO2023198873-A1,"New isoxazolyl-pyrazole derivatives are retinoic            acid-related orphan receptor (ROR)-gamma/ROR-gamma-t            inverse agonists, used to treat e.g. psoriasis,            psoriatic arthritis, autoimmune thyroiditis, Grave's            disease and rheumatoid arthritis",GEGE C;  KOHLHOF H;  MUEHLER A;  VITT D,IMMUNIC AG (IMMU-Non-standard),2023B04168,"   NOVELTY - Isoxazolyl-pyrazole derivatives (I) are                new.    USE - (I) are useful in composition for treating                disease or medical condition comprising psoriasis,                psoriatic arthritis, autoimmune thyroiditis,                Grave's disease, rheumatoid arthritis, vitiligo,                Crohn's disease, ulcerative colitis, inflammatory                bowel disease, ankylosing spondylitis, diabetes                type I, multiple sclerosis, celiac disease,                systemic lupus erythematosus, uveitis, Behcet's                disease, atopic dermatitis, Lichen planus,                Sjogren's syndrome, spinal disc herniation, acne,                graft-versus-host-reaction,                host-versus-graft-reaction, autoimmune hepatitis,                primary biliary cholangitis, primary sclerosing                cholangitis, obesity, lupus nephritis, autoimmune                thyroid disorders including Grave's disease and                Hashimoto's disease, autoimmune uveitis, colitis,                imiquimod-induced psoriasis, juvenile idiopathic                arthritis, myasthenia gravis, systemic sclerosis,                diabetes mellitus, osteoarthritis, infectious viral                diseases including coronavirus disease, respiratory                Syncytial virus and influenza, or cancer including                leukemia, melanoma, lymphoma, carcinoma and                sarcoma, preferably prostate cancer including                castration-resistant prostate cancer (all claimed).                The ability of (I) to treat coronavirus disease                (i.e. severe acute respiratory syndrome coronavirus                2) was tested using viral replication assay or cell                viability assay. The results showed that                (S)-1-(4-(3-(2-chloro-6-fluorophenyl)-4-(pyrimidin-2-yl)isoxazol-5-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)propan-1,1-d(2)-2-ol                exhibited an EC50 value of less than 0.1 &#956;                M.    ADVANTAGE - (I) exhibit improved pharmacokinetics                properties.    DETAILED DESCRIPTION - Isoxazolyl-pyrazole derivatives of formula (I)                and their salts, solvates, solvates of salt,                hydrates or polymorphs, are new.    Ar1=phenyl or heteroaryl (both optionally                substituted by 1-5 R1Ar and having at least one H                optionally replaced by D);    R1Ar=halo, -OH, -CN, alkoxy, haloalkoxy,                alkyl, haloalkyl, mono- or dialkylamino-alkyl,                mono- or di-alkylamino-alkoxy, -COOR', -CONHR',                -CO- R', -SO NHR', -NH-CO-R', -NO , -NH-SO -R', -SO                -R', benzyloxy, -CO-heterocyclyl, -CO-cycloalkyl,                -CONH-cycloalkyl, -CONH-heterocyclyl,                -O-alkyl-heterocyclyl, -O-alkyl-cycloalkyl,                (2-oxa-6-azaspiro[3.3]hept-6-yl)-1-4C-alkoxy,                amino, arylalkyl, cycloalkyl, heterocyclyl, phenyl                or heteroaryl, where each of alkoxy, arylalkyl,                alkyl, cycloalkyl, heterocyclyl, phenyl or                heteroaryl is optionally substituted by at least                one alkyl, haloalkyl, halo or OH and having at                least one H optionally replaced by D;    R'=H, OH, alkyl or haloalkyl, and having at                least one H optionally replaced by D;    Z1=H, halo, -CO-R1z, -CH -O-R1z, -CO-CH -R1z,                -CO-CH -O-R1z, -COOR1z, -NHCO-R1z, -CO-NHR1z,                -N(R1z) , -CN, -NHCOOR1z, -SO -R1z, -SO NHR1z,                -alkyl-O-R1z, -alkyl-O-alkyl-O-R1z, amino, alkyl,                phenyl, heteroaryl, heterocyclyl or cycloalkyl,                where each of the alkyl, phenyl, heteroaryl,                heterocyclyl or cycloalkyl group is optionally                substituted by at least one of halo, alkyl, alkoxy,                haloalkyl, -COO-alkyl, OH or cycloalkyl, and having                at least one H optionally replaced by D;    R1z=H, halo, -OH, alkyl, haloalkyl,                cycloalkyl, heterocyclyl, phenyl or heteroaryl and                having at least one H optionally replaced by                D;    X=H or D;    Y1=H, halo, haloalkyl, alkyl, cycloalkyl,                heterocyclyl or alkylester, where each of the                alkyl, cycloalkyl and heterocyclyl is optionally                substituted by at least one of halo, -OH, -CN,                alkyl, alkoxy, haloalkyl or O-haloalkyl, and having                at least one H optionally replaced by D;    R1=aryl, heteroaryl, cycloalkyl, heterocyclyl                or alkyl, which is optionally substituted by 1-5                R'' and having at least one H optionally replaced                by D; or    alternatively R1=-CH(a1)-(CH )                -C(R2)(R3)-OH;    R''=H, -CO R''', -CONHR''', -CR'''O, -SO                N(R''') ,-SO NHR''', -NR'''-CO-haloalkyl, -NO ,                -NR'''-SO -haloalkyl, -NR'''-SO -alkyl, -SO -alkyl,                -NR'''-CO-alkyl, -CN, alkyl, haloalkyl, cycloalkyl,                aminoalkyl, alkylamino, alkoxy, -OH, -SH,                alkylthio, hydroxyalkyl, hydroxyalkylamino, halo,                haloalkyl, haloalkoxy, amino, heterocyclyl, aryl,                haloaryl, haloarylalkyl, arylalkyl or heteroaryl                and having at least one H optionally replaced by                D;    R'''=H, haloalkyl, hydroxyalkyl, amino,                alkoxy, -N=C(R'') , -NR''-CO-R'', -CR''O, -CO R'',                alkyl, cycloalkyl, aryl, haloaryl, haloarylalkyl,                heteroaryl, heterocyclyl, arylalkyl or aminoalkyl                (all optionally substituted by at least one R'' and                having at least one H atom optionally replaced by                D), where the longest chain allowed in R1 are three                coupled substituents R'' and/or R''';    n=0 or 1; either    R2=H, D, methyl or CD ;    R3=methyl, trifluoromethyl or ethyl; or    R3R2=cyclopropyl having at least one H and                optionally replaced by D and H atoms from the C                atom marked a1 are substituted by D; or    n=1;    R2=H, D or methyl; and    R3=methylene bridge to C atom marked a1 and                having at least one H and optionally replaced by D,                and H atom from C atom marked a1 is substituted by                D.    Provided that, where: at least one H in (I) is                replaced by D with the proviso that the D is not                contained in R2; and the level of D incorporation                at each substituent designated as D is at least                52.5%.     ",,,"B03 (Other heterocyclics.);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).)",B05-A04A;  B07-D08;  B07-E01;  B14-A02;  B14-C03;  B14-C09;  B14-E08;  B14-E10C;  B14-E12;  B14-G02;  B14-H01;  B14-J05;  B14-K01;  B14-L06;  B14-L07;  B14-N03;  B14-N10;  B14-N11;  B14-N12;  B14-N17;  B14-S01;  B14-S04;  B14-S18;  D08-B09A1A,A61K-031/422;  A61K-031/427;  A61K-031/506;  A61P-017/00;  A61P-017/06;  A61P-019/02;  A61P-029/00;  A61P-003/10;  A61P-035/00;  A61P-037/00;  C07B-059/00;  C07D-413/04;  C07D-413/14;  C07D-417/14,WO2023198873-A1   19 Oct 2023   C07D-413/04   202397Pages: 80   English,WO2023198873-A1    WOEP059754    14 Apr 2023,,EP168554    14 Apr 2022,WO2023198873-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2023198873-A1 -- WO2012101261-A1   4SC DISCOVERY GMBH (FSCC)   LEBAN J,  TASLER S,  BAUMGARTNER R,  SAEB W,  CHEVRIER C;  WO2012101263-A1   4SC DISCOVERY GMBH (FSCC)   LEBAN J,  TASLER S,  SAEB W,  CHEVRIER C;  WO2019048541-A1   IMMUNIC AG (IMMU-Non-standard)   FELDING J,  KOHLHOF H,  GROEPPEL M,  MUEHLER R A,  VITT D,  CHEVRIER C,  ZAJA M,  TASLER S;  WO1995026325-A2   ","WO2023198873-A1  HAHN, F. ET AL.:          ""IMU-838, a Developmental DHODH Inhibitor in Phase II for          Autoimmune Disease, Shows Anti-SARS-CoV-2 and          Broad-Spectrum Antiviral Efficacy In Vitro"", VIRUSES,          vol. 12, no. 12, 2020, pages 1394, XP055813677, DOI:          10.3390/v12121394,relevantClaims[1-13],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;11&lt;/pp&gt;&lt;figure&gt;5.C&lt;/figure&gt;];  BONAVIA, A. ET AL.:          ""Identification of broad-spectrum antiviral compounds and          assessment of the druggability of their target for          efficacy against respiratory syncytial virus (RSV)"",          PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol.          108, no. 17, 2011, pages 6739 - 6744, XP055957002, ISSN:          0027-8424, DOI:          10.1073/pnas.1017142108,relevantClaims[1-13],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;6740&lt;/pp&gt;&lt;figure&gt;1&lt;/figure&gt;&lt;compound&gt;6b&lt;/compound&gt;|&lt;pp&gt;6741&lt;/pp&gt;&lt;figure&gt;2.A&lt;/figure&gt;&lt;compound&gt;6a,          6c&lt;/compound&gt;];  ALBRECHT, B.K. ET          AL.: ""Discovery and optimization of substituted          piperidines as potent, selective, CNS-penetrant          alpha4beta2 nicotinic acetylcholine receptor          potentiators"", BIOORGANIC & MEDICINAL CHEMISTRY          LETTERS, vol. 18, no. 19, 2008, pages 5209 - 5212,          XP025433901, ISSN: 0960-894X, [retrieved on 20080828],          DOI:          10.1016/J.BMCL.2008.08.080,relevantClaims[1-13],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;5210&lt;/pp&gt;&lt;figure&gt;2&lt;/figure&gt;Scheme          1|&lt;pp&gt;5211&lt;/pp&gt;&lt;table&gt;1&lt;/table&gt;];  SHAO, L. ET AL.:          ""The kinetic isotope effect in the search for deuterated          drugs"", DRUG NEWS AND PERSPECTIVES, vol. 23, no. 6, 2010,          pages 398 - 404, XP009139025, ISSN:          0214-0934,relevantClaims[1-13],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  CONCERT          PHARMACEUTICALS INC: ""Precision Deuterium Chemistry          Backgrounder"", INTERNET CITATION, 2009, pages 1 - 6,          XP009169265, Retrieved from the Internet          &lt;URL:http://www.concertpharma.com/about/documents/ConcertProductPlatformBackgrounder.pdf&gt;          [retrieved on          20130430],relevantClaims[1-13],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            NAT. REV. DRUG DISCOV., vol. 1 1, no. 763, 2012;            CYTOKINE GROWTH FACTOR REV., vol. 21, no. 413,          2010;            NAT. COMMUN., vol. 10, no. 9, 2019;            DISCOV. MED., vol. 16, no. 123, 2013;  J.          BIOL. CHEM., vol. 292, no. 13925, 2017;            MEDIATORS INFLAMM., vol. 2017, no. 3908061,          2017;            COMP. BIOCHEM. PHYSIOL., vol. 119A, no. 725,          1998;            NAT. REV. DRUG DISCOV., vol. 3, no. 950, 2004;            ANTIMICROB. AGENTS CHEMOTHER., vol. 59, no. 2062,          2015", N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N,230109401 N,,RDHMSA N; RDHMSB N; RDHMSC N; RDHMSD N; RDHMSE N; RDHMSF N; RDHMSG N; RDHMSH N; RDHMSI N; RDHMSJ N; RDHMSK N; RDHMSL N; RDHMSM N; RDHMSN N; RDHMSO N; RDHMSP N; RDHMSQ N; RDHMSR N; RDHMSS N; RDHMST N; RDHMSU N; RDHMSV N; RDHMSW N; RDHMSX N; RDHMSY N; RDHMSZ N; RDHMT0 N; RDHMT1 N; RDHMT2 N; RDHMT3 N; RDHMT4 N; RDHMT5 N; RDHMT6 N; RDHMT7 N,
WO2021217040-A1,"New substituted carbamate and urea derivatives are NOD-like receptor family pyrin domain containing 3 inhibitors used to treat e.g. inflammatory bowel disease, arthritic disease, multiple sclerosis, coronavirus and Alzheimer's disease",BARTA T E;  JUNKINS R D;  GALLOVIC M,IMMVENTION THERAPEUTIX (IMMV-Non-standard),2021C1218W,"   NOVELTY - Substituted carbamate and urea derivatives (I) are new.    USE - (I) are useful for: treating an inflammatory condition in a subject, where the inflammatory condition is an inflammatory bowel disease, an arthritic disease or a neurodegenerative disorder, an autoinflammatory syndrome, an inflammasome-related condition, adult-onset still's disease, systemic juvenile idiopathic arthritis, macrophage activation syndrome, autoinflammation with infantile enterocolitic, bullous pemphigoid, pemphigus vulgaris, idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis, systemic lupus erythematosus, multiple sclerosis, Alzheimer's disease, Parkinson's disease, traumatic brain injury, rheumatoid arthritis, cryopyrin-associated periodic syndromes, vitiligo, multiple self-healing palmoplantar carcinoma, autoimmune Addison's disease, Familial Mediterranean fever, autoimmune thyroiditis, stroke, type 2 diabetes, osteoarthritis, gout, atherosclerosis, hidradenitis suppurativa, psoriasis or pyrin diseases; treating an inflammatory condition resulting from a coronavirus (e.g. Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome coronavirus or Middle East respiratory syndrome), viral, bacterial, fungal, parasitic or other type of infection in a human subject, where the inflammatory condition causes cell death or release of pro-inflammatory cytokines or other inflammatory mediators, cytokine storm syndrome, cytokine release syndrome, sepsis, hemophagocytic lymphohistiocytosis, acute lung injury, acute respiratory distress syndrome or macrophage activation syndrome; and treating an inflammatory condition resulting from a cell therapy, where the inflammatory condition is cytokine storm syndrome or cytokine release syndrome, and causes cell death or release of pro-inflammatory cytokines or other inflammatory mediators (all claimed).    ADVANTAGE - (I) is non-toxic.    DETAILED DESCRIPTION - Substituted carbamate and urea derivatives of formula (A-Q-W1-X-Y1-Z) (I) and their salts and/or solvates or hydrates are new.    A = 1-6C alkyl (e.g. t-butyl), -(0-4C alkyl)-O0-1-cycloalkyl, -(0-4C alkyl)-O0-1-heterocycloalkyl, -(0-4C alkyl)-O0-1-aryl or -(0-4C alkyl)-O0-1-heteroaryl or -(0-2C alkyl)-B1-C1;    B1, C1 = cycloalkyl, heterocycloalkyl, aryl or heteroaryl;    Q, X = -O- or -N(RA)-;    Q, X = not both -O-;    W1 = C(O) or S(O)n;    n = 1 or 2;    Y1 = 1-8C alkyl, 2-8C alkenyl, 2-8C alkynyl, -(0-2C alkyl)-cycloalkyl, -(0-2C alkyl)-heterocycloalkyl, -(2-3C alkenyl)-cycloalkyl or -(2-3C alkenyl)-heterocycloalkyl;    Z = absent, -(0-2C alkyl)-O(RA) or -(0-2C alkyl)-N(RA)(RB);    RA, RB = 1-4C alkyl or (0-3C alkyl)-cyclopropyl, alkynyl (optionally substituted by at least one halo (e.g. fluorinated or perfluorinated) or substituted by one or two methyl, ethyl, oxo, acyl or -C(O)N(RA)(RB), where each cycloalkyl has 3-10 ring carbons and is saturated or partially unsaturated, and optionally includes one or two fused and/or bridged cycloalkyl rings, each fused and/or bridged ring having 3-8 ring members, the bridge is bivalent or trivalent, and each cycloalkyl is substituted with 0-5 RC or is perfluorinated, each heterocycloalkyl has 3-10 ring members and 1-4 heteroatoms, each heteroatom is B, N, O or S and is saturated or partially unsaturated, and optionally includes one or two fused cycloalkyl or aryl rings and/or one or two bridged cycloalkyl rings, each fused and/or bridged ring each having 3-8 ring members, the bridge is bivalent or trivalent, and is substituted with 0-5 RC or is perfluorinated, each aryl is phenyl or naphthyl, and optionally includes one or two fused cycloalkyl or heterocycloalkyl rings, each fused cycloalkyl or heterocycloalkyl ring having 4-8 ring members, and is substituted with 0-5 RC or is perfluorinated, each heteroaryl is 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms, each heteroatom is independently B, N, O or S or is bicyclic heteroaryl having 1-5 heteroatoms, each heteroatom is B, N, O or S and optionally includes one or two fused cycloalkyl or heterocycloalkyl rings, each fused cycloalkyl or heterocycloalkyl ring having 4-8 ring members, and the heteroaryl is substituted with 0-5 RC; and    RC = 1-4C alkyl (e.g. methyl, tert-butyl or -CF3), -Cl, -F, -Br, -CN, -ORA, -C(O)RA, -C(O)NRBRA, -NRARB, -SO3 or -SO2(1C alkyl).    An INDEPENDENT CLAIM is also included for a composition comprising (I) or tert-butyl(4-aminopentyl)carbamate, tert-butyl(4-aminobut-2-yn-1-yl)carbamate, tert-butyl(3-hydroxypropyl)carbamate, tert-butyl ethyl carbamate, tert-butyl(3-amino-2-methylpropyl)carbamate, tert-butyl but-3-en-1-ylcarbamate, tert-butyl(azetidin-3-yl methyl)carbamate, tert-butyl(4-aminobut-2-en-1-yl)carbamate or tert-butyl(4-hydroxybut-2-en-1-yl)carbamate. ",,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).)",B01-E;  B04-B03E;  B04-G01;  B04-G27G;  B05-B01A;  B06-H;  B07-H;  B10-A08;  B10-A09B;  B10-A12C;  B10-A13D;  B14-A01;  B14-A02;  B14-A04;  B14-C02;  B14-C03;  B14-C09;  B14-D01;  B14-E10C1;  B14-F02D1;  B14-F07;  B14-G02D;  B14-G03;  B14-H01;  B14-J01;  B14-K01;  B14-L06;  B14-N11;  B14-N12;  B14-N16;  B14-N17;  B14-S01;  B14-S04A;  B14-S06;  B14-S16;  B14-S18;  B14-S21;  D08-B09A1,C07C-271/12;  A61P-029/00;  C07C-271/16;  C07C-271/18;  C07C-271/20;  C07C-271/34;  C07C-271/52;  C07C-275/20;  C07C-317/46,WO2021217040-A1   28 Oct 2021   202195Pages: 76   English,WO2021217040-A1    WOUS028906    23 Apr 2021,,US015024P    24 Apr 2020;  US166083P    25 Mar 2021,WO2021217040-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2021217040-A1 -- EP887079-A1   PFIZER INC (PFIZ)   DOW R L;  EP1171136-B1   GENZYME CORP (GENZ);  BRIGHAM & WOMENS HOSPITAL INC (BGHM)   ONDERDONK A B,  TZIANABOS A O,  MILLER R J,  CALIAS P;  US2877263-A   ;  US4954501-A   HEUMANN PHARMA GMBH & CO (TRNP)   HERTER R,  ENGLER H,  MORSDORF P,  SCHICKANED H,  PFAHLERT V,  AHRENS K H;  US5760273-A   MITSUBISHI CHEM CORP (MITU)   INABA M,  HASEGAWA K,  HONDA M,  SUZUKI T;  US20130274229-A1   ;  WO2020010451-A1   TRILLIUM THERAPEUTICS INC (TRIL-Non-standard)   SLASSI A,  DOVE P,  ROSA D A,  WANG Z,  WINSTON J T,  LIN H Y;  WO2010097479-A2   SYMRISE GMBH&CO KG (SYMR)   MEYER I,  OERTLING H,  HILLEBRAND N,  GOEMANN C,  BRODHAGE R","WO2021217040-A1  KIM ET AL: ""Design, Synthesis, and Biological Activity of 1,3-Disubstituted Ureas as Potent Inhibitors of the Soluble Epoxide Hydrolase of Increased Water Solubility"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 47, no. 8, 17 March 2004 (2004-03-17), pages 2110 - 2122, XP002396850, ISSN: 0022-2623, DOI: 10.1021/JM030514J,relevantClaims[1-8,17,18],relevantPassages[&lt;pp&gt;2112&lt;/pp&gt;&lt;example&gt;VII,VIII&lt;/example&gt;];  LALIC GOJKO ET AL: ""Scope and Mechanism of Formal S N 2' Substitution Reactions of a Monomeric Imidozirconium Complex with Allylic Electrophiles"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 130, no. 13, 1 April 2008 (2008-04-01), pages 4459 - 4465, XP055823002, ISSN: 0002-7863, DOI: 10.1021/ja7106096,relevantClaims[1-5,8,9,13,14,16-18],relevantPassages[&lt;example&gt;2&lt;/example&gt;];  SMITHMARCH: ""March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure"", 2001, WILEY-INTERSCIENCE;  OR VOGEL: ""A Textbook of Practical Organic Chemistry, Including Qualitative Organic Analysis"", 1978, LONGMAN;  ""Introduction to Modern Liquid Chromatography"", 1969, JOHN WILEY AND SONS;  J. F. W. MCOMIE: ""Protective Groups in Organic Chemistry"", 1973, PLENUM PRESS;  T. W. GREENEP. G. M. WUTS: ""Protective Groups in Organic Synthesis"", 1999, WILEY;  SOROCHINSKII, A. E.TARASEVICH, A. S.ALEKSANDROV, A. M.KUKHAR, V. P.: ""Difluoro compounds, such as compound 106, can be made from the corresponding dibromo species"", ZHURNAL ORGANICHESKOI KHIMII, vol. 17, no. 11, 1981, pages 2339 - 43;  JOCHEN LEHMANN: ""Chemie der Kohlenhydrate: Monosaccharide and Derivate"", vol. 15, 1974, GEORG THIEME VERLAG;  H.-D. JAKUBKEH. JESCHEIT: ""Aminosauren, Peptide, Proteine"", 1982, VERLAG CHEMIE;  J. MARCH: ""Advanced Organic Chemistry"", 2013, JOHN WILEY AND SONS;  KNOLL, WOLFGANGMIEUSSET, JEAN-LUCARION, VLADIMIR B.BRECKER, LOTHARBRINKER, UDO H, ORGANIC LETTERS, vol. 12, no. 10, 2010, pages 2366 - 2369", M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N; 283406-0-0-0 M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N; 1445143-0-0-0 M N;  M N;  M N;  M N; 175088-0-0-0 M N; 283403-0-0-0 M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N; 2629613-1-0-0 K M; 1021552-0-0-0 K M; 184620-0-0-0 K M,226306901 M N; 226306902 M N,00061; 03624; 00833; 00044; 61435,RD4DZZ M N; RD4E00 M N; RD4E01 M N; RD4E02 M N; RD4E03 M N; RD4E04 M N; RD4E05 M N; RD4E06 M N; RD4E07 M N; RD4E08 M N; RD4E09 M N; RD4E0A M N; RD4E0B M N; RD4E0C M N; RD4E0D M N; RD4E0E M N; RD4E0F M N; RD4E0G M N; RD4E0H M N; RD4E0I M N; RD4E0J M N; RD4E0K M N; RD4E0L M N; RD4E0M M N; RD4E0N M N; RD4E0O M N; RD4E0P M N; RD4E0Q M N; RD4E0R M N; RD4E0S M N; RD4E0T M N; RD4E0U M N; RD4E0V M N; RD4E0W M N; RD4E0X M N; RD4E0Y M N; RD4E0Z M N; RD4E10 M N; RD4E11 M N; RD4E12 M N; RD4E13 M N; RD4E14 M N; RD4E15 M N; RD4E16 M N; RD4E17 M N; RD4E18 M N; RD4E19 M N; RA1QLX M N; RD4E1A M N; RD4E1B M N; RD4E1C M N; RD4E1D M N; RD4E1E M N; RD4E1F M N; RD4E1G M N; RD4E1H M N; RD4E1I M N; RD4E1J M N; RD4E1K M N; RD4E1L M N; RD4E1M M N; RD4E1N M N; RD4E1O M N; RD4E1P M N; RD4E1Q M N; RD4E1R M N; RD4E1S M N; RAPOH9 M N; RD4E1T M N; RD4E1U M N; RD4E1V M N; RAF4UP M N; RA1QLU M N; RD4E1W M N; RD4E1X M N; RD4E1Y M N; RD4E1Z M N; RD4E20 M N; RD4E21 M N; RD4E22 M N; RD4E23 M N; RD4E24 M N; RD4E25 M N; RD4E26 M N; RD4E27 M N; RD4E28 M N; RD4E29 M N; RD4E2A M N; RD4E2B M N; RD4E2C M N; RD4E2D M N; RD4E2E M N; RD4E2F M N; RBEZ9W K M; RAIYPI K M; RA012O K M,
WO2024031070-A1,"Forming cationic sophorolipid (SLP) derivative, by            producing linear SLP molecule having carboxylic acid            fatty acid tail and installing amide having cationic            amino acid alkyl ester functional group to the            carboxylic acid tail of the molecule",SPEIGHT L;  MORRIS A;  HAGAMAN D,LOCUS SOLUTIONS IPCO LLC (LOCU-Non-standard),202415637J,"   NOVELTY - Producing (M1) a cationic sophorolipid (SLP)                derivative, comprises: (a) producing a linear SLP                molecule comprising a carboxylic acid fatty acid                tail; and (b) installing an amide comprising at                least one cationic amino acid alkyl ester                functional group to the carboxylic acid tail of the                linear SLP molecule to produce a long-chain                amide.    USE - The method is useful for: producing a cationic                sophorolipid (SLP) derivative as a cationic                surfactant, which is useful for disinfecting,                sanitizing and/or preserving a material and/or                surface that is contaminated with an undesirable or                deleterious microorganism, where the material                and/or surface is a hard surface, a soft porous                surface, a textile or fiber, water or air; and                controlling: Gram-negative and Gram-positive                bacteria, biofilms, viruses, fungi, molds,                protozoa, parasites, helminths, nematodes and/or                algae; controlling food and/or waterborne                microorganisms comprising Bacillus,                Alicyclobacillus, Geobacillus, Lactobacillus,                Streptococci, Micrococcus, Pediococci, Leuconostoc,                Oenococcus, Propionibacterium, Streptococcus,                Enterococcus, Actinomyces, Streptomyces, Erwinia,                Coryne bacteria, Psychrobacter, Pseudomonas,                Alcaligenes, Escherichia, Proteus, Serratia,                Citrobacter, Aeromonas, Acinetobacter, Klebsiella,                Cryptococcus, Aspergillus, Mucor, Saccharomyces,                Zygosaccharomyces, Geotrichum, Candida, PenicilUum,                tapeworms, helminths, nematodes, Toxoplasma,                Trichinella, Giardia, Entamoeba, and                Cryptospordium; infectious and/or opportunistic                pathogens of concern for public health and                healthcare facilities, the infectious and/or                opportunistic pathogens being Salmonella enterica,                Salmonella choleraseus, Staphylococcus aureus                (including MRSA), Staphylococcus saprophyticus,                Streptococcus pyogenes, Streptococcus pneumoniae,                Bacillus anthracis, Legionella pneumophila,                Klebsiella pneumoniae, Shigella dysenleriae, Vibrio                cholera, Vibrio parahaemolytics,                vancomycin-resistant Enterococci, Mycobacterium                tuberculosis, Mycobacterium bovis, Acinetobacter                baumanii, Clostridium difficile, Candida albicans,                Candida auris, Candida parapsilosis, Cryptococcus                neoformans, Aspergillus flavis, and Aspergillus                fumigatus; and both enveloped and non-enveloped                viruses including coronaviruses severe acute                respiratory syndrome coronavirus 1 (SARS-CoV1),                Middle East respiratory syndrome-related                coronavirus, severe acute respiratory syndrome                coronavirus 2 (SARS-CoV2), rotaviruses, Human                Norovirus, HIV, hepatitis A, B, and C,                Coxsackievirus, rhinovirus, influenza viruses A, B,                and C, herpes viruses, cytomegalovirus, and                poliovirus (all claimed). Test details are                described but no results given.    ADVANTAGE - The composition has disinfectant properties.                The cationic surfactant derivatives have enhanced                pH stability and surprising ability to clean soils                while sanitizing and/or disinfecting in a single                application and surfactants are biodegradable and                have reduced toxicity over comparable traditional                surfactants.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    a cationic surfactant having the structure of                formula (R1-NH-CH(R2)-C(R3)(R3)OH) (A) or                (R2-CH(NH2)-C(=O)-NH-R1) (B);    a cleaning composition (C1) comprising the                cationic surfactant, where the composition has pH                2-12;    disinfecting, sanitizing and/or preserving                (M2) a material and/or surface that is contaminated                with an undesirable or deleterious microorganism,                comprising applying the cleaning composition to the                material and/or surface so that the composition is                contacted with the microorganism, where the                microorganism is controlled within 10 minutes or                less of contact with the composition;    purifying (M3) a sophorolipid, comprising                circulating a crude SLP through an ion exchange bed                containing ion exchange sites for a period of time                from 30 minutes to 3 hours;    a conditioning composition (C2) comprising the                cationic surfactant molecule, where the composition                has a pH of 2-12;    conditioning (M4) hair, a fiber or a textile,                comprising contacting the composition (C2) with the                hair, fiber or textile;    improving (M5) the pH stability of a molecule                comprising an ester moiety, comprising converting                the ester moiety to an alcohol; and    producing (M6) the cationic surfactant                compound of formula (X1-NH-CH(Y1)-C(Z1)(Z2)OH) (II)                with stability at pH 2-12 comprising coupling a                biosurfactant or fatty acid-containing substrate X'                with an amide Y' comprising at least one amino acid                side chain to produce an amino-acid functionalized                surfactant XY, and either before, during or after                coupling of XY, reacting Y' or XY with a reducing                agent Z' to reduce any ester groups existing                therein to an alcohol.    R1=-(CH ) -(CH ) -C(=O)-),                (Z)-17-((4,5-dihydroxy-6-(hydroxymethyl)-3-((3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)octadec-9-enoyl                or                8-((4,5-dihydroxy-6-(hydroxymethyl)-3-((3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)nonanoyl;    R2=-CH -CH CH -NH-C(=NH)-NH , -(CH ) -NH or                1H-imidazol-4-yl)methyl;    R3=H, Me, Et, MePh, Bu, sec-Bu or t-Bu;    X1=2-22C fatty amide derived from a fatty acid                or a bio-surfactant comprising a fatty acid                moiety;    Y1=amino acid-derived functional group;                and    Z1, Z2=H or alkyl. ",,,"A96 (Medical, dental, veterinary, cosmetic.);  A97 (Miscellaneous goods not specified elsewhere - including papermaking, gramophone records, detergents, food and oil well applications.);  D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).);  ;  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.)",A12-V03C1;  A12-V04;  A12-W04C;  A12-W12;  D05-C19;  D09-A01;  B04-A08;  B04-A09;  B04-A10;  B04-A98;  B04-B01C1;  B04-C03;  B04-L01;  B04-N01;  B10-B02;  B10-B03B;  B10-C04E5;  B10-E04;  B14-A01A9;  B14-A01B1A;  B14-A02B3;  B14-A02B5;  B14-A04;  B14-A05;  B14-C03;  B14-G02A;  B14-K01D;  B14-S18;  C04-A08;  C04-A09;  C04-A10;  C04-A98;  C04-B01C1;  C04-C03;  C04-L01;  C04-N01;  C10-B02;  C10-B03B;  C10-C04E5;  C10-E04;  C14-A01A9;  C14-A01B1A;  C14-A02B3;  C14-A02B5;  C14-A04;  C14-A05;  C14-C03;  C14-G02A;  C14-K01D;  C14-S18,A01N-043/16;  A01N-063/32;  C11D-001/42;  C11D-001/58;  C12P-019/44,WO2024031070-A1   08 Feb 2024   C12P-019/44   202416Pages: 64   English,WO2024031070-A1    WOUS071706    04 Aug 2023,,US395160P    04 Aug 2022;  US397828P    13 Aug 2022;  US487860P    01 Mar 2023,WO2024031070-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2024031070-A1 -- WO2021127339-A1   LOCUS IP CO LLC (LOCU-Non-standard)   ALIBEK K,  FARMER S;  WO2021185675-A1   BASF SE (BADI);  ZHU B C (ZHUB-Individual)   ZHU B C,  ZHANG Z","WO2024031070-A1  AZIM, A. ET AL.:          ""Amino acid conjugated sophorolipids: a new family of          biologically active functionalized glycolipids"",          BIOCONJUGATE CHEMISTRY, vol. 17, 2006, pages 1523 - 1529,          XP008160841, DOI:          10.1021/bc060094n,relevantClaims[1-8|9-51,55-65],relevantPassages[pages          1523, 1524, 1527; scheme 1];  LIU, Y. ET AL.:          ""Hydrolysis of phosphodiester catalyzed by          metallomicelles with histidine residue: Kinetics and          mechanism"", COLLOIDS AND SURFACES A: PHYSICOCHEMICAL AND          ENGINEERING ASPECTS, vol. 436, 2013, pages 839 - 845,          XP028735144, DOI:          10.1016/j.colsurfa.2013.07.042,relevantClaims[11],relevantPassages[abstract;          scheme 3];  AKONG FIRMIN          OBOUNOU, PASC ANDREEA, EMO MELANIE, GERARDIN-CHARBONNIER          CHRISTINE: ""A supramolecular hydrogel based on an          original pseudopeptidic catanionic surfactant"", NEW          JOURNAL OF CHEMISTRY, ROYAL SOCIETY OF CHEMISTRY, GB,          vol. 37, no. 3, 1 January 2013 (2013-01-01), GB , pages          559 - 562, XP093134732, ISSN: 1144-0546, DOI:          10.1039/C2NJ40960G,relevantClaims[1-51,55-65],relevantPassages[scheme          1; figure 5]",5614-0-0-0 K S; 7583-0-0-0 K S; 7907-0-0-0 K S; 8171-0-0-0 K S; 6705-0-0-0 K S; 240580-0-0-0 K U V; 743-0-0-0 K U V; 4860-0-0-0 K U V; 5413-0-0-0 K U V; 330-0-0-0 K U V; 490-0-0-0 K U V; 861-0-0-0 K U V; 100-0-0-0 K U V; 494-0-0-0 K U V; 189-0-0-0 K U V; 122-0-0-0 K U V; 387-0-0-0 K U V; 146-0-0-0 K U V; 184599-0-0-0 K M; 1013773-0-0-0 K M; 184598-0-0-0 K M; 107017-0-0-0 K M; 200757-0-0-0 K M; 184616-0-0-0 K M; 107779-0-0-0 ; 240580-0-0-0 CL RGT USE; 1013773-0-0-0 CL USE,230593501 K M P; 230593502 K M P,,RA5D9A K S; RA0S3W K S; RA0J5N K S; RA28UF K S; RA3UHM K S; RA0UEH K U V; R07492 K U V; RA25OF K U V; RA0BY2 K U V; R01338 K U V; R00113 K U V; R00137 K U V; R00882 K U V; R08927 K U V; RA2LS6 K U V; R01994 K U V; RA1OXQ K U V; RA0P3T K U V; RA01IK K M; R90202 K M; RA00GC K M; RA018L K M; RA00GT K M; RA00H3 K M; R01863 ,1338-U; 0113-U; 0137-U; 0882-U; 1994-U
WO2022198086-A1;  CA3212208-A1;  AU2022239609-A1;  KR2023171426-A;  CN117321221-A;  EP4308724-A1;  JP2024510270-W,"Detecting target nucleic acid sequence in sample            comprises contacting sample comprising biological            entities, amplifying target nucleic acid sequence in            amplification reaction mixture, and detecting nucleic            acid amplification product",ZHANG H;  MILLER A P;  MERMER B;  TSAI L;  HONG-HWA J;  BRIAN M M;  CHAIRI-CHUN;  CAI L,BECTON DICKINSON & CO (BECT-C);  BECTON DICKINSON & CO (BECT-C);  BECTON DICKINSON & CO (BECT-C);  BECTON DICKINSON & CO (BECT-C),2022C41230,"   NOVELTY - Detecting target nucleic acid sequence in                sample comprises: (a) contacting a sample                comprising biological entities with a lysis buffer                to generate a treated sample, where the lysis                buffer comprises at least one lytic agent capable                of lysing biological entities to release sample                nucleic acids, and the sample nucleic acids are                suspected of comprising a target nucleic acid                sequence; (b) contacting a reagent composition with                the treated sample to generate an amplification                reaction mixture, where the reagent composition                comprises at least one protectants and                amplification reagents; (c) amplifying a target                nucleic acid sequence in the amplification reaction                mixture, thus generating a nucleic acid                amplification product; and (d) detecting the                nucleic acid amplification product, where the                detecting is performed in less than 20 minutes from                the time the reagent composition is contacted with                the treated sample.    USE - The method is useful for detecting a target                nucleic acid sequence in a sample.    ADVANTAGE - The method renatures reduced-denatured                ribonucleases renature at least 1.1-fold more                slowly than denatured ribonucleases; and/or                reduced-denatured deoxyribonucleases renature at                least 1.1-fold more slowly than denatured                deoxyribonucleases.    DETAILED DESCRIPTION - An INDEPENDDENT CLAIM is also included for kit                for detecting a target nucleic acid sequence in a                sample, comprising (a) a lysis buffer comprising                one or more lytic agents capable of lysing                biological entities to release sample nucleic                acids, where the sample nucleic acids are suspected                of comprising a target nucleic acid sequence, and                (b) a reagent composition comprising one or more                protectants and amplification reagents comprising                components for amplifying the target nucleic acid                sequence under isothermal amplification conditions,                where the components for amplifying comprises (i) a                first primer and a second primer, where the first                primer is capable of hybridizing to a sequence of a                first strand of the target nucleic acid sequence,                and the second primer is capable of hybridizing to                a sequence of a second strand of the target nucleic                acid sequence, and (ii) an enzyme having a                hyperthermophile polymerase activity capable of                generating a nucleic acid amplification                product. ",,,"A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)",A12-V03C2;  B04-E01;  B04-E05;  B04-E99;  B04-L04A;  B04-L04B;  B11-C08F8;  B11-C08N2;  B12-K04F;  C04-E01;  C04-E05;  C04-E99;  C04-L04A;  C04-L04B;  C11-C08F8;  C11-C08N2;  C12-K04F;  D05-A02B;  D05-H09;  D05-H18B2;  D05-H99;  S03-E04D;  S03-E14H3,C12Q-001/6816;  C12Q-001/686;  C12Q-001/689;  G01N-021/64;  C12Q-001/6806;  C12Q-001/6848;  C12Q-001/70;  C12Q-001/6844,WO2022198086-A1   22 Sep 2022   C12Q-001/6816   202282Pages: 117   English;  CA3212208-A1   22 Sep 2022   C12Q-001/6816   202376   English;  AU2022239609-A1   05 Oct 2023   C12Q-001/6816   202382   English;  KR2023171426-A   20 Dec 2023   C12Q-001/6848   202304   ;  CN117321221-A   29 Dec 2023   C12Q-001/6816   202404   Chinese;  EP4308724-A1   24 Jan 2024   C12Q-001/6816   202409   English;  JP2024510270-W   06 Mar 2024   C12Q-001/6844   202421   Japanese,WO2022198086-A1    WOUS021015    18 Mar 2022;   CA3212208-A1    CA3212208    18 Mar 2022;   AU2022239609-A1    AU239609    18 Mar 2022;   KR2023171426-A    KR732379    18 Mar 2022;   CN117321221-A    CN80036191    18 Mar 2022;   EP4308724-A1    EP772313    18 Mar 2022;   JP2024510270-W    JP557001    18 Mar 2022,CA3212208-A1 PCT application Application WOUS021015;   CA3212208-A1 Based on Patent WO2022198086;   AU2022239609-A1 PCT application Application WOUS021015;   AU2022239609-A1 Based on Patent WO2022198086;   KR2023171426-A PCT application Application WOUS021015;   KR2023171426-A Based on Patent WO2022198086;   CN117321221-A PCT application Application WOUS021015;   CN117321221-A Based on Patent WO2022198086;   EP4308724-A1 PCT application Application WOUS021015;   EP4308724-A1 Based on Patent WO2022198086;   JP2024510270-W PCT application Application WOUS021015;   JP2024510270-W Based on Patent WO2022198086,US163399P    19 Mar 2021;  US307099P    05 Feb 2022;  CA3212208    14 Sep 2023;  KR732379    21 Sep 2023;  CN80036191    17 Nov 2023,WO2022198086-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA          EP4308724-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    ,,WO2022198086-A1 -- US20110256592-A1   ;  US20170152546-A1   ;  US20200255885-A1   ;  US20200332340-A1   ,,93605-0-0-0 A K; 204644-0-0-0 D K M; 201562-0-0-0 D K M; 135402-0-0-0 ; 107779-0-0-0 ; 92818-0-0-0 ; 97486-1-0-0 ; 95972-0-0-0 ; 97261-0-0-0 ; 444-0-0-0 ,,,RA00NS A K; RA031J D K M; RA0124 D K M; R24032 ; R01863 ; R01857 ; R06563 ; R24033 ; R01859 ; R00351 ,
WO2021262422-A1;  WO2021262422-A9,"Determining presence of multiple gene sequences in            samples involves e.g. combining sample and gene            specific identity indicator primer pools with            corresponding samples, performing gene duplication            process and pooling gene duplication product",HUANG C,HUANG C (HUAN-Individual),2021F0938J,"   NOVELTY - Determining the presence of multiple (at least                one) gene sequences in multiple samples, comprises:                combining sample and gene specific identity                indicator (SGID) primer pools with corresponding                samples, where a first SGID primer pool is mixed                with a first sample and a second SGID primer pool                is mixed with a second sample, the first SGID                primer pool includes at least a first-first SGID                primer and a first-second SGID primer, and the                first-first SGID primer includes a first gene                primer sequence that is complement to a first gene,                a first-first SGID tag sequence, and a universal                primer; performing gene duplication process for                each SGID primer pool and sample combination;                pooling the gene duplication products of at least                the first SGID primer pool and first sample                combination and the second SGID primer pool and                second sample combination together to form a                combined sample pool; and detecting the presence of                the SGID tag sequences in the combined sample                pool.    USE - The method is useful: for determining the                presence of multiple (at least one) gene sequences                in multiple samples; in a primer composition for                determining the presence of multiple gene sequences                in a first sample and a second sample (all                claimed); for detecting any DNA or RNA molecules                from any origin including viruses, pathogens, human                specimens, or genetic materials; in gene expression                analysis, RNA interference validation, microarray                validation, pathogen detection, genetic testing,                and disease research; for detecting severe acute                respiratory syndrome coronavirus 2; for detecting                multiple samples from the same patient, or multiple                samples from multiple patients; and for detecting                high throughput signal.    ADVANTAGE - The method: can perform analysis of the data                for each specimen; utilizes real-time quantitative                reverse transcription PCR technology that enables                reliable detection and measurement of products                generated during each cycle of PCR process;                improves the reverse transcription efficiency and                quantitative PCR sensitivity by combining random                primers and anchored oligo(deoxythymine) primers;                reduces the risk of false positives from                amplification of any contaminating genomic DNA;                allows the detection of large number of genes at                very short time; delivers high accuracy and high                yield of error-free reads; enables tracking                individual target DNA/RNA molecule from a specific                sample; and requires longer than 30 nucleotides for                better results.    DETAILED DESCRIPTION - Determining the presence of multiple (at least                one) gene sequences in multiple samples, comprises:                combining sample and gene specific identity                indicator (SGID) primer pools with corresponding                samples, where a first SGID primer pool is mixed                with a first sample and a second SGID primer pool                is mixed with a second sample, the first SGID                primer pool includes at least a first-first SGID                primer and a first-second SGID primer, the                first-first SGID primer includes a first gene                primer sequence that is complement to a first gene,                a first-first SGID tag sequence, and a universal                primer, the first-second SGID primer includes a                second gene primer sequence that is complement to a                second gene, a first-second SGID tag sequence, and                a universal primer, the second SGID primer pool                includes at least a second-first SGID primer and a                second-second SGID primer, the second-first SGID                primer includes a first gene primer sequence that                is complement to the first gene, a second-first                SGID tag sequence, and a universal primer, and the                second-second SGID primer includes a second gene                primer sequence that is complement to the second                gene, a second-second SGID tag sequence, and a                universal primer; performing gene duplication                process for each SGID primer pool and sample                combination; pooling the gene duplication products                of at least the first SGID primer pool and first                sample combination and the second SGID primer pool                and second sample combination together to form a                combined sample pool; and detecting the presence of                the SGID tag sequences in the combined sample pool.                An INDEPENDENT CLAIM is also included for a primer                composition for determining the presence of                multiple gene sequences in a first sample and a                second sample, comprising a first SGID primer pool                comprising a first-first SGID primer and a                first-second SGID primer, where the first-first                SGID primer includes a first gene primer sequence                that is complement to a first gene, a first-first                SGID tag sequence, and a universal primer, the                first-second SGID primer includes a second gene                primer sequence that is complement to a second                gene, a first-second SGID tag sequence, and a                universal primer, and a second SGID primer pool                comprising a second-first SGID primer and a                second-second SGID primer, the second-first SGID                primer includes a first gene primer sequence that                is complement to the first gene, a second-first                SGID tag sequence, and a universal primer, and the                second-second SGID primer includes a second gene                primer sequence that is complement to the second                gene, a second-second SGID tag sequence, and a                universal primer. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E99;  B04-E01;  B04-E02;  B04-E03;  B04-E05;  B04-F11B2;  B11-C08E3;  B11-C08E6;  B11-C08F8;  B11-C10A;  B12-K04F;  B12-K04G1B;  D05-H99;  D05-H06A;  D05-H12D1;  D05-H18B,C12N-015/11;  C12Q-001/68;  C12Q-001/6844;  C12Q-001/686;  C12Q-001/6876,WO2021262422-A1   30 Dec 2021   C12N-015/11   202205Pages: 30   English;  WO2021262422-A9   02 Jun 2022   C12N-015/11   202245   English,WO2021262422-A1    WOUS036043    04 Jun 2021;   WO2021262422-A9    WOUS036043    04 Jun 2021,,US035094P    25 Jun 2020,WO2021262422-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2021262422-A9:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,WO2021262422-A1 -- US20080269068-A1   ;  US20110092387-A1   ;  US20170175180-A1   ;  US20180010176-A1   ,,,,,,
CN113563475-A;  WO2022022666-A1;  TW202208424-A;  CN113563475-B;  HK40055435-A0;  HK40055435-A1,"New bispecific antibody useful in e.g. preparing            medicines for preventing or treating diseases caused by            new coronavirus infection comprises heavy chain            variable region of monoclonal antibody, and light chain            variable region of monoclonal antibody",TAN S;  LI C;  LI S;  WU Y;  GAO F;  LI Z,CHINESE ACAD SCI MICROBIOLOGY INST (CWSW-C);  CHINESE ACAD SCI MICROBIOLOGY INST (CWSW-C),2021C5124H,"   NOVELTY - Bispecific antibody comprising heavy chain                variable region of monoclonal antibody B38, light                chain variable region of monoclonal antibody B38,                heavy chain variable region of monoclonal antibody                H4, and light chain variable region of monoclonal                antibody H4, where heavy chain variable region of                monoclonal antibody B38 comprises CDR1 comprises                fully defined 8 amino acid sequence (SEQ ID NO:9)                as given in the specification, CDR2 comprises fully                defined 7 amino acid sequence (SEQ ID NO:10) as                given in the specification, and CDR3 comprises                fully defined 9 amino acid sequence (SEQ ID NO:11)                as given in the specification, and light chain                variable region of monoclonal antibody B38 includes                CDR1 comprises fully defined 6 amino acid sequence                (SEQ ID NO:12) as given in the specification, CDR2                comprises fully defined 3 amino acid sequence (SEQ                ID NO:13) as given in the specification, and CDR3                is new.    USE - The bispecific antibody or the gene or the                biological material or the medicinal composition or                the kit is useful in (i) preparing medicines for                preventing or treating diseases caused by new                coronavirus infection, (ii) preparing new                coronavirus diagnostic reagents or diagnostic kits,                (iii) preparing new coronavirus vaccines, (iv)                preventing or treating diseases caused by severe                acute respiratory syndrome coronavirus 2                coronavirus, and (v) detecting new coronaviruses                (all claimed).    ADVANTAGE - The antibody: has higher inhibitory activity;                identifies different sites of the new coronavirus S                protein receptor-binding domain; improves the                selectivity and neutralizing activity of the                maternal monoclonal antibody; and improves the                safety and effectiveness of monoclonal antibody                medicines.    DETAILED DESCRIPTION - Bispecific antibody comprising heavy chain                variable region of monoclonal antibody B38, light                chain variable region of monoclonal antibody B38,                heavy chain variable region of monoclonal antibody                H4, and light chain variable region of monoclonal                antibody H4, where the heavy chain variable region                of monoclonal antibody B38 comprises CDR1 comprises                Gly-Phe-Ile-Val-Ser-Ser-Asn-Tyr amino acid sequence                (SEQ ID NO:9), CDR2 comprises                Ile-Tyr-Ser-Gly-Gly-Ser-Thr amino acid sequence                (SEQ ID NO:10), and CDR3 comprises                Ala-Arg-Glu-Ala-Tyr-Gly-Met-Asp-Val amino acid                sequence (SEQ ID NO:11), the light chain variable                region of monoclonal antibody B38 includes CDR1                comprises Gln-Gly-Ile-Ser-Ser-Tyr amino acid                sequence (SEQ ID NO:12), CDR2 comprises Ala-Ala-Ser                amino acid sequence (SEQ ID NO:13), and CDR3                comprises fully defined 10 amino acid sequence (SEQ                ID NO:14) as given in the specification, the heavy                chain variable region of monoclonal antibody H4                comprises CDR1 comprises                Gly-Tyr-Thr-Phe-Thr-Gly-Tyr-Tyr amino acid sequence                (SEQ ID NO:15), CDR2 comprises                Ile-Asn-Pro-Asn-Ser-Gly-Gly-Thr amino acid sequence                (SEQ ID NO:16), and CDR3 comprises fully defined 19                amino acid sequence (SEQ ID NO:17) as given in the                specification, the light chain variable region of                monoclonal antibody H4 includes CDR1 comprises                fully defined 12 amino acid sequence (SEQ ID NO:18)                as given in the specification, CDR2 with an amino                acid sequence as shown in (SEQ ID NO:19), and CDR3                with an amino acid sequence as shown in (SEQ ID                NO:20), the amino acid sequence of the heavy chain                variable region of the monoclonal antibody B38 is                shown in (SEQ ID NO:32), the amino acid sequence of                the light chain variable region of monoclonal                antibody B38 is shown in (SEQ ID NO:33), the amino                acid sequence of the heavy chain variable region of                the monoclonal antibody H4 is shown in (SEQ ID                NO:34), and the amino acid sequence of the light                chain variable region of monoclonal antibody H4 is                shown in (SEQ ID NO:35), is new.    INDEPENDENT CLAIMS are also included                for:    a biological material, comprising the gene,                which is a recombinant DNA, an expression cassette,                a vector, a host cell, an engineered bacteria or a                cell line;    preparing the bispecific antibody;    a medicinal composition, comprising the                bispecific antibody;    a kit, comprising the bispecific antibody;                and    a medicinal composition in a single dose form,                comprising 180-6000 mg, preferably 500-1000 mg                bispecific antibody, where the medicinal                composition is prepared in a form suitable for                intravenous administration.    (1) a gene encoding the bispecific antibody,                comprising the nucleotide sequence of the light                chain of the bispecific antibody is shown in (SEQ                ID NO:3), and the nucleotide sequence of the heavy                chain is shown in (SEQ ID NO:1), or the nucleotide                sequence of the light chain of the bispecific                antibody is shown in (SEQ ID NO:7), and the                nucleotide sequence of the heavy chain is shown in                (SEQ ID NO:5);    (2)    (3)    (4)    (5)    (6) ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B14-A02B5;  B14-K01D;  B14-S11A;  B04-G24;  B04-G21;  B04-G01;  B04-C01;  B04-E99;  B04-E02A;  B04-E08;  B04-F0100E;  B04-F1000E;  B04-E03A;  B04-E01A;  B04-G0100E;  B04-G2100E;  B04-G2400E;  B04-G27G0E;  B11-C07A;  B12-K04G1B;  B14-S11D3;  B04-F11B2;  D05-H11A;  D05-H99;  D05-H14;  D05-H12;  D05-H17B1;  D05-C12;  D05-H09;  D05-H06A,A61K-039/42;  A61P-031/14;  C07K-016/46;  C12N-015/13;  C12N-015/85;  A61K-039/395;  C07K-016/10;  C12N-015/63;  C12N-005/10;  G01N-033/569,CN113563475-A   29 Oct 2021   C07K-016/46   202215   Chinese;  WO2022022666-A1   03 Feb 2022   C07K-016/46   202215   Chinese;  TW202208424-A   01 Mar 2022   C07K-016/10   202239   Chinese;  CN113563475-B   22 Jul 2022   C07K-016/46   202263   Chinese;  HK40055435-A0   11 Mar 2022   C07K-016/46   202303   Chinese;  HK40055435-A1   25 Nov 2022   C07K-016/46   202314   Chinese,CN113563475-A    CN10849422    27 Jul 2021;   WO2022022666-A1    WOCN109455    30 Jul 2021;   TW202208424-A    TW128394    02 Aug 2021;   CN113563475-B    CN10849422    27 Jul 2021;   HK40055435-A0    HK4045043    21 Dec 2021;   HK40055435-A1    HK4045043    21 Dec 2021,CN113563475-B Previous Publ. Patent CN113563475;   HK40055435-A0 Previous Publ. Patent CN113563475;   HK40055435-A1 Previous Publ. Patent CN113563475,CN10763140    31 Jul 2020;  CN10849422    27 Jul 2021,  WO2022022666-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA          ,,"CN113563475-A -- CN109563166-A   BIOMUNEX PHARM (BIOM-Non-standard);  REGIONAL CANCER MONTPELLIER VAL AURELLE (REGI-Non-standard);  UNIV MONTPELLIER (UMON);  INSERM INST NAT SANTE & RECH                  MEDICALE (INRM)   GERARD P,  LARBOURET C,  LEGER O,  PELEGRIN A,  ZHUKOVSKY E;  CN111196855-A   SUNSHINE GUOJIAN PHARM SHANGHAI CO LTD (SUNS-Non-standard)   ZHU Z,  HUANG H,  LI L;  CN111333722-A   JIANGSU PROVINCIAL CENT DISEASE CONTROL (JIAN-Non-standard)   ZHANG W,  GUO X,  JIAO Y,  ZENG X,  ZHU F,  ZHU B;  CN111378048-A   UNIV FUDAN (UYFU)   YING T,  WANG L,  WU Y;  WO2022022666-A1 -- CN111303280-A   ACAD MILITARY MEDICAL SCI PLA (JSYX)   CHEN W,  LI J,  CHI X,  ZHANG J,  FU L,  YU C,  XU J,  HOU L,  ZHANG G,  FAN P,  HAO M,  DONG Y,  SONG X,  CHEN Y,  FANG T,  LIU S;  CN111333722-A   JIANGSU PROVINCIAL CENT DISEASE CONTROL (JIAN-Non-standard)   ZHANG W,  GUO X,  JIAO Y,  ZENG X,  ZHU F,  ZHU B;  CN111423508-A   JIANGSU CENT DISEASE CONTROL &                  PREVENTIO (JIAN-Non-standard)   ZHANG W,  GUO X,  JIAO Y,  ZENG X,  ZHU F,  ZHU B","CN113563475-A  WU,Y. : ""A          noncompeting pair of human neutralizing antibodies block          COVID-19 virus binding to its receptor ACE2"",          SCIENCE,relevantClaims[1-11],relevantPassages[1274-1278];  : ""IgGCD55x-Gal"",          ,relevantClaims[1-11],relevantPassages[281-284]WO2022022666-A1  YAN WU, FEIRAN          WANG, CHENGUANG SHEN, WEIYU PENG, DELIN LI, CHENG ZHAO,          ZHAOHUI LI, SHIHUA LI, YUHAI BI, YANG YANG, YUHUAN GONG,          HA: ""A noncompeting pair of human neutralizing antibodies          block COVID-19 virus binding to its receptor ACE2"",          SCIENCE (AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF          SCIENCE), AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF          SCIENCE, UNITED STATES, 13 May 2020 (2020-05-13), United          States , pages 1274 - 1278, XP055758869, Retrieved from          the Internet          &lt;URL:https://science.sciencemag.org/content/sci/368/6496/1274.full.pdf&gt;          DOI: 10.1126/science.abc2241,relevantClaims[1, 2, 7, 8,          10-15|3-6, 9],relevantPassages[abstract, supplement          material, page 7, page 1, right-hand column, paragraph          2];  TIANLEI YING, LI          HAOYANG, LU LU, DIMITROV DIMITER S., JIANG SHIBO:          ""Development of human neutralizing monoclonal antibodies          for prevention and therapy of MERS-CoV infections"",          MICROBES AND INFECTION, ELSEVIER, PARIS, FR, vol. 17, no.          2, 1 February 2015 (2015-02-01), FR , pages 142 - 148,          XP055272026, ISSN: 1286-4579, DOI:          10.1016/j.micinf.2014.11.008,relevantClaims[1, 2, 7, 8,          10-15|3-6, 9],relevantPassages[figure 1, page 146,          right-hand column, paragraph 1]",,A000DBK01 M N P; A000DBK04 M N P; A000DBK08 M N P; A000DBK06 M N P; A000DBK03 M N P; A000DBK07 M N P; A000DBK02 M N P; A000DBK05 M N P,,,
US2022313171-A1,"Imaging and treatment or prevention process for            early detection of disease e.g. neurodegenerative            diseases, involves acquiring by way of Magnetic            resonance imaging (MRI) machine, T2-image as anatomical            image, and acquiring by way of MRI machine, chemical            exchange saturation transfer reference image",ALGBURI I F,ALGBURI I F (ALGB-Individual),2022C7885M,"   NOVELTY - Imaging and treatment process involves                acquiring, by way of a Magnetic resonance imaging                (MRI) machine, a T2-image as an anatomical image;                acquiring, by way of the MRI machine, a Chemical                exchange saturation transfer (CEST) reference image                at a particular Southsidechemical shift and at a                signal frequency outside a range of frequency that                decreases magnetization of related proteins;                acquiring, by way of the MRI machine, a multiple of                CEST images at a multiple of specific Swithin,                Swithinpost, Soutside, Soutsidepost, and chemical                shifts and frequencies that decrease the                magnetization of the related proteins; calculating                a difference in magnetization between Soutsideand                Swithinat each specific Swithinchemical shift and                frequency for each image in the multiple of CEST                images; and detecting disease and mapping disease                severity based on the calculated contrast                differences before and after administration of                glucose with or without Mono carboxylic                transporters (MCTs) inhibitor.    USE - Imaging and treatment or prevention methods                for early detection of disease such as                neurodegenerative diseases, immune diseases,                diseases of the musculoskeletal system, Alzheimers                disease, Parkinsons disease, Huntingtons disease,                epilepsy, down syndrome, amyotrophic lateral                sclerosis, multiple sclerosis and other                neurodegenerative diseases and other inflammatory                diseases, and viruses such as severe acute                respiratory syndrome, severe acute respiratory                syndrome coronavirus 2, coronavirus disease, Middle                East respiratory syndrome, influenza virus, Ebola                virus, and ziska virus, human immunodeficiency                virus, hepatitis C virus, oncoviruses, and all                other respiratory, brain, liver, and immune                deficiency viruses, and other viruses which are the                hosts are humans and/or animals and/or insects (all                claimed). Test details are described, but no results are                given.    ADVANTAGE - The method has enhanced the detection of the                expressed proteins in cancer cells in the same time                which can be detected by CEST-MRI (claimed), it has                enhanced the immune system to produce antibodies                against the viruses.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:    (1) an imaging and treatment methods for early                detection of disease, which involves imaging of                agents bind to inflammatory tissues in cancer by                decrease magnetization of the protons of these                agents and transfer of this magnetization to bulk                water and surrounding tissues by way of MRI                machine, acquiring, by MRI machine, a T2-image as                an anatomical image; obtaining, by means of the MRI                machine, a multiple of CEST images (before                injection the agents); acquiring, by the MRI                machine, a multiple of CEST images (after                administration of the agents); calculate (MTR)                asymmetry before administration of the agents                MTRasym- pre; and calculate (MTR) asymmetry after                administration of the agents as MTRasym- post; and                calculating the difference in MTRasym as                MTRasym-contrast=MTRasym-post- MTRasym-pre;                detecting the accumulation of the agents (to                enhance the CEST detection, it is possible to                administration orally or by injection more than one                agent) that can bind to inflammatory tissues and                immune cells based on the calculated MTRasym-                contrast, as the MTRasym -contrast increase as the                agents accumulated in the inflammatory tissues in                cancer; and    (2) a method for treatment, prevention, and                enhance the immune system to kill the viruses                include administration of mono carboxylate                transporter inhibitors combined with or without                administration of glucose, also, combined with or                without antiviral drugs, some drugs of below can                target and inhibit two or more mechanisms in the                viruses infected or hosted cells, which involves                epidermal growth factor receptor proteins                inhibitors like afatinib and other drugs; Na+/H+                exchange inhibitors and/or pyruvate dehydrogenase                kinase inhibitors; chloride-bicarbonate exchange                inhibitors and/or carbonic anhydrases inhibitors;                glucose transporters inhibitors and/or the proton                pump inhibitor Vacuolar (V)-ATPase comprises a                hydrogen/ potassium ion ATPase inhibitor;                hexokinase inhibitors and/or pyruvate kinase M2                inhibitors; hyperthermia therapies and/or                chemotherapy administration that induce                intracellular acidification for example, cisplatin,                and it's analog and other chemotherapy that induce                intracellular acidification; LDH-A lactate                dehydrogenase A inhibitors and/or glutaminase                inhibitors; anti-inflammation drugs and/or MD2M                inhibitors; mitochondria complex I inhibitors                and/or mitochondria complex II inhibitors;                mitochondria complex III inhibitors and/or                mitochondria complex IV inhibitors; and the proton                pump inhibitor, comprises a vacuolar ATPase                inhibitor and/or mitochondria complex V inhibitors;                increase extracellular pH (pHe) by administration                agents contain bicarbonate such as sodium                bicarbonate and other agents; and drugs increase                the endosome and lysosome permeability and cause                them to leak, such as some polyphenols                (epigallocatechin gallate and other drugs), where                above inhbitors are in the formulation drugs are in                amounts effective in a combination to treatment,                prevention, and enhance the immune system to kill                the viruses. ",,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C02 (Heterocyclic.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  P31 (Diagnosis, surgery (A61B).);  S01 (Electrical Instruments);  ",B14-A02B;  B14-C03;  B14-G01;  B14-G03;  B14-H01;  B14-J01;  B14-J05;  B14-J07;  B14-K01;  B14-L06;  B14-N01;  B14-N16;  B14-S01;  B14-S20A;  B10-A07A;  B06-A03;  B10-E02;  B10-B02J;  B10-C03;  B10-D03;  B10-A16;  B08-D02;  B06-A01;  B07-A02B;  B07-D02;  B06-D18;  B10-B02A;  B06-D05;  B10-C04C;  B11-C08;  B12-K04G2D;  C14-A02B;  C14-C03;  C14-G01;  C14-G03;  C14-H01;  C14-J01;  C14-J05;  C14-J07;  C14-K01;  C14-L06;  C14-N01;  C14-N16;  C14-S01;  C14-S20A;  C06-A03;  C10-E02;  C10-A07A;  C10-B02J;  C10-C03;  C10-D03;  C10-A16;  C06-A01;  C08-D02;  C07-A02B;  C07-D02;  C06-D18;  C10-B02A;  C06-D05;  C10-C04C;  C11-C08;  C12-K04G2D;  D05-H09;  P31-A05;  S01-E02A2;  S01-E02A1;  S05-D02B1,A61B-005/00;  A61B-005/055;  A61K-031/353;  A61K-031/517;  A61K-033/00;  A61K-045/06;  A61K-049/04;  A61K-049/10;  G01R-033/28;  G01R-033/48;  G01R-033/485,US2022313171-A1   06 Oct 2022   A61B-005/00   202290   English,US2022313171-A1    US221742    02 Apr 2021,,US221742    02 Apr 2021,,,,,159573-0-0-0 D M K; 89931-0-0-0 D M K; 53318-1-0-0 D M K; 45362-1-0-0 D M K; 98065-0-0-0 D M K; 98069-0-0-0 D M K; 98053-0-0-0 D M K; 102281-0-0-0 D M K; 196870-0-0-0 D M K; 105588-0-0-0 D M K; 101488-0-0-0 D M K; 105502-2-0-0 D M K; 108390-0-0-0 D M K; 85145-2-0-0 D M K; 105172-0-0-0 D M K; 99712-0-0-0 D M K; 95853-1-0-0 D M K; 94291-1-0-0 D M K; 95854-1-0-0 D M K; 3791499-1-0-0 D M K; 95853-0-0-0 D M K; 104714-2-0-0 D M K; 104714-1-0-0 D M K; 108336-1-0-0 D M K;  D M K; 108704-1-0-0 D M K; 219373-1-0-0 D M K; 107011-0-0-0 D M K; 106040-4-0-0 D M K; 82569-2-0-0 D M K; 107036-1-0-0 D M K; 111372-0-0-0 D M K; 108205-1-0-0 D M K; 12641-0-0-0 D M K; 99589-0-0-0 D M K; 141322-0-0-0 D M K; 1580-1-0-0 D M K; 95854-2-0-0 D M K; 3791499-1-0-0 CL USE,,03580; 01662; 70349,R00038 D M K; RA0Q7T D M K; R23448 D M K; RA0AQM D M K; R00647 D M K; RA615E D M K; R20352 D M K; R06755 D M K; RA09VW D M K; RA03RA D M K; R08505 D M K; R19451 D M K; RA021P D M K; R01179 D M K; R00971 D M K; R08504 D M K; RA00TN D M K; R13045 D M K; R07947 D M K; RC8QW2 D M K; RA00TM D M K; R19452 D M K; R04686 D M K; R06321 D M K; RBRXRD D M K; R14561 D M K; RA4C3D D M K; RA08BH D M K; R12084 D M K; R10974 D M K; R16884 D M K; RA00JZ D M K; RA0MFZ D M K; R03008 D M K; R18612 D M K; RA1ZWS D M K; R01416 D M K,0647-S; 1179-S; 0971-S; 1416-S
WO2022061068-A1,"Imaging samples by illuminating samples with incident light, forming reference light from reflected light, mixing lights, receiving diffraction limited spot at sensor rendering detection of particle, determining normalized intensity, and determining properties of particle in samples",AVCI O;  OZA N N,MYRRYM CORP (MYRR-Non-standard),2022442821,"   NOVELTY - Method for imaging one or more samples involves (a) illuminating the one or more samples with incident light, (b) forming a reference light from the reflected light, (c) allowing the scattered light and the reference light to coherently mix to form at least one diffraction limited spot, (d) receiving the at least one diffraction limited spot at a sensor rendering the detection of the at least one particle, (e) determining a normalized intensity for the at least one diffraction limited spot, and (f) determining one or more properties of the at least one particle in the one or more samples based on the at least one diffraction limited spot and the corresponding normalized intensity.    USE - The method or interferometry system is useful for imaging one or more samples.    ADVANTAGE - The method detects nano- and micro-scale particles in a simple and accurate manner without the need for labeling and scanning.    DETAILED DESCRIPTION - Method for imaging one or more samples involves (a) illuminating the one or more samples with incident light, where the one or more samples comprises one or more particles, a first of the incident light interacts with at least one particle of the one or more particles in the one or more samples and returns as scattered light, a second of the incident light returns as reflected light upon specular reflection off of a slide, and the at least one particle is a nano particle or a micro particle, (b) forming a reference light from the reflected light, (c) allowing the scattered light and the reference light to coherently mix to form at least one diffraction limited spot, (d) receiving the at least one diffraction limited spot at a sensor rendering the detection of the at least one particle, (e) determining a normalized intensity for the at least one diffraction limited spot, and (f) determining one or more properties of the at least one particle in the one or more samples based on the at least one diffraction limited spot and the corresponding normalized intensity. An INDEPENDENT CLAIM is included for interferometry system, which comprises a slide having the one or more samples, a light source that illuminates the one or more samples with incident light, one or more lenses that receive and direct the scattered light and the reference light, where the interferometry system allows the scattered light and the reference light to coherently mix to form at least one diffraction limited spot, a sensor that receives the at least one diffraction limited spot, and a controller for determining a normalized intensity for the at least one diffraction limited spot, and determining one or more properties of the at least one particle in the one or more samples based on the at least one diffraction limited spot and the corresponding normalized intensity. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)",B11-C08J;  B12-K04;  D05-H09;  S03-E14H3;  S03-F06A,C12M-001/34;  C12Q-001/04;  C12Q-001/6825;  G01N-015/06;  G01N-015/10,WO2022061068-A1   24 Mar 2022   C12M-001/34   202231Pages: 44   English,WO2022061068-A1    WOUS050801    17 Sep 2021,,US080638P    18 Sep 2020,WO2022061068-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,WO2022061068-A1 -- US20130171621-A1   ;  US20160067780-A1   ;  US20190162647-A1   ,,,,,,
US2024033294-A1,"Preparing fecal microbiota transplant with            palatable odor and flavor to treat e.g. colitis,            involves suspending and filtering fecal sample from            fecal donor, centrifuging filtrate, resuspending and            centrifuging first pellet, centrifuging second            supernatant, resuspending third pellet and            freeze-drying",KLOP J B,NOVEL BIOME SOLUTIONS INC (NOVE-Non-standard),202413741Q,"   NOVELTY - Preparing a fecal microbiota transplant (FMT)                having palatable odor and flavor to facilitate                non-encapsulated oral administration in large                doses, involves: (a) suspending and filtering a                fecal sample acquired from a fecal donor to                generate a filtrate including desired fecal                microbes of fecal sample and a residue; (b)                centrifuging the filtrate to provide a first                supernatant and a first pellet, where the first                pellet includes desired fecal microbes; (c)                resuspending the first pellet and centrifuging to                provide a second supernatant and a second pellet,                where the second supernatant includes desired fecal                microbes; (d) centrifuging the second supernatant                or dilution of second supernatant to obtain a third                supernatant and a third pellet including desired                fecal microbes; (e) resuspending the third pellet                in a presence of cryoprotectant; (f) freezing the                resulting refined suspension; and (g) freeze-drying                the frozen refined suspension to provide FMT.    USE - Method for preparing fecal microbiota                transplant (FMT) for oral dosing to treat colitis,                Crohn's disease, Parkinson's disease, Alzheimer's                disease, post-cancer, chronic digestive issues,                gastrointestinal issues (such as those associated                with long coronavirus disease (Covid)) and autism                spectrum disorder. No biological data given.    ADVANTAGE - The method: provides FMT compositions that are                virtually colorless, tasteless and odorless for                non-encapsulated oral administration in large doses                for patients who are unable to swallow capsules                and/or who do not want or cannot access the                treatment by other established treatment methods                (e.g. capsule, enema, endoscopy, colonoscopy,                nasogastric tube, nasoenteric tube and nasal                jejunal tube); provides FMT that has an odor as                evaluated with a confidence of 95% to be odorless                for more than 50% of a population using a                triangular test and a flavor as evaluated with a                confidence of 80% to be flavorless for more than                50% of a population using a triangular test and                retains a desired activity level of 100% when                stored under predetermined storage conditions                including predetermined temperature of                -80&#176;C to 4&#176;C and time of 1 year;                ensures that at least 50% of the desired fecal                microbes in the fecal sample is retained in the FMT                following the method.    DETAILED DESCRIPTION - Preparing a fecal microbiota transplant (FMT)                having palatable odor and flavor to facilitate                non-encapsulated oral administration in large                doses, involves: (a) suspending and filtering a                fecal sample acquired from a fecal donor to                generate a filtrate including desired fecal                microbes of fecal sample and a residue; (b)                centrifuging the filtrate at a first gravitational                force of 6000-10,000&#215;g for a first                centrifugation length of 2-60 minutes and                optionally resuspending and repeating the                centrifuging once, twice or more, to provide a                first supernatant and a first pellet, where the                first pellet includes desired fecal microbes; (c)                resuspending the first pellet and centrifuging at a                second gravitational force of 250-2000&#215;g                for a second centrifugation length of 2-60 minutes                and optionally decanting the first supernatant and                repeating the centrifuging once, twice or more, to                provide a second supernatant and a second pellet,                where the second supernatant includes desired fecal                microbes; (d) centrifuging the second supernatant                or a dilution of the second supernatant at a third                gravitational force of 6000-10,000&#215;g for a                third centrifugation length of 2-60 minutes and                optionally resuspending and repeating the                centrifuging once, twice or more, to obtain a third                supernatant and a third pellet including desired                fecal microbes; (e) resuspending the third pellet                in a presence of a cryoprotectant, to produce a                refined suspension including desired fecal                microbes; (f) freezing the refined suspension; and                (g) freeze-drying the frozen refined suspension to                provide FMT.    INDEPENDENT CLAIMS are included for:    1. an FMT, which is made by the above                method;    2. a process, which involves:    a. filtering the fecal sample with a filter                medium to generate a filtrate;    b. separating particulate matter of the                filtrate to obtain a first sediment and a first                supernatant;    c. repeatedly resuspending the first sediment                and separating particulate matter of the                resuspended first sediment to obtain a second                sediment and a second supernatant;    d. diluting the second supernatant and                repeatedly separating particulate matter out of the                second supernatant to obtain a third sediment and a                third supernatant;    e. resuspending the third sediment in a                cryoprotectant to obtain a mixture; and    f. freeze-drying the mixture to obtain a                powdered composition, where the powdered                composition is tasteless and odorless; and    3. a method for dividing human fecal matter                into useful output products, including fecal                microbiota transplant having palatable odor and                flavor, which involves:    i. suspending a fecal sample acquired from a                fecal donor in a first volume;    ii. filtering the suspended fecal sample to                generate a filtrate including desired fecal                microbes of the fecal sample;    iii. centrifuging the filtrate at a first                gravitational force of 8000&#215;g for a first                centrifugation length of time of 20 minutes,                retaining a first sediment and discarding a first                supernatant;    iv. adding fresh solvent, resuspending the                first sediment and centrifuging each container                (804, 810)at the first gravitational force for the                first centrifugation length of time, retaining a                second sediment and discarding a second                supernatant;    v. adding fresh solvent, resuspending the                second sediment and centrifuging the first                gravitational force for the first centrifugation                length of time, retaining a third sediment, and                discarding a third supernatant from each                container;    vi. adding fresh solvent, resuspending the                third sediment and centrifuging at a second                gravitational force of 1000&#215;g for a second                centrifugation length of time of 20 minutes,                retaining a fourth supernatant and discarding a                fourth sediment;    vii. centrifuging the fourth supernatant or                its dilution at the second gravitational force for                the second centrifugation length of time, retaining                a fifth supernatant and discarding a fifth                sediment;    viii. centrifuging the fifth supernatant or                its dilution at the second gravitational force for                the second centrifugation length of time, retaining                a sixth supernatant and discarding a sixth                sediment;    ix. centrifuging the sixth supernatant or its                dilution at the first gravitational force for the                first centrifugation length of time, discarding a                seventh supernatant and obtaining a seventh                sediment;    x. resuspending the seventh sediment in a                presence of a cryoprotectant to produce a refined                suspension;    xi. freezing the refined suspension; and    xi. freeze-drying the frozen refined                suspension to provide FMT.    DESCRIPTION OF DRAWING(S) - The drawing shows a view of system for the                production of FMT.    802Filtration system    804, 810Container    808Centrifuge    812Freezer    814Freeze dryer ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.)",B11-C05;  B12-M14;  B04-B04B2;  B14-A02B5;  B14-H01;  B04-F01;  B14-J01A4;  B14-J01A3;  B14-E10C1;  B12-M12N,A61K-035/24;  A61K-009/00,US2024033294-A1   01 Feb 2024   A61K-035/24   202413   English,US2024033294-A1    US228865    01 Aug 2023,US2024033294-A1 Provisional Application US370034P,US370034P    01 Aug 2022;  US228865    01 Aug 2023,,,"US2024033294-A1 -- US10905726-B2   REBIOTIX INC (REBI-Non-standard)   JONES L A,  JONES C R,  BROWN B A,  ERICKSON J",,,,,,
WO2023012356-A2;  WO2023012356-A3;  EP4381103-A2,"Diagnosing subject for inflammatory disease            comprises e.g. determining in sample obtained from            subject level of marker, comparing level determined,            and providing that subject has inflammatory disease            when level of NET protein markers",THIERRY A;  PASTOR B;  PISAREVA E,UNIV MONTPELLIER (UMON-C);  REGIONAL CANCER MONTPELLIER VAL AURELLE (REGI-Non-standard);  INSERM INST NAT SANTE & RECH MEDICALE (INRM-C);  REGIONAL CANCER MONTPELLIER VAL AURELLE (REGI-Non-standard);  UNIV MONTPELLIER (UMON-C);  INSERM INST NAT SANTE & RECH MEDICALE (INRM-C),2023175933,"   NOVELTY - Diagnosing (M1) a subject for an inflammatory                disease comprises (a) determining in a sample                obtained from the subject the level of at least one                marker comprises NET protein markers, circulating                nuclear DNA (cir-nDNA), circulating mitochondrial                DNA (cir-mtDNA) and/or a circulating DNA (cir-DNA)                fragmentation index, (b) comparing the level                determined at step (a) with their predetermined                reference value, and (c) providing that the subject                has an inflammatory disease when the level of the                NET protein markers, cir-nDNA or cir-DNA                fragmentation index determined at step (a) is                higher than its predetermined reference value or                when the level of cir-mtDNA determined at step (a)                is lower than its predetermined reference value,                and providing that the subject has not an                inflammatory disease when the level of the NET                protein markers, cir-nDNA or cir-nDNA fragmentation                index determined at step (a) is lower than its                predetermined reference value.    USE - The method is useful for: diagnosing a subject                for an inflammatory disease, where the inflammatory                disease is pathogen infection, an autoimmune                disease or a cancer, the pathogen infection is the                coronavirus disease (Covid)-19, the cancer is a                colorectal cancer or a metastatic colorectal cancer                (mCRC), the autoimmune disease is a lupus; treating                an inflammatory disease (all claimed). Test details                are described but no results given.    ADVANTAGE - The method: provides the level of the elastase                (NE) can be higher than 2-fold as compared to                reference value, myeloperoxidase (MPO) can be                higher than 2-fold as compared to reference value,                Cir-nDNA can be higher than 2-fold, preferably                5-fold, as compared to reference value, Cir-mtDNA                can be lower than 2-fold, as compared to reference                value, the MNR can be lower than 3 -fold, as                compared to reference value and aCL can be higher                by 1.5-fold, as compared to reference value;                provide significant information of cancer severity,                cancer prognosis or treatment guidance, which could                constitute a significant advance in cancer along                with the advent of immunotherapy and the growing                knowledge of tumor immunology; suitable to                distinguish a healthy subject with a subject                hospitalized for an inflammatory disease and with a                subject hospitalized for an inflammatory disease in                a ICU; and can also be suitable for determining                whether a subject is eligible or not to an                anti-inflammatory disease treatment.    DETAILED DESCRIPTION - Diagnosing (M1) a subject for an inflammatory                disease comprises (a) determining in a sample                obtained from the subject the level of at least one                marker comprises NET protein markers, circulating                nuclear DNA (cir-nDNA), circulating mitochondrial                DNA (cir-mtDNA) and/or a circulating DNA (cir-DNA)                fragmentation index, (b) comparing the level                determined at step (a) with their predetermined                reference value, and (c) providing that the subject                has an inflammatory disease when the level of the                NET protein markers, cir-nDNA or cir-DNA                fragmentation index determined at step (a) is                higher than its predetermined reference value or                when the level of cir-mtDNA determined at step (a)                is lower than its predetermined reference value,                and providing that the subject has not an                inflammatory disease when the level of the NET                protein markers, cir-nDNA or cir-nDNA fragmentation                index determined at step (a) is lower than its                predetermined reference value or when the level of                cir-mtDNA determined at step (a) is higher than its                predetermined reference value. INDEPENDENT CLAIMS                are also included for:    diagnosing (M2) a subject for an inflammatory                disease comprising (a1) determining in a sample                obtained from the subject the level of long and                short fragments of cir-nDNA, (b1) calculated the                ratio of long over short fragments of cir-nDNA                (DII), (c1) comparing the level determined at step                (a1) with their predetermined reference value, and                (d1) providing that the subject has an inflammatory                disease when the calculated ratio determined at                step (b1) is higher than its predetermined                reference value, and providing that the subject has                not an inflammatory disease when the calculated                ratio determined at step (a1) is lower than its                predetermined reference value;    diagnosing (M3) a subject for an inflammatory                disease comprising (a2) determining in a sample                obtained from the subject the level of cir-mtDNA                and cir- nDNA (b2) calculating the MNR ratio                (cir-mtDNA over cir-nDNA ratio), (c2) comparing the                ratio determined at step (b2) with a predetermined                reference value and (d2) providing that the subject                has an inflammatory disease when the calculated                ratio determined at step (b2) is lower than its                predetermined reference value and providing that                the subject has not an inflammatory disease when                the calculated ratio determined at step (b2) is                higher than its predetermined reference                value;    diagnosing (M4) a subject for an inflammatory                disease comprising (a3) extracting the cir-DNA                (cir-nDNA or cir-mtDNA) from a sample obtained from                the subject, (b3) determining the level of at least                one single or double stranded DNA fragment having a                length 20-440 base pairs (bp), (c3) comparing the                level determined at step (b3) with a predetermined                reference value and, (d3) concluding that the                subject suffers from an inflammatory disease when                the level determined at step (c3) differ from the                predetermined reference value;    diagnosing (M5) a subject for an inflammatory                disease comprising the step (a3) as per se, (b4)                determining the level of a first single or double                stranded DNA fragment having a length 20-40 bp,                (c4) determining the level of a second single or                double stranded DNA fragment having a length 20 to                440 bp, (d4) calculating the ratio of the level                determined at step (b4) to the level determined at                step (c4) or alternatively the ratio of the level                determined at step (c4) to the level determined at                step (b4), (e4) comparing the ratio determined at                step (d4) with a predetermined corresponding                reference value and, (f4) concluding that the                subject suffers from an inflammatory disease when                the ratio determined at step (d4) differ from the                predetermined corresponding reference value;    treating an inflammatory disease diagnosed by                the methods (M1)-(M5) comprising administering to a                subject an anti-inflammatory disease treatment;                and    a kit for diagnosing an inflammatory disease                comprising means for determining t marker comprises                NET protein markers (like MPO, NE, anti-cardiolipin                (aCL) and anti-phosphatidylserine), cir-nDNA or                cir- mtDNA. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)",B04-E01A;  B04-L03B;  B04-L05C;  B04-N02;  B04-N16;  B11-C04;  B11-C08F8;  B12-K04E3;  B12-K04F;  B12-K04G1B;  B12-K04G2A;  B12-K04G2F;  B14-A02B5;  B14-C03;  B14-G02D;  B14-H01E1;  B14-H01E7;  D05-A02A;  D05-A02C;  D05-H09;  S03-E09F;  S03-E14H3;  S03-E14H5,C12Q-001/6883;  C12Q-001/6886;  G01N-033/53,WO2023012356-A2   09 Feb 2023   C12Q-001/6883   202319Pages: 89   English;  WO2023012356-A3   16 Mar 2023   C12Q-001/6883   202323   English;  EP4381103-A2   12 Jun 2024   C12Q-001/6883   202449   English,WO2023012356-A2    WOEP072147    05 Aug 2022;   WO2023012356-A3    WOEP072147    05 Aug 2022;   EP4381103-A2    EP762031    05 Aug 2022,EP4381103-A2 PCT application Application WOEP072147;   EP4381103-A2 Based on Patent WO2023012356,EP306103    06 Aug 2021,WO2023012356-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2023012356-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP4381103-A2:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN  ,,";  WO2023012356-A3 -- CN102914651-A   HANGZHOU WATSON BIOLOGICAL TECHNOLOGY CO (HANG-Non-standard)   SU G,  ZHANG K,  GAO Y;  WO2020150656-A1   UNIV JOHNS HOPKINS (UYJO);  UNIV NEW YORK STATE RES FOUND (UNYS);  UNIV TEXAS SYSTEM (TEXA)   VOGELSTEIN B,  KINZLER K W,  COHEN J,  PAPADOPOULOS N,  LENNON A M,  TOMASETTI C,  WANG Y,  NETTO G J,  KARCHIN R,  DOUVILLE C,  HANASH S,  SPRINGER S,  GROLLMAN A,  DICKMAN K;  WO2003090694-A2   EXPRESSION DIAGNOSTICS INC (EXPR-Non-standard)   WOHLGEMUTH J,  FRY K,  WOODWARD R,  LY N","WO2023012356-A3  AI-SHENG HO ET AL:          ""Neutrophil elastase as a diagnostic marker and          therapeutic target in colorectal cancers"", ONCOTARGET, 30          January 2014 (2014-01-30), United States, pages 473 -          480, XP055285793, Retrieved from the Internet          &lt;URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964222/pdf/oncotarget-05-473.pdf&gt;          [retrieved on 20160705], DOI:          10.18632/oncotarget.1631,relevantClaims[1,3,9,15,17,19|20],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;475&lt;/pp&gt;&lt;column&gt;r&lt;/column&gt;&lt;para&gt;last&lt;/para&gt;&lt;ppl&gt;476&lt;/ppl&gt;&lt;coll&gt;l&lt;/coll&gt;&lt;paral&gt;1&lt;/paral&gt;&lt;figure&gt;2&lt;/figure&gt;|&lt;pp&gt;476&lt;/pp&gt;&lt;figure&gt;4&lt;/figure&gt;|&lt;pp&gt;477&lt;/pp&gt;&lt;column&gt;l&lt;/column&gt;&lt;para&gt;2&lt;/para&gt;];  SHOEMARK AMELIA ET          AL: ""A point of care neutrophil elastase activity assay          identifies bronchiectasis severity, airway infection and          risk of exacerbation"", EUR RESPIR J, vol. 53, 28          September 2019 (2019-09-28), pages OA4947, XP093001107,          Retrieved from the Internet          &lt;URL:https://erj.ersjournals.com/content/53/6/1900303.full.pdf&gt;          DOI:          10.1183/13993003.congress-2019.OA4947,relevantClaims[1,3,15,20|9,11,19],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;2&lt;/pp&gt;&lt;para&gt;4&lt;/para&gt;&lt;paral&gt;6&lt;/paral&gt;|&lt;pp&gt;2&lt;/pp&gt;&lt;para&gt;last&lt;/para&gt;&lt;ppl&gt;3&lt;/ppl&gt;&lt;paral&gt;1&lt;/paral&gt;|&lt;pp&gt;4&lt;/pp&gt;&lt;para&gt;last&lt;/para&gt;&lt;ppl&gt;5&lt;/ppl&gt;&lt;figure&gt;2&lt;/figure&gt;];  JEAN-LOUIS GUEANT          ET AL: ""Elastase and exacerbation of neutrophil innate          immunity are involved in multi-visceral manifestations of          COVID-19"", ALLERGY, WILEY-BLACKWELL PUBLISHING LTD,          UNITED KINGDOM, vol. 76, no. 6, 27 February 2021          (2021-02-27), pages 1846 - 1858, XP071463204, ISSN:          0105-4538, DOI:          10.1111/ALL.14746,relevantClaims[1-3,9,11,15,16,19,20],relevantPassages[&lt;pp&gt;1849&lt;/pp&gt;&lt;column&gt;l&lt;/column&gt;&lt;para&gt;2&lt;/para&gt;|&lt;pp&gt;1850&lt;/pp&gt;&lt;figure&gt;1A&lt;/figure&gt;];  PEREZ-SANCHEZ          CARLOS ET AL: ""Early restoration of immune and vascular          phenotypes in systemic lupus erythematosus and rheumatoid          arthritis patients after B cell depletion"", JOURNAL OF          CELLULAR AND MOLECULAR MEDICINE, vol. 23, no. 9, 26          September 2019 (2019-09-26), RO, pages 6308 - 6318,          XP093001203, ISSN: 1582-1838, Retrieved from the Internet          &lt;URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/jcmm.14517&gt;          DOI:          10.1111/jcmm.14517,relevantClaims[1,3,9,11,15,18-20],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;6311&lt;/pp&gt;&lt;column&gt;r&lt;/column&gt;&lt;para&gt;last&lt;/para&gt;&lt;figure&gt;1D          and I&lt;/figure&gt;|&lt;figure&gt;3C and          H&lt;/figure&gt;];  AKGUN EMEL ET AL:          ""Proteins associated with neutrophil degranulation are          upregulated in nasopharyngeal swabs from SARS-CoV-2          patients"", PLOS ONE, vol. 15, no. 10, 20 October 2020          (2020-10-20), pages e0240012, XP055881383, DOI:          10.1371/journal.pone.0240012,relevantClaims[1,3,9,11,15,16,19,20],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;4&lt;/pp&gt;&lt;table&gt;1&lt;/table&gt;|&lt;pp&gt;6&lt;/pp&gt;&lt;para&gt;2&lt;/para&gt;];  LI HAO ET AL:          ""Comprehensive aptamer-based screen of 1317 proteins          uncovers improved stool protein markers of colorectal          cancer"", JOURNAL OF GASTROENTERLOGY, SPRINGER JAPAN KK,          JP, vol. 56, no. 7, 12 June 2021 (2021-06-12), pages 659          - 672, XP037508635, ISSN: 0944-1174, [retrieved on          20210612], DOI:          10.1007/S00535-021-01795-Y,relevantClaims[1,3,9,11,15,17,19,20],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;664&lt;/pp&gt;&lt;figure&gt;2&lt;/figure&gt;];  WANG WEI ET AL:          ""Increased levels of serum myeloperoxidase in patients          with active rheumatoid arthritis"", LIFE SCIENCE, PERGAMON          PRESS, OXFORD, GB, vol. 117, no. 1, 28 September 2014          (2014-09-28), pages 19 - 23, XP029085060, ISSN:          0024-3205, DOI:          10.1016/J.LFS.2014.09.012,relevantClaims[1,3,9,11,15,18-20],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;21&lt;/pp&gt;&lt;figure&gt;1&lt;/figure&gt;];  VOYNOW JUDITH A. ET          AL: ""Neutrophil Elastase and Chronic Lung Disease"",          BIOMOLECULES, vol. 11, no. 8, 21 July 2021 (2021-07-21),          CH, pages 1065, XP093000816, ISSN: 2218-273X, DOI:          10.3390/biom11081065,relevantClaims[1-3,9,11,15-20],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  THIERRY ALAIN R. ET          AL: ""Neutrophil Extracellular Traps and By-Products Play          a Key Role in COVID-19: Pathogenesis, Risk Factors, and          Therapy"", JOURNAL OF CLINICAL MEDICINE, vol. 9, no. 9, 11          September 2020 (2020-09-11), CH, pages 2942, XP093001068,          ISSN: 2077-0383, DOI:          10.3390/jcm9092942,relevantClaims[16],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  KUNNUMAKKARA          AJAIKUMAR B ET AL: ""COVID-19, cytokines, inflammation,          and spices: How are they related?"", LIFE SCIENCE,          PERGAMON PRESS, OXFORD, GB, vol. 284, 16 February 2021          (2021-02-16), XP086798160, ISSN: 0024-3205, [retrieved on          20210216], DOI:          10.1016/J.LFS.2021.119201,relevantClaims[16],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  EFRIMESCU CATALIN I          ET AL: ""Neutrophil Extracellular Trapping Role in Cancer,          Metastases, and Cancer-Related Thrombosis: a Narrative          Review of the Current Evidence Base"", CURRENT ONCOLOGY          REPORTS, CURRENT SCIENCE, GB, vol. 23, no. 10, 3 August          2021 (2021-08-03), XP037549621, ISSN: 1523-3790,          [retrieved on 20210803], DOI:          10.1007/S11912-021-01103-0,relevantClaims[17],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  PISAREVA EKATERINA          ET AL: ""Persistence of neutrophil extracellular traps and          anticardiolipin auto-antibodies in post-acute phase          COVID-19 patients"", JOURNAL OF MEDICAL VIROLOGY, 13          October 2022 (2022-10-13), US, XP093001078, ISSN:          0146-6615, Retrieved from the Internet          &lt;URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jmv.28209&gt;          DOI:          10.1002/jmv.28209,relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  PASTOR BRICE ET AL:          ""Association of neutrophil extracellular traps with the          production of circulating DNA in patients with colorectal          cancer"", ISCIENCE, vol. 25, no. 2, 29 January 2022          (2022-01-29), US, pages 103826, XP093001079, ISSN:          2589-0042, DOI:          10.1016/j.isci.2022.103826,relevantPassages[&lt;pp&gt;W&lt;/pp&gt;]",99094-0-0-0 K M; 2615841-0-0-0 K M; 124125-0-0-0 K M; 2615841-0-0-0 CL USE,,,RA0I5T K M; RBEON7 K M; RA0P86 K M,
WO2022175674-A1,"Producing a modified human cell comprising a            modified TYK2 gene comprises introducing, into a human            cell comprising a TYK2 gene i.e. a DNA-targeting            polypeptide, or a nucleic acid molecule encoding a            DNA-targeting polypeptide",DAVIES J O J;  DENDROU C A,UNIV OXFORD INNOVATION LTD (UYOX-C),2022A8548E,"   NOVELTY - Producing a modified human cell comprising a                modified TYK2 gene comprises: (a) introducing, into                a human cell comprising a TYK2 gene, (i) a                DNA-targeting polypeptide, or (ii) a nucleic acid                molecule encoding a DNA-targeting polypeptide, so                that, when present, the nucleic acid molecule                encoding the DNA-targeting polypeptide is expressed                in the cell to produce a DNA-targeting polypeptide,                the DNA-targeting polypeptide is targeted to a                target nucleotide sequence in the TYK2 gene, and                where the DNA-targeting polypeptide modifies one or                more nucleotides in the TYK2 gene, thus producing a                modified human cell comprising a modified TYK2                gene, where either (i) the target nucleotide                sequence is in the coding region of the TYK2 gene,                and the modification reduces the level of TYK2                kinase activity obtainable from the encoded TYK2                polypeptide, or (ii) the target nucleotide sequence                is in a regulatory region of the TYK2 gene, and the                modification reduces the expressible level of TYK2                polypeptide.    USE - The process is useful for: producing a                modified human cell comprising a modified TYK2                gene, where the cell are used treating an                immune-mediated disease, i.e. Addison's disease,                alopecia, ankylosing spondylitis, Crohns disease,                Grave's disease, hypothyroidism, juvenile                idiopathic arthritis, multiple sclerosis,                pernicious anaemia, primary biliary cirrhosis,                psoriasis, psoriatic arthritis, rheumatoid                arthritis, sarcoidosis, scleroderma, Sjogren                syndrome, systemic lupus erythematosus, type 1                diabetes, ulcerative colitis, vitiligo and                COVID-19, preferably multiple sclerosis or                scleroderma (all claimed). No biological data                given.    ADVANTAGE - The process: reduces pro-inflammatory cytokine                signalling in the cell; and reduces the expressible                level of TYK2 polypeptide in the cell.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    producing a population of cells comprising                human cells with modified (i.e. non-wild-type) TYK2                genes, the process comprising (a) introducing, into                a population of human cells each comprising a TYK2                gene, (i) CRISPR polypeptides with nuclease                activity, or a nucleic acid molecule coding                therefor, and (ii) at least two gRNAs, where the                gRNAs are ones which are capable of targeting the                CRISPR polypeptides to nucleotide sequences in the                TYK2 gene which flank a target nucleotide sequence,                or at least one nucleic acids coding, and (iii) a                donor DNA comprising a modified fragment of a TYK2                gene, and (b) culturing the population of human                cells under conditions so that, when present, the                nucleic acid molecule coding for the CRISPR                polypeptide is expressed in the cells to produce                the CRISPR polypeptides, when present, the nucleic                acid molecule(s) coding for the gRNA is expressed                in the cells to produce the gRNAs, CRISPR                polypeptides are targeted by the gRNAs to make                double-stranded breaks in the TYK2 gene either side                of the target nucleotide sequence;    producing a population of cells comprising                human cells with modified TYK2 genes comprising (a)                introducing, into a population of human cells each                comprising a TYK2 gene, (i) a CRISPR polypeptide                having nuclease activity (e.g. Cas9), and a base                editor polypeptide, or nucleic acid molecules                encoding at least one polypeptides, and (ii) at                least one gRNAs, where the gRNAs are ones which are                capable of targeting the CRISPR polypeptide and/or                the base editor to target nucleotide sequences in                the TYK2 gene, or at least one nucleic acids                coding, (b) culturing the population of human cells                under conditions so that, when present, the nucleic                acid molecules coding for the CRISPR polypeptide                and base editor are expressed in the cells to                produce the CRISPR polypeptides and base editor                polypeptides, when present, the nucleic acid                molecule(s) coding for the gRNAs are expressed in                the cells to produce the gRNAs, the CRISPR                polypeptides are targeted by at least one of the                gRNAs to make double-stranded breaks in the target                nucleotide sequences in the TYK2 genes in a first                portion of the population of cells, and the base                editor polypeptides are targeted by at least one of                the gRNAs to make base edits in the target                nucleotide sequences in the TYK2 genes in a second                portion of the population of cells;    producing a population of cells comprising                human cells with modified TYK2 genes comprising (a)                introducing, into a population of human cells each                comprising a TYK2 gene, (i) a CRISPR polypeptide                having nuclease activity (e.g. Cas9), and a prime                editor polypeptide, or nucleic acid molecules                coding at least one polypeptides, and (ii) at least                one gRNAs (e.g. a gRNA and a pegRNA), (b) culturing                the population of human cells under conditions so                that, when present, the nucleic acid molecules                coding for the CRISPR polypeptide and prime editor                are expressed in the cells to produce the CRISPR                polypeptides and the prime editor polypeptides,                when present, the nucleic acid molecule(s) coding                for the gRNAs are expressed in the cells to produce                the gRNAs, the CRISPR polypeptides are targeted by                at least one of the gRNAs to make double-stranded                breaks in the target nucleotide sequences in the                TYK2 genes in a first portion of the population of                cells, and the prime editor polypeptides are                targeted by at least one of the gRNAs to make prime                edits in the target nucleotide sequences in the                TYK2 genes in a second portion of the population of                cells;    composition comprising at least one modified                human cells or population of cells, optionally                together with at least one adjuvants, carriers or                diluents;    a TYK2 gene, where the nucleotide sequence of                the TYK2 gene comprises (a) (i) a nucleotide                sequence encoding an amino acid sequence having                95-99.5% amino acid sequence identity to SEQ ID NO:                1 , or (ii) a nucleotide sequence having 90-99.9%                nucleotide sequence identity to SEQ ID NO: 2                (comprising a fully defined sequence of 4243                nucleotides as given in the specification) or SEQ                ID NO: 3 (comprising a fully defined sequence of                3971 nucleotides as given in the                specification);    a TYK2 polypeptide, where the amino acid                sequence of the TYK2 polypeptide comprising (a) an                amino acid sequence having 95-99.5% amino acid                sequence identity to SEQ ID NO: 1, and (b) the                amino acid sequence of the TYK2 polypeptide                comprises a non-wild-type amino acid at at least                one of the positions corresponding to the positions                identified;    treating an immune-mediated disease (IMD) in a                human subject comprising administering an modified                human cells or a population of cells, to a subject                in need; and    preventing or reducing the risk of graft                versus host disease, the method comprising                administering an modified human cells or population                of cells. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E02E;  B04-E13;  B04-E99;  B04-F0200E;  B14-C03;  B14-C09;  B14-D01;  B14-E08;  B14-E10C1;  B14-F03;  B14-G02D;  B14-N11;  B14-N12;  B14-N17;  B14-R02;  B14-S01;  B14-S04;  B14-S21;  D05-H12B;  D05-H19C;  D05-H99,C12N-005/0789,WO2022175674-A1   25 Aug 2022   C12N-005/0789   202275Pages: 63   English,WO2022175674-A1    WOGB050445    18 Feb 2022,,GR100108    19 Feb 2021;  GB002758    26 Feb 2021,WO2022175674-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2022175674-A1 -- WO2019126774-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI)   ZHANG F,  ZETSCHE B,  STRECKER J;  WO2019222212-A1   THEMBA INC (THEM-Non-standard)   RABINOWITZ M;  US20180073012-A1   ;  WO2017068379-A1   UNIV OXFORD INNOVATION LTD (UYOX)   HUGHES J R,  DAVIES J;  WO2020161485-A1   UNIV OXFORD INNOVATION LTD (UYOX)   DAVIES J,  HUGHES J","WO2022175674-A1  LI ZHI ET AL: ""Two          common disease-associated TYK2 variants impact exon          splicing and TYK2 dosage"", PLOS ONE, vol. 15, no. 1, 21          January 2020 (2020-01-21), pages 1 - 20, XP055904054,          DOI:          10.1371/journal.pone.0225289,relevantClaims[1-25],relevantPassages[&lt;para&gt;last&lt;/para&gt;];  DENDROU CALLIOPE A          ET AL: ""Resolving TYK2 locus genotype-to-phenotype          differences in autoimmunity"", SCIENCE TRANSLATIONAL          MEDICINE, vol. 8, no. 363, 2 November 2016 (2016-11-02),          pages 1 - 15, XP055904051, DOI:          10.1126/scitranslmed.aag1974,relevantClaims[1-25],relevantPassages[&lt;pp&gt;5&lt;/pp&gt;&lt;column&gt;1&lt;/column&gt;&lt;para&gt;last&lt;/para&gt;&lt;figure&gt;1,2&lt;/figure&gt;];  WU PEILIN ET AL: ""A          TYK2 Gene Mutation c.2395G&gt;A Leads to TYK2          Deficiency: A Case Report and Literature Review"",          FRONTIERS IN PEDIATRICS, vol. 8, 1 January 2020          (2020-01-01), pages 253, XP055923755, Retrieved from the          Internet          &lt;URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267021/pdf/fped-08-00253.pdf&gt;          DOI:          10.3389/fped.2020.00253,relevantClaims[1-25],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            DENDROU ET AL., SCI. TRANS!. MED., vol. 8, no. 363,          2016;            CORTES ET AL., NAT. GENET, vol. 49, no. 1311,          2017;            CORTES ET AL., NAT. GENET., vol. 52, no. 126,          2020;            SCHWARTZ DM ET AL.: ""Type 1/11 cytokines, JAKs, and new          strategies for treating autoimmune diseases"", NAT. REV.          RHEUMATOL., vol. 12, 2016, pages 25 - 36, XP055272570,          DOI: 10.1038/nrrheum.2015.167;            GREEN, MRSAMBROOK, J.: ""Molecular Cloning: A Laboratory          Manual"", 2014;            KOMOR ET AL.: ""CRISPR-Based Technologies for the          Manipulation of Eukaryotic Genomes"", CELL, 2017,          Retrieved from the Internet          &lt;URL:http://dx.doi.Org/10.1016/j.cell.2016.10.044&gt;;            PINERA, NATURE METHODS, vol. 10, no. 10, 2013, pages 973          - 976;            CONG ET AL., SCIENCE, vol. 339, 2013, pages 819 -          823;            KOMOR, A. C., KIM, Y. B., PACKER, M. S., ZURIS, J. A.,          LIU, D. R.: ""Programmable editing of a target base in          genomic DNA without double-stranded DNA cleavage"",          NATURE, vol. 533, 2016, pages 420 - 424, XP055551781,          DOI: 10.1038/nature17946;            BRYSON, D. I.LIU, D. R.: ""Programmable base editing of          A.T to G.C in genomic DNA without DNA cleavage"", NATURE,          vol. 551, 2017, pages 464 - 471, XP037336615, DOI:          10.1038/nature24644;            HU, J. H., MILLER, S. M., GEURTS, M. H., TANG, W. X.,          CHEN, L. W., SUN, N., ZEINA, C. M., GAO, X., REES, H. A.,          LIN, Z., LIU, D. R: ""Evolved Cas9 variants with broad PAM          compatibility and high DNA specificity"", NATURE, vol.          556, 2018, pages 57;            PAIRO-CASTINEIRA ET AL., NATURE, 2020;            KOBLAN, L. W., DOMAN, J. L., WILSON, C., LEVY, J. M.,          TAY, T., NEWBY, G. A., MAIANTI, J. P., RAGURAM, A., LIU,          D. R.: ""Improving cytidine and adenine base editors by          expression optimization and ancestral reconstruction"",          NAT BIOTECHNOL., 2018;            KOMOR, A. C., ZHAO, K. T., PACKER, M. S., GAUDELLI, N.          M., WATERBURY, A. L., KOBLAN, L. W., KIM, Y. B., BADRAN,          A. H., LIU, D. R.: ""Improved base excision repair          inhibition and bacteriophage Mu Gam protein yields          C:G-to-T:A base editors with higher efficiency and          product purity"", SCI ADV, vol. 3, 2017, XP055453964, DOI:          10.1126/sciadv.aao4774;            NISHIDA, K., ARAZOE, T., YACHIE, N., BANNO, S., KAKIMOTO,          M., TABATA, M., MOCHIZUKI, M., MIYABE, A., ARAKI, M.,          HARA, K. Y., SHIMA: ""Targeted nucleotide editing using          hybrid prokaryotic and vertebrate adaptive immune          systems"", SCIENCE, vol. 353, 2016, XP055482712, DOI:          10.1126/science.aaf8729;            DIOGO ET AL., PLOS ONE, vol. 10, 2015, pages          e0122271",200757-0-0-0 K P,,,RA00GT K P,
WO2022173770-A1;  EP4291643-A1;  US2024191281-A1,"Non-naturally occurring composition useful in            system for detecting target nucleic acid and altering            the sequence of a nucleic acid, comprises programmable            nuclease comprising specified amino acid sequence and            engineered guide nucleic acid",RAUCH B J;  DELOUGHERY A;  DRORY RETWITZER M;  PAEZ-ESPINO D;  TRECAZZI C;  HARRINGTON L B;  CHEN J S;  BROUGHTON J P;  RHINES C O;  WRIGHT W D;  VEROSLOFF M;  HENDRIKS C G;  DRORY R M,MAMMOTH BIOSCIENCES INC (MAMM-Non-standard);  MAMMOTH BIOSCIENCES INC (MAMM-Non-standard);  MAMMOTH BIOSCIENCES INC (MAMM-Non-standard),2022A6607M,"   NOVELTY - Non-naturally occurring composition (C1)                comprises a programmable nuclease and an engineered                guide nucleic acid, where the programmable nuclease                comprises an amino acid sequence that is at least                75% identical to any one of SEQ ID NOs: 1-27                (comprising fully defined sequence of 779-1238                amino acids as given in the specification).    USE - The composition is useful in a system for                detecting a target nucleic acid, altering the                sequence of a nucleic acid, introducing a break in                a target nucleic acid and in programmable nuclease                and in a plant cell or plant cell lysate.    ADVANTAGE - The composition utilizes the type VI clustered                regularly interspaced short palindromic repeats/Cas                nucleases that are able to bind to a target nucleic                acid, thus activating trans-collateral nuclease                activity on nucleic acid reports and modifies RNA                sequences using the programmable nucleases.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    a system for detecting a target nucleic acid                comprising the composition (C1) and at least one of                a buffering agent, a salt, a crowding agent, a                detergent, a reducing agent, a competitor, and a                reporter nucleic acid;    a composition (C2) comprising the composition,                and diluent or excipient;    altering (M1) the sequence of a nucleic acid                comprising contacting a target nucleic acid                molecule with the composition or the system;    introducing (M2) a break in a target nucleic                acid, comprising contacting a target nucleic acid                molecule with the composition or the system;    detecting (M3) a target nucleic acid in a                sample, comprising contacting a target nucleic acid                with the composition or the system;    a system or device for detecting a target                nucleic acid in a sample;    a programmable nuclease comprising the                sequence with at least 75% sequence identity to SEQ                ID NOs: 1-27 which binds to an engineered guide                nucleic acid, and the engineered guide nucleic acid                comprises a sequence with at least 75% sequence                identity to SEQ ID NOs: 28-32 (comprising fully                defined sequence of 36-37 amino acids as given in                the specification);    a system for modifying a target nucleic acid                comprising (i) the programmable nuclease and (ii)                the engineered guide nucleic acid;    detecting (M4) a nucleic acid in a sample,                comprising (i) contacting a sample with (a) the                programmable nuclease, (b) the reporter and (c) an                engineered guide nucleic acid, (ii) measuring a                detectable signal produced by cleavage of the                reporter, where the measuring provides detection of                the target nucleic acid in the sample;    altering (M5) the sequence of a nucleic acid,                comprising (i) contacting a nucleic acid molecule                with (a) the programmable nuclease and (b) the                engineered guide nucleic acid;    introducing (M6) a break in a target nucleic                acid, comprising (i) contacting the target nucleic                acid with (a) an engineered guide nucleic acid and                (b) the programmable nuclease;    a recombinant nucleic acid encoding a                programmable nuclease comprising an amino acid                sequence that at least 75% identical to any one of                SEQ ID NOs: 1-27;    a vector comprising the recombinant nucleic                acid;    a non-naturally occurring host cell comprising                the recombinant nucleic acid or the vector;    producing (M6) the programmable nuclease                comprising (a) culturing the non-naturally                occurring host cell under a condition suitable for                production of the programmable nuclease; and    producing (M7) a programmable nuclease using a                host cell comprising (a) introducing into the host                cell the recombinant nucleic acid or the vector and                (b) culturing the host cell under a condition                suitable for production of the programmable                nuclease. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)",B04-B04B1;  B04-B04D4;  B04-B04D5;  B04-B04G;  B04-C01G;  B04-E01;  B04-E02E;  B04-E05;  B04-E08;  B04-E13;  B04-E99;  B04-F0100E;  B04-F0200E;  B04-F0800E;  B04-F0900E;  B04-F1000E;  B04-L05A;  B05-A01A;  B05-A01B;  B05-B02A3;  B05-C07;  B11-C08E3;  B11-C08F8;  B12-K04F;  C04-B04B1;  C04-B04D4;  C04-B04D5;  C04-B04G;  C04-C01G;  C04-E01;  C04-E05;  C04-E08;  C04-E13;  C04-E99;  C04-F0100E;  C04-F0200E;  C04-F0800E;  C04-F0900E;  C04-F1000E;  C04-L05A;  C11-C08E3;  C11-C08F8;  C12-K04F;  D05-A02C;  D05-H09;  D05-H19C;  D05-H99;  S03-E09F;  S03-E14H3,C12N-015/113;  C12N-009/22;  C12Q-001/44;  C12Q-001/6809;  C12N-015/11;  C12Q-001/6823,WO2022173770-A1   18 Aug 2022   C12N-009/22   202278Pages: 274   English;  EP4291643-A1   20 Dec 2023   C12N-009/22   202302   English;  US2024191281-A1   13 Jun 2024   C12Q-001/6823   202449   English,WO2022173770-A1    WOUS015709    08 Feb 2022;   EP4291643-A1    EP753225    08 Feb 2022;   US2024191281-A1    US364359    02 Aug 2023,EP4291643-A1 PCT application Application WOUS015709;   EP4291643-A1 Based on Patent WO2022173770;   US2024191281-A1 Cont of Application WOUS015709;   US2024191281-A1 Provisional Application US209900P;   US2024191281-A1 Provisional Application US147686P;   US2024191281-A1 Provisional Application US147685P;   US2024191281-A1 Provisional Application US147684P;   US2024191281-A1 Provisional Application US147683P,US147683P    09 Feb 2021;  US147684P    09 Feb 2021;  US147685P    09 Feb 2021;  US147686P    09 Feb 2021;  US209900P    11 Jun 2021;  US364359    02 Aug 2023,WO2022173770-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP4291643-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    ,,"WO2022173770-A1 -- US20190309357-A1   ;  US20200399697-A1   ;  WO2019051318-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ZHANG F,  GOOTENBERG J,  ABUDAYYEH O;  WO2021055874-A1   BROAD INST INC (BROD);  MASSACHUSETTS TECHNOLOGY INST (MASI)   ZHANG F,  ALTAE-TRAN H,  KANNAN S",,2418795-0-0-0 K M; 89847-0-0-0 K M; 107360-0-0-0 K M; 104541-0-0-0 K M; 100006-0-0-0 K M; 114-0-0-0 K M; 130323-0-0-0 K M; 2418795-0-0-0 CL USE,,,RBAAY7 K M; RA014O K M; RBXOV1 K M; RA08AV K M; RBXLO8 K M; RBXSZD K M; RBXUUF K M; R01706 K M; RBZ0WT K M,1706-S
WO2023186816-A1,"Use of 5-methoxy-N,N-dimethyltryptamine to treat            patient suffering from anxiety e.g. subthreshold            anxiety, mental or nervous system disorder, and            depressive episodes",TERWEY T;  BURKE C;  GAFFNEY N,GH RES IRELAND LTD (GHRE-Non-standard),2023A3931T,"   NOVELTY - Use of 5-methoxy-N,N-dimethyltryptamine                (5-MeO-DMT) or its salt in treating a patient                suffering from anxiety.    USE - The 5-MeO-DMT or its salt is useful in                treating a patient suffering from anxiety, where                the anxiety the patient is suffering from is a                subthreshold anxiety, the patient has a comorbidity                of anxiety and a further diagnosed disorder, the                patient is also suffering from a mental or nervous                system disorder, mental or nervous system disorder                suffers from a treatment resistant form of the                disorder, disorder characterized by depressive                episodes, disorder characterized by depressive                episodes, major depressive disorder (MDD),                postpartum depression (PPD) suffers from a                treatment resistant form of the disorder, the                patient suffers in addition from compromised                maternal functioning, the patient has a Barkin                Index of Maternal Functioning (BIMF) score of less                than 80, e.g. 65, persistent depressive disorder,                seasonal affective disorder, bipolar disorder,                bipolar II disorder, bipolar I disorder, current                major depressive episode, anxiety, separation                anxiety disorder, agoraphobia, generalized anxiety                disorder (GAD), social anxiety disorder (SAD),                panic disorder, phobia, substance/medication                induced anxiety disorder, somatic symptom disorder,                obsessive compulsive or related disorder including                obsessive compulsive disorder (OCD), body                dysmorphic disorder (BDD), post-traumatic stress                disorder (PTSD), pain disorder, chronic pain,                fibromyalgia, migraine, mental and behavioural                disorder due to psychoactive substance use,                substance use disorder (SUD), psychotic disorder,                schizophrenia, Parkinson's disease, dementia,                Alzheimer's dementia, Parkinson's disease dementia,                dementia with Lewy Bodies, vascular dementia,                fronto-temporal dementia, eating disorder,                attention deficit hyperactivity disorder (ADHD),                personality disorder, schizotypal personality                disorder, borderline personality disorder (BPD),                chronic fatigue syndrome, autism spectrum disorder,                traumatic brain injury and also from the anxiety,                HIV infection and also from the anxiety, post COVID                condition and also from the anxiety, and sleep                disturbance including insomnia suffers from a                treatment resistant form of the disorder (all                claimed). Test details are described but no results                given.    ADVANTAGE - The 5-MeO-DMT provides treatment improves                maternal functioning, where the improvement in                maternal functioning is reflected by an improvement                of the BIMF total score by &#8805; 10%,                preferably &#8805; 20%, the improvement in                maternal functioning, is reflected by at least an                improvement in the BIMF total score on day 7, on                day 14 and/or on day 28 after the last                administration of 5-MeO-DMT or its salt, the                improvement in maternal functioning, as reflected                by at least an improvement in the BIMF total score,                occurs not later than about 6 days after the last                administration of 5-MeO-DMT or its salt and the                improvement in maternal functioning, as reflected                by at least an improvement in the BIMF total score,                persists until at least 14 days after the last                administration of 5-MeO-DMT or its salt, more                preferably until at least 28 days after the last                administration of 5-MeO-DMT or its salt; reduces or                eliminates the anxiety, where the reduction or                elimination of the anxiety is observed 2 hours                after the last administration of 5-MeO-DMT or its                salt, on day 1 , for instance after 24 hours, on                day 7, on day 14 and/or on day 28 after the last                administration of 5-MeO-DMT or its salt, the                reduction or elimination of the anxiety occurs not                less than 2 hours after the last administration of                5-MeO-DMT or its salt, and the reduction or                elimination of the anxiety persists until at least                6 days after the last administration of 5-MeO-DMT                or its salt, in particular until at least 14 days,                more preferably until at least 28 days after the                last administration of 5-MeO-DMT or its salt, leads                to an improvement in the diagnosed disorder in a                patient also suffering from anxiety, where the                improvement in the diagnosed disorder in a patient                also suffering from anxiety, as reflected by a                reduction in the Clinical Global                Impression-Severity (CGI-S) score, is observed 2                hours after the last administration of 5-MeO-DMT or                its salt, on day 1 , for instance after 24 hours,                on day 7, on day 14 and/or on day 28 after the last                administration of 5-MeO-DMT or its salt, the                improvement in the diagnosed disorder in a patient                also suffering from anxiety, as reflected by a                reduction in the Clinical Global                Impression-Severity (CGI-S) score, occurs not less                than 2 hours after the last administration of                5-MeO-DMT or its salt and the improvement in the                diagnosed disorder in a patient also suffering from                anxiety, as reflected by a reduction in the                Clinical Global Impression-Severity (CGI-S) score,                persists until at least 6 days after the last                administration of 5-MeO-DMT or its salt, in                particular until at least 14 days, more preferably                until at least 28 days after the last                administration of 5-MeO-DMT or its salt; leads to                an improvement in anxiety and sleep disturbance and                furthermore to an improvement in the associated                mental or the nervous system disorder or the                medical health condition leading to an associated                mental or nervous system condition, improvement in                the sleep disturbance, where the improvement in the                sleep disturbance, as reflected by a reduction in                the Clinical Global Impression-Severity (CGI-S)                score, is observed on day 1 , for instance after 24                hours, on day 7, on day 14; and/or on day 28 after                the last administration of 5-MeO-DMT or its salt,                and the improvement in the sleep disturbance, as                reflected by a reduction in the Clinical Global                Impression-Severity (CGI-S) score, is observed on                day 7 after the last administration of 5-MeO-DMT or                its salt and preferably persists until at least 28                days; reduces or eliminates patient suffers from                suicial ideation where the occurrence of a peak                psychedelic experience is identified through                achievement of at least 60% of the maximum possible                score in each of the four subscales (mystical,                positive mood, transcendence of time and space, and                ineffability) of the 30-item revised Mystical                Experience Questionnaire (MEQ30) or is identified                through achievement of at least 60% of the maximum                possible score of the Oceanic Boundlessness (OBN)                dimension of the Altered States of Consciousness                (ASC) questionnaire or is identified through                achievement of a Peak Experience Scale (PES) Total                Score of at least 75 and the occurrence of a peak                psychedelic experience is identified through                achievement of a Peak Experience Scale (PES) Total                Score of at least 75. ",,,B02 (Fused ring heterocyclics.),B06-D01;  B12-M01A;  B12-M12Z;  B14-A02B1;  B14-A02B5;  B14-C01;  B14-E11;  B14-E12;  B14-F02C;  B14-J01;  B14-J05;  B14-N16;  B14-N17B,A61K-031/4045;  A61P-025/00;  A61P-025/24,WO2023186816-A1   05 Oct 2023   A61K-031/4045   202384Pages: 273   English,WO2023186816-A1    WOEP057857    27 Mar 2023,,EP000083    27 Mar 2022;  EP000086    27 Mar 2022;  EP153939    30 Jan 2023;  EP153995    30 Jan 2023,WO2023186816-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2023186816-A1 -- WO2019081764-A1   CONSEJO SUPERIOR INVESTIGACIONES CIENTIF (CNSJ);  UNIV MADRID AUTONOMA (UMAD);  BLUMENTECH SL (BLUM-Non-standard);  CENT INVESTIGACION BIOMEDICA RED ENFERME (INVE);  FUNDACIO PRIVADA I INST RECERCA LHOSPITA (PRIV-Non-standard)   PEREZ CASTILLO A M,  RIBA SERRANO J,  MORALES GARCIA J A;  WO2020169851-A1   GH RES LTD (GHRE-Non-standard)   TERWEY T;  EP933093-B1   STORZ M (STOR-Individual);  EP1884254-B1   VAPORMED GMBH & CO KG (VAPO-Non-standard)   STORZ M;  US7458374-B2   HALE R L (HALE-Individual);  SONG S (SONG-Individual);  QUINTANA R J (QUIN-Individual)   HALE R L,  SONG S,  QUINTANA R J;  US9370629-B2   ALEXZA PHARM INC (ALEX-Non-standard)   DAMANI R,  HALE R L,  MYERS D J,  QUINTANA R J,  SOLAS D W,  SONG S,  SONI P,  TOM C,  SHARMA K;  US9687487-B2   ALEXZA MOLECULAR DELIVERY CORP (ALEX-Non-standard)   HALE R L,  HODGES C C,  LLOYD P M,  MUFSON D,  ROGERS D D,  SONG S,  WENSLEY M J,  MYERS D J,  MCKINNEY J A,  QUINTANA R J,  RABINOWITZ J D;  WO2020169850-A1   GH RES IRELAND LTD (GHRE-Non-standard)   TERWEY T","WO2023186816-A1  ALAN K DAVIS ET AL:          ""The epidemiology of 5-methoxy- N, N -dimethyltryptamine          (5-MeO-DMT) use: Benefits, consequences, patterns of use,          subjective effects, and reasons for consumption"", JOURNAL          OF PSYCHOPHARMACOLOGY., vol. 32, no. 7, 30 April 2018          (2018-04-30), GB, pages 779 - 792, XP055695664, ISSN:          0269-8811, DOI:          10.1177/0269881118769063,relevantClaims[1,110,114|1-114|1,2,110,114],relevantPassages[&lt;table&gt;6&lt;/table&gt;];  ALAN K. DAVIS ET          AL: ""5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT) used          in a naturalistic group setting is associated with          unintended improvements in depression and anxiety"",          AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, vol. 45, no.          2, 1 March 2019 (2019-03-01), US, pages 161 - 169,          XP055695498, ISSN: 0095-2990, DOI:          10.1080/00952990.2018.1545024,relevantClaims[1,110,114|1-114|1,110,114],relevantPassages[&lt;table&gt;1&lt;/table&gt;the          whole document];  UTHAUG MALIN V. ET          AL: ""A comparison of reactivation experiences following          vaporization and intramuscular injection (IM) of          synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in          a naturalistic setting"", JOURNAL OF PSYCHEDELIC STUDIES,          vol. 4, no. 2, 1 June 2020 (2020-06-01), pages 104 - 113,          XP093055117, DOI:          10.1556/2054.2020.00123,relevantClaims[1-114],relevantPassages[discussion];            BUSNER, JTAGRUM, S. D: ""The Clinical Global Impressions          Scale: Applying a Research Tool in Clinical Practice"",          PSYCHIATRY, 2007, pages 29 - 37;            OVERALL, J. EGORHAM, D. R: ""The brief psychiatric rating          scale"", PSYCHOLOGICAL REPORTS, vol. 10, 1962, pages          799;            OVERALL, J. E., GORHAM, D. R: ""The Brief Psychiatric          Rating Scale (BPRS): recent developments in ascertainment          and scaling"", PSYCHOPHARMACOLOGY BULLETIN, vol. 22, 1998,          pages 97;            POSNER, KBROWN, G. KSTANLEY, BBRENT, D. A.YERSHOVA, K.          VOQUENDO, M. ACURRIER, G. WMELVIN, G. AGREENHILL, LSHEN,          S: ""The Columbia-Suicide Severity Rating Scale: Initial          Validity and Internal Consistency Findings From Three          Multisite Studies With Adolescents and Adults"", AMERICAN          JOURNAL OF PSYCHIATRY, vol. 168, no. 12, 2011, pages 1266          - 77;            LAKE, C. RSTIRBA, A. LKINNEMAN, R. E. JRCARLSON,          BHOLLOWAY, H. C: ""Mania associated with LSD ingestion"",          AMERICAN JOURNAL OF PSYCHIATRY, vol. 138, no. 11, 1981,          pages 1508 - 9;            HENDIN, H.MPENN, A. D: ""An episode of mania following          self-reported ingestion of psilocybin mushrooms in a          woman previously not diagnosed with bipolar disorder: A          case report"", BIPOLAR DISORDERS, vol. 23, no. 4, 2021,          pages 1 - 3;            SZMULEWICZ, A. GVALERIO, M. PJOSE MSMITH, J. M: ""Switch          to mania after ayahuasca consumption in a man with          bipolar disorder: a case report"", INTERNATIONAL JOURNAL          OF BIPOLAR DISORDERS, vol. 3, 2015, pages 4;            BROWN, TSHAO, WAYUB, SCHONG, DCORNELIUS, C: ""A          Physician's attempt to self-medicate bipolar depression          with N, N-dimethyl-tryptamine (DMT"", JOURNAL OF          PSYCHOACTIVE DRUGS, vol. 49, no. 4, 2017, pages 294 -          296;            BADER, CYNTHIA DDAVID L. DUNNER: ""Antidepressant-induced          hypomania in treatment-resistant depression"", JOURNAL OF          PSYCHIATRIC PRACTICE, vol. 13, no. 4, 2007, pages 233 -          237;            BARRETT FS, J PSYCHOPHARMACOL, vol. 29, no. 11, 2015,          pages 1182 - 90;            ""Springer Science+Business Media"", 2012, article ""STOP,          THAT and One Hundred Other Sleep Scales"";            SPOORMAKER ET AL.: ""Initial validation of the SLEEP-50          questionnaire"", BEHAV SLEEP MED, vol. 3, no. 4, 2005,          pages 227 - 46;            BUYSSE ET AL.: ""The Pittsburgh Sleep Quality Index: a new          instrument for psychiatric practice and research"",          PSYCHIATRY RES, vol. 28, no. 2, May 1989 (1989-05-01),          pages 193 - 213, XP001020700, DOI:          10.1016/0165-1781(89)90047-4;            ARNULF ET AL.: ""A scale for assessing the severity of          arousal disorders"", SLEEP, vol. 37, no. 1, 1 January 2014          (2014-01-01), pages 127 - 36",100670-0-0-0 K U,,,R10866 K U,
CN116496334-A,"New 3,4-dihydropyrimidin-2(1H)-one-based compound            useful in e.g. medicinal composition for preparing            medicines for treating coronavirus disease, Middle East            respiratory syndrome, severe acute respiratory            syndrome, human immunodeficiency virus, hepatitis C            virus, flavivirus, and Ebola virus",XU Y;  CHEN Z;  YU H;  ZHAO B;  ZHANG M,ABBISKO THERAPEUTICS CO LTD (ABBI-Non-standard),202382337D,"   NOVELTY - 3,4-Dihydropyrimidin-2(1H)-one-based compound                (I) and its stereoisomers, tautomers or medicinally                acceptable salts are new.    USE - (I) are useful: in medicinal composition for                preparing medicines for treating coronavirus                disease (COVID-19), Middle East respiratory                syndrome, severe acute respiratory syndrome, human                immunodeficiency virus, hepatitis C virus,                flavivirus, pestivirus, equine encephalitis virus,                Filoviridae virus, Ebola virus, respiratory                syncytial virus and influenza-related viral                infections (all claimed); and as antiviral                inhibitor.    DETAILED DESCRIPTION - 3,4-Dihydropyrimidin-2(1H)-one-based compound                of formula (I) and its stereoisomers, tautomers or                medicinally acceptable salts are new.    either R1= -C(O)Ra, or -C(O)-L-C(O)-Rb;                or    R1and R5or R6together with directly connected                parts = phosphorus-containing moiety of formula                (b); or    R5-R8 = 1-10C alkyl, 2-10C alkenyl, 2-10C                alkynyl, 3-12C cycloalkyl, 3-12C heterocyclyl (all                optionally substituted with 1-10C alkyl (optionally                substituted with halo, or D), D, halo, CN, nitro,                azide, 2-10C alkenyl, 2-10C alkynyl, 3-12C                cycloalkyl, 3-12C heterocyclyl, 6-10C aryl, 5-10C                heteroaryl, =O, =S, 0-8C alkyl-SF5, 0-8C                alkyl-S(O)(=N-R12)R13, 0-8C alkyl-N=S(O)R13R14,                0-8C alkyl-N=SR13R14, 0-8C alkyl-O-S(O)2R15, 0-8C                alkyl-S(O)rR15, 0-8C alkyl-P(O)(OR16)R15, 0-8C                alkyl-O-R16, 0-8C alkyl-C(O)OR16, 0-8C                alkyl-C(O)SR16, 0-8C alkyl-S-C(O)R17, 0-8C                alkyl-C(O)R17, 0-8C alkyl-O-C(O)R17, 0-8C                alkyl-NR18R19, 0-8C alkyl-C(=NR18)R17, 0-8C                alkyl-N(R18)-C(=NR19)R17, 0-8C alkyl-C(O)NR18R19or                0-8C alkyl-N(R18)-C(O)R17), H, D, halo, CN, azido,                O-S(O)2R15, S(O)rR15, O-P(O)(OR16)R15, O-R16,                S-C(O)R17or O-C(O)R17;    Rb= tetrahydrofuran-based moiety of formula                (a), (propane-1,3-diyl dipalmitate)-2-yl, or                O-((2R,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-5-methylhexan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-2-yl)hydroxy;    Rc= 1-10C alkyl, 3-12C cycloalkyl, 3-12C                heterocyclyl, 6-10C aryl or 5-10C heteroaryl (all                optionally substituted with 1-10C alkyl (optionally                substituted with halo, or D), D, halo, CN, nitro,                azido, 2-10C alkenyl, 2-10C alkynyl, 3-12C                cycloalkyl, 3-12C heterocyclyl, 6-10C aryl, 5-10C                heteroaryl, =O, =S, 0-8C alkyl-SF5, 0-8C                alkyl-S(O)(=N-R12)R13, 0-8C alkyl-N=S(O)R13R14,                0-8C alkyl-N=SR13R14, 0-8C alkyl-O-S(O)2R15, 0-8C                alkyl-S(O)rR15, 0-8C alkyl-P(O)(OR16)R15, 0-8C                alkyl-O-R16, 0-8C alkyl-C(O)OR16, 0-8C                alkyl-C(O)SR16, 0-8C alkyl-S-C(O)R17, 0-8C                alkyl-C(O)R17, 0-8C alkyl-O-C(O)R17, 0-8C                alkyl-NR18R19, 0-8C alkyl-C(=NR18)R17, 0-8C                alkyl-N(R18)-C(=NR19)R17, 0-8C alkyl-C(O)NR18R19or                0-8C alkyl-N(R18)-C(O)R17);    R2-R4, R9and R10= 1-10C alkyl (optionally                substituted with halo, or D), H, D, halo, CN,                nitro, azido, 2-10C alkenyl, 2-10C alkynyl, 3-12C                cycloalkyl, 3-12C heterocyclyl, 6-10C aryl, 5-10C                heteroaryl, 0-8C alkyl-SF5, 0-8C                alkyl-S(O)(=N-R12)R13, 0-8C alkyl-N=S(O)R13R14,                0-8C alkyl-N=SR13R14, 0-8C alkyl-O-S(O)2R15, 0-8C                alkyl-S(O)rR15, 0-8C alkyl-P(O)(OR16)R15, 0-8C                alkyl-O-R16, 0-8C alkyl-C(O)OR16, 0-8C                alkyl-C(O)SR16, 0-8C alkyl-S-C(O)R17, 0-8C                alkyl-C(O)R17, 0-8C alkyl-O-C(O)R17, 0-8C                alkyl-NR18R19, 0-8C alkyl-C(=NR18)R17, 0-8C                alkyl-N(R18)-C(=NR19)R17, 0-8C alkyl-C(O)NR18R19 or                0-8C alkyl-N(R18)-C(O)R17; and    R11= 1-10C alkyl, 2-10C alkenyl, 3-12C                cycloalkyl, 3-12C heterocyclyl, 6-10C aryl, 5-10C                heteroaryl (all optionally substituted with 1-10C                alkyl, 2-10C alkenyl, 2-10C alkynyl, 3-12C                cycloalkyl, 3-12C heterocyclyl, 6-10C aryl, 5-10C                heteroaryl, 0-8C alkyl-SF5, 0-8C                alkyl-S(O)(=N-R12)R13, 0-8C alkyl-N=S(O)R13R14,                0-8C alkyl-N=SR13R14, 0-8C alkyl-O-S(O)2R15, 0-8C                alkyl-S(O)rR15, 0-8C alkyl-P(O)(OR16)R15, 0-8C                alkyl-O-R16, 0-8C alkyl-C(O)OR16, 0-8C                alkyl-C(O)SR16, 0-8C alkyl-S-C(O)R17, 0-8C                alkyl-C(O)R17, 0-8C alkyl-O-C(O)R17, 0-8C                alkyl-NR18R19, 0-8C alkyl-C(=NR18)R17, 0-8C                alkyl-N(R18)-C(=NR19)R17, 0-8C alkyl-C(O)NR18R19,                0-8C alkyl-N(R18)-C(O)R17(all optionally                substituted with 1-10C alkyl (optionally                substituted with halo, or D), D, halo, CN, nitro,                azide, 2-10C alkenyl, 2-10C alkynyl, 3-12C                cycloalkyl, 3-12C heterocyclyl, 6-10C aryl, 5-10C                heteroaryl, =O, =S, 0-8C alkyl-SF5, 0-8C                alkyl-S(O)(=N-R12)R13, 0-8C alkyl-N=S(O)R13R14,                0-8C alkyl-N=SR13R14, 0-8C alkyl-O-S(O)2R15, 0-8C                alkyl-S(O)rR15, 0-8C alkyl-P(O)(OR16)R15, 0-8C                alkyl-O-R16, 0-8C alkyl-C(O)OR16, 0-8C                alkyl-C(O)SR16, 0-8C alkyl-S-C(O)R17, 0-8C                alkyl-C(O)R17, 0-8C alkyl-O-C(O)R17, 0-8C                alkyl-NR18R19, 0-8C alkyl-C(=NR18)R17, 0-8C                alkyl-N(R18)-C(=NR19)R17, 0-8C alkyl-C(O)NR18R19or                0-8C alkyl-N(R18)-C(O)R17), D, halo, CN, nitro,                azido, =O, or =S), H, D, C(O)OR17, C(O)R18or                C(O)NR18R19.    Provided that: R11is not hydrogen when Rais                isopropyl.    Full definitions are given in the DEFINITIONS                (Full Definitions) Field.     ",,,"C02 (Heterocyclic.);  C01 (Organophosphorus; organometallic - i.e. compounds containing other than H, C, N, O, S and halogen.);  B03 (Other heterocyclics.)",C04-B03E;  C04-B03D;  C14-K01D;  C14-A02;  B04-B03E;  B04-B03D;  B14-K01D;  B14-A02,A61K-031/7068;  A61P-031/12;  A61P-031/14;  A61P-031/16;  A61P-031/18;  A61P-031/20;  C07H-019/067;  C07H-019/11;  C07J-043/00,CN116496334-A   28 Jul 2023   C07H-019/067   202379   Chinese,CN116496334-A    CN10037650    09 Jan 2023,,CN10088564    25 Jan 2022,,,,, N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N,A002OKP01 N,,,
WO2023247937-A1,"New cyclosporine analog useful e.g. for increasing            efficiency of transduction of isolated population of            mammalian cells, transducing population of mammalian            cells and treating viral infection and Alzheimer's            disease",TOWERS G;  SELWOOD D;  THORNE L;  WARNE J;  GRAHAM B;  PINGITORE V;  DAVISON D;  MORLING K,UCL BUSINESS LTD (UNLO-C),202400014A,"   NOVELTY - A cyclosporine analog (I) or its salt, is                new.    USE - The cyclosporine analog is useful for                increasing efficiency of transduction of an                isolated population of mammalian cells, transducing                a population of mammalian cells and performing gene                therapy. The cyclosporine analog is useful for                treating pathological condition associated with                interferon-inducible transmembrane protein 3                (IFITM3) expression. The pathological condition is                chosen from a viral infection and Alzheimer's                disease. The pathological condition is a                coronavirus disease (COVID)-19. The population of                mammalian cells, human cells, hematopoietic stem                and/or progenitor cells, induced hematopoietic stem                and/or progenitor cells, and/or cells                differentiated from the hematopoietic stem and/or                progenitor cells or induced hematopoietic stem                and/or progenitor cells is useful in pharmaceutical                composition or in therapy (all claimed).    ADVANTAGE - The cyclosporine analog is easy-to-synthesise,                is utilized to enhance HIV-vector infection,                reduces vector dose required and overcomes patient                variability.    DETAILED DESCRIPTION - A cyclosporine analog of formula (I) or its                salt, is new.    R =H, 1-4C alkyl, or 2-4C alkenyl;    R =group of formula (a1) or (a2);    R =ethyl or isopropyl;    R =methyl or ethyl;    R =-CH CH(CH ) , -CH CH(CH )CH CH , -CH(CH )CH                , or -CH(CH )CH CH ;    R =H or moiety that is 1-20C alkyl, 2-20C                alkenyl or 2-20C alkynyl, optionally substituted                with substituents chosen from halo and sulfonic                acid, in which (a) 0-3 carbon atoms are replaced by                groups chosen from 6-10C aryl, 5-10-membered                heteroaryl, 3-7C carbocyclyl and 5-10-membered                heterocyclyl, and (b) up to half of -CH - are                replaced by groups chosen from -O-, -S-, -C(O)- and                -N(1-6C alkyl)-, aryl, heteroaryl, carbocyclyl and                heterocyclyl are optionally substituted with                substituents A , and 0-2 carbon atoms in                carbocyclyl and heterocyclyl are replaced by                -C(O)-;    A =halo, 1-6C alkyl, 1-6C haloalkyl, 1-6C                alkoxy, -(1-6C alkyl) C(O)O(1-6C alkyl), -(1-6C                alkyl) OC(O)(1-6C alkyl), 1-6C alkylthio, -N(R') ,                -CN, -S(O) NH , nitro, or sulfonic acid                group;    n=0 or 1;    R'=H or 1-6C alkyl;    ring A=6-10C arylene or 5-10-membered                heteroaryl;    R'c=moiety chosen from -C(O)O-, -OC(O)-,                -C(O)N(R')-, -N(R')C(O)-, -S(O) N(R')-, -N(R')S(O)                -, -N(R')-C(O)-N(R')-, -N(R')-C(S)-N(R')-, -C(O)CH                -, -CH C(O)-, -C(CF )N(R')-, -N(R')C(CF )-,                -C(O)NF-, -NFC(O)-, -C(CN)=N-O-, -O-N=C(CN)-,                -N(R')C(O)O-, -OC(O)N(R')-, phenyl, 5-6-membered                heteroaryl, 5-6C carbocyclyl and 5-6-membered                heterocyclyl;    R =1-6C alkyl, 2-6C alkenyl or 2-6C                alkynyl;    R ,R =1-6C alkyl, 2-6C alkenyl or 2-6C                alkynyl;    -R'c-R -N(R )(R )=group of formula (a3);    R =-C(O)-, -S(O) -, -N(R')-C(O)-,                -N(R')-C(S)-, -C(CF )-, or -OC(O)-;    ring B'=5-10 membered heterocyclyl;    R ,R =alkyl;and    R =1-6C alkyl, 2-6C alkenyl or 2-6C alkynyl,                optionally substituted with substituents chosen                from halo, sulfonic acid group and hydroxy.    Full definitions are given in the DEFINITIONS                (Full Definitions) Field. INDEPENDENT CLAIMS are                included for the following:    method for transducing a population of                mammalian cells, where the mammalian cells are                human cells, and the population of mammalian cells                is chosen from human hematopoietic stem and/or                progenitor cells, induced human hematopoietic stem                and/or progenitor cells, and/or cells                differentiated from the human hematopoietic stem                and/or progenitor cells or induced human                hematopoietic stem and/or progenitor cells such as                cells chosen from a common myeloid progenitor, a                megakaryocyte, an erythroblast, a mast cell, a                myeloblast, a basophil, a neutrophil, an                eosinophil, a monocyte, a common lymphoid                progenitor, a natural killer cell, a T cell such as                an &#945; /&#946; T cell, a &#947;                &#948; T cell or a regulatory T cell, a B cell                and a plasma cell, involves (a) contacting the                population of cells with the cyclosporine analog                and (b) transducing the population of cells with a                vector derived from HIV-1, HIV-2, simian                immunodeficiency virus (SIV), feline                immunodeficiency virus (FIV), bovine                immunodeficiency virus (BIV), equine infectious                anaemia virus (EIAV), caprine                arthritis-encephalitis virus (CAEV) or Visna                lentivirus, where the steps (a) and (b) are                performed ex vivo or in vitro, the percentage of                mammalian cells, human cells, hematopoietic stem                and/or progenitor cells, induced hematopoietic stem                and/or progenitor cells, and/or cells                differentiated from the hematopoietic stem and/or                progenitor cells or induced hematopoietic stem                and/or progenitor cells transduced by the vector is                increased and/or the vector copy number per cell is                increased, the population of mammalian cells, human                cells, hematopoietic stem and/or progenitor cells,                induced hematopoietic stem and/or progenitor cells,                and/or cells differentiated from the hematopoietic                stem and/or progenitor cells or induced                hematopoietic stem and/or progenitor cells is or                has been obtained from mobilised peripheral blood,                bone marrow or umbilical cord blood and the method                further involves enriching the population for                mammalian cells, human cell, hematopoietic stem                and/or progenitor cells, induced hematopoietic stem                and/or progenitor cells, and/or cells                differentiated from the hematopoietic stem and/or                progenitor cells or induced hematopoietic stem                and/or progenitor cells;    method of gene therapy involves (a)                transducing a population of mammalian cells and (b)                administering the transduced cells to a subject,                where the transduced cells are administered to a                subject as portion of an autologous stem cell                transplant procedure or an allogeneic stem cell                transplant procedure;    population of mammalian cells, human cells,                human hematopoietic stem and/or progenitor cells,                induced human hematopoietic stem and/or progenitor                cells, and/or cells differentiated from the human                hematopoietic stem and/or progenitor cells or                induced human hematopoietic stem and/or progenitor                cells, prepared by the above-mentioned                method;    pharmaceutical composition comprising the                population of mammalian cells, human cells,                hematopoietic stem and/or progenitor cells, induced                hematopoietic stem and/or progenitor cells, and/or                cells differentiated from the hematopoietic stem                and/or progenitor cells or induced hematopoietic                stem and/or progenitor cells; and    cyclosporine derivative of formula (III) or                (IV).                 ",,,"B03 (Other heterocyclics.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E99;  B02-C01;  B04-C01C;  B04-E08;  B04-F0200E;  B04-F0400E;  B14-A02;  B14-J01A4;  B14-L06;  B14-S03A;  B14-S18;  D05-H99;  D05-H14B3,A61K-038/13;  A61K-047/54;  A61P-031/12;  C07K-007/64,WO2023247937-A1   28 Dec 2023   C07K-007/64   202404Pages: 104   English,WO2023247937-A1    WOGB051600    20 Jun 2023,,GB009098    21 Jun 2022,WO2023247937-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2023247937-A1 -- WO2016027089-A1   UCL BUSINESS PLC (UNLO)   SELWOOD D,  BAKER D,  SZABADKAI G,  DUCHEN M R,  HILL J M,  WARNE J N D;  WO2018106928-A1   CONTRAVIR PHARM INC (CONT-Non-standard)   FOSTER R T,  GALLAY P,  TREPANIER D J,  URE D R;  WO2018193118-A1   OSPEDALE SAN RAFFAELE SRL (RAFL);  FOND TELETHON (TETH)   KAJASTE-RUDNITSKI A C,  PETRILLO C,  GENTNER B R,  NALDINI L,  GENOVESE P,  SCHIROLI G;  WO2021229237-A1   UCL BUSINESS LTD (UNLO)   TOWERS G,  SELWOOD D,  THORNE L,  WARNE J;  WO2006023452-A2   HUNT K W (HUNT-Individual);  BURGESS L E (BURG-Individual)   HUNT K W,  BURGESS L E;  WO2011010084-A2   UCL BUSINESS PLC (UNLO)   SELWOOD D,  CROMPTON M;  WO1998005635-A1   ;  WO1998017815-A1   ;  WO1998007859-A2   ;  WO1998009985-A2   ;  WO2015162594-A2   OSPEDALE SAN RAFFAELE SRL (RAFL);  FOND TELETHON (TETH)   KAJASTE-RUDNITSKI A,  MONTINI E","WO2023247937-A1            PETRILLO ET AL., CELL STEMCELL, vol. 23, 2018, pages 820          - 832;  DE          WILDE ET AL., J GEN VIROL., vol. 92, 2011, pages 2542 -          2548;            CELL, vol. 126, no. 4, 2006, pages 663 - 676;            CELL, vol. 131, no. 5, 2007, pages 861 - 872;            SCIENCE, vol. 318, no. 5858, 2007, pages 1917 -          1920;            NAT BIOTECHNOL., vol. 26, no. 1, 2008, pages 101 -          106;            COFFIN, J.M. ET AL.: ""Retroviruses"", 1997, COLD SPRING          HARBOUR LABORATORY PRESS, article ""A review of these          retroviruses is presented"", pages: 758 - 63;            LEWIS, P ET AL., EMBO J., vol. 11, 1992, pages 3053 -          8;            LEWIS, P.F. ET AL., J. VIROL., vol. 68, 1994, pages 510 -          6;            NALDINI, L. ET AL., SCIENCE, vol. 272, 1996, pages 263 -          7;            NALDINI, L. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93,          1996, pages 11382 - 8;            LEAVITT, A.D. ET AL., J. VIROL., vol. 70, 1996, pages 721          - 8;            NIGHTINGALE, S.J. ET AL., MOL. THER., vol. 13, 2006,          pages 1121 - 32;            YLINEN ET AL., JOURNAL OF VIROLOGY, vol. 83, no. 4, 2009,          pages 2044 - 2047;            CARBAJO-LOZOYA ET AL., VIRUS RES., vol. 184, 2014, pages          44 - 53;            NASIRI ET AL., J DERMATOLOG TREAT., 2020, pages 1 -          6;  DE          WILDE ET AL., VIRUS RES., vol. 15, no. 228, 2017, pages 7          - 13;            WARNE, J BIOL CHEM., vol. 291, no. 9, 26 February 2016          (2016-02-26), pages 4356 - 73",200757-0-0-0 K M,230391601 M N; 230391602 M N,63917,RA00GT K M,
WO2022194652-A1;  EP4060045-A1;  CA3212320-A1;  EP4308709-A1,"New genetically engineered plant or part            comprising inactivated gene involved in transcriptional            gene silencing and/or post transcriptional gene            silencing mechanism, and nucleic acid construct, used            e.g. to produce recombinant proteins",MEZIADI C,CORE BIOGENESIS (CORE-Non-standard);  CORE BIOGENESIS (CORE-Non-standard),2022C1775P,"   NOVELTY - Genetically engineered plant or its part                adapted for the production of recombinant proteins                comprising: at least one inactivated gene involved                in the transcriptional gene silencing (TGS) and/or                post transcriptional gene silencing (PTGS)                mechanism corresponding to at least one knocked-out                gene involved in the TGS and/or PTGS mechanism,                and/or at least one nucleic acid RNA interference                (RNAi) construct targeting the RNA molecules                expressed from the gene involved in the TGS and/or                PTGS mechanism; and at least one nucleic acid                construct comprising a strong promoter coupled to a                polynucleotide sequence comprising a coding                sequence of a recombinant protein, where the coding                sequence of the recombinant protein is linked in a                reading frame to an oil body protein coding                sequence, and/or the inactivated gene involved in                the TGS and/or PTGS mechanism includes the                inactivated gene involved in the TGS mechanism and                the inactivated gene involved in the PTGS                mechanism, is new.    USE - The genetically engineered plant or part is                useful for: obtaining nucleic acid construct and                fusion protein; and producing recombinant proteins                (all claimed), where the proteins are used in                cosmetic industry, food industry or                agriculture.    ADVANTAGE - The genetically engineered plant: allows the                production of recombinant proteins with oil bodies                and recombinant proteins purified, in a manner                which is extremely inexpensive, with plants that                may allow switching to open-field production, thus                offering a route to the manufacture of recombinant                proteins; and provides greater recombinant protein                production yield.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1)                a nucleic acid construct comprising a strong                promoter coupled to a polynucleotide sequence                comprising a coding sequence of a recombinant                protein linked in a reading frame to an oil body                protein coding sequence; (2) producing a                recombinant protein in a genetically engineered                plant or its part, comprising inactivating at least                one gene involved in the TGS and/or PTGS mechanism                in a plant or its part by generating at least one                genetic alteration in the coding sequence of the                gene involved in the TGS and/or PTGS mechanism,                where the generating step is performed by using a                method comprising clustered regularly interspaced                short palindrome repeats (CRISPR)-CRISPR associated                protein 9 (CRISPR-Cas9), Transcription                activator-like effector nucleases (TALENs),                meganuclease, targeting induced local lesions in                genomes (TILLING), zinc finger nuclease, synthetic                RNAi, physical and/or chemical mutagenesis, and/or                inserting in the plant at least one nucleic acid                RNA interference construct targeting the RNA                molecules expressed from the gene involved in the                TGS and/or PTGS mechanism, inserting in the plant                at least one nucleic acid construct comprising a                strong promoter coupled to a polynucleotide                sequence comprising a coding sequence of a                recombinant protein, where the coding sequence of                the recombinant protein is linked in a reading                frame to an oil body protein coding sequence,                and/or the step of inactivating at least one gene                includes the inactivation of the gene involved in                the TGS mechanism and the gene involved in the PTGS                mechanism, where the step of inserting is performed                by using a method comprising CRISPR-Cas9, TALENs,                meganuclease, zinc finger nuclease with particle                gun transformation and Agrobacterium tumefaciens,                the step of inactivating may be performed after the                step of inserting, and optionally recovering the                recombinant protein and the oil body protein and                optionally purifying the recombinant protein                recovered; (3) obtaining a genetically engineered                plant or its part; and (4) a fusion protein                comprising a recombinant protein and an oil-body                protein produced by, or obtained from the                genetically engineered plant or its part, or the                genetically engineered plant or its part obtained                from the method, or the selected heterozygotes or                homozygotes new-grown plants. ",,,"C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).)",C04-A0800E;  C04-E02H;  C04-E13;  C04-E99;  C04-F10A;  C04-L05A2;  C04-N08;  D05-H12C;  D05-H16B;  D05-H19C;  D05-H99;  D08-B,C12N-015/82,WO2022194652-A1   22 Sep 2022   C12N-015/82   202288Pages: 33   English;  EP4060045-A1   21 Sep 2022   C12N-015/82   202288   English;  CA3212320-A1   22 Sep 2022   C12N-015/82   202387   English;  EP4308709-A1   24 Jan 2024   C12N-015/82   202408   English,WO2022194652-A1    WOEP056113    10 Mar 2022;   EP4060045-A1    EP305319    16 Mar 2021;   CA3212320-A1    CA3212320    10 Mar 2022;   EP4308709-A1    EP710414    10 Mar 2022,CA3212320-A1 PCT application Application WOEP056113;   CA3212320-A1 Based on Patent WO2022194652;   EP4308709-A1 PCT application Application WOEP056113;   EP4308709-A1 Based on Patent WO2022194652,EP305319    16 Mar 2021;  CA3212320    15 Sep 2023,WO2022194652-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP4060045-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    EP4308709-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN  ,,"WO2022194652-A1 -- US20090197337-A1   ;  US20090265811-A1   ;  EP1608761-B1   ROBERTS NOBLE FOUND INC SAMMUEL (ROBE-Non-standard)   WANG Z,  HARRISON M;  US6420547-B1   UNIV KENTUCKY RES FOUND (KENT)   MAITI I B,  DEY N,  SHEPHERD R J;  EP4060045-A1 -- US20090197337-A1   ;  US20090265811-A1   ;  EP1608761-B1   ROBERTS NOBLE FOUND INC SAMMUEL (ROBE-Non-standard)   WANG Z,  HARRISON M;  US6420547-B1   UNIV KENTUCKY RES FOUND (KENT)   MAITI I B,  DEY N,  SHEPHERD R J","WO2022194652-A1  JAUVION VINCENT ET          AL: ""RDR2 Partially Antagonizes the Production of          RDR6-Dependent siRNA in Sense Transgene-Mediated PTGS"",          vol. 7, no. 1, 5 January 2012 (2012-01-05), pages e29785,          XP055835086, Retrieved from the Internet          &lt;URL:https://doi.org/10.1371/journal.pone.0029785?nosfx=y&gt;          DOI:          10.1371/journal.pone.0029785,relevantClaims[1-3|4-15],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;4&lt;/pp&gt;&lt;column&gt;1&lt;/column&gt;&lt;para&gt;2&lt;/para&gt;&lt;figure&gt;3&lt;/figure&gt;];  MIKAMI TATSUYA ET          AL: ""Transformation efficiency and transgene expression          level in marker-freeRDR6-knockdown transgenic tobacco          plants"", PLANT BIOTECHNOLOGY REPORTS, SPRINGER JAPAN, JP,          vol. 12, no. 6, 30 October 2018 (2018-10-30), pages 389 -          397, XP036650920, ISSN: 1863-5466, [retrieved on          20181030], DOI:          10.1007/S11816-018-0503-X,relevantClaims[1-15],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;393&lt;/pp&gt;&lt;figure&gt;2&lt;/figure&gt;];  SHARMA A K ET AL:          ""Plants as bioreactors: Recent developments and emerging          opportunities"", BIOTECHNOLOGY ADVANCES, ELSEVIER          PUBLISHING, BARKING, GB, vol. 27, no. 6, 1 November 2009          (2009-11-01), pages 811 - 832, XP026675569, ISSN:          0734-9750, [retrieved on 20090630], DOI:          10.1016/J.BIOTECHADV.2009.06.004,relevantClaims[11,15|1-10,12-14],relevantPassages[&lt;pp&gt;817&lt;/pp&gt;&lt;column&gt;2&lt;/column&gt;&lt;para&gt;2&lt;/para&gt;];  VOINNET ET AL:          ""Use, tolerance and avoidance of amplified RNA silencing          by plants"", TRENDS IN PLANT SCIENCE, ELSEVIER SCIENCE,          OXFORD, GB, vol. 13, no. 7, 1 July 2008 (2008-07-01),          pages 317 - 328, XP022822380, ISSN: 1360-1385, [retrieved          on 20080617], DOI:          10.1016/J.TPLANTS.2008.05.004,relevantClaims[1-15];            GLEBA YKLIMYUK VMARILLONNET S: ""Magnifection--a new          platform for expressing recombinant vaccines in plants"",          VACCINE, vol. 23, no. 17-18, 18 March 2005 (2005-03-18),          pages 2042 - 8, XP004777496, DOI:          10.1016/j.vaccine.2005.01.006;            MUSIYCHUK, KONSTANTIN ET AL.: ""A launch vector for the          production of vaccine antigens in plants"", INFLUENZA AND          OTHER RESPIRATORY VIRUSES, vol. 1, no. 1, 2007, pages 19          - 25, XP009058889, DOI:          10.1111/j.1750-2659.2006.00005.x;            MARTINEZ DE ALBA AEELVIRA-MATELOT EVAUCHERET H: ""Gene          silencing in plants: a diversity of pathways"", BIOCHIM          BIOPHYS ACTA, vol. 1829, no. 12, 1 November 2013          (2013-11-01), pages 1300 - 8, XP055758450, DOI:          10.1016/j.bbagrm.2013.10.005;            VOINNET ET AL.: ""Suppression of gene silencing: a general          strategy used by diverse DNA and RNA viruses of plants"",          PROC NATL ACAD SCI USA., 1999;            XIAO, K.ZHANG, C.HARRISON, M.WANG, Z.: ""Isolation and          characterization of a novel plant promoter that directs          strong constitutive expression of transgenes in plants"",          MOLECULAR BREEDING, vol. 15, 2004, pages 221 - 231,          XP019258716;            DEY, N.MAITI, I.B.: ""Structure and promoter/leader          deletion analysis of mirabilis mosaic virus (MMV)          full-length transcript promoter in transgenic plants"",          PLANT MOL. BIOL., vol. 40, 1999, pages 771 -          782;            OUTCHKOUROV NSPETERS JDE JONG JRADEMAKERS WJONGSMA MA:          ""The promoter-terminator of chrysanthemum rbcS1 directs          very high expression levels in plants"", PLANTA, April          2003 (2003-04-01);            MITRA AHIGGINS DWROHE NJ: ""A Chlorella virus gene          promoter functions as a strong promoter both in plants          and bacteria"", BIOCHEM BIOPHYS RES COMMUN, 14 October          1994 (1994-10-14);            MITRA AHIGGINS DWROHE NJ: ""A Chlorella virus gene          promoter functions as a strong promoter both in plants          and bacteria"", BIOCHEM. BIOPHYS. RES COMMUN., 14 October          1994 (1994-10-14)EP4060045-A1  JAUVION VINCENT ET          AL: ""RDR2 Partially Antagonizes the Production of          RDR6-Dependent siRNA in Sense Transgene-Mediated PTGS"",          PLOS ONE, vol. 7, no. 1, 5 January 2012 (2012-01-05),          pages e29785, XP055835086, Retrieved from the Internet          &lt;URL:https://doi.org/10.1371/journal.pone.0029785?nosfx=y&gt;          DOI:          10.1371/journal.pone.0029785,relevantClaims[1-3|4-15],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;4&lt;/pp&gt;&lt;column&gt;1&lt;/column&gt;&lt;para&gt;2&lt;/para&gt;&lt;figure&gt;3&lt;/figure&gt;];  MIKAMI TATSUYA ET          AL: ""Transformation efficiency and transgene expression          level in marker-freeRDR6-knockdown transgenic tobacco          plants"", PLANT BIOTECHNOLOGY REPORTS, SPRINGER JAPAN, JP,          vol. 12, no. 6, 30 October 2018 (2018-10-30), pages 389 -          397, XP036650920, ISSN: 1863-5466, [retrieved on          20181030], DOI:          10.1007/S11816-018-0503-X,relevantClaims[1-15],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;393&lt;/pp&gt;&lt;figure&gt;2&lt;/figure&gt;];  SHARMA A K ET AL:          ""Plants as bioreactors: Recent developments and emerging          opportunities"", BIOTECHNOLOGY ADVANCES, ELSEVIER          PUBLISHING, BARKING, GB, vol. 27, no. 6, 1 November 2009          (2009-11-01), pages 811 - 832, XP026675569, ISSN:          0734-9750, [retrieved on 20090630], DOI:          10.1016/J.BIOTECHADV.2009.06.004,relevantClaims[11,15|1-10,12-14],relevantPassages[&lt;pp&gt;817&lt;/pp&gt;&lt;column&gt;2&lt;/column&gt;&lt;para&gt;2&lt;/para&gt;];  VOINNET ET AL:          ""Use, tolerance and avoidance of amplified RNA silencing          by plants"", TRENDS IN PLANT SCIENCE, ELSEVIER SCIENCE,          OXFORD, GB, vol. 13, no. 7, 1 July 2008 (2008-07-01),          pages 317 - 328, XP022822380, ISSN: 1360-1385, [retrieved          on 20080617], DOI:          10.1016/J.TPLANTS.2008.05.004,relevantClaims[1-15];            GLEBA YKLIMYUK VMARILLONNET S: ""Magnifection--a new          platform for expressing recombinant vaccines in plants"",          VACCINE, vol. 23, no. 17-18, 18 March 2005 (2005-03-18),          pages 2042 - 8, XP004777496, DOI:          10.1016/j.vaccine.2005.01.006;            MUSIYCHUK, KONSTANTIN ET AL.: ""A launch vector for the          production of vaccine antigens in plants."", INFLUENZA AND          OTHER RESPIRATORY VIRUSES, vol. 1, no. 1, 2007, pages 19          - 25, XP009058889, DOI:          10.1111/j.1750-2659.2006.00005.x;            MARTINEZ DE ALBA AEELVIRA-MATELOT EVAUCHERET H.: ""Gene          silencing in plants: a diversity of pathways"", BIOCHIM          BIOPHYS ACTA, vol. 1829, no. 12, 1 November 2013          (2013-11-01), pages 1300 - 8, XP055758450, DOI:          10.1016/j.bbagrm.2013.10.005;            VOINNET ET AL.: ""Suppression of gene silencing: a general          strategy used by diverse DNA and RNA viruses of plants"",          PROC NATL ACAD SCI USA., 1999;            XIAO, K.ZHANG, C.HARRISON, M.WANG, Z.: ""Isolation and          characterization of a novel plant promoter that directs          strong constitutive expression of transgenes in plants"",          MOLECULAR BREEDING, vol. 15, 2004, pages 221 - 231,          XP019258716;            DEY, N.MAITI, I.B.: ""Structure and promoter/leader          deletion analysis of mirabilis mosaic virus (MMV)          full-length transcript promoter in transgenic plants"",          PLANT MOL. BIOL., vol. 40, 1999, pages 771 -          782;            OUTCHKOUROV NSPETERS JDE JONG JRADEMAKERS WJONGSMA MA:          ""he promoter-terminator of chrysanthemum rbcS1 directs          very high expression levels in plants"", PLANTA, April          2003 (2003-04-01);            MITRA AHIGGINS DWROHE NJ: ""A Chlorella virus gene          promoter functions as a strong promoter both in plants          and bacteria"", BIOCHEM BIOPHYS RES COMMUN, 14 October          1994 (1994-10-14);            XIAO, K.ZHANG, C.HARRISON, M.WANG, Z.: ""Isolation and          characterization of a novel plant promoter that directs          strong constitutive expression of transgenes in plants."",          MOLECULAR BREEDING, vol. 15, 2004, pages 221 - 231,          XP019258716;            OUTCHKOUROV NSPETERS JDE JONG JRADEMAKERS WJONGSMA MA:          ""The promoter-terminator of chrysanthemum rbcS1 directs          very high expression levels in plants"", PLANTA, April          2003 (2003-04-01);            MITRA AHIGGINS DWROHE NJ.: ""A Chlorella virus gene          promoter functions as a strong promoter both in plants          and bacteria"", BIOCHEM. BIOPHYS. RES COMMUN., 14 October          1994 (1994-10-14)",184616-0-0-0 M N P Q; 184616-0-0-0 CL NEW PRD RCT USE,,,RA00H3 M N P Q,
WO2023235875-A1,"Analyzing nucleic acid e.g. viral nucleic acid, by            heating treatment sample comprising nucleic acid in            closed heating chamber in hyperbaric condition over            ramp time for producing heat-treated sample, and            analyzing nucleic acid from heat-treated sample",PEYTAVI R,AUTONOMOUS MEDICAL DEVICES INC (AUTO-Non-standard),2023C81255,"   NOVELTY - Method (M1) for analyzing a nucleic acid                involves (A) (a) heating a treatment sample                comprising a nucleic acid in a closed heating                chamber in a hyperbaric condition from a first                temperature to a second temperature above                100&#176; C over a ramp time for producing a                heat-treated sample, and (b) analyzing the nucleic                acid from the heat-treated sample, or (B) (a')                providing a bodily sample chosen from a blood                sample, a lacrimal fluid sample, a saliva sample, a                mucus sample, a sputum sample, a feces sample, a                cerebrospinal fluid sample, and a urine sample,                where the bodily sample comprises a nucleic acid,                (b') heating a treatment sample comprising the                bodily sample in a closed heating chamber in a                hyperbaric condition from a first temperature to a                second temperature above 100&#176; C over a                ramp time, and (c') analyzing the nucleic acid from                the heat-treated sample.    USE - The method is useful for analyzing nucleic                acid. The nucleic acid is DNA, RNA, and chosen from                viral nucleic acid, bacterial nucleic acid,                protozoan nucleic acid, eukaryotic nucleic acid,                and fungal nucleic acid, preferably viral nucleic                acid (all claimed).    ADVANTAGE - The method pretreats sample in a simple and                fast manner, effectively amplifies the nucleic                acid, and improves the shelf life of a point of                care device.    DETAILED DESCRIPTION - Method (M1) for analyzing a nucleic acid                involves (A) (a) heating a treatment sample                comprising a nucleic acid in a closed heating                chamber in a hyperbaric condition from a first                temperature to a second temperature above                100&#176; C over a ramp time for producing a                heat-treated sample, and (b) analyzing the nucleic                acid from the heat-treated sample, (B) (a')                providing a bodily sample chosen from a blood                sample, a lacrimal fluid sample, a saliva sample, a                mucus sample, a sputum sample, a feces sample, a                cerebrospinal fluid sample, and a urine sample,                where the bodily sample comprises a nucleic acid,                (b') heating a treatment sample comprising the                bodily sample in a closed heating chamber in a                hyperbaric condition from a first temperature to a                second temperature above 100&#176; C over a                ramp time, and (c') analyzing the nucleic acid from                the heat-treated sample, where the nucleic acid is                not extracted, isolated, or otherwise purified from                the bodily sample, (C) (a'') heating a treatment                sample comprising an unlysed cell comprising a                nucleic acid in a closed heating chamber in a                hyperbaric condition from a first temperature to a                second temperature above 100&#176; C, and (b'')                analyzing the nucleic acid from the heat-treated                sample, where the nucleic acid is not extracted,                isolated, or otherwise purified from the                heat-treated sample before step (b''), or (D)                (a''') heating a treatment sample comprising a                nucleic acid in a closed heating chamber in a                hyperbaric condition from a first temperature to a                second temperature above 100&#176; C over a                ramp time, and (b''') analyzing the nucleic acid                from the heat-treated sample, where the heating                occurs at a temperature ramp rate from                5-50&#176; C/second. An INDEPENDENT CLAIM is                included for method (M2) for inactivating a                molecular amplification inhibitor in a treatment                sample comprising a nucleic acid, which involves                heating a treatment sample comprising a nucleic                acid and molecular amplification inhibitors in a                closed heating chamber in a hyperbaric heating                condition from a first temperature to a second                temperature over a ramp time above 100&#176; C                for inactivating a molecular amplification                inhibitor of the amplification inhibitors and                producing a heat-treated sample, where the nucleic                acid is not degraded. ",,,"A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",A12-V03B;  A12-V03C2;  A12-W11L;  B04-B04B;  B04-B04D5;  B04-B04G;  B04-C03B;  B04-E01;  B04-E05;  B04-E15;  B04-E99;  B10-B01B;  B11-C07B3;  B11-C08E3;  B11-C08F7A;  B11-C08F8;  B12-K04F;  B12-K04G;  D05-A04A;  D05-H09;  D05-H18A;  D05-H18B;  D05-H99,C12Q-001/6806,WO2023235875-A1   07 Dec 2023   C12Q-001/6806   202304Pages: 78   English,WO2023235875-A1    WOUS067879    02 Jun 2023,,US348750P    03 Jun 2022,WO2023235875-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2023235875-A1 -- EP953635-A1   ORTHO-CLINICAL DIAGNOSTICS INC (ORTH)   BELLY R T,  CHILSON G J;  EP3992300-A1   NEDERLANDSE ORG TOEGEPAST NATUURWETENSCH (NEDE)   KEIJSER B J F,  OSSENDRIJVER M;  US20210395839-A1   ;  WO2019094784-A1   CLICK DIAGNOSTICS INC (CLIC-Non-standard);  SWENSON D (SWEN-Individual)   SWENSON D,  ANDREYEV B,  BRIONES V,  CENA R T,  DE LA ZERDA A,  KELLY C,  LONEY G,  SCHOOLNIK G;  WO2022150385-A1   SALUS DISCOVERY LLC (SALU-Non-standard);  FLAMBEAU DIAGNOSTICS LLC (FLAM-Non-standard)   WARRICK J,  MULLINS B,  MCMINN P,  BEEBE D,  SHOGREN R,  GEIGER M,  ZHONG F,  JUANG D S,  JUANG T D;  WO2023131534-A1   CERTEST BIOTEC SL (CERT-Non-standard)   GENZOR ASIN C G,  GIL RODRIGUEZ M C,  MACHETTI MARECA E,  MARTINEZ SANTOLARIA M,  SOTA DIEZ C","WO2023235875-A1  SMYRLAKI IOANNA ET          AL: ""Massive and rapid COVID-19 testing is feasible by          extraction-free SARS-CoV-2 RT-PCR"", NATURE          COMMUNICATIONS, vol. 11, no. 1, 23 September 2020          (2020-09-23), XP055809208, Retrieved from the Internet          &lt;URL:https://www.nature.com/articles/s41467-020-18611-5.pdf&gt;          DOI:          10.1038/s41467-020-18611-5,relevantClaims[1-78],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;|abstract,          Fig. 1]",199515-0-0-0 K M; 3330-0-0-0 K M; 95972-0-0-0 ; 368-0-0-0 ,,,RA0439 K M; R00195 K M; R24033 ; R00708 ,0195-S
WO2021245655-A1,"Treating or preventing disease caused by            coronavirus, comprises administering cannabinoid            composition comprising cannabinoid and inhaled volatile            anesthetic via inhalation",HAZANI M,ROXX LABS LTD (ROXX-Non-standard),2021E0292G,"   NOVELTY - Treating or preventing a disease caused by a                coronavirus, comprises administering a cannabinoid                composition comprising at least one cannabinoid and                an inhaled volatile anesthetic via inhalation to a                subject.    USE - The method is useful for treating or                preventing disease caused by coronavirus (claimed).                Test details are described but no results                given.    ADVANTAGE - The method utilizes compositions                cannabinoid(s) and inhaled volatile anesthetic, and                are for pulmonary administration i.e. for                aerosolization; and advantageously provide                relatively uniform or homogeneous wetting of porous                surface that may result in small diameter aerosol                droplets having the MMAD value as specified, and                confer ability to yield small diameter aerosol                drops with high efficiency.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) cannabinoid composition, provided in a                dosage form suitable for aerosolization using an                aerosol generating device, for use in treatment or                prevention of a disease caused by a coronavirus,                where the composition comprises at least one                cannabinoid and an inhaled volatile                anesthetic;    (2) aerosol composition comprising 75-99 wt.%                water, 1-6 wt.% least one cannabinoid and 0.02-2%                inhaled volatile anesthetic, where the aerosol                comprises droplets having a mass median aerodynamic                diameter (MMAD) of no more than 5 microns;                and    (3) aerosol generating device cartridge                comprising a liquid container, where the liquid                container contains the composition. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B02 (Fused ring heterocyclics.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  P34 (Sterilising, syringes, electrotherapy (A61L, M, N).)",B06-A03;  B10-C03;  B10-E02;  B10-E04C;  B10-H02B;  B12-M01;  B14-A02B5;  B14-C07;  B14-C08;  P34-A02,A61M-015/06;  A61M-011/04;  A61K-031/352;  A61K-009/14,WO2021245655-A1   09 Dec 2021   A61M-015/06   202104Pages: 88   English,WO2021245655-A1    WOIL050638    30 May 2021,,US032632P    31 May 2020,WO2021245655-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2021245655-A1 -- US20150057341-A1   ;  US20160331034-A1   ;  WO2016019353-A1   MJAR HOLDINGS LLC (MJAR-Non-standard)   COHEN A D,  LOWE J,  FRITZEL J;  WO2020086759-A2   HOAG G E (HOAG-Individual);  SALERNO J (SALE-Individual)   HOAG G E,  SALERNO J","WO2021245655-A1  ROSSI FRANCESCA,          TORTORA CHIARA, ARGENZIANO MAURA, DI PAOLA ALESSANDRA,          PUNZO FRANCESCA: ""Cannabinoid receptor type 2: A possible          target in SARS-CoV-2 (CoV-19) infection?"", INTERNATIONAL          JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 11, 3809, 27          May 2020 (2020-05-27), pages 1 - 16, XP055879942, DOI:          10.3390/ijms21113809,relevantClaims[1-11,18-29,40-46],relevantPassages[Page          9];  GERTRUDE J.          NIEUWENHUIJS-MOEKE, JAYANT S. JAINANDUNSING , MICHEL M.          R. F. STRUYS: ""Sevoflurane, a sigh of relief in          COVID-19?"", BJA: BRITISH JOURNAL OF ANAESTHESIA, vol.          125, no. 2, 1 May 2020 (2020-05-01), pages 118 - 121,          XP055879595,relevantClaims[1-11,18-29,40-46],relevantPassages[Pages:          118,120]",45362-1-0-0 K M; 53318-1-0-0 K M; 108617-1-0-0 K M;  K M; 96693-0-0-0 K M; 98250-0-0-0 K M; 106944-0-0-0 K M; 48226-0-0-0 K M; 490-0-0-0 K M; 861-0-0-0 K M,,03580,RA0AQM K M; RA9DAR K M; R23448 K M; RAVZ1T K M; RC1OQT K M; R01177 K M; R06597 K M; R18871 K M; R14044 K M; R00113 K M; R00137 K M,1177-S; 0113-S; 0137-S
WO2021191829-A1;  CA3173190-A1;  EP4127233-A1;  JP2023519919-W;  HK40088584-A0,"Identifying at least one target nucleic acid            comprises obtaining total nucleic acid from each of the            biological samples, subjecting many polynucleotides to            amplification, detecting amplicons, and determining a            category of amplicons",SANTOS C F;  STATES D J;  FELDMANN J P;  MORAN J D,ANGSTROM BIO INC (ANGS-Non-standard);  ANGSTROM BIO INC (ANGS-Non-standard),2021B3340E,"   NOVELTY - Identifying at least one target nucleic acid                comprises: (a) obtaining many biological samples                from many subjects; (b) obtaining total nucleic                acid from each of the biological samples, where the                total nucleic acid comprises many polynucleotides;                (c) subjecting many polynucleotides to                amplification using an amplification mixture to                produce many amplicons; (d) detecting each of the                amplicons; and (e) determining a category of many                amplicons.    USE - The method is useful for: identifying at least                one target nucleic acid; identifying infection                biological samples; detecting sequence variants in                a nucleic acid sample; and detecting the amplicons                (all claimed).    ADVANTAGE - The method provides accurate, high speed, and                low cost blood analysis, infection diagnosis,                pathogen detection, or other biological or chemical                analyses detection.    DETAILED DESCRIPTION - Identifying (M1) at least one target nucleic                acid comprises: (a) obtaining many biological                samples from many subjects; (b) obtaining total                nucleic acid from each of the biological samples,                where the total nucleic acid comprises many                polynucleotides, where, if the many polynucleotides                comprise RNA molecules, step (b) further comprises                obtaining cDNA reverse-transcribed from the RNA or                reverse-transcribing cDNA from the RNA before                performing the amplification in step (c); (c)                subjecting many polynucleotides to amplification                using an amplification mixture to produce many                amplicons, where the amplification mixture                comprises many primers, a first unique barcode                sequence and its reverse complement, and at least                one pair of adapter sequences, where each of the                primers comprise a set of nucleotides that are                complementary to each of the polynucleotides that                they bind to, where the first unique barcode                sequence identifies the biological sample obtained                from the specific subject, where the pair of                adapter sequences flank the first unique barcode                sequence and its reverse complement, and where each                of the amplicons comprise polynucleotides from a                target amplified region or a control region; (d)                detecting each of the amplicons; and (e)                determining a category of the many amplicons, where                the determining the category of each the plurality                of amplicons comprising the polynucleotides from                the target amplified region indicates that the                corresponding subject has the target nucleic acid.                INDEPENDENT CLAIMS are also included for:    (1) multiplex of array for detecting at least                one target protein from multiple samples, the array                comprising many capture agents bound to a many                uniquely labeled beads, where each unique labeled                bead comprises many unique capture agent, at least                one first oligonucleotide sequence that is designed                to be bound to at least one bead, where the bead is                coated with an antigen that specifically binds at                least one target protein, at least one secondary                antibody conjugated with a second oligonucleotide                sequence which is designed to be amplified to form                a circular amplicon when the second oligonucleotide                sequence is in close proximity to the first                oligonucleotide sequence, and at least one unique                nucleotide barcode sequence in the circular                amplicon;    (2) identifying (M2) at least one infection in                many biological samples, comprising providing the                multiplex array, incubating many biological samples                with many beads under conditions sufficient for at                least one target protein to bind to the unique                capture agent of at least one of the beads, washing                the beads to remove any proteins that do not bind                to the unique capture agents, incubating the beads                with many secondary antibodies under conditions                where each of the plurality of the secondary                antibodies forms a complex with at least one target                protein, and where many complexes corresponding to                the number of the secondary antibodies bound to                many target proteins, are formed, washing the beads                to remove any secondary antibodies that do not form                the complex, incubating the complexes under                conditions to allow hybridization of each of the                second oligonucleotide sequence to each of the                first oligonucleotide sequence such that they form                a circular amplicon, where many amplicons are                generated corresponding to the number of complexes,                and where each of the amplicons comprise                polynucleotides from a target amplified region or a                control region, a unique barcode sequence and its                reverse complement, and a first pair of adapter                sequences, subjecting many amplicons to                amplification, pooling the beads in the array and                simultaneously detecting many amplicons by high                throughput sequencing, and determining a category                of many amplicons and determining the category of                each amplicons comprising the polynucleotides from                the target amplified region indicates infection in                the corresponding biological sample;    (3) detecting (M3) sequence variants in a                nucleic acid sample comprising (a1) performing an                amplification reaction with a amplification mixture                to produce many amplicons, where the amplification                mixture comprises the nucleic acid sample, many                primers, a first unique barcode sequence and its                reverse complement, and a first pair of adapter                sequences, where each of the plurality of the                primers comprise a set of nucleotides that are                complementary to each of the polynucleotides that                they bind to, where the first unique barcode                sequence and its reverse complement identify the                sample obtained from a specific subject, where the                pair of adapter sequences flanks the first unique                barcode sequence and its reverse complement, and                where each of the plurality of amplicons comprise                polynucleotides from a target amplified region or a                control region, where if the sample of nucleic acid                comprises RNA molecules, step (a1) further                comprises obtaining cDNA reverse-transcribed from                the RNA or reverse-transcribing cDNA from the RNA                before performing the amplification reaction, (b1)                detecting, and optionally quantitating many                amplicons, (c1) determining a category of the                amplicons, and (d1) detecting at least sequence                variants in amplicons from step (c1); and    (4) composition comprising an amplicon, where                the amplicon comprises a first unique barcode                sequence and its reverse complement, a pair of                target-specific primers, a target amplified region                and a first pair of adapter sequences, where the                pair of target specific primers is made up of a                forward primer and a reverse primer, each having                sequences complementary to the priming sites in the                target amplified region, where each of the forward                primer and the reverse primer flanks the target                amplified region, where the target specific primers                are flanked by the first unique barcode sequence                and its reverse complement, and where the first                unique barcode sequence and its reverse complement                are flanked by the first pair of adapter                sequences. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S05 (Electrical Medical Equipment);  ",B04-B03C;  B04-E01;  B04-E05;  B04-E99;  B04-G01;  B04-G08;  B04-G27G;  B04-G27M;  B04-L04B;  B11-C07A;  B11-C08E3;  B11-C08F8;  B11-C11;  B12-K04F;  B12-K04G1;  C04-B03C;  C04-E01;  C04-E05;  C04-E99;  C04-G01;  C04-G08;  C04-G27G;  C04-G27M;  C04-L04B;  C11-C07A;  C11-C08E3;  C11-C08F8;  C11-C11;  C12-K04F;  C12-K04G1;  D05-A02B;  D05-H09;  D05-H18B;  D05-H99;  S05-G02G2;  T01-J05B4P;  T01-J06A1,C12Q-001/6869;  G16B-030/00;  G16H-050/30;  C12N-015/11;  C12Q-001/02;  C12Q-001/6888;  C12Q-001/689;  C12Q-001/70;  C40B-040/08;  G01N-033/53,WO2021191829-A1   30 Sep 2021   C12Q-001/6869   202184Pages: 107   English;  CA3173190-A1   30 Sep 2021   C12Q-001/6869   202202   English;  EP4127233-A1   08 Feb 2023   C12Q-001/6869   202312   English;  JP2023519919-W   15 May 2023   C12Q-001/6869   202342   Japanese;  HK40088584-A0   29 Sep 2023   C12Q-001/6869   202427   English,WO2021191829-A1    WOIB052463    24 Mar 2021;   CA3173190-A1    CA3173190    24 Mar 2021;   EP4127233-A1    EP775520    24 Mar 2021;   JP2023519919-W    JP558526    24 Mar 2021;   HK40088584-A0    HK6077201    08 Aug 2023,CA3173190-A1 PCT application Application WOIB052463;   CA3173190-A1 Based on Patent WO2021191829;   EP4127233-A1 PCT application Application WOIB052463;   EP4127233-A1 Based on Patent WO2021191829;   JP2023519919-W PCT application Application WOIB052463;   JP2023519919-W Based on Patent WO2021191829;   HK40088584-A0 PCT application Application WOIB052463;   HK40088584-A0 Based on Patent WO2021191829;   HK40088584-A0 Previous Publ. Patent EP4127233,US994173P    24 Mar 2020;  EP775520    24 Mar 2021;  CA3173190    23 Sep 2022,WO2021191829-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP4127233-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN      ,,"WO2021191829-A1 -- US20090298049-A1   ;  US20150087535-A1   ;  US20160306922-A1   ;  WO2013188471-A2   SEQUENTA INC (SEQU-Non-standard)   FAHAM M,  MOORHEAD M,  WILLIS T,  ZHENG J;  EP4127233-A1 -- US10233490-B2   TIGER SEQUENCING CORP (TIGE-Non-standard)   STAPLETON J A,  WHITEHEAD T;  WO2018226708-A1   UNIV OREGON HEALTH SCI (UYOR);  ILLUMINA INC (ILLU)   ADEY A C,  MULQUEEN R,  STEEMERS F J,  POKHOLOK D K,  NORBERG S","WO2021191829-A1  SAH ET AL.:          ""Complete Genome Sequence of a 2019 Novel Coronavirus          (SARS-CoV-2) Strain Isolated in Nepal"", MICROBIOL RESOUR          ANNOUNC, vol. 9, no. 11, 12 March 2020 (2020-03-12),          pages e00169-20,          XP055862498,relevantClaims[8],relevantPassages[,          abstract];  TYSON ET AL.:          ""MiniON-based long-read sequencing and assembly extends          the Caenorhabditis elegans reference genome"", GENOME          RESEARCH, vol. 28, no. 2, February 2018 (2018-02-01),          pages 266 - 274,          XP055862500,relevantClaims[67],relevantPassages[, pg 267,          col 1, para 3, pg 273, col 1, para 2 - col 2, para          1]EP4127233-A1  HENRI HLNE ET AL:          ""Optimization of multiplexed RADseq libraries using          low-cost adaptors"", GENETICA., vol. 143, no. 2, 11          February 2015 (2015-02-11), NL, pages 139 - 143,          XP093146940, ISSN: 0016-6707, Retrieved from the Internet          &lt;URL:http://link.springer.com/article/10.1007/s10709-015-9828-3/fulltext.html&gt;          DOI:          10.1007/s10709-015-9828-3,relevantClaims[1,3-8,14-15|2|13],relevantPassages[&lt;pp&gt;141&lt;/pp&gt;&lt;ppl&gt;142&lt;/ppl&gt;&lt;figure&gt;1&lt;/figure&gt;];  PERRY ELIZABETH B.          ET AL: ""Tumor diversity and evolution revealed through          RADseq"", ONCOTARGET, vol. 8, no. 26, 27 June 2017          (2017-06-27), pages 41792 - 41805, XP055831652, DOI:          10.18632/oncotarget.18355,relevantClaims[1-8,13-15],relevantPassages[&lt;pp&gt;41793&lt;/pp&gt;&lt;ppl&gt;41794&lt;/ppl&gt;&lt;figure&gt;2-4&lt;/figure&gt;];  KEREN-SHAUL HADAS          ET AL: ""MARS-seq2.0: an experimental and analytical          pipeline for indexed sorting combined with single-cell          RNA sequencing"", NATURE PROTOCOLS, NATURE PUBLISHING          GROUP, GB, vol. 14, no. 6, 17 May 2019 (2019-05-17),          pages 1841 - 1862, XP036793527, ISSN: 1754-2189,          [retrieved on 20190517], DOI:          10.1038/S41596-019-0164-4,relevantClaims[1-4,6-8,14-15|13],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;&lt;figure&gt;2&lt;/figure&gt;];  SKEWES-COX PETER ET          AL: ""Profile Hidden Markov Models for the Detection of          Viruses within Metagenomic Sequence Data"", PLOS ONE, vol.          9, no. 8, 20 August 2014 (2014-08-20), US, pages e105067,          XP093147563, ISSN: 1932-6203, DOI:          10.1371/journal.pone.0105067,relevantClaims[13],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;&lt;figure&gt;1&lt;/figure&gt;|&lt;pp&gt;2&lt;/pp&gt;];  MEYER MATTHIAS ET          AL: ""Parallel tagged sequencing on the 454 platform"",          NATURE PROTOCOLS, NATURE PUBLISHING GROUP, GB, vol. 3,          no. 2, 1 January 2008 (2008-01-01), pages 267 - 278,          XP002560261, ISSN: 1750-2799, [retrieved on 20080131],          DOI:          10.1038/NPROT.2007.520,relevantClaims[1-8,13-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  DAVEY J. W. ET AL:          ""RADSeq: next-generation population genetics"", BRIEFINGS          IN FUNCTIONAL GENOMICS, vol. 9, no. 5-6, 1 December 2010          (2010-12-01), Oxford, UK, pages 416 - 423, XP093146924,          ISSN: 2041-2649, Retrieved from the Internet          &lt;URL:https://watermark.silverchair.com/elq031.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA2EwggNdBgkqhkiG9w0BBwagggNOMIIDSgIBADCCA0MGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMj2vX1TrlIbiJdiy5AgEQgIIDFAc5JbIFogJVlOEVkSPE0GtQTYeKEuuQi813oLswIr8VU-ANIJKZbSw5UbQkt64UuMezg7jxnAgEHXLjTpo6fnjXxy3_7&gt;          DOI:          10.1093/bfgp/elq031,relevantClaims[1-8,13-15],relevantPassages[&lt;figure&gt;1&lt;/figure&gt;];  LAURAE MACCONAILL          ET AL: ""Unique, dual-indexed sequencing adapters with          UMIs effectively eliminate index cross-talk and          significantly improve sensitivity of massively parallel          sequencing"", BMC GENOMICS, BIOMED CENTRAL LTD, LONDON,          UK, vol. 19, no. 1, 8 January 2018 (2018-01-08), pages 1          - 10, XP021252292, DOI:          10.1186/S12864-017-4428-5,relevantClaims[1-8,13-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  TILO BUSCHMANN ET          AL: ""Enhancing the detection of barcoded reads in high          throughput DNA sequencing data by controlling the false          discovery rate"", BMC BIOINFORMATICS, BIOMED CENTRAL ,          LONDON, GB, vol. 15, no. 1, 7 August 2014 (2014-08-07),          pages 264, XP021191527, ISSN: 1471-2105, DOI:          10.1186/1471-2105-15-264,relevantClaims[1-8,13-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            See also references of WO 2021191829A1",201562-0-0-0 D K M,,,RA0124 D K M,
WO2021252323-A2;  WO2021252323-A3;  AU2021288458-A1;  CN115551596-A;  EP4161652-A2;  JP2023528651-W;  US2023330033-A1;  HK40090048-A0;  IN202317001173-A,"New polypeptide comprising specified amino acid            sequences, and is capable of assembling into polymer            including homopolymer and binding to constant region of            immunoglobulin G antibody, used e.g. to treat bacterial            o:r viral infection",DIVINE R;  VULOVIC I;  BAKER D;  SHEFFLER W H;  SEEGER F,UNIV WASHINGTON SEATTLE (UNIW-C);  UNIV WASHINGTON SEATTLE (UNIW-C);  UNIV WASHINGTON SEATTLE (UNIW-C);  UNIV WASHINGTON SEATTLE (UNIW-C),2021E3652F,"   NOVELTY - Polypeptide comprising an amino acid sequence                at least 50%, preferably at least 100% identical to                the amino acid sequences of SEQ ID NOs: 1-9 (each                comprising fully defined sequence of any one of                314-422 amino acids as given in the specification),                where residues in parentheses arc optional (i.e.                not considered in the percent identity                requirement), and the polypeptide is capable of                assembling into a polymer including a homopolymer                and binding to a constant region of an                immunoglobulin (Ig)G antibody, is new.    USE - The polypeptides, nucleic acids, expression                vectors, host cells, polymers, particles, or                compositions are useful: in diagnostic applications                (claimed); for treating disorders e.g. rheumatoid                arthritis, psoriatic arthritis, Crohn's disease,                ulcerative colitis, metastatic breast cancer,                urothelial carcinoma, glioblastoma, cervical                cancer, multiple sclerosis, and multiple myeloma;                and for treating or limiting development of a                bacterial or viral infection.    ADVANTAGE - The polypeptide: is capable of assembling into                a polymer including a homopolymer and binding to a                constant region of an IgG antibody; promotes an                increased half-life in vivo; provides antibody                nanocage design that activates cluster of                differentiation (CD)40 signaling over uncaged IgGs;                and enhances avidity and receptor clustering. The                ability of polypeptide to activate B cells was                tested using in vitro assay. The result showed that                polypeptide (i.e. alpha -CD40) exhibited EC50 log                value of 1.466 mu M.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) a nucleic add encoding the                polypeptide;    (2) an expression vector comprising the                nucleic acid operatively linked to a control                sequence;    (3) a host cell comprising the polypeptide,                nucleic acid, and/or expression vector;    (4) a polymer of the polypeptide, where each                monomer in the polymer comprises an amino acid                sequence at least 50%, preferably at least 100%                identical to the amino acid sequences of SEQ ID                NOs: 1-9, and residues in parentheses are optional                (i.e. not considered in the percent identity                requirement);    (5) a particle (P1) comprising many identical                polymers, and many antibodies comprising fragment                crystallizable (Fc) domains, where each antibody in                the antibodies comprises a first Fc domain and a                second Fc domain, each antibody in the antibodies                is non-covalently bound via the first Fc domain to                one polypeptide monomer chain of a first                homopolymer, and non-covalently bound via the                second Fc domain to one polypeptide monomer of a                second homopolymer and each polypeptide monomer                chain of each homopolymer is non-covalently bound                to one Fc domain, where the particle comprises                dihedral, tetrahedral, octahedral, or icosahedral                symmetry;    (6) a particle (P2) comprising many                polypeptide polymers, where each monomer in the                polymer comprises an amino acid sequence at least                50%, preferably at least 100% identical to the                amino acid sequences of SEQ ID NOs: 1-9 and                residues in parentheses are optional (i.e. not                considered in the percent identity requirement),                and the antibodies comprising Fc domains, where                each antibody in the antibodies comprises a first                Fc domain and a second Fc domain, each antibody in                the antibodies is non-covalently bound via the                first Fc domain to one polypeptide monomer chain of                a first polymer and non-covalently bound via the                second Fc domain to one polypeptide monomer of a                second polymer, and each polypeptide monomer chain                of each polymer is non-covalently bound to one Fc                domain, and the particle comprises dihedral,                tetrahedral, octahedral, or icosahedral                symmetry;    (7) a composition (C1) comprising many                particles (P1)-(P2);    (8) a composition (C2) comprising the                polypeptides, polymers, particles (P1) and (P2), or                composition (C1), and a carrier; and    (9) a polypeptide computational design method                as given in the examples of the                specification. ",,,"A96 (Medical, dental, veterinary, cosmetic.);  A17 (Polymers of unsubstituted aliphatic monoolefins; including polyethylene.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  ;  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",A12-V01;  B04-C01;  B04-E02F;  B04-E03F;  B04-E08;  B04-E99;  B04-F0100E;  B14-C09;  B14-E08;  B14-E10C1;  B14-H01D1;  B14-H01F1;  B14-H01J1;  B14-H01L1;  B14-S01;  C04-C01;  C04-E02F;  C04-E03F;  C04-E08;  C04-E99;  C04-F0100E;  C14-C09;  C14-E08;  C14-E10C1;  C14-H01D1;  C14-H01F1;  C14-H01J1;  C14-H01L1;  C14-S01;  D05-H12A;  D05-H12E;  D05-H14;  D05-H99,A61K-009/51;  A61P-035/00;  C07K-014/32;  C07K-014/435;  C07K-016/28;  A61K-039/395;  A61K-047/69;  A61P-025/28;  A61P-031/04;  A61P-031/12;  A61P-031/14;  A61P-031/16;  A61P-031/18;  A61P-033/00;  A61P-033/02;  A61P-033/06;  C07K-019/00;  C12N-001/15;  C12N-001/19;  C12N-001/21;  C12N-015/62;  C12N-015/63;  C12N-005/10,WO2021252323-A2   16 Dec 2021   A61P-035/00   202201Pages: 76   English;  WO2021252323-A3   10 Feb 2022   202213   English;  AU2021288458-A1   20 Oct 2022   A61P-035/00   202286   English;  CN115551596-A   30 Dec 2022   A61P-035/00   202307   Chinese;  EP4161652-A2   12 Apr 2023   A61P-035/00   202330   English;  JP2023528651-W   05 Jul 2023   C12N-015/62   202354   Japanese;  US2023330033-A1   19 Oct 2023   A61K-009/51   202386   English;  HK40090048-A0   27 Oct 2023   A61P-035/00   202403   English;  IN202317001173-A   15 Dec 2023   A61K-009/51   202414   English,WO2021252323-A2    WOUS036109    07 Jun 2021;   WO2021252323-A3    WOUS036109    07 Jun 2021;   AU2021288458-A1    AU288458    07 Jun 2021;   CN115551596-A    CN80033376    07 Jun 2021;   EP4161652-A2    EP736133    07 Jun 2021;   JP2023528651-W    JP575361    07 Jun 2021;   US2023330033-A1    US17907372    26 Sep 2022;   HK40090048-A0    HK6078905    08 Sep 2023;   IN202317001173-A    IN17001173    05 Jan 2023,AU2021288458-A1 PCT application Application WOUS036109;   AU2021288458-A1 Based on Patent WO2021252323;   CN115551596-A PCT application Application WOUS036109;   CN115551596-A Based on Patent WO2021252323;   EP4161652-A2 PCT application Application WOUS036109;   EP4161652-A2 Based on Patent WO2021252323;   JP2023528651-W PCT application Application WOUS036109;   JP2023528651-W Based on Patent WO2021252323;   US2023330033-A1 Provisional Application US085351P;   US2023330033-A1 Provisional Application US036062P;   US2023330033-A1 PCT application Application WOUS036109;   HK40090048-A0 PCT application Application WOUS036109;   HK40090048-A0 Based on Patent WO2021252323;   HK40090048-A0 Previous Publ. Patent EP4161652;   IN202317001173-A PCT application Application WOUS036109;   IN202317001173-A Based on Patent WO2021252323,US036062P    08 Jun 2020;  US085351P    30 Sep 2020;  EP736133    07 Jun 2021;  US17907372    26 Sep 2022;  CN80033376    04 Nov 2022,WO2021252323-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2021252323-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW      EP4161652-A2:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN          ,,;  WO2021252323-A3 -- US20190240282-A1   ,"WO2021252323-A3  HYO JIN KANG ET AL:          ""Developing an antibody-binding protein cage as a          molecular recognition drug modular nanoplatform"",          BIOMATERIALS, ELSEVIER, AMSTERDAM, NL, vol. 33, no. 21,          15 March 2012 (2012-03-15), pages 5423 - 5430,          XP028487151, ISSN: 0142-9612, [retrieved on 20120320],          DOI:          10.1016/J.BIOMATERIALS.2012.03.055,relevantClaims[1-49,51],relevantPassages[throughout,          e.g. abstract, Materials and Methods];  KIM HANSOL ET AL:          ""Development of an antibody-binding modular nanoplatform          for antibody-guided targeted cell imaging and delivery"",          RSC ADVANCES, vol. 6, no. 23, 1 January 2016          (2016-01-01), GB, pages 19208 - 19213, XP055842694, ISSN:          2046-2069, DOI:          10.1039/C6RA00233A,relevantClaims[1-49,51],relevantPassages[throughout,          e.g. abstract, pg. 19209];  LIM SUNG IN ET AL:          ""Self-assembled protein nanocarrier for intracellular          delivery of antibody"", JOURNAL OF CONTROLLED RELEASE,          ELSEVIER, AMSTERDAM, NL, vol. 249, 7 January 2017          (2017-01-07), pages 1 - 10, XP029927777, ISSN: 0168-3659,          DOI:          10.1016/J.JCONREL.2017.01.007,relevantClaims[1-49,51],relevantPassages[throughout,          e.g. abstract, introduction, pgs. 3-6];  JESSICA MARCANDALLI          ET AL: ""Induction of Potent Neutralizing Antibody          Responses by a Designed Protein Nanoparticle Vaccine for          Respiratory Syncytial Virus"", CELL, vol. 176, no. 6, 1          March 2019 (2019-03-01), Amsterdam NL, pages 1420 -          1431.e17, XP055699521, ISSN: 0092-8674, DOI:          10.1016/j.cell.2019.01.046,relevantClaims[1-49,51],relevantPassages[throughout,          e.g. abstract, pgs. 1421-1425]",184611-0-0-0 N; 1013-0-0-0 ; 107779-0-0-0 ,,,RA00H1 N; R00326 ; R01863 ,
WO2024044768-A2;  WO2024044768-A3,"New nucleic acid encoding first and second subunit            of chimeric cytokine receptor, and the subunit            comprises e.g. cytokine receptor intracellular            signaling domain used in composition to administer            cell-based therapy to treat cancer",LABANIEH L;  MACKALL C;  MAJZNER R,UNIV LELAND STANFORD JUNIOR (STRD-C),202423942L,"   NOVELTY - At least one nucleic acid (N1) encoding a                first subunit of a chimeric cytokine receptor and a                second subunit of the chimeric cytokine receptor,                is new, where the first subunit comprises a first                heterologous dimerization domain and a first                cytokine receptor intracellular signaling domain                (ICD) and the second subunit comprises a second                heterologous dimerization domain cognate for the                first heterologous dimerization domain, and a                second cytokine receptor ICD.    USE - The nucleic acid encoding the first and second                subunit is useful in composition which is used for                administering a cell-based therapy to a subject to                treat the cancer, where the subject has cancer, and                the cancer comprises a solid tumor (carcinoma,                lymphoma, blastoma, or sarcoma), hematological                malignancy (leukemia, lymphoma, or multiple                myeloma) (all claimed) or the cancer is e.g.                prostate cancer, vulval cancer, thyroid cancer,                hepatic carcinoma, head and neck cancer, non-small                cell lung cancer, metastatic melanoma, melanoma,                peritoneal cancer, epithelial ovarian cancer,                glioblastoma multiforme (GBM), metastatic                colorectal cancer, colorectal cancer, pancreatic                ductal adenocarcinoma, and squamous cell carcinoma.                Test details are described but no results                given.    ADVANTAGE - None given.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    a chimeric cytokine receptor comprising the                first and second subunits encoded by the nucleic                acids;    at least one expression construct (CO1)                comprising the nucleic acids operably linked to at                least one promoter;    nucleic acid (N2) encoding a membrane                associated polypeptide comprising a transmembrane                domain and a cytokine receptor ICD, in which the                polypeptide does not comprise an extracellular                cytokine binding domain;    a polypeptide encoded by the nucleic acid                (N2);    an expression construct (CO2) comprising the                nucleic acid operably linked to a promoter;    a cell (C1) comprising the nucleic acids (N1)                or (N2);    a cell (C2) comprising the nucleic acid                (N2);    a cell (C3) comprising the expression                constructs (Co1);    a cell (C4) including the expression construct                (CO2);    a composition comprising a population of cells                (C1-C4), where the composition is suitable for                administration to a subject; and    administering (M1) a cell-based therapy to a                subject comprising administering the composition,                where the cells express the chimeric cytokine                receptor comprising the first and second subunits                encoded by the nucleic acids or the membrane                associated polypeptide encoded by the nucleic                acid. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E02H;  B04-E08;  B04-E99;  B04-F01;  B04-F0100E;  B04-G0100E;  B04-G2300E;  B04-G27D0E;  B04-G27E0E;  B04-G27G0E;  B04-H02H0E;  B04-K01G0E;  B04-K01J0E;  B04-K01R0E;  B04-L05A0E;  B04-L05C0E;  B04-N0600E;  B04-N08;  B04-N1100E;  B04-N1200E;  B05-B01N;  B06-H;  B07-H;  B10-B03B;  B14-H01;  B14-S18;  B14-S21;  D05-H12C;  D05-H12E;  D05-H14;  D05-H99,A61K-039/00;  C07K-014/705;  A61K-035/17;  A61K-048/00,WO2024044768-A2   29 Feb 2024   C07K-014/705   202422Pages: 105   English;  WO2024044768-A3   04 Apr 2024   A61K-035/17   202429   English,WO2024044768-A2    WOUS072943    25 Aug 2023;   WO2024044768-A3    WOUS072943    25 Aug 2023,,US401437P    26 Aug 2022,WO2024044768-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2024044768-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,";  WO2024044768-A3 -- CN108350047-A   AUTOLUS LTD (AUTL)   PULE M,  CORDOBA S,  RIGHI M,  SILLIBOURNE J,  ONUOHA S,  THOMAS S;  WO2018087597-A1   UTI LP (UTIU)   SANTAMARIA P;  WO2021068068-A1   PROVINCIAL HEALTH SERVICES AUTHORITY (PROV-Non-standard);  UVIC IND PARTNERSHIPS INC (UVIC-Non-standard)   NELSON B,  FULLER M,  BOULANGER M J",,93605-0-0-0 M N Q; 184611-0-0-0 M N Q; 200757-0-0-0 M N Q; 1536600-0-0-0 M N Q; 231364-0-0-0 M N Q; 114068-0-0-0 M N Q; 161211-0-0-0 M N Q; 204242-0-0-0 M N Q; 184602-0-0-0 M N Q; 1372378-0-0-0 K M; 1539673-1-0-0 K M; 2088724-1-0-0 K M; 2658726-1-0-0 K M; 2345547-1-0-0 K M;  K M; 99051-1-0-0 K M; 106535-1-0-0 K M; 157540-1-0-0 K M; 161989-1-0-0 K M; 182803-1-0-0 K M; 86228-1-0-0 K M; 195550-1-0-0 K M; 221899-1-0-0 K M; 1704576-3-0-0 K M; 135630-1-0-0 K M;  K M; 345632-1-0-0 K M; 93605-0-0-0 CL NEW RCT USE; 184611-0-0-0 CL NEW RCT USE; 200757-0-0-0 CL NEW RCT USE; 1536600-0-0-0 CL NEW RCT USE; 231364-0-0-0 CL NEW RCT USE; 114068-0-0-0 CL NEW RCT USE; 161211-0-0-0 CL NEW RCT USE; 204242-0-0-0 CL NEW RCT USE; 184602-0-0-0 CL NEW RCT USE; 1372378-0-0-0 CL USE; 1539673-1-0-0 CL USE; 2088724-1-0-0 CL USE; 2658726-1-0-0 CL USE; 2345547-1-0-0 CL USE; 1704576-3-0-0 CL USE,,00998; 00690,RA00NS M N Q; RA00H1 M N Q; RA00GT M N Q; RARMJD M N Q; RA0NI7 M N Q; RA0XBB M N Q; RARILT M N Q; RARILV M N Q; RARNW5 M N Q; RA02ZR M N Q; RA02DV M N Q; RAUJEG K M; RAV3CA K M; RB45QT K M; RB3B4M K M; RBFLON K M; RBEFD2 K M; RBWDQT K M; RA0AIC K M; RA0H1C K M; RA0AIB K M; RA17MV K M; RA1C6R K M; RA02DL K M; RA2YCC K M; RA0GA7 K M; RB0ACK K M; RA01BX K M; RA1V8U K M; RD4EJW K M; RA6LD0 K M; RACKLE K M,
WO2023173114-A2;  WO2023173114-A3,"New adenovirus virus-like particle comprising            recombinant capsid comprising major capsid adenovirus            proteins, minor capsid/cement adenovirus proteins, and            chaperone adenovirus protein L4-100k used to generate            immune response to adenovirus",GALARZA J M;  WEN K;  KUSCHNER R,TECHNOVAX INC (TECH-Non-standard);  US SEC OF ARMY (USSA-C),202397484T,"   NOVELTY - Adenovirus virus-like particle (AdVLP)                comprising: a recombinant capsid comprising: (a)                major capsid adenovirus (AdV) proteins including a                hexon protein, a penton protein, and a fiber                protein, (b) minor capsid/cement AdV proteins,                including a Illa protein, a VI protein, a VIII                protein, and a IX protein, where the minor                capsid/cement AdV proteins structurally support the                major capsid AdV proteins, (c) a chaperone AdV                protein L4-100k, and (d) an accessory scaffold AdV                protein L1-52/55k, is new.    USE - The method is useful for generating an immune                response to at least one adenoviruses in a subject,                where the subject is a human, and the immune                response vaccinates the subject against the                adenoviruses (all claimed), and treating infections                with adeno virus. Test details are described but no                results given.    ADVANTAGE - The method protect humans or other species                against infection with at least one adenovirus                types or serotypes included, displayed, or produced                by the vaccine.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    expression plasmid comprising genes encoding                adenovirus proteins, where the expression plasmid                is suitable for the assembly of adenovirus                virus-like particles (AdVLPs) and the expression                plasmid comprises codon-optimized genes encoding:                (a) major capsid adenovirus (AdV) proteins                including a hexon protein, a penton protein, and a                fiber protein, (b) minor capsid/cement AdV                proteins, including a Illa protein, a VI protein, a                VIII protein, and a IX protein, (c) a chaperone AdV                protein L4-100k, and (d) an accessory scaffold AdV                protein L1-52/55k;    immunogenic composition comprising at least                one AdVLP;    generating an immune response to one or more                adenoviruses in a subject, comprising administering                the immunogenic composition to the subject;                and    producing an adenovirus virus -like particle                (AdVLP). ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-C01G;  B04-E02F;  B04-E03F;  B04-E08;  B04-E99;  B04-F1100E;  B04-N03K;  B11-C04;  D05-H12E;  D05-H99,C12N-015/86;  C12N-007/00;  C07K-014/075;  C07K-014/165;  C12N-015/861;  C12N-007/02,WO2023173114-A2   14 Sep 2023   C12N-015/86   202379Pages: 97   English;  WO2023173114-A3   25 Jan 2024   C12N-015/861   202410   English,WO2023173114-A2    WOUS064176    10 Mar 2023;   WO2023173114-A3    WOUS064176    10 Mar 2023,,US318742P    10 Mar 2022,WO2023173114-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2023173114-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CV;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SC;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW  ,,";  WO2023173114-A3 -- US20060210967-A1   ;  US20060240412-A1   ;  US20100254947-A1   ;  US20200123571-A1   ;  US7582433-B2   ENGELHARD E K (ENGE-Individual)   ENGELHARD E K;  WO2017174573-A1   EMBED TECH TRANSFER LTD (EMBE-Non-standard)   HARRISON B,  MACHALE R;  WO2022003083-A1   REITHERA SRL (REIT-Non-standard)   COLLOCA S,  LAHM A,  RAGGIOLI A,  VITELLI A","WO2023173114-A3  DATABASE NUCLEOTIDE          ANONYMOUS : ""Human mastadenovirus B isolate DRC Kahuzi          Gorilla beringei graueri 6759, complete genome"",          XP093136892, retrieved from          NCBI,relevantClaims[4-14],relevantPassages[; entire          document, especially residues 12037-13803]",,,,,
CN112557645-A;  WO2021180232-A1;  CN112557645-B;  EP4119946-A1;  US2023136600-A1;  EP4119946-A4,"Method for screening epitope polypeptide by            processor involves predicting epitope by all proteomic            sequences of target coronavirus, screening out peptides            with differential responses and aligning differential            peptide segment",LI Y;  WANG J;  ZHENG H;  LIU B;  YAN M;  CAO J;  LI Z;  SHEN L;  LI D;  DING Q;  SUN J;  LIANG Z,ZHUHAI TANYUN INTELLIGENT TECHNOLOGY CO LTD (ZHUH-Non-standard);  ICARBONX ZHUHAI CO LTD (ICAR-Non-standard);  ZHUHAI TANYUN INTELLIGENT TECHNOLOGY CO (ZHUH-Non-standard);  ICARBONX ZHUHAI CO LTD (ICAR-Non-standard);  ICARBONX ZHUHAI CO LTD (ICAR-Non-standard),202136805Y,"   NOVELTY - Method for screening epitope polypeptide,                comprises predicting the epitope using all                proteomic sequences of the target coronavirus,                obtaining the predicted epitope region, screening                out peptides with differential responses between                positive serum samples and control serum samples                infected with the target coronavirus using peptide                chip technology, and recording as differential                peptides, aligning the differential peptide segment                with all the proteomic sequences of the target                coronavirus to obtain the first conserved motif                region, and selecting a region that meets the                epitope screening conditions from the predicted                epitope region and the first conserved motif region                to obtain the epitope polypeptide, where the                epitope screening conditions comprises the                non-phosphorylated region and/or the extramembrane                region of the target coronavirus.    USE - The method is useful for screening epitope                polypeptide by a processor (claimed).    ADVANTAGE - The method has screens a batch of peptides                specifically related to coronavirus infection                through the use of low-cost and high-throughput                peptide chip technology to provide more powerful                peptide products for the prevention and control of                virus.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) a screening device for epitope                polypeptide; and    (2) a storage medium, comprising a set of                instructions for screening epitope                polypeptide.    DESCRIPTION OF DRAWING(S) - The drawing shows a flow chart illustrating                the method useful for screening epitope polypeptide                by processor (Drawing includes non-English language                text). ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)",B04-E99;  B04-B04C;  B04-B04D4;  B04-N03K;  B04-N04;  B11-C10;  B11-C11;  B12-K04G1B;  D05-H99;  D05-H09;  S03-E09F;  S03-E14H,G01N-033/543;  G01N-033/569;  G01N-033/68;  G01N-033/53;  A61K-039/00;  A61K-039/12;  A61P-031/14;  C07K-014/005;  G01N-033/00,CN112557645-A   26 Mar 2021   G01N-033/543   202135Pages: 85   Chinese;  WO2021180232-A1   16 Sep 2021   G01N-033/543   202177   Chinese;  CN112557645-B   08 Mar 2022   G01N-033/543   202225   Chinese;  EP4119946-A1   18 Jan 2023   G01N-033/543   202307   English;  US2023136600-A1   04 May 2023   G01N-033/68   202338   English;  EP4119946-A4   24 Apr 2024   G01N-033/543   202436   English,CN112557645-A    CN11629071    30 Dec 2020;   WO2021180232-A1    WOCN080636    12 Mar 2021;   CN112557645-B    CN11629071    30 Dec 2020;   EP4119946-A1    EP767268    12 Mar 2021;   US2023136600-A1    US17911143    13 Sep 2022;   EP4119946-A4    EP767268    12 Mar 2021,CN112557645-B Previous Publ. Patent CN112557645;   EP4119946-A1 PCT application Application WOCN080636;   EP4119946-A1 Based on Patent WO2021180232;   US2023136600-A1 PCT application Application WOCN080636,CN10176984    13 Mar 2020;  CN10291238    14 Apr 2020;  CN11629071    30 Dec 2020;  WOCN080636    12 Mar 2021,  WO2021180232-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW    EP4119946-A1:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  KH;  LI;  LT;  LU;  LV;  MA;  MC;  MD;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TN;  TR    EP4119946-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  ,,"CN112557645-A -- CN105524984-A   SHENZHEN BGI TECHNOLOGY CO LTD (BGIG)   HOU Y,  LIU G,  LI G,  WU K,  YE X,  LIN H,  ZHU S;  CN108164587-A   CANCER HOSPITAL CHINESE ACAD MEDICINE SC (MSUM)   ZHAO X,  ZHOU D,  ZHENG W,  SUN Y,  DAI S,  LIU F,  ZHOU L;  US20040096820-A1   ;  US20050026215-A1   ;  US20170131276-A1   ;  US6861234-B1   CTL IMMUNOTHERAPIES CORP (MAKD)   SIMARD J J L,  DIAMOND D C,  LEI X;  WO2019006022-A1   BROAD INST INC (BROD);  GEN HOSPITAL CORP (GEHO);  XAVIER R (XAVI-Individual)   XAVIER R,  GRAHAM D B,  LUO C;  WO2021180232-A1 -- CA2485467-A1   JIA W (JIAW-Individual)   JIA W;  CN111848753-A   INST PROCESS ENG CHINESE ACAD SCI (CAGC)   LIU R,  LU S,  XIE X;  CN111978378-A   UNIV WUHAN (UYWU)   XU K,  ZHENG Y,  TANG D,  SONG K;  CN112646005-A   ZHUHAI TANYUN INTELLIGENT TECHNOLOGY CO (ZHUH-Non-standard)   WANG J,  LI Y,  ZHENG H,  LIU B,  LIANG Z,  LI Z,  SHEN L,  LI D,  DING Q,  SUN J,  LUO H,  SONG J;  EP4119946-A4 -- US20060062804-A1   ","CN112557645-A  : """",          ,relevantClaims[1-19],relevantPassages[291-295]WO2021180232-A1  SMITH CHRISTOF C.,          ENTWISTLE SARAH, WILLIS CARYN, VENSKO STEVEN, BECK          WOLFGANG, GARNESS JASON, SAMBADE MARIA, ROUTH ERIC, OLSEN          KE: ""Landscape and Selection of Vaccine Epitopes in          SARS-CoV-2"", 4 June 2020 (2020-06-04), pages 1 - 27,          XP055845161, Retrieved from the Internet          &lt;URL:https://www.biorxiv.org/content/10.1101/2020.06.04.135004v1.full.pdf&gt;          DOI:          10.1101/2020.06.04.135004,relevantClaims[1-19],relevantPassages[the          abstract, and pp. 4-16];  YI ZHIGANG, LING          YUN, ZHANG XIAONAN, CHEN JIELIANG, HU KONGYING, WANG          YUYAN, SONG WUHUI, YING TIANLEI, ZHANG RONG, LU HONGZHOU,          YU: ""Functional Mapping of B-cell Linear Epitopes of          SARS-CoV-2 in COVID-19 Convalescent Population"", EMERGING          MICROBES & INFECTIONS, vol. 9, no. 1, 1 January 2020          (2020-01-01), pages 1988 - 1996, XP055845142, DOI:          10.1080/22221751.2020.1815591,relevantClaims[1-19],relevantPassages[pp.          1988-1996];  LLUC          FARRERA-SOLER,JEAN-PIERRE DAGUER,SOFIA BARLUENGA,OSCAR          VADAS,PATRICK COHEN,SABRINA PAGANO,SABINE YERLY,LAURENT          KAISER,NICOLAS: ""Identification of Immunodominant Linear          Epitopes from SARS-CoV-2 Patient Plasma"", PLOS ONE, vol.          15, no. 9, 9 September 2020 (2020-09-09), pages 1 - 15,          XP055845148, DOI:          10.1371/journal.pone.0238089,relevantClaims[1-19],relevantPassages[e0238089];  ZHANG JIAJIE:          ""Design Synthesis and Immune Reaction of Epitope Peptides          of SARS-CoV Spike Protein"", DOCTORAL DISSERTATION, no. 4,          15 December 2004 (2004-12-15), CN, pages 1 - 107,          XP009530311,relevantClaims[1-19],relevantPassages[the          abstract, and pp. 15-29, 32 and 39-45];  HU HONGBO, LI LI,          KAO RICHARD Y., KOU BINBIN, WANG ZHANGUO, ZHANG LIANG,          ZHANG HUIYUAN, HAO ZHIYONG, TSUI WAYNE H., NI ANPING,          CUI: ""Screening and Identification of Linear B-Cell          Epitopes and Entry-Blocking Peptide of Severe Acute          Respiratory Syndrome (SARS)-Associated Coronavirus Using          Synthetic Overlapping Peptide Library"", JOURNAL OF          COMBINATORIAL CHEMISTRY., vol. 7, no. 5, 1 September 2005          (2005-09-01), pages 648 - 656, XP055814671, ISSN:          1520-4766, DOI:          10.1021/cc0500607,relevantClaims[1-19],relevantPassages[the          abstract, and p. 648, right column, the last paragraph to          p. 651, right column, paragraph 3, Experimental          Section];  WANG XIAOHUA, TONG          DEYAN, XU HUANBIN, XIONG LINGYUN, XIONG SIDONG:          ""Prediction and Prokaryotic Expression of a Multi-Epitope          Mosaic Protein from the SARS-Cov Membrane Protein"",          CURRENT IMMUNOLOGY, vol. 24, no. 5, 20 September 2004          (2004-09-20), CN, pages 380 - 385, XP009530290, ISSN:          1001-2478,relevantClaims[1-19],relevantPassages[pp.          380-385];  HE, FAN:          ""Comparison of S Genome Sequence of SARS- CoV and          Prediction of B Cell Epitopes"", CHINESE JOURNAL OF PUBLIC          HEALTH, vol. 20, no. 8, 10 August 2004 (2004-08-10),          pages 919 - 920, XP009530291, ISSN:          1001-0580,relevantClaims[1-19],relevantPassages[pp. 919          and 920];  LIU, HUAIDONG:          ""Screening and Preliminary Application of Epitopes of          Epitopes of Peste des Petits Ruminants Virus"", MASTER          THESIS, 15 October 2018 (2018-10-15), CN, pages 1 - 72,          XP009530313,relevantClaims[1-19],relevantPassages[the          abstract, and pp. 21-38];  ""Epitope mapping          protocols; IN: Methods in Molecular Biology"", vol. 524,          31 December 2009, HUMANA PRESS, US, ISBN:          978-1-934115-17-6, ISSN: 1064-3745, article JULIANE          BONGARTZ; NICOLE BRUNI; MICHAL OR-GUIL: ""Epitope Mapping          Using Randomly Generated Peptide Library"", pages: 237 -          246, XP009530279, DOI:          10.1007/978-1-59745-450-6_17,relevantClaims[1-19],relevantPassages[pp.          237-246]EP4119946-A4  ABDELMAGEED MIYSSA          I. ET AL: ""Design of multi epitope-based peptide vaccine          against E protein of human COVID-19: An immunoinformatics          approach"", BIORXIV, 2 March 2020 (2020-03-02), pages 1 -          28, XP093136168, Retrieved from the Internet          &lt;URL:https://www.biorxiv.org/content/10.1101/2020.02.04.934232v2.full.pdf&gt;          [retrieved on 20240229], DOI:          10.1101/2020.02.04.934232,relevantClaims[1-15],relevantPassages[&lt;figure&gt;1&lt;/figure&gt;|Materials          and Methods];  MARTINEZ VIEDMA          MARIA DEL PILAR ET AL: ""Peptide Arrays of Three          Collections of Human Sera from Patients Infected with          Mosquito-Borne Viruses"", BIORXIV, 26 May 2019          (2019-05-26), pages 1 - 14, XP093099258, Retrieved from          the Internet          &lt;URL:https://www.biorxiv.org/content/10.1101/650796v1.full.pdf&gt;          [retrieved on 20231108], DOI:          10.1101/650796,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  SYED FARAZ AHMED ET          AL: ""Preliminary Identification of Potential Vaccine          Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based          on SARS-CoV Immunological Studies"", VIRUSES, vol. 12, no.          3, 25 February 2020 (2020-02-25), pages 254, XP055716518,          DOI:          10.3390/v12030254,relevantClaims[1-15],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|Materials          and Methods];  ROBSON B ED -          WESSEL NIELS ET AL: ""Computers and viral diseases.          Preliminary bioinformatics studies on the design of a          synthetic vaccine and a preventative peptidomimetic          antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19)          coronavirus"", COMPUTERS IN BIOLOGY AND MEDICINE, NEW          YORK, NY, US, vol. 119, 26 February 2020 (2020-02-26),          XP086102840, ISSN: 0010-4825, [retrieved on 20200226],          DOI:          10.1016/J.COMPBIOMED.2020.103670,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            See also references of WO 2021180232A1",,,,,
WO2021176397-A2;  IN202011009383-A;  WO2021176397-A3;  EP4114986-A2;  IN202217050380-A;  CN115867561-A;  EP4114986-A4,"New recombinant polypeptide comprising specified            sequence and its variants, used to e.g. produce            recombinant polynucleotide, and to express spike,            membrane and envelope protein from severe acute            respiratory syndrome associated coronavirus",ARORA K;  RASTOGI R;  MEHROTRA N;  KUNDU P;  RUCHIR R,PREMAS BIOTECH PVT LTD (PREM-Non-standard);  PREMAS BIOTECH PVT LTD (PREM-Non-standard),2021A3726D,"   NOVELTY - Recombinant polypeptide comprising SEQ ID NO:                1 (comprising a fully defined amino acid sequence                of 1273 amino acids as given in the specification),                SEQ ID NO: 2 (comprising a fully defined amino acid                sequence of 222 amino acids as given in the                specification), SEQ ID NO: 3 (comprising a fully                defined amino acid sequence of 75 amino acids as                given in the specification and its variants, is                new. The recombinant polypeptide belongs to                proteins including spike (S), membrane (M) and                envelope (E) proteins, respectively from severe                acute respiratory syndrome associated coronavirus                (SARS-CoV) family, and the proteins are either                individually expressed or co-expressed.    USE - The recombinant polypeptide is used in                recombinant molecule, recombinant polynucleotide,                and to express spike, membrane and envelope protein                from SARS-CoV (claimed). No biological data                given.    ADVANTAGE - The recombinant polypeptide provides VLPs with                high yields.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) recombinant molecule, comprising                recombinant polypeptides, where the molecule is a                complex formed by assembly of polypeptides defined                in SEQ ID NOs: 1, 2 and 3 or their variants and is                obtained after co-expression of S, M and E proteins                to form an ordered aggregate;    (2) recombinant polynucleotide, comprising the                SEQ ID NOs: 4, 5 and 6 or their variants, where the                polynucleotides includes from spike (S), membrane                (M) and envelope (E) genes from SARS-CoV family,                and the genes are cloned individually or in                combination;    (3) expressing SARS-CoV proteins, comprising                selecting the target genes from the group                comprising of S, E and M proteins, optimizing and                codon biasing of target gene sequences, preparing                the construct comprising target genes and                yeast-based expression vectors by cloning of target                genes individually or in combination to co-express                the proteins into the expression vector, where the                expression vector is yeast based expression vector                including episomal expression vector and/or                integrative expression vector, and transforming the                constructs into protease deficient yeast host cell                to obtain target proteins;    (4) expressing S protein from SARS-CoV;    (5) expressing M protein from SARS-CoV;    (6) expressing E protein from SARS-CoV;    (7) expressing the SARS-CoV proteins,                comprising co-expressing S, E and M proteins                comprises selecting the S, E and M proteins from                SARS-CoV, optimizing and codon biasing of target                gene sequences, cloning S and E proteins into an                episomal expression vector to obtain a construct                having SEQ ID NO: 10 (comprising a fully defined                nucleotide sequence of 10341 nucleotides as given                in the specification), and M protein into                integrative expression vector to obtain a construct                having SEQ ID NO: 11 (comprising a fully defined                nucleotide sequence of 6364 nucleotides as given in                the specification), preparing the construct                comprising the selected genes and yeast vectors,                transforming the constructs into yeast host, and                over-expressing the target multi-subunit proteins                in the cell;    (8) a construct, comprising the target genes                including S, M and E proteins of SARS-CoV having                SEQ ID NOs: 7, 8 and 9 or variants, individually or                in combination to co-express in yeast-based                expression vectors, where the vectors including                episomal and/or integrative vectors and any two                proteins are expressed in episomal and one protein                is expressed in integrative expression                vector;    (9) recombinant corona virus like particle                (VLP), comprising SARS-CoV proteins, where the                SARS-CoV proteins are a SARS-CoV-virus spike                proteins (S), a SARS-CoV-virus Membrane proteins                (M), and a SARS-CoV-virus envelope proteins (E), or                its variants;    (10) preparing the target VLPs comprising the                target proteins including S, M and E proteins of                SARS-CoV, individually or in combination,                comprising inserting the target gene including S, M                and E proteins of SARS-CoV into protease deficient                yeast host cell by either episomal construct or                integrative construct, transforming the selected                genes in protease deficient yeast host strain,                selecting the transformants on selective YNB                glucose medium and without LEU auxotrophic marker                in case of integrative construct and without URA                auxotrophic marker in case of episomal construct,                transforming the selected genes in protease                deficient yeast host strain, selecting the                transformants on YNB with Glucose without URA and                LEU auxotrophic marker plates, and performing                transformation, where transformation is a                sequential transformation and performed using                Lithium acetate/SS-DNA/PEG mediated protocol;    (11) preparing the target VLPs, comprising the                target M protein of SARS-CoV, individually,                comprising integrating/episomally inserting the M                gene into protease deficient yeast host cell,                transforming the M gene in Protease deficient yeast                host strain, selecting the transformants on YNB                glucose medium without LEU auxotrophic marker in                case of integrative construct and without URA                auxotrophic marker in case of episomal construct,                and performing transformation, where the                transformation is performed using Lithium                acetate/SS-DNA/PEG mediated protocol;    (12) preparing the target VLPs, comprising the                target E and M protein of SARS-CoV, in combination,                comprising integrating/episomally inserting the E                or M gene into protease deficient yeast host cell,                transforming the E or M gene in protease deficient                yeast host strain, selecting the transformants on                YNB glucose medium without LEU auxotrophic marker                in case of integrative construct and without URA                auxotrophic marker in case of episomal construct,                transforming the E or M gene in protease deficient                yeast host strain for co expression, selecting the                transformants on YNB Glucose without URA and LEU                auxotrophic marker plates for co-expression using                episomal and integration vector, and selecting the                transformants on YNB Glucose without URA for                expression of both using episomal vector or YNB                glucose without LEU for expression of both using                integration vector, and performing transformation,                where transformation is performed using Lithium                acetate/SS-DNA/PEG mediated protocol;    (13) preparing the target VLPs, comprising the                target proteins including S, M and E proteins of                SARS-CoV;    (14) producing the scalable amount of                VLPs;    (15) an immunogenic composition, comprising                the VLPs, along with excipients, adjuvants and/or                stabilizers, where the VLP formulation is                administered with or without an adjuvant; and    (16) a vaccine comprising the VLPs induces an                immune response in a subject. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.)",B04-C01G;  B04-E02F;  B04-E03F;  B04-E08;  B04-E99;  B04-L05C;  B04-N03K1E;  B14-A02B5;  B14-S11A;  B14-S11D3;  C04-C01G;  C04-E02F;  C04-E03F;  C04-E08;  C04-E99;  C04-L05C;  C04-N03K1E;  C14-A02B5;  C14-S11A;  C14-S11D3;  D05-A02C;  D05-C12;  D05-H12A;  D05-H12E;  D05-H17A6;  D05-H99;  A10-E01;  A12-V;  A12-V01,A61K-039/215;  A61K-039/00;  C07K-014/005;  A61K-039/12;  C12N-001/36;  A61K-039/155;  C07H-021/04;  C07K-014/165;  C12N-015/86;  C12Q-001/70,WO2021176397-A2   10 Sep 2021   A61K-039/215   202181Pages: 61   English;  IN202011009383-A   10 Sep 2021   A61K-039/00   202182   English;  WO2021176397-A3   21 Oct 2021   C12Q-001/70   202186   English;  EP4114986-A2   11 Jan 2023   C12Q-001/70   202304   English;  IN202217050380-A   27 Jan 2023   C12Q-001/70   202312   English;  CN115867561-A   28 Mar 2023   C07H-021/04   202331   Chinese;  EP4114986-A4   27 Mar 2024   C12Q-001/70   202427   English,WO2021176397-A2    WOIB051828    04 Mar 2021;   IN202011009383-A    IN11009383    04 Mar 2020;   WO2021176397-A3    WOIB051828    04 Mar 2021;   EP4114986-A2    EP764218    04 Mar 2021;   IN202217050380-A    IN17050380    03 Sep 2022;   CN115867561-A    CN80031106    04 Mar 2021;   EP4114986-A4    EP764218    04 Mar 2021,EP4114986-A2 PCT application Application WOIB051828;   EP4114986-A2 Based on Patent WO2021176397;   IN202217050380-A PCT application Application WOIB051828;   IN202217050380-A Based on Patent WO2021176397;   CN115867561-A PCT application Application WOIB051828;   CN115867561-A Based on Patent WO2021176397,IN11009383    04 Mar 2020;  WOIB051828    04 Mar 2021;  CN80031106    26 Oct 2022,WO2021176397-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    WO2021176397-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP4114986-A2:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN      EP4114986-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  ,,;  WO2021176397-A3 -- US20060257852-A1   ,"WO2021176397-A3  CHEN ET AL.:          ""Yeast-expressed recombinant protein of the          receptor-binding domain in SARS- CoV spike protein with          deglycosylated forms as a SARS vaccine candidate"", HUMAN          VACCINES & IMMUNOTHERAPEUTICS, vol. 10, no. 3, 2014,          pages 648 - 658, XP055824794, DOI:          10.4161/hv.27464,relevantClaims[19,          20],relevantPassages[; Abstract, pg 649, Fig 1; pg 652,          col 2 to pg 654, col 1];  MACAULEY-PATRICK ET          AL.: ""Heterologous protein production using the Pichia          pastoris expression system"", YEAST, vol. 22, no. 4, 2005,          pages 249 - 70, XP002474659, DOI:          10.1002/yea.1208,relevantClaims[19,          20],relevantPassages[; Abstract, pg 255]",184616-0-0-0 M N P; 444-0-0-0 ; 184616-0-0-0 CL NEW PRD USE,,,RA00H3 M N P; R00351 ,
WO2022271820-A1,"Composition useful for reducing the risk of having            a viral infection comprises (a) a spatial array            comprising: a capture probes, (b) a biological sample            on the spatial array, and (c) first probes and second            probes",GIACOMELLO S;  SOUNART H E;  HILL A J;  BORGSTROM E L H;  JUREK A;  CHELL J M;  MASARAPU Y,10X GENOMICS INC (TNXG-C),202300737R,"   NOVELTY - Composition comprises (a) a spatial array                comprising: a capture probes, where a capture probe                of many capture probes comprises a spatial barcode                and a capture domain; (b) a biological sample on                the spatial array where the biological sample                comprises a plurality of nucleic acids; (c) first                probes and second probes, where a first probe and a                second probe comprise a sequence that is                substantially complementary to sequences of a host                nucleic acid; and where the first probe or the                second probe comprises a capture domain that is                complementary to the capture domain on a capture                probe, and (d) additionally first coronavirus                probes and second coronavirus probes, where a first                coronavirus probe and a second coronavirus probe                comprise a sequence that is substantially                complementary to sequences of a coronavirus nucleic                acid, and where one of the first coronavirus probe                or the second coronavirus probe comprises a capture                domain that is complementary to the capture domain                of a capture probe.    USE - The composition is useful for: determining the                abundance and/or location of a coronavirus nucleic                acid in a biological sample; and identifying the                presence or absence of a coronavirus infection in a                subject; and treating for reducing the risk of                having a viral infection (all claimed). Test                details are described but no results given.    ADVANTAGE - None given.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) determining the abundance and/or location                of a coronavirus nucleic acid in a biological                sample comprising (a) contacting the biological                sample with a substrate comprising a plurality of                capture probes, where a capture probe comprises a                spatial barcode and a capture domain, (b)                contacting the biological sample many first                coronavirus probes and second coronavirus probes,                where a first coronavirus probe and a second                coronavirus probe comprise a sequence that is                substantially complementary to sequences of the                coronavirus nucleic acid, and where the second                probe comprises a capture probe capture domain that                is complementary to all or a portion of the capture                domain of a capture probe, (c) hybridizing the                first coronavirus probe and the second coronavirus                probe to the coronavirus nucleic acid, (d) ligating                the first coronavirus probe and the second                coronavirus probe, thus generating a ligation                product, (e) releasing the ligation product from                the coronavirus nucleic acid, and (1) determining                (i) all or part of the sequence of the ligation                product, or a complement, and (ii) the spatial                barcode, or a complement, and using the determined                sequence of (i) and (ii) to determine the abundance                and location of the coronavirus nucleic acid in the                biological sample;    (2) identifying the presence or absence of a                coronavirus infection in a subject comprising (a)                obtaining a biological sample from the subject, (b)                contacting the biological sample with a substrate                comprising capture probes, where a capture probe                comprises a spatial barcode and a capture domain,                (c) contacting the biological sample with a first                coronavirus probes and second coronavirus probes,                where a first coronavirus probe and a second                coronavirus probe comprise a sequence that is                substantially complementary to sequences of a                coronavirus nucleic acid, and where the second                coronavirus probe comprises a capture domain that                is complementary to all or a portion of the capture                domain of a capture probe, (d) hybridizing the                first coronavirus probe and the second coronavirus                probe to the coronavirus nucleic acid, (e) ligating                the first coronavirus probe to the second                coronavirus probe, thus generating a coronavirus                ligation product, (f) releasing the coronavirus                ligation product from the coronavirus nucleic acid,                and (g) determining (i) all or part of the sequence                of the coronavirus ligation product, or a                complement thereof, and (ii) the spatial barcode,                or a complement, and using the determined sequence                of (i) and (ii) to identify the presence or absence                of a coronavirus infection in a subject; and    (3) a kit comprising a substrate comprising a                plurality of capture probes, where a capture probe                of the capture probes comprises a spatial barcode                and a capture domain, (b) first coronavirus probes                and second coronavirus probes, where a first                coronavirus probe and a second coronavirus probe                each comprise a sequence that is substantially                complementary to sequences of a coronavirus nucleic                acid, and where one of the first coronavirus probe                or the second coronavirus probe comprises a capture                domain that is complementary to the capture domain                of a capture probe on the substrate, and (c)                instructions for performing. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E01;  B04-E05;  B04-E99;  B04-F02;  B04-F11B2;  B04-L04A;  B04-L05;  B04-L08;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  B14-A02;  D05-A02C;  D05-H06A;  D05-H18B;  D05-H99,C12Q-001/6837;  C12Q-001/6841,WO2022271820-A1   29 Dec 2022   C12Q-001/6837   202305Pages: 270   English,WO2022271820-A1    WOUS034520    22 Jun 2022,,US213582P    22 Jun 2021;  US246581P    21 Sep 2021;  US276202P    05 Nov 2021;  US291040P    17 Dec 2021,WO2022271820-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2022271820-A1 -- WO2020047005-A1   10X GENOMICS INC (TNXG);  LUCERO M Y (LUCE-Individual);  SCHNALL-LEVIN M (SCHN-Individual);  MIKKELSEN T S (MIKK-Individual);  RAMACHANDRAN IYER E P (IYER-Individual)   LUCERO M Y,  SCHNALL-LEVIN M,  MIKKELSEN T S,  RAMACHANDRAN IYER E P;  WO2020176788-A1   10X GENOMICS INC (TNXG);  RAMACHANDRAN IYER E P (IYER-Individual);  MIKKELSEN T S (MIKK-Individual);  TENTORI A M (TENT-Individual);  BHARADWAJ R (BHAR-Individual);  STOECKIUS M (STOE-Individual);  CHELL J M (CHEL-Individual);  UYTINGCO C (UYTI-Individual)   RAMACHANDRAN IYER E P,  MIKKELSEN T S,  TENTORI A M,  BHARADWAJ R,  STOECKIUS M,  CHELL J M,  UYTINGCO C;  WO2020190509-A1   10X GENOMICS INC (TNXG);  FRENZ L (FREN-Individual);  RAMACHANDRAN IYER E P (IYER-Individual);  MIKKELSEN T S (MIKK-Individual)   FRENZ L,  RAMACHANDRAN IYER E P,  MIKKELSEN T S;  WO2017019456-A2   ILLUMINA INC (ILLU)   SO A,  LIU L,  SHEN M R,  SALATHIA N,  STEPHENS K M,  JAGER A,  WILSON T,  FULLERTON J,  RAMIREZ S M,  KAPLAN S,  PANTOJA R,  VENKATESAN B M,  MODIANO S;  US2021150707-A1   10X GENOMICS INC (TNXG)   MCCREATH B,  BORGSTROM E L H,  WEISENFELD N I;  US2021155982-A1   10X GENOMICS INC (TNXG)   YIN Y,  BENT Z,  WILLIAMS S,  FIDDES I,  MELLEN J C,  STAAB J,  WU K J,  WEISENFELD N I,  BAUMGARTNER F,  CLAYPOOLE B,  SHAH P,  DSHKHUNYAN N,  BORGSTROM E L H,  MCCREATH B;  US20130171621-A1   ;  US20150000854-A1   ;  US20160108458-A1   ;  US20170016053-A1   ;  US20170029875-A1   ;  US20170067096-A1   ;  US20170089811-A1   ;  US20170241911-A1   ;  US20180051322-A1   ;  US20180216161-A1   ;  US20180245142-A1   ;  US20190055594-A1   ;  US20190085383-A1   ;  US20190161796-A1   ;  US20190194709-A1   ;  US20190264268-A1   ;  US20190330617-A1   ;  US20200024641-A1   ;  US20200080136-A1   ;  US20200224244-A1   ;  US20200239946-A1   ;  US20200256867-A1   ;  US20200277663-A1   ;  US7709198-B2   LUO Y (LUOY-Individual);  CHEN S (CHEN-Individual)   LUO Y,  CHEN S;  US8604182-B2   LUO Y (LUOY-Individual);  CHEN S (CHEN-Individual)   LUO Y,  CHEN S;  US8951726-B2   LUO Y (LUOY-Individual);  CHEN S (CHEN-Individual)   LUO Y,  CHEN S;  US9593365-B2   SPATIAL TRANSCRIPTOMICS AB (SPAT-Non-standard)   FRISEN J,  STAHL P,  LUNDEBERG J,  SALMEN F;  US9727810-B2   CELLULAR RES INC (BECT)   FODOR S P A,  FAN C,  FU G,  FACER G;  US9783841-B2   UNIV LELAND STANFORD JUNIOR (STRD)   NOLAN G P,  GOLTSEV Y;  US9879313-B2   PROGNOSYS BIOSCI INC (PROG-Non-standard)   CHEE M,  ROUTENBERG D;  US10002316-B2   CELLULAR RES INC (BECT)   FODOR S P A,  FAN C,  FU G,  FACER G;  US10041949-B2   UNIV LELAND STANFORD JUNIOR (STRD)   BENDALL S C,  NOLAN G P,  ANGELO R M;  US10059990-B2   MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   BOYDEN E S,  CHEN F,  ALON S,  CHURCH G,  TILLBERG P W,  MARBLESTONE A,  DAUGHARTHY E;  US10480022-B2   PROGNOSYS BIOSCIENCES INC (PROG-Non-standard)   CHEE M S;  US10724078-B2   KONINK PHILIPS NV (PHIG)   PIERIK A,  VAN DRIEL M,  WIMBERGER-FRIEDL R;  US10774374-B2   SPATIAL TRANSCRIPTOMICS AB (SPAT-Non-standard);  ILLUMINA INC (ILLU)   FRISEN J,  STAHL P,  LUNDEBERG J,  CANN G M,  BAZARGAN L,  ARAVANIS A;  US11501440-B2   10X GENOMICS INC (TNXG)   WEISENFELD N I,  DSHKHUNYAN N,  SHAH P;  WO2018091676-A1   SPATIAL TRANSCRIPTOMICS AB (SPAT-Non-standard)   FRISEN J,  STAHL P,  LUNDEBERG J,  SALMEN F,  VICKOVIC S;  WO2020053655-A1   ZENITH EPIGENETICS LTD (ZENI-Non-standard)   CAMPEAU E,  TSUJIKAWA L,  LAKHOTIA S;  WO2020061066-A1   COMPUTER WORLD SERVICES CORP DBA                  LABSAVVY (COMP-Non-standard)   SCOTT C,  HAMEED F,  SHPUZA F;  WO2020061108-A1   SCHNEIDER ELECTRIC SYSTEMS USA INC (SCHN)   KLING A,  DRIAS Z;  WO2021102003-A1   10X GENOMICS INC (TNXG)   MCCREATH B,  BORGSTROM E L H,  WEISENFELD N I;  WO2020123320-A2   10X GENOMICS INC (TNXG);  UYTINGCO C (UYTI-Individual);  BENT Z (BENT-Individual);  IYER E P R (IYER-Individual);  VALDECANAS F (VALD-Individual);  FREY M L F (FREY-Individual);  SHORT S W (SHOR-Individual);  YIN Y (YINY-Individual);  TENTORI A M (TENT-Individual);  BHARADWAJ R (BHAR-Individual);  COX D M (COXD-Individual);  CHEW J (CHEW-Individual);  LUNDEBERG J (LUND-Individual);  BAVA F A (BAVA-Individual);  KVASTAD L (KVAS-Individual);  PRICE A D (PRIC-Individual)   UYTINGCO C,  BENT Z,  IYER E P R,  VALDECANAS F,  FREY M L F,  SHORT S W,  YIN Y,  TENTORI A M,  COX D M,  CHEW J,  LUNDEBERG J,  BAVA F A,  KVASTAD L,  PRICE A D","WO2022271820-A1  DELOREY TONI M ET          AL: ""COVID-19 tissue atlases reveal SARS-CoV-2 pathology          and cellular targets"", NATURE, NATURE PUBLISHING GROUP          UK, LONDON, vol. 595, no. 7865, 29 April 2021          (2021-04-29), pages 107 - 113, XP037495187, ISSN:          0028-0836, [retrieved on 20210429], DOI:          10.1038/S41586-021-03570-8,relevantClaims[1-46],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  LIU YANG ET AL:          ""High-Spatial-Resolution Multi-Omics Sequencing via          Deterministic Barcoding in Tissue"", CELL, ELSEVIER,          AMSTERDAM NL, vol. 183, no. 6, 13 November 2020          (2020-11-13), pages 1665, XP086400370, ISSN: 0092-8674,          [retrieved on 20201113], DOI:          10.1016/J.CELL.2020.10.026,relevantClaims[1-46],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  MICHAELA ASP ET AL:          ""Spatially Resolved Transcriptomes-Next Generation Tools          for Tissue Exploration"", BIOESSAYS, JOHN WILEY & SONS          LTD, GB, vol. 42, no. 10, 4 May 2020 (2020-05-04), pages          n/a, XP071527643, ISSN: 0265-9247, DOI:          10.1002/BIES.201900221,relevantClaims[1-46],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;|&lt;figure&gt;5&lt;/figure&gt;];            YEAKLEY, PLOS ONE, vol. 12, no. 5, 2017, pages          e0178302;            RODRIQUES ET AL., SCIENCE, vol. 363, no. 6434, 2019,          pages 1463 - 1467;            LEE ET AL., NAT. PROTOC., vol. 10, no. 3, 2015, pages 442          - 458;            TREJO ET AL., PLOS ONE, vol. 14, no. 2, 2019, pages          e0212031;            CHEN ET AL., SCIENCE, vol. 348, no. 6233, 2015, pages          aaa6090;            GAO ET AL., BMC BIOL., vol. 15, 2017, pages 50;            GUPTA ET AL., NATURE BIOTECHNOL., vol. 36, 2018, pages          1197 - 1202;            CREDLE ET AL., NUCLEIC ACIDS RES, vol. 45, no. 14, 21          August 2017 (2017-08-21), pages e128;            VISIUM SPATIAL GENE EXPRESSION REAGENT KITS USER GUIDE,          June 2020 (2020-06-01);            VISIUM SPATIAL TISSUE OPTIMIZATION REAGENT KITS USER          GUIDE, July 2020 (2020-07-01);            HUANG ET AL., ACTA PHARMACOLOGICA SINICA, vol. 41, 2020,          pages 1141 - 1149;            BOLOGNESI ET AL., J. HISTOCHEM. CYTOCHEM., vol. 65, no.          8, 2017, pages 431 - 444;            LIN ET AL., NAT COMMUN., vol. 6, 2015, pages          8390;            PIRICI ET AL., J. HISTOCHEM. CYTOCHEM., vol. 57, 2009,          pages 899 - 905;            ZHANG ET AL., RNA BIOL., vol. 14, no. 1, 2017, pages 36 -          44;            NICHOLS ET AL.: ""RNA Ligases"", CURR. PROTOCOL. MOLEC.          BIOL., vol. 84, no. 1, 2008, pages 1 - 4;            VIOLLET ET AL.: ""T4 RNA Ligase 2 Truncated Active Site          Mutants: Improved Tools for RNA Analysis"", BMC          BIOTECHNOL., vol. 11, 2011, pages 72, XP021105283, DOI:          10.1186/1472-6750-11-72;  HO          ET AL.: ""Bacteriophage T4 RNA Ligase 2 (gp24.1)          Exemplifies a Family of RNA Ligases Found in All          Phylogenetic Domains"", PNAS, vol. 99, no. 20, 2002, pages          12709 - 14;            VIOLLET ET AL.: ""T4 RNA Ligase 2 Truncated Active Site          Mutants: Improved Tools for RNA Analysis"", BMC          BIOTECHNOL, vol. 11;            ""NCBI"", Database accession no. GCA_009858895.3;            CHANG ET AL., AM J MED SCI., vol. 361, no. 1, pages 14 -          22",103599-0-0-0 K M; 201106-0-0-0 K M; 204644-0-0-0 K M; 588592-0-0-0 K M,,,RA0424 K M; RA00R0 K M; RA031J K M; RA81MJ K M,
WO2023037111-A1,"Electrochemical method used in kit for sensing            target protein molecules comprises attaching redox            active tagging moieties, contacting the carrier medium            with electrode and electrochemically determining            whether target protein molecules",DAVIS J;  SHARAFELDIN M;  FLESCHUT F,UNIV OXFORD INNOVATION LTD (UYOX-C),2023287146,"   NOVELTY - Electrochemical method of sensing target                protein molecules comprises: (a) attaching redox                active tagging moieties to protein molecules in                carrier medium that may contain the target protein                molecules, where the redox active tagging moieties                non-specifically bind to protein molecules; (b)                contacting the carrier medium with electrode that                comprehends receptors that specifically bind to                target protein molecules that are bound to the                redox active tagging moieties; and (c)                electrochemically determining whether target                protein molecules are present in the carrier                medium.    USE - The method is useful for kit which is used to                electrochemical sensing of proteins.    ADVANTAGE - The method has high sensitivity, selectivity,                reproducibility, scalability, ease of use, high                speed, and low cost into single platform.    DETAILED DESCRIPTION - An INDEPENDENT CLAIMS is also included for kit                for use in the method comprising redox active                tagging moieties that non-specifically bind to                protein molecules, and electrode that comprises                receptors that specifically bind to target protein                molecules that are bound to the redox active                tagging moieties. ",,,"D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  J04 (Chemical/physical processes/apparatus - including catalysis, catalysts (excluding specific e.g. enzymatic or polymerisation catalysts), colloid chemistry, laboratory apparatus and methods, testing, controlling, general encapsulation, detection and sampling (excluding clinical testing) (B01J, L).);  S03 (Scientific Instrumentation)",D05-H09;  D05-H11;  J04-B03;  S03-E03C;  S03-E09F;  S03-E14H5,B01L-003/00;  G01N-027/327;  G01N-033/543,WO2023037111-A1   16 Mar 2023   G01N-027/327   202325Pages: 44   English,WO2023037111-A1    WOGB052282    08 Sep 2022,,GB012927    10 Sep 2021,WO2023037111-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2023037111-A1 -- CN111537584-A   MILITARY VETERINARY RES INST PLA MILITAR (MILI-Non-standard)   WAN J,  BU S,  LIU W;  US20030104386-A1   ","WO2023037111-A1  SADIK O A ET AL:          ""Status of biomolecular recognition using electrochemical          techniques"", BIOSENSORS AND BIOELECTRONICS, ELSEVIER          SCIENCE LTD, UK, AMSTERDAM , NL, vol. 24, no. 9, 15 May          2009 (2009-05-15), pages 2749 - 2765, XP026053062, ISSN:          0956-5663, [retrieved on 20081021], DOI:          10.1016/J.BIOS.2008.10.003,relevantClaims[14,17-20],relevantPassages[&lt;figure&gt;1&lt;/figure&gt;Conclusions          and future trends];  IDILI ANDREA ET AL:          ""Calibration-Free Measurement of Phenylalanine Levels in          the Blood Using an Electrochemical Aptamer-Based Sensor          Suitable for Point-of-Care Applications"", ACS SENSORS,          vol. 4, no. 12, 2 December 2019 (2019-12-02), US, pages          3227 - 3233, XP093005155, ISSN: 2379-3694, DOI:          10.1021/acssensors.9b01703,relevantClaims[1-20],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;]",,,,,
WO2023092080-A2;  WO2023092080-A3,"New pseudotyped viral particle useful e.g. for            treating patient having cancer e.g. leukemia, comprises            envelope comprising viral envelope glycoprotein domain            fused to variable heavy chain domain and heterologous            polynucleotide",MEARS K;  MANGUSO R;  YATES K;  IBRAHIM K;  ALLEN P,BROAD INST INC (BROD-C);  GEN HOSPITAL CORP (GEHO-C),202356553U,"   NOVELTY - A pseudotyped viral particle comprising (A)                (a) an envelope comprising a viral envelope                glycoprotein domain or its fragment fused to                variable heavy chain (VHH) domain or its fragment,                where the VHH domain or its fragment specifically                binds an antigen present on a target cell and the                viral envelope glycoprotein comprises an alteration                referenced to a measles virus glycoprotein at an                amino acid targeted by a measles virus neutralizing                antibody and (b) a heterologous polynucleotide, or                (B) chimeric polypeptide, is new.    USE - The pseudotyped viral particle is useful in                pharmaceutical composition for delivering a                heterologous polynucleotide to a target cell of a                subject and treating a subject having a cancer. The                cancer is a leukemia or a lymphoma. The subject is                measles-immune. The subject is a mammal, preferably                human (all claimed).    ADVANTAGE - The pseudotyped viral particle resists                neutralization by a measles virus neutralizing                antibody relative to a reference viral particle                pseudotyped with a glycoprotein polypeptide                comprising a measles virus F protein (MeV-Fc)                extravirion domain.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    method for generating a pseudotyped viral                particle for delivering a heterologous                polynucleotide to a target cell;    eukaryotic cell for generating a pseudotyped                viral particle, the eukaryotic cell comprising (a)                a cell membrane comprising a viral envelope                glycoprotein domain or its fragment fused to a VHH                domain or its fragment, where the VHH domain or its                fragment specifically binds an antigen present on a                target cell and the viral envelope glycoprotein                comprises an alteration referenced to a measles                virus glycoprotein at an amino acid targeted by a                measles virus neutralizing antibody, (b) a viral                transfer vector and (c) one or more additional                vectors encoding one or more viral                polypeptides;    mammalian expression vector comprising a                polynucleotide encoding a polypeptide comprising a                viral envelope glycoprotein domain or its fragment                fused to a VHH domain or its fragment, where the                VHH domain or its fragment specifically binds an                antigen present on a target cell and the viral                envelope glycoprotein comprises an alteration                referenced to a measles virus glycoprotein at an                amino acid targeted by a measles virus neutralizing                antibody;    pharmaceutical composition comprising the                pseudotyped viral particle and carrier;    kit for use in the above-mentioned method                comprising the pseudotyped viral particle, the                mammalian expression vector or the pharmaceutical                composition, where the pseudotyped viral particle                comprises a heterologous polynucleotide comprising                a polypeptide-encoding sequence under the control                of a promoter, and instructions for the use of the                kit in the method;    fusion protein suitable for pseudotyping a                viral particle, wherein the fusion protein                comprises a sequence with at least 85% sequence                identity to a sequence chosen from chosen from                DMV-H-MHCII (N11) comprising a polypeptide having a                defined sequence of amino acids (SEQ ID NO: Not                defined), given in the specification, DMV-H-CD7                (Humanized VHH10) comprising a polypeptide having a                defined sequence of amino acids (SEQ ID NO: Not                defined), given in the specification, DMV-H-CD45                (32) comprising a polypeptide having a defined                sequence of amino acids (SEQ ID NO: Not defined),                given in the specification, CDV-H-MHCII (N11)                comprising a polypeptide having a defined sequence                of amino acids (SEQ ID NO: Not defined), given in                the specification, CDV-H-CD7 (Humanized VHH10)                comprising a polypeptide having a defined sequence                of amino acids (SEQ ID NO: Not defined), given in                the specification, CDV-H-CD45 VHH (32) comprising a                polypeptide having a defined sequence of amino                acids (SEQ ID NO: Not defined), given in the                specification, MeV-Hc18-CDV-MHCII (N11) comprising                a polypeptide having a defined sequence of amino                acids (SEQ ID NO: Not defined), given in the                specification, MeV-Hc18-DMV-MHCII (N11) comprising                a polypeptide having a defined sequence of amino                acids (SEQ ID NO: Not defined), given in the                specification, FMV-H-CD45 (32) polypeptide                comprising a polypeptide having a defined sequence                of amino acids (SEQ ID NO: Not defined), given in                the specification, PPRV-H-CD45 (32) comprising a                polypeptide having a defined sequence of amino                acids (SEQ ID NO: Not defined), given in the                specification, RPV-H-CD45 (32) comprising a                polypeptide having a defined sequence of amino                acids (SEQ ID NO: Not defined), given in the                specification and RMV-H-CD45 (32) comprising a                polypeptide having a defined sequence of amino                acids (SEQ ID NO: Not defined), given in the                specification; and    chimeric viral envelope glycoprotein                polypeptide or its fragment suitable for                pseudotyping a viral particle comprising an amino                acid sequence at least 20 amino acids in length                derived from a non-measles virus morbillivirus F                protein extravirion domain N-terminal to an amino                acid sequence at least 20 amino acids in length                derived from a measles virus F protein extravirion                domain. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E08;  B04-E99;  B04-F11;  B04-G01;  B04-G23;  B04-N0200E;  B04-N08;  B14-H01A;  B14-H01G;  C04-E08;  C04-E99;  C04-F11;  C04-G01;  C04-G23;  C04-N0200E;  C04-N08;  C14-H01A;  C14-H01G;  D05-H12D1;  D05-H12E;  D05-H99,A61K-048/00;  C12N-015/86;  C12N-007/04;  C07K-014/12,WO2023092080-A2   25 May 2023   C12N-015/86   202348Pages: 249   English;  WO2023092080-A3   17 Aug 2023   C12N-007/04   202368   English,WO2023092080-A2    WOUS080156    18 Nov 2022;   WO2023092080-A3    WOUS080156    18 Nov 2022,,US280919P    18 Nov 2021;  US280926P    18 Nov 2021;  US359027P    07 Jul 2022,WO2023092080-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2023092080-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CV;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW  ,,,,93605-0-0-0 K U; 105730-0-0-0 K U,,,RA00NS K U; RA012P K U,
WO2023137407-A1,"New nucleic acid primer set comprising first            primer, where first primer comprises first segment of            DNA oligonucleotide and a second segment of DNA            oligonucleotide used to amplify target nucleic acid in            sample",DONG S;  DONG C X;  DONG W X,DONG S (DONG-Individual);  DONG C X (DONG-Individual);  DONG W X (DONG-Individual),2023756989,"   NOVELTY - Nucleic acid primer set comprising a first                primer having a 3' end and a 5' end for amplifying                a target nucleic acid in a sample, where the target                nucleic acid includes a first template strand, and                the first primer comprises a first segment of DNA                oligonucleotide and a second segment of DNA                oligonucleotide, the first segment being at 5' side                of the second segment, the first segment and the                second segment being linked by at least one first                ribonucleotide, at least a portion of the second                segment is capable of specifically hybridizing to                the first template strand, is new.    USE - The nucleic acid primer set or molecular probe                is useful for: amplifying a target nucleic acid in                a sample, where the target nucleic acid includes a                first template strand; detecting a nucleotide                variation in a target nucleic acid in a sample;                detecting amplification of a nucleic acid;                detecting amplification of a nucleic acid; and                detecting an amplicon product in an amplification                reaction system (all claimed).    ADVANTAGE - The nucleic acid primer set: provides highly                efficient nucleic acid amplification; enables easy                and fast detection of nucleic acid targets; enables                quick detection of genetic variations and pathogens                e.g. severe acute respiratory syndrome coronavirus                2.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    amplifying (M1) a target nucleic acid in a                sample, where the target nucleic acid includes a                first template strand, comprising (a) contacting                the sample with a first primer having a 3' end and                a 5' end and comprises a first oligonucleotide                segment and a second oligonucleotide segment, the                first oligonucleotide segment being at 5' side of                and linked with the second oligonucleotide segment                by at least one first ribonucleotide, under                conditions where at least a portion of the second                segment anneals to the first template strand, (b)                producing a first amplicon complementary to the                first template strand by extending the first primer                using the first template strand as the template,                and (c) cleaving the first primer at the position                immediately 5' to the at least one first                ribonucleotide;    detecting (M2) a nucleotide variation in a                target nucleic acid in a sample, the sample                containing a first double-stranded DNA and a second                double stranded DNA, the second double stranded DNA                differing from the first double stranded DNA at                variance position, comprising (a2) contacting the                sample with a first primer having a 3' end and a 5'                end and comprises a first oligonucleotide segment                and a second oligonucleotide segment, the first                oligonucleotide segment being at 5' side of and                linked with the second oligonucleotide segment by                at least one first ribonucleotide, under conditions                so on the first primer overall anneals to a first                template strand of the first double-stranded DNA as                well as the first template strand of the second                double stranded DNA, but the second segment of the                first primer by itself does not anneal to the first                template strand of the first double-stranded DNA or                to the first template strand of the second                double-stranded DNA, where the ribonucleotide of                the first primer is aligned with or in the vicinity                of the variance position so on the first primer is                perfectly matched with the first template strand of                the first double-stranded DNA but not perfectly                matched with the first template strand of the                second double-stranded DNA, (b2) producing a first                amplicon by extending the first primer hybridized                on the first template of the first double-stranded                DNA using the first template strand of the first                double-stranded DNA as the template, and producing                a second amplicon by extending the first primer                hybridized on the first template of the second                double-stranded DNA using the first template strand                of the second double-stranded DNA as the template,                (c2) cleaving the first primer hybridized with the                first template strand of the first double stranded                DNA at the position immediately 5' to the at least                one first ribonucleotide using an RNase to produce                5' side segment cleaved from the first primer                hybridized with the first template strand of the                first double-stranded DNA, while not cleaving the                first primer hybridized with the first template                strand of the second double-stranded DNA, and (d2)                conducting PCR to further amplify the first and                second double-stranded DNA in the presence of the                RNase to thus differentiate the first and second                double-stranded DNA by a quantity of respective                amplicon products;    probe comprising a quencher portion, a                fluorophore portion, and a linker portion linking                the quencher portion and the fluorophore portion,                the linker portion comprises a many                deoxyribonucleotides and a ribonucleotide, where no                fluorescence is given by the fluorophore when then                linker is intact; and    detecting (M3) an amplicon product in an                amplification reaction system, comprising allowing                a molecular probe to specifically hybridize to an                amplicon product in an amplification reaction                system, cleaving the ribonucleotide in the                molecular probe, and detecting fluorescence given                off by the fluorophore portion of the molecular                probe. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-B03C;  B04-E01A;  B04-E05;  B04-E99;  B04-F11B2;  B04-L05A;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  B12-K04G2G;  D05-A02C;  D05-H06A;  D05-H09;  D05-H12D1;  D05-H18B;  D05-H99,C12P-019/34;  C12Q-001/6832;  C12Q-001/6851;  C12Q-001/6853,WO2023137407-A1   20 Jul 2023   C12Q-001/6853   202363Pages: 83   English,WO2023137407-A1    WOUS060598    12 Jan 2023,,US298890P    12 Jan 2022,WO2023137407-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,WO2023137407-A1 -- US20140315197-A1   ;  US20150275257-A1   ;  US20190112625-A1   ;  US20210002717-A1   ;  US20210262021-A1   ,,347844-0-0-0 K M,,,RA31ZL K M,
WO2022089225-A1;  CN114437058-A;  HK40074890-A0;  CA3197010-A1;  AU2021367554-A1;  IL302263-A;  KR2023098265-A;  BR112023008204-A2;  EP4223752-A1;  JP2023550021-W;  US2023399309-A1;  IN202317028834-A;  EP4223752-A4,"New nitrogen-containing cyclic compound useful in            preparation of medicament for preventing and treating            tumor including e.g. lymphoma, blastoma,            medulloblastoma, retinoblastoma, sarcoma, liposarcoma,            synovial cell sarcoma and gastric cancer",LIN X;  LU T;  ROOTING,ZHUHAI YUFAN BIOTECHNOLOGIES CO LTD (ZHUH-Non-standard);  ZHUHAI YUFAN BIOTECHNOLOGIES CO LTD (ZHUH-Non-standard);  ZHUHAI YUFAN BIOTECHNOLOGIES CO LTD (ZHUH-Non-standard);  ZHUHAI YUFAN BIOTECHNOLOGIES CO LTD (ZHUH-Non-standard);  ZHUHAI YUFAN BIOTECHNOLOGIES CO LTD (ZHUH-Non-standard),202260902D,"   NOVELTY - Nitrogen-containing cyclic compound (I), is                new.    USE - (I) is useful in preparation of medicament for                preventing and treating tumor including lymphoma,                blastoma, medulloblastoma, retinoblastoma, sarcoma,                liposarcoma, synovial cell sarcoma, neuroendocrine                tumor, carcinoid tumor, gastrinoma, pancreatic                islet cell carcinoma, mesothelioma, schwannoma,                acoustic neuroma, meningioma, adenocarcinoma,                melanoma, leukemia or lymphoid malignancies,                squamous cell carcinoma, epithelial squamous cell                carcinoma, lung cancer, small cell lung cancer,                non-small cell lung cancer, adenocarcinoma lung                cancer, lung squamous cell carcinoma, peritoneal                cancer, hepatocellular carcinoma, gastric cancer,                colon cancer, pancreatic cancer, glioblastoma,                cervical cancer, ovarian cancer, liver cancer,                bladder cancer, liver cancer, breast cancer,                metastatic breast cancer, colon cancer, rectal                cancer, colorectal cancer, uterine cancer, salivary                gland cancer, kidney cancer, prostate cancer,                vulvar cancer, thyroid cancer, liver cancer, anal                cancer, penile cancer, Merkel cell carcinoma,                esophageal cancer, biliary tract tumor, head and                neck cancer, and hematological malignancies, and                diseases caused by pathogen infection i.e. virus,                preferably hepatitis B virus, human                immunodeficiency virus, hepatitis C virus, human                papillomavirus, Ebola virus, Marburg, influenza,                parainfluenza, dengue, severe acute respiratory                syndrome-coronavirus, and severe acute respiratory                syndrome-coronavirus-2 (all claimed).    ADVANTAGE - (I) has high stability and good                bioavailability in an animal body; good anti-tumor                activity; and is non-toxic.    DETAILED DESCRIPTION - Nitrogen-containing cyclic compound of formula                (I), or its salt, stereoisomer, ester, prodrug or                solvate, is new.    A1 = CR10 or N;    Q1 = O or S;    x and z = 0-6;    y = 0 or 1;    Ar' = aromatic five-membered heterocyclic                group, aromatic six-membered heterocyclic group or                phenyl, where, the aromatic five-membered                heterocyclic group is substituted by furanyl,                thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl,                thiazolyl or selenothiazolyl, and the aromatic                six-membered heterocyclic group is substituted by                pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl,                optionally, the H on the aromatic five-membered                heterocyclic group, the aromatic six-membered                heterocyclic group or the phenyl can be substituted                with D, -SO2, -SO2N (0-10C alkyl) (0-10C alkyl),                -N(0-10C alkyl)SO2 (0-10C alkyl), -CON(0-10C                alkyl)(0-10C alkyl), -N(0-10C alkyl)CO(C 0-10                alkyl), N(0-10C alkyl)COO(0-10C alkyl), -OCON(0-10C                alkyl)(0-10C alkyl), halogen, -CN, -OCH2F, -OCHF2,                -OCF3, 1-10C linear/branched alkyl, -N(0-10C                alkyl)(0-10C alkyl), -O(0-10C alkyl), 3-10C                cycloalkyl, -O-heterocycloalkyl,                -N-heterocycloalkyl, -N-heteroaryl, -O-heteroaryl,                or -S-heteroaryl, where the alkyl moiety can be                optionally substituted by SO2, -SO2N(0-10C                alkyl)(0-10C alkyl), -N(0-10C alkyl)SO2(0-10C                alkyl), -CON(0-10C alkyl)(0-10C alkyl), -N(0-10C                alkyl)CO(0-10C alkyl), -N(0-10C alkyl)COO(0-10C                alkyl), -OCON(0-10C alkyl)(0-10C alkyl), halogen,                -CN, -OCH2F, -OCHF2, -OCF3, -N(0-10C alkyl)(0-10C                alkyl), -O(0-10 alkyl), -CO(0-10C alkyl),                -COO(0-10C alkyl), -N-heterocyclic aryl,                -O-heterocyclic aryl or -S-heterocyclic aryl, where                at least ome H atoms connected to C atom or                heteroatom can be substituted by D;    R2 = -H, -D, halogen, -NO2, -CN, 1-10C                linear/branched alkyl, 3-10C cycloalkyl, -N(0-10C                alkyl)(0-10C alkyl), -CF3, -OCF3, -OCHF2, -OCH2F or                -O(0-10C alkyl), where, at least one H atoms                connected to C atom can be substituted by D;    B1, B2, B3, B4 and B5 = C or N;    R3, R4, R5, R6 and R7 = -H, -D, halogen, -CN,                -O(0-10C alkyl), -CO(0-10C alkyl), -CON(0-10C                alkyl)(0-10C alkyl), 1-10C straight/branched alkyl,                heteroalkyl containing O or N, -N(0-10C                alkyl)(0-10C alkyl), 3-10C cycloalkyl, -C(C)-R10,                -O-heterocycloalkyl, or -N heterocycloalkyl, or R5                and R4, R4 and R3, R3 and R7, R7 and R6 and the                carbon atoms between them form 3-8C cycloalkyl or                3-8C heterocycloalkyl containing -O-, -S-, -N                heteroaryl, -O heteroaryl or -S heteroaryl or                phenyl, where at least one H atoms connected to C                atom or heteroatom can be substituted by D;    R8 and R9 = H, -D, halogen, or 1-10C                straight/branched chain alkyl, where at least one H                atoms to which the C atom is attached can be                substituted with D;    R10 = H, -D, 1-5C straight/branched chain                alkyl, 3-10C cycloalkyl, or hydroxy-based moiety                (asterisk-C(R11)(R12)-OH), where at least one                H-atoms connected to C-atom can be substituted by                D;    R11 and R12 = -H, -D, -CF3, -CHF2H, -CH2F,                1-10C straight chain/branched chain alkyl,                -CH=C(0-10C alkyl)(0-10C alkyl), -C(C)(0-10C                alkyl), 3-10C cycloalkyl, aromatic five-membered                ring group or aromatic six-membered ring group;                and    R11+R12+C = 3-8C cycloalkyl or 3-8C                heterocycloalkyl containing -O-, -S-, 4-9C fused                cycloalkyl, 5-10C spirocycloalkyl, 4-9C bridged                cycloalkyl, 3-7C cyclic lactam, 3-7C cyclic                lactone, or 3-7C cyclic ketone, where at least one                H-atoms connected to C-atom or heteroatom can be                substituted by D, and (I) containing at least one                D.    An INDEPENDENT CLAIM is also included for                crystal form of (I) or its salt, stereoisomer,                ester, prodrug or solvate. ",,,"B03 (Other heterocyclics.);  B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.)",B05-A04A;  B05-B01D;  B06-H;  B07-D04B;  B07-D10;  B14-A02A5;  B14-A02B;  B14-D06C;  B14-H01;  B14-H05,A61K-031/4427;  A61K-031/4433;  A61K-031/444;  A61K-031/4523;  A61K-031/4545;  A61K-031/496;  A61K-031/497;  A61K-031/551;  A61P-035/00;  A61P-035/02;  C07D-401/14;  C07D-405/14;  C07D-417/04;  C07D-417/14;  A61K-031/4439;  C07D-401/04;  C07D-421/14;  A61P-031/12;  A61K-031/4436;  A61P-031/14;  A61P-031/16;  A61P-031/18;  A61P-031/20,WO2022089225-A1   05 May 2022   C07D-417/14   202246Pages: 89   Chinese;  CN114437058-A   06 May 2022   C07D-417/14   202246   Chinese;  HK40074890-A0   13 Jan 2023   C07D-417/14   202330   Chinese;  CA3197010-A1   05 May 2022   C07D-417/14   202346   English;  AU2021367554-A1   01 Jun 2023   C07D-417/14   202346   English;  IL302263-A   01 Jun 2023   A61K-031/4427   202354   English;  KR2023098265-A   03 Jul 2023   C07D-417/14   202356   ;  BR112023008204-A2   06 Jun 2023   C07D-417/14   202359   ;  EP4223752-A1   09 Aug 2023   C07D-417/14   202365   English;  JP2023550021-W   30 Nov 2023   C07D-401/04   202397   Japanese;  US2023399309-A1   14 Dec 2023   C07D-401/04   202301   English;  IN202317028834-A   24 Nov 2023   C07D-417/14   202304   English;  EP4223752-A4   10 Jan 2024   C07D-417/14   202406   English,WO2022089225-A1    WOCN124144    15 Oct 2021;   CN114437058-A    CN11199799    30 Oct 2020;   HK40074890-A0    HK4062615    24 Oct 2022;   CA3197010-A1    CA3197010    15 Oct 2021;   AU2021367554-A1    AU367554    15 Oct 2021;   IL302263-A    IL302263    15 Oct 2021;   KR2023098265-A    KR717976    15 Oct 2021;   BR112023008204-A2    BR11008204    15 Oct 2021;   EP4223752-A1    EP884954    15 Oct 2021;   JP2023550021-W    JP526178    15 Oct 2021;   US2023399309-A1    US18250287    24 Apr 2023;   IN202317028834-A    IN17028834    20 Apr 2023;   EP4223752-A4    EP884954    15 Oct 2021,HK40074890-A0 Previous Publ. Patent CN114437058;   CA3197010-A1 PCT application Application WOCN124144;   CA3197010-A1 Based on Patent WO2022089225;   AU2021367554-A1 PCT application Application WOCN124144;   AU2021367554-A1 Based on Patent WO2022089225;   IL302263-A Based on Patent WO2022089225;   KR2023098265-A PCT application Application WOCN124144;   KR2023098265-A Based on Patent WO2022089225;   BR112023008204-A2 PCT application Application WOCN124144;   BR112023008204-A2 Based on Patent WO2022089225;   EP4223752-A1 PCT application Application WOCN124144;   EP4223752-A1 Based on Patent WO2022089225;   JP2023550021-W PCT application Application WOCN124144;   JP2023550021-W Based on Patent WO2022089225;   US2023399309-A1 PCT application Application WOCN124144;   IN202317028834-A PCT application Application WOCN124144;   IN202317028834-A Based on Patent WO2022089225,CN11199799    30 Oct 2020;  WOCN124144    15 Oct 2021;  BR11008204    28 Apr 2023;  CA3197010    28 Apr 2023;  KR717976    26 May 2023,WO2022089225-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA                EP4223752-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN        EP4223752-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME  ,,"WO2022089225-A1 -- CN1777427-A   SUGEN INC (PFIZ)   CUI J J;  CN110396087-A   ZHUHAI YUFAN BIOTECHNOLOGIES CO LTD (ZHUH-Non-standard)   LIAO X;  WO2006021884-A2   PFIZER INC (PFIZ)   CUI J J,  FUNK L A,  JIA L,  KUNG P,  MENG J J,  NAMBU M D,  PAIRISH M A,  SHEN-HONG,  TRAN-DUBE M B;  EP4223752-A4 -- WO2016201370-A1   DANA FARBER CANCER INST INC (DAND)   HAMMERMAN P,  WONG K,  GRAY N S;  WO2019206049-A1   ZHUHAI YUFAN BIOTECHNOLOGIES CO LTD (ZHUH-Non-standard)   LIAO X;  WO2021254118-A1   ZHUHAI YUFAN BIOTECHNOLOGIES CO LTD (ZHUH-Non-standard)   LIN X,  LU T","EP4223752-A4  FOSTER A B:          ""Deuterium isotope effects in the metabolism of drugs and          xenobiotics: implications for drug design"", ADVANCES IN          DRUG RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 14, 1          January 1985 (1985-01-01), pages 1 - 40, XP009086953,          ISSN:          0065-2490,relevantClaims[1-15],relevantPassages[&lt;pp&gt;5&lt;/pp&gt;&lt;line&gt;7&lt;/line&gt;&lt;linel&gt;12&lt;/linel&gt;|&lt;pp&gt;W&lt;/pp&gt;];            See also references of WO 2022089225A1", N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N,227231401 N,00347; 00654; 00160; 00177; 00178; 00210; 00211; 00212; 41247,RD6YHV N; RD6YHW N; RD6YHX N; RD6YHY N; RD6YHZ N; RD6YI0 N; RD6YI1 N; RD6YI2 N; RD6YI4 N; RD6YI5 N; RD6YI6 N; RD6YI7 N; RD6YI8 N; RD6YI9 N; RD6YIA N; RD6YIC N; RD6YIE N; RD6YIF N; RD6YIG N; RD6YIH N; RD6YII N; RD6YIJ N; RD6YIK N; RD6YIM N; RD6YIN N; RD6YIO N; RD6YIP N; RD6YIQ N; RD6YIR N; RD6YIS N; RD6YIT N; RD6YIU N; RD6YIV N; RD6YIW N; RD6YIX N; RD6YIY N; RD6YIZ N; RD6YJ0 N; RD6YJ1 N; RD6YJ2 N; RD6YJ3 N; RD6YJ4 N; RD6YJ5 N; RD6YJ6 N; RD6YJ7 N; RD6YJ8 N; RD6YJ9 N; RD6YJA N; RD6YJB N; RD6YJC N; RD6YJD N; RD6YJE N; RD6YJF N; RD6YJG N; RD6YJH N; RD6YJI N; RD6YJJ N; RD6YJK N; RD6YJL N; RD6YJM N; RD6YJN N; RD6YJO N; RD6YJP N; RD6YJQ N; RD6YJR N; RD6YJS N; RD6YJT N; RD6YJU N; RD6YJV N; RD6YJW N; RD6YJX N; RD6YJY N; RD6YJZ N; RD6YK0 N; RD6YK1 N; RD6YK2 N; RD6YK3 N; RD6YK4 N; RD6YK5 N; RD6YK6 N; RD6YK7 N; RD6YK8 N; RD6YK9 N; RD6YKA N; RD6YKB N; RD6YKC N; RD6YKD N; RD6YKE N; RD6YKF N; RD6YKG N; RD6YKH N; RD6YKI N; RD6YKJ N; RD6YKK N; RD6YI3 N; RD6YIB N; RD6YID N; RD6YIL N,
WO2024076680-A1;  US2024132512-A1,"New crystalline form 1 of            N-((S)-1-((3R,5'S)-5'-cyano-2-oxospiro(indoline            -3,3'-pyrrolidin)-1'-yl)-4-methyl-1-oxopentan-2-yl)-4,6,7-trifluoro-N-methyl-1H-indole-2-carboxamide            are 3C-Like protease inhibitor used to treating            coronavirus",ZHU K;  WANG T;  HELBLE J;  TOTO A;  ZHANG J;  WU G G;  OR Y S,ENANTA PHARM INC (ENAN-C);  ENANTA PHARM INC (ENAN-C),2024372849,"   NOVELTY - Crystalline form 1 of                N-((S)-1-((3R,5'S)-5'-cyano-2-oxospiro[indoline-3,3'-pyrrolidin]-1'-yl)-4-methyl-1-oxopentan-2-yl)-4,6,7-trifluoro-N-methyl-1H-indole-2-carboxamide                (I), comprising x-ray powder diffraction (XRPD)                pattern having characteristic peaks at values of                two &#952; (&#176; 2&#952; )) of 6.9,                8.3, 10.8, 11.9, 13.2, 13.7, 14.5, 15.4, 16.1,                18.2, 19.2, 20, 20.6, 21.7, 22.3, 23.9, 24.8, 25.2,                25.3, 26.1, 26.7, 27.6, 27.9, 28.9, 29.3, 30.1,                31.3, 31.3, 31.7, 32.5, 32.9, 34.7, 35, 35.8, 36.1,                36.8, 37.1, 37.8, 38.8, and 39.7 is new.    USE - (I) is useful for treating ameliorate or                preventing severe acute respiratory syndrome                coronavirus 2 infection. No biological data                given.    ADVANTAGE - None given.    DETAILED DESCRIPTION - Crystalline form 1 of                N-((S)-1-((3R,5'S)-5'-cyano-2-oxospiro[indoline-3,3'-pyrrolidin]-1'-yl)-4-methyl-1-oxopentan-2-yl)-4,6,7-trifluoro-N-methyl-1H-indole-2-carboxamide                (I), comprising x-ray powder diffraction (XRPD)                pattern having characteristic peaks at values of                two &#952; (&#176; 2&#952; )) of 6.9,                8.3, 10.8, 11.9, 13.2, 13.7, 14.5, 15.4, 16.1,                18.2, 19.2, 20, 20.6, 21.7, 22.3, 23.9, 24.8, 25.2,                25.3, 26.1, 26.7, 27.6, 27.9, 28.9, 29.3, 30.1,                31.3, 31.3, 31.7, 32.5, 32.9, 34.7, 35, 35.8, 36.1,                36.8, 37.1, 37.8, 38.8, and 39.7 is new.                INDEPENDENT CLAIMS are also included for:    crystalline form 2 of (I), comprising XRPD                pattern having characteristic peaks of (&#176;                2&#952; ) of 6.9, 10.8, 11.9, 13.7, 14.5, 16.1,                18.1, 20, 20.6, 21.7, 22.3, 23.9, 24.8, 25.2, 26.1,                26.7, 27.9, 28.8, 29.2, 30.1, 31.3, 32.8, 34.3,                34.7, 35.77, 36.1, 37.1, and 39.9;    crystalline form 3a of (I), comprising (i) a                differential scanning calorimeter thermogram with                an endotherm at 150&#176; C with an onset                temperature at 142&#176; C, an exotherm at                176&#176; C with an onset temperature at                171&#176; C, and endotherm at 252&#176; C                with onset temperature at 25&#176; C, (ii) an                XRPD pattern having principal peaks (2&#952; )                at 7.19, 8.71, 8.92, 11.93, 11.79, 13.97, 14.96,                15.23, 15.55, 16.17, 17.14, 17.45, 17.96, 19.16,                19.56, 29.43, 29.68, 21.89, 22.56, 23.45, 23.83,                24.74, 25.79, 26.26, 26.95, 28.12, 28.64, 29.68,                39.44, 31.28, 31.76, 32.34, 32.79, 33.39, 34.67,                35.56, 36.11, 36.47, 37.97, 37.85, and 38.22;    crystalline form 3b of (I), comprising XRPD                pattern having characteristic peaks at values of                (&#176; 2&#952; ) of 7.1, 8.7, 8.9, 11,                11.7, 13.1, 14.1, 15.2, 15.6, 16.2, 17.1, 17.5, 18,                19.2, 19.6, 20.4, 20.7, 21.9, 22.6, 23.5, 23.8,                24.7, 25.8, 26.3, 27, 28.1, 28.6, 29.7, 30.4, 31.3,                31.8, 32.3, 32.8, 33.3, 34.7, 35.6, 36.1, 36.5,                37.1, 37.9, and 38.2;    crystalline form 4a of (I), comprising XRPD                pattern having characteristic peaks at values of                (&#176; 2&#952; ) of (2&#952; ) of                4.39, 5.14, 7.06, 7.50, 8.47, 8.92, 9.75, 10.08,                10.33,11.03, 11.71, 12.45, 13.09, 13.83, 14.06,                14.62, 14.84, 15.38, 15.78, 15.95,16.91, 17.45,                17.93, 18.54, 19.23, 19.66, 20.07, 20.96, 21.84,                22.50, 23.42, 24.19, 24.91, 25.13, 26.18, 26.54,                27.81, 28.54, 29.41, and 30.99;    crystalline form 4b of (I), comprising XRPD                pattern having characteristic peaks at values of                (&#176; 2&#952; ) of 4.4, 5.1, 7.1, 7.5,                8.5, 8.9, 9.8, 10.1, 10.3, 11, 11.7, 12.5, 13.1,                13.8, 14.1, 14.6, 14.8, 15.4, 15.8, 16, 16.9, 17.5,                17.9, 18.5, 19.2, 19.7, 20.1, 21.0, 21.8, 22.5,                23.4, 24.2, 24.9, 25.1, 26.2, 26.5, 27.8, 28.5,                29.4, and 31;    composition comprising crystalline form;    making composition comprising of (I),                comprises dissolving the crystalline form in                solvent; and    producing (I).     ",,,"B02 (Fused ring heterocyclics.);  K08 (Nucleonics; X-ray techniques - including conversion of chemical elements, nuclear explosives and plasma techniques other than electron beam or plasma welding methods and apparatus and X-ray films (G01T, G21G, H, J, K, H05G, H).)",B06-D01;  B06-S;  B12-M11H2;  B14-A02B5;  B14-D07C;  B14-K01D;  K08-E01,A61K-031/33;  A61K-031/40;  A61K-031/407;  C07D-471/12;  C07D-471/20;  C07D-487/10;  C07D-495/02;  C07D-495/04,WO2024076680-A1   11 Apr 2024   C07D-471/20   202440Pages: 110   English;  US2024132512-A1   25 Apr 2024   C07D-487/10   202440   English,WO2024076680-A1    WOUS034548    05 Oct 2023;   US2024132512-A1    US377105    05 Oct 2023,US2024132512-A1 Provisional Application US413850P,US413850P    06 Oct 2022;  US377105    05 Oct 2023,WO2024076680-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,,, K P,,02456,RD73TZ K P,
WO2023203254-A2;  WO2023203254-A3,"New diamine-based compounds are            N-methyl-D-aspartate receptor inhibitors useful for            treating or preventing e.g. ischemic stroke Alzheimer's            disease, amyotrophic lateral sclerosis, and traumatic            brain injury",STRAUB A;  BADING H;  YAN J,FUNDAMENTAL PHARMA GMBH (FUND-Non-standard),2023B0672H,"   NOVELTY - Diamine-based compounds (I) are new.    USE - (I) are useful for treating or preventing a                disease of the human or animal body, where the                disease is a neurological disease, the disease is a                neurodegenerative disease, the disease comprises                stroke, preferably ischemic stroke and hemorrhagic                stroke, Alzheimer's disease, amyotrophic lateral                sclerosis, Huntington's disease, traumatic brain                injury, post traumatic brain injury,                absent-mindedness, age-related loss of memory,                aging-related memory decline, progressive nuclear                palsy, multiple sclerosis, thalamic degeneration,                glutamate induced excitotoxicity, dystonia,                epilepsy, optic nerve disease, diabetic                retinopathy, glaucoma, pain, preferably neuropathic                pain, anti-N-methyl-d-aspartate receptor                encephalitis, viral encephalopathy, dementia, e.g.                post stroke dementia, HIV dementia,                Creutzfeldt-Jakob dementia, dementia with Lewy                bodies (DLB), dementia with degeneration of the                frontal lobes including Pick's disease, dementia                with corticobasal degeneration, vascular dementia,                microangiopathy, Binswanger's disease, cerebral                ischemia, hypoxia, Parkinson's disease, Batten                disease, schizophrenia, preferably schizophrenia                with dementia, Korsakoffs psychosis, depression,                cerebral malaria, toxoplasmosis (due to the risk of                toxoplasmosis -associated brain damage), HIV                infection/AIDS (due to the risk of HIV)-associated                brain damage, Zika virus infection (due to the                possibility of Zika virus-associated brain damage),                other viral infection potentially leading to                neurodegenerative events and corresponding neuronal                or brain damage, respectively, e.g. viral                meningitis or severe acute respiratory syndrome                coronavirus 2 virus induced encephalitis, brain                tumour, preferably glioblastoma, diseases of the                central nervous system e.g. states of anxiety,                tension and depression, sexual dysfunction                disorders, sleep disorders, pathological                disturbances of the intake of food, stimulants and                addictive substances (claimed).    ADVANTAGE - (I) inhibits NMDA receptor mediated toxicity                very effectively.    DETAILED DESCRIPTION - Diamine-based compounds of formula                (R7-CH(R5)-N(R6)-CH2-CH2-NH2) (I), and their salts,                racemates, (R)- or (S)-enantiomers are new.    R7=substituted heterocyclic moieties of                formulae (IA) and (IB);    R1-R4=H, F, Cl, Br, I, -CN or ethynyl;    R5=H, unsubstituted branched or linear 1-4C                alkyl, fluoro-substituted branched or linear 1-4C                alkyl, unsubstituted propenyl, unsubstituted 3-6C                cycloalkyl, and fluoro-substituted 3-6C cycloalkyl;                and    R6=H, unsubstituted branched or linear 2-6C                alkyl, substituted branched or linear 2-6C alkyl,                unsubstituted 3-6C cycloalkyl, substituted 3-6C                cycloalkyl, unsubstituted 4-8C bicycloalkyl,                substituted 4-8C bicycloalkyl, unsubstituted 4-7C                alkylcycloalkyl, substituted 4-7C alkylcycloalkyl,                unsubstituted 3-6C alkenyl and substituted 3-6C                alkenyl.    Provided that: if R5 is methyl, R7 is (IA),                one of R2 and R3 is H and the other is F, Cl or -CN                and R1 and R4 are H, then R6 is unsubstituted                linear 3-6C alkyl, unsubstituted branched 4-6C                alkyl, substituted branched or linear 2-6C alkyl,                unsubstituted 4-6C cycloalkyl, substituted 3-6C                cycloalkyl, unsubstituted 4-8C bicycloalkyl,                substituted 4-8C bicycloalkyl, unsubstituted 4-7C                alkylcycloalkyl, substituted 4-7C alkylcycloalkyl,                unsubstituted 3-6C alkenyl and substituted 3-6C                alkenyl; if R5 is methyl, R7 is (IA), two of R1,                R2, R3 and R4 are Cl, while the other two are H,                where either R1 and R2, R3 and R4, R1 and R3 or R2                and R4 are Cl, then R6 is unsubstituted branched or                linear 3-6C alkyl, substituted branched or linear                2-6C alkyl, unsubstituted 3-6C cycloalkyl,                substituted 3-6C cycloalkyl, unsubstituted 4-8C                bicycloalkyl, substituted 4-8C bicycloalkyl,                unsubstituted 4-7C alkylcycloalkyl, substituted                4-7C alkylcycloalkyl, unsubstituted 3-6C alkenyl                and substituted 3-6C alkenyl; if R5 is methyl, R7                is (IA), one of R1 and R4 is H and the other is F                or Br and R2 and R3 are H, then R6 is unsubstituted                linear 3-6C alkyl, unsubstituted branched 4-6C                alkyl, substituted branched or linear 2-6C alkyl,                unsubstituted 4-6C cycloalkyl, substituted 3-6C                cycloalkyl, unsubstituted 4-8C bicycloalkyl,                substituted 4-8C bicycloalkyl, unsubstituted 4-7C                alkylcycloalkyl, substituted 4-7C alkylcycloalkyl,                unsubstituted 3-6C alkenyl and substituted 3-6C                alkenyl; and if R5 is ethyl, R7 is (IA), one of R2                and R3 is H and the other is Cl and R1 and R4 are                H, then R6 is unsubstituted linear 3-6C alkyl,                unsubstituted branched 3-6C alkyl, substituted                branched or linear 2-6C alkyl, unsubstituted 3-6C                cycloalkyl, substituted 3-6C cycloalkyl,                unsubstituted 4-8C bicycloalkyl, substituted 4-8C                bicycloalkyl, unsubstituted 4-7Calkylcycloalkyl,                substituted 4-7Calkylcycloalkyl, unsubstituted 3-6C                alkenyl and substituted 3-6C alkenyl; if R5 is H,                and R7 is (IA), then (I) is e.g.                (2-aminoethyl)[(3-chloro-2,6-difluorophenyl)methyl]ethylamine,                (2-aminoethyl)[(5-chloro-2-fluorophenyl)methyl]ethylamine,                (2-aminoethyl)[(3-chloro-2-fluorophenyl)methyl](2,2-difluoroethyl)amine,                (2-aminoethyl)[(3-chloro-2-fluorophenyl)methyl](2,2,2-trifluoroethyl)amine,                and                N-(2-aminoethyl)-N-[(3-chloro-2-fluorophenyl)methyl]cyclopropanamine.                An INDEPENDENT CLAIM is also included for                diamine-based compounds of formula                (R7-CH(R5-N(R6)-CH2-CH2-NH-C(=O)-O-C(CH3)3) (II),                (R7-CH(R5)-N(R6)-CH2-C(=O)-NH2) (III), and                (R7-CH(R5)-N(R6)-C(=O)-CH2-NH2) (IV).     ",,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  B03 (Other heterocyclics.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  ;  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).)",B06-H;  B07-H;  B10-A12C;  B10-A15;  B10-B01B;  B10-B02F;  B14-A02;  B14-A03B;  B14-A03F;  B14-C01;  B14-C03;  B14-F02;  B14-H01J1;  B14-J01;  B14-J05;  B14-J07;  B14-K01D;  B14-L06;  B14-N03;  B14-N16;  B14-N17;  B14-S01;  C06-H;  C07-H;  C10-A12C;  C10-A15;  C10-B01B;  C10-B02F;  C14-A02;  C14-A03B;  C14-A03F;  C14-C01;  C14-C03;  C14-F02;  C14-H01J1;  C14-J01;  C14-J05;  C14-J07;  C14-K01D;  C14-L06;  C14-N03;  C14-N16;  C14-N17;  C14-S01;  D03-H01T2B,A61K-031/137;  A61P-025/28;  C07C-211/29;  C07C-211/35;  C07C-211/38;  C07C-255/58;  C07C-271/20;  C07C-323/25,WO2023203254-A2   26 Oct 2023   C07C-211/29   202392Pages: 214   English;  WO2023203254-A3   21 Dec 2023   C07C-211/29   202303   English,WO2023203254-A2    WOEP060683    24 Apr 2023;   WO2023203254-A3    WOEP060683    24 Apr 2023,,EP169433    22 Apr 2022,WO2023203254-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2023203254-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,";  WO2023203254-A3 -- CN111675626-A   UNIV TIANJIN MEDICAL (UTJM)   DUAN H,  QIN N,  CHEN Y,  NIE J,  WU X,  FAN Y;  EP1490371-B1   BRISTOL-MYERS SQUIBB CO (BRIM)   BELEMA M,  BUNKER A,  NGUYEN V,  BEAULIEU F,  OUELLET C,  MARINIER A,  ROY S,  YANG X,  QIU Y,  ZHANG Y,  MARTEL A,  ZUSI C;  WO2001098278-A1   ;  WO2007017092-A1   BAYER HEALTHCARE AG (FARB)   LAMPE T,  ALONSO-ALIJA C,  BAUSER M,  BECK H,  ROSENTRETER U,  SANDNER P,  STAHL E,  STELTE-LUDWIG B;  WO2007017093-A1   BAYER HEALTHCARE AG (FARB)   LAMPE T,  ALONSO-ALIJA C,  BECK H,  ROSENTRETER U,  SANDNER P,  STAHL E,  STELTE-LUDWIG B;  WO2016029146-A1   UNIV WASHINGTON SEATTLE (UNIW)   BUCKNER F S,  ALVAREZ X B,  FAN E,  GILLESPIE J R,  HOL W G J,  HUANG W,  KOH C Y,  RANADE R M,  SHIBATA S,  VERLINDE C L M,  ZHANG Z;  WO2020078554-A1   FUNDAMENTAL PHARMA GMBH (FUND-Non-standard)   BADING H,  YAN J;  WO2020079244-A1   FUNDAMENTAL PHARMA GMBH (FUND-Non-standard)   BADING H,  YAN J;  WO2005082343-A2   LA JOLLA PHARM CO (LJOL-Non-standard)   SALTER-CID L M,  WANG E Y,  MACDONALD M T,  ZHAO J;  WO2010010435-A2   GLENMARK PHARM SA (GLMK)   IRLAPATI N R,  KHAIRATKAR J N,  KURHE D K,  MUKHOPADHYAY I,  SHELKE S Y,  THOMAS A,  VISWANADHA S;  WO2010052448-A2   UCB PHARMA SA (UNIO)   BUERLI R,  HAUGHAN A F,  MACK S R,  PERRY B G,  RAPHY G,  SAVILLE-STONES E A","WO2023203254-A3  SMRECKI NEVEN ET          AL: ""Preparation and NMR spectroscopic study of          palladium(II) complexes withN-arylalkyliminodiacetamide          derivatives"", JOURNAL OF MOLECULAR STRUCTURE, ELSEVIER          AMSTERDAM, NL, vol. 1122, 27 May 2016 (2016-05-27), pages          192 - 197, XP029643392, ISSN: 0022-2860, DOI:          10.1016/J.MOLSTRUC.2016.05.084,relevantClaims[57],relevantPassages[&lt;figure&gt;1&lt;/figure&gt;];  MUTHAS D ET AL:          ""Synthesis, biological evaluation, and modeling studies          of inhibitors aimed at the malarial proteases plasmepsins          I and II"", BIOORGANIC & MEDICINAL CHEMISTRY,          ELSEVIER, AMSTERDAM, NL, vol. 13, no. 18, 15 September          2005 (2005-09-15), pages 5371 - 5390, XP027393094, ISSN:          0968-0896, [retrieved on          20050811],relevantClaims[57],relevantPassages[&lt;figure&gt;1&lt;/figure&gt;&lt;compound&gt;9f-11f&lt;/compound&gt;];  HARDY G W ET AL:          ""PERIPHERALLY ACTING ENKEPHALIN ANALOGUES. OePOLAR TRI-          AND TETRAPEPTIDES"", JOURNAL OF MEDICINAL CHEMISTRY,          AMERICAN CHEMICAL SOCIETY, US, vol. 32, no. 5, 1 May 1989          (1989-05-01), pages 1108 - 1118, XP000611482, ISSN:          0022-2623, DOI:          10.1021/JM00125A028,relevantClaims[58],relevantPassages[&lt;pp&gt;117&lt;/pp&gt;&lt;para&gt;2&lt;/para&gt;];  DATABASE CHEMCATS          ACS [online] Chemical Abstract Services; 14 February 2023          (2023-02-14), MCKENZIE TRABITZ: ""Enamine MADE Building          Blocks 1"", XP093098590, retrieved from STN Database          accession no.          2133901423,relevantClaims[1-6,9,10,14-22,24,25],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  DATABASE CHEMCATS          ACS [online] Chemical Abstract Services; 6 April 2023          (2023-04-06), AURORA FINE CHEMICALS LLC: ""Aurora Building          Blocks 9"", XP093098600, retrieved from STN Database          accession no.          2141210853,relevantClaims[1-6,9,10,14-22,24,25],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  DATABASE Chemcats          ACS [online] Chemical Abstract Services; 6 April 2023          (2023-04-06), AURORA FINE CHEMICALS LLC: ""Aurora Building          Blocks"", XP093098794, retrieved from STN Database          accession no.          1686693407,relevantClaims[56],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  DATABASE Chemcats          ACS [online] Chemical Abstract Services; 6 April 2023          (2023-04-06), AURORA FINE CHEMICALS LLC: ""Aurora Building          Blocks"", XP093098867, retrieved from STN Database          accession no.          2146494586,relevantClaims[57],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  DATABASE CHEMCATS          ACS [online] Chemical Abstract Services; 14 February 2023          (2023-02-14), MCKENZIE TRABITZ: ""Enamine MADE Building          Blocks"", XP093098942, retrieved from STN Database          accession no. 0384344005;          0351861589,relevantClaims[58],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;]", N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N,230137301 N; 230137302 N; 230137303 N; 230137304 N,48161,RDHNTQ N; RDHNTR N; RDHNTS N; RDHNTT N; RDHNTU N; RDHNTV N; RDHNTW N; RDHNTX N; RDHNTY N; RDHNTZ N; RDHNU0 N; RDHNU1 N; RDHNU2 N; RDHNU3 N; RDHNU4 N; RDHNU5 N; RDHNU6 N; RDHNU7 N; RDHNU8 N; RDHNU9 N; RDHNUA N; RDHNUB N; RDHNUC N; RDHNUD N; RDHNUE N; RDHNUF N; RDHNUG N; RDHNUH N; RDHNUI N; RDHNUJ N; RDHNUK N; RDHNUL N; RDHNUM N; RDHNUN N; RDHNUO N; RDHNUP N; RDHNUQ N; RDHNUR N; RDHNUS N; RDHNUT N; RDHNUU N; RDHNUV N; RDHNUW N; RDHNUX N; RDHNUY N; RDHNUZ N; RDHNV0 N; RDHNV1 N; RDHNV2 N; RDHNV3 N; RDHNV4 N; RDHNV5 N; RDHNV6 N; RDHNV7 N; RDHNV8 N; RDHNV9 N; RDHNVA N; RDHNVB N; RDHNVC N; RDHNVD N; RDHNVE N; RDHNVF N; RDHNVG N; RDHNVH N; RDHNVI N; RDHNVJ N; RDHNVK N; RDHNVL N; RDHNVM N; RDHNVN N; RDHNVO N; RDHNVP N; RDHNVQ N; RDHNVR N; RDHNVS N; RDHNVT N; RDHNVU N; RDHNVV N; RDHNVW N; RDHNVX N; RDHNVY N; RDHNVZ N; RDHNW0 N; RDHNW1 N; RDHNW2 N; RDHNW3 N; RDHNW4 N; RDHNW5 N; RDHNW6 N; RDHNW7 N; RDHNW8 N,
CN115433273-A,"New anti-new coronavirus SARS-CoV2-S-RBD rabbit            recombinant monoclonal antibody with neutralizing            activity useful in preparing medicine for treating            disease or detection reagent, comprising rabbit            recombinant monoclonal antibodies 2B6, 2H5, 4B1, 6B10,            9D5",CAI M;  MEI F;  HONG S;  MA D,SUZHOU DIMA BIOTECHNOLOGY CO LTD (SUZH-Non-standard),2022F7293V,"   NOVELTY - Anti-new coronavirus severe acute respiratory                syndrome coronavirus 2 receptor-binding domain                (SARS- CoV2-S-RBD) rabbit recombinant monoclonal                antibody with neutralizing activity, comprising                rabbit recombinant monoclonal antibodies 2B6, 2H5,                4B1, 6B10, 9D5, is new. e.g. the rabbit recombinant                monoclonal antibody 2B6 comprises heavy chain                complementarity determining regions CDR1: a fully                defined sequence of 8 amino acids (SEQ ID NO: 1),                CDR2: a fully defined sequence of 8 amino acids                (SEQ ID NO: 2) and CDR3: a fully defined sequence                of 12 amino acids (SEQ ID NO: 3), as given in the                specification and light chain complementarity                determining regions CDR1: a fully defined sequence                of 8 amino acids (SEQ ID NO: 4), CDR2: a fully                defined sequence of 3 amino acids (SEQ ID NO: 5)                and CDR3: a fully defined sequence of 11 amino                acids (SEQ ID NO: 6), as given in the                specification.    USE - The antibody, nucleic acid molecule, vector                host cell or conjugate is useful in preparing                medicine for treating disease or detection reagent                (claimed).    ADVANTAGE - The antibody has good specificity and the most                important antibody can block the interaction of the                new coronavirus RBD protein with the receptor ACE2                protein and has potential therapeutic value of                neutralizing virus.    DETAILED DESCRIPTION - Anti-new coronavirus SARS-CoV2-S-RBD rabbit                recombinant monoclonal antibody with neutralizing                activity, comprising rabbit recombinant monoclonal                antibodies 2B6, 2H5, 4B1, 6B10, 9D5, is new. The                rabbit recombinant monoclonal antibody 2B6                comprises heavy chain complementarity determining                regions CDR1: Gly-Val-Thr-Ile-Asn-Asn-Tyr-His(SEQ                ID NO: 1), CDR2: Ile-Tyr-Ala-Asp- Ile-Gly                Val-Thr(SEQ ID NO: 2) and CDR3: a fully defined                sequence of 12 amino acids (SEQ ID NO: 3), as given                in the specification and light chain                complementarity determining regions CDR1: Gln-Ser                -Val -Ala -Ser -Asn -Asn -Tyr(SEQ ID NO: 4), CDR2:                Gly-Ala-Ser(SEQ ID NO: 5) and CDR3: a fully defined                sequence of 11 amino acids (SEQ ID NO: 6), as given                in the specification. The rabbit recombinant                monoclonal antibody 2H5 comprises heavy chain                complementarity determining regions CDR1:                Gly-Phe-Ser-Leu-Ser-Ser-Tyr-Ala(SEQ ID NO: 10),                CDR2: Ile-Ser-Asn-Ser-Gly-Ser-Ala(SEQ ID NO: 11)                and CDR3: a fully defined sequence of 14 amino                acids (SEQ ID NO: 12), as given in the                specification and light chain complementarity                determining regions CDR1:                Glu-Asn-Ile-Tyr-Arg-Phe(SEQ ID NO: 13), CDR2:                Phe-Val-Asp(SEQ ID NO: 14) and CDR3: a fully                defined sequence of 12 amino acids (SEQ ID NO: 15),                as given in the specification. The rabbit                recombinant monoclonal antibody 4B1 comprises heavy                chain complementarity determining regions CDR1:                Gly-Phe-Ser-Leu-Ser-Arg-Tyr-Ala(SEQ ID NO: 19),                CDR2: Ile-Ser-Ser-Ser-Gly-Ser-Thr(SEQ ID NO: 20)                and CDR3: a fully defined sequence of 19 amino                acids (SEQ ID NO: 21), as given in the                specification and light chain complementarity                determining regions CDR1:                Gln-Asn-Ile-Tyr-Ser-Asn(SEQ ID NO: 22), CDR2:                Gly-Ala-Ser(SEQ ID NO: 23) and CDR3: a fully                defined sequence of 13 amino acids (SEQ ID NO: 24),                as given in the specification. The rabbit                recombinant monoclonal antibody 6B10 comprises                heavy chain complementarity determining regions                CDR1: Gly-Phe-Ser-Leu-Ser-Phe-Tyr-Tyr(SEQ ID NO:                28), CDR2: Ile-Gly-Ser-Gly-Gly-Thr-Thr(SEQ ID NO:                29) and CDR3: Val-Arg-Glu-Ala-Gly-Tyr-                Ser-Thr-Thr-Leu(SEQ ID NO: 30), as given in the                specification and light chain complementarity                determining regions CDR1:                Gln-Ile-Ile-Gly-Ser-Asn(SEQ ID NO: 31), CDR2:                Ser-Ala-Ser(SEQ ID NO: 32) and CDR3: a fully                defined sequence of 12 amino acids (SEQ ID NO: 33),                as given in the specification. The rabbit                recombinant monoclonal antibody 9D5 comprises heavy                chain complementarity determining regions CDR1:                Gly-Phe-Ser-Arg-Ser-Gly-Tyr-Tyr(SEQ ID NO: 37),                CDR2: Ile-Tyr-Thr-Asn-Gly-Asp-Thr(SEQ ID NO: 38)                and CDR3: a fully defined sequence of 15 amino                acids (SEQ ID NO: 39), as given in the                specification and light chain complementarity                determining regions CDR1:                Gln-Ser-Ile-Asn-Asn-Ile(SEQ ID NO: 40), CDR2:                Asp-Ala-Ser(SEQ ID NO: 41) and CDR3: a fully                defined sequence of 12 amino acids (SEQ ID NO: 42),                as given in the specification.    INDEPENDENT CLAIMS are also included                for:    a nucleic acid molecule comprising, nucleic                acid sequence capable of encoding the heavy chain                complementarity determining region or the light                chain complementarity determining region of the                anti-new coronavirus SARS-CoV2-S-RBD rabbit                recombinant monoclonal antibody with neutralizing                activity    a vector, comprising the nucleic acid                molecule    a host cell, comprising the anti-new                coronavirus SARS-CoV2-S-RBD rabbit recombinant                monoclonal antibody with neutralizing                activity    a conjugate, comprising the antibody;                and    a medicinal composition comprising, a main                component and an auxiliary component, where the                main component comprises the anti-new coronavirus                SARS-CoV2-S-RBD rabbit recombinant monoclonal                antibody with neutralizing activity and the                auxiliary component is group consisting of carrier                or excipient and optionally other biologically                active substance. ",,,"D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  S03 (Scientific Instrumentation)",D05-H14;  D05-H12E;  D05-H12A;  D05-H11A2;  D05-H99;  C04-F0100E;  C04-E03A;  C04-E02A;  C04-C01G;  C04-G21;  C04-G08;  C04-E08;  C04-E99;  B04-F0100E;  B04-E03A;  B04-E02A;  B04-C01G;  B04-G21;  B04-G08;  B04-E08;  B04-E99;  S03-E09F;  S03-E14H3,A61K-039/42;  A61P-031/14;  C07K-016/10;  G01N-033/569,CN115433273-A   06 Dec 2022   C07K-016/10   202311   Chinese,CN115433273-A    CN10627997    05 Jun 2021,,CN10627997    05 Jun 2021,,,,,184587-0-0-0 U K,,,RA00C8 U K,
WO2021094792-A1;  EP4061393-A1,"Developing delivery platform to produce            deliverable protein transduction domain (PTD)-in vitro            transcribed-mRNA therapeutics, comprises combining PTD            technology with IVT-mRNA via covalent chemical            binding-conjugation",PAPADOPOULOU L;  VIZIRIANAKIS I;  PAPPAS I;  MILIOTOU A,UNIV THESSALONIKI ARISTOTLE ELKE (UYTH-Non-standard);  UNIV THESSALY (UYTH-Non-standard);  UNIV THESSALONIKI ARISTOTLE (UYTH-Non-standard);  UNIV THESSALY (UYTH-Non-standard),2021557245,"   NOVELTY - Developing a delivery platform to produce                deliverable protein transduction domain (PTD)-in                vitro transcribed (IVT)-mRNA therapeutics, where                PTDs technology is used as a transduction delivery                platform for IVT-mRNAs, and the delivery platform                is accomplished a covalent chemical reaction                between the IVT-mRNA molecules and a selected                transduction peptide, preferably peptide having                specified amino acid sequence, comprises combining                the PTD technology with IVT-mRNA via covalent                chemical binding-conjugation, where the IVT-mRNA is                conjugated to the PTD using the connection between                the PTD transporter and the IVT-mRNA molecule is                stabilized, thus also stabilizing IVT-mRNA:PTD                complex, and the IVT-mRNAs constituting a molecule                are submitted to an intracellular delivery through                the covalently conjugation to the appropriate PTD,                preferably the peptide having specified amino acid                sequence, after which the IVT-mRNA's are directed                to ribosomes and translated into targeted proteins                to reveal effect.    USE - The method is useful for developing a delivery                platform to produce deliverable PTD-IVT-mRNA, where                PTDs technology is used as a transduction delivery                platform for IVT-mRNAs, which is useful for:                improving health including food; treating diseases                including multiple types of cancer, Zika virus,                Ebola virus, hepatitis C virus, influenza virus and                severe acute respiratory syndrome coronavirus 2; a                broad spectrum of disorders both acute and chronic;                and treating cancer e.g. herpes simplex virus                1-thymidine kinase or other cancers-related                viruses. No biological data given.    ADVANTAGE - The method: is safe; utilizes mRNA molecules                that do not interfere with the host genome, thus no                triggering oncogenic mutations take place; provides                PTD-IVT-mRNA complexes that exhibit high stability                in low and high serum and plasma conditions, as                compared to naked IVT-mRNA, and also appears to be                very stable even in human plasma for longer                periods, as expected to be injected intravenously                during the administration; achieves high rates of                transfection in cellular models even increase of                seven folds of the translation levels of the                desired protein, and increases the mean fluorescent                intensity three times, in comparison with the                control cells; and is fast and low cost,                facilitates the safety, while there is no                integration into the host genome and the transient                nature of IVT-mRNA, enhances the stability of the                IVT-mRNAs, and increases the expression levels of                the corresponding protein.    DETAILED DESCRIPTION - Developing a delivery platform to produce                deliverable protein transduction domain (PTD)-in                vitro transcribed (IVT)-mRNA therapeutics, where                PTDs technology is used as a transduction delivery                platform for IVT-mRNAs, and the delivery platform                is accomplished a covalent chemical reaction                between the IVT-mRNA molecules and a selected                transduction peptide, preferably peptide having an                amino acid sequence of Pro-Phe-Val-Tyr-Leu-Ile,                comprises combining the PTD technology with                IVT-mRNA via covalent chemical binding-conjugation,                where the IVT-mRNA is conjugated to the PTD using                the connection between the PTD transporter and the                IVT-mRNA molecule is stabilized, thus also                stabilizing IVT-mRNA:PTD complex, and the IVT-mRNAs                constituting a molecule are submitted to an                intracellular delivery through the covalently                conjugation to the appropriate PTD, preferably the                peptide having an amino acid sequence of                Pro-Phe-Val-Tyr-Leu-Ile, after which the IVT-mRNA's                are directed to ribosomes and translated into                corresponding targeted proteins to reveal their                effect. INDEPENDENT CLAIMS are also included                for:    (1) delivery platform produced according to a                method for deliverable PTD-IVT-mRNA therapeutics,                where PTDs technology is used as a transduction                delivery platform for IVT-mRNAs, comprising a                covalent chemical reaction between the IVT-mRNA                molecules and a selected transduction peptide,                where the platform includes the combination of the                PTD technology with IVT-mRNA via covalent chemical                binding- conjugation, the IVT-mRNA is conjugated to                the PTD having the stability of the connection                between the PTD transporter and the IVT-mRNA                molecule, thus providing very stable IVT-mRNA:PTD                complex, the IVT-mRNAs are delivered                intracellularly through the covalent conjugation to                the PTD, and the IVT-mRNA's are directed to                ribosomes and translated into corresponding                targeted proteins revealing their effect; and    (2) use of PTDs technology as a transduction                delivery platform for IVT-mRNAs, where the delivery                platform is accomplished by a covalent chemical                reaction between the IVT-mRNA molecules with                puromycin, which is conjugated via an amide bond to                the selected PTD, especially the peptide having an                amino acid sequence of Pro-Phe-Val-Tyr-Leu-Ile                accomplished by a covalent chemical reaction                between the IVT-mRNA molecules and a selected                transduction peptide, preferably peptide having an                amino acid sequence of Pro-Phe-Val-Tyr-Leu-Ile                including the combination of the PTD technology                with IVT-mRNA via covalent chemical reaction of the                IVT-mRNAs with puromycin, which is conjugated via                an amide bond to the PTD using the stability of the                connection between the PTD transporter and the                IVT-mRNA molecule is increased, thus generating a                PTD-IVT-mRNA complex which is very stable, and the                IVT-mRNAs constituting a selected generation of                molecules are submitted to an intracellular                delivery through the covalently conjugation to the                selected PTD, after which the IVT-mRNAs are                directed to the ribosomes and translated into the                corresponding targeted proteins, thus generating an                effect. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C07 (Apparatus, formulation, general. including veterinary syringes, general formulations where the active compound is not central to the invention (e.g. wettable powders) and analysis.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).);  A96 (Medical, dental, veterinary, cosmetic.)",B04-B03D;  B04-C01B;  B04-E02;  B04-E03;  B04-E07D;  B04-E99;  B04-L08;  B06-D09;  B10-A20;  B14-A02B;  B14-H01;  B14-K01D;  B14-S18;  C04-B03D;  C04-C01B;  C04-E02;  C04-E03;  C04-E07D;  C04-E99;  C04-L08;  C06-D09;  C10-A20;  C14-A02B;  C14-H01;  C14-K01D;  C14-S18;  D03-H01T2B;  D05-H12A;  D05-H99;  A12-E09;  A12-E13;  A12-V01,A61K-038/00;  A61K-047/51,WO2021094792-A1   20 May 2021   202148Pages: 31   English;  EP4061393-A1   28 Sep 2022   A61K-038/00   202279   English,WO2021094792-A1    WOGR000059    11 Nov 2020;   EP4061393-A1    EP823912    11 Nov 2020,EP4061393-A1 PCT application Application WOGR000059;   EP4061393-A1 Based on Patent WO2021094792,GR100504    11 Nov 2019,WO2021094792-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP4061393-A1:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  KH;  LI;  LT;  LU;  LV;  MA;  MC;  MD;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TN;  TR  ,,"WO2021094792-A1 -- EP1816192-A1   JAPAN SCI&TECHNOLOGY AGENCY (JSTA);  NAT INST ADVANCED IND SCI&TECHNOLOGY (NIIT)   NEMOTO N,  MANISH B;  US20030100004-A1   ;  US20170035914-A1   ;  US20180235897-A1   ;  WO2009069935-A2   FORHUMAN TECH CO LTD (FORH-Non-standard)   LEE S,  CHOI K","WO2021094792-A1  KHALID A. HAJJ ET          AL: ""Tools for translation: non-viral materials for          therapeutic mRNA delivery"", NATURE REVIEWS MATERIALS,          vol. 2, no. 10, 12 September 2017 (2017-09-12),          XP055657784, DOI:          10.1038/natrevmats.2017.56,relevantClaims[1-30],relevantPassages[Page          5, Table 1, Figure 8];  S GUAN ET AL:          ""Nanotechnologies in delivery of mRNA therapeutics using          nonviral vector-based delivery systems"", GENE THERAPY,          vol. 24, no. 3, 17 January 2017 (2017-01-17), GB, pages          133 - 143, XP055400049, ISSN: 0969-7128, DOI:          10.1038/gt.2017.5,relevantClaims[1-30];  E. BOeHMOVA ET AL:          ""Cell-Penetrating Peptides: a Useful Tool for the          Delivery of Various Cargoes Into Cells"", PHYSIOLOGICAL          RESEARCH., 21 September 2018 (2018-09-21), CZ, pages S267          - S279, XP055679676, ISSN: 0862-8408, DOI:          10.33549/physiolres.933975,relevantClaims[1,28,30],relevantPassages[S268          right column and Table 3];  DATABASE MEDLINE          [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA,          MD, US; 29 May 2019 (2019-05-29), TUSUP MARINA ET AL:          ""Design of in vitroTranscribed mRNA Vectors for Research          and Therapy."", XP002802335, Database accession no.          NLM31118121,relevantClaims[1-30],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;]",105730-0-0-0 K M; 3075384-1-0-0 K M; 201106-0-0-0 K M; 105034-1-0-0 K M; 131518-0-1-0 K M; 86729-0-0-0 ; 8781-0-0-0 ; 3075384-1-0-0 CL USE,,,RA012P K M; RBOL4T K M; RA00R0 K M; R11093 K M; R08603 K M; R24070 ; R00444 ,
WO2021116446-A1;  AU2020401358-A1;  CN114787148-A;  KR2022112824-A;  CA3159943-A1;  EP4073062-A1;  BR112022010839-A2;  IL293558-A;  JP2023505877-W;  US2023055741-A1;  MX2022007179-A1;  HK40082167-A0;  AU2020401358-B2;  AU2024203206-A1,"New compound-linker construct comprising            substituted fused heterocyclyl compounds and linker,            used to treat e.g. cancer, infectious diseases, and            autoimmune diseases and as immunogenic composition or            as vaccine adjuvant",ZAWADZKA M I;  STASI L P;  ROGACKI M K;  CWIERTNIA G W;  DUDEK L P;  GIBAS A J;  RAJDA A;  FABRITIUS C;  RADZIMIERSKI A;  MAHAJAN T R;  LES M W;  ZUCHOWICZ K;  WRONOWSKI M;  SYNAK D J;  TANGIRALA S R;  JAWAZCA M I;  LOGAKI M K;  SIEGE E G;  ANNA L A;  MAHAZAN T;  LES M;  ZHUKOVIC C;  SNACK D J;  TANGIRALA S,RYVU THERAPEUTICS SA (RYVU-Non-standard);  RYVU THERAPEUTICS SA (RYVU-Non-standard);  RYVU THERAPEUTICS SA (RYVU-Non-standard);  RYVU THERAPEUTICS SA (RYVU-Non-standard),2021660469,"   NOVELTY - Compound-linker construct comprising (a)                substituted fused heterocyclyl compounds (I) and                (b) a linker L1, is new.    USE - The compound-linker construct and conjugate                are useful: for treating disease comprising cancer,                pre-cancerous syndromes, infectious diseases,                inflammatory diseases, allergic diseases, or                autoimmune diseases; and as immunogenic composition                or as vaccine adjuvant (all claimed), where the                cancer is e.g. prostate cancer, renal carcinoma,                melanoma, pancreatic cancer, cervical cancer,                ovarian cancer, colon cancer, head and neck cancer,                lung cancer, fibrosarcoma, and breast cancer, the                autoimmune disease is e.g. systemic lupus                erythematosus, Addison's disease,                glomerulonephritis, chronic thyroiditis,                thrombocytopenia, atopic dermatitis, myasthenia                gravis, multiple sclerosis, inflammatory bowel                disease, and ulcerative colitis and the infectious                disease is e.g. HIV and severe acute respiratory                syndrome coronavirus 2. Test details are described                but no results for the compound-linker construct of                the claim is given.    DETAILED DESCRIPTION - Compound-linker construct comprising (a) a                substituted fused heterocyclyl compounds of formula                (I) or their salts, stereoisomers, tautomers or                N-oxide and (b) a linker L1, is new.    X2 = CR3 or N;    R1, R2, R3 = 4-6C saturated, partially or                fully unsaturated, or aromatic carbocyclyl,                carbocyclyl-1-2C-alkyl, heterocyclyl,                heterocyclyloxy, or heterocyclyl-1-2C-alkyl, 8-10C                saturated, partially or fully unsaturated, or                aromatic carbobicyclyl or heterobicyclyl (all                optionally substituted by Rx1), H, OH, NRc1Rd1, CN,                halo, 1-4C alkyl, NRc1Rd1-1-4C alkyl, 1-4C alkoxy,                aryloxy, benzyloxy, C(=O)Re1, NRf1C(=O)Re1,                NRF-(1-4C alkylene)-C(=O)Re1, NRf1-(1-4C                alkylene)-NRc1Rd1, or O-(1-4C                alkylene)-NRc1Rd1;    R4 = 5-6C aromatic carbocyclyl or                heterocyclyl, or a 9-10C aromatic carbobicyclyl or                heterobicyclyl (all optionally substituted by Rx1),                where the heterocyclyl or heterobicyclyl comprises                at least one N and optionally at least one O, N or                S, where the N- and/or S are oxidized or                non-oxidized;    R5 = 5-6C saturated heterocyclyl (all                optionally substituted by Ry1), where the                heterocyclyl comprises at least one N and                optionally at least one O, N or S, where the N-                and/or S are oxidized or non-oxidized;    R1a = 3-4C saturated carbocyclyl or                heterocyclyl (optionally substituted by Rx1), H,                1-4C -alkyl, HO(C=O)-1-4C-alkyl, NRc1Rd1-1-4C                alkyl, 1-2C-alkoxy-1-4C alkyl, where heterocyclyl                comprises at least one O, N or S, where the N                and/or S are oxidized or non-oxidized; either    Rc1, Rd1 = H, or 1-2C-alkyl; or    Rc1Rd1N = 5-6C saturated, partially or fully                unsaturated, or aromatic heterocyclyl (optionally                substituted by at least one Rx1), where the                heterocyclyl comprises O, N or S, and the N- and/or                S are oxidized or non-oxidized;    Re1 = 5-6C saturated, partially or fully                unsaturated, or aromatic heterocyclyl (optionally                substituted by at least one Rf1), H, 1-2C-alkyl,                NRc1Rd1-1-4C alkyl, phenyl, benzyl, ORg2, or                NRh1Ri1, where the heterocyclyl comprises O, N or                S, and the N- and/or S are oxidized or                non-oxidized;    Rf1 = H, 1-2C-alkyl, 3-6C-cycloalkyl, phenyl,                benzyl, or C(=O)NRh1Ri1; either    Rg1, Rh1, Ri1 = H, 1-2C-alkyl, 5-6C aromatic                carbocyclyl, carbocyclyl-1-2C-alkyl, heterocyclyl,                or heterocyclyl-1-2C-alkyl, where the heterocyclyl                comprise at least one, O, N or S, and N is oxidized                or non-oxidized; or    Rh1Ri1N = 5-6C saturated, partially or fully                unsaturated, or aromatic heterocyclyl (all                optionally substituted by Rx1), where heterocyclyl                comprises at least one of O, N or S, where N-                and/or S are oxidized or non-oxidized; either    Rx1 = OH, NRc1Rd1, halo, CN, NO2, 1-2C-alkyl,                1-2C-haloalkyl, NRc1Rd1-1-4C alkyl, RCO-1-4C alkyl,                1-2C-alkoxy, C(=O)Re1; and    Ry1 = 5-6C saturated, partially or fully                unsaturated, or aromatic carbocyclyl,                carbocyclyl-1-2C-alkyl, heterocyclyl, and                heterocyclyl-1-2C-alkyl (all optionally                substituted), halo, CN, OH, 1-2C-alkyl,                HO-1-2C-alkyl, 3-6C-cycloalkyl, 1-2C-alkoxy,                NRc1R1, S(=O)2NRc1Rd1, or C(=O)Re1, where the                heterocyclyl comprise O, N or S, where the N-                and/or S are oxidized or non-oxidized; or    Rx1Rx1, Ry1Ry1 = O; or    Rx1Rx1C = 3-5C saturated, partially or fully                unsaturated, or aromatic carbocyclyl; or    Ry1Ry1C = 3C carbocyclyl; and    X1 = CH or N.    Provided that either any one of R1, R2, or R3                is NRc1Rd1, NRc1Rd1-1-4C alkyl, NRf1-(1-4C                alkylene)-NRc1Rd1, O-(1-4C alkylene)-NRc1Rd1, or                8-10C saturated, partially or fully unsaturated, or                aromatic carbobicyclyl or heterobicyclyl (all                optionally substituted by Rx1) or any one of R1,                R2, or R3 is NRf1C(=O)Re1, where Re1 is                NRc1Rd1-1-4C alkyl or R1a is NRc1Rd1-1-4C alkyl, or                1-2C-alkoxy-1-4C alkyl or any one of the R1, R2,                R3, R4, R5, R1a carries RX1, where Rx1 is OH,                NRc1Rd1, NRc1Rd1-1-4C alkyl, or Rc1O-1-4Calkyl. An                INDEPENDENT CLAIM is also included for a conjugate                comprising (I) or its salt, stereoisomer, tautomer,                or N-oxide, a linker L2 and a targeting moiety                T1. ",,,"B02 (Fused ring heterocyclics.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).);  ;  A96 (Medical, dental, veterinary, cosmetic.)",B04-C01;  B04-C03C;  B04-D01;  B04-E01;  B04-G01;  B04-G23;  B04-H06;  B04-K01;  B04-N04;  B04-Q;  B14-A01;  B14-A02;  B14-A04;  B14-C03;  B14-D01;  B14-E08;  B14-E10C1;  B14-F03;  B14-G02A;  B14-G02D;  B14-H01;  B14-J05;  B14-K01D;  B14-L01;  B14-L06;  B14-N10;  B14-N11;  B14-N17;  B14-S01;  B14-S11C;  B14-S16;  B14-S18;  D05-H11;  D08-B;  A10-E01;  A11-C01C;  A12-V01,A61K-031/4709;  A61P-029/00;  A61P-035/00;  C07D-401/14;  C07D-405/14;  C07D-413/14;  A61P-037/00;  A61P-037/08;  C07D-471/04;  A61K-031/496;  A61K-031/497;  A61K-031/501;  A61K-031/5377;  A61K-038/05;  A61K-039/39;  A61K-039/395;  A61K-047/68;  A61P-031/00;  A61P-037/02;  A61P-037/04;  C07K-016/18;  C07K-016/22;  C07K-016/28;  C07K-005/06;  A61K-047/54,WO2021116446-A1   17 Jun 2021   202156Pages: 344   English;  AU2020401358-A1   26 May 2022   C07D-401/14   202243   English;  CN114787148-A   22 Jul 2022   C07D-401/14   202263   Chinese;  KR2022112824-A   11 Aug 2022   C07D-401/14   202266   ;  CA3159943-A1   17 Jun 2021   C07D-401/14   202272   English;  EP4073062-A1   19 Oct 2022   C07D-401/14   202285   English;  BR112022010839-A2   13 Sep 2022   C07D-401/14   202292   ;  IL293558-A   01 Aug 2022   A61P-035/00   202313   English;  JP2023505877-W   13 Feb 2023   C07D-401/14   202315   Japanese;  US2023055741-A1   23 Feb 2023   C07D-401/14   202317   English;  MX2022007179-A1   19 Jul 2022   A61P-029/00   202390   Spanish;  HK40082167-A0   02 Jun 2023   C07D-401/14   202395   English;  AU2020401358-B2   15 Feb 2024   C07D-401/14   202416   English;  AU2024203206-A1   30 May 2024   C07D-401/14   202446   English,WO2021116446-A1    WOEP085833    11 Dec 2020;   AU2020401358-A1    AU401358    11 Dec 2020;   CN114787148-A    CN80085971    11 Dec 2020;   KR2022112824-A    KR723487    11 Dec 2020;   CA3159943-A1    CA3159943    11 Dec 2020;   EP4073062-A1    EP821008    11 Dec 2020;   BR112022010839-A2    BR11010839    11 Dec 2020;   IL293558-A    IL293558    11 Dec 2020;   JP2023505877-W    JP535699    11 Dec 2020;   US2023055741-A1    US17783940    09 Jun 2022;   MX2022007179-A1    MX007179    10 Jun 2022;   HK40082167-A0    HK6071245    11 Apr 2023;   AU2020401358-B2    AU401358    11 Dec 2020;   AU2024203206-A1    AU203206    15 May 2024;   AU2024203206-A1    AU203206    15 May 2024,AU2020401358-A1 PCT application Application WOEP085833;   AU2020401358-A1 Based on Patent WO2021116446;   CN114787148-A PCT application Application WOEP085833;   CN114787148-A Based on Patent WO2021116446;   KR2022112824-A PCT application Application WOEP085833;   KR2022112824-A Based on Patent WO2021116446;   CA3159943-A1 PCT application Application WOEP085833;   CA3159943-A1 Based on Patent WO2021116446;   EP4073062-A1 PCT application Application WOEP085833;   EP4073062-A1 Based on Patent WO2021116446;   BR112022010839-A2 PCT application Application WOEP085833;   BR112022010839-A2 Based on Patent WO2021116446;   IL293558-A Based on Patent WO2021116446;   JP2023505877-W PCT application Application WOEP085833;   JP2023505877-W Based on Patent WO2021116446;   US2023055741-A1 PCT application Application WOEP085833;   MX2022007179-A1 PCT application Application WOEP085833;   MX2022007179-A1 Based on Patent WO2021116446;   HK40082167-A0 PCT application Application WOEP085833;   HK40082167-A0 Based on Patent WO2021116446;   HK40082167-A0 Previous Publ. Patent EP4073062;   AU2020401358-B2 PCT application Application WOEP085833;   AU2020401358-B2 Based on Patent WO2021116446;   AU2024203206-A1 Div ex Application AU401358,EP460066    11 Dec 2019;  AU401358    11 Dec 2020;  EP821008    11 Dec 2020;  CA3159943    30 May 2022;  BR11010839    02 Jun 2022;  CN80085971    10 Jun 2022;  KR723487    07 Jul 2022;  AU203206    15 May 2024,WO2021116446-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA          EP4073062-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN                  ,,"WO2021116446-A1 -- GB2563642-A   CURADEV PHARMA LTD (CURA-Non-standard)   BANERJEE M,  MIDDYA S,  BASU S,  GHOSH R,  PRYDE D C,  YADAV D,  SHRIVASTAVA R,  SURYA A;  WO2019238786-A1   RYVU THERAPEUTICS SA (RYVU-Non-standard)   DOBRZANSKA M P,  ZAWADZKA M I,  RADZIMIERSKI A,  TOPOLNICKI G W,  CWIERTNIA G W,  MAHAJAN T R,  FABRITIUS C,  CHMIELEWSKI S,  GLUZA K M,  ALVAREZ J,  ROGACKI M K,  MROCZKOWSKA M;  WO2020249773-A1   RYVU THERAPEUTICS SA (RYVU-Non-standard)   ZAWADZKA M I,  STASI L P,  ROGACKI M K,  CWIERTNIA G W,  DUDEK L P,  DOBRZANSKA M P,  TOPOLNICKI G W,  GIBAS A J,  RAJDA A,  SUDOL S,  GLUZA K M,  FABRITIUS C;  CN114787148-A -- CN104603126-A   NOVARTIS AG (NOVS)   ALTMANN E,  HOMMEL U,  LORTHIOIS E L J,  MAIBAUM J K,  OSTERMANN N,  RANDL S A,  VULPETTI A,  ROGEL O;  GB2563642-A   CURADEV PHARMA LTD (CURA-Non-standard)   BANERJEE M,  MIDDYA S,  BASU S,  GHOSH R,  PRYDE D C,  YADAV D,  SHRIVASTAVA R,  SURYA A;  WO2019238786-A1   RYVU THERAPEUTICS SA (RYVU-Non-standard)   DOBRZANSKA M P,  ZAWADZKA M I,  RADZIMIERSKI A,  TOPOLNICKI G W,  CWIERTNIA G W,  MAHAJAN T R,  FABRITIUS C,  CHMIELEWSKI S,  GLUZA K M,  ALVAREZ J,  ROGACKI M K,  MROCZKOWSKA M;  WO2020249773-A1   RYVU THERAPEUTICS SA (RYVU-Non-standard)   ZAWADZKA M I,  STASI L P,  ROGACKI M K,  CWIERTNIA G W,  DUDEK L P,  DOBRZANSKA M P,  TOPOLNICKI G W,  GIBAS A J,  RAJDA A,  SUDOL S,  GLUZA K M,  FABRITIUS C","WO2021116446-A1  ALEKSANDAR R.          TODOROV ET AL: ""Tautomeric Switching and Metal-Cation          Sensing of Ligand-Equipped          4-Hydroxy-/4-oxo-1,4-dihydroquinolines"", CHEMISTRY A          EUROPEAN JOURNAL, vol. 18, no. 23, 4 June 2012          (2012-06-04), DE, pages 7269 - 7277, XP055497664, ISSN:          0947-6539, DOI:          10.1002/chem.201103868,relevantClaims[1-16],relevantPassages[&lt;pp&gt;7272&lt;/pp&gt;&lt;compound&gt;3&lt;/compound&gt;];  H.          ISHIKAWAG. N. BARBER, NATURE, vol. 455, 2008, pages 674 -          678;  P.          GAO ET AL., CELL, vol. 153, 2013, pages 1094 -          1107;            GAO ET AL., SCIENCE, vol. 341, no. 6148, 2013, pages 903          - 791;  L.          CORRALES ET AL., J IMMUNOTHER CANCER, vol. 1, 2013, pages          015;  L.          CORRALES ET AL., CELL REP., vol. 11, no. 7, 19 May 2015          (2015-05-19), pages 1018 - 30;            S-R. WOO ET AL., TRENDS IMMUNOL., vol. 36, no. 4, 2015,          pages 250;  J.          FU ET AL., SCI. TRANS. MED., vol. 7, pages 283 -          52;  L.          CORRALESTF. GAJEWSKI, CLIN CANCER RES, vol. 21, no. 21,          2015, pages 4774 - 9;  L.          ZITVOGEL ET AL., NATURE REVIEWS IMMUNOLOGY, vol. 15, no.          7, 2015, pages 405 - 414;  J.          MOISAN ET AL., AM. J. PHYSIOL. LUNG CELL MOL. PHYSIOL.,          vol. 290, 2006, pages L987 - 995;  H.          LEMOS ET AL., J. IMMUNOL, vol. 192, no. 12, 2014, pages          5571 - 8;  E.          CIRULLI ET AL., SCIENCE, vol. 347, no. 6229, 2015, pages          1436 - 41;  A.          FREISCHMIDT ET AL., NAT. NEUROSCI., vol. 18, no. 5, pages          631 - 6;  S.          RAKOFF-NAHOUM, CELL, vol. 118, no. 2, 2004, pages 229 -          41;            PERSING ET AL., TRENDS MICROBIOL, vol. 10, 2002, pages 32          - 7;            DUBENSKY ET AL., THERAPEUTIC ADVANCES IN VACCINES, 5          September 2013 (2013-09-05);            BARBER ET AL., NAT. REV. IMMUNOL., vol. 15, no. 2, 2015,          pages 87 - 103;            MADAMANIA, CELL HOST & MICROBE, vol. 19, no. 2, 2016,          pages 150 - 158;            HOLM ET AL., NAT COMM., vol. 7, 2016, pages          10680;  MA          ET AL., PNAS, vol. 112, no. 31, 2015, pages E4306 -          E4315;            WASSERMANN ET AL., CELL HOST MICROBE, vol. 17, no. 6,          2015, pages 811 - 810;            LIU ET AL., J VIROL, vol. 90, no. 20, 2016, pages 9406 -          19;            CHEN ET AL., PROTEIN CELL, vol. 5, no. 5, 2014, pages 369          - 81;            DING ET AL., J HEPATOL, vol. 59, no. 1, 2013, pages 52 -          8;            NITTA ET AL., HEPATOLOGY, vol. 57, no. 1, 2013, pages 46          - 58;            SUN ET AL., PLOS ONE, vol. 7, no. 2, 2012, pages          e30802;            AGUIRRE ET AL., PLOS PATHOG, vol. 8, no. 10, 2012, pages          e1002934;            ISHIKAWA ET AL., NATURE, vol. 461, no. 7265, 2009, pages          788 - 92;            STOREK ET AL., J IMMUNOL., vol. 194, no. 7, 2015, pages          3236 - 45;            JIN ET AL., J IMMUNOL., vol. 187, no. 5, 2011, pages 2595          - 601;  J.          P. HUBER ET AL., J IMMUNOL, vol. 185, no. 5, 2010, pages          2551 - 817;            SHARMA ET AL., IMMUNITY, vol. 35, no. 2, 2011, pages 194          - 207;            HERZNER ET AL., NAT IMMUNOL, vol. 16, no. 10, 2015, pages          1025 - 33;  Y.          J. CROW ET AL., NAT. GENET., vol. 38, no. 8, 2006, pages          38917 - 920;  D.          B. STETSON ET AL., CELL, 2008, pages 134587 -          598;  J.          D. BARGH ET AL., CHEM. SOC. REV., 2019;            BECK, A., NAT. REVS. DRUG DISC., vol. 16, 2017, pages 315          - 337;            ORAVA, E., BIOCHEM. BIOPHYS. ACTA, vol. 1798, 2010, pages          2190 - 2200;            MOUSAVIZADEH, A., COLLOIDS SURFACES B., vol. 158, 2017,          pages 507 - 517;            POLAKIS, P., PHARMACOL. REVS., vol. 68, 2016, pages 3 -          19;            BR. J. CANCER, vol. 70, 1994, pages 1126 - 1130CN114787148-A  ALEKSANDAR R.          TODOROV: ""Tautomeric Switching and Metal-Cation Sensing          of Ligand-Equipped 4-Hydroxy-/4-oxo-1,          4-dihydroquinolines"", CHEMISTRY., vol. 18, no. 23, 4 June          2012 (2012-06-04), pages 7269 - 7277, XP055497664, DOI:          10.1002/chem.201103868,relevantClaims[1-19]",184587-0-0-0 M N Q; 184611-0-0-0 M N Q; 93605-0-0-0 M N Q; 105730-0-0-0 M N Q; 184592-0-0-0 M N Q; 1536600-0-0-0 M N Q; 1537531-1-0-0 M N Q; 123286-0-0-0 M N Q; 104225-0-0-0 M N Q; 202589-0-0-0 M N Q; 101835-0-0-0 M N Q; 184598-0-0-0 M N Q; 184616-0-0-0 M N Q; 444-0-0-0 ; 184587-0-0-0 CL NEW RCT USE; 184611-0-0-0 CL NEW RCT USE; 93605-0-0-0 CL NEW RCT USE; 105730-0-0-0 CL NEW RCT USE; 184592-0-0-0 CL NEW RCT USE; 1536600-0-0-0 CL NEW RCT USE; 1537531-1-0-0 CL NEW RCT USE; 123286-0-0-0 CL NEW RCT USE; 104225-0-0-0 CL NEW RCT USE; 202589-0-0-0 CL NEW RCT USE; 101835-0-0-0 CL NEW RCT USE; 184598-0-0-0 CL NEW RCT USE; 184616-0-0-0 CL NEW RCT USE,224700901 M N Q; 224700902 M N Q; 224700903 M N Q; 224700904 M N Q,01683; 41662,RA00C8 M N Q; RA00H1 M N Q; RA00NS M N Q; RA012P M N Q; RA0120 M N Q; RARMJD M N Q; RARN9W M N Q; RA03RK M N Q; RA063L M N Q; RA01SD M N Q; RA0367 M N Q; RA00GC M N Q; RA00H3 M N Q; R00351 ,
CN115261336-A;  US2023393122-A1;  WO2023237126-A1;  CN115261336-B,"Use of human extra embryonic trophoblast cell            model for use in virus preparation, preparation of            vaccines against viruses, virus detection, preparation            and/or screening of therapeutic drugs for viral            diseases, where trophoblast cell model is prepared by            providing human extra embryonic early cells",LIU F;  RUAN D;  LIU P,CENT TRANSLATIONAL STEM CELL BIOLOGY LTD (TRAN-Non-standard);  CENT TRANSLATIONAL STEM CELL BIOLOGY LTD (TRAN-Non-standard);  CENT TRANSLATIONAL STEM CELL BIOLOGY LTD (TRAN-Non-standard),2022D86372,"   NOVELTY - Use of human extra embryonic trophoblast cell                model in virus preparation, is claimed.    USE - Human extraembryonic trophoblast cell model                for use in virus preparation, preparation of                vaccines against viruses, virus detection,                preparation and/or screening of therapeutic drugs                for viral diseases(claimed).    ADVANTAGE - The cell model provides important                transformational prospects for the transformation                application of very early stem cells/early                placental cells. ",,,"D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.)",D05-H99;  D05-H08B;  D05-H07;  B11-A04A;  B04-B04H;  B04-E99;  B04-F11;  B04-F02;  B14-S11A;  B14-A02,C12N-007/00;  C12Q-001/02;  C12Q-001/70;  C12R-001/93;  C12Q-001/6851;  G01N-033/50,CN115261336-A   01 Nov 2022   C12N-007/00   202203   Chinese;  US2023393122-A1   07 Dec 2023   G01N-033/50   202399   English;  WO2023237126-A1   14 Dec 2023   C12N-007/00   202301   English;  CN115261336-B   29 Mar 2024   C12N-007/00   202429   Chinese,CN115261336-A    CN10631030    06 Jun 2022;   US2023393122-A1    US345934    30 Jun 2023;   WO2023237126-A1    WOCN105028    30 Jun 2023;   CN115261336-B    CN10631030    06 Jun 2022,US2023393122-A1 Provisional Application US402032P;   CN115261336-B Previous Publ. Patent CN115261336,CN10631030    06 Jun 2022;  US402032P    29 Aug 2022,    WO2023237126-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,"CN115261336-A -- CN105624194-A   AGRO-BIOLOGICAL GENE RES CENT GDAAS (AGRO-Non-standard)   BAI Y,  CHEN Z,  JIANG Z,  ZHU C;  CN109975264-A   UNIV ANHUI AGRIC (UYAH)   CAO Z,  TONG X,  ZHANG D,  WANG Y,  NING W,  QI X,  GAO D,  XU T,  ZHANG Y;  CN113966393-A   UNIV HONG KONG (UYHK)   LIU P,  GAO X,  RUAN D;  CN114456259-A   UNIV SHANGHAITECH (USKJ);  SHOX SCI LTD (SHOX-Non-standard)   WANG H,  QIANG M,  LERNER R A,  YANG G,  MA P;  WO2018035138-A1   ORGANOVO INC (ORGA-Non-standard);  UNIV OREGON HEALTH SCI (UYOR);  PRESNELL S C (PRES-Individual);  KING S M (KING-Individual);  NGUYEN D L G (NGUY-Individual);  JO M (JOMM-Individual);  PELZ R S (PELZ-Individual);  ALLEN-PETERSEN B (ALLE-Individual);  LANGER E (LANG-Individual)   PRESNELL S C,  KING S M,  NGUYEN D L G,  JO M,  PELZ R S,  ALLEN-PETERSEN B,  LANGER E;  WO2021106765-A1   UNIV KYOTO (KYOU)   TAKASHIMA Y,  IO S;  WO2022075384-A1   MICAN TECHNOLOGIES INC (MICA-Non-standard);  UNIV OSAKA (OSAU)   SHIMIZU J,  TANGA N,  YAMADA M,  MIYAZAKI K,  SHIODA T,  NAKAYAMA E,  SASAKI T,  KOKETSU R;  WO2021195470-A2   VANDA PHARM INC (VAPH)   POLYMEROPOULOS M H,  SMIESZEK S,  PRZYCHODZEN B,  POLYMEROPOULOS V M;  WO2023237126-A1 -- CN105624194-A   AGRO-BIOLOGICAL GENE RES CENT GDAAS (AGRO-Non-standard)   BAI Y,  CHEN Z,  JIANG Z,  ZHU C;  CN109975264-A   UNIV ANHUI AGRIC (UYAH)   CAO Z,  TONG X,  ZHANG D,  WANG Y,  NING W,  QI X,  GAO D,  XU T,  ZHANG Y;  CN113966393-A   UNIV HONG KONG (UYHK)   LIU P,  GAO X,  RUAN D;  CN114456259-A   UNIV SHANGHAITECH (USKJ);  SHOX SCI LTD (SHOX-Non-standard)   WANG H,  QIANG M,  LERNER R A,  YANG G,  MA P;  CN115261336-A   CENT TRANSLATIONAL STEM CELL BIOLOGY LTD (TRAN-Non-standard)   LIU F,  RUAN D,  LIU P;  WO2018035138-A1   ORGANOVO INC (ORGA-Non-standard);  UNIV OREGON HEALTH SCI (UYOR);  PRESNELL S C (PRES-Individual);  KING S M (KING-Individual);  NGUYEN D L G (NGUY-Individual);  JO M (JOMM-Individual);  PELZ R S (PELZ-Individual);  ALLEN-PETERSEN B (ALLE-Individual);  LANGER E (LANG-Individual)   PRESNELL S C,  KING S M,  NGUYEN D L G,  JO M,  PELZ R S,  ALLEN-PETERSEN B,  LANGER E;  WO2021106765-A1   UNIV KYOTO (KYOU)   TAKASHIMA Y,  IO S;  WO2022075384-A1   MICAN TECHNOLOGIES INC (MICA-Non-standard);  UNIV OSAKA (OSAU)   SHIMIZU J,  TANGA N,  YAMADA M,  MIYAZAKI K,  SHIODA T,  NAKAYAMA E,  SASAKI T,  KOKETSU R;  WO2021195470-A2   VANDA PHARM INC (VAPH)   POLYMEROPOULOS M H,  SMIESZEK S,  PRZYCHODZEN B,  POLYMEROPOULOS V M;  CN115261336-B -- CN105624194-A   AGRO-BIOLOGICAL GENE RES CENT GDAAS (AGRO-Non-standard)   BAI Y,  CHEN Z,  JIANG Z,  ZHU C;  CN109975264-A   UNIV ANHUI AGRIC (UYAH)   CAO Z,  TONG X,  ZHANG D,  WANG Y,  NING W,  QI X,  GAO D,  XU T,  ZHANG Y;  CN113966393-A   UNIV HONG KONG (UYHK)   LIU P,  GAO X,  RUAN D;  CN114456259-A   UNIV SHANGHAITECH (USKJ);  SHOX SCI LTD (SHOX-Non-standard)   WANG H,  QIANG M,  LERNER R A,  YANG G,  MA P;  WO2018035138-A1   ORGANOVO INC (ORGA-Non-standard);  UNIV OREGON HEALTH SCI (UYOR);  PRESNELL S C (PRES-Individual);  KING S M (KING-Individual);  NGUYEN D L G (NGUY-Individual);  JO M (JOMM-Individual);  PELZ R S (PELZ-Individual);  ALLEN-PETERSEN B (ALLE-Individual);  LANGER E (LANG-Individual)   PRESNELL S C,  KING S M,  NGUYEN D L G,  JO M,  PELZ R S,  ALLEN-PETERSEN B,  LANGER E;  WO2021106765-A1   UNIV KYOTO (KYOU)   TAKASHIMA Y,  IO S;  WO2022075384-A1   MICAN TECHNOLOGIES INC (MICA-Non-standard);  UNIV OSAKA (OSAU)   SHIMIZU J,  TANGA N,  YAMADA M,  MIYAZAKI K,  SHIODA T,  NAKAYAMA E,  SASAKI T,  KOKETSU R;  WO2021195470-A2   VANDA PHARM INC (VAPH)   POLYMEROPOULOS M H,  SMIESZEK S,  PRZYCHODZEN B,  POLYMEROPOULOS V M","CN115261336-A  LOKKI A :          ""Complement activation and regulation in preeclamptic          placenta"", FRONT IMMUNO, vol. 2018, pages 100 -          14,relevantClaims[1-19];  WEATHERBEE B :          ""Expression of SARS-CoV-2 receptorACE2and the          proteaseTMPRSS2suggests susceptibility of the human          embryo in the first trimester"", OPEN BIOL, vol. 6, no.          10, pages 1162 - 1169,relevantClaims[1-19];  ZHOU J : ""Is          SARS-CoV-2 Infection a Risk Factor for Early Pregnancy          Loss? ACE2 and TMPRSS2 Coexpression and Persistent          Replicative Infection in Primitive Trophoblast"", J INFECT          DIS, vol. 224, no. 6, pages          661,relevantClaims[68-9|1-516];  RUAN D : ""Human          early syncytiotrophoblasts are highly susceptible to          SARS-CoV-2 infection"", CELL REP MED, vol. 3, no. 12,          pages 1 - 10,relevantClaims[1-19];  GAO X :          ""Establishment of porcine and human expanded potential          stem cells"", NAT CELL BIOL, vol. 21, no. 6, pages 687 -          699, XP036796369, DOI:          10.1038/s41556-019-0333-2,relevantClaims[1-19];  ASHARY N:          ""Single-Cell RNA-seq Identifies Cell Subsets in Human          Placenta That Highly Expresses Factors Driving          Pathogenesis of SARS-CoV-2"", FRONT CELL DEV BIOL, vol. 8,          pages 3,relevantClaims[68-9];  KALLOL S :          ""Activation of the Interferon Pathway in Trophoblast          Cells Productively Infected with SARS-CoV-2"", STEM CELLS          DEV, vol. 3, pages 225 -          236,relevantClaims[1-19];  : ""SARS-CoV-2"", ,          no. 1, pages 063 - 32,relevantClaims[1-19];  : """", , vol. 31,          no. 3, pages 273 - 276,relevantClaims[1-18];  : """", , vol. 27,          no. 12, pages 1296 - 1300,relevantClaims[1-19]WO2023237126-A1  ZHOU JIE, CHOI          SEHEE, LIU HEIDI, ZHANG JIALIN, TIAN YUCHEN, EDLOW ANDREA          G, EZASHI TOSHIHIKO, ROBERTS R MICHAEL, MA WENJUN,          SCHUST: ""Is SARS-CoV-2 Infection a Risk Factor for Early          Pregnancy Loss? ACE2 and TMPRSS2 Coexpression and          Persistent Replicative Infection in Primitive          Trophoblast"", JOURNAL OF INFECTIOUS DISEASES, UNIVERSITY          OF CHICAGO PRESS, US, vol. 224, no. Supplement_6, 8          December 2021 (2021-12-08), US , pages S660 - S669,          XP093114511, ISSN: 0022-1899, DOI:          10.1093/infdis/jiab309,relevantClaims[1-26],relevantPassages[see          the abstract, the right column of page s661, page          s662];  ASHARY NANCY, BHIDE          ANSHUL, CHAKRABORTY PRIYANKA, COLACO STACY, MISHRA          ANURADHA, CHHABRIA KARISMA, JOLLY MOHIT KUMAR, MODI          DEEPAK: ""Single-Cell RNA-seq Identifies Cell Subsets in          Human Placenta That Highly Expresses Factors Driving          Pathogenesis of SARS-CoV-2"", FRONTIERS IN CELL AND          DEVELOPMENTAL BIOLOGY, FRONTIERS MEDIA, CH, vol. 8, 19          August 2020 (2020-08-19), CH , pages 783, XP093114514,          ISSN: 2296-634X, DOI:          10.3389/fcell.2020.00783,relevantClaims[1-26],relevantPassages[see          the abstract]CN115261336-B            Zhang Xiaowong, editor-in-chief, ""Clinical Obstetrics and          Gynaecological Disease Treatment"", Hubei Science and          Technology Publishing House, 2018, (April 2018, edition          1), page 100.;            Zhou J et al. Is SARS-CoV-2 Infection a Risk Factor for          Early Pregnancy Loss? ACE2 and TMPRSS2 Coexpression and          Persistent Replicative Infection in Primitive          Trophoblast; Zhou J etc.; ""J Infect Dis""; volume 224          (S6); abstract, page S661, page 3, page S662, page 3,          page S664, page 1, page S664, page 4, page S666, page 2,          page S666, page 2;;  Is          SARS-CoV-2 Infection a Risk Factor for Early Pregnancy          Loss? ACE2 and TMPRSS2 Coexpression and Persistent          Replicative Infection in Primitive Trophoblast. 2021,          volume 224 (S6), summary, page S661, page 3, page S662,          page 3, page S664, page 1, page S664, page 4, page S666,          page 2.;            Ashary N. Single-Cell RNA-seq Identise Cell Subsets in          Human Placenta That Expies Factors Driving Pathogenesis          of SARS-CoV-2; Ashary N, etc.; ""Front Cell Dev Biol"";          Volume 8; Summary, page 3, paragraph 3, page 4, paragraph          5;;            Ruan D et al. Human early          syncytiotrophotrophotrophotrophotrophotrophotrophotrophotrophotrophotrophotrophotrophotrophotrophotrophotrophotrophotrophotrophotro;          ""Cell Rep Med""; Volume 3 (Phase 12); Page 1-10;            Gao X et al. Establishment of a body and a body; Gao X          and so on; ""Nat Cell Biol""; Volume 21 (Phase 6); Page          687-699;;            Kallol S and so on. Activation of the Interferon Pathway          in Trophoblast Cells Producer SARS-CoV-2; Kallol S, etc.;          ""Stem Cells Dev""; Volume 3; Page 225-236;            Down Navy. The infection characteristics of the          SARS-CoV-2 variant and the screening and mechanism          research of anti-viral drugs; the Tang Navy; the Chinese          PhD thesis full text database (Electronic Journal)          Medical and Health Technology (Phase 1); and the          E063-32;            High Luhua and so on. Human trophoblast cell culture          supernatant and detection of hepatitis C virus in lysis          solution; high Luhua et al., Journal of Clinical Liver          and Biliary Disease; volume 27 (Phase 12); page          1296-1300;            Weatherbee B. Expression of SARS-CoV-2 receptor ACE2 and          the protease TMPRSS2 in the first trimester; WeatherB,          etc.; ""Open Biol""; Volume 6 (Phase 10); pages          1162-1169;;            Lokki A and so on. Complement activation and regulation          in preeclamp; Lokki A, etc.; ""Front Immuno""; Volume          5;;  Li          Zewu and others. Research on the relationship between new          coronavirus infection and bad pregnancy results of          pregnant women; Li Zewu, et al; Chinese Journal of Birth          Health; Volume 31 (Phase 3); p. 273-276",,,,,
WO2021222438-A1;  US2021361598-A1;  CA3177262-A1;  EP4143218-A1;  CN115803336-A;  JP2023524229-W;  HK40089435-A0;  EP4143218-A4,"Preventing, reducing severity of, delaying onset            of or treating post-intensive care or at risk of            developing cognitive dysfunction, comprises            administering (E)-1-benzylidene-2-phenylhydrazine            derivatives",VILLAFRANCA J E;  KISSINGER C R;  KISSINGER C,ABREXA PHARM INC (ABRE-Non-standard);  ABREXA PHARM INC (ABRE-Non-standard);  ABREXA PHARM INC (ABRE-Non-standard),2021C2320U,"   NOVELTY - Preventing, reducing the severity of, delaying                the onset of, or treating post-intensive care                cognitive dysfunction (PICCD) in a subject, or a                subject at risk of developing PICCD, comprises                administering, or the subject at risk,                (E)-1-benzylidene-2-phenylhydrazine derivatives                (I).    USE - The method is useful for e.g. treating,                preventing, reducing severity of, delaying onset of                or treating post-intensive care or at risk of                developing cognitive dysfunction, cognitive                impairment or a cognitive disorder resulting from,                or caused by respiratory distress, Alzheimer's                disease, Parkinson's disease, Huntington's disease,                amyotrophic lateral sclerosis, glaucoma, retinal                degeneration, macular degeneration, age-related                hearing loss, mild cognitive impairment and                progressive supranuclear palsy (all claimed). Test                details are described but no results given.    DETAILED DESCRIPTION - Preventing, reducing the severity of, delaying                the onset of, or treating post-intensive care                cognitive dysfunction (PICCD) in a subject, or a                subject at risk of developing PICCD, comprises                administering, or the subject at risk,                (E)-1-benzylidene-2-phenylhydrazine derivatives of                formula (I) or their salts, stereoisomers or                tautomers.    R2 = H or methyl;    R3 = trifluoromethyl or other fluoro                substituted alkyl;    L3 = carbonyl;    R6 = alkyl, substituted alkyl, cycloalkyl,                substituted cycloalkyl, hydroxyl, alkoxy,                substituted alkoxy, aryloxy, substituted aryloxy,                mercapto, alkylthio, arylthio, carbonyl, aryl,                substituted aryl, substituted heterocyclic,                halogen, CN, cyanoalkyl, N, amino, amidino,                carbamate, S(O)nR7 or C(O)R8 or    2R6 = optionally substituted heteroaryl or                heteroalkyl ring fused with the adjoining phenyl                moiety;    R7 = H, R9, NH2, HNR9 or NR9R10;    R8 = OH, OR9, NH2, NHR9 or NR9R10;    R9, R10 = optionally substituted alkyl;    a = 0-5; and    n = 1-2.    An INDEPENDENT CLAIM is also included for                treating, preventing, inhibiting, reducing the                severity of, or delaying the onset of a cognitive                impairment or a cognitive disorder resulting from,                or caused by respiratory distress in a subject,                comprising administering (I), to a subject who is                at risk of having respiratory distress, who has or                is experiencing respiratory distress, or who has                previously experienced respiratory distress. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  S03 (Scientific Instrumentation)",B10-A19;  B14-J01;  B14-K01;  B14-N02;  B14-N03;  B14-N16;  S03-E09;  S03-E14H,C07K-014/47;  G01N-033/68;  A61K-031/167;  A61P-025/28,WO2021222438-A1   04 Nov 2021   C07K-014/47   202194Pages: 66   English;  US2021361598-A1   25 Nov 2021   A61K-031/167   202196   English;  CA3177262-A1   04 Nov 2021   C07K-014/47   202306   English;  EP4143218-A1   08 Mar 2023   C07K-014/47   202321   English;  CN115803336-A   14 Mar 2023   C07K-014/47   202324   Chinese;  JP2023524229-W   09 Jun 2023   A61K-031/167   202347   Japanese;  HK40089435-A0   13 Oct 2023   C07K-014/47   202402   English;  EP4143218-A4   29 May 2024   A61K-031/167   202446   English,WO2021222438-A1    WOUS029689    28 Apr 2021;   US2021361598-A1    US242755    28 Apr 2021;   CA3177262-A1    CA3177262    28 Apr 2021;   EP4143218-A1    EP796112    28 Apr 2021;   CN115803336-A    CN80042333    28 Apr 2021;   JP2023524229-W    JP565823    28 Apr 2021;   HK40089435-A0    HK6078133    28 Aug 2023;   EP4143218-A4    EP796112    28 Apr 2021,US2021361598-A1 Provisional Application US016724P;   CA3177262-A1 PCT application Application WOUS029689;   CA3177262-A1 Based on Patent WO2021222438;   EP4143218-A1 PCT application Application WOUS029689;   EP4143218-A1 Based on Patent WO2021222438;   CN115803336-A PCT application Application WOUS029689;   CN115803336-A Based on Patent WO2021222438;   JP2023524229-W PCT application Application WOUS029689;   JP2023524229-W Based on Patent WO2021222438;   HK40089435-A0 PCT application Application WOUS029689;   HK40089435-A0 Based on Patent WO2021222438;   HK40089435-A0 Previous Publ. Patent CN115803336,US016724P    28 Apr 2020;  CN80042333    28 Apr 2021;  US242755    28 Apr 2021;  WOUS029689    28 Apr 2021;  CA3177262    28 Oct 2022;  CN80042333    12 Dec 2022,WO2021222438-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      EP4143218-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN        EP4143218-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  ,,"WO2021222438-A1 -- US20100305181-A1   ;  WO2019164997-A1   ONEIL M (ONEI-Individual);  KIDON B (KIDO-Individual);  JANZ B (JANZ-Individual);  WU H (WUHH-Individual)   KIDON B,  JANZ B,  WU H;  WO2020180823-A1   ABREXA PHARM INC (ABRE-Non-standard)   VILLAFRANCA E J,  KISSINGER C;  EP4143218-A4 -- US20100099775-A1   ;  WO2017015660-A1   SALK INST BIOLOGICAL STUDIES (SALK)   CURRAIS A J,  MAHER P A,  SCHUBERT D R,  GOLDBERG J,  PRIOR M,  FISCHER W H,  DAUGHERTY D;  WO2017140684-A2   UNIV TOULOUSE CENT HOSPITALIER (UYTO-Non-standard);  UNIV TOULOUSE III SABATIER PAUL (UTOS);  INSERM INST NAT SANTE & RECH                  MEDICALE (INRM)   DRAY C,  FRANCES B,  LABASTE F,  MINVILLE V,  VALET P,  VINEL C","WO2021222438-A1  JOSeRAIMUNDOA. DE          AZEVEDO;WIDLANISOUSA MONTENEGRO;DJANEPEREIRA          RODRIGUES;SUELLENC. DE C. SOUZA;VANESSAF.S.          ARAUJO;MARGARETHPE: ""Long-term cognitive outcomes among          unselected ventilated and non-ventilated ICU patients"",          JOURNAL OF INTENSIVE CARE, BIOMED CENTRAL LTD, LONDON,          UK, vol. 5, no. 1, 17 February 2017 (2017-02-17), London,          UK , pages 1 - 5, XP021241834, DOI:          10.1186/s40560-017-0213-4,relevantClaims[1-3,23-27],relevantPassages[,          5 pages, especially: abstract; pg 3, col 2, para 2; pg 4,          col 1, para 2.]EP4143218-A4  QI CHEN ET AL: ""A          Novel Neurotrophic Drug for Cognitive Enhancement and          Alzheimer's Disease"", PLOS ONE, vol. 6, no. 12, 14          December 2011 (2011-12-14), pages e27865, XP055134062,          ISSN: 1932-6203, DOI:          10.1371/journal.pone.0027865,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  LIAN LEJING ET AL:          ""Antidepressant-like effects of a novel curcumin          derivative J147: Involvement of 5-HT1A receptor"",          NEUROPHARMACOLOGY, vol. 135, 1 June 2018 (2018-06-01),          AMSTERDAM, NL, pages 506 - 513, XP093148780, ISSN:          0028-3908, DOI:          10.1016/j.neuropharm.2018.04.003,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  DATABASE MEDLINE          [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA,          MD, US; 2007, DORAISWAMY P MURALI ET AL: ""Donepezil for          cognitive decline following coronary artery bypass          surgery: a pilot randomized controlled trial."",          XP002811333, Database accession no.          NLM17514186,relevantClaims[1-3,5-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  DATABASE EMBASE          [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1          March 2016 (2016-03-01), NEEDHAM D M ET AL: ""Rosuvastatin          versus placebo for delirium in intensive care and          subsequent cognitive impairment in patients with          sepsis-associated acute respiratory distress syndrome: An          ancillary study to a randomised controlled trial"",          XP002811334, Database accession no.          EMB-20160080902,relevantClaims[1-3,5-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  ANGELES FARRAN M ET          AL: ""The structures of          1,4-diaryl-5-trifluoromethyl-1H-1,2,3-triazoles related          to J147, a drug for treating Alzheimer's disease"", ACTA          CRYSTALLOGRAPHICA SECTION C STRUCTURAL CHEMISTRY,          WILEY-BLACKWELL PUBLISHING, INC, US, vol. 74, no. 4, 6          April 2018 (2018-04-06), pages 513 - 522, XP072456686,          ISSN: 2053-2296, DOI:          10.1107/S2053229618004394,relevantClaims[1-3,5-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  OBERMAN K. ET AL:          ""J147 affects cognition and anxiety after surgery in          Zucker rats"", PHYSIOLOGY AND BEHAVIOR, vol. 273, 1          January 2024 (2024-01-01), GB, pages 114413, XP093148761,          ISSN: 0031-9384, DOI:          10.1016/j.physbeh.2023.114413,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            See also references of WO 2021222438A1",,226320901 K U,,,
WO2024107122-A1,"Inducing, stimulating and/or promoting hair growth            and/or hair regeneration comprises treating hair of            subject with conditioned medium derived from culture of            mesenchymal stem cells of the umbilical cord",PHAN T T;  LANG N,CELLRESEARCH CORP PTE LTD (CELL-Non-standard),202452322T,"   NOVELTY - Inducing, stimulating and/or promoting hair                growth and/or hair regeneration comprises treating                hair of subject with conditioned medium derived                from culture of mesenchymal stem cells of the                umbilical cord.    USE - The method is useful for inducing, stimulating                and/or promoting hair growth and/or hair                regeneration comprises treating hair of subject                with conditioned medium derived from culture of                mesenchymal stem cells of the umbilical cord.    ADVANTAGE - The method improves hair growth and healing                processes after hair transplantation.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    alleviating and/or reducing hair loss and/or                hair thinning comprising treating hair of a subject                with conditioned medium derived from culture of                mesenchymal stem cells of the umbilical cord;    producing conditioned medium comprising (a)                culturing mesenchymal stem cells of the umbilical                cord in a culture medium comprising DMEM                (Dulbecco's modified eagle medium), F12 (Ham's F12                Medium), M171 (Medium 171 ) and FBS (Fetal Bovine                Serum), (b) removing the mesenchymal stem cells of                the umbilical cord from the culture medium, and (c)                culturing the mesenchymal stem cells of the                umbilical cord in a culture medium;    conditioned medium derived from mesenchymal                stem cells of the umbilical cord;    composition comprising conditioned medium;                and    use of conditioned medium derived from culture                of mesenchymal stem cells of umbilical cord for                inducing, stimulating and/or promoting hair growth                and/or hair regeneration, and/or for alleviating                and/or reducing hair loss and/or hair thinning of a                subject, where the use is preferably a cosmetic                use. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).)",B04-C02E4;  B04-F02B;  B04-N02;  B11-C04;  B14-R02;  B14-S21A;  D05-H08B;  D08-B03A,A61K-035/28;  A61K-008/98;  A61P-017/14;  C12N-005/0775,WO2024107122-A1   23 May 2024   A61K-035/28   202448Pages: 143   English,WO2024107122-A1    WOSG050772    17 Nov 2023,,WOSG050834    17 Nov 2022,WO2024107122-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,,,91481-0-0-0 K M; 97115-1-0-0 K M; 95154-0-0-0 K M,,,R24034 K M; R03231 K M; RA007V K M,
WO2022214691-A1;  CA3215002-A1;  AU2022253683-A1;  CN117321035-A;  KR2024007144-A;  EP4320100-A1;  JP2024515062-W;  HK40097518-A0;  US2024199535-A1,"New substituted heterocyclic compounds are            dihydroorotate dehydrogenase inhibitors used to treat            e.g. rheumatism, acute immunological disorders,            autoimmune diseases, diseases caused by malignant cell            proliferation, and inflammatory diseases",GEGE C;  KOHLHOF H;  MUEHLER A;  VITT D;  MUHLER A;  WITT D;  MUELLER A,IMMUNIC AG (IMMU-Non-standard);  IMMUNIC AG (IMMU-Non-standard);  IMMUNIC AG (IMMU-Non-standard);  IMMUNIC AG (IMMU-Non-standard);  IMMUNIC AG (IMMU-Non-standard),2022C8986B,"   NOVELTY - Substituted heterocyclic compounds (I) are                new.    USE - (I) are useful for preventing and/or treating                diseases, where the disease comprises rheumatism,                acute immunological disorders, autoimmune diseases,                diseases caused by malignant cell proliferation,                inflammatory diseases, diseases that are caused by                protozoal infestations in humans and animals,                diseases that are caused by viral infections and                Pneumocystis carinii, fibrosis, uveitis, rhinitis,                asthma, transplantation or arthropathy, graft                versus host and host versus graft reactions,                rheumatoid arthritis, multiple sclerosis,                amyotrophic lateral sclerosis, lupus erythematosus,                inflammatory bowel disease, cancer, COVID-19,                influenza, ulcerative colitis, Crohn's disease,                primary sclerosing cholangitis or psoriasis (all                claimed).    ADVANTAGE - (I) are synergistic, orally bioavailable, and                potent.    DETAILED DESCRIPTION - Substituted heterocyclic compounds of formula                (I) and their enantiomers, diastereomers,                tautomers, prodrugs, solvates, or salts are                new.    A1=5-membered heteroaryl, cyclopentenyl or                heterocyclopentenyl, (all having at least one H                atom optionally replaced by D), each optionally                substituted by 1-5 halo, CN, NO 2 , (=O), OH,                1-4C-alkyl, O-1-4C-alkyl, fluoro-1-4C-alkyl,                O-fluoro-1-4C-alkyl, CO 2 H or SO 3 H, (all having                at least one H atom in alkyl optionally replaced by                D);    B1=4-10-membered heterocycloalkyl (comprising                1-4 N, O and S), 5-10-membered heteroaryl                (comprising 1-6 N, O and S), 5-10-membered                cycloalkyl, or 6- or 10-membered aryl, each                optionally substituted by 1-4 halo, -CN, -NO 2 ,                (=O), 1-4C-alkyl, 0-6C-alkylene-OR27,                0-6C-alkylene-(3-6-membered cycloalkyl),                0-6C-alkylene-(3-6-membered heterocycloalkyl),                0-6C-alkylene-S(=O) n (=NR29) m R27, 0-6C alkylene-                NR27S(=O) x (=NR29) y R27, 0-6C-alkylene-S(=O) x                (=NR29) y NR27R28, 0-6C-alkylene-NR27, S(=O) x                (=NR29) y NR27R28, 0-6C-alkylene-CO 2 R27,                0-6C-alkylene-O-COR27, 0-6C-alkylene- CONR27R28,                0-6C-alkylene-NR27-COR27,                0-6C-alkylene-NR27-CONR27R28, 0-6C-alkylene-O-                CONR27R28, 0-6C-alkylene-NR27-CO 2 R27, or                0-6C-alkylene-NR27R28, where alkyl, alkylene,                3-6-membered cycloalkyl or 3-6-membered                heterocycloalkyl is optionally substituted by 1-6                halo, -CN, (=O), -OH, 1-4C-alkyl, halo-1-4C-alkyl,                -O-1-4C-alkyl or -O-halo-1-4C-alkyl and optionally                two adjacent substituents in the aryl or heteroaryl                moiety form 5-8-membered partially unsaturated                cycle optionally comprising 1-3 O, S or N, this                additional cycle optionally substituted by 1-4                halo, -CN, (=O), -OH, 1-4C-alkyl, halo-1-4C-alkyl,                -O-1-4C-alkyl or -O-halo-1-4C-alkyl, the residue                -NR2 on ring B1 is in a 1,4-orientation with                respect to ring C1, and each having at least one H                atom optionally replaced by D;    C1=4-10-membered heterocycloalkyl (comprising                1-4 N, O and S), 5-10-membered heteroaryl                (comprising 1-6 N, O and S), 5-10-membered                cycloalkyl, or 6- or 10-membered aryl, each                optionally substituted by 1-4 halo, -CN, -NO 2 ,                (=O), 1-4C-alkyl, 0-6C-alkylene-OR31,                0-6C-alkylene-(3-6-membered cycloalkyl),                0-6C-alkylene-(3-6-membered heterocycloalkyl),                0-6C-alkylene-S(=O) n (=NR33) m R31,                0-6C-alkylene-NR31S(=O) x (=NR33) y R31,                0-6C-alkylene-S(=O)-x(=NR33) y NR31R32,                0-6C-alkylene-NR31, S(=O) x (=NR33) y NR31R32,                0-6C-alkylene-CO 2 R31, 0-6C-alkylene-O-COR31,                0-6C-alkylene- CONR31R32, 0-6C-alkylene-NR31-COR31,                0-6C-alkylene-NR31-CONR31R32, 0-6C-alkylene-O-                CONR31R32, 0-6C-alkylene-NR31-CO 2 R31, or                0-6C-alkylene-NR31R32, each having at least one H                atom optionally replaced by D;    X1=H, D, halo, -CN, -NO 2 , 1-6C-alkyl,                -O-1-6C-alkyl, O-halo-1-6C-alkyl,                0-6C-alkylene-OR41, 0-6C-alkylene-(3-6-membered                cycloalkyl), 0-6C-alkylene-(3-6-membered                heterocycloalkyl), 0-6C-alkylene-S(=O) n (=NR43) m                R41, 0-6C-alkylene-NR41S(=O) x (=NR43) y R41,                0-6C-alkylene-S(=O) x (=NR43) y NR41R42,                0-6C-alkylene-NR41S(=O) x (=NR43) y NR41R42,                0-6C-alkylene-CO 2 R41, 0-6C-alkylene-O-COR41,                0-6C-alkylene-CONR41R42, 0-6C-alkylene-NR41-COR41,                0-6C-alkylene-NR41-CONR41R42,                0-6C-alkylene-O-CONR41R42, 0-6C-alkylene-NR41-CO 2                R41, 0-6C-alkylene-NR41R42, each having at least                one H atom optionally replaced by D;    R1=1-6C-alkyl (optionally substituted by                3-6-membered heterocycloalkyl (comprising 1-4 N, O                and S), 1-3 halo, -CN, 1-4C-alkyl, halo-1-4C-alkyl,                3-6-membered cycloalkyl, halo-(3-6-membered                cycloalkyl), halo-(3-6-membered heterocycloalkyl),                -OH, (=O), -O-1-4C-alkyl or -O-halo-1-4C-alkyl), H                or D;    R2=H optionally replaced by D; either    R27, R28, R31, R32, R41, R42=1-6C-alkyl,                3-6-membered cycloalkyl, 3-6-membered                heterocycloalkyl (all optionally substituted by                3-6-membered heterocycloalkyl, halo-(3-6-membered                heterocycloalkyl) (both having 1-4 N, O and S), 1-3                halo, -CN, 1-4C-alkyl, halo-1-4C-alkyl,                3-6-membered cycloalkyl, halo-(3-6-membered                cycloalkyl), -OH, (=O), -O-1-4C-alkyl or                -O-halo-1-4C-alkyl) or H, each having at least one                H atom optionally replaced by D; or    NR27R28, NR31R32, NR41R42=3-6-membered cycle                comprising C atoms and optionally comprising 1 or 2                O, S or N, optionally substituted by 1-3 halo, -CN,                1-4C-alkyl, halo-1-4C-alkyl, 3-6-membered                cycloalkyl, halo-(3-6-membered cycloalkyl),                3-6-membered heterocycloalkyl, halo-(3-6-membered                heterocycloalkyl), -OH, (=O), -O-1-4C-alkyl or                -O-halo-1-4C-alkyl, each having at least one H atom                optionally replaced by D;    R29, R33, R43=1-6C-alkyl, -CO-O-1-6C-alkyl,                3-6-membered cycloalkyl, 3-6-membered                heterocycloalkyl (all optionally substituted by                3-6-membered heterocycloalkyl, halo-(3-6-membered                heterocycloalkyl) (both having 1-4 N, O and S), 1-3                halo, -CN, 1-4C-alkyl, halo-1-4C-alkyl,                3-6-membered cycloalkyl, halo-(3-6-membered                cycloalkyl), -OH, oxo, -O-1-4C-alkyl or                -O-halo-1-4C-alkyl), H, -CN, or -NO 2 , each having                at least one H atom optionally replaced by D;                and    n, m, x, y=0-2.    Provided that the sum of integer m and n for                the residue linked to the same sulfur atom is 0-2,                the sum of integer x and y for the residue linked                to the same S atom is 1 or 2, at least one hydrogen                in A1, B1, C1, R2, R27-R29, R31-R33, R41-R43 and/or                X1 is replaced by D and the level of D                incorporation at each substituent designated as D                is at least 52.5%. An INDEPENDENT CLAIM is also                included for a composition comprising (I) and a                carrier or excipient.     ",,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).)",B05-A04A;  B06-H;  B07-H;  B10-A08;  B10-A10;  B10-A12C;  B10-A15;  B10-B01B;  B10-B03B;  B10-B04B;  B10-C04C;  B10-D03;  B14-A02;  B14-C03;  B14-C06;  B14-C09B;  B14-E08;  B14-E10C1;  B14-G02D;  B14-H01;  B14-J01;  B14-K01A;  B14-N03;  B14-N04;  B14-N12;  B14-N16;  B14-N17;  B14-S01;  B14-S14;  D08-B09A1,C07D-213/30;  C07D-265/30;  C07D-277/24;  C07D-333/24;  A61K-031/196;  A61K-031/381;  A61K-031/4418;  C07C-233/59;  C07C-233/60;  C07D-213/64;  C07D-213/75;  C07D-217/02;  C07D-307/30;  C07D-333/40;  C07D-471/04;  A61K-031/19;  A61K-031/223;  A61K-031/277;  A61K-031/341;  A61K-031/426;  A61K-031/437;  A61K-031/472;  A61K-031/5375;  A61K-045/00;  A61P-001/04;  A61P-001/16;  A61P-011/02;  A61P-011/06;  A61P-017/06;  A61P-019/02;  A61P-021/00;  A61P-025/04;  A61P-027/02;  A61P-029/00;  A61P-031/12;  A61P-031/14;  A61P-031/16;  A61P-033/02;  A61P-033/08;  A61P-037/02;  A61P-037/06;  A61P-043/00;  C07B-059/00;  C07C-235/82;  C07D-277/34;  C07D-295/135;  C07D-217/04;  C07D-213/73;  C07D-213/68;  C07C-233/74;  A61K-031/44;  A61K-031/167;  A61K-031/16;  C07C-233/75,WO2022214691-A1   13 Oct 2022   C07D-213/30   202288Pages: 101   English;  CA3215002-A1   13 Oct 2022   C07D-213/30   202386   English;  AU2022253683-A1   26 Oct 2023   C07D-213/30   202387   English;  CN117321035-A   29 Dec 2023   C07D-213/30   202404   Chinese;  KR2024007144-A   16 Jan 2024   C07C-233/60   202407   ;  EP4320100-A1   14 Feb 2024   C07D-213/30   202414   English;  JP2024515062-W   04 Apr 2024   C07C-235/82   202429   Japanese;  HK40097518-A0   15 Mar 2024   C07D-213/30   202447   English;  US2024199535-A1   20 Jun 2024   C07C-233/75   202452   English,WO2022214691-A1    WOEP059527    08 Apr 2022;   CA3215002-A1    CA3215002    08 Apr 2022;   AU2022253683-A1    AU253683    08 Apr 2022;   CN117321035-A    CN80035549    08 Apr 2022;   KR2024007144-A    KR738184    08 Apr 2022;   EP4320100-A1    EP721769    08 Apr 2022;   JP2024515062-W    JP561906    08 Apr 2022;   HK40097518-A0    HK6085647    18 Jan 2024;   US2024199535-A1    US18554365    06 Oct 2023,CA3215002-A1 PCT application Application WOEP059527;   CA3215002-A1 Based on Patent WO2022214691;   AU2022253683-A1 PCT application Application WOEP059527;   AU2022253683-A1 Based on Patent WO2022214691;   CN117321035-A PCT application Application WOEP059527;   CN117321035-A Based on Patent WO2022214691;   KR2024007144-A PCT application Application WOEP059527;   KR2024007144-A Based on Patent WO2022214691;   EP4320100-A1 PCT application Application WOEP059527;   EP4320100-A1 Based on Patent WO2022214691;   JP2024515062-W PCT application Application WOEP059527;   JP2024515062-W Based on Patent WO2022214691;   HK40097518-A0 PCT application Application WOEP059527;   HK40097518-A0 Based on Patent WO2022214691;   HK40097518-A0 Previous Publ. Patent CN117321035;   US2024199535-A1 PCT application Application WOEP059527,EP167690    09 Apr 2021;  EP181134    23 Jun 2021;  CN80035549    08 Apr 2022;  CA3215002    10 Oct 2023;  KR738184    06 Nov 2023;  CN80035549    16 Nov 2023,WO2022214691-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA          EP4320100-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN        ,,"WO2022214691-A1 -- WO2010052027-A1   4SC AG (FSCC)   GROEPPEL M,  LEBAN J;  WO2012001148-A1   4SC AG (FSCC)   AMMENDOLA A,  DIEDERICHS J,  LEBAN J,  VITT D;  WO2015154820-A1   PANOPTES PHARMA GMBH (PANO-Non-standard)   STROBL S;  WO2018177151-A1   UNIV XIAMEN (UYXI)   LI Y,  JIN L,  ZHU Y,  LU Y,  WEI Y,  YAO B,  XU S,  ZHENG X;  WO2010128050-A2   4SC AG (FSCC)   VITT D,  GROEPPEL M,  BAUMGARTNER R,  LEBAN J;  WO2004056746-A1   4SC AG (FSCC)   LEBAN J,  KRALIK M;  WO2004056747-A1   4SC AG (FSCC)   LEBAN J,  KRAMER B,  BAUMGARTNER R,  AULINGER-FUCHS K,  TASLER S;  WO2004056797-A1   4SC AG (FSCC)   LEBAN J,  TASLER S;  WO2008018426-A1   CHUGAI SEIYAKU KK (CHUS)   SHIMMA N,  EBIIKE H,  OHWADA J,  KAWADA H,  MORIKAMI K,  NAKAMURA M,  YOSHIDA M,  ISHII N,  HASEGAWA M,  YAMAMOTO S,  KOYAMA K;  WO2012001151-A1   4SC AG (FSCC)   AMMENDOLA A,  DIEDERICHS J,  LEBAN J,  VITT D;  WO2015169944-A1   PANOPTES PHARMA GMBH (PANO-Non-standard)   OBERMAYR F,  SPERL S;  WO2016045587-A1   CHANGZHOU YINSHENG PHARM CO LTD (CHAN-Non-standard);  UNIV SICHUAN (USCU)   ZHANG Y,  FU Z,  WANG J,  LI J,  CHEN S,  WEI Y,  YU L,  TAO X;  WO2018059314-A1   SICHUAN KELUN-BIOTECH BIOPHARMACEUTICA (SCKL)   LIU G,  YU H,  YANG D,  HE T,  SONG H,  ZENG H,  HU X,  LIU R,  WANG L,  WANG J;  WO2019101888-A1   IMMUNIC AG (IMMU-Non-standard)   GROEPPEL M,  VITT D,  KOHLHOF H,  MUEHLER A;  WO2019113462-A1   UNIV EMORY (UEMR)   PAINTER G R,  BLUEMLING G R,  NATCHUS M G,  GUTHRIE D;  WO2019170848-A1   PANOPTES PHARMA GMBH (PANO-Non-standard)   SPERL S,  OBERMAYR F;  WO2019175396-A1   IMMUNIC AG (IMMU-Non-standard)   VITT D,  MUEHLER A,  GROEPPEL M,  KOHLHOF H;  WO2003006425-A2   4SC AG (FSCC)   KRAMER B,  LEBAN J,  GARCIA G,  SAEB W;  WO2009140279-A2   CONCERT PHARM INC (CNPH)   HARBESON S L","WO2022214691-A1  FOSTER A B:          ""Deuterium isotope effects in the metabolism of drugs and          xenobiotics: implications for drug design"", ADVANCES IN          DRUG RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 14, 1          January 1985 (1985-01-01), pages 1 - 40, XP009086953,          ISSN:          0065-2490,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  ANDREASMUEHLER ET          AL: ""Safety, Tolerability andPharmacokinetics          ofVidofludimus calcium (IMU-838) After Single andMultiple          Ascending Oral Doses inHealthy Male Subjects"", EUROPEAN          JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2 May          2020 (2020-05-02), pages 557 - 573, XP055860527,          Retrieved from the Internet          &lt;URL:https://link.springer.com/content/pdf/10.1007/s13318-020-00623-7.pdf&gt;          [retrieved on          20211111],relevantClaims[1-15],relevantPassages[&lt;pp&gt;558&lt;/pp&gt;];  PIRALI TRACEY ET          AL: ""Applications of Deuterium in Medicinal Chemistry"",          JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, no. 11, 14          January 2019 (2019-01-14), US, pages 5276 - 5297,          XP055777808, ISSN: 0022-2623, Retrieved from the Internet          &lt;URL:https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b01808&gt;          DOI:          10.1021/acs.jmedchem.8b01808,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  GUPTA MONIKA ET AL:          ""Deuteration as a Tool for Optimization of Metabolic          Stability and Toxicity of Drugs"", GLOBAL JOURNAL OF          PHARMACY & PHARMACEUTICAL SCIENCES, vol. 1, no. 4, 27          March 2017 (2017-03-27), XP055860642, Retrieved from the          Internet          &lt;URL:https://juniperpublishers.com/gjpps/pdf/GJPPS.MS.ID.555566.pdf&gt;          DOI:          10.19080/GJPPS.2017.01.555566,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  J.          MED. CHEM., vol. 62, 2019, pages 5276;            BIOORG. MED. CHEM. LETT., vol. 14, 2004, pages          55;            BIOORG. MED. CHEM. LETT., vol. 15, 2005, pages          4854;            BIOORG. MED. CHEM. LETT., vol. 16, 2006, pages          267;  J.          MED. CHEM., vol. 49, 2006, pages 1239;            COMP. BIOCHEM. PHYSIOL., vol. 119A, 1998, pages          725;            SYNTHESIS, vol. 51, 2019, pages 1319;            ANGEW. CHEM. INT. ED., vol. 57, 2018, pages          3022;  J.          AM. CHEM. SOC., vol. 138, 2016, pages 11132;            CHEM. COMMUN., vol. 54, 2018, pages 4589;  J.          AM. CHEM. SOC., vol. 124, 2002, pages 8206;            INT. J. MOL. SCI., vol. 22, 2021, pages 575", M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N,227928601 M N,01197,RD8ZFW M N; RD8ZFX M N; RD8ZFY M N; RD8ZFZ M N; RD8ZG0 M N; RD8ZG1 M N; RD8ZG2 M N; RD8ZG3 M N; RD8ZG4 M N; RD8ZG5 M N; RD8ZG6 M N; RD8ZG7 M N; RD8ZG8 M N; RD8ZG9 M N; RD8ZGA M N; RD8ZGB M N; RD8ZGC M N; RD8ZGD M N; RD8ZGE M N; RD8ZGF M N; RD8ZGG M N; RD8ZGH M N; RD8ZGI M N; RD8ZGJ M N; RD8ZGK M N; RD8ZGL M N; RD8ZGM M N; RD8ZGN M N,
WO2021202791-A1;  US2021333214-A1,"Indicator useful for determining exposure to            analyte or detecting analytes of interest such as            nucleic acids e.g. DNA, comprises substrate, and            interface comprising first sensor responsive to first            analyte, second sensor responsive to second analyte,            and display configured to display readout",OLGUIN ALVAREZ C E;  WROBEL S;  DIETZ H;  OLGUIN A C E,LOGICINK CORP (LOGI-Non-standard);  OLGUIN ALVAREZ C E (ALVA-Individual);  WROBEL S (WROB-Individual);  DIETZ H (DIET-Individual);  LOGICINK CORP (LOGI-Non-standard),2021B5206F,"   NOVELTY - Indicator comprises a substrate, and an                interface disposed on the substrate, where the                interface comprises a first sensor responsive to a                first analyte, the first sensor comprises a first                sensing modality, the first sensing modality being                a biochemical modality or a chemical modality, and                the first sensor being configured to provide a                first colorimetric signal upon interaction with the                first analyte, a second sensor responsive to a                second analyte, where the second sensor comprises a                second sensing modality, the second sensing                modality being a biochemical modality or a chemical                modality, and the second sensor being configured to                provide a second colorimetric signal upon                interaction with the second analyte, and a display                configured to display a colorimetric readout.    USE - The indicator is useful for determining                exposure to at least one analyte or detecting                analytes of interest chosen from nucleic acids e.g.                DNA, or RNA, proteins, peptides, and other amino                acid chains.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a method for determining exposure to at                least one analyte involves providing an indicator                comprising a substrate, an interface disposed on                the substrate, determining exposure to at least one                of the first analyte and the second analyte, and                displaying the colorimetric readout on the display;                and    (2) a system comprising an indicator                comprising a substrate, and an interface disposed                on the substrate, and a reactive solution, where                the reactive solution is configured to interact                with one or more of the first signal and the second                signal to produce a colorimetric readout. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  J04 (Chemical/physical processes/apparatus - including catalysis, catalysts (excluding specific e.g. enzymatic or polymerisation catalysts), colloid chemistry, laboratory apparatus and methods, testing, controlling, general encapsulation, detection and sampling (excluding clinical testing) (B01J, L).);  A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  S03 (Scientific Instrumentation)",B04-C01;  B04-E01;  B04-F10;  B04-N04;  B11-C07B1;  B12-K04F;  B12-K04G2;  D05-H09;  J04-B01;  J04-B03;  A12-E13;  A12-L04B;  A12-W11L;  S03-E09F;  S03-E14H3;  S03-E14H5,G01N-033/52;  G01N-021/27;  G01N-021/78;  G01N-027/414,WO2021202791-A1   07 Oct 2021   202191Pages: 57   English;  US2021333214-A1   28 Oct 2021   G01N-021/78   202191   English,WO2021202791-A1    WOUS025245    31 Mar 2021;   US2021333214-A1    US219527    31 Mar 2021,US2021333214-A1 Provisional Application US002960P,US002960P    31 Mar 2020;  US219527    31 Mar 2021,WO2021202791-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,"WO2021202791-A1 -- US20090053104-A1   ;  WO2005111588-A1   3M INNOVATIVE PROPERTIES CO (MINN)   RAKOW N A,  LYONS C S,  MAKI S P;  WO2015157691-A1   HARVARD COLLEGE (HARD)   AIZENBERG J,  BURGESS I,  KOAY N,  DUFFY M,  KAY T,  SHIRMAN E,  ABEDZADEH N;  WO2018152372-A1   ISENSE LLC (ISEN-Non-standard)   LIM S H,  MARUNIAK A,  GRATACOS N Q;  US2021333214-A1 -- US20130035567-A1   ;  US20180064377-A1   ;  US20190111422-A1   ;  US7361472-B2   GENICON SCI CORP (GENI-Non-standard)   YGUERABIDE J,  YGUERABIDE E,  WARDEN L,  PETERSON T;  US11307184-B2   ISENSE LLC (ISEN-Non-standard)   LIM S H,  MARUNIAK A,  GRATACOS N Q","WO2021202791-A1            WEN-MING WANGHONG-ZHONG JIN: ""Skin microbiome: An actor          in the pathogenesis of psoriasis"", CHIN MED J (ENGL, vol.          131, no. 1, 2018, pages 95 - 98;            SOUVIK MUKHERJEERUPAK MITRAARINDAM MAITRASATYARANJAN          GUPTASRIKALA KUMARANAMIT CHAKRABORTTYPARTHA P. MAJUMDER:          ""Sebum and hydration levels in specific regions of human          face significantly predict the nature and diversity of          facial skin microbiome"", SCI REP, vol. 6, 2016, pages          36062;            ELIZABETH A. GRICEJULIA A. SEGRE: ""The skin microbiome"",          NATURE REVIEWS MICROBIOLOGY, vol. 9, 2011, pages 244 -          253, XP055344752, DOI: 10.1038/nrmicro2537;            ELIZABETH A. GRICE: ""The skin microbiome: potential for          novel diagnostic and therapeutic approaches to cutaneous          disease"", SEMIN CUTAN MED SURG, vol. 33, no. 2, 2014,          pages 98 - 103, XP055506616, DOI:          10.12788/j.sder.0087;            HEIDI H. KONG: ""Skin microbiome: genomics-based insights          into the diversity and role of skin microbes"", TRENDS MOL          MED, vol. 17, no. 6, 2011, pages 320 - 328, XP055101645,          DOI: 10.1016/j.molmed.2011.01.013;  BS          ALLADIN-MUSTANCJ MITRANJM GIBBS-DAVIS: ""Achieving room          temperature DNA amplification by dialing in          destabilization"", CHEM COMMUN (CAMB, vol. 51, no. 44, 4          June 2015 (2015-06-04), pages 9101 - 4;            GERASIMOVA, YULIA V.DMITRY M. KOLPASHCHIKOV:          ""Enzyme-assisted target recycling (EATR) for nucleic acid          detection"", CHEMICAL SOCIETY REVIEWS, vol. 43, no. 17,          2014, pages 6405 - 6438, XP055324226, DOI:          10.1039/C4CS00083H;            SOUVIK MUKHERJEERUPAK MITRAARINDAM MAITRASATYARANJAN          GUPTASRIKALA KUMARANAMIT CHAKRABORTTYPARTHA P. MAJUMDER:          ""Sebum, serum, and hydration levels in specific regions          of human face significantly predict the nature and          diversity of facial skin microbiome"", SCI REP, vol. 6,          2016, pages 36062;            MUKHERJEE, S.MITRA, R.MAITRA, AGUPTA, S.KUMARAN,          S.CHAKRABORTTY, AMAJUMDER, P. P.: ""Sebum and Hydration          Levels in Specific Regions of Human Face Significantly          Predict the Nature and Diversity of Facial Skin          Microbiome"", SCIENTIFIC REPORTS, vol. 6, 2016, pages          36062;            NAKAKO SHIBAGAKIWATARU SUDACECILE CLAVAUDPHILIPPE          BASTIENLENA TAKAYASUERICA IIOKARINA KUROKAWANAOKO          YAMASHITAYASUE HATTORICHIE SHI: ""Aging-related changes in          the diversity of women's skin microbiomes associated with          oral bacteria"", SCI REP, vol. 7, 2017, pages 10567,          XP055554307, DOI: 10.1038/s41598-017-10834-9",,,,,
WO2023056202-A2;  CA3232648-A1;  AU2022358446-A1,"Composition used for treating infection and            cancer, comprises nanoparticles, nucleic acid coding            for protein or its functional fragment, and compound            capable of enhancing expression of protein or its            functional fragment in mammalian cells",KHANDHAR A P;  BERUBE B;  KRIEGER K;  ERASMUS J H;  GULATI G;  SIMPSON A,HDT BIO CORP (HDTB-Non-standard);  HDT BIO CORP (HDTB-Non-standard);  HDT BIO CORP (HDTB-Non-standard),202335729R,"   NOVELTY - Composition comprises (a) nanoparticles, a                nucleic acid coding for a protein or its functional                fragment, and a compound capable of enhancing                expression of the protein or its functional                fragment in mammalian cells, or (b) nanoparticles,                a first nucleic acid coding for a protein or its                functional fragment, and a second nucleic acid                coding for an expression enhancer or its functional                fragment, where the expression enhancer or the its                functional fragment increases expression of the                protein or the its functional fragment in mammalian                cells.    USE - The composition is useful in pharmaceutical                composition for treating infection and cancer in                subject by modulating a level or activity of NFkB                relative to levels or activity                interferon-&#947; in the cell. The subject has                a solid tumor or a blood cancer, or lung cancer.                The solid tumor is a carcinoma, a melanoma, or a                sarcoma. The blood cancer is lymphoma or leukemia.                The lung cancer is adenocarcinoma, squamous cell                carcinoma, small cell cancer or non-small cell                cancer (all claimed).    ADVANTAGE - None given.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    a suspension comprising the composition;                and    method for modifying the level or activity of                nuclear factor kappa-light-chain-enhancer of                activated B (NF-kB) relative to                interferon-&#947; levels or activity in the                cell involving contacting a cell with the                above-mentioned composition. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.)",B01-D02;  B04-A08;  B04-A09;  B04-A10;  B04-A98;  B04-B01B;  B04-B01C1;  B04-B01C3;  B04-B04C1;  B04-C01;  B04-C03;  B04-C03B;  B04-C03C;  B04-E02F;  B04-E03F;  B04-E99;  B04-F02A;  B04-F04;  B04-G01;  B04-M01;  B04-N02;  B05-A01B;  B05-A03A2;  B05-A03B1;  B05-B01P;  B05-B02C;  B05-C07;  B05-C08;  B06-H;  B07-H;  B10-A09A;  B10-A13C;  B10-A22;  B10-B02F;  B10-B02J;  B10-B03B;  B10-B04B;  B10-C04C;  B10-C04E3;  B10-C04E5;  B10-G02;  B10-J02;  B12-M11Q1;  B14-A01;  B14-A02;  B14-A04;  B14-D06C;  B14-H01;  B14-S18;  C04-A08;  C04-A09;  C04-A10;  C04-A98;  C04-B01B;  C04-B01C1;  C04-B01C3;  C04-B04C1;  C04-C01;  C04-C03;  C04-C03B;  C04-C03C;  C04-E02F;  C04-E03F;  C04-E99;  C04-F02A;  C04-F04;  C04-G01;  C04-M01;  C04-N02;  C05-A03A2;  C05-B01P;  C05-B02C;  C05-C08;  C10-A13C;  C10-A22;  C10-B02J;  C10-B03B;  C10-G02;  C10-J02;  C12-M11Q1;  C14-A01;  C14-A02;  C14-A04;  C14-H01;  D05-H08B;  D05-H99;  A12-V01;  A12-W14,C12N-000/00;  A61K-038/00;  C12N-015/88;  A61K-048/00;  A61K-009/107;  A61K-009/51,WO2023056202-A2   06 Apr 2023   C12N-000/00   202336Pages: 202   English;  CA3232648-A1   06 Apr 2023   A61K-038/00   202426   English;  AU2022358446-A1   18 Apr 2024   A61K-048/00   202433   English,WO2023056202-A2    WOUS076820    21 Sep 2022;   CA3232648-A1    CA3232648    21 Sep 2022;   AU2022358446-A1    AU358446    21 Sep 2022,CA3232648-A1 PCT application Application WOUS076820;   AU2022358446-A1 PCT application Application WOUS076820;   AU2022358446-A1 Based on Patent WO2023056202,US247113P    22 Sep 2021;  CA3232648    21 Mar 2024,WO2023056202-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      ,,,,900-0-0-0 K M; 104374-0-0-0 K M; 103243-0-0-0 K M; 103242-0-0-0 K M; 90158-0-0-0 K M; 1004798-0-0-0 K M; 1159621-0-0-0 K M; 1311733-0-0-0 K M; 1401099-0-0-0 K M; 1577414-0-0-0 K M; 1577568-0-0-0 K M; 1996627-0-0-0 K M; 2023741-0-0-0 K M;  K M; 2325937-0-0-0 K M; 2971559-0-0-0 K M; 197131-0-0-0 K M; 298274-0-0-0 K M; 404893-0-0-0 K M; 561150-0-0-0 K M; 564769-0-0-0 K M; 607047-0-0-0 K M; 166620-0-0-0 K M; 135651-0-0-0 K M; 714162-0-0-0 K M; 502636-0-0-0 K M; 135652-1-0-0 K M; 502637-0-0-0 K M; 714924-1-1-0 K M; 207793-0-0-0 K M; 584893-0-0-0 K M; 93406-3-0-0 K M; 174010-0-0-0 K M; 1230051-0-0-0 K M;  K M;  K M; 130172-0-0-0 K M; 3143684-0-0-0 K M; 1657697-2-1-0 K M;  K M;  K M;  K M;  K M; 1040055-0-0-0 K M;  K M;  K M; 482514-0-0-0 K M; 277418-0-0-0 K M;  K M; 1657697-1-0-0 K M; 2951494-1-0-0 K M;  K M; 3012358-0-0-0 K M;  K M;  K M;  K M; 596872-0-0-0 K M; 99061-1-0-0 K M; 99061-0-0-0 K M;  K M; 2385346-1-0-0 K M;  K M; 1102535-0-0-0 K M; 2097419-0-0-0 K M; 2097233-0-0-0 K M; 2097420-0-0-0 K M; 2351-0-0-0 K M; 2351-0-5-2 K M;  K M; 779403-0-0-0 K M; 2117-0-1-0 K M; 99222-0-0-0 K M; 99408-0-0-0 K M; 102701-2-0-0 K M; 103920-1-0-0 K M; 105439-0-0-0 K M; 107016-0-0-0 K M; 107450-1-0-0 K M; 107451-1-0-0 K M; 107453-1-0-0 K M; 107454-1-0-0 K M; 107648-0-0-0 K M; 109477-0-0-0 K M; 129535-1-0-0 K M; 6695-0-0-0 K M; 7117-0-0-0 K M; 144419-0-0-0 K M; 686-0-0-0 K M; 17530-0-0-0 K M; 51640-0-0-0 K M; 92-0-0-0 K M; 277-0-0-0 K M;  K M; 1135072-0-0-0 K M; 351093-0-0-0 K M; 8349-1-0-0 K M; 84757-2-0-0 K M; 129578-1-0-0 K M; 444-0-0-0 ; 7447-0-0-0 ; 7560-0-0-0 ; 1004798-0-0-0 CL USE; 1159621-0-0-0 CL USE; 1311733-0-0-0 CL USE; 1401099-0-0-0 CL USE; 1577414-0-0-0 CL USE; 1577568-0-0-0 CL USE; 1996627-0-0-0 CL USE; 2023741-0-0-0 CL USE; 2325937-0-0-0 CL USE; 2971559-0-0-0 CL USE; 1230051-0-0-0 CL USE; 3143684-0-0-0 CL USE; 1657697-2-1-0 CL USE; 1040055-0-0-0 CL USE; 1657697-1-0-0 CL USE; 2951494-1-0-0 CL USE; 3012358-0-0-0 CL USE; 2385346-1-0-0 CL USE; 1102535-0-0-0 CL USE; 2097419-0-0-0 CL USE; 2097233-0-0-0 CL USE; 2097420-0-0-0 CL USE; 1135072-0-0-0 CL USE,,01605; 01269; 00931; 02397; 01183; 41758; 00096; 09942; 01261,R02044 K M; RA0GM6 K M; RA0B83 K M; RA00NG K M; RA0218 K M; R24040 K M; RANXDW K M; RANGFQ K M; RAY7JO K M; RAQ4VK K M; RB352D K M; RASTWX K M; RAT1H6 K M; RAT1H7 K M; RAUBP0 K M; RB8OHB K M; RBYD6L K M; RBUETP K M; RBEFD1 K M; RBPW1P K M; RA28R6 K M; RA9WQM K M; RAB43R K M; RACALN K M; RA9NED K M; RAHSJT K M; RA1VLZ K M; RA0MRI K M; RBEYV5 K M; RA69HH K M; RADX79 K M; RA69HI K M; RALASW K M; RA05OG K M; RA82G8 K M; RAENBE K M; RA1GFX K M; RAL2Y1 K M; RDB0X0 K M; RCR5LI K M; R04651 K M; RBQ1VQ K M; RAU8KV K M; RDBHBC K M; RDBHBD K M; RCRCAG K M; RDBHBJ K M; RBJYLP K M; RBT9JU K M; RDBHBE K M; RA5UCY K M; RAPME7 K M; RDBHBF K M; RAU8KU K M; RBU2OG K M; RBWF7N K M; RDBHBG K M; RBN861 K M; RC3F68 K M; RDBHBH K M; RCC6TL K M; RA87UH K M; RA4YD7 K M; RBJYL1 K M; RCPTLF K M; RB9LH0 K M; RCR8ZE K M; RAPGRD K M; RB3HOM K M; RB3HJH K M; RB3HON K M; R00418 K M; RBDGRQ K M; RCQRZF K M; RABQ9X K M; R05327 K M; R01833 K M; RA00JW K M; R01117 K M; R00954 K M; RA04F6 K M; R03239 K M; R01694 K M; R01540 K M; R02049 K M; R01539 K M; R10262 K M; R04912 K M; R14120 K M; R01538 K M; RA08KK K M; R09355 K M; R01356 K M; R00119 K M; R01966 K M; R14121 K M; R03875 K M; R01544 K M; R00123 K M; RDBHBI K M; RAJ31V K M; RAIB2V K M; R00148 K M; R00498 K M; R00880 K M; RA6DYT K M; R00351 ; R00009 ; R00448 ,2044-S; 0418-S; 1833-S; 1117-S; 0954-S; 1508-S; 1694-S; 1540-S; 2049-S; 1539-S; 1538-S; 1356-S; 0119-S; 1966-S; 1544-S; 0123-S; 0148-S; 0498-S; 0880-S
WO2023235870-A1,Treating patient at risk of thrombosis with            thrombocytopenia syndrome (TTS) or reducing risk of            thrombosis with TTS associated with adenoviral vector            therapy involves administering low negative charge            adenoviral vector therapy,ABBINK P;  BAROUCH D H,VECTOR SCI INC (VECT-Non-standard);  BETH ISRAEL DEACONESS MEDICAL CENT (BEIS-C),2023C76269,   NOVELTY - Method for treating a subject at risk of                thrombosis with thrombocytopenia syndrome (TTS)                associated with adenoviral vector therapy or                reducing the risk of thrombosis with TTS associated                with adenoviral vector therapy involves                administering to a subject at risk of TTS low                negative charge adenoviral vector therapy.    USE - The method or low negative charge adenoviral                vector therapy is useful for treating a subject at                risk of thrombosis with TTS associated with                adenoviral vector therapy or reducing the risk of                thrombosis with TTS associated with adenoviral                vector therapy (claimed).    ADVANTAGE - None given.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for use of                low negative charge adenoviral vector therapy for                treating a subject at risk of thrombosis with TTS                associated with adenoviral vector therapy or                reducing the risk of thrombosis with TTS associated                with adenoviral vector therapy. ,,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-B03D;  B04-C01;  B04-C02E1;  B04-C02X;  B04-E08;  B04-E15;  B04-E99;  B04-F11A1;  B04-G23;  B06-H;  B07-B01;  B07-D05;  B07-E01;  B07-E03;  B10-C03;  B14-F04;  B14-G03;  B14-H01;  B14-S03A;  B14-S11A;  B14-S18;  B14-S25;  D05-H11;  D05-H12E;  D05-H12F;  D05-H99,A61K-035/761;  C07K-014/005;  C12N-015/86;  C12N-007/00,WO2023235870-A1   07 Dec 2023   A61K-035/761   202304Pages: 181   English,WO2023235870-A1    WOUS067871    02 Jun 2023,,US365720P    02 Jun 2022;  US401323P    26 Aug 2022;  WOUS067709    31 May 2023,WO2023235870-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2023235870-A1 -- WO2019118480-A1   BETH ISRAEL DEACONESS MEDICAL CENT (BEIS)   BAROUCH D H,  ABBINK P,  IAMPIETRO M J,  HAVENGA M J E;  WO2023235763-A1   VECTOR SCI INC (VECT-Non-standard);  BETH ISRAEL DEACONESS MEDICAL CENT (BEIS)   ABBINK P,  BAROUCH D H;  WO2014078688-A2   BETH ISRAEL DEACONESS MEDICAL CENT (BEIS);  UNIV WASHINGTON ST LOUIS (UNWL)   BAROUCH D H,  VIRGIN H,  ABBINK P;  WO2022197720-A2   BETH ISRAEL DEACONESS MEDICAL CENT (BEIS);  TRIAD NAT SECURITY LLC (USGO)   BAROUCH D H,  KORBER B T,  THEILER J","WO2023235870-A1  BILOTTA CLIO ET AL:          ""COVID-19 Vaccine-Related Thrombosis: A Systematic Review          and Exploratory Analysis"", FRONTIERS IN IMMUNOLOGY, vol.          12, 29 November 2021 (2021-11-29), XP093080002, DOI:          10.3389/fimmu.2021.729251,relevantClaims[1,2,44,45],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;|p.          10, r.c., 3rd and 4th paragraphs];  COUGHLAN LYNDA ET          AL: ""Adenovirus-based vaccines-a platform for pandemic          preparedness against emerging viral pathogens"", MOLECULAR          THERAPY, vol. 30, no. 5, 1 May 2022 (2022-05-01), US,          pages 1822 - 1849, XP093008388, ISSN: 1525-0016, DOI:          10.1016/j.ymthe.2022.01.034,relevantClaims[1,2,55,56|1-43,55-60],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;|&lt;pp&gt;1836&lt;/pp&gt;&lt;ppl&gt;1839&lt;/ppl&gt;|p.          1841: Future directions];  LEDFORD HEIDI:          ""COVID vaccines and blood clots: what researchers know so          far"", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol.          596, no. 7873, 24 August 2021 (2021-08-24), pages 479 -          481, XP037546598, ISSN: 0028-0836, [retrieved on          20210824], DOI:          10.1038/D41586-021-02291-2,relevantClaims[1,2,55,56|1-43,55-60],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;|p.          480, r.c., 4th full paragraph];  BAKER ALEXANDER T.          ET AL: ""ChAdOx1 interacts with CAR and PF4 with          implications for thrombosis with thrombocytopenia          syndrome"", SCIENCE ADVANCES, vol. 7, no. 49, 3 December          2021 (2021-12-03), XP093081811, DOI:          10.1126/sciadv.abl8213,relevantClaims[1,2,55,56|1-43,55-60],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;|p.          9 of 14, l.c., second paragraph];            PAVORD ET AL., N ENGL J MED, vol. 385, 2021, pages 1680 -          1689;            ALAKUNLE, NAT REV MICROBIOL, vol. 20, no. 9, 2022, pages          507 - 508;            SINGHAL, INDIAN J. PEDIATR. DOI:          10.1007/S12098-022-04348-0, 2022;            LAI, J MICROBIOL IMMUNOL INFECT, DOI:          10.1016/J.JMII.2022.07.004, 2022;            LAI, J MICROBIOL IMMUNOL INFECT. DOI:          10.1016/J.JMII.2022.07.004, 2022;            TITANJI, OPEN FORUM INFECT DIS, vol. 9, no. 7, 2022,          pages ofac310;            BENITES-ZAPATA, ANN CLIN MICROBIOL ANTIMICROB, vol. 21,          2022, pages 36;            ""GenBank"", Database accession no. AIY35100.1;            SIEVERSHIGGINS, PROTEIN SCIENCE, vol. 27, 2018, pages 135          - 145;            SPRANGERS ET AL., J. CLIN. MICROBIOL, vol. 41, 2003,          pages 5046 - 5052;            KOVESDIHEDLEY, VIRUSES, vol. 2, 2010, pages 1681 -          1673;            WOLD ET AL., CURR. GENE THER., vol. 13, 2013, pages 421 -          433;            JUHL ET AL., EUR J HAEMATOL., vol. 76, no. 5, 2006, pages          420 - 426;            THIELE ET AL., BLOOD, vol. 138, no. 4, 2021, pages 299 -          303;            POL ET AL., ONCOIMMUNOLOGY, vol. 5, 2016, pages          e1117740;            BAKER ET AL., CANCERS, vol. 10, 2018, pages 201;            GORADEL ET AL., J CELL PHYSIOL, 2018, pages 1 -          11;            PETERKUHNEL, CANCERS, vol. 12, 2020, pages 3354;            BULCHA ET AL., SIGNAL TRANSDUCTION AND TARGETED THERAPY,          vol. 6, 2021, pages 53;            MOON ET AL., NPJ VACCINES, vol. 7, 2022, pages          26;            VANDER STRAETEN ET AL., NAT BIOTECHNOL, 2023, Retrieved          from the Internet          &lt;URL:https://doi.org/10.10381s41587-023-01774-z&gt;;            NGUYEN ET AL., NAT. COMMUN., vol. 8, 2017, pages          14945;            BAKER ET AL., SCI. ADV., vol. 7, 2021, pages          eabl8213",96796-0-0-0 K M; 896726-0-0-0 K M; 94231-0-0-0 K M; 174388-1-0-0 K M; 813685-1-0-0 K M; 87874-0-0-0 K M; 91005-0-0-0 K M; 91332-1-0-0 K M; 93507-0-0-0 K M; 99028-1-0-0 K M; 102820-1-0-0 K M; 199852-0-0-0 K M; 36645-0-0-0 K M; 451473-0-0-0 K M; 702820-1-0-0 K M; 710281-0-0-0 K M; 736241-1-0-0 K M; 684249-2-0-0 K M,230313401 K M; 230313402 K M; 230313403 K M; 230313404 K M; 230313405 K M; 230313406 K M; 230313407 K M; 230313408 K M; 230313409 K M; 230313410 K M; 230313411 K M; 230313412 K M; 230313413 K M; 230313414 K M; 230313415 K M; 230313416 K M; 230313417 K M; 230313418 K M; 230313419 K M,03010; 00061; 01345; 01586; 01188; 07955,R01867 K M; RAE5RQ K M; RA181E K M; RA0J2O K M; RA1DKC K M; RACFJT K M; R00034 K M; R10146 K M; R22347 K M; R00159 K M; RA0KVH K M; RAAQSK K M; RA7RM2 K M; R00487 K M; R14664 K M; RA9W39 K M; RAA8IM K M; RAADA6 K M; RAL9WD K M; RA9Y22 K M,1867-S; 0034-S; 0159-S; 0487-S
WO2022221527-A1;  TW202308638-A;  CA3215348-A1;  AU2022257016-A1;  KR2023171975-A;  CN117279641-A;  RU2023129266-A;  BR112023018570-A2;  EP4322957-A1;  JP2024514325-W,"Treating or preventing e.g. drug-induced            thrombocytopenia, by administering Bruton's tyrosine            kinase inhibitor e.g.            (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile",SMITH C W;  WATSON S P;  NICOLSON P L R;  LANGRISH C;  NICHOLSON P L R;  LANGRISCH C;  SMIT K U;  UOTSON S P;  NIKOLSON F L R;  LENGRISH K,PRINCIPIA BIOPHARMA INC (SNFI-C);  PRINCIPIA BIOPHARMA INC (SNFI-C),2022D1893L,"   NOVELTY - Method for treating or preventing drug-induced                thrombocytopenia (DITP) in a human, treating or                preventing vaccine-induced thrombosis and                thrombocytopenia syndrome (VITT) in a human,                increasing platelet count in a human subject with                DITP or VITT, or reducing platelet aggregation in a                human subject with DITP or VITT, involves                administering Bruton's tyrosine kinase (BTK)                inhibitor chosen from                (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile                (I),                (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile                (II) or its their salts.    USE - The method is useful for treating or                preventing DITP and VITT in human, increasing                platelet count in a human subject with DITP or                VITT, or reducing platelet aggregation in a human                subject with DITP or VITT.    ADVANTAGE - None given.    DETAILED DESCRIPTION - Method for treating or preventing drug-induced                thrombocytopenia (DITP) in a human, treating or                preventing vaccine-induced thrombosis and                thrombocytopenia syndrome (VITT) in a human,                increasing platelet count in a human subject with                DITP or VITT, or reducing platelet aggregation in a                human subject with DITP or VITT, involves                administering Bruton's tyrosine kinase (BTK)                inhibitor chosen from                (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile                of formula (I),                (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile                of formula (II) or its their salts.     ",,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  C02 (Heterocyclic.);  ;  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.)",B01-A02;  B01-C05;  B01-D02;  B02-A;  B02-C04;  B02-P02;  B02-R;  B04-A02;  B04-B03A;  B04-C01;  B04-C02E1;  B04-G01C;  B04-G21;  B04-H04;  B04-H05;  B04-H19;  B05-A03B3;  B05-B01A;  B05-C01;  B06-H;  B07-H;  B10-B02D;  B10-B02F;  B10-B03B;  B10-C02;  B10-C03;  B10-C04C;  B10-C04D;  B10-C04E6;  B10-D03;  B10-E04A;  B14-F04;  B14-L06;  B14-S18;  C01-A02;  C01-C05;  C01-D02;  C02-A;  C02-C04;  C02-P02;  C02-R;  C04-A02;  C04-B03A;  C04-C01;  C04-C02E1;  C04-G01C;  C04-G21;  C04-H04;  C04-H05;  C04-H19;  C05-A03B3;  C05-B01A;  C05-C01;  C06-H;  C07-H;  C10-B02D;  C10-B02F;  C10-B03B;  C10-C02;  C10-C03;  C10-C04C;  C10-C04D;  C10-C04E6;  C10-D03;  C10-E04A;  C14-F04;  C14-L06;  C14-S18;  D05-A02C;  D05-H07;  D05-H11A;  A10-E01;  A12-V01,A61K-031/519;  A61P-007/00;  A61P-007/02;  A61P-007/04;  A61P-043/00,WO2022221527-A1   20 Oct 2022   A61K-031/519   202292Pages: 45   English;  TW202308638-A   01 Mar 2023   A61K-031/519   202338   Chinese;  CA3215348-A1   20 Oct 2022   202386   English;  AU2022257016-A1   30 Nov 2023   A61K-031/519   202397   English;  KR2023171975-A   21 Dec 2023   A61K-031/519   202304   ;  CN117279641-A   22 Dec 2023   A61K-031/519   202402   Chinese;  RU2023129266-A   08 Dec 2023   A61K-031/519   202408   Russian;  BR112023018570-A2   28 Nov 2023   A61K-031/519   202408   ;  EP4322957-A1   21 Feb 2024   A61K-031/519   202417   English;  JP2024514325-W   01 Apr 2024   A61K-031/519   202428   Japanese,WO2022221527-A1    WOUS024806    14 Apr 2022;   TW202308638-A    TW114317    14 Apr 2022;   CA3215348-A1    CA3215348    14 Apr 2022;   AU2022257016-A1    AU257016    14 Apr 2022;   KR2023171975-A    KR739001    14 Apr 2022;   CN117279641-A    CN80028534    14 Apr 2022;   RU2023129266-A    RU129266    14 Apr 2022;   BR112023018570-A2    BR11018570    14 Apr 2022;   EP4322957-A1    EP721215    14 Apr 2022;   JP2024514325-W    JP562944    14 Apr 2022,CA3215348-A1 PCT application Application WOUS024806;   CA3215348-A1 Based on Patent WO2022221527;   AU2022257016-A1 PCT application Application WOUS024806;   AU2022257016-A1 Based on Patent WO2022221527;   KR2023171975-A PCT application Application WOUS024806;   KR2023171975-A Based on Patent WO2022221527;   CN117279641-A PCT application Application WOUS024806;   CN117279641-A Based on Patent WO2022221527;   RU2023129266-A PCT application Application WOUS024806;   RU2023129266-A Based on Patent WO2022221527;   BR112023018570-A2 PCT application Application WOUS024806;   BR112023018570-A2 Based on Patent WO2022221527;   EP4322957-A1 PCT application Application WOUS024806;   EP4322957-A1 Based on Patent WO2022221527;   JP2024514325-W PCT application Application WOUS024806;   JP2024514325-W Based on Patent WO2022221527,US175976P    16 Apr 2021;  BR11018570    13 Sep 2023;  CA3215348    12 Oct 2023;  CN80028534    13 Oct 2023;  KR739001    13 Nov 2023;  RU129266    16 Nov 2023,WO2022221527-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA                EP4322957-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    ,,"WO2022221527-A1 -- US20210106584-A1   ;  WO2016100914-A1   GOURLAY S (GOUR-Individual)   GOURLAY S;  WO2012158764-A1   PRINCIPIA BIOPHARMA INC (SNFI)   GOLDSTEIN D M,  BRAMELD K A;  WO2014039899-A1   PRINCIPIA BIOPHARMA INC (SNFI)   OWENS T,  VERNER E;  WO2015127310-A1   PRINCIPIA BIOPHARMA INC (SNFI)   GOURLAY S,  MASJEDIZADEH M R;  WO2016105531-A1   NUNN P (NUNN-Individual);  BERNER B (BERN-Individual);  MASJEDIZADEH M (MASJ-Individual)   NUNN P,  BERNER B,  MASJEDIZADEH M;  WO2018005849-A1   PRINCIPIA BIOPHARMA INC (SNFI)   FERDOUS A J,  MASJEDIZADEH M R,  LIN W","WO2022221527-A1  VON HUNDELSHAUSEN          PHILIPP ET AL: ""Vaccine-Induced Immune Thrombotic          Thrombocytopenia (VITT): Targeting Pathomechanisms with          Bruton Tyrosine Kinase Inhibitors"", THROMBOSIS AND          HAEMOSTASIS, vol. 121, no. 11, 13 April 2021          (2021-04-13), DE, pages 1395 - 1399, XP055936740, ISSN:          0340-6245, DOI:          10.1055/a-1481-3039,relevantClaims[2,5,10-16|1,3,4,6-9,17-24],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|paragraph          bridging pages          1396-1397|&lt;pp&gt;1398&lt;/pp&gt;&lt;column&gt;1&lt;/column&gt;&lt;para&gt;l&lt;/para&gt;];  GOLDMANN LUISE ET          AL: ""Oral Bruton tyrosine kinase inhibitors block          activation of the platelet Fc receptor CD32a (FcgRIIA): a          new option in HIT?"", BLOOD ADVANCES, vol. 3, no. 23, 14          January 2020 (2020-01-14), pages 4021 - 4033,          XP055936927, ISSN: 2473-9529, DOI:          10.1182/bloodadvances.2019001362,relevantClaims[4],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;figure&gt;1-3&lt;/figure&gt;&lt;table&gt;1&lt;/table&gt;];  VAYNE CAROLINE ET          AL: ""Pathophysiology and Diagnosis of Drug-Induced Immune          Thrombocytopenia"", JOURNAL OF CLINICAL MEDICINE, vol. 9,          no. 7, 13 July 2020 (2020-07-13), pages 2212,          XP055936996, DOI:          10.3390/jcm9072212,relevantClaims[1-20],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;pp&gt;2&lt;/pp&gt;&lt;table&gt;1&lt;/table&gt;];            GREINACHER ET AL.: ""Thrombotic thrombocytopenia after          ChAdOxl nCov-19 vaccination"", N ENGL J MED,          2021;            GREINACHER ET AL.: ""Autoimmune heparin-induced          thrombocytopenia"", J THROMB HAEMOST, vol. 15, no. 11,          2017, pages 2099 - 114;            NICOLSON PL ET AL., HAEMATOLOGICA, vol. 106, no. 1, 2020,          pages 208 - 219;            VON HUNDELSHAUSEN ET AL., THROMB HAEMOST, 13 April 2021          (2021-04-13);            LANGRISH CL ET AL., JLMMUNOL, vol. 206, no. 7, 1 April          2021 (2021-04-01), pages 1454 - 1468;  S.          M. BERGE ET AL.: ""describes pharmaceutically acceptable          salts"", J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages          1 - 19;            LLOYD, THE ART, SCIENCE AND TECHNOLOGY OF PHARMACEUTICAL          COMPOUNDING, 1999;            NICOLSON ET AL.: ""Low-dose BTK inhibitors selectively          block platelet activation by CLEC-2"", HAEMATOLOGICA, vol.          106, no. 1, 2021, pages 208 - 19;            SCHLUTZ ET AL.: ""Thrombosis and thrombocytopenia after          ChAdOxl nCoV-19 vaccination"", N ENGL J MED,          2021;            WARKENTIN: ""High-dose intravenous immunoglobulin for the          treatment and prevention of heparin-induced          thrombocytopenia: a review"", EXPERT REV HEMATOL, vol. 12,          no. 8, 2019, pages 685 - 98;            RUBINO ET AL.: ""A comparative study of platelet factor          4-enhanced platelet activation assays for the diagnosis          of heparin-induced thrombocytopenia"", H THROMBO HAEMOST,          vol. 19, no. 4, 2021, pages 1096 - 102;            VAYNE ET AL.: ""Beneficial effect of exogenous platelet          factor 4 for detecting pathogenic heparin-induced          thrombocytopenia antibodies"", BR J HAEMATOL, vol. 179,          no. 5, 2017, pages 811 - 9;            PADMANABHAN ET AL.: ""A novel PF4-dependent platelet          activation assay identifies patients likely to have          heparin-induced thrombocytopenia/thrombosis"", CHEST, vol.          150, no. 3, 2016, pages 506 - 15;            WARKENTIN ET AL.: ""The platelet serotonin-release assay"",          AM J HEMATOL, vol. 90, no. 6, 2015, pages 564 -          72",86910-1-0-0 K M; 86977-0-0-0 K M; 87364-1-0-0 K M; 131206-1-0-0 K M; 8198-0-0-0 K M; 87874-0-0-0 K M; 87917-0-0-0 K M; 88150-0-0-0 K M; 90035-0-0-0 K M; 15132-2-0-0 K M; 90344-1-0-0 K M; 1530637-1-0-0 K M; 90997-1-0-0 K M; 91332-1-0-0 K M; 92441-0-0-0 K M; 93100-0-0-0 K M; 93507-0-0-0 K M; 94351-1-0-0 K M; 94879-2-0-0 K M; 95294-0-0-0 K M; 2358-0-0-0 K M; 95735-0-0-0 K M; 95875-0-0-0 K M; 95995-1-0-0 K M; 96010-1-0-0 K M; 97132-0-0-0 K M; 97209-0-0-0 K M; 97728-1-0-0 K M; 99028-1-0-0 K M; 94678-1-0-0 K M; 100410-0-0-0 K M; 100436-0-0-0 K M; 100514-1-0-0 K M; 100922-0-0-0 K M; 101187-0-0-0 K M; 102107-0-0-0 K M; 104084-1-0-0 K M; 104827-0-0-0 K M; 105654-1-0-0 K M; 102516-2-0-0 K M; 108017-0-0-0 K M; 108456-1-0-0 K M; 108489-0-0-0 K M; 108923-0-0-0 K M; 109308-0-0-0 K M; 110009-0-0-0 K M; 110025-1-0-0 K M; 111250-0-0-0 K M; 5735-0-0-0 K M; 116397-1-0-0 K M; 121198-1-0-0 K M; 123715-0-0-0 K M; 127393-0-0-0 K M; 128531-1-0-0 K M; 130323-0-0-0 K M; 465-1-0-0 K M; 7556-0-0-0 K M; 149090-0-0-0 K M; 9091-0-0-0 K M; 182442-1-0-0 K M; 208563-0-0-0 K M; 12641-0-0-0 K M; 20152-0-0-0 K M; 36645-0-0-0 K M; 44063-0-0-0 K M; 60080-1-0-0 K M; 433263-0-0-0 K M; 436339-20-0-0 K M; 65200-1-0-0 K M; 72366-0-0-0 K M; 77147-0-0-0 K M; 83270-0-0-0 K M; 86318-0-0-0 K M; 90849-0-0-0 K M; 87413-0-0-0 K M; 1919660-1-0-0 K M; 108008-0-0-0 K M; 7891-1-0-0 K M; 22768-1-0-0 K M; 82701-1-0-0 K M; 93722-1-0-0 K M; 1316181-1-0-0 K M; 2318167-0-0-0 K M; 91375-0-0-0 K M; 91489-0-0-0 K M; 92245-1-0-0 K M; 96796-0-0-0 K M; 97854-0-0-0 K M; 97855-0-0-0 K M; 102650-1-0-0 K M; 114052-0-0-0 K M; 166620-0-0-0 K M; 197131-0-0-0 K M; 463982-0-0-0 K M; 896726-0-0-0 K M; 97867-0-0-1 K M; 564781-0-0-0 K M; 444-0-0-0 ; 1530637-1-0-0 CL USE; 1919660-1-0-0 CL USE; 1316181-1-0-0 CL USE; 2318167-0-0-0 CL USE,,01391; 01174; 45408; 00211; 01261; 01345; 01586; 01010; 00096; 41252; 00081; 40201; 70379; 56380; 54753; 60980; 03676; 08295; 05708; 45911; 49740,R03581 K M; R01218 K M; RA3MZJ K M; R04792 K M; RA0VH2 K M; RAJELK K M; R00034 K M; R02063 K M; R01259 K M; R11768 K M; R01986 K M; R12516 K M; RA04L6 K M; RB6U95 K M; R19990 K M; RAA1WI K M; R22347 K M; RA11MS K M; R04380 K M; R00159 K M; R03935 K M; R03432 K M; R20553 K M; R00678 K M; R00082 K M; R06407 K M; RA0EH0 K M; RA01IY K M; R00175 K M; R21452 K M; R15097 K M; RA0KVH K M; R19799 K M; RA298O K M; R03742 K M; R23271 K M; R06241 K M; R04574 K M; R00267 K M; R03877 K M; R09271 K M; R01324 K M; R07487 K M; R20748 K M; R01445 K M; RA0HYU K M; RA0EGZ K M; R03243 K M; R01245 K M; R12099 K M; R04258 K M; R22667 K M; R00758 K M; RA0CQV K M; RA0AEM K M; RA5GNT K M; RA027G K M; RA4ACO K M; RBZ0WT K M; R01096 K M; R01987 K M; R14131 K M; RA0V66 K M; R00165 K M; RA1KUP K M; RA4282 K M; RA7LEX K M; R03008 K M; R01446 K M; R00487 K M; R14664 K M; R01203 K M; R00180 K M; RA4TIX K M; RA4VVD K M; R04150 K M; R03057 K M; R00129 K M; R22668 K M; RA4FNO K M; R07922 K M; R17554 K M; RAZS9G K M; R01087 K M; R00014 K M; R00061 K M; R02018 K M; RA02G5 K M; RAX3LY K M; RAXNUO K M; RB9E9V K M; RA063W K M; RA09LI K M; RA0O3V K M; R06377 K M; R13259 K M; R01867 K M; RA022K K M; RA02SP K M; RA0AO4 K M; RA8B76 K M; RA1VLZ K M; RA28R6 K M; RAB17O K M; RAE5RQ K M; RA2Q7A K M; RAPOR1 K M; RAUGL6 K M; R00351 ,1218-S; 0034-S; 2063-S; 1259-S; 1986-S; 0159-S; 0678-S; 0082-S; 0175-S; 0267-S; 1324-S; 1445-S; 1245-S; 0758-S; 1096-S; 1987-S; 0165-S; 1446-S; 0487-S; 1203-S; 0180-S; 0129-S; 1087-S; 0014-S; 0061-S; 2018-S; 1867-S
WO2023162903-A1,"Liquid useful as standard sample for e.g.            developing and implementing cancer diagnostic            technology targeting exosomes, comprises lipid            particles associated with protein chosen from membrane            protein and viral protein",MASATOSHI M;  MANABU T;  AYUKA N;  AKIHIRO Y;  YUTO O;  KAISEI S;  KENSAKU M,UNIV HOKKAIDO NAT CORP (UHOK-C),202390565G,"   NOVELTY - Liquid comprises lipid particles associated                with a protein, where (a) the protein is a membrane                protein which is a marker protein of an exosome or                its partial fragment and in which at least a                portion of the membrane protein exists outside the                lipid particles, or (b) the protein is a viral                protein or its partial fragment, and at least a                portion of the protein exists outside the lipid                particles.    USE - The lipid particle-containing liquid is useful                as a standard sample for developing and                implementing cancer diagnostic technology targeting                exosomes, antibody neutralization test methods,                which are standard methods for testing infectious                diseases, and drug discovery (e.g. neutralizing                antibody development, RNA delivery and protein                vaccines).    ADVANTAGE - The lipid particle-containing liquid easily                controls the particle size and components of the                lipid particles contained in the lipid                particle-containing liquid, and suppresses                denaturation of membrane proteins and viral                proteins associated with the lipid particles by                appropriately diluting the organic solvent used as                the lipid solvent in the channel structure. The                lipid particle-containing liquid does not contain                viral genome, and is not infectious and does not                proliferate, hence is suitable for experiments at                biosafety level 2 (BSL-2).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    method for preparing the liquid involves (a)                using a substrate and a channel structure provided                inside the substrate, where the channel structure                comprises at least two introduction paths, a first                introduction path for introducing a first fluid and                a second introduction path for introducing a second                fluid, which are independent of each other on its                upstream side, the introduction path merges at a                merging site, and has a dilution flow path toward                the downstream side of the merging site, (b)                supplying an aqueous solution comprising a membrane                protein or a viral protein to the first                introduction path, (c) supplying a lipid-containing                compatible organic solvent solution to a second                introduction path, and (d) obtaining liquid in the                dilution channel; and    a kit for preparing the liquid comprising (i)                substrate and channel structure provided inside the                substrate, where the channel structure comprises at                least two introduction paths, a first introduction                path for introducing a first fluid and a second                introduction path for introducing a second fluid,                which are independent of each other on its upstream                side, the introduction path merges at a merging                site, and has a dilution flow path toward the                downstream side of the merging site, (ii) a                membrane protein that is an exosome marker protein                or its partial fragment, or a viral protein or its                partial fragment, and (iii) lipids. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-B01B;  B04-E12;  B04-E13;  B04-E99;  B04-F12;  B04-N03K;  B04-N04;  B04-N16;  B11-C08E;  B12-K04E;  B12-K04F;  B12-K04G1A;  D05-H09;  D05-H19C;  D05-H99,A61K-031/7088;  A61K-039/12;  A61K-039/215;  A61K-047/10;  A61K-047/24;  A61K-047/42;  A61K-047/44;  A61K-009/10;  A61K-009/127;  A61P-031/12;  A61P-031/14;  A61P-043/00;  C07K-017/02;  C12N-015/113;  C12N-015/115,WO2023162903-A1   31 Aug 2023   A61K-047/44   202374Pages: 86   Japanese,WO2023162903-A1    WOJP005885    20 Feb 2023,,JP025530    22 Feb 2022;  JP025776    22 Feb 2022,WO2023162903-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,,,,,,,
WO2023172441-A2;  WO2023172441-A3,Treating respiratory virus infection and            inflammatory diseases comprises administering transient            receptor potential vanilloid-type 4 inhibitor to            subject which has or is at risk of respiratory virus            infection,BAI H;  INGBER D E,HARVARD COLLEGE (HARD-C),2023974629,"   NOVELTY - Treating a respiratory virus infection in a                subject comprises administering a transient                receptor potential vanilloid-type 4 (TRPV4)                inhibitor to the subject, where the subject has or                is at risk of a respiratory virus infection.    USE - The method is useful for: treating a                respiratory virus infection in a subject, where the                subject has at least one symptom of a respiratory                virus infection, the symptoms are related to                aberrant inflammation, the aberrant inflammation is                aberrant pulmonary inflammation, the subject has an                inflammatory disease, the subject has acute                respiratory distress syndrome, and the subject is a                human (all claimed); and treating inflammatory                diseases, and/or respiratory inflammation. Test                details are described but no results given.    ADVANTAGE - The method administers TRPV4 inhibitor in an                amount which reduces an inflammatory immune                response induced by the respiratory virus infection                in the subject, relative to a control, reduces                inflammatory cytokine production in the subject,                relative to a control, reduces viral replication in                the subject, relative to a control, and reduces                viral load in the subject, relative to a                control. ",,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E07;  B04-E13;  B04-G01;  B04-H02;  B04-H05;  B04-L05A;  B06-B01;  B06-D02;  B14-A02;  B14-C03;  B14-K01;  B14-L06;  B14-S18;  D05-H19C,A61K-041/00;  A61P-031/12;  A61P-011/00;  A61P-029/00,WO2023172441-A2   14 Sep 2023   A61K-041/00   202381Pages: 48   English;  WO2023172441-A3   16 Nov 2023   A61P-031/12   202393   English,WO2023172441-A2    WOUS014445    03 Mar 2023;   WO2023172441-A3    WOUS014445    03 Mar 2023,,US317388P    07 Mar 2022,WO2023172441-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2023172441-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,";  WO2023172441-A3 -- US20130203715-A1   ;  US20180235931-A1   ;  US20190091206-A1   ;  US20210145937-A1   ;  WO2017077528-A2   SALZMAN LOVELACE INVESTMENTS LTD (SALZ-Non-standard)   BARRETT E G,  SALZMAN A L","WO2023172441-A3  ABDELMOATY SALLY,          WIGERBLAD GUSTAF, BAS DUYGU B., CODELUPPI SIMONE,          FERNANDEZ-ZAFRA TERESA, EL-AWADY EL-SAYED, MOUSTAFA          YASSER, AB: ""Spinal Actions of Lipoxin A4 and          17(R)-Resolvin D1 Attenuate Inflammation-Induced          Mechanical Hypersensitivity and Spinal TNF Release"", PLOS          ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 8, no. 9, US ,          pages e75543, XP093112277, ISSN: 1932-6203, DOI:          10.1371/journal.pone.0075543,relevantClaims[1-5,          7-11],relevantPassages[; entire document, especially          abstract, pg 2 col 1 para 2];  CLARK D. RUSSELL;          JUeRGEN SCHWARZE: ""The role of proresolution lipid          mediators in infectious disease"", CANCER RESEARCH,          WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 141, no. 2, 9          January 2014 (2014-01-09), GB , pages 166 - 173,          XP071276686, ISSN: 0019-2805, DOI:          10.1111/imm.12206,relevantClaims[5],relevantPassages[;          entire document];  KUEBLER WOLFGANG          M., JORDT SVEN-ERIC, LIEDTKE WOLFGANG B.: ""Urgent          reconsideration of lung edema as a preventable outcome in          COVID-19: inhibition of TRPV4 represents a promising and          feasible approach"", AMERICAN JOURNAL OF PHYSIOLOGY - LUNG          CELLULAR AND MOLECULAR PHYSIOLOGY, AMERICAN PHYSIOLOGICAL          SOCIETY, US, vol. 318, no. 6, 1 June 2020 (2020-06-01),          US , pages 1239 - 1243, XP093112280, ISSN: 1040-0605,          DOI: 10.1152/ajplung.00161.2020,relevantClaims[1-5,          7-11],relevantPassages[; entire document]", K M; 1542278-2-0-0 K M; 2418795-0-0-0 K M; 97854-0-0-0 K M; 184587-0-0-0 K M; 105730-0-0-0 K M; 97961-0-0-0 K M; 97959-0-0-0 K M; 1542278-2-0-0 CL USE; 2418795-0-0-0 CL USE,229958401 K M; 229958402 K M,00061,RCWQ81 K M; RARQX4 K M; RBAAY7 K M; RA022K K M; RA00C8 K M; RA012P K M; RA09LE K M; RA01IL K M,
WO2023019194-A1;  US2023115214-A1;  WO2023019194-A9;  CA3228419-A1;  EP4384215-A1,"Dry oil-in-water emulsion composition useful for            inducing immune response, comprises sugar or sugar            alcohol",CUI Z;  WILLIAMS R O;  ABOULFOTOUH K;  MOON C;  XU H;  WILLIAMS R O I,UNIV TEXAS SYSTEM (TEXA-C);  UNIV TEXAS SYSTEM (TEXA-C);  UNIV TEXAS SYSTEM BOARD REGENTS (TEXA-C);  UNIV TEXAS SYSTEM BOARD REGENTS (TEXA-C),2023213015,"   NOVELTY - Dry oil-in-water (O/W) emulsion composition                comprises a sugar or a sugar alcohol.    USE - The composition is useful for inducing an                immune response in a subject, where the subject has                or is at risk of contracting diphtheria, tetanus,                pertussis, influenza, pneumonia, otitis media,                bacteremia, meningitis, hepatitis, cirrhosis,                anthrax poisoning, rabies, warts, poliomyelitis,                Japanese encephalitis, coronavirus diseases,                cancer, Clostridium tetani, Streptococcus                pneumoniae, hepatitis A, hepatitis B, hemophilus                influenza, Corynebacterium diphtheriae, Bordetella                pertussis, human papillomavirus, Bacillus                anthracis, Rabies virus, Japanese encephalitis                virus, coronavirus or Poliovirus, or has tumor or                is at risk of developing tumor (all claimed). No                biological data given.    ADVANTAGE - The composition has the potential to be                administered via non-invasive routes (i.e.                intranasal, pulmonary, transcutaneous with or                without microneedles) and stored at ambient                temperatures which significantly reduce the costs                of vaccination programs.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    preparing (M1) an adjuvant thin film,                comprising applying a liquid adjuvant composition                to a freezing surface, where the liquid adjuvant                composition comprises O/W nanoemulsion and a sugar                or sugar alcohol, and allowing the liquid adjuvant                composition to disperse and freeze on the freezing                surface thereby forming a thin film;    inducing (M2) an immune response in a subject,                comprising administering the composition or its                solvated, reconstituted or rehydrated version, or                the adjuvant thin film to the patient; and    the adjuvant thin film made by method                (M1). ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C07 (Apparatus, formulation, general. including veterinary syringes, general formulations where the active compound is not central to the invention (e.g. wettable powders) and analysis.);  ;  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).);  A96 (Medical, dental, veterinary, cosmetic.);  P33 (Medical aids, oral administration (A61G, H, J).)",B04-C02A2;  B04-C03;  B05-A01A;  B05-A01B;  B05-A03A4;  B05-A03B1;  B05-B02A3;  B05-C04;  B05-C05;  B05-C07;  B06-D09;  B07-A02;  B07-D09;  B10-A07B;  B10-A09A;  B10-A17;  B10-B02D;  B10-B02J;  B10-C02;  B10-C04E5;  B10-C04E6;  B10-J02A;  B12-M03;  B14-A01;  B14-A02A5;  B14-A02A6;  B14-A02B;  B14-C03;  B14-H01;  B14-K01;  B14-M01;  B14-N02;  B14-N12;  B14-N16;  B14-N17;  B14-S11;  B14-S18;  C04-C02A2;  C04-C03;  C05-A01;  C05-A03A4;  C05-A03B1;  C05-B02A3;  C05-C04;  C05-C05;  C05-C07;  C06-D09;  C07-A02;  C07-D09;  C10-A07B;  C10-A09A;  C10-A17;  C10-B02D;  C10-B02J;  C10-C02;  C10-C04E5;  C10-C04E6;  C10-J02A;  C14-A01;  C14-A02A5;  C14-A02A6;  C14-A02B;  C14-C03;  C14-H01;  C14-K01;  C14-M01;  C14-N02;  C14-N12;  C14-N16;  C14-N17;  C14-S11;  C14-S18;  D05-C21;  A06-A00E3;  A12-V01;  A12-V03D;  P33-M,A61J-003/02;  A61K-039/39;  A61K-047/44;  A61P-037/04;  C12N-007/00;  A61K-039/145;  A61K-047/06;  A61K-047/26;  A61K-009/19,WO2023019194-A1   16 Feb 2023   A61K-039/39   202321Pages: 68   English;  US2023115214-A1   13 Apr 2023   A61K-039/145   202334   English;  WO2023019194-A9   14 Sep 2023   A61K-039/39   202376   English;  CA3228419-A1   16 Feb 2023   202414   English;  EP4384215-A1   19 Jun 2024   A61K-039/39   202451   English,WO2023019194-A1    WOUS074813    11 Aug 2022;   US2023115214-A1    US819259    11 Aug 2022;   WO2023019194-A9    WOUS074813    11 Aug 2022;   CA3228419-A1    CA3228419    11 Aug 2022;   EP4384215-A1    EP786669    11 Aug 2022,US2023115214-A1 Provisional Application US232091P;   CA3228419-A1 PCT application Application WOUS074813;   EP4384215-A1 PCT application Application WOUS074813;   EP4384215-A1 Based on Patent WO2023019194,US232091P    11 Aug 2021;  US819259    11 Aug 2022;  CA3228419    08 Feb 2024,WO2023019194-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    WO2023019194-A9:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP4384215-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN  ,,WO2023019194-A1 -- US20160144023-A1   ;  US20200268880-A1   ,"WO2023019194-A1  ANONYMOUS:          ""Feasibility of Freeze-Drying Oil-in-Water Emulsion          Adjuvants and Subunit Proteins to Enable Single-Vial          Vaccine Drug Products - ScienceDirect"", 24 February 2017          (2017-02-24), pages 1 - 3, XP055982788, Retrieved from          the Internet          &lt;URL:https://www.sciencedirect.com/science/article/abs/pii/S0022354917301338&gt;          [retrieved on          20221117],relevantClaims[1-5,7-15|16-39,43-45|6,16-39,43-45],relevantPassages[&lt;ppl&gt;1491&lt;/ppl&gt;&lt;coll&gt;1&lt;/coll&gt;|&lt;ppl&gt;1493&lt;/ppl&gt;&lt;coll&gt;2&lt;/coll&gt;|&lt;ppl&gt;1494&lt;/ppl&gt;&lt;coll&gt;1&lt;/coll&gt;|&lt;figure&gt;2&lt;/figure&gt;];  XINRAN LI ET AL: ""A          method of lyophilizing vaccines containing aluminum salts          into a dry powder without causing particle aggregation or          decreasing the immunogenicity following reconstitution"",          JOURNAL OF CONTROLLED RELEASE, vol. 204, 1 April 2015          (2015-04-01), AMSTERDAM, NL, pages 38 - 50, XP055195275,          ISSN: 0168-3659, DOI:          10.1016/j.jconrel.2015.02.035,relevantClaims[16-39,43-45|16-39,43-45],relevantPassages[&lt;paral&gt;2.2&lt;/paral&gt;];  ABOULFOTOUH KHALED          ET AL: ""Next-Generation COVID-19 Vaccines Should Take          Efficiency of Distribution into Consideration"", AAPS          PHARMSCITECH, vol. 22, no. 3, 9 April 2021 (2021-04-09),          XP037420000, DOI:          10.1208/S12249-021-01974-3,relevantClaims[16-39,43-45|16-39,43-45],relevantPassages[&lt;ppl&gt;126&lt;/ppl&gt;&lt;coll&gt;2&lt;/coll&gt;];  JOSHUA D ENGSTROM          ET AL: ""Formation of Stable Submicron Protein Particles          by Thin Film Freezing"", PHARMACEUTICAL RESEARCH, KLUWER          ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 25, no.          6, 21 February 2008 (2008-02-21), pages 1334 - 1346,          XP019613107, ISSN:          1573-904X,relevantClaims[16-39,43-45|16-39,43-45],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  ABOULFOTOUH KHALED          ET AL: ""Formulation of dry powders of vaccines containing          MF59 or AddaVax by Thin-Film Freeze-Drying: Towards a dry          powder universal flu vaccine"", INTERNATIONAL JOURNAL OF          PHARMACEUTICS, ELSEVIER, NL, vol. 624, 13 July 2022          (2022-07-13), XP087146960, ISSN: 0378-5173, [retrieved on          20220713], DOI:          10.1016/J.IJPHARM.2022.122021,relevantClaims[1-45],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];            MATTHIAS ET AL.: ""Rational design of an influenza subunit          vaccine powder with sugar glass technology: preventing          conformational changes of haemagglutinin during freezing          and freeze-drying"", VACCINE, vol. 25, no. 20, 2007, pages          6447 - 6457, XP022189695, DOI:          10.1016/j.vaccine.2007.06.054;            LIEBERMAN, PHARMACEUTICAL DOSAGE FORMS, vol. 1-3,          1992;            LLOYD, THE ART, SCIENCE AND TECHNOLOGY OF PHARMACEUTICAL          COMPOUNDING, 1999;            PICKAR, DOSAGE CALCULATIONS, 1999;            ""Remington: The Science and Practice of Pharmacy"", 2003,          LIPPINCOTT, WILLIAMS & WILKINS;            ABOULFOTOUH ET AL.: ""Next-Generation COVID-19 Vaccines          Should Take Efficiency of Distribution into          Consideration"", AAPS PHARMSCITECH, vol. 22, 2021, pages          126, XP037445227, DOI:          10.1208/s12249-021-01974-3;            ALVING ET AL.: ""Adjuvants for human vaccines"", CURR OPIN          IMMUNOL, vol. 24, 2012, pages 310 - 315, XP028495547,          DOI: 10.1016/j.coi.2012.03.008;            CHEN ET AL.: ""Improving the reach of vaccines to          low-resource regions, with a needle-free vaccine delivery          device and long-term thermostabilization"", J CONTROL          RELEASE, vol. 152, 2011, pages 349 - 355, XP028376831,          DOI: 10.1016/j.jconrel.2011.02.026;            ENGSTROM ET AL.: ""Formation of stable submicron protein          particles by thin film freezing"", PHARM, vol. 25, 2008,          pages 1334 - 1346, XP019613107;            HELLER ET AL.: ""Manipulation of Lyophilization-Induced          Phase Separation: Implications For Pharmaceutical          Proteins"", BIOTECHNOLOGY PROGRESS, vol. 13, 1997, pages          590 - 596, XP000881623, DOI: 10.1021/bp970081b;            KOKANG: ""Immunology and efficacy of MF59-adjuvanted          vaccines"", HUM VACCIN IMMUNOTHER, vol. 14, 2018, pages          3041 - 3045;            RANDOLPH: ""Phase separation of excipients during          lyophilization: effects on protein stability"", J, vol.          86, 1997, pages 1198 - 1203, XP000704761, DOI:          10.1021/js970135b;            VAN DIEPEN ET AL.: ""The adjuvant AlhydroGel elicits          higher antibody titres than AddaVax when combined with          HIV-1 subtype C gp140 from CAP256"", PLOS ONE, 2018, pages          13",1062-0-0-0 K M; 107032-0-0-0 K M; 900-0-0-0 K M; 133912-0-0-0 K M; 104413-0-0-0 K M; 104427-0-0-0 K M; 114599-0-0-0 K M; 151993-0-0-0 K M; 104881-0-0-0 K M; 2853-1-0-0 K M; 686-0-0-0 K M; 2021-0-1-0 K M; 100007-0-0-0 K M; 107773-0-0-0 K M; 866-0-0-0 K M; 127-0-0-0 K M; 89828-0-0-0 K M; 137853-0-0-0 K M; 146870-0-8-0 K M; 60-0-0-0 K M; 107317-0-0-0 K M; 2-1-0-0 K M; 154729-0-1-0 K M; 849-0-2-0 K M; 114-0-0-0 K M; 2623-1-0-0 K M; 130323-0-0-0 K M; 63-0-0-0 K M; 294-0-0-0 K M; 882-1-0-0 K M; 129496-0-0-0 K M; 2006-0-0-0 K M; 129481-5-0-0 K M; 86590-0-0-0 K M; 129510-0-2-0 K M; 129510-1-0-0 K M; 129499-0-0-0 K M; 109254-1-0-0 K M; 949-1-0-0 K M; 51640-0-0-0 K M; 7447-0-0-0 ; 7560-0-0-0 ; 1911-0-0-0 ; 86729-0-0-0 ; 95972-0-0-0 ; 444-0-0-0 ; 92818-0-0-0 ; 107779-0-0-0 ; 238-0-0-0 ,,,RA00D5 K M; RA012F K M; R02044 K M; RA0GM6 K M; R01835 K M; R06717 K M; RA01KS K M; RA01KR K M; RA02AR K M; RA169J K M; RA02ZP K M; R00135 K M; R01966 K M; R01376 K M; RBXMP2 K M; R01680 K M; R03040 K M; RA08R1 K M; R01520 K M; R01678 K M; R01895 K M; R08618 K M; RAS23N K M; RASN6A K M; RAU4YW K M; R01081 K M; R01151 K M; R01514 K M; R04265 K M; RA22F0 K M; RA2H74 K M; R04004 K M; RA00DB K M; R01706 K M; R07736 K M; RBZ0WT K M; R01711 K M; R01193 K M; R00297 K M; R00115 K M; R00104 K M; R04091 K M; R01636 K M; R00318 K M; R06551 K M; R04093 K M; R00300 K M; R06064 K M; R00290 K M; R07423 K M; R03875 K M; R00009 ; R00448 ; R00446 ; R24070 ; R24033 ; R00351 ; R01857 ; R01863 ; R00370 ,2044-S; 1835-S; 0135-S; 1966-S; 1680-S; 1701-S; 1520-S; 1678-S; 1895-S; 1081-S; 1151-S; 1514-S; 0900-S; 0419-S; 1706-S; 0540-S; 1711-S; 1193-S; 0297-S; 0115-S; 0104-S; 1636-S; 0318-S; 1661-S; 0300-S; 0290-S
CN116440285-A,"Long-lasting of coronavirus peptide therapeutic            agents useful for increasing efficacy of coronavirus            polypeptide therapeutic agents against coronavirus,            comprises conjugating immunoglobulin G Fc-binding            peptide with coronavirus polypeptide therapeutic            agent",YANG X;  XIA S;  WANG X;  WANG Q;  XU W;  SU X;  JIANG S;  LU L,UNIV FUDAN (UYFU-C);  SHANXI JINBO BIOLOGICAL PHARM CO LTD (SHAN-Non-standard),2023785806,"   NOVELTY - Long-lasting of coronavirus peptide                therapeutic agents comprises conjugating an                immunoglobulin G (IgG) Fc-binding peptide with                coronavirus polypeptide therapeutic agent, where                coronavirus polypeptide therapeutic agent comprises                fully defined sequence of 36 amino acids (SEQ ID                NO:1), fully defined sequence of 36 amino acids                (SEQ ID NO:2), and fully defined sequence of 42                amino acids (SEQ ID NO:3), as given in the                specification, or variants obtained by                substituting, deleting and/or adding at least one                amino acid residue, where the IgG Fc binding                peptide comprises fully defined sequence of 13                amino acids (SEQ ID NO:4), as given in the                specification, or variants obtained by                substituting, deleting and/or adding at least one                amino acid residue, the IgG Fc binding peptide is                coupled to the N-terminus or C-terminus of the                coronavirus polypeptide therapeutic agent, the IgG                Fc-binding peptide is coupled to the coronavirus                polypeptide therapeutic agent directly or via                linker.    USE - The method is useful for long-lasting of                coronavirus peptide therapeutic agents, which is                useful for increasing the efficacy of coronavirus                polypeptide therapeutic agents against coronavirus.                Can also be useful in the preparation of medicines                or kits for inhibiting the proliferation of                coronavirus, treating and/or preventing diseases or                symptoms caused by coronavirus, and increasing the                efficacy of a coronavirus polypeptide therapeutic                agent against coronavirus or for increasing the                binding ability of an IgG Fc-binding peptide to IgG                protein (all claimed).    ADVANTAGE - The method can make the coronavirus                polypeptide therapeutic agent long-lasting or                increase the efficacy of the coronavirus                polypeptide therapeutic agent.    DETAILED DESCRIPTION - Long-lasting of coronavirus peptide                therapeutic agents comprises conjugating an                immunoglobulin G (IgG) Fc-binding peptide with                coronavirus polypeptide therapeutic agent, where                the coronavirus polypeptide therapeutic agent                comprises fully defined sequence of 36 amino acids                (SEQ ID NO:1), as given in the specification, fully                defined sequence of 36 amino acids (SEQ ID NO:2),                as given in the specification, and fully defined                sequence of 42 amino acids (SEQ ID NO:3), as given                in the specification, or variants obtained by                substituting, deleting and/or adding at least one                amino acid residue, where the IgG Fc binding                peptide comprises fully defined sequence of 13                amino acids (SEQ ID NO:4), as given in the                specification, or variants obtained by                substituting, deleting and/or adding at least one                amino acid residue, the IgG Fc binding peptide is                coupled to the N-terminus or C-terminus of the                coronavirus polypeptide therapeutic agent, the IgG                Fc-binding peptide is coupled to the coronavirus                polypeptide therapeutic agent directly or via                linker, the linker is a flexible joint or rigid                linker, preferably (GS)n, (GGS)n, (GGGS)n, or                (GGGGS)n, and n is an integer from 1-20, and the                coronavirus polypeptide therapeutic agent is a                coronavirus polypeptide fusion inhibitor.    INDEPENDENT CLAIMS are also included                for:    fusion polypeptide, comprising coronavirus                polypeptide therapeutic agent and IgG Fc binding                peptide, where the coronavirus polypeptide                therapeutic agent comprises an amino acid sequence                of (SEQ ID NO: 1-3) or variants obtained by                substituting, deleting and/or adding at least one                amino acid residue, the IgG Fc-binding peptide                comprises amino acid sequence of (SEQ ID NO: 4) or                variants obtained by substituting, deleting and/or                adding at least one amino acid residue, the IgG Fc                binding peptide is coupled to the N-terminus or                C-terminus of the coronavirus polypeptide                therapeutic agent, preferably the IgG Fc-binding                peptide is coupled to the coronavirus polypeptide                therapeutic agent directly or through a linker, the                fusion polypeptide comprises fully defined sequence                of 49 amino acids (SEQ ID NO:5), as given in the                specification, or variants obtained by                substituting, deleting and/or adding at least one                amino acid residue;    nucleic acid encoding the fusion                polypeptide;    vector, comprising the nucleic acid, where the                vector comprises nucleotides encoding a                purification tag, nucleotides encoding a leader,                and/or regulatory elements, the purification tag is                His tag, GST tag, MBP tag, SUMO tag or NusA tag,                and the regulatory element is promoter, terminator                and/or enhancer;    host cell, comprising a nucleic acid or a                vector, where the host cell is a eukaryotic cell or                a prokaryotic cell, the eukaryotic cell is a yeast                cell, an animal cell and/or an insect cell, and the                prokaryotic cell is an cell;Escherichia coli    composition, comprising the fusion                polypeptide, nucleic acid, vector, host cell and                medicinally acceptable carrier, further comprises                an additional anti-coronavirus drug, where the form                of the composition is tablet, capsule, dropping                pill, aerosol, pill, powder, solution, suspension,                emulsion, granule, liposome, transdermal agent,                suppository or lyophilized powder, the                anti-coronavirus drug is an antibody or small                molecule drug, the coronavirus is group consisting                of Human coronavirus 229E (HCoV-229E), Human                coronavirus NL63 (HCoV-NL63), Human coronavirus                OC43 (HCoV-OC43), Human coronavirus HKU1                (HCoV-HKU1), severe acute respiratory syndrome                coronavirus, middle east respiratory syndrome                coronavirus and severe acute respiratory syndrome                coronavirus 2, the antibody is ambavirimab,                romisevirimab, sotrovimab, imdevimab, casirivimab,                tixagevimab, cilgavimab, bamlanivimab, etesevimab,                amubarvimab and/or romlusevimab, and the small                molecule drug is monogravir, nematvir, ritonavir                and/or azivudine;    in vitro methods of inhibiting coronavirus                proliferation in cells, comprising contacting the                cell with the fusion polypeptide or composition;                and    method for increasing the efficacy of                coronavirus polypeptide therapeutic agents against                coronavirus or increasing the binding capacity of                IgG Fc-binding peptides to IgG proteins, comprising                conjugating an IgG Fc-binding peptide with a                coronavirus polypeptide therapeutic agent. ",,,"D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B03 (Other heterocyclics.)",D05-H14;  D05-H12C;  D05-H11;  D05-H99;  B04-F0100E;  B04-G27G0E;  B04-N08;  B04-Q01;  B04-G01;  B04-G23;  B14-S18;  B04-B03A;  B04-B03D;  B07-F01;  B07-D03;  B04-K01W;  B04-G21;  B04-E02H;  B04-C01G;  B04-G27G;  B14-H01B;  B04-E08;  B04-E99,A61K-038/17;  A61K-047/68;  A61P-031/14;  C07K-014/47;  C07K-019/00,CN116440285-A   18 Jul 2023   A61K-047/68   202375   Chinese,CN116440285-A    CN10423264    19 Apr 2023,,CN10423264    19 Apr 2023,,,,, M K;  M K;  M K;  M K;  M K;  M K;  M K;  M K;  M K; 86228-1-0-0 M K;  M K;  M K; 1517824-1-0-0 M K; 1517824-1-0-0 CL USE,,00690,RD4MVV M K; RD2LI1 M K; RD2LI0 M K; RD6O9M M K; RD6O9L M K; RD399Y M K; RD3HG4 M K; RDBTZ7 M K; RDBTZ8 M K; RA02DL M K; RCY57N M K; RD4EJW M K; RBC7EO M K,
WO2022135136-A1;  CN116635037-A;  EP4263532-A1;  US2024076299-A1,"New arylnaphthalene glycoside derivatives useful            for treating, preventing or delaying progression of            viral infection including human immunodeficiency virus,            avian influenza A virus, vesicular stomatitis virus, or            coronavirus",ZHANG H;  ZHU Y;  TSANG N Y;  ZHAO Y;  ZENG Y,UNIV HONG KONG BAPTIST (UNHK-C);  UNIV HONG KONG BAPTIST (UNHK-C);  UNIV HONG KONG BAPTIST (UNHK-C),2022849159,"   NOVELTY - Arylnaphthalene glycoside derivatives (I) are                new.    USE - (I) are useful for: treating, preventing or                delaying progression of a viral infection in a                subject, where the viral infection is human                immunodeficiency virus (HIV), influenza i.e. avian                influenza A virus (H5N1), vesicular stomatitis                virus (VSV) , or coronavirus (CoV) i.e. severe                acute respiratory syndrome coronavirus 2, and the                subject is human or animal; and inhibiting viral                replication (all claimed). The ability of (I) to                treat avian influenza A virus was tested in A549                cells using standard plaque assay. The results                showed that                ((3S,4R)-5-((9-(2H-1,3-benzodioxol-5-yl)-6,7-dimethoxy-1-oxo-1H,3H-naphtho(2,3-c)furan-4-yl)oxy)-3,4-dihydroxyoxolan-3-yl)methyl                acetate exhibited an EC50 value of 0.30 nM.    ADVANTAGE - (I) are safe and effective antiviral agents                against a wide-spectrum of viruses with no or low                toxicity to the host.    DETAILED DESCRIPTION - Arylnaphthalene glycoside derivatives of                formula (I) and their salts are new.    X = O or S; either    R1-R9 = H, alkyl, akenyl, alkynyl, cycloalkyl,                heterocycloalkyl, aryl, aralkyl, heteroaryl,                haloalkyl, halo, cyano, NO2, -OR26, -C(=O)R27,                -C(=O)N(R26)R27, -C(=O)OR26, -OC(=O)R26,                -OSi(R25)(R26)R27, -S(=O)2R26, -S(=O)2N(R26)R27,                -N(R26)R27, -N(R26)N(R26)R27, -N(R26)C(=O)R27, -N                (R26)S(=O)2R27 or a moiety comprising 1-30 plural                valence atoms comprising C, N, O and S; or    CR1R2, CR2R3, CR3R4, CR5R6, CR6R7, CR7R8, or                CR8R9 = cyclic group which is optionally                substituted with halo or a moiety comprising 1-30                plural valence atoms comprising C, N, O and                S;    R10, R11 = oxo or while one of R10 and R11 is                H or halo, the other one of R10 and R11 comprises                R25, -OR25, -C(=O)R25, and -C(=O)OR25;    R12, R13 = oxo or while one of R12 and R13 is                H or halo, the other one of R12 and R13 comprises                R25, -OR25, -C(=O)R25, and -C(=O)OR25;    R19, R20 = monosaccharide, disaccharide,                trisaccharide, and tetrasaccharide (all optionally                substituted), oxo, or while one of R19 and R20 is H                or halo, the other one of R19 and R20 comprises                R25, -OR25, -C(=O)R25, -C(=O)OR25,                -OC(=O)N(R25)R25; either    R21, R22 = oxo, or while one of R21 and R22 is                H, halo, R25 or -OR25, the other one of R21 and R22                comprises R25, -OR25, -C(=O)R25, -OC(=O)N(R25)R25,                -C(=O)OR25, -CH2R29, -CH2OR29, -C(=O)R29; or    CR19R21 = 5-6 membered heterocyclyl optionally                substituted with 1-5 group comprising R25;    R23, R24 = monosaccharide, disaccharide,                trisaccharide, and tetrasaccharide (all optionally                substituted), oxo, or while one of R23 and R24 is H                or halo, the other one of R23 and R24 comprising                R25, -OR25, -C(=O)R25, -C(=O)OR25;    R25 = H, halo, trichloromethyl,                trifluoromethyl, cyano, nitro, -OR26, -C(=O)R27,                -C(=O)N(R26)R27, -C(=O)OR26, -OC(=O)R26,                -OSi(R25)(R26)R27, -S(=O)2R26, -S(=O)2N(R26)R27,                -N(R26)R27, -N(R26)N(R26)R27, -N(R26)C(=O)R27,                -N(R26)S(=O)2R27, -N3, -OS(=O)2CF3, hydrocarbyl                optionally substituted with 1-5 group (s)                comprising R28, heterocyclcyl optionally                substituted with 1-5 group (s) comprising R28, and                -(CH2)k-heterocyclyl optionally substituted with                1-5 group (s) comprising R28;    k = 1-6;    R26, R27 = H or hydrocarbyl and heterocyclyl,                either of which is optionally substituted with 1-5                group (s) comprising halo, cyano, amino, hydroxy,                1-6C alkyl and 1-6C alkoxy;    R28 = halo, trichloromethyl, trifluoromethyl,                cyano, nitro, oxo, =NR26, -OR26, -C(=O)R27,                -C(=O)N(R26)R27, -C(=O)OR26, -OC(=O)R26,                -OSi(R25)(R26)R27, -S(=O)2R26, -S (=O)2N(R26)R27,                -N(R26)R27, -N(R26)N(R26)R27, -N(R26)C(=O)R27 and                -N(R26)S(=O)2R27; and    R29 = H, halo, trichloromethyl,                trifluoromethyl, cyano, nitro, -OR26, -C(=O)R27,                -C(=O)N(R26)R27, -C(=O)OR26, -OC(=O)R26,                -OSi(R25)(R26)R27, -S(=O)2R26, -S(=O)2N(R26)R27,                -N(R26)R27, -N(R26)N(R26)R27, -N(R26)C(=O)R27, -N                (R26)S(=O)2R27, -N3, -OS(=O)2CF3, optionally                substituted monosaccharide, optionally substituted                disaccharide, optionally substituted trisaccharide,                optionally substituted tetrasaccharide, hydrocarbyl                optionally substituted with 1-5 group (s)                comprising R28, and heterocyclyl optionally                substituted with 1-5 group (s) comprising                R28.    Provided that (I) does not include e.g.                tuberculatin,                ((3S,4R)-5-((9-(2H-1,3-benzodioxol-5-yl)-6,7-dimethoxy-1-oxo-1H,3H-naphtho(2,3-c)furan-4-yl)oxy)-3,4-dihydroxyoxolan-3-yl)methyl                acetate,                9-(2H-1,3-benzodioxol-5-yl)-4-(((5S,9R)-9-hydroxy-2,2-dimethyl-1,3,7-trioxaspiro(4.4)nonan-8-yl)oxy)-6,7-dimethoxy-1H,3H-naphtho(2,3-c)furan-1-one,                9-(2H-1,3-benzodioxol-5-yl)-4-(((3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-(((3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl)oxy)oxolan-2-yl)oxy)-6,7-dimethoxy-1H,3H-naphtho(2,3-c)furan-1-one,                and                9-(2H-1,3-benzodioxol-5-yl)-4-(((3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-(((3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl)oxy)oxolan-2-yl)oxy)-6,7-dimethoxy-1H,3H-naphtho(2,3-c)furan-1-one. ",,,B02 (Fused ring heterocyclics.),B05-B01B;  B06-A03;  B06-B02;  B14-A02;  B14-C03;  B14-K01D;  B14-N06A,A61K-031/7028;  A61P-031/12;  A61P-031/14;  A61P-031/16;  A61P-031/18;  C07D-407/14;  A61K-031/365;  A61K-036/19;  C07D-493/04;  C07F-007/18,WO2022135136-A1   30 Jun 2022   C07D-407/14   202261Pages: 118   English;  CN116635037-A   22 Aug 2023   A61K-031/7028   202372   Chinese;  EP4263532-A1   25 Oct 2023   C07D-407/14   202388   English;  US2024076299-A1   07 Mar 2024   C07D-493/04   202421   English,WO2022135136-A1    WOCN136032    07 Dec 2021;   CN116635037-A    CN80085935    07 Dec 2021;   EP4263532-A1    EP909133    07 Dec 2021;   US2024076299-A1    US18258224    19 Jun 2023,CN116635037-A PCT application Application WOCN136032;   CN116635037-A Based on Patent WO2022135136;   EP4263532-A1 PCT application Application WOCN136032;   EP4263532-A1 Based on Patent WO2022135136;   US2024076299-A1 Provisional Application US199329P;   US2024076299-A1 PCT application Application WOCN136032,US199329P    21 Dec 2020;  CN80085935    19 Jun 2023;  US18258224    19 Jun 2023,WO2022135136-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP4263532-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    ,,"WO2022135136-A1 -- WO2013019662-A1   UNIV ILLINOIS FOUND (UNII)   ZHANG H,  SOEJARTO D;  WO2019182947-A1   PURDUE RES FOUND (PURD)   DAVISSON V J,  LINDSTROM A R;  WO2021037077-A1   UNIV HONG KONG BAPTIST (UNHK)   ZHANG H,  LI W,  TSANG N Y;  WO2021041852-A1   UNIV YESHIVA EINSTEIN COLLEGE MEDICINE (YESH)   DIAZ-GRIFFERO F;  WO2021206309-A1   DONG WHA PHARM CO LTD (DONG-Non-standard)   YOON J B,  HWANG Y,  LEE M,  LEEHYEONYONG;  WO2021229602-A1   GODAVARI BIOREFINERIES CO LTD (GODA-Non-standard)   ATHAVALE M,  GAVADE S,  KHARKAR P,  SRIVASTAVA S","WO2022135136-A1  STEFANIK MICHAL,          STRAKOVA PETRA, HAVIERNIK JAN, MILLER ANDREW D., RUZEK          DANIEL, EYER LUDEK: ""Antiviral Activity of Vacuolar          ATPase Blocker Diphyllin against SARS-CoV-2"",          MICROORGANISMS, vol. 9, no. 3, pages 471, XP055946670,          DOI:          10.3390/microorganisms9030471,relevantClaims[1-1418-2428-32],relevantPassages[471(pages          1-10)];  ASANO JUN, KAZUHIRO          CHIBA, MASAHIRO TADA, TAKAO YOSHII: ""Antiviral activity          of lignans and their glycosides from Justicia          procumbens"", PHYTOCHEMISTRY, vol. 42, no. 3, 1 June 1996          (1996-06-01), pages 713 - 717, XP055924677, DOI:          10.1016/0031-9422(96)00024-6,relevantClaims[1-1419-2429-32|1-1719-2729-32],relevantPassages[pages          713-717];  DATABASE REGISTRY 1          December 2015 (2015-12-01), ANONYMOUS :          ""Naphtho[2,3-c]furan-1(3H)-one,          9-(1,3-benzodioxol-5-yl)-6,7-dimethoxy-4-(5-          O-.beta.-D-xylopyranosyl-D-apio-.beta.-D-furanosyl)- (CA          INDEX NAME)"", XP055946777, retrieved from STN Database          accession no. 1821497-29-3 (+ 1627958-97-7 1572180-17-6          1055038-89-5 1054646-22-8 881422-02-2 464195-59-3          408358-51-0 303085-28-1 303084-57-3 220182-12-7          177912-20-8 133174-11-5 133137-56-1 133084-22-7          133084-19-2          90706-11-9),relevantClaims[1-48-1012|1-1719-2729-32],relevantPassages[pages          1-17];  CHEN HUI-WEN; CHENG          JENNA XIAO; LIU MING-TSAN; KING KEVIN; PENG JU-YI; ZHANG          XIN-QUAN; WANG CHING-HO; SHRESTA SUJAN; SCHOOLEY ROBE:          ""Inhibitory and combinatorial effect of diphyllin, a          v-ATPase blocker, on influenza viruses"", ANTIVIRAL          RESEARCH, ELSEVIER BV, NL, vol. 99, no. 3, 29 June 2013          (2013-06-29), NL , pages 371 - 382, XP028728462, ISSN:          0166-3542, DOI:          10.1016/j.antiviral.2013.06.014,relevantClaims[1-13          15-1719-2325-2729-32],relevantPassages[pages          371382];  C CHANG, M LIN, S          LEE, K LIU, F HSU, J LIN: ""Differential inhibition of          reverse transcriptase and cellular DNA polymerase-          activities by lignans isolated from Chinese herbs,          Phyllanthus myrtifolius Moon, and tannins from Lonicera          japonica Thunb and Castanopsis hystrix"", ANTIVIRAL          RESEARCH, vol. 27, no. 4, 1 August 1995 (1995-08-01),          pages 367 - 374, XP055154716, ISSN: 01663542, DOI:          10.1016/0166-3542(95)00020-M,relevantClaims[1-1419-2429-32],relevantPassages[pages          367-374];  ZHANG HONG-JIE;          RUMSCHLAG-BOOMS EMILY; GUAN YI-FU; LIU KANG-LUN; WANG          DONG-YING; LI WAN-FEI; NGUYEN VAN HUNG; CUONG NGUYEN          MANH; S: ""Anti-HIV diphyllin glycosides fromJusticia          gendarussa"", PHYTOCHEMISTRY, ELSEVIER, AMSTERDAM , NL,          vol. 136, 1 January 1900 (1900-01-01), Amsterdam , NL ,          pages 94 - 100, XP029934524, ISSN: 0031-9422, DOI:          10.1016/j.phytochem.2017.01.005,relevantClaims[1-1419-2429-32],relevantPassages[pages          94-100]", N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N; 127163-1-0-0 N,227440701 N,00956; 03010; 03058,RD7HUR N; RD7HUS N; RD7HUT N; RD7HUU N; RD7HUV N; RD7HUW N; RD7HUX N; RD7HUY N; RD7HUZ N; RD7HV0 N; RD7HV1 N; RD7HV2 N; RD7HV3 N; RD7HV4 N; RD7HV5 N; RD7HV6 N; RD7HV7 N; RD7HV8 N; RD7HV9 N; RD7HVA N; RD7HVB N; RD7HVC N; RD7HVD N; RD7HVE N; RD7HVF N; RD7HVG N; RD7HVH N; RBH8VL N,
WO2022108995-A1;  US2024002361-A1,"Treating, preventing, or reducing neuropathic pain            and viral infection, comprises providing formulation            comprising heterocyclic compounds",KHANNA R;  MOUTAL A;  PEREZ-MILLER S,ARIZONA BOARD OF REGENTS (UYAZ-C);  ARIZONA BOARD OF REGENTS (UYAZ-C),202273067E,"   NOVELTY - Treating, preventing, or reducing (M1)                neuropathic pain in a patient, comprises providing                a formulation comprising heterocyclic compounds (I)                or its salts in amount to treat, prevent, or reduce                the neuropathic pain.    USE - The methods are useful for: treating,                preventing, or reducing neuropathic pain in a                patient; and treating, preventing or reducing a                viral infection in a patient, where the viral                infection involves a host's respiratory system, and                the viral infection stems from severe acute                respiratory syndrome coronavirus-2 (all                claimed).    DETAILED DESCRIPTION - Treating, preventing, or reducing (M1)                neuropathic pain in a patient, comprises providing                a formulation comprising heterocyclic compounds of                formula (I) or its salts in amount to treat,                prevent, or reduce the neuropathic pain.    C1 = C;    A1, B1, X1, Y1, Z1 = C or N, where the A1, B1,                C1, X1, Y1, Z1 are bonded to none, one, or two                hydrogen atoms according to valency;    R1-R4, RA1, RB1 = alkyl, alkenyl, aryl,                heteroaryl, amino, 3-20C cyclyl (all optionally                substituted), absent, hydrogen, oxo-, OH, -NR5R6,                -C(O)NR9R10, -C(O)R11, carboxy, or sulfonyl;                or    ZR3, YR4 = substituted heteroaryl;    R5, R6 = alkyl, aryl, heteroaryl (all                optionally substituted), or H; either    R9, R10 = H or optionally substituted alkyl;                or    NR9R10 = substituted heterocyclyl;    R11 = OH, -SH, -NH2, halo, -CN, -OCN, -CNO,                -NO2, or- COOH, preferably, R11 is OH; and    -Y1(R4)-X1(R1)-B1(RB1)-A1(RA1)-C1(R2)= e.g. =                -Y1(R4)=X1(R1)-CO-NH-C(R2)= (Ia) (where in (Ia), X1                is C and Y1 is C or N, (1) R1 is H, or optionally                substituted (e.g. substituted 1-10C alkyl (e.g.                substituted 1C alkyl, preferably directly bonded to                carboxy group)), R2 is -NR5R6, optionally                substituted heteroaryl, optionally substituted aryl                (e.g. substituted by unsubstituted 1-10C alkoxy                (e.g. methoxy), unsubstituted 1-10C alkyl (e.g.                ethyl), OH, halo, unsubstituted anilinyl,                unsubstituted aroxy, unsubstituted heterocyclyl                (e.g. 4-morpholinyl), carboxy, acyl, cyano-, -SH,                nitro-, and/or -NR7R8, unsubstituted 3-20C cyclyl                (e.g. unsubstituted 3C cyclyl e.g. cyclopropyl),                substituted 3-20C cyclyl, unsubstituted                heterocyclyl, substituted heterocyclyl (e.g.                substituted piperidinyl                (1-methyl-5-hydroxymethylpiperidin-3-yl)),                substituted alkyl (e.g. substituted 1-10C alkyl                (e.g. substituted 1-3C alkyl, e.g. isopropyl,                substituted 1C alkyl, preferably directly bonded to                a secondary amino group containing unsubstituted                heteroaryl, substituted heteroaryl, unsubstituted                aryl, substituted aryl, unsubstituted heterocyclyl,                substituted heterocyclyl (e.g.                pyrrolidin-2-one-5-yl), preferably containing                unsubstituted heteroaryl or substituted                heterocyclyl, or unsubstituted alkyl, R5, R6 is H,                unsubstituted aryl, substituted aryl (e.g.                substituted with unsubstituted 1-10C alkoxy (e.g.                methoxy), unsubstituted 1-10C alkyl (e.g. ethyl),                hydroxy, halo, unsubstituted anilinyl,                unsubstituted aroxy, unsubstituted heterocyclyl                (e.g. 4-morpholinyl), carboxy, acyl, cyano-, - SH,                nitro-, and/or -NR7R8, unsubstituted heteroaryl,                substituted heteroaryl (e.g. substituted by -NR7R8,                OH, halo, cyano-, -SH, nitro-, unsubstituted                alkoxy, and/or carboxy), preferably where at least                one of R5 and R6 is optionally substituted aryl,                optionally substituted heteroaryl, optionally                substituted 3-20C cyclyl or optionally substituted                heterocyclyl, R7, R8 is H, unsubstituted alkyl,                unsubstituted aryl, unsubstituted heteroaryl,                unsubstituted 3-20C cyclyl, unsubstituted                heterocyclyl, or unsubstituted alkyl, preferably                where R7 and R8 are both hydrogen, unsubstituted                3-20C cyclyl, substituted 3-20C cyclyl,                unsubstituted heterocyclyl, substituted                heterocyclyl, unsubstituted alkyl, or substituted                alkyl, R4 is absent, H, substituted aryl (e.g.                substituted by unsubstituted 1-10C alkoxy (e.g.                methoxy), and/or unsubstituted 1-10C alkyl (e.g.                methyl)), unsubstituted aryl (e.g. phenyl),                substituted heteroaryl (e.g. substituted by                unsubstituted 1-10C alkyl (e.g. methyl),                unsubstituted 1-10C alkoxy (e.g. methoxy),                unsubstituted heterocyclyl (e.g. 4-morpholinyl,                1-pyrrolidinyl), unsubstituted 1-10C alkyl (e.g.                methyl) and unsubstituted heterocyclyl (e.g.                4-morpholinyl), or unsubstituted 1-10C alkyl (e.g.                methyl) and unsubstituted heterocyclyl (e.g.                1-pyrrolidinyl)), unsubstituted heteroaryl (e.g.                pyridinyl, e.g. pyridin-3yl), unsubstituted alkyl                (e.g. unsubstituted 1-10C alkyl (e.g. methyl)),                substituted alkyl, or -NR5R6, and (2) X1-R1 and                Y1-R4 together form an unsubstituted heteroaryl                (e.g. thiophene), substituted heteroaryl), or                -C(R2)=C(H)-CO-NH-C(R4)= (Ib) (R2 is -NR5R6, where                the R5 and R6 are hydrogen, optionally substituted                aryl, optionally substituted heteroaryl (e.g.                substituted by -NR7R8, OH, halo, cyano-, -SH,                nitro-, and/or unsubstituted alkoxy, the R7 and R8                are hydrogen, unsubstituted alkyl, unsubstituted                aryl, unsubstituted heteroaryl, unsubstituted 3-20C                cyclyl, unsubstituted heterocyclyl, or                unsubstituted alkyl, preferably the R7 and R8 are                both H, unsubstituted 3-20C cyclyl, substituted                3-20C cyclyl, unsubstituted heterocyclyl,                substituted heterocyclyl, unsubstituted alkyl, or                substituted alkyl, preferably at least one of R5                and R6 is unsubstituted aryl, substituted aryl,                unsubstituted heteroaryl, substituted heteroaryl,                unsubstituted 3-20C cyclyl, substituted 3-20C                cyclyl, unsubstituted heterocyclyl or substituted                heterocyclyl, R4 is hydrogen, substituted aryl                (e.g. substituted with unsubstituted 1-10C alkoxy                (e.g. methoxy)), unsubstituted aryl, or substituted                heteroaryl (e.g. substituted by -NR7R8, hydroxy,                halo, cyano-, -SH, nitro-, or unsubstituted                alkoxy)).    INDEPENDENT CLAIMS are also included                for:    (1) treating, preventing or reducing (M2) a                viral infection in a patient, comprising providing                a formulation comprising (I) in an amount to treat,                prevent, or reduce the viral infection;    (2) (I);    (3) formulation comprising (I) in a carrier;                and    (4) modulating (M3) neuropilin-1                (NRP-1)-mediated signaling in a subject, comprising                administering amount of (I) the subject to reduce                NRP-1 signaling in cells of the subject. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B03 (Other heterocyclics.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B06-H;  B07-H;  B10-A10;  B10-A14;  B10-A15;  B10-A25;  B10-B01;  B10-B02A;  B10-B02D;  B10-B02E;  B10-B02F;  B10-B02G;  B10-B02J;  B10-B03;  B10-B04;  B10-C04;  B10-D01;  B10-D03;  B10-E02;  B10-E04;  B10-F02;  B10-G02;  B10-G03;  B10-H01;  B10-H02;  B10-J02;  B14-A02;  B14-C01;  B14-K01D;  B14-L01;  B14-L06;  D05-H,A61K-038/53;  A61P-031/14;  C07D-239/22;  C07D-401/12;  C07D-401/14;  C07D-403/04;  C07D-403/12;  C07D-413/04,WO2022108995-A1   27 May 2022   A61K-038/53   202250Pages: 139   English;  US2024002361-A1   04 Jan 2024   C07D-401/12   202403   English,WO2022108995-A1    WOUS059667    17 Nov 2021;   US2024002361-A1    US18253891    22 May 2023,US2024002361-A1 Provisional Application US117336P;   US2024002361-A1 PCT application Application WOUS059667,US117336P    23 Nov 2020;  US18253891    22 May 2023,WO2022108995-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,,, K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U;  K U,227283301 K U; 227283302 K U; 227283303 K U; 227283304 K U,12010; 00160; 00177; 00178; 00210; 00211; 00212; 41247,RD74YV K U; RD74YW K U; RD74YX K U; RD74YY K U; RD74YZ K U; RD74Z0 K U; RD74Z1 K U; RD74Z2 K U; RD74Z3 K U; RD74Z4 K U; RD74Z5 K U; RD74Z6 K U; RD74Z7 K U; RD74Z8 K U; RD74Z9 K U; RD74ZA K U; RD74ZB K U; RD74ZC K U; RD74ZD K U; RD74ZE K U; RD74ZF K U; RD74ZG K U; RD74ZH K U; RD74ZI K U,
WO2021252709-A1,"Method of treating, ameliorating and/or preventing viral infection in subject e.g. mammal, involves administering agent(s) chosen from dyclonine (1-(4-butoxyphenyl)-3-(1-piperidyl)propan-1-one), eperisone, tolperisone, caretapentan, scopolamine, trihexylphenodyl and dolasetron to subject",WELSH W J;  PENG Y,UNIV RUTGERS STATE NEW JERSEY (RUTF-C),2021E3647J,"   NOVELTY - Method of treating, ameliorating, and/or preventing viral infection involves administering at least one agent chosen from dyclonine (1-(4-butoxyphenyl)-3-(1-piperidyl)propan-1-one), or its salt, solvate, or isotopically labeled derivative, a compound e.g. ((R)-(+)-1-(4-chlorophenyl)-3-(4-(2-methoxyethyl)piperazin-1-yl)methyl-2-pyrrolidinone L-tartrate) (MS-377), (1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'-oxoethyl)- piperidine hydrogen bromide) (DuP 734), E-100, E-5482, eperisone, tolperisone, caretapentan, 1-(2-(3,4-dichlorophenyl)ethyl)-4-methylpiperazine dihydrochloride (BD-1063), donezepil, fluphenazine, clorgyline, nemonapride, amiodarone, haloperidol, ( alpha )-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol (BMS-181100), scopolamine, phenoxybenzamine, trihexylphenodyl, dolasetron, diphenhydramine, SIRA, suloctidil, enclomiphene, clemastine, nadolol, moclobemide, difenidol, propranolol or dextromethorphan, alizapride, and amine compound (I), to the subject.    USE - The method is useful for treating, ameliorating and/or preventing viral infection, pain, proliferative disease, neurological disease, neurodegenerative disease, substance abuse disorder, depressive disorder, ocular disorder and glaucoma in subject. The virus is a Coronavirus, hepatitis C virus (HCV), or HIV. The subject is a mammal, preferably human. The Coronavirus is at least one of Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus, and/or severe acute respiratory syndrome coronavirus 2. The virus is hepatitis C virus (HCV). The pain comprises chronic pain, neuropathic pain, nociceptive pain, hyperalgesia, and/or allodynia (all claimed).    DETAILED DESCRIPTION - Method of treating, ameliorating, and/or preventing viral infection involves administering at least one agent chosen from dyclonine (1-(4-butoxyphenyl)-3-(1-piperidyl)propan-1-one), or its salt, solvate, or isotopically labeled derivative, a compound chosen from ((R)-(+)-1-(4-chlorophenyl)-3-(4-(2-methoxyethyl)piperazin-1-yl)methyl-2-pyrrolidinone L-tartrate) (MS-377), (1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'-oxoethyl)- piperidine hydrogen bromide) (DuP 734), E-100, E-5482, eperisone, tolperisone, caretapentan, 1-(2-(3,4-dichlorophenyl)ethyl)-4-methylpiperazine dihydrochloride (BD-1063), donezepil, fluphenazine, clorgyline, nemonapride, amiodarone, haloperidol, ( alpha )-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol (BMS-181100), scopolamine, phenoxybenzamine, trihexylphenodyl, dolasetron, diphenhydramine, SIRA, suloctidil, enclomiphene, clemastine, nadolol, moclobemide, difenidol, propranolol, encainide, dextromethorphan, alizapride, amisulpride, lidocaine, arotinolol, propafenone, metoclopramide, phenyltoloxamine, captodiamine, acebutolol, and mepivacaine; and amine compound of formula (I), or a salt, solvate, isotopically labeled derivative, enantiomer, diastereoisomer, or tautomer to the subject.    A1 = N when A2 is NR3, and A3 is C, NR3 when A2 is N or A3 is C, or N when A2 is CR3 and A3 is N;    R1,R2 = H, 1-8C alkyl, 2-8C alkenyl, 2-8C alkynyl, or 3-10C cycloalkyl (all optionally substituted with F, Cl, Br, I, 1-8C alkyl, 1-8C haloalkyl or 3-8C cycloalkyl);    or R1+R2+N = 3- to 8- membered heterocyclyl optionally substituted by F, Cl, Br, I, 1-8C alkyl, 1-8C haloalkyl, 2-8C alkenyl, 2-8C alkenyl, phenyl, heteroaryl, or (aryl)-1-6C alkyl, in which two substituents bound to the same atom of the heterocyclyl optionally combine to form 2-7C alkylene optionally substituted with at least one substituent chosen from F, Cl, Br, I, 1-8C alkyl, 1-8C haloalkyl, 2-8C alkenyl, 2-8C alkenyl, phenyl, heteroaryl, or (aryl)-1-6C alkyl, and two substituents bound to distinct atoms of the heterocyclyl optionally combine to form 1-7C alkylene optionally substituted with at least one substituent selected F, Cl, Br, I, 1-8C alkyl, 1-C haloalkyl, 2-8C alkenyl, 2-8C alkenyl, phenyl, heteroaryl, and (aryl)-1-6C alkyl;    Y' = -(CH2)n- optionally substituted by 1-6C alkyl,1-6C haloalkyl, F, Cl, Br, or I;    n = 0, 1, 2, 3, 4, 5, or 6;    X = -CH2-, -O-, -NH-, -N(1-6C alkyl)-, or -S-, in which CH2 is optionally substituted with at least one chosen from 1-6C alkyl,1-6C haloalkyl, F, Cl, Br, or I;    R3 = 1-84C alkyl, 2-4C alkenyl, 2-4C alkynyl, or 3-6C cycloalkyl (all optionally substituted with 1-4C alkyl, 1-4C haloalkyl, F, Cl, Br, or I);    R4a-R4e = H, F, Cl, Br, I, 1-8C alkyl, 1-8C haloalkyl, 1-8C haloalkoxy, 2-6C alkenyl, 2-8C alkynyl, 3-10C cycloalkyl, phenyl, phenoxy, or benzyloxy (all optionally substituted by 1-6C alkyl, 1-6C haloalkyl, F, Cl, Br, or I);    or R4c+R4d = 4-8C cycloalkyl, phenyl, or heterocyclyl (all optionally substituted by F, Cl, Br, I, 1-8C alky, 1-8C haloalkyl, 2-8C alkenyl, or 2-8C alkynyl);and    heterocyclyl = pyrrolyl, furanyl or thiophenyl.    INDEPENDENT CLAIMS are included for the following:    (1) method of increasing or decreasing activity of at least one sigma receptor selected sigma 1 receptor (SIR) and sigma 2 receptor (S2R), which involves contacting the at least one sigma receptor with dyclonine (1-(4-butoxyphenyl)-3-(1-piperidyl)propan-1-one), or salt, solvate, or isotopically labeled derivative;    (2) method for inhibiting, treating, and/or preventing pain in subject, which involves administering the therapeutically effective amount of dyclonine (1-(4-butoxyphenyl)-3-(1-piperidyl)propan-1-one), or its salt, solvate, or isotopically labeled derivative to the subject;    (3) method of inhibiting, treating, and/or preventing disease or disorder in a subject, which involves administering the dyclonine (1-(4-butoxyphenyl)-3-(1-piperidyl)propan-1-one), or its salt, solvate, or isotopically labeled derivative to the subject; and    (4) deuterated dyclonine, which is at least one chosen from formulae (A)-(G). ",,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.)",B04-A01;  B04-A04;  B05-A04A;  B05-C07;  B06-H;  B07-H;  B10-B02G;  B10-B03B;  B10-C02;  B14-A02;  B14-C01;  B14-J01;  B14-K01;  B14-L01;  B14-L06;  B14-M01C;  B14-N03;  B14-S18,A61K-041/00,WO2021252709-A1   16 Dec 2021   A61K-041/00   202204Pages: 113   English,WO2021252709-A1    WOUS036719    10 Jun 2021,,US037396P    10 Jun 2020,WO2021252709-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2021252709-A1 -- US20080031979-A1   ;  US20150011585-A1   ;  US20170065540-A1   ;  WO2010101649-A2   GASTAMINZA P (GAST-Individual);  CHISARI F (CHIS-Individual)   GASTAMINZA P,  CHISARI F","WO2021252709-A1  DATABASE Pubchem Compound 18 December 2015 (2015-12-18), ""1,1'-(Pyrazine-2,6-diylbisoxy)-3,3'-(pyrazine-2,6-diylbisoxy)-5,5'-[oxybis(ethyleneoxyethyleneoxyethyleneoxy)]dibenzene | C32H34N4O11"", XP055883441, retrieved from NCBI Database accession no. 101888175,relevantClaims[1-6],relevantPassages[Date Accessed: 26 October 2021 (26.10.2021); pg. 2]",93810-0-0-0 K M; 202698-1-1-0 K M; 93789-0-1-0 K M;  K M; 56413-0-0-0 K M; 109153-0-0-0 K M; 103592-0-0-0 K M; 119492-0-0-0 K M; 93856-0-0-0 K M; 95442-0-0-0 K M; 91348-0-0-0 K M; 101764-1-0-0 K M; 87294-0-0-0 K M; 96686-0-0-0 K M; 106757-1-0-0 K M; 103846-0-0-0 K M; 93637-0-0-0 K M; 93450-0-0-0 K M; 109424-0-0-0 K M; 108096-1-0-0 K M; 91310-1-0-0 K M; 91216-0-0-0 K M; 101568-1-0-0 K M; 101165-0-0-0 K M; 93084-0-0-0 K M; 104827-0-0-0 K M; 105355-1-0-0 K M; 86937-0-0-0 K M; 89027-0-1-0 K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M,226507301 K M; 226507302 K M,65782; 00096; 00995; 00691; 44762; 00993,R11454 K M; RA872A K M; RARZ59 K M; RCZ035 K M; R16267 K M; R16270 K M; R08398 K M; RA12AO K M; R23222 K M; R00288 K M; R23145 K M; RA61W6 K M; R13744 K M; R00066 K M; R00046 K M; R00193 K M; RA0614 K M; R00170 K M; R22027 K M; R21176 K M; RA48RJ K M; R04283 K M; R04151 K M; R17761 K M; R21369 K M; R01324 K M; R04536 K M; R10604 K M; R23747 K M; RD4X8B K M; RD4X8C K M; RD4X8D K M; RD4X8E K M; RD4X8F K M; RD4X8G K M; RD4X8H K M; RCTF7N K M; RCTF7O K M; RCTF7P K M; RCTF7Q K M; RCTF7R K M; RCTF7S K M; RCTF7X K M; RCTF7Y K M; RCTF7W K M; RCTF7V K M; RD4X8I K M; RCTF7T K M; RCTF84 K M; RCTF83 K M; RCTF82 K M; RCTF81 K M; RCTF80 K M; RCTF7Z K M; RCTF85 K M; RCTF86 K M; RCTF87 K M; RCTF88 K M; RCTF89 K M; RCTF8B K M; RCTF8C K M; RCTF8D K M; RCTF8E K M; RCTF8F K M; RCTF8G K M; RCTF8H K M; RCTF8I K M; RCTF8J K M; RCTF8K K M; RCTF8L K M; RCTF8M K M; RCTF8R K M; RCTF8Q K M; RCTF8N K M; RCTF8S K M; RCTF8T K M; RCTF8U K M; RCTF8V K M; RCTF8X K M; RCTF8Y K M; RCTF8Z K M; RCTF90 K M; RCTF97 K M; RCTF96 K M; RCTF95 K M; RCTF94 K M; RCTF93 K M; RCTF92 K M; RCTF98 K M; RCTF99 K M; RCTF9A K M; RD4X8J K M; RD4X8K K M; RD4X8L K M; RD4X8M K M; RD4X8N K M; RD4X8O K M,0288-S; 0066-S; 0046-S; 0193-S; 0170-S; 1324-S
WO2023101886-A1;  CA3239735-A1;  AU2022399364-A1,"System useful for balancing imbalanced dataset            obtained from biological sample, comprises computer            subsystem, and component executed by computer subsystem            and comprising generative adversarial network trained            with training sets",YAZAR W;  SARWAL R;  GHOSH S,NEPHROSANT INC (NEPH-Non-standard);  KIDNEYMETRIX INC (KIDN-Non-standard);  NEPHROSANT INC (NEPH-Non-standard),202358932T,"   NOVELTY - System (S1) comprises: at least one computer                subsystem; and at least one component executed by                the computer subsystem, where the component                comprises a generative adversarial network trained                with (a) a first training set comprising data                corresponding to an amount of cell-free DNA (cfDNA)                biomarker from a subject with an organ injury                designated as a first training input and (b) a                second training set comprising data corresponding                to an amount of cfDNA biomarker from a subject                without the organ injury designated as a second                training input, and the first and the second                datasets are imbalanced and the computer subsystem                is configured for generating a set of synthetic                features for the first dataset and/or the second                dataset by inputting a portion of the data from the                first training input and the second training input                into the generative adversarial network.    USE - The systems are useful for balancing                imbalanced dataset obtained from a biological                sample, and analyzing dataset obtained from                biological sample (all claimed).    ADVANTAGE - None given.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    ystem (S2) comprising the computer subsystem,                and the component executed by the computer                subsystem, where the component comprises generative                adversarial network trained with training set                corresponding to an amount of cfDNA from subject,                and the computer subsystem is configured for                generating a synthetic dataset from the biological                sample by inputting a subset of the training data                into the generative adversarial network; and    non-transitory computer-readable medium,                storing program instructions executable on the                computer system for performing a                computer-implemented method for generating a                simulated image of a specimen, where the                computer-implemented method comprises the computer                subsystem, and the component executed by the                computer subsystem, where the component comprises a                generative adversarial network trained with a                training set corresponding to an amount of cfDNA                from subject, the computer subsystem is configured                for generating a synthetic dataset from the                biological sample by inputting a sub-set of the                training data into the generative adversarial                network, the component comprises a generative                adversarial network trained with a training set                comprising data corresponding to an amount of cfDNA                biomarker from a subject a first training set                comprising data corresponding to an amount of cfDNA                biomarker from a subject with an organ injury                designated as a first training input, a second                training set comprising data corresponding to an                amount of cfDNA biomarker from a subject without                the organ injury designated as a second training                input, and the first and the second datasets are                imbalanced and the computer subsystem are                configured for generating a set of synthetic                features for the first dataset and/or the second                dataset by inputting a portion of the data from the                first training input and the second training input                into the generative adversarial network. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  P31 (Diagnosis, surgery (A61B).);  S05 (Electrical Medical Equipment);  T01 (Digital Computers)",B04-E01A;  B04-E12;  B04-E99;  B04-N02;  B04-N16;  B11-C08E;  B11-C11;  B12-K04G;  D05-H09;  D05-H99;  P31-A05;  S05-D01G;  T01-J13A;  T01-N01E;  T01-N03B1;  T01-S03,A61B-005/145;  C12N-015/11;  G06V-010/00,WO2023101886-A1   08 Jun 2023   A61B-005/145   202349Pages: 60   English;  CA3239735-A1   08 Jun 2023   202446   English;  AU2022399364-A1   20 Jun 2024   A61B-005/145   202452   English,WO2023101886-A1    WOUS050974    23 Nov 2022;   CA3239735-A1    CA3239735    23 Nov 2022;   AU2022399364-A1    AU399364    23 Nov 2022,CA3239735-A1 PCT application Application WOUS050974;   AU2022399364-A1 PCT application Application WOUS050974;   AU2022399364-A1 Based on Patent WO2023101886,US284590P    30 Nov 2021;  CA3239735    30 May 2024,WO2023101886-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      ,,"WO2023101886-A1 -- US20070020605-A1   ;  US20160053301-A1   ;  US20200182886-A1   ;  US20200218947-A1   ;  WO2015173435-A1   UNIV KATHOLIEKE LEUVEN KU LEUVEN R &                  D (UYLN)   CLAES P;  WO2020092259-A1   MOLECULAR STETHOSCOPE INC (MOLE-Non-standard)   NERENBERG M,  IBARRA A,  ZHUANG J","WO2023101886-A1  GAO QIJUAN, JIN          XIU, XIA ENHUA, WU XIANGWEI, GU LICHUAN, YAN HANWEI, XIA          YINGCHUN, LI SHAOWEN: ""Identification of Orphan Genes in          Unbalanced Datasets Based on Ensemble Learning"",          FRONTIERS IN GENETICS, vol. 11, XP093071879, DOI:          10.3389/fgene.2020.00820,relevantClaims[1-32,          52],relevantPassages[entire document]",86886-0-0-0 A K,,,R24039 A K,
WO2023287669-A2;  US2023042422-A1;  US2023052518-A1;  US2023090531-A1;  US11639520-B2;  US2023167487-A2;  US11702686-B1;  US2023235381-A1;  WO2023287669-A3;  US2023340573-A1;  US11821025-B2;  US2023399682-A1;  US2024026425-A1;  US11970730-B2;  US11987839-B2;  US2024191234-A1,Reaction mixture used in cascade assay to detect            target nucleic acid of interest in sample comprises            first and second ribonucleoprotein complexes having            first and second nucleic acid-guided nuclease and guide            RNAs respectively,GANGULI A;  MOSTAFA A;  BERGER J;  PANDEY A;  BASHIR R,LABSIMPLY INC (LABS-Non-standard);  UNIV ILLINOIS FOUND (UNII-C);  LABSIMPLY INC (LABS-Non-standard);  UNIV ILLINOIS FOUND (UNII-C);  VEDABIO INC (VEDA-Non-standard),2023105817,"   NOVELTY - Reaction mixture (RM1) comprises a first                ribonucleoprotein (RNP) complex (RNP1) comprising a                first nucleic acid-guided nuclease and a first                guide RNA (gRNA), where the first gRNA comprises a                sequence complementary to a target nucleic acid of                interest, and the first nucleic acid-guided                nuclease exhibit cis-cleavage activity and/or                trans-cleavage activity, a second ribonucleoprotein                complex (RNP2) comprising a second nucleic                acid-guided nuclease and a second gRNA that is not                complementary to the target nucleic acid of                interest, where the second nucleic acid-guided                nuclease exhibits cis-cleavage activity and/or                trans-cleavage activity, and many blocked nucleic                acid molecules comprising a sequence complementary                to the second gRNA, and the blocked nucleic acid                molecules cannot activate the RNP 1 or the                RNP2.    USE - The reaction mixture is useful: in a cascade                assay for detecting a target nucleic acid of                interest in a sample; and in syndromic testing (all                claimed), where the target nucleic acid is from                e.g. adenovirus, coronavirus HKU1, coronavirus                NL63, coronavirus 229E, coronavirus OC43, severe                acute respiratory syndrome coronavirus 2, human                metapneumovirus, human rhinovirus, enterovirus,                influenza A, Klebsiella aerogenes, Klebsiella                oxytoca, Moraxella catarrhalis, Proteus spp.,                Salmonella enterica, Serratia marcescens,                Haemophilus influenzae, and Neisseria                meningitidis.    ADVANTAGE - None given.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    reaction mixture (RM2) comprising a first                complex comprising the first nucleic acid-guided                nuclease and a first guide RNA (gRNA), a second                complex comprising the second nucleic acid-guided                nuclease and a second gRNA that is not                complementary to the target nucleic acid of                interest, and many blocked nucleic acid molecules                comprising a sequence complementary to the second                gRNA, where the blocked nucleic acid molecule                cannot activate the first or second complex;    a reaction mixture (RM3) comprising the RNP1                complex, the RNP2 complex and many blocked nucleic                acid molecules comprising a sequence complementary                to the second gRNA, where the blocked nucleic acid                molecules do not bind to the RNP 1 complex or the                RNP2 complex;    a reaction mixture (RM4) comprising a first                complex comprising a first nucleic acid-guided                nuclease and a first guide RNA (gRNA), a second                complex comprising a second nucleic acid-guided                nuclease and a second gRNA that is not                complementary to the target nucleic acid of                interest, and blocked nucleic acid molecules;    a cascade assay for detecting a target nucleic                acid of interest in a sample comprising providing                the reaction mixture (M1) and contacting the                reaction mixture with the sample under conditions                that allow the target nucleic acid of interest in                the sample to bind to RNP1, where upon binding of                the target nucleic acid of interest RNP1 becomes                active initiating trans-cleavage of at least one of                the blocked nucleic acid molecules, thus producing                at least one unblocked nucleic acid molecule and at                least one unblocked nucleic acid molecule binds to                RNP2 initiating cleavage of at least one further                blocked nucleic acid molecule, and detecting                products of the cleavage, thus detecting the target                nucleic acid of interest in the sample;    a kit for detecting a target nucleic acid of                interest in a sample comprising RNP1, RNP2, many                blocked nucleic acid molecules comprising a                sequence corresponding to the second gRNA, and a                reporter moiety, where the reporter molecule                comprises a nucleic acid molecule and/or is                operably linked to the blocked nucleic acid                molecule and produces a detectable signal upon                trans-cleavage activity by the RNP1 or the RNP2, to                identify the presence of the target nucleic acid of                interest in the sample;    a blocked nucleic acid molecule comprising a                first region recognized by a ribonucleoprotein                (RNP) complex, at least one second region not                complementary to the first region, and at least one                third region complementary and hybridized to the                first region, where cleavage of the second regions                results in dehybridization of the third region from                the first region, resulting in an unblocked nucleic                acid molecule;    unblocking (M2) a blocked nucleic acid                comprising providing a blocked nucleic acid                molecule comprising the first region recognized by                RNP complex, second regions not complementary to                the first region, and third regions complementary                and hybridized to the first region, where cleavage                of the second regions results in dehybridization of                the third region from the first region, resulting                in an unblocked nucleic acid molecule, and                initiating cleavage of the one or more second                regions, where the blocked nucleic acid molecule                becomes an unblocked nucleic acid molecule;    composition of matter (CM1) comprising first                region recognized by RNP complex, second regions of                not complementary to the first region, and third                regions complementary and hybridized to the first                region, and the RNP complex comprising a gRNA that                is complementary to the first region and a nucleic                acid-guided nuclease, where the nucleic acid-guided                nuclease exhibits sequence-specific and/or                non-sequence-specific nuclease activity;    a cascade assay (M3) for detecting a target                nucleic acid of interest in a sample;    composition of matter, comprising the                ribonucleoprotein (RNP) complex and a blocked                nucleic acid molecule;    a reaction mixture (RM5) comprises;    a cascade assay (M4) for detecting a target                nucleic acid of interest in a sample;    a kit for detecting a target nucleic acid of                interest in a sample;    a composition of matter (CM2);    unblocking (M5) a circular high Kd blocked                nucleic acid molecule;    a cascade assay (M6) for detecting a target                nucleic acid of interest in a sample;    a composition of matter (CM3);    a composition of matter (CM4);    composition of matter (CM5);    a composition of matter (CM6); and    yndromic testing (M7). ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E01;  B04-E02;  B04-E03K;  B04-E07;  B04-E12;  B04-E13;  B04-E99;  B04-L05A;  B04-N02;  B11-C08F8;  B12-K04F;  B14-S18;  D05-H09;  D05-H19C;  D05-H99,C12N-009/22;  C12Q-001/6823;  C12Q-001/682;  C12Q-001/6806;  C12N-015/11;  C07H-021/02;  C07H-021/04;  C12N-009/14;  C12Q-001/44;  C12Q-001/6839;  C12N-015/113,WO2023287669-A2   19 Jan 2023   C12Q-001/6823   202312Pages: 248   English;  US2023042422-A1   09 Feb 2023   C12Q-001/6823   202314   English;  US2023052518-A1   16 Feb 2023   C12Q-001/6823   202315   English;  US2023090531-A1   23 Mar 2023   C12N-009/22   202325   English;  US11639520-B2   02 May 2023   C12N-009/22   202336   English;  US2023167487-A2   01 Jun 2023   C12Q-001/6823   202345   English;  US11702686-B1   18 Jul 2023   C12Q-001/6823   202358   English;  US2023235381-A1   27 Jul 2023   C12Q-001/6823   202362   English;  WO2023287669-A3   24 Aug 2023   C12Q-001/44   202370   English;  US2023340573-A1   26 Oct 2023   C12Q-001/6823   202388   English;  US11821025-B2   21 Nov 2023   C12Q-001/6823   202395   English;  US2023399682-A1   14 Dec 2023   C12Q-001/6823   202302   English;  US2024026425-A1   25 Jan 2024   C12Q-001/6823   202409   English;  US11970730-B2   30 Apr 2024   C12Q-001/6823   202440   English;  US11987839-B2   21 May 2024   C12Q-001/6823   202442   English;  US2024191234-A1   13 Jun 2024   C12N-015/113   202449   English,WO2023287669-A2    WOUS036610    09 Jul 2022;   US2023042422-A1    US861209    09 Jul 2022;   US2023052518-A1    US861207    09 Jul 2022;   US2023090531-A1    US861208    09 Jul 2022;   US11639520-B2    US861208    09 Jul 2022;   US2023167487-A2    US861209    09 Jul 2022;   US11702686-B1    US106420    06 Feb 2023;   US2023235381-A1    US106420    06 Feb 2023;   WO2023287669-A3    WOUS036610    09 Jul 2022;   US2023340573-A1    US204337    31 May 2023;   US11821025-B2    US204337    31 May 2023;   US2023399682-A1    US208272    10 Jun 2023;   US2024026425-A1    US372098    24 Sep 2023;   US11970730-B2    US208272    10 Jun 2023;   US11987839-B2    US372098    24 Sep 2023;   US2024191234-A1    US586417    23 Feb 2024,US2023042422-A1 Provisional Application US289112P;   US2023042422-A1 Provisional Application US220987P;   US2023052518-A1 Provisional Application US289112P;   US2023052518-A1 Provisional Application US220987P;   US2023090531-A1 Provisional Application US289112P;   US2023090531-A1 Provisional Application US220987P;   US11639520-B2 Provisional Application US220987P;   US11639520-B2 Provisional Application US289112P;   US11639520-B2 Previous Publ. Patent US2023090531;   US2023167487-A2 Provisional Application US289112P;   US2023167487-A2 Provisional Application US220987P;   US2023167487-A2 Previous Publ. Patent US2023042422;   US11702686-B1 Cont of Application US861208;   US11702686-B1 Provisional Application US220987P;   US11702686-B1 Provisional Application US289112P;   US11702686-B1 Cont of Patent US11639520;   US2023235381-A1 Cont of Application US861208;   US2023235381-A1 Provisional Application US289112P;   US2023235381-A1 Provisional Application US220987P;   US2023235381-A1 Cont of Patent US11639520;   US2023340573-A1 Cont of Application US861208;   US2023340573-A1 Cont of Application US106420;   US2023340573-A1 Provisional Application US289112P;   US2023340573-A1 Provisional Application US220987P;   US2023340573-A1 Cont of Patent US11702686;   US2023340573-A1 Cont of Patent US11639520;   US11821025-B2 Cont of Application US861208;   US11821025-B2 Cont of Application US106420;   US11821025-B2 Provisional Application US220987P;   US11821025-B2 Provisional Application US289112P;   US11821025-B2 Previous Publ. Patent US2023340573;   US11821025-B2 Cont of Patent US11702686;   US11821025-B2 Cont of Patent US11639520;   US2023399682-A1 Cont of Application US861208;   US2023399682-A1 Cont of Application US106420;   US2023399682-A1 Cont of Application US204337;   US2023399682-A1 Provisional Application US289112P;   US2023399682-A1 Provisional Application US220987P;   US2023399682-A1 Cont of Patent US11639520;   US2023399682-A1 Cont of Patent US11702686;   US2024026425-A1 Cont of Application US861208;   US2024026425-A1 Cont of Application US106420;   US2024026425-A1 Cont of Application US204337;   US2024026425-A1 Cont of Application US208272;   US2024026425-A1 Provisional Application US289112P;   US2024026425-A1 Provisional Application US220987P;   US2024026425-A1 Cont of Patent US11821025;   US2024026425-A1 Cont of Patent US11702686;   US2024026425-A1 Cont of Patent US11639520;   US11970730-B2 Cont of Application US861208;   US11970730-B2 Cont of Application US106420;   US11970730-B2 Cont of Application US204337;   US11970730-B2 Provisional Application US289112P;   US11970730-B2 Provisional Application US220987P;   US11970730-B2 Previous Publ. Patent US2023399682;   US11970730-B2 Cont of Patent US11639520;   US11970730-B2 Cont of Patent US11702686;   US11987839-B2 Cont of Application US861208;   US11987839-B2 Cont of Application US106420;   US11987839-B2 Cont of Application US204337;   US11987839-B2 Cont of Application US208272;   US11987839-B2 Provisional Application US220987P;   US11987839-B2 Provisional Application US289112P;   US11987839-B2 Previous Publ. Patent US2024026425;   US11987839-B2 Cont of Patent US11821025;   US11987839-B2 Cont of Patent US11702686;   US11987839-B2 Cont of Patent US11639520;   US2024191234-A1 Cont of Application US076262;   US2024191234-A1 Cont of Application US204329;   US2024191234-A1 Cont of Application US208262;   US2024191234-A1 Cont of Application US518914;   US2024191234-A1 Provisional Application US402055P;   US2024191234-A1 Provisional Application US289112P;   US2024191234-A1 Cont of Patent US11946052;   US2024191234-A1 Cont of Patent US11820983;   US2024191234-A1 Cont of Patent US11884922;   US2024191234-A1 Cont of Patent US11859182,US220987P    12 Jul 2021;  US289112P    13 Dec 2021;  US861207    09 Jul 2022;  US861208    09 Jul 2022;  US861209    09 Jul 2022;  US106420    06 Feb 2023;  US204337    31 May 2023;  US208272    10 Jun 2023;  US372098    24 Sep 2023;  US586417    23 Feb 2024,WO2023287669-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA                WO2023287669-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW                ,,";  US2023042422-A1 -- US20190241954-A1   ;  US11639520-B2 -- US20180282722-A1   ;  US20200010879-A1   ;  US20200056167-A1   ;  US20210102242-A1   ;  US10253365-B1   UNIV CALIFORNIA (REGC)   DOUDNA J A,  CHEN J S,  HARRINGTON L B,  MA E;  US10266886-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S;  US10266887-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S;  US10337051-B2   UNIV CALIFORNIA (REGC)   DOUDNA C J H,  DOUDNA J A,  EAST-SELETSKY A,  KNIGHT S C,  OCONNELL M R;  US10494664-B2   UNIV CALIFORNIA (REGC)   DOUDNA J A,  OCONNELL M R,  EAST-SELETSKY A,  KNIGHT S C,  DOUDNA C J H;  US11021740-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S;  US11060115-B2   ABUDAYYEH O O (ABUD-Individual);  BROAD INST INC (BROD);  GOOTENBERG J S (GOOT-Individual);  HARVARD COLLEGE (HARD);  JOUNG J (JOUN-Individual);  KONERMANN S (KONE-Individual);  KOONIN E (KOON-Individual);  LANDER E S (LAND-Individual);  MAKAROVA K S (MAKA-Individual);  MASSACHUSETTS INST TECHNOLOGY (MASI);  MINAKHIN L (MINA-Individual);  SEMENOVA E (SEME-Individual);  SEVERINOV K (SEVE-Individual);  SHMAKOV S (SHMA-Individual);  UNIV RUTGERS STATE NEW JERSEY (RUTF);  WOLF Y I (WOLF-Individual);  ZHANG F (ZHAN-Individual);  SKOLKOVO SCI & TECHNOLOGY INST (SKOL-Non-standard)   ABUDAYYEH O O,  GOOTENBERG J S,  JOUNG J,  KONERMANN S,  KOONIN E,  LANDER E S,  MAKAROVA K S,  MINAKHIN L,  SEMENOVA E,  SEVERINOV K,  SHMAKOV S,  WOLF Y I,  ZHANG F;  US11104937-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD);  GEN HOSPITAL CORP (GEHO)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S,  BHATTACHARYYA R,  HUNG D;  US11118224-B2   UNIV CALIFORNIA (REGC)   DOUDNA J A,  CHEN J S,  HARRINGTON L B,  MA E;  US11174515-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S,  REGEV A;  US11421250-B2   ABUDAYYEH O O (ABUD-Individual);  BROAD INST INC (BROD);  GOOTENBERG J S (GOOT-Individual);  HARVARD COLLEGE (HARD);  JOUNG J (JOUN-Individual);  KONERMANN S (KONE-Individual);  KOONIN E (KOON-Individual);  LANDER E S (LAND-Individual);  MAKAROVA K S (MAKA-Individual);  MASSACHUSETTS INST TECHNOLOGY (MASI);  MINAKHIN L (MINA-Individual);  SEMENOVA E (SEME-Individual);  SEVERINOV K (SEVE-Individual);  SHMAKOV S (SHMA-Individual);  UNIV RUTGERS STATE NEW JERSEY (RUTF);  WOLF Y I (WOLF-Individual);  ZHANG F (ZHAN-Individual);  SKOLKOVO SCI & TECHNOLOGY INST (SKOL-Non-standard)   ABUDAYYEH O O,  GOOTENBERG J S,  JOUNG J,  KONERMANN S,  KOONIN E,  LANDER E S,  MAKAROVA K S,  MINAKHIN L,  SEMENOVA E,  SEVERINOV K,  SHMAKOV S,  WOLF Y I,  ZHANG F;  US11447824-B2   UNIV CALIFORNIA (REGC)   DOUDNA J A,  CHEN J S,  HARRINGTON L B,  MA E;  WO2020191376-A1   SHERLOCK BIOSCI (SHER-Non-standard)   BROWN C W,  BLAKE W J,  DHANDA R K;  WO2020191248-A8   BROAD INST INC (BROD);  HARVARD COLLEGE (HARD)   LIU D R,  ANZALONE A V,  NELSON J;  US11702686-B1 -- US20180282722-A1   ;  US20190241954-A1   ;  US20190256900-A1   ;  US20200010879-A1   ;  US20200056167-A1   ;  US20200165594-A1   ;  US20200277600-A1   ;  US20200392473-A1   ;  US20210102242-A1   ;  US20210108267-A1   ;  US20210166783-A1   ;  US20210269866-A1   ;  US20210317527-A1   ;  US20210388437-A1   ;  US20220025463-A1   ;  US20220333208-A1   ;  US10253365-B1   UNIV CALIFORNIA (REGC)   DOUDNA J A,  CHEN J S,  HARRINGTON L B,  MA E;  US10266886-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S;  US10266887-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S;  US10337051-B2   UNIV CALIFORNIA (REGC)   DOUDNA C J H,  DOUDNA J A,  EAST-SELETSKY A,  KNIGHT S C,  OCONNELL M R;  US10494664-B2   UNIV CALIFORNIA (REGC)   DOUDNA J A,  OCONNELL M R,  EAST-SELETSKY A,  KNIGHT S C,  DOUDNA C J H;  US11021740-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S;  US11060115-B2   ABUDAYYEH O O (ABUD-Individual);  BROAD INST INC (BROD);  GOOTENBERG J S (GOOT-Individual);  HARVARD COLLEGE (HARD);  JOUNG J (JOUN-Individual);  KONERMANN S (KONE-Individual);  KOONIN E (KOON-Individual);  LANDER E S (LAND-Individual);  MAKAROVA K S (MAKA-Individual);  MASSACHUSETTS INST TECHNOLOGY (MASI);  MINAKHIN L (MINA-Individual);  SEMENOVA E (SEME-Individual);  SEVERINOV K (SEVE-Individual);  SHMAKOV S (SHMA-Individual);  UNIV RUTGERS STATE NEW JERSEY (RUTF);  WOLF Y I (WOLF-Individual);  ZHANG F (ZHAN-Individual);  SKOLKOVO SCI & TECHNOLOGY INST (SKOL-Non-standard)   ABUDAYYEH O O,  GOOTENBERG J S,  JOUNG J,  KONERMANN S,  KOONIN E,  LANDER E S,  MAKAROVA K S,  MINAKHIN L,  SEMENOVA E,  SEVERINOV K,  SHMAKOV S,  WOLF Y I,  ZHANG F;  US11104937-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD);  GEN HOSPITAL CORP (GEHO)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S,  BHATTACHARYYA R,  HUNG D;  US11118224-B2   UNIV CALIFORNIA (REGC)   DOUDNA J A,  CHEN J S,  HARRINGTON L B,  MA E;  US11174515-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S,  REGEV A;  US11421250-B2   ABUDAYYEH O O (ABUD-Individual);  BROAD INST INC (BROD);  GOOTENBERG J S (GOOT-Individual);  HARVARD COLLEGE (HARD);  JOUNG J (JOUN-Individual);  KONERMANN S (KONE-Individual);  KOONIN E (KOON-Individual);  LANDER E S (LAND-Individual);  MAKAROVA K S (MAKA-Individual);  MASSACHUSETTS INST TECHNOLOGY (MASI);  MINAKHIN L (MINA-Individual);  SEMENOVA E (SEME-Individual);  SEVERINOV K (SEVE-Individual);  SHMAKOV S (SHMA-Individual);  UNIV RUTGERS STATE NEW JERSEY (RUTF);  WOLF Y I (WOLF-Individual);  ZHANG F (ZHAN-Individual);  SKOLKOVO SCI & TECHNOLOGY INST (SKOL-Non-standard)   ABUDAYYEH O O,  GOOTENBERG J S,  JOUNG J,  KONERMANN S,  KOONIN E,  LANDER E S,  MAKAROVA K S,  MINAKHIN L,  SEMENOVA E,  SEVERINOV K,  SHMAKOV S,  WOLF Y I,  ZHANG F;  US11447824-B2   UNIV CALIFORNIA (REGC)   DOUDNA J A,  CHEN J S,  HARRINGTON L B,  MA E;  WO2020191376-A1   SHERLOCK BIOSCI (SHER-Non-standard)   BROWN C W,  BLAKE W J,  DHANDA R K;  WO2020191248-A8   BROAD INST INC (BROD);  HARVARD COLLEGE (HARD)   LIU D R,  ANZALONE A V,  NELSON J;  WO2023287669-A3 -- US20180023081-A1   ;  US20190112648-A1   ;  US20190201550-A1   ;  US20200010879-A1   ;  US20200157611-A1   ;  US20210102183-A1   ;  US2024026425-A1 -- WO2014178562-A1   GENEMATRIX INC (GENE-Non-standard)   YOO W,  KIM S,  HONG S,  SHIN S,  KIM J,  CHOI H S;  US11970730-B2 -- CN114058679-A   UNIV SHENZHEN (UYSZ)   ZHANG Y,  LIU Y;  CN114262730-A   UNIV CHONGQING MEDICAL INT INST VITRO (UYCH-Non-standard)   HU X,  ZENG H,  YANG X;  US20140377748-A1   ;  US20160083785-A1   ;  US20180023081-A1   ;  US20180155716-A1   ;  US20180282722-A1   ;  US20190112648-A1   ;  US20190201550-A1   ;  US20190241954-A1   ;  US20190256900-A1   ;  US20200010879-A1   ;  US20200056167-A1   ;  US20200157611-A1   ;  US20200165594-A1   ;  US20200277600-A1   ;  US20200392473-A1   ;  US20210102183-A1   ;  US20210102242-A1   ;  US20210108267-A1   ;  US20210163944-A1   ;  US20210166783-A1   ;  US20210269866-A1   ;  US20210317527-A1   ;  US20210388437-A1   ;  US20220025463-A1   ;  US20220333208-A1   ;  US20230193368-A1   ;  US10253365-B1   UNIV CALIFORNIA (REGC)   DOUDNA J A,  CHEN J S,  HARRINGTON L B,  MA E;  US11273442-B1   MAMMOTH BIOSCI INC (MAMM-Non-standard);  CHEN J S (CHEN-Individual);  TEHRANCHI A (TEHR-Individual);  LANE A B (LANE-Individual);  BROUGHTON J P (BROU-Individual);  HARRINGTON L B (HARR-Individual);  TSALOGLOU M (TSAL-Individual);  MIAO X (MIAO-Individual);  FASCHING C L (FASC-Individual);  SINGH J (SING-Individual);  GALARZA P P D (GALA-Individual)   CHEN J S,  TEHRANCHI A,  LANE A B,  BROUGHTON J P,  HARRINGTON L B,  TSALOGLOU M,  MIAO X,  FASCHING C L,  SINGH J,  GALARZA P P D;  US10266886-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S;  US10266887-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S;  US10337051-B2   UNIV CALIFORNIA (REGC)   DOUDNA C J H,  DOUDNA J A,  EAST-SELETSKY A,  KNIGHT S C,  OCONNELL M R;  US10494664-B2   UNIV CALIFORNIA (REGC)   DOUDNA J A,  OCONNELL M R,  EAST-SELETSKY A,  KNIGHT S C,  DOUDNA C J H;  US11021740-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S;  US11060115-B2   ABUDAYYEH O O (ABUD-Individual);  BROAD INST INC (BROD);  GOOTENBERG J S (GOOT-Individual);  HARVARD COLLEGE (HARD);  JOUNG J (JOUN-Individual);  KONERMANN S (KONE-Individual);  KOONIN E (KOON-Individual);  LANDER E S (LAND-Individual);  MAKAROVA K S (MAKA-Individual);  MASSACHUSETTS INST TECHNOLOGY (MASI);  MINAKHIN L (MINA-Individual);  SEMENOVA E (SEME-Individual);  SEVERINOV K (SEVE-Individual);  SHMAKOV S (SHMA-Individual);  UNIV RUTGERS STATE NEW JERSEY (RUTF);  WOLF Y I (WOLF-Individual);  ZHANG F (ZHAN-Individual);  SKOLKOVO SCI & TECHNOLOGY INST (SKOL-Non-standard)   ABUDAYYEH O O,  GOOTENBERG J S,  JOUNG J,  KONERMANN S,  KOONIN E,  LANDER E S,  MAKAROVA K S,  MINAKHIN L,  SEMENOVA E,  SEVERINOV K,  SHMAKOV S,  WOLF Y I,  ZHANG F;  US11104937-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD);  GEN HOSPITAL CORP (GEHO)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S,  BHATTACHARYYA R,  HUNG D;  US11118224-B2   UNIV CALIFORNIA (REGC)   DOUDNA J A,  CHEN J S,  HARRINGTON L B,  MA E;  US11174470-B2   MAMMOTH BIOSCI INC (MAMM-Non-standard)   HARRINGTON L B,  CHEN J S,  BROUGHTON J P,  GALARZA P P D,  HARTONO W J,  WITTE I P,  SINGH J;  US11174515-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S,  REGEV A;  US11421250-B2   ABUDAYYEH O O (ABUD-Individual);  BROAD INST INC (BROD);  GOOTENBERG J S (GOOT-Individual);  HARVARD COLLEGE (HARD);  JOUNG J (JOUN-Individual);  KONERMANN S (KONE-Individual);  KOONIN E (KOON-Individual);  LANDER E S (LAND-Individual);  MAKAROVA K S (MAKA-Individual);  MASSACHUSETTS INST TECHNOLOGY (MASI);  MINAKHIN L (MINA-Individual);  SEMENOVA E (SEME-Individual);  SEVERINOV K (SEVE-Individual);  SHMAKOV S (SHMA-Individual);  UNIV RUTGERS STATE NEW JERSEY (RUTF);  WOLF Y I (WOLF-Individual);  ZHANG F (ZHAN-Individual);  SKOLKOVO SCI & TECHNOLOGY INST (SKOL-Non-standard)   ABUDAYYEH O O,  GOOTENBERG J S,  JOUNG J,  KONERMANN S,  KOONIN E,  LANDER E S,  MAKAROVA K S,  MINAKHIN L,  SEMENOVA E,  SEVERINOV K,  SHMAKOV S,  WOLF Y I,  ZHANG F;  US11447824-B2   UNIV CALIFORNIA (REGC)   DOUDNA J A,  CHEN J S,  HARRINGTON L B,  MA E;  WO2014143228-A1   INTEGRATED DNA TECHNOLOGIES INC (DANH)   WALDER J A,  BEHLKE M A,  ROSE S D,  DOBOSY J R,  RUPP S M;  WO2016201138-A1   UNIV CALIFORNIA (REGC);  CHEN J S (CHEN-Individual)   CHEN J S,  STERNBERG S H,  DOUDNA J A,  LAFRANCE B;  WO2020191376-A1   SHERLOCK BIOSCI (SHER-Non-standard)   BROWN C W,  BLAKE W J,  DHANDA R K;  WO2021021532-A1   MAMMOTH BIOSCI INC (MAMM-Non-standard)   BROUGHTON J P,  CHEN J S,  HARRINGTON L B;  WO2021146534-A1   JUMPCODE GENOMICS INC (JUMP-Non-standard)   BROWN K;  WO2021236651-A1   UNIV CALIFORNIA (REGC)   SAVAGE D,  HSU P,  PRYWES N,  CHARLES E J,  KNOTT G J,  DESMARAIS J J,  KIM S,  DUGAN E,  LUKARSKA M,  CHANDRASEKARAN S S,  LAMMERS N C,  LIU T Y,  MOK A,  LAREAU L;  WO2022061166-A1   MAMMOTH BIOSCIENCES INC (MAMM-Non-standard)   BROUGHTON J P,  CHEN J S;  WO2023056451-A1   MAMMOTH BIOSCIENCES INC (MAMM-Non-standard)   BROUGHTON J P,  CHEN J S,  HUBBELL S;  WO2023081902-A1   UNIV FLORIDA RES FOUND INC (UYFL)   RANANAWARE S,  JAIN P K,  ANEKAR S,  VESCO E;  WO2023114052-A1   LABSIMPLY INC (LABS-Non-standard)   GANGULI A,  MOSTAFA A,  BERGER J,  PANDEY A;  WO2023278629-A1   MAMMOTH BIOSCIENCES INC (MAMM-Non-standard)   CHING J,  FASCHING C L,  BROUGHTON J P,  HENDRIKS C G,  JAIN S,  CHEN J S,  SHAPIRO S J,  PATNO T J;  WO2021108717-A2   BROAD INST INC (BROD);  HARVARD COLLEGE (HARD)   LIU D R,  DOMAN J L,  RAGURAM A;  WO2022133108-A2   MAMMOTH BIOSCI INC (MAMM-Non-standard)   CHING J,  BROUGHTON J P,  CHEN J S,  SHAPIRO S J,  HAWKINS E M,  JAIN S,  KREINDLER L,  HUBBELL S;  WO2022266513-A2   MAMMOTH BIOSCIENCES INC (MAMM-Non-standard)   PATNO T J,  LEE P Y F,  BLIZARD B A,  MIAO X,  LESINSKI J,  BROWN R A,  DRZAL D T,  SHAPIRO S J,  BAIK J,  CHEN J S,  BROUGHTON J P,  FASCHING C L,  CHING J,  JAIN S,  VERMA D,  VEROSLOFF M,  SPRATT D,  FANTIN N J;  WO2023015259-A2   MAMMOTH BIOSCIENCES INC (MAMM-Non-standard)   FASCHING C L,  BROUGHTON J P,  CHING J,  CHEN J S,  HENDRIKS C G,  MCKAY B A P;  WO2023114090-A2   LABSIMPLY INC (LABS-Non-standard)   GANGULI A,  PANDEY A,  MOSTAFA A,  BERGER J;  WO2023287669-A2   LABSIMPLY INC (LABS-Non-standard);  UNIV ILLINOIS FOUND (UNII)   GANGULI A,  MOSTAFA A,  BERGER J,  PANDEY A,  BASHIR R;  WO2020191248-A8   BROAD INST INC (BROD);  HARVARD COLLEGE (HARD)   LIU D R,  ANZALONE A V,  NELSON J;  US11987839-B2 -- WO2014178562-A1   GENEMATRIX INC (GENE-Non-standard)   YOO W,  KIM S,  HONG S,  SHIN S,  KIM J,  CHOI H S;  CN114058679-A   UNIV SHENZHEN (UYSZ)   ZHANG Y,  LIU Y;  CN114262730-A   UNIV CHONGQING MEDICAL INT INST VITRO (UYCH-Non-standard)   HU X,  ZENG H,  YANG X;  US20140377748-A1   ;  US20160083785-A1   ;  US20180023081-A1   ;  US20180155716-A1   ;  US20180282722-A1   ;  US20190112648-A1   ;  US20190201550-A1   ;  US20190241954-A1   ;  US20190256900-A1   ;  US20200010879-A1   ;  US20200056167-A1   ;  US20200157611-A1   ;  US20200165594-A1   ;  US20200277600-A1   ;  US20200392473-A1   ;  US20210102183-A1   ;  US20210102242-A1   ;  US20210108267-A1   ;  US20210163944-A1   ;  US20210166783-A1   ;  US20210269866-A1   ;  US20210317527-A1   ;  US20210388437-A1   ;  US20220025463-A1   ;  US20220333208-A1   ;  US20230193368-A1   ;  US10253365-B1   UNIV CALIFORNIA (REGC)   DOUDNA J A,  CHEN J S,  HARRINGTON L B,  MA E;  US11273442-B1   MAMMOTH BIOSCI INC (MAMM-Non-standard);  CHEN J S (CHEN-Individual);  TEHRANCHI A (TEHR-Individual);  LANE A B (LANE-Individual);  BROUGHTON J P (BROU-Individual);  HARRINGTON L B (HARR-Individual);  TSALOGLOU M (TSAL-Individual);  MIAO X (MIAO-Individual);  FASCHING C L (FASC-Individual);  SINGH J (SING-Individual);  GALARZA P P D (GALA-Individual)   CHEN J S,  TEHRANCHI A,  LANE A B,  BROUGHTON J P,  HARRINGTON L B,  TSALOGLOU M,  MIAO X,  FASCHING C L,  SINGH J,  GALARZA P P D;  US10266886-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S;  US10266887-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S;  US10337051-B2   UNIV CALIFORNIA (REGC)   DOUDNA C J H,  DOUDNA J A,  EAST-SELETSKY A,  KNIGHT S C,  OCONNELL M R;  US10494664-B2   UNIV CALIFORNIA (REGC)   DOUDNA J A,  OCONNELL M R,  EAST-SELETSKY A,  KNIGHT S C,  DOUDNA C J H;  US11021740-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S;  US11060115-B2   ABUDAYYEH O O (ABUD-Individual);  BROAD INST INC (BROD);  GOOTENBERG J S (GOOT-Individual);  HARVARD COLLEGE (HARD);  JOUNG J (JOUN-Individual);  KONERMANN S (KONE-Individual);  KOONIN E (KOON-Individual);  LANDER E S (LAND-Individual);  MAKAROVA K S (MAKA-Individual);  MASSACHUSETTS INST TECHNOLOGY (MASI);  MINAKHIN L (MINA-Individual);  SEMENOVA E (SEME-Individual);  SEVERINOV K (SEVE-Individual);  SHMAKOV S (SHMA-Individual);  UNIV RUTGERS STATE NEW JERSEY (RUTF);  WOLF Y I (WOLF-Individual);  ZHANG F (ZHAN-Individual);  SKOLKOVO SCI & TECHNOLOGY INST (SKOL-Non-standard)   ABUDAYYEH O O,  GOOTENBERG J S,  JOUNG J,  KONERMANN S,  KOONIN E,  LANDER E S,  MAKAROVA K S,  MINAKHIN L,  SEMENOVA E,  SEVERINOV K,  SHMAKOV S,  WOLF Y I,  ZHANG F;  US11104937-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD);  GEN HOSPITAL CORP (GEHO)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S,  BHATTACHARYYA R,  HUNG D;  US11118224-B2   UNIV CALIFORNIA (REGC)   DOUDNA J A,  CHEN J S,  HARRINGTON L B,  MA E;  US11174470-B2   MAMMOTH BIOSCI INC (MAMM-Non-standard)   HARRINGTON L B,  CHEN J S,  BROUGHTON J P,  GALARZA P P D,  HARTONO W J,  WITTE I P,  SINGH J;  US11174515-B2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ABUDAYYEH O,  COLLINS J J,  GOOTENBERG J,  ZHANG F,  LANDER E S,  REGEV A;  US11421250-B2   ABUDAYYEH O O (ABUD-Individual);  BROAD INST INC (BROD);  GOOTENBERG J S (GOOT-Individual);  HARVARD COLLEGE (HARD);  JOUNG J (JOUN-Individual);  KONERMANN S (KONE-Individual);  KOONIN E (KOON-Individual);  LANDER E S (LAND-Individual);  MAKAROVA K S (MAKA-Individual);  MASSACHUSETTS INST TECHNOLOGY (MASI);  MINAKHIN L (MINA-Individual);  SEMENOVA E (SEME-Individual);  SEVERINOV K (SEVE-Individual);  SHMAKOV S (SHMA-Individual);  UNIV RUTGERS STATE NEW JERSEY (RUTF);  WOLF Y I (WOLF-Individual);  ZHANG F (ZHAN-Individual);  SKOLKOVO SCI & TECHNOLOGY INST (SKOL-Non-standard)   ABUDAYYEH O O,  GOOTENBERG J S,  JOUNG J,  KONERMANN S,  KOONIN E,  LANDER E S,  MAKAROVA K S,  MINAKHIN L,  SEMENOVA E,  SEVERINOV K,  SHMAKOV S,  WOLF Y I,  ZHANG F;  US11447824-B2   UNIV CALIFORNIA (REGC)   DOUDNA J A,  CHEN J S,  HARRINGTON L B,  MA E;  WO2014143228-A1   INTEGRATED DNA TECHNOLOGIES INC (DANH)   WALDER J A,  BEHLKE M A,  ROSE S D,  DOBOSY J R,  RUPP S M;  WO2016201138-A1   UNIV CALIFORNIA (REGC);  CHEN J S (CHEN-Individual)   CHEN J S,  STERNBERG S H,  DOUDNA J A,  LAFRANCE B;  WO2020191376-A1   SHERLOCK BIOSCI (SHER-Non-standard)   BROWN C W,  BLAKE W J,  DHANDA R K;  WO2021021532-A1   MAMMOTH BIOSCI INC (MAMM-Non-standard)   BROUGHTON J P,  CHEN J S,  HARRINGTON L B;  WO2021146534-A1   JUMPCODE GENOMICS INC (JUMP-Non-standard)   BROWN K;  WO2021236651-A1   UNIV CALIFORNIA (REGC)   SAVAGE D,  HSU P,  PRYWES N,  CHARLES E J,  KNOTT G J,  DESMARAIS J J,  KIM S,  DUGAN E,  LUKARSKA M,  CHANDRASEKARAN S S,  LAMMERS N C,  LIU T Y,  MOK A,  LAREAU L;  WO2022061166-A1   MAMMOTH BIOSCIENCES INC (MAMM-Non-standard)   BROUGHTON J P,  CHEN J S;  WO2023056451-A1   MAMMOTH BIOSCIENCES INC (MAMM-Non-standard)   BROUGHTON J P,  CHEN J S,  HUBBELL S;  WO2023081902-A1   UNIV FLORIDA RES FOUND INC (UYFL)   RANANAWARE S,  JAIN P K,  ANEKAR S,  VESCO E;  WO2023114052-A1   LABSIMPLY INC (LABS-Non-standard)   GANGULI A,  MOSTAFA A,  BERGER J,  PANDEY A;  WO2023278629-A1   MAMMOTH BIOSCIENCES INC (MAMM-Non-standard)   CHING J,  FASCHING C L,  BROUGHTON J P,  HENDRIKS C G,  JAIN S,  CHEN J S,  SHAPIRO S J,  PATNO T J;  WO2021108717-A2   BROAD INST INC (BROD);  HARVARD COLLEGE (HARD)   LIU D R,  DOMAN J L,  RAGURAM A;  WO2022133108-A2   MAMMOTH BIOSCI INC (MAMM-Non-standard)   CHING J,  BROUGHTON J P,  CHEN J S,  SHAPIRO S J,  HAWKINS E M,  JAIN S,  KREINDLER L,  HUBBELL S;  WO2022266513-A2   MAMMOTH BIOSCIENCES INC (MAMM-Non-standard)   PATNO T J,  LEE P Y F,  BLIZARD B A,  MIAO X,  LESINSKI J,  BROWN R A,  DRZAL D T,  SHAPIRO S J,  BAIK J,  CHEN J S,  BROUGHTON J P,  FASCHING C L,  CHING J,  JAIN S,  VERMA D,  VEROSLOFF M,  SPRATT D,  FANTIN N J;  WO2023015259-A2   MAMMOTH BIOSCIENCES INC (MAMM-Non-standard)   FASCHING C L,  BROUGHTON J P,  CHING J,  CHEN J S,  HENDRIKS C G,  MCKAY B A P;  WO2023114090-A2   LABSIMPLY INC (LABS-Non-standard)   GANGULI A,  PANDEY A,  MOSTAFA A,  BERGER J;  WO2023287669-A2   LABSIMPLY INC (LABS-Non-standard);  UNIV ILLINOIS FOUND (UNII)   GANGULI A,  MOSTAFA A,  BERGER J,  PANDEY A,  BASHIR R;  WO2020191248-A8   BROAD INST INC (BROD);  HARVARD COLLEGE (HARD)   LIU D R,  ANZALONE A V,  NELSON J","US2023042422-A1            Shi et al. (2021) A CRISPR-Cas autocatalysis-driven          feedback amplification network for supersensitive DNA          diagnostics. Science Advances, 7:eabc78902, pages 1-9          (Year: 2021)US11639520-B2            The Board of Trustees of the University of Illinois,          Crispr Cascade, International PCT Application No.          PCT/US22/33985, filed Jun. 17, 2022.;            Li, et al., Applying CRISPR-Cas12a as Signal Amplifier to          Construct Biosensors for Non-DNA Targets in Ultra-low          Concentrations, ACS Sensors, doi:          10.1021/acssensors.9b02305, pp. 1-23, Mar. 12,          2020.;            Kim, et al., Chimeric crRNAs with 19 DNA residues in the          guide region show retained DNA cleavage activity of Cas9          with a potential to improve the specificity, The Royal          Society of Chemistry, pp. 1-16, 2019.;            Kim, et al., Enhancement of target specificity of          CRISPR-Cas12a by using a chimeric DNA-RNA guide, Nucleic          Acids Research, doi: 10.1093/nar/gkaa605, vol. 48, No.          15, pp. 8601-8616, Jul. 20, 2020.;            Swarts, et al., Mechanistic Insights into the Cis- and          Trans-acting Deoxyribonuclease Activities of Cas12a, Mol          Cell, doi: 10.1016/j.molcel.2018.11.021, pp. 1-28, Feb.          7, 2019.;            Nguyen, et al., Enhancement of trans-cleavage activity of          Cas12a with engineered crRNA enables amplified nucleic          acid detection, Nature Communications, doi:          10.1038/s41467-020-18615-1, pp. 1-13, 2020.;            Ooi, et al., An engineered CRISPR-Cas12a variant and          DNA-RNA hybrid guides enable robust and rapid COVID-10          testing, Nature Communications, doi:          10.1038/s41467-021-21996-6, pp. 1-23, 2021.;            Shi, et al., A CRISPR-Cas autocatalysis-driven feedback          amplification network for supersensitive DNA diagnostics,          Science Advances, doi: 10.1126/sciadv.abc7802, pp. 1-9,          Jan. 27, 2021.;            Chen, et al., CRISPR-Cas12a target binding unleashes          indiscriminate single-stranded DNase activity, Howard          Hughes Medical Institute, Science, 360(6387), pp.          436-439, Apr. 27, 2018.;            Liu, et al., Accelerated RNA detection using tandem          CRISPR nucleases, Nature Chemical Biology, vol. 17,          doi:10.1038/s41589-021-0084202, pp. 982-988, Sep.          2021.;            Gootenberg, et al., Nucleic acid detection with          CRISPR-Cas13a/C2c2, Science, doi:10.1126/science.aam9321,          pp. 438-442, Apr. 28, 2017.US11702686-B1            Fozouni, et al., Amplification-free detection of          SARS-CoV-2 with CRISPR-Cas13a and mobile phone          microscopy, Cell, doi.org/10.1016/j.cell.2020.12.001, pp.          323-333, Jan. 21, 2021.;            Kaminski, et al., CRISPR-based diagnostics, Nature          Biomedical Engineering, vol. 5,          doi.org/10.1038/s41551-021-00760-7, pp. 643-656, Jul.          2021.;            Zhou, et al., CRISPR/Cas13a Powered Portable          Electrochemiluminescence Chip for Ultrasensitive and          Specific MiRNA Detection, Advanced Science News, doi:          10.1002/advs.201903661, pp. 1-10, 2020.;            Zhao, et al., CRISPR-Cas13a system: A novel tool for          molecular diagnostics, Frontiers in Microbiology,          doi:10.3389/fmicb.2022.1060947, pp. 1-18, Dec. 8,          2022.;            Zhou, et al., A Decade of CRISPR Gene Editing in China          and Beyond: A Scientometric Landscape, The CRISPR          Journal, vol. 4, No. 3, doi:10.1089/crispr.2020.0148, pp.          313-320, 2021.;            Shinoda, et al., Automated amplification-free digital RNA          detection platform for rapid and sensitive SARS-CoV-2          diagnosis, Communications Biology,          doi.org/10.1038/s42003-022-03433-6, pp. 1-8, May 26,          2022.;            Gupta, et al., Cas13d: A New Molecular Scissor for          Transcriptome Engineering, Frontiers in Cell and          Developmental Biology, vol. 10,          doi:10.3389/fcell.2022.866800, pp. 1-22, Mar. 31,          2022.;            Schunder, et al., First indication for a functional          CRISPR/Cas system in Francisella tularensis,          International Journal of Medical Microbiology, vol. 303,          Issue 2, doi:10.1016/j.ijmm.2012.11.004, pp. 1-29, Mar.          2013.;            Sha, et al., Cascade CRISPR/cas enables          amplification-free microRNA sensing with fM-sensitivity          and single-base-specificity, ChemComm,          doi:10.1039/d0cc06412b, pp. 247-250 and 1-15,          2021.;            Yang, et al., Engineered LwaCas13a with enhanced          collateral activity for nucleic acid detection, Nature          Chemical Biology, vol. 19,          doi:10.1038/s41589-022-01135-y, pp. 45-54, Jan.          2023.;            Li, et al., Applying CRISPR-Cas12a as Signal Amplifier to          Construct Biosensors for Non-DNA Targets in Ultra-low          Concentrations, ACS Sensors, doi:          10.1021/acssensors.9b02305, pp. 1-23, Mar. 12,          2020.;            Kim, et al., Chimeric crRNAs with 19 DNA residues in the          guide region show retained DNA cleavage activity of Cas9          with a potential to improve the specificity, The Royal          Society of Chemistry, pp. 1-16, 2019.;            Kim, et al., Enhancement of target specificity of          CRISPR-Cas12a by using a chimeric DNA-RNA guide, Nucleic          Acids Research, doi: 10.1093/nar/gkaa605, vol. 48, No.          15, pp. 8601-8616, Jul. 20, 2020.;            Swarts, et al., Mechanistic Insights into the Cis- and          Trans-acting Deoxyribonuclease Activities of Cas12a, Mol          Cell, doi: 10.1016/j.molcel.2018.11.021, pp. 1-28, Feb.          7, 2019.;            Nguyen, et al., Enhancement of trans-cleavage activity of          Cas12a with engineered crRNA enables amplified nucleic          acid detection, Nature Communications, doi:          10.1038/s41467-020-18615-1, pp. 1-13, 2020.;            Ooi, et al., An engineered CRISPR-Cas12a variant and          DNA-RNA hybrid guides enable robust and rapid COVID-10          testing, Nature Communications, doi:          10.1038/s41467-021-21996-6, pp. 1-23, 2021.;            Shi, et al., A CRISPR-Cas autocatalysis-driven feedback          amplification network for supersensitive DNA diagnostics,          Science Advances, doi: 10.1126/sciadv.abc7802, pp. 1-9,          Jan. 27, 2021.;            The Board of Trustees of the University of Illinois,          CRISPR Cascade, International PCT Application No.          PCT/US22/33985, filed Jun. 17, 2022.;            Chen, et al., CRISPR-Cas12a target binding unleashes          indiscriminate single-stranded DNase activity, Howard          Hughes Medical Institute, Science, 360(6387), pp.          436-439, Apr. 27, 2018.;            Liu, et al., Accelerated RNA detection using tandem          CRISPR nucleases, Nature Chemical Biology, vol. 17,          doi:10.1038/s41589-021-0084202, pp. 982-988, Sep.          2021.;            Gootenberg, et al., Nucleic acid detection with          CRISPR-Cas13a/C2c2, Science, doi:10.1126/science.aam9321,          pp. 438-442, Apr. 28, 2017.;            East-Seletsky, et al., RNA targeting by functionally          orthogonal Type VI-A CRISPR-Cas enzymes, Howard Hughes          Medical Institute, Mol Cell, pp. 373-383, May 4,          2017.;            Schmidt, et al., Application of locked nucleic acids to          improve aptamer in vivo stability and targeting function,          Nucleic Acids Research, vol. 32, No. 19,          doi:10.1093/nar/gkh862, pp. 5757-5765, Oct. 27,          2004.;            Makarova, et al., Evolutionary classification of          CRISPR-Cas systems: a burst of class 2 and derived          variants, Nature Reviews | Microbiology, vol. 18, pp.          67-83, Feb. 2020.;            Gleditzsch, et al., PAM identification by CRISPR-Cas          effector complexes: diversified mechanisms and          structures, RNA Biology, vol. 16, No. 4,          doi.org/10.1080/15476286.2018.1504546, pp. 504-517, Jul.          20, 2018.;            Kellner, et al., Sherlock: Nucleic acid detection with          CRISPR nucleases, Nat Protoc.,          doi:10.1038/s41596-019-0210-2, pp. 2986-3012, Oct.          2019.US2024026425-A1            Sha Y et al. Chem Commun (Camb). 2021 Jan 7;57(2):247-250          (Year: 2021);            Harrington et al., Science 362, 839842 (2018) (Year:          2018);            Schmidt KS et al. Nucleic Acids Res. 2004 Oct          27;32(19):5757-65 (Year: 2004);            Gleditzsch D et al. RNA Biol. 2019 Apr;16(4):504-517          (Year: 2019);            Yuan et al., Anal.Chem.2020, 92, 40294037 (Year:          2020);            Wang et al., Anal. Chem. 2021, 93, 1337313381 (Year:          2021);            Swarts et al., Mol Cell. 2019 February 07; 73(3): 589600          (Year: 2019);            Perez-Arnaiz et al., Journal of Molecular Biology, Vol.          391, No. 5, pages 797-807, September 4, 2009 (Year:          2009);            Mar Alba (Alba M. Replicative DNA polymerases. Genome          Biol. 2001;2(1):REVIEWS3002. (Year: 2001);            East-Seletsky A, O'Connell MR, Knight SC, Burstein D,          Cate JH, Tjian R, Doudna JA. Two distinct RNase          activities of CRISPR-C2c2 enable guide-RNA processing and          RNA detection. Nature. 2016 Oct 13;538(7624):270-273.          doi: 10.1038/nature19802. Epub 2016 Sep 26. (Year:          2016);            English translation of WO2014178562 (Year:          2014);            Leenay RT, Beisel CL. Deciphering, Communicating, and          Engineering the CRISPR PAM. J Mol Biol. 2017 Jan          20;429(2):177-191 (Year: 2017)US11970730-B2            International Search Report and Written Opinion for          International Application No. PCT/US2022/036610, dated          Jun. 29, 2023, p. 1-93.;            International Search Report and Written Opinion for          International Application No. PCT/US2022/052032, dated          Apr. 18, 2023, p. 1-19.;            Zhang, et al, An aM-level cascade CRISPR-Dx system          (ASCas) for rapid detection of RNA without          pre-amplification, Biosensors and Bioelectronics,          doi:10.1016/j.bios.2023.115248, Mar. 28, 2023, p.          1-5.;            Zeng, et al., Rapid RNA detection through intra-enzyme          chain replacement-promoted Cas13a cascade cyclic reaction          without amplification, Analytica Chimica Acta,          doi:10.1016/j.aca.2022.340009, May 31, 2022, p.          1-10.;            Liu, et al., Directed Evolution of CRISPR/Cas Systems for          Precise Gene Editing, Trends in Biotechnology, vol. 39,          No. 3, Mar. 2021, p. 262-273.;            Collias, et al., CRISPR technologies and the search for          the PAM-free nuclease, Nature Communications, doi:          10.1038/s41467-020-20633-y, 2021, p. 1-12.;            Huyke, et al., Enzyme Kinetics and Detector Sensitivity          Determine Limits of Detection of Amplification-Free          CRISPR-Cas12 and CRISPR-Cas13 Diagnostics, Analytical          Chemistry, doi:10.1021/acs.analchem.2601670, Jun. 27,          2022, p. 9826-9834.;            International Search Report and Written Opinion for          International Application No. PCT/US22/52320, dated Jun.          15, 2023, p. 1-46.;            Mullally, et al., 5 modifications to CRISPR-Cas9 gRNA can          change the dynamics and size of R-loops and inhibit DNA          cleavage, Nucleic Acids Research,          DOI:10.1093/nar/gkaa477, Jun. 2020, vol. 48, No. 12, p.          6811-6823.;            Hong, et al., Comparison and optimization of          CRISPR/dCas9/gRNA genome-labeling systems for live cell          imaging, Genome Biology, DOI: 10.1186/s13059-018-1413-5,          2018, p. 7-8.;            Li, et al., CRISPR-Cas 12a has both cis- and          trans-cleavage activities on single-stranded DNA, Cell          Research, DOI: 10.1038/s41422-018-0022-x, Feb. 5, 2018,          p. 1-3.;            Dong, et al., An anti-CRISPR protein disables type V          Cas12a by acetylation, PubMed,          DOI:10.1038/s41594-019-0206-1, Feb. 28, 2023, p.          1-1.;            Nguyen, et al., Enhancement of trans-cleavage activity of          Cas12a with engineered crRNA enables amplified nucleic          acid detection, Nature Communications, DOI:          10.1038/s41467-020-18615-1, 2020, p. 1-13.;            Coehlo, et al., CRISPR GUARD protects off-target sites          from Cas9 nuclease activity using short guide RNAs,          Nature Communications, DOI: 10.1038/s41467-020-17952-5,          Aug. 17, 2020, p. 1-12.;            Li, et al., Applying CRISPR-Cas12a as Signal Amplifier to          Construct Biosensors for Non-DNA Targets in Ultra-low          Concentrations, ACS Sensors, doi:          10.1021/acssensors.9b02305, pp. 1-23, Mar. 12,          2020.;            Kim, et al., Chimeric crRNAs with 19 DNA residues in the          guide region show retained DNA cleavage activity of Cas9          with a potential to improve the specificity, The Royal          Society of Chemistry, pp. 1-16, 2019.;            Kim, et al., Enhancement of target specificity of          CRISPR-Cas12a by using a chimeric DNA-RNA guide, Nucleic          Acids Research, doi: 10.1093/nar/gkaa605, vol. 48, No.          15, pp. 8601-8616, Jul. 20, 2020.;            Swarts, et al., Mechanistic Insights into the Cis- and          Trans-acting Deoxyribonuclease Activities of Cas12a, Mol          Cell, doi: 10.1016/j.molcel.2018.11.021, pp. 1-28, Feb.          7, 2019.;            Nguyen, et al., Enhancement of trans-cleavage activity of          Cas12a with engineered crRNA enables amplified nucleic          acid detection, Nature Communications, doi:          10.1038/s41467-020-18615-1, pp. 1-13, 2020.;            Ooi, et al., An engineered CRISPR-Cas12a variant and          DNA-RNA hybrid guides enable robust and rapid COVID-10          testing, Nature Communications, doi:          10.1038/s41467-021-21996-6, pp. 1-23, 2021.;            Shi, et al., A CRISPR-Cas autocatalysis-driven feedback          amplification network for supersensitive DNA diagnostics,          Science Advances, doi: 10.1126/sciadv.abc7802, pp. 1-9,          Jan. 27, 2021.;            The Board of Trustees of the University of Illinois,          CRISPR Cascade, International PCT Application No.          PCT/US22/33985, filed Jun. 17, 2022.;            Chen, et al., CRISPR-Cas12a target binding unleashes          indiscriminate single-stranded DNase activity, Howard          Hughes Medical Institute, Science, 360(6387), pp.          436-439, Apr. 27, 2018.;            Liu, et al., Accelerated RNA detection using tandem          CRISPR nucleases, Nature Chemical Biology, vol. 17, doi:          10.1038/s41589-021-0084202, pp. 982-988, Sep.          2021.;            Gootenberg, et al., Nucleic acid detection with          CRISPR-Cas13a/C2c2, Science, doi:10.1126/science.aam9321,          pp. 438-442, Apr. 28, 2017.;            Fozouni, et al., Amplification-free detection of          SARS-CoV-2 with CRISPR-Cas13a and mobile phone          microscopy, Cell, doi.org/10.1016/j.cell.2020.12.001, pp.          323-333, Jan. 21, 2021.;            Kaminski, et al., CRISPR-based diagnostics, Nature          Biomedical Engineering, vol. 5,          doi.org/10.1038/s41551-021-00760-7, pp. 643-656, Jul.          2021.;            Zhou, et al., CRISPR/Cas13a Powered Portable          Electrochemiluminescence Chip for Ultrasensitive and          Specific MiRNA Detection, Advanced Science News, doi:          10.1002/advs.201903661, pp. 1-10, 2020.;            Zhao, et al., CRISPR-Cas13a system: A novel tool for          molecular diagnostics, Frontiers in Microbiology,          doi:10.3389/fmicb.2022.1060947, pp. 1-18, Dec. 8,          2022.;            Zhou, et al., A Decade of CRISPR Gene Editing in China          and Beyond: A Scientometric Landscape, The CRISPR          Journal, vol. 4, No. 3, doi:10.1089/crispr.2020.0148, pp.          313-320, 2021.;            Shinoda, et al., Automated amplification-free digital RNA          detection platform for rapid and sensitive SARS-CoV-2          diagnosis, Communications Biology,          doi.org/10.1038/s42003-022-03433-6, pp. 1-8, May 26,          2022.;            Gupta, et al., Cas13d: A New Molecular Scissor for          Transcriptome Engineering, Frontiers in Cell and          Developmental Biology, vol. 10,          doi:10.3389/fcell.2022.866800, pp. 1-22, Mar. 31,          2022.;            Schunder, et al., First indication for a functional          CRISPR/Cas system in Francisella tularensis,          International Journal of Medical Microbiology, vol. 303,          Issue 2, doi:10.1016/j.ijmm.2012.11.004, pp. 1-29, Mar.          2013.;            Sha, et al., Cascade CRISPR/cas enables          amplification-free microRNA sensing with fM-sensitivity          and single-base-specificity, ChemComm,          doi:10.1039/d0cc06412b, pp. 247-250 and 1-15,          2021.;            Yang, et al., Engineered LwaCas13a with enhanced          collateral activity for nucleic acid detection, Nature          Chemical Biology, vol. 19,          doi:10.1038/s41589-022-01135-y, pp. 45-54, Jan.          2023.;            East-Seletsky, et al., RNA targeting by functionally          orthogonal Type VI-A CRISPR-Cas enzymes, Howard Hughes          Medical Institute, Mol Cell, pp. 373-383, May 4,          2017.;            Schmidt, et al., Application of locked nucleic acids to          improve aptamer in vivo stability and targeting function,          Nucleic Acids Research, vol. 32, No. 19,          doi:10.1093/nar/gkh862, pp. 5757-5765, Oct. 27,          2004.;            Makarova, et al., Evolutionary classification of          CRISPR-Cas systems: a burst of class 2 and derived          variants, Nature Reviews | Microbiology, vol. 18, pp.          67-83, Feb. 2020.;            Gleditzsch, et al., PAM identification by CRISPR-Cas          effector complexes: diversified mechanisms and          structures, RNA Biology, vol. 16, No. 4,          doi.org/10.1080/15476286.2018.1504546, pp. 504-517, Jul.          20, 2018.;            Kellner, et al., SHERLOCK: Nucleic acid detection with          CRISPR nucleases, Nat Protoc.,          doi:10.1038/s41596-019-0210-2, pp. 2986-3012, Oct.          2019.US11987839-B2            Sha Y et al. Chem Commun (Camb). Jan. 7,          2021;57(2):247-250 (Year: 2021).;            Harrington et al., Science 362, 839-842 (2018) (Year:          2018).;            Schmidt KS et al. Nucleic Acids Res. Oct. 27,          2004;32(19):5757-65 (Year: 2004).;            Gleditzsch D et al. RNA Biol. Apr. 2019; 16(4):504-517          (Year: 2019).;            Yuan et al., Anal. Chem.2020, 92, 4029-4037 (Year:          2020).;            Wang et al., Anal. Chem. 2021, 93, 13373-13381 (Year:          2021).;            Swarts et al., Mol Cell. Feb. 7, 2019; 73(3): 589-600          (Year: 2019).;            Perez-Arnaiz et al., Journal of Molecular Biology, vol.          391, No. 5, pp. 797-807, Sep. 4, 2009 (Year:          2009).;            Mar Alba (Alba M. Replicative DNA polymerases. Genome          Biol. 2001;2(1):REVIEWS3002. (Year: 2001).;            East-Seletsky A, O'Connell MR, Knight SC, Burstein D,          Cate JH, Tjian R, Doudna JA. Two distinct RNase          activities of CRISPR-C2c2 enable guide-RNA processing and          RNA detection. Nature. Oct. 13, 2016;538(7624):270-273.          doi: 10.1038/nature 19802. Epub Sep. 26, 2016. (Year:          2016).;            English translation of WO2014178562 (Year:          2014).;            Leenay RT, Beisel CL. Deciphering, Communicating, and          Engineering the CRISPR PAM. J Mol Biol. Jan. 20,          2017;429(2):177-191 (Year: 2017).;            Li, et al., Applying CRISPR-Cas12a as Signal Amplifier to          Construct Biosensors for Non-DNA Targets in Ultra-low          Concentrations, ACS Sensors, doi:          10.1021/acssensors.9b02305, pp. 1-23, Mar. 12,          2020.;            Kim, et al., Chimeric crRNAs with 19 DNA residues in the          guide region show retained DNA cleavage activity of Cas9          with a potential to improve the specificity, The Royal          Society of Chemistry, pp. 1-16, 2019.;            Kim, et al., Enhancement of target specificity of          CRISPR-Cas12a by using a chimeric DNA-RNA guide, Nucleic          Acids Research, doi: 10.1093/nar/gkaa605, vol. 48, No.          15, pp. 8601-8616, Jul. 20, 2020.;            Swarts, et al., Mechanistic Insights into the Cis- and          Trans-acting Deoxyribonuclease Activities of Cas12a, Mol          Cell, doi: 10.1016/j.molcel.2018.11.021, pp. 1-28, Feb.          7, 2019.;            Nguyen, et al., Enhancement of trans-cleavage activity of          Cas12a with engineered crRNA enables amplified nucleic          acid detection, Nature Communications, doi:          10.1038/s41467-020-18615-1, pp. 1-13, 2020.;            Ooi, et al., An engineered CRISPR-Cas12a variant and          DNA-RNA hybrid guides enable robust and rapid COVID-10          testing, Nature Communications, doi:          10.1038/s41467-021-21996-6, pp. 1-23, 2021.;            Shi, et al., A CRISPR-Cas autocatalysis-driven feedback          amplification network for supersensitive DNA diagnostics,          Science Advances, doi: 10.1126/sciadv.abc7802, pp. 1-9,          Jan. 27, 2021.;            The Board of Trustees of the University of Illinois,          CRISPR Cascade, International PCT Application No.          PCT/US22/33985, filed Jun. 17, 2022.;            Chen, et al., CRISPR-Cas12a target binding unleashes          indiscriminate single-stranded DNase activity, Howard          Hughes Medical Institute, Science, 360(6387), pp.          436-439, Apr. 27, 2018.;            Liu, et al., Accelerated RNA detection using tandem          CRISPR nucleases, Nature Chemical Biology, vol. 17,          doi:10.1038/s41589-021-0084202, pp. 982-988, Sep.          2021.;            Gootenberg, et al., Nucleic acid detection with          CRISPR-Cas13a/C2c2, Science, doi:10.1126/science.aam9321,          pp. 438-442, Apr. 28, 2017.;            Fozouni, et al., Amplification-free detection of          SARS-CoV-2 with CRISPR-Cas13a and mobile phone          microscopy, Cell, doi.org/10.1016/j.cell.2020.12.001, pp.          323-333, Jan. 21, 2021.;            Kaminski, et al., CRISPR-based diagnostics, Nature          Biomedical Engineering, vol. 5,          doi.org/10.1038/s41551-021-00760-7, pp. 643-656, Jul.          2021.;            Zhou, et al., CRISPR/Cas13a Powered Portable          Electrochemiluminescence Chip for Ultrasensitive and          Specific MiRNA Detection, Advanced Science News, doi:          10.1002/advs.201903661, pp. 1-10, 2020.;            Zhao, et al., CRISPR-Cas13a system: A novel tool for          molecular diagnostics, Frontiers in Microbiology,          doi:10.3389/fmicb.2022.1060947, pp. 1-18, Dec. 8,          2022.;            Zhou, et al., A Decade of CRISPR Gene Editing in China          and Beyond: A Scientometric Landscape, The CRISPR          Journal, vol. 4, No. 3, doi:10.1089/crispr.2020.0148, pp.          313-320, 2021.;            Shinoda, et al., Automated amplification-free digital RNA          detection platform for rapid and sensitive SARS-CoV-2          diagnosis, Communications Biology,          doi.org/10.1038/s42003-022-03433-6, pp. 1-8, May 26,          2022.;            Gupta, et al., Cas13d: A New Molecular Scissor for          Transcriptome Engineering, Frontiers in Cell and          Developmental Biology, vol. 10, doi:          10.3389/fcell.2022.866800, pp. 1-22, Mar. 31,          2022.;            Schunder, et al., First indication for a functional          CRISPR/Cas system in Francisella tularensis,          International Journal of Medical Microbiology, vol. 303,          Issue 2, doi:10.1016/j.ijmm.2012.11.004, pp. 1-29, Mar.          2013.;            Sha, et al., Cascade CRISPR/cas enables          amplification-free microRNA sensing with fM-sensitivity          and single-base-specificity, ChemComm,          doi:10.1039/d0cc06412b, pp. 247-250 and 1-15,          2021.;            Yang, et al., Engineered LwaCas13a with enhanced          collateral activity for nucleic acid detection, Nature          Chemical Biology, vol. 19, doi:          10.1038/s41589-022-01135-y, pp. 45-54, Jan.          2023.;            East-Seletsky, et al., RNA targeting by functionally          orthogonal Type VI-A CRISPR-Cas enzymes, Howard Hughes          Medical Institute, Mol Cell, pp. 373-383, May 4,          2017.;            Schmidt, et al., Application of locked nucleic acids to          improve aptamer in vivo stability and targeting function,          Nucleic Acids Research, vol. 32, No. 19,          doi:10.1093/nar/gkh862, pp. 5757-5765, Oct. 27,          2004.;            Makarova, et al., Evolutionary classification of          CRISPR-Cas systems: a burst of class 2 and derived          variants, Nature Reviews | Microbiology, vol. 18, pp.          67-83, Feb. 2020.;            Gleditzsch, et al., PAM identification by CRISPR-Cas          effector complexes: diversified mechanisms and          structures, RNA Biology, vol. 16, No. 4,          doi.org/10.1080/15476286.2018.1504546, pp. 504-517, Jul.          20, 2018.;            Kellner, et al., SHERLOCK: Nucleic acid detection with          CRISPR nucleases, Nat Protoc.,          doi:10.1038/s41596-019-0210-2, pp. 2986-3012, Oct.          2019.;            Liu, et al., Directed Evolution of CRISPR/Cas Systems for          Precise Gene Editing, Trends in Biotechnology, vol. 39,          No. 3, Mar. 2021, p. 262-273.;            International Search Report and Written Opinion for          International Application No. PCT/US2022/036610, dated          Jun. 29, 2023, p. 1-93.;            International Search Report and Written Opinion for          International Application No. PCT/US22/52320, dated Jun.          15, 2023, p. 1-46.;            International Search Report and Written Opinion for          International Application No. PCT/US2022/052032, dated          Apr. 18, 2023, p. 1-19.;            Zhang, et al, An aM-level cascade CRISPR-Dx system          (ASCas) for rapid detection of RNA without          pre-amplification, Biosensors and Bioelectronics,          doi:10.1016/j.bios.2023.115248, Mar. 28, 2023, p.          1-5.;            Zeng, et al., Rapid RNA detection through intra-enzyme          chain replacement-promoted Cas13a cascade cyclic reaction          without amplification, Analytica Chimica Acta,          doi:10.1016/j.aca.2022.340009, May 31, 2022, p.          1-10.;            Collias, et al., CRISPR technologies and the search for          the PAM-free nuclease, Nature Communications, doi:          10.1038/s41467-020-20633-y, 2021, p. 1-12.;            Huyke, et al., Enzyme Kinetics and Detector Sensitivity          Determine Limits of Detection of Amplification-Free          CRISPR-Cas12 and CRISPR-Cas13 Diagnostics, Analytical          Chemistry, doi:10.1021/acs.analchem.2601670, Jun. 27,          2022, p. 9826-9834.;            Mullally, et al., 5 modifications to CRISPR-Cas9 gRNA can          change the dynamics and size of R-loops and inhibit DNA          cleavage, Nucleic Acids Research,          DOI:10.1093/nar/gkaa477, Jun. 2020, vol. 48, No. 12, p.          6811-6823.;            Hong, et al., Comparison and optimization of          CRISPR/dCas9/gRNA genome-labeling systems for live cell          imaging, Genome Biology, DOI: 10.1186/s13059-018-1413-5,          2018, p. 7-8.;            Li, et al., CRISPR-Cas 12a has both cis- and          trans-cleavage activities on single-stranded DNA, Cell          Research, DOI: 10.1038/s41422-018-0022-x, Feb. 5, 2018,          p. 1-3.;            Dong, et al., An anti-CRISPR protein disables type V          Cas12a by acetylation, PubMed,          DOI:10.1038/s41594-019-0206-1, Feb. 28, 2023, p.          1-1.;            Coehlo, et al., CRISPR Guard protects off-target sites          from Cas9 nuclease activity using short guide RNAs,          Nature Communications, DOI: 10.1038/s41467-020-17952-5,          Aug. 17, 2020, p. 1-12.",105730-0-0-0 A N P; 2356798-0-0-0 A N P; 93605-0-0-0 A N P; 2418795-0-0-0 N; 184616-0-0-0 N; 105730-0-0-0 CL DET NEW PRD; 2356798-0-0-0 CL DET NEW PRD; 93605-0-0-0 CL DET NEW PRD; 2418795-0-0-0 CL NEW,,,RA012P A N P; RB8ZO3 A N P; RA00NS A N P; RBAAY7 N; RA00H3 N,
WO2022271743-A1;  EP4359556-A1,"Detecting target microorganism in sample comprises            e.g. contacting filtered mixture with loop mediated            isothermal amplification reagents and primer sets            specific to DNA or RNA of target microorganism, and            amplifying to produce amplicons",CHAKRABORTY S,UNIV JOHNS HOPKINS (UYJO-C);  UNIV JOHNS HOPKINS (UYJO-C),202300728T,"   NOVELTY - Detecting (M1) a target microorganism in a                sample, comprises: (a) obtaining or having obtained                a sample from a subject, where the sample comprises                or is suspected of comprising the target                microorganism; (b) contacting the sample with a                lysis solution to form a mixture; (c) filtering the                mixture of the step (b) through a filter to form a                filtered mixture, where the filtered mixture                comprises DNA or RNA of the target microorganism;                (d) contacting the filtered mixture of the step (c)                with loop mediated isothermal amplification (LAMP)                reagents and at least one primer sets specific to                the DNA or RNA of the target microorganism, where                the LAMP reagents and the primer sets are                lyophilized; (e) amplifying the DNA or RNA of the                target microorganism, thus producing at least one                amplicons; and (f) detecting the presence or                absence of the amplicons, where the presence of at                least one of the amplicons indicates the presence                of the target microorganism.    USE - The method is useful for: detecting a target                microorganism in a sample, where the target                microorganism is a virus or a bacteria, the target                microorganism is E. coli, Shigella spp, Vibrio                cholerae, non-cholera Vibrio spp, Campylobacter                spp, Mycobacterium spp, Salmonella spp, an enteric                virus, a coronavirus, or human papillomavirus, the                E. coli is an enterotoxigenic E. coli, an                enteropathogenic E. coli, an enteroaggregative E.                coli, an enteroinvasive E. coli, an                enterohemorrhagic E. coli, a shiga toxin-producing                E. coli, a verocytotoxin-producing E. coli or a                diffusely adherent E. coli, the enterotoxigenic E.                coli (ETEC) is ETEC H10407, ETEC B7A, ETEC E24377A,                ETEC 335093, ETEC 335140, or ETEC 335152, the                Mycobacterium spp is M. tuberculosis, the                Salmonella spp is S. typhi (preferred) or S.                paratyphi, the enteric virus is norovirus,                sapovirus, astrovirus, rotavirus, or adenovirus,                the coronavirus is severe acute respiratory                syndrome coronavirus 2, the Shigella spp is S.                flexneri, S. sonnei, S. dysenteriae, or S. boydii,                and the sample is a blood, stool, sputum,                oropharyngeal, nasopharyngeal, pap smear, or saliva                sample; detecting pathogenic E. coli in a sample,                where the pathogenic E. coli is ETEC H10407, ETEC                B7A, ETEC E24377A, ETEC 335093, ETEC 335140, or                ETEC 335152, and the sample is a stool sample;                detecting Shigella spp in a sample; and detecting a                Salmonella spp. in a sample, where the sample is a                blood sample or a stool sample (all claimed).    ADVANTAGE - The method: reduces mortality and long-term                growth potential among children infected with                Shigella; and utilizes rapid LAMP based diagnostic                test i.e. a diagnostic assay for ETEC and Shigella,                which is simple, rapid and inexpensive and at the                same time sufficiently sensitive, can be scaled up                and is appropriate to apply in the resource poor                endemic settings, requires minimal equipment, and                results in a user-friendly manner.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1)                detecting (M2) pathogenic Escherichia colin a                sample, comprising (a1) obtaining or having                obtained a sample from a subject, where the sample                comprises or is suspected of comprising the                pathogenic E. coli, the step (b) as per se, (c1)                filtering the mixture of the step (b) through a                filter to form a filtered mixture, where the                filtered mixture comprises DNA or RNA of the                pathogenic E. coli, and (d1) contacting the                filtered mixture of the step (c1) with LAMP                reagents and the primer sets specific to the DNA or                RNA of the pathogenic E. coli, where the LAMP                reagents and the primer sets are lyophilized, (e1)                amplifying DNA or RNA of the pathogenic E. coli,                thus producing the amplicons, and (f1) detecting                the presence or absence of the amplicons, where the                presence of the amplicons indicates the presence of                the pathogenic E. coli; (2) detecting (M3) Shigella                sppin a sample, comprising (a2) obtaining or having                obtained a sample from a subject, where the sample                comprises or is suspected of comprising the                Shigella spp, the step (b) as per se, (c2)                filtering the mixture of the step (b) through a                filter to form a filtered mixture, where the                filtered mixture comprises DNA or RNA of the                Shigella spp, (d2) contacting the filtered mixture                of the step (c2) with LAMP reagents and the primer                sets specific to the DNA or RNA of the Shigella                spp, where the LAMP reagents and the primer sets                are lyophilized, (e2) amplifying DNA or RNA of the                Shigella spp, thus producing the amplicons, and                (f2) detecting the presence or absence of the                amplicons, where the presence of the amplicons                indicates the presence of the Shigella spp; (3)                detecting (M4) a Salmonella spp.in a sample,                comprising (a3) obtaining or having obtained a                sample from a subject, where the sample comprises                or is suspected of comprising the Salmonella spp.,                the step (b) as per se, (c3) filtering the mixture                of the step (b) through a filter to form a filtered                mixture, where the filtered mixture comprises DNA                or RNA of the Salmonella spp., (d3) contacting the                filtered mixture of the step (c3) with LAMP                reagents and the primer sets specific to the DNA or                RNA of the Salmonella typhi, where the LAMP                reagents and the primer sets are lyophilized, (e3)                amplifying DNA or RNA of the Salmonella spp., thus                producing the amplicons, and (f3) detecting the                presence or absence of the amplicons, where the                presence of the amplicons indicates the presence of                the Salmonella typhi; and (4) a kit for detecting a                target microorganism in a sample, comprising a                lysis buffer, a filter, a lyophilized buffer, LAMP                reagents, and the primer sets specific to the DNA                or RNA of the target microorganism, where the LAMP                reagents and the primer sets are lyophilized. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-B04B2;  B04-B04D5;  B04-B04G;  B04-E01;  B04-E05;  B04-E99;  B04-F10;  B11-C08F8;  B11-C08N2A;  B12-K04F;  B12-K04G1C;  D05-H04;  D05-H09;  D05-H18B2;  D05-H99,C12Q-001/6806;  C12Q-001/6844;  C12Q-001/689;  C12R-001/19,WO2022271743-A1   29 Dec 2022   C12Q-001/6806   202305Pages: 143   English;  EP4359556-A1   01 May 2024   C12Q-001/6806   202437   English,WO2022271743-A1    WOUS034399    21 Jun 2022;   EP4359556-A1    EP829183    21 Jun 2022,EP4359556-A1 PCT application Application WOUS034399;   EP4359556-A1 Based on Patent WO2022271743,US212876P    21 Jun 2021,WO2022271743-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP4359556-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN  ,,WO2022271743-A1 -- US20080182312-A1   ;  US20150299774-A1   ;  US20190136295-A1   ,"WO2022271743-A1  AJAMI NADIM J.,          YOUMANS BONNIE P., HIGHLANDER SARAH K., DUPONT HERBERT          L., PETROSINO JOSEPH F., JIANG ZHI-DONG: ""Development and          Accuracy of Quantitative Real-Time Polymerase Chain          Reaction Assays for Detection and Quantification of          Enterotoxigenic Escherichia coli (ETEC) Heat Labile and          Heat Stable Toxin Genes in Travelers' Diarrhea Samples"",          THE AMERICAN SOCIETY OF TROPICAL MEDICINE AND HYGIENE,          vol. 90, no. 1, 8 January 2014 (2014-01-08), US , pages          124 - 132, XP093020945, ISSN: 0002-9637, DOI:          10.4269/ajtmh.13-0383,relevantClaims[38,          39,41,(42,43)/(38,39,41 )],relevantPassages[. Especially          abstract, pg 124 col 1 para 1.];  CHAKRABORTY SUBHRA,          CONNOR SEAN, VELAGIC MIRZA: ""Development of a simple,          rapid, and sensitive diagnostic assay for enterotoxigenic          E. coli and Shigella spp applicable to endemic          countries"", PLOS NEGLECTED TROPICAL DISEASES, vol. 16,          no. 1, 28 January 2022 (2022-01-28), pages 1 - 14,          XP093020949, DOI:          10.1371/journal.pntd.0010180,relevantClaims[1-3,          35-43],relevantPassages[. Especially entire          article.]",,,,,
WO2021206922-A1;  EP4133077-A1;  US2023193284-A1,Double stranded RNA agent used e.g. to inhibit            expression of transmembrane serine protease 2 comprises            sense strand and antisense strand forming double            stranded region and comprising nucleotide sequence that            comprises contiguous nucleotides,AKINC A;  MCININCH J D;  ANGLERO-RODRIGUEZ Y;  SCHLEGEL M K,ALNYLAM PHARM INC (ALNY-C);  ALNYLAM PHARM INC (ALNY-C);  ALNYLAM PHARM INC (ALNY-C),2021B6599R,"   NOVELTY - Double stranded (ds) (A1) RNA (dsRNA) agent                comprises either e.g. a sense strand and an                antisense strand forming a double stranded region,                where the sense strand comprises a nucleotide                sequence comprising at least 15 contiguous                nucleotides, with 0-3 mismatches of a portion of                the nucleotide sequence of SEQ ID NO: 1 (comprising                a fully defined sequence of 3450 nucleotides as                given in the specification), or a nucleotide                sequence having at least 90% nucleotide sequence                identity to a portion of the nucleotide sequence of                SEQ ID NO: 1, and the antisense strand comprises a                nucleotide sequence comprising at least 15                contiguous nucleotides with 0-3 mismatches of the                corresponding portion of the nucleotide sequence of                SEQ ID NO: 6, or a nucleotide sequence having at                least 90% nucleotide sequence identity to a portion                of the nucleotide sequence of SEQ ID NO: 6, where                the sense strand or the antisense strand is                conjugated to at least one lipophilic                moieties.    USE - The dsRNA agent is useful for: inhibiting                expression of TMPRSS2 in a cell, where the cell is                within a subject, and the subject is a human;                inhibiting entry of a coronavirus into a cell;                treating a subject having a coronavirus infection,                a subject at risk of having a coronavirus                infection, or a subject at risk of developing a                coronavirus infection, where the subject having the                coronavirus infection is infected with a severe                acute respiratory syndrome (SARS) virus, a Middle                East respiratory syndrome virus, or a                SARS-2-coronavirus-2 virus; ameliorating at least                on sign or symptom of the disease; treating or                preventing coronavirus-associated disorder (all                claimed); treating or preventing a                TMPRSS2-associated disease e.g. coronavirus                disease-19, in a subject; inhibiting replication of                the coronavirus in the cell; and inhibiting priming                of a coronavirus S protein in a cell. Test details                are described but no results given.    ADVANTAGE - The dsRNA agent: inhibits expression of the                TMPRSS2 gene by at least 50%; results in an                improvement in viral load of lung function, or a                stoppage or reduction of the rate of loss of lung                function, reduction of fever, and reduction of                cough in the subject; reduces side effects related                to high systemic absorption, and increases                accumulation at the desired target; and enables the                targeted degradation of mRNAs of the corresponding                gene (a TMPRSS2 gene) in mammals.    DETAILED DESCRIPTION - Double stranded (ds) (A1) RNA (dsRNA) agent                comprises either a sense strand and an antisense                strand forming a double stranded region, where the                sense strand comprises a nucleotide sequence                comprising at least 15 contiguous nucleotides, with                0-3 mismatches of a portion of the nucleotide                sequence of SEQ ID NO: 1 (comprising a fully                defined sequence of 3450 nucleotides as given in                the specification), or a nucleotide sequence having                at least 90% nucleotide sequence identity to a                portion of the nucleotide sequence of SEQ ID NO: 1,                and the antisense strand comprises a nucleotide                sequence comprising at least 15 contiguous                nucleotides with 0-3 mismatches of the                corresponding portion of the nucleotide sequence of                SEQ ID NO: 6 (comprising a fully defined sequence                of 3450 nucleotides as given in the specification),                or a nucleotide sequence having at least 90%                nucleotide sequence identity to a portion of the                nucleotide sequence of SEQ ID NO: 6, where the                sense strand or the antisense strand is conjugated                to at least one lipophilic moieties, or a sense                strand and an antisense strand forming a double                stranded region, where the antisense strand                comprises a region complementary to part of an mRNA                encoding a transmembrane serine protease 2                (TMPRSS2) gene (a nucleotide sequence of SEQ ID NO:                1), each strand independently is 14-30 nucleotides                in length, and the sense strand or the antisense                strand is conjugated to the lipophilic moieties.                INDEPENDENT CLAIMS are also included for:    (1) double stranded (A2) RNA interference                (RNAi) agent comprising a sense strand and an                antisense strand forming a double stranded region,                where the antisense strand comprises at least 15                contiguous nucleotides differing by not greater                than 3 nucleotides from any one of the antisense                nucleotide sequences as given in any one of tables                2-3 of the specification, each strand independently                is 14-30 nucleotides in length, and the sense                strand or the antisense strand is conjugated to the                lipophilic moieties;    (2) a cell containing the dsRNA agents                (A1)-(A2);    (3) a composition comprising either the dsRNA                agents (A1)-(A2), or the dsRNA agents (A1)-(A2) and                a lipid formulation;    (4) a device for oral inhalative                administration comprising dsRNA agents                (A1)-(A2);    (5) inhibiting (M1) expression of a TMPRSS2                gene in a cell, comprising (a) contacting the cell                with the dsRNA agents (A1)-(A2), or the composition                or the device, and (b) maintaining the cell                produced in the step (a) for a time to obtain                degradation of the TMPRSS2 gene, thus inhibiting                expression of the TMPRSS2 gene in the cell;    (6) inhibiting (M2) entry of a coronavirus                into a cell, comprising the step (a) as per se, and                maintaining the cell produced in the step (a) for a                time to obtain degradation of a TMPRSS2 gene in the                cell, thus inhibiting entry of the coronavirus into                the cell; and    (7) treating (M3) a subject having a                coronavirus infection, a subject at risk of having                a coronavirus infection, or a subject at risk of                developing a coronavirus infection, comprising                administering the dsRNA agents (A1)-(A2), or the                composition or the device to the subject, thus                treating the subject. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B01-D02;  B04-E01B;  B04-E99;  B04-F01;  B10-C04D;  B10-C04E5;  B10-E04A;  B10-E04C;  B10-E04D;  B12-M01B;  B12-M12N;  B14-A02B5;  B14-K01D;  B14-L06;  B14-S03C;  B14-S11A;  B14-S18;  B15-A00;  D05-H99,C12N-015/113;  C12N-015/10,WO2021206922-A1   14 Oct 2021   C12N-015/113   202192Pages: 184   English;  EP4133077-A1   15 Feb 2023   C12N-015/113   202315   English;  US2023193284-A1   22 Jun 2023   C12N-015/113   202352   English,WO2021206922-A1    WOUS024076    25 Mar 2021;   EP4133077-A1    EP719427    25 Mar 2021;   US2023193284-A1    US956884    30 Sep 2022,EP4133077-A1 PCT application Application WOUS024076;   EP4133077-A1 Based on Patent WO2021206922;   US2023193284-A1 Cont of Application WOUS024076;   US2023193284-A1 Provisional Application US006364P;   US2023193284-A1 Provisional Application US050137P,US006364P    07 Apr 2020;  US050137P    10 Jul 2020;  US956884    30 Sep 2022,WO2021206922-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP4133077-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    ,,"WO2021206922-A1 -- WO2004094636-A1   GALAPAGOS GENOMICS NV (APAG);  VAN DER SCHUEREN J (VSCH-Individual)   ARTS G J F,  LAMBRECHT M J Y,  DJOKIC K,  CLASEN R J,  MESIC E,  GRIFFIOEN S,  BERGS C J L;  WO2014005596-A1   UNIV AARHUS (UYUA)   HOWARD K A,  BIENK K,  KRAGH-HANSEN U;  WO2019217459-A1   ALNYLAM PHARM INC (ALNY)   NAIR J K,  MAIER M,  JADHAV V,  MILSTEIN S,  BROWN K,  PARMAR R G,  RAJEEV K G,  MANOHARAN M,  KELIN A V,  JAYARAMAN M,  CHARISSE K,  CASTORENO A,  THEILE C S,  FITZGERALD K;  WO2020069055-A1   ALNYLAM PHARM INC (ALNY)   NAIR J K,  MAIER M A,  JADHAV V R,  KEATING M,  FITZGERALD K,  MILSTEIN S,  BROWN K;  WO2010039548-A2   ALNYLAM PHARM INC (ALNY)   MANOHARAN M,  RAJEEV K G,  YAMADA T,  BUTLER D,  JAYAPRAKASH K N,  JAYRAMAN M,  MATSUDA S,  PANDEY R K,  PENG C G;  US513030-A   ;  US564562-A   ;  US3687808-A   LELAND STANFORD JUNIOR UN (LEL-Non-standard);  US4469863-A   TSO P O P (TSOP-Individual)   TSO P O P,  MILLER P S;  US4476301-A   CNRS CENT NAT RECH SCI (CNRS)   IMBACH J L,  GOSSELIN G J M;  US4587044-A   UNIV JOHNS HOPKINS (UYJO)   MILLER P S,  TSO P O P;  US4605735-A   WAKUNAGA SEIYAKU KK (WAKT)   MIYOSHI K,  SUZUKI M,  FUWA T;  US4667025-A   WAKUNAGA SEIYAKU KK (WAKT)   MIYOSHI K,  FUWA T;  US4683202-A   CETUS CORP (CETU)   MULLIS K B,  ARNHEIM N,  SAIKI R K,  ERLICH H A,  HORN G T,  SCHARF S J;  US4762779-A   AMGEN (AMGE)   SNITMAN D L;  US4789737-A   WAKUNAGA SEIYAKU KK (WAKT)   MIYOSHI K,  FUWA T;  US4824941-A   GORDON J (GORD-Individual)   GORDON J,  MINKS M A;  US4828979-A   LIFE TECHNOL INC (LIFE-Non-standard)   KLEVAN L,  GEBEYEHU G,  RAO P;  US4835263-A   CNRS CENT NAT RECH SCI (CNRS)   NGUYEN T T,  HELENE C;  US4837028-A   LIPOSOME TECHNOLOGY INC (LIPO-Non-standard);  LINEAR TECHNOLOGY CORP (LIRT)   ALLEN T M,  GABIZON A;  US4845205-A   INST PASTEUR (INSP);  CNRS CENT NAT RECH SCI (CNRS)   DINH T H,  IGOLEN J,  GOYETTE C;  US4876335-A   WAKUANGA SEIYAKU KK (WAKU-Non-standard)   YAMANE A,  KAWASOE T,  TSUKUMO N,  MIYOSHI K;  US4897355-A   SYNTEX (USA) (SYNT)   EPPSTEIN D A,  FELGNER P L,  GADEK T R,  JONES G H,  ROMAN R B;  US4904582-A   SYNTHETIC GENETICS (SYNT-Non-standard)   TULLIS R H;  US4948882-A   SYNGENE INC (SYNG-Non-standard)   RUTH J L;  US4958013-A   UNIV NORTHWESTERN (NOUN)   LETSINGER R L;  US4981957-A   CNRS CENT NAT RECH SCI (CNRS)   LEBLEU B,  BAYARD B;  US5023243-A   MOLECULAR BIOSYSTEMS INC (ACEP)   TULLIS R H;  US5034506-A   ANTIVIRALS INC (ANTI-Non-standard)   SUMMERTON J E,  WELLER D D;  US5082830-A   ENZO BIOCHEM INC (ENZO)   BRAKEL C L,  COOK A F,  VUOCOLO E;  US5109124-A   BIOGEN INC (BIOJ)   RAMACHANDR K,  CATE R L;  US5112963-A   MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN (PLAC)   PIELES U,  ENGLISCH U,  CRAMER F;  US5118800-A   CALIFORNIA INST OF TECHN (CALY)   SMITH L M,  FUNG S,  KAISER R J;  US5118802-A   CALIFORNIA INST OF TECHN (CALY)   SMITH L M,  FUNG S,  KAISER R J;  US5134066-A   MONSANTO CO (MONS)   ROGERS E,  DEVADAS B,  GRAY S H,  ADAMS S P;  US5138045-A   ISIS PHARMA INC (ISSP)   COOK P D,  GUINOSSO C J;  US5166315-A   ANTI GENE DEV GROUP (ANTI-Non-standard)   SUMMERTON J E,  WELLER D D;  US5171678-A   CNRS CENT NAT RECH SCI (CNRS)   BEHR J P,  LOEFFLER J P;  US5175273-A   GENENTECH INC (GETH)   BISCHOFBERGER N W,  MATTEUCCI M D;  US5177195-A   IMPERIAL CHEM IND PLC (ICIL);  ZENECA LTD (ZENE)   GREGORY P,  MISTRY P M;  US5185444-A   ANTIVIRALS INC (ANTI-Non-standard)   SUMMERTON J E,  WELLER D D;  US5188897-A   UNIV TEMPLE (UTEM)   SUHADOLNIK R J,  PFLEIDERER W;  US5214134-A   STERLING DRUG INC (STER)   WEIS A L,  HAUSHEER F H;  US5214136-A   GILEAD SCI INC (GILE)   LIN K Y,  MATTEUCCI M;  US5216141-A   BENNER S A (BENN-Individual);  BENNES MARREL SA (BENN)   BENNER S A;  US5218105-A   ISIS PHARMA INC (ISSP)   COOK P D,  GUINOSSO C J;  US5235033-A   ANTI GENE DEV GROUP (ANTI-Non-standard)   SUMMERTON J E,  WELLER D D,  STIRCHAK E P;  US5245022-A   STERLING DRUG INC (STER)   WEIS A L,  HAUSHEER F H,  CHATURVEDU P V C,  DELECKI D J,  CAVANAUGH P F,  MOSKWA P S,  OAKES F T;  US5254469-A   EASTMAN KODAK CO (EAST)   WARREN H C,  OAKES F T;  US5258506-A   CHIRON CORP (CHIR)   URDEA M S,  HORN T;  US5262536-A   DU PONT DE NEMOURS & CO E I (DUPO)   HOBBS F W;  US5264423-A   US DEPT HEALTH & HUMAN SERVICE (USSH);  US SEC OF COMMERCE (USDC)   COHEN J S,  NECKERS L,  STEIN C,  LOKE S L,  SHINOZUKA K;  US5264564-A   GILEAD SCI INC (GILE)   MATTEUCCI M;  US5272250-A   SOOD A (SOOD-Individual);  SPIELVOGEL B F (SPIE-Individual)   SPIELVOGEL B F,  SOOD A;  US5276019-A   US DEPT HEALTH & HUMAN SERVICE (USSH);  US SEC OF COMMERCE (USDC)   COHEN J S,  NECKERS L,  STEIN C,  LOKE S L,  SHINOZUKA K;  US5278302-A   UNIVERSITY PATENTS INC (UYPA);  COMPETITIVE TECHNOLOGIES INC (COMP-Non-standard);  US5283185-A   UNIV TENNESSEE RES CORP (TEEE)   EPAND R M,  BOTTEGA R,  HUANG L;  US5286717-A   US DEPT HEALTH & HUMAN SERVICES (USSH)   SHINOZUKA K,  STEIN C,  LOKE S L,  COHEN J S,  NECKERS L;  US5292873-A   UNIV NEW YORK STATE RES FOUND (UNYS)   ROKITA S E,  CHATTERJEE M;  US5317098-A   MILLAR S L (MILL-Individual);  SHIZUYA H (SHIZ-Individual)   SHIZUYA H,  MILLAR S L;  US5319080-A   CIBA GEIGY AG (CIBA);  NOVARTIS AG (NOVS)   LEUMANN C;  US5321131-A   WORCESTER FOUND EXPERIMENTAL BIOLOGY (WORC-Non-standard)   AGRAWAL S,  TANG J;  US5359044-A   CIBA GEIGY UK LTD (CIBA);  ISIS PHARM INC (ISSP)   COOK P D,  BASCHANG G;  US5367066-A   CHIRON CORP (CHIR)   URDEA M S,  HORN T;  US5371241-A   PHARMACIA P-L BIOCHEMICALS INC (PHAA)   BRUSH C K;  US5391723-A   NEORX CORP (NEOR)   PRIEST J H;  US5393878-A   CIBA GEIGY AG (CIBA);  NOVARTIS AG (NOVS)   LEUMANN C;  US5399676-A   GILEAD SCI INC (GILE)   FROEHLER B,  TOOLE J J;  US5405938-A   ANTIVIRALS INC (ANTI-Non-standard)   SUMMERTON J E,  WELLER D D;  US5405939-A   UNIV TEMPLE (UTEM)   SUHADOLNIK R J,  PFLEIDERER W;  US5414077-A   GILEAD SCI INC (GILE)   LIN K Y,  MATTEUCCI M;  US5416203-A   UNIV NORTHWESTERN (NOUN)   LETSINGER R L;  US5432272-A   BENNER S A (BENN-Individual)   BENNER S A;  US5434257-A   GILEAD SCI INC (GILE)   MATTEUCCI M D,  CAO X;  US5445934-A   AFFYMAX TECHNOLOGIES NV (GLAX)   PIRRUNG M C,  READ J L,  FODOR S P,  STRYER L;  US5446137-A   SYNTEX USA INC (SYNT)   SCHMIDT B,  MAAG H,  ROSE S J;  US5451463-A   CLONTECH LAB INC (TAKI)   KENT M A,  NELSON P S;  US5453496-A   UNIVERSITY PATENTS INC (UYPA);  COMPETITIVE TECHNOLOGIES INC (COMP-Non-standard);  US5455233-A   SPIELVOGEL B F (SPIE-Individual)   SPIELVOGEL B F,  SOOD A,  HALL I H,  SHAW B R;  US5457187-A   UNIV NEBRASKA (UNEB)   IVERSEN P L,  GMEINER W H;  US5459255-A   ISIS PHARM INC (ISSP)   COOK P D,  RAMASAMY K S,  MANOHARAN M;  US5466677-A   CIBA GEIGY AG (CIBA);  NOVARTIS AG (NOVS)   BAXTER A D,  BAYLIS E K,  COLLINGWOOD S P,  TAYLOR R J,  DE MESMAEKER A,  SCHMIT C;  US5466786-A   GILEAD SCI INC (GILE)   BUHR C A,  MATTEUCCI M;  US5470967-A   DU PONT DE NEMOURS & CO E I (DUPO)   HUIE E M,  TRAINOR G L;  US5476925-A   UNIV NORTHWESTERN (NOUN)   GRYAZNOV S M,  LETSINGER R L;  US5484908-A   GILEAD SCI INC (GILE)   FROEHLER B,  WAGNER R,  MATTEUCCI M,  JONES R J,  GUTIERREZ A J,  PUDLO J;  US5486603-A   GILEAD SCI INC (GILE)   BUHR C A;  US5489677-A   ISIS PHARM INC (ISSP)   SANGHVI Y S,  COOK P D;  US5502177-A   GILEAD SCI INC (GILE)   MATTEUCCI M D,  JONES R J,  LIN K;  US5510475-A   HYBRIDON INC (HYBR)   AGRAWAL S,  TANG J;  US5512439-A   DYNAL AS (DYNA-Non-standard);  HORNES E (HORN-Individual)   HORNES E,  KORSNES L;  US5512667-A   MICROPROBE CORP (MICR-Non-standard)   REED M W,  MEYER R B,  PETRIE C R,  TABONE J C;  US5514785-A   MICROPROBE CORP (MICR-Non-standard)   VANNESS J,  TABONE J C,  PETRIE C E,  VERMEULEN N;  US5519126-A   UNIV VIRGINIA (UYVI-Non-standard)   HECHT S M;  US5519134-A   ISIS PHARM INC (ISSP)   ACEVEDO O L,  HEBERT N;  US5525465-A   FLOREY INST EXPERIMENTAL PHYSIOLOGY (FLOR-Non-standard)   HARALAMBIDIS J,  TREGEAR G W;  US5525711-A   US DEPT HEALTH & HUMAN SERVICES (USSH)   HAWKINS M E,  PFLEIDERER W,  DAVIS M D,  BALIS F;  US5536821-A   WORCESTER FOUND BIOMEDICAL RES (WORC-Non-standard)   TANG J,  AGRAWAL S;  US5539082-A   NIELSEN P E (NIEL-Individual);  BUCHARDT O (BUCH-Individual);  EGHOLM M (EGHO-Individual);  BERG R H (BERG-Individual)   NIELSEN P E,  BUCHARDT O,  EGHOLM M,  BERG R H;  US5541307-A   ISIS PHARM INC (ISSP)   COCK P D,  SANGHVI Y S,  MORVAN F;  US5541313-A   MOLECULAR BIOSYSTEMS INC (ACEP)   RUTH J L;  US5541316-A   HENKEL KGAA (HENK)   ENGELSKIRCHEN K,  FISCHER H,  VERHOLT H;  US5543152-A   INEX PHARM CORP (INEX-Non-standard)   WEBB M S,  BALLY M B,  MAYER L D,  MILLER J M,  TARDI P G;  US5545730-A   CHIRON CORP (CHIR)   URDEA M S,  HORN T;  US5550111-A   UNIV TEMPLE (UTEM)   SUHADOLNIK R J,  PFLEIDERER W;  US5552538-A   CHIRON CORP (CHIR)   URDEA M S,  HORN T;  US5552540-A   FLOREY INST EXPER (FLOR-Non-standard)   HARALAMBID J;  US5561225-A   SOUTHERN RES INST (SOUR)   MONTGOMERY J A,  CROOKS P A,  SECRIST J A,  MADDRY J A,  REYNOLDS R C;  US5563253-A   WORCESTER FOUND BIOMEDICAL RES (WORC-Non-standard)   TANG J,  AGRAWAL S;  US5565552-A   UNIV TEXAS SYSTEM (TEXA);  PHARMACYCLICS INC (ABBO)   SESSLER J L,  IVERSON B L,  SANSOM P I,  CROFTS S P,  MAGDA D;  US5567810-A   STERLING DRUG INC (STER)   WEIS A L,  HAUSHEER F H,  CHATURVEDU P V C,  DELECKI D J,  CAVANAUGH P F,  MOSKWA P S,  OAKES F T;  US5567811-A   AMERSHAM INT PLC (AMSH)   MISIURA K;  US5571799-A   BASCO LTD (BASC-Non-standard)   TKACHUK Z,  KVASYUK E,  MATSUKA G,  MIKHAILOPULO I;  US5574142-A   MICROPROBE CORP (MICR-Non-standard)   MEYER R B,  GALL A A,  REED M W;  US5576427-A   STERLING WINTHROP INC (STER)   COOK P D,  DELECKI D J,  GUINOSSO C;  US5578717-A   CHIRON CORP (CHIR)   URDEA M S,  HORN T;  US5578718-A   ISIS PHARM INC (ISSP)   MANOHARAN M,  COOK P D;  US5580731-A   CHIRON CORP (CHIR)   CHANG C,  URDEA M S,  HORN T;  US5585481-A   GEN-PROBE INC (HOGC)   BHATT R S,  REYNOLDS M A,  ARNOLD L J;  US5587361-A   ISIS PHARM INC (ISSP)   COOK P D,  HOKE G;  US5587371-A   PHARMACYCLICS INC (ABBO);  UNIV TX SYSTEMS (TEXA)   HEMMI G W,  MAGDA D,  KRAL V A,  SESSLER J L,  MODY T D;  US5587469-A   ISIS PHARM INC (ISSP)   COOK P D,  RAMASAMY K S,  MANOHARAN M;  US5591584-A   CHIRON CORP (CHIR)   CHANG C,  URDEA M S,  HORN T;  US5591722-A   SOUTHERN RES INST (SOUR)   SECRIST J A,  MONTGOMERY J A;  US5594121-A   GILEAD SCI INC (GILE)   FROEHLER B,  MATTEUCCI M;  US5595726-A   UNIV TX SYSTEMS (TEXA);  PHARMACYCLICS INC (ABBO)   SESSLER J L,  IVERSON B,  MAGDA D;  US5596086-A   GILEAD SCI INC (GILE)   MUNGER J,  JONES R J,  MATTEUCCI M;  US5596091-A   UNIV CALIFORNIA (REGC)   SWITZER C;  US5597696-A   BECTON DICKINSON CO (BECT)   LINN C,  PITNER J B,  MIZE P D;  US5597909-A   CHIRON CORP (CHIR)   URDEA M S,  HORN T;  US5599923-A   UNIV TEXAS SYSTEM (TEXA);  PHARMACYCLICS INC (ABBO)   SESSLER J L,  MODY T D,  HEMMI G W;  US5599928-A   UNIV TEXAS SYSTEM (TEXA);  PHARMACYCLICS INC (ABBO)   MODY T D,  HEMMI G W,  SESSLER J L;  US5602240-A   ISIS PHARM INC (ISSP);  CIBA GEIGY AG (CIBA)   DE MESMAEKER A,  LEBRETON J,  WALDNER A,  COOK P D;  US5608046-A   ISIS PHARM INC (ISSP)   COOK P D,  TENG K;  US5610289-A   ISIS PHARM INC (ISSP)   COOK P D,  SANGHVI YS,  VASSEUR J,  DEBART F;  US5610300-A   CIBA GEIGY AG (CIBA);  NOVARTIS AG (NOVS)   ALTMANN K,  IMWINKELRIED R,  ESCHENMOSER A;  US5614617-A   ISIS PHARM INC (ISSP)   COOK P D,  SANGHVI Y S;  US5618704-A   ISIS PHARM INC (ISSP)   SANGHVI Y S,  COOK P D;  US5623070-A   ISIS PHARM INC (ISSP)   COOK P D,  SANGHVI Y S;  US5625050-A   AMGEN INC (AMGE)   BEATON G,  FISHER E F;  US5627053-A   RIBOZYME PHARM INC (ALNY)   BEIGELMAN L,  STINCHCOMB D T,  JARVIS T,  DRAPER K,  PAVCO P,  MCSWIGGEN J,  GUSTOFSON J,  USMAN N,  WINCOTT F,  MATULIC-ADAMIC J,  KARPEISKY A,  THOMPSON J D,  MODAK A,  BURGIN A;  US5633360-A   GILEAD SCI INC (GILE)   BUHR C,  LIN K,  KENT K,  BISCHOFBERGER N,  WAGNER R;  US5639873-A   CENT NAT RECH SCI (CNRS)   BARASCUT J,  IMBACH J;  US5646265-A   ISIS PHARM INC (ISSP)   MCGEE D P C;  US5658873-A   DEGUSSA AG (DEGS)   BERTSCH-FRANK B,  KLASEN C,  LIESER T,  MUELLER K,  BEWERSDORF M;  US5663312-A   STERLING WINTHROP INC (STER)   CHATURVEDULA P V C;  US5670633-A   ISIS PHARM INC (ISSP)   COOK P D,  KAWASAKI A M;  US5677195-A   AFFYMAX TECHNOLOGIES NV (GLAX)   MODLIN D N,  ALDWIN L,  BUCHKO C J,  FODOR S P A,  WINKLER J L,  ROSS D A;  US5677437-A   ISIS PHARM INC (ISSP)   TENG K,  SANGHVI Y S,  COOK P D;  US5677439-A   STERLING DRUG INC (STER)   WEIS A L,  HAUSHEER F H,  CHATURVEDU P V C,  DELECKI D J,  CAVANAUGH P F,  MOSKWA P S,  OAKES F T;  US5681941-A   ISIS PHARM INC (ISSP)   COOK P D,  MANOHARAN M,  RAMASAMY K S;  US5688941-A   ISIS PHARM INC (ISSP)   TENG K,  COOK P D;  US5700920-A   CIBA GEIGY AG (CIBA);  NOVARTIS AG (NOVS)   ALTMANN K,  IMWINKELRIED R,  ESCHENMOSER A;  US5705188-A   NIPPON SHINYAKU CO LTD (NNSH)   YANO J,  OHGI T;  US5714331-A   BUCHARDT O (BUCH-Individual);  EGHOLM M (EGHO-Individual);  NIELSEN P E (NIEL-Individual);  BERG R H (BERG-Individual)   BUCHARDT O,  EGHOLM M,  NIELSEN P E,  BERG R H;  US5719262-A   BUCHARDT D (BUCH-Individual);  ISIS PHARM INC (ISSP)   NIELSEN P,  EGHOLM M,  BERG R H,  BUCHARDT O;  US5744305-A   AFFYMETRIX INC (AFFY)   PIRRUNG M C,  READ J L,  FODOR S P,  STRYER L;  US5750692-A   ISIS PHARM INC (ISSP)   ACEVEDO O L,  ANDREWS R S,  COOK P D;  US5770722-A   AFFYMAX TECHNOLOGIES NV (GLAX)   LOCKHART D J,  CHEE M S,  VETTER D,  DIGGELMANN M;  US5854033-A   UNIV YALE (UYYA)   LIZARDI P M,  CAPLAN M;  US5874219-A   AFFYMETRIX INC (AFFY)   TRULSON M,  FODOR S P,  RAVA R P;  US5976567-A   INEX PHARM CORP (INEX-Non-standard)   SCHERRER P,  CULLIS P R,  HOPE M,  REIMER D L,  BALLY M B,  WHEELER J J,  ZHANG Y;  US5981501-A   INEX PHARM CORP (INEX-Non-standard)   WHEELER J J,  HOPE M,  CULLIS P R,  BALLY M B;  US6015886-A   CHEMGENES CORP (CHEM-Non-standard);  OLIGOS ETC INC (OLIG-Non-standard)   DALE R M K,  ARROW A,  RAZA S K,  SRIVASTAVA S C;  US6028188-A   GENTA INC (GENT-Non-standard)   HOGREFE R I,  ARNOLD L J,  RILEY T A,  SCHWARTZ D A,  VAGHEFI M M,  BROWN B D,  REYNOLDS M A;  US6054299-A   CONRAD C A (CONR-Individual)   CONRAD C A;  US6124445-A   ISIS PHARM INC (ISSP)   RAYNER B,  MANOHARAN M,  GOSSELIN G,  IMBACH J;  US6147200-A   ISIS PHARM INC (ISSP)   MANOHARAN M,  COOK P D,  FRASER A S,  PRAKASH T P,  KAWASAKI A M;  US6160109-A   ISIS PHARM INC (ISSP)   JUST G,  XIN Z,  MARSAULT E,  JIN Y,  WANG J,  MANOHARAN M;  US6166197-A   ISIS PHARM INC (ISSP)   COOK P D,  SANGHVI Y S,  SPRANKLE K G,  ROSS B S,  GRIFFEY R H,  SPRINGER R H;  US20030027780-A1   ;  US20040171570-A1   ;  US20080039618-A1   ;  US20090012281-A1   ;  US20100324120-A1   ;  US20110313020-A1   ;  US20120157511-A1   ;  US20130011922-A1   ;  US20130096289-A1   ;  US20130190383-A1   ;  US6169170-B1   LYNX THERAPEUTICS INC (LYNX-Non-standard)   GRYAZNOV S M,  SCHULTZ R G,  CHEN J;  US6172209-B1   ISIS PHARM INC (ISSP)   COOK P D,  MANOHARAN M,  KAWASAKI A M;  US6191105-B1   PROTEIN DELIVERY INC (PROT-Non-standard)   EKWURIBE N N,  RAMASWAMY M,  RADHAKRISHNAN B,  ALLAUDEEN H S;  US6222025-B1   ISIS PHARM INC (ISSP)   COOK P D,  SANGHVI Y S,  SPRANKLE K G,  ROSS B S,  GRIFFEY R H,  SPRINGER R H;  US6235887-B1   GILEAD SCI INC (GILE)   FROEHLER B,  WAGNER R,  MATTEUCCI M,  JONES R J,  GUTIERREZ A J,  PUDLO J;  US6239265-B1   ISIS PHARM INC (ISSP)   COOK P D;  US6268490-B1   IMANISHI T (IMAN-Individual)   IMANISHI T,  OBIKA S;  US6277603-B1   ISIS PHARM INC (ISSP)   COOK P D;  US6294664-B1   ISIS PHARM INC (ISSP)   RAVIKUMAR V,  COLE D L;  US6320017-B1   INEX PHARM CORP (INEX-Non-standard)   ANSELL S M;  US6326199-B1   ISIS PHARM INC (ISSP)   COOK P D;  US6346614-B1   WORCESTER FOUND EXPERIMENTAL BIOLOGY (WORC-Non-standard)   METELEV V,  AGRAWAL S;  US6380368-B1   ISIS PHARM INC (ISSP)   FROEHLER B,  WAGNER R,  MATTENCCI M,  JONES R J,  GUTIERREZ A J,  PUDLO J;  US6444423-B1   MOLECULAR DYNAMICS INC (GENE)   MEADE T J,  WELCH T W;  US6525191-B1   RAMASAMY K S (RAMA-Individual)   RAMASAMY K S;  US6528640-B1   RIBOZYME PHARM INC (ALNY)   MCSWIGGEN J,  USMAN N,  BLATT L,  BEIGELMAN L,  BURGIN A,  KARPEISKY A,  MATULIC-ADAMIC J,  SWEEDLER D,  DRAPER K,  CHOWRIRA B,  STINCHCOMB D,  BEAUDRY A,  ZINNEN S,  LUGWIG J,  SPROAT B S;  US6531590-B1   ISIS PHARM INC (ISSP)   MANOHARAN M,  GUSAEV A;  US6534484-B1   INEX PHARM CORP (INEX-Non-standard)   WHEELER J J,  BALLY M B,  ZHANG Y,  REIMER D L,  HOPE M,  CULLIS P R,  SCHERRER P;  US6534639-B1   ISIS PHARM INC (ISSP)   MANOHARAN M,  COOK P D,  PRAKASH T P,  MOHAN V;  US6576752-B1   ISIS PHARM INC (ISSP)   COOK P D,  MANOHARAN M,  KAWASAKI A M;  US6586410-B1   INEX PHARM CORP (INEX-Non-standard)   WHEELER J J,  BALLY M B,  ZHANG Y,  REIMER D L,  HOPE M,  CULLIS P R,  SCHERRER P;  US6608035-B1   HYBRIDON INC (HYBR)   AGRAWAL S,  DIASIO R B,  ZHANG R;  US6617438-B1   RIBOZYME PHARM INC (ALNY)   MCSWIGGEN J,  USMAN N,  BLATT L,  BEIGELMAN L,  BURGIN A,  KARPEISKY A,  MATULIC-ADAMIC J,  SWEEDLER D,  DRAPER K,  CHOWRIRA B,  STINCHCOMB D,  BEAUDRY A,  ZINNEN S,  LUGWIG J,  SPROAT B S;  US6670461-B1   EXIQON AS (EXIQ-Non-standard)   WENGEL J,  NIELSEN P;  US6783931-B1   ISIS PHARM INC (ISSP)   MANOHARAN M,  COOK P D,  BENNETT C F;  US6867294-B1   ISIS PHARM INC (ISSP)   SANGHVI Y S,  MANOHARAN M;  US6887906-B1   ISIS PHARM INC (ISSP)   TENG C,  HARDEE G;  US6900297-B1   ISIS PHARM INC (ISSP)   COOK P D,  MANOHARAN M,  GUINOSSO C J;  US7015315-B1   ISIS PHARM INC (ISSP)   ECKER D J,  COOK P D,  MONIA B P,  FREIER S M,  SANGHVI Y S;  US7037646-B1   ISIS PHARM INC (ISSP)   COOK P D,  MANOHARAN M,  GUINOSSO C J;  US7070802-B1   PLIVA INC (PLIV)   BHALANI V T,  PATEL S P;  US7273933-B1   ISIS PHARM INC (ISSP)   KROTZ A H,  RAVIKUMAR V T;  US7495088-B1   ENZO BIOCHEM INC (ENZO)   BRAKEL C L,  WETMUR J G,  QUARTIN R S;  US7569686-B1   ISIS PHARM INC (ISSP)   ALLERSON C,  BHAT B,  MIGAWA M T,  PRAKASH T P,  SETH P P,  SWAYZE E E,  VASQUEZ G,  XIA J;  US6639062-B2   ISIS PHARM INC (ISSP)   COOK P D,  MANOHARAN M,  KAWASAKI A M;  US6683167-B2   WORCESTER FOUND EXPERIMENTAL BIOLOGY (WORC-Non-standard)   METELEV V,  AGRAWAL S;  US6747014-B2   TENG C (TENG-Individual);  COOK P D (COOK-Individual);  TILLMAN L (TILL-Individual);  HARDEE G E (HARD-Individual);  ECKER D J (ECKE-Individual);  MANOHARAN M (MANO-Individual)   TENG C,  COOK P D,  TILLMAN L,  HARDEE G E,  ECKER D J,  MANOHARAN M;  US6770748-B2   IMANISHI T (IMAN-Individual)   IMANISHI T,  OBIKA S;  US6794499-B2   EXIQON AS (EXIQ-Non-standard)   WENGEL J,  NIELSEN P;  US6815432-B2   INEX PHARM CORP (INEX-Non-standard)   WHEELER J J,  BALLY M B,  ZHANG Y,  REIMER D L,  HOPE M,  CULLIS P R,  SCHERRER P;  US6858225-B2   SEMPLE S C (SEMP-Individual);  KLIMUK S K (KLIM-Individual);  HARASYM T (HARA-Individual);  HOPE M J (HOPE-Individual);  ANSELL S M (ANSE-Individual);  CULLIS P (CULL-Individual);  SCHERRER P (SCHE-Individual);  DEBEYER D (DEBE-Individual)   SEMPLE S C,  KLIMUK S K,  HARASYM T,  HOPE M J,  ANSELL S M,  CULLIS P,  SCHERRER P,  DEBEYER D;  US6858715-B2   ISIS PHARM INC (ISSP)   RAVIKUMAR V T,  MANOHARAN M,  CAPALDI D C,  KROTZ A,  COLE D L,  GUZAEV A;  US6878805-B2   ISIS PHARM INC (ISSP)   MANOHARAN M,  MAIER M;  US6998484-B2   CUREON AS (CURE-Non-standard)   KOCH T,  JENSEN F R;  US7034133-B2   EXIQON AS (EXIQ-Non-standard)   WENGEL J,  NIELSEN P;  US7041816-B2   ISIS PHARM INC (ISSP)   RAVIKUMAR V T,  MANOHARAN M,  CAPALDI D C,  KROTZ A,  COLE D L,  GUZAEV A;  US7045610-B2   EPOCH BIOSCIENCES INC (EPOC-Non-standard)   DEMPCY R O,  GALL A A,  LOKHOV S G,  AFONINA I A,  SINGER M J,  KUTYAVIN I V,  VERMEULEN N M J;  US7053207-B2   EXIQON AS (EXIQ-Non-standard)   WENGEL J;  US7063860-B2   UNIV PITTSBURGH (UPIT)   CHANCELLOR M B,  FRASER M O,  CHUANG Y,  DE GROAT W C,  HUANG L,  YOSHIMURA N;  US7084125-B2   EXIQON AS (EXIQ-Non-standard)   WENGEL J;  US7157099-B2   ITALFARMACO SPA (ITAF)   AUTUORI F,  BIANCHINI C,  BOTTONI G,  LEONI F,  MASCAGNI P,  MONZANI W,  PICCOLO O;  US7321029-B2   GERON CORP (GERN)   GRYAZNOV S,  SCHULTZ R G;  US7399845-B2   ISIS PHARM INC (ISSP)   SWAYZE E E,  SETH P P;  US7427605-B2   CALANDO PHARM INC (CALA-Non-standard)   DAVIS M E,  HEIDEL J D,  ROOSI J J;  US7427672-B2   IMANISHI T (IMAN-Individual)   IMANISHI T,  OBIKA S,  MIYASHITA K;  US7741457-B2   ISIS PHARM INC (ISSP)   BHANOT S,  GEARY R S,  MCKAY R,  MONIA B P,  SETH P P,  SIWKOWSKI A M,  SWAYZE E E,  WANCEWICZ E;  US7858769-B2   SIRNA THERAPEUTICS INC (ALNY)   JADHAV V,  ZINNEN S;  US8022193-B2   ISIS PHARM INC (ISSP)   BHANOT S,  GEARY R S,  MCKAY R,  MONIA B P,  SETH P P,  SIWKOWSKI A M,  SWAYZE E E,  WANCEWICZ E;  US8030467-B2   ISIS PHARM INC (ISSP)   BHANOT S,  GEARY R S,  MCKAY R,  MONIA B P,  SETH P P,  SIWKOWSKI A M,  SWAYZE E E,  WANCEWICZ E;  US8058069-B2   PROTIVA BIOTHERAPEUTICS INC (PRTO)   MACLACHLAN I,  JUDGE A;  US8101348-B2   MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN (PLAC)   TUSCHL T,  MARTINEZ J,  PATKANIOWSKA A,  URLAUB H,  LUEHRMANN R;  US8106022-B2   ALNYLAM PHARM INC (ALNY)   MANOHARAN M,  RAJEEV K G,  NARAYANANNAIR J K,  MAIER M;  US8158601-B2   ALNYLAM PHARM INC (ALNY);  AKINC A (AKIN-Individual);  DORKIN J R (DORK-Individual);  QIN X (QINX-Individual);  CANTLEY W (CANT-Individual);  MANOHARAN M (MANO-Individual);  RAJEEV K G (RAJE-Individual);  NARAYANANNAIR J K (NARA-Individual);  JAYARAMAN M (JAYA-Individual)   CHEN J,  ANSELL S,  AKINC A,  DORKIN J R,  QIN X,  CANTLEY W,  MANOHARAN M,  RAJEEV K G,  NARAYANANNAIR J K,  JAYARAMAN M;  US8278283-B2   ISIS PHARM INC (ISSP)   SWAYZE E E,  SETH P P;  US8278425-B2   ISIS PHARM INC (ISSP)   PRAKASH T P,  SWAYZE E E,  BHAT B;  US8278426-B2   ISIS PHARM INC (ISSP)   SETH P P,  SWAYZE E E;  US8314227-B2   NASTECH PHARM CO INC (NASE)   WENGEL J;  US39464-E   ISIS PHARM INC (ISSP)   COOK P D,  MANOHARAN M;  WO1988004924-A   ;  WO1991016024-A   ;  WO1994000569-A1   ;  WO1994002595-A1   ;  WO1996037194-A1   ;  WO1997013499-A1   ;  WO1998039359-A1   ;  WO2000022113-A1   ;  WO2000022114-A1   ;  WO2009127060-A1   PROTIVA BIOTHERAPEUTICS INC (PRTO)   LAM K,  MACLACHLAN I,  YAWORSKI E;  WO2010011895-A1   ALNYLAM PHARM INC (ALNY)   MAIER M,  ADDEPALLI H,  MANOHARAN M;  WO2010054406-A1   ALNYLAM PHARM INC (ALNY)   MANOHARAN M,  RAJEEV K G,  BUTLER D,  NARAYANANNAIR J K,  JAYARAMAN M,  ELTEPU L;  WO2010129709-A1   ALNYLAM PHARM INC (ALNY);  MANOHARAN M (MANO-Individual);  RAJEEV K G (RAJE-Individual);  JAYARAMAN M (JAYA-Individual);  BUTLER D (BUTL-Individual);  JUNG M E (JUNG-Individual)   MANOHARAN M,  RAJEEV K G,  JAYARAMAN M,  BUTLER D,  JUNG M E;  WO2011005861-A1   ALNYLAM PHARM INC (ALNY)   MANOHARAN M,  RAJEEV K G;  WO2011031520-A1   IDERA PHARM INC (HYBR)   AGRAWAL S,  KANDIMALLA E,  PUTTA M,  LAN T,  BHAGAT L,  WANG D,  YU D;  WO2012177906-A1   ALNYLAM PHARM INC (ALNY)   SAH D,  BUMCROT D,  SEHGAL A;  WO2013036868-A1   MARINA BIOTECH INC (MARI-Non-standard)   MATRAY T J,  MACIAGIEWICZ I M,  HOUSTON M E;  WO2013075035-A1   ALNYLAM PHARM INC (ALNY)   RAJEEV K G,  ZIMMERMANN T,  MANOHARAN M,  MAIER M,  KUCHIMANCHI S,  CHARISSE K;  WO2014179620-A1   ISIS PHARM INC (ISSP)   THAZHA P P,  PUNIT P S,  ERIC E S;  WO2019055633-A1   ARROWHEAD PHARM INC (AROW)   LI Z,  ZHU R,  WONG S;  WO1993024640-A2   ;  WO1996040964-A2   ;  WO1997030731-A2   ;  WO1999014226-A2   ;  WO2000003683-A2   ;  WO2007091269-A2   QUARK PHARM INC (QUPH)   AYGUN H,  FEINSTEIN E;  WO2007117686-A2   IDERA PHARM INC (HYBR)   KANDIMALLA E R,  LAN T,  LI Y,  YU D,  WANG D,  PUTTA M R,  AGRAWAL S;  WO2008042973-A2   ALNYLAM PHARM INC (ALNY)   MANOHARAN M,  RAJEEV K G,  AKINC A,  JAYAPRAKASH K N,  JAYRAMAN M,  MAIER M A;  WO2009014887-A2   IDERA PHARM INC (HYBR)   KANDIMALLA E R,  LAN T,  WANG D,  BHAGAT L,  AGRAWAL S;  WO2010088537-A2   ALNYLAM PHARM INC (ALNY)   AKINC A,  QUERBES W,  WONG F,  DORKIN J R,  QIN X,  CANTLEY W,  BORODOVSKY A,  DE S,  MANOHARAN M,  JAYARAMAN M,  RAJEEV K G;  WO2010141511-A2   HALO-BIO RNAI THERAPEUTICS INC (HALO-Non-standard)   HAUSER T M;  WO2011133876-A2   ALNYLAM PHARM INC (ALNY)   MANOHARAN M,  RAJEEV K G,  LACKEY J,  JAYAPRAKASH N K;  WO2014179627-A2   ISIS PHARM INC (ISSP)   PRAKASH T P,  SETH P P,  SWAYZE E E","WO2021206922-A1  M. KAWASE ET AL:          ""Simultaneous Treatment of Human Bronchial Epithelial          Cells with Serine and Cysteine Protease Inhibitors          Prevents Severe Acute Respiratory Syndrome Coronavirus          Entry"", JOURNAL OF VIROLOGY, vol. 86, no. 12, 11 April          2012 (2012-04-11), US, pages 6537 - 6545, XP055731965,          ISSN: 0022-538X, DOI:          10.1128/JVI.00094-12,relevantClaims[1-95|1-72,86-88],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;&lt;figure&gt;2,          3,          9&lt;/figure&gt;|&lt;pp&gt;W&lt;/pp&gt;];  SHEN LI WEN ET AL:          ""TMPRSS2: A potential target for treatment of influenza          virus and coronavirus infections"", BIOCHIMIE, vol. 142, 1          August 2017 (2017-08-01), pages 1 - 10, XP085244550,          ISSN: 0300-9084, DOI:          10.1016/J.BIOCHI.2017.07.016,relevantClaims[1-95|1-72,86-88],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  HOFFMANN MARKUS ET          AL: ""SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2          and Is Blocked by a Clinically Proven Protease          Inhibitor"", CELL, ELSEVIER, AMSTERDAM NL, vol. 181, no.          2, 5 March 2020 (2020-03-05), pages 271, XP086136225,          ISSN: 0092-8674, [retrieved on 20200305], DOI:          10.1016/J.CELL.2020.02.052,relevantClaims[1-95|1-72,86-88],relevantPassages[&lt;figure&gt;1,          3,          4&lt;/figure&gt;|&lt;pp&gt;W&lt;/pp&gt;];  S. BERTRAM ET AL:          ""TMPRSS2 and TMPRSS4 Facilitate Trypsin-Independent          Spread of Influenza Virus in Caco-2 Cells"", JOURNAL OF          VIROLOGY, vol. 84, no. 19, 14 July 2010 (2010-07-14), US,          pages 10016 - 10025, XP055231346, ISSN: 0022-538X, DOI:          10.1128/JVI.00239-10,relevantClaims[1-81|1-72],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;&lt;figure&gt;5&lt;/figure&gt;|&lt;pp&gt;W&lt;/pp&gt;];  MATSUYAMA SHUTOKU          ET AL: ""Enhanced isolation of SARS-CoV-2 by          TMPRSS2-expressing cells"", PROCEEDINGS OF THE NATIONAL          ACADEMY OF SCIENCES, vol. 117, no. 13, 31 March 2020          (2020-03-31), US, pages 7001 - 7003, XP055813015, ISSN:          0027-8424, DOI:          10.1073/pnas.2002589117,relevantClaims[1-95],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  NAOKO          IWATA-YOSHIKAWA ET AL: ""TMPRSS2 Contributes to Virus          Spread and Immunopathology in the Airways of Murine          Models after Coronavirus Infection."", JOURNAL OF          VIROLOGY, vol. 93, no. 6, 9 January 2019 (2019-01-09),          US, XP055731958, ISSN: 0022-538X, DOI:          10.1128/JVI.01815-18,relevantClaims[1-95],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  LI          W ET AL., NATURE, vol. 426, 2003, pages 450 -          454;            GLOWACKA I. ET AL., J. VIROL., vol. 85, 2011, pages 4122          - 4134;            MATSUYAMA S. ET AL., J. VIROL., vol. 84, 2010, pages          12658 - 12664;  LI          F ET AL., SCIENCE, vol. 309, 2005, pages 1864 -          1868;  LI          W. ET AL., EMBO J., vol. 24, 2005, pages 1634 -          1643;            HOFFMANN M., CELL, vol. 181, 2020, pages 1 - 10;            ZUMLA A. ET AL., NATURE REVIEWS DRUG DISCOVERY, vol. 15,          no. 5, 2016, pages 327 - 47;            CHENG V.C. ET AL., CLIN. MICROBIAL. REV., vol. 20, 2007,          pages 660 - 694;            CHAN J.F. ET AL., CLIN. MICROBIAL. REV., vol. 28, 2015,          pages 465 - 522;            GROOT, R.J. ET AL., J. VIROL., vol. 87, 2013, pages 7790          - 7792;            LEE N. ET AL., N. ENGL. J. MED., vol. 348, 2003, pages          1986 - 1994;            PEIRIS J. S. ET AL., LANCET, vol. 36, 2003, pages 1319 -          1325;            PEIRIS JS. ET AL., NAT. MED., vol. 10, 2003, pages 88 -          97;            ""GenBank"", Database accession no.          XM_005548643.2;            ELBASHIR ET AL., GENES DEV, vol. 15, 2001, pages          188;            BERNSTEIN ET AL., NATURE, vol. 409, 2001, pages          363;            NYKANEN ET AL., CELL, vol. 107, 2001, pages 309;            LIMA ET AL., CELL, vol. 150, 2012, pages 883 -          894;            DIAS, N. ET AL., MOL CANCER THER, vol. 1, 2002, pages 347          - 355;            TETKO ET AL., J. CHEM. INF. COMPUT. SCI., vol. 41, 2001,          pages 1407 - 21;            KETTING ET AL., GENES DEV, vol. 15, no. 20, 15 October          2001 (2001-10-15), pages 2654 - 9;            HAMMOND, SCIENCE, vol. 293, no. 5532, 10 August 2001          (2001-08-10), pages 1146 - 50;            ELBASHIR ET AL., EMBO J., vol. 20, 2001, pages 6877 -          6888;            CHURANA, RNA, vol. 14, 2007, pages 1714 - 1719;            KIM ET AL., NAT BIOTECH, vol. 23, 2005, pages 222 -          226;            NIELSEN ET AL., SCIENCE, vol. 254, 1991, pages 1497 -          1500;            MARTIN ET AL., HELV. CHIM. ACTA, vol. 78, 1995, pages 486          - 504;            NUC. ACIDS SYMP. SERIES, vol. 52, 2008, pages 133 -          134;            KABANOV ET AL., FEBS LETT., vol. 259, 1990, pages 327 -          330;            ENGLISCH ET AL., ANGEWANDTE CHEMIE, INTERNATIONAL          EDITION, vol. 30, 1991, pages 613;            MANOHARAN ET AL., BIORG. MED. CHEM. LET., vol. 3, 1993,          pages 2765 - 2770;            ELMEN, J. ET AL., NUCLEIC ACIDS RESEARCH, vol. 33, no. 1,          2005, pages 439 - 447;            MOOK, OR. ET AL., MOL CANE THER, vol. 6, no. 3, 2007,          pages 833 - 843;            GRUNWELLER, A. ET AL., NUCLEIC ACIDS RESEARCH, vol. 31,          no. 12, 2003, pages 3185 - 3193;            CHATTOPADHYAYA ET AL., J. ORG. CHEM., vol. 74, 2009,          pages 118 - 134;            FLUITER ET AL., MOL. BIOSYST., vol. 10, 2009, pages          1039;            MIKHAILOV, TETRAHEDRON LETTERS, vol. 26, no. 17, 1985,          pages 2059;            LETSINGER ET AL., PROC. NATL. ACID. SCI. USA, vol. 86,          1989, pages 6553 - 6556;            MANOHARAN ET AL., BIORG. MED. CHEM. LET., vol. 4, 1994,          pages 1053 - 1060;            MANOHARAN ET AL., ANN. N.Y. ACAD. SCI., vol. 660, 1992,          pages 306 - 309;            OBERHAUSER ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages          533 - 538;            SAISON-BEHMOARAS ET AL., EMBO J, vol. 10, 1991, pages          1111 - 1118;            SVINARCHUK ET AL., BIOCHIMIE, vol. 75, 1993, pages 49 -          54;            MANOHARAN ET AL., TETRAHEDRON LETT., vol. 36, 1995, pages          3651 - 3654;            SHEA ET AL., NUCL. ACIDS RES., vol. 18, 1990, pages 3777          - 3783;            MANOHARAN ET AL., NUCLEOSIDES & NUCLEOTIDES, vol. 14,          1995, pages 969 - 973;            MISHRA ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1264, 1995,          pages 229 - 237;            CROOKE ET AL., J. PHARMACOL. EXP. THER., vol. 277, 1996,          pages 923 - 937;            LAM ET AL., NATURE, vol. 354, 1991, pages 82 -          84;            ZITZMANN ET AL., CANCER RES., vol. 62, 2002, pages 5139 -          43;            AOKI ET AL., CANCER GENE THERAPY, vol. 8, 2001, pages 783          - 787;            HAUBNER ET AL., JOUR. NUCL. MED., vol. 42, 2001, pages          326 - 336;            SIMEONI ET AL., NUCL. ACIDS RES., vol. 31, 2003, pages          2717 - 2724;            KUBO, T. ET AL., BIOCHEM. BIOPHYS. RES. COMM., vol. 365,          no. 1, 2007, pages 54 - 61;            LETSINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86,          1989, pages 1173 - 1177;            MANOHARAN ET AL., BIOORG. MED. CHEM. LETT., vol. 4, 1994,          pages 1053;            MANOHARAN ET AL., BIOORG. MED. CHEM. LET., vol. 3, 1993,          pages 2765;            SAISON-BEHMOARAS ET AL., EMBO J., vol. 10, 1991, pages          111;            AKHTAR S.JULIAN RL., TRENDS CELL. BIOL., vol. 2, no. 5,          1992, pages 139 - 144;            TOLENTINO, MJ. ET AL., RETINA, vol. 24, 2004, pages 132 -          138;            REICH, SJ. ET AL., MOL. VIS., vol. 9, 2003, pages 210 -          216;            PILLE, J. ET AL., MOL. THER., vol. 11, 2005, pages 267 -          274;            HOWARD, KA. ET AL., MOL. THER., vol. 14, 2006, pages 476          - 484;            LI, S. ET AL., MOL. THER., vol. 15, 2007, pages 515 -          523;            DORN, G. ET AL., NUCLEIC ACIDS, vol. 32, 2004, pages          e49;            TAN, PH ET AL., GENE THER, vol. 12, 2005, pages 59 -          66;            MAKIMURA, H., BMC NEUROSCI, vol. 3, 2002, pages          18;            SHISHKINA, GT. ET AL., NEUROSCIENCE, vol. 129, 2004,          pages 521 - 528;            THAKKER, ER. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol.          101, 2004, pages 17270 - 17275;            AKANEYA,Y. ET AL., J. NEUROPHYSIOL., vol. 93, 2005, pages          594 - 602;            ZHANG, X. ET AL., J. BIOL. CHEM., vol. 279, 2004, pages          10677 - 10684;            BITKO, V. ET AL., NAT. MED., vol. 11, 2005, pages 50 -          55;            SOUTSCHEK, J. ET AL., NATURE, vol. 432, 2004, pages 173 -          178;            MCNAMARA, JO. ET AL., NAT. BIOTECHNOL., vol. 24, 2006,          pages 1005 - 1015;            KIM SH. ET AL., JOURNAL OF CONTROLLED RELEASE, vol. 129,          no. 2, 2008, pages 107 - 116;            SORENSEN, DR. ET AL., J. MOL. BIOL, vol. 327, 2003, pages          761 - 766;            VERMA, UN. ET AL., CLIN. CANCER RES., vol. 9, 2003, pages          1291 - 1300;            ARNOLD, AS ET AL., J. HYPERTENS., vol. 25, 2007, pages          197 - 205;            ZIMMERMANN, TS. ET AL., NATURE, vol. 441, 2006, pages 111          - 114;            CHIEN, PY. ET AL., CANCER GENE THER, vol. 12, 2005, pages          321 - 328;            PAL, A. ET AL., INT J. ONCOL., vol. 26, 2005, pages 1087          - 1091;            BONNET ME. ET AL., PHARM. RES., 2008;            AIGNER, A., J. BIOMED. BIOTECHNOL., 2006, pages          71659;            LIU, S., MOL. PHARM., vol. 3, 2006, pages 472 -          487;            TOMALIA, DA. ET AL., BIOCHEM. SOC. TRANS., vol. 35, 2007,          pages 61 - 67;            YOO, H. ET AL., PHARM. RES., vol. 16, 1999, pages 1799 -          1804;            COUTURE, A ET AL., TIG, vol. 12, 1996, pages 5 -          10;            GASSMANN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 92,          1995, pages 1292;            FELGNER, P. L. ET AL., PROC. NATL. ACAD. SCI. USA, vol.          84, 1987, pages 7851 - 7855;            BANGHAM ET AL., M. MOL. BIOL., vol. 23, 1965, pages          238;            OLSON ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 557, 1979,          pages 9;            SZOKA ET AL., PROC. NATL. ACAD. SCI., vol. 75, 1978,          pages 4194;            MAYHEW ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 775, 1984,          pages 169;            KIM ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 728, 1983, pages          339;            FUKUNAGA ET AL., ENDOCRINOL, vol. 115, 1984, pages          757;            MAYER ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 858, 1986,          pages 161;            WANG ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 147,          1987, pages 980 - 985;            ZHOU ET AL., JOURNAL OF CONTROLLED RELEASE, vol. 19,          1992, pages 269 - 274;            FELGNER, J. BIOL. CHEM., vol. 269, 1994, pages          2550;            NABEL, PROC. NATL. ACAD. SCI., vol. 90, 1993, pages          11307;            NABEL, HUMAN GENE THER, vol. 3, 1992, pages 649;            GERSHON, BIOCHEM., vol. 32, 1993, pages 7143;            STRAUSS, EMBO J., vol. 11, 1992, pages 417;  HU          ET AL., S.T.P.PHARMA. SCI., vol. 4, no. 6, 1994, pages          466;            ALLEN ET AL., FEBS LETTERS, vol. 223, 1987, pages          42;  WU          ET AL., CANCER RESEARCH, vol. 53, 1993, pages          3765;            PAPAHADJOPOULOS ET AL., ANN. N.Y. ACAD. SCI., vol. 507,          1987, pages 64;            GABIZON ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 85,          1988, pages 6949;            TAKAHASHI ET AL., J. PHARM. PHARMACOL., vol. 40, 1988,          pages 252;            GAO, X.HUANG, L., BIOCHIM. BIOPHYS. RES. COMMUN., vol.          179, 1991, pages 280;            ZHOU, X. ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1065, 1991,          pages 8;            WEINER ET AL., JOURNAL OF DRUG TARGETING, vol. 2, 1992,          pages 405 - 410;            PLESSIS ET AL., ANTIVIRAL RESEARCH, vol. 18, 1992, pages          259 - 265;            MANNINO, R. J.FOULD-FOGERITE, S., BIOTECHNIQUES, vol. 6,          1998, pages 682 - 690;            ITANI, T. ET AL., GENE, vol. 56, 1987, pages 267 -          276;            NICOLAU, C. ET AL., METH. ENZYMOL., vol. 149, 1987, pages          157 - 176;            STRAUBINGER, R. M.PAPAHADJOPOULOS, D., METH. ENZYMOL.,          vol. 101, 1983, pages 512 - 527;            ALLEN, LV.POPOVICH NG.ANSEL HC.: ""Ansel's Pharmaceutical          Dosage Forms and Drug Delivery Systems"", 2004, LIPPINCOTT          WILLIAMS & WILKINS;            YAMASHITA ET AL., J. PHARM. SCI., vol. 79, 1990, pages          579 - 583;            LEUNGSHAH: ""Controlled Release of Drugs: Polymers and          Aggregate Systems"", 1989, VCH PUBLISHERS, pages: 185 -          215;            CONSTANTINIDES ET AL., PHARMACEUTICAL RESEARCH, vol. 11,          1994, pages 1385 - 1390;            RITSCHEL, METH. FIND. EXP. CLIN. PHARMACOL., vol. 13,          1993, pages 205;  HO          ET AL., J. PHARM. SCI., vol. 85, 1996, pages 138 -          143;            LEE ET AL., CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER          SYSTEMS, 1991, pages 92;            MALMSTEN, M.: ""Surfactants and polymers in drug          delivery"", 2002, INFORMA HEALTH CARE;            KATDARE, A. ET AL.: ""Excipient development for          pharmaceutical, biotechnology, and drug delivery"", 2006,          CRC PRESS;            MURANISHI, CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER          SYSTEMS, vol. 7, 1990, pages 1 - 33;  EL          HARIRI ET AL., J. PHARM. PHARMACOL., vol. 44, 1992, pages          651 - 654;            BRUNTON ET AL.: ""Goodman & Gilman's The          Pharmacological Basis of Therapeutics"", 1996,          MCGRAW-HILL, pages: 934 - 935;            YAMAMOTO ET AL., J. PHARM. EXP. THER., vol. 263, 1992,          pages 25;            JARRETT, J. CHROMATOGR., vol. 618, 1993, pages 315 -          339;            BUUR ET AL., J. CONTROL REL., vol. 14, 1990, pages 43 -          51;            YAMASHITA ET AL., J. PHARM. PHARMACOL., vol. 39, 1987,          pages 621 - 626;            BARANY, PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages          189 - 193;            GUATELLI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87,          1990, pages 1874 - 1878;            LIZARDI ET AL., BIOLTECHNOLOGY, vol. 6, 1988, pages          1197;            ""NCBI"", Database accession no. NM_005656.4",8349-1-0-0 K M; 4210-1-0-0 K M; 52941-1-0-0 K M; 10897-1-0-0 K M; 3222-0-0-0 K M; 7117-0-0-0 K M; 84325-1-0-0 K M;  K M; 192157-0-0-0 K M; 1191267-0-0-0 K M; 113133-0-0-0 K M; 85158-0-0-0 K M; 813-0-0-0 K M; 4336-3-0-0 K M; 1191267-0-0-0 CL USE,,03624; 05262,R00148 K M; R00486 K M; R01322 K M; RA620O K M; R01211 K M; R10826 K M; R00121 K M; R01356 K M; RA006H K M; RC031J K M; R22657 K M; RAK9N2 K M; R03912 K M; RA35EK K M; R01300 K M; R01307 K M,0148-S; 0486-S; 1322-S; 1211-S; 0121-S; 1356-S; 1300-S; 1307-S
WO2023081959-A1;  AU2022387275-A1,New immunotherapeutic protein comprising            immunoglobulin heavy chain polypeptide comprising            fragment crystallizable region component comprising            constant heavy chain domain 3 or 4 used to treat            disease e.g. infectious diseases,HOGARTH P M;  WINES B D,MACFARLANE BURNET INST MEDICAL RES & PUB (MACF-Non-standard);  MACFARLANE BURNET INST MEDICAL RES & PUB (MACF-Non-standard),202352489R,"   NOVELTY - Immunotherapeutic protein comprising at least                one immunoglobulin heavy chain polypeptide                comprising fragment crystallizable (Fc) region                component comprising at least a constant heavy                chain domain 3 (CH3) domain or at least a constant                heavy domain 4 (CH4) domain, is new, where the                polypeptide includes an amino acid substitution at                a position corresponding to His429 of the amino                acid sequence of human immunoglobulin (Ig)G1 heavy                chain (Eu numbering).    USE - The immunotherapeutic protein is useful for                treating or preventing a disease or condition in a                subject, where the disease or condition is                autoimmune diseases and conditions, other                inflammatory diseases, infectious diseases and                proliferative diseases (claimed), where                proliferative disease is breast cancers, acute                lymphoblastic leukemia, chronic lymphocytic                leukemia, adenocarcinoma, lymphomas, multiple                myeloma and X-linked proliferative disease,                infectious disease is coronavirus disease-19,                emerging viral infections, and parasitic infections                i.e. infections by drug-resistant malaria,                autoimmune disease is systemic lupus erythematosus                and type 1 diabetes, and the subject is mammal,                preferably human.    ADVANTAGE - None given.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    treating or preventing (M1) a disease or                condition, comprising administering                immunotherapeutic protein to the subject, where the                disease or condition is selected from autoimmune                diseases and conditions, other inflammatory                diseases, infectious and proliferative                diseases;    composition or medicament comprising the                immunotherapeutic protein and a carrier, diluent                and/or excipient, where the pH of the composition                or medicament is mildly acidic;    composition or medicament comprising a mixture                of at least two different immunotherapeutic                proteins, and a carrier, diluent and/or                excipient;    a kit of parts comprising the                immunotherapeutic protein; and    producing the immunotherapeutic protein. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E99;  B04-G01;  B04-G27G0E;  B05-A01B;  B05-C07;  B11-C04;  B14-A01;  B14-A02;  B14-A03B;  B14-A04;  B14-B02;  B14-C03;  B14-G02D;  B14-H01;  B14-N17;  B14-S04;  D05-H17A6;  D05-H99,C07K-016/46;  C07K-019/00;  C12N-009/48,WO2023081959-A1   19 May 2023   C07K-016/46   202343Pages: 207   English;  AU2022387275-A1   06 Jun 2024   C07K-016/46   202447   English,WO2023081959-A1    WOAU051287    26 Oct 2022;   AU2022387275-A1    AU387275    26 Oct 2022,AU2022387275-A1 PCT application Application WOAU051287;   AU2022387275-A1 Based on Patent WO2023081959,AU903609    11 Nov 2021;  AU901632    15 Jun 2022,WO2023081959-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,"WO2023081959-A1 -- US10457737-B2   RES DEV FOUND (RESD)   GEORGIOU G,  LEE C","WO2023081959-A1  BAE HAE-DUCK,          KOBAYASHI MISATO, HORIO FUMIHIKO, MURAI ATSUSHI:          ""Identification of the amino acid residues involved in          human IgG transport into egg yolks of Japanese quail          (Coturnix japonica)"", MOLECULAR IMMUNOLOGY, PERGAMON, GB,          vol. 47, no. 7-8, 1 April 2010 (2010-04-01), GB , pages          1404 - 1410, XP093067651, ISSN: 0161-5890, DOI:          10.1016/j.molimm.2010.02.011,relevantClaims[1-2, 4-6,          62],relevantPassages[Abstract; Materials and Methods          2.3-2.4];  PETERSON CAROL,          MALONE CHRISTINE C., WILLIAMS RALPH C.:          ""Rheumatoid-factor-reactive sites on CH 3 established by          overlapping 7-mer peptide epitope analysis"", MOLECULAR          IMMUNOLOGY, PERGAMON, GB, vol. 32, no. 1, 1 January 1995          (1995-01-01), GB , pages 57 - 75, XP093067652, ISSN:          0161-5890, DOI:          10.1016/0161-5890(94)00122-H,relevantClaims[1, 3-4,          62],relevantPassages[Abstract; Table 3; page 60, column          2, paragraph 3]",184616-0-0-0 M N; 114-0-0-0 K M; 184616-0-0-0 CL NEW USE,,,RA00H3 M N; R01706 K M,1706-S
WO2020236626-A1;  US2022233756-A1,"System for removing microbes from biological fluid            of subject, comprises filter cartridge comprising beads            with complement receptor, and tubing line for            conducting the biological fluid from subject to filter            cartridge",HERZLINGER G A;  HERZLINGER R E,HERZLINGER G A (HERZ-Individual);  HERZLINGER R E (HERZ-Individual);  HERZLINGER R E (HERZ-Individual);  HERZLINGER G A (HERZ-Individual),2020B63370,"   NOVELTY - System (10) for removing microbes from a                biological fluid of a subject, comprises at least                one filter cartridge (22) comprising beads with at                least one complement receptor attached to it or                otherwise associated with it; and at least one                tubing line for conducting the biological fluid                from the subject to the filter cartridge (e.g. and                back to the subject).    USE - The systems and methods are useful for                removing microbes from a biological fluid of a                subject; for treating a biological fluid of a                subject having a microbial disease (e.g., infection                or other disease caused by a pathogenic organism,                e.g., virus, bacteria, fungus, or protozoa); and                for treating a biological fluid of a subject having                a microbial infection (all claimed).    ADVANTAGE - The system enhances attachment of the                complement receptors to at least one pathogen in                the biological fluid; and enhances the killing of                the infectious microbes.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:    (1) a bead for use in a system for removing                microbes from a biological fluid of a subject, the                bead having at least one complement receptor                attached to it or otherwise associated with                it;    (2) system for treating a biological fluid of                a subject having a microbial disease (e.g.,                infection or other disease caused by a pathogenic                organism, e.g., virus, bacteria, fungus, or                protozoa), comprising a pump (16,18); a tubing line                fluidly connected to the pump; and a treatment                filter, where the pump conducts the biological                fluid from the subject to the treatment filter                (e.g. back to the subject), and where the treatment                filter comprises a high surface area polymer having                a substance immobilized thereupon or associated                with it, the substance comprising one or more                complement receptors;    (3) a filter cartridge for use in a system for                removing microbes from a biological fluid of a                subject, comprising at least one bead comprising at                least one complement receptor;    (4) treating a biological fluid of a subject                having a microbial disease (e.g. extracorporeal                treatment), which involves contacting the                biological fluid of the subject with a high surface                area polymer having a substance immobilized upon it                or associated with it, the substance comprising one                or more complement receptors;    (5) operating the system which involves                conducting a flow of the biological fluid over the                surface of the high surface area polymer in the                treatment filter, where the polymer activates or                enhances activation of the complement receptors,                thus enhancing the in the biological fluid                attachment of the complement receptors onto at                least one pathogen in the biological fluid;    (6) removing microbes from a biological fluid                of a subject, which involves contacting the                biological fluid of the subject with particles                (and/or fibers or other substrate) associated with                a complement receptor, where the particles (and/or                fibers or other substrate) bind microbes in the                biological fluid; and    (7) treating a biological fluid of a subject                having a microbial infection, which involves                introducing a dialysate to a peritoneal cavity of                the subject, where the dialysate comprises at least                one complement receptor, such that the dialysate is                in contact with the biological fluid; and removing                the dialysate from the biological fluid after                sufficient time to opsonize a pathogen. ",,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  C02 (Heterocyclic.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.);  P34 (Sterilising, syringes, electrotherapy (A61L, M, N).)",B01-D02;  B02-C04;  B02-D;  B02-R;  B02-T;  B02-V01;  B04-C01;  B04-C03;  B06-A03;  B07-H;  B10-D03;  B14-A01;  B14-A02;  B14-A04;  B14-B02;  B14-S18;  C01-D02;  C02-C04;  C02-D;  C02-R;  C02-T;  C02-V01;  C04-C01;  C04-C03;  C06-A03;  C07-H;  C10-D03;  C14-A01;  C14-A02;  C14-A04;  C14-B02;  C14-S18;  D05-A03;  A04-E02E;  A04-E08;  A04-F06E5;  A04-G02E3;  A05-F01E3;  A05-H02;  A05-J10;  A11-C07;  A12-V;  A12-V01;  A12-V03D;  A12-W11A;  P34-A02,A61K-039/395;  A61K-045/00;  A61M-001/10;  A61M-001/16;  A61M-001/28;  A61M-001/30;  A61M-001/34;  A61M-001/36;  B01D-069/08;  B01D-071/06,WO2020236626-A1   26 Nov 2020   A61K-039/395   202001Pages: 84   English;  US2022233756-A1   28 Jul 2022   A61M-001/36   202261   English,WO2020236626-A1    WOUS033210    15 May 2020;   US2022233756-A1    US17611784    16 Nov 2021,US2022233756-A1 PCT application Application WOUS033210;   US2022233756-A1 Provisional Application US879338P;   US2022233756-A1 Provisional Application US849683P;   US2022233756-A1 Provisional Application US947480P,US849683P    17 May 2019;  US879338P    26 Jul 2019;  US947480P    12 Dec 2019;  US17611784    16 Nov 2021,WO2020236626-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,WO2020236626-A1 -- US20090162356-A1   ;  US20100217181-A1   ;  US20110045049-A1   ;  US20120071413-A1   ;  US20130129728-A1   ;  US20160084835-A1   ;  US20170189601-A1   ,"WO2020236626-A1  FELIX POPPELAARS,          BERNARDO FARIA, MARIANA GAYA DA COSTA, CASPER F. M.          FRANSSEN, WILLEM J. VAN SON, STEFAN P. BERGER, MOHAMED R.          DA: ""The Complement System in Dialysis: A Forgotten          Story?"", FRONTIERS IN IMMUNOLOGY, vol. 9, 25 January 2018          (2018-01-25), pages 71, XP055761612, DOI:          10.3389/fimmu.2018.00071,relevantClaims[1-3, 5-7, 9-11,          14-16,18-21, 37-39, 52, 53, 58,59, 61-65, 71-73,          87-89,91,92],relevantPassages[. entire          document]",104432-0-0-0 K M; 199377-0-0-0 K M; 104427-0-0-0 K M; 104494-0-0-0 K M; 104333-0-0-0 K M; 104471-0-0-0 K M; 485515-1-0-0 K M; 92282-1-0-0 K M; 107855-1-0-0 K M; 140848-1-0-0 K M; 121198-1-0-0 K M; 108017-0-0-0 K M; 157515-1-0-0 K M; 1102303-1-0-0 K M; 125266-1-0-0 K M; 802558-1-0-0 K M; 101388-1-0-0 K M; 197336-1-0-0 K M; 218237-1-2-0 K M; 197337-1-0-0 K M; 142657-1-0-0 K M; 110025-1-0-0 K M; 105654-1-0-0 K M; 20152-0-0-0 K M; 1013955-0-0-0 K M; 90706-1-0-0 K M; 95757-1-0-0 K M; 1145-0-0-0 ; 7200-0-0-0 ; 1013-0-0-0 ; 621-0-0-0 ; 7447-0-0-0 ; 1102303-1-0-0 CL USE; 1013955-0-0-0 CL USE,,60980; 51845; 51846; 00061; 00012; 56380; 00088; 40201,RA01SI K M; RA06UF K M; RA01KR K M; RA01EC K M; R00975 K M; RA009X K M; RA5WJ2 K M; RA1I1U K M; RA0LZ1 K M; R06200 K M; RA0AEM K M; R01445 K M; RABNKP K M; RAIEFO K M; RA2WIU K M; RAEAHJ K M; RA088M K M; RA6CTI K M; RB8QTK K M; RACKSU K M; R01382 K M; R04258 K M; R07487 K M; R01446 K M; R90317 K M; R00112 K M; R08376 K M; R00964 ; R00479 ; R00326 ; R00338 ; R00009 ,0975-S; 1445-S; 1382-S; 1446-S; 0112-S
WO2022235546-A1,"Lung model apparatus used to provide human            alveolar lung model, comprises elastic hydrogel            disposed within a housing, comprising many sacs, and a            pressure chamber disposed within the housing and            adjacent to the hydrogel",ZHANG Y S,BRIGHAM & WOMENS HOSPITAL INC (BGHM-C),2022E07211,"   NOVELTY - Lung model apparatus comprises: an elastic                hydrogel disposed within a housing, where the                hydrogel comprising of sacs; and a pressure chamber                disposed within the housing and adjacent to the                hydrogel, where the pressure chamber coupled to the                hydrogel such that changes in pressure within the                pressure chamber cause deformation of the                hydrogel.    USE - The apparatus is useful for providing a human                alveolar lung model (claimed).    ADVANTAGE - The apparatus is economical.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for                making a lung model, comprising disposing many                beads into an opening in a housing, pouring a                hydrogel-precursor into the opening of the housing                within an interstitial space of the beads,                crosslinking the hydrogel-precursor to produce a                hydrogel, and dissolving the beads to produce an                elastic hydrogel structure comprising many                sacs. ",,,"A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",A03-A00A;  A10-E17B;  A12-V03D;  B04-C02D;  B04-N02;  B11-C15;  D05-H,C12M-003/00;  C12N-005/00;  C12N-005/22,WO2022235546-A1   10 Nov 2022   C12M-003/00   202295Pages: 81   English,WO2022235546-A1    WOUS027234    02 May 2022,,US183033P    02 May 2021,WO2022235546-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2022235546-A1 -- US20200347359-A1   ;  US20210062129-A1   ;  US10087422-B2   HARVARD COLLEGE (HARD)   INGBER D E,  PARKER K K,  HAMILTON G A,  BAHINSKI A;  WO2020073043-A1   UNIV PENNSYLVANIA (UPEN);  HUH D (HUHD-Individual);  GEORGESCU A (GEOR-Individual)   HUH D,  GEORGESCU A",,86923-0-0-0 K M; 95972-0-0-0 K M; 133925-0-0-0 ,,,RA04J1 K M; R24033 K M; R01866 ,
WO2021102585-A1;  CA3162930-A1;  AU2020390448-A1;  CN114761438-A;  EP4065608-A1;  JP2023506381-W;  US2023203532-A1;  EP4065608-A4,"Recombinant tumor-selective viral particle, where            targeted EVs are used for binding targeting moiety to            target molecule of target cell, comprises nucleic acid            encoding recombinant polypeptide for directing            extracellular vesicle",ILKOW C S;  BELL J C;  WHELAN J T;  CRUPI M F J;  DUONG J N;  LICHTY B D;  ATHERTON M J;  WANG F;  PAUMIER Y P;  BOULTON S D;  MOHAMMADIAZAD M;  SINGARAVELU R,UNIV MCMASTER (MCST-C);  OTTAWA HOSPITAL RES INST (OTTA-Non-standard);  UNIV MCMASTER (MCST-C);  OTTAWA HOSPITAL RES INST (OTTA-Non-standard);  OTTAWA HEALTH RES INST (OTTA-Non-standard);  UNIV MCMASTER (MCST-C);  OTTAWA HOSPITAL RES INST (OTTA-Non-standard);  OTTAWA HOSPITAL RES INST (OTTA-Non-standard);  UNIV MCMASTER (MCST-C),202159816U,"   NOVELTY - Recombinant tumor-selective viral particle                comprises a nucleic acid encoding a recombinant                polypeptide for directing an extracellular vesicle                (EV) to target cell, a recombinant polypeptide                comprising targeting moiety for directing EV to                target molecule expressed by at least one target                cell, EV-anchoring polypeptide, and intravesicular                polypeptide.    USE - Targeted EVs are used for binding a targeting                moiety to a target molecule of a target cell, for                delivering a payload molecule to a target cell, for                delivering a cargo molecule to a target cell (all                claimed).    ADVANTAGE - The platelet-derived extracellular vesicles                (PEV) Delivery of immunologic adjuvants ( STING or                ERAdP pathway activators, e.g. bacterial                dinucleotide cyclases such as CdaA and MtbDisa                which are c-di-AMP cyclases, and VCA0848, which is                a c-di-GMP cyclase, or mouse/human cGAS) to DCs via                PEVs may result in activation of STING and/or                ERAdP, which enhances DC antigen presentation                capacity, and increases expression of T cell                co-stimulatory molecules, thus boosting the APC                activity. In some instances, these platforms can be                used in combination with vaccine approaches.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a recombinant polypeptide for directing an                extracellular vesicle (EV) one target cell                comprising targeting moiety for directing EV to                target molecule expressed by target cell,                EV-anchoring polypeptide, and intravesicular                polypeptide;    (2) a nucleic acid molecule encoding the                recombinant polypeptide;    (3) a vector, which comprises the nucleic                acid;    (4) a recombinant viral genome, which                comprises the nucleic acid, or a nucleic acid                complementary;    (5) a viral particle, which comprises the                nucleic acid, or a nucleic acid                complementary;    (6) a host cell, which comprises the nucleic                acid, the vector, the recombinant viral genome, or                the viral particle;    (7) a composition, which comprises the nucleic                acid, the vector, the recombinant viral genome, the                viral particle, or the targeted EVs, together with                a excipient, diluent, or carrier;    (8) a method of binding a targeting moiety to                a target molecule of a target cell, which involves                contacting target cell with the targeted EVs;    (9) a method of delivering a payload molecule                or cargo molecule to a target cell, which involves                contacting target cell with the targeted EVs;    (10) a method of stimulating an immune                response to an antigen, which involves                administering to a subject the nucleic acid, the                vector, the recombinant viral genome, the viral                particle, or the targeted EVs, where target cell                comprises an immune cell, and where EV therapeutic                payload polypeptide comprises an antigen;    (11) a method of killing target cells, which                involves administering to a subject the nucleic                acid, the vector, the recombinant viral genome, the                viral particle, or the targeted EVs, where EV                therapeutic payload polypeptide comprises a                cytotoxic molecule. The targeted EVs further                comprise a separate EV cargo molecule. The EV cargo                molecule comprises an API. The targeted EVs are                exosomes, microvesicles, ectosomes, apoptotic                bodies. The antigen comprises a disease                cell-specific antigen, a tumor-specific                antigen;    (12) a method of reprogramming immune cells,                which involves contacting the immune cells with the                nucleic acid, the vector, the recombinant viral                genome, the viral particle as defined in any one of                claims 133 to 137, or the targeted EVs, where one                EV therapeutic payload molecule comprises an                immunomodulatory molecule;    (13) a method of directing an immune response                to a target disease cell, which involves                administering to a subject the nucleic acid, the                vector, the recombinant viral genome, the viral                particle, or the targeted EVs, where recombinant                polypeptide comprises two targeting moieties which                specifically bind, respectively, to two different                target molecules, where two different target                molecules are expressed, respectively, by an immune                cell and a disease cell;    (14) a method of preparing therapeutic                targeted EVs for a subject, which involves                contacting cells obtained from a subject with the                nucleic acid, the vector, the recombinant viral                genome, or the viral particle, and collecting the                targeted EVs; and    (15) a method of producing targeted EVs, which                involves expressing the nucleic acid in cells, or                culturing the host cell to produce EVs, and                collecting EVs. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C07 (Apparatus, formulation, general. including veterinary syringes, general formulations where the active compound is not central to the invention (e.g. wettable powders) and analysis.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-B04M1;  B04-C01;  B04-E01;  B04-E02F;  B04-E02G;  B04-E08;  B04-E99;  B04-F0100E;  B04-F02;  B04-F04B1A;  B04-F04B1B;  B04-F04B2A;  B04-F04B2B;  B04-F04B2C;  B04-F09;  B04-F11B0E;  B04-N03K0E;  B04-N06;  B14-H01;  B14-S18;  C04-B04M1;  C04-C01;  C04-E01;  C04-E02F;  C04-E02G;  C04-E08;  C04-E99;  C04-F0100E;  C04-F02;  C04-F04B1A;  C04-F04B1B;  C04-F04B2A;  C04-F04B2B;  C04-F04B2C;  C04-F09;  C04-F11B0E;  C04-N03K;  C04-N06;  C14-H01;  C14-S18;  D05-H12B2;  D05-H12E;  D05-H14;  D05-H99,A61K-035/76;  A61K-038/44;  A61K-039/00;  A61K-047/42;  A61K-009/00;  A61K-009/14;  A61P-035/00;  A61P-037/04;  C07K-014/005;  C07K-014/08;  C07K-014/145;  C07K-014/165;  C07K-014/705;  C07K-016/28;  C07K-019/00;  C12N-001/21;  C12N-015/33;  C12N-015/62;  C12N-015/85;  C12N-015/86;  C12N-015/87;  C12N-005/10;  C12N-007/01;  A61K-035/761;  A61K-035/763;  A61K-035/766;  A61K-035/768;  C12N-015/861;  C12N-015/863;  C12N-015/869;  A61K-031/7088;  A61K-031/7105;  A61K-035/12;  A61K-038/16;  A61K-038/19;  A61K-038/43;  A61K-038/46;  A61K-039/39;  A61K-039/395;  A61K-045/00;  A61K-047/46;  A61K-047/64;  A61K-047/68;  A61K-048/00;  A61P-031/00;  A61P-037/02;  C07K-014/785;  C12N-001/15;  C12N-001/19;  C12N-015/12;  C12N-015/13;  C12N-015/63;  C07K-016/30;  C07K-016/40,WO2021102585-A1   03 Jun 2021   202153Pages: 211   English;  CA3162930-A1   03 Jun 2021   202252   English;  AU2020390448-A1   14 Jul 2022   202257   English;  CN114761438-A   15 Jul 2022   C07K-019/00   202262   Chinese;  EP4065608-A1   05 Oct 2022   C07K-019/00   202281   English;  JP2023506381-W   16 Feb 2023   C12N-015/62   202315   Japanese;  US2023203532-A1   29 Jun 2023   C12N-015/86   202353   English;  EP4065608-A4   13 Mar 2024   C07K-019/00   202424   English,WO2021102585-A1    WOCA051630    27 Nov 2020;   CA3162930-A1    CA3162930    27 Nov 2020;   AU2020390448-A1    AU390448    27 Nov 2020;   CN114761438-A    CN80082162    27 Nov 2020;   EP4065608-A1    EP893234    27 Nov 2020;   JP2023506381-W    JP528551    27 Nov 2020;   US2023203532-A1    US17780129    26 May 2022;   EP4065608-A4    EP893234    27 Nov 2020,CA3162930-A1 PCT application Application WOCA051630;   CA3162930-A1 Based on Patent WO2021102585;   AU2020390448-A1 PCT application Application WOCA051630;   AU2020390448-A1 Based on Patent WO2021102585;   CN114761438-A PCT application Application WOCA051630;   CN114761438-A Based on Patent WO2021102585;   EP4065608-A1 PCT application Application WOCA051630;   EP4065608-A1 Based on Patent WO2021102585;   JP2023506381-W PCT application Application WOCA051630;   JP2023506381-W Based on Patent WO2021102585;   US2023203532-A1 Provisional Application US941768P;   US2023203532-A1 PCT application Application WOCA051630,US941768P    28 Nov 2019;  WOCA051630    27 Nov 2020;  CA3162930    26 May 2022;  CN80082162    26 May 2022;  US17780129    26 May 2022,WO2021102585-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        EP4065608-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN      EP4065608-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  ,,"WO2021102585-A1 -- WO2019027847-A1   UNIV SOUTHERN CALIFORNIA (USCA);  ZHANG Y (ZHAN-Individual);  SHI X (SHIX-Individual);  CHENG Q (CHEN-Individual)   ZHANG Y,  SHI X,  CHENG Q;  WO2019199941-A1   UNIV NORTHWESTERN (NOUN)   LEONARD J N,  STRANFORD D M","WO2021102585-A1  GAROFALO, M. ET          AL.: ""Antitumor effect of oncolytic virus and paclitaxel          encapsulated in extracellular vesicles for lung cancer          treatment"", JOURNAL OF CONTROLLED RELEASE, vol. 283, no.          10, 10 August 2018 (2018-08-10), pages 223 - 234,          XP055529611, ISSN: 01683659, DOI: 10.1016/j.jconrel.          2018.05.01,relevantClaims[1,2, 123-125, 127-129,          131-133,and 135-137],relevantPassages[*whole          document*];  CHULPANOVA DARIA          S., KITAEVA KRISTINA V., JAMES VICTORIA, RIZVANOV ALBERT          A., SOLOVYEVA VALERIYA V.: ""Therapeutic prospects of          extracellular vesicles in cancer treatment"", FRONTIERS IN          IMMUNOLOGY, vol. 9, 1534, 3 July 2018 (2018-07-03), pages          1 - 10, XP055815545, ISSN: 1664-3224, DOI:          10.3389/fimmu.2018.01534,relevantClaims[88-94, 97-107,          and 195-219],relevantPassages[*whole document,          particularly Table 1*];  WALKER SIERRA,          BUSATTO SARA, PHAM ANTHONY, TIAN MING, SUH ANNIE, CARSON          KELSEY, QUINTERO ASTRID, LAFRENCE MARIA, MALIK HANNA,          SANT: ""Extracellular vesicle-based drug delivery systems          for cancer treatment"", THERANOSTICS, vol. 9, no. 26, 17          October 2019 (2019-10-17), pages 8001 - 8017,          XP055830157, ISSN: 1838-7640, DOI:          10.7150/thno.37097,relevantClaims[88-94, 97-107, and          195-219],relevantPassages[*whole document, particularly          Table 2]",200757-0-0-0 M N; 105730-0-0-0 M N; 184611-0-0-0 M N; 184602-0-0-0 M N; 200757-0-0-0 CL NEW USE; 105730-0-0-0 CL NEW USE; 184611-0-0-0 CL NEW USE; 184602-0-0-0 CL NEW USE,,,RA00GT M N; RA012P M N; RA00H1 M N; RA02DV M N,
CN115819484-A,"Double-stranded oligonucleotide useful in            medicinal composition for preparing medicine for            treating and preventing diseases and symptoms related            to mRNA level of target gene expression i.e. hepatitis            B virus gene, comprises e.g. sense strand and antisense            strand",WANG C;  LI H;  LIU G;  YANG Z;  LIANG Z,BEIJING RIBO DEV PHARM TECHNOLOGY CO LTD (BEIJ-Non-standard);  SUZHOU RIBO LIFE SCI CO LTD (SUZH-Non-standard),2023342840,"   NOVELTY - Double-stranded oligonucleotide comprises                sense strand and antisense strand, where the each                strand has 14 to 30 nucleotides, each nucleotide in                the double-stranded oligonucleotide is                independently modified or unmodified nucleotide,                and part of the sense strand and the antisense                strand are reversely complementary to form                double-stranded region, the 5' terminal nucleotide                of the antisense strand is nucleotide with ribose                5' modification, the modified nucleotide is                phosphate group-containing tetrahydrofuran compound                (I), and the group R0constitutes the 5' overhang of                the antisense strand.    USE - The double-stranded oligonucleotide is useful                in medicinal composition for preparing medicine for                treating and preventing diseases and symptoms                related to mRNA level of target gene expression                i.e. hepatitis B virus gene (all claimed).    ADVANTAGE - The double-stranded oligonucleotide: is used                in medicinal composition and/or oligonucleotide                conjugate, which has excellent activity and low                toxicity.    DETAILED DESCRIPTION - Double-stranded oligonucleotide comprises                sense strand and antisense strand, where each                strand has 14 to 30 nucleotides, each nucleotide in                the double-stranded oligonucleotide is                independently modified or unmodified nucleotide,                and part of the sense strand and the antisense                strand are reversely complementary to form                double-stranded region, the 5' terminal nucleotide                of the antisense strand is nucleotide with ribose                5' modification, the modified nucleotide is                phosphate group-containing tetrahydrofuran compound                of formula (I), and the group R0constitutes the 5'                overhang of the antisense strand.    R0= tetrahydrofuran-based compound of formula                (II);    R201= hydroxy group or phosphate group;    G1= OH, O- or OJ1;    J1= 1-6C alkyl or 3-6C cycloalkyl (both                optionally substituted);    Either Bx1= H, heterocyclic base or base                substitution group, and the 3' end of the sense                strand if including an overhang;    Or Bx1= does not pair with the base of the                overhang;    Base substitution group = phenyl (optionally                substituted);    Bx2= heterocyclic base;    Z = divalent linking groups including alkene                moiety of formula (Z1-Z2), alkyne moiety of formula                (Z3) or alkane moiety of formula (Z4-Z5);    Or Z = 1,2-cycloalkylene or heterocyclylene                group with 3-6 carbon atoms or substituted                1,2-cycloalkylene or heterocyclylene group with 3-6                carbon atoms;    P1and P2= 1-6C alkyl, 1-6C alkoxy or 2-6C                alkenyl (all optionally substituted), H or                halo;    P3= O or S;    X1= H or hydroxy;    X2= 1-6C alkoxy (optionally substituted), H,                halo or hydroxy;    T2= phosphate subunit or phosphorothioate                subunit;    Y1-Y8= H, halo, hydroxy, methyl, ethyl,                n-propyl or isopropyl; and    Curved line = indicates the point at which the                group is covalently attached.    INDEPENDENT CLAIMS are also included                for:    Oligonucleotide conjugate comprising                double-stranded oligonucleotide and conjugate group                connected to the double-stranded oligonucleotide,                where the conjugate group comprises linker and                medicinal targeting group and/or delivery adjunct                group, and the double-stranded oligonucleotide,                linker and the targeting group or the delivery                auxiliary group are sequentially connected                covalently or non-covalently, each of the targeting                groups is ligands capable of binding to cell                surface receptors, and each delivery-assisting                group is groups capable of increasing the                biocompatibility of the oligonucleotide conjugate                in the delivery target organ or tissue;    Use of double-stranded oligonucleotide,                medicinal composition and/or oligonucleotide                conjugate in preparing medicine for treating and                preventing diseases or symptoms related to the mRNA                level of target gene expression;    Method of regulating the expression level of a                target gene in cell in vitro, comprising                double-stranded oligonucleotide with an efficient                amount, medicinal composition and/or the                oligonucleotide conjugate are contacted with the                cells; and    Test kit comprising double-stranded                oligonucleotide, medicinal composition and/or                oligonucleotide conjugate.     ",,,"D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B03 (Other heterocyclics.)",D05-H12;  D05-H99;  B04-E15;  B14-S03A;  B04-Q04;  B04-B03B;  B04-B03C;  B14-S18;  B04-E01;  B14-A02A5;  B04-E99,A61K-031/713;  A61P-031/20;  C07H-021/02;  C12N-015/113,CN115819484-A   21 Mar 2023   C07H-021/02   202336   Chinese,CN115819484-A    CN10873191    22 Jul 2022,,CN10835255    23 Jul 2021,,,,,93605-0-0-0 M K; 105730-0-0-0 M K,,,RA00NS M K; RA012P M K,
WO2022041760-A1,Purifying trimeric fusion protein involves e.g. contacting sample including trimeric fusion protein having heterologous polypeptide sequence fused to carboxy-terminal polypeptide sequence of procollagen with soluble endo180 polypeptide,LIANG P,SICHUAN CLOVER BIOPHARM INC (SICH-Non-standard),2022397026,"   NOVELTY - Purifying a trimeric fusion protein from a sample, comprises: (a) contacting a sample comprising a trimeric fusion protein with a soluble endo180 polypeptide linked to a support, where the trimeric fusion protein comprises a heterologous polypeptide sequence fused to a carboxy-terminal polypeptide sequence of a procollagen, the carboxy-terminal polypeptide sequence is capable of self trimerization and specifically binding to the soluble endo180 polypeptide, and the trimeric fusion protein and the soluble endo180 polypeptide form a complex on the support; (b) removing unbound and/or non-specifically bound molecules from the complex; and (c) dissociating the complex to release the trimeric fusion protein, thus purifying the trimeric fusion protein from the sample.    USE - The method is useful for: purifying any protein that contains procollagen e.g. a carboxy-terminal polypeptide sequence of a procollagen; obtaining nucleic acid, vector, and virus or cell; producing the recombinant polypeptides; and purifying a trimeric fusion protein from a sample (all claimed), which is useful for treating diseases e.g. cancer. No biological data given.    ADVANTAGE - The method: is capable of reversibly binding a carboxy-terminal polypeptide sequence of a procollagen e.g. forming a complex with a trimeric fusion protein comprising a carboxy-terminal polypeptide sequence of a procollagen; and allows for efficient purification of proteins containing a carboxy-terminal polypeptide sequence of a procollagen e.g. trimeric fusion proteins.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:    (1) purifying (M2) any protein that contains procollagen e.g. a carboxy-terminal polypeptide sequence of a procollagen, comprising contacting a target molecule with a binding reagent, where the target molecule comprises a heterologous polypeptide sequence linked to a carboxy-terminal polypeptide sequence of a procollagen, the binding reagent comprises an endo180 ectodomain sequence comprising a sequence of endo180 domain (D) 6, a sequence of endo180 D7, a sequence of endo180 D8, a sequence of endo180 D9, and/or a sequence of endo180 D10 (e.g. at least one copies of D6, D7, D8, D9, D10, D1-6, D2-6, D3-6, D4-6, D5-6, D1-7, D2-7, D3-7, D4-7, D5-7, D6-7, D1-8, D2-8, D3-8, D4-8, D5-8, D6-8, D7-8, D1-9, D2-9, D3-9, D4-9, D5-9, D6-9, D7-9, D8-9, D1-10, D2-10, D3-10, D4-10, D5-10, D6-10, D7-10, D8-10, and/or D9-10), and the target molecule and the binding reagent form a complex via binding between all or a portion of the carboxy-terminal polypeptide sequence and all or a portion of the endo180 ectodomain sequence;    (2) a recombinant (P1) polypeptide comprising (i) an endo180 ectodomain sequence comprising sequence of endo180 D6, a sequence of endo180 D7, a sequence of endo180 D8, a sequence of endo180 D9, and/or a sequence of endo180 D10 (e.g. at least one copies of D6, D7, D8, D9, D10, D1-6, D2-6, D3-6, D4-6, D5-6, D1-7, D2-7, D3-7, D4-7, D5-7, D6-7, D1-8, D2-8, D3-8, D4-8, D5-8, D6-8, D7-8, D1-9, D2-9, D3-9, D4-9, D5-9, D6-9, D7-9, D8-9, D1-10, D2-10, D3-10, D4-10, D5-10, D6-10, D7-10, D8-10, and/or D9-10), optionally where the polypeptide lacks an endo180 D1 sequence, an endo180 D2 sequence, an endo180 D3 sequence, an endo180 D4 sequence, endo180 D5 sequence, an endo180 D7 sequence, an endo180 D8 sequence, an endo180 D9 sequence and/or an endo180 D10 sequence;    (3) a recombinant (P2) polypeptide comprising the component (i) as per se, where the endo180 ectodomain sequence is fused to a heterologous polypeptide sequence;    (4) a recombinant (P3) polypeptide comprising a sequence at least 70%, preferably at least 99%, or 100% identical to an amino acid sequences of SEQ ID NOs: 1, 2, 3, 4, 43, 44, 45, or 46 (each comprising fully defined sequence of any one of 396-1632 amino acids as given in the specification), or their fragment or variant;    (5) a nucleic acid encoding the recombinant polypeptides (P1)-(P3);    (6) a vector comprising the nucleic acid;    (7) a virus or cell comprising the nucleic acid or the vector, optionally where the virus or cell has a recombinant genome;    (8) producing (M3) the recombinant polypeptides (P1)-(P3), comprising expressing the recombinant polypeptide, and recovering the recombinant polypeptide; and    (9) a complex comprising a molecule comprising a heterologous polypeptide sequence linked to a carboxy-terminal polypeptide sequence of a procollagen, and a binding partner comprising the component (i) as per se, where all or a portion of the carboxy-terminal polypeptide sequence binds to all or a portion of the endo180 ectodomain sequence. ",,,"A96 (Medical, dental, veterinary, cosmetic.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",A11-C03;  A12-W11L;  B04-C01G;  B04-E02F;  B04-E08;  B04-E99;  B04-F0100E;  B04-F1100E;  B04-N08;  B11-B03A;  B14-H01;  B14-S03A;  D05-H10;  D05-H12A;  D05-H12E;  D05-H13;  D05-H14;  D05-H17C;  D05-H99,C07K-001/22;  C07K-014/705;  C07K-019/00;  C12N-015/12;  C12N-015/63;  C12N-005/10,WO2022041760-A1   03 Mar 2022   C07K-001/22   202224Pages: 75   English,WO2022041760-A1    WOCN087055    13 Apr 2021,,WOCN112439    31 Aug 2020,WO2022041760-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,,,184616-0-0-0 K P,,,RA00H3 K P,
CN111825771-A,"Anti-virus anti-bacterial biological missile            comprises guidance device, leading-in device and            killing device, the guidance device is a guidance            device is special monoclonal antibody capable of being            combined with specific target cell",BAI T,BAI T (BAIT-Individual),2020A7517N,"   NOVELTY - Anti-virus anti-bacterial biological missile                comprises guidance device, leading-in device and                killing device, the guidance device is a guidance                device is special monoclonal antibody capable of                being combined with the specific target cell or the                specific target gene in the normal human body cell,                or a broad-spectrum protein guidance device capable                of being combined with the receptor of the whole                normal cell of human body, the leading-in device is                composed of transduction protein, and the killing                device is polypeptide or protein with diversified                killing function or repression function virus or                bacteria.    USE - Used as anti-virus anti-bacterial biological                missile.    ADVANTAGE - The biological missile: can target AIDS, viral                infections, including crown virus, bacterial                infections, and other three categories, can                directly and accurately deliver various drugs to                the target cells, thus combining into one                biological missile with multi-purpose functions of                anti-AIDS, anti-virus and anti-bacterial infection,                which becomes a multi-functional biological missile                that can treat a variety of diseases. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C07 (Apparatus, formulation, general. including veterinary syringes, general formulations where the active compound is not central to the invention (e.g. wettable powders) and analysis.);  C02 (Heterocyclic.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B02-B;  B02-V01;  B04-B04C1;  B04-C01;  B04-E01;  B04-E02F;  B04-E07C;  B04-G01;  B04-G07;  B04-G08;  B04-G21;  B04-N03K;  B11-C04;  B14-A01;  B14-A02;  B14-S18;  C02-B;  C02-V01;  C04-B04C1;  C04-C01;  C04-E01;  C04-E02F;  C04-E07C;  C04-G01;  C04-G07;  C04-G08;  C04-G21;  C04-N03K;  C11-C04;  C14-A01;  C14-A02;  C14-S18;  D05-H11;  D05-H12,A61K-038/10;  A61K-038/16;  A61K-038/17;  A61K-038/36;  A61K-047/68;  A61P-031/04;  A61P-031/12;  A61P-031/14;  A61P-031/18;  C07K-019/00,CN111825771-A   27 Oct 2020   C07K-019/00   202095Pages: 12   Chinese,CN111825771-A    CN10719070    23 Jul 2020,,CN10719070    23 Jul 2020,,,,,184587-0-0-0 K M; 93605-0-0-0 K M; 105730-0-0-0 K M; 1099829-0-0-0 K M; 1562508-1-0-0 K M; 104434-1-0-0 K M; 88302-1-0-0 K M; 110025-1-0-0 K M; 200757-0-0-0 K M; 1099829-0-0-0 CL USE; 1562508-1-0-0 CL USE,,11705; 60980,RA00C8 K M; RA00NS K M; RA012P K M; RAOI2R K M; RAS6IN K M; RA056I K M; RA056D K M; R04258 K M; RA00GT K M,
WO2024049749-A1,"Product of manufacture, formulation, mixture or            kit used to e.g. stabilize detect presence of protease            in fluid comprises compound capable of making into            reversibly aggregated nanoparticles and compound            conjugated to polyethylene glycol",JOKERST J;  RETOUT M G;  YIM W,UNIV CALIFORNIA (REGC-C),202424728S,"   NOVELTY - Product of manufacture, formulation, mixture                or kit comprises (a) a compound capable of making                or forming into reversibly aggregated (or                substantially reversibly aggregated) nanoparticles                (NPs), and (b) a compound conjugated to a                polyethylene glycol.    USE - The product of manufacture, formulation,                mixture or kit is useful for stabilizing (or                substantially stabilizing) nanoparticles in a                reversible aggregate, and, detecting the presence                of a protease in a fluid (claimed).    ADVANTAGE - None given.    DETAILED DESCRIPTION - Product of manufacture, formulation, mixture                or kit comprises (a) a compound X capable of making                or forming into reversibly aggregated (or                substantially reversibly aggregated) nanoparticles                (NPs), and (b) a compound Z1 conjugated to a                polyethylene glycol (PEG) i.e. (Z1-PEGy), or a many                Z1-PEGy. INDEPENDENT CLAIMS are also included                for:    preparing the citrate-stabilized nanoparticles                using a Turkevich method comprising (aa) rapidly                injecting an aqueous solution of sodium citrate                tribasic dihydrate (SCTD) (150 mg SCTD, 5 ml                aqueous solution) into an aqueous solution of                chloroauric acid (45 mg Chloroauric acid, 300 ml                aqueous solution) under boiling conditions and                vigorous stirring, to produce a reaction mixture,                and (bb) leaving the reaction mixture boiling while                stirring for another 15 minutes and then cooling                down to room temperature (RT) to generate a deep                red dispersion, and then purifying deep red                dispersion by applying one round of centrifugation                at 18000 g for 30 minute to generate a pellet of                gold nanoparticle-citrate, and discarding the pink                supernatant, and redispersing the resulting pellet                of gold-nanoparticle-citrate in deionized water by                sonication and storing at ambient conditions;    a solution or formulation comprising many                Arg-Arg-nanoparticles and the Z1-PEGy-peptide and                optionally a saline solution, water, a cell lysate                or a biological solution; and    detecting a protease in a sample, comprising                mixing the Arg-Arg-nanoparticles and the                Z1-PEGy-Y1-peptide in a sample, and presence of a                protease capable of specifically recognizing and                cleaving the peptide is detected via a proteolytic                cleavage that releases Z1-PEGx fragments (from                Z1-PEG-Y1-peptide), thus inducing the dissociation                of the gold-nanoparticle-citrate assemblies and                turning the solution from blue to red. ",,,"A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)",A10-E01;  A12-V03C2;  A12-W14;  B04-C01;  B04-C03C;  B04-E99;  B04-L05C;  B05-A01B;  B05-A03B;  B05-C07;  B10-C02;  B11-C08E3;  B11-C12;  B12-K04E2;  B12-K04G;  D05-H09;  D05-H99;  S03-E09F,B82Y-005/00;  C12N-009/50;  G01N-033/50;  G01N-033/543;  G01N-033/569,WO2024049749-A1   07 Mar 2024   B82Y-005/00   202429Pages: 170   English,WO2024049749-A1    WOUS031261    28 Aug 2023,,US401914P    29 Aug 2022,WO2024049749-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,WO2024049749-A1 -- US20180335429-A1   ;  US20190300870-A1   ,"WO2024049749-A1  RETOUT MAURICE,          MANTRI YASH, JIN ZHICHENG, ZHOU JIAJING, NOEeL GREGOIRE,          DONOVAN BRIAN, YIM WONJUN, JOKERST JESSE V.:          ""Peptide-Induced Fractal Assembly of Silver Nanoparticles          for Visual Detection of Disease Biomarkers"", ACS NANO,          AMERICAN CHEMICAL SOCIETY, US, vol. 16, no. 4, 26 April          2022 (2022-04-26), US , pages 6165 - 6175, XP093147794,          ISSN: 1936-0851, DOI:          10.1021/acsnano.1c11643,relevantClaims[1-3,          6-8],relevantPassages[. entire document];  RETOUT MAURICE,          AMER LUBNA, YIM WONJUN, CREYER MATTHEW N., LAM BENJAMIN,          TRUJILLO DIEGO F., POTEMPA JAN, ODONOGHUE ANTHONY J., CH:          ""A Protease-Responsive Polymer/Peptide Conjugate and          Reversible Assembly of Silver Clusters for the Detection          of Porphyromonas gingivalis Enzymatic Activity"", ACS          NANO, AMERICAN CHEMICAL SOCIETY, US, vol. 17, no. 17, 12          September 2023 (2023-09-12), US , pages 17308 - 17319,          XP093147798, ISSN: 1936-0851, DOI:          10.1021/acsnano.3c05268,relevantClaims[1-3,          6-8],relevantPassages[. entire document]",900-0-0-0 K M Q; 849-0-2-0 K M; 96358-0-0-0 K M; 96353-0-0-0 K M; 114-0-0-0 K M; 444-0-0-0 ,230782001 K M Q; 230782002 K M Q; 230782003 K M Q; 230782004 K M Q; 230782005 K M Q; 230782006 K M Q; 230782007 K M Q; 230782008 K M Q; 230782009 K M Q; 230782010 K M Q; 230782011 K M Q; 230782012 K M Q; 230782013 K M Q; 230782014 K M Q; 230782015 K M Q; 230782016 K M Q; 230782017 K M Q,,R02044 K M Q; RA0GM6 K M Q; R04004 K M; RA00DB K M; RADQ01 K M; R03080 K M; R01706 K M; R00351 ,2044-S; 0419-S; 1706-S
CN111297969-A;  WO2021189743-A1,"Use of Chaiyin composition in preparing medicine            for preventing coronavirus, preferably human            coronavirus (HCoV)-229E",ZHANG G;  ZHANG Z;  GUAN Y;  CHENG G,LUNAN PHARM CO LTD (LNZY-C);  LUNAN PHARM GROUP CORP (LNZY-C),202059304G,"   NOVELTY - Use of Chaiyin composition in preparing                medicine for preventing coronavirus.    USE - The composition is useful for preparing                medicine for preventing coronavirus, preferably                HcoV-229E (claimed). ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  A96 (Medical, dental, veterinary, cosmetic.)",B04-A08;  B04-A10;  B04-A98;  B04-C02A1;  B04-C02A3;  B04-C02B1;  B05-A01B;  B05-B02C;  B07-A02B;  B12-M12N;  B14-A02B5;  B14-S18;  A03-A00A;  A03-A02;  A03-A05;  A12-V01;  A12-W05,A61K-036/78;  A61K-047/69;  A61P-031/14;  A61K-036/534;  A61K-036/538;  A61K-036/539;  A61K-036/634;  A61K-036/736;  A61K-009/22;  A61K-009/52,CN111297969-A   19 Jun 2020   A61K-036/78   202062Pages: 22   Chinese;  WO2021189743-A1   30 Sep 2021   A61K-036/78   202180   Chinese,CN111297969-A    CN10215794    25 Mar 2020;   WO2021189743-A1    WOCN105694    30 Jul 2020,,CN10215794    25 Mar 2020,  WO2021189743-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"CN111297969-A -- CN102188533-A   LUNAN HOPE PHARM CO LTD (LNZY)   ZHAO Z,  ZHANG Z;  WO2021189743-A1 -- CN1425449-A   LUNAN PHARM CO LTD (LNZY)   LI G;  CN111228357-A   LUNAN PHARM CO LTD (LNZY)   HAN Z,  ZHANG W;  CN111297969-A   LUNAN PHARM CO LTD (LNZY)   ZHANG G,  ZHANG Z,  GUAN Y,  CHENG G","CN111297969-A  : ""16"",          HTTP://WWW.STDAILY.COM/KJRB/KJRBBM/2020-03/05/CONTENT_894365.SHTML,relevantClaims[510|1-10],relevantPassages[1-216-8];  : """",          HTTPS://WWW.JIANKANGZHICHU.COM/ARTICLE/DETAIL/582545.HTML,relevantClaims[510|1-10],relevantPassages[1-213-5];  : """",          ,relevantClaims[510],relevantPassages[9-11101-2113];  : """",          ,relevantClaims[1-10],relevantPassages[15-2317212142]WO2021189743-A1  WANG JI-FENG, ZHANG          WEI-DAN: ""Efficacy of Chaiyin Koufuye on Recurrent Upper          Rrespiratory Tract Infection"", JOURNAL OF CLINICAL          MEDICINE IN PRACTICE, vol. 15, no. 11, 30 June 2011          (2011-06-30),          XP055854148,relevantClaims[1-10],relevantPassages[pp.          111-112];  CHINA ASSOCIATION          OF CHINESE MEDICINE: ""The Guideline to the Diagnosis and          Treatment of Chinese Medicine for Severe Acute          Respiratory Syndrome"", ACTA CHINESE MEDICINE AND          PHARMACOLOGY, vol. 9, no. 11, 1 November 2003          (2003-11-01), pages 1 - 2, XP055854151,relevantClaims[1,          2, 6, 7|3-5, 8-10],relevantPassages[pp.          579-586];  CHEN, XIAOHUA:          ""Chinese Medicine Anti-Epidemic in Progress: Interview          with Chen Shilin, President of the Chinese Medicine          Branch of the China Association for Quality"", CHINA          QUALITY, no. 465, 1 March 2020 (2020-03-01), pages 9 -          11, XP055854156, DOI:          10.16434/j.cnki.zgzl.2020.03.001,relevantClaims[1, 2, 6,          7, 10|3-5, 8, 9],relevantPassages[pp. 9-11];  BAO YAN-YAN, SHI          YU-JING, SHAN-SHAN GUO, GENG ZI-HAN, YING-JIE GAO, LEI          BAO, ONG-HUA ZHAO, JING SUN, ZHANG GUI-MIN, GUAN, YONG-X:          ""Study on Therapeutic Effect of Chaiyin Particles on          Combining Disease with Syndrome of Human Coronavirus          Pneumonia with Pestilence Attacking Lung Syndrome based          on Regulation of Immune Function"", CHINA JOURNAL OF          CHINESE MATERIA MEDICA, vol. 45, no. 13, 1 July 2020          (2020-07-01), pages 3020 - 3027,          XP055854161,relevantClaims[1-10],relevantPassages[pp.          3021-3027]",90356-0-0-0 K M; 90357-0-0-0 K M; 92021-0-0-0 K M; 107016-0-0-0 K M; 56978-2-0-0 K M; 2-1-0-0 K M; 135402-0-0-0 ; 107779-0-0-0 ; 133916-0-0-0 ,,49969,R01852 K M; R01853 K M; RA05OE K M; R04818 K M; RA06UR K M; R01694 K M; R00241 K M; R01514 K M; R24032 ; R01863 ,1852-S; 1853-S; 1694-S; 0241-S; 1514-S
WO2021034674-A1;  AU2020333654-A1;  CA3151356-A1;  KR2022048021-A;  CN114555836-A;  SG11202201426-A;  EP4013897-A1;  BR112022002827-A2;  US2022288119-A1;  JP2022545654-W;  HK40066609-A0;  IL290620-A;  MX2022001967-A1;  RU2022106383-A,Preventing viral infection or reactivation of            latent virus by third-party allogeneic T cell therapy            involves prophylactically administering patient with            first antigen-specific T cell line that is a polyclonal            third party T cell line,VERA VALDES J F;  LEEN A M;  TZANNOU I;  VERA V J F;  FERNANDO V J;  MARIE L A;  GENEIA C P;  VALDES J F V;  VERA V KH F;  LIN A M;  TSANNU I,BAYLOR COLLEGE MEDICINE (BAYU-C);  BAYLOR COLLEGE MEDICINE (BAYU-C);  BAYLOR COLLEGE MEDICINE (BAYU-C);  BAYLOR COLLEGE MEDICINE (BAYU-C),202119491U,"   NOVELTY - Preventing a viral infection or reactivation                of a latent virus by a third-party allogeneic T                cell therapy involves prophylactically                administering patient with a first antigen-specific                T cell line that is a polyclonal third party T cell                line. The T cell line comprises antigen specificity                for one or more viral antigen and T cell line                comprises a HLA type that matches patient's HLA                type on 2 or more HLA alleles.    USE - Method for preventing a viral infection or                reactivation of a latent virus by a third-party                allogeneic T cell therapy, where subject has an                immune deficiency condition which is primary immune                deficiency and HIV infection, and patient has                leukemia, myeloma, or lymphoma and is in need of a                hematopoietic stem cell transplant therapy (all                claimed).    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method                for controlling a viral infection or reactivation                of a latent virus by a third-party allogeneic T                cell therapy, which involves prophylactically                administering patient with a first antigen-specific                T cell line that is a polyclonal third party T cell                line. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-F04B1A;  B14-A02;  B14-G01;  B14-G02;  B14-H01A;  B14-H01G;  B14-H01L1;  B14-S21;  B14-S25;  C04-F04B1A;  C14-A02;  C14-G01;  C14-G02;  C14-H01A;  C14-H01G;  C14-H01L1;  C14-S21;  D05-H08B,A61K-035/17;  A61K-039/12;  C12Q-001/70;  A61K-039/00;  A61K-039/295;  A61P-031/20;  C12N-005/0783;  A61P-031/12;  A61P-031/14;  A61P-031/16;  A61P-031/18;  A61P-031/22;  A61P-037/04;  A61P-043/00,WO2021034674-A1   25 Feb 2021   C12Q-001/70   202122Pages: 86   English;  AU2020333654-A1   17 Mar 2022   C12Q-001/70   202223   English;  CA3151356-A1   25 Feb 2021   C12Q-001/70   202225   English;  KR2022048021-A   19 Apr 2022   A61K-039/12   202235   ;  CN114555836-A   27 May 2022   C12Q-001/70   202246   Chinese;  SG11202201426-A   30 Mar 2022   C12Q-001/70   202251   English;  EP4013897-A1   22 Jun 2022   C12Q-001/70   202251   English;  BR112022002827-A2   10 May 2022   C12Q-001/70   202253   ;  US2022288119-A1   15 Sep 2022   A61K-035/17   202275   English;  JP2022545654-W   28 Oct 2022   A61K-035/17   202287   Japanese;  HK40066609-A0   19 Aug 2022   C12Q-001/70   202302   English;  IL290620-A   01 Apr 2022   A61K-039/00   202307   English;  MX2022001967-A1   16 May 2022   A61K-035/17   202382   Spanish;  RU2022106383-A   18 Sep 2023   C12Q-001/70   202384   Russian,WO2021034674-A1    WOUS046389    14 Aug 2020;   AU2020333654-A1    AU333654    14 Aug 2020;   CA3151356-A1    CA3151356    14 Aug 2020;   KR2022048021-A    KR708864    14 Aug 2020;   CN114555836-A    CN80071822    14 Aug 2020;   SG11202201426-A    SG11001426    14 Aug 2020;   EP4013897-A1    EP854294    14 Aug 2020;   BR112022002827-A2    BR11002827    14 Aug 2020;   US2022288119-A1    US17635197    14 Feb 2022;   JP2022545654-W    JP510102    14 Aug 2020;   HK40066609-A0    HK6055903    29 Jun 2022;   IL290620-A    IL290620    14 Aug 2020;   MX2022001967-A1    MX001967    15 Feb 2022;   RU2022106383-A    RU106383    14 Aug 2020,AU2020333654-A1 PCT application Application WOUS046389;   AU2020333654-A1 Based on Patent WO2021034674;   CA3151356-A1 PCT application Application WOUS046389;   CA3151356-A1 Based on Patent WO2021034674;   KR2022048021-A PCT application Application WOUS046389;   KR2022048021-A Based on Patent WO2021034674;   CN114555836-A PCT application Application WOUS046389;   CN114555836-A Based on Patent WO2021034674;   SG11202201426-A PCT application Application WOUS046389;   SG11202201426-A Based on Patent WO2021034674;   EP4013897-A1 PCT application Application WOUS046389;   EP4013897-A1 Based on Patent WO2021034674;   BR112022002827-A2 PCT application Application WOUS046389;   BR112022002827-A2 Based on Patent WO2021034674;   US2022288119-A1 PCT application Application WOUS046389;   US2022288119-A1 Provisional Application US887806P;   JP2022545654-W PCT application Application WOUS046389;   JP2022545654-W Based on Patent WO2021034674;   HK40066609-A0 PCT application Application WOUS046389;   HK40066609-A0 Based on Patent WO2021034674;   HK40066609-A0 Previous Publ. Patent EP4013897;   IL290620-A Based on Patent WO2021034674;   MX2022001967-A1 PCT application Application WOUS046389;   MX2022001967-A1 Based on Patent WO2021034674;   RU2022106383-A PCT application Application WOUS046389;   RU2022106383-A Based on Patent WO2021034674,US887806P    16 Aug 2019;  EP854294    14 Aug 2020;  US17635197    14 Feb 2022;  BR11002827    15 Feb 2022;  CA3151356    15 Feb 2022;  KR708864    16 Mar 2022;  RU106383    16 Mar 2022;  CN80071822    13 Apr 2022,WO2021034674-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA            EP4013897-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN                ,,WO2021034674-A1 -- US20190144826-A1   ,"WO2021034674-A1  LEEN ET AL.:          ""Multicenter study of banked third-party virus-specific T          cells to treat severe viral Infections after          hematopoietic stem cell transplantation"", BLOOD, vol.          121, no. 26, 27 June 2013 (2013-06-27), pages 5113 -          5123, XP086507634, DOI:          10.1182/blood-2013-02-486324,relevantClaims[1-3],relevantPassages[.          especially, Abstract; page 5113, col. 2, para 2; page          5114, col. 1, para 1; page 5114, col. 2, para 1;          page.5114, Table 2]",200757-0-0-0 K M,,,RA00GT K M,
US2021308109-A1;  WO2021207054-A1;  CN115335049-A;  CA3174413-A1;  EP4132521-A1;  JP2023521030-W,Method of reducing plasma level of macrophage            migratory inhibitory factor in subject by administering            ibudilast to subject,MATSUDA K;  IWAKI Y,MEDICINOVA INC (MEDI-Non-standard);  MEDICINOVA INC (MEDI-Non-standard);  MEDICINOVA INC (MEDI-Non-standard),2021B5046H,"   NOVELTY - Method of reducing plasma level of macrophage                migratory inhibitory factor (MIF) in a subject in                need of it involves administering ibudilast or its                pharmaceutical salt to the subject.    USE - The method is useful for reducing plasma level                of macrophage migratory inhibitory factor in a                subject, where the subject is diagnosed with or                suffering from microorganism infection or from                sepsis; diagnosed with or suffering from severe                viral-induced pneumonia; diagnosed with or                suffering from mild to severe acute respiratory                distress syndrome; diagnosed with or suffering from                cancer; diagnosed with or suffering from a                neurodegenerative disease or disorder; and/or                diagnosed with or suffering from an autoimmune                disorder.    ADVANTAGE - The method inhibits the catalytic and                chemotactic functions of MIF. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B02 (Fused ring heterocyclics.);  C07 (Apparatus, formulation, general. including veterinary syringes, general formulations where the active compound is not central to the invention (e.g. wettable powders) and analysis.);  C02 (Heterocyclic.)",B14-A01;  B14-C03;  B14-G02;  B14-H01;  B14-K01;  B14-D07A;  B14-L06;  B12-M12Z;  B06-D05;  B14-A04;  B14-A02;  B14-J01;  C06-D05;  C12-M12Z;  C14-A01;  C14-A02;  C14-A04;  C14-C03;  C14-D07A;  C14-G02;  C14-H01;  C14-J01;  C14-K01;  C14-L06,A61K-031/437;  A61K-009/00;  A61K-009/48;  A61P-011/00;  A61K-045/06;  A61P-025/28;  A61P-031/14;  A61P-035/00;  A61P-037/00;  A61K-039/395;  A61K-045/00;  A61K-009/72;  A61P-017/06;  A61P-019/02;  A61P-021/02;  A61P-025/00;  A61P-025/08;  A61P-025/16;  A61P-031/04;  A61P-031/10;  A61P-031/12;  A61P-031/16;  A61P-035/02;  A61P-037/02;  A61P-037/08;  A61P-043/00,US2021308109-A1   07 Oct 2021   A61K-031/437   202216   English;  WO2021207054-A1   14 Oct 2021   A61K-031/437   202216   English;  CN115335049-A   11 Nov 2022   A61K-031/437   202294   Chinese;  CA3174413-A1   14 Oct 2021   A61K-031/437   202204   English;  EP4132521-A1   15 Feb 2023   A61K-031/437   202315   English;  JP2023521030-W   23 May 2023   A61K-031/437   202343   Japanese,US2021308109-A1    US222673    05 Apr 2021;   WO2021207054-A1    WOUS025732    05 Apr 2021;   CN115335049-A    CN80024762    05 Apr 2021;   CA3174413-A1    CA3174413    05 Apr 2021;   EP4132521-A1    EP721728    05 Apr 2021;   JP2023521030-W    JP560218    05 Apr 2021,US2021308109-A1 Provisional Application US005792P;   CN115335049-A PCT application Application WOUS025732;   CN115335049-A Based on Patent WO2021207054;   CA3174413-A1 PCT application Application WOUS025732;   CA3174413-A1 Based on Patent WO2021207054;   EP4132521-A1 PCT application Application WOUS025732;   EP4132521-A1 Based on Patent WO2021207054;   JP2023521030-W PCT application Application WOUS025732;   JP2023521030-W Based on Patent WO2021207054,US005792P    06 Apr 2020;  US222673    05 Apr 2021;  CN80024762    27 Sep 2022;  CA3174413    30 Sep 2022,  WO2021207054-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      EP4132521-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    ,,";  WO2021207054-A1 -- WO2009009529-A1   MEDICINOVA INC (MEDI-Non-standard)   GAMMANS R E,  KALAFER M E,  LOCKE K W,  MATSUDA K;  WO2019157428-A1   MEDICINOVA INC (MEDI-Non-standard)   MATSUDA K;  WO2005051293-A2   COMBINATORX INC (COBM)   JOST-PRICE E R,  MANIVASAKAM P,  SMITH B,  SLAVONIC M S,  AUSPITZ B A;  US20060160843-A1   ;  US6395747-B1   KYORIN PHARM CO LTD (KYOR);  SAKODA S (SAKO-Individual)   SAKODA S;  US8138201-B2   MEDICINOVA INC (MEDI-Non-standard)   GAMMANS R E,  KALAFER M E,  LOCKE K W,  MATSUDA K;  US9314452-B2   MEDICINOVA INC (MEDI-Non-standard)   GAMMANS R E,  KALAFER M E,  LOCKE K W,  MATSUDA K","US2021308109-A1            Luyt, ""Virus-induced acute respiratory distress syndrome:          Epidemiology, management and outcome"", Presse Med., 2011          Dec; 40(12): e561e568.WO2021207054-A1  CLANCHY FELIX I. L.          ET AL: ""Ibudilast Inhibits Chemokine Expression in          Rheumatoid Arthritis Synovial Fibroblasts and Exhibits          Immunomodulatory Activity in Experimental Arthritis"",          ARTHRITIS & RHEUMATOLOGY (HOBOKEN), vol. 71, no. 5,          12 April 2019 (2019-04-12), US, pages 703 - 711,          XP055817114, ISSN: 2326-5191, Retrieved from the Internet          &lt;URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/art.40787&gt;          DOI:          10.1002/art.40787,relevantClaims[1,2,35-38,42],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  YANG DONGJIE ET AL:          ""Ibudilast, a Phosphodiesterase-4 Inhibitor, Ameliorates          Acute Respiratory Distress Syndrome in Neonatal Mice by          Alleviating Inflammation and Apoptosis"", MEDICAL SCIENCE          MONITOR, vol. 26, no. 26, 7 February 2020 (2020-02-07),          pages 922281, XP055816525, Retrieved from the Internet          &lt;URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146065/pdf/medscimonit-26-e922281.pdf&gt;          DOI:          10.12659/MSM.922281,relevantClaims[1,23-25],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  CHO YOONSANG ET AL:          ""Allosteric inhibition of macrophage migration inhibitory          factor revealed by ibudilast"", vol. 107, no. 25, 22 June          2010 (2010-06-22), pages 11313 - 11318, XP009518431,          ISSN: 0027-8424, Retrieved from the Internet          &lt;URL:http://www.pnas.org/cgi/doi/10.1073/pnas.1002716107&gt;          DOI:          10.1073/PNAS.1002716107,relevantClaims[1,23-25],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  KAR NENG LAI ET AL:          ""Role for macrophage migration inhibitory factor in acute          respiratory distress syndrome"", THE JOURNAL OF PATHOLOGY,          vol. 199, no. 4, 1 April 2003 (2003-04-01), pages 496 -          508, XP055068590, ISSN: 0022-3417, DOI:          10.1002/path.1291,relevantClaims[1,23-25],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  THIERRY CALANDRA ET          AL: ""Macrophage migration inhibitory factor: a regulator          of innate immunity"", NATURE REVIEWS IMMUNOLOGY, vol. 3,          no. 10, 1 October 2003 (2003-10-01), GB, pages 791 - 800,          XP055430236, ISSN: 1474-1733, DOI:          10.1038/nri1200,relevantClaims[1,31-33,35|1,23-25],relevantPassages[&lt;pp&gt;797&lt;/pp&gt;&lt;ppl&gt;798&lt;/ppl&gt;&lt;table&gt;2&lt;/table&gt;];  ROLAN P ET AL:          ""Ibudilast: a review of its pharmacology, efficacy and          safety in respiratory and neurological disease"", EXPERT          OPIN PHARMACOTHER, ASHLEY PUBLICATIONS LTD, LONDON, UK,          vol. 10, no. 17, 1 December 2009 (2009-12-01), pages 2897          - 2904, XP009131305, ISSN: 1465-6566, DOI:          10.1517/14656560903426189,relevantClaims[1,23-25],relevantPassages[&lt;pp&gt;2897&lt;/pp&gt;];  DHEIR HAMAD ET AL:          ""Does Macrophage Migration Inhibitory Factor predict the          prognosis of COVID-19 disease?"", THE JOURNAL OF INFECTION          IN DEVELOPING COUNTRIES, vol. 15, no. 03, 31 March 2021          (2021-03-31), pages 398 - 403, XP055817285, Retrieved          from the Internet          &lt;URL:https://www.jidc.org/index.php/journal/article/download/14009/2485&gt;          DOI:          10.3855/jidc.14009,relevantClaims[1,20-26],relevantPassages[see          Discussion];            NEWS.MEDICAL.NET; PHARMACEUTICAL NEWS, 2 August 2005          (2005-08-02);  J.          GRIFFITH HARDMANL. L. LIMBIRDA. GILMAN: ""FDA's Orange          Book, Goodman & Gilman The Pharmacological Basis of          Therapeutics"", 2005, WORTH PUBLISHERS, INC.;            THE MERCK MANUAL, 2007;            THE MERCK MANUAL OF MEDICAL INFORMATION, 2003;            CAS , no. 50847-11-5;            GIBSON ET AL., EUR J PHARMACOL, vol. 538, 2006, pages 39          - 42;            YANG ET AL., CELL DEATH AND DISEASE, vol. 7, 2016, pages          e2234;            OBERNOLTE, R. ET AL.: ""The cDNA of a human lymphocyte          cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene          family"", GENE, vol. 129, 1993, pages 239 - 247,          XP023539050, DOI: 10.1016/0378-1119(93)90274-7;            RILE, G. ET AL.: ""Potentiation of ibudilast inhibition of          platelet aggregation in the presence of endothelial          cells"", THROMB. RES., vol. 102, 2001, pages 239 -          246;            SOUNESS, J. E. ET AL.: ""Possible role of cyclic AMP          phosphodiesterases in the actions of ibudilast on          eosinophil thromboxane generation and airways smooth          muscle tone"", BR. J. PHARMACOL., vol. 111, 1994, pages          1081 - 1088, XP001018672;            SUZUMURA, A. ET AL.: ""Ibudilast suppresses TNF.alpha.          production by glial cells functioning mainly as type III          phosphodiesterase inhibitor in CNS"", BRAIN RES., vol.          837, 1999, pages 203 - 212, XP002496894, DOI:          10.1016/S0006-8993(99)01666-2;            TAKUMA, K. ET AL.: ""Ibudilast attenuates astrocyte          apoptosis via cyclic GMP signaling pathway in an in vitro          reperfusion model"", BR. J. PHARMACOL., vol. 133, 2001,          pages 841 - 848;            SANFTNER ET AL., XENOBIOTICA, vol. 39, 2009, pages 964 -          977;            CHO ET AL., PNAS-USA, vol. 7, 10 June 2010 (2010-06-10),          pages 11313 - 8;            ""Remington: The Science & Practice of Pharmacy"",          1995, WILLIAMS & WILLIAMS;            ""Physician's Desk Reference"", 1998, MEDICAL          ECONOMICS;            KIBBE, A. H.: ""Handbook of Pharmaceutical Excipients"",          2000, AMERICAN PHARMACEUTICAL ASSOCIATION;            JEFFERY ET AL., PHARM. RES., vol. 10, 1993, pages 362 -          368;            MCGEE ET AL., J. MICROENCAP., 1996",97514-0-0-0 U K,,01199,R09299 U K,
WO2023227617-A1;  EP4282980-A1,"Amplifying nucleic acid which is suspected to be            present in a sample in a low copy number, comprises            providing first reaction mixture in reaction chamber,            subjecting first reaction mixture in chamber, and            providing second reaction mixture",NIINIVAARA A;  SAHARINEN J;  KIRVESKARI J,MOBIDIAG OY (MOBI-Non-standard);  MOBIDIAG OY (MOBI-Non-standard),2023C49121,"   NOVELTY - Amplifying a nucleic acid which is suspected                to be present in a sample in a low copy number,                comprises: providing a first reaction mixture in a                reaction chamber where the first reaction mixture                comprises a first portion of the sample; subjecting                the first reaction mixture in the reaction chamber                to conditions allowing a pre-amplification of the                nucleic acid in order to obtain a first                preamplification mixture; providing a second                reaction mixture in the reaction chamber where the                second reaction mixture comprises a subset of the                first pre-amplification mixture and a second                portion of the sample.    USE - The method is useful for amplifying a nucleic                acid which is suspected to be present in a sample                in a low copy number (claimed).    ADVANTAGE - The method: allows the amplification of target                nucleic acids suspected to be present in a low copy                number; and overcome inhibition by amplification                reaction inhibitory substances.    DETAILED DESCRIPTION - Amplifying a nucleic acid which is suspected                to be present in a sample in a low copy number,                comprises: providing a first reaction mixture in a                reaction chamber where the first reaction mixture                comprises a first portion of the sample; subjecting                the first reaction mixture in the reaction chamber                to conditions allowing a pre-amplification of the                nucleic acid in order to obtain a first                preamplification mixture; providing a second                reaction mixture in the reaction chamber where the                second reaction mixture comprises a subset of the                first pre-amplification mixture and a second                portion of the sample, subjecting the second                reaction mixture to conditions allowing a                pre-amplification of the nucleic acid in order to                obtain a second pre-amplification mixture,                optionally, repeating steps (iii) and (iv) a number                N additional times in order to obtain an (N+2)                pre-amplification mixture, and subjecting the                second pre-amplification mixture obtained in step                (iv) or the (N+2) pre-amplification mixture                obtained in step (v) to conditions allowing an                amplification of the nucleic acid in order to                obtain an amplification mixture, where the sample                has a total sample volume which exceeds a volume                capacity of the reaction chamber. An INDEPENDENT                CLAIM is also included for amplifying a nucleic                acid which is suspected to be present in a sample                in a low copy number, where the method comprises                providing a first reaction mixture in a reaction                chamber where the first reaction mixture comprises                a first portion of the sample, subjecting the first                reaction mixture in the reaction chamber to                conditions allowing a pre-amplification of the                nucleic acid in order to obtain a first                preamplification mixture, removing a subset of the                first pre-amplification mixture from the reaction                chamber in order to provide a remaining subset of                the first pre-amplification mixture in the reaction                chamber, providing a second reaction mixture in the                reaction chamber where the second reaction mixture                comprises the remaining subset of the first                pre-amplification mixture and a second portion of                the sample, subjecting the second reaction mixture                to conditions allowing a pre-amplification of the                nucleic acid in order to obtain a second                pre-amplification mixture; vi. optionally,                repeating steps iii) to v) a number N additional                times in order to obtain an (N+2) pre-amplification                mixture, subjecting the second pre-amplification                mixture obtained in step (v) or the (N+2)                pre-amplification mixture obtained in step (vi) to                conditions allowing an amplification of the nucleic                acid in order to obtain an amplification mixture,                where the sample has a total sample volume which                exceeds a volume capacity of the reaction chamber,                or comprising providing the sample in a sample                chamber, transferring a first portion of the sample                to a reaction chamber in order to obtain a first                reaction mixture, subjecting the first reaction                mixture in the reaction chamber to conditions                allowing a pre-amplification of the nucleic acid in                order to obtain a first preamplification mixture,                transferring at least a subset of the first                pre-amplification mixture from the reaction chamber                to the sample chamber comprising a second portion                of the sample in order to provide a combined                pre-amplification sample mixture; v. transferring a                portion of the combined pre-amplification sample                mixture to the reaction chamber in order to provide                the second reaction mixture, subjecting the second                reaction mixture to conditions allowing a                pre-amplification of the nucleic acid in order to                obtain a second pre-amplification mixture; vii.                optionally, repeating steps iii) and iv) a number N                additional times in order to obtain an (N+2)                pre-amplification mixture, and/or subjecting the                second pre-amplification mixture obtained in step                (v) or the (N+2) pre-amplification mixture obtained                in step (vi) to conditions allowing an                amplification of the nucleic acid in order to                obtain an amplification mixture, where the sample                has a total sample volume which exceeds a volume                capacity, or comprising providing a first reaction                mixture in a reaction chamber where the first                reaction mixture comprises a first portion of the                sample, subjecting the first reaction mixture in                the reaction chamber to conditions allowing a                pre-amplification of the nucleic acid in order to                obtain a first preamplification mixture, providing                a second reaction mixture in the reaction chamber                where the second reaction mixture comprises a                subset of the first pre-amplification mixture and a                second portion of the sample, subjecting the second                reaction mixture to conditions allowing an                amplification of the nucleic acid in order to                obtain an amplification mixture, where the sample                has a total sample volume which exceeds a volume                capacity of the reaction chamber. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E01;  B04-E05;  B04-E99;  B11-C08E3;  B11-C08F8;  B12-K04F;  C04-E01;  C04-E05;  C04-E99;  C11-C08E3;  C11-C08F8;  C12-K04F;  D05-H09;  D05-H18B,C12Q-001/6848,WO2023227617-A1   30 Nov 2023   C12Q-001/6848   202300Pages: 60   English;  EP4282980-A1   29 Nov 2023   C12Q-001/6848   202300   English,WO2023227617-A1    WOEP063820    23 May 2023;   EP4282980-A1    EP174952    23 May 2022,,EP174952    23 May 2022,WO2023227617-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP4282980-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN  ,,"WO2023227617-A1 -- WO2013171140-A1   WARTHOE P (WART-Individual)   WARTHOE P;  WO2022112655-A1   MOBIDIAG OY (MOBI-Non-standard)   NIINIVAARA A,  SAHARINEN J,  KIRVESKARI J;  WO2007130951-A2   CEPHEID (CPHE)   SMITH J H,  PERSING D H,  WORTMAN A,  CHANG R,  SWENSON D;  WO2020104390-A2   BIOCARTIS NV (BIOC-Non-standard)   HAESENDONCKX M;  EP320308-A   BIOTECHNICA INT INC (BIOY);  ABBOTT LABORATORIES (ABBO)   BACKMAN K C,  WANG C N J;  US4683195-A   CETUS CORP (CETU)   MULLIS K B,  ARNHEIM N,  SAIKI R K,  ERLICH H A,  HORN G T,  SCHARF S J;  US4683202-A   CETUS CORP (CETU)   MULLIS K B,  ARNHEIM N,  SAIKI R K,  ERLICH H A,  HORN G T,  SCHARF S J;  US4786600-A   UNIV COLUMBIA NEW YORK (UYCO)   KRAMER F R,  MIELE E A,  MILLS D R;  US4800159-A   CETUS CORP (CETU)   MULLIS K B,  ARNHEIM N,  SAIKI R K,  ERLICH H A,  HORN G T,  SCHARF S J;  US4868105-A   CHIRON CORP (CHIR)   UREDA M S,  WARNER B,  HORN J;  US5124246-A   CHIRON CORP (CHIR)   URDEA M S,  WARNER B,  RUNNING J A,  KOLBERG J A,  CLYNE J M,  SANCHEZPES R,  HORN T;  US5130238-A   CANGENE CORP (CANG-Non-standard)   MALEK L T,  DAVEY C,  HENDERSON G,  SOOKNANAN R;  US5177196-A   MICROPROBE CORP (MICR-Non-standard)   MEYER R B,  ADAMS A D,  PETRIE C R;  US5399491-A   GEN-PROBE INC (HOGC)   FULTZ T J,  KACIAN D L;  US5422252-A   BECTON DICKINSON CO (BECT)   WALKER T G,  NADEAU J G,  LITTLE M C;  US5437990-A   UNIV LELAND STANFORD JUNIOR (STRD)   BURG L J,  POULETTY P,  BOOTHROYD J C;  US5554516-A   GEN-PROBE INC (HOGC)   KACIAN D L,  MCALLISTER D L,  MCDONOUGH S H,  DATTAGUPTA N;  US7282328-B2   KONG H (KONG-Individual);  VINCENT M (VINC-Individual);  XU Y (XUYY-Individual)   KONG H,  VINCENT M,  XU Y;  US7374885-B2   GEN-PROBE INC (HOGC)   BECKER M M,  LAM W,  LIVEZEY K W,  BRENTANO S T,  KOLK D P,  SCHRODER A R W;  WO1988001302-A   ;  WO1988010315-A   ;  WO1994003472-A1   ;  WO1995003430-A1   ;  WO2014018885-A2   GEN-PROBE INC (HOGC)   GILLY M J,  VIJAYSRI N S,  CARRICK J M,  WANG X,  YAMAGATA S K;  WO2018075633-A2   GEN-PROBE INC (HOGC)   MIICK S,  DARBY P M,  JACKSON J A,  AUBIN S M J;  EP4282980-A1 -- WO2013171140-A1   WARTHOE P (WART-Individual)   WARTHOE P;  WO2022112655-A1   MOBIDIAG OY (MOBI-Non-standard)   NIINIVAARA A,  SAHARINEN J,  KIRVESKARI J;  WO2007130951-A2   CEPHEID (CPHE)   SMITH J H,  PERSING D H,  WORTMAN A,  CHANG R,  SWENSON D;  WO2020104390-A2   BIOCARTIS NV (BIOC-Non-standard)   HAESENDONCKX M;  EP320308-A   BIOTECHNICA INT INC (BIOY);  ABBOTT LABORATORIES (ABBO)   BACKMAN K C,  WANG C N J;  US4683195-A   CETUS CORP (CETU)   MULLIS K B,  ARNHEIM N,  SAIKI R K,  ERLICH H A,  HORN G T,  SCHARF S J;  US4683202-A   CETUS CORP (CETU)   MULLIS K B,  ARNHEIM N,  SAIKI R K,  ERLICH H A,  HORN G T,  SCHARF S J;  US4786600-A   UNIV COLUMBIA NEW YORK (UYCO)   KRAMER F R,  MIELE E A,  MILLS D R;  US4800159-A   CETUS CORP (CETU)   MULLIS K B,  ARNHEIM N,  SAIKI R K,  ERLICH H A,  HORN G T,  SCHARF S J;  US4868105-A   CHIRON CORP (CHIR)   UREDA M S,  WARNER B,  HORN J;  US5124246-A   CHIRON CORP (CHIR)   URDEA M S,  WARNER B,  RUNNING J A,  KOLBERG J A,  CLYNE J M,  SANCHEZPES R,  HORN T;  US5130238-A   CANGENE CORP (CANG-Non-standard)   MALEK L T,  DAVEY C,  HENDERSON G,  SOOKNANAN R;  US5177196-A   MICROPROBE CORP (MICR-Non-standard)   MEYER R B,  ADAMS A D,  PETRIE C R;  US5399491-A   GEN-PROBE INC (HOGC)   FULTZ T J,  KACIAN D L;  US5422252-A   BECTON DICKINSON CO (BECT)   WALKER T G,  NADEAU J G,  LITTLE M C;  US5437990-A   UNIV LELAND STANFORD JUNIOR (STRD)   BURG L J,  POULETTY P,  BOOTHROYD J C;  US5554516-A   GEN-PROBE INC (HOGC)   KACIAN D L,  MCALLISTER D L,  MCDONOUGH S H,  DATTAGUPTA N;  US20050186588-A1   ;  US7282328-B2   KONG H (KONG-Individual);  VINCENT M (VINC-Individual);  XU Y (XUYY-Individual)   KONG H,  VINCENT M,  XU Y;  US7374885-B2   GEN-PROBE INC (HOGC)   BECKER M M,  LAM W,  LIVEZEY K W,  BRENTANO S T,  KOLK D P,  SCHRODER A R W;  WO1988001302-A   ;  WO1988010315-A   ;  WO1994003472-A1   ;  WO1995003430-A1   ;  WO2018075633-A2   GEN-PROBE INC (HOGC)   MIICK S,  DARBY P M,  JACKSON J A,  AUBIN S M J","WO2023227617-A1  DANIEL ANDERSSON ET          AL: ""Properties of targeted preamplification in DNA and          cDNA quantification"", EXPERT REVIEWS IN MOLECULAR          DIAGNOSTICS, vol. 15, no. 8, 3 August 2015 (2015-08-03),          GB, pages 1085 - 1100, XP055341095, ISSN: 1473-7159, DOI:          10.1586/14737159.2015.1057124,relevantClaims[1-32],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            CHEN ET AL., NUCLEIC ACIDS RES, vol. 23, 1995, pages 2661          - 2668;            SINGH ET AL., CHEM. COMM., 1998, pages 455 -          456;            WENGEL J, ACC. CHEM. RES., vol. 32, 1998, pages 301 -          310;            PALISSA ET AL., Z. CHEM., vol. 27, 1987, pages          216;            CHEN ET AL., NUCL. ACIDS RES., vol. 23, 1995, pages 2662          - 2668;            CARUTHERS ET AL.: ""Chemical Synthesis of Deoxynucleotides          by the Phosphoramidite Method"", METHODS ENZYMOL., vol.          154, 1987, pages 287, XP001008645, DOI:          10.1016/0076-6879(87)54081-2;            BARONE ET AL.: ""In Situ Activation of          bis-dialkylaminephosphines--a New Method for Synthesizing          Deoxyoligonucleotides on Polymer Supports"", NUCLEIC ACIDS          RES., vol. 12, no. 10, 1984, pages 4051EP4282980-A1  DANIEL ANDERSSON ET          AL: ""Properties of targeted preamplification in DNA and          cDNA quantification"", EXPERT REVIEWS IN MOLECULAR          DIAGNOSTICS, vol. 15, no. 8, 3 August 2015 (2015-08-03),          GB, pages 1085 - 1100, XP055341095, ISSN: 1473-7159, DOI:          10.1586/14737159.2015.1057124,relevantClaims[1-32],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            CHEN ET AL., NUCLEIC ACIDS RES., vol. 23, 1995, pages          2661 - 2668;            SINGH ET AL., CHEM. COMM., 1998, pages 455 -          456;            WENGEL J., ACC. CHEM. RES., vol. 32, 1998, pages 301 -          310;            PALISSA ET AL., Z. CHEM., vol. 27, 1987, pages          216;            CHEN ET AL., NUCL. ACIDS RES., vol. 23, 1995, pages 2662          - 2668;            CARUTHERS ET AL.: ""Chemical Synthesis of Deoxynucleotides          by the Phosphoramidite Method"", METHODS ENZYMOL., vol.          154, 1987, pages 287, XP001008645, DOI:          10.1016/0076-6879(87)54081-2;            BARONE ET AL.: ""In Situ Activation of          bis-dialkylaminephosphines--a New Method for Synthesizing          Deoxyoligonucleotides on Polymer Supports"", NUCLEIC ACIDS          RES., vol. 12, no. 10, 1984, pages 4051",,,,,
WO2015143335-A1;  US2017096455-A1;  US9884895-B2,"New chimeric coronavirus spike protein comprises a            first region comprising a portion of a coronavirus            spike protein ectodomain, useful for producing an            immune response to a coronavirus, and for treating a            coronavirus infection",BARIC R;  AGNIHOTHRAM S;  YOUNT B,UNIV NORTH CAROLINA (UNCR-C),201558027D,"   NOVELTY - A chimeric coronavirus spike protein                comprising, in orientation from amino to carboxy                terminus: (a) a first region comprising a portion                of a coronavirus spike protein ectodomain that                precedes a coronavirus spike protein receptor                binding domain (RBD); (b) a second region                comprising a coronavirus spike protein RBD of a                second coronavirus; (c) a third region comprising a                portion of a coronavirus spike protein S1 domain;                and (d) a fourth region comprising a portion of a                coronavirus spike protein from the start of the                fusion protein domain through the carboxy terminal                end, is new.    USE - The chimeric coronavirus spike protein,                nucleic acid molecule, vector, VRP, VLP,                coronavirus particle, composition and methods are                useful for producing an immune response to a                coronavirus in a subject, for treating a                coronavirus infection in a subject in need, for                preventing a disease or disorder caused by a                coronavirus infection in a subject, for protecting                a subject from the effects of coronavirus                infection, for identifying a coronavirus spike                protein for administration to elicit an immune                response to coronavirus in a subject infected by a                coronavirus and/or a subject at risk of coronavirus                infection and/or to a subject for whom eliciting an                immune response to a coronavirus is needed or                desired, and for identifying an antibody that                neutralizes a coronavirus infecting a subject (all                claimed).    ADVANTAGE - The chimeric coronavirus spike protein,                nucleic acid molecule, vector, VRP, VLP,                coronavirus particle, composition and methods can                be efficiently used in treating and/or preventing a                disease or disorder caused by a coronavirus                infection.    DETAILED DESCRIPTION - A chimeric coronavirus spike protein                comprising, in orientation from amino to carboxy                terminus: (a) a first region comprising a portion                of a coronavirus spike protein ectodomain that                precedes a coronavirus spike protein receptor                binding domain (RBD) as located in a nonchimeric                coronavirus spike protein, of a first coronavirus;                (b) a second region comprising a coronavirus spike                protein RBD of a second coronavirus that is                different from the first coronavirus; (c) a third                region comprising a portion of a coronavirus spike                protein S1 domain as located in a nonchimeric                coronavirus spike protein immediately downstream of                the RBD, contiguous with a portion a coronavirus                spike protein S2 domain as located immediately                upstream of a fusion protein domain in a                nonchimeric coronavirus spike protein, where the                third region is of the first coronavirus; and (d) a                fourth region comprising a portion of a coronavirus                spike protein from the start of the fusion protein                domain through the carboxy terminal end as located                in a nonchimeric coronavirus spike protein of a                third coronavirus that is different from the first                coronavirus and the second coronavirus, is new.                INDEPENDENT CLAIMS are included for:    (1) an isolated nucleic acid molecule encoding                the chimeric coronavirus spike protein;    (2) a vector comprising the isolated nucleic                acid molecule encoding the chimeric coronavirus                spike protein;    (3) a Venezuelan equine encephalitis replicon                particle (VRP) comprising the isolated nucleic acid                molecule encoding the chimeric coronavirus spike                protein;    (4) a virus like particle (VLP) comprising the                chimeric coronavirus spike protein and a matrix                protein of any virus that can form a VLP;    (5) a coronavirus particle comprising the                chimeric coronavirus spike protein;    (6) a population of VLPs, VRPs and/or                coronavirus particles;    (7) a composition comprising the chimeric                spike protein, the nucleic acid molecule, the                vector, the VRP, the VLP, the coronavirus particle,                and/or the population in a pharmaceutically                acceptable carrier;    (8) a method of identifying a coronavirus                spike protein for administration to elicit an                immune response to coronavirus in a subject                infected by a coronavirus and/or a subject at risk                of coronavirus infection and/or to a subject for                whom eliciting an immune response to a coronavirus                is needed or desired; and    (9) a method of identifying an antibody that                neutralizes a coronavirus infecting a                subject. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E99;  B04-E02F;  B04-E08;  B04-N03K0E;  B11-C07A;  B11-C08E;  B12-K04A4A;  B14-A02B5;  B14-G01;  B14-S11A;  C04-E99;  C04-E02F;  C04-E08;  C11-C07;  C11-C08E;  C12-K04A4A;  C14-A02B5;  C14-G01;  C14-S11A;  D05-H99;  D05-H09;  D05-H12C;  D05-H12E,A61K-039/215;  A61P-031/12;  C07K-014/165;  C12N-015/50;  A61K-039/12;  C07K-014/005;  C07K-016/10;  C12N-007/00;  A61K-039/00;  A61K-039/395;  A61K-045/06,WO2015143335-A1   24 Sep 2015   C07K-014/165   201567Pages: 72   English;  US2017096455-A1   06 Apr 2017   C07K-014/005   201726   English;  US9884895-B2   06 Feb 2018   C07K-016/10   201814   English,WO2015143335-A1    WOUS021773    20 Mar 2015;   US2017096455-A1    US15124992    09 Sep 2016;   US9884895-B2    US15124992    09 Sep 2016,US2017096455-A1 PCT application Application WOUS021773;   US2017096455-A1 Provisional Application US968279P;   US9884895-B2 PCT application Application WOUS021773;   US9884895-B2 Provisional Application US968279P;   US9884895-B2 Based on Patent WO2015143335;   US9884895-B2 Previous Publ. Patent US2017096455,US968279P    20 Mar 2014;  US15124992    09 Sep 2016,WO2015143335-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JP;  KE;  KG;  KN;  KP;  KR;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      ,,"WO2015143335-A1 -- WO1993023422-A1   ;  WO2005002500-A2   MERCK&CO INC (MERI);  IST RICERCHE BIOL MOLECOLARE ANGELETTI (ISTR)   KIM P S,  ECKERT D,  GARSKY V M,  FREIDINGER R M,  GELEZIUNAS R,  PESSI A;  WO2005081716-A2   UNIV JOHNS HOPKINS (UYJO)   WU T,  HUNG C,  KIM T W;  US9884895-B2 -- US3610795-A   IRSID INST RECH SIDERURGIE FR (IRSF);  US4474893-A   UNIV TEXAS SYSTEM (TEXA)   READING C L;  US4676980-A   US DEPT HEALTH & HUMAN SERVICE (USSH)   SEGAL D;  US4816567-A   GENENTECH INC (GETH);  CITY OF HOPE (CITY)   CABILLY S,  HOLMES W E,  WETZEL R B,  HEYNEKER H L,  RIGGS A D;  US5879881-A   HYBRITECH INC (HYBR-Non-standard)   RUBENSTEIN A S;  US20030073147-A1   ;  WO1993023422-A1   ;  WO2005002500-A2   MERCK&CO INC (MERI);  IST RICERCHE BIOL MOLECOLARE ANGELETTI (ISTR)   KIM P S,  ECKERT D,  GARSKY V M,  FREIDINGER R M,  GELEZIUNAS R,  PESSI A;  WO2005081716-A2   UNIV JOHNS HOPKINS (UYJO)   WU T,  HUNG C,  KIM T W","WO2015143335-A1  AGNIHOTHRAM S ET          AL.: ""Evaluation of serologic and antigenic relationships          between middle eastern respiratory syndrome coronavirus          and other coronaviruses to develop vaccine platforms for          the rapid response to emerging coronaviruses"", J INFECT          DIS., vol. 209, no. 7, 18 November 2013 (2013-11-18),          pages 995 - 1006, XP055227760, [retrieved on          20140401];  AGNIHOTHRAM S ET          AL.: ""Evaluation of serologic and antigenic relationships          between middle eastern respiratory syndrome coronavirus          and other coronaviruses to develop vaccine platforms for          the rapid response to emerging coronaviruses"", J INFECT          DIS., vol. 209, no. 7, 18 November 2013 (2013-11-18),          pages 995 - 1006, XP055227760, [retrieved on          20140401],relevantClaims[1-23]US9884895-B2            Agnihothram et al. ""Evaluation of Serologic and Antigenic          Relationships Between Middle Eastern Respiratory Syndrome          Coronavirus and Other Coronaviruses to Develop Vaccine          Platforms for the Rapid Response to Emerging          Coronaviruses"" &lt;xhtml:i &gt;The Journal of          Infectious Diseases&lt;/xhtml:i&gt;209:995-1006          (2014).;            International Search Report and the Written Opinion of          the International Searching Authority corresponding to          International Patent Application No. PCT/US2015/021773          (12 pages) (dated Jun. 10, 2015).;            GenBank Accession No. ACJ60694.1, ""Spike glycoprotein          [recombinant coronavirus]"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 26,          2016.;            GenBank Accession No. AAP13441.1, ""S protein [SARS          coronavirus Urbani]"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 25,          2016.;            GenBank Accession No. ABG47069, ""Spike protein [Bat CoV          279/2005]"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 19,          2006.;            GenBank Accession No. ABN10848.1, ""Spike glycoprotein          [Bat coronavirus HKU4-2]"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Feb. 7,          2007.;            GenBank Accession No. AFS88936.1, ""S protein [Human          betacoronavirus 2c EMC/2012]"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Dec. 4,          2012.;            GenBank Accession No. ABN10902.1, ""Spike glycoprotein          [Bat coronavirus HKU5-5]"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Feb. 7,          2007.;            GenBank Accession No. FJ211859, ""Recombinant coronavirus          clone Bat SARS-CoV, complete sequence"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 11 pages, Jul. 26,          2016.;            GenBank Accession No. FJ211860, ""Recombinant coronavirus          clone Bat-SRBD spike glycoprotein gene, complete cds"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 3          pages, Dec. 31, 2008.;            GenBank Accession No. DQ022305, ""Bat SARS coronavirus          HKU3-1, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Oct. 25,          2005.;            GenBank Accession No. DQ084199, ""Bat SARS coronavirus          HKU3-2, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Sep. 28,          2005.;            GenBank Accession No. DQ084200, ""Bat SARS coronavirus          HKU3-3, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Sep. 28,          2005.;            GenBank Accession No. DQ412043, ""Bat SARS coronavirus          Rm1, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Jul. 13,          2006.;            GenBank Accession No. DQ648857, ""Bat coronavirus          (BtCoV/279/2005), complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 11 pages, Jul. 19,          2006.;            GenBank Accession No. DQ412042, ""Bat SARS coronavirus          Rf1, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Jul. 13,          2016.;            GenBank Accession No. DQ648856, ""Bat coronavirus          (BtCoV/273/2005), complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 11 pages, Jul. 19,          2006.;            GenBank Accession No. DQ071615, ""Bat SARS coronavirus          Rp3, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Jan. 25,          2006.;            GenBank Accession No. AY686863, ""SARS coronavirus A022,          complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Jul. 21,          2006.;            GenBank Accession No. AY278554, ""SARS coronavirus          CUHK-W1, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 14 pages, Jul. 31,          2003.;            GenBank Accession No. AY278489, ""SARS coronavirus GD01,          complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Sep. 1,          2009.;            GenBank Accession No. AY515512, ""SARS coronavirus          HC/SZ/61/03, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 8 pages, Jan. 1,          2005.;            Genbank accession No. AY304488, ""SARS coronavirus SZ16,          complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;8 pages, Nov. 5,          2003.;            GenBank Accession No. AY278741, ""SARS coronavirus Urbani,          complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;14 pages, Jul. 25,          2016.;            GenBank Accession No. AY572035, ""SARS coronavirus          civet010, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Dec. 1,          2005.;            GenBank Accession No. DQ497008, ""SARS coronavirus strain          MA-15, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Mar. 20,          2007.;            GenBank Accession No. KC881005, ""Bat SARS-like          coronavirus RsSHC014, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Nov. 22,          2013.;            GenBank Accession No. KC881006, Bat SARS-like coronavirus          Rs3367, complete genome, &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Nov. 22,          2013.;            GenBank Accession No. KC881007, ""Bat SARS-like          coronavirus WIV1 spike protein (S) gene, complete cds"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 3          pages, Nov. 22, 2013.;            GenBank Accession No. KF600652.1, ""Middle East          respiratory syndrome coronavirus isolate          Riyadh&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2012, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Jul. 24,          2014.;            GenBank Accession No. KF600651.1, ""Middle East          respiratory syndrome coronavirus isolate"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 13          pages, Jul. 24, 2014.;            GenBank Accession No. KF600647.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;17&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Jul. 24,          2014.;            GenBank Accession No. KF600645.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;15&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Jul. 24,          2014.;            GenBank Accession No. KF600644.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;16&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Jul. 24,          2014.;            GenBank Accession No. KF600634, ""Middle East respiratory          syndrome coronavirus isolate Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;21&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Jul. 24,          2014.;            GenBank Accession No. KF600632, ""Middle East respiratory          syndrome coronavirus isolate Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;19&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Jul. 24,          2014.;            GenBank Accession No. KF600630.1, ""Middle East          respiratory syndrome coronavirus isolate          Buraidah&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;1&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Jul. 24,          2014.;            GenBank Accession No. KF600628.1, ""Middle East          respiratory syndrome coronavirus isolate          Hafr-Al-Batin&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;1&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Jul. 24,          2014.;            GenBank Accession No. KF600627.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;12&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Jul. 24,          2014.;            GenBank Accession No. KF600620.1, ""Middle East          respiratory syndrome coronavirus isolate          Bisha&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;1&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2012, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Jul. 24,          2014.;            GenBank Accession No. KF600613.1, ""Middle East          respiratory syndrome coronavirus isolate          Riyadh&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;3&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Jul. 24,          2014.;            GenBank Accession No. KF600612.1, ""Middle East          respiratory syndrome coronavirus isolate          Riyadh&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;1&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2012, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Jul. 24,          2014.;            GenBank Accession No. KF186565.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;3&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Jul. 24,          2014.;            GenBank Accession No. KF186567.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;1&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Jul. 24,          2014.;            GenBank Accession No. KF186566.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Jul. 24,          2014.;            GenBank Accession No. KF186564.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;4&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Jul. 24,          2014.;            GenBank Accession No. KF192507.1, ""Middle East          respiratory syndrome coronavirus, complete genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 13          pages, Jul. 24, 2014.;            GenBank Accession No. NC&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;019843, ""Middle East          respiratory syndrome coronavirus, complete genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 16          pages, Sep. 9, 2014.;            GenBank Accession No. KC667074, ""Human betacoronavirus 2c          England-Qatar/2012, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Apr. 30,          2013.;            GenBank Accession No. KF600656.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;13d&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 2          pages, Jul. 24, 2014.;            GenBank Accession No. KF600655.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;7a&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 8          pages, Jul. 24, 2014.;            GenBank Accession No. KF600654.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;9b&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 2          pages, Jul. 24, 2014.;            GenBank Accession No. KF600649.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;9c&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 2          pages, Jul. 24, 2014.;            GenBank Accession No. KF600648.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;9a&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 3          pages, Jul. 24, 2014.;            GenBank Accession No. KF600646.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;11b&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 4          pages, Jul. 24, 2014.;            GenBank Accession No. KF600643.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;14b&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 7          pages, Jul. 24, 2014.;            GenBank Accession No. KF600642.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;10b&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 3          pages, Jul. 24, 2014.;            GenBank Accession No. KF600640.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;13e&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 2          pages, Jul. 24, 2014.;            GenBank Accession No. KF600639.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;9e&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 2          pages, Jul. 24, 2014.;            GenBank Accession No. KF600638.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;8b&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 3          pages, Jul. 24, 2014.;            GenBank Accession No. KF600637.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;13c&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 2          pages, Jul. 24, 2014.;            GenBank Accession No. KF600636.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;11c&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 7          pages, Jul. 24, 2014.;            GenBank Accession No, KF600635.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;8d&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 2          pages, Jul. 24, 2014.;            GenBank Accession No. KF600631.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;22e&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 3          pages, Jul. 24, 2014.;            GenBank Accession No. KF600626.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;8c&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 5          pages, Jul. 24, 2014.;            GenBank Accession No. KF600625.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;22b&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 2          pages, Jul. 24, 2014.;            GenBank Accession No. KF600624.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;10c&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 2          pages, Jul. 24, 2014.;            GenBank Accession No. KF600623.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;7b&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 5          pages, Jul. 24, 2014.;            GenBank Accession No. KF600622.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;9d&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 3          pages, Jul. 24, 2014.;            GenBank Accession No. KF600621.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;22f&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 2          pages, Jul. 24, 2014.;            GenBank Accession No. KF600619.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;22d&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 3          pages, Jul. 24, 2014.;            GenBank Accession No. KF600618.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;8a&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 2          pages, Jul. 24, 2014.;            GenBank Accession No. KF600616.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;13b&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 3          pages, Jul. 24, 2014.;            GenBank Accession No. KF600615.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;14a&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 4          pages, Jul. 24, 2014.;            GenBank Accession No. KF600614.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;10e&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 2          pages, Jul. 24, 2014.;            GenBank Accession No. KF600641.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;10d&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 1          page, Jul. 24, 2014.;            GenBank Accession No. KF600633.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;22c&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 2          pages, Jul. 24, 2014.;            GenBank Accession No. KF600629.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;11a&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 2          pages, Jul. 24, 2014.;            GenBank Accession No. KF600617.1, ""Middle East          respiratory syndrome coronavirus isolate          Al-Hasa&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;22a&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;2013, partial genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 2          pages, Jul. 24, 2014.;            GenBank Accession No. KC869678.2, ""Coronavirus          Neoromicia/PML-PHE1/RSA/2011 RNA-dependent RNA polymerase          (ORF1b) gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Aug. 27,          2013.;            GenBank Accession No. KF493885.1, ""Bat Coronavirus          Taper/CII&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;KDS&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;287/Bisha/Saudi          Arabia/2012 RNA-directed RNA polymerase gene, partial          cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 1 page, Nov. 14,          2013.;            GenBank Accession No. KF493888.1, ""Bat coronavirus          Rhhar/CII&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;KSA&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;003/Bisha/Saudi          Arabia/2013 RNA-directed RNA polymerase gene, partial          cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 1 page, Nov. 14,          2013.;            GenBank Accession No. KF493887.1, ""Bat coronavirus          Pikuh/CII&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;KSA&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;001/Riyadh/Saudi          Arabia/2013 RNA-directed RNA polymerase gene, partial          cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 1 page, Nov. 14,          2013.;            GenBank Accession No. KF493886.1, ""Bat coronavirus          Rhhar/CII&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;KSA&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;002/Bisha/Saudi          Arabia/2013 RNA-directed RNA polymerase gene, partial          cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 1 page, Nov. 14,          2013.;            GenBank Accession No. KF493884.1, ""Bat coronavirus          Rhhar/CII&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;KSA&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;004/Bisha/Saudi          Arabia/2013 RNA-directed RNA polymerase gene, partial          cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 1 page, Nov. 14,          2013.;            GenBank Accession No. EF065506, ""Bat coronavirus HKU4-2,          complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Feb. 7,          2007.;            GenBank Accession No. NC&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;009019, ""Bat          coronavirus HKU4-1, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Mar. 28,          2016.;            GenBank Accession No. EF065507, ""Bat coronavirus HKU4-3,          complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Feb. 7,          2007.;            GenBank Accession No. EF065508, ""Bat coronavirus HKU4-4,          complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Feb. 7,          2007.;            GenBank Accession No. NC&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;008315, ""Bat          coronavirus (BtCoV/133/2005), complete genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 12          pages, May 22, 2007.;            GenBank Accession No. EF065512, ""Bat coronavirus HKU5-5,          complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Feb. 7,          2007.;            GenBank Accession No. NC&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;009020, ""Bat          coronavirus HKU5-1, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Mar. 28,          2016.;            GenBank Accession No. EF065510, ""Bat coronavirus HKU5-2,          complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Feb. 7,          2007.;            GenBank Accession No. EF065511, ""Bat coronavirus HKU5-3,          complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Feb. 7,          2007.;            GenBank Accession No. KC776174.1, ""Human betacoronavirus          2c Jordan-N3/2012, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Mar. 25,          2013.;            GenBank Accession No. JX869059.2, ""Human betacoronavirus          2c EMC/2012, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Dec. 4,          2012.;            GenBank Accession No. KC522089.1, ""Pipistrellus bat          coronavirus HKU5 isolate 33R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522088.1, ""Pipistrellus bat          coronavirus HKU5 isolate 32R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522087.1, ""Pipistrellus bat          coronavirus HKU5 isolate 31R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522086.1, ""Pipistrellus bat          coronavirus HKU5 isolate 30R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522085.1, ""Pipistrellus bat          coronavirus HKU5 isolate 28R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522084.1, ""Pipistrellus bat          coronavirus HKU5 isolate 27R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522083.1, ""Pipistrellus bat          coronavirus HKU5 isolate 26R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522082.1, ""Pipistrellus bat          coronavirus HKU5 isolate 24R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522081.1, ""Pipistrellus bat          coronavirus HKU5 isolate 22R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522080.1, ""Pipistrellus bat          coronavirus HKU5 isolate 21R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522079.1, ""Pipistrellus bat          coronavirus HKU5 isolate 20R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522078.1, ""Pipistrellus bat          coronavirus HKU5 isolate 19R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522077.1, ""Pipistrellus bat          coronavirus HKU5 isolate 18R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522076.1, ""Pipistrellus bat          coronavirus HKU5 isolate 17R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522075.1, ""Pipistrellus bat          coronavirus HKU5 isolate 16R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522104.1, ""Pipistrellus bat          coronavirus HKU5 isolate 33S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522103.1, ""Pipistrellus bat          coronavirus HKU5 isolate 32S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522102.1, ""Pipistrellus bat          coronavirus HKU5 isolate 31S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522101.1, ""Pipistrellus bat          coronavirus HKU5 isolate 30S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522100.1, ""Pipistrellus bat          coronavirus HKU5 isolate 28S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522099.1, ""Pipistrellus bat          coronavirus HKU5 isolate 27S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522098.1, ""Pipistrellus bat          coronavirus HKU5 isolate 26S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522097.1, ""Pipistrellus bat          coronavirus HKU5 isolate 24S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522096.1, ""Pipistrellus bat          coronavirus HKU5 isolate 22S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522095.1, ""Pipistrellus bat          coronavirus HKU5 isolate 21S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522094.1, ""Pipistrellus bat          coronavirus HKU5 isolate 20S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522093.1, ""Pipistrellus bat          coronavirus HKU5 isolate 19S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522092.1, ""Pipistrellus bat          coronavirus HKU5 isolate 18S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522091.1, ""Pipistrellus bat          coronavirus HKU5 isolate 17S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522090.1, ""Pipistrellus bat          coronavirus HKU5 isolate 16S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522119.1, ""Pipistrellus bat          coronavirus HKU5 isolate 33N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522118.1, ""Pipistrellus bat          coronavirus HKU5 isolate 32N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522117.1, ""Pipistrellus bat          coronavirus HKU5 isolate 31N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522116.1, ""Pipistrellus bat          coronavirus HKU5 isolate 30N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522115.1, ""Pipistrellus bat          coronavirus HKU5 isolate 28N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522114.1, ""Pipistrellus bat          coronavirus HKU5 isolate 27N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522113.1, ""Pipistrellus bat          coronavirus HKU5 isolate 26N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522112.1, ""Pipistrellus bat          coronavirus HKU5 isolate 24N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522111.1, ""Pipistrellus bat          coronavirus HKU5 isolate 22N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522110.1, ""Pipistrellus bat          coronavirus HKU5 isolate 21N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522109.1, ""Pipistrellus bat          coronavirus HKU5 isolate 20N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522108.1, ""Pipistrellus bat          coronavirus HKU5 isolate 19N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522107.1, ""Pipistrellus bat          coronavirus HKU5 isolate 18N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522106.1, ""Pipistrellus bat          coronavirus HKU5 isolate 17N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522105.1, ""Pipistrellus bat          coronavirus HKU5 isolate 16N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522048.1, ""Tylonycteris bat          coronavirus HKU4 isolate 15R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522047.1, ""Tylonycteris bat          coronavirus HKU4 isolate 14R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522046.1, ""Tylonycteris bat          coronavirus HKU4 isolate 12R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522045.1, ""Tylonycteris bat          coronavirus HKU4 isolate 11R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522044.1, ""Tylonycteris bat          coronavirus HKU4 isolate 10R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522043.1, ""Tylonycteris bat          coronavirus HKU4 isolate 9R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522042.1, ""Tylonycteris bat          coronavirus HKU4 isolate 8R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522041.1, ""Tylonycteris bat          coronavirus HKU4 isolate 7R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522040.1, ""Tylonycteris bat          coronavirus HKU4 isolate 6R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522039.1, ""Tylonycteris bat          coronavirus HKU4 isolate 5R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522038.1, ""Tylonycteris bat          coronavirus HKU4 isolate 4R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522037.1, ""Tylonycteris bat          coronavirus HKU4 isolate 3R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522036.1, ""Tylonycteris bat          coronavirus HKU4 isolate 2R RNA-dependent RNA polymerase          gene, partial cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522061.1, ""Tylonycteris bat          coronavirus HKU4 isolate 15S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522060.1, ""Tylonycteris bat          coronavirus HKU4 isolate 14S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522059.1, ""Tylonycteris bat          coronavirus HKU4 isolate 12S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522058.1, ""Tylonycteris bat          coronavirus HKU4 isolate 11S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522057.1, ""Tylonycteris bat          coronavirus HKU4 isolate 10S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522056.1, ""Tylonycteris bat          coronavirus HKU4 isolate 9S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522055.1, ""Tylonycteris bat          coronavirus HKU4 isolate 8S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522054.1, ""Tylonycteris bat          coronavirus HKU4 isolate 7S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522053.1, ""Tylonycteris bat          coronavirus HKU4 isolate 6S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522052.1, ""Tylonycteris bat          coronavirus HKU4 isolate 5S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522051.1, ""Tylonycteris bat          coronavirus HKU4 isolate 4S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522050.1, ""Tylonycteris bat          coronavirus HKU4 isolate 3S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522049.1, ""Tylonycteris bat          coronavirus HKU4 isolate 2S spike glycoprotein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Jul. 15,          2013.;            GenBank Accession No. KC522074.1, ""Tylonycteris bat          coronavirus HKU4 isolate 15N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522073.1, ""Tylonycteris bat          coronavirus HKU4 isolate 14N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522072.1, ""Tylonycteris bat          coronavirus HKU4 isolate 12N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522071.1, ""Tylonycteris bat          coronavirus HKU4 isolate 11N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522070.1, ""Tylonycteris bat          coronavirus HKU4 isolate 10N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522069.1, ""Tylonycteris bat          coronavirus HKU4 isolate 9N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522068.1, ""Tylonycteris bat          coronavirus HKU4 isolate 8N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522067.1, ""Tylonycteris bat          coronavirus HKU4 isolate 7N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522066.1, ""Tylonycteris bat          coronavirus HKU4 isolate 6N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522065.1, ""Tylonycteris bat          coronavirus HKU4 isolate 5N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522064.1, ""Tylonycteris bat          coronavirus HKU4 isolate 4N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15          2013.;            GenBank Accession No. KC522063.1, ""Tylonycteris bat          coronavirus HKU4 isolate 3N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. KC522062.1, ""Tylonycteris bat          coronavirus HKU4 isolate 2N nucleocapsid protein gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jul. 15,          2013.;            GenBank Accession No. NC&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;007025, ""Feline          coronavirus, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Dec. 1,          2009.;            GenBank Accession No. NC&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;002306, ""Feline          infectious peritonitis virus, complete genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 12          pages, Dec. 13, 2013.;            GenBank Accession No. DQ811789.2, ""TGEV virulent Purdue,          complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Apr. 29,          2011.;            GenBank Accession No. DQ811786.2, ""TGEV Miller M60,          complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Apr. 29,          2011.;            GenBank Accession No. DQ811788.1, ""TGEV Purdue P115,          complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 11 pages, Jul. 14,          2016.;            GenBank Accession No. DQ811785.1, ""TGEV Miller M6,          complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 11 pages, Jul. 14,          2016.;            GenBank Accession No. X52157.1, ""Coronavirus TGEV mRNA          for nucleoprotein, 5' region"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 1 pages, Jul. 26,          2016.;            GenBank Accession No. AJ011482.1, ""Porcine transmissible          gastroenteritis virus minigenome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 5 pages, Nov. 14,          2006.;            GenBank Accession No. KC962433.1, ""Transmissible          gastroenteritis virus isolate TGEV-HX, complete genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 11          pages, Apr. 1, 2015.;            GenBank Accession No. AJ271965.2, ""Transmissible          gastroenteritis virus complete genome, genomic RNA"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 13          pages, Apr. 15, 2005.;            GenBank Accession No. JQ693060.1, ""Transmissible          gastroenteritis virus isolate KT3 nucleocapsid protein          (N) gene, complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Mar. 22,          2013.;            GenBank Accession No. KC609371.1, ""Transmissible          gastroenteritis virus isolate ZH spike protein mRNA,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, May 21,          2013.;            GenBank Accession No. JQ693059.1, ""Transmissible          gastroenteritis virus isolate KT2 nucleocapsid protein          (N) gene, complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Mar. 22,          2013.;            GenBank Accession No. JQ693058.1, ""Transmissible          gastroenteritis virus isolate DAE nucleocapsid protein          (N) gene, complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Mar. 22,          2013.;            GenBank Accession No. JQ693057.1, ""Transmissible          gastroenteritis virus isolate 133 nucleocapsid protein          (N) gene, complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Mar. 22,          2013.;            GenBank Accession No. JQ693052.1, ""Transmissible          gastroenteritis virus isolate KT3 spike glycoprotein (S)          gene, complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Mar. 22,          2013.;            GenBank Accession No. JQ693051.1, ""Transmissible          gastroenteritis virus isolate KT2 spike glycoprotein (S)          gene, complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Mar. 22,          2013.;            GenBank Accession No. JQ693050.1, ""Transmissible          gastroenteritis virus isolate DAE spike glycoprotein (S)          gene, complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Mar. 22,          2013.;            GenBank Accession No. NC&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;001961.1, ""Porcine          respiratory and reproductive syndrome virus, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 11 pages, Nov. 2,          2012.;            GenBank Accession No. DQ811787, ""PRCV ISU-1, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 11 pages, Jul. 14,          2016.;            GenBank Accession No. NC&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;010437, ""Bat          coronavirus 1A, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Mar. 28,          2016.;            GenBank Accession No. NC&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;010436, ""Bat          coronavirus 1B, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Apr. 23,          2008.;            GenBank Accession No. NC&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;010438, ""Bat          coronavirus HKU8, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Mar. 28,          2016.;            GenBank Accession No. DQ648858, ""Bat coronavirus          (BtCoV/512/2005) ORF1, spike protein, putative ORF3,          envelope protein, matrix protein, and nucleocapsid          protein genes, complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 11 pages, Jul. 19,          2006.;            GenBank Accession No. NC&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;003436, ""Porcine          epidemic diarrhea virus, complete genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 12          pages, Feb. 10, 2015.;            GenBank Accession No. DQ355224.1, ""Porcine epidemic          diarrhea virus strain CH/S nucleocapsid protein (N) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Feb. 1,          2006.;            GenBank Accession No. DQ355223.1, ""Porcine epidemic          diarrhea virus strain S nucleocapsid protein (N) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Feb. 1,          2006.;            GenBank Accession No. DQ355221.1, ""Porcine epidemic          diarrhea virus strain CV777 nucleocapsid protein (N)          gene, complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Feb. 1,          2006.;            GenBank Accession No. JN601062.1, ""Porcine epidemic          diarrhea virus strain CH/GXNN/2011 N protein (N) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jun. 3,          2013.;            GenBank Accession No. JN601061.1, ""Porcine epidemic          diarrhea virus strain CH/SDRZ-2/2011 N protein (N) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jun. 3,          2013.;            GenBank Accession No. JN601060.1, ""Porcine epidemic          diarrhea virus strain CH/SDRZ-1/2011 N protein (N) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jun. 3,          2013.;            GenBank Accession No. JN601059.1, ""Porcine epidemic          diarrhea virus strain CH/HLJHG/2011 N protein (N) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jun. 3,          2013.;            GenBank Accession No. JN601058.1, ""Porcine epidemic          diarrhea virus strain CH/GDQY-3/2011 N protein (N) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jun. 3,          2013.;            GenBank Accession No. JN601057.1, ""Porcine epidemic          diarrhea virus strain CH/GDQY-1/2011 N protein (N) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jun. 3,          2013.;            GenBank Accession No. JN601056.1, ""Porcine epidemic          diarrhea virus strain CH/GDQY-1/2011 N protein (N) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jun. 3,          2013.;            GenBank Accession No. JN601055.1, ""Porcine epidemic          diarrhea virus strain CH/FJND/2011 N protein (N) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jun. 3,          2013.;            GenBank Accession No. JN601054.1, ""Porcine epidemic          diarrhea virus strain CH/BJYQ-2/2011 N protein (N) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jun. 3,          2013.;            GenBank Accession No. JN601053.1, ""Porcine epidemic          diarrhea virus strain CH/BJYQ-1/2011 N protein (N) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jun. 3,          2013.;            GenBank Accession No. JN601052.1, ""Porcine epidemic          diarrhea virus strain CH/HNZZ/2011 N protein (N) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Jun. 3,          2013.;            GenBank Accession No. JN400902.1, ""Porcine epidemic          diarrhea virus strain CH/HBQX/10 membrane glycoprotein          (M) gene, complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Apr. 3,          2013.;            GenBank Accession No. JN547395.1, ""Porcine epidemic          diarrhea virus strain CH/HBQX/10 non-structural protein          gene, complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 3,          2013.;            GenBank Accession No. FJ687473.1, ""Porcine epidemic          diarrhea virus isolate CPF1074 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687472.1, ""Porcine epidemic          diarrhea virus isolate PFF1051 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687471.1, ""Porcine epidemic          diarrhea virus isolate CPF531 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687470.1, ""Porcine epidemic          diarrhea virus isolate PFF514 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687469.1, ""Porcine epidemic          diarrhea virus isolate PFF513 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687468.1, ""Porcine epidemic          diarrhea virus isolate PFF381 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687467.1, ""Porcine epidemic          diarrhea virus isolate CPF299 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687466.1, ""Porcine epidemic          diarrhea virus isolate PFF285 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687465.1, ""Porcine epidemic          diarrhea virus isolate CPF259 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687464.1, ""Porcine epidemic          diarrhea virus isolate BIF256 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687463.1, ""Porcine epidemic          diarrhea virus isolate CPF193 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687462.1, ""Porcine epidemic          diarrhea virus isolate PFF188 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687461.1, ""Porcine epidemic          diarrhea virus isolate VF131 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687460.1, ""Porcine epidemic          diarrhea virus isolate BIF118 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687459.1, ""Porcine epidemic          diarrhea virus isolate MF78 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687458.1, ""Porcine epidemic          diarrhea virus isolate V25010 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687457.1, ""Porcine epidemic          diarrhea virus isolate M2366 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687456.1, ""Porcine epidemic          diarrhea virus isolate M2227 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687455.1, ""Porcine epidemic          diarrhea virus isolate M1763 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687454.1, ""Porcine epidemic          diarrhea virus isolate e1697 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687453, ""Porcine epidemic          diarrhea virus isolate e1642 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687452.1, ""Porcine epidemic          diarrhea virus isolate M1595 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687451.1, ""Porcine epidemic          diarrhea virus isolate BI1108 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687450.1, ""Porcine epidemic          diarrhea virus isolate BI981 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. FJ687449.1, ""Porcine epidemic          diarrhea virus isolate BI976 membrane protein (M) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, Apr. 6,          2011.;            GenBank Accession No. AF500215.1, ""Porcine epidemic          diarrhea virus spike protein (Spk1) gene, complete cds"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 3          pages, Aug. 23, 2005.;            GenBank Accession No. KF476061.1, ""Porcine epidemic          diarrhea virus isolate CHHEB ORF3 protein (ORF3) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, May 5,          2014.;            GenBank Accession No. KF476060.1, ""Porcine epidemic          diarrhea virus isolate CHZHZ-04 putative ORF3 protein          (ORF3) gene, complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, May 5,          2014.;            GenBank Accession No. KF476059.1, ""Porcine epidemic          diarrhea virus isolate CHJCH ORF3 protein (ORF3) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, May 5,          2014.;            GenBank Accession No. KF476058.1, ""Porcine epidemic          diarrhea virus isolate CHXIP-03 putative ORF3 protein          (ORF3) gene, complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, May 5,          2014.;            GenBank Accession No. KF476057.1, ""Porcine epidemic          diarrhea virus isolate CHLSHAN ORF3 protein (ORF3) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, May 5,          2014.;            GenBank Accession No. KF476056.1, ""Porcine epidemic          diarrhea virus isolate CHFH putative ORF3 protein (ORF3)          gene, complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, May 5,          2014.;            GenBank Accession No. KF476055.1, ""Porcine epidemic          diarrhea virus isolate CHLH ORF3 protein (ORF3) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, May 5,          2014.;            GenBank Accession No. KF476054.1, ""Porcine epidemic          diarrhea virus isolate CHFCH-01 ORF3 protein (ORF3) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, May 5,          2014.;            GenBank Accession No. KF476053.1, ""Porcine epidemic          diarrhea virus isolate CHLY-09 ORF3 protein (ORF3) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, May 5,          2014.;            GenBank Accession No. KF476052.1, ""Porcine epidemic          diarrhea virus isolate CHXIP-01 ORF3 protein (ORF3) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, May 5,          2014.;            GenBank Accession No. KF476051.1, ""Porcine epidemic          diarrhea virus isolate CHKF-01 ORF3 protein (ORF3) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, May 5,          2014.;            GenBank Accession No. KF476050.1, ""Porcine epidemic          diarrhea virus isolate CHQX-02 ORF3 protein (ORF3) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, May 5,          2014.;            GenBank Accession No. KF476049.1, ""Porcine epidemic          diarrhea virus isolate CHXY-02 ORF3 protein (ORF3) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, May 5,          2014.;            GenBank Accession No. KF476048.1, ""Porcine epidemic          diarrhea virus isolate CHYF-01 ORF3 protein (ORF3) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 2 pages, May 5,          2014.;            GenBank Accession No. KF177258.1, ""Porcine epidemic          diarrhea virus isolate YJ7C spike protein (S) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Sep. 18,          2013.;            GenBank Accession No. KF177257.1, ""Porcine epidemic          diarrhea virus isolate YJ3F spike protein (S) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Sep. 18,          2013.;            GenBank Accession No. KF177256.1, ""Porcine epidemic          diarrhea virus isolate JY7C spike protein (S) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Sep. 18,          2013.;            GenBank Accession No. KF177255.1, ""Porcine epidemic          diarrhea virus isolate JY6C spike protein (S) gene,          complete cds"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 3 pages, Sep. 18,          2013.;            GenBank Accession No. NC&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;002645, ""Human          coronavirus 229E, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Apr. 28,          20710.;            GenBank Accession No. NC&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;005831, ""Human          coronavirus NL63, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 11 pages, Mar. 29,          2016.;            GenBank Accession No. EF203066, ""Bat coronavirus HKU2          strain HKU2/HK/298/2006, complete genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 12          pages, Oct. 9, 2007.;            GenBank Accession No. EF203067.1, ""Bat coronavirus HKU2          strain HKU2/HK/33/2006, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Oct. 9,          2007.;            GenBank Accession No. EF203065, ""Bat coronavirus HKU2          strain HKU2/HK/46/2006, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Oct. 9,          2007.;            GenBank Accession No. EF203064, ""Bat coronavirus HKU2          strain HKU2/GD/430/2006, complete genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 12          pages, Oct. 9, 2007.;            GenBank Accession No. DQ339101, ""Human coronavirus HKU1          strain N5P8 genotype A/B recombinant, complete genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 12          pages, Jun. 30, 2006.;            GenBank Accession No. NC&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;001846, ""Mouse          hepatitis virus strain MHV-A59 C12 mutant, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Mar. 29,          2016.;            GenBank Accession No. NC&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;007732, ""Porcine          hemagglutinating encephalomyelitis virus, complete          genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Dec. 1,          2009.;            GenBank Accession No. NC&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;005147, ""Human          coronavirus OC43, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 13 pages, Dec. 13,          2013.;            GenBank Accession No. NC&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;003045, ""Bovine          coronavirus, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 16 pages, Feb. 10,          2015.;            GenBank Accession No. EF065514, ""Bat coronavirus HKU9-2,          complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 11 pages, Feb. 7,          2007.;            GenBank Accession No. NC&lt;xhtml:sub          &gt;_&lt;/xhtml:sub&gt;009021, ""Bat          coronavirus HKU9-1, complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 12 pages, Dec. 8,          2008.;            GenBank Accession No. EF065515, ""Bat coronavirus HKU9-3,          complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 11 pages, Feb. 7,          2007.;            GenBank Accession No. EF065516, ""Bat coronavirus HKU9-4,          complete genome"", &lt;xhtml:i          &gt;NCBI&lt;/xhtml:i&gt;, 11 pages, Feb. 7,          2007.;            GenBank Accession No. DQ001339, ""Avian infectious          bronchitis virus isolate IBV-p65, complete genome"",          &lt;xhtml:i &gt;NCBI&lt;/xhtml:i&gt;, 11          pages, Oct. 17, 2005.;            Akerstroem et al. ""Protein G: a powerful tool for binding          and detection of monoclonal and polyclonal antibodies"",          &lt;xhtml:i &gt;J          Immunol&lt;/xhtml:i&gt;1985;          135:2589-2592.;            Chen et al. ""Boosting with recombinant vacccinia          increases HPV-16 E7-specific T cell precursor frequencies          of HPV-16 E7-expressing DNA vaccines"", &lt;xhtml:i          &gt;Vaccine&lt;/xhtml:i&gt;,          18(19):2015-2022, Apr. 3, 2000 (Abstract Only).;            Gonzalo et al. ""Enhanced CD8+ T cell response to HIV-1          env by combined immunization with influenza and vaccinia          virus recombinants"", &lt;xhtml:i          &gt;Vaccine&lt;/xhtml:i&gt;, 17(7-8):887-892,          Feb. 26, 1999 (Abstract Only).;            Hanke et al. ""Enhancement of MHC class I-restricted          peptide-specific T cell induction by a DNA prime/MVA          boost vaccination regime"", &lt;xhtml:i          &gt;Vaccine&lt;/xhtml:i&gt;, 16(5):439-445,          Mar. 1998 (Abstract Only).;            Huse et al. ""Generation of a large combinatorial library          of the immunoglobulin repertoire in phage lambda"",          &lt;xhtml:i &gt;Science&lt;/xhtml:i&gt;,          Dec. 8, 1989, vol. 246, Issue 4935, pp. 1275-1281          (Abstract Only).;            Kohler and Milstein, ""Continuous cultures of fused cells          secreting antibody of predefined specificity"",          &lt;xhtml:i &gt;Nature&lt;/xhtml:i&gt;,          vol. 256:494-497, Aug. 7, 1975.;            Kronvall et al. ""A Surface Component in Group A, C, and G          Streptococci with Non-Immune Reactivity for          Immunoglobulin G"", &lt;xhtml:i &gt;J.          Immunol&lt;/xhtml:i&gt;. 111:1401-1406          (1973).;            Maddox et al. ""Elevated Serum Levels in Human Pregnancy          of a Molecule Immunochemically Similar to Eosinophil          Granule Major Basic Protein"", &lt;xhtml:i &gt;J.          Exp. Med&lt;/xhtml:i&gt;. 158:1211-1226 (Oct.          1983).;            Pancholi et al. ""DNA Prime-Canarypox Boost with          Polycistronic Hepatitis C Virus (HCV) Genes Generates          Potent Immune Responses to HCV Structural and          Nonstructural Proteins"", &lt;xhtml:i &gt;J.          Infect. Dis&lt;/xhtml:i&gt;. 182:18-27,          2000.;            Walker et al. ""Interaction of human IgG chimeric          antibodies with the human FcRI and FcRII receptors:          requirements for antibody-mediated host cell-target cell          interaction"", &lt;xhtml:i &gt;Molec.          Immunol&lt;/xhtml:i&gt;. Apr. 1989; 26(4):403-411          (Abstract Only).;            International Preliminary Report on Patentability          Corresponding to International Application No.          PCT/US2015/021773; dated Sep. 29, 2016; 8          pages.",,,,,
WO2022125448-A1;  AU2021395241-A1;  CA3202768-A1;  CN116635948-A;  EP4256566-A1;  JP2023553890-W;  HK40098157-A0,"Generating reconstructed consensus sequence coding            for portion of immunoglobulin involves obtaining RNA            sequence data for many biological samples, processing            the RNA sequence data, and generating reconstructed            consensus sequence",BIASCI D;  DE SANTIAGO DOMINGOS DE JESUS;  TAPTAS B C;  RAKOCEVIC G;  DE SANTIAGO D D J;  TOPTAS B C,TOTIENT INC (TOTI-Non-standard);  TOTIENT INC (TOTI-Non-standard);  ABSCI LLC (ABSC-Non-standard);  ABSCI CORP (ABSC-Non-standard);  ABSCI CORP (ABSC-Non-standard),202281376A,"   NOVELTY - Generating (M1) a reconstructed consensus                sequence coding for at least a portion of an                immunoglobulin, comprises (a) obtaining RNA                sequence data for many biological samples obtained                from subjects having a disease or disorder, (b)                processing the RNA sequence data to identify many                unique immunoglobulin clonotypes, and (c)                generating a reconstructed consensus sequence                coding for at least a portion of the immunoglobulin                based on the unique immunoglobulin                clonotypes.    USE - The methods are useful for: generating a                reconstructed consensus sequence coding for at                least a portion of an immunoglobulin; designing an                immunoglobulin candidate for treating cancer, where                the cancer is brain cancer, renal cancer, ovarian                cancer, prostate cancer, colon cancer, lung cancer,                squamous cell carcinoma of head and neck, or                melanoma or skin cutaneous melanoma; identifying                protein dimers associated with a disease or                disorder from mRNA sequencing data, where the                disease is autoimmune disease or infection;                generating a reconstructed consensus sequence                coding for at least a portion of a protein dimer;                and preparing a composition for treating cancer                (all claimed), and the infection is severe acute                respiratory syndrome-coronavirus-2 and the cancer                is e.g. sarcoma, fibrosarcoma, fibrous                histiocytoma, myxosarcoma, liposarcoma,                leiomyosarcoma, rhabdomyosarcoma, embryonal                rhabdomyosarcoma, alveolar rhabdomyosarcoma,                stromal sarcoma, mixed tumor, nephroblastoma,                hepatoblastoma, carcinosarcoma, phyllodes tumor,                synovial sarcoma, mesothelioma, dysgerminoma,                embryonal carcinoma, teratoma, hemangiosarcoma,                hemangioendothelioma, hemangiopericytoma,                lymphangiosarcoma, osteosarcoma, juxtacortical                osteosarcoma, chondrosarcoma, chondroblastoma,                mesenchymal chondrosarcoma, and odontogenic tumor.                No biological data given.    ADVANTAGE - The method produces the reconstructed                consensus sequence which produces antibody having                KD value of 1 mu M or 1 pM.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) designing (M2) an immunoglobulin candidate                for treating cancer, comprising (aa) obtaining RNA                sequence data for many biological samples obtained                from subjects diagnosed with cancer, (b) as per se,                and (cc) generating a reconstructed consensus                sequence coding for at least a portion of an                immunoglobulin based on the unique immunoglobulin                clonotypes, where the immunoglobulin is a candidate                for treating cancer;    (2) generating (M3) a reconstructed consensus                sequence coding for at least a portion of an                immunoglobulin, comprising (a), (b) as per se, (ac)                selecting a seed sequence from a predicted                reference sequence and searching the RNA sequence                data for the seed sequence using a fuzzy pattern                searching algorithm in order to identify at least                one of the heavy D and light V-J junction for the                sequences, (ad) filtering the RNA sequence data to                eliminate sequences that fail to achieve a                threshold match ratio with the predicted reference                sequence, (e) selecting a new seed sequence from                the predicted reference sequence and searching the                RNA sequence data for the new seed sequence, (f)                iteratively repeating step (e) until a threshold                percentage of a J segment of the at least one of                sequence has been assembled, (g) aligning and                assembling many unique clonotypes based on the                sequences, and (h) generating a reconstructed                consensus sequence based on the aligned unique                clonotypes;    (3) a computer-implemented system (S1) for                generating a reconstructed consensus sequence                coding for at least a portion of an immunoglobulin,                comprising at least one processor, an operating                system configured to perform executable                instructions, a memory, and instructions executable                by the processor to perform steps comprising steps                (a-c) or (aa), (b) and (c) as per se;    (4) a computer-implemented system (S2) for                generating a reconstructed consensus sequence                coding for at least a portion of an immunoglobulin,                comprising at least one processor, an operating                system configured to perform executable                instructions, a memory, and instructions executable                by processor to perform steps comprising (a), (b),                (ac), (ad), (e), (f), (g), (h) as per se;    (5) non-transitory computer readable medium                (ME1) or (ME2) comprising machine-executable code                that, upon execution by computer processors,                implements the method (M1) or (M2);    (6) non-transitory computer readable medium                (ME2) comprising machine-executable code that, upon                execution by one or more computer processors,                implements the method (M3);    (7) identifying (M4) protein dimers associated                with a disease or disorder from mRNA sequencing                data, comprising (ab) obtaining RNA sequence data                for biological samples obtained from subjects                having the disease or disorder, (cb) processing the                RNA sequence data to identify mRNA isoforms, (ca)                inferring at least one protein dimer from the                unique mRNA isoforms, the protein dimer comprising                a first protein isoform and a second protein                isoform inferred from the mRNA isoforms, and (da)                generating a reconstructed consensus sequence                coding for the protein dimer based on the mRNA                isoforms;    (8) generating (M5) a reconstructed consensus                sequence coding for at least a portion of a protein                dimer, comprising (af) obtaining RNA sequence data                for many biological samples obtained from subjects                having a disease or disorder, (bf) processing the                RNA sequence data to identify unique protein                isoforms, and (cf) generating a reconstructed                consensus sequence coding for at least a portion of                the protein dimer based on the unique protein                isoforms;    (9) preparing (M6) a composition for treating                cancer, comprising the protein dimer that is coded                at least partly by the reconstructed consensus                sequence;    (10) a computer-implemented system (S3) for                generating a reconstructed consensus sequence                coding for at least a portion of a protein dimer,                comprising at least one processor, an operating                system configured to perform executable                instructions, a memory, and instructions executable                by the processor to perform steps (af-cf) as per                se; and    (11) a computer-implemented system for                generating a reconstructed consensus sequence                coding for at least a portion of a protein dimer,                comprising at least one processor, an operating                system configured to perform executable                instructions, a memory, and instructions executable                by the processor to perform steps comprising (ag)                obtaining RNA sequence data for biological samples                obtained from subjects having a disease or                disorder, (bg) processing the ribonucleic acid                sequence data to identify many mRNA isoforms, (cg)                inferring at least one protein dimer from unique                mRNA isoforms, the at least one protein dimer                comprising a first protein isoform and a second                protein isoform inferred from the mRNA isoforms,                and (dg) generating a reconstructed consensus                sequence coding for the at least one protein dimer                based on mRNA isoforms. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S05 (Electrical Medical Equipment);  T01 (Digital Computers)",B04-E07;  B04-E99;  B04-G01;  B04-G21;  B04-G27A;  B04-G27G;  B04-G27M;  B11-C07A;  B11-C08F7A;  B11-C10;  B11-C11;  B12-K04F;  B14-G02D;  B14-H01;  D05-H09;  D05-H18A;  D05-H99;  S05-G02G9;  T01-F05G;  T01-J05B1;  T01-J05B3;  T01-J06A1;  T01-S03,C07K-016/00;  C12Q-001/6869;  G16B-020/30;  G16B-050/00;  G16H-050/00;  C12Q-001/68;  G16B-020/20;  G16B-030/00;  G16B-030/10;  G16B-030/20;  C07K-016/18,WO2022125448-A1   16 Jun 2022   G16B-020/30   202255Pages: 131   English;  AU2021395241-A1   22 Jun 2023   G16B-020/30   202351   English;  CA3202768-A1   16 Jun 2022   G16B-030/20   202352   English;  CN116635948-A   22 Aug 2023   G16H-050/00   202377   Chinese;  EP4256566-A1   11 Oct 2023   G16B-020/30   202383   English;  JP2023553890-W   26 Dec 2023   G16B-030/00   202304   Japanese;  HK40098157-A0   28 Mar 2024   G16B-020/30   202447   English,WO2022125448-A1    WOUS062027    06 Dec 2021;   AU2021395241-A1    AU395241    06 Dec 2021;   CA3202768-A1    CA3202768    06 Dec 2021;   CN116635948-A    CN80082508    06 Dec 2021;   EP4256566-A1    EP904193    06 Dec 2021;   JP2023553890-W    JP534656    06 Dec 2021;   HK40098157-A0    HK6085836    23 Jan 2024,AU2021395241-A1 PCT application Application WOUS062027;   AU2021395241-A1 Based on Patent WO2022125448;   CA3202768-A1 PCT application Application WOUS062027;   CA3202768-A1 Based on Patent WO2022125448;   CN116635948-A PCT application Application WOUS062027;   CN116635948-A Based on Patent WO2022125448;   EP4256566-A1 PCT application Application WOUS062027;   EP4256566-A1 Based on Patent WO2022125448;   JP2023553890-W PCT application Application WOUS062027;   JP2023553890-W Based on Patent WO2022125448;   HK40098157-A0 PCT application Application WOUS062027;   HK40098157-A0 Based on Patent WO2022125448;   HK40098157-A0 Previous Publ. Patent EP4256566,US122406P    07 Dec 2020;  EP904193    06 Dec 2021;  CA3202768    19 May 2023;  CN80082508    07 Jun 2023,WO2022125448-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        EP4256566-A1:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  KH;  LI;  LT;  LU;  LV;  MA;  MC;  MD;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TN;  TR      ,,"WO2022125448-A1 -- US20140342360-A1   ;  WO2020223392-A2   TOTIENT INC (TOTI-Non-standard)   BIASCI D,  RAKOCEVIC G,  TOPTAS B C,  DE SANTIAGO DOMINGOS DE JESUS","WO2022125448-A1  UPADHYAY AMIT A.,          KAUFFMAN ROBERT C., WOLABAUGH AMBER N., CHO ALICE, PATEL          NIRAV B., REISS SAMANTHA M., HAVENAR-DAUGHTON COLIN, DA:          ""BALDR: a computational pipeline for paired heavy and          light chain immunoglobulin reconstruction in single-cell          RNA-seq data"", GENOME MEDICINE, vol. 10, no. 1, 1          December 2018 (2018-12-01), XP055911978, DOI:          10.1186/s13073-018-0528-3,relevantClaims[43-48],relevantPassages[,          especially, Abstract; page 16, Col. 1, para 2; Fig 2,          Fig. 7];  JIANG ET AL.:          ""VDJ-Seq: Deep Sequencing Analysis of Rearranged          Immunoglobulin Heavy Chain Gene to Reveal Clonal          Evolution Patterns of B Cell Lymphoma"", J VIS EXP, vol.          106, 28 December 2015 (2015-12-28), pages          e53215,relevantClaims[1],relevantPassages[, whole          document.]",,,,,
WO2023094680-A1;  CA3239177-A1,"New aza crown ether used in photodynamic therapy            or cytoluminescent therapy, treat e.g. atherosclerosis,            multiple sclerosis, diabetes, diabetic retinopathy,            arthritis, rheumatoid arthritis, fungal, chlamydial,            bacterial, HIV and cancer",MARCUCCIO S M;  STEPHENS A N;  DONNER C D;  CHO H;  NOVAKOVIC S,RMW CHO GROUP LTD (RMWC-Non-standard);  VENNER SHIPLEY LLP (VENN-Non-standard);  RMW CHO GROUP LTD (RMWC-Non-standard),202357399E,"   NOVELTY - Aza crown ether (A) are new.    USE - (A) are useful for: in photodynamic therapy or                cytoluminescent therapy; treating atherosclerosis,                multiple sclerosis, diabetes, diabetic retinopathy,                arthritis, rheumatoid arthritis, fungal, viral,                chlamydial, bacterial, nanobacterial or parasitic                infectious disease, HIV, Aids, infection with sars                virus (preferably severe acute respiratory syndrome                coronavirus 2 (SARS-C0V-2)), Asian (chicken) flu                virus, Dengue virus, herpes simplex or herpes                zoster, hepatitis, viral hepatitis, cardiovascular                disease, coronary artery stenosis, carotid artery                stenosis, intermittent claudication, dermatological                condition, acne, psoriasis, a disease benign or                malignant cellular hyperproliferation or by areas                of neovascularization, a benign or malignant tumor,                early cancer, cervical dysplasia, soft tissue                sarcoma, a germ cell tumor, retinoblastoma,                age-related macular degeneration, lymphoma,                Hodgkin's lymphoma, head and neck cancer, oral or                mouth cancer, or cancer of the blood, prostate,                cervix, uterus, vaginal or other female adnexa,                breast, naso-pharynx, trachea, larynx, bronchi,                bronchioles, lung, hollow organs, esophagus,                stomach, bile duct, intestine, colon, colorectum,                rectum, bladder, ureter, kidney, liver, gall                bladder, spleen, brain, lymphatic system, bones,                skin or pancreas, malignant cellular                hyperproliferation or by areas of                neovascularization, treating benign or malignant                tumor; early cancer, cervical dysplasia, soft                tissue sarcoma, germ cell tumor, retinoblastoma,                age-related macular degeneration, lymphoma,                Hodgkin's lymphoma, head and neck cancer, oral or                mouth cancer, or cancer of the blood, prostate,                cervix, uterus, vaginal or other female adnexa,                breast, naso-pharynx, trachea, larynx, bronchi,                bronchioles, lung, hollow organs, esophagus,                stomach, bile duct, intestine, colon, colorectum,                rectum, bladder, ureter, kidney, liver, gall                bladder, spleen, brain, lymphatic system, bones,                skin or pancreas; and photodynamic diagnosis in                human or animal disease (all claimed). The ability                of (A) to treat cancer was tested in Human ovarian                cancer cell line SKOV3 cell line using in vitro                assay. The result show that                [3-(3-{3-[(4S,5S)-10,15-diethyl-2,5,9,14,19-pentamethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1(3),(6).1(8),(11).1(13),(16)]tetracosa-1,3(24),6,8,10,12,14,16(22),17,19-decaen-4-yl]-N-methylpropanamido}propoxy)propyl]triphenylphosphanium                chloride exhibited IC90 value of 0.003 &#956;                M.    ADVANTAGE - (A): have enhanced phototoxicity; and have no                side effects.    DETAILED DESCRIPTION - Aza crown ether (A) of formulae (I) or (II)                and their salts are new.    R1=-CH OR2, -CH SR2, -CH S(O)R2, -CH S(O) R2,                -CH N(R2) , -R2, -C(O)-OR3, -C(O)-SR3, -C(O)-N(R3)                , -C(S)-OR3, -C(S)-SR3 or -C(S)-N(R3)2;    R2=H, -C(O)R4, -C(O)-OR4, -C(O)-SR4,                -C(O)-N(R4) , -C(S)-OR4, -C(S)-SR4, -C(S)-N(R4) ,                -R&#945; -H, -R&#946; , -R&#945;                -R&#946; , -R&#945; -OH, -R&#945;                -OR&#946; , -R&#945; -SH, -R&#945;                -SR&#946; , -R&#945; -S(O)R&#946; ,                -R&#945; -S(O) R&#946; , -R&#945; -NH ,                -R&#945; -NH(R&#946; ), -R&#945;                -N(R&#946; ) , -R&#945; -X, -R&#945;                -[N(R5) ]Y1, -R&#945; -[P(R5)3]Y1, -R&#945;                -[R8]Y1, -R&#945; -[N(R5)2(R5a)], -R&#945;                -[P(R5) (R5a)] or -R&#945; -[R8a];    R3, R4=-H, -R&#945; -H, -R&#946; ,                -R&#945; -R&#946; , -R&#945; -OH,                -R&#945; -OR&#946; , -R&#945; -SH,                -R&#945; -SR&#946; , -R&#945; -NH ,                -R&#945; -NH(R&#946; ), -R&#945;                -N(R&#946; ) , -R&#945; -X, -R&#945;                -[N(R5) ]Y1, -R&#945; -[P(R5) ]Y1, -R&#945;                -[R8]Y1, -R&#945; -[N(R5) (R5a)], -R&#945;                -[P(R5)2(R5a)] or -R&#945; -[R8a];    R&#945;=1-42C alkylene group optionally                substituted with 1-4C alkyl, 1-4C haloalkyl or halo                groups, and where carbon atoms in the backbone of                the alkylene group may optionally replaced by a                heteroatom or group O, S, NH or NMe;    R&#946;=saturated or unsaturated                hydrocarbyl group contains N, O, S, P or Se as                heteroatoms (optionally substituted) or cyclic                groups;    R5=1-4C alkyl, 1-4C haloalkyl, -(CH CH2O) -H,                -(CH CH O) -CH , phenyl or 5-6C heteroaryl                optionally substituted with 1-6C alkyl, 1-6C                haloalkyl, -O(1-6C alkyl), -O(1-6C haloalkyl),                halo, -CO H, -CO Z, -CO NH , -O-(CH CH O) -H or                -O-(CH CH O) -CH groups;    R5a=phenyl, 5-6C heteroaryl substituted with                -CO (both optionally substituted with 1-6C alkyl,                1-6C haloalkyl, -O(1-6C alkyl), -O(1-6C haloalkyl),                halo, -CO H, -CO Z, -CO NH , -O-(CH CH O) -H or                -O-(CH CH O) -CH groups), 1-4C alkyl, 1-4C                haloalkyl, -(CH CH O) -H or -(CH CH O) -CH ;                either    R6=H, -C(O)-OR3, -C(O)-SR3, -C(O)-N(R3) ,                -C(S)-OR3, -C(S)-SR3 or -C(S)-N(R3) ; or    R7=H, -C(O)-OR3, -C(O)-SR3, -C(O)-N(R3) ,                -C(S)-OR3, -C(S)-SR3 or -C(S)-N(R3) ; or    R6R7=-C(O)-O-;    R8=-[NC5H5] (optionally substituted with 1-6C                alkyl, 1-6C haloalkyl, -O(1-6C alkyl), -O(1-6C                haloalkyl), halo, -CO H, -CO Z, -CO NH , -O-(CH CH                O) -H or -O-(CH CH O) -CH groups);    R8a=-[NC5H5] substituted with -CO optionally                substituted with 1-6C alkyl, 1-6C haloalkyl,                -O(1-6C alkyl), -O(1-6C haloalkyl), halo, -CO H,                -CO Z, -CO NH , -O-(CH CH O) -H or -O-(CH CH O) -CH                groups;    n=1-6;    X=halo group;    Y1=counter anion;    Z=counter cation; and    M =metal cation.    INDEPENDENT CLAIMs are also included                for:    composition comprising (A) and carrier or                diluent;    photodynamic diagnosis of a human or animal                disease, comprising administering (A) to a human or                animal; and    combination or kit comprising (a) (A), and (b)                immune checkpoint inhibitor.     ",,,"B02 (Fused ring heterocyclics.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C02 (Heterocyclic.);  C01 (Organophosphorus; organometallic - i.e. compounds containing other than H, C, N, O, S and halogen.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).);  A96 (Medical, dental, veterinary, cosmetic.)",B04-G02;  B04-G21;  B05-A03;  B05-B01D;  B05-B01E;  B06-D18;  B14-A01;  B14-A02;  B14-A04;  B14-B02;  B14-C09;  B14-F01;  B14-F02;  B14-F07;  B14-H01;  B14-H01B;  B14-H01F1;  B14-H01G1;  B14-H01H2;  B14-H01K1;  B14-H01L;  B14-K01D;  B14-L06;  B14-N03;  B14-N13;  B14-N14;  B14-N17;  B14-S01;  B14-S04;  B14-S26;  B14-S27;  C04-G21;  C05-A03;  C05-B01D;  C05-B01E;  C06-D18;  C14-A01;  C14-A02;  C14-A04;  C14-B02;  C14-C09;  C14-F01;  C14-F02;  C14-F07;  C14-H01;  C14-H01B;  C14-H01F1;  C14-H01G1;  C14-H01H2;  C14-H01K1;  C14-H01L;  C14-K01D;  C14-L06;  C14-N03;  C14-N13;  C14-N14;  C14-N17;  C14-S01;  C14-S04;  C14-S26;  C14-S27;  D05-H11A;  A12-E07C;  A12-V01;  A12-V03C2;  A12-W14,A61K-031/41;  C07D-487/22,WO2023094680-A1   01 Jun 2023   C07D-487/22   202354Pages: 208   English;  CA3239177-A1   01 Jun 2023   C07D-487/22   202446   English,WO2023094680-A1    WOEP083554    28 Nov 2022;   CA3239177-A1    CA3239177    28 Nov 2022,CA3239177-A1 PCT application Application WOEP083554,GB017140    26 Nov 2021;  GB008167    01 Jun 2022;  CA3239177    24 May 2024,WO2023094680-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,,,2971559-0-0-0 K M; 2325937-0-0-0 K M; 4027028-0-0-0 K M;  K M;  K M;  K M; 607047-0-0-0 K M;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N;  M N; 444-0-0-0 ; 2971559-0-0-0 CL USE; 2325937-0-0-0 CL USE; 4027028-0-0-0 CL USE,229062601 M N; 229062602 M N,05479; 57142,RBPW1P K M; RBEFD1 K M; RC8YTJ K M; RBVJ5P K M; RC2OV0 K M; RC1TSA K M; RC2EBM K M; RAHSJT K M; RDEJ74 M N; RDEJ75 M N; RDEJ76 M N; RDEJ77 M N; RDEJ78 M N; RDEJ79 M N; RDEJ7A M N; RDEJ7B M N; RDEJ7C M N; RDEJ7D M N; RDEJ7E M N; RDEJ7F M N; RDEJ7G M N; RDEJ7H M N; RDEJ7I M N; RDEJ7J M N; RDEJ7K M N; RDEJ7L M N; RDEJ7M M N; RDEJ7N M N; RDEJ7O M N; RDEJ7P M N; RDEJ7Q M N; RDEJ7R M N; RDEJ7S M N; RDEJ7T M N; RDEJ7U M N; RDEJ7V M N; RDEJ7W M N; RDEJ7X M N; RDEJ7Y M N; RDEJ7Z M N; RDEJ80 M N; RDEJ81 M N; RDEJ82 M N; RDEJ83 M N; RDEJ84 M N; RDEJ85 M N; RDEJ86 M N; RDEJ87 M N; RDEJ88 M N; RDEJ89 M N; RDEJ8A M N; RDEJ8B M N; R00351 ,
CN114149415-A,New peptidomimetic compound i.e. substituted            N-isopropyl-2-(2-(methyl(prop-1-en-2-yl)amino)acetyl)octahydro-1H-cyclopenta(c)pyridine-3-carboxamide            useful as 3C-type cysteine protease inhibitor for            treating and preventing viral infections,ZHANG X;  QIU Y;  WANG T;  WU Q;  LIAO J;  ZHANG K;  NI Y;  XIE Y;  HAO H;  XIAO Y;  JIANG S,UNIV CHINA PHARM (UYCP-C),202240022A,"   NOVELTY - Peptidomimetic compound i.e. substituted                N-isopropyl-2-(2-(methyl(prop-1-en-2-yl)amino)acetyl)octahydro-1H-cyclopenta[c]pyridine-3-carboxamide                (I) and their tautomers, stereoisomers, solvates,                salts of solvates, metabolites, metabolic                precursors, promedicines or salts, are new.    USE - (I) is useful in medicinal composition for:                preparing the 3C-type cysteine protease inhibitor                of RNA virus; preparing medicines for treating and                preventing viral infections (claimed) including                severe acute respiratory syndrome coronavirus,                hepatitis B virus, hepatitis C virus, H1N1, Ebola                and severe acute respiratory syndrome coronavirus 2                infections.    ADVANTAGE - (I) can effectively inhibit 3C-type cysteine                protease (claimed).    DETAILED DESCRIPTION - Peptidomimetic compound i.e. substituted                N-isopropyl-2-(2-(methyl(prop-1-en-2-yl)amino)acetyl)octahydro-1H-cyclopenta[c]pyridine-3-carboxamide                of formula (I) and their tautomers, stereoisomers,                solvates, salts of solvates, metabolites, metabolic                precursors, promedicines or salts, are new.    R6and R7= H, hydroxy, amino, cyano, aldehyde,                halogen, 1-8C alkyl, cyano (1-8C alkyl), amino                (1-8C alkyl), hydroxy (1-8C alkyl), carboxy (1-8C                alkyl), 1-8C alkylamino-1-8C alkyl, 1-8C                alkoxy-1-8C alkyl, 1-8C alkoxy, 1-8C alkylmercapto,                1-8C alkylamino, 2-8C alkenyl, 2-8C alkynyl, 1-8C                ester, 1-8C carbamate, 1-8C ureido, 1-8C ketone,                unsubstituted or R6-1substituted 3-10C cycloalkyl,                unsubstituted or R6-2 substituted 3-10C                cycloalkoxyl, unsubstituted or R6-3substituted                3-10C cycloalkylthiol, unsubstituted or R6-4                substituted 3-10C cycloalkylamino, unsubstituted or                R6-5substituted heteroaryl, unsubstituted or R6-6                substituted heteroarylhydroxy, unsubstituted or                R6-7substituted heteroarylthiol, unsubstituted or                R6-8substituted heteroarylamino, unsubstituted or                R6-9substituted heterocycloalkyl, unsubstituted or                R6-10substituted heterocyclic hydroxy,                unsubstituted or R6-11substituted heterocyclic                mercapto, unsubstituted or R6-12substituted                heterocyclic amino, unsubstituted or                R6-13substituted 3-10C cycloalkyl-(1-6C alkyl)-,                unsubstituted or R6-14substituted heteroaryl-(1-6C                alkyl)-, unsubstituted or 6-15C substituted                heterocycloalkyl-(1-6C alkyl)-, unsubstituted or                R6-16 substituted 6-10C aryl, unsubstituted or                R6-17substituted 6-10C aryl-(1-6C alkyl)-,                unsubstituted or R6-18substituted 6-10C aryloxy,                unsubstituted or R6-19substituted 6-10C arylthiol,                or unsubstituted or R6-20substituted 6-10C                arylamino;    R6-1-R6-4= hydroxy, cyano, amino, halogen,                1-6C alkyl, halo(1-6C alkyl), hydroxy(1-6C alkyl),                1-6C alkoxy or 1-6C alkylamino;    R6-5 and R6-8 = hydroxy, cyano, halogen,                nitro, 1-6C alkyl, 2-8C alkenyl, 2-6C alkynyl, 1-6C                alkoxy, 6-10C aryloxy, heteroaryloxy, (3-10C                cycloalkyl)-oxy, halo(1-6C alkyl), hydroxy(1-6C                alkyl), amino(1-6C alkyl), 1-6C alkylamino-1-6C                alkoxy-, 3-10C cycloalkyl, 3-10C cycloalkyl-(1-6C                alkyl)-, 3-10C cycloalkyl-(1-6C alkane oxy),                unsubstituted or R6-1-1substituted 6-10C aryl,                6-10C aryl-(1-6C alkyl)-, unsubstituted or                R6-1-2substituted 6-10C aryl-(1-6C alkoxy)-,                heterocycloalkyl, heterocycloalkyl-(1-6C alkyl)-,                unsubstituted or R6-1-3substituted heteroaryl,                heteroaryl-(1-6C alkyl)-, heteroaryl-(1-6C                alkoxy)-, -NR6-1- 4R6-1 -5,                -(C=O)R6-1-6,-(C=O)NR6-1-7R6-1-8,-NR6-                1-9(C=O)R6-1-10,-(C=O)OR6-1-11, -O(C=O)R6-1-12,                -(S=O)2NR6-1-13R6-1-14, -NR6-1-15(S=O)2R6-1-16, or                -(S =O)2R6-1-17;    R6-1-1, R6-1-2and R6-1-3= 1-4C alkyl, hydroxy                (1-4C alkyl), halogen, cyano, hydroxy, 1-4C                alkylamino, 1-4C alkoxy or halo(1-4C alkyl);    R6-1-4-R6-1-17= H or 1-4C alkyl;    R6-9-R6-13= hydroxy, cyano, amino, halogen,                1-6C alkyl, halo(1-6C alkyl), hydroxy(1-6C alkyl),                1-6C alkoxy or 1-6C alkylamino;    R6-14and R6-20= hydroxy, cyano, halogen,                nitro, 1-6C alkyl, 2-8C alkenyl, 2-6C alkynyl, 1-6C                alkoxy, 6-10C aryloxy, heteroaryloxy, (3-10C                cycloalkyl)-oxy, halo(1-6C alkyl), hydroxy(1-6C                alkyl), amino (1-6C alkyl), 1-6C alkylamino-1-6C                alkoxy-, 3-10C cycloalkyl, 3-10C cycloalkyl- (1-6C                alkyl)-, 3-10C cycloalkyl-(1-6C alkoxy),                unsubstituted or R6-2-1substituted 6-10C aryl,                6-10C aryl-(1-6C alkyl)-, unsubstituted or R6-2-2                substituted 6-10C aryl-(1-6C alkoxy)-,                heterocycloalkyl, heterocycloalkyl-(1-6C alkyl)-,                unsubstituted or R6-2-3 substituted heteroaryl,                heteroaryl-(1-6C alkyl)-, heteroaryl-(1-6C                alkoxy)-,                -NR6-2-4R6-2-5,-(C=O)R6-2-6,-(C=O)NR6-2-7R6-2 -8, -                NR6-2-9(C=O)R6-2-10, -(C=O)OR6-2-11,                -O(C=O)R6-2-12, -(S=O)2NR6- 2-13R6-2-14, -NR6-2-                15(S=O)2R6-2-16, or -(S=O)2R6-2-17; R6-2-1, R6-2-2                and R6-2-3= 1-4C alkyl, hydroxy (1-4C alkyl),                halogen, cyano, hydroxy, 1-4C alkylamino, 1-4C                alkoxy or halo (1-4C alkyl);    R6-2-4-R6-2-17= H or 1-4C alkyl;    T = 3-methylpyrrolidin-2-one derivative of                formula (x), 3-methylpiperidin-2-one derivative of                formula (y) or propionamide derivative of formula                (z);    Either R8and R9= H, hydroxy, cyano, 1-8C                alkyl, cyano (1-8C alkyl), amino (1-8C alkyl), 1-8C                alkylamino-1-8C alkyl, hydroxy (1-8C alkyl), 2-8C                alkenyl, 2-8C alkynyl, 1-8C alkoxy-1-8C alkyl,                unsubstituted or R8-1substituted 3-10C cycloalkyl,                unsubstituted or R8-2substituted heterocycloalkyl,                unsubstituted or R8-3substituted 3-10C                cycloalkyl-(1-6C alkyl)-, unsubstituted or                R8-4substituted heterocycloalkyl-(1-6C alkyl)-,                unsubstituted or R8-5substituted 6-10C aryl-(1-6C                alkyl)-;    or R8and R9= unsubstituted or R8-6substituted                heterocycloalkyl formed together with the nitrogen                atom to which they are attached.    Full definitions are given in the DEFINITIONS                (Full Definitions) Field.    An INDEPENDENT CLAIM is included for                Preparation of (I).     ",,,B02 (Fused ring heterocyclics.),B14-A02;  B14-D07C;  B14-K01D;  B06-H,A61K-031/403;  A61P-031/12;  A61P-031/14;  A61P-031/16;  C07D-403/12;  C07D-403/14;  C07D-405/14,CN114149415-A   08 Mar 2022   C07D-403/12   202272   Chinese,CN114149415-A    CN10842567    26 Jul 2021,,CN10842567    26 Jul 2021,,,"CN114149415-A -- CN1763002-A   UNIV TSINGHUA (UYQI);  SHANGHAI ORGANIC CHEM INST (SHRG);  RAO Z (RAOZ-Individual)   YANG H,  XUE X,  BARTLAM M,  YANG K,  MA D,  XIE W;  CN106928206-A   SHANGHAI INST MATERIA MEDICA CAS (CAMM);  UNIV LUBECK INST BIOCHEMISTRY (UYLU-Non-standard)   CHEN K,  HILGENFELD R,  JIANG H,  LI J,  LIN D,  LIU H,  NIAN Y,  ZHOU Y;  CN114466838-A   PFIZER INC (PFIZ)   OWEN D R,  PETTERSSON M Y,  REESE M R,  SAMMONS M F,  TUTTLE J B,  VERHOEST P R,  WEI L,  YANG Q,  YANG X;  WO2005113580-A1   PFIZER INC (PFIZ)   HOFFMAN R L,  KANIA R S,  NIEMAN J A,  PLANKEN S P,  SMITH G J;  WO2020030143-A1   CHINESE ACAD SCI SHANGHAI MATERIA MEDIC (CAMM);  UNIV FUDAN (UYFU)   LIU H,  JIANG S,  DAI W,  LU L,  PENG J,  XIA S,  WANG J,  LI J,  JIANG H,  CHEN K;  WO2003062265-A2   SCHERING CORP (SCHE);  CORVAS INT INC (CORV)   SAKSENA A K,  GIRIJAVALLABHN V M,  LOVEY R G,  JAO E,  BENNETT F,  MC CORMICK J L,  WANG H,  PIKE R E,  BOGEN S L,  CHAN T,  LIU Y,  ZHU Z,  NJOROGE G F,  ARASAPPAN A,  PAREKH T,  GANGULY A K,  CHEN K X,  VENKATRAMAN S,  VACCARO H A,  PINTO P A,  SANTHANAM B,  KEMP S J,  LEVY O E,  LIM-WILBY M,  TAMURA S Y,  WU W,  HENDRATA S,  HUANG Y,  WONG J K,  NAIR L G;  WO2018042343-A2   GLAXOSMITHKLINE INTELLECTUAL PROPERTY (GLAX)   BOTYANSZKI J,  CATALANO J G,  CHONG P Y,  DICKSON H,  JIN Q,  LEIVERS A,  LIAO X,  MAYNARD A,  MILLER J,  SHOTWELL J B,  TAI V W,  THALJI R","CN114149415-A  BETHANY HALFORD:          ""Pfizer unveils its oral SARS-CoV-2 inhibitor"", C&EN,          pages 7,relevantClaims[1-6, 8-10]", N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD;  CL NEW PRD; 2658099-0-1-0 CL RGT USE; 63091-0-0-0 CL RGT USE; 5286-0-0-0 CL RGT USE; 2-1-0-0 CL RGT USE; 107320-0-0-0 CL RGT USE,A000XGS02 N P; A000XGS05 N P; A000XGS03 N P; A000XGS06 N P; A000XGS01 N P; A000XGS04 N P,00690,RD7I52 N P,
WO2023187599-A1;  WO2023187599-A4,"Treating viral disease by administering solid            dispersion to human/mammal/animal/bird, comprises            contacting active ingredient and matrix host substance            to form solid dispersion, and dissolving solid            dispersion in solvent",DIDENKO K,DIDENKO K (DIDE-Individual),2023A40726,"   NOVELTY - Treating (M1) viral disease by administering                the solid dispersion to a human/mammal/animal/bird,                comprises: contacting an active ingredient and a                matrix host substance to form a solid dispersion                under conditions sufficient to form a solid                dispersion; and (optionally) dissolving solid                dispersion in solvent to form the liquid                solubilized noncovalent complex (to form solutions,                gels, colloids, sols, suspensions, etc.) under                conditions sufficient to form the liquid                solubilized noncovalent complex.    USE - The method is useful for treating viral                disease (claimed) comprising severe acute                respiratory syndrome coronavirus 2, dengue,                chikungunya, yellow fever, Zika and other viral                infections.    ADVANTAGE - The method improves the pharmacokinetic or                toxicity profile of the active ingredient. The                pharmacokinetic profile (bioavailability) of (I)                was tested in cattle using biological assay. The                results showed that solid dispersion (comprising                (I)) exhibited maximum concentration (Cmax) value                of 1.07/|0.16 &#968; M, at a dosage of 600                &#956; g/kg.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    treating (M2) viral disease by administering                the solid dispersion or the noncovalent complex, to                a human/mammal/animal/bird, where the carrier                substance molecule of the solid dispersion or the                noncovalent complex interacts with the biological                membranes of the organism in such a way that the                transfer of molecules ions or metabolites of active                ingredient across this biological membrane is                improved, permeability of active ingredient is                improved in the form of the noncovalent complex,                thus, the scope of solid dispersions and                noncovalent complexes with special permeability                properties (solid dispersions and noncovalent                complexes with high permeability-highly permeable                solid dispersions and noncovalent complexes);    treating (M3) viral diseases in a                human/mammal/animal/bird, comprising administering                a stabilized aqueous formulation which comprises                avermectin, solvent, surface active agent and                cosolvent or a stabilized formulation which                comprises avermectin solutions in fat/oil or                avermectin emulsion;    treating (M4) viral disease by administering                the solid dispersion or the noncovalent complex to                a human/mammal/animal/bird, where the solid                dispersion or the noncovalent complex of active                ingredient has a higher bioavailability than the                active ingredient itself is presented;    treating (M5) viral disease by administering                the solid dispersion or the noncovalent complex to                a human/mammal/animal/bird, where the solid                dispersion or the noncovalent complex of active                pharmaceutical ingredient has a lower toxicity and                cytotoxicity than the active ingredient itself is                presented;    treating (M6) disease by administering the                solid dispersion or the noncovalent complex to a                human/mammal/animal/bird, where the solid                dispersion or the noncovalent complex of active                ingredient has a different pharmokinetic parameters                than the active pharmaceutical ingredient itself is                presented;    preparing (M7) the solid dispersion or the                noncovalent complex;    obtaining (M8) solid dispersions comprising                (1) solvent evaporation and cryogenic methods, (2)                melting methods and hot-stage extrusion methods,                (3) mechanochemical methods (but not excluding                other methods), particle size of solid dispersion                may vary and depends on the equipment device (e.g.                nozzle size), equipment operation parameters, the                degree of grinding of the finished product, the                usual particle size is 0.5-1000 &#956; m, but                can exceed 1000 &#956; m, and the resulting                solid dispersion can also be ground to submicron                size after it is obtained;    treating (M9) diseases in a                human/mammal/animal/bird;    treating (M10) viral diseases in a                human/mammal/animal/bird, comprising administering                noncovalent complex of formula                ([GUEST]k[HOST]n(SOLVENTS)m) (II) (as well as their                solutions, gels, colloids, sols, etc.), that is a                bioavailable highly permeable noncovalent complex,                which is obtained by adding solvent to the                bioavailable highly permeable solid dispersion of                (I), where (I) is obtained by co-treating guest                drug compound with a host substance, the guest drug                compound comprises GUEST 1-9 as given in the                specification or their derivatives, the solvent                usually is water, but other solvents and their                mixtures can be used, where guest molecular                information is given based on the InChi derived                from the InChlKey indicated for each of the guest                drugs in parentheses after the name of the guest                drug compound, in the second position after the                sequence numbers, the molecular information of                guest drug compounds can be used on its own as well                as on the basis of it, the molecular informations                can be obtained for pharmaceutical salts, esters,                ethers, free bases and other salts of these free                bases, the host molecular information represents                the molecular information of a monomer of a host                substance polymer, or the smallest representable                part of a host substance copolymer (defining that                copolymer), or host substance molecule (if host                substance is in monomolecular form) for compounds                that are selected from the host substances, the                solvent molecular information is water if solvent                is water, but other solvents can also be                used;    medical dosage form of (I) of enhanced                bioavailability and permeability comprising a                bioavailable highly permeable solid dispersion or                aqueous solutions or their suspensions, where the                (I) is obtained by co-treating guest drug with a                host substance;    medical dosage form (II) (as well as their                solutions, gels, colloids, sols, etc), that is a                bioavailable highly permeable noncovalent complex,                which is obtained by adding solvent to the                bioavailable highly permeable solid dispersion of                (I), where the (I) is obtained by co-treating guest                drug compound with a host substance;    preparing (M11) a medical dosage form of (I)                of enhanced bioavailability and permeability                comprising bioavailable highly permeable solid                dispersion or aqueous solutions or their                suspensions, where (I) is obtained by co-treating                guest drug with a host substance; and    preparing (M12) a medical dosage form of (II)                (as well as their solutions, gels, colloids, sols,                etc), that is a bioavailable highly permeable                noncovalent complex, which is obtained by adding                solvent to the bioavailable highly permeable solid                dispersion of (I), where the (I) is obtained by                co-treating guest drug compound with a host                substance.    k=1-100; and    m=1-10000. ",,,"A96 (Medical, dental, veterinary, cosmetic.);  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.)",A08-S02;  A12-V;  A12-V01;  A12-W09;  D03-H;  D03-H01T2;  B01-D02;  B02-A;  B04-B01B;  B04-C02A1;  B04-C02A2;  B04-C02B;  B04-C02D;  B04-C02E1;  B04-C02E2;  B04-C02E3;  B04-C02E4;  B04-C02X;  B04-C03;  B04-E99;  B05-A03B1;  B05-B01P;  B05-B02A3;  B05-B02C;  B07-A02;  B07-D04A;  B10-A07A;  B10-A07B;  B10-A09B;  B10-A22;  B10-C01;  B10-C02;  B10-C04E3;  B10-C04E5;  B10-E04C;  B10-G02;  B12-M14;  B14-A02;  B14-K01D;  B14-S12;  C01-D02;  C02-A;  C04-B01B;  C04-C02A1;  C04-C02A2;  C04-C02B;  C04-C02D;  C04-C02E1;  C04-C02E2;  C04-C02E3;  C04-C02E4;  C04-C02X;  C04-C03;  C04-E99;  C05-A03B1;  C05-B01P;  C05-B02A3;  C05-B02C;  C07-A02;  C07-D04A;  C10-A07A;  C10-A07B;  C10-A09B;  C10-A22;  C10-C02;  C10-C04E3;  C10-C04E5;  C10-E04C;  C10-G02;  C12-M14;  C14-A02;  C14-K01D;  C14-S12,A61K-031/365;  A61K-047/30;  A61K-009/10;  A61P-031/00,WO2023187599-A1   05 Oct 2023   A61K-009/10   202392Pages: 63   English;  WO2023187599-A4   14 Dec 2023   A61K-009/10   202301   English,WO2023187599-A1    WOIB052993    27 Mar 2023;   WO2023187599-A4    WOIB052993    27 Mar 2023,,US324087P    27 Mar 2022;  US398038P    15 Aug 2022,WO2023187599-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2023187599-A4:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,WO2023187599-A1 -- US20090311325-A1   ;  US20100266628-A1   ;  US20210244705-A1   ,,88042-0-0-0 K M; 88640-0-0-0 K M; 1911-0-0-0 K M; 2117-0-1-0 K M; 55285-2-0-0 K M; 95816-0-0-0 K M; 96319-1-0-0 K M; 2623-0-0-0 K M; 21-0-0-0 K M; 97824-1-0-0 K M; 2853-1-0-0 K M; 99087-1-0-0 K M; 99222-0-0-0 K M; 265-0-0-0 K M; 102639-0-0-0 K M; 103918-0-0-0 K M; 103921-0-0-0 K M; 159573-1-0-0 K M; 107016-0-0-0 K M; 107456-1-0-0 K M; 2021-0-3-0 K M; 110654-1-0-0 K M; 4-0-0-0 K M; 129625-0-0-0 K M; 129626-0-0-0 K M; 129629-0-2-0 K M; 134125-0-0-0 K M; 490-0-0-0 K M; 135560-1-0-0 K M; 129514-0-1-0 K M; 7785-0-0-0 K M; 149267-0-0-0 K M; 159573-0-0-0 K M; 60-0-0-0 K M; 63-0-0-0 K M; 686-0-0-0 K M; 196455-0-0-0 K M; 196509-7-0-0 K M;  K M; 23902-0-0-0 K M; 41621-0-0-0 K M; 849-0-0-0 K M; 861-0-0-0 K M; 949-1-0-0 K M; 511447-0-1-0 K M; 56978-2-0-0 K M; 188771-0-1-0 K M; 90650-1-0-0 K M; 86729-0-0-0 K M; 86923-0-0-0 K M; 90356-0-0-0 K M; 90357-0-0-0 K M; 90359-0-0-0 K M; 90877-0-0-0 K M; 91821-0-0-0 K M; 92830-0-0-0 K M; 94618-0-0-0 K M; 96300-0-0-0 K M; 96529-0-0-0 K M; 96778-0-0-0 K M; 96796-0-0-0 K M; 97115-1-0-0 K M; 97485-1-0-0 K M; 97486-1-0-0 K M; 97487-0-0-0 K M; 100739-1-0-0 K M; 103468-0-0-0 K M; 104328-1-0-0 K M; 104401-0-0-0 K M; 104424-0-0-0 K M; 104488-0-0-0 K M; 104491-0-0-0 K M; 104492-0-0-0 K M; 107307-0-0-0 K M; 107779-0-0-0 K M; 110577-0-0-0 K M; 114270-0-0-0 K M; 114325-0-0-0 K M; 133912-0-0-0 K M; 133925-0-0-0 K M; 900-0-0-0 K M; 1062-0-0-0 K M; 200757-0-0-0 K M; 219367-0-0-0 K M; 97982-1-0-0 K M; 92818-0-0-0 K M; 105014-0-0-0 K M;  K M; 107780-0-0-0 K M; 107783-0-0-0 K M; 273628-0-0-0 K M; 100049-0-0-0 K M; 90363-1-0-0 ; 135402-0-0-0 ; 90688-1-0-0 ; 135412-0-0-0 ; 90114-0-0-0 ; 829-0-0-0 ; 10151-0-0-0 ; 444-0-0-0 ; 238-0-0-0 ,,42530; 42533; 06384,R21441 K M; R03361 K M; R00446 K M; R05327 K M; R01168 K M; R03440 K M; R03492 K M; R16409 K M; R00540 K M; R00822 K M; R00543 K M; R14434 K M; R00135 K M; R10352 K M; R01833 K M; RA00JW K M; R00900 K M; RA29YP K M; R08754 K M; R17037 K M; RA04F7 K M; R00038 K M; R01694 K M; R00032 K M; R01456 K M; R00545 K M; RA0338 K M; R00840 K M; R01616 K M; R00173 K M; R05324 K M; RA1438 K M; RA1HEQ K M; R18623 K M; R00113 K M; RA0337 K M; R04227 K M; R01126 K M; R10097 K M; R12638 K M; R13789 K M; R01081 K M; R01711 K M; R01966 K M; RACTRE K M; RA64CM K M; RAHRZY K M; R00744 K M; R10553 K M; R00419 K M; R00137 K M; R00290 K M; R07423 K M; RA6G4V K M; R00241 K M; RB36SB K M; R17388 K M; RA08P8 K M; R24070 K M; RA04J1 K M; R01852 K M; R01853 K M; RA05OE K M; R16917 K M; RA0B9L K M; R01875 K M; RA0696 K M; RA002W K M; R03275 K M; R01858 K M; RA02KY K M; R01872 K M; R03104 K M; RA024U K M; R01867 K M; R03231 K M; R03005 K M; R06563 K M; RA083K K M; R16918 K M; RA0NLR K M; R01860 K M; RA02KX K M; R17032 K M; R03882 K M; RA009Z K M; RA03FM K M; RA04WZ K M; RA012N K M; RA01EA K M; R06725 K M; R01863 K M; R16377 K M; RA03GS K M; R16922 K M; RA0NLS K M; R01835 K M; R06717 K M; R01866 K M; R07226 K M; R02044 K M; RA0GM6 K M; RA00D5 K M; RA00GT K M; RA0Y4U K M; R01873 K M; R01857 K M; RA05SQ K M; RCYGW4 K M; RA0HHA K M; RA0LJZ K M; RA1JLV K M; RA01JH K M; R01865 ; R24032 ; R03233 ; R24069 ; R24036 ; R00835 ; R00460 ; R00351 ; R00370 ,1017-S; 0446-S; 0540-S; 0822-S; 0543-S; 0135-S; 1833-S; 0900-S; 0038-S; 1694-S; 0032-S; 1456-S; 0545-S; 0840-S; 1616-S; 0173-S; 1174-S; 0113-S; 0120-S; 1126-S; 1081-S; 1711-S; 1966-S; 0744-S; 0419-S; 0137-S; 0290-S; 0241-S; 1852-S; 1853-S; 1875-S; 1858-S; 1872-S; 1867-S; 1860-S; 1866-S; 1863-S; 1835-S; 2044-S; 1873-S; 1857-S
WO2023215230-A1,"Determining presence and size and content of            aggregated protein in test sample, by blocking capture            substrate non-specific binding sites, incubating            capture substrate with test sample, and determining            content of detectable label",GUTKNECHT M;  ROTHSTEIN T L,UNIV WESTERN MICHIGAN STRYKER MEDICINE (UYWM-Non-standard),2023B66764,"   NOVELTY - Determining the presence and at least one of,                the size and content of an aggregated protein in a                test sample, comprises: (a) providing a capture                substrate comprising a microparticle conjugated to                a first capture moiety; (b) blocking the capture                substrate non-specific binding sites; (c)                incubating the capture substrate with a test sample                suspected of having the aggregated protein for a                period of time sufficient for the aggregated                protein to specifically bind to the first capture                moiety, where the first capture moiety binds                specifically to the aggregate protein if present,                thus forming an capture complex on the capture                substrate; (d) incubating the capture substrate                with a second capture moiety that specifically                binds to the aggregated protein, where the second                capture moiety is coupled to a signalling moiety,                and the signaling moiety comprises a detectable                label; and (e) determining the content of                detectable label present on the surface of the                capture substrate.    USE - The method is useful for determining the                presence and at least one of, the size and content                of an aggregated protein in a test sample.    ADVANTAGE - The method provides an assay for the                qualitative and quantitative assessment of                aggregated proteins in solution using a                microparticle immunocapture assay that combines the                advantages inherent to a specific first and second                capture moiety that binds specifically to an                aggregated protein which can reveal at the same                time the amount and the size of aggregates measured                in a sample, fluid, tissue, cavity, or                pharmacological product.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    composition, comprising (a) a first component                comprising many capture substrate microparticles,                each microparticle conjugated to a first capture                moiety antibody and their antigen binding fragment,                or receptor, or ligand, or aptamer, an amino acid                sequence, or lipid, or DNA nucleotide sequence, or                RNA nucleotide sequence, the first capture moiety                antibody and their antigen binding fragment, or                receptor, or ligand, or aptamer, an amino acid                sequence, or lipid, or DNA nucleoside sequence, or                RNA nucleoside sequence, operable to bind to a                single epitope or antigen, or sequence of amino                acids of an aggregated protein involved in a                protein aggregation mediated disease, or other                aggregating species involved in disease, (b) a                second component comprising a second capture moiety                that comprises an antibody, a receptor, a ligand,                an aptamer, an amino acid sequence, a lipid, or DNA                nucleotide sequence, or RNA nucleotide sequence, as                the first capture moiety, where the second capture                moiety is conjugated to a signalling moiety that                comprises at least one of a detectable label and a                first binding partner that is operable to bind                specifically to a detectable label that is coupled                to a second binding partner, and (c) optionally, a                third component a detectable label coupled to a                second binding partner, where the first and second                binding partners bind specifically;    ystem, comprising a processor, and a                non-transitory computer readable medium comprising                instructions that cause the processor to count a                number of positive aggregate protein capture                complexes present in a test sample, where each of                the positive aggregate protein capture complexes                comprise a first capture moiety, an aggregate                protein, a second capture moiety, a signalling                moiety and a fluorescently labelled detectable                label, determine the total number of aggregate                protein capture complexes acquired by a detection                device, calculate the percentage of positive                aggregate protein capture complexes among the total                number of aggregate protein capture complexes, and                determine the number and/or proportion of positive                aggregate protein capture complexes that comprised                the test sample; and    kit, comprising many microparticles comprising                a first capture moiety that specifically binds an                aggregate protein of interest, and a composition                comprising a second capture moiety that                specifically binds to the aggregate protein, where                the second capture moiety is coupled to a                signalling moiety, and the first and second capture                moieties bind to the same epitope or antigen                present on the aggregated protein. ",,,"A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  J04 (Chemical/physical processes/apparatus - including catalysis, catalysts (excluding specific e.g. enzymatic or polymerisation catalysts), colloid chemistry, laboratory apparatus and methods, testing, controlling, general encapsulation, detection and sampling (excluding clinical testing) (B01J, L).);  L03 (Electro-(in)organic - chemical features of conductors, resistors, magnets, capacitors and switches, electric discharge lamps, semiconductor and other materials, batteries, accumulators and thermoelectric devices, including fuel cells, magnetic recording media, radiation emission devices, liquid crystals and basic electric elements. Growing of single crystals of semiconductors and their doping are included, but semiconductor devices, where the manufacture is not claimed are excluded. Electrography, electrophotography, magnetography, electrolysis, electrophoresis, power plant, X-ray and plasma-techniques, ion exchange resins, polyelectrolytes, electroplating, metal electrodeposition, electroforming, anodising, electrolytic cleaning, cathodic protection and electrolytic or electrothermic production or refining of metals are all covered elsewhere (Sections G, J, K and M).);  S03 (Scientific Instrumentation);  ",A12-V03C2;  A12-W11L;  B04-B04C;  B04-C03;  B04-E01;  B04-E07F;  B04-E99;  B04-G01;  B04-N02;  B04-N03J;  B04-N04;  B06-F03;  B07-A02B;  B11-C07A3;  B11-C07A5;  B11-C08C1;  B11-C08F;  B11-C11;  B12-K04F;  D05-H09;  D05-H99;  J04-B01;  J04-B03;  J04-F;  L03-H03A;  L03-X;  S03-E09F;  S03-E14H5;  T01-J03;  T01-J06A;  T01-S03,C07K-016/18;  G01N-033/533;  G01N-033/534;  G01N-033/538;  G01N-033/541;  G01N-033/68,WO2023215230-A1   09 Nov 2023   G01N-033/68   202396Pages: 135   English,WO2023215230-A1    WOUS020576    01 May 2023,,US337128P    01 May 2022,WO2023215230-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,WO2023215230-A1 -- US20080131917-A1   ;  US20090011443-A1   ;  US20110129468-A1   ;  US20170261521-A1   ,,1383422-0-0-0 K M; 90158-0-0-0 K M; 95141-0-0-0 K M; 95972-0-0-0 K M; 96786-0-0-0 K M; 102573-0-0-0 K M; 104333-0-0-0 K M; 104401-0-0-0 K M; 104471-0-0-0 K M; 104481-0-0-0 K M; 104492-0-0-0 K M; 297125-0-0-0 K M; 900-0-0-0 K M; 1062-0-0-0 K M; 107017-0-0-0 K M; 105609-0-0-0 K M; 111025-1-0-0 K M; 249809-1-0-0 K M; 2408-0-0-0 K M; 444-0-0-0 ; 86886-0-0-0 ; 368-0-0-0 ; 133921-0-0-0 ; 1013-0-0-0 ; 1145-0-0-0 ; 92818-0-0-0 ; 107779-0-0-0 ; 1383422-0-0-0 CL USE,,00945,RAOGVL K M; R24040 K M; RA01A2 K M; R24033 K M; RA04LJ K M; R02035 K M; R00975 K M; RA009Z K M; RA009X K M; RA00CA K M; RA01EA K M; RA20EO K M; R02044 K M; RA0GM6 K M; RA00D5 K M; RA018L K M; RA1QWN K M; RA13TI K M; RA11F8 K M; R00172 K M; R00351 ; R24039 ; R00708 ; R01861 ; R00326 ; R00964 ; R01857 ; R01863 ,2035-S; 0975-S; 2044-S; 0172-S
WO2024108109-A1;  US2024197860-A1,"New self-amplifying RNA (saRNA) useful in            pharmaceutical composition for expressing cargo of            interest and treating cancer, comprises modified            nucleotides comprising pyrimidine nucleoside phosphate            with specific moiety and cargo of interest",MCGEE J E;  KIRSCH J R;  BRESSLER E;  GRINSTAFF M W;  WONG W;  SERTSE L Y;  LI K,UNIV BOSTON (UBOS-C);  UNIV BOSTON (UBOS-C),202452317X,"   NOVELTY - A self-amplifying RNA (saRNA) comprising at                least 25% modified nucleotides, where the modified                nucleotides comprise a pyrimidine nucleoside                phosphate with a moiety on carbon 5 of the                pyrimidine and the moiety is chosen from methyl,                ethyl, propyl, trifluoromethyl, hydroxymethyl,                hydroxyethyl and hydroxypropyl functional groups                and at least one cargo of interest, is new.    USE - The saRNA, nucleic acid, vector or cell is                useful in pharmaceutical composition for expressing                at least one cargo of interest in subject. The                subject is a human. The subject is a livestock                animal or a pet (all claimed). The pharmaceutical                composition is useful for treating cancer.    ADVANTAGE - The saRNA increases the level of expression of                a cargo protein in the cell, has increased                stability and efficacy, modifies and controls                activity of cells by expression of proteins, and is                utilized for ex vivo or in vivo modification of                cells.    DETAILED DESCRIPTION - A self-amplifying RNA (saRNA) comprising (A)                at least 25% modified nucleotides, where the                modified nucleotides comprise a pyrimidine                nucleoside phosphate with a moiety on carbon 5 of                the pyrimidine and the moiety is chosen from                methyl, ethyl, propyl, trifluoromethyl,                hydroxymethyl, hydroxyethyl and hydroxypropyl                functional groups and at least one cargo of                interest, (B) 5'-3': (a) at least one                non-structural protein derived from at least one                virus, (b) a subgenomic promoter (SGP) derived from                at least one virus and (c) at least one cargo of                interest, where the saRNA comprises at least 25%                modified nucleotides, the modified nucleotides are                chosen from 5-methylcytidine, 5-methyluridine,                5-hydroxymethyluridine and 5-hydroxymethylcytidine,                the initiating nucleotide comprises an adenosine or                adenosine analog and the initiating nucleotide of                the saRNA is methylated at the 2'O position of the                ribose (Cap1), (C) 5'-3': (a) a 5' cap, (b)                non-structural protein 1 (nsp1), nsp2, nsp3 and/or                nsp4, each derived from at least one virus, (c) SGP                derived from at least one virus, (d) a 5'                untranslated region (UTR) derived from at least one                virus, (e) the at least one cargo of interest, (f)                a 3' UTR derived from at least one virus and (g) a                poly-A tail, where the saRNA comprises at least 25%                modified nucleotides, the modified nucleotides are                chosen from 5-methylcytidine, 5- methyluridine,                5-hydroxymethyluridine and 5-hydroxymethylcytidine,                the initiating nucleotide comprises an adenosine or                adenosine analog and the initiating nucleotide of                the saRNA is methylated at the 2'O position of the                ribose (Cap1), (D) 5'-3': (a) at least one                non-structural protein derived from at least one                virus, (b) SGP derived from at least one virus and                (c) at least one cargo of interest, or (E) 5'-3':                (a) a 5' cap, (b) nsp1, nsp2, nsp3 and/or nsp4,                each derived from at least one virus, (c) SGP                derived from at least one virus, (d) a 5' UTR                derived from at least one virus, (e) at least one                cargo of interest, (f) a 3' UTR derived from at                least one virus and (g) a poly-A tail, is new.                INDEPENDENT CLAIMS are included for the                following:    nucleic acid encoding or comprising the                saRNA;    vector encoding or comprising the saRNA;    composition comprising the saRNA;    cell contacted with the saRNA, the nucleic                acid, the vector or the composition; and    method for expressing at least one cargo of                interest in a cell involves contacting the cell                with the saRNA or administering to the subject the                pharmaceutical composition. ",,,"A96 (Medical, dental, veterinary, cosmetic.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  ;  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",A12-V;  A12-V01;  B04-B03A;  B04-B03D;  B04-E01B;  B04-E01X;  B04-E02K;  B04-E03K;  B04-E08;  B04-E99;  B04-F0100E;  B07-H;  B14-H01;  B14-S21;  C04-B03A;  C04-B03D;  C04-E01X;  C04-E02K;  C04-E03K;  C04-E08;  C04-E99;  C04-F0100E;  C07-H;  C14-H01;  C14-S21;  D05-H12A;  D05-H12E;  D05-H12H;  D05-H14;  D05-H99,A61K-031/7088;  C12N-015/63;  C12N-015/67;  A61K-039/00;  A61K-039/215;  A61P-037/04;  C07K-014/005;  C07K-014/575;  C07K-016/28;  C07K-016/32;  C12N-015/86,WO2024108109-A1   23 May 2024   C12N-015/63   202450Pages: 323   English;  US2024197860-A1   20 Jun 2024   A61K-039/215   202452   English,WO2024108109-A1    WOUS080263    17 Nov 2023;   US2024197860-A1    US512730    17 Nov 2023,US2024197860-A1 Provisional Application US538540P;   US2024197860-A1 Provisional Application US460506P;   US2024197860-A1 Provisional Application US426597P,US426597P    18 Nov 2022;  US460506P    19 Apr 2023;  US538540P    15 Sep 2023;  US512730    17 Nov 2023,WO2024108109-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,"WO2024108109-A1 -- WO2022069577-A1   EVOX THERAPEUTICS LTD (EVOX-Non-standard)   GUPTA D,  EL ANDALOUSSI S,  WIKLANDER O,  NORDIN J;  WO2022150712-A1   STRAND THERAPEUTICS INC (STRA-Non-standard)   KITADA T,  BECRAFT J,  SOWELL R,  KHURANA J,  SIMON A,  BARBERIO J,  ZHAO W,  LEMAIRE A,  SHAH A;  WO2022157153-A2   GLAXOSMITHKLINE BIOLOGICALS SA (GLAX)",,833290-2-0-0 N; 1372378-0-0-0 N; 1539673-1-0-0 N; 2013118-0-0-0 N; 2088724-1-0-0 N; 2246321-1-0-0 N; 1685542-3-0-0 N; 2611702-1-0-0 N; 538791-1-0-0 N; 86228-1-0-0 N; 100880-1-0-0 N; 417710-1-0-0 N;  N; 1372378-0-0-0 CL NEW; 1539673-1-0-0 CL NEW; 2013118-0-0-0 CL NEW; 2088724-1-0-0 CL NEW; 2246321-1-0-0 CL NEW; 1685542-3-0-0 CL NEW; 2611702-1-0-0 CL NEW,,00690; 71558; 00993,RACU4Q N; RAQ7CV N; RAUJEG N; RAV3CA N; RB45QT N; RB1PTD N; RB3B4M N; RB6N5A N; RBD9V3 N; RBELH8 N; RA70NZ N; RA02DL N; R23688 N; RA76PC N; RCXD3O N,
WO2023060167-A1;  US2023173091-A1;  TW202323279-A;  CA3233732-A1;  AU2022361048-A1;  KR2024069776-A,"New targeted complement-activating molecule            comprising target-binding domain, and            complement-activating serine protease effector domain            used to e.g. treat cancer, autoimmune disease and            microbial infection e.g. fungal infection",ALI M Y I;  DEMOPULOS G A;  DOULAMI C;  SCHWAEBLE H;  YABUKI M;  IBRAHIM A M Y;  DOULA C T,OMEROS CORP (OMRS-C);  OMEROS CORP (OMRS-C);  OMEROS CORP (OMRS-C);  OMEROS CORP (OMRS-C),202337839R,"   NOVELTY - Targeted complement-activating molecule                comprising (a) a target-binding domain, and (b) a                complement-activating serine protease effector                domain, is new.    USE - The targeted complement-activating molecule is                useful for: activating at least one complement                pathway in a mammalian subject, where the                activation of the complement pathway comprises                activation of the complement classical pathway,                complement lectin pathway, and complement                alternative pathway; inducing CDC, CDCC, or CDCP in                a target cell; treating cancer in mammalian                subject, where the cancer is a solid tumor cancer                or hematological cancer; autoimmune disease in                mammalian subject; microbial infection in a                mammalian subject, where the infection is a                bacterial infection, a viral infection, a fungal                infection, or a parasitic infection, where the                bacterial pathogen is e.g. Neisseria meningitidis,                Streptococcus pneumoniae, Staphylococcus aureus                (all preferred), Borrelia burgdorferi, Escherichia                coli, Klebsiella pneumoniae, Treponema pallidum,                Neisseria gonorrhea, Salmonella species,                Helicobacter species, Shigella species, and                Listeria species, where the viral pathogen is an                Epstein-Barr virus, HIV-1 (preferred), severe acute                respiratory syndrome (SARS)-coronavirus (CoV)-2, a                Herpesvirus, influenza virus, West Nile virus,                Cytomegalovirus, or a Coronavirus, the fungal                pathogen is Candida albicans (preferred) or                Aspergillus species, and the parasitic pathogen is                Schistosoma mansoni, Plasmodium falciparum                (preferred), or Trypanosoma cruzei (all claimed),                or the cancer is e.g. liver cancer, kidney cancer,                lymphoma, leukemia, lung cancer, melanoma,                metastatic melanoma, mesothelioma, myeloma,                neuroblastoma, ovarian cancer, prostate cancer,                pancreatic cancer, renal cancer, skin cancer, and                uterine cancer, the autoimmune disease is e.g.                autoimmune diabetes, autoimmune encephalitis,                pemphigus vulgaris, vasculitis, Sjogren syndrome,                and myasthenia gravis.    ADVANTAGE - The targeted complement-activating molecule:                binds to a target with an affinity 1 &#956; M                and 1 pM; has a serine protease activity that is at                least 70%, preferably 90% of the serine protease                activity of the serine protease domain alone; binds                to a target on a cell surface and activates a                complement pathway when administered to a mammalian                subject; and induces CDC, CDCC, and/or CDCP.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    a polynucleotide (P1) encoding the                molecule;    a polynucleotide (P2) encoding the fusion                protein;    a cloning vector or expression cassette                comprising the polynucleotide (P1) o(P2);    a cloning vector (V1) or expression cassette                (EC1) comprising a first polynucleotide encoding                the fusion protein and a second polynucleotide,                where the second polynucleotide encodes an antibody                heavy chain or fragment, if the fusion protein                comprises an antibody light chain or fragment, and                the second polynucleotide encodes an antibody light                chain or fragment if the fusion protein comprises                an antibody heavy chain or fragment;    a first cloning vector (V2) or expression                cassette (EC2) comprising a first polynucleotide                encoding the fusion protein and a second cloning                vector or expression cassette comprising a second                polynucleotide, where the second polynucleotide                encodes an antibody heavy chain or fragment if the                fusion protein comprises an antibody light chain or                fragment, and the second polynucleotide encodes an                antibody light chain or fragment if the fusion                protein comprises an antibody heavy chain or                fragment;    a host cell expressing the molecule, or                comprising the cloning vector(s) (V1 or V2) or                expression cassette(s) (EC1 or EC2);    producing the complement-activating molecule;                and    inducing complement dependent cell death                (CDC), complement-dependent cell-mediated                cytotoxicity (CDCC) or complement-dependent                cellular phagocytosis (CDCP) in a target cell,                comprising contacting the target cell with the                molecule or the composition comprising the molecule                and at least one excipient, where the contacting                results in complement deposition on the target                cell, thus leading to complement-mediated cell                death. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).)",B04-C01;  B04-E02A;  B04-E02H;  B04-E03A;  B04-E08;  B04-E99;  B04-F0100E;  B04-G01;  B04-G21;  B11-A04A;  B14-A01;  B14-A02;  B14-A04;  B14-B02;  B14-C03;  B14-F02;  B14-G02D;  B14-H01;  B14-J05;  B14-K01D;  B14-L06;  B14-N16;  B14-N17;  B14-S04;  C04-C01;  C04-E02A;  C04-E02H;  C04-E03A;  C04-E08;  C04-E99;  C04-G21;  C14-A01;  C14-A02;  C14-A04;  C14-B02;  C14-C03;  C14-F02;  C14-G02D;  C14-H01;  C14-J05;  C14-K01D;  C14-L06;  C14-N16;  C14-N17;  C14-S04;  D05-H08A;  D05-H12B;  D05-H12E;  D05-H14;  D05-H99,A61K-038/17;  A61P-035/00;  A61P-037/00;  C07K-016/28;  C07K-016/40;  A61K-047/68;  A61P-031/04;  A61P-031/10;  G01N-033/543;  G01N-033/569;  A61K-039/395;  A61P-031/12;  C07K-016/18;  C07K-016/46;  C12N-015/13;  A61K-039/00;  C12N-009/64,WO2023060167-A1   13 Apr 2023   A61K-038/17   202337Pages: 314   English;  US2023173091-A1   08 Jun 2023   A61K-047/68   202347   English;  TW202323279-A   16 Jun 2023   C07K-016/18   202364   Chinese;  CA3233732-A1   13 Apr 2023   A61K-038/17   202430   English;  AU2022361048-A1   02 May 2024   A61K-038/17   202437   English;  KR2024069776-A   20 May 2024   C07K-016/28   202442   ,WO2023060167-A1    WOUS077663    06 Oct 2022;   US2023173091-A1    US938421    06 Oct 2022;   TW202323279-A    TW138094    06 Oct 2022;   CA3233732-A1    CA3233732    06 Oct 2022;   AU2022361048-A1    AU361048    06 Oct 2022;   KR2024069776-A    KR713055    06 Oct 2022,US2023173091-A1 Provisional Application US253211P;   CA3233732-A1 PCT application Application WOUS077663;   AU2022361048-A1 PCT application Application WOUS077663;   AU2022361048-A1 Based on Patent WO2023060167;   KR2024069776-A PCT application Application WOUS077663;   KR2024069776-A Based on Patent WO2023060167,US253211P    07 Oct 2021;  US938421    06 Oct 2022;  CA3233732    02 Apr 2024;  KR713055    19 Apr 2024,WO2023060167-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA            ,,WO2023060167-A1 -- US20060188963-A1   ;  US20190016824-A1   ,,184587-0-0-0 K M; 184616-0-0-0 K M; 166620-0-0-0 K M; 114052-0-0-0 K M;  K M,,,RA00C8 K M; RA00H3 K M; RA1VLZ K M; RA8B76 K M; RBUETP K M,
WO2024056905-A1,"Immunoassay useful as lifestyle product for            detecting biologically active antigen, preferably            hormone, protein or drug in biological sample of            individual comprises sample application area for            applying biological sample of individual",EILERS A;  PLOENNINGS E;  PFEIL-COENEN S,PHAEOSYNT GMBH (PHAE-Non-standard),202430158Q,"   NOVELTY - Immunoassay comprises a sample application                area for applying a biological sample of an                individual, where biological sample is preferably                urine, whole blood, saliva, milk or serum, capture                region having immobilized first antibody directed                against biologically active antigen, preferably                against hormone, protein, peptide or drug,                conjugate region having second antibody directed                against biologically active antigen, preferably                against hormone, protein, peptide or drug. The                first antibody and/or second antibody is                recombinant antibody obtained from diatom or                unicellular plant, recombinant antibody is provided                in a purity of at least 90%, preferably at least                95%.    USE - The immunoassay is useful as lifestyle product                for detection of nutrition-associated parameters,                as point of care (PoC) diagnostics, preferably                detection of biologically active antigens (all                claimed).    ADVANTAGE - The immunoassay allows easy interpretation of                immunoassay result, is easy in handling for                non-medical personnel, economical, ensures germline                cells have antibody genes integrated into their                genome to ensure long-term production and long-term                production requires selfing or grafting of                transgenic plants.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    device, comprising a container, preferably                housing and immunoassay arranged, preferably                lateral flow immunoassay;    kit, comprising a device and instructions for                performing the immunoassay;    method for detecting biologically active                protein in biological sample, preferably urine,                whole blood, saliva, milk or serum, comprising (a)                obtaining biological sample from an individual, (b)                analyzing biological sample using an immunoassay,                which is adapted to detect the biologically active                protein; and    auxiliary protein as covering, masking and/or                supporting protein in immunoassay, comprising                auxiliary protein is obtained recombinantly from                stably transformed diatom or unicellular                plant. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).);  J04 (Chemical/physical processes/apparatus - including catalysis, catalysts (excluding specific e.g. enzymatic or polymerisation catalysts), colloid chemistry, laboratory apparatus and methods, testing, controlling, general encapsulation, detection and sampling (excluding clinical testing) (B01J, L).);  A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  S03 (Scientific Instrumentation)",B04-B04B1;  B04-B04D2;  B04-B04D5;  B04-B04G;  B04-B04K;  B04-E99;  B04-F11;  B04-G0100E;  B04-H02J;  B04-H05C;  B04-J05H;  B04-K01J;  B04-N02;  B11-C07A4;  B12-K04E;  C04-B04B1;  C04-B04D2;  C04-B04D5;  C04-B04G;  C04-B04K;  C04-E99;  C04-F11;  C04-G0100E;  C04-H02J;  C04-H05C;  C04-J05H;  C04-K01J;  C04-N02;  C11-C07A4;  C12-K04G;  D03-K03;  D05-H09;  D05-H99;  J04-B01;  J04-B03;  A12-E13;  A12-V01;  A12-V03C2;  S03-E09F;  S03-E14H1;  S03-E14H2;  S03-E14H5,C12N-015/82;  G01N-033/543,WO2024056905-A1   21 Mar 2024   G01N-033/543   202426Pages: 90   German,WO2024056905-A1    WOEP075545    15 Sep 2023,,LU103006    15 Sep 2022,WO2024056905-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2024056905-A1 -- EP2444495-A1   ALGENICS (ALGE-Non-standard)   LEJEUNE A,  MICHEL R,  CADORET J,  CARLIER A;  EP2660323-A1   ALGENICS (ALGE-Non-standard)   CARLIER A,  MICHEL R,  LEJEUNE A,  CADORET J;  EP2671950-A1   UNIV PHILIPPS MARBURG (UYPH)   HEMPEL F,  MAIER U;  US6080560-A   MONSANTO CO (MONS)   RUSSELL D R,  FULLER J T;  WO2021021605-A1   UNIV VANDERBILT (UVAN)   CROWE J E,  VOGT M R","WO2024056905-A1  MELNIK STANISLAV ET          AL: ""Cloning and plant-based production of antibody          MC10E7 for a lateral flow immunoassay to detect          [4-arginine]microcystin in freshwater"", vol. 16, no. 1, 5          June 2017 (2017-06-05), GB, pages 27 - 38, XP093028342,          ISSN: 1467-7644, Retrieved from the Internet          &lt;URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fpbi.12746&gt;          DOI:          10.1111/pbi.12746,relevantClaims[26,27|1-27],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;&lt;figure&gt;5&lt;/figure&gt;];  FRANZISKA HEMPEL ET          AL: ""An engineered diatom acting like a plasma cell          secreting human IgG antibodies with high efficiency"",          MICROBIAL CELL FACTORIES, vol. 11, no. 1, 1 January 2012          (2012-01-01), pages 126, XP055040968, ISSN: 1475-2859,          DOI:          10.1186/1475-2859-11-126,relevantClaims[1-27],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  SLATTERY SAMUEL S.          ET AL: ""Phosphate-regulated expression of the SARS-CoV-2          receptor-binding domain in the diatom Phaeodactylum          tricornutum for pandemic diagnostics"", vol. 12, no. 1, 29          April 2022 (2022-04-29), XP093027998, Retrieved from the          Internet          &lt;URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051505/pdf/41598_2022_Article_11053.pdf&gt;          DOI:          10.1038/s41598-022-11053-7,relevantClaims[26,27|1-27],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  YANGMIN GONG ET AL:          ""Microalgae as platforms for production of recombinant          proteins and valuable compounds: progress and prospects"",          JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY,          SPRINGER, BERLIN, DE, vol. 38, no. 12, 1 September 2011          (2011-09-01), pages 1879 - 1890, XP019982203, ISSN:          1476-5535, DOI:          10.1007/S10295-011-1032-6,relevantClaims[1-27],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  FRANZISKA HEMPEL ET          AL: ""Algae as Protein Factories: Expression of a Human          Antibody and the Respective Antigen in the Diatom          Phaeodactylum tricornutum"", PLOS ONE, PUBLIC LIBRARY OF          SCIENCE, US, vol. 6, no. 12, 1 December 2011          (2011-12-01), pages e28424 - 1, XP002681385, ISSN:          1932-6203, DOI:          10.1371/JOURNAL.PONE.0028424,relevantClaims[1-27],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  GRIESBECK C ET AL:          ""Chlamydomonas reinhardtii"", MOLECULAR BIOTECHNOLOGY,          SPRINGER US, NEW YORK, vol. 34, no. 2, Sp. Iss. SI, 1          October 2006 (2006-10-01), pages 213 - 223, XP002681386,          ISSN:          1073-6085,relevantClaims[1-27],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  AYALA MARTA ET AL:          ""Production of Plantibodies in Nicotiana Plants"",          ANTIBODY-DRUG CONJUGATES; IN: METHODS IN MOLECULAR          BIOLOGY; ISSN 1064-3745; VOL. 263; [METHODS IN MOLECULAR          BIOLOGY; ISSN 1064-3745], HUMANA PRESS, US, vol. 483, 1          January 2009 (2009-01-01), pages 103 - 134, XP008118830,          ISBN: 978-1-62703-541-5, [retrieved on 20090129], DOI:          10.1007/978-1-59745-407-0_7,relevantClaims[1-27],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  O'KENNEDY RICHARD          ET AL: ""Technology advancements in antibody          purification"", ANTIBODY TECHNOLOGY JOURNAL, vol. Volume          6, 26 August 2016 (2016-08-26), pages 17 - 32,          XP093107407, ISSN: 2230-3170, Retrieved from the Internet          &lt;URL:https://www.dovepress.com/getfile.php?fileID=32094&gt;          DOI: 10.2147/ANTI.S64762",1536600-0-0-0 K M; 90158-0-0-0 K M; 90882-0-0-0 K M; 95085-0-0-0 K M; 95972-0-0-0 K M; 297125-0-0-0 K M; 1536600-0-0-0 CL USE,,,RARMJD K M; R24040 K M; RA01BZ K M; RA13E0 K M; R24033 K M; RA20EO K M,
CA3151035-A1;  US2022280529-A1,"Use of immunogenic composition to elicit immune            response, comprising immunogen and metal-based            coordination complex",DUMOULIN-WHITE R;  MANDEL A,THERALASE TECHNOLOGIES INC (THER-Non-standard);  THERALASE TECHNOLOGIES INC (THER-Non-standard),2022B3502U,"   NOVELTY - Use of an immunogenic composition to elicit an                immune response in a patient, comprising an                immunogen and a metal-based coordination complex,                where the immunogen is inactivated or attenuated by                the metal-based coordination complex.    USE - The composition is useful for: eliciting an                immune response in a patient; treating and                preventing microbial and/or viral infections,                preferably coronavirus infections, including the                severe acute respiratory syndrome                (SARS)-coronavirus (CoV)-2 virus. Test details are                described but no results for the composition of the                claim is given.    ADVANTAGE - The composition is a monovalent, bivalent,                multivalent or polyvalent vaccine to elicit a                therapeutic and/or protective immune response                against the immunogen.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    preparing (M1) the attenuated immunogenic                composition, comprising providing an immunogenic                composition comprising an immunogen, and adding a                metal-based coordination complex to the immunogenic                composition to inactivate or attenuate the                immunogen in the immunogenic composition to provide                the attenuated immunogenic composition; and    an attenuated immunogenic composition prepared                by the method (M1). ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B02 (Fused ring heterocyclics.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-N06;  B05-A03B;  B05-B02C;  B06-H;  B07-D04B;  B07-D12;  B10-A09B;  B14-A02;  B14-G01;  B14-K01D;  B14-S11A;  B14-S11D1;  B14-S11D2;  B14-S18;  B14-S27;  D05-H07,A61K-039/00;  A61K-041/10;  A61K-041/17;  A61P-031/12;  A61P-031/14;  A61P-031/16;  A61P-037/04;  A61K-031/555;  A61K-039/125,CA3151035-A1   04 Sep 2022   A61K-039/00   202284Pages: 84   English;  US2022280529-A1   08 Sep 2022   A61K-031/555   202284   English,CA3151035-A1    CA3151035    04 Mar 2022;   US2022280529-A1    US192597    04 Mar 2021,,US192597    04 Mar 2021,,,";  US2022280529-A1 -- US20070212379-A1   ;  US20210369835-A1   ;  US11020475-B1   UNIV IND & ACADEMIC COOP IN CHUNGNAM                  NAT (UCHU)   JANG Y,  SEO S;  WO2018209203-A1   THERALASE BIOTECH INC (THER-Non-standard)   MANDEL A","US2022280529-A1            Pacific Immunology, Antigens vs Immunogens. Retrieved          from the Internet on 11/28/2022,          https://www.pacificimmunology.com/resources/antigens/antigens-vs-immunogens/#:~:text=An%20immunogen%20refers%20to%20a,not%20necessarily%20be%20an%20immunogen.          (Year: 2022);            Translation of CN 112107683. Published 12/22/2020.          Retrieved from Google Patents on 01/05/2023,          https://patents.google.com/patent/CN112107683A/en?q=(%22photodynamic%22+virus+vaccine)&oq=(%22photodynamic%22+virus+vaccine)          (Year: 2020)",3006400-0-0-0 M N; 109227-0-0-0 K M; 3006400-0-0-0 CL NEW USE,227881302 M N; 227881301 M N; 227881303 M N; 227881304 M N; 227881305 M N; 227881306 M N; 227881307 M N; 227881308 M N,66838,RBN3IY M N; RA03SE K M,
WO2023086350-A1;  US2023159545-A1;  US11858945-B2,"New substituted alkyne compounds are viral 3C            protease inhibitors useful for treating or preventing            virus infection, acute asthma, lung disease, acute lung            infection, and chronic lung infection",PANARESE J D;  BARTLETT S;  WANG G;  OR Y S,ENANTA PHARM INC (ENAN-C);  ENANTA PHARM INC (ENAN-C),202352513E,"   NOVELTY - Substituted alkyne compounds (I), are                new.    USE - (I) are useful for: treating or preventing a                virus infection, including a virus infection from                an RNA-based virus, a coronavirus, a rhinovirus and                a norovirus, in a subject susceptible to or                suffering from the virus infection, where the                coronavirus comprises a 229E, NL63, OC43, HKU1,                severe acute respiratory syndrome coronavirus or a                middle east respiratory syndrome coronavirus, and                the subject is a human; inhibiting viral 3C                protease or viral 3CL protease in a mammal; and                treating a respiratory disorder, including acute                asthma, lung disease secondary to environmental                exposures, acute lung infection, chronic lung                infection, in a subject.    ADVANTAGE - None given.    DETAILED DESCRIPTION - Substituted alkyne compounds of formula (I),                are new.    A=-R11, -OR12, or -NR13R14;    ring B=aryl or heteroaryl (both optionally                substituted);    Q1=-1-8C alkyl, -3-8C cycloalkyl, 3-8-membered                heterocyclic, aryl, -R15S(O) R16, -R15C(O)R16,                -R15C(O)OR16, -R15C(O)NR13 (all optionally                substituted), or H; either    R1-R3=-1-8C alkyl, -2-8C alkenyl, -2-8C                alkynyl, -3-8C cycloalkyl, 3-8-membered                heterocycloalkyl, aryl, arylalkyl, heteroaryl,                heteroarylalkyl (all optionally substituted) or H;                or    CR1R2=3-8 membered carbocyclic ring or 3-8                membered heterocyclic ring (both optionally                substituted);    R4=-1-4C alkyl, 2-4C-alkenyl, or -3-6C                cycloalkyl (all optionally substituted), or                H;    R11, R12=-1-8C alkyl, -2-8C alkenyl, -2-8C                alkynyl, -3-8C cycloalkyl, 3-8-membered                heterocycloalkyl, aryl, arylalkyl, heteroaryl, or                heteroarylalkyl (all optionally substituted);                either    R13, R14=-1-8C alkyl, -2-8C alkenyl, -2-8C                alkynyl, -3-8C cycloalkyl, 3-8-membered                heterocycloalkyl, aryl, arylalkyl, heteroaryl,                heteroarylalkyl (all optionally substituted) or                H;    NR13R14=3-8- membered heterocyclic ring                (optionally substituted);    R15=-1-8C alkyl (optionally substituted);                and    R16=-1-8C alkyl, -2-8C alkenyl, -2-8C alkynyl,                4-3-8C cycloalkyl, 3-8-membered heterocycloalkyl,                aryl, arylalkyl, heteroaryl, or heteroarylalkyl                (all optionally substituted).     ",,,B02 (Fused ring heterocyclics.),B06-H;  B06-S;  B14-A01;  B14-A02;  B14-A04;  B14-D07C;  B14-K01,A61P-031/20;  C07D-487/10;  C07D-519/00,WO2023086350-A1   19 May 2023   C07D-487/10   202344Pages: 59   English;  US2023159545-A1   25 May 2023   C07D-487/10   202344   English;  US11858945-B2   02 Jan 2024   C07D-487/10   202403   English,WO2023086350-A1    WOUS049350    09 Nov 2022;   US2023159545-A1    US983484    09 Nov 2022;   US11858945-B2    US983484    09 Nov 2022,US2023159545-A1 Provisional Application US278550P;   US11858945-B2 Provisional Application US278550P;   US11858945-B2 Previous Publ. Patent US2023159545,US278550P    12 Nov 2021;  US983484    09 Nov 2022,WO2023086350-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      ,,"WO2023086350-A1 -- US20140148494-A1   ;  US20220162216-A1   ;  US20220162231-A1   ;  WO2012099454-A1   UNIV SAINS MALAYSIA (UYSA-Non-standard)   ISMAIL R,  ALI M A,  TAN S C,  YEONG K Y,  ANG C W,  SURESH KUMAR R,  OSMAN H","WO2023086350-A1  KELEMEN ET AL.:          ""Spiro[pyrrolidine-3,3'-oxindoles] and Their Indoline          Analogues as New 5-HT6 Receptor Chemotypes"", MOLECULES,          vol. 22, 14 December 2017 (2017-12-14), pages 1 - 25,          XP055971801, DOI:          10.3390/molecules22122221,relevantClaims[1-16],relevantPassages[;          pg. 9, Table 4: 39a]US2023159545-A1            Owen; Science 2021, 374, 1586-1593.          https://doi.org/10.1126/science.abl4784 (Year:          2021);            International Search Report and Written Opinion of the          International Searching Authority, Application          PCT/US2022/049350. Mailed 10 February 2023. (Year:          2023)", N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N,228989401 N,01123; 02456; 01272,RDCL0E N; RDCL0F N; RDCL0G N; RDCL0H N; RDCL0I N; RDCL0J N; RDCL0K N; RDCL0L N; RDCL0M N; RDCL0N N; RDCL0O N; RDCL0P N; RDCL0Q N; RDCL0R N; RDCL0S N; RDCL0T N; RDCL0U N; RDCL0V N; RDCL0W N; RDCL0X N; RDCL0Y N,
WO2023091766-A2;  TW202330922-A;  WO2023091766-A3,"New respiratory syncytial virus RNA encoding RSV            fusion glycoprotein protein or its immunogenic            fragment, useful for preventing symptomatic RSV            infection, inducing immune response to RSV and treating            subject infected with RSV",BROWN D;  ANANTHASWAMY N;  CHEN R,RNAIMMUNE INC (RNAI-Non-standard),202356556T,"   NOVELTY - A respiratory syncytial virus (RSV) RNA                encoding an RSV fusion glycoprotein (F) protein or                its immunogenic fragment, is new. The RNA encoding                a peptide comprises one or more non-naturally                occurring amino acid mutations chosen from a                cysteine (C) as amino acid corresponding to Ser155                of a 574 amino acid sequence (SEQ ID NOs: 87 or 53)                fully defined in the specification (Ser155C), a                phenylalanine (F) as amino acid corresponding to                Ser190 of SEQ ID NOs: 87 or 53 (Ser190Phe), a                leucine (L) as amino acid corresponding to Val207                of SEQ ID NOs: 87 or 53 (Val207Leu), or a cysteine                (C) as amino acid corresponding to Ser290 of SEQ ID                NOs: 87 or 53 (Ser290Cys).    USE - The RSV RNA is useful in composition for                preventing symptomatic RSV infection, inducing an                immune response to RSV and treating a subject                infected with RSV (claimed).    ADVANTAGE - The RNA reduces a RSV viral load.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    a polypeptide encoded by the RNA, or its                equivalent;    a polynucleotide comprising one of 4 (1254)                base pair sequences (SEQ ID NOs: 8, 12, 6 and 10)                all fully defined in the specification or its                equivalent, the equivalent of SEQ ID NO: 8, 12, 6                and 10 encodes one of 4 (419) amino acid sequences                (SEQ ID NO: 7, 11, 5 and 9) all fully defined in                the specification or its equivalent respectively or                encoding the RNA or the polypeptide, or its                complementary polynucleotide, optionally the                polynucleotide is chosen from DNA, an RNA, a hybrid                of DNA and RNA, or their analogs, the                polynucleotide comprises a 1722 base pair sequence                (SEQ ID NO: 88) fully defined in the specification                or a 1668 base pair sequence (SEQ ID NO: 93) fully                defined in the specification;    an optimized F protein scaffold peptide,                comprising SEQ ID NO: 87 or a 556 amino acid                sequence (SEQ ID NO: 92) fully defined in the                specification;    an RNA encoding the peptide, comprising a 1722                base pair sequence (SEQ ID NO: 89) fully defined in                the specification or a 1668 base pair sequence (SEQ                ID NO: 94) fully defined in the                specification;    a vector comprising the polynucleotide;    a cell comprising one or more of: the RNA, the                polypeptide, the polynucleotide, or the                vector;    a method for producing the RNA involves                culturing the cell under conditions suitable for                expressing the RNA or contacting the polynucleotide                or the vector with an RNA polymerase, ATP, cytidine                triphosphate (CTP), guanosine-5'-triphosphate                (GTP), and uridine triphosphate (UTP) or a                chemically modified UTP under conditions suitable                for expressing the RNA;    a composition comprising the RNA and                carrier;    a method for producing the composition                involves contacting the RNA with an HKP, thereby                the RNA and the HKP are self-assembled into                nanoparticles or contacting the RNA with a lipid,                thereby the RNA and the lipid are self-assembled                into lipid nanoparticles (LNPs);    a method for one or more of: preventing                symptomatic RSV infection, inducing an immune                response to RSV, treating a subject infected with                RSV, or reducing a RSV viral load, involves                administering one or more of the RNA or one or more                of the composition, and optionally the subject is a                human patient, chosen from an infant, a pediatric                patient, or a pregnant human or an adult 60 years                old or older;    an inhalation system comprising the RNA, or                the composition and a nebulizer; and    a kit for use in the method, comprising                instructions for use and one or more of: the RNA,                the composition, the inhalation system or the RNA,                the polypeptide, the polynucleotide, the vector, or                the cell, the composition, an HKP, or a lipid                optionally a cationic lipid or the polynucleotide                or the vector, an RNA polymerase, ATP, CTP, GTP,                and UTP or a chemically modified UTP. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  ;  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.)",B01-D02;  B04-B01B;  B04-C01G;  B04-C03C;  B04-E01B;  B04-E02F;  B04-E02H;  B04-E03F;  B04-E08;  B04-E99;  B04-F0100E;  B04-F0200E;  B04-F07A0E;  B04-F0900E;  B04-F10A3E;  B04-F1100E;  B04-L04A;  B04-N03K1;  B04-N04;  B05-B01P;  B07-A04;  B10-A22;  B10-B02B;  B10-B02J;  B12-M01B;  B12-M11Q1;  B14-A02B;  B14-K01;  C04-B01B;  C04-C01G;  C04-E01B;  C04-E02F;  C04-E02H;  C04-E03F;  C04-E08;  C04-E99;  C04-F0200E;  C04-F07A0E;  C04-F0900E;  C04-F10A3E;  C04-F1100E;  C04-N03K1;  C04-N04;  C12-M01B;  C14-A02B;  C14-K01;  D05-A02B;  D05-H12A;  D05-H12C;  D05-H12E;  D05-H14;  D05-H99;  A10-E01;  A12-V01,A61K-039/12;  C12N-015/86;  A61K-031/713;  A61P-031/12;  C12N-015/33;  C12N-015/63;  C12N-015/64;  A61P-031/14;  C07K-014/135,WO2023091766-A2   25 May 2023   A61K-039/12   202348Pages: 201   English;  TW202330922-A   01 Aug 2023   C12N-015/33   202378   Chinese;  WO2023091766-A3   28 Sep 2023   C07K-014/135   202380   English,WO2023091766-A2    WOUS050620    21 Nov 2022;   TW202330922-A    TW144475    21 Nov 2022;   WO2023091766-A3    WOUS050620    21 Nov 2022,,US281578P    19 Nov 2021,WO2023091766-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    WO2023091766-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,;  WO2023091766-A3 -- US20140024076-A1   ;  US20140271699-A1   ;  US20170319682-A1   ,,218588-0-0-0 K M; 900-0-0-0 K M; 40293-1-0-0 K M; 93537-0-0-0 K M; 135651-0-0-0 K M;  K M; 2152743-1-0-0 K M;  K M; 2609036-1-0-0 K M;  K M; 8349-1-0-0 K M; 444-0-0-0 ; 2152743-1-0-0 CL USE; 2609036-1-0-0 CL USE,,,RA0DQN K M; R02044 K M; RA0GM6 K M; R06521 K M; RA0KCF K M; RA1F77 K M; R06520 K M; RA0DG3 K M; RA0MRI K M; RC53SA K M; RB4NNS K M; RCWE7Y K M; RBEJFC K M; RCSSIP K M; R00148 K M; R00351 ,2044-S; 0148-S
WO2022098685-A2;  WO2022098685-A3;  KR2023113755-A;  EP4241278-A2;  CN116802743-A;  JP2023550309-W;  US2023398149-A1,"Treating cancer e.g. multiple myeloma in subject,            by administering alkylating agent to subject, isolating            peripheral blood mononuclear cells from subject,            manufacturing chimeric antigen receptor T cells, and            administering cells to subject",RYTLEWSKI J A;  MASHADI-HOSSEIN A;  CAMPBELL T;  FULLER J;  LITTLELEVSKY J A,CELGENE CORP (CGEN-C);  JUNO THERAPEUTICS INC (CGEN-C);  CELGENE CORP (CGEN-C);  JUNO THERAPEUTICS INC (CGEN-C);  JUNO THERAPEUTICS INC (CGEN-C);  JUNO THERAPEUTICS INC (CGEN-C);  CELGENE CORP (CGEN-C),202263780K,"   NOVELTY - Method (A) for treating a tumor or a cancer in                a subject involves (i) (a) administering an                alkylating agent to the subject, (b) isolating                peripheral blood mononuclear cells (PBMCs) from the                subject at least 6 months after step (a), (c)                determining that at least 20% of the PBMCs are T                cells, (d) manufacturing chimeric antigen receptor                (CAR) T cells from the PBMCs based on determination                in step (c), and (e) administering the CAR T cells                to the subject.    USE - The method (A) is useful for treating tumor or                cancer in a subject. The method (F) is useful for                treating condition in subject. The subject is a                human. The tumor or cancer is lymphoma, lung                cancer, breast cancer, prostate cancer,                adrenocortical carcinoma, thyroid carcinoma,                nasopharyngeal carcinoma, melanoma, skin carcinoma,                colorectal carcinoma, a desmoid tumor, a                desmoplastic small round cell tumor, an endocrine                tumor, a Ewing sarcoma, a peripheral primitive                neuroectodermal tumor, a solid germ cell tumor, a                hepatoblastoma, a neuroblastoma, a                non-rhabdomyosarcoma soft tissue sarcoma, an                osteosarcoma, a retinoblastoma, a rhabdomyosarcoma,                a Wilms tumor, a glioblastoma, a myxoma, a fibroma,                a lipomachronic lymphocytic leukemia (small                lymphocytic lymphoma), B-cell prolymphocytic                leukemia, lymphoplasmacytic lymphoma, Waldenstrom                macroglobulinemia, splenic marginal zone lymphoma,                plasma cell myeloma, plasmacytoma, extranodal                marginal zone B cell lymphoma, MALT lymphoma, nodal                marginal zone B cell lymphoma, follicular lymphoma,                mantle cell lymphoma, diffuse large B cell                lymphoma, mediastinal (thymic) large B cell                lymphoma, intravascular large B cell lymphoma,                primary effusion lymphoma, Burkitt lymphoma, T                lymphocyte prolymphocytic leukemia, T lymphocyte                large granular lymphocytic leukemia, aggressive NK                cell leukemia, adult T lymphocyte                leukemia/lymphoma, extranodal NK/T lymphocyte                lymphoma, nasal type, enteropathy-type T lymphocyte                lymphoma, hepatosplenic T lymphocyte lymphoma,                blastic NK cell lymphoma, mycosis fungoides, Sezary                syndrome, primary cutaneous anaplastic large cell                lymphoma, lymphomatoid papulosis,                angio-immunoblastic T lymphocyte lymphoma,                peripheral T lymphocyte lymphoma (unspecified),                anaplastic large cell lymphoma, Hodgkin lymphoma, a                non-Hodgkin lymphoma, or multiple myeloma. The                non-Hodgkin's lymphoma is Burkitt lymphoma, chronic                lymphocytic leukemia/small lymphocytic lymphoma                (CLL/SLL), diffuse large B cell lymphoma,                follicular lymphoma, immunoblastic large cell                lymphoma, precursor B-lymphoblastic lymphoma, or                mantle cell lymphoma. The multiple myeloma is                high-risk multiple myeloma or relapsed and                refractory multiple myeloma. The multiple myeloma                is high risk multiple myeloma, preferably R-ISS                stage III disease and/or a disease characterized by                early relapse. The condition is cancer, an immune                disease (e.g. an autoimmune disease), a                cardiovascular disease, fibrosis, an infectious                disease or a neurological condition (all                claimed).    ADVANTAGE - The method determines optimal exposure washout                period of prior treatment regimens using a                time-to-event model.    DETAILED DESCRIPTION - Method (A) for treating a tumor or a cancer in                a subject involves (i) (a) administering an                alkylating agent to the subject, (b) isolating                peripheral blood mononuclear cells (PBMCs) from the                subject at least 6 months after step (a), (c)                determining that at least 20% of the PBMCs are T                cells, (d) manufacturing chimeric antigen receptor                (CAR) T cells from the PBMCs based on determination                in step (c), and (e) administering the CAR T cells                to the subject, (ii) (a) isolating PBMCs from the                subject, and determining that at least 20% of the                PBMCs are T cells, (b) manufacturing CAR T cells                from the PBMCs based on determination in step (a),                and (c) administering the CAR T cells to the                subject, where the subject had previously received                an alkylating agent for treatment of the cancer                prior to step (a), or the step (a) occurs at least                6 months after the subject received the alkylating                agent, (iii) (a) determining that the subject has                not been administered the alkylating agent less                than 6 months prior to the determining step, (b)                isolating PBMCs from the subject, (c) manufacturing                CAR T cells from the PBMCs, and (d) administering                the CAR T cells to the subject, or (iv)                administering T cells expressing CAR T cells                manufactured from PBMCs isolated from the patient,                to the subject. The subject has been determined to                have been administered the alkylating agent at                least 6 months prior at time of the isolation. The                cancer is caused by B-cell maturation agent (BCMA)                expressing cells in a subject. INDEPENDENT CLAIMS                are included for the following:    (1) a method (B) for manufacturing CAR T cells                directed to BCMA (BCMA CAR T cells) from a                subject;    (2) a method (C) for determining whether a                subject having cancer is treated with a CAR T                therapy involves determining the percentage of                cluster of differentiation (CD) 3+ T cells in the                subject relative to the number of PMBCs, where (i)                if the subject has less than 20% CD3+T cells                relative to the number of PBMCs, not administering                the CAR T therapy to the subject, and (ii) if the                subject has more than 20% CD3+ T cells relative to                the number of PBMCs, then administering the CAR T                therapy to the subject;    (3) a method (D) for treating a cancer in a                subject involves determining that the percentage of                CD3+ T cells in the subject relative to the number                of PMBCs is higher than 20%, and administering a                CAR T therapy to the subject;    (4) a method (E) for determining an optimal                washout period for commencing a therapy for                treatment of a condition in a subject after a prior                exposure;    (5) method (F) for treating a condition in a                subject involves (a) administering a therapy for                treating the condition to the subject, where the                therapy is administered after a prior exposure, and                the time to administer the therapy after the prior                exposure (i.e. the washout period) is calculated                using the method (E);    (6) a system comprising at least one data                processor, and memory storing instructions which                implement the method (E) when executed by the at                least one data processor; and    (7) a non-transitory computer program product                storing instructions which implement the method (E)                when executed by at least one computing                device. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S05 (Electrical Medical Equipment);  T01 (Digital Computers)",B04-E99;  B04-F04B1A;  B04-F04B1E;  B05-A03B3;  B05-B01J;  B05-C01;  B05-C07;  B06-D05;  B06-D10;  B06-E05;  B07-A02B;  B07-D09;  B07-D13;  B10-A03;  B10-A09B;  B10-A19;  B10-B01A;  B10-B01B;  B10-B02A;  B10-B04B;  B10-C02;  B11-C08E;  B11-C11;  B12-K04E3;  B14-A01;  B14-A02;  B14-A04;  B14-C03;  B14-F01;  B14-F02;  B14-G02D;  B14-G03;  B14-H01;  B14-H05;  B14-J01;  B14-L06;  B14-S03A;  B14-S18;  B14-S21;  B14-S25;  B14-S26;  D05-H09;  D05-H99;  S05-G02G4;  T01-J03;  T01-J06A1;  T01-S03,A61K-039/00;  A61P-035/00;  C07K-014/725;  G16H-020/10;  A61K-035/17;  A61K-039/395;  A61K-047/68;  A61P-035/02;  C12N-005/10;  G01N-033/53;  G01N-033/574;  C07K-014/705;  C07K-016/28;  G16H-020/17;  A61K-031/675,WO2022098685-A2   12 May 2022   202246Pages: 362   English;  WO2022098685-A3   09 Jun 2022   G16H-020/10   202247   English;  KR2023113755-A   01 Aug 2023   A61K-039/00   202363   ;  EP4241278-A2   13 Sep 2023   G16H-020/10   202375   English;  CN116802743-A   22 Sep 2023   G16H-020/10   202380   Chinese;  JP2023550309-W   01 Dec 2023   A61K-035/17   202398   Japanese;  US2023398149-A1   14 Dec 2023   A61K-035/17   202301   English,WO2022098685-A2    WOUS057805    03 Nov 2021;   WO2022098685-A3    WOUS057805    03 Nov 2021;   KR2023113755-A    KR718751    03 Nov 2021;   EP4241278-A2    EP815791    03 Nov 2021;   CN116802743-A    CN80088285    03 Nov 2021;   JP2023550309-W    JP528090    03 Nov 2021;   US2023398149-A1    US18035280    03 May 2023,KR2023113755-A PCT application Application WOUS057805;   KR2023113755-A Based on Patent WO2022098685;   EP4241278-A2 PCT application Application WOUS057805;   EP4241278-A2 Based on Patent WO2022098685;   CN116802743-A PCT application Application WOUS057805;   CN116802743-A Based on Patent WO2022098685;   JP2023550309-W PCT application Application WOUS057805;   JP2023550309-W Based on Patent WO2022098685;   US2023398149-A1 Provisional Application US121658P;   US2023398149-A1 Provisional Application US109804P;   US2023398149-A1 Provisional Application US120166P;   US2023398149-A1 PCT application Application WOUS057805,US109804P    04 Nov 2020;  US120166P    01 Dec 2020;  US121658P    04 Dec 2020;  US18035280    03 May 2023;  KR718751    02 Jun 2023;  CN80088285    28 Jun 2023,WO2022098685-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2022098685-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP4241278-A2:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN        ,,";  WO2022098685-A3 -- WO2019108900-A1   NOVARTIS AG (NOVS);  UNIV PENNSYLVANIA (UPEN)   PRUTEANU-MALINICI I,  MANSFIELD K,  ENGELS B,  MELENHORST J J,  COHEN A D,  STADTMAUER E A,  GARFALL A,  MILONE M C,  FRAIETTA J A;  WO2020014333-A1   CELGENE CORP (CGEN)   HEGE K,  PATEL P,  NOVICK S","WO2022098685-A3  KORELL FELIX ET AL:          ""Current Challenges in Providing Good Leukapheresis          Products for Manufacturing of CAR-T Cells for Patients          with Relapsed/Refractory NHL or ALL"", CELLS, vol. 9, no.          5, 15 May 2020 (2020-05-15), pages 1225, XP055891555,          ISSN: 2073-4409, DOI:          10.3390/cells9051225,relevantClaims[1,3,6,7,15-23,48,51,52,58-66,92,94,97,98|96],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  KANSAGRA ANKIT J ET          AL: ""Clinical Utilization of Chimeric Antigen Receptor T          Cells in B Cell Acute Lymphoblastic Leukemia: An Expert          Opinion from the European Society for Blood and Marrow          Transplantation and the American Society for Blood and          Marrow Transplantation"", BIOLOGY OF BLOOD AND MARROW          TRANSPLANTATION, vol. 25, no. 3, 1 March 2019          (2019-03-01), XP085647686, ISSN: 1083-8791, DOI:          10.1016/J.BBMT.2018.12.068,relevantClaims[1,3,6,7,15-24,26,29,38-45,48,51,52,58-66,72,73,79-98],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  RYTLEWSKI JULIE ET          AL: ""Effects of Prior Alkylating Therapies on Preinfusion          Patient Characteristics and Starting Material for CAR T          Cell Product Manufacturing in Late-Line Multiple          Myeloma"", BLOOD, vol. 136, no. Supplement 1, 5 November          2020 (2020-11-05), pages 7 - 8, XP055894400, Retrieved          from the Internet          &lt;URL:https://ashpublications.org/blood/article/136/Supplement%201/7/471183/Effects-of-Prior-Alkylating-Therapies-on&gt;,relevantClaims[1,3,6,7,15-24,26,29,38-45,48,51,52,58-66,72,73,79-98],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;]",200757-0-0-0 K P; 87064-0-0-0 K M; 88573-0-0-0 K M; 89522-0-0-0 K M; 90035-0-0-0 K M; 90091-0-0-0 K M; 90702-0-0-0 K M; 91104-0-0-0 K M; 67298-0-0-0 K M; 92243-0-0-0 K M; 97676-0-0-0 K M; 1420602-0-0-0 K M; 22595-0-0-0 K M; 90741-0-0-0 K M; 106545-2-0-0 K M; 102458-1-0-0 K M; 140-0-0-0 K M; 104702-0-0-0 K M; 12502-1-0-0 K M; 108489-0-0-0 K M; 108818-0-0-0 K M; 93938-1-0-0 K M; 1420602-0-0-0 CL USE,,00212; 07746; 54753; 76954,RA00GT K P; R14101 K M; RACDI6 K M; R08220 K M; R11768 K M; R08219 K M; R01215 K M; R03071 K M; R00008 K M; R08225 K M; R08228 K M; RAP5O8 K M; R08229 K M; R00055 K M; R01166 K M; RA0N2X K M; R03247 K M; R08235 K M; RA03YT K M; RA0EGZ K M; R00062 K M; RA2YUX K M,1215-S; 0008-S; 0055-S; 1166-S; 0062-S
WO2022221835-A2;  WO2022221835-A3;  TW202307212-A;  AU2022258955-A1;  CA3197160-A1;  AU2022258955-A9;  IL302091-A;  KR2023124888-A;  IN202327033120-A;  CN116940588-A;  RU2023107815-A;  JP2023552265-W;  BR112023005961-A2;  EP4322996-A2;  US2024066113-A1;  HK40094249-A0,"New modified nucleic acid molecule encoding            modified spike protein comprising amino acid            substitution of asparagine to glutamine at N-linked            glycosylation sequons, used to prevent or treat corona            virus infection e.g. alpha-corona virus",WONG C;  WU C;  MA C;  FAN C;  PAN C;  WU J;  WENG Q;  VON CH KH;  VU CH I;  MA CH;  FAN CH I,ACAD SINICA (SNIC-C);  WONG C (WONG-Individual);  ACAD SINICA (SNIC-C);  ACAD SINICA (SNIC-C);  ZHOU M (ZHOU-Individual);  ACAD SINICA (SNIC-C);  ACAD SINICA (SNIC-C);  CHOU M (CHOU-Individual),2022D2251N,"   NOVELTY - Modified nucleic acid molecule encoding a                modified spike protein comprising at least one                amino acid substitution of asparagine (N) to                glutamine (Q) at N-linked glycosylation sequons                (I), is new.    USE - The molecule is useful preventing or treating                a corona virus (CoV) infection i.e. &#945;                -CoV, &#946; -CoV, &#947; -CoV, &#948;                -CoV2, or &#956; -CoV2 (all claimed). Test                details are described but no results given.    ADVANTAGE - None given.    DETAILED DESCRIPTION - Modified nucleic acid molecule encoding a                modified spike protein comprising at least one                amino acid substitution of asparagine (N) to                glutamine (Q) at N-linked glycosylation sequons of                formula (N-X1-S1/T1) (I), is new.    X1=amino acid residue except proline;                and    S1/T1=serine or threonine residue.    INDEPENDENT CLAIMS are also included                for:    combo vaccine, comprising the mRNA vaccine and                additional vaccine;    nanoparticle, which is guanidine-based and                used as carrier for delivering the modified nucleic                acid molecule to a subject;    mRNA nanocluster comprising the vaccine                formulated in a lipid nanoparticle;    mRNA nanocluster, comprising a lipid                nanoparticle encapsulated with the mRNA vaccine,                where the biodegradable lipid nanoparticle                comprises guanidine-based and zwitterionic units,                the guanidine-based as well as zwitterionic groups                attach to a lipid tail, and the guanidine-based                groups adhere to mRNA, thus forming salt bridges                between the guanidinium groups and the phosphates                in the mRNA;    nanoparticle composition, comprising a                nanoparticle attached with the mRNA vaccine;    preventing or treating a coronavirus                infection, comprising administering the modified                nucleic acid molecule, the nanoparticle, the mRNA                nanocluster or a nanoparticle composition to a                subject infected with, or at risk of infected with                a coronavirus;    boosting an adaptive immune response,                comprising administering modified nucleic acid                molecule, the nanoparticle, the mRNA nanocluster or                the nanoparticle composition to a subject;    immunogenic peptide, comprising at least one                amino acid sequence comprising (SEQ ID NO: 41                (comprising a fully defined sequence of 13 amino                acids as given in specification)), (SEQ ID NO: 42                (comprising a fully defined sequence of 16 amino                acids as given in specification)), (SEQ ID NO: 43                (comprising a fully defined sequence of 11 amino                acids as given in specification)), (SEQ ID NO: 44                (comprising a fully defined sequence of 13 amino                acids as given in specification)), (SEQ ID NO: 45                (comprising a fully defined sequence of 13 amino                acids as given in specification)), (SEQ ID NO: 46                (comprising a fully defined sequence of 15 amino                acids as given in specification)), (SEQ ID NO: 47                (comprising a fully defined sequence of 13 amino                acids as given in specification)), (SEQ ID NO: 48                (comprising a fully defined sequence of 14 amino                acids as given in specification)), (SEQ ID NO: 49                (comprising a fully defined sequence of 19 amino                acids as given in specification)), (SEQ ID NO: 50                (comprising a fully defined sequence of 14 amino                acids as given in specification)), (SEQ ID NO: 51                (comprising a fully defined sequence of 11 amino                acids as given in specification)) and (SEQ ID NO:                52 (comprising a fully defined sequence of 11 amino                acids as given in specification)) or an amino acid                sequence having at least 99% identity to any of SEQ                ID NOs: 41-52; and    immunogenic composition, comprising the                immunogenic peptide. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  ;  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.)",B04-B01B;  B04-C01;  B04-E02;  B04-E03;  B04-E99;  B04-N04;  B06-D01;  B07-D09;  B10-A17;  B10-B02;  B12-M11Q;  B12-M11Q1;  B14-A02;  B14-S11A;  B14-S18;  D05-H07;  D05-H99;  A05-J11;  A12-V01;  A12-W05;  A12-W14,A61K-039/215;  C12N-015/86;  C07K-014/005;  A61K-009/127;  A61P-031/14;  C07K-014/615;  C12N-015/50;  A61K-039/00;  A61K-039/12;  A61K-031/7088;  A61K-031/7115;  A61K-031/712;  A61K-031/713;  A61K-048/00;  A61P-043/00;  C07K-014/165,WO2022221835-A2   20 Oct 2022   A61K-039/215   202291Pages: 85   English;  WO2022221835-A3   16 Mar 2023   A61K-039/215   202323   English;  TW202307212-A   16 Feb 2023   C12N-015/50   202332   Chinese;  AU2022258955-A1   11 May 2023   A61K-039/215   202339   English;  CA3197160-A1   20 Oct 2022   A61K-039/215   202340   English;  IL302091-A   01 Jun 2023   C07K-014/005   202360   English;  KR2023124888-A   28 Aug 2023   C07K-014/005   202370   ;  IN202327033120-A   13 Oct 2023   A61K-039/215   202388   English;  CN116940588-A   24 Oct 2023   C07K-014/005   202395   Chinese;  RU2023107815-A   12 Oct 2023   A61K-039/215   202301   Russian;  JP2023552265-W   15 Dec 2023   C12N-015/50   202302   Japanese;  BR112023005961-A2   24 Oct 2023   A61K-039/215   202408   ;  EP4322996-A2   21 Feb 2024   A61K-039/215   202417   English;  US2024066113-A1   29 Feb 2024   A61K-039/215   202419   English;  HK40094249-A0   12 Jan 2024   C07K-014/005   202442   English,WO2022221835-A2    WOUS071679    12 Apr 2022;   WO2022221835-A3    WOUS071679    12 Apr 2022;   TW202307212-A    TW113932    12 Apr 2022;   AU2022258955-A1    AU258955    12 Apr 2022;   CA3197160-A1    CA3197160    12 Apr 2022;   AU2022258955-A9    AU258955    12 Apr 2022;   IL302091-A    IL302091    12 Apr 2022;   KR2023124888-A    KR714874    12 Apr 2022;   IN202327033120-A    IN27033120    10 May 2023;   CN116940588-A    CN80006776    12 Apr 2022;   RU2023107815-A    RU107815    12 Apr 2022;   JP2023552265-W    JP520111    12 Apr 2022;   BR112023005961-A2    BR11005961    12 Apr 2022;   EP4322996-A2    EP789117    12 Apr 2022;   US2024066113-A1    US18029758    31 Mar 2023;   HK40094249-A0    HK6082840    20 Nov 2023,AU2022258955-A1 PCT application Application WOUS071679;   AU2022258955-A1 Based on Patent WO2022221835;   CA3197160-A1 PCT application Application WOUS071679;   CA3197160-A1 Based on Patent WO2022221835;   AU2022258955-A9 PCT application Application WOUS071679;   AU2022258955-A9 Based on Patent WO2022221835;   IL302091-A Based on Patent WO2022221835;   KR2023124888-A PCT application Application WOUS071679;   KR2023124888-A Based on Patent WO2022221835;   IN202327033120-A PCT application Application WOUS071679;   IN202327033120-A Based on Patent WO2022221835;   CN116940588-A PCT application Application WOUS071679;   CN116940588-A Based on Patent WO2022221835;   RU2023107815-A PCT application Application WOUS071679;   RU2023107815-A Based on Patent WO2022221835;   JP2023552265-W PCT application Application WOUS071679;   JP2023552265-W Based on Patent WO2022221835;   BR112023005961-A2 PCT application Application WOUS071679;   BR112023005961-A2 Based on Patent WO2022221835;   EP4322996-A2 PCT application Application WOUS071679;   EP4322996-A2 Based on Patent WO2022221835;   US2024066113-A1 Provisional Application US264737P;   US2024066113-A1 Provisional Application US173752P;   US2024066113-A1 PCT application Application WOUS071679;   HK40094249-A0 PCT application Application WOUS071679;   HK40094249-A0 Based on Patent WO2022221835;   HK40094249-A0 Previous Publ. Patent CN116940588,US173752P    12 Apr 2021;  US264737P    01 Dec 2021;  CN80006776    12 Apr 2022;  CA3197160    28 Mar 2023;  BR11005961    30 Mar 2023;  RU107815    30 Mar 2023;  CN80006776    31 Mar 2023;  US18029758    31 Mar 2023;  KR714874    28 Apr 2023,WO2022221835-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2022221835-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW                      EP4322996-A2:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN      ,,";  WO2022221835-A3 -- CN112626124-A   GUANGZHOU DOUBLLE BIOPROD CO LTD (GUAN-Non-standard)   HUANG W,  ZHOU X,  TIAN S;  US10953089-B1   NOVAVAX INC (NOVV)   SMITH G,  MASSARE M J,  TIAN J;  WO2021019102-A2   ACM BIOLABS PTE LTD (ACMB-Non-standard)   NALLANI M,  CORNELL T A,  KHAN A K,  DECAILLOT F;  WO2022221835-A2   ACAD SINICA (SNIC);  WONG C (WONG-Individual)   WONG C,  WU C,  MA C,  FAN C","WO2022221835-A3  ZHENG JIE; YAMADA          YOSHIYUKI; FUNG TO SING; HUANG MEI; CHIA RAYMOND; LIU          DING XIANG: ""Identification of N-linked glycosylation          sites in the spike protein and their functional impact on          the replication and infectivity of coronavirus infectious          bronchitis virus in cell culture"", VIROLOGY, ELSEVIER,          AMSTERDAM, NL, vol. 513, 1 January 1900 (1900-01-01),          AMSTERDAM, NL , pages 65 - 74, XP085287342, ISSN:          0042-6822, DOI:          10.1016/j.virol.2017.10.003,relevantClaims[1-2, 4,          20/1-20/2, 20/4, 21/1-21/2, 21/4|3, 5-7, 20/3, 21/3|8-19,          22];  W. DOWLING, E.          THOMPSON, C. BADGER, J. L. MELLQUIST, A. R. GARRISON, J.          M. SMITH, J. PARAGAS, R. J. HOGAN, C. SCHMALJOHN:          ""Influences of Glycosylation on Antigenicity,          Immunogenicity, and Protective Efficacy of Ebola Virus GP          DNA Vaccines"", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY          FOR MICROBIOLOGY, US, vol. 81, no. 4, 15 February 2007          (2007-02-15), US , pages 1821 - 1837, XP055430913, ISSN:          0022-538X, DOI: 10.1128/JVI.02098-06,relevantClaims[3,          5/3, 6/3, 7/6/3, 20/3,21/3]",100540-0-0-0 M N; 184611-0-0-0 M N; 100540-0-0-0 CL NEW USE; 184611-0-0-0 CL NEW USE,228024201 M N,,RA0U37 M N; RA00H1 M N,
WO2022175842-A1;  EP4295155-A1,"Kit used e.g. to test state of immunization in            subject with respect to pathogenic microorganism,            comprises container having target ligand in dried or            lyophilized form, and lateral flow test device with            flow path defined by first test strip",MELIOLI G;  PIZZI M;  GALLO V;  SALVI M,ELTEK SPA (ETEK-C);  ELTEK SPA (ETEK-C),2022A8605N,"   NOVELTY - Kit comprises: a container containing at least                one target ligand (2d), characteristic of the                pathogenic microorganism, where the target ligand                is in dried or lyophilized form, and the target                ligand intended to be mixed with a buffer solution                and a dose of a biological sample of the subject to                obtain a test sample; and a lateral flow test                device with at least one flow path defined by at                least one first test strip (20) which comprises a                receiving zone (21), a conjugation zone (22) and a                detection zone (23), where at least one labeled                anti-ligand specific for the target ligand is                reversibly immobilized in the conjugation zone of                the first test strip and at least one capture                anti-ligand is irreversibly immobilized in the                detection zone of the first test strip, and the                first test strip is configured for causing a flow                of the test sample adducted to the receiving zone                through the conjugation zone and the detection                zone.    USE - The kit is useful for: testing a state of                immunization in a subject with respect to a                pathogenic microorganism in vitro (all claimed);                and treating other subjects severely affected by                the virus, preferably by the severe acute                respiratory syndrome coronavirus 2. No biological                data given.    ADVANTAGE - The kit: allows to quickly and easily assess                whether the subject in question has acquired the                ability to defend himself from the virus or not;                evaluates the presence of antibodies, preferably                antibodies directed against the spike protein                (anti-spike), capable of counteracting or stopping                the progress of viral replication; allows viral                proteins in lyophilized or dried form to be stored                for a longer period of time and at room                temperature, compared to the case of supply of                viral proteins already in liquid solution; is                preferably designed to allow the use, as a starting                biological sample, of a saliva sample of the                subject, hence makes the carrying out of the test                quicker and less invasive, compared to the case of                a biological sample comprising blood obtained from                a finger-pricking device or from a classic                sampling; and is able to be perform even by                non-expert operators i.e. operators not necessarily                having the technical skills normally required for a                classic laboratory test.    DETAILED DESCRIPTION - Kit comprises: a container containing at least                one target ligand (2d), characteristic of the                pathogenic microorganism, where the target ligand                is in dried or lyophilized form, and the target                ligand intended to be mixed with a buffer solution                and a dose of a biological sample of the subject to                obtain a test sample; and a lateral flow test                device with at least one flow path defined by at                least one first test strip (20) which comprises a                receiving zone (21), a conjugation zone (22) and a                detection zone (23), where at least one labeled                anti-ligand specific for the target ligand is                reversibly immobilized in the conjugation zone of                the first test strip and at least one capture                anti-ligand is irreversibly immobilized in the                detection zone of the first test strip, and the                first test strip is configured for causing a flow                of the test sample adducted to the receiving zone                through the conjugation zone and the detection                zone, in a way that if the target ligand is                completely masked by antibodies present in the                biological sample during passage of the test sample                through the first test strip, the target ligand                cannot form a complex neither with the labeled                anti-ligand nor with the capture anti-ligand, if                the target ligand not completely masked by                antibodies present in the biological sample during                passage of the test sample through the first test                strip, the target ligand forms a complex with the                labeled anti-ligand and drags the labeled                anti-ligand and subsequently forms a complex with                the capture anti-ligand, and possible absence or                presence of the labeled anti-ligand in the                detection zone, at the capture anti-ligand is                optically detectable at the detection zone to                enable to infer, thus information concerning a                state of immunization of the subject. An                INDEPENDENT CLAIM is also included for in vitro                testing an immunization state in a subject with                respect to a pathogenic microorganism, comprising                (i) providing a dose of the target ligand,                characteristic of the pathogenic microorganism,                where the target ligand is in dried or lyophilized                form, (ii) providing a dose of a buffer solution,                (iii) providing a biological sample from the                subject, (iv) mixing together the dose of target                ligand, the dose of buffer solution and a dose of                the biological sample to obtain a test sample, (v)                providing a lateral flow test device with the flow                path defined by the first test strip, which                includes at least a receiving zone, a conjugation                zone and a detection zone, where in the conjugation                zone the labeled anti-ligand, specific for the                target ligand, is reversibly immobilized, and in                the detection zone the capture anti-ligand is                irreversibly immobilized, (vi) supplying a dose of                the test sample to the receiving zone of the first                test strip, to cause a relative flow of the dose of                the test sample through the conjugation zone and                the detection zone, in a way that if the target                ligand is completely masked by antibodies present                in the biological sample, during passage of the                dose of the test sample through the first test                strip, the target ligand cannot form a complex                neither with the labeled anti-ligand nor with the                capture anti-ligand, and if the target ligand is                not completely masked by antibodies present in the                biological sample during passage of the dose of the                test sample through the first test strip, the                target ligand forms a complex with the labeled                anti-ligand, dragging the labeled anti-ligand                therewith, and subsequently forms a complex also                with the capture anti-ligand, and (vii) checking                optically in the detection zone possible absence or                presence of the labeled anti-ligand at the capture                anti-ligand, and inferring information concerning a                state of immunization of the subject.    DESCRIPTION OF DRAWING(S) - The figure shows a schematic view of the                mechanism of operation of a diagnostic assay,                respectively in the case of immunization and                non-immunization to a pathogenic                microorganism.    2dTarget ligand    20First test strip    21Receiving zone    22Conjugation zone    23Detection zone ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  J04 (Chemical/physical processes/apparatus - including catalysis, catalysts (excluding specific e.g. enzymatic or polymerisation catalysts), colloid chemistry, laboratory apparatus and methods, testing, controlling, general encapsulation, detection and sampling (excluding clinical testing) (B01J, L).);  S03 (Scientific Instrumentation)",B04-F01;  B04-G01;  B11-C07A5;  B11-C12;  B12-K04E;  B14-A02B5;  B14-G01;  B14-K01D;  B14-S11;  D05-H04;  D05-H05;  D05-H06;  J04-B01;  S03-E09F;  S03-E14H,G01N-033/543;  G01N-033/68,WO2022175842-A1   25 Aug 2022   G01N-033/543   202274Pages: 54   English;  EP4295155-A1   27 Dec 2023   G01N-033/543   202304   English,WO2022175842-A1    WOIB051384    16 Feb 2022;   EP4295155-A1    EP705903    16 Feb 2022,EP4295155-A1 PCT application Application WOIB051384;   EP4295155-A1 Based on Patent WO2022175842,IT00003641    17 Feb 2021,WO2022175842-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP4295155-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN  ,,"WO2022175842-A1 -- EP3734286-A1   EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA (EURM);  US20050112559-A1   ;  US20120178105-A1   ;  US20130130404-A1   ;  US8956859-B1   AVIEX TECHNOLOGIES LLC (AVIE-Non-standard)   BERMUDES D G;  WO2005069002-A1   CALYPTE BIOMEDICAL CORP (CALY-Non-standard)   MINK R,  GOTTFRIED T,  ENNIS J,  SMITH P;  WO2019032669-A1   ORASURE TECHNOLOGIES INC (ORAS-Non-standard)   YEARWOOD G,  REED M;  WO2020046857-A1   UNIV VANDERBILT (UVAN);  BAYLOR COLLEGE MEDICINE (BAYU)   CROWE J E,  ESTES M;  WO2020086664-A1   ORASURE TECHNOLOGIES INC (ORAS-Non-standard)   REED M,  DAVIS M,  GUILLON G,  FISCHL M","WO2022175842-A1  ZHENGTU LI ET AL:          ""Development and clinical application of a rapid IgM?IgG          combined antibody test for SARS?CoV?2 infection          diagnosis"", JOURNAL OF MEDICAL VIROLOGY, vol. 92, no. 9,          13 April 2020 (2020-04-13), US, pages 1518 - 1524,          XP055737277, ISSN: 0146-6615, DOI:          10.1002/jmv.25727,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;]",96353-0-0-0 K M,,,R03080 K M,
WO2021188966-A1;  US2023152316-A1,"New peptide that binds to spike protein of            coronavirus, comprising specific amino acid sequence,            useful for e.g. reducing probability of viral infection            caused by a coronavirus e.g. human coronavirus 229E,            and human coronavirus OC43",PENTELUTE B L;  ZHANG G;  POMPLUN S;  LOFTIS A R;  LOAS A,MASSACHUSETTS INST TECHNOLOGY (MASI-C);  MASSACHUSETTS INST TECHNOLOGY (MASI-C),2021B5887S,"   NOVELTY - Peptide (P1) that specifically binds to the                spike protein of a coronavirus, comprising amino                acid sequence of SEQ ID NO: 133, is new.    USE - The peptides in combination with carrier are                useful for: reducing probability of viral infection                in a human subject, where the viral infection is                caused by a coronavirus and the coronavirus                comprises human coronavirus 229E, human coronavirus                OC43, severe acute respiratory syndrome                coronavirus, human coronavirus NL63, human                coronavirus HKU1, Middle East respiratory                syndrome-related coronavirus and severe acute                respiratory syndrome coronavirus 2 (preferred) and                the human subject is at least 50 years of age; and                detecting the presence of a viral infection in a                human subject, where the viral infection is caused                by the coronavirus and the subject may not have a                symptom, or may have a symptom associated with                viral infection comprising e.g. fever, cough,                shortness of breath, pain or pressure in the chest,                confusion, bluish lips or face, pneumonia,                bronchitis, runny nose, sneezing, chills,                exacerbated asthma, nasal congestion, sore throat,                unwillingness to drink, convulsions, ongoing                vomiting, abdominal pain, and multi-organ failure                (all claimed). Test details are described but no                results given.    ADVANTAGE - The peptide binds the spike protein receptor                binding domain of the coronavirus with a KD of less                than 500 nM, preferably 1 nm or lower.    DETAILED DESCRIPTION - Peptide (P1) that specifically binds to the                spike protein of a coronavirus comprising amino                acid sequence of formula                (X1-X2-X3-X4-X5-X6-X7-X8-Leu-Asp-X11-X12-Asn-His-Glu-X16-Glu-Asp-X19-X20-X21-X22-X23)                (SEQ ID NO: 133) (I), is new.    X1 = Ile or absent;    X2, X3 = Glu or absent;    X4 = Gln or absent;    X6 = Lys, K1, Ala, Ser, Gln, His, Thr, or                absent;    X7 = Thr or alpha aminoisobutyric acid;                either    X5 = Ala, 2-aminoisobutyric acid, or                absent;    X8 = Phe, Ser, Thr, His, Asn, or Asp;    X12 = Phe, or alpha aminoisobutyric                acid;    X16 = Ala or alpha aminoisobutyric acid;    X20 = Phe, 2-aminoisobutyric acid or absent;                or    X5X8, X5X12, X5X16, X8X12, X8X16, X8X20,                X20X16 = tetrasubstituted moieties of formula                (Ia);    X11 = Lys;    X19 = Leu or absent;    X21 = Tyr or absent;    X22 = Gln or absent;    X23 = Ser or absent, where when X2, X3, X4,                X5, or X6 are absent, all previous residues are                also absent, where when X19, X20, X21, or X22 are                absent, all subsequent residues are also                absent;    R1 = NHC(O), S-S, S-(aryl)-S,                S-(aryl)-(aryl)-S, S-(perfluoroaryl)-S,                S-(perfluoroaryl)-(perfluoroaryl)-S-S-(1-6C                alkyl)-S, S-CH2-C(O)-CH2-S, -NH-(aryl)-NH,                NHC(O)-(aryl)-C(O)NH, NHC(O)-(aryl)-(aryl)-C(O)NH,                NHC(O)-(perfluoroaryl)-C(O)NH,                NHC(O)-(perfluoroaryl)-(perfluoroaryl)-C(O)NH,                NHC(O)-(1-6C alkyl)-C(O)NH,                NHC(O)-CH2-C(O)-CH2-C(O)NH, 2-6C alkenyl, or                heteroaryl;    K1 = lysine residue covalently bound at its                zeta-nitrogen with C(O)(CH2)mCH3 or where the                N-terminal amino of the peptide is optionally                substituted with C(O)(CH2)mCH3 or                OH(-CH2-CH2-O)n-CH2-C(=O), the C-terminus of the                peptide comprises a C-terminal acid or C-terminal                amide;    m = 0-16;    n = 4-1000; and    p = 1-6.    INDEPENDENT CLAIMS are also included                for:    (1) a peptide (P2) that specifically binds to                the spike protein of a coronavirus, comprising an                amino acid sequence of formula                (X0-X1-X2-X3-X4-X5a-X6-X7a-X8a-X9-X10-X11a-X12a-X13a-X14a-X15a-X16a-X17a-X18X19X20a-X21a-X22a-X23a-X24a                (SEQ ID NO: 134);    (2) a peptide (P3) comprising amino acid                sequence Gly-Leu-Gly-Lys-Gly-Asp-Phe-Arg (SEQ ID                NO: 99) and Ala-Gln-Met-Tyr-Pro-Leu-Gln-Glu-Gly                (SEQ ID NO: 100);    (3) a multivalent coronavirus (CoV)-2 spike                binding peptide of formula ((A1)-L1-(B1)b-NH2)                (III);    (4) detecting the presence of a viral                infection in a human subject comprising (a)                contacting a sample from the subject with the                composition (C1) comprising peptide (P3) and                carrier, and (b) detecting specific binding between                the composition and an antibody that specifically                binds the infecting virus, where specific binding                between the antibody and the composition indicates                the presence of viral infection in the subject;                and    (5) a kit comprising the composition (C1) and                a solid phase substrate.    X0 = Gln-Ser-Thr,                Ala-Gln-Met-Tyr-Pro-Leu-Gln-Glu-Gly (SEQ ID NO:                135), Ala-Gln-Met-Tyr-Pro-Leu-Gln-Glu-Gly-Gly (SEQ                ID NO: 136), or absent; either    X5a = Ala, Lys, 2-amino isobutyric acid, or                absent;    X8a = Phe, Ser, Thr, His, Asn, Asp, Glu, Ala,                2-amino isobutyric acid, or absent;    X12a = Phe, Lys, Ala, 2-amino isobutyric acid,                or absent;    X16a = Ala, Glu, 2-amino isobutyric acid,                4-aminopiperidine-4-carboxylic acid (Pip), or                absent;    X20a = Phe, Lys, Ala, 2-amino isobutyric acid                or absent; or    X5aX8a, X8aX12a, X8aX16a, X12aX5a, X12aX8a,                X12aX16a, X16aX20a = (Ia);    X9 = Leu, Glu, Ala or absent;    X10 = Asp, Glu, Ala, cysteic acid, or                absent;    X7a = Thr, Leu, Asp, Tyr, Ala,                2-aminoisobutyric acid, disubstituted moiety of                formula (IIa) or absent;    X11a = Lys, Gln, Trp, Ala, (IIa) or                absent;    X13a = Asn, Lys, His, Asp, Ala or                absent;    X14a = His, Glu, Val, Ala, 2-amino isobutyric                acid, 4-aminopiperidine-4-carboxylic acid (Pip), 4-                fluorophenylalanine, or absent;    X15a, X17a = Glu, Ala, or absent;    X18a = Asp, Ala, or absent;    X19a = Leu, Lys, Ala, 2-amino isobutyric acid,                ornithine, Pip or absent;    X21a = Tyr, Ala, (IIa) or absent;    X22a = Gln, Lys, or absent;    X23a = Ser, 2-amino isobutyric acid or                absent;    X24a = e.g. Ser, Ser-Leu-Ala-Ser (SEQ ID NO:                137), and Ser-Gly-Gly-Leu-Gly-Lys-Gly-Asp-Phe-Arg                (SEQ ID NO: 138) or absent, where when any of X1                through X12a are absent, all residues prior to the                absent residue are also absent, where when any of                X13a through X23a are absent, all residues                subsequent to the absent residue are also absent,                and where at least 12 consecutive residues are not                absent;    R2 = aryl, heteroaryl, or 3-8C cycloalkyl (all                optionally substituted with 1-6C alkyl, aryl,                nitro, halo, cyano, amino, hydroxy, or 1-3C)                alkylamino;    X7b = Thr, Leu, Asp, Tyr, Ala, 2-amino                isobutyric acid, or absent;    L1 = alkyl or heteroalkyl linker 4-50 Angstrom                , -(NH(-CH2-CH-CH2-C(O))a-CH2-C(=O)-CH2)- or                absent;    B1 = disubstituted moiety of formulae (IVa) or                (IVb);    A1 = peptide of formula                (X0-X1-X2-X3X4-X5a-X6a-X7b-X8a-X9-X10a-X11a-X12a-X13X14X15a-X16-X17a-X18a-X19a-X20a-X21a-X22a-X23a-X24a)                (SEQ ID NO: 143);    a = 1-12; and    b = 1-9. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-C01;  B04-E99;  B04-G08;  B04-N04A;  B11-C07A;  B12-K04G1B;  B14-A02;  B14-C01;  B14-C03;  B14-C04;  B14-E05;  B14-J01A4;  B14-J07;  B14-K01;  B14-N04;  B14-N05B;  D05-H09;  D05-H99,A61K-039/395;  C07H-021/04;  C07K-014/435;  C07K-016/18;  C07K-016/40;  G01N-033/569,WO2021188966-A1   23 Sep 2021   A61K-039/395   202188Pages: 91   English;  US2023152316-A1   18 May 2023   G01N-033/569   202342   English,WO2021188966-A1    WOUS023262    19 Mar 2021;   US2023152316-A1    US17906400    15 Sep 2022,US2023152316-A1 Provisional Application US991886P;   US2023152316-A1 Provisional Application US016925P;   US2023152316-A1 PCT application Application WOUS023262,US991886P    19 Mar 2020;  US016925P    28 Apr 2020;  US17906400    15 Sep 2022,WO2021188966-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,"WO2021188966-A1 -- US20030004311-A1   ;  US20050107297-A1   ;  US20120082693-A1   ;  US20180265595-A1   ;  US20190358170-A1   ;  WO2019069307-A1   YISSUM RES DEV CO HEBREW UNIV JERUSALEM (YISS)   KAEMPFER R,  ARAD G",,184611-0-0-0 M N;  M N;  M N; 184611-0-0-0 CL NEW USE,226023701 M N,,RA00H1 M N; RD3TQ0 M N; RD3TQ1 M N,
WO2022261382-A1,"Laboratory technique comprises isolating cell-free            DNA from sample, adding first Tracer DNA composition            before/after isolation of DNA, targeted amplification            of DNA at target loci, high-throughput sequencing,            quantifying total cell-free DNA",TRINCHIERI G;  DZUTSEV A K;  MCCULLOCH J A;  RODRIGUES R R;  DAVAR D;  ZAROUR H M,US DEPT HEALTH & HUMAN SERVICES (USSH-C);  UNIV PITTSBURGH COMMONWEALTH SYSTEM HIGH (UPIT-C),2022F5242V,"   NOVELTY - Laboratory technique (M1) comprises (a)                isolating cell-free DNA from a biological sample,                where a first Tracer DNA composition is added                before or after isolation of the cell-free DNA, (b)                performing targeted amplification of the isolated                cell-free DNA at at least 100 more different target                loci in a single reaction volume using at least 100                different primer pairs, (c) sequencing the                amplification products by high-throughput                sequencing to generate at least one sequencing                reads, and (d) quantifying the amount of total                cell-free DNA using sequencing reads derived from                the first Tracer DNA composition.    USE - The method is useful for laboratory technique,                utilizing a Tracer DNA to quantitate cell-free DNA                in a biological sample and amplifying and                sequencing DNA (all claimed).    ADVANTAGE - The method: uses an estimate percentage of                donor-derived cell-free DNA in combination with a                measurement of the total cell-free DNA                concentration to determine the likelihood of organ                failure; uses an absolute donor-derived cell-free                DNA concentration or its function in combination                with a measurement of the total cell-free DNA                concentration to determine the likelihood of organ                failure.    DETAILED DESCRIPTION - Laboratory technique (M1) comprises either:                (a) isolating cell-free DNA from a biological                sample, where a first Tracer DNA composition is                added before or after isolation of the cell-free                DNA, (b) performing targeted amplification of the                isolated cell-free DNA at at least 100 more                different target loci in a single reaction volume                using at least 100 different primer pairs, (c)                sequencing the amplification products by                high-throughput sequencing to generate at least one                sequencing reads, and (d) quantifying the amount of                total cell-free DNA using sequencing reads derived                from the first Tracer DNA composition; (a)                isolating cell-free DNA from a biological sample of                the transplant recipient, where the isolated                cell-free DNA comprises donor-derived cell-free DNA                and recipient-derived cell-free DNA, and a first                Tracer DNA composition is added before or after                isolation of the cell-free DNA, (b) performing                targeted amplification of the isolated cell-free                DNA at at least 100 different target loci in a                single reaction volume using at least 100 different                primer pairs, (c) sequencing the amplification                products by high-throughput sequencing to generate                at least one sequencing reads, and (d) quantifying                the amount of donor-derived cell-free DNA and the                amount of total cell-free DNA, where the amount of                total cell-free DNA is quantified using sequencing                reads derived from the first Tracer DNA                composition; or (a) isolating cell-free DNA from a                biological sample of a retransplant recipient,                where the isolated cell-free DNA comprises                donor-derived cell-free DNA derived from a first                donor, donor-derived cell-free DNA derived from a                second donor, and recipient-derived cell-free DNA,                (b) performing targeted amplification of the                cell-free DNA at at least 100 different target loci                in a single reaction volume using at least 100                different primer pairs, (c) sequencing the                amplification products by high-throughput                sequencing to generate at least one sequencing                reads, and (d) quantifying the amount of total                donor-derived cell-free DNA, where the amount of                donor-derived cell-free DNA from the first donor,                and/or the amount of donor-derived cell-free DNA                from the second donor. INDEPENDENT CLAIMS are also                included for:    utilizing (M2) a Tracer DNA to quantitate                cell-free DNA in a biological sample, comprising:                (a) isolating cell-free DNA from the biological                sample, where a first Tracer DNA composition is                added before or after isolation of the cell-free                DNA, (b) performing targeted amplification of the                cell-free DNA at at least 100 different target loci                in a single reaction volume using at least 100                different primer pairs, (c) sequencing the                amplification products by high-throughput                sequencing to generate at least one sequencing                reads, and (d) quantifying the amount of total                cell-free DNA using the sequencing reads derived                from the first Tracer DNA composition; and    amplifying and sequencing DNA (M3), comprising                (a) extracting DNA from a blood sample of a                transplant recipient (e.g. kidney transplant                recipient), where the DNA comprises donor-derived                cell-free DNA and recipient-derived cell-free DNA,                (b) performing targeted amplification at 500-50000                target loci in a single reaction volume using                500-50000 primer pairs to obtain amplicons, (c)                sequencing the amplicons by high-throughput                sequencing, and (d) quantifying an absolute amount                of donor-derived cell-free DNA and a percentage of                donor-derived cell-free DNA out of total cell-free                DNA, where (i) the percentage of donor-derived                cell-free DNA or its function above a first                threshold, preferably above 1% and/or (ii) the                absolute amount of donor-derived cell-free DNA or                its function above a second threshold (e.g. above 7                is indicative of kidney transplant rejection),                preferably the concentration of donor-derived                cell-free DNA above 78 copies/ml is indicative of                transplant rejection (kidney transplant rejection)                and the function of the absolute amount of                donor-derived cell-free DNA is calculated by                multiplying the percentage of donor-derived                cell-free DNA with the number of reads of total                cell-free DNA divided by the number of reads of                Tracer DNA per plasma volume. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  T04 (Computer Peripheral Equipment)",B04-B04B1;  B04-B04D4;  B04-B04D5;  B04-E01A;  B04-E05;  B04-E99;  B04-F02;  B11-C08E3;  B11-C08F8;  B11-C10A;  B12-K04F;  B12-K04G;  C04-B04B1;  C04-B04D4;  C04-B04D5;  C04-E01;  C04-E05;  C04-E99;  C04-F02;  C11-C08E3;  C11-C08F8;  C11-C10A;  C12-K04F;  C12-K04G;  D05-H09;  D05-H18B;  D05-H99;  T04-D07D3,A61K-035/17;  A61K-035/741;  A61K-039/395;  A61P-035/00,WO2022261382-A1   15 Dec 2022   A61P-035/00   202204Pages: 100   English,WO2022261382-A1    WOUS032917    09 Jun 2022,,US208719P    09 Jun 2021,WO2022261382-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,WO2022261382-A1 -- US20160354416-A1   ;  US20200129570-A1   ;  US20200138804-A1   ;  US20210038654-A1   ,,,,,,
WO2021243045-A1;  AU2021280311-A1;  CA3180334-A1;  IN202227059529-A;  EP4158060-A1;  CN115917001-A;  US2023203573-A1;  JP2023528777-W,"Laboratory technique comprises isolating cell-free            DNA from sample, adding first Tracer DNA composition            before/after isolation of DNA, targeted amplification            of DNA at target loci, high-throughput sequencing,            quantifying total cell-free DNA",SWENERTON R;  ZIMMERMANN B;  AHMED E;  LIANG N;  RYAN A;  LU F;  VAN HUMMELEN P;  RHEIN A,NATERA INC (NTRA-C);  NATERA INC (NTRA-C),2021D9246Y,"   NOVELTY - Laboratory technique (M1) comprises (a)                isolating cell-free DNA from a biological sample,                where a first Tracer DNA composition is added                before or after isolation of the cell-free DNA, (b)                performing targeted amplification of the isolated                cell-free DNA at least 100 more different target                loci in a single reaction volume using at least 100                different primer pairs, (c) sequencing the                amplification products by high-throughput                sequencing to generate at least one sequencing                reads, and (d) quantifying the amount of total                cell-free DNA using sequencing reads derived from                the first Tracer DNA composition.    USE - The method is useful for laboratory technique,                utilizing a Tracer DNA to quantitate cell-free DNA                in a biological sample and amplifying and                sequencing DNA (all claimed).    ADVANTAGE - The method: utilizes an estimate percentage of                donor-derived cell-free DNA in combination with a                measurement of the total cell-free DNA                concentration to determine the likelihood of organ                failure; and utilizes an absolute donor-derived                cell-free DNA concentration or its function in                combination with a measurement of the total                cell-free DNA concentration to determine the                likelihood of organ failure.    DETAILED DESCRIPTION - Laboratory technique (M1) comprises either:                (a) isolating cell-free DNA from a biological                sample, where a first Tracer DNA composition is                added before or after isolation of the cell-free                DNA, (b) performing targeted amplification of the                isolated cell-free DNA at at least 100 more                different target loci in a single reaction volume                using at least 100 different primer pairs, (c)                sequencing the amplification products by                high-throughput sequencing to generate at least one                sequencing reads, and (d) quantifying the amount of                total cell-free DNA using sequencing reads derived                from the first Tracer DNA composition; (a)                isolating cell-free DNA from a biological sample of                the transplant recipient, where the isolated                cell-free DNA comprises donor-derived cell-free DNA                and recipient-derived cell-free DNA, and a first                Tracer DNA composition is added before or after                isolation of the cell-free DNA, (b) performing                targeted amplification of the isolated cell-free                DNA at at least 100 different target loci in a                single reaction volume using at least 100 different                primer pairs, (c) sequencing the amplification                products by high-throughput sequencing to generate                at least one sequencing reads, and (d) quantifying                the amount of donor-derived cell-free DNA and the                amount of total cell-free DNA, where the amount of                total cell-free DNA is quantified using sequencing                reads derived from the first Tracer DNA                composition; or (a) isolating cell-free DNA from a                biological sample of a retransplant recipient,                where the isolated cell-free DNA comprises                donor-derived cell-free DNA derived from a first                donor, donor-derived cell-free DNA derived from a                second donor, and recipient-derived cell-free DNA,                (b) performing targeted amplification of the                cell-free DNA at at least 100 different target loci                in a single reaction volume using at least 100                different primer pairs, (c) sequencing the                amplification products by high-throughput                sequencing to generate at least one sequencing                reads, and (d) quantifying the amount of total                donor-derived cell-free DNA, where the amount of                donor-derived cell-free DNA from the first donor,                and/or the amount of donor-derived cell-free DNA                from the second donor. INDEPENDENT CLAIMS are also                included for:    (1) utilizing (M2) a Tracer DNA to quantitate                cell-free DNA in a biological sample, comprising:                (a) isolating cell-free DNA from the biological                sample, where a first Tracer DNA composition is                added before or after isolation of the cell-free                DNA, (b) performing targeted amplification of the                cell-free DNA at at least 100 different target loci                in a single reaction volume using at least 100                different primer pairs, (c) sequencing the                amplification products by high-throughput                sequencing to generate at least one sequencing                reads, and (d) quantifying the amount of total                cell-free DNA using the sequencing reads derived                from the first Tracer DNA composition; and    (2) amplifying and sequencing DNA (M3),                comprising (a) extracting DNA from a blood sample                of a transplant recipient (e.g. kidney transplant                recipient), where the DNA comprises donor-derived                cell-free DNA and recipient-derived cell-free DNA,                (b) performing targeted amplification at 500-50000                target loci in a single reaction volume using                500-50000 primer pairs to obtain amplicons, (c)                sequencing the amplicons by high-throughput                sequencing, and (d) quantifying an absolute amount                of donor-derived cell-free DNA and a percentage of                donor-derived cell-free DNA out of total cell-free                DNA, where (i) the percentage of donor-derived                cell-free DNA or its function above a first                threshold, preferably above 1% and/or (ii) the                absolute amount of donor-derived cell-free DNA or                its function above a second threshold (e.g. above 7                is indicative of kidney transplant rejection),                preferably the concentration of donor-derived                cell-free DNA above 78 copies/ml is indicative of                transplant rejection (kidney transplant rejection)                and the function of the absolute amount of                donor-derived cell-free DNA is calculated by                multiplying the percentage of donor-derived                cell-free DNA with the number of reads of total                cell-free DNA divided by the number of reads of                Tracer DNA per plasma volume. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  T04 (Computer Peripheral Equipment)",B04-B04D5;  B04-E01A;  B04-E05;  B04-E99;  B11-C08E3;  B11-C08F7A;  B11-C08F8;  B11-C10A;  B12-K04F;  B12-K04G;  C04-B04D5;  C04-E01A;  C04-E05;  C04-E99;  C11-C08E3;  C11-C08F7A;  C11-C08F8;  C11-C10A;  C12-K04F;  C12-K04G;  D05-H09;  D05-H18A;  D05-H18B;  D05-H99;  T04-D07D3,C12Q-001/6851;  C12Q-001/6883;  C12Q-001/686;  C12Q-001/6876;  C12Q-001/6869,WO2021243045-A1   02 Dec 2021   C12Q-001/6851   202102Pages: 100   English;  AU2021280311-A1   24 Nov 2022   C12Q-001/6851   202295   English;  CA3180334-A1   02 Dec 2021   202296   English;  IN202227059529-A   10 Feb 2023   C12Q-001/6851   202316   English;  EP4158060-A1   05 Apr 2023   C12Q-001/6851   202329   English;  CN115917001-A   04 Apr 2023   C12Q-001/6851   202333   Chinese;  US2023203573-A1   29 Jun 2023   C12Q-001/6851   202353   English;  JP2023528777-W   06 Jul 2023   C12Q-001/6869   202355   Japanese,WO2021243045-A1    WOUS034561    27 May 2021;   AU2021280311-A1    AU280311    27 May 2021;   CA3180334-A1    CA3180334    27 May 2021;   IN202227059529-A    IN27059529    18 Oct 2022;   EP4158060-A1    EP734623    27 May 2021;   CN115917001-A    CN80037971    27 May 2021;   US2023203573-A1    US17925693    16 Nov 2022;   JP2023528777-W    JP572339    27 May 2021,AU2021280311-A1 PCT application Application WOUS034561;   AU2021280311-A1 Based on Patent WO2021243045;   CA3180334-A1 PCT application Application WOUS034561;   CA3180334-A1 Based on Patent WO2021243045;   IN202227059529-A PCT application Application WOUS034561;   IN202227059529-A Based on Patent WO2021243045;   EP4158060-A1 PCT application Application WOUS034561;   EP4158060-A1 Based on Patent WO2021243045;   CN115917001-A PCT application Application WOUS034561;   CN115917001-A Based on Patent WO2021243045;   US2023203573-A1 Provisional Application US031879P;   US2023203573-A1 Provisional Application US186735P;   US2023203573-A1 Provisional Application US155717P;   US2023203573-A1 PCT application Application WOUS034561;   JP2023528777-W PCT application Application WOUS034561;   JP2023528777-W Based on Patent WO2021243045,US031879P    29 May 2020;  US155717P    02 Mar 2021;  US186735P    10 May 2021;  CA3180334    14 Oct 2022;  US17925693    16 Nov 2022;  CN80037971    25 Nov 2022,WO2021243045-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        EP4158060-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN        ,,"WO2021243045-A1 -- WO2011051283-A1   LIFECODEXX AG (LIFE-Non-standard)   BENZ M,  HOFMANN W,  POHL T,  VON KALLE C;  WO2020041449-A1   ZYMO RES CORP (ZYMO-Non-standard)   KEMP R,  FORMAN S,  TANG S,  WEINSTEIN M;  WO2020106987-A1   KARIUS INC (KARI-Non-standard)   BERCOVICI S,  BLAIR L,  BLAUWKAMP T A,  EUGSTER P J,  HOLLEMON D,  HONG D K,  KAWLI T,  KOWARSKY M A,  LINDNER M M S,  ROSEN M J,  SPACEK D,  VILFAN I D;  US2021222230-A1   NATERA INC (NTRA)   WONG A,  DODD M,  LACROUTE P,  HILL M,  ZIMMERMANN B;  US20120270212-A1   ;  US20130123120-A1   ;  US20180025109-A1   ;  WO2015164432-A1   NATERA INC (NTRA)   BABIARZ J,  CONSTANTIN T P,  EUBANK L A,  GEMELOS G,  HILL M M,  KIRKIZLAR H E,  RABINOWITZ M,  SAKARYA O,  SIGURJONSSON S,  ZIMMERMAN B;  WO2018083467-A1   UCL BUSINESS PLC (UNLO);  NATERA INC (NTRA)   SWANTON R C,  ABBOSH C;  WO2019200228-A1   NATERA INC (NTRA)   ZIMMERMANN B,  SALARI R,  SWENERTON R,  WU H,  SETHI H;  WO2020010255-A1   NATERA INC (NTRA)   MOSHKEVICH S,  ZIMMERMANN B,  CONSTANTIN T P,  KIRKIZLAR H E,  RYAN A,  SIGURJONSSON S,  ACOSTA ARCHILA F,  SWENERTON R;  WO2020018522-A1   NATERA INC (NTRA)   EGILSSON A,  GEMELOS G,  SIGURJONSSON S;  WO2017181202-A2   NATERA INC (NTRA);  UCL BUSINESS PLC (UNLO)   ZIMMERMANN B,  CONSTANTIN T P,  SALARI R,  KIRKIZLAR H E,  SWANTON R C,  JAMAL-HANJANI M,  ABBOSH C,  WILSON G","WO2021243045-A1  TARA SIGDEL ET AL:          ""Plasma Donor-Derived Cell-Free DNA Quantification by          massively multiplex PCR Distinguishes Kidney Transplant          Acute Rejection"", TRANSPLANTATION, vol. 102, no. 7s, 20          July 2018 (2018-07-20), pages s178 - s179, XP055615196,          DOI:          10.1097/01.tp.0000542820.29939.c0,relevantClaims[50-66|1-49],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  TARA SIGDEL ET AL:          ""Optimizing Detection of Kidney Transplant Injury by          Assessment of Donor-Derived Cell-Free DNA via Massively          Multiplex PCR"", JOURNAL OF CLINICAL MEDICINE, no. 1, 23          December 2018 (2018-12-23), CH, pages 19, XP055615415,          ISSN: 2077-0383, DOI:          10.3390/jcm8010019,relevantClaims[50-66],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  GRANT C O'CONNELL          ET AL: ""High Interspecimen Variability in Nucleic Acid          Extraction Efficiency Necessitates the Use of Spike-In          Control for Accurate qPCR-based Measurement of Plasma          Cell-Free DNA Levels"", LABORATORY MEDICINE, vol. 48, no.          4, 23 September 2017 (2017-09-23), US, pages 332 - 338,          XP055688106, ISSN: 0007-5027, DOI:          10.1093/labmed/lmx043,relevantClaims[1-49],relevantPassages[see          whole doc. esp. p. 334, 1. col., last par. ff];  SPINDLER KAREN-LISE          G. ET AL: ""Cell-Free DNA in Metastatic Colorectal Cancer:          A Systematic Review and Meta-Analysis"", THE ONCOLOGIST,          vol. 22, no. 9, 4 August 2017 (2017-08-04), pages 1049 -          1055, XP055831511, ISSN: 1083-7159, Retrieved from the          Internet          &lt;URL:https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2016-0178&gt;          DOI:          10.1634/theoncologist.2016-0178,relevantClaims[1-66],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            SIGDEL ET AL.: ""Optimizing Detection of Kidney Transplant          Injury by Assessment of Donor-Derived Cell-Free DNA via          Massively Multiplex PCR"", J. CLIN. MED., vol. 8, no. 1,          2019, pages 19, XP055615415, DOI:          10.3390/jcm8010019;            ABBOSH ET AL., NATURE, vol. 545, 2017, pages 446 -          451;            ZIMMERMANN ET AL., PRENAT. DIAGN., vol. 32, 2012, pages          1233 - 1241",,,,,
US2021299083-A1;  WO2021195400-A1;  WO2022203718-A1;  AU2021242300-A1;  AU2021433087-A1;  CA3172124-A1;  EP4103283-A1;  EP4106749-A1;  KR2023005181-A;  CA3172420-A1;  JP2023519382-W;  CN115916190-A;  CN115916343-A;  JP2023526159-W;  KR2023165107-A;  MX2022011867-A1;  MX2022011765-A1;  EP4103283-A4;  US11975106-B2,"Treating coronavirus infection of mammalian            subject, comprises administering coronavirus-complexing            amount of halogenated xanthene",WACHTER E A;  HOROWITZ B;  RODRIGUES D;  PERSHING E V;  NARENDRAN A;  EDWARD V P;  DOMINIC R;  BRUCE H;  ERIC A B;  RODRIGUEZ D;  NAREDRAN A,UNIV CALGARY (UYCA-Non-standard);  PROVECTUS PHARMATECH INC (PROV-Non-standard);  PROVECTUS PHARMATECH INC (PROV-Non-standard);  UTI LP (UTIU-C);  PROVECTUS PHARMATECH INC (PROV-Non-standard);  UTI LP (UTIU-C);  PROVECETUS PHARMATECH INC (PROV-Non-standard);  PROVECTUS PHARMATECH INC (PROV-Non-standard);  UTI LP (UTIU-C);  UTI LTD PARTERSHIP (UTIP-Non-standard);  UTI LP (UTIU-C),2021B2046J,"   NOVELTY - Treating (M1) a coronavirus infection of a                mammalian subject, comprises administering a                coronavirus-complexing amount of a halogenated                xanthene (HX), and its salt or amide whose nitrogen                atom is unsubstituted, substituted with at least                two 1-4C alkyl groups that are the same or                different or together with the amido nitrogen form                a 5 or 6-membered ring and its 1-4C alkyl ester or                aromatic derivative, where the aromatic derivative                is an ester or amide formed from an alcohol or                monosubstituted amine having a 5- or 6-membered                aromatic ring, or a 5, 6 or 6, 6-fused aromatic                ring system that contains 0-2 hetero ring atoms                that are independently nitrogen, oxygen or sulfur                to the mammalian subject.    USE - The method is useful for: treating a                coronavirus infection of a mammalian subject;                inducing type I IFN response in a mammalian subject                having a hematologic malignancy; enhancing a                mammalian immunogen-specific immune response; and                inducing type I IFN response in a mammalian subject                that presents with a microbial infection, or having                a cancerous tumor, where the mammal or mammalian                subject is a human, and the microbial infection is                a viral infection, a bacterial infection, a fungal                infection (all claimed), and parasite                infection. The ability of complex to treat viral                infection was tested in cultured human airway                epithelial cells (calu-3) cells by measuring cell                viability using in vitro assay. The result showed                that the 0.01 microM to 100 mM rose bengal                exhibited EC50 value of 0.015 microM after 48                hours.    ADVANTAGE - The method: utilizes HX molecule, which                exhibits immunotherapeutic properties in selected                oncology and virology conditions, and binds tightly                to severe acute respiratory syndrome coronavirus 2                main protease, and utilizes short circulatory                half-lives of the HX compounds that facilitate                application of these molecules for acute STING                activation, and maximize innate immune system                signaling potential while avoiding chronic                activation that could lead to counterproductive                inflammatory response and possibly autoimmune                disease; and avoids potential onset of toxicity to                normal tissue.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) inducing (M2) type I interferon (IFN)                response in a mammalian subject that presents with                a microbial infection, or having a cancerous tumor,                comprising administering or systemically                administering a HX, and its salt or amide whose                nitrogen atom is unsubstituted, substituted with at                least two 1-4C alkyl groups that are the same or                different or together with the amido nitrogen form                a 5- or 6-membered ring and its C1-C4 alkyl ester                or aromatic derivative, where the aromatic                derivative is an ester or amide formed from an                alcohol or monosubstituted amine having a 5- or                6-membered aromatic ring, or a 5, 6- or 6, 6-fused                aromatic ring system that contains 0-2 hetero ring                atoms that are independently nitrogen, oxygen or                sulfur to induce stimulator of interferon genes                (STING) dimerization;    (2) inducing (M3) type I IFN response in a                mammalian subject having a hematologic malignancy,                comprising systemically administering a less than                cytotoxic amount of a HX and its salt, 1-4C alkyl                ester, other aliphatic or aromatic derivative or                amide whose nitrogen atom is unsubstituted,                substituted with at least two 1-4C alkyl groups                that are the same or different or together with the                amido nitrogen form a 5- or 6-membered ring and its                1-4C alkyl ester or aromatic derivative, where the                aromatic derivative is an ester or amide formed                from an alcohol or monosubstituted amine having a                5- or 6-membered aromatic ring, or a 5, 6- or 6,                6-fused aromatic ring system that contains 0-2                hetero ring atoms that are independently nitrogen,                oxygen or sulfur to the mammalian subject to induce                STING dimerization;    (3) enhancing (M4) a mammalian                immunogen-specific immune response comprising                contacting mammalian cells present in vivo with an                adjuvant-efficient amount of a HX and its salt or                amide whose nitrogen atom is unsubstituted,                substituted with at least two 1-4C alkyl groups                that are the same or different or together with the                amido nitrogen form a 5- or 6-membered ring and its                1-4C alkyl ester or aromatic derivative, where the                aromatic derivative is an ester or amide formed                from an alcohol or monosubstituted amine having a                5- or 6-membered aromatic ring, or a 5, 6- or 6,                6-fused aromatic ring system that contains 0-2                hetero ring atoms that are independently nitrogen,                oxygen or sulfur, and an immunogen to which the                response is to be enhanced;    (4) treating (M5) a coronavirus infection of a                mammalian subject comprising administering a                remdesivir, and coronavirus-complexing amount of a                HX and its salt or amide whose nitrogen atom is                unsubstituted, substituted with at least two 1-4C                alkyl groups that are the same or different or                together with the amido nitrogen form a 5- or                6-membered ring and its 1-4C alkyl ester and                aromatic derivative, where the aromatic derivative                is an ester or amide formed from an alcohol or                monosubstituted amine having a 5- or 6-membered                aromatic ring, or a 5, 6- or 6, 6-fused aromatic                ring system that contains 0-2 hetero ring atoms                that are independently nitrogen, oxygen or sulfur                to the mammalian subject;    (5) a composition comprising a                coronavirus-complexing amount of each of remdesivir                and a HX and its salt or amide whose nitrogen atom                is unsubstituted, substituted with at least two                1-4C alkyl groups that are the same or different or                together with the amido nitrogen form a 5- or                6-membered ring and its 1-4C alkyl ester or                aromatic derivative, where the aromatic derivative                is an ester or amide formed from an alcohol or                monosubstituted amine having a 5- or 6-membered                aromatic ring, or a 5, 6- or 6, 6-fused aromatic                ring system that contains 0-2 hetero ring atoms                that are independently nitrogen, oxygen or sulfur                dissolved or dispersed in an aqueous carrier;                and    (6) treating (M6) a coronavirus infection of a                mammalian subject comprising administering a whole                antibody or its paratope-containing portions that                bind to the coronavirus spike protein and a                coronavirus-complexing amount of a HX compound and                its salt or amide whose nitrogen atom is                unsubstituted, substituted with at least two 1-4C                alkyl groups that are the same or different or                together with the amido nitrogen form a 5- or                6-membered ring and its 1-4C alkyl ester or                aromatic derivative, where the aromatic derivative                is an ester or amide formed from an alcohol or                monosubstituted amine having a 5- or 6-membered                aromatic ring, or a 5, 6- or 6, 6-fused aromatic                ring system that contains 0-2 hetero ring atoms                that are independently nitrogen, oxygen or sulfur                to the mammalian subject. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B14-A02B5;  B14-G01;  B14-S18;  B04-G08;  B04-G23;  B04-N03K;  B04-C01;  B14-L01;  B14-C03;  B04-B03E;  B06-A03;  C04-B03E;  C06-A03;  C04-C01;  C04-G08;  C04-G23;  C04-N03K;  C14-A02B5;  C14-C03;  C14-G01;  C14-S18;  D05-H11,A61K-031/352;  A61K-031/706;  A61K-045/06;  A61K-047/14;  A61P-031/14;  C07D-311/82;  C07D-413/10;  A61K-031/4178;  A61K-031/5383;  A61K-031/675;  A61K-039/39;  A61P-037/04;  A61K-039/00;  A61K-039/12;  A61P-031/04;  A61P-031/10;  A61P-035/00;  A61P-035/02;  A61P-043/00;  A61K-039/02;  A61P-031/12;  A61P-033/00;  A61K-009/00;  A61P-037/00;  A61K-009/28,US2021299083-A1   30 Sep 2021   A61K-031/352   202193   English;  WO2021195400-A1   30 Sep 2021   A61P-031/14   202193   English;  WO2022203718-A1   29 Sep 2022   A61K-031/4178   202281   English;  AU2021242300-A1   13 Oct 2022   A61P-031/14   202288   English;  AU2021433087-A1   20 Oct 2022   A61K-031/4178   202288   English;  CA3172124-A1   30 Sep 2021   202297   English;  EP4103283-A1   21 Dec 2022   A61P-031/14   202203   English;  EP4106749-A1   28 Dec 2022   A61K-031/4178   202301   English;  KR2023005181-A   09 Jan 2023   A61K-031/352   202305   ;  CA3172420-A1   29 Mar 2023   A61K-039/39   202330   English;  JP2023519382-W   10 May 2023   A61K-031/352   202338   Japanese;  CN115916190-A   04 Apr 2023   A61K-031/4178   202340   Chinese;  CN115916343-A   04 Apr 2023   A61P-031/14   202340   Chinese;  JP2023526159-W   21 Jun 2023   A61K-039/39   202351   Japanese;  KR2023165107-A   05 Dec 2023   A61K-039/39   202399   ;  MX2022011867-A1   09 Nov 2022   A61K-031/4178   202401   Spanish;  MX2022011765-A1   09 Nov 2022   A61P-031/14   202401   Spanish;  EP4103283-A4   28 Feb 2024   A61K-031/352   202420   English;  US11975106-B2   07 May 2024   A61K-009/28   202439   English,US2021299083-A1    US212723    25 Mar 2021;   WO2021195400-A1    WOUS024185    25 Mar 2021;   WO2022203718-A1    WOUS052506    29 Sep 2021;   WO2022203718-A1    WOUS052506    29 Sep 2021;   AU2021242300-A1    AU242300    25 Mar 2021;   AU2021433087-A1    AU433087    29 Sep 2021;   CA3172124-A1    CA3172124    25 Mar 2021;   EP4103283-A1    EP774987    25 Mar 2021;   EP4106749-A1    EP930603    29 Sep 2021;   KR2023005181-A    KR737068    25 Mar 2021;   CA3172420-A1    CA3172420    29 Sep 2021;   JP2023519382-W    JP558583    25 Mar 2021;   CN115916190-A    CN80037073    29 Sep 2021;   CN115916343-A    CN80037128    25 Mar 2021;   JP2023526159-W    JP558585    29 Sep 2021;   KR2023165107-A    KR737069    29 Sep 2021;   MX2022011867-A1    MX011867    23 Sep 2022;   MX2022011765-A1    MX011765    22 Sep 2022;   EP4103283-A4    EP774987    25 Mar 2021;   US11975106-B2    US212723    25 Mar 2021,US2021299083-A1 Provisional Application US000231P;   AU2021242300-A1 PCT application Application WOUS024185;   AU2021242300-A1 Based on Patent WO2021195400;   AU2021433087-A1 PCT application Application WOUS052506;   CA3172124-A1 PCT application Application WOUS024185;   CA3172124-A1 Based on Patent WO2021195400;   EP4103283-A1 PCT application Application WOUS024185;   EP4103283-A1 Based on Patent WO2021195400;   EP4106749-A1 PCT application Application WOUS052506;   EP4106749-A1 Based on Patent WO2022203718;   KR2023005181-A PCT application Application WOUS024185;   KR2023005181-A Based on Patent WO2021195400;   CA3172420-A1 PCT application Application WOUS052506;   CA3172420-A1 Based on Patent WO2022203718;   JP2023519382-W PCT application Application WOUS024185;   JP2023519382-W Based on Patent WO2021195400;   CN115916190-A PCT application Application WOUS052506;   CN115916190-A Based on Patent WO2022203718;   CN115916343-A PCT application Application WOUS024185;   CN115916343-A Based on Patent WO2021195400;   JP2023526159-W PCT application Application WOUS052506;   JP2023526159-W Based on Patent WO2022203718;   KR2023165107-A PCT application Application WOUS052506;   KR2023165107-A Based on Patent WO2022203718;   MX2022011867-A1 PCT application Application WOUS052506;   MX2022011867-A1 Based on Patent WO2022203718;   MX2022011765-A1 PCT application Application WOUS024185;   MX2022011765-A1 Based on Patent WO2021195400;   US11975106-B2 Provisional Application US000231P;   US11975106-B2 Previous Publ. Patent US2021299083,US000231P    26 Mar 2020;  US212723    25 Mar 2021;  WOUS024185    25 Mar 2021;  CA3172124    16 Sep 2022;  CA3172420    20 Sep 2022;  KR737068    24 Oct 2022;  KR737069    24 Oct 2022;  CN80037073    22 Nov 2022;  CN80037128    22 Nov 2022,  WO2021195400-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW  WO2022203718-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW        EP4103283-A1:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  KH;  LI;  LT;  LU;  LV;  MA;  MC;  MD;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TN;  TR  EP4106749-A1:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  KH;  LI;  LT;  LU;  LV;  MA;  MC;  MD;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TN;  TR                    EP4103283-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR    ,,"US2021299083-A1 -- EP471794-B1   OKLAHOMA MEDICAL RES FOUND (OKLH)   SCHINAZI R F;  US20050249739-A1   ;  US20120157435-A1   ;  WO2021195400-A1 -- EP471794-B1   OKLAHOMA MEDICAL RES FOUND (OKLH)   SCHINAZI R F;  US3859286-A   RICHARDSON MERRELL INC (RICH);  US20050249739-A1   ;  US20120157435-A1   ;  WO2002062333-A1   ;  WO2022203718-A1 -- US20020022032-A1   ;  US20020150541-A1   ;  US20090117199-A1   ;  US20120263677-A1   ;  US20170173079-A1   ;  WO1990013296-A   ;  WO2021195400-A1   UNIV CALGARY (UYCA-Non-standard);  PROVECTUS PHARMATECH INC (PROV-Non-standard)   WACHTER E A,  HOROWITZ B,  RODRIGUES D,  PERSHING E V,  NARENDRAN A;  CN115916343-A -- CN108495648-A   PROVECTUS PHARMATECH INC (PROV-Non-standard);  SINGER J (SING-Individual);  WACHTER E (WACH-Individual);  SARNAIK A (SARN-Individual);  PILON-THOMAS S (PILO-Individual);  LIU H (LIUH-Individual)   SINGER J,  WACHTER E,  SARNAIK A,  PILON-THOMAS S,  LIU H;  CN109394752-A   PHILADELPHIA HEALTH & EDUCATION CORP (PHIL-Non-standard)   CHANG J,  GUO F,  BLOCK T M,  GUO J;  EP471794-A4   OKLAHOMA MEDICAL RES FOUND (OKLH)   SCHINAZI R F;  US20110262482-A1   ;  US20170173079-A1   ;  US20190350893-A1   ;  WO1990013296-A   ;  EP4103283-A4 -- US20190350893-A1   ","WO2021195400-A1  SHEAHAN TIMOTHY P.,          SIMS AMY C., GRAHAM RACHEL L., MENACHERY VINEET D.,          GRALINSKI LISA E., CASE JAMES B., LEIST SARAH R., PYRC          KRZ: ""Broad-spectrum antiviral GS-5734 inhibits both          epidemic and zoonotic coronaviruses"", SCIENCE          TRANSLATIONAL MEDICINE, vol. 9, no. 396, 28 June 2017          (2017-06-28), pages eaal3653, XP055783008, ISSN:          1946-6234, DOI:          10.1126/scitranslmed.aal3653,relevantClaims[22-30,          34/(22-25)];  ANONYMOUS:          ""Remdesivir "", WIKIPEDIA, 25 March 2020 (2020-03-25),          XP055864921, Retrieved from the Internet          &lt;URL:https://en.wikipedia.org/w/index.php?title=Remdesivir&oldid=947234163&gt;          [retrieved on 20211123],relevantClaims[22, 27]WO2022203718-A1  BERGER G. ET AL.:          ""Pharmacological Modulation of the STING Pathway for          Cancer Immunotherapy"", TRENDS IN MOLECULAR MEDICINE, vol.          25, no. 5, 2019, pages 412 - 427, XP085669252, DOI:          10.1016/j.molmed. 2019.02.00 7,relevantClaims[13-21|1,          11, 22],relevantPassages[; see entire document,          especially, pg 412-415, 417-418, 421]CN115916343-A  ;;;: """", , no. 02,          29 February 2020 (2020-02-29), pages 6 -          10,relevantClaims[1-34]",184616-0-0-0 M K; 184587-0-0-0 M K; 2629613-1-0-0 M K; 106031-0-1-0 M K; 129622-0-0-0 M K; 2629613-1-0-0 CL USE,,61435,RA00H3 M K; RA00C8 M K; RBEZ9W M K; R16604 M K; R01934 M K,1934-S
CN116617382-A;  HK40090393-A0;  CN116617382-B,New coronavirus vaccine has nucleic acid molecule            containing first open reading frame (encoding S protein            of coronavirus Delta variant strain) and second open            reading frame (encoding BA.5S protein of coronavirus            Omikron mutant strain) useful in preventing/treating            diseases caused by coronavirus,LUO L;  LI S;  LEI Y;  LIU Q;  LIU J;  PENG Y;  YUCAI P;  JUN L;  QI L;  YIXIN L;  SHUANG L;  LIPING L,ZHUHAI LIFANDA BIOTECHNOLOGY CO LTD (ZHUH-Non-standard);  LIVERNA THERAPEUTICS INC (LIVE-Non-standard),202391700H,"   NOVELTY - Coronavirus vaccine comprising a nucleic acid                molecule containing a first open reading frame and                a second open reading frame, is new. The first open                reading frame encodes the S protein of the new                coronavirus Delta variant strain. The second open                reading frame encodes the BA.5S protein of the new                coronavirus Omikron mutant strain.    USE - The coronavirus vaccine and the method are                useful in preparing product for preventing/treating                diseases caused by the new coronavirus                (claimed).    ADVANTAGE - The vaccine is a multivalent vaccine.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    preparing the coronavirus vaccine; and    a product comprising the coronavirus                vaccine. ",,,"D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  A96 (Medical, dental, veterinary, cosmetic.)",D05-H07;  D05-H99;  B14-S18;  B10-C04E6;  B10-C02;  B05-A01B;  B15-E00A;  B04-C03C;  B01-D02;  B10-B03B;  B05-C07;  B05-B01P;  B04-B01B;  B04-E02H;  B14-K01D;  B14-A02B5;  B04-N06;  B04-N03K1;  B12-M11Q1;  B04-E03F;  B04-E02F;  B14-S11A;  B04-E99;  A10-E01;  A12-V01,A61K-039/215;  A61K-047/24;  A61K-047/28;  A61K-009/51;  A61P-031/14;  C12N-015/50,CN116617382-A   22 Aug 2023   A61K-039/215   202388   Chinese;  HK40090393-A0   10 Nov 2023   A61K-039/215   202412   Chinese;  CN116617382-B   02 Feb 2024   A61K-039/215   202415   Chinese,CN116617382-A    CN10792889    30 Jun 2023;   HK40090393-A0    HK4078582    04 Sep 2023;   CN116617382-B    CN10792889    30 Jun 2023,HK40090393-A0 Previous Publ. Patent CN116617382;   CN116617382-B Previous Publ. Patent CN116617382,CN11207683    30 Sep 2022;  CN10792889    30 Jun 2023,,,"CN116617382-A -- CN111218458-A   ZHUHAI LIFANDA BIOTECHNOLOGY CO LTD (ZHUH-Non-standard)   PENG Y,  SU X,  LIU J,  XIANG S,  LUO L,  LIU Q,  LI S,  LEI Y;  CN112386684-A   FOSHAN ZHAOTAI INNOVATION BIOTECHNOLOGY CO                  LTD (FOSH-Non-standard)   LI P,  QIN L,  TANG C,  JIANG Z,  ZHAO R,  CUI Y,  YAO Y,  HU D;  CN113521269-A   PFIZER INC (PFIZ);  BIONTECH SE (BNTC)   NAUTA M,  PEETERS D J,  VAN DOORSLAER T F S,  BADKAR A V,  DARVARI R,  WARNE N W,  JEAN J,  HENDRIKSE D P G,  SAHIN U,  GUELER A,  KUHN A,  MUIK A,  VOGEL A,  WALZER K,  WITZEL S,  HEIN S,  TUERECI O;  CN114150004-A   GUANGZHOU N BIOMED CO LTD (GUAN-Non-standard)   GUAN S,  WANG Q,  YANG C,  CHEN L;  CN114150005-A   GUANGZHOU N BIOMED CO LTD (GUAN-Non-standard)   GUAN S,  WANG Q,  YANG C,  CHEN L;  CN114478718-A   CHINA NAT PHARM CNBG BIOTECHNOLOGY RES (CHNA-Non-standard)   SHEN F,  ZHENG F,  CHEN S,  MA Z,  HOU Y,  HOU J,  ZHANG H,  JIN Y,  LIU N,  HAN Z,  LIU Z,  LEI Z,  ZHANG X,  SHAO S,  TANG F,  DU L,  SU J,  LIANG Y,  ZHANG J,  LI Q;  CN114507675-A   ZHUHAI LIFANDA BIOTECHNOLOGY CO LTD (ZHUH-Non-standard)   FANG Z,  LI S,  LEI Y,  LIU Q,  LIU J,  PENG Y;  CN114634556-A   CHINESE ACAD SCI MICROBIOLOGY INST (CWSW)   ZHENG T,  XU K,  DAI L,  GAO F;  CN114989308-A   CHINESE ACAD SCI MICROBIOLOGY INST (CWSW)   MA X,  CHEN Q,  DU P,  DAI L,  WANG Q,  GAO F;  CN115043938-A   WANG H (WANG-Individual);  JIANG Z (JIAN-Individual);  DUAN L (DUAN-Individual)   WANG H,  JIANG Z,  DUAN L;  CN115089700-A   CENT ING GENETICA & BIOTECNOLOGIA (CIGB);  YONGZHOU CHINA CUBA BIOTECHNOLOGY CO LTD (YONG-Non-standard)   HU L,  LIU J,  M D ALEJANDRO M` C,  DAI L,  L V L,  TAN M,  GERARDO E N G,  FU W,  M L A,  TAN C,  H G V,  JIANG S,  RICARDO S R,  AI P,  CHEN R,  P N Y,  YANG K,  EDITH S P,  L M Y,  HC L;  US20030220274-A1   ;  CN116617382-B -- CN111218458-A   ZHUHAI LIFANDA BIOTECHNOLOGY CO LTD (ZHUH-Non-standard)   PENG Y,  SU X,  LIU J,  XIANG S,  LUO L,  LIU Q,  LI S,  LEI Y;  CN112386684-A   FOSHAN ZHAOTAI INNOVATION BIOTECHNOLOGY CO                  LTD (FOSH-Non-standard)   LI P,  QIN L,  TANG C,  JIANG Z,  ZHAO R,  CUI Y,  YAO Y,  HU D;  CN113521269-A   PFIZER INC (PFIZ);  BIONTECH SE (BNTC)   NAUTA M,  PEETERS D J,  VAN DOORSLAER T F S,  BADKAR A V,  DARVARI R,  WARNE N W,  JEAN J,  HENDRIKSE D P G,  SAHIN U,  GUELER A,  KUHN A,  MUIK A,  VOGEL A,  WALZER K,  WITZEL S,  HEIN S,  TUERECI O;  CN114150004-A   GUANGZHOU N BIOMED CO LTD (GUAN-Non-standard)   GUAN S,  WANG Q,  YANG C,  CHEN L;  CN114150005-A   GUANGZHOU N BIOMED CO LTD (GUAN-Non-standard)   GUAN S,  WANG Q,  YANG C,  CHEN L;  CN114478718-A   CHINA NAT PHARM CNBG BIOTECHNOLOGY RES (CHNA-Non-standard)   SHEN F,  ZHENG F,  CHEN S,  MA Z,  HOU Y,  HOU J,  ZHANG H,  JIN Y,  LIU N,  HAN Z,  LIU Z,  LEI Z,  ZHANG X,  SHAO S,  TANG F,  DU L,  SU J,  LIANG Y,  ZHANG J,  LI Q;  CN114507675-A   ZHUHAI LIFANDA BIOTECHNOLOGY CO LTD (ZHUH-Non-standard)   FANG Z,  LI S,  LEI Y,  LIU Q,  LIU J,  PENG Y;  CN114634556-A   CHINESE ACAD SCI MICROBIOLOGY INST (CWSW)   ZHENG T,  XU K,  DAI L,  GAO F;  CN114668837-A   SUZHOU XIANGLONG BIOMEDICAL TECHNOLOGY (SUZH-Non-standard)   YANG S;  CN114989308-A   CHINESE ACAD SCI MICROBIOLOGY INST (CWSW)   MA X,  CHEN Q,  DU P,  DAI L,  WANG Q,  GAO F;  CN115043938-A   WANG H (WANG-Individual);  JIANG Z (JIAN-Individual);  DUAN L (DUAN-Individual)   WANG H,  JIANG Z,  DUAN L;  CN115089700-A   CENT ING GENETICA & BIOTECNOLOGIA (CIGB);  YONGZHOU CHINA CUBA BIOTECHNOLOGY CO LTD (YONG-Non-standard)   HU L,  LIU J,  M D ALEJANDRO M` C,  DAI L,  L V L,  TAN M,  GERARDO E N G,  FU W,  M L A,  TAN C,  H G V,  JIANG S,  RICARDO S R,  AI P,  CHEN R,  P N Y,  YANG K,  EDITH S P,  L M Y,  HC L;  US20030220274-A1   ","CN116617382-A  ANGELA R. BRANCHE :          ""SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary          Analyses"", MEDRXIV, pages 1 -          34,relevantClaims[1-10]CN116617382-B            Angela R. Branche et al. SARS-CoV-2 Variant Vaccine          Boosters Trial: Preliminary Analyses; Angela R. Branche          et al; medRxiv; Page 1-34",900-0-0-0 M K;  M K; 109100-1-0-0 M K; 363862-0-1-0 M K; 1230051-0-0-0 M K; 93537-0-0-0 M K; 93407-0-0-0 M K; 93406-1-0-0 M K;  M K;  M K; 93538-0-0-0 M K;  M K; 849-0-0-0 M K; 60-0-0-0 M K; 8349-1-0-0 M K; 444-0-0-0 ; 1230051-0-0-0 CL USE,,,R02044 M K; RBUTR3 M K; RA0CQN M K; RA3DYK M K; RAL2Y1 M K; R06520 M K; R06737 M K; RA0GCK M K; RD3B3G M K; RD2DN8 M K; RA0GCJ M K; RCWNCN M K; R00419 M K; R01081 M K; R00148 M K; R00351 ,2044-S; 0419-S; 1081-S; 0148-S
WO2022113114-A1;  IN202021051801-A;  US2022170118-A1,"Determining viruses in biological samples comprises creating, by a sample decoding device, a pooling matrix for pooling and testing biological samples, receiving, by the sample decoding device and determining by the sample decoding device",GOPALKRISHNAN M;  GHOSH S;  RAJWADE A V;  PALAKODETI D;  KRISHNA S;  SABYASACHI G;  SANDEEP K,INDIAN INST TECHNOLOGY BOMBAY (IITB-C);  STEM CELL SCI & REGENERATIVE MEDICINE (STEM-Non-standard);  NAT CENT BIOLOGICAL SCI (NABI-Non-standard);  ALGORITHMIC BIOLOGICS PRIVATE LTD (ALGO-Non-standard);  STEM CELL SCI & REGENERATIVE MEDICINE (STEM-Non-standard);  NAT CENT BIOLOGICAL SCI (NABI-Non-standard);  ALGORITHMIC BIOLOGICS PRIVATE LTD (ALGO-Non-standard);  NAT CENT BIOLOGICAL SCI (NABI-Non-standard);  STEM CELL SCI & REGENERATIVE MEDICINE (STEM-Non-standard);  INDIAN INST TECHNOLOGY BOMBAY (IITB-C),2022764469,"   NOVELTY - Determining viruses in biological samples comprises: creating, by a sample decoding device , a pooling matrix for pooling and testing of many biological samples, where the pooling matrix indicates many pools for many biological samples to be tested and at least two pools for each biological sample, where a pooling is performed to include each of the biological sample in the determined at least two pools of the many pools and tests are performed on the pools; receiving, by the sample decoding device, input cycle threshold values (Ct values) of many pools, on completion of performing the tests on many pools; and determining, by the sample decoding device, a status of each biological sample by processing the Ct values of each pool using a non-adaptive testing method and a compressed sensing method, where the status of each the biological sample indicates whether the viruses are present in the biological samples or not.    USE - The method is useful for determining viruses in biological samples (claimed).    ADVANTAGE - The method: improves the throughput and has improved efficacy.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a sample decoding device comprising a memory, and a processor coupled to the memory configured to create a pooling matrix for pooling and testing of many biological samples, where the pooling matrix indicates many pools for many biological samples to be tested and at least two pools for each biological sample, where a pooling is performed to include each of the biological sample in the determined at least two pools and tests are performed on the many pools; receive input cycle threshold values of many pools, on completion of performing the tests on many pools; and determine a status of each biological sample by processing the Ct values of each pool using a non-adaptive testing method and a compressed sensing method, where the status of each biological sample indicates whether the viruses are present in the biological samples or not. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E01;  B04-E05;  B04-F11;  B11-C08F8;  B11-C08K;  B11-C08N3;  B11-C10A;  B12-K04F;  D05-H06A;  D05-H18B,C12Q-001/70;  A61B-005/15;  A61K-039/215;  C12Q-001/6806;  C12Q-001/686;  G16B-025/20;  G16H-010/40,WO2022113114-A1   02 Jun 2022   C12Q-001/70   202248Pages: 50   English;  IN202021051801-A   27 May 2022   C12Q-001/6806   202248   English;  US2022170118-A1   02 Jun 2022   C12Q-001/70   202248   English,WO2022113114-A1    WOIN051107    26 Nov 2021;   IN202021051801-A    IN21051801    27 Nov 2020;   US2022170118-A1    US535998    27 Nov 2021,,IN21051801    27 Nov 2020,WO2022113114-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      ,,"WO2022113114-A1 -- EP2821507-A1   CNRS CENT NAT RECH SCI (CNRS);  UNIV PERPIGNAN VIA DOMITIA (UYPE-Non-standard)   FALIEX E,  MEISTERTZHEIM A;  US20060136148-A1   ",,,,,,
WO2021016049-A1;  US2022265755-A1;  US2023226135-A9,"New peptide comprising specified amino acid            sequence, used e.g. to treat subject having disorder            associated with blood brain barrier permeability, and            to reduce adverse effects of immune response in subject            having hyperimmune response",NEWELL-ROGERS M K;  NEWELL E,BCELL SOLUTIONS INC (BCEL-Non-standard);  BCELL SOLUTIONS INC (BCEL-Non-standard),202110668M,"   NOVELTY - Peptide comprising an amino acid sequence (I)                (SEQ ID NO: 379), is new.    USE - The peptide is useful for: treating a subject                having a disorder associated with BBB permeability;                reducing adverse effects of an immune response in a                subject having a hyperimmune response or reducing                adverse effects of an immune therapy in a subject                having a hyperimmune response, where the subject                has an infectious disease, and the subject has a                post-infectious chronic inflammatory syndrome;                treating a subject having a post-infectious chronic                inflammatory syndrome; treating a disorder, where                the disorder is a psychiatric or neurological                disease (including attention deficit hyperactivity                disorder, Parkinson's disease, pediatric                acute-onset neuropsychiatric syndrome, pediatric                autoimmune neuropsychiatric disorders associated                with streptococcal infections, Huntington's chorea,                epilepsy, convulsions, Tourette syndrome, obsessive                compulsive disorder, memory deficits and                dysfunction, a learning deficit, a panic disorder,                narcolepsy, nociception, autism, tardive                dyskinesia, social phobia, pseudodementia,                neuropathic pain, postoperative pain, inflammatory                pain, phantom limb pain, schizophrenia, mania,                depression, anxiety, or a neurodegenerative                disorder (e.g. senile dementia or an intellectual                impairment disorder), is a damaged tissue and                promoting wound healing of a chronic wound, is an                imbalance and improving cognition or cessation of                addiction, where the addiction is smoking, vaping,                alcohol and/or drugs, and is a proliferative and                non-neuronal immune disorders (including autoimmune                disease, inflammatory bowel disease, Crohn's                disease, asthma, macular degeneration (e.g. dry                age-related macular degeneration (AMD), wet AMD),                retinopathy (e.g. diabetic retinopathy), kidney                disease, preeclampsia, type 1 diabetes, arthritis                (e.g. osteoarthritis and rheumatoid arthritis),                psoriatic arthritis or sepsis (all claimed);                modulating the neurological and immune function                through targeting of acetylcholine and CLIP;                treating, inhibiting the development of, or                otherwise dealing with, a multitude of illnesses                and conditions including transplant and cell graft                rejection, Alzheimer's, Lewy body dementia,                hypertension, late stage Ebola, Hantavirus or                coronavirus-induced hyperinflammatory conditions,                and cancer; treating a cancer (e.g. biliary tract                cancer, bladder cancer, brain cancer including                glioblastoma and medulloblastoma, breast cancer,                cervical cancer, choriocarcinoma, colon cancer,                endometrial cancer, esophageal cancer, gastric                cancer, hematological neoplasms including acute                lymphocytic and myelogenous leukemia, multiple                myeloma, intraepithelial neoplasms including                Bowen's disease and Paget's disease, liver cancer,                lung cancer, lymphomas including Hodgkin's disease                and lymphocytic lymphomas, oral cancer, ovarian                cancer, pancreatic cancer, prostate cancer, rectal                cancer, sarcomas including leiomyosarcoma,                rhabdomyosarcoma, liposarcoma, fibrosarcoma and                osteosarcoma, skin cancer including melanoma,                Kaposi's sarcoma, testicular cancer thyroid cancer,                renal cancer including adenocarcinoma, and Wilms                tumor; and inhibiting the development of multiple                sclerosis, systemic lupus erythematosus, viral                endocarditis, viral encephalitis, Graves' disease,                autoimmune thyroiditis, autoimmune myositis, and                discoid lupus erythematosus. Test details are                described but no results given.    ADVANTAGE - The peptide: avoids potentially adverse effect                or reduces side effects; prevents or stops further                progression of neurodegeneration; and prevents or                inhibits a decrease in T helper cells, as compared                to the levels in the absence of peptide                treatment.    DETAILED DESCRIPTION - Peptide comprising an amino acid sequence of                formula                (Ala-Asn-Ser-Gly-Z1-Ile-Z2-Leu-Ala-Z3-Gly-Gly-Gln-Tyr)                (I) (SEQ ID NO: 379), is new.    Z1 and Z2 = each independently comprising 2-5                amino acids; and    Z3 = 1-2 amino acids.    INDEPENDENT CLAIMS are also included                for:    (1) a composition comprising the peptide and a                carrier;    (2) treating (M1) a subject having a disorder                associated with blood brain barrier (BBB)                permeability, comprising identifying a subject                having a disorder associated with BBB permeability,                and administering an isolated selective alpha 7                nicotinic acetylcholine receptor ( alpha 7nAChR)                agonist to the subject in an efficient amount to                treat the disorder associated with BBB, where the                selective alpha 7nAChR agonist is an isolated                peptide;    (3) reducing (M2) adverse effects of an immune                response in a subject having a hyperimmune                response, comprising systemically administering an                isolated compound comprising a selective alpha                7nAChR agonist to reduce or eliminate a cytokine                storm in the subject, where the alpha 7nAChR                agonist is a peptide comprising the amino acid                sequence of SEQ ID NO: 379;    (4) reducing (M3) adverse effects of an immune                therapy in a subject having a hyperimmune response,                comprising systemically administering an isolated                peptide and a small molecule nicotinic                acetylcholine ( alpha 7nACh) receptor agonist to                the subject, where the isolated peptide and alpha                7nACh receptor agonist are administered to reduce                or eliminate a cytokine storm;    (5) treating (M4) a subject having a                post-infectious chronic inflammatory syndrome,                comprising identifying a subject having a                post-infectious chronic inflammatory syndrome and                systemically administering an isolated peptide to                the subject to treat a post-infectious chronic                inflammatory syndrome;    (6) treating (M5) a disorder, comprising                administering an isolated compound to a subject                having the disorder, optionally an isolated                peptide, where the isolated compound is a nicotinic                acetylcholine ( alpha 7nACh) receptor agonist and a                MHC class II associated invariant peptide (CLIP)                inhibitor; and    (7) treating (M6) a disorder, comprising                administering an isolated compound to the subject,                optionally an isolated peptide and a small molecule                nicotinic acetylcholine ( alpha 7nACh) receptor                agonist, where the isolated compound is an alpha                7nACh receptor agonist and a CLIP inhibitor to                treat the disorder. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-B03B;  B04-C01;  B04-E99;  B14-A01;  B14-A02;  B14-A04;  B14-C01;  B14-C03;  B14-C09;  B14-D01C;  B14-E10C1;  B14-F01;  B14-F02B;  B14-G02C;  B14-G02D;  B14-G03;  B14-H01;  B14-J01;  B14-J05;  B14-J07;  B14-K01A;  B14-L01;  B14-L06;  B14-M01B;  B14-N01;  B14-N03;  B14-N10;  B14-N11;  B14-N14;  B14-N16;  B14-N17;  B14-S01;  B14-S04;  B14-S06;  B14-S16;  B14-S18;  D05-H99,A61K-038/10;  A61P-025/00;  A61P-029/00;  A61P-031/12;  C07K-014/00;  C07K-007/08;  A61K-038/00;  A61P-019/02;  C07K-014/165;  C07K-014/31;  C07K-014/315,WO2021016049-A1   28 Jan 2021   A61K-038/10   202114Pages: 99   English;  US2022265755-A1   25 Aug 2022   A61K-038/00   202269   English;  US2023226135-A9   20 Jul 2023   A61K-038/00   202359   English,WO2021016049-A1    WOUS042399    16 Jul 2020;   US2022265755-A1    US17627359    14 Jan 2022;   US2023226135-A9    US17627359    14 Jan 2022,US2022265755-A1 PCT application Application WOUS042399;   US2022265755-A1 Provisional Application US876513P;   US2022265755-A1 Provisional Application US003128P;   US2023226135-A9 Provisional Application US003128P;   US2023226135-A9 Provisional Application US876513P;   US2023226135-A9 PCT application Application WOUS042399;   US2023226135-A9 Previous Publ. Patent US2022265755,US876513P    19 Jul 2019;  US003128P    31 Mar 2020;  US17627359    14 Jan 2022,WO2021016049-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      ,,"WO2021016049-A1 -- US20100152239-A1   ;  WO2015035414-A1   SCOTT & WHITE HEALTHCARE (SCOT-Non-standard);  UNIV TEXAS A & M SYSTEM (UTAM)   NEWELL M K,  SHAPIRO L,  TOBIN R;  WO2010011347-A2   UNIV COLORADO (COLS);  VIRAL GENETICS INC (VIRA-Non-standard)   AGADJANYAN M,  KELEDJIAN H,  NEWELL E,  NEWELL M K","WO2021016049-A1  MUHAMMAD SAJJAD,          HAASBACH EMANUEL, KOTCHOURKO MARIA, STRIGLI ANNE, KRENZ          ANTJE, RIDDER DIRK A., VOGEL ANNETTE B., MARTI HUGO H.,          A: ""Influenza Virus Infection Aggravates Stroke Outcome"",          STROKE, vol. 42, 2011, pages 783 - 791,          XP055786633,relevantClaims[0];  DASH PRAMOD K.,          ZHAO JING, KOBORI NOBUHIDE, REDELL JOHN B., HYLIN MICHAEL          J., HOOD KIMBERLY N., MOORE ANTHONY N.: ""Activation of          Alpha 7 Cholinergic Nicotinic Receptors Reduce          Blood-Brain Barrier Permeability following Experimental          Traumatic Brain Injury"", THE JOURNAL OF NEUROSCIENCE,          vol. 36, no. 9, 2016, pages 2809 - 2818,          XP055786643,relevantClaims[0]",2044670-1-0-0 M N; 37900-1-0-0 M N; 2044670-1-0-0 CL NEW USE; 37900-1-0-0 CL NEW USE,222990201 M N; 222990202 M N,,RB2DBW M N; R00255 M N; RA0JCP M N,0255-S
US2021292743-A1;  WO2021185336-A1;  AU2021239220-A1;  CA3175618-A1;  CN115335518-A;  EP4121530-A1;  BR112022018784-A2;  IN202217052671-A;  JP2023535104-W;  HK40080986-A0;  HK40080985-A0,"Isolating RNA components from fluid mixture            comprising RNA components and contaminants, by adding            fluid mixture to aqueous two-phase system (ATPS)            comprising first phase solution and second phase            solution, and isolating RNA components from first phase            solution",CHIU Y T;  KITTUR H M;  CHUNG C Y T;  MOSLEY G L;  ZHAO Y,PHASE SCI INT LTD (PHAS-Non-standard);  PHASE SCI INT LTD (PHAS-Non-standard);  PHASE SCI INT LTD (PHAS-Non-standard);  PHASE SCI INT LTD (PHAS-Non-standard);  PHASE SCI INT LTD (PHAS-Non-standard);  PHASE SCI INT LTD (PHAS-Non-standard),2021B0089N,"   NOVELTY - Method for isolating RNA components from a                fluid mixture comprising RNA components and                contaminants, involves (a) adding the fluid mixture                to an aqueous two-phase system (ATPS) comprising a                first phase solution and a second phase solution,                such that the RNAs partition to the first phase                solution and the contaminants partition to the                second phase solution, and (b) isolating the RNA                components from the first phase solution, where the                method is performed based on the steps depicted in                figure 1 or 2 of the patent specification.    USE - The method is useful for isolating RNA                components from a fluid mixture comprising RNA                components and contaminants (claimed).    ADVANTAGE - The method enables multiple steps, rely on                solid-liquid phase based interactions such as                column-based or bead-based extraction methods,                provides accurate result on molecular assay, and                does not require column or beads.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a composition comprising a first phase                component and a second phase component capable of                forming an aqueous two-phase system (ATPS), where                the first phase component comprises a polymer                having a molecular weight of 2000 Da or less, and                the second phase component comprises one or more                salt components chosen from ionic compounds and                polyelectrolytes;    (2) a kit comprising the composition;                and    (3) a method for isolating RNAs from a fluid                mixture comprising RNAs and contaminants using the                kit involves (a) adding 875 mul deoxyribonuclease                (DNase)/ribonuclease (RNase)-free water into one                vial of proteinase powder (25 mg) and mixing well                to form solution B1, storing solution B1 at                4degreesC, (b) adding 155 mul DNase/RNase-free                water into one vial of reducing agent powder (24                mg) and mixing well to form solution B2, storing                solution B2 at -20degreesC, (c) transferring                140-1000 mul fluid mixture into a 1.5 ml                microcentrifuge tube at room temperature, adding                buffer solution such that the microcentrifuge tube                contains 1 ml liquid, (d) adding the following                reagents to the microcentrifuge tube in 10 mul                solution B1, 11 mul solution B2, 5.6 mul carrier                nucleic acid solution and 100 mul lysing reagent to                form a mixture, (e) vortexing the mixture and                incubating at room temperature for 10 minutes, (f)                pipet-mixing the mixture and transferring the                mixture into a tube of the composition to form                solution C, (g) centrifuging solution C tube and                vortexing until it is homogenous, (h) centrifuging                solution C tube at 4300x g for 1 minute to form a                top phase and a clear bottom phase, (i) extracting                120 mul or less top phase and transferring the top                phase to a new 2 ml microcentrifuge tube without                transferring any of the clear bottom phase, (j)                adding 230 mul DNase/Rnase-free water to a new 2 ml                microcentrifuge tube, adding DNase/Rnase-free water                until the total volume reaches 350 mul, (k) adding                the reagents comprising 510 mul solution of                precipitation salt, 2 mul solution of                co-precipitant and 860 mul 100% isopropanol to the                new 2 ml microcentrifuge tube to form a second                mixture, (l) vortexing the second mixture until                homogenous and incubating the second mixture at                room temperature for 5 minutes, (m) centrifuging                the mixture at 4300x g for 10 minutes, (n)                discarding all of the supernatant and adding 1 ml                40% isopropanol, (o) centrifuging the mixture at                4300x g for 2 minutes, (p) discarding all of the                supernatant and adding 1 ml 70% ethanol, (q)                centrifuging the mixture at 4300xg for 2 minutes,                (r) discarding all of the supernatant, (s) drying                the pellet at room temperature for at least 10                minutes until completely dried, (t) re-suspending                the pellet in at least 10 mul resuspension buffer,                and (u) adding a buffer directly to the dry pellet                and pipette-mixing up and down for 30 times or                more. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E01B;  B11-B03A;  B04-L05;  B11-C07A4;  B11-C08E3;  B11-C08F8;  B12-K04F;  B11-C07B3;  B11-C07B6;  B11-C08E6;  B11-C08A;  B11-C08B;  B04-F02;  B04-F12;  B04-F11;  B04-C03;  B05-B02A3;  B10-C02;  B05-C05;  B05-A01B;  B05-C01;  B10-E04C;  B10-C04E6;  B10-A15;  B04-H19;  B05-B01G;  B05-Z;  B15-C00;  B05-C08;  B05-A01A;  B10-E03;  B05-A03;  B01-D02;  B10-E04B;  B10-B01B;  B04-N02;  B04-D01;  B14-S18;  D05-H13;  D05-H18B;  D05-H09;  D05-H10;  D05-H06A;  D05-A02,C12N-015/10;  C12Q-001/68;  G01N-033/48;  C12Q-001/6806,US2021292743-A1   23 Sep 2021   C12N-015/10   202193   English;  WO2021185336-A1   23 Sep 2021   C12N-015/10   202193   English;  AU2021239220-A1   04 Aug 2022   C12N-015/10   202263   English;  CA3175618-A1   23 Sep 2021   202284   English;  CN115335518-A   11 Nov 2022   C12N-015/10   202294   Chinese;  EP4121530-A1   25 Jan 2023   C12N-015/10   202308   English;  BR112022018784-A2   31 Jan 2023   C12N-015/10   202318   ;  IN202217052671-A   16 Jun 2023   C12N-015/10   202353   English;  JP2023535104-W   16 Aug 2023   C12N-015/10   202367   Japanese;  HK40080986-A0   12 May 2023   C12N-015/10   202369   English;  HK40080985-A0   12 May 2023   C12N-015/10   202369   English,US2021292743-A1    US249936    19 Mar 2021;   WO2021185336-A1    WOCN081650    19 Mar 2021;   AU2021239220-A1    AU239220    19 Mar 2021;   CA3175618-A1    CA3175618    19 Mar 2021;   CN115335518-A    CN80019480    19 Mar 2021;   EP4121530-A1    EP722367    19 Mar 2021;   BR112022018784-A2    BR11018784    19 Mar 2021;   IN202217052671-A    IN17052671    15 Sep 2022;   JP2023535104-W    JP557116    19 Mar 2021;   HK40080986-A0    HK6069839    10 Mar 2023;   HK40080985-A0    HK6069838    10 Mar 2023,US2021292743-A1 Provisional Application US992222P;   AU2021239220-A1 PCT application Application WOCN081650;   AU2021239220-A1 Based on Patent WO2021185336;   CA3175618-A1 PCT application Application WOCN081650;   CA3175618-A1 Based on Patent WO2021185336;   CN115335518-A PCT application Application WOCN081650;   CN115335518-A Based on Patent WO2021185336;   EP4121530-A1 PCT application Application WOCN081650;   EP4121530-A1 Based on Patent WO2021185336;   BR112022018784-A2 PCT application Application WOCN081650;   BR112022018784-A2 Based on Patent WO2021185336;   IN202217052671-A PCT application Application WOCN081650;   IN202217052671-A Based on Patent WO2021185336;   JP2023535104-W PCT application Application WOCN081650;   JP2023535104-W Based on Patent WO2021185336;   HK40080986-A0 PCT application Application WOCN081650;   HK40080986-A0 Based on Patent WO2021185336;   HK40080986-A0 Previous Publ. Patent CN115335518;   HK40080985-A0 PCT application Application WOCN081650;   HK40080985-A0 Based on Patent WO2021185336;   HK40080985-A0 Previous Publ. Patent EP4121530,US992222P    20 Mar 2020;  CN80019480    19 Mar 2021;  EP722367    19 Mar 2021;  US249936    19 Mar 2021;  CN80019480    07 Sep 2022;  CA3175618    15 Sep 2022;  BR11018784    19 Sep 2022,  WO2021185336-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        EP4121530-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN            ,,"US2021292743-A1 -- US3728285-A   MARUZEN PETROCHEM CO LTD (MAZP);  TOYO RUBBER IND CO LTD (TOYF);  WO2021185336-A1 -- WO2017041030-A1   UNIV CALIFORNIA (REGC)   KAMEI D T,  CHIU Y T,  WU B M,  MOSLEY G L;  WO2019144030-A1   CHIU Y T (CHIU-Individual)   CHIU Y T;  WO2019055926-A2   CHIU Y T (CHIU-Individual)   CHIU Y T","WO2021185336-A1  LUECHAU F ET AL:          ""Primary capture of high molecular weight nucleic acids          using aqueous two-phase systems"", SEPARATION AND          PURIFICATION TECHNOLOGY, ELSEVIER SCIENCE, AMSTERDAM, NL,          vol. 66, no. 1, 7 April 2009 (2009-04-07), pages 202 -          207, XP025982190, ISSN: 1383-5866, [retrieved on          20090316], DOI:          10.1016/J.SEPPUR.2008.12.008,relevantClaims[30-39,44|46,47],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;|&lt;figure&gt;1&lt;/figure&gt;];  LUECHAU F ET AL:          ""Partition of plasmid DNA in polymer-salt aqueous          two-phase systems"", SEPARATION AND PURIFICATION          TECHNOLOGY, ELSEVIER SCIENCE, AMSTERDAM, NL, vol. 66, no.          2, 20 April 2009 (2009-04-20), pages 397 - 404,          XP026077450, ISSN: 1383-5866, [retrieved on 20081211],          DOI:          10.1016/J.SEPPUR.2008.12.003,relevantClaims[30-39,44|46,47],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  VIJAYARAGAVAN K.          SAAGAR ET AL: ""Separation of porcine parvovirus from          bovine serum albumin using PEG-salt aqueous two-phase          system"", JOURNAL OF CHROMATOGRAPHY B, vol. 967, 1          September 2014 (2014-09-01), NL, pages 118 - 126,          XP055823937, ISSN: 1570-0232, DOI:          10.1016/j.jchromb.2014.07.025,relevantClaims[1-53],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  ERIK JUE ET AL:          ""Using an aqueous two-phase polymer-salt system to          rapidly concentrate viruses for improving the detection          limit of the lateral-flow immunoassay : Concentrating          Viruses in a Polymer-Salt System"", BIOTECHNOLOGY AND          BIOENGINEERING, vol. 111, no. 12, 1 December 2014          (2014-12-01), US, pages 2499 - 2507, XP055415958, ISSN:          0006-3592, DOI:          10.1002/bit.25316,relevantClaims[1-53],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  PAZ SEAN ET AL: ""A          simplified SARS-CoV-2 detection protocol for research          laboratories"", PLOS ONE, vol. 15, no. 12, 18 December          2020 (2020-12-18), pages e0244271, XP055820327, DOI:          10.1371/journal.pone.0244271,relevantClaims[1-53],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            CAS, no. 69226-89-73",588592-0-0-0 M K; 1918353-0-0-0 M K; 1690438-0-0-0 M K; 780125-0-0-0 M K; 2332887-0-0-0 M K; 1362006-0-0-0 M K; 103599-0-0-0 M K; 1035792-1-0-0 M K; 2210273-1-0-0 M K; 90356-0-0-0 M K; 109563-0-0-0 M K; 900-0-0-0 M K; 1062-0-0-0 M K; 104380-0-0-0 M K; 104472-0-0-0 M K; 104492-0-0-0 M K; 199546-0-0-0 M K; 108831-0-0-0 M K; 264578-0-0-0 M K; 93605-0-0-0 M K; 104379-0-0-0 M K; 105730-0-0-0 M K; 184592-0-0-0 M K; 102649-0-0-0 M K; 135370-0-0-0 M K; 96300-0-0-0 M K; 155-0-0-0 M K; 849-0-2-0 M K; 87324-0-1-0 M K; 107367-0-0-0 M K; 107355-0-6-0 M K; 194671-0-0-0 M K; 11-0-0-0 M K; 218-0-0-0 M K; 292-0-0-0 M K; 1774-0-0-0 M K; 384093-0-1-0 M K; 600561-0-0-0 M K; 95-0-0-0 M K; 163-0-0-0 M K; 138286-1-0-0 M K; 209-0-0-0 M K; 244-0-0-0 M K; 783-0-0-0 M K; 801-0-0-0 M K; 296010-0-0-0 M K; 308199-0-0-0 M K; 114-0-0-0 M K; 122-0-0-0 M K; 127-0-0-0 M K; 141-0-0-0 M K; 473-0-0-0 M K; 490-0-0-0 M K; 2590-0-0-0 M K; 98156-0-0-0 M K; 107320-0-0-0 M K; 129890-0-0-0 M K; 89-0-0-0 M K; 99-0-1-0 M K; 3330-0-0-0 M K; 99491-0-1-0 M K; 107339-0-0-0 M K; 102219-0-0-0 M K; 130393-0-1-0 M K; 90650-1-0-0 M K; 1362006-0-0-0 CL USE; 2332887-0-0-0 CL USE; 1690438-0-0-0 CL USE; 1918353-0-0-0 CL USE; 1035792-1-0-0 CL USE; 2210273-1-0-0 CL USE,,,RA81MJ M K; RAZR96 M K; RAUY2N M K; RABQT8 M K; RB8HC8 M K; RANWQ7 M K; RA0424 M K; RAH0S0 M K; RB5VEI M K; R01852 M K; RA0426 M K; R02044 M K; RA00D5 M K; RA02L0 M K; R23531 M K; RA01EA M K; RA04QI M K; RA03NA M K; RA1CNC M K; RA00NS M K; RA035M M K; RA012P M K; RA0120 M K; RA0GHH M K; R16461 M K; R01872 M K; R01772 M K; R04004 M K; R01786 M K; R01744 M K; R01690 M K; RAE82W M K; R00246 M K; R01829 M K; R11788 M K; R08271 M K; RA3T5P M K; RA8ALV M K; R01152 M K; R24060 M K; R00035 M K; R01732 M K; R01208 M K; R01423 M K; R01970 M K; RA1ZJX M K; RA28O9 M K; R01706 M K; R01994 M K; R01678 M K; RAAGVS M K; R00201 M K; R00113 M K; RAOR8C M K; RA02LH M K; R01997 M K; RBXVXT M K; R01080 M K; R01425 M K; R00195 M K; R01679 M K; R01722 M K; RA0S2Q M K; R04530 M K; R17388 M K,1852-S; 2044-S; 1872-S; 1772-S; 0419-S; 1786-S; 1744-S; 1690-S; 0246-S; 1829-S; 1152-S; 0035-S; 1732-S; 1208-S; 1423-S; 1970-S; 1706-S; 1994-S; 1678-S; 0201-S; 0113-S; 1997-S; 1080-S; 1425-S; 0195-S; 1679-S; 1722-S; 0497-S
WO2022036280-A1;  US2022211751-A1;  BR112023001995-A2;  EP4196094-A1;  CN116367845-A;  IN202317016230-A,"Non-aqueous high molecular iodine concentration            solution used to treat or prevent condition associated            with parasite and microorganism, infection, and/or            inhibit tumor recurrence comprises molecular iodine,            glycerol, and ethanol",KESSLER J;  DUAN E;  DUAN Y,I2PURE CORP (ITWO-Non-standard);  I2PURE CORP (ITWO-Non-standard);  I2PURE CORP (ITWO-Non-standard),202224758C,"   NOVELTY - Non-aqueous high molecular iodine                concentration solution comprises 1500 ppm molecular                iodine, 99 wt.% glycerol, and less than or equal to                1 wt.% ethanol.    USE - The solution is useful for: killing or                inhibiting the growth of a parasite and/or a                microorganism on or in a subject, treating or                preventing a condition associated with a parasite                and/or a microorganism of a subject, the condition                associated with the virus including coronavirus                disease-19, severe acute respiratory syndrome,                ebola, herpes, AIDS, hepatitis A, hepatitis B, and                Hepatitis C, the condition associated with the                bacterium includes tuberculosis, periodontitis,                acnes, rosacea, impetigo, cellulitis, folliculitis,                and infections caused by the bacterium, the                condition associated with the fungus including                ringworm, yeast infection, and seborrheic                dermatitis, the condition associated with the                parasite includes mite dermatitis caused e.g.,                scabies, red mite infestation, cercarial                dermatitis, tropical rat mite dermatitis; killing                microbes, treating or preventing a skin condition                of a subject, where the skin condition includes                skin conditions associated with a biological                reaction of a subject to an exogenously introduced                irritant, skin conditions associated with an                autoimmune disease, acne and rosacea, the                autoimmune disease includes diabetes, scleroderma,                psoriasis, dermatomyositis, epidermolysis bullosa,                and bullous pemphigoid, the condition is diabetes,                and the skin condition includes acanthosis                nigricans, bullosis diabeticorum (diabetic                blisters), digital sclerosis, disseminated                granuloma annulare, eruptive xanthomatosis, and                necrobiosis lipoidica diabeticorum, the condition                being associated with an immune response, the                condition being associated with an inflammatory                response, fostering wound-healing or preventing a                wound of a subject, and treating a surgical site to                foster healing, prevent infection, and/or inhibit                tumor recurrence in a subject, where the surgical                site comprises a tumor, the tumor comprises benign                tumor, a premalignant tumor, or a malignant tumor,                the benign tumor includes adenomas, fibromas,                hemangiomas, and lipomas, the premalignant tumor                includes actinic keratosis, cervical dysplasia,                metaplasia of the lung, and leukoplakia, the                malignant tumor includes e.g. carcinomas, sarcomas,                germ cell tumors, blastomas, adenocarcinoma,                melanoma, basal cell carcinoma, squamous cell                carcinoma, invasive ductal carcinoma,                rhabdomyosarcoma, synovial sarcoma, adrenal tumor,                carcinoid tumor, neuroendocrine tumors,                paragangliomas, pheochromocytomas, thyroid                carcinoma, pancreatic tumor, nasopharyngeal                carcinoma, ovarian tumor, testicular tumor,                thoracic tumor, and retinoblastoma, and the                malignant tumor being caused by a cancer. The                cancer includes e.g. breast cancer, cervical                cancer, colon cancer, rectal cancer, colorectal                cancer, and testicular cancer. The surgery being a                spinal surgery (all claimed). Test details are                described but no results given.    ADVANTAGE - The solution is alcohol-free or substantially                alcohol free, or water-free or substantially                water-free, has biostatic resistance, biocidal                resistance, or has prolonged biocidal                activity.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) high molecular iodine concentration                composition, comprising 1025-66000 ppm molecular                iodine, and greater than or equal to 95 wt.%,                preferably greater than or equal to 99 wt.% organic                carrier, where the high molecular iodine                concentration composition being non-staining, stain                free or substantially stain free;    (2) formulation, comprising the high molecular                iodine concentration composition;    (3) killing or inhibiting the growth of a                parasite and/or a microorganism on or in a subject,                comprising administering high molecular iodine                concentration composition or formulation to the                subject;    (4) treating or preventing (M1) a condition                associated with a parasite and/or a microorganism                of a subject, comprising administering high                molecular iodine concentration composition or                formulation to the subject;    (5) killing (M2) microbes, comprising                administering 1500 ppm high concentration molecular                iodine solution, and 99 wt.% glycerol to a                treatment area on a human subject;    (6) treating or preventing (M3) a skin                condition of a subject, fostering wound-healing or                preventing a wound of a subject, and treating a                surgical site to foster healing, prevent infection,                and/or inhibit tumor recurrence in a subject,                comprising administering high molecular iodine                concentration composition or formulation to the                subject; and    (7) making high molecular iodine concentration                solution, comprising dissolving molecular iodine                into an absolute ethanol to form an iodine-ethanol                mixture, combining the molecular iodine-ethanol                mixture with a glycerol to form an                iodine-ethanol-glycerol mixture having a final                concentration of 1,500 ppm of molecular iodine, and                mixing the iodine-ethanol-glycerol mixture until                the mixture becomes a homogenous solution, or                dissolving molecular iodine into a propylene glycol                to from an iodine concentrate having a molecular                iodine concentration of 100,000 ppm, diluting the                molecular iodine with an organic carrier including                pure glycerol, pure propylene glycol, propylene                glycol with 10% citric acid, propylene glycol with                5% citric acid, and propylene glycol with 1% citric                acid to form high molecular iodine concentration                solution having a final concentration of 1,500 ppm                of molecular iodine. ",,,"A96 (Medical, dental, veterinary, cosmetic.);  ;  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  B06 (Inorganics - including fluorides for toothpastes etc.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  S05 (Electrical Medical Equipment)",A12-V01;  D08-B09A1;  D08-B09A1A;  D09-A01C;  D09-C04B;  B04-C02A2;  B04-C02D;  B04-C03B;  B04-N02;  B05-C07;  B07-A02B;  B10-A10;  B10-C02;  B10-E04C;  B10-E04D;  B10-G02;  B12-M07;  B14-A01;  B14-A02;  B14-A04;  B14-B04A;  B14-C03;  B14-G01B;  B14-G02D;  B14-H01;  B14-H05;  B14-J05;  B14-K01;  B14-N06B;  B14-N17;  B14-S04;  C04-C02A2;  C04-C02D;  C04-C03B;  C04-N02;  C05-C07;  C07-A02B;  C10-A10;  C10-C02;  C10-E04C;  C10-E04D;  C10-G02;  C12-M07;  C14-A01;  C14-A02;  C14-A04;  C14-B02;  C14-B04A;  C14-C03;  C14-G01B;  C14-G02D;  C14-H01;  C14-H05;  C14-J05;  C14-K01;  C14-N06B;  C14-N17;  C14-S04;  C14-U01E;  S05-B,A61K-033/18;  A61K-047/10;  A61K-009/08;  A61P-031/02;  A61P-031/04;  A61P-031/10;  A61K-031/56;  A61K-047/12;  A61K-009/00;  A61P-035/00;  A61P-043/00,WO2022036280-A1   17 Feb 2022   A61K-009/08   202223Pages: 144   English;  US2022211751-A1   07 Jul 2022   A61K-033/18   202255   English;  BR112023001995-A2   28 Feb 2023   A61K-009/08   202325   ;  EP4196094-A1   21 Jun 2023   A61K-009/08   202350   English;  CN116367845-A   30 Jun 2023   A61K-033/18   202357   Chinese;  IN202317016230-A   24 Nov 2023   A61K-009/00   202304   English,WO2022036280-A1    WOUS046035    13 Aug 2021;   US2022211751-A1    US402467    13 Aug 2021;   BR112023001995-A2    BR11001995    13 Aug 2021;   EP4196094-A1    EP856832    13 Aug 2021;   CN116367845-A    CN80070420    13 Aug 2021;   IN202317016230-A    IN17016230    10 Mar 2023,US2022211751-A1 Provisional Application US065479P;   US2022211751-A1 Provisional Application US068969P;   US2022211751-A1 Provisional Application US077520P;   US2022211751-A1 Provisional Application US080769P;   US2022211751-A1 Provisional Application US147743P;   US2022211751-A1 Provisional Application US211543P;   BR112023001995-A2 PCT application Application WOUS046035;   BR112023001995-A2 Based on Patent WO2022036280;   EP4196094-A1 PCT application Application WOUS046035;   EP4196094-A1 Based on Patent WO2022036280;   CN116367845-A PCT application Application WOUS046035;   CN116367845-A Based on Patent WO2022036280;   IN202317016230-A PCT application Application WOUS046035;   IN202317016230-A Based on Patent WO2022036280,US065479P    13 Aug 2020;  US068969P    21 Aug 2020;  US077520P    11 Sep 2020;  US080769P    20 Sep 2020;  US147743P    09 Feb 2021;  US211543P    16 Jun 2021;  US402467    13 Aug 2021;  BR11001995    02 Feb 2023;  CN80070420    13 Apr 2023,WO2022036280-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      EP4196094-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN      ,,"WO2022036280-A1 -- US20180360048-A1   ;  US20190381093-A1   ;  US20200129543-A1   ;  US2022211751-A1 -- CN106163577-A   IOTECH INT LLC (IOTE-Non-standard)   KESSLER J,  KOLSKY R E,  MOSKOWITZ H;  US20190381093-A1   ;  US20200129543-A1   ",,104380-0-0-0 K M; 90026-0-0-0 K M; 101234-0-0-0 K M; 90114-0-0-0 K M; 96529-0-0-0 K M; 96536-0-0-0 K M; 109215-0-0-0 K M; 133925-0-0-0 K M; 95972-0-0-0 K M; 133912-0-0-0 K M; 100739-1-0-0 K M; 97486-1-0-0 K M; 75-0-0-0 K M; 7243-3-0-0 E K M; 313022-0-0-0 E K M; 532684-0-0-0 E K M; 490-0-0-0 E K M; 849-0-0-0 E K M; 861-0-0-0 E K M; 813-0-0-0 E K M; 130752-0-0-0 E K M; 131510-0-0-0 E K M; 25-0-0-0 E K M; 33-0-0-0 E K M; 331-0-0-0 E K M; 135412-0-0-0 ; 444-0-0-0 ; 1911-0-0-0 ; 313022-0-0-0 CL DIS USE; 532684-0-0-0 CL DIS USE; 130752-0-0-0 CL DIS USE; 131510-0-0-0 CL DIS USE,,,RA02L0 K M; RA037T K M; RA01SX K M; R14113 K M; R16698 K M; R24036 K M; R03104 K M; R24037 K M; RA02KU K M; R01866 K M; R07226 K M; R24033 K M; R01835 K M; R06717 K M; R01860 K M; RA02KX K M; R06563 K M; RA083K K M; R01687 K M; RA9YCD E K M; RA2CDL E K M; RA6W0E E K M; R00113 E K M; R00419 E K M; R00137 E K M; R01300 E K M; R07332 E K M; R08574 E K M; R00274 E K M; R00271 E K M; R00302 E K M; R24069 ; R00351 ; R00446 ,1866-S; 1835-S; 1860-S; 1687-S; 0113-S; 0419-S; 0137-S; 1300-S; 0274-S; 0271-S; 0302-S
WO2021216541-A1;  US2022023204-A1;  AU2021260578-A1;  CA3175301-A1;  KR2023005244-A;  IL297450-A;  EP4138791-A1;  CN115996707-A;  JP2023522103-W;  IN202217061580-A,"Dry powder used in treating lung diseases            comprises polynucleotide molecules retaining            substantial biological activity and/or have been            stabilized and first excipient, where dry powder have            been produced by an ultra-rapid freezing process",SMYTH H D C;  ZHANG H;  CUI Z;  WANG J;  XU H;  ZHANG Y;  GHOSH D;  LEAL J;  SOTO M;  WILLIAMS R O;  MOON C;  SAHAKIJPIJARN S;  SMITH HUGH D C;  HAILU Z;  JEONG-RUNG C;  JE-RYANG W;  XUHAIWE;  FESTIVAL M N;  GOSHDEVADIUTI;  JASMEME R;  MELISSA S;  SAWITREE S P;  SOATTO M,UNIV TEXAS SYSTEM BOARD REGENTS (TEXA-C);  UNIV TEXAS SYSTEM (TEXA-C);  UNIV TEXAS SYSTEM (TEXA-C);  UNIV TEXAS SYSTEM (TEXA-C);  UNIV TEXAS SYSTEM (TEXA-C),2021C1213Q,"   NOVELTY - Dry powder comprises polynucleotide molecules                and at least a first excipient, where dry powder                have been produced by an ultra-rapid freezing                process (URF), where the polynucleotide molecules                retain substantial biological activity and/or have                been stabilized by the URF process.    USE - The composition is useful in treating lung                disease i.e. interstitial lung diseases, chronic                obstructive pulmonary disease (COPD), asthma,                cystic fibrosis (CF), pulmonary fibrosis, primary                ciliary dyskinesia (PCD), genetic disease or                infection (claimed). Test details are described but                no results given.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included                for    (1) an inhaler comprising powder;    (2) producing (M1) powder composition                comprising (a) mixing an encapsulated                polynucleotide molecule and first excipient in a                solvent to form a precursor solution, (b)                depositing the precursor solution onto a surface at                a temperature suitable to cause the solvent to                freeze, and (c) removing the solvent to obtain the                powder composition;    (3) treating (M2) lung disease, lung injury or                lung infection comprising administering composition                of any one composition or a composition produced by                the methods to a subject;    (4) stimulating (M3) an immune response in a                subject comprising administering the composition or                a composition produced by the methods to a subject,                where the polynucleotide molecules encode an                antigen; and    (5) treating (M4) a disease in a subject                comprising (i) reconstituting a composition or a                composition produced by the methods, in a vehicle,                and (ii) administering the reconstituted                composition to the subject. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B06 (Inorganics - including fluorides for toothpastes etc.);  A96 (Medical, dental, veterinary, cosmetic.)",B04-E99;  B01-D02;  B04-B01B;  B04-B03C;  B04-C02A2;  B04-C02C;  B04-C02D;  B04-C03;  B04-E07;  B04-E07C;  B04-E07E;  B04-E08;  B04-E13;  B04-F01;  B04-F10;  B04-F11;  B04-L05A2;  B04-N02;  B05-A01A;  B05-A01B;  B05-B01P;  B05-C01;  B05-C04;  B05-C05;  B05-C07;  B07-A02;  B10-A07B;  B10-B02J;  B10-C04E6;  B10-E02;  B12-M01B;  B12-M11G;  B14-J05;  B14-K01;  B14-S18;  A10-E09;  A12-V;  A12-V01;  A12-W05;  A12-W14,A61K-009/16;  A61K-009/19;  A61K-009/51;  A61K-045/06;  A61K-047/46;  A61K-009/00;  A61K-031/713;  A61K-039/00;  A61K-047/61;  A61P-011/00;  A61P-031/04;  A61K-047/18;  A61K-047/26;  A61K-031/7088;  A61K-035/76;  A61K-035/761;  A61K-039/39;  A61K-047/02;  A61K-047/10;  A61K-047/12;  A61K-047/24;  A61K-047/28;  A61K-047/32;  A61K-047/34;  A61K-047/36;  A61K-047/38;  A61K-047/42;  A61K-047/51;  A61K-048/00;  A61K-009/72;  A61P-011/06,WO2021216541-A1   28 Oct 2021   A61K-009/51   202194Pages: 158   English;  US2022023204-A1   27 Jan 2022   A61K-009/00   202211   English;  AU2021260578-A1   03 Nov 2022   A61K-009/51   202290   English;  CA3175301-A1   28 Oct 2021   A61K-009/16   202204   English;  KR2023005244-A   09 Jan 2023   A61K-009/16   202305   ;  IL297450-A   01 Dec 2022   A61K-009/00   202318   English;  EP4138791-A1   01 Mar 2023   A61K-009/51   202319   English;  CN115996707-A   21 Apr 2023   A61K-009/16   202339   Chinese;  JP2023522103-W   26 May 2023   A61K-031/713   202344   Japanese;  IN202217061580-A   15 Sep 2023   A61K-009/51   202378   English,WO2021216541-A1    WOUS028140    20 Apr 2021;   US2022023204-A1    US235771    20 Apr 2021;   AU2021260578-A1    AU260578    20 Apr 2021;   CA3175301-A1    CA3175301    20 Apr 2021;   KR2023005244-A    KR740575    20 Apr 2021;   IL297450-A    IL297450    20 Apr 2021;   EP4138791-A1    EP724891    20 Apr 2021;   CN115996707-A    CN80047291    20 Apr 2021;   JP2023522103-W    JP563375    20 Apr 2021;   IN202217061580-A    IN17061580    28 Oct 2022,US2022023204-A1 Provisional Application US012792P;   AU2021260578-A1 PCT application Application WOUS028140;   AU2021260578-A1 Based on Patent WO2021216541;   CA3175301-A1 PCT application Application WOUS028140;   CA3175301-A1 Based on Patent WO2021216541;   KR2023005244-A PCT application Application WOUS028140;   KR2023005244-A Based on Patent WO2021216541;   IL297450-A Based on Patent WO2021216541;   EP4138791-A1 PCT application Application WOUS028140;   EP4138791-A1 Based on Patent WO2021216541;   CN115996707-A PCT application Application WOUS028140;   CN115996707-A Based on Patent WO2021216541;   JP2023522103-W PCT application Application WOUS028140;   JP2023522103-W Based on Patent WO2021216541;   IN202217061580-A PCT application Application WOUS028140;   IN202217061580-A Based on Patent WO2021216541,US012792P    20 Apr 2020;  US235771    20 Apr 2021;  CA3175301    12 Oct 2022;  KR740575    18 Nov 2022;  CN80047291    19 Dec 2022,WO2021216541-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA            EP4138791-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN        ,,;  US2022023204-A1 -- US20180333457-A1   ,,90158-0-0-0 K M; 99094-0-0-0 K M; 105730-0-0-0 K M; 105731-0-0-0 K M; 93605-0-0-0 K M; 184610-0-0-0 K M; 200757-0-0-0 K M;  K M; 114599-0-0-0 E K M; 1062-0-0-0 E K M; 107307-0-0-0 E K M; 92818-0-0-0 E K M; 104492-0-0-0 E K M; 104374-0-0-0 E K M; 97486-1-0-0 E K M; 900-0-0-0 E K M; 99222-0-0-0 K M; 40293-1-0-0 K M; 93407-0-0-0 K M; 93537-0-0-0 K M; 135548-1-0-0 K M; 2380690-1-0-0 K M; 60-0-0-0 K M; 114-0-0-0 K M; 109649-0-0-0 K M; 2362-0-0-0 E K M; 2853-1-0-0 E K M; 129498-0-0-0 E K M; 109254-1-0-0 E K M; 949-1-0-0 E K M; 107456-1-0-0 E K M; 2006-0-0-0 E K M; 87072-0-0-0 E K M; 8349-1-0-0 K M; 7560-0-0-0 ; 7447-0-0-0 ; 107779-0-0-0 ; 133925-0-0-0 ; 444-0-0-0 ; 238-0-0-0 ; 2380690-1-0-0 CL USE; 114599-0-0-0 CL DIS USE; 107307-0-0-0 CL DIS USE; 92818-0-0-0 CL DIS USE; 104492-0-0-0 CL DIS USE; 104374-0-0-0 CL DIS USE; 97486-1-0-0 CL DIS USE; 129498-0-0-0 CL DIS USE; 109254-1-0-0 CL DIS USE; 107456-1-0-0 CL DIS USE; 87072-0-0-0 CL DIS USE,,,R24040 K M; RA0I5T K M; RA012P K M; RA26IR K M; RA00NS K M; RA013I K M; RA00GT K M; RBUTR3 K M; RA02AR E K M; RA00D5 E K M; R06725 E K M; R01857 E K M; RA01EA E K M; RA0B83 E K M; R06563 E K M; RA083K E K M; R02044 E K M; RA0GM6 E K M; R01833 K M; RA00JW K M; R06521 K M; RA0KCF K M; RA1F77 K M; R06737 K M; R06520 K M; RA0DG3 K M; RACQ5A K M; RB9HZM K M; R01081 K M; R01706 K M; RA08LL K M; R05417 E K M; R00135 E K M; R01221 E K M; R06064 E K M; R00290 E K M; R07423 E K M; R00032 E K M; R00104 E K M; R04091 E K M; R03497 E K M; R04071 E K M; RA0INT E K M; R00148 K M; R00448 ; R00009 ; R01863 ; R07226 ; R00351 ; R00370 ,1866-S; 1857-S; 2044-S; 1833-S; 1081-S; 1706-S; 0135-S; 1221-S; 0290-S; 0032-S; 0104-S; 0148-S
CA3137825-A1,New recombinant glycoprotein comprising            coronavirus polypeptide antigen having a glycosylation            pattern used in immunogenic composition (e.g. vaccine)            to treat coronavirus,SLATTERY S S;  GIGUERE D J;  FLATLEY M;  GLOOR G B;  EDGELL D R,SUNCOR ENERGY INC (SNCR-C),202325013F,"   NOVELTY - Recombinant glycoprotein comprising                coronavirus polypeptide antigen having a                glycosylation pattern produced by, or                characteristic of, post-translational modification                by Phaeodactylum tricomutum, is new.    USE - The recombinant glycoprotein is used in                immunogenic composition (e.g. vaccine) for                triggering the production of antibodies against a                coronavirus polypeptide antigen, detecting                antibodies specific to a coronavirus polypeptide                antigen in a biological sample, and in expression                cassette or expression vector (e.g. plasmid),                regulating the production of a recombinant protein,                increasing secretion and/or expression of a                recombinant protein being expressed in an algae                microorganism, and targeting a recombinant                glycoprotein expressed in Phaeodactylum tricornutum                for degradation and/or for intracellularretention,                where the algae microorganism is Phaeodactylum                tricornutum or host cells (e.g. diatom host cells                or cells of the same clade of Phaeodactylum                tricornutum) (all claimed), and treating                coronavirus. No biological data given.    ADVANTAGE - The recombinant glycoprotein has antiviral                effect against coronavirus.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (i)                immunogenic composition (e.g. vaccine), comprising                the recombinant protein, and adjuvant; (ii)                Phaeodactylum tricornutumhost cell that produces                (and preferably secretes) the recombinant                glycoprotein, where the host cell comprises an                exogenous expression cassette encoding the                recombinant glycoprotein operably linked to a                promoter (e.g. an HASP1 promoter); (iii) diagnostic                device comprising recombinant protein for detecting                the presence and/or concentration of antibodies                that bind to recombinant protein; (iv)                antigen-antibody complex comprising the recombinant                protein and an anti-coronavirus antibody that                cross-reacts therewith, where the antibody is from                a biological sample from a subject; (v) triggering                the production of antibodies against a coronavirus                polypeptide antigen, comprising administering the                immunogenic composition to a subject; (vi)                detecting antibodies specific to a coronavirus                polypeptide antigen in a biological sample,                comprising (a) contacting the biological sample                with the recombinant glycoprotein, and (b)                detecting a complex formed between antibodies                specific to the coronavirus polypeptide antigen and                the recombinant glycoprotein; (vii) polynucleotide                encoding the recombinant protein; (viii) expression                cassette or expression vector (e.g. plasmid),                comprising the polynucleotide, operably linked to a                promoter, where the promoter is heterologous with                respect to the polynucleotide; (ix) P.                tricornutumchromosome comprising the                polynucleotide, or the expression cassette; (x)                Phaeodactylum tricornutumhost cell that produces                the recombinant glycoprotein, where the host cell                comprises the expression cassette, or P.                tricornutumchromosome; (xi) producing a recombinant                protein, comprising: (a1) providing Phaeodactylum                tricornutumor other suitable host cells (e.g.                diatom host cells or cells of the same clade of                Phaeodactylum tricornutumcomprising a                polynucleotide encoding the recombinant protein in                an expression cassette under control of an HASP1                (highly abundant secreted protein 1) promoter, and                (b1) culturing the host cells in a production                medium for a sufficient period of time to induce                expression of the recombinant protein, the                production medium being maintained an inorganic                phosphate concentration sufficiently low in which                the recombinant protein is expressed at a level                higher than when the host cells are cultured under                corresponding conditions in a phosphate-replete                medium; (x) regulating the production of a                recombinant protein, comprising providing culture                of suitable host cells (e.g. Phaeodactylum                tricornutumor other suitable microorganisms e.g.                diatoms) comprising a polynucleotide encoding the                recombinant protein in an expression cassette under                control of an HASP1 (highly abundant secreted                protein 1) promoter, and controlling the inorganic                phosphate levels in the culture to regulate the                expression of the recombinant protein, where the                inorganic phosphate levels are maintained above a                repression threshold level for a sufficient period                of time when expression of the recombinant protein                is to be repressed, and the inorganic phosphate                levels are maintained below an induction threshold                level for a sufficient period of time when                expression of the recombinant protein is to be                induced; (xi) increasing secretion and/or                expression of a recombinant protein being expressed                in an algae microorganism, comprising providing a                host cell algae microorganism comprising an                expression cassette or vector comprising a                polynucleotide encoding the recombinant protein,                where the polynucleotide does not encode a Tobacco                Etch Virus(TEV) protease cleavage site, and                culturing the host cells in a production medium for                a sufficient period of time to induce expression                and/or secretion of the recombinant protein; (x)                expression cassette or vector (e.g. plasmid) for                increasing the expression and/or secretion of a                recombinant protein in a host cell algae                microorganism, comprising a polynucleotide encoding                the recombinant protein and which does not encode a                Tobacco Etch Virus (TEV) protease cleavage site;                and (xi) targeting a recombinant glycoprotein                expressed in Phaeodactylum tricornutumfor                degradation and/or for intracellularretention,                comprising engineering a TEV protease cleavage site                into the recombinant glycoprotein, and culturing                the Phaeodactylum tricornutumin which the                recombinant glycoprotein is cleaved by an                endogenous protease of the Phaeodactylum                tricornutum. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-B04C1;  B04-C01;  B04-E08;  B04-E99;  B04-F0100E;  B04-G01;  B04-L04C;  B04-N03K;  B04-N0400E;  B04-N0600E;  B07-D09;  B12-K04F;  B12-K04G1B;  B14-S11A;  B14-S11D3;  B14-S11F;  D05-A02B;  D05-H07;  D05-H11;  D05-H12E;  D05-H14A;  D05-H99,C07K-014/165;  C07K-016/10;  C12N-001/13;  C12N-015/50;  C12N-015/79;  C12P-021/02;  C12P-021/06,CA3137825-A1   28 Feb 2023   C12N-015/50   202327Pages: 17   English,CA3137825-A1    CA3137825    05 Nov 2021,,CA3129298    30 Aug 2021,,,,,216954-0-0-0 K M; 129481-5-0-0 K M,,,RA0CHO K M; R01636 K M,1636-S
WO2021205032-A1;  AU2021252156-A1;  CA3168954-A1;  BR112022017215-A2;  KR2023008741-A;  CN115698289-A;  EP4133075-A1;  IL297060-A;  JP2023521785-W;  US2023287413-A1;  IN202217057697-A;  MX2022012544-A1,"Use of composition comprising inhibitor of micro            RNA (miR)-21, and moiety for delivering inhibitor of            miR-21 to macrophage, for treating pulmonary fibrosis            in subject, and preventing macrophage pro-inflammatory            polarization, inflammation, myofibroblast            transformation or fibrosis",ENGELHARDT S;  RAMANUJAM D P;  ENGELHARD S,UNIV MUENCHEN TECH (MUEN-C);  UNIV TECH MUENCHEN (MUEN-C);  UNIV TECH MUNCHEN (MUEN-C);  UNIV TECH MUENCHEN (MUEN-C);  UNIV TECH MUNCHEN (MUEN-C);  UNIV TECH MUENCHEN (MUEN-C);  UNIV TECH MUENCHEN (MUEN-C),2021B66307,"   NOVELTY - Use of a composition is claimed for treating                pulmonary fibrosis. The composition comprises an                inhibitor of micro RNA (miR)-21, and a moiety for                delivering inhibitor of miR-21 to a                macrophage.    USE - The composition is useful in preparation of                medicine for (i) treating pulmonary fibrosis in                subject, and (ii) preventing macrophage                pro-inflammatory polarization, inflammation,                myofibroblast transformation, and/or fibrosis. The                pulmonary fibrosis is caused or associated by                pulmonary support or mechanical ventilation,                preferably ARDS (all claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:    (1) a composition comprising an inhibitor of                miR-21 and the moiety;    (2) a method (M1) for producing the                composition; and    (3) a method (M2) for treating pulmonary                fibrosis involves administering the composition, to                a subject. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E99;  B04-B03C;  B04-C01;  B04-E01;  B04-E06;  B04-E07D;  B04-G01;  B04-G23;  B05-B02C;  B07-A02B;  B10-A07A;  B10-A07D;  B14-C03;  B14-K01;  B14-L06;  B14-S03B;  B14-S18;  D05-H99;  D05-H11,A61K-047/54;  A61K-009/00;  A61P-011/00;  A61P-031/14;  C12N-015/113;  A61K-031/7088;  A61P-043/00;  A61P-017/02;  A61K-031/7105;  A61K-031/712;  A61K-031/7125;  A61K-045/08;  A61K-047/66;  A61K-047/68;  A61K-009/127;  A61K-009/14;  A61P-029/00;  A61P-009/00;  A61P-009/10,WO2021205032-A1   14 Oct 2021   C12N-015/113   202190   English;  AU2021252156-A1   03 Nov 2022   C12N-015/113   202289   English;  CA3168954-A1   14 Oct 2021   A61K-009/00   202290   English;  BR112022017215-A2   18 Oct 2022   C12N-015/113   202294   ;  KR2023008741-A   16 Jan 2023   A61K-047/54   202312   ;  CN115698289-A   03 Feb 2023   C12N-015/113   202314   Chinese;  EP4133075-A1   15 Feb 2023   C12N-015/113   202315   English;  IL297060-A   01 Dec 2022   A61P-011/00   202318   English;  JP2023521785-W   25 May 2023   A61K-045/08   202343   Japanese;  US2023287413-A1   14 Sep 2023   C12N-015/113   202375   English;  IN202217057697-A   01 Sep 2023   C12N-015/113   202375   English;  MX2022012544-A1   07 Nov 2022   C12N-015/113   202304   Spanish,WO2021205032-A1    WOEP059360    09 Apr 2021;   AU2021252156-A1    AU252156    09 Apr 2021;   CA3168954-A1    CA3168954    09 Apr 2021;   BR112022017215-A2    BR11017215    09 Apr 2021;   KR2023008741-A    KR739237    09 Apr 2021;   CN115698289-A    CN80027447    09 Apr 2021;   EP4133075-A1    EP716768    09 Apr 2021;   IL297060-A    IL297060    09 Apr 2021;   JP2023521785-W    JP561618    09 Apr 2021;   US2023287413-A1    US17995722    07 Oct 2022;   IN202217057697-A    IN17057697    07 Oct 2022;   MX2022012544-A1    MX012544    06 Oct 2022,AU2021252156-A1 PCT application Application WOEP059360;   AU2021252156-A1 Based on Patent WO2021205032;   CA3168954-A1 PCT application Application WOEP059360;   CA3168954-A1 Based on Patent WO2021205032;   BR112022017215-A2 PCT application Application WOEP059360;   KR2023008741-A PCT application Application WOEP059360;   KR2023008741-A Based on Patent WO2021205032;   CN115698289-A PCT application Application WOEP059360;   CN115698289-A Based on Patent WO2021205032;   EP4133075-A1 PCT application Application WOEP059360;   EP4133075-A1 Based on Patent WO2021205032;   IL297060-A Based on Patent WO2021205032;   JP2023521785-W PCT application Application WOEP059360;   JP2023521785-W Based on Patent WO2021205032;   US2023287413-A1 PCT application Application WOEP059360;   IN202217057697-A PCT application Application WOEP059360;   IN202217057697-A Based on Patent WO2021205032;   MX2022012544-A1 PCT application Application WOEP059360;   MX2022012544-A1 Based on Patent WO2021205032,EP169160    09 Apr 2020;  CA3168954    22 Aug 2022;  CN80027447    08 Oct 2022;  KR739237    09 Nov 2022,WO2021205032-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW            EP4133075-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN            ,,"WO2021205032-A1 -- AU2014256406-A1   UNIV WUERZBURG JULIUS MAXIMILIANS (UWUE)   THUM T,  BAUERSACHS J,  ENGELHARDT S,  GROSS C;  US20130289093-A1   ;  US20180216170-A1   ;  WO2015061536-A1   REGULUS THERAPEUTICS INC (REGU-Non-standard)   BHAT B;  WO2015154002-A1   OHIO STATE INNOVATION FOUND (OHIS)   LEE R J;  EP2260101-B1   UNIV WUERZBURG MAXIMILIAN JULIUS (UWUE)   THUM T,  BAUERSACHS J,  ENGELHARDT S,  GROSS C;  US4946778-A   GENEX CORP (GEMX)   LADNER R C,  BIRD R E,  HARDMAN K;  US5571894-A   CIBA GEIGY AG (CIBA)   WELS W S,  HYNES N E,  HARWERTH I,  GRONER B,  HARDMAN N,  ZWICKL M;  US5587458-A   ARONEX PHARM INC (ARON-Non-standard)   BIRD R E,  KING C R,  KASPRZYK P G;  US5641870-A   GENENTECH INC (GETH)   RINDERKNECHT E H,  ZAPATA G A;  US20020004586-A1   ;  WO2001077342-A1   ;  WO2009106367-A1   UNIV WUERZBURG MAXIMILIAN JULIUS (UWUE)   THUM T,  BAUERSACHS J,  ENGELHARDT S,  GROSS C;  WO1993016185-A2   ","WO2021205032-A1  ANONYMOUS: ""MRC1          mannose receptor C-type 1 [Homo sapiens (human)] - Gene -          NCBI"", 22 June 2021 (2021-06-22), XP055817974, Retrieved          from the Internet          &lt;URL:https://www.ncbi.nlm.nih.gov/gene/4360#gene-expression&gt;          [retrieved on          20210625],relevantClaims[1-41],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            LIU, J EXP MED., vol. 207, 2010, pages 1589 -          97;            THUM, NATURE, vol. 456, 2008, pages 980 - 984;            ZHANG, CANCER RES, vol. 75, no. 9, 2015, pages 1 -          9;            ARDITE, J CELL BIOL, vol. 196, no. 1, 2012, pages 163 -          175;            KHVOROVA, NATURE BIOTECH, vol. 35, 2017, pages 238 -          248;            JULIANO RL: ""The delivery of therapeutic          oligonucleotides"", NUCLEIC ACIDS RES., vol. 44, no. 14,          19 August 2016 (2016-08-19), pages 6518 - 48,          XP055491290, DOI: 10.1093/nar/gkw236;            XUE Y ET AL., CHEM SOC REV, 2021;            BENIZRI, BIOCONJUGATE CHEM, vol. 30, 2019, pages 366 -          383;            JONATHAN, CHEM SOC REV, vol. 48, 2019, pages          4361;            COIN ET AL.: ""Solid-phase peptide synthesis: from          standard procedures to the synthesis of difficult          sequences"", NATURE PROTOCOLS, vol. 2, 2007, pages 3247 -          3256, XP001538986, DOI: 10.1038/nprot.2007.454;            RIECHMANN, NATURE, vol. 332, no. 6162, 1988, pages 323 -          327;            HARLOWLANE: ""Using antibodies: a laboratory manual."",          1999, COLD SPRING HARBOR LABORATORY PRESS;            ALTSHULER, BIOCHEMISTRY (MOSCOW, vol. 75, no. 13, 2010,          pages 1584 - 1605;            HOLLINGER, NATURE BIOTECHNOLOGY, vol. 23, 2005, pages          1126 - 1136;            KHVOROVAWATTS, NATURE BIOTECHNOLOGY, vol. 35, 2017, pages          238 - 248;            RUPAIMOOLESLACK, NATURE REVIEWS IN DRUG DISCOVERY,          2017;            SAMBROOK, RUSSELL: ""Molecular Cloning: A Laboratory          Manual"", 2001, COLD SPRING HARBOR LABORATORY          PRESS;            STEPHENS, BIOSTATISTICS, vol. 18, no. 2, 2017, pages 275          - 294;            BAHIT, JACC: HEART FAILURE, vol. 6, no. 3, 2018, pages          179 - 186;            BARTEL, CELL, vol. 173, no. 1, 2018, pages 20 -          51;            BASHORE, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,          vol. 59, no. 24, 2012, pages 2221 - 2305;            BOSSON, MOL CELL, vol. 56, no. 3, 2016, pages 347 -          359;            BRENNAN, SCIENCE, vol. 229, no. 4708, 1985, pages 81 -          83;            BROWN, NATURE BIOTECHNOLOGY, vol. 25, no. 12, 2007, pages          1457 - 1467;            CARDIN, CIRCULATION: ARRHYTHMIA AND ELECTROPHYSIOLOGY,          vol. 5, no. 5, 2012, pages 1027 - 1035;            CARTER, BIO/TECHNOLOGY, vol. 10, no. 2, 1992, pages 163 -          167;            COLE, JOURNAL OF IMMUNOLOGICAL METHODS, vol. 78, no. 2,          1985, pages 271 - 278;            HINKEL, CIRCULATION, vol. 128, no. 10, 2012, pages 1066 -          1075;            JONES, NATURE, vol. 321, no. 6069, 1986, pages 522 -          525;            JULIANO, NUCLEIC ACIDS RESEARCH, vol. 44, no. 14,          2016;            KOeHLER, NATURE, vol. 256, no. 5517, 1975, pages 495 -          497;            KOZBOR, IMMUNOL TODAY, vol. 4, no. 3, 1983, pages 72 -          79;            LI, NATURE REVIEWS DRUG DISCOVERY, vol. 13, no. 8, 2014,          pages 622 - 638;            LU, NATURE REVIEWS CARDIOLOGY, vol. 16, 2019, pages 661 -          674;            MARTINEZ-POMARES, J. LEUKOC. BIOL., vol. 92, 2012, pages          1177 - 1186;            MENDELL, CELL, vol. 148, no. 6, 2012, pages 1172 -          1187;            MILSTEIN, NATURE, vol. 305, no. 5934, 1983, pages 537 -          540;            MORIMOTO, J BIOL CHEM, vol. 267, no. 31, 1992, pages          21987 - 21990;            PATRICK, JOURNAL OF CLINICAL INVESTIGATION, vol. 120, no.          11, 2010, pages 3912 - 3916;            PELLICORI, HEART FAILURE REVIEW, vol. 25, 2019, pages 147          - 159;            POTERE, FRONT CARDIOVASC MED, vol. 6, 26 April 2019          (2019-04-26), pages 51;            PRESTA, CURRENT OPINION IN BIOTECHNOLOGY, vol. 3, no. 4,          1992, pages 394 - 398;            RAMANUJAM, MOLECULAR THERAPY, vol. 24, no. 11, 2016,          pages 1939 - 1948;            RAMILOWSKI, NAT. COMMUN, vol. 6, no. 1, 2015, pages          7866;            RUPAIMOOLE, NATURE REVIEWS DRUG DISCOVERY, vol. 16, 2017,          pages 203 - 222;            SAYED, JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 26,          2010, pages 20281 - 20290;            SGALLA, RESPIRATORY RESEARCH, vol. 19, no. 1, 2018, pages          1 - 18;            SHALABY, THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 175,          no. 1, 1992, pages 217 - 225;            SKELLY, CELL REPORTS, vol. 22, no. 3, 2018, pages 600 -          610;            SOOD, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF          THE UNITED STATES OF AMERICA, vol. 103, no. 8, 2006,          pages 2746 - 2751;            TUTT, JOURNAL OF IMMUNOLOGY, vol. 147, no. 1, 1991, pages          60 - 69;            WESSELS, NATURE COMMUNICATIONS, vol. 10, no. 1, 2019,          pages 1626;            XU, JOURNAL OF INFECTION, vol. 80, 2020, pages 394 -          400;            YANG, ACS NANO, vol. 13, 2019, pages 1029 -          1041;            YONA, IMMUNITY, vol. 38, no. 1, 2013, pages 79 -          91",107016-0-0-0 K M; 129625-0-0-0 K M; 86377-1-0-0 K M; 1359072-1-0-0 K M; 93605-0-0-0 K M; 105730-0-0-0 K M; 184587-0-0-0 K M; 1359072-1-0-0 CL USE,226191501 K M,,R01694 K M; R01616 K M; R19528 K M; RANUGV K M; RA00NS K M; RA012P K M; RA00C8 K M,1694-S; 1616-S
WO2021229574-A1,"Disinfecting upper respiratory airways, comprises            administering composition for inhalation comprising            ethanol and excipient comprising thickening agent via            inhalation",HAZANI M,COROLABS LTD (CORO-Non-standard),2021D0658N,"   NOVELTY - Disinfecting the upper respiratory airways,                comprises administering a composition for                inhalation comprising ethanol and an excipient via                inhalation to a subject, where the excipient                comprises a thickening agent, and the composition                has a viscosity of at least 2 mPa.second and vapor                pressure of not greater than 3 kPa at a temperature                of 25 degrees C and a pressure of 1                atmosphere.    USE - The method is useful for disinfecting upper                respiratory airways for preventing severe lower                respiratory tract infections. No biological data                given.    ADVANTAGE - The method is safe and effective method.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) a composition for inhalation provided in a                dosage form for aerosolization using an aerosol                generating device, and in disinfecting the upper                respiratory airways of a subject, comprising                ethanol and excipient comprising a thickening                agent, where the composition for inhalation has a                viscosity of at least 2 mPa.second and vapor                pressure of not greater than 3 kPa at a temperature                of 25 degrees C and a pressure of 1 atmosphere;                and    (2) an electronic aerosol generating device                cartridge comprising a liquid container, where the                liquid container contains the composition for                inhalation.    DESCRIPTION OF DRAWING(S) - The figure shows a schematic view of an                electronic cigarette comprising a cartridge and an                actuator.    Electronic cigarette (100)    Cartridge housing (102)    Cartridge (106)    Cartridge internal compartment (108)    Actuator (114) ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  A96 (Medical, dental, veterinary, cosmetic.);  P34 (Sterilising, syringes, electrotherapy (A61L, M, N).);  P42 (Spraying, atomising (B05).);  S05 (Electrical Medical Equipment);  V06 (Electromechanical Transducers and Small Machines)",B04-C03C;  B05-A01B;  B10-C04E6;  B10-E04C;  B10-E04D;  B11-C04;  B14-A02;  B14-A04;  B14-K01;  A05-H03;  A05-H04;  A09-D03;  A12-V01;  A12-V03C1;  A12-V03D;  P34-A02;  P42-A;  P42-T05C;  P42-U13;  S05-M04;  V06-V01B;  V06-V01N;  V06-V04C;  V06-V04K,A61K-031/045;  A61K-047/10;  A61K-009/00;  A61P-031/02;  A61P-031/04;  A61P-031/12;  A61M-015/00;  B05B-017/06,WO2021229574-A1   18 Nov 2021   A61K-031/045   202101Pages: 88   English,WO2021229574-A1    WOIL050544    12 May 2021,,US023920P    13 May 2020,WO2021229574-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2021229574-A1 -- US20200060349-A1   ;  US20200268656-A1   ;  US9913820-B2   UNIV TEXAS SYSTEM (TEXA)   RAAD I,  ROSENBLATT J","WO2021229574-A1  TSUMORU SHINTAKE:          ""Possibility of Disinfection of SARS-CoV-2 (COVID-19) in          Human Respiratory Tract by Controlled Ethanol Vapor          Inhalation"", ARXIV.ORG, CORNELL UNIVERSITY LIBRARY, 201          OLIN LIBRARY CORNELL UNIVERSITY ITHACA, NY 14853, 15          March 2020 (2020-03-15), 201 Olin Library Cornell          University Ithaca, NY 14853 ,          XP081630898,relevantClaims[1-42],relevantPassages[Whole          document]",33-0-0-0 K M; 490-0-0-0 K M; 861-0-0-0 K M; 89821-0-0-0 K M; 114599-0-0-0 K M; 444-0-0-0 ; 238-0-0-0 ,,,R00271 K M; R00113 K M; R00137 K M; R00233 K M; RA02AR K M; R00351 ; R00370 ,0271-S; 0113-S; 0137-S; 0233-S
WO2021243122-A2;  WO2021243122-A8;  WO2021243122-A3;  AU2021279079-A1;  KR2023018394-A;  CA3180554-A1;  IL298131-A;  BR112022023591-A2;  EP4157345-A2;  JP2023527556-W;  US2023242594-A1;  IN202217066819-A;  CN116802193-A;  VN96129-A;  HK40089187-A0;  MX2022015040-A1,New engineered protein comprising an engineered            coronavirus S protein ectodomain that comprises            specified sequence used to prevent coronavirus            infection or a disease associate with coronavirus            infection,MCLELLAN J;  MAYNARD J;  CHASSE A;  FINKELSTEIN I;  JAVANMARDI M;  SCHAUB J;  KUO H;  CHOU C;  GOLDSMITH J;  HJORTH C;  HSIEH C;  BYRNE P;  JOHNSON N;  WANG N;  WRAPP D;  JASON M;  JENNIFER M;  ANDREA C;  ILLYA F;  MOHAMMAD J;  JEFFREY S;  KUOHENG-CHE;  CHOUCHIA-WAY;  COOKING G;  CHRISTIE Y;  CHING-LIN S;  BAYNPATRICK;  NICOLE J;  SHUANG W N;  DANIEL R;  BYRNE N;  BURN P;  XIE Q;  ZHOU J,UNIV TEXAS SYSTEM (TEXA-C);  DARTMOUTH COLLEGE (DARC-C);  UNIV TEXAS SYSTEM (TEXA-C);  DARTMOUTH COLLEGE (DARC-C);  UNIV TEXAS SYSTEM (TEXA-C);  DARTMOUTH COLLEGE (DARC-C);  DARTMOUTH COLLEGE (DARC-C);  UNIV TEXAS SYSTEM (TEXA-C),2021D9401T,"   NOVELTY - Engineered protein comprising an engineered                coronavirus S protein ectodomain that comprises                having sequence at least 90% identical to: (a)                positions 14-1208 of SEQ ID NO: 1 or 2 (not                defined); (b) positions 14-1160 of SEQ ID NO: 1 or                2; or (c) positions 319-1208 of SEQ ID NO: 1 or 2,                is new. The engineered protein comprises                substitutions relative to the sequence of SEQ ID                NO: 1 or 2: Phe-817-Pro, Ala-892-Pro, Ala-899-Pro,                Ala-942-Pro, Lys-986-Pro, and Val-987-Pro.    USE - The engineered protein is useful for                preventing coronavirus infection or a disease                associate with coronavirus infection (claimed). No                biological data given.    ADVANTAGE - The engineered protein exhibit enhanced                conformational stability and/or antigenicity.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) engineered protein, comprising an                engineered coronavirus S protein ectodomain having                at least 90% identity to: (a) positions 14-1208 of                SEQ ID NO: 1 or 2, (b) positions 14-1160 of SEQ ID                NO: 1 or 2, or (c) positions 319-1208 of SEQ ID NO:                1 or 2, where the engineered protein comprising at                least one mutation relative to the sequence of SEQ                ID NO: 1 or 2, and at least one mutation comprising                (1) an engineered disulfide bond, (2) a cavity                filling substitution, and/or (3) a substitution                that provides an electrostatic or polar                interaction;    (2) engineered protein, comprising an                engineered coronavirus S protein ectodomain having                at least 90% identity to: (a) positions 14-1208 of                SEQ ID NO: 1 or 2, (b) positions 14-1160 of SEQ ID                NO: 1 or 2, or (c) positions 319-1208 of SEQ ID NO:                1 or 2, the engineered protein comprising at least                one mutation relative to the sequence of SEQ ID NO:                1 or 2, and at least one mutation comprising (i) a                substitution at a position corresponding to:                Thr-724, Thr-752, Thr-778, Thr-961, 11013,                His-1058, Ser-735, Thr-859, 1770, Ala-1015,                Leu-727, Ser-1021, Glu-901, Ser-875, Thr-912,                His-1088, Leu-Ile-141, Val-1040, Leu-966, Ala-766,                Thr-778, Leu-938, Val-963, Val-911, Asn-1108,                Val-705, Ala-893, Asn-703, Ala-672, Ala-694,                Ala-1080, 11132, Pro-862, Thr-859, Thr-547,                Asn-978, Thr-961, Ser-758, Glu-762, Asp-18,                Ser-659, Ser-698, Arg-1039, Val-722, Ala-930,                Ala-903, Glu-913, Ser-974, Asp-979, Pro-728,                Val-951, Val-736, Leu-858, Ser-884, Ala-893,                Pro-807, Ser-875, Thr-791, Ala-879, Gly-799,                Ala-924, Val-826, Ala-899, Glu-779, Phe-817,                Leu-865, Thr-866, Ala-892, Ala-899, Thr-912,                Ala-570, Val-963, Thr-874, Ser-1055, Val-729,                Ala-1022, Leu-894, Ala-713, Leu-828, His-1058,                Leu-822, Ala-1056, Glu-965, Ser-1003, Ala-972,                Glu-992, 1980, Ala-1078, Val-1133, His-1088,                Thr-1120, 1870, Ser-1055, Thr-1117, Asp-1139,                Thr-1116, Tyr-1138, 1896, Gly-885, Gln-901,                Phe-1103, Pro-1112, Gly-889, Leu-1034, Glu-819,                Ser-1055, Ala-972, 1980, 11081, Asn-1135, Glu-819,                Gln-1054, Glu-957, 11130, Val-1040, His-1088,                Arg-1000, Ala-944, Thr-724, Ala-944, Ser-730,                Ser-730, Gly-769, Ala-893, Glu-895, Lys-921,                Leu-922, Asn-978, Ala-942, Gly-946, Ser-975,                Ala-890, Ser-1003, and/or (ii) a deletion                corresponding to positions 829-851, 675-686,                673-684, 1161-1208, or 1142-1208, and/or (iii) a                substitution of two amino acids for amino acid                positions 673-686;    (3) engineered coronavirus trimer comprising                at least one subunit;    (4) composition, comprising carrier, an                engineered protein, or engineered trimer;    (5) nucleic acid molecule comprising a                nucleotide sequence that encodes an amino acid                sequence of an engineered protein;    (6) preventing coronavirus infection or a                disease associate with coronavirus infection in a                subject, comprising administering composition or                nucleic acid molecule to the subject; and    (7) composition, comprising an engineered                protein bound to an antibody. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E02H;  B04-E99;  B04-N03K0E;  B04-N08;  B14-A02B5;  B14-S22;  D05-H12C;  D05-H99,C07K-014/165;  A61K-039/12;  C07K-014/005;  A61K-039/215;  A61P-031/14;  A61K-039/385;  A61K-039/39;  A61K-047/62;  A61P-037/04;  C07K-014/01;  C07K-016/00;  C07K-019/00;  C12N-015/34;  C12N-015/50;  C12N-015/62;  C12N-015/63,WO2021243122-A2   02 Dec 2021   C07K-014/165   202104Pages: 99   English;  WO2021243122-A8   06 Jan 2022   C07K-014/165   202204   English;  WO2021243122-A3   10 Feb 2022   A61K-039/12   202213   English;  AU2021279079-A1   15 Dec 2022   A61K-039/12   202201   English;  KR2023018394-A   07 Feb 2023   C07K-014/005   202313   ;  CA3180554-A1   02 Dec 2021   C07K-014/165   202314   English;  IL298131-A   01 Jan 2023   C07K-014/005   202318   English;  BR112022023591-A2   27 Dec 2022   A61K-039/12   202318   ;  EP4157345-A2   05 Apr 2023   A61K-039/12   202330   English;  JP2023527556-W   29 Jun 2023   C12N-015/50   202356   Japanese;  US2023242594-A1   03 Aug 2023   C07K-014/005   202364   English;  IN202217066819-A   18 Aug 2023   A61K-039/12   202371   English;  CN116802193-A   22 Sep 2023   C07K-014/005   202385   Chinese;  VN96129-A   25 Jul 2023   C07K-014/165   202390   ;  HK40089187-A0   06 Oct 2023   A61K-039/12   202403   English;  MX2022015040-A1   27 Feb 2023   A61K-039/12   202424   Spanish,WO2021243122-A2    WOUS034713    28 May 2021;   WO2021243122-A8    WOUS034713    28 May 2021;   WO2021243122-A3    WOUS034713    28 May 2021;   AU2021279079-A1    AU279079    28 May 2021;   KR2023018394-A    KR742842    28 May 2021;   CA3180554-A1    CA3180554    28 May 2021;   IL298131-A    IL298131    28 May 2021;   BR112022023591-A2    BR11023591    28 May 2021;   EP4157345-A2    EP811955    28 May 2021;   JP2023527556-W    JP573585    28 May 2021;   US2023242594-A1    US18000112    28 Nov 2022;   IN202217066819-A    IN17066819    21 Nov 2022;   CN116802193-A    CN80049973    28 May 2021;   VN96129-A    VN008305    28 May 2021;   HK40089187-A0    HK6078087    25 Aug 2023;   MX2022015040-A1    MX015040    28 Nov 2022,AU2021279079-A1 PCT application Application WOUS034713;   AU2021279079-A1 Based on Patent WO2021243122;   KR2023018394-A PCT application Application WOUS034713;   KR2023018394-A Based on Patent WO2021243122;   CA3180554-A1 PCT application Application WOUS034713;   CA3180554-A1 Based on Patent WO2021243122;   IL298131-A Based on Patent WO2021243122;   BR112022023591-A2 PCT application Application WOUS034713;   BR112022023591-A2 Based on Patent WO2021243122;   EP4157345-A2 PCT application Application WOUS034713;   EP4157345-A2 Based on Patent WO2021243122;   JP2023527556-W PCT application Application WOUS034713;   JP2023527556-W Based on Patent WO2021243122;   US2023242594-A1 Provisional Application US032502P;   US2023242594-A1 PCT application Application WOUS034713;   IN202217066819-A PCT application Application WOUS034713;   IN202217066819-A Based on Patent WO2021243122;   CN116802193-A PCT application Application WOUS034713;   CN116802193-A Based on Patent WO2021243122;   VN96129-A PCT application Application WOUS034713;   VN96129-A Based on Patent WO2021243122;   HK40089187-A0 PCT application Application WOUS034713;   HK40089187-A0 Based on Patent WO2021243122;   HK40089187-A0 Previous Publ. Patent EP4157345;   MX2022015040-A1 PCT application Application WOUS034713;   MX2022015040-A1 Based on Patent WO2021243122,US032502P    29 May 2020;  EP811955    28 May 2021;  BR11023591    21 Nov 2022;  CA3180554    28 Nov 2022;  US18000112    28 Nov 2022;  KR742842    06 Dec 2022;  VN008305    19 Dec 2022;  CN80049973    28 Jan 2023,WO2021243122-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2021243122-A8:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2021243122-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA            EP4157345-A2:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN                ,,,"WO2021243122-A3  MACGOWAN STUART A;          BARTON GEOFFREY J: ""Missense variants in ACE2 are          predicted to encourage and inhibit interaction with          SARS-CoV-2 Spike and contribute to genetic risk in          COVID-19"", BIORXIV, 4 May 2020 (2020-05-04), pages 1 -          38, XP055864444, Retrieved from the Internet          &lt;URL:https://www.biorxiv.org/content/10.1101/2020.05.03.074781v1.abstract&gt;          [retrieved on 20210830],relevantClaims[1, 21-23 and          28-33],relevantPassages[, Especially pg 3 para 2, pg 5          para 1, pg 6 para 1];  DATABASE UniProtKB          [online] 22 April 2020 (2020-04-22), ""SPlKE_SARS2"",          retrieved from UniProt Database accession no.          PODTC2,relevantClaims[1, 21-23 and          28-33],relevantPassages[Entire document; sequence          residues 1-1208];  SCHMIDT I., SKINNER          M., SIDDELL S.: ""Nucleotide sequence of the gene encoding          the surface projection glycoprotein of coronavirus          MHV-JHM"", UNIPROTKB ACCESSION NO. P11225, 1987, pages 47          - 56, XP055906284, Retrieved from the Internet          &lt;URL:https://www.uniprot.org/uniprot/P11225&gt;          [retrieved on 20210913],relevantClaims[1, 21-23 and          28-33],relevantPassages[Entire document; sequence          residues 1-1235];  ZHANG X; KOUSOULAS          K G; STORZ J: ""Comparison of the nucleotide and deduced          amino acid sequences of the S genes specified by virulent          and avirulent strains of bovine coronaviruses"", UNIPROTKB          ACCESSION NO: P25192, 1 May 1992 (1992-05-01), pages 1 -          8, XP026368734, Retrieved from the Internet          &lt;URL:https://www.uniprot.org/uniprot/P25192&gt;          [retrieved on 20210913],relevantClaims[1, 21-23 and          28-33],relevantPassages[Entire document; sequence          residues 1-1324]",184616-0-0-0 M N Q; 184616-0-0-0 CL NEW RCT USE,,,RA00H3 M N Q,
WO2022183012-A1;  US2022362303-A1;  AU2022227009-A1;  BR112023017086-A2;  EP4297589-A1;  KR2024004268-A;  CN117750889-A,"Composition useful in dietary supplement for            treating, alleviating, or preventing inflammation of            the gastrointestinal tract, comprises pro-reparative            factor, nutritional protease inhibitor, and carrier or            excipient",PLAYFORD R J;  WEISER M J;  MARCHBANK T;  TEN BRUGGENCATE S J;  STAGNITTI G;  BRUGGENCATE S J M;  PLAYFORDRAYMONDJOHN;  JAMES W M;  MARCHBANKTANIA;  TENBRUGGENCATESANDRAJOHANAMARI;  GEORGE S,PANTHERYX INC (PANT-Non-standard);  PANTHERYX INC (PANT-Non-standard);  PANTHERYX INC (PANT-Non-standard);  PANTHERYX INC (PANT-Non-standard);  PANTHERYX INC (PANT-Non-standard),2022B2462C,"   NOVELTY - Composition (C1) comprises a pro-reparative                factor, a nutritional protease inhibitor, and                optionally carrier or excipient.    USE - The composition is useful in dietary                supplement for treating, alleviating, or preventing                inflammation of the gastrointestinal tract, where                the disease or disorder is inflammatory bowel                disease, non-steroidal antiinflammatory drug (Nthe)                gastrointestinal disorder, chemotherapy-induced                mucositis, radiation-induced mucositis,                pseudomembranous colitis, gastritis, peptic ulcers,                necrotizing entercolitis, irritable bowel syndrome,                leaky gut, small intestinal bacterial overgrowth                (SIBO), non-ulcer dyspepsia, or functional                dyspepsia, the inflammatory bowel disease is                ulcerative colitis, indeterminate colitis, and                Crohn's disease (all claimed), preferably foods and                beverages, and for supporting normal                gastrointestinal and immune function. No biological                data given.    ADVANTAGE - The combination: provides more beneficial oral                bioavailability profile; can be in a dry, powdered,                semi solid, solid, paste, or liquid form.    DETAILED DESCRIPTION - INDEPENDENT CLAIMs are also included                for:    composition (C2) comprising a pro-reparative                factor, a stabilizing agent, and optionally a                carrier or excipient;    dosage form comprising the compositions                (C1)-(C2);    method (M1) of treating, alleviating, or                preventing a disease or disorder associated with                inflammation of the gastrointestinal tract in a                subject, comprising administering a composition                comprising (a) a pro-reparative factor and an                immune factor, (b) a nutritional protease                inhibitor, and (c) optionally carrier or excipient                to the subject;    method (M2) of treating, alleviating, or                preventing a disease or disorder associated with                inflammation of the gastrointestinal tract in a                subject, comprising administering a composition                comprising (a1) pro-reparative factor and/or an                immune factor, (b1) a stabilizing agent and (c1)                optionally carrier or excipient to the                subject;    method (M3) of enhancing a vaccination                antibody titer in a subject, comprising (a2) orally                administering the composition (i) a pro-reparative                factor and an immune factor, (ii) a nutritional                protease inhibitor, (iii) optionally carrier or                excipient, and (iv) optionally a stabilizing agent,                and (b) administering a vaccine to the                subject;    dietary supplement comprising the compositions                (C1)-(C2); and    composition (C3) comprising a purified                lactoferrin, a stabilizing agent, and optionally                carrier or excipient. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  ;  A96 (Medical, dental, veterinary, cosmetic.)",B04-E99;  B04-B04K;  B04-B04N;  B04-C02A2;  B04-C02B2;  B04-C02D;  B04-C03B;  B04-G01;  B04-G27G0E;  B04-H0600E;  B04-N01;  B04-N02;  B04-N06;  B05-B01P;  B07-A02B;  B10-G02;  B12-M12N;  B12-M12Z;  B14-C03;  B14-D07C;  B14-E01;  B14-E08;  B14-E10;  B14-E11;  B14-S11;  D05-H99;  D03-B14;  D03-F06;  D03-H01G;  D03-H01T2B;  D05-A04D;  D05-H10;  D05-H17A2;  A12-V01;  A12-W09,A23L-033/115;  A23L-033/18;  A23L-033/185;  A23L-033/19;  A61K-038/18;  A61K-009/20;  A23L-033/00;  A23L-033/125;  A61K-035/12;  A61K-035/20;  A61K-036/48;  A61K-038/17;  A61K-038/57;  A61K-039/39;  A61K-047/14;  A61K-047/36;  A61P-001/00,WO2022183012-A1   01 Sep 2022   A23L-033/115   202276Pages: 128   English;  US2022362303-A1   17 Nov 2022   A61K-035/20   202293   English;  AU2022227009-A1   21 Sep 2023   A23L-033/115   202377   English;  BR112023017086-A2   19 Sep 2023   A23L-033/115   202388   ;  EP4297589-A1   03 Jan 2024   A23L-033/115   202402   English;  KR2024004268-A   11 Jan 2024   A23L-033/19   202407   ;  CN117750889-A   22 Mar 2024   A23L-033/115   202428   Chinese,WO2022183012-A1    WOUS017937    25 Feb 2022;   US2022362303-A1    US681166    25 Feb 2022;   AU2022227009-A1    AU227009    25 Feb 2022;   BR112023017086-A2    BR11017086    25 Feb 2022;   EP4297589-A1    EP760498    25 Feb 2022;   KR2024004268-A    KR733082    25 Feb 2022;   CN117750889-A    CN80031259    25 Feb 2022,US2022362303-A1 Provisional Application US154495P;   AU2022227009-A1 PCT application Application WOUS017937;   AU2022227009-A1 Based on Patent WO2022183012;   BR112023017086-A2 PCT application Application WOUS017937;   BR112023017086-A2 Based on Patent WO2022183012;   EP4297589-A1 PCT application Application WOUS017937;   EP4297589-A1 Based on Patent WO2022183012;   KR2024004268-A PCT application Application WOUS017937;   KR2024004268-A Based on Patent WO2022183012;   CN117750889-A PCT application Application WOUS017937;   CN117750889-A Based on Patent WO2022183012,US154495P    26 Feb 2021;  US681166    25 Feb 2022;  BR11017086    24 Aug 2023;  KR733082    25 Sep 2023;  CN80031259    26 Oct 2023,WO2022183012-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        EP4297589-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN      ,,"WO2022183012-A1 -- US20120283185-A1   ;  US20160206733-A1   ;  WO2019106147-A1   NESTEC SA (NEST)   AFFOLTER M,  AMEYE L,  GARCIA-RODENAS C L;  WO2020176637-A1   PANTHERYX INC (PANT-Non-standard);  GRABOWSKY M (GRAB-Individual);  PLAYFORD R J (PLAY-Individual);  STARZL T W (STAR-Individual);  MARCHBANK T (MARC-Individual);  KELLY P (KELL-Individual);  CHOUDHRY N (CHOU-Individual)   GRABOWSKY M,  PLAYFORD R J,  STARZL T W,  MARCHBANK T,  KELLY P,  CHOUDHRY N",,99094-0-0-0 K M; 290162-0-0-0 K M; 90158-0-0-0 K M; 86923-0-0-0 K M; 94618-0-0-0 K M; 107779-0-0-0 K M; 107411-0-0-0 K M; 104225-0-0-0 K M; 123286-0-0-0 K M; 811715-0-0-0 K M; 104395-0-0-0 K M; 109254-1-0-0 K M; 109506-0-0-0 K M; 99222-0-0-0 K M; 133925-0-0-0 ,227772202 K M; 227772201 K M,,RA0I5T K M; RA1VD9 K M; R24040 K M; RA04J1 K M; R01858 K M; RA02KY K M; R01863 K M; RA11A9 K M; RA063L K M; RA03RK K M; RACQNF K M; RA0JRQ K M; R06064 K M; R05220 K M; R01833 K M; RA00JW K M; R07226 ,1858-S; 1863-S; 1833-S
WO2023187743-A1,"New chimeric polypeptide comprising microbial            polypeptide operably connected downstream to a            heterologous, structure-stabilizing moiety used to            elicit immune response to microbial polypeptide, and            treat or prevent microbial infection",CHAPPELL K;  WATTERSON D;  TARDIOTA N;  SCHEMBRI M A,UNIV QUEENSLAND (UYQU-C);  CHAPPELL K (CHAP-Individual),2023A3930T,"   NOVELTY - Chimeric polypeptide comprising a microbial                polypeptide operably connected downstream to a                heterologous, structure-stabilizing moiety (SSM),                where the structure-stabilizing moiety is a                polypeptide comprising, in an N- to C-terminal                order, a first heptad repeat region (FHRR) and a                second heptad repeat region (SHRR), the FHRR                comprises amino acid sequence having at least 60%                sequence identity to the amino acid sequence of SEQ                ID NO: 80 or SEQ ID NO: 81, and the SHRR comprises                amino acid sequence having at least 40% sequence                identity to the amino acid sequence of SEQ ID NO:                82 or SEQ ID NO: 83; and/or the FHRR comprises an                amino acid sequence having at least 90% sequence                similarity to the amino acid sequence of SEQ ID NO:                80 or SEQ ID NO: 81, and the SHRR comprises or                consists of an amino acid sequence having at least                70% sequence similarity to the amino acid sequence                of SEQ ID NO: 82 or SEQ ID NO: 83, is new.    USE - The chimeric polypeptide, nucleic acid, host                cell, chimeric polypeptide complex, composition                (C1), an antigen-binding molecule, or a composition                (C2) is useful for eliciting an immune response to                a microbial polypeptide, or a complex of the                microbial polypeptide and treating or preventing a                microbial infection in a subject (all claimed).                Test details are described but no results                given.    ADVANTAGE - The chimeric polypeptide provides an enhanced                stimulation of the immune response and thus for                eliciting a more potent, persistent broadly                neutralizing antibody response.    DETAILED DESCRIPTION - Chimeric polypeptide comprising a microbial                polypeptide operably connected downstream to a                heterologous, structure-stabilizing moiety (SSM),                where the structure-stabilizing moiety is a                polypeptide comprising, in an N- to C-terminal                order, a first heptad repeat region (FHRR) and a                second heptad repeat region (SHRR), the FHRR                comprises amino acid sequence having at least 60%                sequence identity to the amino acid sequence of SEQ                ID NO: 80 (comprising a fully defined sequence of                37 amino acids as given in the specification) or                SEQ ID NO: 81 (comprising a fully defined sequence                of 37 amino acids as given in the specification),                and the SHRR comprises amino acid sequence having                at least 40% sequence identity to the amino acid                sequence of SEQ ID NO: 82 (comprising a fully                defined sequence of 39 amino acids as given in the                specification) or SEQ ID NO: 83 (comprising a fully                defined sequence of 39 amino acids as given in the                specification); and/or the FHRR comprises an amino                acid sequence having at least 90% sequence                similarity to the amino acid sequence of SEQ ID NO:                80 or SEQ ID NO: 81, and the SHRR comprises or                consists of an amino acid sequence having at least                70% sequence similarity to the amino acid sequence                of SEQ ID NO: 82 or SEQ ID NO: 83, is new.                INDEPENDENT CLAIMS are also included for:    chimeric polypeptide comprising a first                (poly)peptide operably connected downstream to a                structure-stabilizing moiety, where the                structure-stabilizing moiety, where the first                (poly)peptide is a therapeutic (poly)peptide;    nucleic acid comprising a polynucleotide                sequence encoding a chimeric polypeptide;    host cell comprising the nucleic acid;    producing a chimeric polypeptide complex,                comprising combining chimeric polypeptides under                conditions suitable for the formation of a chimeric                polypeptide complex, where a chimeric polypeptide                complex is produced that comprises three chimeric                polypeptide subunits and is characterized by a                six-helix bundle formed by homo- trimerization of                the structure-stabilizing moieties of the three                chimeric polypeptides;    chimeric polypeptide complex that comprises                three chimeric polypeptide subunits, where each                subunit is a chimeric polypeptide, and the complex                is characterized by a six-helix bundle formed by                homo-trimerization of the structure-stabilizing                moieties of the three chimeric polypeptides;    composition comprising a chimeric polypeptide,                or a chimeric polypeptide complex and carrier,                diluent or adjuvant;    identifying an agent that binds with: a                microbial polypeptide or a complex, comprising                contacting a candidate agent with a microbial                polypeptide-containing chimeric polypeptide or a                microbial polypeptide-containing chimeric                polypeptide complex, and detecting binding of the                candidate agent to the chimeric polypeptide or                chimeric polypeptide complex, where the candidate                agent is part of a compound library (e.g., small                molecule or macromolecule library);    producing an antigen-binding molecule that                specifically binds to: a microbial polypeptide, or                a complex, comprising immunizing a subject with a                microbial polypeptide-containing chimeric                polypeptide, or a microbial polypeptide-containing                chimeric polypeptide complex, or a composition,                identifying and/or isolating a B cell from the                immunised subject, which specifically binds to the                microbial polypeptide or complex and producing the                antigen-binding molecule expressed by that B                cell;    antigen-binding molecule that specifically                binds to: the microbial polypeptide of a microbial                polypeptide-containing chimeric polypeptide and/or                the microbial polypeptide of at least one subunits                of a microbial polypeptide-containing chimeric                polypeptide complex;    composition (C1), comprising an                antigen-binding molecule, carrier, diluent or                adjuvant;    composition (C2), comprising the nucleic                acid;    eliciting an immune response to: a microbial                polypeptide, or a complex in a subject, comprising                administering a microbial polypeptide-containing                chimeric polypeptide, a microbial                polypeptide-containing chimeric polypeptide                complex, or a composition (C1) or a composition                (C2) to the subject;    treating or preventing a microbial infection                in a subject, comprising administering a microbial                polypeptide-containing chimeric polypeptide, a                microbial polypeptide-containing chimeric                polypeptide complex, or a composition, antigen                binding molecule or a composition (C1) or                composition (C2) to the subject; and    vaccine, comprising microbial                polypeptide-containing chimeric polypeptide, a                microbial polypeptide-containing chimeric                polypeptide complex, a composition (C1) or                composition (C2). ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.)",B04-C01;  B04-C03C;  B04-E02F;  B04-E03F;  B04-E99;  B04-F0100E;  B04-N04;  B04-N08;  B11-C04;  B11-C07A;  B12-K04;  B14-A01;  B14-A02;  B14-A04;  B14-G01;  C04-C01;  C04-C03C;  C04-E02F;  C04-E03F;  C04-E99;  C04-F0100E;  C04-N04;  C04-N08;  C11-C04;  C11-C07A;  C12-K04;  C14-A01;  C14-A02;  C14-A04;  C14-G01;  D05-H09;  D05-H12A;  D05-H14;  D05-H99;  A12-V;  A12-V01,A61K-039/00;  A61K-039/02;  A61K-039/118;  A61K-039/12;  A61K-039/40;  A61K-039/42;  A61P-031/04;  A61P-031/12;  C07K-014/005;  C07K-014/135;  C07K-014/155;  C07K-014/165;  C07K-014/465;  C07K-016/08;  C07K-016/12;  C12N-007/00,WO2023187743-A1   05 Oct 2023   C07K-014/005   202388Pages: 239   English,WO2023187743-A1    WOIB053263    31 Mar 2023,,EP166085    31 Mar 2022,WO2023187743-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2023187743-A1 -- US9249197-B2   CHIRON SPA (CHIR)   ARICO M,  COMANDUCCI M;  US10716842-B2   NOVARTIS AG (NOVS)   GRANDI G,  GRIFANTINI R M,  FINCO O;  WO2014079842-A1   NOVARTIS AG (NOVS)   CARFI A,  SWANSON K;  WO2018176103-A1   UNIV QUEENSLAND (UYQU)   CHAPPELL K J,  WATTERSON D,  YOUNG P R;  WO2022043908-A1   UNIV QUEENSLAND (UYQU);  CHAPPELL K (CHAP-Individual)   CHAPPELL K,  YOUNG P,  WATTERSON D",,900-0-0-0 K M; 444-0-0-0 ,,,R02044 K M; RA0GM6 K M; R00351 ,2044-S
CN117126071-A;  WO2024032753-A1,New nitrogen-containing chain compound useful in            lipid carrier for lipid nanoparticles and for            delivering nucleic acid preventive and therapeutic            agents to mammalian cells and organs,WANG B;  CHEN L;  GUO J;  ZHANG B;  ZHANG F;  JIANG T;  YU H;  LU J;  LIN J,SHANGHAI RNACURE BIOPHARMA CO LTD (SHAN-Non-standard);  SHANGHAI RNACURE BIOPHARMA CO LTD (SHAN-Non-standard),2023C6931F,"   NOVELTY - Nitrogen-containing chain compound (I) and its                medicinally acceptable salts are new.    USE - (I) are useful in lipid carrier for lipid                nanoparticles (all claimed), and for delivering                nucleic acid preventive and therapeutic agents to                mammalian cells and organs.    ADVANTAGE - The lipid carrier is composed of (I): can                encapsulate nucleic acid medicines, and exert their                effects when used in delivering nucleic acid                preventive and therapeutic agents to mammalian                cells and organs.    DETAILED DESCRIPTION - Nitrogen-containing chain compound of formula                (I) and its medicinally acceptable salts are                new.    X = 1-6C alkylene or 3-6C cycloalkylene;    Y, Z = 1-10C alkylene (optionally substituted                with 1-3 hydroxy, halo or 1-6C alkyl);    A1and A2 = ((hydroxy)(oxo)methyl)-O-yl;    R1= 1-20C alkyl (optionally substituted with                1-3 R1-1), or 2-20C alkenyl (optionally substituted                with 1-3 R1-2);    R1-1= 3-15C cycloalkyl (optionally substituted                with 1-3 R1-1-4), hydroxy, 1-10C alkyl, or                carbonyl-containing moiety of formula (a), (b), or                (c);    R2= 1-20C alkyl (optionally substituted with                R2-1), or 2-20C alkenyl (optionally substituted                with 1-3 R2-2);    R2-1= 3-15C cycloalkyl (optionally substituted                with 1-3 R2-1-4), hydroxy, 1-10C alkyl, or                carbonyl-containing moiety of formula (d), (e) or                (f);    R1-1-1, R1-1-2, R1-1-3, R1-1-4, R2-1-1,                R2-1-2, R2-1-3, R2-1-4= 1-6C alkyl; and    R1-2, R2-2 = hydroxy or 1-10C alkyl.    Provided that: R1= e.g. 1-20C alkyl                (substituted with 1-3 hydroxy), cyclopentane                (optionally substituted with 1-3 R1-1-4),                cyclododecane (optionally substituted with 1-3                R1-1-4), cyclohexylmethyl, 2-cyclohexylethan-1-yl,                4-cyclohexylbutan-1-yl, 6-cyclohexylhexan-1-yl or                4,4-dimethylpentan-1-yl when X is 1-6C                alkylene.    INDEPENDENT CLAIMS are also included                for:    preparation of (I);    lipid carrier, comprising substance Z, which                is (I);    lipid nanoparticles, comprising therapeutic                and/or preventive agents and the lipid carrier;                and    composition, comprising substance Z, which is                (I).     ",,,"D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  C07 (Apparatus, formulation, general. including veterinary syringes, general formulations where the active compound is not central to the invention (e.g. wettable powders) and analysis.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  A96 (Medical, dental, veterinary, cosmetic.)",D05-H12D;  D05-H12A;  C12-M19B;  C14-S18;  C15-E00;  C12-M11Q1;  C10-B03B;  C10-B02J;  C09-B;  C05-B02A3;  C05-B01P;  C04-E01;  C04-C03C;  C04-B01B;  C01-D02;  B04-E07;  B12-M19B;  B14-S18;  B12-M11Q1;  B04-C03C;  B04-E01;  B15-E00;  B09-B;  B01-D02;  B05-B01P;  B04-B01B;  B10-B03B;  B05-B02A3;  B10-B02J;  A12-V;  A10-E20;  A10-E24;  A10-E18;  A12-W05;  A12-W14;  A12-V01,A61K-031/7088;  A61K-047/18;  A61K-009/127;  A61K-009/51;  C07C-229/16,CN117126071-A   28 Nov 2023   C07C-229/16   202410   Chinese;  WO2024032753-A1   15 Feb 2024   C07C-229/16   202415   Chinese,CN117126071-A    CN11016686    11 Aug 2023;   WO2024032753-A1    WOCN112482    11 Aug 2023;   WO2024032753-A1    WOCN112482    11 Aug 2023,,CN10969100    12 Aug 2022,  WO2024032753-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CV;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SC;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW  ,,";  WO2024032753-A1 -- CN113636947-A   ACUITAS THERAPEUTICS INC (ACUI-Non-standard)   ANSELL S M,  DU X;  CN114044741-A   BEIJING YUEKANG KECHUANG MEDICAL TECHNOL (BEIJ-Non-standard)   HUANG D,  WANG H,  YU X,  CHEN X,  ZHANG H,  SONG G;  CN117126071-A   SHANGHAI RNACURE BIOPHARMA CO LTD (SHAN-Non-standard)   WANG B,  CHEN L,  GUO J,  ZHANG B,  ZHANG F,  JIANG T,  YU H,  LU J,  LIN J",,93605-0-0-0 M K; 105730-0-0-0 M K;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P;  M N P; 130323-0-0-0 M K; 2351-0-0-0 M K; 93537-0-0-0 M K; 131951-0-0-0 M K; 93406-1-0-0 M K; 40293-1-0-0 M K; 109956-1-0-0 M K; 4015-0-0-0 M K; 68-0-0-0 U V K; 104533-0-0-0 U V K; 8349-1-0-0 M K; 84757-1-0-0 M K; 94395-1-0-0 M K; 89902-1-0-0 M K; 104504-2-0-0 M K; 89187-1-0-0 M K; 109167-1-0-0 M K; 444-0-0-0 ; 104533-0-0-0 CL RGT USE,A003C5C04 M K; A003C5C03 M K; A003C5C07 M K; A003C5C05 M K; A003C5C06 M K; A003C5C01 M K; A003C5C08 M N P; A003C5C02 M N P,00509; 06384; 05686; 06668,RA00NS M K; RA012P M K; RBZ0WT M K; R00418 M K; R06520 M K; R09650 M K; RA0GCK M K; R06521 M K; R18626 M K; R00179 M K; R01391 U V K; R01715 U V K; R00148 M K; RA92HG M K; R00147 M K; R11100 M K; RA0N0J M K; R13235 M K; R17972 M K; R00351 ,0418-S; 0179-S; 1391-U; 1715-U; 0148-S; 0147-S
US2020391210-A1;  WO2020251802-A1;  AU2020290981-A1;  CA3143241-A1;  KR2022033484-A;  EP3982716-A1;  CN114302643-A;  SG11202112898-A;  JP2022536493-W;  US11724256-B2;  EP3982716-A4;  JP7356519-B2;  JP2024012280-A;  CN114302643-B;  AU2020290981-B2;  AU2024201054-A1,Detecting set of targets of sample involves e.g.            capturing set of cells of sample in proximity to set of            functionalized particles in single cell format at set            of microwells of sample processing substrate and            performing lysis of set of cells,HANDIQUE K,BIO-RAD LAB INC (BIRA-C);  BIO-RAD LAB INC (BIRA-C);  BIO-RAD LAB INC (BIRA-C);  BIO-RAD LAB INC (BIRA-C);  BIO-RAD LAB INC (BIRA-C),2020C6053U,"   NOVELTY - Detecting (M1) a set of targets of a sample,                comprises e.g.: (a) capturing a set of cells of the                sample in proximity to a set of functionalized                particles, in single cell format, at a set of                microwells of a sample processing substrate; (b)                performing lysis of the set of cells, at the sample                processing substrate, thus allowing binding of                released biomarkers from the set of cells to the                set of functionalized particles; (c) performing a                reverse transcription operation, at the set of                microwells of the sample processing substrate, with                content bound to the set of functionalized                particles; (d) performing a second strand synthesis                operation with content bound to the set of                functionalized particles, with products of the                reverse transcription operation; (e) performing an                amplification operation at the set of                functionalized particles, with products of the                second strand synthesis operation.    USE - The method is useful: for detecting a set of                targets of a sample; for processing a sample                automatically; in a sample processing assembly (all                claimed); for processing, analyzing and capturing                single cell automatically in the sample processing                field; for detecting antibody, other protein, mRNA,                and/or other applications associated with spatial                transcriptomics; for enabling single-cell                proteogenomic applications; and for analyzing                mRNA.    ADVANTAGE - The method: provides cost-effective, rapid,                integrated, and automated systems for analyzing                large numbers of single cells with generation of                quantitative measurements (e.g. large numbers of                proteins and/or other biomarkers per cell);                provides high performance solutions (e.g. in terms                of high cell number, in terms of high multiplexing                performance and in terms of full automation) for                rapid dissemination of technologies across                different users; enables better accuracy of a                protocol, as compared to conventional systems and                methods (e.g. better accuracy in the addition of                the correct reagents, better temperature control of                reagents, rapid processing of critical liquid                handling steps, precise incubation times, optimal                bead washing and separation and automated bar code                reading); prevents accidents (e.g. knocking the                system, spills of reagents, and contamination of                sample or instrument); and minimizes number of                manual operations performed by a user, and provides                relevant system status reports to ensure smooth                operation and sample processing.    DETAILED DESCRIPTION - Detecting (M1) a set of targets of a sample,                comprises: (a) capturing a set of cells of the                sample in proximity to a set of functionalized                particles, in single cell format, at a set of                microwells of a sample processing substrate; (b)                performing lysis of the set of cells, at the sample                processing substrate, thus allowing binding of                released biomarkers from the set of cells to the                set of functionalized particles; (c) performing a                reverse transcription operation, at the set of                microwells of the sample processing substrate, with                content bound to the set of functionalized                particles; (d) performing a second strand synthesis                operation with content bound to the set of                functionalized particles, with products of the                reverse transcription operation; (e) performing an                amplification operation at the set of                functionalized particles, with products of the                second strand synthesis operation; (f) hybridizing                each of a set of probes, corresponding to a set of                fluorophores, to products of the amplification                operation; and (g) generating an image dataset of                light emitted by the set of probes, thus enabling                detection of the set of targets of the sample.                INDEPENDENT CLAIMS are also included for:    (1) a system (100) for automatically                processing a sample, comprising a deck (110)                configured to support and position comprising a                reagent cartridge at a first region of the first                side of the deck and a sample processing substrate                at a second region of the first side, a gantry                (170) coupled to the deck and comprising a set of                tracks defining paths of movement along a set of                axes, within a 3 dimensional volume bound by the                first side of the deck, for a pipette interface,                and a base (180) opposite the first side of the                deck and supporting comprising a heating and                cooling subsystem (150) comprising a set of thermal                bodies, a pumping subsystem comprising a vacuum                port into the second region and imaging subsystem                comprising an illumination subsystem comprising a                set of a set of emitters configured for light                transmission through a set of filters and a set of                optical elements, for uniform illumination of the                sample processing substrate at the deck and a                detection subsystem comprising a set of lenses for                shaping light from the sample processing substrate                onto a detector;    (2) a sample processing assembly, comprising a                sample processing substrate comprising a microwell                region comprising a set of microwells configured to                capture a set of cells in single-cell format, a                base coupled to a sample processing substrate and                defining an inlet reservoir fluidly coupled to the                sample processing substrate, and an access region                into the microwell region of the sample processing                substrate, a particle capture region, proximal to                the access region and configured for co-capture of                a set of functionalized particles in proximity to                the set of cells, and an elastomeric valve coupling                the sample processing substrate to the base along a                flow path from the microwell region to an outlet of                the sample processing substrate; and    (3) detecting (M2) a set of targets of a                sample, comprising capturing a tissue sample in                proximity to a set of functionalized particles in                single array format at a set of microwells of a                sample processing substrate, performing lysis of                the tissue sample at the sample processing                substrate, thus allowing binding of released                biomarkers from the tissue section to the set of                functionalized particles, and the steps (c)-(g) as                per se.    DESCRIPTION OF DRAWING(S) - The figure shows a schematic representations                of a system for automated single cell sample                processing.    System (100)    Deck (110)    Heating and cooling subsystem (150)    Gantry (170)    Base (180) ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  J04 (Chemical/physical processes/apparatus - including catalysis, catalysts (excluding specific e.g. enzymatic or polymerisation catalysts), colloid chemistry, laboratory apparatus and methods, testing, controlling, general encapsulation, detection and sampling (excluding clinical testing) (B01J, L).);  A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  S03 (Scientific Instrumentation)",B04-E02;  B04-E03;  B04-E05;  B04-F01;  B04-G08;  B04-G27A;  B04-G27D;  B04-G27E;  B04-G27G;  B04-G27M;  B11-C07A5;  B11-C07B2;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B11-C08J;  B11-C11;  B12-K04F;  D05-H09;  D05-H18B;  J04-B01;  J04-B03;  J04-F;  A12-E13;  A12-L04B;  A12-W11L;  S03-E13D;  S03-E14H3;  S03-E14H5,B01L-003/00;  C12M-001/00;  C12Q-001/6813;  C12Q-001/6888;  G01N-001/40;  G01N-015/14;  A01H-005/00;  A01K-067/027;  A61K-039/395;  A61K-045/00;  A61P-011/00;  C07K-016/00;  G01N-015/10;  G01N-033/569;  G01N-035/00;  G01N-035/04;  C12M-001/34;  C12M-001/36;  C12R-001/93;  C12Q-001/6844;  G01N-035/02;  G01N-035/08;  G01N-037/00;  C12M-001/32;  C07K-016/10;  C12N-015/11;  C12Q-001/6851;  C12Q-001/6869;  C12Q-001/6876;  G01N-035/10;  C12Q-001/68,US2020391210-A1   17 Dec 2020   B01L-003/00   202101Pages: 51   English;  WO2020251802-A1   17 Dec 2020   A01H-005/00   202101   English;  AU2020290981-A1   16 Dec 2021   A01H-005/00   202102   English;  CA3143241-A1   17 Dec 2020   A01H-005/00   202211   English;  KR2022033484-A   16 Mar 2022   G01N-035/00   202227   ;  EP3982716-A1   20 Apr 2022   A01H-005/00   202232   English;  CN114302643-A   08 Apr 2022   A01H-005/00   202234   Chinese;  SG11202112898-A   30 Dec 2021   A01H-005/00   202235   English;  JP2022536493-W   17 Aug 2022   C12Q-001/6813   202267   Japanese;  US11724256-B2   15 Aug 2023   B01L-003/00   202366   English;  EP3982716-A4   06 Sep 2023   A01H-005/00   202374   English;  JP7356519-B2   04 Oct 2023   C12Q-001/6813   202382   Japanese;  JP2024012280-A   30 Jan 2024   C12Q-001/6851   202416   Japanese;  CN114302643-B   27 Feb 2024   C12Q-001/68   202419   Chinese;  AU2020290981-B2   07 Mar 2024   A01H-005/00   202420   English;  AU2024201054-A1   07 Mar 2024   C12Q-001/6813   202424   English,US2020391210-A1    US890417    02 Jun 2020;   WO2020251802-A1    WOUS035704    02 Jun 2020;   AU2020290981-A1    AU290981    02 Jun 2020;   CA3143241-A1    CA3143241    02 Jun 2020;   KR2022033484-A    KR701278    02 Jun 2020;   EP3982716-A1    EP822446    02 Jun 2020;   CN114302643-A    CN80057564    02 Jun 2020;   SG11202112898-A    SG11012898    02 Jun 2020;   JP2022536493-W    JP573419    02 Jun 2020;   US11724256-B2    US890417    02 Jun 2020;   EP3982716-A4    EP822446    02 Jun 2020;   JP7356519-B2    JP573419    02 Jun 2020;   JP2024012280-A    JP157472    22 Sep 2023;   CN114302643-B    CN80057564    02 Jun 2020;   AU2020290981-B2    AU290981    02 Jun 2020;   AU2024201054-A1    AU201054    19 Feb 2024;   AU2024201054-A1    AU201054    19 Feb 2024,US2020391210-A1 Provisional Application US861826P;   US2020391210-A1 Provisional Application US907791P;   AU2020290981-A1 PCT application Application WOUS035704;   AU2020290981-A1 Based on Patent WO2020251802;   CA3143241-A1 PCT application Application WOUS035704;   CA3143241-A1 Based on Patent WO2020251802;   KR2022033484-A PCT application Application WOUS035704;   KR2022033484-A Based on Patent WO2020251802;   EP3982716-A1 PCT application Application WOUS035704;   EP3982716-A1 Based on Patent WO2020251802;   CN114302643-A PCT application Application WOUS035704;   CN114302643-A Based on Patent WO2020251802;   SG11202112898-A PCT application Application WOUS035704;   SG11202112898-A Based on Patent WO2020251802;   JP2022536493-W PCT application Application WOUS035704;   JP2022536493-W Based on Patent WO2020251802;   US11724256-B2 Provisional Application US861826P;   US11724256-B2 Provisional Application US907791P;   US11724256-B2 Previous Publ. Patent US2020391210;   JP7356519-B2 PCT application Application WOUS035704;   JP7356519-B2 Previous Publ. Patent JP2022536493;   JP7356519-B2 Based on Patent WO2020251802;   JP2024012280-A Div ex Application JP573419;   CN114302643-B PCT application Application WOUS035704;   CN114302643-B Previous Publ. Patent CN114302643;   CN114302643-B Based on Patent WO2020251802;   AU2020290981-B2 PCT application Application WOUS035704;   AU2020290981-B2 Based on Patent WO2020251802;   AU2024201054-A1 Div ex Application AU290981,US861826P    14 Jun 2019;  US907791P    30 Sep 2019;  AU290981    02 Jun 2020;  US890417    02 Jun 2020;  WOUS035704    02 Jun 2020;  CA3143241    10 Dec 2021;  KR701278    13 Jan 2022;  CN80057564    14 Feb 2022;  AU201054    19 Feb 2024,  WO2020251802-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        EP3982716-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN          EP3982716-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR            ,,";  WO2020251802-A1 -- US20050095582-A1   ;  US20080248043-A1   ;  US20120316074-A1   ;  US20140051595-A1   ;  US20140329301-A1   ;  US20150011432-A1   ;  US20160008814-A1   ;  US20170153219-A1   ;  US20170370951-A1   ;  CN114302643-A -- CN104350374-A   FLUIDIGM CORP (FLGM);  FOWLER B (FOWL-Individual);  KIMBALL J (KIMB-Individual);  MAUNG M T (MAUN-Individual);  MAY A (MAYA-Individual);  NORRIS M C (NORR-Individual);  TOPPANI D G (TOPP-Individual);  UNGER M A (UNGE-Individual);  WANG J (WANG-Individual);  WEST J A A (WEST-Individual)   FOWLER B,  KIMBALL J,  MAUNG M T,  MAY A,  NORRIS M C,  TOPPANI D G,  UNGER M A,  WANG J,  WEST J A A;  CN104853802-A   SCRIPPS RES INST (SCRI);  MINDERA CORP (MIND-Non-standard)   CAPEK P,  DICKERSON T J,  MAHMOOD N A,  MAHMOOD T A;  CN109661474-A   FLUIDIGM CORP (FLGM)   LIVAK K J,  FEKETE R A;  US20050095582-A1   ;  US20120316074-A1   ;  US20140272965-A1   ;  US11724256-B2 -- CA2994321-A1   HANDYLAB INC (HAND-Non-standard)   WU B,  ALTHAUS J S,  BRAHMASANDRA S N,  HANDIQUE K,  PHADKE N;  CN103894248-A   NAT CENT NANOSCIENCE & TECHNOLOGY                  CHINA (NANI)   HU Z,  WEI Z;  CN103998394-A   DENOVO SCI (DENO-Non-standard)   GOGOL P,  HANDIQUE K,  JAVDANI S S,  SIEMER C;  CN104789468-A   CHINESE ACAD SCI INST MICROELECTRONICS (CAMI)   HUANG C,  LUO J,  ZHAO C;  EP2414548-A2   ILLUMINA INC (ILLU)   LINNARSSON S;  EP2414548-B1   ILLUMINA INC (ILLU)   LINNARSSON S;  JP2006098696-A   FUJI DENKI GAZO DEVISE KK (FJIE)   TANAKA Y,  KITAGAWA S,  ASAKAWA T;  JP2009195160-A   HITACHI LTD (HITA)   KAJIYAMA T,  KAMBARA H,  SHIRAI M;  JP2013500496-A   CHAMBERLIN I (CHAM-Individual);  CLINTON C M (CLIN-Individual);  GLEZER E N (GLEZ-Individual);  JEFFREY-COKER B (JEFF-Individual);  KOCHAR M (KOCH-Individual);  KOVACS S (KOVA-Individual);  LE D (LEDD-Individual);  LEIMKUEHLER A (LEIM-Individual);  PINCKNEY G (PINC-Individual);  ROTH K (ROTH-Individual);  SIGAL G (SIGA-Individual);  YIN F (YINF-Individual)   CHAMBERLIN I,  CLINTON C M,  GLEZER E N,  JEFFREY-COKER B,  KOCHAR M,  KOVACS S,  LE D,  LEIMKUEHLER A,  PINCKNEY G,  ROTH K,  SIGAL G,  YIN F;  JP2013541959-A   BIONEER CORP (BINR);  KIM J H (KIMJ-Individual)   JEONG B R,  KIM K S,  LEE J I,  LEE Y W,  PARK H O;  JP2015527588-A   UNIV YALE (UYYA)   FAN R,  LU Y,  CHEN J;  JP2017063716-A   SONY CORP (SONY)   MATSUMOTO M,  SHINODA M,  WATANABE Y;  US4475411-A   COULTER ELECTRONICS INC (COUE);  US4551435-A   IMMUNICON INC (IMMU-Non-standard)   LIBERTI P A,  POLLARA P;  US4710635-A   BECTON DICKINSON CO (BECT)   CHUPP V;  US5266269-A   NIPPON KODEN CORP (NIOE)   YOSHIKAWA K,  NIIYAMA Y;  US5281540-A   ABBOTT LAB (ABBO)   MERKH C W,  DEFREESE J D,  DURLEY B A;  US5491343-A   BROOKER G (BROO-Individual)   BROOKER G;  US5541064-A   CELL ANALYSIS SYSTEMS INC (CELL-Non-standard)   BACUS J W,  MARDER R J;  US5547849-A   BIOMETRIC IMAGING INC (BIOM-Non-standard)   BAER T M,  DIETZ L J,  DUBROW R S,  HAYTER P G,  HODGES M,  MANIAN B S,  SHARTLE R J;  US5851488-A   BIOCIRCUITS CORP (BIOC-Non-standard)   SAUL T,  SCHWARTZ H L,  GUION T,  RIBI H O;  US5883370-A   PSC INC (PSCP-Non-standard)   BLACKMAN M E,  WALKER R A;  US5888370-A   UNIV TEXAS SYSTEM (TEXA)   BECKER F F,  GASCOYNE P R C,  HUANG Y,  WANG X;  US5993630-A   UNIV TEXAS SYSTEM (TEXA)   BECKER F F,  GASCOYNE P R C,  HUANG Y,  WANG X;  US5993632-A   UNIV TEXAS SYSTEM (TEXA)   BECKER F F,  GASCOYNE P R C,  HUANG Y,  WANG X;  US6016712-A   ACCUMETRICS (ACCU-Non-standard)   WARDEN L,  KAPLAN D E;  US6127177-A   GEN HOSPITAL CORP DBA MASSACHUSETTS GEN (GEHO);  MASSACHUSETTS INST TECHNOLOGY (MASI)   TONER M,  RUSSO M,  BIEGANSKI R;  US6133030-A   MASSACHUSETTS INST TECHNOLOGY (MASI);  GEN HOSPITAL CORP (GEHO)   BHATIA S,  YARMUSH M,  TONER M;  US6150180-A   CALIPER TECHNOLOGIES CORP (CLPE)   PARCE J W,  KOPF-SILL A R,  BOUSSE L J;  US20020009759-A1   ;  US20020028431-A1   ;  US20020036142-A1   ;  US20020036823-A1   ;  US20020098535-A1   ;  US20020109838-A1   ;  US20020119482-A1   ;  US20020192808-A1   ;  US20030129676-A1   ;  US20030138941-A1   ;  US20040029241-A1   ;  US20040106130-A1   ;  US20040160599-A1   ;  US20040191891-A1   ;  US20040218472-A1   ;  US20040229349-A1   ;  US20040248318-A1   ;  US20050001176-A1   ;  US20050014201-A1   ;  US20050037343-A1   ;  US20050042685-A1   ;  US20050063863-A1   ;  US20050095582-A1   ;  US20050112589-A1   ;  US20050118640-A1   ;  US20050158804-A1   ;  US20050164236-A1   ;  US20050181463-A1   ;  US20050265815-A1   ;  US20060040274-A1   ;  US20060040407-A1   ;  US20060050142-A1   ;  US20060115380-A1   ;  US20060128006-A1   ;  US20060141045-A1   ;  US20060147959-A1   ;  US20060160243-A1   ;  US20060257992-A1   ;  US20060263250-A1   ;  US20070026381-A1   ;  US20070053800-A1   ;  US20070111302-A1   ;  US20070154960-A1   ;  US20070161051-A1   ;  US20070172903-A1   ;  US20070243523-A1   ;  US20070252265-A1   ;  US20070264675-A1   ;  US20070275418-A1   ;  US20080003224-A1   ;  US20080014589-A1   ;  US20080068588-A1   ;  US20080090239-A1   ;  US20080096212-A1   ;  US20080113906-A1   ;  US20080124726-A1   ;  US20080182273-A1   ;  US20080206751-A1   ;  US20080207615-A1   ;  US20080220422-A1   ;  US20080234264-A1   ;  US20080240539-A1   ;  US20080248043-A1   ;  US20080317325-A1   ;  US20090014360-A1   ;  US20090061450-A1   ;  US20090081773-A1   ;  US20090141593-A1   ;  US20090153844-A1   ;  US20090162853-A1   ;  US20090215088-A1   ;  US20090220979-A1   ;  US20090221059-A1   ;  US20090258383-A1   ;  US20090317836-A1   ;  US20100087325-A1   ;  US20100120077-A1   ;  US20100127168-A1   ;  US20100210009-A1   ;  US20100232675-A1   ;  US20100233693-A1   ;  US20100261179-A1   ;  US20100291584-A1   ;  US20100304485-A1   ;  US20100304978-A1   ;  US20110003380-A1   ;  US20110005932-A1   ;  US20110045994-A1   ;  US20110053151-A1   ;  US20110104718-A1   ;  US20110117634-A1   ;  US20110143964-A1   ;  US20110227558-A1   ;  US20110236904-A1   ;  US20110280467-A1   ;  US20120021456-A1   ;  US20120129190-A1   ;  US20120156675-A1   ;  US20120164679-A1   ;  US20120194805-A1   ;  US20120316074-A1   ;  US20130011832-A1   ;  US20130116102-A1   ;  US20130171628-A1   ;  US20130230860-A1   ;  US20130244906-A1   ;  US20130259635-A1   ;  US20130309778-A1   ;  US20140051595-A1   ;  US20140155295-A1   ;  US20140173443-A1   ;  US20140212881-A1   ;  US20140213487-A1   ;  US20140272965-A1   ;  US20140315237-A1   ;  US20140329301-A1   ;  US20140357511-A1   ;  US20140370612-A1   ;  US20150011432-A1   ;  US20150089359-A1   ;  US20150093306-A1   ;  US20150133319-A1   ;  US20150160135-A1   ;  US20150160931-A1   ;  US20150204864-A1   ;  US20150299784-A1   ;  US20150376609-A1   ;  US20160008814-A1   ;  US20160024572-A1   ;  US20160024761-A1   ;  US20160053253-A1   ;  US20160060621-A1   ;  US20160130649-A1   ;  US20160199838-A1   ;  US20160209319-A1   ;  US20160251714-A1   ;  US20160289669-A1   ;  US20160314242-A1   ;  US20160367991-A1   ;  US20170044525-A1   ;  US20170153219-A1   ;  US20170307502-A1   ;  US20170320038-A1   ;  US20170321252-A1   ;  US20170335385-A1   ;  US20170356027-A1   ;  US20170370951-A1   ;  US20180030515-A1   ;  US20180037942-A1   ;  US20180051321-A1   ;  US20180080075-A1   ;  US20180094298-A1   ;  US20180094312-A1   ;  US20180105808-A1   ;  US20180112266-A1   ;  US20180127744-A1   ;  US20180127823-A1   ;  US20180274027-A1   ;  US20180282804-A1   ;  US20190002814-A1   ;  US20190060902-A1   ;  US20120071355-A9   ;  US6174683-B1   BIOCEPT INC (BIOC-Non-standard)   HAHN S,  FAGNANI R,  TSINBERG P;  US6221663-B1   MASSACHUSETTS INST TECHNOLOGY (MASI);  GEN HOSPITAL CORP (GEHO)   BHATIA S,  YARMUSH M,  TONER M;  US6228624-B1   IMMUNIVEST CORP (IMMU-Non-standard)   TERSTAPPEN L W M M;  US6281008-B1   TOYO BOSEKI KK (TOYM)   SHIGERU K,  KATSUYA D,  YUTAKA T;  US6287832-B1   UNIV TEXAS SYSTEM (TEXA)   BECKER F F,  GASCOYNE P R C,  HUANG Y,  WANG X;  US6365362-B1   IMMUNIVEST (IMMU-Non-standard);  UNIV TEXAS SOUTHWESTERN MEDICAL CENT DAL (TEXA)   TERSTAPPEN L W M M,  RAO G C,  UHR J W,  RACILA E V,  LIBERTI P A;  US6410724-B1   INST PASTEUR (INSP);  INSERM INST NAT SANTE & RECH                  MEDICALE (INRM)   DEJEAN A,  BUENDIA M,  PINEAU P,  NAGAI H,  TIOLLAIS P;  US6433134-B1   BIOCEPT INC (BIOC-Non-standard)   PATRON A P,  PERVIN A;  US6525997-B1   INT BUSINESS MACHINES CORP (IBMC)   NARAYANASWAMI C,  RAGHUNATH M T;  US6623983-B1   IMMUNIVEST CORP (IMMU-Non-standard)   TERSTAPPEN L W M M,  RAO G C;  US6641708-B1   UNIV TEXAS SYSTEM (TEXA)   BECKER F F,  GASCOYNE P R C,  HUANG Y,  WANG X;  US6692952-B1   MASSACHUSETTS INST TECHNOLOGY (MASI)   BRAFF R,  VOLDMAN J,  GRAY M L,  SCHMIDT M A,  TONER M;  US6821484-B1   LANGERHANS APS (LANG-Non-standard)   GREGERSEN S;  US7198901-B1   BIOCEPT INC (BIOC-Non-standard)   RACHLIN D J;  US9145540-B1   SENG ENTERPRISES LTD (SENG-Non-standard)   DEUTSCH M,  DEUTSCH A;  US10376889-B1   INSCRIPTA INC (INSC-Non-standard)   MASQUELIER D,  BELGRADER P,  VAN HATTEN B,  BERNATE J,  CHABANSKY B;  US10401373-B1   THERANOS IP CO LLC (THRN)   HOLMES E A,  SMITH T,  LOO A,  YOUNG D;  US10533152-B1   INSCRIPTA INC (INSC-Non-standard)   BELGRADER P,  MASQUELIER D,  CHABANSKY B,  BERNATE J,  GARST A,  FOX R;  US10633693-B1   CELSEE DIAGNOSTICS INC (BIRA)   HANDIQUE K,  STARK J,  DEOL Y,  SHARMA V;  US6563634-B2   OLYMPUS OPTICAL CO LTD (OLYU)   SHIMADA M,  SHIMADA Y,  KITAGAWA H;  US6613525-B2   ACLARA BIOSCIENCES INC (ACLA-Non-standard)   NELSON R J,  HOOPER H H,  HAUSER A K,  SINGH S,  WILLIAMS S J,  SASSI A P;  US6645731-B2   IMMUNIVEST (IMMU-Non-standard);  UNIV TEXAS SOUTHWESTERN MEDICAL CENT DAL (TEXA)   TERSTAPPEN L W M M,  RAO G C,  UHR J W,  RACILA E V,  LIBERTI P A;  US6790330-B2   UNIV TEXAS SYSTEM (TEXA)   GASCOYNE P R C,  BECKER F F,  VYKOUKAL J;  US6861259-B2   COLUMBUS R L (COLU-Individual)   COLUMBUS R L;  US6866823-B2   WARDLAW S C (WARD-Individual)   WARDLAW S C;  US6960449-B2   CELL WORKS INC (CELL-Non-standard)   WANG Z,  TS'O P O P;  US7008789-B2   PERKIN-ELMER CORP (PEKE)   GAMBINI M R,  ATWOOD J G,  YOUNG E F,  LAKATOS E J,  CERRONE A L;  US7035170-B2   INT BUSINESS MACHINES CORP (IBMC)   NARAYANASWAMI C,  RAGHUNATH M T;  US7046357-B2   CIPHERGEN BIOSYSTEMS INC (VRML)   WEINBERGER S R,  HLOUSEK L;  US7148492-B2   AFFYMETRIX INC (AFFY)   LONEY G C,  WEINER N K;  US7172866-B2   BIOCEPT INC (BIOC-Non-standard)   HAHN S,  FAGNANI R,  DONG X,  EDMAN C F,  TSINBERG P;  US7217520-B2   BIOCEPT INC (BIOC-Non-standard)   TSINBERG P,  ROYCROFT P,  FALCOVITZ-GERASSI Y H,  HAHN S;  US7238521-B2   HAHN S (HAHN-Individual);  STEADMAN J (STEA-Individual);  TSINBERG P (TSIN-Individual);  WATANASKUL T (WATA-Individual);  GERASSI Y (GERA-Individual)   HAHN S,  STEADMAN J,  TSINBERG P,  WATANASKUL T,  GERASSI Y;  US7248352-B2   HAMAMATSU A (HAMA-Individual);  NOGUCHI M (NOGU-Individual);  NISHIYAMA H (NISH-Individual);  OHSHIMA Y (OHSH-Individual);  JINGU T (JING-Individual);  UTO S (UTOS-Individual)   HAMAMATSU A,  NOGUCHI M,  NISHIYAMA H,  OHSHIMA Y,  JINGU T,  UTO S;  US7258990-B2   BIOCEPT INC (BIOC-Non-standard)   FALCOVITZ-GERASSI Y,  TSINBERG P;  US7266777-B2   UNIVERSAL ELECTRONICS INC (UVEL)   SCOTT W,  CHAMBERS C A,  SCOTT C,  YUH H,  AMMARI R;  US7294468-B2   GEN HOSPITAL CORP (GEHO);  DANA FARBER CANCER INST INC (DAND)   BELL D W,  HABER D A,  JANNE P A,  JOHNSON B E,  LYNCH T J,  MEYERSON M,  PAEZ J G,  SELLERS W R,  SETTLEMAN J E,  SORDELLA R;  US7316897-B2   BIOCOM SA (BIOC-Non-standard)   BISCONTE DE SAINT JULIEN J;  US7332288-B2   IMMUNIVEST (IMMU-Non-standard);  UNIV TEXAS SOUTHWESTERN MEDICAL CENT DAL (TEXA)   TERSTAPPEN L W M M,  RAO G C,  UHR J W,  RACILA E V,  LIBERTI P A;  US7338760-B2   NTU VENTURES PTE LTD (NTUV-Non-standard);  DEFENCE SCI & TECHNOLOGY AGENCY (DEFE-Non-standard)   YAP P H E,  GONG H,  AYI T C;  US7354389-B2   AUTOGENOMICS INC (AUTO-Non-standard)   KURESHY F,  MAHANT V,  SINGH S,  SHEN X;  US7439062-B2   BIOCEPT INC (BIOC-Non-standard)   BHATT R S,  TSINBERG P;  US7449558-B2   YAO S Q (YAOS-Individual);  YEO S D (YEOS-Individual)   YAO S Q,  YEO S D;  US7449778-B2   SANDER R (SAND-Individual)   SANDER R;  US7507528-B2   ADNAGEN AG (ADNA-Non-standard)   ALBERT W,  STEFFENS P,  KREHAN A,  WASCHUETZA S;  US7588672-B2   FLUIDIGM CORP (FLGM)   UNGER M A;  US7595157-B2   BIOCEPT INC (BIOC-Non-standard)   TSINBERG P;  US7597528-B2   UHLMANN PAC-SYSTEME GMBH & CO KG (UHLN)   RODI W;  US7604777-B2   IMMUNIVEST CORP (IMMU-Non-standard)   COLUMBUS R L;  US7638464-B2   BIOCEPT INC (BIOC-Non-standard)   FAGNANI R,  HAHN S,  DONG X,  PIRCHER T,  MATSUMOTO S,  TSINBERG P;  US7695956-B2   BIOCEPT INC (BIOC-Non-standard)   TSINBERG P,  TANG Z;  US7704322-B2   CALIFORNIA INST OF TECHNOLOGY (CALY);  UNIV CALIFORNIA (REGC)   HANSEN C L,  QUAKE S R,  BERGER J M;  US7710563-B2   HESS H F (HESS-Individual);  BETZIG R E (BETZ-Individual)   HESS H F,  BETZIG R E;  US7738320-B2   GENERAL ELECTRIC CO (GENE)   TAHA B H;  US7763704-B2   UNIV SINGAPORE NAT (UNUS)   DING J L,  HO B;  US7815863-B2   IMMUNIVEST CORP (IMMU-Non-standard)   KAGAN M,  RAO G C,  PROHASKA J,  ALDEN T;  US7858757-B2   ADNAGEN AG (ADNA-Non-standard)   HOLLMANN C,  ZIMMERMANN S,  STACHELHAUS S,  ALBERT W;  US7863012-B2   RAO G C (RAOG-Individual);  LARSON C (LARS-Individual);  REPOLLET M (REPO-Individual);  RUTNER H (RUTN-Individual);  TERSTAPPEN L W M M (TERS-Individual);  OHARA S M (OHAR-Individual);  GROSS S (GROS-Individual)   RAO G C,  LARSON C,  REPOLLET M,  RUTNER H,  TERSTAPPEN L W M M,  OHARA S M,  GROSS S;  US7901950-B2   IMMUNIVEST CORP (IMMU-Non-standard)   CONNELLY M C,  DOYLE G V,  RAO G C,  TERSTAPPEN L W M M;  US7964349-B2   GEN HOSPITAL CORP (GEHO);  DANA FARBER CANCER INST INC (DAND)   BELL D W,  HABER D A,  JANNE P A,  JOHNSON B E,  LYNCH T J,  MEYERSON M,  PAEZ J G,  SELLERS W R,  SETTLEMAN J E,  SORDELLA R;  US8008032-B2   CELLPOINT DIAGNOSTICS INC (CELL-Non-standard)   BARNES H,  FORSYTH A;  US8013298-B2   KHURSHEED A (KHUR-Individual)   KHURSHEED A;  US8021614-B2   HUANG L R (HUAN-Individual);  BARBER T A (BARB-Individual);  CARVALHO B L (CARV-Individual);  KAPUR R (KAPU-Individual);  VERNUCCI P (VERN-Individual);  TONER M (TONE-Individual);  WANG Z (WANG-Individual)   HUANG L R,  BARBER T A,  CARVALHO B L,  KAPUR R,  VERNUCCI P,  TONER M,  WANG Z;  US8103080-B2   AMNIS CORP (AMNI-Non-standard)   GEORGE T C,  BASIJI D A,  HALL B E,  ORTYN W E,  SEO M J,  MORRISSEY P J,  ZIMMERMAN C A;  US8105769-B2   GEN HOSPITAL CORP (GEHO);  DANA FARBER CANCER INST INC (DAND)   BELL D W,  HABER D A,  JANNE P A,  JOHNSON B E,  LYNCH T J,  MEYERSON M,  PAEZ J G,  SELLERS W R,  SETTLEMAN J E,  SORDELLA R;  US8105780-B2   SU X (SUXX-Individual);  ROBELEK R (ROBE-Individual);  KNOLL W (KNOL-Individual);  OSHEA S (OSHE-Individual)   SU X,  ROBELEK R,  KNOLL W,  OSHEA S,  O'SHEA S;  US8131053-B2   AMNIS CORP (AMNI-Non-standard)   ORTYN W,  BASIJI D,  LIANG L,  VENKATACHALAM V,  MORRISSEY P;  US8158410-B2   BIOCEPT INC (BIOC-Non-standard)   TANG Z,  BHATT R S,  TSINBERG P;  US8174698-B2   PETER Y (PETE-Individual);  MASSON J (MASS-Individual);  ST-GELAIS R (STGE-Individual)   MASSON J,  PETER Y,  ST-GELAIS R;  US8175371-B2   AMNIS CORP (AMNI-Non-standard)   GEORGE T C,  BASIJI D A,  HALL B E,  ORTYN W E,  SEO M J,  MORRISSEY P J,  ZIMMERMAN C A;  US8186913-B2   GEN HOSPITAL CORP DBA MASSACHUSETTS GEN (GEHO)   TONER M,  DICARLO D,  EDD J,  IRIMIA D,  RUSSOM A;  US8211301-B2   ABBOTT LAB (ABBO)   SAFAR S G,  GALITZ C M,  HERCHENBACH S L,  DUNN C M,  MCDOWELL L L;  US8232112-B2   WILLSON R C (WILL-Individual);  RUCHHOEFT P (RUCH-Individual)   WILLSON R C,  RUCHHOEFT P;  US8252517-B2   MASSACHUSETTS INST TECHNOLOGY (MASI)   DENDUKURI D,  DOYLE P S,  JANG J,  THOMAS E L,  ULLAL C K;  US8293524-B2   FLUXION BIOSCIENCES INC (FLUX-Non-standard)   IONESCU-ZANETTI C,  KHINE M,  SCHWARTZ M,  BLATZ A;  US8304230-B2   GEN HOSPITAL CORP (GEHO);  GPB SCI LLC (GPBS-Non-standard)   TONER M,  TRUSKEY G,  KAPUR R;  US8329422-B2   IMMUNIVEST CORP (IMMU-Non-standard)   RAO G C,  LARSON C,  REPOLLET M,  RUTNER H,  TERSTAPPEN L,  O'HARA S M,  GROSS S;  US8372579-B2   GEN HOSPITAL CORP (GEHO);  GPB SCI LLC (GPBS-Non-standard)   TONER M,  TRUSKEY G,  KAPUR R;  US8372584-B2   LIVING MICROSYSTEMS INC (LIVI-Non-standard);  CELLPOINT DIAGNOSTICS INC (CELL-Non-standard);  GEN HOSPITAL CORP (GEHO)   SHOEMAKER D,  FUCHS M,  KRUEGER N X,  TONER M,  GRAY D,  KAPUR R,  WANG Z;  US8406498-B2   AMNIS CORP (AMNI-Non-standard)   ORTYN W,  BASIJI D,  MORRISSEY P,  GEORGE T,  HALL B,  ZIMMERMAN C,  PERRY D;  US8465916-B2   GEN HOSPITAL CORP (GEHO);  DANA FARBER CANCER INST INC (DAND)   BELL D W,  HABER D A,  JANNE P A,  JOHNSON B E,  LYNCH T J,  MEYERSON M,  PAEZ J G,  SELLERS W R,  SETTLEMAN J E,  SORDELLA R;  US8628923-B2   FLUIDIGM CORP (FLGM)   HAMILTON A,  LIN M,  MIR A,  PIEPRZYK M;  US8658418-B2   FLUIDIGM CORP (FLGM)   CHOU H,  DARIDON A,  FARRELL K,  FOWLER B,  HAO C,  JAVADI S,  LIAU Y,  MANGER I D,  NASSEF H R,  NORTON P,  THRONDSET W;  US8680025-B2   COONEY C G (COON-Individual)   COONEY C G;  US8730479-B2   QUANTALIFE INC (BIRA)   ARBORE M A,  HURST J E,  KLEIN D L,  MASQUELIER D A,  NESS K D;  US8765454-B2   ZHOU X (ZHOU-Individual);  GAO X (GAOX-Individual);  GULARI E (GULA-Individual)   ZHOU X,  GAO X,  GULARI E;  US8771609-B2   SIEMENS AG (SIEI)   EHBEN T,  GUMBRECHT W,  STANZEL M,  ZILCH C;  US8802367-B2   HITACHI LTD (HITA)   TANIGUCHI K,  KAMBARA H,  KAJIYAMA T;  US8936945-B2   UNIV MICHIGAN (UNMI)   HANDIQUE K,  BURNS M A;  US8986988-B2   MASSACHUSETTS INST TECHNOLOGY (MASI)   ANDERSON D G,  BOSE S,  HONG S,  KARNIK R N,  KARP J M,  LANGER R S,  MEI Y;  US9103754-B2   DENOVO SCI (DENO-Non-standard)   GOGOL P,  HANDIQUE K,  JAVDANI S S,  SIEMER C;  US9110026-B2   BIOPICO SYSTEMS (BIOP-Non-standard)   COLLINS J;  US9133499-B2   UNIV CALIFORNIA (REGC)   DI CARLO D,  HUR S C,  MACH A J;  US9174216-B2   DENOVO SCI INC (DENO-Non-standard)   HANDIQUE K,  GLEASON K,  PAYNE A,  GOGOI P,  JAVDANI S S,  SIEMER C,  ZHOU Y;  US9188586-B2   UNIV YALE (UYYA)   FAN R,  LU Y,  CHEN J;  US9194001-B2   BRENNER S (BREN-Individual)   BRENNER S;  US9200245-B2   MOLECULAR CYTOMICS LTD (MOLE-Non-standard)   DEUTSCH M,  HERZBERG M,  TIROSH R,  DEUTSCH A;  US9201060-B2   MASSACHUSETTS INST TECHNOLOGY (MASI);  WHITEHEAD INST (WHED)   JAENISCH R,  KIRAK O,  SKELLEY A M,  VOLDMAN J;  US9249459-B2   FLUIDIGM CORP (FLGM)   HAMILTON A,  LIN M,  MIR A,  PIEPRZYK M;  US9260753-B2   HARVARD COLLEGE (HARD)   XIE X S,  SHIROGUCHI K,  SIMS P A,  JIA T Z;  US9290808-B2   FODOR S P A (FODO-Individual);  FU G K (FUGK-Individual)   FODOR S P A,  FU G K;  US9290809-B2   FODOR S P A (FODO-Individual);  FU G K (FUGK-Individual)   FODOR S P A,  FU G K;  US9304065-B2   FLUIDIGM CORP (FLGM);  FOWLER B (FOWL-Individual);  KIMBALL J (KIMB-Individual);  MAUNG M T (MAUN-Individual);  MAY A (MAYA-Individual);  NORRIS M C (NORR-Individual);  TOPPANI D G (TOPP-Individual);  UNGER M A (UNGE-Individual);  WANG J (WANG-Individual);  WEST J A A (WEST-Individual)   FOWLER B,  KIMBALL J,  MAUNG M T,  MAY A,  NORRIS M C,  TOPPANI D G,  UNGER M A,  WANG J,  WEST J A A;  US9315768-B2   RIJKSUNIV LEIDEN (RIJK)   VROUWE E X,  WIELHOUWER E M,  OONK J,  OLDE RIEKERINK M B,  RICHARDSON M K;  US9315857-B2   AFFYMETRIX INC (AFFY)   FU G K,  FODOR S P A;  US9329170-B2   UNIV LELAND STANFORD JUNIOR (STRD)   CLARKE M F,  DALERBA P D,  DIEHN M,  KALISKY T,  LEYRAT A,  LIU H,  QUAKE S R;  US9364829-B2   FLUIDIGM CORP (FLGM)   HEID C A,  DARIDON A;  US9410201-B2   10X TECHNOLOGIES INC (TNXG)   HINDSON B,  SAXONOV S,  NESS K,  HARDENBOL P;  US9429500-B2   FLUIDIGM CORP (FLGM);  FOWLER B (FOWL-Individual);  KIMBALL J (KIMB-Individual);  MAUNG M T (MAUN-Individual);  MAY A (MAYA-Individual);  NORRIS M C (NORR-Individual);  TOPPANI D G (TOPP-Individual);  UNGER M A (UNGE-Individual);  WANG J (WANG-Individual);  WEST J A A (WEST-Individual)   FOWLER B,  KIMBALL J,  MAUNG M T,  MAY A,  NORRIS M C,  TOPPANI D G,  UNGER M A,  WANG J,  WEST J A A;  US9506845-B2   FLUIDIGM CORP (FLGM);  FOWLER B (FOWL-Individual);  KIMBALL J (KIMB-Individual);  MAUNG M T (MAUN-Individual);  MAY A (MAYA-Individual);  NORRIS M C (NORR-Individual);  TOPPANI D G (TOPP-Individual);  UNGER M A (UNGE-Individual);  WANG J (WANG-Individual);  WEST J A A (WEST-Individual)   FOWLER B,  KIMBALL J,  MAUNG M T,  MAY A,  NORRIS M C,  TOPPANI D G,  UNGER M A,  WANG J,  WEST J A A;  US9507609-B2   SYRP INC (SYRP-Non-standard)   GLAZER A,  NORRIS J,  DRUXERMAN J,  NORRIS A;  US9513195-B2   DENOVO SCI (DENO-Non-standard)   GOGOL P,  HANDIQUE K,  JAVDANI S S,  SIEMER C;  US9567645-B2   CELLULAR RES INC (BECT)   FACER G R,  FAN C,  FODOR S P A,  FU G K,  WILHELMY J;  US9567646-B2   CELLULAR RES INC (BECT)   FACER G R,  FAN C,  FODOR S P A,  FU G K,  WILHELMY J;  US9598736-B2   CELLULAR RES INC (BECT)   FACER G R,  FAN C,  FODOR S P A,  FU G K,  WILHELMY J;  US9610581-B2   DENOVO SCI INC (DENO-Non-standard)   HANDIQUE K,  GLEASON K,  PAYNE A,  GOGOI P,  JAVDANI S S,  SIEMER C,  ZHOU Y;  US9637799-B2   CELLULAR RES INC (BECT)   FACER G R,  FAN C,  FODOR S P A,  FU G K,  WILHELMY J;  US9701998-B2   10X TECHNOLOGIES INC (TNXG)   HINDSON B,  SAXONOV S;  US9707562-B2   DENOVO SCI INC (DENO-Non-standard)   HANDIQUE K,  GLEASON K,  PAYNE A,  GOGOI P,  SIEMER C,  ZHOU Y,  SEPEHRI S J;  US9708659-B2   CELLULAR RES INC (BECT)   FODOR S P A,  FU G K;  US9757707-B2   WAFERGEN INC (TAKI)   HUSAIN S A,  GRISWOLD B L,  SLATER M,  ESPINOZA P,  DUNNE J,  HEIN G,  SRINIVASAN M;  US9802193-B2   DENOVO SCI INC (DENO-Non-standard)   HANDIQUE K,  GLEASON K,  PAYNE A,  GOGOI P,  JAVDANI S S,  SIEMER C,  ZHOU Y;  US9840732-B2   FLUIDIGM CORP (FLGM)   ANDERSON M,  CHEN P,  FOWLER B,  KAPER F,  LEBOFSKY R,  MAY A;  US9845502-B2   CELLULAR RES INC (BECT)   FODOR S P A,  FU G K;  US9850483-B2   UNIV LELAND STANFORD JUNIOR (STRD)   CLARKE M F,  QUAKE S R,  DALERBA P D,  LIU H,  LEYRAT A,  KALISKY T,  DIEHN M,  ROTHENBERG M,  WANG J;  US9952126-B2   FLUIDIGM CORP (FLGM);  FOWLER B (FOWL-Individual);  KIMBALL J (KIMB-Individual);  MAUNG M T (MAUN-Individual);  MAY A (MAYA-Individual);  NORRIS M C (NORR-Individual);  TOPPANI D G (TOPP-Individual);  UNGER M A (UNGE-Individual);  WANG J (WANG-Individual);  WEST J A A (WEST-Individual)   FOWLER B,  KIMBALL J,  MAUNG M T,  MAY A,  NORRIS M C,  TOPPANI D G,  UNGER M A,  WANG J,  WEST J A A;  US9995662-B2   WAFERGEN INC (TAKI)   DUNNE J,  ESPINOZA P,  GRISWOLD B L,  HEIN G,  HUSAIN S A,  SLATER M,  SRINIVASAN M;  US10391492-B2   CELSEE DIAGNOSTICS INC (BIRA)   HANDIQUE K,  SHARMA V,  GOGOI P,  CHOW W,  PAYNE A,  GLEASON K,  BONIFACE B,  CONNOLLY J,  TUCK S;  US10391493-B2   CELSEE DIAGNOSTICS INC (BIRA)   HANDIQUE K,  SHARMA V;  US10947581-B2   CELSEE DIAGNOSTICS INC (BIRA)   HANDIQUE K,  STARK J,  DEOL Y,  SHARMA V;  WO2006098696-A1   ATTOGENIX BIOSYSTEMS PTE LTD (ATTO-Non-standard)   OVISO D F J,  TING D N;  WO2010142954-A1   OXFORD GENE TECHNOLOGY IP LTD (OXFO-Non-standard)   LUEERSSEN D W K,  MALLEO D;  WO2013176767-A1   UNIV NORTH CAROLINA (UNCR)   RAMSEY J M,  HENLEY W,  OBLATH E;  WO2016149639-A1   UNIV LELAND STANFORD JUNIOR (STRD);  WHALEN W (WHAL-Individual);  CELLA GENOMICS INC (CELL-Non-standard)   FATHOLLAHI B,  STEARNS D G,  WHALEN W;  WO2016151719-A1   HITACHI LTD (HITA)   SHIRAI MASATAKA,  SAKAI TOMOYUKI;  WO2016162997-A1   HITACHI LTD (HITA)   TANABE MAIKO,  SHIRAI MASATAKA,  SAKAI TOMOYUKI;  WO2016191533-A1   UNIV COLUMBIA NEW YORK (UYCO)   SIMS P A,  BOSE S,  YUAN J;  WO2018013723-A1   FLUIDIGM CORP (FLGM)   LIVAK K J,  FEKETE R A;  WO2019006436-A1   INSCRIPTA INC (INSC-Non-standard)   MASQUELIER D,  BELGRADER P,  BERNATE J,  GILL R,  NESS K;  WO2003035909-A2   NTU VENTURES PTE LTD (NTUV-Non-standard);  DEFENCE SCI & TECHNOLOGY AGENCY (DEFE-Non-standard)   YAP P H E,  GONG H,  AYI T C;  WO2010120818-A2   UNIV WASHINGTON SEATTLE (UNIW)   CHIU D T,  SCHIRO P G,  KUO J S;  WO2011017094-A2   CHAMBERLIN I (CHAM-Individual);  CLINTON C M (CLIN-Individual);  GLEZER E N (GLEZ-Individual);  JEFFREY-COKER B (JEFF-Individual);  KOCHAR M (KOCH-Individual);  KOVACS S (KOVA-Individual);  LE D (LEDD-Individual);  LEIMKUEHLER A (LEIM-Individual);  PINCKNEY G (PINC-Individual);  ROTH K (ROTH-Individual);  SIGAL G (SIGA-Individual);  YIN F (YINF-Individual)   CHAMBERLIN I,  CLINTON C M,  GLEZER E N,  JEFFREY-COKER B,  KOCHAR M,  KOVACS S,  LE D,  LEIMKUEHLER A,  PINCKNEY G,  ROTH K,  SIGAL G,  YIN F;  WO2012057548-A2   BIONEER CORP (BINR);  KIM J H (KIMJ-Individual)   JEONG B R,  KIM K S,  LEE J I,  LEE Y W,  PARK H O;  WO2018058073-A2   CELLULAR RES INC (BECT);  BECTON DICKINSON & CO (BECT)   FAN C,  CHANG C,  SHUM E,  ZOELLNER O,  BANSAL N,  GHADIALI J,  LAM G Y,  JENSEN E,  ROHRER J,  GAYLORD B,  MARTIN J,  VIDAL J G;  EP3982716-A4 -- WO2019046307-A1   CELSEE DIAGNOSTICS INC (BIRA)   HANDIQUE K,  SHARMA V;  WO2019104337-A1   UNIV COLUMBIA NEW YORK (UYCO)   SIMS P A,  BOSE S,  ZHOU J","WO2020251802-A1  STAHL ET AL.:          ""Visualization and Analysis of Gene Expression in Tissue          Sections by Spatial Transcriptomics"", SCIENCE, vol. 353,          1 July 2016 (2016-07-01), pages 78 - 82, XP002784680,          DOI:          10.1126/science.aaf2403,relevantClaims[5,11,25],relevantPassages[.          entire document];  MURPHY ET AL.:          ""Recent Advances in the Use of Microfluidic Technologies          for Single Cell Analysis"", ANALYST, vol. 143, 26 October          2017 (2017-10-26), pages 60 - 80,          XP055772711,relevantClaims[1-25],relevantPassages[.          entire document]US11724256-B2            Dura, Burak , et al., scFTD-seq: freeze-thaw lysis based,          portable approach toward highly distributed single-cell 3          mRNA profiling, Nucleic Acids Research, 2019, vol. 47,          No. 3, published online Nov. 20, 2018.;            High-throughput imaging of a unique continuous flow          microfluidics plate, Scikon Innovation, Application Note,          May 2016,          https://www.moleculardevices.com/en/assets/app-note/dd/img/high-throughput-imaging-of-a-unique-continuous-flow-microfluidics-plate#gref.;            Chen, H. , et al., High-throughput, deterministic single          cell trapping and long-term clonal cell culture in          microfluidic devices, Lab Chip. Feb. 21,          2015;15(4):1072-83. doi: 10.1039/c41c01176g. PMID:          25519528.;            Sarkar, S. , et al., Phenotypic drug profiling in droplet          microfluidics for better targeting of drug-resistant          tumors, Lab on a chip., vol. 15, 23 (2015): 4441-50.          doi:10.1039/c51c00923e.;            Yeh, EC , et al., Self-powered integrated microfluidic          point-of-care low-cost enabling (SIMPLE) chip, Sci Adv.          Mar. 22, 2017;3(3):e1501645. doi:10.1126/sciadv.1501645.          PMID: 28345028; PMCID: PM 5362183.;            Yuan, J. , et al., An Automated Microwell Platform for          Large-Scale Single Cell RNA-Seq., Sci Rep. Sep. 27,          2016;6:33883. doi: 10.1038/srep33883. PMID: 27670648;          PMCID: PMC5037380.;            International Search Report and Written Opinion for          application No. PCT/US20/035704 dated Sep. 9,          2020.;            International Search Report and Written Opinion for          application No. PCT/US20/31502 dated Sep. 16,          2020.;            Murphy, Travis W., et al., Recent advances in the use of          microfluidic technologies for signs;e cell analysis,          Analyst, Oct. 26, 2017, vol. 143, pp. 60-80.;            Stahl, Patrik L., et al., Visualization and analysis of          gene expression in tissue sections by spatial          transcriptomics, sciencemag.org, Jul. 2016, vol. 353,          Issue 6294, pp. 78-82.;            Australian Examination Report for Application No.          2018323449, dated Feb. 25, 2020.;            Guo, P. et al. Microfluidic capture and release of          bacteria in a conical nanopore array. Lab Chip. vol. 12,          p. 558-561, 2012, published online Nov. 2011.;            International Search Report and Written Opinion for PCT          Application No. PCT/US17/62099 dated Feb. 12,          2018.;            International Search Report and Written Opinion of the          ISA for application No. PCT/US20/022902 dated Apr. 22,          2020.;            International Search Report for PCT Application No.          PCT/US2018/048353 dated Nov. 5, 2018.;            Lindstrom, Sara (Royal Institute of Technology,          Stockholm, Sweden, 2009, pp. 1-80).;            International Preliminary Report on Patentability for PCT          Application No. PCT/US17/62099 dated May 31,          2019.;            Seale, K. T. et al. Mirrored pyramidal wells for          simultaneous multiple vantage point microscopy. Journal          of Microscopy (2008) 232 1-6. (Year: 2008).;            Sugio, Yoshihiro; et al., An agar-based on-chip          neural-cell-cultivation system for stepwise control of          network pattern generation during cultivation, Dept. of          Life Sciences, Graduate School of Arts and Sciences,          University of Tokyo, Jun. 24, 2003.;            Supplemental information from Tan et al. PNAS (2007) 104.          (Year: 2007).;            Tan, Wei-Heang et al. A trap-and-release integrated          microfluidic system for dynamic microarray applications.          PNAS (2007) 104 1146-1151. (Year: 2007).EP3982716-A4  JINZHOU YUAN ET AL:          ""SCOPE-Seq: a scalable technology for linking live cell          imaging and single-cell RNA sequencing"", GENOME BIOLOGY,          vol. 19, no. 227, 24 December 2018 (2018-12-24),          XP055680743, DOI:          10.1186/s13059-018-1607-x,relevantClaims[1-15],relevantPassages[Fig.          1; page 3, left col. ""In SCOPE-Seq, we load          ..."";];  MURPHY TRAVIS W. ET          AL: ""Recent advances in the use of microfluidic          technologies for single cell analysis"", ANALYST, vol.          143, no. 1, 1 January 2018 (2018-01-01), UK, pages 60 -          80, XP055772711, ISSN: 0003-2654, DOI:          10.1039/C7AN01346A,relevantClaims[1-15],relevantPassages[Fig.          4B]",,,,,
WO2023158487-A1,"Targeted delivery vehicle useful for delivering            cargo to cell of interest, comprises lipid bilayer            membrane, fusogen embedded in lipid bilayer membrane,            targeting moiety, and cargo within vesicle",ZHANG F;  STREBINGER D,BROAD INST INC (BROD-C);  MASSACHUSETTS INST TECHNOLOGY (MASI-C),202389705Y,"   NOVELTY - Targeted delivery vehicle comprises: a lipid                bilayer membrane, where the lipid bilayer membrane                forms a vesicle; a fusogen embedded in the lipid                bilayer membrane; a targeting moiety embedded in                the lipid bilayer membrane, where the targeting                moiety is separate and different from the fusogen;                and a cargo within the vesicle.    USE - The targeted delivery vehicle is useful for:                delivering a cargo to a cell of interest; and gene                therapy applications.    ADVANTAGE - The targeted delivery vehicle is modular,                specific and versatile.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    targeted delivery of a cargo comprising                administering a targeted delivery vehicle to a                subject in need of the cargo;    vector system for producing the targeted                delivery vehicle, where the vector system comprises                at least one vectors encoding the fusogen and the                targeting moiety;    host cell comprising or transformed with the                vector system;    host cell for producing the targeted delivery                vehicle, where the host cell comprising at least                one polynucleotides encoding the fusogen and the                targeting moiety; and    producing the targeted delivery vehicle,                comprising expressing at least one polynucleotide                encoding the fusogen and the targeting moiety in a                host cell in the presence of the cargo. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E08;  B04-E99;  B04-F0100E;  B12-M10E;  B12-M11F;  B14-S03A;  C04-E08;  C04-E99;  C04-F0100E;  C12-M10E;  C12-M11F;  C14-S03A;  D05-H12E;  D05-H14;  D05-H99,A61K-038/00;  A61K-047/68;  C07K-014/005;  C12N-015/86,WO2023158487-A1   24 Aug 2023   C12N-015/86   202373Pages: 212   English,WO2023158487-A1    WOUS052871    14 Dec 2022,,US310324P    15 Feb 2022;  US335195P    26 Apr 2022,WO2023158487-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2023158487-A1 -- US20210198698-A1   ;  WO2021055855-A1   BROAD INST INC (BROD);  MASSACHUSETTS TECHNOLOGY INST (MASI)   ZHANG F,  SEGEL M;  WO2021138480-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI)   ZHANG F,  FAURE G,  STREBINGER D,  SAITO M","WO2023158487-A1  MICHAEL SEGEL ET          AL.: ""Mammalian retrovirus-like protein PEG10 packages          its own mRNA and can be pseudotyped for mRNA delivery"",          SCIENCE, vol. 373, 20 August 2021 (2021-08-20), pages 882          - 889, XP055919110, DOI:          10.1126/science.abg6155,relevantClaims[1],relevantPassages[;          Title; abstract; page 4, third column, second to last          paragraph]",,,,,
WO2023077147-A2;  WO2023077147-A3,"Inducing or stimulating T cell mediated immune            response to T cell antigens comprises administering            mechanically disrupted epithelial tissue intact,            non-replicating or replication-impaired poxvirus,            expressing or including T cell antigens",KUPPER T S;  CARDINAL M,PELLIS THERAPEUTICS INC (PELL-Non-standard);  BRIGHAM & WOMENS HOSPITAL INC (BGHM-C),202347577Q,"   NOVELTY - Inducing or stimulating T cell mediated immune                response to at least one T cell antigens in                epithelial tissues in a subject having reduced                number of peripheral B cells in the blood compared                to a healthy control, comprises administering                mechanically disrupted epithelial tissue an intact,                non-replicating or replication-impaired poxvirus,                expressing or including at least one T cell                antigens, where the T cell antigens induce a T cell                mediated immune response in the subject.    USE - The method is useful for inducing or                stimulating T cell mediated immune response to at                least one T cell antigens in epithelial tissues in                a subject having reduced number of peripheral B                cells in the blood compared to a healthy control                (all claimed). Test details are described but no                results given.    ADVANTAGE - The method: enhances therapeutic efficacy and                protective immune response; and robust and                long-lasting immunity.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    kit comprising an intact, non-replicating or                replication-impaired poxvirus, and a device for                mechanically disrupting a subject's epidermal                tissue for use in the method; and    dosage unit for immunization by mechanical                disruption of an epidermal tissue comprising                inducing or stimulating a protective T cell                mediated immune response to a T cell antigen in an                epithelial tissue comprising skin, lung, oral                mucosa, gastrointestinal tract, or reproductive                mucosa for use in the method. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E99;  B04-B04C2;  B04-F0200E;  B11-C04;  B14-G01;  B14-S11D3;  B14-S12;  C04-E99;  C04-B04C2;  C04-F0200E;  C11-C04;  C14-G01;  C14-S11;  C14-S11D3;  C14-S12;  D05-H99;  D05-H07,A61K-000/00;  A61K-039/145;  A61P-031/16,WO2023077147-A2   04 May 2023   A61K-000/00   202341Pages: 194   English;  WO2023077147-A3   08 Jun 2023   A61K-039/145   202348   English,WO2023077147-A2    WOUS079034    01 Nov 2022;   WO2023077147-A3    WOUS079034    01 Nov 2022,,US274385P    01 Nov 2021,WO2023077147-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2023077147-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,";  WO2023077147-A3 -- WO2010050913-A1   BRIGHAM & WOMENS HOSPITAL INC (BGHM)   KUPPER T S,  LIU L L;  WO2012151272-A2   BRIGHAM&WOMENS HOSPITAL INC (BGHM)   KUPPER T S,  LIU L,  CLARK R A","WO2023077147-A3  LIU LUZHENG ET AL:          ""Epidermal injury and infection during poxvirus          immunization is crucial for the generation of highly          protective T cell-mediated immunity"", NATURE MEDICINE,          NATURE PUBLISHING GROUP US, NEW YORK, vol. 16, no. 2, 17          January 2010 (2010-01-17), pages 224 - 227, XP037922226,          ISSN: 1078-8956, [retrieved on 20100117], DOI:          10.1038/NM.2078,relevantClaims[1-11|12-35],relevantPassages[&lt;figure&gt;2b,          4h&lt;/figure&gt;]",,,,,
WO2020200186-A1;  CN113311164-A;  EP3949978-A1;  CN114025785-A;  IN202117049535-A;  JP2022531838-W;  EP3949978-A4;  US2024043511-A1;  JP7475366-B2,Use of reagents in preparing products for            preventing and/treating chronic inflammatory            diseases,LIANG H;  LIU Y;  YU Y,UNIV SUN YAT-SEN (UYSY-C);  UNIV SUN YAT-SEN (UYSY-C);  UNIV SUN YAT-SEN (UYSY-C);  GUANGZHOU ENMAI BIOTECHNOLOGY CO LTD (GUAN-Non-standard);  UNIV SUN YAT-SEN (UYSY-C),202098093X,"   NOVELTY - Use of reagents in preparing products for                preventing and/treating chronic inflammatory                diseases, is claimed. The agent is at least one of                substance that inhibits the activity of IFP35                and/or NMI secreted to the outside of the cell as                an abnormal content of inflammatory factors,                substances that inhibit the content and/or activity                of IFP35 and/or NMI that are secreted outside the                cell as inflammatory factors, substances that                inhibit IFP35 and/or NMI from being secreted out of                the cell as inflammatory factors, substances that                inhibit the abnormal increase in the content and/or                activity of IFP35 and/or NMI, substances that                inhibit IFP35 and/or NMI from being secreted                outside the cell, inhibiting IFP35 and/or NMI as                inflammatory factors that cause chronic                inflammatory diseases or inhibiting IFP35 and/or                NMI as DAMPs that cause chronic inflammatory                diseases.    USE - The reagents is useful in preparing products                for preventing and/treating chronic inflammatory                diseases (claimed).    DETAILED DESCRIPTION - Use of reagents in preparing products for                preventing and/treating chronic inflammatory                diseases, is claimed. The agent is at least one of                substance that inhibits the activity of IFP35                and/or NMI secreted to the outside of the cell as                an abnormal content of inflammatory factors,                substances that inhibit the content and/or activity                of IFP35 and/or NMI that are secreted outside the                cell as inflammatory factors, substances that                inhibit IFP35 and/or NMI from being secreted out of                the cell as inflammatory factors, substances that                inhibit the abnormal increase in the content and/or                activity of IFP35 and/or NMI, substances that                inhibit IFP35 and/or NMI from being secreted                outside the cell, inhibiting IFP35 and/or NMI as                inflammatory factors that cause chronic                inflammatory diseases or inhibiting IFP35 and/or                NMI as DAMPs that cause chronic inflammatory                diseases, substances that inhibit IFP35 and/or NMI                up-regulating the expression and secretion of some                inflammatory factors, where the inflammatory                factors are interferon, TNF, IL1 and/or IL6, and                inhibiting the action of IFP35 and/or NMI with TLR4                A substance that activates NF~kB through TLR4/MD2                INDEPENDENT CLAIMS are also included for:    (1) preventing and treating chronic                inflammatory disease, comprising applying reagent                into organism;    (2) use of substances detecting IFP35 and NMI                in preparing products for diagnosing chronic                inflammatory diseases, where the products are                fluorescent luminescence detection reagents or                kits, chemiluminescence detection reagents or kits,                Elisa detection reagents or kits, PCR detection                reagents or kits;    (3) diagnosing whether an organism has chronic                inflammatory diseases, comprising (i) detecting                whether the expression of IFP35/NMI in the                biological tissue (e.g. spinal cord tissue) is                significantly increased, (ii) detecting whether                IFP35/NMI is secreted into the blood or body fluid                of the organism (e.g. cerebrospinal fluid), (iii)                detecting whether the organisms blood or body                fluids (e.g. cerebrospinal fluid) contain IFP35                and/or NMI, and detecting the content of IFP35                and/or NMI in the blood or body fluid of the                organism (e.g. cerebrospinal fluid), (iv) detecting                content of IFP35 and/or NMI that is secreted into                the blood or body fluid of the organism (e.g.                cerebrospinal fluid) to assist in the medical                diagnosis of clinical inflammatory diseases, and                (v) detecting secreted IFP35 and/or NMI and other                inflammatory factors in the organism (e.g. TNF,                IL1, IL6, etc.) and biomarkers procalcitonin (PCT),                where the difference and correlation between                increased expression of C-reactive protein (CRP)                and increased secretion into the blood;    (4) antibody, polypeptide or antigen-binding                fragment;    (5) nucleic acid molecule encoding the                antibody;    (6) diagnosing or evaluating the degree of                inflammatory response in a virus-infected                individual includes measuring the amount of                interferon inducible protein 35kD (IFP35) and/or                N-Myc interacting protein (NMI) in a biological                sample obtained from the individual;    (7) kit for diagnosing or evaluating the                degree of inflammation in individuals infected with                the virus, comprising reagents for determining the                amount of interferon inducible protein 35kD (IFP35)                and/or N-Myc interacting protein (NMI) in a                biological sample obtained from the                individual;    (8) treating or alleviating inflammatory                response of individuals infected with the virus,                comprising administering interferon-inducible                protein 35kD (IFP35) and/or N-Myc interacting                protein (NMI) inhibitor into individual; and    (9) medicinal composition for treating or                alleviating the inflammatory response of an                individual infected with a virus, comprising                interferon-inducible protein 35kD (IFP35) and/or                N-Myc interacting protein (NMI) inhibitor, and                medicinally acceptable carrier; and    (10) use of kit in diagnosing or assisting in                the diagnosis of critically ill or critically ill                individuals. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E01B;  B04-E02A;  B04-E03A;  B04-E06;  B04-E07;  B04-E99;  B04-G01;  B04-G23;  B04-N02;  B04-N12;  B11-C07A4;  B11-C07B3;  B11-C07B4;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G;  B14-A02;  B14-C03;  B14-G01A;  B14-L01;  B14-L03;  B14-L06;  D05-H11;  D05-H12A;  D05-H99,A61K-038/17;  A61K-039/395;  A61P-029/00;  A61P-035/00;  A61K-045/00;  A61P-031/14;  A61P-031/16;  C12Q-001/6883;  G01N-033/68;  A61K-048/00;  C07D-471/04;  G01N-033/574;  A61K-031/7105;  A61K-031/713;  A61P-001/00;  A61P-001/02;  A61P-001/16;  A61P-001/18;  A61P-011/00;  A61P-011/06;  A61P-013/12;  A61P-017/00;  A61P-017/06;  A61P-019/02;  A61P-021/00;  A61P-025/00;  A61P-025/28;  A61P-027/02;  A61P-003/04;  A61P-003/10;  A61P-031/12;  A61P-035/02;  A61P-037/08;  A61P-043/00;  A61P-009/00;  A61P-009/10;  C07K-016/18;  C12N-015/113;  C12N-015/13;  G01N-033/53,WO2020200186-A1   08 Oct 2020   A61K-038/17   202085Pages: 29   Chinese;  CN113311164-A   27 Aug 2021   G01N-033/68   202173   Chinese;  EP3949978-A1   09 Feb 2022   A61K-038/17   202213   English;  CN114025785-A   08 Feb 2022   A61K-038/17   202218   Chinese;  IN202117049535-A   04 Mar 2022   G01N-033/68   202225   English;  JP2022531838-W   12 Jul 2022   A61K-045/00   202263   Japanese;  EP3949978-A4   29 Mar 2023   A61K-038/17   202329   English;  US2024043511-A1   08 Feb 2024   C07K-016/18   202413   English;  JP7475366-B2   26 Apr 2024   A61K-045/00   202438   Japanese,WO2020200186-A1    WOCN082296    31 Mar 2020;   CN113311164-A    CN10122554    27 Feb 2020;   EP3949978-A1    EP783545    31 Mar 2020;   CN114025785-A    CN80026317    31 Mar 2020;   IN202117049535-A    IN17049535    29 Oct 2021;   JP2022531838-W    JP560209    31 Mar 2020;   EP3949978-A4    EP783545    31 Mar 2020;   US2024043511-A1    US17600842    01 Oct 2021;   JP7475366-B2    JP560209    31 Mar 2020,EP3949978-A1 PCT application Application WOCN082296;   EP3949978-A1 Based on Patent WO2020200186;   CN114025785-A PCT application Application WOCN082296;   CN114025785-A Based on Patent WO2020200186;   IN202117049535-A PCT application Application WOCN082296;   IN202117049535-A Based on Patent WO2020200186;   JP2022531838-W PCT application Application WOCN082296;   JP2022531838-W Based on Patent WO2020200186;   US2024043511-A1 PCT application Application WOCN082296;   JP7475366-B2 PCT application Application WOCN082296;   JP7475366-B2 Previous Publ. Patent JP2022531838;   JP7475366-B2 Based on Patent WO2020200186,CN10256220    01 Apr 2019;  CN10122554    27 Feb 2020;  WOCN082296    31 Mar 2020;  CN80026317    29 Sep 2021,WO2020200186-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP3949978-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN        EP3949978-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR      ,,"WO2020200186-A1 -- CN107427552-A   CHINESE ACAD SCI BIOPHYSICS INST (CABP)   LIANG H,  LIU Y,  LIU Z,  SHEN J,  XIAHOU Z,  YAN R;  EP921192-A1   LEADD BV (LEAD-Non-standard)   NOTEBORN M H M,  DANEN-VAN OORSCHOT A A A M;  CN114025785-A -- CN101365802-A   BIOMERIEUX SA (INMR);  EXONHIT THERAPEUTICS SA (EXON-Non-standard)   KRAUSE A,  LEISSNER P,  PAYE M,  MOUGIN B,  SCHWEIGHOFFER F,  BRACCO L;  CN107427552-A   CHINESE ACAD SCI BIOPHYSICS INST (CABP)   LIANG H,  LIU Y,  LIU Z,  SHEN J,  XIAHOU Z,  YAN R;  US20180258484-A1   ;  WO1999028460-A2   ;  EP3949978-A4 -- WO2016026258-A1   CHINESE ACAD SCI BIOPHYSICS INST (CABP)   LIANG H,  LIU Y,  LIU Z,  SHEN J,  XIAHOU Z,  YAN R;  WO1999028460-A2   ","WO2020200186-A1  STRAUSBERG, R.L.,          ET.: ""interferon-induced protein 35{Homo sapiens]"",          GENBANK:AAH01356.1, 15 July 2006 (2006-07-15),          XP55741518, DOI:          20200623132310Y,relevantClaims[13],relevantPassages[sequence];  STRAUSBERG, R.L.,          ET.: ""Nmi[Homo sapiens]"", GENBANK:AAC1249.1, 9 April 1998          (1998-04-09), DOI:          20200623132454Y,relevantClaims[13],relevantPassages[sequence]CN114025785-A  : ""NmiUL23"",          ,relevantClaims[1-49],relevantPassages[126-132];  MARTIN S. WEBER ET          AL.: ""The role of antibodies in multiple sclerosis"",          BIOCHIMICA ET BIOPHYSICA          ACTA,relevantClaims[1-49],relevantPassages[239-245];  ZHIKAI XIAHOU ET          AL.: ""NMI and IFP35 serve as proinflammatory DAMPs during          cellular infection and injury"", NATURE          COMMUNICATIONS,relevantClaims[1-49],relevantPassages[1-11];  """",          ,relevantClaims[1-49],relevantPassages[118-120]EP3949978-A4            See also references of WO 2020200186A1",,,,,
WO2021203104-A1;  AU2021247302-A1;  CA3173793-A1;  KR2023006825-A;  EP4125944-A1;  CN115942942-A;  JP2023521662-W;  HK40087798-A0;  US2024050550-A1,Composition used to deliver self-replicating alpha            virus-based expression system to stimulate immune            comprises self-replicating alpha-virus-based expression            system and cassette,FERGUSON A;  ROUSSEAU R;  YELENSKY R;  SUN J X;  DAVIS M J;  JOOSS K;  RAPPAPORT A R;  SCALLAN C D;  GITLIN L;  PALMER C D;  RUSSO R;  SUN J;  SCALAN C D;  FERGUS A,GRITSTONE BIO INC (GRIT-Non-standard);  GRITSTONE BIO INC (GRIT-Non-standard);  GRITSTONE BIO INC (GRIT-Non-standard);  GRITSTONE BIO INC (GRIT-Non-standard),2021B52203,"   NOVELTY - Composition (C2), comprises (a) the                self-replicating alpha -virus-based expression                system, comprising at least one vector, comprising                (a1) RNA alphavirus backbone, comprising (i) at                least one promoter nucleotide sequence, and (a2) at                least one polyadenylation (poly(A)) sequence, and                (b) cassette, comprising (a3) at least one                antigen-encoding nucleic acid sequence comprising                nucleic acid sequence encoding infectious disease                organism peptide comprising pathogen-derived                peptide, virus-derived peptide, bacteria-derived                peptide, fungus-derived peptide, and                parasite-derived peptide, optionally a 5'-linker                sequence, and (c) optionally 3'-linker sequence,                optionally, second promoter nucleotide sequence                operably linked to the at least one                antigen-encoding nucleic acid sequence and                optionally, at least one second poly(A) sequence,                where the second poly(A) sequence is native poly(A)                sequence or exogenous poly(A) sequence to alpha                -virus, and lipid-nanoparticle (LNP) which                encapsulates the system.    USE - The compositions are useful for: delivering a                self-replicating alpha -virus-based expression                system; and stimulating immune response in a                subject (all claimed). The ability of composition                to produce T-cell response was tested in mice by                measuring mean cluster of differentiation (CD)8+ %                using in vivo assay. The result showed that the                mice treated with the composition (comprised of                ChAdV) exhibited 20.71% CD8% response%.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) a composition (C2) for delivering the                self-replicating alpha -virus-based expression                system, comprising (aa) an RNA alphavirus backbone,                where the RNA alphavirus backbone comprises the                nucleic acid sequence of SEQ ID NO: 6, where the                RNA alpha -virus backbone sequence comprises a 26S                promoter nucleotide sequence and a poly(A)                sequence, where the 26S promoter sequence is                endogenous to the RNA alphavirus backbone, and                where the poly(A) sequence is endogenous to the RNA                alphavirus backbone, and (bb) a cassette integrated                between the 26S promoter nucleotide sequence and                the poly (A) sequence, where the cassette is                operably linked to the 26S promoter nucleotide                sequence, and the LNP;    (2) a composition (C3) for delivering                chimpanzee adenovirus (ChAdV)-based expression                system, comprising the ChAdV-based expression                system, comprising the viral particle comprising a                ChAdV vector, comprising a ChAdV backbone,                comprising a modified ChAdV68 sequence comprising                at least 2-36 nucleotides of SEQ ID NO: 1, where                the nucleotides lack nucleotides 577-3403 of SEQ ID                NO: 1 corresponding to E1 deletion, nucleotides                27125-31825 of the SEQ ID NO: 1 corresponding to E3                deletion and optionally nucleotides 34916-35642 of                the SEQ ID NO: 1 corresponding to a partial E4                deletion, a cytomegalovirus promoter nucleotide                sequence and SV40 polyadenylation (poly(A))                sequence and the cassette, where the cassette is                inserted within the E1 deletion and the cassette is                operably linked to the CMV promoter nucleotide                sequence and the SV40 poly(A) sequence;    (3) a composition (C3) for delivering                self-replicating alphavirus-based expression                system, comprising the self-replicating                alphavirus-based expression system and the                cassette, where the cassette comprises at least one                antigen-encoding nucleic acid sequence comprising a                nucleic acid sequence encoding an infectious                disease organism peptide and optionally a 5' linker                sequence, and optionally a 3' linker sequence,                optionally, a second promoter nucleotide sequence                operably linked to the at least one                antigen-encoding nucleic acid sequence, and                optionally, at least one second poly(A) sequence,                where the second poly(A) sequence is a native                poly(A) sequence or an exogenous poly(A) sequence                to the alphavirus, and the LNP;    (4) stimulating immune response in a subject,                comprising administering the compositions (C1) or                (C3);    (5) a kit comprising the composition (C3) and                instructions for use;    (6) stimulating an immune response in a                subject, comprising administering a composition for                delivery of a self-replicating alphavirus- based                expression system and cassette, where the cassette                comprises optionally, a second promoter nucleotide                sequence operably linked to the at least one                antigen-encoding nucleic acid sequence and                optionally, at least one second poly(A) sequence,                and LNP; and    (7) stimulating an immune response in a                subject, comprising administering a composition                (C3), where the cassette comprises at least one                antigen-encoding nucleic acid sequence, optionally                a 5' linker sequence, and optionally a 3' linker                sequence, and where the cassette is operably linked                to the promoter nucleotide sequence and the poly(A)                sequence. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.)",B01-D02;  B04-B01B;  B04-C01;  B04-C03C;  B04-E01;  B04-E02;  B04-E04;  B04-E08;  B04-E99;  B04-F11A1;  B04-F11B;  B04-G01;  B04-G02;  B04-G23;  B04-H02;  B04-L03;  B04-L05A;  B04-N02;  B05-B01P;  B10-B04B;  B11-C11;  B14-G01;  B14-S11A;  B14-S18;  C01-D02;  C04-B01B;  C04-C01;  C04-C03C;  C04-E02;  C04-E04;  C04-E08;  C04-E99;  C04-F11A1;  C04-F11B;  C04-G02;  C04-G23;  C04-L03;  C04-L05A;  C04-N02;  C05-B01P;  C10-B04B;  C11-C11;  C14-G01;  C14-S11A;  C14-S18;  D05-H10;  D05-H99;  A05-H03;  A12-V01;  A12-W05,A61K-035/00;  A61K-035/76;  A61K-038/04;  A61K-039/00;  A61K-039/12;  A61K-048/00;  A61P-031/12;  A61P-031/16;  A61P-031/18;  C12N-015/86;  A61K-038/20;  A61K-039/04;  A61K-039/145;  A61K-039/215;  A61K-039/29;  A61K-039/395;  A61K-047/18;  A61K-047/24;  A61K-047/28;  A61K-009/127;  A61P-031/06;  A61P-031/20;  A61P-031/22;  A61P-037/04;  B82Y-005/00;  C12N-015/12;  C12N-015/861;  C12N-015/867;  C12N-015/88,WO2021203104-A1   07 Oct 2021   A61K-035/00   202191Pages: 241   English;  AU2021247302-A1   10 Nov 2022   A61K-035/00   202291   English;  CA3173793-A1   07 Oct 2021   A61K-035/00   202202   English;  KR2023006825-A   11 Jan 2023   A61K-039/12   202305   ;  EP4125944-A1   08 Feb 2023   A61K-035/00   202312   English;  CN115942942-A   07 Apr 2023   A61K-035/00   202333   Chinese;  JP2023521662-W   25 May 2023   C12N-015/867   202343   Japanese;  HK40087798-A0   15 Sep 2023   A61K-035/00   202395   English;  US2024050550-A1   15 Feb 2024   A61K-039/145   202415   English,WO2021203104-A1    WOUS025828    05 Apr 2021;   AU2021247302-A1    AU247302    05 Apr 2021;   CA3173793-A1    CA3173793    05 Apr 2021;   KR2023006825-A    KR738618    05 Apr 2021;   EP4125944-A1    EP780767    05 Apr 2021;   CN115942942-A    CN80040267    05 Apr 2021;   JP2023521662-W    JP560207    05 Apr 2021;   HK40087798-A0    HK6076659    27 Jul 2023;   US2024050550-A1    US937751    03 Oct 2022,AU2021247302-A1 PCT application Application WOUS025828;   AU2021247302-A1 Based on Patent WO2021203104;   CA3173793-A1 PCT application Application WOUS025828;   CA3173793-A1 Based on Patent WO2021203104;   KR2023006825-A PCT application Application WOUS025828;   KR2023006825-A Based on Patent WO2021203104;   EP4125944-A1 PCT application Application WOUS025828;   EP4125944-A1 Based on Patent WO2021203104;   CN115942942-A PCT application Application WOUS025828;   CN115942942-A Based on Patent WO2021203104;   JP2023521662-W PCT application Application WOUS025828;   JP2023521662-W Based on Patent WO2021203104;   HK40087798-A0 PCT application Application WOUS025828;   HK40087798-A0 Based on Patent WO2021203104;   HK40087798-A0 Previous Publ. Patent EP4125944;   US2024050550-A1 Cont of Application WOUS025828;   US2024050550-A1 Provisional Application US005160P,US005160P    03 Apr 2020;  EP780767    05 Apr 2021;  CA3173793    28 Sep 2022;  US937751    03 Oct 2022;  KR738618    03 Nov 2022;  CN80040267    02 Dec 2022,WO2021203104-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        EP4125944-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN          ,,"WO2021203104-A1 -- US6376236-B1   CHIRON CORP (CHIR)   DUBENSKY T W,  POLO J M,  IBANEZ C E,  DRIVER D A;  US6770283-B1   BIOPTION AB (BIOP-Non-standard)   GAROFF H,  LILJESTROEM P;  US8216834-B2   IST RICERCHE BIOL MOLECOLARE ANGELETTI (ISTR)   CIRILLO A,  COLLOCA S,  ERCOLE B B,  MEOLA A,  NICOSIA A,  SPORENO E;  WO2016122414-A1   AGENCY SCI TECHNOLOGY & RES (SGST);  UNIV NANYANG TECHNOLOGICAL (UYTU)   KAM Y J,  LEE W L W,  LIM S,  LUM F M,  NG F P L,  SU C,  YU K;  WO2018208856-A1   GRITSTONE ONCOLOGY INC (GRIT-Non-standard)   BLAIR W,  JOOSS K,  RAPPAPORT A R,  SCALLAN C D,  GITLIN L;  WO2005071093-A2   IST RICERCHE BIOL MOLECOLARE ANGELETTI (ISTR)   CIRILLO A,  COLLOCA S,  ERCOLE B B,  MEOLA A,  NICOSIA A,  SPORENO E",,8349-1-0-0 K M; 99222-0-0-0 K M; 2380690-1-0-0 K M; 86944-0-0-0 K M; 97942-0-0-0 K M; 220514-0-0-0 K M; 307556-0-0-0 K M; 900-0-0-0 K M; 105730-0-0-0 K M; 184611-0-0-0 K M; 93605-0-0-0 K M; 520167-0-0-0 K M; 485836-0-0-0 K M; 114365-0-0-0 K M; 97946-0-0-0 K M; 444-0-0-0 ; 2380690-1-0-0 CL USE,,,R00148 K M; R01833 K M; RA00JW K M; RB9HZM K M; RA02YD K M; RA05NO K M; RA04OB K M; RA0F7A K M; RA287Z K M; R02044 K M; RA0GM6 K M; RA012P K M; RA00H1 K M; RA00NS K M; RA6MMB K M; RA5WRV K M; RA03SD K M; R06364 K M; R16207 K M; R00351 ,0148-S; 1833-S; 2044-S
WO2021209009-A1;  EP4136255-A1;  CN115956115-A;  US2023193355-A1;  EP4136255-A4,"Analyzing or sequencing single cell, preferably            cancer cell, involves partitioning cell and bead            attached with barcode oligonucleotides into partition,            hybridizing first and second barcode oligonucleotides,            reverse transcribing RNA targets, amplifying, and            analyzing amplified barcoded cDNAs",FANG N;  ZHU W;  DING X,SINGLERON NANJING BIOTECHNOLOGIES LTD (SING-Non-standard);  SINGLERON NANJING BIOTECHNOLOGIES LTD (SING-Non-standard);  SINGLERON BIOTECHNOLOGIES CO LTD (SING-Non-standard);  SINGLERON NANJING BIOTECHNOLOGIES LTD (SING-Non-standard),2021B8866L,"   NOVELTY - Method (M1) for analyzing single cell involves                partitioning a cell and a bead attached with                several barcode oligonucleotides into a partition,                where each barcode oligonucleotide of the barcode                oligonucleotides comprises a cell barcode and a                unique molecular identifier (UMI), where first                barcode oligonucleotides of the barcode                oligonucleotides each comprises a poly-dT sequence                capable of binding to a polyadenylation (poly-A)                tail of a first mRNA target, hybridizing the first                barcode oligonucleotides and the second barcode                oligonucleotides attached to the bead in the                partition with RNA targets associated with the cell                in the partition, reverse transcribing the RNA                targets hybridized to the first barcode                oligonucleotides and the second barcode                oligonucleotides to generate barcoded cDNAs,                amplifying the barcoded cDNAs, and analyzing the                amplified barcoded cDNAs, or their products.    USE - The method is useful for analyzing or                sequencing single cell or generating beads (all                claimed). The method is also used for detecting                target genes of interest and normal transcripts                simultaneously at single cell resolution. The cell                is a cancer cell.    DETAILED DESCRIPTION - Method (M1) for analyzing single cell involves                partitioning a cell and a bead attached with                several barcode oligonucleotides into a partition,                where each barcode oligonucleotide of the barcode                oligonucleotides comprises a cell barcode and a                unique molecular identifier (UMI), where first                barcode oligonucleotides of the barcode                oligonucleotides each comprises a poly-dT sequence                capable of binding to a polyadenylation (poly-A)                tail of a first mRNA target, where second barcode                oligonucleotides of the barcode oligonucleotides                each comprises a poly-dT sequence and a probe                sequence, where the probe sequence is a non-poly-dT                sequence and is capable of binding to a second RNA                target at a sequence i.e. not a poly-A sequence,                hybridizing the first barcode oligonucleotides and                the second barcode oligonucleotides attached to the                bead in the partition with RNA targets associated                with the cell in the partition, reverse                transcribing the RNA targets hybridized to the                first barcode oligonucleotides and the second                barcode oligonucleotides to generate barcoded                cDNAs, amplifying the barcoded cDNAs, and analyzing                the amplified barcoded cDNAs, or their products.                INDEPENDENT CLAIMS are included for the                following:    (1) a method (M2) for sequencing single                cell;    (2) a composition comprising a beads, where                the cell barcodes of the barcode oligonucleotides                attached to each of the beads are identical, where                the cell barcodes of barcodes oligonucleotide                attached to different beads of the beads are                different, where the beads comprises at least 100                beads;    (3) a kit comprising a composition, and                instructions of using the composition for single                cell sequencing or analysis; and    (4) a method (M3) of generating beads                comprising barcode oligonucleotides involves (1)                providing a beads each attached to a                oligonucleotide barcodes, where each barcode                oligonucleotide of the barcode oligonucleotides                comprises a cell barcode, a UMI, and a poly-dT                sequence, and adding a probe sequence i.e. non a                poly-dT sequence and is capable of binding to a                nucleic acid target, to 3'-end of each of barcode                oligonucleotides of the barcode oligonucleotides or                (2) providing a beads each attached to a                oligonucleotide barcodes, where each barcode                oligonucleotide of the barcode oligonucleotides                comprises a cell barcode and a UMI, and adding (i)                a poly-dT sequence and/or (ii) a probe sequence                i.e. a non-poly-dT sequence and is capable of                binding to a nucleic acid target to 3'-end of each                of barcode oligonucleotides of the barcode                oligonucleotides. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  T04 (Computer Peripheral Equipment)",B04-B03C;  B04-E01;  B04-E02;  B04-E03;  B04-E05;  B04-E99;  B04-F01;  B04-F02A;  B04-N04;  B11-C08E3;  B11-C08F7A;  B11-C08F8;  B11-C11;  B12-K04F;  B12-K04G2A;  D05-H09;  D05-H10;  D05-H18A;  D05-H18B;  D05-H99;  T04-C02,C12M-001/00;  C12Q-001/68;  C12Q-001/6806,WO2021209009-A1   21 Oct 2021   C12Q-001/68   202189Pages: 103   English;  EP4136255-A1   22 Feb 2023   C12Q-001/68   202316   English;  CN115956115-A   11 Apr 2023   C12M-001/00   202338   Chinese;  US2023193355-A1   22 Jun 2023   C12Q-001/6806   202352   English;  EP4136255-A4   05 Jun 2024   C12Q-001/68   202448   English,WO2021209009-A1    WOCN087517    15 Apr 2021;   EP4136255-A1    EP787533    15 Apr 2021;   CN115956115-A    CN80047351    15 Apr 2021;   US2023193355-A1    US17996195    13 Oct 2022;   EP4136255-A4    EP787533    15 Apr 2021,EP4136255-A1 PCT application Application WOCN087517;   EP4136255-A1 Based on Patent WO2021209009;   CN115956115-A PCT application Application WOCN087517;   CN115956115-A Based on Patent WO2021209009;   US2023193355-A1 PCT application Application WOCN087517,WOCN085185    16 Apr 2020;  WOCN087525    28 Apr 2020;  WOCN085610    06 Apr 2021;  WOCN087517    15 Apr 2021;  CN80047351    16 Dec 2022,WO2021209009-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP4136255-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN      EP4136255-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  ,,"WO2021209009-A1 -- CN110199019-A   PROCURE LIFE SCI INC (PROC-Non-standard)   CHEE M,  GUNDERSON K,  WEINER M P;  WO2019104337-A1   UNIV COLUMBIA NEW YORK (UYCO)   SIMS P A,  BOSE S,  ZHOU J;  WO2017124101-A2   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  GIERAHN T M (GIER-Individual);  LOVE C J (LOVE-Individual);  HUGHES T K (HUGH-Individual);  WADSWORTH M H (WADS-Individual);  SHALEK A K (SHAL-Individual);  CARROLL S (CARR-Individual)   GIERAHN T M,  LOVE C J,  HUGHES T K,  WADSWORTH M H,  SHALEK A K,  CARROLL S;  EP4136255-A4 -- US20190285626-A1   ;  WO2017139690-A1   10X GENOMICS INC (TNXG);  HUTCHINSON CANCER RES CENT FRED (CANC)   ZHENG X,  BIELAS J H,  GREGORY M T,  HINDSON B,  MIKKELSEN T S,  WILSON R,  RYVKIN P;  WO2019104337-A1   UNIV COLUMBIA NEW YORK (UYCO)   SIMS P A,  BOSE S,  ZHOU J;  WO2019157529-A1   10X GENOMICS INC (TNXG)   BELHOCINE K,  BELL J,  BENT Z,  BHARADWAJ R,  HINDSON C,  RAHIMI LENJI M,  LIN B K,  MAKAREWICZ A,  MCDERMOTT G,  MEER E,  MESCHI F,  MIKKELSEN T S,  OKEEFFE C J,  PFEIFFER K,  PRICE A D,  RYVKIN P,  SCHNALL-LEVIN M,  TAYLOR S,  TERRY J M,  WHEELER T D,  YIN Y,  ZHENG X,  ZIRALDO S B,  IYER E P R,  MARTINEZ L J A;  WO2019195166-A1   10X GENOMICS INC (TNXG)   BENT Z,  RYVKIN P,  TERRY J M,  MCDERMOTT G,  FREY M;  WO2019084058-A2   MASSACHUSETTS INST TECHNOLOGY (MASI);  VAN HUMBECK J F (VHUM-Individual);  CARROLL S (CARR-Individual)   VAN HUMBECK J F,  CARROLL S,  SHALEK A K,  NAVIA A,  WADSWORTH M H,  HUGHES T K","WO2021209009-A1  EVANZ. MACOSKO,          ANINDITA BASU, RAHUL SATIJA, JAMES NEMESH, KARTHIK          SHEKHAR, MELISSA GOLDMAN, ITAY TIROSH, ALLISONR. BIALAS,          NOLA: ""Highly Parallel Genome-wide Expression Profiling          of Individual Cells Using Nanoliter Droplets"", CELL,          ELSEVIER, AMSTERDAM NL, vol. 161, no. 5, 1 May 2015          (2015-05-01), Amsterdam NL , pages 1202 - 1214,          XP055323004, ISSN: 0092-8674, DOI:          10.1016/j.cell.2015.05.002,relevantClaims[61|1-60],relevantPassages[figures          1 and 2];  LAFZI ATEFEH;          MOUTINHO CATIA; PICELLI SIMONE; HEYN HOLGER: ""Tutorial:          guidelines for the experimental design of single-cell RNA          sequencing studies"", NATURE PROTOCOLS, NATURE PUBLISHING          GROUP, GB, vol. 13, no. 12, 16 November 2018          (2018-11-16), GB , pages 2742 - 2757, XP036643359, ISSN:          1754-2189, DOI:          10.1038/s41596-018-0073-y,relevantClaims[1-61],relevantPassages[the          whole document]EP4136255-A4  SANJAY M. PRAKADAN          ET AL: ""Scaling by shrinking: empowering single-cell          'omics' with microfluidic devices"", NATURE REVIEWS          GENETICS, 10 April 2017 (2017-04-10), GB, XP055367559,          ISSN: 1471-0056, DOI:          10.1038/nrg.2017.15,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;|&lt;figure&gt;4&lt;/figure&gt;];            See also references of WO 2021209009A1",,,,,
WO2023138679-A1;  CN116515876-A,"Synthesizing flavonoids used as antioxidant,            antitumor, antibacterial, and heart protection,            comprises taking amine compound as substrate with            prokaryotic cell, e.g. exogenous genes encoding            enzymes, and down-regulating target gene",WANG Y;  LI J;  JI D,CAS CENT EXCELLENCE MOLECULAR PLANT SCI (CASB-C);  CAS CENT EXCELLENCE MOLECULAR PLANT SCI (CASB-C),202378787R,"   NOVELTY - Synthesizing flavonoids comprises: providing                recombinant prokaryotic cells, which include                exogenous genes encoding enzymes e.g. phenylalanine                ammonia lyase, 4-aroma soyate-coenzyme A ligase,                chalcone synthase, chalcone isomerase, and flavone                synthase I, up-regulate E. coli transmembrane                protein rhodanase single domain rhodanese (Ygap) in                the prokaryotic cell, and down-regulating the                target gene or target gene combination group e.g.                nucleotide sequence of the structural gene (pyrB),                acetyl-coenzyme A (CoA) carboxylase &#946;                (accB), acetyl-CoA carboxylase (accC),                4-(N-succino)-5-aminoimidazole-4-carboxamide                ribonucleotide synthetase (purC), Chlamydiaceae                genomes (glyA), transketolase (tktA), &#946;                -ketoacyl-acyl carrier protein (fabB),                3-isopropylmalate dehydratase (leuD),                3-isopropylmalate dehydratase (leuC), anaerobic                glycerol-3-phosphate dehydrogenase (glpC); and                taking amine compound (I) as the substrate with the                flavonoid compound synthesized by the prokaryotic                cell.    USE - The method is useful for synthesizing                flavonoids (claimed), which is used as antioxidant,                antitumor, antibacterial, and heart protection. No                biological data given.    ADVANTAGE - The method: provides flavonoids, which has                physiological activities, e.g. antioxidant,                antitumor, antibacterial, and heart protection; has                fast speed and less influence from external                factors; utilizes microorganisms, which provides                flavonoids much higher than that of plant                extraction; and achieves more economical and                convenient manufacture of the flavonoids.    DETAILED DESCRIPTION - Synthesizing flavonoids comprises: providing                recombinant prokaryotic cells, which include                exogenous genes encoding enzymes e.g. phenylalanine                ammonia lyase, 4-aroma soyate-coenzyme A ligase,                chalcone synthase, chalcone isomerase, and flavone                synthase I, up-regulate E. coli transmembrane                protein rhodanase single domain rhodanese (Ygap) in                the prokaryotic cell, and down-regulating the                target gene or target gene combination group e.g.                nucleotide sequence of the structural gene (pyrB),                acetyl-coenzyme A (CoA) carboxylase &#946;                (accB), acetyl-CoA carboxylase (accC),                4-(N-succino)-5-aminoimidazole-4-carboxamide                ribonucleotide synthetase (purC), Chlamydiaceae                genomes (glyA), transketolase (tktA), &#946;                -ketoacyl-acyl carrier protein (fabB),                3-isopropylmalate dehydratase (leuD),                3-isopropylmalate dehydratase (leuC), anaerobic                glycerol-3-phosphate dehydrogenase (glpC),                2-amino-4-hydroxy-6-hydroxymethyldihydropteridine                pyrophosphokinase (folK), and 2-isopropylmalate                synthetase (leuA); and taking amine compound of                formula (I) as the substrate with the flavonoid                compound synthesized by the prokaryotic cell, where                the flavonoid compound is chrysin compound.    R1=H, or OH.    INDEPENDENT CLAIM are also included for: (1)                prokaryotic cell for synthesizing flavonoids                comprising prokaryotic cell includes exogenous                coding genes for the group of enzymes phenylalanine                ammonia lyase, 4-coumaric acid coenzyme A ligase,                chamomile chalcone synthase, chalcone isomerase and                flavone synthase I, and, Escherichia                colitransmembrane protein rhodanase Ygap is                up-regulated in the prokaryotic cell, or target                gene or target group in the prokaryotic cell Gene                combinations are down-regulated pyrB, accC, accB,                purC, glyA, tktA, fabB, leuD, leuC, glpC, folK,                leuA, and the flavonoids are chrysin compounds; (2)                kit (K1) for producing flavonoids comprising                prokaryotic cells; (3) kit (K2) for establishing                host cell to synthesis of flavonoids comprising                expression of phenylalanine ammonia lyase,                4-coumaric acid-CoA ligase, check the construct of                cholone synthase, chalcone isomerase and flavone                synthase I, the construct of expressing Escherichia                colitransmembrane protein rhodanase Ygap, or the                construct of expressing down-regulator, described                below the regulator down-regulates the target gene                or target gene combination group of pyrB, accC,                accB, purC, glyA, tktA, fabB, leuD, leuC, glpC,                folK, leuA, optionally, the kit also includes                construct expressing the gene encoding flavone                6-hydroxylase, cytochrome P450 oxidoreductase; and                (4) application of regulating agent in promoting                the biosynthesis of flavonoids comprising                Escherichia colitransmembrane protein rhodanase                Ygap or its up-regulator, modulation downregulates                target gene or combination of target genes of pyrB,                accC, accB, purC, glyA, tktA, fabB, leuD, leuC,                glpC, folK, leuA.     ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B02 (Fused ring heterocyclics.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E13;  B04-E99;  B06-A01;  B11-A02;  B14-A01;  B14-D07C;  B14-F01;  B14-H01;  B14-S08;  D05-C22;  D05-H19C;  D05-H99,C07K-019/00;  C12N-001/19;  C12N-001/21;  C12N-015/53;  C12N-015/62;  C12N-015/70;  C12N-015/75;  C12N-015/81;  C12N-009/02;  C12P-017/06;  C12R-001/19;  C12N-015/113;  C12N-015/52;  C12N-015/54;  C12N-015/60;  C12N-015/61,WO2023138679-A1   27 Jul 2023   C12N-015/70   202366Pages: 41   Chinese;  CN116515876-A   01 Aug 2023   C12N-015/70   202366   Chinese,WO2023138679-A1    WOCN073308    20 Jan 2023;   CN116515876-A    CN10066386    20 Jan 2022,,CN10066386    20 Jan 2022,WO2023138679-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,"WO2023138679-A1 -- CN106191155-A   CHINESE ACAD SCI SHANGHAI BIOLOGICAL SCI (CABS)   LIU Q,  SONG S,  WANG J,  WANG Y,  XIONG Z;  CN110885846-A   CHINESE ACAD SCI SHANGHAI BIOLOGICAL SCI (CABS)   WANG Y,  LI J,  TIAN C;  CN113322288-A   CAS CENT EXCELLENCE MOLECULAR PLANT SCI (CASB)   WANG Y,  SUN Y,  CHEN Z;  US20120034661-A1   ","WO2023138679-A1  WU, JUNJUN:          ""Engineering Escherichia Coli Based on Synthetic Biology          For Production of Flavonoid Scaffolds"", CHINESE DOCTORAL          DISSERTATIONS FULL-TEXT DATABASE, vol. 2015, no. 11, 15          November 2015          (2015-11-15),relevantClaims[13|1-12],relevantPassages[B016-4,          see abstract];  WU JUNJUN, YU          OLIVER, DU GUOCHENG, ZHOU JINGWEN, CHEN JIAN:          ""Fine-Tuning of the Fatty Acid Pathway by Synthetic          Antisense RNA for Enhanced (2S)-Naringenin Production          from L-Tyrosine in Escherichia coli"", APPLIED AND          ENVIRONMENTAL MICROBIOLOGY, AMERICAN SOCIETY FOR          MICROBIOLOGY, US, vol. 80, no. 23, 31 October 2014          (2014-10-31), US , pages 7283 - 7292, XP093079909, ISSN:          0099-2240, DOI:          10.1128/AEM.02411-14,relevantClaims[13|1-12],relevantPassages[pages          7283-7292, see abstract, and material and          method];  JI DONGNI, LI          JIANHUA, XU FANGLIN, REN YUHONG, WANG YONG: ""Improve the          Biosynthesis of Baicalein and Scutellarein via          Manufacturing Self-Assembly Enzyme Reactor In Vivo"", ACS          SYNTHETIC BIOLOGY, AMERICAN CHEMICAL SOCIETY, WASHINGTON          DC ,USA, vol. 10, no. 5, 21 May 2021 (2021-05-21),          Washington DC ,USA , pages 1087 - 1094, XP093079911,          ISSN: 2161-5063, DOI:          10.1021/acssynbio.0c00606,relevantClaims[5],relevantPassages[pages          1087-1094, see abstract, and result and          discussion]",90899-0-0-0 K P; 88325-0-0-0 K P; 764244-0-0-0 K P; 87593-0-0-0 K P; 8184-0-0-0 K U V; 129495-0-0-0 K U V; 103859-0-0-0 K U V; 2012608-0-0-0 K U V; 753625-0-0-0 K U V; 336757-0-0-0 K U V; 219889-0-0-0 K U V; 200757-0-0-0 K U V; 294466-0-0-0 K U V; 286136-0-0-0 K U V; 350364-0-0-0 K U V; 103859-0-0-0 CL RGT USE; 2012608-0-0-0 CL RGT USE; 753625-0-0-0 CL RGT USE; 336757-0-0-0 CL RGT USE; 219889-0-0-0 CL RGT USE; 200757-0-0-0 CL RGT USE; 294466-0-0-0 CL RGT USE; 286136-0-0-0 CL RGT USE; 350364-0-0-0 CL RGT USE; 129495-0-0-0 CL RGT USE,,,R09222 K P; R07938 K P; RB0TEN K P; R06069 K P; R00243 K U V; R01372 K U V; RA1YGC K U V; RB1PF0 K U V; RAB6J2 K U V; RA2TLH K U V; RA0EQI K U V; RA00GT K U V; RA1YGD K U V; RA3DGQ K U V; RA1SJ4 K U V; RA33VU K U V,0243-U; 1372-U
WO2021030251-A1;  US2021047425-A1;  TW202120551-A;  CA3149494-A1;  AU2020328507-A1;  CN114127121-A;  KR2022061977-A;  SG11202200958-A;  EP4013788-A1;  JP2022544549-W;  IL290452-A;  HK40062439-A0;  BR112022002406-A2;  MX2022001732-A1;  RU2022106259-A,"New anti-cluster of differentiation (CD)39            antibody, or its antigen-binding fragment useful in            pharmaceutical preparation for detecting presence or            level of CD39 polypeptide, or improving anti-tumor T            cell immunity",SHANG Y W;  YAN W S;  SHAN I V,PURINOMIA BIOTECH INC (PURI-Non-standard);  PURINOMIA BIOTECH INC (PURI-Non-standard);  PURINOMIA BIOTECH INC (PURI-Non-standard);  BEIJING ENRUINI BIOTECHNOLOGY CO LTD (BEIJ-Non-standard);  PURINOMIA BIOTECH INC (PURI-Non-standard);  BEIJING EIRENE BIOTECH INC (BEIJ-Non-standard),202117755P,"   NOVELTY - An anti-cluster of differentiation (CD)39                antibody, or its antigen-binding fragment, where                the antibody, or its antigen-binding fragment                comprises (i) at least one antigen binding domain                that binds ectonucleoside triphosphate                diphosphohydrolase-1 (CD39) at a site such that the                anti-CD39 antibody forms a stable immune complex,                and (ii) a fragment crystallizable (Fc) gamma                -receptor IIIa (FcgRIIIa) binding moiety that binds                FcgRIIIa receptor and confers antibody-dependent                cellular cytotoxicity (ADCC) activity against CD39+                cells to the anti-CD39 antibody.    USE - The anti-CD39 antibody, or its antigen-binding                fragment is useful in pharmaceutical preparation                for (a) detecting the presence or level of CD39                polypeptide, (b) improving anti-tumor T cell                immunity, (c) promoting immune cell infiltration                into tumors, (d) reducing type II NKT cells                suppression of intratumoral immune cell function,                (e) reducing Treg suppression of intratumoral                immune cell function, (f) reducing TAMs suppression                of intratumoral immune cell function, (g) promoting                an anti-tumor immune response, (h) promoting T-cell                mediated immune function in a tumor of a subject,                (i) treating Mycobacterium tuberculosis, and                visceral leishmaniasis or (j) treating a solid                tumor, chosen from pancreatic cancer, liver cancer,                lung cancer, stomach cancer, esophageal cancer,                head and neck squamous cell carcinoma, prostate                cancer, colon cancer, breast cancer, lymphoma,                gallbladder cancer, renal cancer, multiple myeloma,                ovarian cancer, cervical cancer or glioma or                treating a liquid tumor, preferably leukemia. The                subject is an animal model of cancer. The subject                is a mammal, preferably human or a rodent (all                claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a pharmaceutical preparation comprising at                least one anti-CD39 antibody, or its                antigen-binding fragment, and excipients, buffers                or solutions;    (2) an isolated nucleic acid molecule that (i)                hybridizes with the complement of a nucleic acid                encoding an immunoglobulin heavy and/or light chain                polypeptide of the anti-CD39 antibody, or its                antigen-binding fragment, (ii) has a sequence with                at least 90% identity across its full length to a                nucleic acid encoding an immunoglobulin heavy                and/or light chain polypeptide of the anti-CD39                antibody, or its antigen-binding fragment or (iii)                encodes an immunoglobulin heavy and/or light chain                polypeptide of the anti-CD39 antibody, or its                antigen-binding fragment under stringent                conditions;    (3) an isolated immunoglobulin heavy and/or                light chain polypeptide encoded by the nucleic                acid;    (4) a vector comprising the isolated nucleic                acid, where the vector is an expression                vector;    (5) a host cell comprising the isolated                nucleic acid that (a) expresses the anti-CD39                antibody, or its antigen-binding fragment, (b)                comprises the immunoglobulin heavy and/or light                chain polypeptide and/or (c) comprises the                vector;    (6) a device or kit comprising at least one                anti-CD39 antibody, or its antigen-binding                fragment, a label to detect at least one anti-CD39                antibody, or its antigen-binding fragment, or a                complex comprising the anti-CD39 antibody, or its                antigen-binding fragment or the pharmaceutical                composition, isolated nucleic acid molecule,                isolated immunoglobulin heavy and/or light chain                polypeptide, vector, and/or host cell;    (7) a method (M1) of producing at least one                anti-CD39 antibody, or its antigen-binding                fragment;    (8) a method (M2) of detecting the presence or                level of CD39 polypeptide;    (9) a method (M3) for improving anti-tumor T                cell immunity by depleting intratumoral CD39 high                cells;    (10) a method (M4) for promoting immune cell                infiltration into tumors;    (11) a method (M5) for reducing type II                natural killer (NK)-T cells suppression of                intratumoral immune cell function;    (12) a method (M6) for reducing regulatory T                cells (Treg) suppression of intratumoral immune                cell function;    (13) a method (M7) for reducing                tumor-associated macrophages (TAMs) suppression of                intratumoral immune cell function;    (14) a method (M8) for promoting an anti-tumor                immune response; and    (15) a method (M9) for promoting T-cell                mediated immune function in a tumor of a                subject. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B02 (Fused ring heterocyclics.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-B04C;  B04-E02A;  B04-E03A;  B04-E08;  B04-E99;  B04-F0100E;  B04-G03;  B04-G04;  B04-G23;  B04-L05;  B05-A04;  B11-C07A;  B11-C08A;  B11-C08D1;  B12-K04E;  B14-A01B1A;  B14-A03F;  B14-G01;  B14-G03;  B14-H01;  B14-S18;  B14-S25;  C04-B04C;  C04-E02A;  C04-E03A;  C04-E08;  C04-E99;  C04-F0100E;  C04-G03;  C04-G04;  C04-G23;  C04-L05;  C04-N04;  C05-A04;  C11-C07A;  C11-C08A;  C11-C08D1;  C12-K04E;  C14-A01B1A;  C14-A03F;  C14-G01;  C14-H01;  C14-S18;  C14-S25;  D05-H09;  D05-H11;  D05-H12A;  D05-H12E;  D05-H14;  D05-H99,C07K-016/28;  A61P-035/00;  A61K-039/00;  A61K-039/395;  A61K-045/06;  A61P-035/02;  C07K-016/46;  C12N-015/13;  A61K-045/00;  A61K-047/68;  A61K-048/00;  A61K-009/08;  A61P-031/00;  A61P-043/00;  C12N-001/15;  C12N-001/19;  C12N-001/21;  C12N-015/63;  C12N-005/10;  C12P-021/08;  G01N-033/53,WO2021030251-A1   18 Feb 2021   C07K-016/28   202120Pages: 200   English;  US2021047425-A1   18 Feb 2021   C07K-016/28   202120   English;  TW202120551-A   01 Jun 2021   C07K-016/28   202174   Chinese;  CA3149494-A1   18 Feb 2021   202221   English;  AU2020328507-A1   17 Mar 2022   C07K-016/28   202223   English;  CN114127121-A   01 Mar 2022   C07K-016/46   202228   Chinese;  KR2022061977-A   13 May 2022   C07K-016/28   202242   ;  SG11202200958-A   25 Feb 2022   C07K-016/28   202246   English;  EP4013788-A1   22 Jun 2022   C07K-016/28   202251   English;  JP2022544549-W   19 Oct 2022   C12N-015/13   202284   Japanese;  IL290452-A   01 Apr 2022   C07K-016/28   202307   English;  HK40062439-A0   10 Jun 2022   C07K-016/46   202307   Chinese;  BR112022002406-A2   19 Jul 2022   C07K-016/28   202307   ;  MX2022001732-A1   06 May 2022   C07K-016/28   202382   Spanish;  RU2022106259-A   14 Sep 2023   C07K-016/28   202403   Russian,WO2021030251-A1    WOUS045589    10 Aug 2020;   US2021047425-A1    US988802    10 Aug 2020;   TW202120551-A    TW127122    10 Aug 2020;   CA3149494-A1    CA3149494    10 Aug 2020;   AU2020328507-A1    AU328507    10 Aug 2020;   CN114127121-A    CN80036163    10 Aug 2020;   KR2022061977-A    KR708046    10 Aug 2020;   SG11202200958-A    SG11000958    10 Aug 2020;   EP4013788-A1    EP764817    10 Aug 2020;   JP2022544549-W    JP509074    10 Aug 2020;   IL290452-A    IL290452    10 Aug 2020;   HK40062439-A0    HK6052081    21 Apr 2022;   BR112022002406-A2    BR11002406    10 Aug 2020;   MX2022001732-A1    MX001732    09 Feb 2022;   RU2022106259-A    RU106259    10 Aug 2020,US2021047425-A1 Provisional Application US885509P;   CA3149494-A1 PCT application Application WOUS045589;   CA3149494-A1 Based on Patent WO2021030251;   AU2020328507-A1 PCT application Application WOUS045589;   AU2020328507-A1 Based on Patent WO2021030251;   CN114127121-A PCT application Application WOUS045589;   CN114127121-A Based on Patent WO2021030251;   KR2022061977-A PCT application Application WOUS045589;   KR2022061977-A Based on Patent WO2021030251;   SG11202200958-A PCT application Application WOUS045589;   SG11202200958-A Based on Patent WO2021030251;   EP4013788-A1 PCT application Application WOUS045589;   EP4013788-A1 Based on Patent WO2021030251;   JP2022544549-W PCT application Application WOUS045589;   JP2022544549-W Based on Patent WO2021030251;   IL290452-A Based on Patent WO2021030251;   HK40062439-A0 PCT application Application WOUS045589;   HK40062439-A0 Based on Patent WO2021030251;   HK40062439-A0 Previous Publ. Patent CN114127121;   BR112022002406-A2 PCT application Application WOUS045589;   BR112022002406-A2 Based on Patent WO2021030251;   MX2022001732-A1 PCT application Application WOUS045589;   MX2022001732-A1 Based on Patent WO2021030251;   RU2022106259-A PCT application Application WOUS045589;   RU2022106259-A Based on Patent WO2021030251,US885509P    12 Aug 2019;  CN80036163    10 Aug 2020;  US988802    10 Aug 2020;  CN80036163    15 Nov 2021;  CA3149494    01 Feb 2022;  BR11002406    08 Feb 2022;  KR708046    10 Mar 2022;  RU106259    14 Mar 2022,WO2021030251-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA                EP4013788-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN              ,,"WO2021030251-A1 -- WO2019027935-A1   TIZONA THERAPEUTICS (TIZO-Non-standard)   SOROS V,  KOVALENKO M,  CORBIN J,  BEERS C,  WIDBOOM P F,  WARFIELD J R;  CA1176565-A   SYNTEX USA INC (SYNT)   KENT J S,  SANDERS L M,  LEWIS D H,  TICE T R;  DE3218121-A   LESKOVAT P (LESK-Individual);  EP3089-A   SILIUM SOC FR (SILI-Non-standard);  DAVID B (DAVI-Individual)   DAVID B;  EP36676-A   UNIV CALIFORNIA (REGC)   HUNT C A,  PAPAHADJOP D;  EP52322-A   GERSONDE K (GERS-Individual)   GERSONDE K,  SCHAEL W;  EP88046-A   CIBA GEIGY AG (CIBA)   HAUSER H;  EP102324-A   CIBA GEIGY AG (CIBA)   HAUSER H;  EP133988-A   HOECHST AG (FARH)   KONIG W,  SEIDEL H R,  SANDOW J K;  EP142641-A   EHRENFELD U (EHRE-Individual);  EP143949-A   TERUMO CORP (TERU)   NAKAGAME F,  HONDA H,  MARUYAMA T,  SAITO N,  KIMOTO T;  EP158277-A   HOECHST AG (FARH)   SANDOW J K;  EP2235061-A1   HOFFMANN LA ROCHE&CO AG F (HOFF)   AUER J,  BERSON A,  BORIE D C,  BRANDT M,  LORA J M,  RIES S R;  EP517565-A2   FIDIA SPA (FIDI)   CALLEGARO L,  ROMEO A,  BENEDETTI L;  JP2008118008-A   NIPPON TELEGRAPH & TELEPHONE CORP (NITE)   TSUCHISAWA Y,  ITABASHI S,  FUKUDA H,  YAMADA K,  WATANABE T,  SHINOSHIMA H,  SHINOJIMA H,  TSUCHIZAWA Y;  US3773919-A   DU PONT DE NEMOURS & CO E I (DUPO);  US3854480-A   ;  US3887699-A   YOLLES S (YOLL-Individual)   YOLLES S;  US4452775-A   SYNTEX (USA) (SYNT)   KENT J S;  US4485045-A   RESEARCH CORP (RESE)   REGEN S L;  US4544545-A   UNIV MASSACHUSETTS (UMAC)   RYAN D J,  DAVIS M A,  MELCHIOR D L;  US4650764-A   WISCONSIN ALUMNI RES FOUND (WISC)   TEMIN H M,  WATANABE S;  US4675189-A   SYNTEX (USA) (SYNT)   KENT J S,  LEWIS D H,  SANDERS L M,  RICE T R;  US4676980-A   US DEPT HEALTH & HUMAN SERVICE (USSH)   SEGAL D;  US4816567-A   GENENTECH INC (GETH);  CITY OF HOPE (CITY)   CABILLY S,  HOLMES W E,  WETZEL R B,  HEYNEKER H L,  RIGGS A D;  US4897268-A   SOUTHERN RES INST (SOUR)   TICE T R,  GILLEY R M;  US5075109-A   UAB RES FOUNDATION (UABR);  SOUTHERN RES INST (SOUR)   TICE T T,  ELDRIDGE J H,  GILLEY R M,  STASS J K;  US5133974-A   KV PHARM CO (KVPH-Non-standard)   PARADISSIS G N,  GAREGNANI J A,  WHALEY R S;  US5149655-A   AGRACETUS INC (CETU)   MCCABE D E,  MARTINELL B J;  US5151254-A   SUZUKI JIDOSHA KOGYO KK (SUZM);  SUZUKI KK (SUZM)   ARAI H,  KAWAI M,  MIYAI K;  US5206152-A   ARCH DEV CORP (ARCD)   SUKHATME V P;  US5252479-A   RESEARCH CORP TECHNOLOGIES INC (RESE)   SRIVASTAVA A;  US5399346-A   US DEPT HEALTH & HUMAN SERVICES (USSH)   BLAESE R M,  ROSENBERG S A,  ANDERSON W F;  US5407609-A   SOUTHERN RES INST (SOUR)   TICE T R,  GILLEY R M;  US5407686-A   SIDMAK LAB INC (SIDM-Non-standard)   BHALANI V T,  PATEL S P;  US5545806-A   GENPHARM INT INC (GENP-Non-standard)   LONBERG N,  KAY R M;  US5545807-A   MED RES COUNCIL (MEDI-Non-standard);  AGRIC & FOOD RES COUNCIL (AGRI-Non-standard)   BRUGGEMANN M;  US5569825-A   GENPHARM INT INC (GENP-Non-standard)   LONBERG N,  KAY R M;  US5625126-A   GENPHARM INT INC (GENP-Non-standard)   LONBERG N,  KAY R M;  US5633425-A   GENPHARM INT INC (GENP-Non-standard)   KAY R M,  LONBERG N;  US5635483-A   UNIV ARIZONA STATE (UYAS)   PETTIT G R,  BARKOCZY J;  US5654010-A   ALKERMES CONTROLLED THERAPEUTICS (AMES)   JOHNSON O L,  GANMUKHI M M,  BERSTEIN H,  AUER H,  KHAN M A;  US5661016-A   GENPHARM INT INC (GENP-Non-standard)   LONBERG N,  KAY R M;  US5663149-A   UNIV ARIZONA STATE (UYAS)   PETTIT G R,  SRIRANGAM J K,  KANTOCI D;  US5736152-A   ATRIX LAB INC (ATRI-Non-standard)   DUNN R L;  US5750373-A   GENENTECH INC (GETH)   GARRARD L J,  HENNER D J,  BASS S,  GREENE R,  LOWMAN H B,  WELLS J A,  MATTHEWS D J;  US5770429-A   GENPHARM INT INC (GENP-Non-standard)   LONBERG N,  KAY R M;  US5780588-A   UNIV ARIZONA STATE (UYAS)   PETTIT G R,  SRIRANGAM J K;  US5811097-A   UNIV CALIFORNIA (REGC)   ALLISON J P,  LEACH D R,  KRUMMEL M F;  US5811128-A   SOUTHERN RES INST (SOUR);  UAB RES FOUND (UABR)   ELDRIDGE J H,  STAAS J K,  TICE T R,  GILLEY R M;  US5814344-A   UAB RES FOUND (UABR);  SOUTHERN RES INST (SOUR)   ELDRIDGE J H,  STAAS J K,  GILLEY R M,  TICE T R;  US5820883-A   UAB RES FOUND (UABR);  SOUTHERN RES INST (SOUR)   TICE T R,  ELDRIDGE J H,  STAAS J K,  GILLEY R M;  US5821337-A   GENENTECH INC (GETH)   CARTER P J,  PRESTA L G;  US5853763-A   UAB RES FOUND (UABR);  SOUTHERN RES INST (SOUR)   ELDRIDGE J H,  STAAS J K,  GILLEY R M,  TICE T R;  US5928647-A   DANA FARBER CANCER INST INC (DAND)   ROCK K;  US5942252-A   SOUTHERN RES INST (SOUR);  UAB RES FOUND (UABR)   TICE T R,  GILLEY R M,  ELDRIDGE J H,  STAAS J K;  US6075181-A   CELL GENESYS INC (BISP)   KUCHERLAPATI R,  JAKOBOVITS A,  KLAPHOLZ S,  BRENNER D G,  CAPON D J;  US6080728-A   MIXSON A J (MIXS-Individual)   MIXSON A J;  US6150584-A   ABGENIX INC (AMGE)   KUCHERLAPATI R,  BRENNER D G,  KLAPHOLZ S,  JAKOBOVITS A,  CAPON D J;  US20050052630-A1   ;  US20050079574-A1   ;  US20050119455-A1   ;  US20050266000-A1   ;  US20070061900-A1   ;  US20070117126-A1   ;  US20070160598-A1   ;  US20070237764-A1   ;  US20070292936-A1   ;  US20090002360-A1   ;  US20100028330-A1   ;  US20120039906-A1   ;  US20120114649-A1   ;  US20130123345-A1   ;  US20140199334-A1   ;  US20140294898-A1   ;  US6214345-B1   BRISTOL-MYERS SQUIBB CO (BRIM)   FIRESTONE R A,  DUBOWCHIK G M;  US6372716-B1   GENETICS INST INC (GEMY)   BUSH L,  WEBB C;  US6566329-B1   NOVO NORDISK AS (NOVO)   MEYN G,  SORENSEN H H,  CHRISTENSEN T;  US6682736-B1   PFIZER INC (PFIZ);  ABGENIX INC (AMGE)   HANSON D C,  NEVEU M J,  MUELLER E E,  HANKE J H,  GILMAN S C,  DAVIS C G,  CORVALAN J R;  US8026223-B1   UNIV SOUTH FLORIDA (UYSF)   HELLER R,  LUCAS M L;  US6685940-B2   GENENTECH INC (GETH)   ANDYA J,  CLELAND J L,  HSU C C,  LAM X M,  OVERCASHIER D E,  SHIRE S J,  YANG J Y,  WU S S;  US6982321-B2   WINTER G P (WINT-Individual)   WINTER G P;  US7041870-B2   MEDAREX INC (BRIM);  KIRIN BEER KK (KIRI)   TOMIZUKA K,  ISHIDA I,  LONBERG N,  HALK E;  US7087409-B2   SCRIPPS RES INST (SCRI)   BARBAS C F,  RADER C;  US7189826-B2   INST HUMAN GENETICS & BIOCHEMISTRY (HUMA-Non-standard)   RODMAN T C;  US7245963-B2   DRAGHIA-AKLI R (DRAG-Individual);  CARPENTER R H (CARP-Individual);  KERN D R (KERN-Individual);  WESTERSTEN A (WEST-Individual);  WILKINSON W R (WILK-Individual)   DRAGHIA-AKLI R,  CARPENTER R H,  KERN D R,  WESTERSTEN A,  WILKINSON W R;  US7527791-B2   GENENTECH INC (GETH)   ADAMS C W,  FERRARA N,  FILVAROFF E,  MAO W,  PRESTA L G,  TEJADA M L;  US7592326-B2   KARAOLIS D K R (KARA-Individual)   KARAOLIS D K R;  US7709458-B2   KARAOLIS D K R (KARA-Individual)   KARAOLIS D K R,  RAUFMAN J;  US7923251-B2   UNIV LELAND STANFORD JUNIOR (STRD)   CHALBERG T W,  BLUMENKRANZ M,  PALANKER D V,  VANKOV A,  HUIE P,  MARMOR M F,  CALOS M P;  US7943743-B2   MEDAREX INC (BRIM)   KORMAN A J,  SELBY M J,  WANG C,  SRINIVASAN M,  PASSMORE D B,  HUANG H,  CHEN H;  US8008449-B2   ONO PHARM CO LTD (ONOY);  MEDAREX INC (BRIM)   KORMAN A J,  SRINIVASAN M,  WANG C,  SELBY M J,  CHEN B,  CARDARELLI J M;  US8101169-B2   UNIV LELAND STANFORD JUNIOR (STRD)   CHALBERG T W,  BLUMENKRANZ M,  PALANKER D V,  VANKOV A,  HUIE P,  MARMOR M F,  CALOS M P;  US8283171-B2   UNIV LELAND STANFORD JUNIOR (STRD)   CHALBERG T W,  BLUMENKRANZ M,  PALANKER D V,  VANKOV A,  HUIE P,  MARMOR M F,  CALOS M P;  US8354509-B2   ORGANON NV (ORGA)   CARVEN G J,  VAN EENENNAAM H,  DULOS G J;  US8609089-B2   AMPLIMMUNE INC (ASTR)   LANGERMANN S;  WO1989005345-A   ;  WO1990006997-A   ;  WO1991000360-A   ;  WO1992005266-A   ;  WO1992007573-A1   ;  WO1992011033-A1   ;  WO1992014829-A1   ;  WO1992020373-A1   ;  WO1993008829-A1   ;  WO1993015722-A1   ;  WO1994020069-A1   ;  WO1994020078-A1   ;  WO1994023701-A1   ;  WO1994026877-A1   ;  WO1996006638-A1   ;  WO1996007399-A1   ;  WO1996027011-A1   ;  WO1996029998-A1   ;  WO1997003692-A1   ;  WO1998007408-A1   ;  WO1999040934-A1   ;  WO2005087201-A1   OCTOPLUS TECHNOLOGIES BV (OCTO-Non-standard)   VERRIJK R;  WO2006121168-A1   ONO PHARM CO LTD (ONOY);  MEDAREX INC (BRIM)   KORMAN A J,  SRINIVASAN M,  WANG C,  SELBY M J,  CHEN B,  CARDARELLI J M;  WO2007000860-A1   PIONEER CORP (PIOE)   TAKAHASHI K,  KOBAYASHI T;  WO2009101611-A1   CURETECH LTD (CURE-Non-standard)   RODIONOV G,  ROTEM-YEHUDAR R;  WO2010077634-A1   GENENTECH INC (GETH)   CHEUNG J,  CHIU H,  IRVING B,  LEHAR S M,  MAECKER H,  MARIATHASAN S,  WU Y;  WO2012168944-A1   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY)   SASIKUMAR P G,  RAMACHANDRA M,  VADLAMANI S K,  SHRIMALI K R,  SUBBARAO K;  WO2013132317-A1   AURIGENE DISCOVERY TECHNOLOGIES LTD (REDY)   POTTAYIL GOVINDAN NAIR S,  RAMACHANDRA M,  NAREMADDEPALLI SEETHARAMAIAH S;  WO2014066700-A1   TOCAGEN INC (TOCA-Non-standard)   GRUBER H E,  JOLLY D J,  LIN A H,  LOGG C R,  KASAHARA N;  WO2014093936-A1   ADURO BIOTECH INC (ADUR-Non-standard)   DUBENSKY T W,  KANNE D B,  LEONG M L L,  LEMMENS E E,  GLICKMAN L H;  WO2014179335-A1   SLOAN KETTERING CANCER RES INST (SLOK);  UNIV ROCKEFELLER (UYRQ);  UNIV RUTGERS STATE NEW JERSEY (RUTF);  UNIV BONN (UYRF)   PATEL D J,  TUSCHL T,  ASCANO M,  WU Y,  LIU Y,  BARCHET W,  HARTMANN G,  ZILLINGER T,  JONES R,  GAFFNEY B L,  GAO P;  WO2014189805-A1   UNIV CALIFORNIA (REGC);  ADURO BIOTECH INC (ADUR-Non-standard)   DUBENSKY T W,  GLICKMAN L H,  KANNE D B,  LEMMENS E E,  LEONG M L L,  VANCE R E;  WO2015021077-A1   TOCAGEN INC (TOCA-Non-standard)   LIN A H,  GRUBER H E,  IBANEZ C,  JOLLY D J;  WO2015050364-A1   KOREA RES INST BIOSCIENCE &                  BIOTECHNOLOG (KRIB)   WON M S,  BAN H S,  KIM B K,  NAM S W,  LEE K,  LEE Y,  LEE H,  KIM D U,  PARK K C;  WO2015148683-A1   TOCAGEN INC (TOCA-Non-standard)   GRUBER H E,  JOLLY D J,  LIN A H,  ROBBINS J M,  OSTERTAG D G;  WO2015185565-A1   GLAXOSMITHKLINE INTELLECTUAL PROPERTY (GLAX)   BIGGADIKE K,  CHAMPIGNY A C,  COE D M,  NEEDHAM D,  TAPE D T;  WO2016096174-A1   INVIVOGEN (INVI-Non-standard)   VERNEJOUL F,  TIRABY G,  LIOUX T;  WO2016112359-A1   ONCOSEC MEDICAL INC (ONCO-Non-standard)   PIERCE R H,  WRIGHT J H;  WO2016145102-A1   ADURO BIOTECH INC (ADUR-Non-standard)   KATIBAH G E,  KANNE D,  SUNG L,  GAUTHIER K,  GLICKMAN L H,  LEONG J,  MCWHIRTER S M,  DUBENSKY T W;  WO2016154473-A1   ONCOSEC MEDICAL INC (ONCO-Non-standard);  PIERCE R H (PIER-Individual);  DAUD A (DAUD-Individual)   PIERCE R H,  DAUD A;  WO2017027645-A1   MERCK SHARP & DOHME CORP (MERI)   ALTMAN M D,  ANDRESEN B M,  CHANG W,  CHILDERS M L,  CUMMING J N,  HAIDLE A M,  HENDERSON T J,  JEWELL J P,  LIANG R,  LIM J,  LIU H,  LU M,  NORTHRUP A B,  OTTE R D,  SIU T,  TROTTER B W,  TRUONG Q T,  WALSH S P,  ZHAO K;  WO2017027646-A1   MERCK SHARP & DOHME CORP (MERI)   ALTMAN M D,  ANDRESEN B M,  CHANG W,  CHILDERS M L,  CUMMING J N,  HAIDLE A M,  HENDERSON T J,  JEWELL J P,  LIANG R,  LIM J,  LIU H,  LU M,  NORTHRUP A B,  OTTE R D,  SIU T,  TROTTER B W,  TRUONG Q T,  WALSH S P,  ZHAO K;  WO2017040815-A1   TOCAGEN INC (TOCA-Non-standard)   JOLLY D J,  LIN A H,  HOFACRE A;  WO2017075477-A1   ADURO BIOTECH INC (ADUR-Non-standard);  NOVARTIS AG (NOVS)   KATIBAH G E,  KANNE D,  SUNG L,  GAUTHIER K,  GLICKMAN L H,  LEONG J,  MCWHIRTER S M,  DUBENSKY T W,  MCKENNA J,  CANHAM S M,  NDUBAKU C O;  WO2017089334-A1   INNATE PHARMA (INNA);  OREGA BIOTECH (OREG-Non-standard)   BASTID J,  GAUTHIER L,  PATUREL C,  PERROT I,  ROUSSEL A,  AMIGUES B;  WO2017106795-A1   ONCOSEC MEDICAL INC (ONCO-Non-standard);  CAMPBELL J (CAMP-Individual);  CANTON D A (CANT-Individual)   CAMPBELL J,  CANTON D A,  PIERCE R H;  WO1996040072-A2   ;  WO2002088172-A2   ;  WO2003026577-A2   SEATTLE GENETICS INC (SEGE)   SENTER P D,  TOKI B E;  WO2004009664-A2   OMEROS CORP (OMRS);  INST MATERIALS RES & ENG (MATE-Non-standard)   LI J,  LI X,  NI X,  LEONG K W;  WO2004010957-A2   FRANCISCO J A (FRAN-Individual);  RISDON G (RISD-Individual);  WAHL A F (WAHL-Individual);  SIEGALL C (SIEG-Individual);  SENTER P D (SENT-Individual);  DORONINA S (DORO-Individual);  TOKI B E (TOKI-Individual)   FRANCISCO J A,  RISDON G,  WAHL A F,  SIEGALL C,  SENTER P D,  DORONINA S,  TOKI B E;  WO2005081711-A2   SEATTLE GENETICS INC (SEGE)   DORONINA S O,  SENTER P D,  TOKI B E,  EBENS A J,  KLINE T B,  POLAKIS P,  SLIWKOWSKI M X,  SPENCER S D;  WO2005082023-A2   GENENTECH INC (GETH);  SEATTLE GENETICS INC (SEGE)   FENG B;  WO2005084390-A2   SEATTLE GENETICS INC (SEGE)   ALLEY S C,  TORGOV M,  SUN M;  WO2006132670-A2   SEATTLE GENETICS INC (SEGE)   DORONINA S O,  MENDELSOHN B A;  WO2007005874-A2   MEDAREX INC (BRIM)   KORMAN A J,  SELBY M J,  WANG C,  SRINIVASAN M,  PASSMORE D B,  HUANG H,  CHEN H;  WO2007011968-A2   SEATTLE GENETICS INC (SEGE)   JEFFREY S;  WO2007054279-A2   GBF GES BIOTECH FORSCHUNG GMBH (GBFB)   EBENSEN T,  MORR M,  GUZMAN C A;  WO2009114335-A2   MERCK&CO INC (MERI)   CASIMIRO D R,  FINNEFROCK A C,  FREED D C,  FU T,  LI F,  TANG A;  WO2010027827-A2   AMPLIMMUNE INC (ASTR)   LANGERMANN S;  WO2010045002-A2   TOCAGEN INC (TOCA-Non-standard)   GRUBER H E,  JOLLY D,  PEREZ O;  WO2010148203-A2   TOCAGEN INC (TOCA-Non-standard)   JOLLY D J,  IBANEZ C;  WO2011066342-A2   AMPLIMMUNE INC (ASTR)   LANGERMANN S;  WO2011126864-A2   TOCAGEN INC (TOCA-Non-standard)   GRUBER H E,  JOLLY D J,  PEREZ O D,  LOGG C R;  WO2012058673-A2   TOCAGEN INC (TOCA-Non-standard)   GRUBER H E,  JOLLY D J,  OSTERTAG D G,  BURNETT R S,  LIN A H,  HUANG T,  ROBBINS J M;  WO2014066655-A2   DHILLON P (DHIL-Individual);  MCCLUSKEY B (MCCL-Individual)   DHILLON P,  MCCLUSKEY B;  WO2016054555-A2   NOVARTIS AG (NOVS);  CAO Z A (CAOZ-Individual);  RONG X (RONG-Individual);  PINZON-ORTIZ M C (PINZ-Individual);  LONGMIRE T (LONG-Individual);  LEE B H (LEEB-Individual)   CAO Z A,  RONG X,  PINZON-ORTIZ M C,  LONGMIRE T,  LEE B H;  WO2016161201-A2   ONCOSEC MEDICAL INC (ONCO-Non-standard)   BAHRAMI A,  DENISON A E,  HAYDEN C S,  CONNOLLY R J,  PIERCE R H,  BROWN D W,  JOHNSON E T,  RAGLAND R R,  CAMPBELL J","WO2021030251-A1  SEBASTIAN FM          H?USLER ET AL: ""Anti-CD39 and anti-CD73 antibodies A1 and          7G2 improve targeted therapy in ovarian cancer by          blocking adenosine-dependent immune evasion"", AM J TRANSL          RES, vol. 6, no. 2, 15 January 2014 (2014-01-15), pages          129 - 139,          XP055240896,relevantClaims[1-6,19,20,32,41|7-9,11-50],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            OHTA ET AL., PROC NATL ACAD SCI USA, vol. 103, 2006,          pages 13132 - 7;            PERROT ET AL., CELL REPORTS, vol. 27, 2019, pages 2411 -          2425;            LI, CANCER DISCOVERY, vol. 9, no. 12, 2020;            JUNGER ET AL., NAT. REV. IMMUNOL., vol. 11, 2011, pages          201 - 212;            MONCRIEFFE ET AL., J. IMMUNOL., vol. 185, 2010, pages          1993 - 1998;            ANTONIOLI ET AL., TRENDS MOL. MED., vol. 19, 2013, pages          355 - 367;            PARODI ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 62,          2013, pages 851 - 862;            BOER ET AL., EUR. J. IMMUNOL., vol. 43, 2013, pages 1925          - 1932;  XU          ET AL., NEURO-ONCOL., vol. 15, 2013, pages 1160 -          1172;            ZAREK ET AL., BLOOD, vol. 111, 2008, pages 251 -          259;            LOKSHIN ET AL., CANE. RES., vol. 66, 2006, pages 7758 -          7765;            BOERNER ET AL., J. IMMUNOL., vol. 147, no. 1, 1991, pages          2235 - 2244;            DEAGLIO ET AL., J. EXP. MED., vol. 204, 2007, pages 1257          - 1265;            BORSELLINO ET AL., BLOOD, vol. 110, 2007, pages 1225 -          1232;            PULTE ET AL., CLIN. LYMPH. MYELOMA LEUK., vol. 11, 2011,          pages 367 - 372;            CANALE ET AL., CANCER RES., vol. 78, no. 1, 2017, pages          115 - 28;            GUPTA ET AL., PLOS PATHOG., vol. 11, no. 10, 2015, pages          el005177;            MATHEW ET AL., SCIENCE, 2020;            KACZMAREK ET AL., J. BIOL. CHEM., vol. 271, 1996, pages          33116 - 33122;            MALISZEWSKI ET AL., J. IMMUNOL., vol. 152, 1994, pages          5368 - 3583;            HEINE ET AL., EUR. J. BIOCHEM., vol. 268, 2001, pages 364          - 373;            SMITH ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1386, 1998,          pages 65 - 78;  WU          ET AL., MOL. BIOL. CELL, vol. 16, 2005, pages 1661 -          1672;            SCHULTE AM ESCH ET AL., BIOCHEM., vol. 38, 1999, pages          2248 - 2258;            YANG ET AL., BIOCHEM., vol. 40, 2001, pages 3943 -          4940;            WANGGUIDOTTI, J. BIOL. CHEM., vol. 273, 1998, pages 11392          - 11399;            WARD ET AL., NATURE, vol. 341, 1989, pages 544 -          546;            CHANCARTER, NAT. REV. IMMUNOL., vol. 10, 2010, pages          301;            HOOGENBOOMWINTER, J. MOL. BIOL., vol. 222, 1991, pages          581;  AL          LAZIKANI ET AL., J. MOL. BIOL., vol. 273, 1997, pages 927          - 948;            NICOLAOU ET AL., ANGEW. CHEM INTL. ED. ENGL., vol. 33,          1994, pages 183 - 186;            JONES ET AL., NATURE, vol. 321, 1986, pages 522 -          525;            KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001;            BRODEUR ET AL.: ""Monoclonal Antibody Production          Techniques and Applications"", 1987, MARCEL DEKKER, INC.,          pages: 51 - 63;            MUNSONPOLLARD, ANAL. BIOCHEM., vol. 107, 1980, pages          220;            RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 -          327;            PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593          - 596;            ROSENBERG ET AL., SCIENCE, vol. 242, 1988, pages 1575 -          1578;            BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages          81;            SHALABY ET AL., J. EXP. MED., vol. 175, 1992, pages 217 -          225;            LONBERG ET AL., NATURE, vol. 368, 1994, pages 812 -          859;            FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996,          pages 826 - 51;            LONBERGHUSZAR, INTERN. REV. IMMUNOL., vol. 13, 1995,          pages 65 - 93;            MILSTEINCUELLO, NATURE, vol. 305, 1983, pages 537 -          539;            TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655 -          3659;            SURESH ET AL., METHODS IN ENZYMOLOGY, vol. 121, 1986,          pages 210;            KOSTELNY ET AL., J. IMMUNOL., vol. 148, no. 5, 1992,          pages 2918 - 2922;            HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90,          1993, pages 6444 - 6448;            CARON ET AL., J. EXP MED., vol. 176, 1992, pages 1191 -          1195;            WOLFF ET AL., CANCER RESEARCH, vol. 53, 1993, pages 2560          - 2565;            STEVENSON ET AL., ANTI-CANCER DRUG DESIGN, vol. 3, 1989,          pages 219 - 230;            ALMAGROFRANSSON, FRONT. BIOSCI., vol. 13, 2008, pages          1619 - 1633;            QUEEN ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 86, 1989,          pages 10029 - 10033;            DALL'ACQUA ET AL., METHODS, vol. 36, 2005, pages 61 -          68;            PADLAN, MOL. IMMUNOL., vol. 28, 1991, pages 489 -          498;            KLIMKA ET AL., BR. J. CANCER, vol. 83, 2000, pages 252 -          260;            PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages          2623;            CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992,          pages 4285;            BACA ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 10678          - 10684;            ROSOK ET AL., J BIOL. CHEM., vol. 271, 1996, pages 22611          - 22618;            VAN DIJKVAN DE WINKEL, CURR. OPIN. PHARMACOL., vol. 5,          2001, pages 368 - 74;            LONBERG, CURR. OPIN. IMMUNOL., vol. 20, 2008, pages 450 -          459;            LONBERG, NAT. BIOTECH., vol. 23, 2005, pages 1117 -          1125;  LI          ET AL., PROC. NATL. ACAD. SCI USA, vol. 103, 2006, pages          3557 - 3562;            NI, XIANDAI MIANYIXUE, vol. 26, no. 4, 2006, pages 265 -          268;            VOLLMERSBRANDLEIN, HISTOLOGY AND HISTOPATHOLOGY, vol. 20,          no. 3, 2005, pages 927 - 937;            VOLLMERSBRANDLEIN, METHODS AND FINDINGS IN EXPERIMENTAL          AND CLINICAL PHARMACOLOGY, vol. 27, no. 3, 2005, pages          185 - 91;            BROWN ET AL., J. IMMUNOL., vol. 170, no. 9, 2003, pages          1257 - 175;            MCCAFFERTY ET AL., NATURE, vol. 352, 1991, pages 624 -          628;            HOOGENBOOMWINTER, J. MOL. BIOL., vol. 227, 1992, pages          381 - 388;            SIDHU ET AL., J. MOL. BIOL., vol. 340, no. 5, 2004, pages          1073 - 1093;            FELLOUSE, PROC. NATL. ACAD. SCI. USA, vol. 101, no. 34,          2004, pages 12467 - 12472;            LEE ET AL., J. IMMUNOL. METHODS, vol. 284, no. 1-2, 2004,          pages 119 - 132;            WINTER ET AL., ANN. REV. IMMUNOL., vol. 12, 1994, pages          433 - 455;            GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 -          734;            MORI, K ET AL., CYTOTECHNOLOGY, vol. 55, 2007, pages          109;            SATOH M ET AL., EXPERT OPIN BIOL THER., vol. 6, 2006,          pages 1161 - 1173;            WOLFF ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989,          pages 9011 - 9014;            AGATA ET AL., INT IMMUNOL, vol. 8, 1996, pages 765 -          101;            WILSON, CLIN. EXP. IMMUNOL., vol. 107, no. 1, 1997, pages          31 - 32;            WIVEL ET AL.: ""Gene Therapy"", vol. 12, 1998, article          ""Hematology/Oncology Clinics of North America"", pages:          483 - 501;            ROMANO ET AL., STEM CELLS, vol. 18, 2000, pages 19 -          39;            WILSON ET AL., J. VIROL., vol. 63, 1989, pages 2374 -          2378;            BOESEN ET AL., BIOTHERAPY, vol. 6, 1994, pages 291 -          302;            CLOWES, J. CLIN. INVEST., vol. 93, 1994, pages 644 -          651;            KIEM ET AL., BLOOD, vol. 83, 1994, pages 1467 -          1473;            SALMONSGUNZBERG, HUMAN GENE THERAPY, vol. 4, 1993, pages          151 - 159;            MILLER ET AL., METH. ENZYMOL., vol. 217, 1993, pages 581          - 599;            GROSSMANWILSON, CURR. OPIN. IN GENETICS AND DEVEL., vol.          3, 1993, pages 110 - 114;            BUCHSCHER ET AL., J. VIROL., vol. 66, 1992, pages 1635 -          1640;            SOMMERFELT ET AL., VIROL., vol. 176, 1990, pages 58 -          59;            MILLER ET AL., J. VIROL., vol. 65, 1991, pages 2220 -          2224;            DUARTE ET AL., CANCER LETTERS, vol. 324, 2012, pages 160          - 170;            NIGHTINGALE ET AL., MOL. THER., vol. 13, 2006, pages 1121          - 1132;            SHACKLEFORD ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol.          85, 1998, pages 9655 - 9659;            ""Human Gene Therapy"", vol. 6, 1994, article ""Recombinant          DNA Advisory Committee Data Management Report"", pages:          535 - 548;            DIETZ ET AL., VECTOR ENGINEERING AND DELIVERY MOLECULAR          THERAPY, vol. 21, no. 8, 2013, pages 1526 -          1535;            HOU ET AL., MOLECULAR THERAPYMETHODS & CLINICAL          DEVELOPMENT, 2015;            CHEN Z YHE C YEHRHARDT AKAY M A., MOL THER., vol. 8, no.          3, September 2003 (2003-09-01), pages 495 - 500;            GRACEY MANIAR L EMANIAR J MCHEN Z YLU JFIRE A ZKAY M A.,          MOL THER., vol. 21, no. 1, January 2013 (2013-01-01),          pages 131 - 8;  HO          ET AL., J. IMMUNOL., vol. 175, no. 9, 2005, pages 6226 -          34;            ROEP ET AL., SCI. TRANSL. MED., vol. 5, no. 191, 2013,          pages 191ra82;            WOFFENDIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91,          no. 24, 1994, pages 11581;            CHAIBERG ET AL., INVESTIGATIVE OPHTHALMOLOGY & VISUAL          SCIENCE, vol. 47, 2006, pages 4083 - 4090;            LUO ET AL., PHYS. PLASMA, vol. 5, 1998, pages 2868 -          2870;            CONNOLLY ET AL., HUMAN VACCINES &          IMMUNE-THERAPEUTICS, vol. 8, 2012, pages 1729 -          1733;            CONNOLLY ET AL., BIOELECTROCHEMISTRY, vol. 103, 2015,          pages 15 - 21;            MAHAPATRO A ET AL., J NANOBIOTECHNOL, vol. 9, 2011, pages          55;  LI          ET AL., AGNEW CHEM INT ED ENL, vol. 54, no. 10, 2015,          pages 2941 - 4;            ""Remington: The Science and Practice of Pharmacy"", 2012,          PHARMACEUTICAL PRESS;            YAN ET AL., BIOORG. MED. CHEM LETT., vol. 18, 2008, pages          5631 - 4;            THOMAS, M.L., J EXP MED, vol. 181, 1995, pages 1953 -          6;            VIVIER, EDAERON, M, IMMUNOL TODAY, vol. 18, 1997, pages          286 - 91;            FREEMAN ET AL., J EXP MED, vol. 192, 2000, pages 1027 -          34;            LATCHMAN ET AL., NAT IMMUNOL, vol. 2, 2001, pages 261 -          8;            CARTER ET AL., EUR J IMMUNOL, vol. 32, 2002, pages 634 -          43;            DONG ET AL., NAT. MED., vol. 8, 2002, pages 787 -          9;            DONG ET AL., J. MOL. MED., vol. 81, 2003, pages 281 -          7;            BLANK ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 54, 2005,          pages 307 - 314;            KONISHI ET AL., CLIN. CANCER RES., vol. 10, 2004, pages          5094 - 100;            IWAI ET AL., PROC. NAT'L. ACAD. SCI. USA, vol. 99, 2002,          pages 12293 - 7;            HAMID, O. ET AL., NEW ENGLAND JOURNAL OF MEDICINE, vol.          369, no. 2, 2013, pages 134 - 44;            HUXLEY ET AL., CELL CHEMICAL BIOLOGY, vol. 11, 2004,          pages 1651 - 1658;            WOYKE ET AL., ANTIMICROB. AGENTS AND CHEMOTHER., vol. 45,          no. 12, 2001, pages 3580 - 3584;            PETTIT ET AL., ANTIMICROB. AGENTS AND CHEMOTHER., vol.          42, 1998, pages 2961 - 2965;            HARTLEY J. A. ET AL., CANCER RES, vol. 70, no. 17, 2010,          pages 6849 - 6858;            ANTONOW D. ET AL., CANCER J, vol. 14, no. 3, 2008, pages          154 - 169;            HOWARD P. W. ET AL., BIOORG MED CHEM LETT, vol. 19, 2009,          pages 6463 - 6466;            SAGNOU ET AL., BIOORG MED CHEM LETT, vol. 10, no. 18,          2000, pages 2083 - 2086;            LEE ET AL., BIOCONJ. CHEM., vol. 10, 1999, pages 973 -          981;            WEN ET AL., BIOCONJ. CHEM., vol. 12, 2001, pages 545 -          553;            HUNTER ET AL., NATURE, vol. 144, 1962, pages          945;            DAVID ET AL., BIOCHEMISTRY, vol. 13, 1974, pages          1014;            PAIN ET AL., J. IMMUNOL. METH., vol. 40, 1981, pages          219;            NYGREN, J., HISTOCHEM. AND CYTOCHEM., vol. 30, 1982,          pages 407;            HORA ET AL., BIO/TECHNOLOGV., vol. 8, 1990, pages 755 -          758;            HWANG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980,          pages 4030 - 4034;  U.          SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 -          556;            LANGER ET AL., J. BIOMED. MATER. RES., vol. 15, 1981,          pages 167 - 277;  R.          LANGER ET AL., CHEM. TECH., vol. 12, 1982, pages 98 -          105;            EPPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82,          1985, pages 3688 - 3692;            JOHNSON ET AL., NAT. MED., vol. 2, 1996, pages 795 -          799;            YASUDA, BIOMED. THER., vol. 27, 1993, pages 1221 -          1223;            CLELAND: ""Vaccine Design: The Subunit and Adjuvant          Approach"", 1995, PLENUM PRESS, article ""Design and          Production of Single Immunization Vaccines Using          Polylactide Polyglycolide Microsphere Systems"", pages:          439 - 462;            LEWIS: ""Biodegradable Polymers as Drug Delivery Systems"",          1990, MARCEL DEKKER, article ""Controlled release of          bioactive agents from lactide/glycolide polymer"", pages:          1 - 41;            SINHA ET AL., J. CONTROL. RELEASE, vol. 90, 2003, pages          261;            ZHU ET AL., NAT. BIOTECHNOL., vol. 18, 2000, pages          24;            DAI ET AL., COLLOIDS SURF B BIOINTERFACES, vol. 41, 2005,          pages 117;            CORTIVO ET AL., BIOMATERIALS, vol. 12, 1991, pages 727 -          730;            ILIUM ET AL., J. CONTROLLED REL., vol. 29, 1994, pages          133 - 141;            SAWHNEY ET AL., MACROMOLECULES, vol. 26, 1993, pages 581          - 587US2021047425-A1            Al-Lazikani, B. et al, Standard conformations for the          canonical structures of immunoglobulins,1997, Journal of          Molecular Biology, Volume 273, 927-948. (Year:          1997);            Junker, F. et al, Fc Gamma Receptors and Their Role in          Antigen Uptake, Presentation, and T Cell Activation,          2020, Frontiers in Immunology, Volume 11, 1393. (Year:          2020)",184587-0-0-0 A K M Q; 87635-0-0-0 A K M Q; 93605-0-0-0 A K M Q; 105730-0-0-0 A K M Q; 184611-0-0-0 A K M Q; 184587-0-0-0 CL DET RCT USE; 87635-0-0-0 CL DET RCT USE; 93605-0-0-0 CL DET RCT USE; 105730-0-0-0 CL DET RCT USE; 184611-0-0-0 CL DET RCT USE,,,RA00C8 A K M Q; RA0MKY A K M Q; RA00NS A K M Q; RA012P A K M Q; RA00H1 A K M Q,
CA3179062-A1;  WO2023062353-A1;  WO2023062354-A2;  WO2023062354-A3;  CN118119375-A,"Nanoparticle useful for e.g. stimulating or            enhancing therapeutic or protective immune response,            and treating proliferative disorder such as cancer,            comprises outer lipid shell, inner aqueous core            comprising imiquimod and cytokine such as            interleukin-2",MOODY M;  HORSBURGH B;  MOODY M D,IMMUNOVA THERAPEUTICS LTD (IMMU-Non-standard);  NEWIMMUNE II LLC (NEWI-Non-standard),202338629K,"   NOVELTY - Nanoparticle for co-delivery and optionally                sustained release of imiquimod and a protein                cytokine such as interleukin (IL)-2, comprises an                outer lipid shell and an inner aqueous core                encapsulated within the outer lipid shell, the                inner aqueous core comprises imiquimod; and the                nanoparticle further comprises a protein cytokine                such as IL-2 releasably attached to, associated                with and/or encapsulated within the lipid shell.                The inner aqueous core comprises a host molecule                that is capable of reversibly forming a complex                with imiquimod. The inner aqueous core of the                nanoparticle has a pH of at least about 6.5;                optionally a pH of at least 7, or a pH of about 7-9                or about 7.5-9.    USE - The nanoparticle is useful in preparation of                medicament or composition for stimulating or                enhancing a therapeutic or protective immune                response, treating a proliferative disorder such as                cancer and immunizing the subject against a viral,                bacterial or fungal infection, colonization or                disease, or against a proliferative disorder such                as cancer. The proliferative disorder comprises                melanoma or metastatic melanoma, and/or basal cell                carcinoma or metastatic basal cell carcinoma,                and/or cutaneous squamous cell carcinoma, and/or                Merkel cell carcinoma, and/or breast cancer, and/or                extramammary Paget's disease, and/or renal cell                carcinoma or metastatic renal cell carcinoma,                and/or head and neck cancer or metastatic head and                neck cancer, and/or wherein the cancer includes                pancreatic cancer, or bladder cancer, or prostate                cancer, or lymphoma, or liver cancer, or colorectal                cancer, or uveal melanoma, or esophageal cancer, or                lung cancer, or their metastases (all                claimed).    ADVANTAGE - The nanoparticles are designed to facilitate                coordinated, controlled, sustained and optionally                localized delivery of imiquimod and, optionally, a                protein cytokine such as IL-2, to a patient in need                of immunotherapy.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    a nanoparticulate composition comprising                several nanoparticles, preferably comprising an                aqueous solution, dispersion or suspension of                nanoparticles;    a method for stimulating or enhancing a                therapeutic or protective immune response or for                treating a proliferative disorder such as cancer in                a patient, involves administering the                composition;    a method for manufacturing the nanoparticle                involves (a) solubilizing imiquimod in aqueous                solution at a pH buffered to about pH 6 or below,                preferably to about pH 4-6, or to about pH 4.5-6,                or to about pH 4-5.5, or to about pH 5-6, followed                by (b) combining the resulting aqueous solution                with lipids to form lipid shell nanoparticles                encapsulating imiquimod, followed by (c) increasing                the buffered pH of the formulation to about pH 6.5                or above, or to about pH 7 or above, or to about pH                6.5-9;    a vaccine adjuvant comprising several                nanoparticles that comprise an outer lipid shell                and an inner aqueous core encapsulated within the                outer lipid shell, the inner aqueous core comprises                imiquimod and a host molecule that is capable of                reversibly forming a complex with imiquimod;    a vaccine composition comprising: (a) an                antigen that is capable of inducing an immune                response and/or a polynucleotide that encodes an                antigen capable of inducing an immune response and                (b) a vaccine adjuvant comprising                nanoparticles;    a method for inducing an immune response                involves administering the vaccine composition or                vaccine adjuvant in conjunction with a                vaccine;    a method for manufacturing the vaccine                adjuvant involves (a) solubilizing imiquimod with                the host molecule in aqueous solution at a pH                buffered to pH 6 or below, (b) combining the                resulting aqueous solution with lipids to form                lipid shell nanoparticles encapsulating imiquimod                and (c) increasing the buffered pH of the                formulation to about pH 6.5 or above; and    a method for producing the vaccine composition                involves providing a vaccine adjuvant and adding an                antigen that is capable of inducing an immune                response and/or a polynucleotide that encodes an                antigen capable of inducing an immune                response. ",,,"A96 (Medical, dental, veterinary, cosmetic.);  B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B02 (Fused ring heterocyclics.);  ;  C02 (Heterocyclic.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",A12-V01;  A12-W14;  A12-W15;  B04-B04C;  B04-C01;  B04-C02;  B04-C02A;  B04-C02B1;  B04-C03A;  B04-C03B;  B04-C03C;  B04-C03D;  B04-C03F;  B04-E01;  B04-E02J;  B04-E03J;  B04-G01;  B04-H02B;  B04-N02;  B06-D17;  B06-F05;  B12-M10A;  B12-M11Q1;  B12-M18;  B14-A04;  B14-G01;  B14-H01;  B14-N01;  B14-N10;  B14-S11A;  B14-S11B;  B14-S11C;  B14-S11F;  C04-C01;  C04-C02;  C04-C02A;  C04-C02B1;  C04-C03A;  C04-C03B;  C04-C03C;  C04-C03D;  C04-C03F;  C04-E01;  C04-E02J;  C04-E03J;  C04-G01;  C04-H02B;  C04-N02;  C06-D17;  C06-F05;  C12-M10A;  C12-M11Q1;  C12-M18;  C14-A04;  C14-G01;  C14-H01;  C14-N01;  C14-N10;  C14-S11A;  C14-S11B;  C14-S11C;  C14-S11F;  D05-H07;  D05-H10,A61K-031/4745;  A61K-038/20;  A61K-039/39;  A61K-047/40;  A61K-047/69;  A61K-009/51;  A61K-009/64;  A61K-009/66;  A61P-035/00;  A61P-037/04;  A61K-039/215;  A61K-047/10;  A61K-009/00;  A61K-009/127;  A61P-031/14;  A61K-045/06;  A61P-035/04,CA3179062-A1   11 Apr 2023   A61K-047/69   202339Pages: 96   English;  WO2023062353-A1   20 Apr 2023   A61K-009/00   202339   English;  WO2023062354-A2   20 Apr 2023   A61K-009/00   202339   English;  WO2023062354-A3   01 Jun 2023   A61K-009/00   202347   English;  CN118119375-A   31 May 2024   A61K-009/00   202448   Chinese,CA3179062-A1    CA3179062    11 Oct 2022;   WO2023062353-A1    WOGB052569    11 Oct 2022;   WO2023062354-A2    WOGB052570    11 Oct 2022;   WO2023062354-A3    WOGB052570    11 Oct 2022;   CN118119375-A    CN80068770    11 Oct 2022,CN118119375-A PCT application Application WOGB052569;   CN118119375-A Based on Patent WO2023062353,US254253P    11 Oct 2021;  GB001351    02 Feb 2022;  US321886P    21 Mar 2022;  CN80068770    11 Apr 2024,  WO2023062353-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW  WO2023062354-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW  WO2023062354-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW    ,,";  WO2023062353-A1 -- US9066940-B2   TELORMEDIX SA (TELO-Non-standard)   LEONI L,  MAJ R,  PATTARINO F,  VECCHIO C;  WO2013155487-A1   UNIV YALE (UYYA)   FAHMY T M,  STERN E,  FLAVELL R A,  PARK J,  SIEFERT A;  WO2020220000-A1   TLC BIOPHARMACEUTICALS INC (TLCB-Non-standard);  TAIWAN LIPOSOME CO LTD (TALI-Non-standard)   TSENG Y,  CHIU H;  WO2023062354-A3 -- JP08099897-A   ;  US20160331743-A1   ;  US20180296850-A1   ;  WO2013155487-A1   UNIV YALE (UYYA)   FAHMY T M,  STERN E,  FLAVELL R A,  PARK J,  SIEFERT A;  WO2020220000-A1   TLC BIOPHARMACEUTICALS INC (TLCB-Non-standard);  TAIWAN LIPOSOME CO LTD (TALI-Non-standard)   TSENG Y,  CHIU H","WO2023062353-A1  CHRISTOPHER B FOX          ET AL: ""A nanoliposome delivery system to synergistically          trigger TLR4 AND TLR7"", JOURNAL OF NANOBIOTECHNOLOGY,          BIOMED CENTRAL, vol. 12, no. 1, 26 April 2014          (2014-04-26), pages 17, XP021184854, ISSN: 1477-3155,          DOI:          10.1186/1477-3155-12-17,relevantClaims[1-3,7-12,15,16,18-22,26,30-33,35|1-35],relevantPassages[right          col. on p.2 to table 1 on p.3|first paragraph on          p.5|paragraph bridging pages 6 and 7];  VARSHNEY DHRUV ET          AL: ""Employing Drug Delivery Strategies to Overcome          Challenges Using TLR7/8 Agonists for Cancer          Immunotherapy"", THE AAPS JOURNAL, SPRINGER INTERNATIONAL          PUBLISHING, CHAM, vol. 23, no. 4, 28 June 2021          (2021-06-28), XP037542240, DOI:          10.1208/S12248-021-00620-X,relevantClaims[1-35],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];            HICKS ET AL., BLOOD, vol. 104, no. 11, 2004, pages          3481;            JOHNSTON ET AL., VACCINE, vol. 24, no. 11, 10 March 2006          (2006-03-10), pages 1958 - 65;            HUNG ET AL., LANCET INFECT DIS., vol. 16, no. 2, February          2016 (2016-02-01), pages 209 - 18;            ADAMS ET AL., J. CLIN. ONCOL, vol. 25, no. 18, pages          8545;            CHOLLETT ET AL., PHARM. DEV. TECHNOL, vol. 4, no. 1,          January 1999 (1999-01-01), pages 35 - 43;            HAYASHI ET AL., INT. J. UROL, vol. 17, no. 5, May 2010          (2010-05-01), pages 483 - 90;            GUEDES ET AL., J. BRAZ. CHEM. SOC, vol. 31, no. 8, 2020,          pages 1732 - 1745;            RAMINENI ET AL., J. PHARM. SCI, vol. 102, no. 2, February          2013 (2013-02-01), pages 593 - 603;            FOX ET AL., JOURNAL OF NANOBIOTECHNOLOGY, vol. 12, 2014,          pages 17;            JIMENEZ-SANCHEZ ET AL., PHARM. RES, vol. 32, 2015, pages          311 - 320;            LOOK ET AL., BIOMATERIALS, vol. 35, 2014, pages 1089 -          1095;            HUNG ET AL., LANCET INFECT. DIS, vol. 16, no. 2, February          2016 (2016-02-01), pages 209 - 18;            ZHANG ET AL., CLINICAL AND VACCINE IMMUNOLOGY, vol. 21,          no. 4, 2014, pages 570 - 579;            AUDERSET ET AL., FRONT IMMUNOL, vol. 11, 11 November 2020          (2020-11-11), pages 580974WO2023062354-A3  OU WENQUAN ET AL:          ""Regulatory T Cells Tailored with pH-Responsive Liposomes          Shape an Immuno-Antitumor Milieu against Tumors"", APPLIED          MATERIALS & INTERFACES, vol. 11, no. 40, 9 October          2019 (2019-10-09), US, pages 36333 - 36346, XP055963893,          ISSN: 1944-8244, DOI:          10.1021/acsami.9b11371,relevantClaims[1,2,4-30],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;]",97946-0-0-0 K M; 93605-0-0-0 K M; 105730-0-0-0 K M; 184587-0-0-0 K M; 200757-0-0-0 K M; 184611-0-0-0 K M; 184616-0-0-0 K M; 2185-1-0-0 K M; 130297-1-0-0 K M; 92021-0-0-0 K M; 104413-0-0-0 K M; 104427-0-0-0 K M; 104374-0-0-0 K M; 1062-0-0-0 K M; 86886-0-0-0 K M; 91481-0-0-0 K M; 95972-0-0-0 K M; 104380-0-0-0 K M; 135370-0-0-0 K M; 90356-0-0-0 K M; 104486-0-0-0 K M; 184619-0-0-0 K M; 104389-0-0-0 K M; 97733-0-0-0 K M; 116849-0-0-0 K M; 2038035-0-0-0 K M; 270029-0-0-0 K M; 1188269-0-0-0 K M; 135402-0-0-0 ; 107779-0-0-0 ; 1911-0-0-0 ; 3112-0-0-0 ; 444-0-0-0 ; 238-0-0-0 ; 5938-0-0-0 ; 133659-0-0-0 ; 7447-0-0-0 ; 7560-0-0-0 ; 104420-0-0-0 ; 192393-0-0-0 ; 2038035-0-0-0 CL USE; 1188269-0-0-0 CL USE,,49968; 42995; 49969; 02763; 02700,R06364 K M; R16207 K M; RA00NS K M; RA012P K M; RA00C8 K M; RA00GT K M; RA00H1 K M; RA00H3 K M; R04817 K M; R01856 K M; R04818 K M; RA06UR K M; RA01KS K M; RA01KR K M; RA0B83 K M; RA00D5 K M; R24039 K M; R24034 K M; R24033 K M; RA02L0 K M; RA037T K M; R16461 K M; R01852 K M; R16492 K M; RA08SW K M; RA05GF K M; R19961 K M; RA65YP K M; RB2LDK K M; RA1GVV K M; RB2LDL K M; R24032 ; R01863 ; R00446 ; R00901 ; R00351 ; R00370 ; R01295 ; R17298 ; R00009 ; R00448 ; R24028 ; R24090 ,1852-S
US2021338678-A1,"Composition for treating cancers, comprises            L-methylfolate, adenosylcobalamin, methylcobalamin, and            bioactive compound (comprising active ingredient of            drug or vaccine) or salt that does not comprise vitamin            or elemental metal",ZABLOW S B,BIOVIT INC (BIOV-Non-standard),2021C7991X,"   NOVELTY - Composition comprises an amount of: (1)                L-methylfolate, (2) adenosylcobalamin, (3)                methylcobalamin, and (4) at least one bioactive                compound or salt of the bioactive compound. The                bioactive compound does not comprise a vitamin or                an elemental metal.    USE - The composition is useful for treating                (claimed) e.g. cancers.    ADVANTAGE - Supplementation with optimal, bioactive forms                of vitamins B12 and B9 can boost cellular responses                to other bioactive compounds, such as drugs or                vaccines, and can increase efficiency of these                compounds.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a kit                comprising the composition and an instruction of                how to use the composition. ",,,"A96 (Medical, dental, veterinary, cosmetic.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",A12-V01;  A12-V04;  A12-W09;  B14-S04;  B14-E01;  B14-D01;  B14-P01;  B14-A01;  B14-J07;  B14-S11C;  B14-D02A2;  B14-F06;  B14-J01B3;  B14-C02;  B14-F02B;  B14-N01A;  B14-E09;  B14-C01;  B14-N17B;  B14-E11;  B14-P02;  B14-J01A;  B14-D07C;  B14-L06;  B14-D07B;  B14-L01;  B04-J01;  B04-C01H;  B04-H03;  B14-A02;  B14-D06B;  B04-G04;  B04-G21;  B04-G03;  B14-G03;  B14-D05D;  B04-J05H;  B04-G02;  B04-K01J0E;  B04-G27G0E;  B04-G2300E;  B04-G0200E;  B14-S16;  B10-A08;  B15-B12A;  B10-B02E;  B10-B03B;  B05-A01B;  B05-C04;  B10-A17;  B10-B02A;  B06-H;  B07-H;  B02-T;  B01-D02;  B01-C05;  B01-A02;  B01-C06;  B01-C04;  B10-C02;  B01-B02;  B01-B03;  B01-B01;  B05-C07;  B01-C01;  B10-B01A;  B02-C;  B04-C01C;  B02-A;  B02-E;  B02-P;  B02-D;  B02-V01;  B02-M;  B02-G;  B05-B01E;  B10-B02J;  B10-D03;  B10-A12C;  B05-B01M;  B04-C02A2;  B05-C05;  B10-E02;  B10-B04B;  B14-S18;  D05-H11A,A61K-039/215;  A61K-039/20;  A61K-039/04;  A61K-039/285;  A61K-039/145;  A61K-039/00;  A61K-039/29;  A61K-039/235;  A61K-031/19;  A61K-031/36;  A61K-031/4164;  A61K-031/5383;  A61K-038/14;  A61K-031/665;  A61K-031/58;  A61K-031/167;  A61K-031/37;  A61K-031/5513;  A61K-031/138;  A61K-031/5575;  A61K-031/426;  A61K-031/341;  A61K-031/65;  A61K-031/7032;  A61K-033/00;  A61K-031/64;  A61K-031/7036;  A61K-031/137;  A61K-031/4439;  A61K-031/155;  A61K-031/513;  A61K-031/7048;  A61K-031/7042;  A61K-031/4985;  A61K-031/522;  A61K-038/26;  A61K-038/28;  A61K-045/06;  A61K-031/573;  A61K-031/714;  A61K-031/519,US2021338678-A1   04 Nov 2021   A61K-031/519   202203   English,US2021338678-A1    US246494    30 Apr 2021,US2021338678-A1 Provisional Application US018443P,US018443P    30 Apr 2020;  US246494    30 Apr 2021,,,US2021338678-A1 -- US20140073598-A1   ,,1021429-0-0-0 M K; 404893-0-0-0 M K; 1380994-0-0-0 M K; 95649-0-0-0 M K; 156205-0-0-0 M K; 90882-0-0-0 M K; 97854-0-0-0 M K; 1465052-0-0-0 M K; 86276-1-0-0 M K; 772476-0-0-0 M K; 2329170-0-0-0 M K; 318804-0-0-0 M K; 3214922-0-0-0 M K; 94827-2-0-0 M K; 92282-1-0-0 M K; 100739-1-0-0 M K; 1360175-1-0-0 M K; 1395204-1-0-0 M K; 76493-0-0-0 M K; 111925-0-0-0 M K; 2232351-1-0-0 M K; 118277-2-0-0 M K; 821032-1-0-0 M K; 2003065-1-0-0 M K; 100311-1-0-0 M K; 91423-1-0-0 M K; 928127-0-0-0 M K; 123381-1-0-0 M K; 875232-1-0-0 M K; 467711-1-0-0 M K; 8218-1-0-0 M K; 111061-0-0-0 M K; 109127-0-0-0 M K; 96161-1-0-0 M K; 37371-0-0-0 M K; 105470-1-0-0 M K; 96148-0-0-0 M K; 86289-1-0-0 M K; 6284-0-0-0 M K; 107956-1-0-0 M K; 96168-0-0-0 M K; 191235-1-0-0 M K; 107317-0-0-0 M K; 111250-0-0-0 M K; 1148274-1-0-0 M K; 99135-0-0-0 M K; 76120-1-0-0 M K; 26073-0-0-0 M K; 93863-0-0-0 M K; 99408-0-0-0 M K; 8343-0-0-0 M K; 77147-0-0-0 M K; 18536-0-0-0 M K; 94879-2-0-0 M K; 6418-1-0-0 M K; 101071-1-0-0 M K; 36645-0-0-0 M K; 94336-2-0-0 M K; 76120-0-0-0 M K; 105375-0-0-0 M K; 108322-0-1-0 M K; 228519-0-0-0 M K; 108322-2-0-0 M K; 104584-0-1-0 M K; 104700-0-0-0 M K; 20152-0-0-0 M K; 125310-0-0-0 M K; 28954-1-0-0 M K; 91190-1-0-0 M K; 88182-1-0-0 M K;  M K; 94423-1-0-0 M K; 100940-0-0-0 M K; 108400-1-0-0 M K; 91082-0-0-0 M K; 171260-0-0-0 M K; 111236-1-0-0 M K; 102107-0-0-0 M K; 159358-1-0-0 M K; 104084-1-0-0 M K; 90336-1-0-0 M K; 93690-0-0-0 M K; 87346-1-0-0 M K; 142657-1-0-0 M K; 157515-1-0-0 M K; 101051-1-1-0 M K; 125266-1-0-0 M K; 99447-1-0-0 M K; 106154-1-0-0 M K; 109093-1-0-0 M K; 96010-1-0-0 M K; 101051-1-0-0 M K; 159480-1-0-0 M K; 90346-1-0-0 M K; 197336-1-0-0 M K; 111052-1-0-0 M K; 102303-0-0-0 M K; 131122-0-0-0 M K; 143959-1-0-0 M K; 101798-1-0-0 M K; 7515-0-0-0 M K; 88192-1-0-0 M K; 1102303-1-0-0 M K; 90322-1-0-0 M K; 15132-2-0-0 M K; 101579-1-0-0 M K; 95553-1-0-0 M K; 105651-1-0-0 M K; 121198-1-0-0 M K; 105654-1-0-0 M K; 102915-1-0-0 M K; 103831-0-0-0 M K; 86295-0-0-0 M K; 94603-0-0-0 M K; 100833-0-0-0 M K; 94678-1-0-0 M K; 102290-1-0-0 M K; 94585-1-0-0 M K; 7891-1-0-0 M K; 93722-1-0-0 M K; 100338-1-0-0 M K; 6478-1-0-0 M K; 102310-2-0-0 M K; 94705-1-0-0 M K; 143361-1-0-0 M K; 102308-1-0-0 M K; 92753-1-0-0 M K; 93050-1-0-0 M K; 87153-1-0-0 M K; 93095-1-0-0 M K; 92758-1-0-0 M K; 95349-1-0-0 M K; 101191-1-0-0 M K; 95480-0-0-0 M K; 92755-1-0-0 M K; 88764-1-0-0 M K; 133078-1-0-0 M K; 91256-1-0-0 M K; 109300-1-0-0 M K; 95309-1-0-0 M K; 95348-1-0-0 M K; 86893-1-0-0 M K; 95326-1-0-0 M K; 8313-1-0-0 M K; 8313-1-1-0 M K; 86368-1-0-0 M K; 82701-1-0-0 M K; 1021429-0-0-0 CL USE; 1380994-0-0-0 CL USE; 1395204-1-0-0 CL USE; 2232351-1-0-0 CL USE; 2003065-1-0-0 CL USE; 1465052-0-0-0 CL USE; 2329170-0-0-0 CL USE; 3214922-0-0-0 CL USE; 1148274-1-0-0 CL USE; 102155-1-0-0 CL USE; 111237-1-0-0 CL USE; 110025-1-0-0 CL USE; 140848-1-0-0 CL USE; 90344-1-0-0 CL USE; 100514-1-0-0 CL USE; 1102303-1-0-0 CL USE; 111946-1-0-0 CL USE; 136156-1-0-0 CL USE; 90292-1-0-0 CL USE; 102950-0-0-0 CL USE; 91248-0-0-0 CL USE; 111364-0-0-0 CL USE; 125860-1-0-0 CL USE; 109180-1-0-0 CL USE; 110138-0-0-0 CL USE; 91317-0-0-0 CL USE; 99116-0-0-0 CL USE; 102181-2-0-0 CL USE; 104674-0-0-0 CL USE; 95795-0-0-0 CL USE; 110009-0-0-0 CL USE; 94949-0-0-0 CL USE; 110924-0-0-0 CL USE; 44063-0-0-0 CL USE; 96404-2-0-0 CL USE; 86331-0-0-0 CL USE; 112268-2-0-0 CL USE; 109424-0-0-0 CL USE; 1402541-0-0-0 CL USE; 97699-0-0-0 CL USE; 106918-0-0-0 CL USE; 1035574-1-0-0 CL USE; 93450-0-0-0 CL USE; 102770-0-0-0 CL USE; 91746-0-0-0 CL USE; 88634-1-0-0 CL USE; 105687-0-0-0 CL USE; 83270-0-0-0 CL USE; 99625-0-0-0 CL USE; 104047-0-0-0 CL USE; 97397-0-0-0 CL USE; 95442-0-0-0 CL USE; 108996-0-0-0 CL USE; 111168-0-0-0 CL USE; 96686-0-0-0 CL USE; 99606-0-0-0 CL USE; 4856-0-0-0 CL USE; 88887-0-0-0 CL USE; 1360175-1-0-0 CL USE; 386027-2-0-0 CL USE; 99097-1-0-0 CL USE; 100007-0-0-0 CL USE; 134454-1-0-0 CL USE; 101531-2-0-0 CL USE; 94245-3-0-0 CL USE; 109129-0-0-0 CL USE; 87611-1-0-0 CL USE; 25857-0-0-0 CL USE; 90013-1-0-0 CL USE; 152427-1-0-0 CL USE; 106854-1-0-0 CL USE; 87172-0-0-0 CL USE,,01232; 05475; 11829; 03624; 59271; 01829; 01683; 03279; 00534; 54107; 00094; 51845; 66867; 60980; 00588; 01279; 56380; 00061; 00012; 47063; 47155; 40201; 45911; 49740; 05595; 11276,RAHH5T M K; RAB43R M K; RAGCHO M K; RA01C0 M K; RA078Q M K; RA01BZ M K; RA022K M K; RB51ZU M K; RA0I7N M K; RANDSR M K; RBP8SB M K; RA5J8Q M K; RBTHFV M K; RA0O2G M K; RA1I1U M K; R01860 M K; RB68R5 M K; RAOMA7 M K; R00608 M K; RA052X M K; RB6CL4 M K; RAS2JO M K; RACKV7 M K; RB1IFB M K; RA13IL M K; R06175 M K; RAFNYW M K; RA27XA M K; RADPMW M K; RA5JGT M K; R00048 M K; R23694 M K; R16584 M K; R23695 M K; R00250 M K; RA1MB7 M K; R04288 M K; R12239 M K; R00163 M K; R04492 M K; R07873 M K; RA0IZ9 M K; R01151 M K; R22667 M K; RAJD4D M K; R22683 M K; RA1IY2 M K; R14399 M K; R18483 M K; R01117 M K; R04588 M K; R00129 M K; R01255 M K; R03432 M K; R06378 M K; R21800 M K; R00487 M K; R00210 M K; R04401 M K; R09668 M K; R14921 M K; RA0LCD M K; R04292 M K; R11461 M K; R00186 M K; R01446 M K; RA1O3S M K; RA1IG3 M K; R21291 M K; RA00N3 M K; RBTK7Q M K; R00960 M K; R01257 M K; R18407 M K; R10124 M K; RA44TS M K; RA0C1G M K; R00267 M K; RA3RCB M K; R03877 M K; R10571 M K; RA0YL3 M K; R02055 M K; R01382 M K; RABNKP M K; R15953 M K; RA2WIU M K; RADBCO M K; R07901 M K; R02067 M K; RA01IY M K; R04156 M K; RA03ZR M K; R13721 M K; RA6CTI M K; RA0VTW M K; R04550 M K; R08282 M K; R21876 M K; RA088N M K; R00088 M K; R20865 M K; RAIEFO M K; R04389 M K; R01986 M K; R09266 M K; R06799 M K; R18825 M K; RA0AEM M K; R07487 M K; R00265 M K; R00005 M K; RA14RO M K; R10194 M K; R14541 M K; R19799 M K; R00280 M K; R00141 M K; R00014 M K; RA02G5 M K; R00308 M K; R00145 M K; R04886 M K; RA2UMU M K; R12244 M K; R11774 M K; R06861 M K; RA02G4 M K; R16077 M K; R18640 M K; R14703 M K; R07550 M K; R10358 M K; R11684 M K; R15087 M K; R04714 M K; R15088 M K; R06018 M K; R00402 M K; R07161 M K; R03207 M K; R14702 M K; R10734 M K; R00011 M K; R00003 M K; RA622T M K; R02018 M K,1860-S; 0608-S; 0048-S; 0250-S; 0163-S; 1151-S; 1117-S; 0129-S; 1255-S; 0487-S; 0210-S; 0186-S; 1446-S; 0960-S; 1257-S; 0267-S; 2055-S; 1382-S; 2067-S; 0088-S; 1986-S; 0265-S; 0005-S; 0280-S; 0141-S; 0014-S; 0308-S; 0145-S; 0402-S; 0011-S; 0003-S; 2018-S
WO2023220457-A1,"Population of engineered lipid bilayer particles            used to deliver cargo entity to lymphocyte comprises            targeting chimeric polypeptide having targeting domain            arranged on particle surface, and fusogen entity            polypeptide",ROSANELLI J D;  EDELSTEIN H I;  LEONARD J N;  STRANFORD D,UNIV NORTHWESTERN (NOUN-C);  SYENEX INC (SYEN-Non-standard),2023B9297V,"   NOVELTY - Population of engineered lipid bilayer                particles comprises: (i) a targeting chimeric                polypeptide comprising (a) a targeting domain                arranged so that the targeting domain is on the                particle surface, where the targeting domain                comprises a binding moiety that specifically binds                to a target ligand on surfaces of recipient cells                of interest; linked directly or indirectly with (b)                a transmembrane domain; and (ii) a fusogen entity                polypeptide comprising (a) fusogen moiety arranged                so that the fusogen moiety is on the particle                surface, linked directly or indirectly with (b) a                transmembrane domain.    USE - The engineered lipid bilayer particles is                useful for: targeting delivery of a cargo entity to                a lymphocyte; and delivering a cargo entity to a                recipient cell (all claimed). Test details are                described but no results given.    ADVANTAGE - The particles: achieving delivery of a cargo                (e.g., a nucleic acid cargo, polypeptide cargo, a                nucleocapsid cargo) to a recipient cell or cell                population using engineered lipid bilayer                particles; and can confer surprising improved                delivery attributes.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    a targeting chimeric polypeptide comprising                (a) a targeting domain comprising a binding moiety                that specifically binds to a target ligand on                surfaces of recipient cells of interest, linked                directly or indirectly with (b) a transmembrane                domain;    a system comprising a first polynucleotide                encoding a fusogen entity polypeptide, and a second                polynucleotide encoding a targeting chimeric                polypeptide;    a nucleic acid encoding the chimeric targeting                polypeptide and/or fusion entity polypeptide;    a cell comprising the population or the                nucleic acid ;    producing a lymphocyte-targeting lipid bilayer                particle, comprising culturing the cell, and                harvesting lipid bilayer particle produced by the                cell;    targeting delivery of a cargo entity to a                lymphocyte, comprising administering to an                individual the population, where the lipid bilayer                particle comprises a cargo molecule;    targeting delivery of a cargo entity to a                lymphocyte, comprising obtaining a population of                lymophcytes from an individual, and contacting the                population of lymphocytes ex vivo with the                population, where the lipid bilayer particle                comprises a cargo molecule;    manufacturing a population of lipid bilayer                particles comprising isolating lipid bilayer                particles produced by engineered production cells                engineered to express a fusogen entity polypeptide,                and targeting entity polypeptide, that the lipid                bilayer particles contain the fusogen entity and                targeting chimeric polypeptides on their                surfaces;    delivering (M1) a cargo entity to a recipient                cell comprising contacting the recipient cell with                a duction cell was engineered to express a fusogen                entity polypeptide, and a targeting chimeric                ppopulation of lipid bilayer particles prepared                from a engineered production cell, which engineered                proolypeptide, so that the lipid bilayer particles                contain the fusogen entity and targeting chimeric                polypeptides on their surfaces;    manufacturing a production cell comprising                engineering the production cell to express a                fusogen entity polypeptide, and a targeting                chimeric polypeptide, so that the production cell                produced lipid bilayer particles that contain the                fusogen entity and targeting chimeric polypeptides                on their surfaces; and    a recipient cell containing a cargo entity and                where the recipient cell membrane includes a                targeting chimeric polypeptide and a fusogen entity                polypeptide, and a nucleus. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-B01B;  B04-E02F;  B04-E03F;  B04-E13;  B04-E99;  B04-F04B1;  B04-G01;  B04-L05A2;  B04-N04;  B11-A04A;  D05-H08;  D05-H12A;  D05-H19C;  D05-H99,A61K-047/69;  A61P-031/12;  C07K-014/47;  C07K-016/08,WO2023220457-A1   16 Nov 2023   A61K-047/69   202300Pages: 179   English,WO2023220457-A1    WOUS022166    13 May 2023,,US341914P    13 May 2022,WO2023220457-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2023220457-A1 -- US20210403885-A1   ;  WO2010129310-A1   ROSWELL PARK CANCER INST (ROSW-Non-standard)   CHENCHIK A,  GUDKOV A,  KOMAROV A,  VENKATESH N;  WO2019199941-A1   UNIV NORTHWESTERN (NOUN)   LEONARD J N,  STRANFORD D M;  WO2019226945-A1   UNIV SINGAPORE NAT (UNUS)   CAMPANA D;  WO2020102578-A1   FLAGSHIP PIONEERING INNOVATIONS V INC (FLAG)   VON MALTZAHN G A,  MILWID J M,  RUBENS J R,  MEE M T,  GORDON N F,  SHAH J V,  TRUDEAU K M,  HARTLEY B J;  WO2021178661-A1   ONCOSEC MEDICAL INC (ONCO-Non-standard)   MUKHOPADHYAY A,  RODRIGUEZ J,  CANTON D A,  TWITTY C G,  JAFFE K,  OCONNOR D J;  US4683195-A   CETUS CORP (CETU)   MULLIS K B,  ARNHEIM N,  SAIKI R K,  ERLICH H A,  HORN G T,  SCHARF S J;  US4897355-A   SYNTEX (USA) (SYNT)   EPPSTEIN D A,  FELGNER P L,  GADEK T R,  JONES G H,  ROMAN R B;  US4946787-A   SYNTEX (USA) INC (SYNT)   EPSTEN D A,  FELGNER P L,  GADEK T R,  JONES G H,  ROMAN R B;  US5049386-A   SYNTEX (USA) INC (SYNT)   EPPSTEIN D A,  FELGNER P L,  GADEK T R,  JONES G H,  ROMAN R B;  US7396664-B2   REGENERON PHARM INC (REGN)   PAPADOPOULOS N J,  DAVIS S,  YANCOPOULOS G D;  WO1991016024-A   ;  WO1991017424-A   ","WO2023220457-A1            GUPTA ET AL.: ""Nucleic acid delivery for therapeutic          applications"", ADV. DRUG DELIVERY REVIEWS, vol. 178,          2021, pages 113834, XP086844152, DOI:          10.1016/j.addr.2021.113834;            ""Molecular Cloning: A Laboratory Manual"", 2001;            ""Current Protocols in Molecular Biology"", 2007, ACADEMIC          PRESS, INC., article ""Methods in Enzymology"";            MACPHERSON ET AL.: ""PCR 1: A Practical Approach"", 1991,          IRL PRESS AT OXFORD UNIVERSITY PRESS;            MACPHERSON ET AL., PCR 2: A PRACTICAL APPROACH,          1995;            ANDERSON, NUCLEIC ACID HYBRIDIZATION, 1999;            FRESHNEY, CULTURE OF ANIMAL CELLS: A MANUAL OF BASIC          TECHNIQUE, 2005;            PERBAL: ""Gene Transfer Vectors for Mammalian Cells"",          1984, COLD SPRING HARBOR LABORATORY, article ""A Practical          Guide to Molecular Cloning"";            ""Immobilized Cells and Enzymes"", 1986, IRL          PRESS;            ""Gene Transfer and Expression in Mammalian Cells"",          2003;            ""Immunochemical Methods in Cell and Molecular Biology"",          1987, ACADEMIC PRESS;            MAKKERH ET AL., CURR BIOL, vol. 6, no. 8, 1996, pages          1025 - 1027;            DOYLE ET AL., CELLS, vol. 8, no. 7, 2019, pages          727;            HOLLIGER, P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90,          1993, pages 6444 - 6448;            POLJAK, R. J., STRUCTURE, vol. 2, no. 1, 1994, pages 121          - 1123;            TATIANA A. TATUSOVATHOMAS L. MADDEN: ""Blast 2 sequences -          a new tool for comparing protein and nucleotide          sequences"", FEMS MICROBIOL LETT, vol. 174, 1999, pages          247 - 250",,,,,
WO2023102661-A1;  CA3240433-A1,"Composition used to e.g. prepare cargo for            intracellular delivery having increased stability, and            to treat cancer, comprises steroid acid-peptide            conjugate covalently linked to and/or mixed with cargo            for intracellular delivery",BEAUDOIN S,DEFENCE THERAPEUTICS INC (DEFE-Non-standard);  DEFENCE THERAPEUTICS INC (DEFE-Non-standard),2023617549,"   NOVELTY - Composition comprises a steroid acid-peptide                conjugate covalently linked to and/or mixed with a                cargo for intracellular delivery.    USE - The composition or cell culture is useful for:                delivering a cargo intracellularly; preparing a                cargo for intracellular delivery having increased                stability; enhancing presentation of an antigen of                interest in a subject or cells; vaccinating a                subject against an infectious disease (e.g. virus,                bacteria and fungus); treating cancer in a subject;                and generating enhancing presentation of an antigen                of interest in a subject or in nonprofessional                antigen presenting cells (e.g. MSCs), and                manufacturing a e.g. vaccine for generating an                immune response in a subject (all claimed). Test                details are described but no results given.    ADVANTAGE - The composition: increases the intracellular,                cytosolic, and/or nuclear delivery of a                biologically active cargo (e.g. therapeutic cargo                or diagnostic cargo) in vitro or in vivo, as                compared to a corresponding composition lacking the                steroid acid-peptide conjugate, increases                presentation of an antigenic polypeptide cargo by                target cells e.g. by professional anti-presenting                cells (e.g. dendritic cells, macrophages, B cells,                or non-immune cells engineered for overexpression                of an immunoproteasome), or by non-professional                antigen-presenting cells (e.g. wild-type,                engineered, primary, and/or cultured non-immune                cells e.g. MCSs), increases intracellular reactive                oxygen species production in target cells e.g. by                professional anti-presenting cells (e.g. dendritic                cells, macrophages, B cells, or non-immune cells                engineered for overexpression of an                immunoproteasome), or by non-professional                antigen-presenting cells (e.g. wild-type,                engineered, primary, and/or cultured non-immune                cells e.g. MCSs), and/or transforms                immunosuppressive cells (e.g. immunosuppressive                MSCs) into immunostimulatory and/or                pro-inflammatory MSCs; and shows synergistic                efficacy in treating T-cell lymphoma in mice by                decreasing tumor volumes and increasing survival                rates.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    delivering (M1) a cargo intracellularly,                comprising providing the composition, and                administering the composition to target cells in                vitro or in vivo;    preparing (M2) a cargo for intracellular                delivery having increased stability, comprising                covalently linking the cargo to a sufficient number                of steroid acid-peptide moieties to produce a                covalently-modified cargo that exhibits greater                stability (e.g. thermal stability) than the                corresponding unmodified cargo;    a cell culture comprising either non-antigen                presenting cells (e.g. mesenchymal stromal cells                (MSCs)) and the composition, or non-antigen                presenting cells (MSCs) pulsed with an antigen                covalently linked to and/or mixed with a steroid                acid-peptide conjugate;    a vaccine comprising the composition, or                comprising cells produced using the cell                culture;    enhancing (M3) presentation of an antigen of                interest in a subject or cells, comprising                administering to the subject or in non-antigen                presenting cells (e.g. MSCs), the composition, or                cells produced using the cell culture;    vaccinating (M4) a subject against an                infectious disease, comprising administering to the                subject the composition or cells produced using the                cell culture, where the antigen comprises an                antigenic fragment of a pathogen (e.g. virus,                bacteria, and fungus) causing the infectious                disease; and    treating (M5) cancer in a subject, comprising                administering to the subject the composition or                cells produced using the cell culture, where the                antigen is an overexpressed or aberrantly expressed                in cells causing the cancer. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  ;  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B01-D02;  B04-C01;  B04-C02;  B04-E01;  B04-E13;  B04-E99;  B04-F01;  B04-L05A2;  B04-N04;  B04-Q;  B14-A01;  B14-A02;  B14-A04;  B14-H01;  B14-S11A;  B14-S11B;  B14-S11D3;  C01-D02;  C04-C01;  C04-C02;  C04-E01;  C04-E13;  C04-E99;  C04-F01;  C04-L05A2;  C04-N04;  C04-Q;  C14-A01;  C14-A02;  C14-A04;  C14-H01;  C14-S11A;  C14-S11B;  C14-S11D3;  D05-H07;  D05-H08B;  D05-H19C;  D05-H99,A61K-038/46;  A61K-039/385;  A61K-047/64;  A61K-049/00;  A61P-035/00;  A61P-037/04;  C07K-014/00;  C07K-007/06;  C07K-007/08;  C12N-015/10;  C12N-005/0775;  C12N-005/078;  C12N-009/22,WO2023102661-A1   15 Jun 2023   A61K-047/64   202354Pages: 87   English;  CA3240433-A1   15 Jun 2023   A61K-047/64   202448   English,WO2023102661-A1    WOCA051795    08 Dec 2022;   CA3240433-A1    CA3240433    08 Dec 2022,CA3240433-A1 PCT application Application WOCA051795,US265125P    08 Dec 2021;  US362487P    05 Apr 2022;  CA3240433    07 Jun 2024,WO2023102661-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,"WO2023102661-A1 -- US11291717-B1   DEFENCE THERAPEUTICS INC (DEFE-Non-standard)   BEAUDOIN S;  WO2017156630-A1   SOCPRA SOC COMMERCIALISATION PROD RECH (UYSH)   BEAUDOIN S,  LEYTON J V;  WO2018165752-A1   UNIV SOUTH AUSTRALIA (UAUS);  CENT ADELAIDE LOCAL HEALTH NETWORK INC (ADEL-Non-standard);  SOCPRA SOC COMMERCIALISATION PROD RECH (UYSH)   LEYTON J V,  MARSAULT E,  BEAUDOIN S,  BOUDREAULT P,  BONIN M,  LOPEZ A;  WO2022126239-A1   DEFENCE THERAPEUTICS INC (DEFE-Non-standard)   BEAUDOIN S;  WO2022232945-A1   DEFENCE THERAPEUTICS INC (DEFE-Non-standard)   BEAUDOIN S","WO2023102661-A1  BEAUDOIN ET AL.:          ""ChAcNLS, a novel modification to antibody-conjugates          permitting target cell -specific endosomal escape,          localization to the nucleus, and enhanced total          intracellular delivery"", MOLECULAR PHARMACEUTICS, vol.          13, 2016, pages 1915 - 1926, XP055403560, DOI:          10.1021/acs.molpharmaceut.6b00075,relevantClaims[1-3 and          5-26],relevantPassages[. (see entire document)];  EL-KADIRY ABED          EL-HAKIM, BEAUDOIN SIMON, PLOUFFE SEBASTIEN, RAFEI          MOUTIH: ""Accum Technology: A Novel Conjugable Primer for          Onco-Immunotherapy"", MOLECULES, vol. 27, no. 12, pages          3807, XP093005333, DOI:          10.3390/molecules27123807,relevantClaims[20, 25, 29, 31,          32 and 36-41],relevantPassages[. (see entire          document)];  AZUAR ARMIRA, ZHAO          LILI, HEI TSUI TING, NEVAGI RESHMA J., BARTLETT STACEY,          HUSSEIN WALEED M., KHALIL ZEINAB G., CAPON ROBERT J., T:          ""Cholic Acid-based Delivery System for Vaccine Candidates          against Group A Streptococcus"", ACS MEDICINAL CHEMISTRY          LETTERS, AMERICAN CHEMICAL SOCIETY, US, vol. 10, no. 9,          12 September 2019 (2019-09-12), US , pages 1253 - 1259,          XP055947553, ISSN: 1948-5875, DOI:          10.1021/acsmedchemlett.9b00239,relevantClaims[1-41],relevantPassages[.          (see entire document)];  LU JUANE, WU TAO,          ZHANG BIAO, LIU SUKE, SONG WENJUN, QIAO JIANJUN, RUAN          HAIHUA: ""Types of nuclear localization signals and          mechanisms of protein import into the nucleus"", CELL          COMMUNICATION AND SIGNALING, vol. 19, no. 1, 1 December          2021 (2021-12-01), XP093073531, DOI:          10.1186/s12964-021-00741-y,relevantClaims[1-41],relevantPassages[.          (see entire document)]",98373-2-0-0 K M; 92661-1-0-0 K M; 98273-2-0-0 K M; 131253-0-0-0 K M; 108374-1-0-0 K M; 108380-1-0-0 K M; 108385-2-0-0 K M; 4210-2-0-0 K M; 98373-1-0-0 K M; 96293-3-0-0 K M; 96303-1-0-0 K M;  K M; 4210-1-0-0 K M; 108371-2-0-0 K M; 108378-1-0-0 K M; 96293-1-0-0 K M; 96297-1-0-0 K M; 184611-0-0-0 K M; 184616-0-0-0 K M; 184614-0-0-0 K M; 2418795-0-0-0 K M; 200757-0-0-0 K M; 105730-0-0-0 K M; 93605-0-0-0 K M; 2418795-0-0-0 CL USE,,,R01281 K M; R00497 K M; R01251 K M; RD9QL9 K M; R08868 K M; R20447 K M; R03457 K M; R19158 K M; R16116 K M; R04203 K M; RAWJZY K M; RA1QRF K M; RDB13M K M; R00486 K M; RA5FGB K M; R16062 K M; RA1QRC K M; R08867 K M; RA00H1 K M; RA00H3 K M; RA0121 K M; RBAAY7 K M; RA00GT K M; RA012P K M; RA00NS K M,1281-S; 0497-S; 1251-S; 0485-S; 0486-S
WO2023284763-A1;  TW202308665-A;  CN117580952-A;  EP4372086-A1,"Double-stranded oligonucleotide comprising e.g.            sense strand and antisense strand, sense strand            comprises first nucleotide sequence, antisense strand            comprises second nucleotide sequence useful in            preparing medicine for treating diseases",LIANG Z;  ZHANG H;  GAO S;  LI H,SUZHOU RIBO LIFE SCI CO LTD (SUZH-Non-standard);  SUZHOU RIBO LIFE SCI CO LTD (SUZH-Non-standard);  SUZHOU RIBO LIFE SCI CO LTD (SUZH-Non-standard),2023138932,"   NOVELTY - Double-stranded oligonucleotide comprising                e.g. a sense strand and an antisense strand, the                sense strand comprises nucleotide sequence I, and                the antisense strand comprises nucleotide sequence                II, and the nucleotide sequence I and the                nucleotide sequence II both consist of 19                nucleotides. Each nucleotide in the nucleotide                sequence I and the nucleotide sequence II is a                modified or unmodified nucleotide. The nucleotide                sequence I and the nucleotide sequence II are at                least partially reverse complementary to form a                double-stranded region. The nucleotide sequence II                is at least partially reverse complementary to the                first nucleotide sequence, and the first nucleotide                sequence is a 19-nucleotide nucleoside in the mRNA                expressed by the target gene acid sequence. In the                direction from the 5' end to the 3' end, at least                one of the 3-6 nucleotides in the nucleotide                sequence II is a stabilizing modified nucleotide,                and the nucleus other than the 3-9 nucleotides in                the nucleotide sequence II.    USE - The double-stranded oligonucleotide, the                medicine composition or the oligonucleotide                conjugate is useful in preparing a medicine for                treating and/or preventing diseases or symptoms                related to mRNA levels expressed by a target gene                e.g. hepatitis B or dyslipidemia (claimed).    ADVANTAGE - The double-stranded oligonucleotide can                effectively treat and/or prevent diseases or                disorders associated with target gene expression,                and has reduced off-target effects, has a reduced                target-removing effect, and further improves the                target gene expression regulating activity.    DETAILED DESCRIPTION - Double-stranded oligonucleotide comprising a                sense strand and an antisense strand, the sense                strand comprises nucleotide sequence I, and the                antisense strand comprises nucleotide sequence II,                and the nucleotide sequence I and the nucleotide                sequence II both consist of 19 nucleotides. Each                nucleotide in the nucleotide sequence I and the                nucleotide sequence II is a modified or unmodified                nucleotide. The nucleotide sequence I and the                nucleotide sequence II are at least partially                reverse complementary to form a double-stranded                region. The nucleotide sequence II is at least                partially reverse complementary to the first                nucleotide sequence, and the first nucleotide                sequence is a 19-nucleotide nucleoside in the mRNA                expressed by the target gene acid sequence. In the                direction from the 5' end to the 3' end, at least                one of the 3-6 nucleotides in the nucleotide                sequence II is a stabilizing modified nucleotide,                and the nucleus other than the 3-9 nucleotides in                the nucleotide sequence II, the none of the                nucleotides is a stabilized modified nucleotide,                and the stabilized modified nucleotide refers to a                nucleotide in which the ribose 2' hydroxy group of                the nucleotide is replaced by a stabilized                modification group, which is not the same as the                nucleotide at the corresponding position. Compared                with the double-stranded oligonucleotide of the                modified nucleotide, the thermal stability of the                double-stranded oligonucleotide comprising the                stabilizing modified nucleotide increases, and the                steric hindrance of the stabilizing modifying group                is greater than 2'-O-methyl. INDEPENDENT CLAIMS are                also included for:    a medicine composition comprising the                double-stranded oligonucleotide and a                carrier;    an oligonucleotide conjugate comprising the                double-stranded oligonucleotide and a conjugated                group conjugated to the double-stranded                oligonucleotide, the conjugated group comprises a                linker and a targetting group and/or a delivery                assisting group, and each of the targetting groups                is a ligand capable of binding to a cell surface                receptor, each delivery assisting group being                capable of increasing the biocompatibility of the                oligonucleotide conjugate in delivering a target                organ or tissue;    modulating the expression level of a target                gene in a cell, comprising contacting a specific                amount of the double-stranded oligonucleotide,                and/or the medicine composition and/or the                oligonucleotide conjugate with the cell; and    a kit comprising the double-stranded                oligonucleotide, and/or the medicine composition                and/or the oligonucleotide conjugate. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-B03C;  B04-E99;  B04-Q04;  B14-A02A5;  B14-C03;  B14-F06A;  B14-L06;  D05-H12D6;  D05-H99,A61K-048/00;  A61P-031/00;  A61P-009/00;  C12N-015/113;  A61K-031/7088;  A61K-031/713,WO2023284763-A1   19 Jan 2023   C12N-015/113   202314Pages: 116   Chinese;  TW202308665-A   01 Mar 2023   A61K-031/713   202338   Chinese;  CN117580952-A   20 Feb 2024   C12N-015/113   202421   Chinese;  EP4372086-A1   22 May 2024   C12N-015/113   202442   English,WO2023284763-A1    WOCN105340    13 Jul 2022;   TW202308665-A    TW126699    15 Jul 2022;   CN117580952-A    CN80046071    13 Jul 2022;   EP4372086-A1    EP841396    13 Jul 2022,CN117580952-A PCT application Application WOCN105340;   CN117580952-A Based on Patent WO2023284763;   EP4372086-A1 PCT application Application WOCN105340;   EP4372086-A1 Based on Patent WO2023284763,CN10807463    16 Jul 2021;  CN80046071    27 Dec 2023,WO2023284763-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      EP4372086-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN  ,,"WO2023284763-A1 -- CN102124107-A   SIRNA THERAPEUTICS INC (ALNY)   MCSWIGGEN J,  JADHAV V,  VAISH N K,  GUERCIOLINI R,  VARGEESE C;  CN110944675-A   SUZHOU RIBO LIFE SCI CO LTD (SUZH-Non-standard)   ZHANG H,  GAO S,  KANG D;  CN110945130-A   SUZHOU RIBO LIFE SCI CO LTD (SUZH-Non-standard)   ZHANG H,  GAO S,  KANG D,  KONG L;  CN110945132-A   SUZHOU RIBO LIFE SCI CO LTD (SUZH-Non-standard)   ZHANG H,  GAO S,  KANG D;  CN110997917-A   SUZHOU RIBO LIFE SCI CO LTD (SUZH-Non-standard)   ZHANG H,  GAO S,  KANG D;  CN110997919-A   SUZHOU RIBO LIFE SCI CO LTD (SUZH-Non-standard)   ZHANG H,  GAO S,  KANG D;  CN112423794-A   SUZHOU RIBO LIFE SCI CO LTD (SUZH-Non-standard)   ZHANG H,  GAO S,  KANG D;  US20100069461-A1   ;  US20170081667-A1   ","WO2023284763-A1  SONG XINYUN, WANG          XIAOXIA, MA YUAN, LIANG ZICAI, YANG ZHENJUN, CAO HUIQING:          ""Site-Specific Modification Using the 2-Methoxyethyl          Group Improves the Specificity and Activity of siRNAs"",          MOLECULAR THERAPY-NUCLEIC ACIDS, CELL PRESS, US, vol. 9,          1 December 2017 (2017-12-01), US , pages 242 - 250,          XP093024030, ISSN: 2162-2531, DOI:          10.1016/j.omtn.2017.10.003,relevantClaims[1-62],relevantPassages[pages          242-250]",93605-0-0-0 K M; 105730-0-0-0 K M,,,RA00NS K M; RA012P K M,
WO2021119832-A1;  TW202136294-A;  AR120870-A1;  CN115003693-A;  EP4077374-A1;  JP2023507033-W;  US2023242676-A1;  EP4077374-A4,"New polypeptide useful in composition or protein            complex for treating cancer, infection or immune            dysregulation, comprises specific amino acid            sequence",WARGACHUCK R;  GUPTA A;  DACRUZ L;  YOUNG D;  MORIN N;  YAO S;  WARGACHUK R;  MODIN N;  DA CRUZ L;  YOUNG D S;  DA C L,KISOJI BIOTECHNOLOGY INC (KISO-Non-standard);  KISOJI BIOTECHNOLOGY INC (KISO-Non-standard);  KISOJI BIOTECHNOLOGY INC (KISO-Non-standard),202170464B,"   NOVELTY - A polypeptide comprising an amino acid                sequence in amino (N)- to carboxy (C)-terminal                fashion, is new.    USE - The polypeptide is useful in composition or                protein complex for treating a disorder or disease.                The disorder or disease is cancer, infection or                immune dysregulation (all claimed).    ADVANTAGE - The polypeptide has increased avidity, and                increased specificity of cell targeting.    DETAILED DESCRIPTION - A polypeptide comprising an amino acid                sequence of formula:                X-((Aba)-(Lb))m-(DD)-((Lc)-(Abd))n-Y' (I), where m                is 0, 1 or greater than 1, n is 0, 1, 2 or greater                than 2, Aba or Abd comprise an antigen binding                domain comprising one or more complementarity                determining regions (CDRs) of an antibody, X or Y'                comprises an amino acid sequence, Lb and Lc                comprise one or more linkers, Lc does not comprise                a cleavable linker, and DD comprises a dimerization                domain, in amino (N)- to carboxy (C)-terminal                fashion, is new. The dimerization domain comprises                a CH3 domain comprising one or more mutations at                positions corresponding to Asp399, Asp/Glu356                and/or Lys370 based on European Union (EU)                numbering, or a CH3 domain comprising one or more                mutations at positions corresponding to Asp399,                Glu357 and/or Lys439 based on EU numbering.                INDEPENDENT CLAIMS are included for the                following:    (1) a pharmaceutical composition comprising                the polypeptide and carrier;    (2) a nucleic acid encoding the                polypeptide;    (3) a vector comprising the nucleic                acid;    (4) a cell expressing the polypeptide, or                comprising the nucleic acid or the vector;    (5) a kit comprising the polypeptide, the                nucleic acid, the vector or the cell;    (6) a protein complex comprising (i) a first                polypeptide comprising one or more antigen binding                domains and a first dimerization domain (DD1)                comprising a CH3 domain comprising one or more                mutations at positions corresponding to Asp399,                Asp/Glu356 and/or Lys370, and (ii) a second                polypeptide comprising one or more antigen binding                domains and a second dimerization domain (DD2)                comprising a CH3 domain comprising one or more                mutations at positions corresponding to Asp399,                Glu357 and/or Lys439, where the first and second                polypeptide are identical or different, and first                and second polypeptides form a dimer;    (7) a composition comprising the protein                complex;    (8) a method (M1) for making the protein                complex involves transforming cells with one or                more vectors comprising the nucleic acid;    (9) a kit comprising one or more nucleic acids                encoding a dimerization domain of a human antibody,                one or more nucleic acids encoding an antigen                binding domain and one or more nucleic acids                encoding a linker, in same or separate vials;    (10) a method (M2) for producing the nucleic                acid encoding the polypeptide involves covalently                assembling one or more DNA segments encoding a                dimerization domain of a human antibody and one or                more DNA segments encoding an antigen binding                domain and one or more DNA segments encoding a                linker, where each DNA segment comprises a unique                overhang that allow assembly at unique position                into a DNA construct for encoding a polypeptide                chain; and    (11) a method (M3) for making the polypeptide                or the protein complex. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-C01;  B04-E01;  B04-E02H;  B04-E08;  B04-E99;  B04-F0100E;  B04-G0100E;  B04-G02;  B04-G04;  B04-G2300E;  B04-G27G0E;  B04-N0400E;  B04-N08;  B14-A01;  B14-A02;  B14-A04;  B14-G01;  B14-H01;  D05-H12C;  D05-H12E;  D05-H14;  D05-H17C;  D05-H99,A61K-039/395;  A61K-047/68;  A61P-031/04;  A61P-035/00;  A61P-037/02;  C07K-016/00;  C07K-016/18;  C07K-016/28;  C07K-016/46;  C12N-015/13;  C12P-021/00;  A61K-047/55;  A61P-031/00;  C12N-001/15;  C12N-001/19;  C12N-001/21;  C12N-015/63;  C12N-005/10;  C12P-021/08;  C07K-016/40;  A61K-039/00;  C07K-016/30;  C12N-015/62;  C12P-021/02,WO2021119832-A1   24 Jun 2021   C07K-016/00   202156Pages: 192   English;  TW202136294-A   01 Oct 2021   C07K-016/00   202104   Chinese;  AR120870-A1   23 Mar 2022   C07K-016/00   202261   Spanish;  CN115003693-A   02 Sep 2022   C07K-016/00   202276   Chinese;  EP4077374-A1   26 Oct 2022   C07K-016/00   202286   English;  JP2023507033-W   20 Feb 2023   C12N-015/13   202317   Japanese;  US2023242676-A1   03 Aug 2023   C07K-016/46   202363   English;  EP4077374-A4   27 Dec 2023   C07K-016/00   202402   English,WO2021119832-A1    WOCA051753    18 Dec 2020;   TW202136294-A    TW145364    21 Dec 2020;   AR120870-A1    AR103608    21 Dec 2020;   CN115003693-A    CN80094676    18 Dec 2020;   EP4077374-A1    EP902077    18 Dec 2020;   JP2023507033-W    JP538373    18 Dec 2020;   US2023242676-A1    US17786708    20 Dec 2022;   EP4077374-A4    EP902077    18 Dec 2020,CN115003693-A PCT application Application WOCA051753;   CN115003693-A Based on Patent WO2021119832;   EP4077374-A1 PCT application Application WOCA051753;   EP4077374-A1 Based on Patent WO2021119832;   JP2023507033-W PCT application Application WOCA051753;   JP2023507033-W Based on Patent WO2021119832;   US2023242676-A1 Provisional Application US951701P;   US2023242676-A1 PCT application Application WOCA051753,US951701P    20 Dec 2019;  WOCA051753    18 Dec 2020;  CN80094676    26 Jul 2022;  US17786708    20 Dec 2022,WO2021119832-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        EP4077374-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN      EP4077374-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  ,,"WO2021119832-A1 -- WO2013012733-A1   BIOGEN IDEC MA INC (BIOJ)   TAYLOR F R,  CARAVELLA J A,  LUGOVSKOY A A,  SAEED-KOTHE A,  GARBER E;  WO2016192613-A1   UNIV SUN YAT-SEN (UYSY)   WANG Z;  EP4077374-A4 -- US20140348839-A1   ;  US20170198051-A1   ;  US20190345235-A1   ","EP4077374-A4  LAURSEN NICK S. ET          AL: ""Universal protection against influenza infection by          a multidomain antibody to influenza hemagglutinin"",          SCIENCE, vol. 362, no. 6414, 2 November 2018          (2018-11-02), US, pages 598 - 602, XP055830000, ISSN:          0036-8075, DOI:          10.1126/science.aaq0620,relevantClaims[1-3,6-8,10,11,15-19,21-25],relevantPassages[&lt;pp&gt;3&lt;/pp&gt;&lt;para&gt;3&lt;/para&gt;&lt;figure&gt;3&lt;/figure&gt;];  WANG FENG ET AL:          ""Design and characterization of mouse IgG1 and IgG2a          bispecific antibodies for use in syngeneic models"", MABS,          vol. 12, no. 1, 19 September 2019 (2019-09-19), US, pages          1685350, XP055844337, ISSN: 1942-0862, DOI:          10.1080/19420862.2019.1685350,relevantClaims[1-25],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  HUDIE WEI ET AL:          ""Structural basis of a novel heterodimeric Fc for          bispecific antibody production"", ONCOTARGET, vol. 8, no.          31, 1 August 2017 (2017-08-01), pages 51037 - 51049,          XP055560253, DOI:          10.18632/oncotarget.17558,relevantClaims[1-25],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  ARAI R ET AL:          ""Design of the linkers which effectively separate domains          of a bifunctional fusion protein"", PROTEIN ENGINEERING,          OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 14, no. 8, 1          August 2001 (2001-08-01), pages 529 - 532, XP002334380,          ISSN: 0269-2139, DOI:          10.1093/PROTEIN/14.8.529,relevantClaims[7],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            See also references of WO 2021119832A1",184587-0-0-0 M N P Q; 184587-0-0-0 CL NEW PRD RCT USE,224736501 K M; 224736502 K M; 224736503 K M,,RA00C8 M N P Q,
WO2021207676-A1;  US2023134835-A1,"Preparing carotenoid, crocetin used as aqueous            solution for preparing pharmaceutical composition for            manufacturing medicament for treating disease/condition            in subject, involves reacting aldehyde with olefin            forming agent, and hydrolyzing",NIYIKIZA C;  MOYO V M;  GENG B,LEAF HOLDINGS GROUP LLC (LEAF-Non-standard);  LEAF HOLDINGS GROUP LLC (LEAF-Non-standard),2021B6631Y,"   NOVELTY - Preparing carotenoid (I) involves reacting                aldehyde (II) with olefin forming agent to form                ester (1-4C alkyl ester, such as ethyl ester),                where olefin forming agent is capable of reacting                with aldehyde to form structural moiety of alkyl                chain derivative (III-V), or geometric isomer, and,                when at least one Q is hydrogen or counterion,                hydrolyzing ester to form carotenoid (I).    USE - Method for preparing carotenoid of formula                (I), crocetin of formula (XI) used as aqueous                solution for preparing pharmaceutical composition                for manufacture of medicament for increasing                delivery of oxygen to cells for treatment or                prevention of disease or condition in subject;                reducing systemic levels of lipopolysaccharides                (LPS), endotoxin or another trigger of systemic                inflammation in subject, where disease or condition                is ischemia (tissue hypoperfusion) or hypoxia; lung                disease; acute respiratory distress syndrome;                cardiovascular disease; heart attack or stroke;                shock; bacterial infection; viral infection; Ebola,                Dengue or Marburg infection; fungal infection;                parasitic infection or condition associated with                parasitic infection; endotoxemia or condition                associated with endotoxemia; bacteremia; sepsis;                sclerosis; inflammatory bowel disease; metabolic                disease; insulin resistance or condition associated                with insulin resistance; diabetes; liver disease;                kidney disease (all claimed).    ADVANTAGE - The method for preparing carotenoid of formula                (I) helps in increasing delivery of oxygen to cells                for treatment or prevention of disease or condition                in subject; reduces systemic levels of LPS,                endotoxin or another trigger of systemic                inflammation in subject.    DETAILED DESCRIPTION - Preparing carotenoid of formula (I) involves                reacting aldehyde of Formula (II) with olefin                forming agent to form ester (1-4C alkyl ester, such                as ethyl ester), where olefin forming agent is                capable of reacting with aldehyde to form                structural moiety of alkyl chain derivative of                formulae (III-V), or geometric isomer, and, when at                least one Q is hydrogen or counterion, hydrolyzing                ester to form carotenoid of Formula (I).. For                carotenoid of formula (I):    Polyene Carotenoid=3, 4, 5, 6, 7, 8, 9, 10,                3-5, 6-8, 9-10, or more than 9, conjugated double                bonds, and methyl or low alkyl (2-3C)                substitutions;    Y'=bond, alkyl chain derivative of formulae                (III-V), or geometric isomer, provided that at                least one Y has -C(O)-O- functional group;                and    Q=ionizable group, hydrogen, substituted 1-4C                alkyl, or counterion.    For aldehyde of Formula (II):    Q2-Y2=HC(O)-, and when only one of Q2-Y2 is                HC(O)-, then other Q2-Y2 is same as Y'-Q- in                Formula I.    INDEPENDENT CLAIMS are included for                following:    (1) a crocetin compound of formula (XI), such                as TSC, which is in substantially pure form, with                applicable purity profile with purity of greater                than 95%, preferably, greater than 97%, greater                than 98%, greater than 99%, by HPLC area percentage                with detection wavelength at 254 nm, and 420                nm;    (2) a method for preparing pharmaceutical                composition, which comprises formulating carotenoid                of Formula (I), or crocetin of formula (XI);    (3) a method for preparing a crocetin of                formula (XI), which is in substantially pure form,                with applicable purity profile, such as have less                than 3% of other geometric isomers by HPLC area                percentage with detection wavelength at 254                nanometer (nm), and 420 nm, preferably, less than                2% such as less than 1.5%, or less than 1% of other                geometric isomers, which involves reacting                dialdehyde of Formula (XII), where dialdehyde                contains less than 10% of other geometric isomers                by HPLC area percentage with detection wavelength                at 330 nm, preferably, less than 5% such as less                than 3%, or less than 2% of other geometric                isomers, with olefin forming agent of Formula                (XIII) to form intermediate compound of Formula                (XIV); isolating intermediate compound of Formula                (XIV) in substantially pure form; hydrolyzing in                compound of Formula (XI), when at least one R10,                which is hydrogen, or counterion;    (4) a aqueous solution, which comprises                liposome;    (5) a pharmaceutical composition, which                comprises liposome;    (6) a use of pharmaceutical composition, which                is provided in manufacture of medicament for                treatment, or prevention of disease, or condition                in subject;    (7) a method for treating, or preventing                disease, or condition in subject needing such                treatment, or prevention, which involves                administering effective amount of pharmaceutical                composition to subject;    (8) a method for increasing delivery of oxygen                to cells, and tissues in subject, which involves                administering effective amount of pharmaceutical                composition to subject; and    (9) a method for reducing systemic levels of                LPS, endotoxin, or another trigger of systemic                inflammation in subject in need, which involves                administering effective amount of pharmaceutical                composition.    . ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  B06 (Inorganics - including fluorides for toothpastes etc.);  ;  C02 (Heterocyclic.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.)",B12-M11F;  B14-A01;  B14-A02;  B14-A04;  B14-B02;  B14-C03;  B14-E10C1;  B14-F01;  B14-F02;  B14-K01;  B14-N10;  B14-N12;  B14-N16;  B14-S04;  B14-S05;  B14-S06;  B14-S13;  B14-S18;  B15-A00A;  C12-M11F;  C14-A01;  C14-A02;  C14-A04;  C14-B02;  C14-C03;  C14-E10C1;  C14-F01;  C14-F02;  C14-K01;  C14-N10;  C14-N12;  C14-N16;  C14-S04;  C14-S05;  C14-S06;  C14-S13;  C14-S18;  C14-U05;  C15-A00;  A05-H03;  A12-V01,A61K-031/01;  A61K-047/22;  A61K-047/24;  A61K-045/06;  C07C-045/67;  C07C-051/41;  C07C-067/343,WO2021207676-A1   14 Oct 2021   A61K-031/01   202192Pages: 136   English;  US2023134835-A1   04 May 2023   C07C-051/41   202337   English,WO2021207676-A1    WOUS026683    09 Apr 2021;   US2023134835-A1    US17917910    07 Oct 2022,US2023134835-A1 Provisional Application US007777P;   US2023134835-A1 PCT application Application WOUS026683,US007777P    09 Apr 2020;  US17917910    07 Oct 2022,WO2021207676-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,"WO2021207676-A1 -- US8632832-B2   PHARES PHARM RES NV (PHAR-Non-standard)   LEIGH S,  LEIGH M L S,  VAN HOOGEVEST P;  US8691555-B2   MICROBIA PRECISION ENG (IOOD)   BAILEY R B,  MADDEN K T,  TRUEHEART J,  DOTEN R,  MAYORGA M,  DUNN J G,  DUEPPEN D;  WO2019213538-A1   LEAF HOLDINGS GROUP LLC (LEAF-Non-standard)   NIYIKIZA C,  MOYO V M,  GENG B,  XU Z,  KHALIFA K,  KIM G;  WO2003101184-A2   CALIFORNIA INST OF TECHNOLOGY (CALY)   ARNOLD F H,  UMENO D",,147083-0-0-0 K U V; 2-1-0-0 K U V; 104530-0-0-0 K U V; 1-0-0-0 K U V; 96212-1-0-0 K U V; 2623-0-0-0 K U V; 129502-0-0-0 K U V; 849-0-0-0 K U V; 11-0-0-0 K U V; 7560-0-0-0 K U V; 89821-0-0-0 K U V; 99990-0-0-0 K U V; 107324-0-0-0 K U V; 68-0-0-0 K U V; 107317-0-0-0 K U V; 104516-0-2-0 K U V; 444-0-0-0 ; 147083-0-0-0 CL RGT USE; 104530-0-0-0 CL RGT USE; 96212-1-0-0 CL RGT USE; 129502-0-0-0 CL RGT USE; 89821-0-0-0 CL RGT USE; 99990-0-0-0 CL RGT USE; 107324-0-0-0 CL RGT USE; 107317-0-0-0 CL RGT USE; 104516-0-2-0 CL RGT USE,226226401 K M P; 226226402 K M P; 226226403 K M P; 226226404 K M P,,R01513 K U V; R01514 K U V; R01512 K U V; R00247 K U V; R01327 K U V; R00540 K U V; R00116 K U V; R00419 K U V; R00246 K U V; R00448 K U V; R00233 K U V; R04953 K U V; R01287 K U V; R01391 K U V; R01151 K U V; R01202 K U V; R00351 ,1513-U; 1514-U; 1512-U; 0247-U; 1327-U; 0540-U; 0116-U; 0419-U; 0246-U; 0448-U; 0233-U; 1287-U; 1391-U; 1151-U; 1202-U
WO2022047108-A1;  US2022064591-A1;  TW202225398-A;  CA3192999-A1;  AU2021332355-A1;  IN202347020327-A;  KR2023058094-A;  BR112023003273-A2;  CN116209772-A;  IL300828-A;  EP4204578-A1;  JP2023542820-W;  HK40091395-A0;  MX2023002417-A1,"Culturing eukaryotic cells for improved cell            culture performance comprises propagating or            maintaining eukaryotic cells in defined cell culture            medium, and maintaining cells in asparagine            supplemented cell culture medium",BENNUN-SERRANO S;  LAWRENCE S M;  JOHNSON A S;  SERRANO S B;  SEAN M L,REGENERON PHARM INC (REGN-C);  REGENERON PHARM INC (REGN-C);  REGENERON PHARM INC (REGN-C);  REGENERON PHARM INC (REGN-C),2022398051,"   NOVELTY - Culturing eukaryotic cells for improved cell                culture performance comprises propagating or                maintaining eukaryotic cells in a defined cell                culture medium, where the defined cell culture                medium is supplemented with 3.6-43.2 mM asparagine                during early fed-batch cell culture and from                3.6-21.6 mM during late fed-batch cell culture, and                maintaining cells in asparagine supplemented cell                culture medium for at least a portion of the early                and late fed-batch cell culture, where cell culture                performance parameter is improved by the asparagine                supplementation, as compared to a similar method                with a lower amount of asparagine supplementation                or no asparagine supplementation in early and/or                late fed-batch cell culture.    USE - The method is useful for culturing eukaryotic                cells for improved cell culture performance.    ADVANTAGE - The method improves cell growth parameters                includes cell growth rate, cell density, cell                viability, asparagine concentration, asparagine                related amino acid concentration, ammonium ion                concentration, and alanine concentration.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) preventing asparagine sequence variants in                a polypeptide of interest expressed from mammalian                cells in cell culture, comprising propagating or                maintaining mammalian cells in a defined cell                culture medium, where the defined cell culture                medium is supplemented with 3.6-43.2 mM asparagine                during early fed-batch cell culture and 3.6-21.6 mM                during late fed-batch cell culture, and maintaining                cells in asparagine supplemented cell culture                medium for at least a portion of the early and late                fed-batch cell culture under conditions sufficient                for expression of the polypeptide of interest,                where extracellular asparagine levels are                maintained in the cell culture medium during at                least early stage fed-batch cell culture above a                depletion limit of 0.1 mM in which the polypeptide                of interest expressed by the mammalian cells                comprise less than 0.30% of asparagine sequence                variants at all individual sequence variant                loci;    (2) detecting asparagine sequence variants in                a polypeptide of interest expressed from mammalian                cells in cell culture, comprising propagating or                maintaining mammalian cells in a defined cell                culture medium, expressing a recombinant protein of                interest from the eukaryotic cells, measuring                intracellular and/or extracellular concentrations                of asparagine or asparagine related amino acids in                the cell culture or defined cell culture medium,                and correlating the measured concentrations of                asparagine or asparagine related amino acids to the                presence of asparagine sequence variants in the                expressed polypeptide of interest; and    (3) monitoring and controlling cell culture                parameters, comprising measuring cell culture                parameters in a cell culture in situ using freezing                point depression, electrochemistry, digital                imaging, photometry, bioprocess analyzer, or Raman                spectroscopy, comparing the measured one or more                cell culture parameters to a predetermined set                point value for the cell culture parameter to                determine if the one or more cell culture                parameters are within a predetermined threshold                range, and adjusting cell culture parameters if a                cell culture parameter is determined to be out of                the predetermined threshold range. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E99;  B04-F01;  B04-G0100E;  B04-G0400E;  B04-G2100E;  B04-G2400E;  B04-N0400E;  B04-N08;  B11-A04A;  B11-C08A;  B11-C08E1;  B11-C08J;  B12-K04;  D05-H08B;  D05-H09;  D05-H99,C07K-016/00;  C12P-021/02;  C12N-001/04;  C12N-001/38;  A61P-025/14;  A61P-007/02;  C07K-016/22;  C12N-015/10;  H01L-031/0224;  C12N-005/071;  C12P-013/20;  C12N-001/00;  C12P-021/08,WO2022047108-A1   03 Mar 2022   202224Pages: 96   English;  US2022064591-A1   03 Mar 2022   C12N-001/38   202225   English;  TW202225398-A   01 Jul 2022   C12N-001/04   202271   Chinese;  CA3192999-A1   03 Mar 2022   202324   English;  AU2021332355-A1   23 Mar 2023   C12P-021/02   202325   English;  IN202347020327-A   31 Mar 2023   A61P-007/02   202330   English;  KR2023058094-A   02 May 2023   C12N-005/071   202337   ;  BR112023003273-A2   02 May 2023   C12P-021/02   202343   ;  CN116209772-A   02 Jun 2023   C12P-021/02   202350   Chinese;  IL300828-A   01 Apr 2023   C12N-001/38   202350   English;  EP4204578-A1   05 Jul 2023   C12P-021/02   202354   English;  JP2023542820-W   12 Oct 2023   C12N-001/00   202383   Japanese;  HK40091395-A0   01 Dec 2023   C12P-021/02   202439   English;  MX2023002417-A1   22 Mar 2023   C12P-021/02   202442   Spanish,WO2022047108-A1    WOUS047870    27 Aug 2021;   US2022064591-A1    US458929    27 Aug 2021;   TW202225398-A    TW131819    27 Aug 2021;   CA3192999-A1    CA3192999    27 Aug 2021;   AU2021332355-A1    AU332355    27 Aug 2021;   IN202347020327-A    IN47020327    23 Mar 2023;   KR2023058094-A    KR709931    27 Aug 2021;   BR112023003273-A2    BR11003273    27 Aug 2021;   CN116209772-A    CN80063115    27 Aug 2021;   IL300828-A    IL300828    27 Aug 2021;   EP4204578-A1    EP786285    27 Aug 2021;   JP2023542820-W    JP513579    27 Aug 2021;   HK40091395-A0    HK6080491    09 Oct 2023;   MX2023002417-A1    MX002417    27 Feb 2023,US2022064591-A1 Provisional Application US072740P;   US2022064591-A1 Provisional Application US072745P;   CA3192999-A1 PCT application Application WOUS047870;   CA3192999-A1 Based on Patent WO2022047108;   AU2021332355-A1 PCT application Application WOUS047870;   AU2021332355-A1 Based on Patent WO2022047108;   IN202347020327-A PCT application Application WOUS047870;   IN202347020327-A Based on Patent WO2022047108;   KR2023058094-A PCT application Application WOUS047870;   KR2023058094-A Based on Patent WO2022047108;   BR112023003273-A2 PCT application Application WOUS047870;   BR112023003273-A2 Based on Patent WO2022047108;   CN116209772-A PCT application Application WOUS047870;   CN116209772-A Based on Patent WO2022047108;   IL300828-A Based on Patent WO2022047108;   EP4204578-A1 PCT application Application WOUS047870;   EP4204578-A1 Based on Patent WO2022047108;   JP2023542820-W PCT application Application WOUS047870;   JP2023542820-W Based on Patent WO2022047108;   HK40091395-A0 PCT application Application WOUS047870;   HK40091395-A0 Based on Patent WO2022047108;   HK40091395-A0 Previous Publ. Patent EP4204578;   MX2023002417-A1 PCT application Application WOUS047870;   MX2023002417-A1 Based on Patent WO2022047108,US072740P    31 Aug 2020;  US072745P    31 Aug 2020;  EP786285    27 Aug 2021;  US458929    27 Aug 2021;  BR11003273    23 Feb 2023;  CA3192999    24 Feb 2023;  CN80063115    15 Mar 2023;  KR709931    22 Mar 2023,WO2022047108-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA                    EP4204578-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN        ,,"WO2022047108-A1 -- US20130096283-A1   ;  US10526631-B1   ARES TRADING SA (MERE)   SOLACROUP T,  STETTLER M,  BROLY H;  WO2013006479-A2   AMGEN INC (AMGE)   FOLLSTAD B D,  MCCOY R E,  MORRIS A E;  US4072565-A   DOW CHEM CO (DOWC);  US4560655-A   IMMUNEX CORP (IMMV)   BAKER P E;  US4615977-A   ASAHI KASEI KOGYO KK (ASAH)   HASEGAWA A,  HORIGUCHI S;  US4786599-A   CNRS CENT NAT RECH SCI (CNRS);  CHESSEBEUF M (CHES-Individual);  INSERM INST NAT SANTE & RECH                  MEDICALE (INRM)   CHESSEBEUF M,  PADIEU P;  US5122469-A   GENENTECH INC (GETH)   MATHER J P,  TSAO M C;  US5705364-A   GENENTECH INC (GETH);  HOFFMANN LA ROCHE & CO AG F (HOFF)   ETCHEVERRY T,  RYLL T,  LESSLAUER W,  SCHREITMULLER T,  RICHTER W;  US5856179-A   GENENTECH INC (GETH)   FORMAN L W,  CHEN M;  US5976833-A   SUNTORY LTD (SUNR)   FURUKAWA K,  OHSUYE K;  US6048728-A   CHIRON CORP (CHIR)   HOWARTH W,  MAIORELLA B,  INLOW D;  US2021253701-A1   REGENERON PHARM INC (REGN)   SMITH E,  HABER L,  BABB R,  CHEN G,  MACDONALD D;  US20100331527-A1   ;  US20140044730-A1   ;  US20140088295-A1   ;  US20140271642-A1   ;  US20140271653-A1   ;  US20140271658-A1   ;  US20140271681-A1   ;  US20150203579-A1   ;  US20150203580-A1   ;  US20150259423-A1   ;  US20150266966-A1   ;  US20150313194-A1   ;  US20150337029-A1   ;  US20150337045-A1   ;  US20160017029-A1   ;  US20160075778-A1   ;  US20160215040-A1   ;  US6180401-B1   GENENTECH INC (GETH)   CHEN M,  FORMAN L W;  US6528286-B1   GENENTECH INC (GETH)   RYLL T;  US6924124-B1   IMMUNEX CORP (IMMV)   SINGH P;  US6927004-B2   ASML NETHERLANDS BV (ASML)   EURLINGS M F A,  VAN DIJSSELDONK A J J,  DIERICHS M M T M;  US7087411-B2   REGENERON PHARM INC (REGN)   PAPADOPOULOS N J,  DAVIS S,  YANCOPOULOS G D;  US7279159-B2   DALY T J (DALY-Individual);  FANDL J P (FAND-Individual);  PAPADOPOULOS N J (PAPA-Individual)   DALY T J,  FANDL J P,  PAPADOPOULOS N J;  US7294484-B2   WYETH RES IRELAND LTD (AMHP)   DRAPEAU D,  LUAN Y,  MERCER J R,  WANG W,  LASKO D;  US7429491-B2   WYETH (AMHP)   DRAPEAU D,  STANEK T C,  LUAN Y;  US7582298-B2   STEVENS S (STEV-Individual);  HUANG T T (HUAN-Individual);  MARTIN J H (MART-Individual);  FAIRHURST J L (FAIR-Individual);  RAFIQUE A (RAFI-Individual);  SMITH E (SMIT-Individual);  POBURSKY K J (POBU-Individual);  PAPADOPOULOS N J (PAPA-Individual);  FANDL J P (FAND-Individual);  CHEN G (CHEN-Individual);  KAROW M (KARO-Individual)   STEVENS S,  HUANG T T,  MARTIN J H,  FAIRHURST J L,  RAFIQUE A,  SMITH E,  POBURSKY K J,  PAPADOPOULOS N J,  FANDL J P,  CHEN G,  KAROW M;  US7666416-B2   ETCHEVERRY T (ETCH-Individual);  RYLL T (RYLL-Individual)   ETCHEVERRY T,  RYLL T;  US7879984-B2   REGENERON PHARM INC (REGN)   ALLISON E M,  MARTIN J H,  STEVENS S,  WANG L;  US8043617-B2   REGENERON PHARM INC (REGN)   STEVENS S,  HUANG T T,  MARTIN J H,  FAIRHURST J L,  RAFIQUE A,  SMITH E,  POBURSKY K J,  PAPADOPOULOS N J,  FANDL J P,  CHEN G,  KAROW M;  US8062640-B2   REGENERON PHARM INC (REGN)   HUANG T T,  MACDONALD D,  MARTIN J H,  SLEEMAN M W;  US8309088-B2   REGENERON PHARM INC (REGN)   MACDONALD L,  TORRES R,  MORRA M R,  MARTIN J H,  REINHARDT J C,  TISEO P;  US8735095-B2   REGENERON PHARM INC (REGN)   STEVENS S,  HUANG T T,  MARTIN J H,  FAIRHURST J L,  RAFIQUE A,  TORRES M,  POBURSKY K J,  LEIDICH R W,  WINDSOR J A,  MIKULKA W R,  AHRENS D M,  SHI E,  PAPADOPOULOS N J;  US8871209-B2   REGENERON PHARM INC (REGN)   STITT T,  LATRES E;  US8945559-B2   REGENERON PHARM INC (REGN);  DIX D B (DIXD-Individual);  TANG X (TANG-Individual)   DIX D B,  TANG X;  US9018356-B2   REGENERON PHARM INC (REGN)   SLEEMAN M W,  GUSAROVA V,  MURPHY A J;  US9079948-B2   REGENERON PHARM INC (REGN)   ORENGO J,  MURPHY A J;  US9096879-B2   BIOGEN IDEC MA INC (BIOJ)   KHETAN A,  HUANG Y,  DOLNIKOVA J,  PEDERSON N,  YUSUF-MAKAGIANSAR H,  CHEN P,  RYLL T;  US9132192-B2   DALY C (DALY-Individual);  THURSTON G (THUR-Individual);  PAPADOPOULOS N J (PAPA-Individual)   DALY C,  THURSTON G,  PAPADOPOULOS N J;  US9173880-B2   REGENERON PHARM INC (REGN);  DIX D B (DIXD-Individual);  GRAHAM K S (GRAH-Individual);  KAMEN D E (KAME-Individual);  WALSH S M (WALS-Individual)   DIX D B,  GRAHAM K S,  KAMEN D E,  WALSH S M;  US9228014-B2   REGENERON PHARM INC (REGN)   CLASSON B J,  KOSTIC A,  DUAN X;  US9260515-B2   REGENERON PHARM INC (REGN)   STITT T,  LATRES E;  US9265827-B2   REGENERON PHARM INC (REGN)   WIEGAND S J,  LOBOV I B;  US9302015-B2   DELFINO F J (DELF-Individual);  REGENERON PHARM INC (REGN);  KELLY M P (KELL-Individual);  KIRSHNER J R (KIRS-Individual);  NITTOLI T (NITT-Individual);  PAPADOPOULOS N J (PAPA-Individual);  THURSTON G (THUR-Individual)   DELFINO F J,  KELLY M P,  KIRSHNER J R,  NITTOLI T,  PAPADOPOULOS N J,  THURSTON G;  US9353176-B2   REGENERON PHARM INC (REGN)   MACDONALD L,  TORRES R,  MORRA M R,  MARTIN J H,  REINHARDT J C,  TISEO P;  US9402898-B2   REGENERON PHARM INC (REGN)   WALSH S M,  DIX D B;  US30985-E   CARTAYA O A (CART-Individual)   CARTAYA O A;  WO2014144198-A1   REGENERON PHARM INC (REGN)   OSHODI S,  JOHNSON A,  LAWRENCE S;  WO2005028626-A2   RAVEN BIOTECHNOLOGIES INC (RAVE-Non-standard)   TSAO M C","WO2022047108-A1  LI-XIANG ZHANG ET          AL: ""Responses of CHO-DHFR cells to ratio of asparagine          to glutamine in feed media: cell growth, antibody          production, metabolic waste, glutamate, and energy          metabolism"", BIORESOURCES AND BIOPROCESSING, vol. 3, no.          1, 8 February 2016 (2016-02-08), XP055715739, DOI:          10.1186/s40643-015-0072-6,relevantClaims[1-3,5,6,9-14,22-24,27-31,34-37,39-41,49|4,7,8,15-21,25,26,32,33,38,42-48],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            GAMBHIR, A. ET AL., J BIOSCIENCE BIOENG, vol. 95, no. 4,          2003, pages 317 - 327;            SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory          Manual"", 1989, COLD SPRING HARBOR LABORATORY          PRESS;            TAYLOR ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages          6287 - 6295;            BYM ET AL., NATURE, vol. 344, 1990, pages 677;            JULIO E. CELIS: ""Cell Biology: A Laboratory Handbook"",          1998, ACADEMIC PRESS;            KIPRIYANOV ET AL., HUMAN ANTIBODIES AND HYBRIDOMAS, vol.          6, 1995, pages 93 - 101;            WARD ET AL., NATURE, vol. 241, 1989, pages 544 -          546;            HOLLIGER ET AL., PNAS USA, vol. 90, 1993, pages 6444 -          6448;            POLJAK ET AL., STRUCTURE, vol. 2, 1994, pages 1121 -          1123;            KIPRIYANOV ET AL., MOL. IMMUNOL., vol. 31, 1994, pages          1047 - 1058;            ASHKENAZI ET AL., PROC. NATL. ACAD. SCL USA, vol. 88,          1991, pages 10535;            HOLLENBAUGH ET AL.: ""Construction of Immunoglobulin          Fusion Proteins"", CURRENT PROTOCOLS IN IMMUNOLOGY,          1992;  C.          ALTAMIRANO ET AL., BIOTECHNOL PROG., vol. 26, no. 5,          pages 1400 - 10;            EAGLE, SCIENCE, vol. 112, no. 3168, 1955, pages 501 -          504;            HAM, PROC. NAT'L. ACAD. SCI. USA, vol. 53, 1965, pages          288 - 293;            PROC. NATL. ACAD. SCI. USA., vol. 38, no. 8, August 1952          (1952-08-01), pages 747 - 752;            HOLMESWOLF, BIOPHYS. BIOCHEM. CYTOL., vol. 10, 1961,          pages 389 - 401;            DAVIDSONWAYMOUTH, BIOCHEM. J., vol. 39, no. 2, 1945,          pages 188 - 199;            WILLIAM'S ET AL., EXP. CELL RES., vol. 69, 1971, pages          105;            MOORE ET AL., J. AMER. MED. ASSOC., vol. 199, 1967, pages          519 - 524;            BETTGER ET AL., PROC. NAT'L. ACAD. SCI. USA, vol. 78, no.          9, 1981, pages 5588 - 5592;            ORR ET AL., APPL. MICROBIOL., vol. 25, no. 1, 1973, pages          49 - 54;  Y.          M. HUANG ET AL., BIOTECHNOL PROG, vol. 26, no. 5, pages          1400 - 10;            ""Current Protocols in Molecular Biology"", 1988, WILEY          & SONS;            KAUFMAN, R. J., LARGE SCALE MAMMALIAN CELL CULTURE, 1990,          pages 15 - 69",2612993-0-0-0 K M; 2659936-0-0-0 K M;  K M;  K M;  K M;  K M;  K M;  K M; 2612993-0-0-0 CL USE; 2659936-0-0-0 CL USE,,,RBKO2C K M; RBM5NX K M; RC3R1R K M; RC434Q K M; RC6XGQ K M; RCZMOG K M; RD2LI0 K M; RD2LI1 K M,
WO2022232056-A1,"Testing device used to test different target            molecules comprises sample chamber, reagent reservoir,            sample fluidic line, reagent fluidic line, and common            fluidic line, and diagnostic indicator",ABATE A;  CHIU C;  LANGER K;  WEISGERBER D,CHAN ZUCKERBERG BIOHUB INC (CHAN-Non-standard);  UNIV CALIFORNIA (REGC-C),2022D7571W,"   NOVELTY - Testing device (100), comprises a sample                chamber to receive a sample, a reagent reservoir                containing a reagent used to determine a presence                of a target molecule in the sample, a sample                fluidic line (108), a reagent fluidic line (110),                and a common fluidic line (109), the sample fluidic                line being fluidically coupled to the sample                chamber and the common fluidic line and the reagent                fluidic line being fluidically coupled to the                reagent reservoir and to the common fluidic line,                and a diagnostic indicator coupled to the common                fluidic line, where the sample and the reagent flow                through the respective sample fluidic line and the                reagent fluidic line toward the common fluidic line                and form a mixture within the common fluidic line                and the common fluidic line enables a threshold                incubation period of the mixture prior to the                mixture flowing to the diagnostic indicator.    USE - The testing device is useful for testing                different target molecules.    ADVANTAGE - None given.    DESCRIPTION OF DRAWING(S) - The figure shows the schematic view of the                testing device.    100Testing device    108Sample fluidic line    109Common fluidic line    110Reagent fluidic line    116Pump ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-B04G;  B04-E01;  B04-E05;  B04-L04A;  B11-C07B3;  B11-C08C1;  B11-C08F8;  B11-C08N2A;  B12-K04F;  B12-K04G;  B12-K04G1B;  D05-H06A;  D05-H18B2,C12Q-001/68;  C12Q-001/70,WO2022232056-A1   03 Nov 2022   C12Q-001/68   202294Pages: 35   English,WO2022232056-A1    WOUS026191    25 Apr 2022,,US180051P    26 Apr 2021,WO2022232056-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,WO2022232056-A1 -- US5246354-A   ABBOTT LAB (ABBO)   PARDINAS G P;  US20050148091-A1   ;  US20050239056-A1   ;  US20070275475-A1   ;  US20100285975-A1   ;  US20110312713-A1   ;  US20140087359-A1   ;  US20190181322-A1   ,,204644-0-0-0 K M; 218588-0-0-0 K M,,,RA031J K M; RA0DQN K M,
WO2024033450-A1,"Collection device used to detect neurodegenerative            diseases, has solid matrix incorporating inactivating            solution adapted to inactivate substantially all of            pathogen present in biofluid sample and preserve            portion of analyte of interest",SHARMA P,HEMODX AS (HEMO-Non-standard),202418168K,"   NOVELTY - Collection device comprises a solid matrix                incorporating an inactivating solution adapted to                inactivate substantially all of at least one                pathogen present in the biofluid sample and                preserve at least a portion of the analyte of                interest in a format that permits subsequent                analysis, where the inactivating solution comprises                a combination of protein denaturants comprising at                least one detergent, at least one chaotropic salt,                at least one weak base, at least one chelator and                at least one reducing agent, in use, when the                biofluid sample is provided to the solid matrix,                substantially all of the pathogens in the biofluid                sample is inactivated and at least a portion of any                analyte of interest present in the biofluid sample                is preserved in a format that permits subsequent                analysis, and the biofluid sample is suspected of                comprising the analyte of interest and                pathogens.    USE - The device is useful for: collecting and                storing an analyte of interest from a biofluid                sample; detecting analyte of interest provided from                a dried biofluid; and detecting neurodegenerative                diseases, preferably Alzheimer disease and                Parkinson disease (all claimed).    ADVANTAGE - The device: allows collection of biofluids and                stabilization of analytes so that both DNA and RNA                may be analyzed, the collection device; and                determines genotypes using gene based methods and                RNA, e.g. miRNA or mRNA for large scale miRNA or                gene expression profiling for diagnosing or                monitoring diseases, selecting therapy, and                determining disease severity.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    detecting (M1) an analyte of interest provided                from a dried biofluid, from the collection device,                where the analyte of interest is a nucleic acid,                the collection device comprises a solid matrix that                was pre-treated with an inactivating solution                adapted to inactivate substantially all of the                pathogens present in the biofluid sample and                preserve at least a portion of the analyte of                interest in a format that permits subsequent                analysis, the inactivating solution comprises a                combination of protein denaturants comprising at                least one detergent, at least one chaotropic salt,                at least one weak base, at least one chelator and                at least one reducing agent, comprising (a) washing                a portion of the solid matrix comprising the dried                biofluid with prewash buffer at room temperature to                form a previously dried biofluid, where the prewash                buffer comprises 60-80% ethanol, and inactivating                solution comprising a combination of protein                denaturants comprising at least one detergent, at                least one chaotropic salt, at least one weak base,                at least one chelator and at least one reducing                agent, (b) washing a portion of the solid matrix                comprising the previously dried biofluid with a                first wash solution, where the first wash solution                comprises at least 70% ethanol, and (c) eluting the                analyte of interest from the solid matrix by                incubating the solid matrix RNAase free                water;    detecting (M2) an analyte of interest provided                from a dried biofluid, from the collection device,                where the analyte of interest is a protein, a                polypeptide, an oligopeptide or a peptide, the                collection device comprises a solid matrix that was                pre-treated with an inactivating solution adapted                to inactivate substantially all of the pathogens                present in the biofluid sample and preserve at                least a portion of the analyte of interest in a                format that permits subsequent analysis, the                inactivating solution comprises a combination of                protein denaturants comprising at least one                detergent, at least one chaotropic salt, at least                one weak base, at least one chelator and at least                one reducing agent, comprising eluting the analyte                of interest from the solid matrix by incubating at                least a portion of the solid matrix comprising the                dried biofluid with an elution buffer, then                removing the elution buffer, and the elution buffer                comprises at least one buffering salt, at least one                solubilization agent and at least one protease                inhibitor;    detecting (M2) an analyte of interest provided                from a dried biofluid, from the collection device,                where the analyte of interest is a protein, a                polypeptide, an oligopeptide or a peptide, the                collection device comprises a solid matrix that was                pre-treated with an inactivating solution adapted                to preserve at least a portion of the analyte of                interest in a format that permits subsequent                analysis, the inactivating solution comprises at                least one protease inhibitor and at least one                solublizing agent, comprising eluting the analyte                of interest from the solid matrix by incubating at                least a portion of the solid matrix comprising the                dried biofluid with the elution buffer, then                removing the elution buffer;    a kit comprising the collection device and at                least one of pipettor to drop the biofluid sample                onto the collection device, a biofluid sample                collection cup, a biohazard marked bag, desiccant,                and a return shipping envelope for storage and                transport of biofluid samples to a designated                laboratory for analysis;    undertaking at least one of profiling the                microbiome, genotyping purposes, diagnosing                diseases, selecting therapy, and determining                disease severity using the collection device;                and    undertaking at least one of profiling the                microbiome, genotyping purposes, diagnosing                diseases, selecting therapy, and determining                disease severity using the collection device. ",,,"A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  P31 (Diagnosis, surgery (A61B).);  S03 (Scientific Instrumentation)",A12-V03C2;  A12-W11L;  B04-E99;  B01-D02;  B04-C01A;  B04-C03C;  B04-E01;  B04-N02;  B04-N16;  B05-A01A;  B05-A01B;  B05-B01G;  B05-B02A3;  B05-C07;  B06-D02;  B07-D11;  B07-E03;  B10-A09A;  B10-A14;  B10-A17;  B10-B01B;  B10-B02D;  B10-B03B;  B10-C02;  B10-E03;  B10-J02;  B11-C08C;  B11-C08F;  B12-K04;  B12-K04G2D;  B14-D07A1;  B14-J01A3;  B14-J01A4;  D05-H99;  D05-H09;  P31-A05;  S03-E09F;  S03-E14H3;  S03-E14H5,A61B-010/00;  C12M-001/26;  C12Q-001/04;  C12Q-001/24;  C12Q-001/6888;  C12Q-001/70;  G01N-033/50,WO2024033450-A1   15 Feb 2024   C12Q-001/04   202420Pages: 87   English,WO2024033450-A1    WOEP072116    09 Aug 2023,,GB011645    09 Aug 2022,WO2024033450-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2024033450-A1 -- AU2012211365-A1   LONGHORN VACCINES&DIAGNOSTICS LLC (LONG-Non-standard)   DAUM L T,  FISCHER G W;  EP4163397-A1   SEEGENE INC (SGEE);  SG MEDICAL INC (SGME-Non-standard)   CHUN J Y,  LEE J,  KWON H,  KO Y,  LEE S;  US5939259-A   SCHLEICHER & SCHUELL INC (SCHL-Non-standard)   HARVEY M A,  KING T H,  KREMER R D,  BURGHOFF R L;  US20130338351-A1   ;  WO2016081100-A1   GE HEALTHCARE UK LTD (GENE);  GENERAL ELECTRIC CO (GENE)   TATNELL P J,  HORTON J K;  WO2017214338-A1   DRAWBRIDGE HEALTH INC (DRAW-Non-standard)   BEYERLEIN D,  CLARK S,  JACKSON A,  RAVA R P;  WO2018215375-A1   GENERAL ELECTRIC CO (GENE);  GE HEALTHCARE LTD (GENE)   PATEL P L,  CHEN L,  SCHWANDT M,  REAMS K,  HANSEN T;  WO2021246820-A1   SEEGENE INC (SGEE);  SG MEDICAL INC (SGME-Non-standard)   CHUN J Y,  LEE J,  KWON H,  KO Y,  LEE S;  WO2022103978-A1   BIOCEPT INC (BIOC-Non-standard);  ARNOLD L (ARNO-Individual)   ARNOLD L;  WO2016109799-A2   UNIV ROCKEFELLER (UYRQ);  MAX K (MAXK-Individual);  BERTRAM K (BERT-Individual);  AKAT K (AKAT-Individual);  TUSCHL T H (TUSC-Individual);  LI J (LIJJ-Individual);  BOGARDUS K (BOGA-Individual)   MAX K,  BERTRAM K,  AKAT K,  TUSCHL T H,  LI J,  BOGARDUS K;  US20130289265-A1   ","WO2024033450-A1            FREEMAN ET AL.: ""State of the Science in Dried Blood          Spots"", CLINICAL CHEMISTRY, vol. 64, 1 April 2018          (2018-04-01), pages 656 - 679;            AMADO ET AL.: ""One decade of salivary proteomics: Current          approaches and outstanding challenges"", CLINICAL          BIOCHEMISTRY, vol. 46, 2013, pages 506 - 517,          XP028996893, DOI:          10.1016/j.clinbiochem.2012.10.024;            YAN ET AL.: ""Systematic comparison of the human saliva          and plasma proteomes"", PROTEOMICS - CLINICAL          APPLICATIONS, vol. 3, 2009, pages 116 - 134;            PAWLIK ET AL.: ""The Role of Salivary Biomarkers in the          Early Diagnosis of Alzheimer's Disease and Parkinson's          Disease"", DIAGNOSTICS, vol. 11, no. 3, 2021, pages          71;            CORMAN VMLANDT OKAISER MMOLENKAMP RMEIJER ACHU DK ET AL.:          ""Detection of 2019 novel coronavirus"", EURO SURVEILL,          2019, pages 25",105730-0-0-0 A K; 93605-0-0-0 A K; 184611-0-0-0 A K; 297125-0-0-0 A K; 98661-0-0-0 A K; 109510-0-0-0 K M; 102649-0-0-0 K M; 102219-0-0-0 K M; 104477-1-0-0 K M; 104479-0-0-0 K M; 130111-0-0-0 K M; 422-0-1-0 K M; 107339-0-0-0 K M; 107352-0-0-0 K M; 129390-0-0-0 K M; 104533-0-0-0 K M; 146870-0-8-0 K M; 102648-0-0-0 K M; 107316-0-0-0 K M; 130323-0-0-0 K M; 849-0-0-0 K M; 112469-0-0-0 K M; 941-0-0-0 K M; 5177-0-0-0 K M; 3330-0-0-0 K M; 93978-0-0-0 K M; 14922-0-0-0 K M; 2351-0-0-0 K M; 473-0-0-0 K M; 882-1-0-0 K M; 93558-0-0-0 K M; 123074-0-0-0 K M; 993865-1-0-0 K M; 92661-1-0-0 K M; 4210-1-0-0 K M; 444-0-0-0 ,,,RA012P A K; RA00NS A K; RA00H1 A K; RA20EO A K; RA03W4 A K; RA0JE1 K M; RA0GHH K M; RA0S2Q K M; R01869 K M; R01870 K M; R04478 K M; R10859 K M; RA6LSL K M; R01722 K M; R01691 K M; R01341 K M; R01715 K M; RAS23N K M; RASN6A K M; RAU4YW K M; RA0GHG K M; R02052 K M; RBZ0WT K M; R00419 K M; R09297 K M; R08785 K M; R06051 K M; R00195 K M; R04439 K M; R09157 K M; R01164 K M; R00418 K M; R00201 K M; R00297 K M; RA08P6 K M; RA0BBR K M; RAU6AB K M; R00497 K M; R00486 K M; R00351 ,1869-S; 1870-S; 0956-S; 1722-S; 1691-S; 1341-S; 1715-S; 2052-S; 0419-S; 0195-S; 1164-S; 0418-S; 0201-S; 0297-S; 0497-S; 0486-S
WO2023102567-A2;  WO2023102567-A3,"Composition used to control growth of bacteria,            fungi, protozoa, or virus, comprises polymer comprising            moiety comprising nitrogen containing compound, and            grafting enhancer and/or grafting adjuvant,            crosslinking reagent",BOULOUSSA O,DEBOGY MOLECULAR INC (DEBO-Non-standard),202358948L,"   NOVELTY - Composition (C1) comprises a polymer                comprising at least one moiety comprising nitrogen                containing compound (XVIIa), and at least one                grafting enhancer and/or grafting adjuvant,                optionally a crosslinking reagent.    USE - The composition is useful: in a surface; for                controlling the growth of at least one bacteria,                fungi, protozoa, or virus; in coating; in solution                (all claimed); and for grafting onto surfaces used                in various applications to contain and control the                spread of infectious pathogens, where the                applications include e.g. transportation, commerce,                home, work place, sporting equipment, pet care,                consumer products, beauty and hygiene, public                spaces, construction, industrial, food                applications, health care, and defense.    ADVANTAGE - The composition: utilizes polymers that has                both biocidal and biocompatibility properties; and                prevents and reduces the colonization and                proliferation of germs (e.g. bacteria, viruses, and                fungi) on surfaces.    DETAILED DESCRIPTION - Composition (C1) comprises a polymer                comprising at least one moiety comprising nitrogen                containing compound of formula                ((R3)3Si(CH2)wN(-G1-)(-R4)-(CH2)vSi(-R3)3) (XVIIa),                and at least one grafting enhancer and/or grafting                adjuvant, optionally a crosslinking reagent.    G1=single bond, or linking group;    R3=optionally substituted alkoxy;    R4=optionally substituted alkyl;    v=3-10; and    w=3-10.    INDEPENDENT CLAIMS are also included                for:    composition (C2) comprising a polymer                comprising at least one moiety comprising nitrogen                containing compound of formula                ((R3)3Si(CH2)wN(-C(=O)-CH2-)-(CH2)vSi(-R3)3) (XXI)                and at least one grafting enhancer and/or grafting                adjuvant, optionally a crosslinking reagent;    composition (C3) comprising a polymer                comprising at least one moiety                4-(1,2-ethyl)-1-[2-(3,4-dihydroxyphenyl)-2-oxoethyl]pyridin-1-ium                and at least one grafting enhancer and/or grafting                adjuvant, optionally a crosslinking reagent;    composition (C4) comprising a polymer                comprising at least one moiety comprising                heterocyclic compound of formula (V) and at least                one grafting enhancer and/or grafting adjuvant,                optionally a crosslinking reagent;    composition (C5) comprising a polyethylenimine                (PEI) polymer comprising at least one moiety                comprising dihydroxy group containing compounds of                formulae (IXa), (IXb), or (IXh) and at least one                grafting enhancer and/or grafting adjuvant,                optionally a crosslinking reagent;    composition (C6) comprising a PEI polymer                comprising at least one moiety comprising nitrogen                containing compound of formula (IXf), or its                substructure, and at least one grafting enhancer                and/or grafting adjuvant, optionally a crosslinking                reagent;    composition (C7) comprising a PEI polymer                comprising at least one moiety comprising nitrogen                containing compound of formula (IXg), or its                substructure, and at least one grafting enhancer                and/or grafting adjuvant, optionally a crosslinking                reagent;    composition (C8) comprising a PEI polymer                comprising at least one moiety comprising silicon                containing compound of formula (-(CH2)vSi(R3a)3)                (XIa), and at least one grafting enhancer and/or                grafting adjuvant, optionally a crosslinking                reagent;    composition (C9) comprising a PEI polymer                comprising at least one moiety comprising nitrogen                containing compound of formula (Xlb), or its                substructure, and at least one grafting enhancer                and/or grafting adjuvant, optionally a crosslinking                reagent;    composition (C10) comprising PEI polymer                comprising at least one moiety comprising nitrogen                containing compound of formula (XIc), or its                substructure, and at least one grafting enhancer                and/or grafting adjuvant, optionally a crosslinking                reagent;    urface having the composition (C1)-(C10)                grafted on its;    controlling (M1) the growth of at least one                bacteria, fungi, protozoa, or virus, comprising                grafting the composition (C1)-(C10) onto a                surface;    coating comprising metal oxide nanoparticles                and the composition (C1)-(C10);    olution (S1) comprising an alcohol and the                composition (C1)-(C10);    preparing (M2) the composition (C1)-(C10),                comprising mixing at least one grafting enhancer                and/or grafting adjuvant, optionally a crosslinking                reagent, with the polymer;    preparing (M3) the solution (S1), comprising                adding at least one grafting enhancer and/or                grafting adjuvant, optionally a crosslinking                reagent, to a solution comprising an alcohol and                the polymer;    preparing (M4) a conjugated biomolecule,                comprising grafting a catechol moiety of formula                (lb) on to a surface, and reacting the substituted                benzene compound of formula (lb1) with a                biomolecule of formula (XLb); and    olution (S2) comprising an alcohol and a PEI                polymer comprising (XIa), and at least one grafting                enhancer and/or grafting adjuvant, optionally a                crosslinking reagent, where the solution comprises                70-80 wt.%, optionally 75 wt.% (XIa), and 20-30                vol.%, optionally 25 vol.% grafting enhancer and/or                grafting adjuvant, optionally a crosslinking                reagent.    R2=optionally substituted alkyl, preferably                methyl or hexyl;    R5=10C alkyl, or                2-(3,4-dihydroxyphenyl)-2-oxoethyl;    R3=optionally substituted alkoxy, optionally                methoxy;    R5a=6C alkyl, or                2-(3,4-dihydroxyphenyl)-2-oxoethyl;    R5b=optionally substituted alkyl or                (XIa);    R5c=6C alkyl, or (XIa);    X1=halo, optionally substituted amine, azido,                or C(O)OR4c, or SR4c;    R4c=H, or optionally substituted alkyl;    X2=reactive group and/or leaving group,                preferably reactive group and/or leaving group                comprising -SH, -N , ethyne                (2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl, or                (3-methyl-2,4-dimethylidenecyclopentyl)sulfanyl                compound of formula (Q1);    R1=linker, preferably phenyl, ethyl compound                of formula (-CH ) -) (Q2), 4                4-[(4-phenyl)methyl]phenyl, oxygen containing                compound of formulae (-(CH -O-CH -O-) -) (Q3), or                (-O-(CH -CH -O) -CH -) (Q4), or ethyl;    n=1-5;    Z1=reactive group and/or leaving group,                preferably reactive group and/or leaving group                comprising -SH, -N , ethyne, or                (1-ethynyl-2,5-dioxopyrrolidin-3-yl)sulfanyl;                and    B1=biomolecule.    Provided that: at least one R5 is                2-(3,4-dihydroxyphenyl)-2-oxoethyl; at least one                R5a is 2-(3,4-dihydroxyphenyl)-2-oxoethyl at least                one R5b is (XIa); and at least one R5c is                (XIa).                                                 ",,,"A97 (Miscellaneous goods not specified elsewhere - including papermaking, gramophone records, detergents, food and oil well applications.);  A82 (Coatings, impregnations, polishes - excluding textile finishing.);  G02 (Inks, paints, polishes  polymer-based paints and inks are also classified in Section A (C09D, F, G).);  D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).);  ",A04-C;  A04-D08;  A10-E01;  A12-V03C1;  G02-A05;  D03-H01T2B,A61K-047/32;  C08L-027/22;  A01N-055/00;  C08F-283/00;  C08L-079/02,WO2023102567-A2   08 Jun 2023   C08L-027/22   202354Pages: 271   English;  WO2023102567-A3   12 Oct 2023   C08F-283/00   202384   English,WO2023102567-A2    WOUS080921    05 Dec 2022;   WO2023102567-A3    WOUS080921    05 Dec 2022,,US286069P    05 Dec 2021;  US379371P    13 Oct 2022,WO2023102567-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2023102567-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,";  WO2023102567-A3 -- JP2001244383-A   SUMITOMO BAKELITE CO LTD (SUMB)   YAGI T;  US4410669-A   DEGUSSA AG (DEGS)   PANSTER P,  KLEINSCHMI P;  US20100196724-A1   ;  US20130196948-A1   ;  US20180146669-A1   ;  US11045788-B1   UNIV GUANGXI (UYGU)   HE H,  CHEN R,  SHI X,  LIN J,  ZHAO C,  LU Q,  QIN C,  WANG S;  US10532330-B2   CALIFORNIA INST OF TECHNOLOGY (CALY);  KOREA ADVANCED SCI & TECHNOLOGY INST (KOAD)   DIALLO M S,  GODDARD W A,  PARK S,  CHO M;  WO2021248098-A1   DEBOGY MOLECULAR INC (DEBO-Non-standard)   BOULOUSSA O;  WO2023102567-A2   DEBOGY MOLECULAR INC (DEBO-Non-standard)   BOULOUSSA O","WO2023102567-A3  DATABASE PUBCHEM          SUBSTANCE ANONYMOUS : ""SID 141004347"", XP093101448,          retrieved from          PUBCHEM,relevantClaims[1],relevantPassages[. entire          document];  DATABASE PUBCHEM          SUBSTANCE ANONYMOUS : ""SID 402933117"", XP093101446,          retrieved from          PUBCHEM,relevantClaims[1],relevantPassages[. entire          document];  DATABASE PUBCHEM          SUBSTANCE ANONYMOUS : ""SCHEMBL1683657"", XP093101444,          retrieved from          PUBCHEM,relevantClaims[1],relevantPassages[. entire          document]",192545-0-0-0 ; 90356-0-0-0 ; 135411-0-0-0 ; 135416-0-0-0 ; 192544-0-0-0 ; 1013-0-0-0 ; 104333-0-0-0 ; 395-0-0-0 ; 131134-0-0-0 ; 1606-0-0-0 ; 8781-0-0-0 ; 368-0-0-0 ; 8720-0-0-0 ; 417-0-0-0 ; 1145-0-0-0 ,,,R24078 ; R01852 ; R24068 ; R24076 ; R24077 ; R00326 ; R00975 ; R00817 ; R08306 ; R01176 ; R00444 ; R00708 ; R00815 ; R00820 ; R00964 ,
WO2021168577-A1;  CA3168968-A1;  EP4110401-A1;  JP2023516010-W;  EP4110401-A4,"System used to e.g. deliver payload nucleic acid            into colonic epithelial cells comprises e.g.            Bifidobacterium having plasmid and transporter nucleic            acid, bacterial secretion signal peptide, DNA-binding            domain, and cell penetrating peptide",GRAVES H A;  RAITHATHA S;  SIEVERS E;  RAMACHANDRAN U;  ZHANG K;  TOPCHIY E;  GILL N;  SAYER S;  SHAH F;  STEER C;  THOMAS R;  CHENG M;  SIVARAMAN S;  LU L;  YURIST-DOUTSCH S;  TYURIN O;  MACKENZIE L,SYMVIVO CORP (SYMV-Non-standard);  SYMVIVO CORP (SYMV-Non-standard),2021A18981,"   NOVELTY - System comprises Bifidobacterium sp. bacterium                comprising plasmid and transporter nucleic acid in                operative association with first promoter and first                terminator, bacterial secretion signal peptide,                DNA-binding domain, and cell penetrating peptide,                DNA-binding domain, the bacterial secretion signal                peptide, and the cell penetrating peptide, the                payload nucleic acid in operative association with                a second promoter and a second terminator                configured to express the payload nucleic acid in                the colonic epithelial cell, the colonic immune                cell, and/or the cell of the lamina propria, and                produce the payload protein or the payload                RNA.    USE - The system is useful for delivering a payload                nucleic acid into colonic epithelial cells, colonic                immune cells, and/or cells of the lamina propria of                a subject and producing a payload encoded by the                payload nucleic acid in the colonic epithelial                cells, colonic immune cells, and/or cells of the                lamina propria. The DNA vaccine is useful for:                causing an adaptive immune response in the subject                against the pathogen or the pathology, where the                pathogen is a virus (preferred), bacteria or a                parasite; vaccinating a subject against a pathogen;                vaccinating a subject against a coronavirus; and                vaccinating a subject against a pathology (all                claimed). Test details are described but no results                given.    DETAILED DESCRIPTION - System comprises Bifidobacterium sp. bacterium                comprising a plasmid and a transporter nucleic acid                in operative association with first promoter and                first terminator configured to express the                transporter nucleic acid in the bacterium, the                transporter nucleic acid having sequence encoding a                transporter polypeptide comprising, an                amino-terminal to carboxy-terminal order, bacterial                secretion signal peptide, DNA-binding domain, and                cell penetrating peptide, the DNA-binding domain                configured for association with the plasmid to form                a polypeptide-plasmid complex, the bacterial                secretion signal peptide configured for secretion                of the polypeptide-plasmid complex from the                bacterium, and the cell penetrating peptide                configured for importing the polypeptide-plasmid                complex into a colonic epithelial cell, a colonic                immune cell, and/or a cell of the lamina propria of                the subject and the plasmid comprising a payload                nucleic acid encoding a payload protein or a                payload RNA, the payload nucleic acid in operative                association with a second promoter and a second                terminator configured to express the payload                nucleic acid in the colonic epithelial cell, the                colonic immune cell, and/or the cell of the lamina                propria, and produce the payload protein or the                payload RNA. INDEPENDENT CLAIMS are also included                for: (1) delivering a payload nucleic acid into                colonic epithelial cells, colonic immune cells,                and/or cells of the lamina propria of a subject and                causing the cells to produce a payload encoded by                the payload nucleic acid, comprising administering                the Bifidobacterium sp. bacterium to the subject;                and (2) a DNA vaccine comprising a Bifidobacterium                sp. bacterium and the plasmid comprising a payload                nucleic acid encoding a payload protein, the                payload nucleic acid in operative association with                a second promoter and a second terminator                configured to express the payload gene in the cell                and produce the payload protein, where the payload                protein is a component of a pathogen or where the                payload protein comprises an antigen that is                specific for or associated with a pathology,                optionally where the pathology is a cancer. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E01;  B04-E08;  B04-E99;  B04-F0200E;  B04-F10B0E;  B04-H02;  B04-H05;  B04-H08;  B14-A01;  B14-A02;  B14-B02;  B14-G03;  B14-H01;  B14-S03A;  B14-S11A;  B14-S11B1;  B14-S11B3;  B14-S11C;  B14-S11D3;  D05-H07;  D05-H14A1;  D05-H99,A61K-035/74;  A61K-039/00;  A61K-047/62;  A61P-037/04;  C12N-001/21;  C12N-015/63;  C12N-015/74;  C12N-015/87;  A61K-047/46;  A61P-031/14;  C12N-015/19;  C12N-015/20;  C12N-015/24;  C12N-015/26;  C12N-015/31;  C12N-015/50;  C12N-015/85;  C12N-005/10;  A61K-035/745;  A61K-039/12;  C12N-015/11,WO2021168577-A1   02 Sep 2021   A61K-047/62   202175Pages: 106   English;  CA3168968-A1   02 Sep 2021   A61K-047/62   202290   English;  EP4110401-A1   04 Jan 2023   A61K-047/62   202303   English;  JP2023516010-W   17 Apr 2023   C12N-015/85   202332   Japanese;  EP4110401-A4   27 Mar 2024   A61K-047/62   202427   English,WO2021168577-A1    WOCA050236    25 Feb 2021;   CA3168968-A1    CA3168968    25 Feb 2021;   EP4110401-A1    EP760109    25 Feb 2021;   JP2023516010-W    JP551783    25 Feb 2021;   EP4110401-A4    EP760109    25 Feb 2021,CA3168968-A1 PCT application Application WOCA050236;   CA3168968-A1 Based on Patent WO2021168577;   EP4110401-A1 PCT application Application WOCA050236;   EP4110401-A1 Based on Patent WO2021168577;   JP2023516010-W PCT application Application WOCA050236;   JP2023516010-W Based on Patent WO2021168577,US981464P    25 Feb 2020;  US079841P    17 Sep 2020;  WOCA050236    25 Feb 2021;  CA3168968    22 Aug 2022,WO2021168577-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP4110401-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    EP4110401-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  ,,"WO2021168577-A1 -- CA2978315-A1   SYNLOGIC INC (SYNL-Non-standard)   FALB D,  ISABLLE V M,  KOTULA J W,  MILLER P F;  US20150232862-A1   ;  US20200157534-A1   ",,1281342-0-0-0 K M; 97854-0-0-0 K M; 97940-0-0-0 K M; 97946-0-0-0 K M; 97954-0-0-0 K M; 97959-0-0-0 K M; 97961-0-0-0 K M; 109602-0-0-0 K M; 162188-0-0-0 K M; 1281342-0-0-0 CL USE,,,RAM5H1 K M; RA022K K M; RA04OA K M; R06364 K M; R16207 K M; RA03SC K M; RA01IL K M; RA09LE K M; RA06YS K M; RA04OC K M,
WO2023067596-A1;  IL287372-A;  CA3235433-A1;  AU2022369499-A1,"New dual-function antigen binding molecule            comprising antibody or its antigen binding fragment,            useful in pharmaceutical composition for treating            cancer, preferably epidermal growth factor            receptor-positive cancer e.g. breast cancer",BURKOVITZ A;  DIAMANT N C;  AHARONI A,TROJAN BIO LTD (TROJ-Non-standard);  TROJAN BIO LTD (TROJ-Non-standard);  TROJAN BIO LTD (TROJ-Non-standard),202344281H,"   NOVELTY - A dual-function antigen binding molecule, is                new. The dual-function antigen binding molecule                comprises (a) a first antibody or its antigen                binding fragment comprising at least one                immunogenic peptide inserted into a CDR of antibody                or its antigen binding fragment, and (b) a second                antibody capable of binding epidermal growth factor                receptor (EGFR), where the insertion comprises                removal of CDR sequence, the antibody is chosen                from cetuximab, panitumumab and necitumumab or                antibody comprising at least 85% sequence identity                to it.    USE - The dual-function antigen binding molecule is                useful in pharmaceutical composition for treating                cancer in subject. The cancer is an epidermal                growth factor receptor (EGFR) positive cancer (all                claimed) including breast cancer, prostate cancer,                lung cancer, pancreas cancer, and colon                cancer.    ADVANTAGE - The dual-function antigen binding molecule has                high stability and binding affinity.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    antibody or its antigen binding fragment                comprising at least one immunogenic peptide                inserted into a variable region of antibody or its                antigen binding fragment, where the insertion                comprises removal of antibody or its antigen                binding fragment sequence;    pharmaceutical composition comprising the                dual-function antigen binding molecule or antibody                or its antigen binding fragment and a carrier,                excipient or adjuvant;    nucleic acid molecule comprising at least one                open reading frame, where the open reading frame                encodes a dual-function antigen binding molecule or                antibody or its antigen binding fragment;    expression vector comprising at least one                regulatory element operatively linked to the                nucleic acid molecule;    method for treating cancer in a subject                involves administering pharmaceutical composition                to subject, and treating cancer in the subject;                and    method for engineering the antibody or its                antigen binding fragment involves selecting an                antibody or its antigen binding fragment of                interest, receiving structural analysis of selected                antibody or its antigen binding domain bound to its                target, determining at least one CDR of selected                antibody or antigen binding domain which is not                required for binding to target based on structural                analysis, immunogenic peptide and engineering                antibody or its antigen binding fragment, or                selecting an antibody or antigen binding fragment                of interest, receiving a database of immunogenic                peptides, performing pairwise alignment of peptides                of a variable region of selected antibody or its                antigen binding fragment of interest with                immunogenic peptides of database, determining a                peptide from selected antibody or its antigen                binding fragment and an immunogenic peptide with an                alignment score above a predetermined threshold,                and replacing determined peptide from selected                antibody or its antigen binding fragment with                determined immunogenic peptide, and engineering an                antibody or its antigen binding fragment. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  T01 (Digital Computers)",B04-B04C2;  B04-E02A;  B04-E03A;  B04-E08;  B04-E99;  B04-F11B;  B04-G02;  B04-G21;  B04-K01J;  B14-H01;  D05-H11;  D05-H12A;  D05-H12E;  D05-H99;  T01-J05A2G;  T01-J05B4P;  T01-M02C2,A61K-039/395;  A61P-035/00;  C07K-016/28;  C07K-016/30;  C07K-016/46;  C12N-015/63,WO2023067596-A1   27 Apr 2023   C07K-016/28   202338Pages: 115   English;  IL287372-A   01 May 2023   A61K-039/395   202354   English;  CA3235433-A1   27 Apr 2023   C07K-016/28   202434   English;  AU2022369499-A1   30 May 2024   C07K-016/28   202446   English,WO2023067596-A1    WOIL051102    18 Oct 2022;   IL287372-A    IL287372    18 Oct 2021;   CA3235433-A1    CA3235433    18 Oct 2022;   AU2022369499-A1    AU369499    18 Oct 2022,CA3235433-A1 PCT application Application WOIL051102;   AU2022369499-A1 PCT application Application WOIL051102;   AU2022369499-A1 Based on Patent WO2023067596,IL287372    18 Oct 2021;  CA3235433    17 Apr 2024,WO2023067596-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        ,,"WO2023067596-A1 -- WO2021158073-A1   UNIV AJOU IND ACAD COOP FOUND (UYAJ)   KIM Y S,  KIM J,  JUNG K,  LEE S,  SON M","WO2023067596-A1  WHITNEY SHATZ, SHAN          CHUNG, BING LI, BRETT MARSHALL, MAX TEJADA, WILSON PHUNG,          WENDY SANDOVAL, ROBERT F KELLEY, JUSTIN M SCHEER:          ""Knobs-into-holes antibody production in mammalian cell          lines reveals that asymmetric afucosylation is sufficient          for full antibody-dependent cellular cytotoxicity"", MABS,          LANDES BIOSCIENCE, US, vol. 5, no. 6, 1 November 2013          (2013-11-01), US , pages 872 - 881, XP055282425, ISSN:          1942-0862, DOI:          10.4161/mabs.26307,relevantClaims[2,3],relevantPassages[the          whole document]",1004798-0-0-0 K M; 1536600-0-0-0 K M; 94297-1-0-0 K M; 298274-0-0-0 K M; 564769-0-0-0 K M; 1004798-0-0-0 CL USE; 1536600-0-0-0 CL USE,,,RANXDW K M; RARMJD K M; RA02JJ K M; RA9WQM K M; RA9NED K M,
WO2023062377-A1,"Assessing whether subject is at risk of developing            severe symptoms of disease and/or becoming contagious            after exposure, or possible exposure, to respiratory            virus, by measuring level of expression of            spermatogenesis-associated serine-rich 2-like",MANN A J;  BASAL A,ORPH PHARMA IP CO LTD (ORPH-Non-standard),202340261A,"   NOVELTY - Method (M1) for assessing whether a subject is                at risk of developing severe symptoms of disease                and/or becoming contagious after exposure, or                possible exposure, to a respiratory virus, involves                (a) measuring a level of expression of                spermatogenesis-associated serine-rich 2-like                (SPATS2L) in a biological sample obtained from the                subject and (b) analyzing the measured level of                expression of SPATS2L to assess whether the subject                is at risk of developing severe symptoms of disease                and/or becoming contagious.    USE - The method (M1) is useful for assessing                whether a subject is at risk of developing severe                symptoms of disease and/or becoming contagious                after exposure, or possible exposure, to a                respiratory virus. The method (M2) is useful for                quantifying the level of expression of SPATS2L in a                subject at risk of developing severe symptoms of                disease and/or becoming contagious following                exposure, or possible exposure, to a respiratory                virus. The computer-implemented method (M4) is                useful for assessing whether a subject is at risk                of developing severe symptoms of disease and/or                becoming contagious after exposure, or possible                exposure, to a respiratory virus (all                claimed).    ADVANTAGE - The method is more accurate, sensitive,                specific and rapid.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    a method (M2) for quantifying the level of                expression of SPATS2L in a subject at risk of                developing severe symptoms of disease and/or                becoming contagious following exposure, or possible                exposure, to a respiratory virus, involves (a)                obtaining a biological sample from the subject and                (b) measuring a level of expression of SPATS2L in                the sample by RNA transcriptomics analysis;    a method (M3) for conducting a clinical trial                or field study, involves (a) measuring levels of                expression of SPATS2L in biological samples                obtained from several subjects, (b) analyzing the                measured level of expression of SPATS2L in each                sample to assess whether a respective subject is at                risk of developing severe symptoms of disease                and/or becoming contagious and (c) including or                excluding a subject who is assessed to be at risk                of developing severe symptoms of disease and/or                becoming contagious in the clinical trial or field                study or in a subgroup of the clinical trial or                field study;    a computer-implemented method (M4) for                assessing whether a subject is at risk of                developing severe symptoms of disease and/or                becoming contagious after exposure, or possible                exposure, to a respiratory virus, involves (a)                receiving by a computer input data representing a                measured level of expression of SPATS2L in a                biological sample obtained from the subject, (b)                processing by a computer the input data to analyze                the level of expression to assess the likelihood                that the subject will develop severe symptoms of                disease and/or become contagious and (c) outputting                by a computer output data representing the                likelihood of the subject developing severe                symptoms of disease and/or becoming                contagious;    a method (M5) for providing electronic data                representing whether a subject is at risk of                developing severe symptoms of disease and/or                becoming contagious after exposure, or possible                exposure, to a respiratory virus, involves (a)                measuring a level of expression of SPATS2L in a                biological sample obtained from the subject, (b)                receiving by a computer the measured level of                expression and encoding by the computer the                measured level of expression in computer-readable                form, and (c) transmitting by a computer the                encoded measured level of expression to a remote                computer for evaluation in accordance with a method                (M4);    a computer program comprising instructions                which, when carried out by a computer, cause the                computer to carry out step (b) of the                methods;    a computer network comprising (a) at least one                server, (b) at least one other computing device and                (c) a data communication link between the server                and the other device, where the at least one other                device is configured to transmit data to the at                least one server, the data comprising the level of                expression of SPATS2L in a biological sample                obtained from a subject and the at least one server                is configured to analyze the level of expression of                SPATS2L to assess whether the subject is at risk of                developing severe symptoms of disease and/or                becoming contagious by executing the method;                and    a kit for assessing whether a subject is at                risk of developing severe symptoms of disease                and/or becoming contagious after exposure, or                possible exposure, to a respiratory virus,                comprising a reagent that allows quantitation of a                SPATS2L oligonucleotide. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  T01 (Digital Computers)",B04-B03C;  B04-E01B;  B04-E05;  B04-E99;  B11-C08E6;  B11-C08F7A;  B11-C08F8;  B11-C08N3;  B11-C11;  B12-K04F;  B12-K04G1B;  D05-H09;  D05-H18A;  D05-H18B;  D05-H99;  T01-J30D;  T01-N01B;  T01-N01D;  T01-N01E;  T01-N02A3C;  T01-S03,C12Q-001/6883,WO2023062377-A1   20 Apr 2023   C12Q-001/6883   202341Pages: 73   English,WO2023062377-A1    WOGB052609    13 Oct 2022,,GB014656    13 Oct 2021,WO2023062377-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2023062377-A1 -- WO2018007788-A1   HVIVO SERVICES LTD (HVIV-Non-standard)   WHITTAKER P A,  TORBETT N E;  WO2019122909-A1   HVIVO SERVICES LTD (HVIV-Non-standard)   DAVIES A H,  CHOY P,  SAUNDERS V,  BAHSOUN B,  VASHIST S,  TORBETT N E,  WHITTAKER P A","WO2023062377-A1  FAN JINGHAN ET AL:          ""Comparative transcriptome analysis reveals involvement          of TLR-2 signaling in the pathogenesis of intracranial          aneurysm"", JOURNAL OF CLINICAL NEUROSCIENCE, CHURCHILL          LIVINGSTONE, GB, vol. 47, 21 October 2017 (2017-10-21),          pages 258 - 263, XP085307175, ISSN: 0967-5868, DOI:          10.1016/J.JOCN.2017.07.016,relevantClaims[47|3,4,8-42,45,46,48-50],relevantPassages[page          36, line 13];  DAVENPORT EMMA E ET          AL: ""Transcriptomic profiling facilitates classification          of response to influenza challenge"", JOURNAL OF MOLECULAR          MEDICINE, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG,          vol. 93, no. 1, 28 October 2014 (2014-10-28), pages 105 -          114, XP035416346, ISSN: 0946-2716, [retrieved on          20141028], DOI:          10.1007/S00109-014-1212-8,relevantClaims[1,2,6,7,43,44|3,4,8-42,45,46,48-50|5],relevantPassages[title;          Fig. 1; Fig. 3, legend; Fig. 3, SPATS2L is the 20th          marker from the top in Fig. 3;];  JULIUS MULLER ET          AL: ""Development of an objective gene expression panel as          an alternative to self-reported symptom scores in human          influenza challenge trials"", JOURNAL OF TRANSLATIONAL          MEDICINE, vol. 15, no. 1, 8 June 2017 (2017-06-08),          XP055478297, DOI:          10.1186/s12967-017-1235-3,relevantClaims[1,2,6,7,43,44|3,4,8-42,45,46,48-50],relevantPassages[Fig.          2a and b; Fig. 3b and 4b; whole document];  BARTON AMBER J. ET          AL: ""Transcriptomics in Human Challenge Models"",          FRONTIERS IN IMMUNOLOGY, vol. 8, 18 December 2017          (2017-12-18), pages 1 - 12, XP093012703, DOI:          10.3389/fimmu.2017.01839,relevantClaims[1-50],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  CHRISTOPHER W.          WOODS ET AL: ""A Host Transcriptional Signature for          Presymptomatic Detection of Infection in Humans Exposed          to Influenza H1N1 or H3N2"", PLOS ONE, vol. 8, no. 1, 1          January 2013 (2013-01-01), pages e52198, XP055472707,          DOI:          10.1371/journal.pone.0052198,relevantClaims[1-50],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  ZAN ANNA ET AL:          ""DeepFlu: a deep learning approach for forecasting          symptomatic influenza A infection based on pre-exposure          gene expression"", BIORXIV, 20 May 2021 (2021-05-20),          pages 1 - 9, XP093012710, Retrieved from the Internet          &lt;URL:www&gt; [retrieved on 20230110], DOI:          10.1101/2020.12.02.407940,relevantClaims[1-50],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            HODINKA, MICROBIOL. SPECTR, vol. 4, no. 4, 2016;            ROLFES ET AL.: ""Estimated Influenza Illnesses, Medical          Visits, Hospitalizations, and Deaths Averted by          Vaccination in the United States"", CDC, 2016;            MOLINARI ET AL., VACCINE, vol. 25, no. 27, 2007, pages          5086 - 5096;            COX ET AL., LANCET, vol. 354, no. 9186, 1999, pages 1277          - 1282;            LAU ET AL., J INFECT DIS, vol. 201, no. 10, 2010, pages          1509 - 16;  DE          VINCENZO ET AL., N. ENGL. J. MED, vol. 371, no. 8, 2014,          pages 711 - 22;  DE          VINCENZO ET AL., N. ENGL. J. MED, vol. 373, no. 21, 2015,          pages 2048 - 58;            WOODS ET AL.: ""A Host Transcriptional Signature for          Presymptomatic Detection of Infection in Humans Exposed          to Influenza HINI or H3N2"", PLOS ONE, vol. 8, no. 1,          2013, pages e52198, XP055472707, DOI:          10.1371/journal.pone.0052198;            MULLER ET AL.: ""Development of an objective gene          expression panel as an alternative to self-reported          symptom scores in human influenza challenge trials"", J.          TRANSL. MED, vol. 15, 2017, pages 134, XP055478297, DOI:          10.1186/s12967-017-1235-3;            YE, J., COULOURIS, G., ZARETSKAYA: ""Primer-BLAST: A tool          to design target-specific primers for polymerase chain          reaction"", BMC BIOINFORMATICS, vol. 13, 2012, pages 134,          XP021132324, Retrieved from the Internet          &lt;URL:https://doi.org/10.1186/1471-2105-13-134&gt;          DOI: 10.1186/1471-2105-13-134;            WOODS ET AL., PLOS ONE, vol. 8, no. 1, 2013, pages          e52198;            MULLER ET AL., J TRANSL. MED, vol. 15, 2017, pages          134",,,,,
WO2023283601-A1;  IN202417006005-A;  EP4366769-A1,"New herpes simplex virus 2 vaccine comprising            isolated polypeptides, useful for treating suppressing,            inhibiting, or preventing intracellular pathogen            infection in subject",FERNANDEZ A;  GERSHBURG E;  PREDKI P,RATIONAL VACCINES INC (RATI-Non-standard);  RATIONAL VACCINES INC (RATI-Non-standard),202306562V,"   NOVELTY - Herpes simplex virus 2 (HSV-2) vaccine                comprising at least 3, preferably at least 12                isolated polypeptides comprises e.g. i. a                polypeptide comprising DBP or an immunogenic                fragment or variant thereof, ii. a polypeptide                comprising MCP or an immunogenic fragment or                variant thereof, iii. a polypeptide comprising gB                or an immunogenic fragment or variant thereof, iv.                a polypeptide comprising RIR1 or an immunogenic                fragment or variant thereof, v. a polypeptide                comprising TRX1 or an immunogenic fragment or                variant thereof, vi. a polypeptide comprising UL25                or an immunogenic fragment or variant thereof, vii.                a polypeptide comprising UL26 or an immunogenic                fragment or variant thereof, viii. a polypeptide                comprising TRX2 or an immunogenic fragment or                variant thereof, ix. a polypeptide comprising gD or                an immunogenic fragment or variant thereof, x. a                polypeptide comprising gC or an immunogenic                fragment or variant thereof, is new.    USE - The herpes simplex virus 2 vaccine is useful                for treating, suppressing, inhibiting, or                preventing an intracellular pathogen infection in a                subject (claimed). Test details are described but                no results given.    ADVANTAGE - None given.    DETAILED DESCRIPTION - INDEPENDENT CLAMS are also included for:    a herpes simplex virus 2 (HSV-2) vaccine                comprising at least 3, preferably at least 10                isolated polypeptides comprises i. a polypeptide                comprising DBP or an immunogenic fragment or                variant thereof, ii. a polypeptide comprising MCP                or an immunogenic fragment or variant thereof, iii.                a polypeptide comprising gB or an immunogenic                fragment or variant thereof, iv. a polypeptide                comprising RIR1 or an immunogenic fragment or                variant thereof, v. a polypeptide comprising TRX1                or an immunogenic fragment or variant thereof, vi.                a polypeptide comprising UL25 or an immunogenic                fragment or variant thereof, vii. a polypeptide                comprising UL26 or an immunogenic fragment or                variant thereof, viii. a polypeptide comprising                TRX2 or an immunogenic fragment or variant thereof,                ix. a polypeptide comprising gD or an immunogenic                fragment or variant thereof, x. a polypeptide                comprising gC or an immunogenic fragment or variant                thereof, and xi. a polypeptide comprising VP22 or                an immunogenic fragment or variant thereof;    a herpes simplex virus 2 (HSV-2) vaccine                comprising a combination of isolated immunogenic                HSV-2 polypeptides or fragments or variants                thereof, where at least 30% or at least 50% of the                anti -HSV-2 antibodies identified in serum of                HSV-2-infected individuals specifically bind the                polypeptides in the combination, according to table                1 as given in the specification;    treating (M1), suppressing, inhibiting, or                preventing an intracellular pathogen infection in a                subject, comprising administering to the subject of                the vaccine;    generating (M2) an immune response to an                intracellular pathogen in a subject, comprising                administering to the subject an the vaccine;    identifying (M3) at least one protein                components for use in a vaccine against an                intracellular pathogen, comprising a) contacting a                cell lysate prepared from cells infected with an                intracellular pathogen, with serum obtained from                blood of a subject previously infected by the                intracellular pathogen, under conditions and for a                time sufficient for antibodies against the                intracellular pathogen present in the serum to bind                intracellular pathogen antigens in the cell lysate,                thereby forming a mixture comprising                antibody/antigen complexes b) separating the                antibody/antigen complexes from the mixture,                optionally by immunoprecipitation c) identifying,                and optionally quantifying, antigens present in the                antibody/antigen complexes where the antigens                identified in c), and immunogenic fragments,                variants, or epitopes thereof, are protein                components that may be used in a vaccine against                the intracellular pathogen, thereby identifying at                least one protein components for use in a vaccine                against the intracellular pathogen;    producing (M4) a vaccine against an                intracellular pathogen, comprising preparing a                vaccine composition comprising at least one protein                components identified;    a vaccine produced according to the method;                and    treating (M5), suppressing, inhibiting, or                preventing an intracellular pathogen infection in a                subject, comprising administering to the subject of                the vaccine. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-C01;  B04-E99;  B04-G02;  B11-C07A5;  B11-C08A;  B12-K04;  B14-S11A;  D05-H07;  D05-H09;  D05-H11;  D05-H99,A61K-038/00;  A61K-039/245;  C07K-014/005,WO2023283601-A1   12 Jan 2023   A61K-039/245   202310Pages: 211   English;  IN202417006005-A   15 Mar 2024   A61K-039/245   202427   English;  EP4366769-A1   15 May 2024   A61K-039/245   202440   English,WO2023283601-A1    WOUS073512    07 Jul 2022;   IN202417006005-A    IN17006005    30 Jan 2024;   EP4366769-A1    EP838579    07 Jul 2022,IN202417006005-A PCT application Application WOUS073512;   IN202417006005-A Based on Patent WO2023283601;   EP4366769-A1 PCT application Application WOUS073512;   EP4366769-A1 Based on Patent WO2023283601,US219271P    07 Jul 2021,WO2023283601-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP4366769-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN  ,,WO2023283601-A1 -- US20050130132-A1   ;  US20130171234-A1   ;  US20200385703-A1   ,,,,,,
WO2024078645-A2,"New Cas protein useful in preparing reagent or            medicine for diagnosing, treating or preventing            diseases or disorders related to target nucleic acid            e.g. blood system, ophthalmic, liver, metabolic, cancer            or infectious diseases or conditions",LIANG J;  CHEN C;  SUN Y;  PAN W;  SI K;  HUANG L,GUANGZHOU REFORGENE MEDICINE CO LTD (GUAN-Non-standard);  ZHEJIANG SYNSORBIO TECHNOLOGY CO LTD (ZHEJ-Non-standard),202439684N,"   NOVELTY - Cas protein, comprising e.g. amino acid                sequences with at least 50% identity, is new.    USE - The Cas protein, the guide polynucleotide, the                Cas protein inactivating variant, the fusion                protein or conjugate, the nucleic acid, the                CRISPR-Cas protein system, the vector system, the                delivery system, the cell, the medicine composition                or the kit is useful in preparing reagent or                medicine for diagnosing, treating and/or preventing                diseases or disorders related to the target nucleic                acid including a blood system disease or condition,                an ophthalmic disease or condition, a nervous                system disease or condition, a respiratory system                disease or condition, a liver disease or condition,                a metabolic system disease or condition, a cancer                or an infectious disease (all claimed).    ADVANTAGE - The Cas protein can form a complex with a                directing polynucleotide that specifically binds to                and cleaves a target nucleic acid, and can form a                complex with a directing polynucleotide that                specifically binds to and cleaves target DNA.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    a guide polynucleotide, comprising (i) a                direct repeat sequence that is at least 50%                identical to any one of (SEQ ID NOs: 462-922), (ii)                a guide sequence engineered to hybridize to a                target nucleic acid, the direct repeat sequence is                linked to the guide sequence, and the guide                polynucleotide is capable of forming a complex with                the Cas protein and directing the complex to the                target sequence-specific binding of nucleic                acids;    a Cas protein inactivated variant, comprising                a nuclease activity inactivated variant of the Cas                protein, the Cas protein inactive variant is a dead                Cas protein inactive variant or a nickase Cas                protein inactive variant, the inactivated variant                of the Cas protein is inactivated of the Ruvc                domain of the Cas protein;    a fusion protein or conjugate, comprising (1)                Cas protein, or inactivated Cas protein variant,                and (2) homologous or heterologous functional                domains, alternatively, the homologous or                heterologous functional domain is subcellular                localization signal, DNA binding domain, protease                domain, transcription activation domain,                transcription inhibition domain, nuclease structure                domain, deaminase domain, uracil DNA glycosylase                domain (UDG), uracil DNA glycosylase inhibitory                domain (UGI), methylase, demethylase, transcription                release factor, Histone acetylase domain, histone                deacetylase domain, DNA ligase, affinity tag,                reporter tag, affinity domain and/or reporter                domain;    a fusion protein or conjugate, comprising (1)                Cas protein or inactivated Cas protein variant, and                (2) homologous or heterologous functional domains,                alternatively, the homologous or heterologous                functional domain is subcellular localization                signal, DNA binding domain, protease domain,                transcription activation domain, transcription                inhibition domain, nuclease structure domain,                deaminase domain, uracil DNA glycosylase domain                (UDG), uracil DNA glycosylase inhibitory domain                (UGI), methylase, demethylase, transcription                release factor, Histone acetylase domain, histone                deacetylase domain, DNA ligase, affinity tag,                reporter tag, affinity domain and/or reporter                domain;    a CRISPR-Cas protein system, comprising (a)                the Cas protein, the guidance polynucleotide, the                guide polynucleotide, the inactive variant of the                Cas protein, the fusion protein or conjugate or the                nucleic acid, and (b) a guide polynucleotide, or a                polynucleotide encoding the guide polynucleotide                nucleotide sequence, and the Cas protein functional                domain or the fusion protein or conjugate forms a                complex with the guide polynucleotide;    a vector system comprising at least one                recombinant vectors, the recombinant vector                includes the isolated nucleic acid, or the                CRISPR-Cas protein system, optionally, the                recombinant vector also contains regulatory                sequences, alternatively, the polynucleotide                sequence encoding the Cas protein, Cas protein                inactive variant or fusion protein or conjugate is                operably linked to the regulatory sequence, and/or                the polynucleotide encoding the guide                polynucleotide sequence is operably linked to the                regulatory sequence;    a delivery system, comprising (1) a delivery                tool, and (2) a Cas protein, a directing                polynucleotide, a Cas protein inactivating variant,                a fusion protein or conjugate, a nucleic acid, the                CRISPR-Cas protein system or the vector system,                optionally, the delivery tool is a virus, lipid                nanoparticle, nanoparticle, liposome, exosome,                micro-vesicle, or gene gun, optionally, the                delivery tool is a lipid nanoparticle comprising                the directing polynucleotide and an mRNA encoding                the Cas protein, the Cas protein inactivating                variant, or the fusion protein or conjugate;    a cell, comprising the Cas protein, the                guidance polynucleotide, the inactivated variant of                the Cas protein, or the Cas protein, the fusion                protein or conjugate, the nucleic acid, the                CRISPR-Cas protein system, the vector system or the                vector system delivery system, optionally, the                cells are prokaryotic cells, the cells are                eukaryotic cells, or the eukaryotic cells are                mammalian cells;    a medicine composition, comprising the Cas                protein, the guidance polynucleotide, the Cas                protein inactivation variant, the fusion protein or                conjugate, the nucleic acid, the CRISPR-Cas protein                system, the vector system, the delivery system or                the cell, preferably, the medicine composition                contains excipients;    a kit, comprising the Cas protein, the guide                polynucleotide, the Cas protein inactivating                variant, the fusion protein or conjugate, the                nucleic acid, the CRISPR-Cas protein system, the                vector system, the delivery system, the cell or the                medicine composition;    detecting, binding or cleaving a target                nucleic acid;    changing cell state; and    diagnosing, treating or preventing a disease                or condition associated with a target nucleic                acid. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E01;  B04-E08;  B04-E13;  B04-E99;  B04-F0100E;  B04-F1100E;  B04-L05A2;  B04-N0400E;  B04-N08;  B11-C07B3;  B11-C08D1;  B11-C08F;  B11-C08F8;  B12-K04E1;  B12-K04F;  B12-K04G2;  B14-J01;  B14-K01;  B14-N03;  B14-N12;  B14-N17;  D05-H09;  D05-H12E;  D05-H14;  D05-H19C;  D05-H99,C12N-009/22,WO2024078645-A2   18 Apr 2024   C12N-009/22   202437Pages: 81   Chinese,WO2024078645-A2    WOCN142927    28 Dec 2023,,WOCN142927    28 Dec 2023,WO2024078645-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,,,,,,,
WO2023009820-A1;  EP4376862-A1,Use of substantially complete sinonasal microbial            composition e.g. to reduce symptoms/severity of            symptoms associated with chronic rhinosinusitis            includes administering composition having sinonasal            microbes of e.g. Firmicutes,ENSIGN L;  BURGESS J;  GUNDELUND RASMUSSEN T;  BINNE U K;  VAN HYLCKAMA VLEIG J E T,ZEPHYRUS THERAPEUTICS INC (ZEPH-Non-standard);  ZEPHYRUS THERAPEUTICS INC (ZEPH-Non-standard),202315680W,"   NOVELTY - Use of substantially complete sinonasal                microbial composition for reducing symptoms or the                severity of symptoms associated with chronic                rhinosinusitis (CRS) in a recipient subject                comprises administering the composition to                sinonasal cavities of the recipient subject, where                the composition comprises sinonasal microbes of at                least one of Actinobacteria, Bacteroidetes,                Firmicutes or Proteobacteria.    USE - The composition is useful for reducing                symptoms or the severity of symptoms associated                with chronic rhinosinusitis (CRS) in a recipient                subject, treating the sinonasal cavities of a                recipient, reducing the number of repeated sinus                medical therapy and/or sinus surgery in a recipient                subject, and reducing inflammation including local                (e.g., the sinonasal cavities) or affecting larger                areas of the body (e.g., upper airway inflammation)                (all claimed).    ADVANTAGE - The composition: reduces the symptoms or the                severity of symptoms associated with CRS comprises                treating CRS; relieves symptoms of nasal                congestion/obstruction, facial discomfort/pain or                pressure, tenderness and swelling around the                patient's eyes, cheeks, nose or forehead, nasal                discharge, headache, hyposmia, anosmia, ear                pain/pressure, aching in the upper jaw and teeth,                cough, sore throat, fatigue, irritability, and                nausea. The ability of the composition to reduce                the symptoms of CRS was tested by sinonasal outcome                test 22 (SNOT-22) score by in vitro assay. The                results showed that the average SNOT-22 score in                the responders was reduced by half (54.5%).    DETAILED DESCRIPTION - Use (M1) of substantially complete sinonasal                microbial composition for reducing symptoms or the                severity of symptoms associated with chronic                rhinosinusitis (CRS) in a recipient subject                comprises administering the composition to                sinonasal cavities of the recipient subject. The                composition comprises sinonasal microbes of at                least one of Actinobacteria, Bacteroidetes,                Firmicutes or Proteobacteria. The composition is                obtainable by (e) processing collected mucosal                fluid comprising sinonasal microbes from sinonasal                cavities of a healthy donor subject in a                centralized processing facility, (f) assessing the                absence of at least one pathogens, (g) assessing                viability and/or quantity of the sinonasal                microbes, and (h) releasing the composition                comprising the processed mucosal fluid for the                aforementioned use if a predetermined level is                obtained in step (b) and (c), where steps (b) and                (c) can be performed prior to and/or after the                processing in step (a) for obtaining the                composition. The composition is formulated into a                dosage form in at least one discrete units. The                amount is predetermined and effective in reducing                the symptoms or the severity of symptoms associated                with CRS. INDEPENDENT CLAIMS are also included                for:    use (M2) of substantially complete sinonasal                microbial composition in treating the sinonasal                cavities of a recipient subject in need of                treatment exhibiting an adverse condition affecting                the sinonasal cavities, comprising administering                the composition to sinonasal cavities of the                recipient subject for treating the adverse                condition, where the composition is formulated into                a dosage form, the dosage form comprises the                composition in at least one discrete units, the                amount is predetermined and effective in treating                the adverse condition, where the composition                comprises sinonasal microbes of at least one of                Actinobacteria, Bacteroidetes, Firmicutes or                Proteobacteria;    use (M3) of substantially complete sinonasal                microbial composition in reducing the number of                repeated sinus medical therapy and/or sinus surgery                in a recipient subject in need of such treatment,                the method comprising administering the composition                to sinonasal cavities of the recipient subject for                reducing the number of repeated sinus medical                therapy and/or sinus surgery, where the composition                is formulated into a dosage form, where the dosage                form comprises the composition in at least one                discrete units, where the amount is predetermined                and effective in reducing the number of repeated                sinus medical therapy and/or sinus surgery, where                the composition comprises sinonasal microbes of at                least one of Actinobacteria, Bacteroidetes,                Firmicutes or Proteobacteria;    producing (M4) a substantially complete                sinonasal microbial composition in a centralized                processing facility comprising receiving and                processing collected mucosal fluid comprising                sinonasal microbes from sinonasal cavities of a                healthy donor subject, assessing the absence of at                least one pathogens, assessing viability and/or                quantity of the sinonasal microbes, and releasing a                composition comprising the processed mucosal fluid                if a predetermined level is obtained in step (b)                and (c), optionally, discarding the composition if                a predetermined level in step (b) and (c) is not                obtained, where the steps (b) and (c) can be                performed prior to (e.g., with the mucosal fluid                sample) and/or after the processing in step (a)                (e.g., with the composition), e.g., by removing a                portion of the mucosal fluid sample or composition                for testing (e.g., nucleic acid sequencing) for                obtaining the composition;    an isolated substantially complete sinonasal                microbial composition produced or obtainable by the                method; and    medical kit comprising an applicator for                delivery of the substantially complete sinonasal                microbial composition to the human sinonasal                cavities, where the composition is optionally a                fluid, aerosol, mist or dry powder. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C07 (Apparatus, formulation, general. including veterinary syringes, general formulations where the active compound is not central to the invention (e.g. wettable powders) and analysis.);  C02 (Heterocyclic.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B02-C;  B02-C03;  B02-C04;  B02-E;  B02-M;  B02-P02;  B02-P03;  B02-T;  B04-F04;  B04-F09;  B04-F10;  B04-H02;  B04-H05C;  B04-H06F;  B04-H08;  B04-N06;  B06-E03;  B14-C03;  B14-S18;  C02-C;  C02-C03;  C02-C04;  C02-E;  C02-M;  C02-P02;  C02-P03;  C02-T;  C04-F04;  C04-F09;  C04-F10;  C04-H02;  C04-H05C;  C04-H06F;  C04-H08;  C04-N06;  C06-E03;  C12-M01A;  C14-C03;  C14-S18;  D05-H08A,A61K-035/741;  A61K-009/00;  C12N-001/04,WO2023009820-A1   02 Feb 2023   A61K-035/741   202318Pages: 129   English;  EP4376862-A1   05 Jun 2024   A61K-035/741   202447   English,WO2023009820-A1    WOUS038882    29 Jul 2022;   EP4376862-A1    EP783387    29 Jul 2022,EP4376862-A1 PCT application Application WOUS038882;   EP4376862-A1 Based on Patent WO2023009820,US226846P    29 Jul 2021,WO2023009820-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP4376862-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN  ,,"WO2023009820-A1 -- WO2013155370-A1   UNIV CALIFORNIA (REGC)   LYNCH S,  GOLDBERG A,  PLETCHER S D;  WO2018017658-A1   STEVENS C (STEV-Individual)   STEVENS C;  WO2018209308-A1   UNIV CALIFORNIA (REGC)   LYNCH S;  WO2010036876-A2   UNIV NEW YORK (UYNY)   BLASER M J,  CHO I","WO2023009820-A1  CHARLES DERALD D.          ET AL: ""Development of a Novel ex vivo Nasal Epithelial          Cell Model Supporting Colonization With Human Nasal          Microbiota"", FRONTIERS IN CELLULAR AND INFECTION          MICROBIOLOGY, vol. 9, 21 May 2019 (2019-05-21),          XP055973213, DOI:          10.3389/fcimb.2019.00165,relevantClaims[89-100|1-101|65-88,101],relevantPassages[&lt;pp&gt;5&lt;/pp&gt;&lt;para&gt;1&lt;/para&gt;abstract];  COPE E K ET AL:          ""Novel Microbiome-Based Therapeutics for Chronic          Rhinosinusitis"", CURRENT ALLERGY AND ASTHMA REPORTS,          SPRINGER US, NEW YORK, vol. 15, no. 3, 17 March 2015          (2015-03-17), pages 1 - 10, XP035471316, ISSN: 1529-7322,          [retrieved on 20150317], DOI:          10.1007/S11882-014-0504-Y,relevantClaims[1-64,89-101|1-101],relevantPassages[&lt;pp&gt;5&lt;/pp&gt;&lt;column&gt;1&lt;/column&gt;|&lt;pp&gt;3&lt;/pp&gt;&lt;column&gt;2&lt;/column&gt;&lt;ppl&gt;4&lt;/ppl&gt;&lt;coll&gt;1&lt;/coll&gt;|&lt;pp&gt;7&lt;/pp&gt;&lt;column&gt;1&lt;/column&gt;];  HOFFMANN DIANE E.          ET AL: ""A proposed definition of microbiota          transplantation for regulatory purposes"", GUT MICROBES,          vol. 8, no. 3, 20 March 2017 (2017-03-20), United States,          pages 208 - 213, XP055973218, ISSN: 1949-0976, Retrieved          from the Internet          &lt;URL:https://www.tandfonline.com/doi/pdf/10.1080/19490976.2017.1293223&gt;          DOI:          10.1080/19490976.2017.1293223,relevantClaims[89-101],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];  KUMPITSCH CHRISTINA          ET AL: ""The microbiome of the upper respiratory tract in          health and disease"", BMC BIOLOGY, vol. 17, no. 1, 1          December 2019 (2019-12-01), XP055865590, Retrieved from          the Internet          &lt;URL:https://bmcbiol.biomedcentral.com/track/pdf/10.1186/s12915-019-0703-z.pdf&gt;          DOI:          10.1186/s12915-019-0703-z,relevantClaims[1-101],relevantPassages[&lt;pp&gt;1&lt;/pp&gt;&lt;column&gt;2&lt;/column&gt;&lt;table&gt;2&lt;/table&gt;|&lt;pp&gt;8&lt;/pp&gt;&lt;column&gt;2&lt;/column&gt;];  MICHAEL HOGGARD ET          AL: ""Evidence of microbiota dysbiosis in chronic          rhinosinusitis : Bacterial Dysbiosis in CRS"",          INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, vol. 7,          no. 3, 23 November 2016 (2016-11-23), Oxford, pages 230 -          239, XP055767873, ISSN: 2042-6976, DOI:          10.1002/alr.21871,relevantClaims[1-101],relevantPassages[&lt;pp&gt;231&lt;/pp&gt;&lt;column&gt;1&lt;/column&gt;&lt;figure&gt;-&lt;/figure&gt;&lt;table&gt;-&lt;/table&gt;abstract];  ANDERS MAe;RTENSSON          ET AL: ""Clinical efficacy of a topical lactic acid          bacterial microbiome in chronic rhinosinusitis: A          randomized controlled trial"", LARYNGOSCOPE INVESTIGATIVE          OTOLARYNGOLOGY, vol. 2, no. 6, 8 November 2017          (2017-11-08), pages 410 - 416, XP055562144, ISSN:          2378-8038, DOI:          10.1002/lio2.93,relevantClaims[1-101],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];            ENGLAND ET AL.: ""Nasal pH measurement: a reliable and          repeatable parameter"", CLIN OTOLARYNGOL ALLIED SCI, vol.          24, no. 1, February 1999 (1999-02-01), pages 67 -          8;            MAJIMA ET AL.: ""Rheologic properties of nasal mucus from          patients with chronic sinusitis"", AMERICAN JOURNAL OF          RHINOLOGY, vol. 7, 1 September 1993 (1993-09-01), pages          217 - 221;            TOGIAS ET AL.: ""The osmolarity of nasal secretions          increases when inflammatory mediators are released in          response to inhalation of cold, dry air"", AM REV RESPIR          DIS, vol. 137, no. 3, March 1988 (1988-03-01), pages 625          - 9;  MA          BIEL: ""Antimicrobial Photodynamic Therapy Treatment of          Chronic Recurrent Sinusitis Biofilms"", INT FORUM ALLERGY          RHINOL, vol. 1, no. 5, September 2011 (2011-09-01), pages          329 - 334, XP055595204, DOI: 10.1002/alr.20089;            CHOWDHURY ET AL.: ""Investigating the minimal clinically          important difference for SNOT-22 symptom domains in          surgically managed chronic rhinosinusitis"", INT. FORUM          ALLERGY RHINOL., vol. 7, no. 12, December 2017          (2017-12-01), pages 1149 - 1155;            MARTENSSON ET AL.: ""Clinical efficacy of a topical lactic          acid bacterial microbiome in chronic rhinosinusitis: A          randomized controlled trial"", LARYNGOSCOPE INVESTIG          OTOLARYNGOL, vol. 2, no. 6, 8 November 2017 (2017-11-08),          pages 410 - 416, XP055562144, DOI:          10.1002/lio2.93",87346-1-0-0 K M; 88707-2-0-0 K M; 2210159-1-0-0 K M; 133027-2-1-0 K M; 91190-1-0-0 K M; 94336-2-0-0 K M; 101388-1-0-0 K M; 102915-1-0-0 K M; 95293-1-0-0 K M; 90292-1-0-0 K M; 90283-1-0-0 K M; 15132-2-0-0 K M; 94423-1-0-0 K M; 142657-1-0-0 K M; 101051-1-0-0 K M; 97925-0-0-0 K M; 97954-0-0-0 K M; 97957-0-0-0 K M; 97959-0-0-0 K M; 97961-0-0-0 K M; 97940-0-0-0 K M; 111285-0-0-0 K M; 1281342-0-0-0 K M; 1760989-0-0-0 K M; 662345-0-0-0 K M; 1411866-0-0-0 K M; 1531296-0-0-0 K M; 109602-0-0-0 K M; 109233-0-0-0 K M; 97914-0-0-0 K M; 1320701-0-0-0 K M; 184602-0-0-0 K M; 200757-0-0-0 K M; 1274055-1-0-0 K M; 1281342-0-0-0 CL USE; 1760989-0-0-0 CL USE; 1411866-0-0-0 CL USE; 1531296-0-0-0 CL USE; 1320701-0-0-0 CL USE; 1274055-1-0-0 CL USE; 2210159-1-0-0 CL USE,,00088; 41250; 00534; 00012; 00061; 00090,R02055 K M; R00222 K M; RB5VBG K M; R14282 K M; R21291 K M; R00210 K M; RA088M K M; R00265 K M; R09265 K M; R02048 K M; R01180 K M; R01986 K M; R00960 K M; R01382 K M; R04156 K M; R16255 K M; RA01ZP K M; RA03SC K M; RA04OE K M; RA01IL K M; RA09LE K M; RA04OA K M; RA04OD K M; RAM5H1 K M; RAY7JT K M; RAY8TP K M; RAFGBC K M; RBDRWX K M; RARIIF K M; RA06YS K M; RA0365 K M; R12268 K M; RA03HS K M; RAT0N7 K M; RA02DV K M; RA00GT K M; RALZXM K M,2055-S; 0222-S; 0210-S; 0265-S; 2048-S; 1180-S; 1986-S; 0960-S; 1382-S
CN112481289-A;  EP4008336-A1;  WO2022116528-A1;  US2022177910-A1;  US2022177908-A1;  CN114630909-A;  HK40041077-A0;  US11634727-B2;  CN112481289-B;  HK40041077-A1;  CN114630909-B,"New recombinant nucleic acid molecule useful in            production of protein, comprising internal ribosome            entry site element and useful in preparation of mRNA            infectious disease vaccines, and mRNA-based dendritic            cell tumor vaccines",SUN Z;  ZUO C;  ZHU J;  GAO S;  LI N,JIANGSU PURECELL BIOMEDICAL TECHNOLOGY (JIAN-Non-standard);  SUZHOU CUREMED BIOMEDICAL TECHNOLOGY CO (SUZH-Non-standard);  SUZHOU CUREMED BIOMEDICAL TECHNOLOGY CO (SUZH-Non-standard);  SUZHOU CUREMED BIOMEDICAL TECHNOLOGY CO (SUZH-Non-standard);  JIANGSU PURECELL BIOMEDICAL TECHNOLOGY (JIAN-Non-standard);  PURECODON HONG KONG BIOPHARMA LTD (PURE-Non-standard);  SUZHOU CUREMED BIOMEDICAL TECHNOLOGY CO (SUZH-Non-standard);  PURECODON HONG KONG BIOPHARMA LTD (PURE-Non-standard),202130423A,"   NOVELTY - Recombinant nucleic acid molecule, comprising                internal ribosome entry site (IRES) element, is                new. The IRES element comprises (i) a nucleotide                sequence comprising a fully defined sequence of 741                nucleotides (SEQ ID NO: 8) as given in the                specification, a fully defined sequence of 682                nucleotides (SEQ ID NO: 9) as given in the                specification, a fully defined sequence of 742                nucleotides (SEQ ID NO: 10) as given in the                specification, and a fully defined sequence of 737                nucleotides (SEQ ID NO: 11) as given in the                specification; (ii) a nucleotide sequence                comprising the reverse complement of the sequence                shown in any one of SEQ ID NO: 8-11; (iii) the                reverse complement sequence of the sequence capable                of hybridizing with the nucleotide sequence shown                in (i) or (ii) under high stringency hybridization                conditions or very high stringency hybridization                conditions; and (iv) a sequence having at least                90%, preferably at least 99% sequence identity to                the nucleotide sequence shown in (i) or (ii).    USE - The recombinant nucleic acid molecule, the                recombinant expression vector, the linear RNA, the                circular RNA, or recombinant host cell is useful in                the production of protein (claimed) and useful in                the preparation of mRNA infectious disease                vaccines, therapeutic mRNA tumor vaccines, and                mRNA-based dendritic cell tumor vaccines,                mRNA-based gene therapy, mRNA-based chimeric                antigen receptor T cell therapy, protein supplement                therapy and other fields have important application                value.    ADVANTAGE - The IRES element can increase the protein                expression level of circular RNA in eukaryotic                cells, achieves efficient and persistent expression                of protein.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) a recombinant expression vector,                comprising the recombinant nucleic acid                molecule;    (2) a linear RNA, comprising recombinant                nucleic acid molecule or transcriptional formation                of the recombinant expression vector, preferably                the linear RNA includes 5'homology arm, 3'intron,                second exon, 5'spacer, IRES element, coding region,                3'spacer, first exon, 5'intron and 3'homology                arm;    (3) a circular RNA, comprising recombinant                nucleic acid molecule, or the recombinant                expression vector formed by circularization after                transcription, or formed by the linear RNA                circularization, optionally the circular RNA                includes a second exon, a 5'spacer, an IRES                element, a coding region, a 3'spacer, and a first                exon that are sequentially connected;    (4) a recombinant host cell, comprising the                recombinant nucleic acid molecule, the recombinant                expression vector, the linear RNA or the circular                RNA;    (5) a composition, comprising (i) recombinant                nucleic acid molecule, recombinant expression                vector, linear RNA, circular RNA, or the                recombinant host cell, or (ii) recombinant nucleic                acid molecule, recombinant expression vector,                linear RNA, circular RNA, or the target polypeptide                expressed by the recombinant host cell;    (6) a method for preparing protein, comprising                expressing the recombinant nucleic acid molecule,                recombinant expression vector, linear RNA, circular                RNA or target protein in the recombinant host cell;                and    (7) method of preventing or treating diseases,                comprising (i) recombinant nucleic acid molecule,                recombinant expression vector, linear RNA, circular                RNA, or the recombinant host cell, or (ii)                recombinant nucleic acid molecule, recombinant                expression vector, linear RNA, circular RNA or the                target polypeptide expressed by the recombinant                host cell. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-B04C8;  B04-C01;  B04-E01;  B04-E07;  B04-E08;  B04-E99;  B04-F0100E;  B04-G01;  B04-G04;  B04-G21;  B04-H01;  B04-H02Q;  B04-K01;  B04-N0200E;  B04-N0400E;  B14-H01;  B14-S03;  B14-S11;  B14-S21;  D05-H12E;  D05-H14;  D05-H17A;  D05-H99,C12N-015/11;  C12N-015/79;  C12N-015/85;  C12N-005/10;  A61K-038/00;  A61K-038/17;  A61K-048/00;  A61K-039/215;  C07K-019/00;  G01N-033/569;  C07K-014/005;  C07K-014/47;  C07K-014/505;  C07K-014/54;  C07K-014/735;  C07K-016/28;  A61P-031/14;  C12N-015/62,CN112481289-A   12 Mar 2021   C12N-015/79   202128   Chinese;  EP4008336-A1   08 Jun 2022   A61K-038/00   202247   English;  WO2022116528-A1   09 Jun 2022   C12N-015/79   202248   Chinese;  US2022177910-A1   09 Jun 2022   C12N-015/85   202249   English;  US2022177908-A1   09 Jun 2022   C12N-015/85   202249   English;  CN114630909-A   14 Jun 2022   C12N-015/62   202252   Chinese;  HK40041077-A0   13 Aug 2021   C12N-015/79   202303   Chinese;  US11634727-B2   25 Apr 2023   A61K-048/00   202336   English;  CN112481289-B   27 Jun 2023   C12N-015/79   202356   Chinese;  HK40041077-A1   26 Jan 2024   C12N-015/79   202442   Chinese;  CN114630909-B   28 May 2024   C12N-015/62   202447   Chinese,CN112481289-A    CN11408937    04 Dec 2020;   EP4008336-A1    EP177528    03 Jun 2021;   WO2022116528-A1    WOCN103688    30 Jun 2021;   US2022177910-A1    US486204    27 Sep 2021;   US2022177908-A1    US337612    03 Jun 2021;   CN114630909-A    CN80002235    30 Jun 2021;   HK40041077-A0    HK4030941    12 May 2021;   US11634727-B2    US486204    27 Sep 2021;   CN112481289-B    CN11408937    04 Dec 2020;   HK40041077-A1    HK4030941    12 May 2021;   HK40041077-A1    HK4030941    12 May 2021;   CN114630909-B    CN80002235    30 Jun 2021,US2022177910-A1 Cont of Application US337612;   CN114630909-A PCT application Application WOCN103688;   HK40041077-A0 Previous Publ. Patent CN112481289;   US11634727-B2 Cont of Application US337612;   US11634727-B2 Previous Publ. Patent US2022177910;   CN112481289-B Previous Publ. Patent CN112481289;   HK40041077-A1 Previous Publ. Patent CN112481289;   CN114630909-B PCT application Application WOCN103688;   CN114630909-B Previous Publ. Patent CN114630909;   CN114630909-B Based on Patent WO2022116528,CN11408937    04 Dec 2020;  CN11491280    17 Dec 2020;  HK4030941    12 May 2021;  CN80002235    24 Aug 2021,  EP4008336-A1:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  KH;  LI;  LT;  LU;  LV;  MA;  MC;  MD;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TN;  TR  WO2022116528-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW                  ,,"CN112481289-A -- CN110392577-A   CUREVAC AG (CUEV);  BOEHRINGER INGELHEIM INT GMBH (BOEH)   HEIDENREICH R,  FIEDLER K,  FOTIN-MLECZEK M,  KOWALCZYK A,  ELBERS K,  WURM M;  CN111778256-A   GUANGDONG MICROBIOLOGY GUANGDONG DETECTI (GDIN)   CHEN D,  GUO Y,  QI L,  WU Q,  XIE Y,  TANG X,  WANG D;  US20200080106-A1   ;  WO2020180752-A1   FLAGSHIP PIONEERING INNOVATIONS V INC (FLAG)   KAHVEJIAN A,  PLUGIS N M,  DE BOER A S,  CARMONA E M,  STEWART M H;  WO2020198403-A2   FLAGSHIP PIONEERING INNOVATIONS V INC (FLAG)   KAHVEJIAN A,  PLUGIS N M,  DE BOER A S,  CIFUENTES-ROJAS C,  PAEK K Y;  EP4008336-A1 -- CN112481289-A   JIANGSU PURECELL BIOMEDICAL TECHNOLOGY (JIAN-Non-standard)   SUN Z,  ZUO C,  ZHU J;  WO2019236673-A1   MASSACHUSETTS TECHNOLOGY INST (MASI)   ANDERSON D G,  WESSELHOEFT R A,  KOWALSKI P S;  WO2020219563-A1   TCR2 THERAPEUTICS INC (TCRT-Non-standard)   KIEFFER-KWON P,  LIBERZON E,  HOFMEISTER R,  BAEUERLE P A,  GETTS D;  WO2020237227-A1   MASSACHUSETTS TECHNOLOGY INST (MASI);  ORNA THERAPEUTICS INC (ORNA-Non-standard);  WESSELHOEFT A (WESS-Individual);  ANDERSON D G (ANDE-Individual);  FUSE S (FUSE-Individual);  GOODMAN B (GOOD-Individual);  HORHOTA A (HORH-Individual);  SQUILLONI R (SQUI-Individual)   WESSELHOEFT A,  ANDERSON D G,  FUSE S,  GOODMAN B,  HORHOTA A,  SQUILLONI R;  US20200080106-A1   ;  WO2022116528-A1 -- CN111944064-A   CHINESE ACAD SCI MICROBIOLOGY INST (CWSW)   YANG L,  LIU W;  CN112481289-A   JIANGSU PURECELL BIOMEDICAL TECHNOLOGY (JIAN-Non-standard)   SUN Z,  ZUO C,  ZHU J;  CN112707968-A   JIANGSU PURECELL BIO MEDICINE TECHNOLOGY (JIAN-Non-standard)   SUN Z,  ZUO C,  GAO S,  LI N;  WO2019236673-A1   MASSACHUSETTS TECHNOLOGY INST (MASI)   ANDERSON D G,  WESSELHOEFT R A,  KOWALSKI P S;  US2022177910-A1 -- US11203767-B2   MASSACHUSETTS TECHNOLOGY INST (MASI)   ANDERSON D G,  WESSELHOEFT R A,  KOWALSKI P S;  US11352640-B2   MASSACHUSETTS TECHNOLOGY INST (MASI)   ANDERSON D G,  WESSELHOEFT R A,  KOWALSKI P S;  US11352641-B2   MASSACHUSETTS TECHNOLOGY INST (MASI)   ANDERSON D G,  WESSELHOEFT R A,  KOWALSKI P S;  US11447796-B2   MASSACHUSETTS TECHNOLOGY INST (MASI)   ANDERSON D G,  WESSELHOEFT R A,  KOWALSKI P S;  CN114630909-A -- CN111732638-A   CHONGQING BOWEI BAITAI BIOLOGICAL PHARM CO                  LTD (CHON-Non-standard);  SHANGHAI BOWEI BIOLOGICAL TECHNOLOGY CO (SHAN-Non-standard)   FU W,  DING S,  GAO X,  ZHANG Q,  SHEN Q;  CN112481289-A   JIANGSU PURECELL BIOMEDICAL TECHNOLOGY (JIAN-Non-standard)   SUN Z,  ZUO C,  ZHU J;  CN112707968-A   JIANGSU PURECELL BIO MEDICINE TECHNOLOGY (JIAN-Non-standard)   SUN Z,  ZUO C,  GAO S,  LI N;  WO2019236673-A1   MASSACHUSETTS TECHNOLOGY INST (MASI)   ANDERSON D G,  WESSELHOEFT R A,  KOWALSKI P S;  WO2020219563-A1   TCR2 THERAPEUTICS INC (TCRT-Non-standard)   KIEFFER-KWON P,  LIBERZON E,  HOFMEISTER R,  BAEUERLE P A,  GETTS D;  WO2020237227-A1   MASSACHUSETTS TECHNOLOGY INST (MASI);  ORNA THERAPEUTICS INC (ORNA-Non-standard);  WESSELHOEFT A (WESS-Individual);  ANDERSON D G (ANDE-Individual);  FUSE S (FUSE-Individual);  GOODMAN B (GOOD-Individual);  HORHOTA A (HORH-Individual);  SQUILLONI R (SQUI-Individual)   WESSELHOEFT A,  ANDERSON D G,  FUSE S,  GOODMAN B,  HORHOTA A,  SQUILLONI R;  US11634727-B2 -- US20200080106-A1   ;  US9428767-B2   DNA2.0 INC (DNAT-Non-standard)   CAVES K,  GOVINDRAJAN S,  MINSHULL J,  WELCH M;  US11203767-B2   MASSACHUSETTS TECHNOLOGY INST (MASI)   ANDERSON D G,  WESSELHOEFT R A,  KOWALSKI P S;  US11352640-B2   MASSACHUSETTS TECHNOLOGY INST (MASI)   ANDERSON D G,  WESSELHOEFT R A,  KOWALSKI P S;  US11352641-B2   MASSACHUSETTS TECHNOLOGY INST (MASI)   ANDERSON D G,  WESSELHOEFT R A,  KOWALSKI P S;  US11447796-B2   MASSACHUSETTS TECHNOLOGY INST (MASI)   ANDERSON D G,  WESSELHOEFT R A,  KOWALSKI P S;  WO2015157579-A2   DNA2.0 INC (DNAT-Non-standard)   CAVES K,  GOVINDRAJAN S,  MINSHULL J,  WELCH M;  CN110392577-A   CUREVAC AG (CUEV);  BOEHRINGER INGELHEIM INT GMBH (BOEH)   HEIDENREICH R,  FIEDLER K,  FOTIN-MLECZEK M,  KOWALCZYK A,  ELBERS K,  WURM M;  CN111778256-A   GUANGDONG MICROBIOLOGY GUANGDONG DETECTI (GDIN)   CHEN D,  GUO Y,  QI L,  WU Q,  XIE Y,  TANG X,  WANG D;  CN112481289-A   JIANGSU PURECELL BIOMEDICAL TECHNOLOGY (JIAN-Non-standard)   SUN Z,  ZUO C,  ZHU J;  US20200090106-A1   ;  WO2019236673-A1   MASSACHUSETTS TECHNOLOGY INST (MASI)   ANDERSON D G,  WESSELHOEFT R A,  KOWALSKI P S;  WO2020180752-A1   FLAGSHIP PIONEERING INNOVATIONS V INC (FLAG)   KAHVEJIAN A,  PLUGIS N M,  DE BOER A S,  CARMONA E M,  STEWART M H;  WO2020219563-A1   TCR2 THERAPEUTICS INC (TCRT-Non-standard)   KIEFFER-KWON P,  LIBERZON E,  HOFMEISTER R,  BAEUERLE P A,  GETTS D;  WO2020237227-A1   MASSACHUSETTS TECHNOLOGY INST (MASI);  ORNA THERAPEUTICS INC (ORNA-Non-standard);  WESSELHOEFT A (WESS-Individual);  ANDERSON D G (ANDE-Individual);  FUSE S (FUSE-Individual);  GOODMAN B (GOOD-Individual);  HORHOTA A (HORH-Individual);  SQUILLONI R (SQUI-Individual)   WESSELHOEFT A,  ANDERSON D G,  FUSE S,  GOODMAN B,  HORHOTA A,  SQUILLONI R;  WO2020198403-A2   FLAGSHIP PIONEERING INNOVATIONS V INC (FLAG)   KAHVEJIAN A,  PLUGIS N M,  DE BOER A S,  CIFUENTES-ROJAS C,  PAEK K Y;  CN112481289-B -- CN110392577-A   CUREVAC AG (CUEV);  BOEHRINGER INGELHEIM INT GMBH (BOEH)   HEIDENREICH R,  FIEDLER K,  FOTIN-MLECZEK M,  KOWALCZYK A,  ELBERS K,  WURM M;  CN111778256-A   GUANGDONG MICROBIOLOGY GUANGDONG DETECTI (GDIN)   CHEN D,  GUO Y,  QI L,  WU Q,  XIE Y,  TANG X,  WANG D;  US20200080106-A1   ;  WO2020180752-A1   FLAGSHIP PIONEERING INNOVATIONS V INC (FLAG)   KAHVEJIAN A,  PLUGIS N M,  DE BOER A S,  CARMONA E M,  STEWART M H;  WO2020198403-A2   FLAGSHIP PIONEERING INNOVATIONS V INC (FLAG)   KAHVEJIAN A,  PLUGIS N M,  DE BOER A S,  CIFUENTES-ROJAS C,  PAEK K Y;  CN114630909-B -- CN111732638-A   CHONGQING BOWEI BAITAI BIOLOGICAL PHARM CO                  LTD (CHON-Non-standard);  SHANGHAI BOWEI BIOLOGICAL TECHNOLOGY CO (SHAN-Non-standard)   FU W,  DING S,  GAO X,  ZHANG Q,  SHEN Q;  CN112481289-A   JIANGSU PURECELL BIOMEDICAL TECHNOLOGY (JIAN-Non-standard)   SUN Z,  ZUO C,  ZHU J;  CN112707968-A   JIANGSU PURECELL BIO MEDICINE TECHNOLOGY (JIAN-Non-standard)   SUN Z,  ZUO C,  GAO S,  LI N;  WO2019236673-A1   MASSACHUSETTS TECHNOLOGY INST (MASI)   ANDERSON D G,  WESSELHOEFT R A,  KOWALSKI P S;  WO2020219563-A1   TCR2 THERAPEUTICS INC (TCRT-Non-standard)   KIEFFER-KWON P,  LIBERZON E,  HOFMEISTER R,  BAEUERLE P A,  GETTS D;  WO2020237227-A1   MASSACHUSETTS TECHNOLOGY INST (MASI);  ORNA THERAPEUTICS INC (ORNA-Non-standard);  WESSELHOEFT A (WESS-Individual);  ANDERSON D G (ANDE-Individual);  FUSE S (FUSE-Individual);  GOODMAN B (GOOD-Individual);  HORHOTA A (HORH-Individual);  SQUILLONI R (SQUI-Individual)   WESSELHOEFT A,  ANDERSON D G,  FUSE S,  GOODMAN B,  HORHOTA A,  SQUILLONI R","EP4008336-A1            PARDI, N. ET AL.: ""Nucleoside-modified mRNA vaccines          induce potent T follicularhelper and germinal center B          cell responses"", J. EXP. MED., vol. 215, 2018, pages 1571          - 1588, XP055545604, DOI: 10.1084/jem.20171450;            LIANG, F. ET AL.: ""Efficient targeting and activation of          antigen-presenting cells in vivo after modified mRNA          vaccine administration in rhesus macaques"", MOL. THER.,          vol. 25, 2017, pages 2635 - 2647, XP055545594, DOI:          10.1016/j.ymthe.2017.08.006;            PARDI, N. ET AL.: ""Zika virus protection by a single          low-dose nucleoside-modifiedmRNA vaccination"", NATURE,          vol. 543, 2017, pages 248 - 251;            UGUR SAHINKATALIN KARIKOOZLEM TIIRECI: ""mRNA-based          therapeutics developing a new class of drugSo"", NATURE          REVIEWS DRUG DISCOVERY, vol. 13, 2014, pages 759 - 780,          XP055544673, DOI: 10.1038/nrd4278;            JAMIE L.SHIRLEYYPE P.DE JONGCOXTERHORSTROLAND W.HERZOG:          ""Immune Responses to Viral Gene Therapy Vectors"",          MOLECULAR THERAPY, vol. 28, no. 3, 4 March 2020          (2020-03-04), pages 709 - 722;            KIS, Z. ET AL.: ""Emerging technologies for low-cost,          rapid vaccine manufacture"", BIOTECHNOL. J., vol. 14,          2018, pages e1800376;            ""mRNA vaccines a new era in vaccinology"", NAT. REV. DRUG          DISCOV., vol. 17, pages 261 - 279;            RAMANATHAN, A. ET AL.: ""mRNA capping: biological          functions and applications"", NUCLEIC ACIDS RES., vol. 44,          2016, pages 7511 - 7526, XP055388045, DOI:          10.1093/nar/gkw551;            LIMA, S.A. ET AL.: ""Short poly(A) tails are a conserved          feature of highly expressedgenes"", NAT. STRUCT. MOL.          BIOL., vol. 24, 2017, pages 1057 - 1063;            BARRETT, S. P.SALZMAN, J.: ""Circular RNAs: analysis,          expression and potential functions"", DEVELOPMENT, vol.          143, 2016, pages 1838 - 1847, XP055520715, DOI:          10.1242/dev.128074;            SABINE MULLERBETTINA APPEL: ""In vitro circularization of          RNA"", RNA BIOLOGY, vol. 14, no. 8, 2017, pages 1018 -          1027, XP055488935, DOI:          10.1080/15476286.2016.1239009;            CECH,T.R.BASS,B.L., ANNU. REV. BIOCHEM., vol. 55, 1986,          pages 599 - 629;            CECH,T.R., ANNU. REV. BIOCHEM., vol. 59, 1990, pages 543          - 568;            M.PUTTARAJUMICHAEL D.BEEN, NUCLEIC ACIDS RESEARCH, vol.          20, no. 20, pages 5357 - 5364;            SAMBROOK ET AL.: ""Molecular Cloning: Experiment The          conditions described in the laboratory manual"", 1989,          COLD SPRING HARBOR LABORATORY PRESS;            PROC NATL ACAD SCI US A., vol. 106, no. 23, 9 June 2009          (2009-06-09), pages 9197 - 9202WO2022116528-A1  DATABASE NUCLEOTIDE          29 December 2003 (2003-12-29), ANONYMOUS: ""Human          echovirus 24 strain DeCamp complete genome"", XP055937794,          retrieved from GENBANK Database accession no.          AY302548,relevantClaims[1, 3],relevantPassages[see          sequence and related information];  DATABASE NUCLEOTIDE          29 December 2003 (2003-12-29), ANONYMOUS: ""Human          echovirus 29 strain JV-10 complete genome"", XP055937797,          retrieved from GENBANK Database accession no.          AY302552,relevantClaims[1, 3],relevantPassages[see          sequence and related information];  DATABASE NUCLEOTIDE          29 December 2003 (2003-12-29), ANONYMOUS: ""Human          echovirus 33 strain Toluca-3 complete genome"",          XP055937803, retrieved from GENBANK Database accession          no. AY302556,relevantClaims[1, 3],relevantPassages[see          sequence and related information]CN114630909-A  NIKOLAOS SIAFAKAS :          ""Classification and Structure of Echovirus 5-UTR          Sequences"", VIRUS GENES , pages 293 -          306,relevantClaims[1-22];  : ""RNA"", ( ), pages          670 - 673,relevantClaims[1-22]US11634727-B2            Oberste et al., J. Virol. 78 (2), 855-867 (2004) Evidence          for frequent recombination within species human          enterovirus B based on complete genomic sequences of all          thirty-seven serotypes.;            Zhang et al et al., J. Med. Virol. 41 (2), 129-137 (1993)          Attenuation of a reactivated cardiovirulent          coxsackievirus B3: The 5-nontranslated region does not          contain major attenuation determinants.;            Kennell, Progr. Nucleic Acid Res. Mol. Biol. 11:259-301,          1971.;            Qing et al., Biomedical and Environmental Sciences vol.          29, Issue 10, Oct. 2016, pp. 767-772; Comparative Genomic          Analysis of Enterovirus 71 Revealed Six New Potential          Neurovirulence-associated Sites.;            Transcription (biology) From Wikipedia, the free          encyclopedia; pp. 1-14; downloaded on Mar. 29,          2022.;            Single-nucleotide polymorphism From Wikipedia, the free          encyclopedia pp. downloaded Mar. 31, 2022.;            Barrett et al., Circular RNAs: analysis, expression and          potential functions, Development, Jun. 1, 2016,          143:1838-1847.;            Cech et al., Biological Catalysis by RNA, Annual Review          of Biochemistry, 1986, 55:559-629.;            Cech et al., Self-Splicing of Group I Introns, Annual          Review of Biochemistry, 1990, 59:543-568.;  De          Breyne et al., Direct functional interaction of          initiation factor eIF4G with type 1 internal ribosomal          entry sites, Proceedings of the National Academy of          Sciences USA, Jun. 2009, 106(23):9197-9202.;            Kis et al., Emerging technologies for low-cost, rapid          vaccine manufacture, Biotechnology Journal, Dec. 10,          2018, 14(1):e1800376, 36 pages.;            Liang et al., Efficient Targeting and Activation of          Antigen-Presenting Cells In Vivo after Modified mRNA          Vaccine Administration in Rhesus Macaques, Molecular          Therapy, Dec. 2017, 25(12):2635-2647.;            Lima et al., Short Poly(A) Tails are a Conserved Feature          of Highly Expressed Genes, Nature Structural and          Molecular Biology, Dec. 2017, 24(12):1057-1063, 20          pages.;            Muller et al., In vitro circularization of RNA, RNA          Biology, 2017, 14(8):1018-1027.;            Pardi et al., mRNA vaccinesa new era in vaccinology,          Nature Reviews Drug Discovery, Jan. 12, 2018,          17(4):261-279, 43 pages.;            Pardi et al., Nucleoside-modified mRNA vaccines induce          potent T follicular helper and germinal center B cell          responses, Journal of Experimental Medicine, May 8, 2018,          215(6):1571-1588.;            Pardi et al., Zika virus protection by a single low dose          nucleoside modified mRNA vaccination, Nature, Mar. 9,          2017, 543(7644):248-251, 21 pages.;            Puttaraju et al., Group I permuted intronexon (PIE)          sequences self-splice to produce circular exons, Nucleic          Acids Research, Oct. 25, 1992,          20(20):5357-5364.;            Ramanathan et al., mRNA capping: biological functions and          applications, Nucleic Acids Research, Jun. 17, 2016,          44(16):7511-7526.;            Sahin et al., mRNA-based therapeuticsdeveloping a new          class of drugs, Nature Reviews Drug Discovery, Oct. 2014,          13:759-780.;            Shirley et al., Immune Responses to Viral Gene Therapy          Vectors, Molecular Therapy, Mar. 2020,          28(3):709-722.;            Wesselhoeft et al., Engineering circular RNA for potent          and stable translation in eukaryotic cells, Nature          Conununications, 2018, 9:2629, 10 pages (Exhibit          A).CN114630909-B            Hsia Shijin and so on. Research status and vision of          circular RNA; Xia Shijin et al; ""Chinese Journal of          Pulmonary Disease (Electronic Edition)""; Page          670-673;;            NIKOLAOS SIAFAKAS, etc. Classification and Structure of          Echovirus 5' -UTR Sequences; NIKOLAOS SIAFAKAS and so on;          ""Virus Genes""; pages 293-306",1383422-0-0-0 K M; 1383422-0-0-0 CL USE,,,RAOGVL K M,
WO2023026301-A1;  IN202121038492-A;  CA3229958-A1;  AU2022335015-A1;  KR2024046787-A,"Preparing freeze-dried formulation of mRNA            comprises subjecting liquid mixture having mRNA            adsorbed onto lipid nano-emulsion particles and            lyoprotectant in glass vial to pre-cooling, freezing,            reducing pressure, heating frozen mixture,            equilibrating freeze-drying chamber and removing glass            vial",KAVIRAJ S;  SINGH S;  RAUT S;  KARDILE P;  SINGH A;  SWARNENDU K;  KABIRAJSWARNENDU;  SINGSHANZAI;  RAUTSUNIL;  KARDILPAVAN,GENNOVA BIOPHARMACEUTICALS LTD (GENN-Non-standard);  GENNOVA BIOPHARMACEUTICALS LTD (GENN-Non-standard);  GENNOVA BIOPHARMACEUTICALS LTD (GENN-Non-standard),202323732W,"   NOVELTY - A method for the preparation of a freeze-dried                formulation of mRNA, comprises (a) providing a                liquid mixture having an mRNA adsorbed onto lipid                nano-emulsion particles and a lyoprotectant in a                glass vial, (b) subjecting the liquid mixture to                pre-cooling in a freeze dryer chamber, (c) freezing                the liquid mixture to a freezing temperature in the                freeze dryer chamber, (d) reducing the pressure in                the freeze drying chamber to a pressure below                atmospheric pressure in desired two pressure                reducing steps and increasing temperature under                desired three heating steps at a desired heating                rate, (e) further heating the frozen mixture in the                freeze drying chamber to a pressure further below                atmospheric pressure in a desired pressure reducing                step, and (f) stoppering the glass vial and then                equilibrating the freeze drying chamber to                atmospheric pressure and temperature and removing                the glass vial containing the lyophilized                formulation for a pharmaceutical application.    USE - The method is used for preparing freeze-dried                formulation of mRNA (claimed) molecules adsorbed                onto lipid nano-emulsion particles or nano-carriers                for gene therapy as well as prophylactic and                therapeutic vaccination against many infectious and                malignant diseases, preferably for pharmaceutical                applications like vaccines and therapeutics. No                biological data given.    ADVANTAGE - The lyophilized formulation is stable at                5&#176; C for 30-300 days, and has an                outstanding integrity of the mRNA after completion                of the lyophilization process. The method for                lyophilization of mRNA-based complex formulation is                scalable and reproducible, time and                cost-efficient.    DETAILED DESCRIPTION - A method for the preparation of a freeze-dried                formulation of mRNA, comprises (a) providing a                liquid mixture having an mRNA adsorbed onto lipid                nano-emulsion particles and a lyoprotectant in a                glass vial, (b) subjecting the liquid mixture to                pre-cooling in a freeze dryer chamber to a desired                temperature and for a desired time, (c) freezing                the liquid mixture to a freezing temperature in the                freeze dryer chamber under a desired cooling rate                and holding it for a desired time forming a frozen                mixture, (d) reducing the pressure in the freeze                drying chamber to a pressure below atmospheric                pressure in desired two pressure reducing steps and                increasing temperature under desired three heating                steps at a desired heating rate, thereby primary                drying the frozen mixture, (e) further heating the                frozen mixture in the freeze drying chamber to a                pressure further below atmospheric pressure in a                desired pressure reducing step and increasing                temperature under a desired heating step, thereby                secondary drying the frozen mixture forming a                lyophilized formulation, and (f) stoppering the                glass vial and then equilibrating the freeze drying                chamber to atmospheric pressure and temperature                under nitrogen gas and removing the glass vial                containing the lyophilized formulation for a                pharmaceutical application. An INDEPENDENT CLAIM is                included for the freeze-dried formulation                comprising (a) an mRNA capable of in-vivo                expressing a protein, adsorbed onto, (b) a lipid                nano-emulsion particles carrier, and (c) forming a                stable mRNA complex in which the mRNA maintaining                its integrity upon storage at 5&#176; C for                30-300 days. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  A96 (Medical, dental, veterinary, cosmetic.)",B04-B01B;  B04-E01B;  B11-C05;  B12-M11P;  B12-M11Q2;  B14-A01;  B14-A02;  B14-A04;  B14-H01;  B14-S03A;  B14-S11;  A10-E07B;  A10-E08A;  A10-E08B;  A12-V01;  A12-W14,A61K-009/19;  A61K-009/00;  A61K-009/107;  A61K-009/51;  C12N-015/113;  A61K-039/00;  A61K-039/12;  A61K-047/26;  A61K-009/14;  A61P-031/14;  C12N-015/88,WO2023026301-A1   02 Mar 2023   A61K-009/19   202327Pages: 48   English;  IN202121038492-A   03 Mar 2023   A61K-009/19   202328   English;  CA3229958-A1   02 Mar 2023   A61K-009/19   202418   English;  AU2022335015-A1   14 Mar 2024   A61K-009/19   202423   English;  KR2024046787-A   09 Apr 2024   A61K-009/19   202435   ,WO2023026301-A1    WOIN050753    24 Aug 2022;   IN202121038492-A    IN21038492    25 Aug 2021;   CA3229958-A1    CA3229958    24 Aug 2022;   AU2022335015-A1    AU335015    24 Aug 2022;   KR2024046787-A    KR709783    24 Aug 2022,CA3229958-A1 PCT application Application WOIN050753;   AU2022335015-A1 PCT application Application WOIN050753;   AU2022335015-A1 Based on Patent WO2023026301;   KR2024046787-A PCT application Application WOIN050753;   KR2024046787-A Based on Patent WO2023026301,IN21038492    25 Aug 2021;  CA3229958    22 Feb 2024;  KR709783    22 Mar 2024,WO2023026301-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA          ,,,"WO2023026301-A1  GERHARDT ALANA,          VOIGT EMILY, ARCHER MICHELLE, REED SIERRA, LARSON ELISE,          VAN HOEVEN NEAL, KRAMER RYAN, FOX CHRISTOPHER, CASPER          COR: ""A Thermostable, Flexible RNA Vaccine Delivery          Platform for Pandemic Response"", BIORXIV, 2 February 2021          (2021-02-02), XP093041169, Retrieved from the Internet          &lt;URL:https://www.biorxiv.org/content/10.1101/2021.02.01.429283v1.full.pdf&gt;          [retrieved on 20230421], DOI:          10.1101/2021.02.01.429283,relevantClaims[1-23, 25, 26|24,          27, 28],relevantPassages[Whole Document including the          Supplementary Materials Whole Document];  ANDERSON, E. J. ET          AL.: ""Safety and immunogenicity of SARS-CoV-2 mRNA-1273          vaccine in older adults"", N. ENGL. J. MED., vol. 383,          2020, pages 2427 - 2438, XP093024721, DOI:          10.1056/NEJMoa2028436,relevantClaims[24, 27,          28],relevantPassages[. Whole document especially abstract          and page 2428];  POLACK, F. P. ET          AL.: ""Safety and efficacy of the BNT162b2 mRNA Covid-19          vaccine"", N. ENGL. J. MED., vol. 383, 2020, pages 2603 -          2615, XP055820495, DOI:          10.1056/NEJMoa2034577,relevantClaims[24, 27,          28],relevantPassages[. Whole document especially          abstract]",444-0-0-0 ,,,R00351 ,
WO2021214204-A1;  US2022249704-A1;  US2022273820-A1;  IN202247059384-A;  AU2021260099-A1;  CA3173922-A1;  BR112022019782-A2;  KR2023004735-A;  IL297417-A;  EP4139452-A1;  CN115867654-A;  JP2023522246-W;  CN116585464-A;  US11779659-B2;  HK40089626-A0;  MX2022013255-A1;  US11951185-B2;  CN118121722-A,"Composition or medical preparation used in            pharmaceutical composition that is packaged as kit for            treating disease such as muscular dystrophy, comprises            RNA polynucleotide comprising 5'cap comprising Capl            structure",SAHIN U;  GUELER A;  KUHN A;  MUIK A;  VOGEL A;  WALZER K;  WITZEL S;  HEIN S;  TUERECI O;  BOROS G;  MAHINY A J;  REINHOLZ J;  KARIKO K;  GULER A;  TURECI O;  GILER A;  TIRECI O;  BALZER K;  BITCHELL S;  SERVANT S;  TURETSI O;  MAHINI A;  REINHOLTZ J;  FOGEL A;  KUEHN A,BIONTECH SE (BNTC-C);  BIONTECH SE (BNTC-C);  BIONTECH SE (BNTC-C);  BIONTECH SE (BNTC-C),2021C0916Q,"   NOVELTY - Composition or medical preparation comprises                an RNA polynucleotide comprising 5'cap comprising                Capl structure approximal sequence comprising                positions +1, +2,+3, +4, and +5 RNA polynucleotide                and a sequence encoding a payload, where sequence                is sequences comprising 3 nucleobases of (SEQ ID                NOs: 1-4), given in the specification.    USE - Composition or medical preparation used in                pharmaceutical composition that is packaged as kit                for treating disease or disorder with aberrant                expression of polypeptide such as rare disease,                metabolic disorder, muscular dystrophy,                cardiovascular disease, or monogenic disease, and                inducing immune response in subject where immune                response is prophylactic immune response or                therapeutic immune response (all claimed).    ADVANTAGE - The composition or medical preparation by                self-hybridization inhibit binding of transcription                and/or translation factors to an RNA polynucleotide                by self-hybridizing to a complementary sequence in                the RNA polynucleotide.    DETAILED DESCRIPTION - Composition or medical preparation comprises                an RNA polynucleotide comprising 5'cap comprising                Capl structure approximal sequence comprising                positions +1, +2,+3, +4, and +5 RNA polynucleotide                and a sequence encoding a payload, where Capl                structure comprises m7G(5')ppp(5')(2'OMeNi)pN2,                where N1 is position +1 of the RNA polynucleotide,                and N2 is position +2 of RNA polynucleotide,and N1                and N2 are each independently chosen from adenine                (A), cytosine (C), glycine (G), or uracil (U) and                approximal sequence comprises N1 and N2 of Capl                structure, and sequence selected from sequences                comprising 3 nucleobases of (SEQ ID NOs: 1-4), that                are A3-A4-X5, C3-A4-X5, A3-C4-A5 and A3-U4-G5; or a                sequence comprising 3 nucleobases of (SEQ ID NO:                7), that is X3-Y4-X5, where X3 is (nucleotide X at                position +3 in SEQ ID NO: 7) or X5(nucleotide X at                position +5 in SEQ ID NO: 1 or SEQ ID NO: 2)is each                independently chosen from A,G, C, or U; and Y4(                nucleotide Y at position +4 in SEQ ID NO: 7) is not                C.    INDEPENDENT CLAIMS are included for:    Pharmaceutical composition comprising RNA                polynucleotide of composition or medical                preparation, formulated as a particle;    Method of manufacturing a pharmaceutical                composition by combining an RNA polynucleotide with                lipids to form lipid nanoparticles that encapsulate                the RNA;    Nucleic acid template suitable to produce cap                1-capped RNA, in which the first five nucleotides                transcribed from the template strand of the nucleic                acid template comprise the sequence N1pN2pN3pN4pNs,                where N1 is any nucleotide, preferably T; N2 is any                nucleotide, preferably C; N3 is any nucleotide,                preferably T or G; N4 is any nucleotide; and Ns is                any nucleotide;    An in vitro transcription reaction comprising                template DNA comprising a polynucleotide sequence                complementary to an RNA polynucleotide sequence,                polymerase and RNA polynucleotide;    Method for producing capped RNA by                transcribing a nucleic acid template in the                presence of a cap structure, where the cap                structure comprises G*ppp(m12'-O)N1pN2, where N 1                is complementary to position +1 of the nucleic acid                template and N2 is complementary to position +2 of                the nucleic acid template, and Ni and N2 are                independently chosen from A, C, G or U, where                position +3 of the nucleic acid template is any                nucleotide, preferably T or G; position +4 of the                nucleic acid template is any nucleotide; and                position +5 of the nucleic acid template is any                nucleotide;    DNA polynucleotide composition comprises a                sequence complementary to an RNA polynucleotide                sequence;    method of inducing an immune response in a                subject by administering to a subject, a                pharmaceutical composition comprising an RNA                polynucleotide formulated in a lipid nanoparticle                (LNP) or a lipoplex (LPX) particle;    Method of vaccination of a subject by                administering a pharmaceutical composition                comprising an RNA polynucleotide formulated in a                lipid nanoparticle (LNP) or a lipoplex (LPX)                particle;    Method of decreasing interaction with IFIT1 of                an RNA polynucleotide that comprises a 5' cap and a                cap proximal sequence comprising positions +1, +2,                +3, +4, and +5 of the RNA polynucleotide, which                involves providing a variant of the RNA                polynucleotide that differs from the parental RNA                polynucleotide by substitution of one or more                residues within the cap proximal sequence, and                determining that interaction of the variant with                IFIT1 is decreased relative to that of the parental                RNA polynucleotide;    Method of producing a polypeptide by providing                an RNA polynucleotide;    Method of increasing translatability of an RNA                polynucleotide that comprises a 5' cap, a cap                proximal sequence that comprises positions +1, +2,                +3, +4, and +5 of the RNA polynucleotide and a                sequence encoding a payload;    Method of increasing translation of an RNA                polynucleotide comprising a 5' cap that includes a                Capl structure, a cap proximal sequence and a                sequence encoding a payload, and improvement that                comprises residues in a cap proximal sequence A at                position +1 of the RNA polynucleotide, G at                position +2 of the RNA polynucleotide, A at                position +3 of the RNA polynucleotide, A at                position +4 of the RNA polynucleotide, and U at                position +5 of the RNA polynucleotide; and    Method of providing a framework for an RNA                polynucleotide. ",,,"A96 (Medical, dental, veterinary, cosmetic.);  A25 (Polyurethanes; polyethers.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",A10-E01;  A12-V01;  B01-D02;  B01-E;  B04-B01B;  B04-B03F;  B04-B04C;  B04-C01;  B04-C03C;  B04-E01B;  B04-E99;  B04-G01;  B04-J02;  B04-L01;  B04-N02A;  B04-N03A;  B05-B01P;  B10-B02B;  B12-M11Q;  B14-F01;  B14-F02;  B14-J05E;  B14-S11;  B14-S13;  B14-S18;  D05-H12;  D05-H99,A61K-039/215;  A61K-045/06;  C07H-021/00;  C07H-021/02;  C12N-015/00;  C12N-015/10;  C12N-015/11;  A61K-031/7088;  A61K-039/00;  A61K-039/12;  A61K-048/00;  A61P-035/00;  A61K-009/127;  C12N-007/00;  A61P-025/00;  A61P-025/16;  A61P-025/18;  A61P-025/28;  A61P-043/00;  A61K-009/51;  A61P-031/14;  C12N-015/88;  A61K-031/7105;  A61K-031/711;  A61K-031/7115;  A61K-031/712;  A61K-038/00;  A61K-009/00;  C12N-015/67;  C12P-019/34;  C12P-021/02;  A61K-047/44;  A61P-037/02;  B82Y-005/00;  A61K-047/24;  A61K-047/28;  C12N-015/113,WO2021214204-A1   28 Oct 2021   C12N-015/11   202193Pages: 257   English;  US2022249704-A1   11 Aug 2022   A61K-048/00   202266   English;  US2022273820-A1   01 Sep 2022   A61K-048/00   202271   English;  IN202247059384-A   28 Oct 2022   A61P-025/00   202289   English;  AU2021260099-A1   24 Nov 2022   C12N-015/11   202295   English;  CA3173922-A1   28 Oct 2021   A61K-039/215   202204   English;  BR112022019782-A2   13 Dec 2022   C12N-015/11   202302   ;  KR2023004735-A   06 Jan 2023   C12N-015/11   202304   ;  IL297417-A   01 Dec 2022   A61K-048/00   202318   English;  EP4139452-A1   01 Mar 2023   C12N-015/11   202319   English;  CN115867654-A   28 Mar 2023   C12N-015/11   202330   Chinese;  JP2023522246-W   29 May 2023   C12N-015/11   202344   Japanese;  CN116585464-A   15 Aug 2023   A61K-039/215   202374   Chinese;  US11779659-B2   10 Oct 2023   A61K-048/00   202382   English;  HK40089626-A0   20 Oct 2023   C12N-015/11   202402   English;  MX2022013255-A1   24 Jan 2023   C12N-015/11   202416   Spanish;  US11951185-B2   09 Apr 2024   A61K-048/00   202430   English;  CN118121722-A   04 Jun 2024   A61K-048/00   202451   Chinese,WO2021214204-A1    WOEP060508    22 Apr 2021;   US2022249704-A1    US565842    30 Dec 2021;   US2022273820-A1    US565921    30 Dec 2021;   IN202247059384-A    IN47059384    18 Oct 2022;   AU2021260099-A1    AU260099    22 Apr 2021;   CA3173922-A1    CA3173922    22 Apr 2021;   BR112022019782-A2    BR11019782    22 Apr 2021;   KR2023004735-A    KR740675    22 Apr 2021;   IL297417-A    IL297417    22 Apr 2021;   EP4139452-A1    EP720748    22 Apr 2021;   CN115867654-A    CN80041726    22 Apr 2021;   JP2023522246-W    JP563994    22 Apr 2021;   CN116585464-A    CN10385622    22 Apr 2021;   US11779659-B2    US565842    30 Dec 2021;   HK40089626-A0    HK6077512    11 Aug 2023;   MX2022013255-A1    MX013255    20 Oct 2022;   US11951185-B2    US565921    30 Dec 2021;   CN118121722-A    CN10244486    22 Apr 2021,US2022249704-A1 Cont of Application WOEP060508;   US2022273820-A1 Cont of Application WOEP060508;   IN202247059384-A PCT application Application WOEP060508;   IN202247059384-A Based on Patent WO2021214204;   AU2021260099-A1 PCT application Application WOEP060508;   AU2021260099-A1 Based on Patent WO2021214204;   CA3173922-A1 PCT application Application WOEP060508;   CA3173922-A1 Based on Patent WO2021214204;   BR112022019782-A2 PCT application Application WOEP060508;   BR112022019782-A2 Based on Patent WO2021214204;   KR2023004735-A PCT application Application WOEP060508;   KR2023004735-A Based on Patent WO2021214204;   IL297417-A Based on Patent WO2021214204;   EP4139452-A1 PCT application Application WOEP060508;   EP4139452-A1 Based on Patent WO2021214204;   CN115867654-A PCT application Application WOEP060508;   CN115867654-A Based on Patent WO2021214204;   JP2023522246-W PCT application Application WOEP060508;   JP2023522246-W Based on Patent WO2021214204;   CN116585464-A Div ex Application CN80041726;   US11779659-B2 Cont of Application WOEP060508;   US11779659-B2 Previous Publ. Patent US2022249704;   HK40089626-A0 PCT application Application WOEP060508;   HK40089626-A0 Based on Patent WO2021214204;   HK40089626-A0 Previous Publ. Patent EP4139452;   MX2022013255-A1 PCT application Application WOEP060508;   MX2022013255-A1 Based on Patent WO2021214204;   US11951185-B2 Cont of Application WOEP060508;   US11951185-B2 Previous Publ. Patent US2022273820;   CN118121722-A Div ex Application CN80041726,WOEP061239    22 Apr 2020;  WOEP066968    18 Jun 2020;  WOEP068174    26 Jun 2020;  WOEP069805    13 Jul 2020;  WOEP071733    31 Jul 2020;  WOEP071839    03 Aug 2020;  WOEP073668    24 Aug 2020;  WOEP081544    09 Nov 2020;  WOEP081981    12 Nov 2020;  WOEP082601    18 Nov 2020;  WOEP082989    20 Nov 2020;  WOEP083435    25 Nov 2020;  WOEP084342    02 Dec 2020;  WOEP085145    08 Dec 2020;  WOEP085653    10 Dec 2020;  WOEP087844    23 Dec 2020;  WOEP050027    04 Jan 2021;  WOEP050874    15 Jan 2021;  WOEP050875    15 Jan 2021;  WOEP051772    26 Jan 2021;  WOEP052572    03 Feb 2021;  WOEP052716    04 Feb 2021;  WOEP054622    24 Feb 2021;  WOEP059947    16 Apr 2021;  EP720748    22 Apr 2021;  CA3173922    28 Sep 2022;  BR11019782    30 Sep 2022;  KR740675    21 Nov 2022;  CN80041726    08 Dec 2022,WO2021214204-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA                  EP4139452-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN                  ,,"WO2021214204-A1 -- WO2008157688-A2   UNIV LOUISIANA STATE & AGRIC & MECH                  COLL (LOUU)   JEMIELITY J,  GRUDZIEN-NOGALSKA E M,  KOWALSKA J,  DARZYNKIEWICZ E,  RHOADS R E;  WO2013143683-A1   BIONTECH AG (BNTC);  UNIV MAINZ TRON TRANSLATIONALE ONKOLOGIE (UMTT);  UNIV MAINZ GUTENBURG JOHANNES (UMGJ)   SAHIN U,  HAAS H,  KREITER S,  DIKEN M,  FRITZ D,  MENG M,  KRANZ L M,  REUTER K;  WO2016005324-A1   BIONTECH RNA PHARM GMBH (BNTC);  UNIV MAINZ TRON TRANSLATIONALE ONKOLOGIE (UMTT)   EBERLE F,  SAHIN U,  KUHN A,  VALLAZZA B,  DIKEN M;  US2022249704-A1 -- WO2020150152-A1   GENENTECH INC (GETH);  BIONTECH SE (BNTC)   MUELLER L,  FINE G D;  CN116585464-A -- CN108291230-A   BIONTECH RNA PHARM GMBH (BNTC);  UNIV MAINZ TRON TRANSLATIONALE ONKOLOGIE (UMTT)   ORLANDINI VON NIESSEN A,  FESSER S,  VALLAZZA B,  BEISSERT T,  KUHN A,  SAHIN U,  POLEGANOV M A;  CN110337305-A   SANOFI (SNFI);  BIONTECH RNA PHARM GMBH (BNTC)   GIESEKE F,  SAHIN U,  WIEDERSCHAIN D G,  WAGENAAR T R;  US20200069793-A1   ;  US11779659-B2 -- WO2020150152-A1   GENENTECH INC (GETH);  BIONTECH SE (BNTC)   MUELLER L,  FINE G D;  AU2015210364-A1   TEKMIRA PHARM CORP (TEKM-Non-standard);  UNIV BRITISH COLUMBIA (UYBR);  LAHERTY C D (LAHE-Individual)   CHEN J,  CIUFOLINI M A,  CULLIS P R,  HOPE M J,  MADDEN T D,  MUI B,  SEMPLE S C;  AU2019264591-A1   MERCK SHARP & DOHME CORP (MERI)   BARTZ S,  BROWN D,  ROBINSON M;  AU2015280499-B2   ANSELL S M (ANSE-Individual);  DU X (DUXX-Individual)   ANSELL S M,  DU X;  AU2016253972-B2   UNIV PENNSYLVANIA (UPEN);  ACUITAS THERAPEUTICS INC (ACUI-Non-standard);  TAM Y (TAMY-Individual);  HOPE M J (HOPE-Individual)   TAM Y,  HOPE M J,  WEISSMAN D,  PARDI N;  CN110167587-A   MODERNATX INC (MODR)   CIARAMELLA G;  CN112226445-A   CHENGDU OLYMVAX BIOTECHNOLOGY CO LTD (CHEN-Non-standard);  IMMORNA HANGZHOU BIOTECHNOLOGY CO LTD (IMMO-Non-standard)   WANG Z;  CN113186203-A   STEMIRNA SHANGHAI BIOTECHNOLOGY CO LTD (STEM-Non-standard)   LI H,  ZHANG L,  MA X,  LI S,  YU B,  LIN A,  ZHANG J,  YAO W,  ZHANG Y,  HUANG L,  LIU N,  WU W,  LIU J,  SHEN M;  CN106795096-B   ANSELL S M (ANSE-Individual);  DU X (DUXX-Individual)   ANSELL S M,  DU X;  DE202021003575-U1   CUREVAC AG (CUEV)   RAUCH S,  GROSSE H W,  PETSCH B;  EP2791160-A1   MODERNA THERAPEUTICS (MODR)   AFEYAN N B,  DE FOUGEROLLES A,  ELBASHIR S M,  SCHRUM J P,  VALENCIA P,  WOOD K M;  EP2833894-A1   MODERNA THERAPEUTICS (MODR)   BANCEL S,  HUANG E Y;  EP3134131-A1   MODERNA THERAPEUTICS INC (MODR)   BOUCHON A,  CIARAMELLA G,  HUANG E Y;  EP3160938-A1   ANSELL S M (ANSE-Individual);  DU X (DUXX-Individual)   ANSELL S M,  DU X;  EP3169693-A1   MODERNA THERAPEUTICS INC (MODR)   NELSON J A,  FRALEY A,  RHODEN SMITH A;  EP3218508-A1   MODERNA THERAPEUTICS INC (MODR)   REYNDERS J V W,  CHAKRABORTY T,  HOGE S,  MCFADYEN I J;  EP3289083-A1   UNIV PENNSYLVANIA (UPEN);  ACUITAS THERAPEUTICS INC (ACUI-Non-standard);  TAM Y (TAMY-Individual);  HOPE M J (HOPE-Individual)   TAM Y,  HOPE M J,  WEISSMAN D,  PARDI N;  EP3334828-A1   CUREVAC AG (CUEV)   WILLIAMS J;  EP3362460-A1   MODERNATX INC (MODR)   BUTORA G,  STANTON M,  STEELE T;  EP3362461-A1   MODERNATX INC (MODR)   BUTORA G,  STANTON M,  STEELE T;  EP3364949-A1   MODERNATX INC (MODR)   VALIANTE N,  ZAKS T,  HUANG E Y,  CIARAMELLA G;  EP3368507-A1   ACUITAS THERAPEUTICS INC (ACUI-Non-standard)   ANSELL S M,  DU X;  EP3386484-A1   MODERNATX INC (MODR)   BESIN G,  HOGE S,  SENN J,  BENENATO K,  SABNIS S;  EP3394030-A1   MODERNATX INC (MODR)   BENENATO K E,  BUTCHER W;  EP3468537-A1   MODERNATX INC (MODR)   SMITH M,  ALMARSSON O,  BRITO L;  EP3501550-A1   MODERNA THERAPEUTICS (MODR)   BANCEL S,  CHAKRABORTY T,  DE FOUGEROLLES A,  EJEBE K,  ELBASHIR S M,  ELLSWORTH J L,  GUILD J,  HATALA P,  JOHN M,  ROY A,  SCHRUM J P,  WHORISKEY S,  WOOD K M;  EP3505176-A1   MODERNA THERAPEUTICS (MODR)   BANCEL S,  CHAKRABORTY T,  DE FOUGEROLLES A,  EJEBE K,  ELBASHIR S M,  ELLSWORTH J L,  GUILD J,  HATALA P,  JOHN M,  ROY A,  SCHRUM J P,  WHORISKEY S,  WOOD K M;  EP3512944-A1   MODERNATX INC (MODR)   HOGE S,  ISSA W,  MIRACCO E J,  NELSON J,  RABIDEAU A E,  BUTORA G;  EP3520820-A1   MODERNA THERAPEUTICS INC (MODR)   BANCEL S,  CHAKRABORTY T,  DE FOUGEROLLES A,  ELBASHIR S M,  JOHN M,  ROY A,  WHORISKEY S,  WOOD K M,  HATALA P,  SCHRUM J P,  EJEBE K,  ELLSWORTH J L,  GUILD J;  EP3520821-A1   MODERNA THERAPEUTICS (MODR)   BANCEL S,  CHAKRABORTY T,  DE FOUGEROLLES A,  EJEBE K,  ELBASHIR S M,  ELLSWORTH J L,  GUILD J,  HATALA P,  JOHN M,  ROY A,  SCHRUM J P,  WHORISKEY S,  WOOD K M;  EP3532070-A1   MODERNATX INC (MODR)   HUANG E Y,  TSE S,  IACOVELLI J,  MCKINNEY K,  HOPSON K;  EP3538067-A1   MODERNATX INC (MODR)   BRADER M;  EP3540060-A1   CUREVAC GMBH (CUEV)   WOCHNER A;  EP3577221-A1   MODERNATX INC (MODR);  MCFADYEN I (MCFA-Individual);  PRESNYAK V (PRES-Individual)   MCFADYEN I,  PRESNYAK V,  MAUGER D;  EP3578200-A1   CUREVAC GMBH (CUEV)   FOTIN-MLECZEK M,  KALLEN K,  PROBST J;  EP3578205-A1   AFEYAN N B (AFEY-Individual);  BANCEL S (BANC-Individual);  SCHRUM J (SCHR-Individual);  MODERNA THERAPEUTICS INC (MODR)   AFEYAN N B,  BANCEL S,  SCHRUM J;  EP3578659-A1   CUREVAC GMBH (CUEV)   THESS A;  EP3586861-A1   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   GUILD B C,  DEROSA F,  HEARTLEIN M;  EP3590949-A1   SCHRUM J (SCHR-Individual)   SCHRUM J;  EP3595676-A1   MODERNATX INC (MODR)   CIARAMELLA G,  HIMANSU S,  PRESNYAK V,  BENENATO K,  KUMARASINGHE E S;  EP3595727-A1   MODERNATX INC (MODR);  UNIV OREGON STATE (UORE);  PATEL S (PATE-Individual);  ROBINSON E (ROBI-Individual);  BROWN A (BROW-Individual)   PATEL S,  ROBINSON E,  BROWN A,  ALMARSSON O,  BENENATO K E,  SABNIS S,  SAHAY G,  NARAYANA A K;  EP3596041-A1   MODERNATX INC (MODR)   BENENATO K E,  KUMARASINGHE E S,  CORNEBISE M;  EP3596042-A1   MODERNATX INC (MODR)   ALMARSSON O,  CHEUNG E;  EP3607074-A1   MODERNATX INC (MODR)   BRITO L,  BESIN G;  EP3625345-A1   MODERNATX INC (MODR)   MOORE M J,  KOEHRER C,  JAIN R,  PRESNYAK V;  EP3638215-A1   MODERNATX INC (MODR)   HOGE S,  SCHARITER J,  BOWERMAN C,  SMITH M H,  XIA Y;  EP3682905-A1   MODERNA THERAPEUTICS (MODR)   BANCEL S,  DE FOUGEROLLES A,  HATALA P,  ROY A,  SCHRUM J P,  SIDDIQI S;  EP3886897-A1   CUREVAC AG (CUEV)   RAUCH S,  GROSSE H W,  PETSCH B;  EP3901260-A1   BIONTECH RNA PHARM GMBH (BNTC)   SAHIN U,  GUELER A,  KUHN A,  MUIK A,  VOGEL A,  WALZER K,  WITZEL S,  HEIN S,  TUERECI O;  EP3901261-A1   BIONTECH RNA PHARM GMBH (BNTC)   SAHIN U,  GUELER A,  KUHN A,  MUIK A,  VOGEL A,  WALZER K,  WITZEL S,  HEIN S,  TUERECI O;  EP2691101-A2   MODERNA THERAPEUTICS (MODR)   AFEYAN N B,  BANCEL S,  DE FOUGEROLLES A,  ELBASHIR S M,  SCHRUM J P,  SIECZKIEWICZ G J;  EP2833892-A2   MODERNA THERAPEUTICS (MODR)   BANCEL S,  CHAKRABORTY T,  DE FOUGEROLLES A,  EJEBE K,  ELBASHIR S M,  ELLSWORTH J L,  GUILD J,  HATALA P,  JOHN M,  ROY A,  SCHRUM J P,  WHORISKEY S,  WOOD K M;  EP3350157-A2   MODERNATX INC (MODR)   BENENATO K E,  KUMARASINGHE E S,  CORNEBISE M;  EP3350333-A2   MODERNA THERAPEUTICS INC (MODR)   BUTORA G,  FRALEY A W,  MIRACCO E J,  NELSON J,  RHODEN-SMITH A,  STANTON M;  EP3364983-A2   MODERNATX INC (MODR)   CIARAMELLA G,  HIMANSU S;  EP3452101-A2   CUREVAC AG (CUEV)   FOTIN-MLECZEK M,  HOERR I;  EP3668522-A2   MODERNATX INC (MODR)   HOGE S,  CIARAMELLA G;  EP1392341-B1   VON DER MUELBE F (VMUE-Individual)   VON DER MUELBE F,  HOERR I,  PASCOLO S;  EP1685844-B1   CUREVAC GMBH (CUEV)   HOERR I,  VON DER MUELBE F,  PASCOLO S;  EP1797886-B1   CUREVAC GMBH (CUEV)   HOERR I,  VON DER MUELBE F,  PASCOLO S;  EP1857122-B1   VON DER MUELBE F (VMUE-Individual)   VON DER MUELBE F,  HOERR I,  PASCOLO S;  EP2506857-B1   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   GUILD B C,  DEROSA F,  HEARTLEIN M;  EP2717893-B1   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   GUILD B C,  DEROSA F,  HEARTLEIN M;  EP2763701-B1   MODERNA THERAPEUTICS (MODR)   BANCEL S,  DE FOUGEROLLES A,  HATALA P,  ROY A,  SCHRUM J P,  SIDDIQI S;  EP2958588-B1   CUREVAC GMBH (CUEV)   FOTIN-MLECZEK M,  KALLEN K,  PROBST J;  EP2970955-B1   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   HEARTLEIN M,  DEROSA F,  DIAS A,  KARVE S;  EP2971102-B1   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   HEARTLEIN M,  DEROSA F,  DIAS A;  EP3036330-B1   CUREVAC GMBH (CUEV)   BAUMHOF P;  EP3062798-B1   CUREVAC GMBH (CUEV)   SCHLAKE T,  THESS A;  EP3090060-B1   CUREVAC GMBH (CUEV)   WOCHNER A;  EP3134506-B1   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   DEROSA F,  DIAS A,  KARVE S,  HEARTLEIN M;  EP3260541-B1   CUREVAC GMBH (CUEV)   THESS A;  EP3292873-B1   CUREVAC GMBH (CUEV)   FOTIN-MLECZEK M,  KALLEN K,  PROBST J;  EP3318248-B1   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   GUILD B C,  DEROSA F,  HEARTLEIN M;  EP3492109-B1   MODERNA THERAPEUTICS (MODR)   BANCEL S,  DE FOUGEROLLES A,  HATALA P,  ROY A,  SCHRUM J P,  SIDDIQI S;  EP3718565-B1   MODERNATX INC (MODR)   CIARAMELLA G,  HIMANSU S;  JP10113117-A   TANAKA T (TANA-Individual)   TANAKA T;  JP6594421-B2   ANSELL S M (ANSE-Individual);  DU X (DUXX-Individual)   ANSELL S M,  DU X;  TW200515917-A   US DEPT OF HEALTH & HUMAN SERVICES (USSH)   NABEL G J,  YANG Z,  HUANG Y,  KONG W;  US4898278-A   NALGE CO INC (NALG-Non-standard)   LEONCAVALL R A,  KOVER L J,  PHILLIPS G R;  US20030194759-A1   ;  US20050002953-A1   ;  US20050095582-A1   ;  US20050249742-A1   ;  US20090093433-A1   ;  US20090286852-A1   ;  US20100017904-A1   ;  US20110300205-A1   ;  US20120082693-A1   ;  US20120101148-A1   ;  US20130102034-A1   ;  US20130115272-A1   ;  US20130236974-A1   ;  US20130245103-A1   ;  US20130259923-A1   ;  US20130266640-A1   ;  US20140147432-A1   ;  US20140148502-A1   ;  US20140193482-A1   ;  US20140206752-A1   ;  US20140308304-A1   ;  US20140378538-A1   ;  US20150051268-A1   ;  US20150056253-A1   ;  US20150141499-A1   ;  US20150265698-A1   ;  US20150307542-A1   ;  US20150315541-A1   ;  US20150376115-A1   ;  US20160022580-A1   ;  US20160024140-A1   ;  US20160024141-A1   ;  US20160032273-A1   ;  US20160038612-A1   ;  US20160235864-A1   ;  US20160243221-A1   ;  US20160317647-A1   ;  US20170043037-A1   ;  US20170056528-A1   ;  US20170130255-A1   ;  US20170166905-A1   ;  US20170202979-A1   ;  US20170204152-A1   ;  US20170362627-A1   ;  US20180000953-A1   ;  US20180002393-A1   ;  US20180086816-A1   ;  US20180112221-A1   ;  US20180161422-A1   ;  US20180237766-A1   ;  US20180237849-A1   ;  US20180243225-A1   ;  US20180243230-A1   ;  US20180256628-A1   ;  US20180256750-A1   ;  US20180271795-A1   ;  US20180271970-A1   ;  US20180273576-A1   ;  US20180273977-A1   ;  US20180274009-A1   ;  US20180291425-A1   ;  US20180303925-A1   ;  US20180303929-A1   ;  US20180311336-A1   ;  US20180311343-A1   ;  US20180318409-A1   ;  US20180318446-A1   ;  US20180353618-A1   ;  US20180369374-A1   ;  US20180369419-A1   ;  US20180371047-A1   ;  US20190000959-A1   ;  US20190002890-A1   ;  US20190008938-A1   ;  US20190008948-A1   ;  US20190015501-A1   ;  US20190030129-A1   ;  US20190060458-A1   ;  US20190062762-A1   ;  US20190071682-A1   ;  US20190078087-A1   ;  US20190085368-A1   ;  US20190100748-A1   ;  US20190144480-A1   ;  US20190153428-A1   ;  US20190160185-A1   ;  US20190167811-A1   ;  US20190175517-A1   ;  US20190175727-A1   ;  US20190192646-A1   ;  US20190192653-A1   ;  US20190211368-A1   ;  US20190216951-A1   ;  US20190218546-A1   ;  US20190225644-A1   ;  US20190240317-A1   ;  US20190241633-A1   ;  US20190247417-A1   ;  US20190255194-A1   ;  US20190275170-A1   ;  US20190298657-A1   ;  US20190298658-A1   ;  US20190300906-A1   ;  US20190314291-A1   ;  US20190314292-A1   ;  US20190314524-A1   ;  US20190336452-A1   ;  US20190336595-A1   ;  US20190351040-A1   ;  US20190351048-A1   ;  US20190382774-A1   ;  US20190390181-A1   ;  US20200010528-A1   ;  US20200030432-A1   ;  US20200030460-A1   ;  US20200032274-A1   ;  US20200038499-A1   ;  US20200054737-A1   ;  US20200060971-A1   ;  US20200061185-A1   ;  US20200069599-A1   ;  US20200069793-A1   ;  US20200069794-A1   ;  US20200071689-A1   ;  US20200085916-A1   ;  US20200109420-A1   ;  US20200113832-A1   ;  US20200121809-A1   ;  US20200123100-A1   ;  US20200129445-A1   ;  US20200129608-A1   ;  US20200129615-A1   ;  US20200147176-A1   ;  US20200155706-A1   ;  US20200163878-A1   ;  US20200164038-A1   ;  US20200206362-A1   ;  US20200208145-A1   ;  US20200247861-A1   ;  US20200254086-A1   ;  US20200268664-A1   ;  US20200282046-A1   ;  US20200282047-A1   ;  US20200332293-A1   ;  US20200338214-A1   ;  US20200354423-A1   ;  US20200383922-A1   ;  US20200392518-A1   ;  US20200399629-A1   ;  US20200405844-A1   ;  US20210023199-A1   ;  US20210030683-A1   ;  US20210030866-A1   ;  US20210040473-A1   ;  US20210046173-A1   ;  US20210060175-A1   ;  US20210077634-A1   ;  US20210107861-A1   ;  US20210128716-A1   ;  US20210187097-A1   ;  US20210217484-A1   ;  US20210220467-A1   ;  US20210228707-A1   ;  US20210228708-A1   ;  US20210251898-A1   ;  US20210261597-A1   ;  US20210290756-A1   ;  US20210299244-A1   ;  US20210299278-A1   ;  US20210371452-A1   ;  US20210379181-A1   ;  US20210388032-A1   ;  US20220016234-A1   ;  US20220040285-A1   ;  US20220040292-A1   ;  US20220072155-A1   ;  US20220105201-A1   ;  US20220193226-A1   ;  US20220202930-A1   ;  US20220211838-A1   ;  US20220211841-A1   ;  US20220218815-A1   ;  US20220218816-A1   ;  US20220273820-A1   ;  US20230073461-A1   ;  US20230075979-A1   ;  US6381981-B1   ADVANCED TISSUE SCI INC (ADTI-Non-standard)   YADDGO J,  KEMMERRER S,  BANKERT C;  US10350303-B1   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   GUILD B C,  DEROSA F,  HEARTLEIN M;  US10465190-B1   MODERNATX INC (MODR)   CHEN J,  DOUSIS A;  US10702600-B1   MODERNATX INC (MODR)   CIARAMELLA G,  HIMANSU S;  US11547673-B1   BIONTECH RNA PHARM GMBH (BNTC)   SAHIN U,  GUELER A,  KUHN A,  MUIK A,  VOGEL A,  WALZER K,  WITZEL S,  HEIN S,  TUERECI O;  US7736850-B2   INST PASTEUR (INSP);  CNRS CENT NAT RECH SCI (CNRS)   VAN DER WERF S,  ESCRIOU N,  CRESCENZO C B,  MANUGUERRA J C,  KUNST F,  CALLENDRET B,  BETTON J M,  LORIN V,  GERBAUD S,  BURGUIERE A M,  AZEBI S;  US7901708-B2   PROTIVA BIOTHERAPEUTICS LTD (PROT-Non-standard)   MACLACHLAN I,  JEFFS L,  PALMER L R,  GIESBRECHT C;  US8058069-B2   PROTIVA BIOTHERAPEUTICS INC (PRTO)   MACLACHLAN I,  JUDGE A;  US8153773-B2   UNIV LOUISIANA STATE & AGRIC & MECH                  COLL (LOUU)   JEMIELITY J,  GRUDZIEN-NOGALSKA E M,  KOWALSKA J,  DARZYNKIEWICZ E,  RHOADS R E;  US8278036-B2   UNIV PENNSYLVANIA (UPEN)   KARIKO K,  WEISSMAN D;  US8329070-B2   PROTIVA BIOTHERAPEUTICS LTD (PROT-Non-standard)   MACLACHLAN I,  JEFFS L,  PALMER L R,  GIESBRECHT C;  US8691966-B2   UNIV PENNSYLVANIA (UPEN)   KARIKO K,  WEISSMAN D;  US8710200-B2   MODERNA THERAPEUTICS (MODR)   AFEYAN N B,  BANCEL S,  DE FOUGEROLLES A,  ELBASHIR S M,  SCHRUM J P,  SIECZKIEWICZ G J;  US8748089-B2   UNIV PENNSYLVANIA (UPEN)   KARIKO K,  WEISSMAN D;  US8754062-B2   MODERNA THERAPEUTICS (MODR)   BANCEL S,  DE FOUGEROLLES A,  HATALA P,  ROY A,  SCHRUM J P,  SIDDIQI S;  US8822663-B2   AFEYAN N B (AFEY-Individual);  BANCEL S (BANC-Individual);  SCHRUM J (SCHR-Individual);  MODERNA THERAPEUTICS INC (MODR)   AFEYAN N B,  BANCEL S,  SCHRUM J;  US8835108-B2   UNIV PENNSYLVANIA (UPEN)   KARIKO K,  WEISSMAN D;  US8999380-B2   MODERNA THERAPEUTICS (MODR)   BANCEL S,  CHAKRABORTY T,  DE FOUGEROLLES A,  EJEBE K,  ELBASHIR S M,  ELLSWORTH J L,  GUILD J,  HATALA P,  JOHN M,  ROY A,  SCHRUM J P,  WHORISKEY S,  WOOD K M;  US9220755-B2   MODERNA THERAPEUTICS (MODR)   BANCEL S,  CHAKRABORTY T,  DE FOUGEROLLES A,  EJEBE K,  ELBASHIR S M,  ELLSWORTH J L,  GUILD J,  HATALA P,  JOHN M,  ROY A,  SCHRUM J P,  WHORISKEY S,  WOOD K M;  US9221891-B2   MODERNA THERAPEUTICS (MODR)   BANCEL S,  CHAKRABORTY T,  DE FOUGEROLLES A,  EJEBE K,  ELBASHIR S M,  ELLSWORTH J L,  GUILD J,  HATALA P,  JOHN M,  ROY A,  SCHRUM J P,  WHORISKEY S,  WOOD K M;  US9283287-B2   MODERNA THERAPEUTICS (MODR)   AFEYAN N B,  DE FOUGEROLLES A,  ELBASHIR S M,  SCHRUM J P,  VALENCIA P,  WOOD K M;  US9295717-B2   BIONTECH AG (BNTC);  UNIV MAINZ GUTENBERG JOHANNES (UMGJ);  UNIV WARSZAWSKI (UWAR)   SAHIN U,  KUHN A,  DARZYNKIEWICZ E,  JEMIELITY J,  KOWALSKA J;  US9303079-B2   MODERNA THERAPEUTICS (MODR)   BANCEL S,  CHAKRABORTY T,  DE FOUGEROLLES A,  EJEBE K,  ELBASHIR S M,  ELLSWORTH J L,  GUILD J,  HATALA P,  JOHN M,  ROY A,  SCHRUM J P,  WHORISKEY S,  WOOD K M;  US9334328-B2   SCHRUM J (SCHR-Individual)   SCHRUM J;  US9364435-B2   PROTIVA BIOTHERAPEUTICS INC (PRTO)   LAM K,  MACLACHLAN I,  YAWORSKI E;  US9428535-B2   MODERNA THERAPEUTICS (MODR)   BANCEL S,  DE FOUGEROLLES A,  HATALA P,  ROY A,  SCHRUM J P,  SIDDIQI S;  US9464124-B2   MODERNA THERAPEUTICS (MODR)   BANCEL S,  SCHRUM J P;  US9476055-B2   UNIV MAINZ GUTENBERG JOHANNES (UMGJ)   SAHIN U,  HOLTKAMP S,  TUERECI O,  KREITER S;  US9492386-B2   PROTIVA BIOTHERAPEUTICS LTD (PROT-Non-standard)   MACLACHLAN I,  JEFFS L,  PALMER L R,  GIESBRECHT C;  US9504651-B2   PROTIVA BIOTHERAPEUTICS LTD (PROT-Non-standard)   MACLACHLAN I,  JEFFS L,  PALMER L R,  GIESBRECHT C;  US9512456-B2   MODERNA THERAPEUTICS INC (MODR)   WANG Y,  RAMAKRISHNAN D,  DE FOUGEROLLES A,  WHORISKEY S;  US9533047-B2   MODERNA THERAPEUTICS (MODR)   AFEYAN N B,  BANCEL S,  DE FOUGEROLLES A,  ELBASHIR S M,  SCHRUM J P,  SIECZKIEWICZ G J;  US9597380-B2   MODERNA THERAPEUTICS INC (MODR)   CHAKRABORTY T,  BANCEL S,  HOGE S G,  ROY A,  DE FOUGEROLLES A,  AFEYAN N B;  US9657295-B2   SCHRUM J (SCHR-Individual)   SCHRUM J;  US9669089-B2   CUREVAC GMBH (CUEV)   THESS A,  SCHLAKE T,  PROBST J;  US9737619-B2   ACUITAS THERAPEUTICS INC (ACUI-Non-standard)   ANSELL S M,  DU X;  US9738593-B2   ANSELL S M (ANSE-Individual);  DU X (DUXX-Individual)   ANSELL S M,  DU X;  US9750824-B2   UNIV PENNSYLVANIA (UPEN)   KARIKO K,  WEISSMAN D;  US9850269-B2   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   DEROSA F,  DIAS A,  KARVE S,  HEARTLEIN M;  US9868691-B2   MODERNATX INC (MODR)   BENENATO K E,  KUMARASINGHE E S,  CORNEBISE M;  US9868692-B2   MODERNATX INC (MODR)   BENENATO K E,  KUMARASINGHE E S,  CORNEBISE M;  US9872900-B2   MODERNA THERAPEUTICS INC (MODR)   BOUCHON A,  CIARAMELLA G,  HUANG E Y;  US9957499-B2   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   HEARTLEIN M,  DEROSA F,  DIAS A,  KARVE S;  US9970047-B2   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   HEARTLEIN M,  DEROSA F,  DIAS A;  US10022435-B2   MODERNA THERAPEUTICS INC (MODR)   BOUCHON A,  CIARAMELLA G,  HUANG E Y;  US10064934-B2   MODERNATX INC (MODR)   CIARAMELLA G;  US10064935-B2   MODERNATX INC (MODR)   CIARAMELLA G,  JOHN S,  MOUSAVI K;  US10064959-B2   SCHRUM J (SCHR-Individual)   SCHRUM J;  US10106490-B2   ACUITAS THERAPEUTICS INC (ACUI-Non-standard)   ANSELL S M,  DU X;  US10106800-B2   UNIV MAINZ GUTENBERG JOHANNES (UMGJ)   SAHIN U,  HOLTKAMP S,  TUERECI O,  KREITER S;  US10124055-B2   MODERNATX INC (MODR)   CIARAMELLA G;  US10166298-B2   ACUITAS THERAPEUTICS INC (ACUI-Non-standard)   ANSELL S M,  DU X;  US10207010-B2   MODERNATX INC (MODR)   BESIN G,  HOGE S,  SENN J,  BENENATO K,  SABNIS S;  US10232055-B2   UNIV PENNSYLVANIA (UPEN)   KARIKO K,  WEISSMAN D;  US10238754-B2   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   GUILD B C,  DEROSA F,  HEARTLEIN M;  US10266485-B2   MODERNATX INC (MODR)   BENENATO K E,  KUMARASINGHE E S,  CORNEBISE M;  US10272150-B2   MODERNATX INC (MODR)   CIARAMELLA G,  HIMANSU S;  US10273269-B2   MODERNATX INC (MODR)   CIARAMELLA G;  US10286086-B2   MODERNA THERAPEUTICS INC (MODR)   BUTORA G,  CONLEE C R,  DE FOUGEROLLES A,  FRALEY A W,  ROY A,  STANTON M;  US10385088-B2   MODERNA THERAPEUTICS INC (MODR)   FRALEY A W,  ROY A,  STANTON M;  US10413618-B2   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   GUILD B C,  DEROSA F,  HEARTLEIN M;  US10442756-B2   MODERNATX INC (MODR)   BENENATO K E,  KUMARASINGHE E S,  CORNEBISE M;  US10449244-B2   MODERNATX INC (MODR)   CIARAMELLA G,  HUANG E Y,  BAHL K,  ZAKS T,  HIMANSU S;  US10493143-B2   MODERNATX INC (MODR)   CIARAMELLA G,  HIMANSU S;  US10493167-B2   MODERNA THERAPEUTICS (MODR)   BANCEL S,  CHAKRABORTY T,  DE FOUGEROLLES A,  EJEBE K,  ELBASHIR S M,  ELLSWORTH J L,  GUILD J,  HATALA P,  JOHN M,  ROY A,  SCHRUM J P,  WHORISKEY S,  WOOD K M;  US10494399-B2   TRILINK BIOTECHNOLOGIES INC (TRIL-Non-standard)   HOGREFE R I,  LEBEDEV A,  MCCAFFREY A P,  SHIN D;  US10519189-B2   TRILINK BIOTECHNOLOGIES INC (TRIL-Non-standard)   HOGREFE R I,  LEBEDEV A,  MCCAFFREY A P,  SHIN D;  US10543269-B2   MODERNATX INC (MODR)   CIARAMELLA G,  HIMANSU S;  US10577403-B2   MODERNA THERAPEUTICS (MODR)   BANCEL S,  CHAKRABORTY T,  DE FOUGEROLLES A,  EJEBE K,  ELBASHIR S M,  ELLSWORTH J L,  GUILD J,  HATALA P,  JOHN M,  ROY A,  SCHRUM J P,  WHORISKEY S,  WOOD K M;  US10583203-B2   MODERNA THERAPEUTICS (MODR)   BANCEL S,  CHAKRABORTY T,  DE FOUGEROLLES A,  EJEBE K,  ELBASHIR S M,  ELLSWORTH J L,  GUILD J,  HATALA P,  JOHN M,  ROY A,  SCHRUM J P,  WHORISKEY S,  WOOD K M;  US10648017-B2   CUREVAC GMBH (CUEV)   WOCHNER A;  US10653712-B2   MODERNATX INC (MODR)   HOGE S,  ISSA W,  MIRACCO E J,  NELSON J,  RABIDEAU A E,  BUTORA G;  US10653767-B2   MODERNATX INC (MODR)   CIARAMELLA G,  HIMANSU S;  US10695419-B2   MODERNATX INC (MODR)   CIARAMELLA G,  JOHN S;  US10702599-B2   MODERNATX INC (MODR)   CIARAMELLA G,  HIMANSU S;  US10703789-B2   MODERNA THERAPEUTICS (MODR)   BANCEL S,  CHAKRABORTY T,  DE FOUGEROLLES A,  EJEBE K,  ELBASHIR S M,  ELLSWORTH J L,  GUILD J,  HATALA P,  JOHN M,  ROY A,  SCHRUM J P,  WHORISKEY S,  WOOD K M;  US10709779-B2   MODERNA THERAPEUTICS INC (MODR)   BOUCHON A,  CIARAMELLA G,  HUANG E Y;  US10717982-B2   BIONTECH RNA PHARM GMBH (BNTC);  UNIV MAINZ TRON TRANSLATIONALE ONKOLOGIE (UMTT)   EBERLE F,  SAHIN U,  KUHN A,  VALLAZZA B,  DIKEN M;  US10723692-B2   ACUITAS THERAPEUTICS INC (ACUI-Non-standard)   ANSELL S M,  DU X;  US10738306-B2   CUREVAC GMBH (CUEV)   THESS A;  US10760070-B2   CUREVAC AG (CUEV)   FUNKNER A,  DORNER S,  SEWING S,  KAMM J,  BROGHAMMER N,  KETTERER T,  MUTZKE T;  US10772975-B2   MODERNA THERAPEUTICS (MODR)   BANCEL S,  CHAKRABORTY T,  DE FOUGEROLLES A,  EJEBE K,  ELBASHIR S M,  ELLSWORTH J L,  GUILD J,  HATALA P,  JOHN M,  ROY A,  SCHRUM J P,  WHORISKEY S,  WOOD K M;  US10808242-B2   BIONTECH RNA PHARM GMBH (BNTC)   KARIKO K,  SAHIN U;  US10857105-B2   MODERNATX INC (MODR)   BENENATO K E,  KUMARASINGHE E S,  CORNEBISE M;  US10912826-B2   CUREVAC GMBH (CUEV)   THESS A,  SCHLAKE T,  PROBST J;  US10913768-B2   TRILINK BIOTECHNOLOGIES INC (TRIL-Non-standard)   HOGREFE R I,  LEBEDEV A,  MCCAFFREY A P,  SHIN D;  US10925935-B2   MODERNATX INC (MODR)   CHAKRABORTY T,  BANCEL S,  HOGE S G,  ROY A,  DE FOUGEROLLES A,  AFEYAN N B;  US10925958-B2   MODERNATX INC (MODR)   CIARAMELLA G;  US11040112-B2   ACUITAS THERAPEUTICS INC (ACUI-Non-standard)   ANSELL S M,  DU X;  US11045540-B2   MODERNATX INC (MODR)   CIARAMELLA G;  US11241493-B2   CUREVAC AG (CUEV)   RAUCH S,  GROSSE H W,  PETSCH B;  WO2004002453-A1   PROTIVA BIOTHERAPEUTICS LTD (PROT-Non-standard)   MACLACHLAN I,  JEFFS L,  PALMER L R,  GIESBRECHT C;  WO2004004743-A1   CUREVAC GMBH (CUEV)   HOERR I,  VON DER MUELBE F,  PASCOLO S;  WO2009127060-A1   PROTIVA BIOTHERAPEUTICS INC (PRTO)   LAM K,  MACLACHLAN I,  YAWORSKI E;  WO2011015347-A1   BIONTECH AG (BNTC);  UNIV MAINZ GUTENBERG JOHANNES (UMGJ);  UNIV WARSZAWSKI (UWAR)   SAHIN U,  KUHN A,  DARZYNKIEWICZ E,  JEMIELITY J,  KOWALSKA J;  WO2011068810-A1   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   GUILD B C,  DEROSA F,  HEARTLEIN M;  WO2012045075-A1   SCHRUM J (SCHR-Individual)   SCHRUM J;  WO2012170930-A1   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   GUILD B C,  DEROSA F,  HEARTLEIN M;  WO2013052523-A1   MODERNA THERAPEUTICS (MODR)   BANCEL S,  DE FOUGEROLLES A,  HATALA P,  ROY A,  SCHRUM J P,  SIDDIQI S;  WO2013090648-A1   MODERNA THERAPEUTICS (MODR)   AFEYAN N B,  DE FOUGEROLLES A,  ELBASHIR S M,  SCHRUM J P,  VALENCIA P,  WOOD K M;  WO2013143699-A1   CUREVAC GMBH (CUEV)   THESS A;  WO2013151671-A1   MODERNA THERAPEUTICS (MODR)   BANCEL S,  HUANG E Y;  WO2014089239-A1   ALNYLAM PHARM INC (ALNY)   AKINC A,  MAIER M,  KUMAR V;  WO2014127917-A1   CUREVAC GMBH (CUEV)   FOTIN-MLECZEK M,  KALLEN K,  PROBST J;  WO2014144711-A1   MODERNA THERAPEUTICS INC (MODR)   SPIVAK V B,  SHAHROKH Z,  ISSA W J;  WO2014152659-A1   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   HEARTLEIN M,  DEROSA F,  DIAS A;  WO2014152966-A1   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   HEARTLEIN M,  DEROSA F,  DIAS A,  KARVE S;  WO2014159813-A1   MODERNA THERAPEUTICS INC (MODR)   HOGE S G,  HUANG E Y,  CHAKRABORTY T,  ELBASHIR S M;  WO2014164253-A1   MODERNA THERAPEUTICS INC (MODR)   CHAKRABORTY T,  BANCEL S,  HOGE S G,  ROY A,  DE FOUGEROLLES A,  AFEYAN N B;  WO2015005253-A1   DAIICHI SANKYO CO LTD (DAUC)   KOIZUMI M,  ONISHI Y,  NIWA T,  TAMURA M,  KASUYA Y;  WO2015024667-A1   CUREVAC GMBH (CUEV)   BAUMHOF P;  WO2015062738-A1   CUREVAC GMBH (CUEV)   SCHLAKE T,  THESS A;  WO2015101416-A1   CUREVAC GMBH (CUEV)   WOCHNER A;  WO2015164674-A1   MODERNA THERAPEUTICS INC (MODR)   BOUCHON A,  CIARAMELLA G,  HUANG E Y;  WO2015164773-A1   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   DEROSA F,  DIAS A,  KARVE S,  HEARTLEIN M;  WO2015199952-A1   ANSELL S M (ANSE-Individual);  DU X (DUXX-Individual)   ANSELL S M,  DU X;  WO2016005004-A1   BIONTECH RNA PHARM GMBH (BNTC);  UNIV MAINZ TRON TRANSLATIONALE ONKOLOGIE (UMTT)   EBERLE F,  SAHIN U,  KUHN A,  VALLAZZA B,  DIKEN M;  WO2016005324-A1   BIONTECH RNA PHARM GMBH (BNTC);  UNIV MAINZ TRON TRANSLATIONALE ONKOLOGIE (UMTT)   EBERLE F,  SAHIN U,  KUHN A,  VALLAZZA B,  DIKEN M;  WO2016010840-A1   NOVARTIS AG (NOVS);  BOWMAN K A (BOWM-Individual);  GARDNER N (GARD-Individual);  JEANNOTTE T (JEAN-Individual);  VARGEESE C (VARG-Individual)   BOWMAN K A,  GARDNER N,  JEANNOTTE T,  VARGEESE C;  WO2016011226-A1   MODERNA THERAPEUTICS INC (MODR)   NELSON J A,  FRALEY A,  RHODEN SMITH A;  WO2016045732-A1   BIONTECH RNA PHARM GMBH (BNTC)   HAAS H,  ESPARZA BORQUEZ I H;  WO2016077123-A1   MODERNA THERAPEUTICS INC (MODR)   REYNDERS J V W,  CHAKRABORTY T,  HOGE S,  MCFADYEN I J;  WO2016091391-A1   CUREVAC AG (CUEV)   THESS A,  SCHLAKE T,  GRUND S;  WO2016164762-A1   MODERNA THERAPEUTICS INC (MODR)   ELLSWORTH J L,  BOLEN J B,  GREGOIRE F M,  GUILD J;  WO2016165831-A1   CUREVAC AG (CUEV)   KETTERER T,  MUTZKE T,  WIGGENHORN M,  SCHAUBHUT F,  VON DER MULBE F;  WO2016176330-A1   UNIV PENNSYLVANIA (UPEN);  ACUITAS THERAPEUTICS INC (ACUI-Non-standard);  TAM Y (TAMY-Individual);  HOPE M J (HOPE-Individual)   TAM Y,  HOPE M J,  WEISSMAN D,  PARDI N;  WO2016180430-A1   CUREVAC AG (CUEV)   VON DER MUELBE F,  REIDEL L,  KETTERER T;  WO2016184575-A1   CUREVAC AG (CUEV)   EBER F J,  YAZDAN PANAH B,  SEWIG S,  KETTERER T,  MUTZKE T,  ROOS T,  SONNTAG M,  WIGGENHORN M,  KOLLAND K;  WO2016193206-A1   CUREVAC AG (CUEV)   FUNKNER A,  DORNER S,  SEWING S,  KAMM J,  BROGHAMMER N,  KETTERER T,  MUTZKE T;  WO2016201377-A1   MODERNA THERAPEUTICS INC (MODR);  YI-CHUN HUANG E (HUAN-Individual);  HOGE S (HOGE-Individual)   YI-CHUN HUANG E,  HOGE S;  WO2017015457-A1   MODERNATX INC (MODR)   CIARAMELLA G;  WO2017025447-A1   CUREVAC AG (CUEV)   WILLIAMS J;  WO2017036889-A1   BIONTECH RNA PHARM GMBH (BNTC)   KARIKO K,  SAHIN U;  WO2017053297-A1   TRILINK BIOTECHNOLOGIES INC (TRIL-Non-standard)   HOGREFE R I,  LEBEDEV A,  MCCAFFREY A P,  SHIN D;  WO2017059902-A1   BIONTECH RNA PHARM GMBH (BNTC);  UNIV MAINZ TRON TRANSLATIONALE ONKOLOGIE (UMTT)   ORLANDINI VON NIESSEN A,  FESSER S,  VALLAZZA B,  BEISSERT T,  KUHN A,  SAHIN U;  WO2017066781-A1   MODERNATX INC (MODR)   BUTORA G,  STANTON M,  STEELE T;  WO2017066789-A1   MODERNATX INC (MODR)   BUTORA G,  STANTON M,  STEELE T;  WO2017066793-A1   MODERNATX INC (MODR)   BUTORA G,  STANTON M,  STEELE T;  WO2017070601-A1   MODERNATX INC (MODR)   CIARAMELLA G;  WO2017070618-A1   MODERNATX INC (MODR)   VALIANTE N,  ZAKS T,  HUANG E Y,  CIARAMELLA G;  WO2017075531-A1   ACUITAS THERAPEUTICS INC (ACUI-Non-standard)   ANSELL S M,  DU X;  WO2017099823-A1   MODERNATX INC (MODR)   BESIN G,  HOGE S,  SENN J,  BENENATO K,  SABNIS S;  WO2017112865-A1   MODERNATX INC (MODR)   BENENATO K E,  BUTCHER W;  WO2017127750-A1   MODERNATX INC (MODR)   HUANG E Y,  FREDERICK J,  MCKINNEY K,  HENDERSON C,  CHEUNG-ONG K,  BOLEN J,  KELSEY S M,  MORIN M,  GURUMURTHY S,  BENENATO K,  HOGE S,  MCFADYEN L,  PRESNYAK V;  WO2017201333-A1   MODERNATX INC (MODR)   BENENATO K,  HOGE S,  MARTINI P,  MCFADYEN I,  PRESNYAK V,  KUMARASINGHE E S;  WO2017218704-A1   MODERNATX INC (MODR)   SMITH M,  ALMARSSON O,  BRITO L;  WO2018053209-A1   MODERNATX INC (MODR)   HOGE S,  ISSA W,  MIRACCO E J,  NELSON J,  RABIDEAU A E,  BUTORA G;  WO2018075827-A1   ARCTURUS THERAPEUTICS INC (ARCT-Non-standard)   CHIVUKULA P,  TANIS S P,  PAYNE J E;  WO2018078053-A1   CUREVAC AG (CUEV);  ACUITAS THERAPEUTICS INC (ACUI-Non-standard)   BAUMHOF P,  FOTIN-MLECZEK M,  HEIDENREICH R,  HOPE M J,  JASNY E,  LAZZARO S,  LIN P J C,  LUTZ J,  MUI B,  PETSCH B,  RAUCH S,  SCHMIDT K E,  TAM Y;  WO2018081459-A1   MODERNATX INC (MODR)   HUANG E Y,  TSE S,  IACOVELLI J,  MCKINNEY K,  HOPSON K;  WO2018081462-A1   MODERNATX INC (MODR)   MARQUARDT D,  AMATO N J;  WO2018081480-A1   ACUITAS THERAPEUTICS INC (ACUI-Non-standard)   HOPE M J,  MUI B,  LIN P J C,  BARBOSA C,  MADDEN T,  ANSELL S M,  DU X;  WO2018089540-A1   MODERNATX INC (MODR)   BRADER M;  WO2018144778-A1   MODERNATX INC (MODR);  MCFADYEN I (MCFA-Individual);  PRESNYAK V (PRES-Individual)   MCFADYEN I,  PRESNYAK V,  MAUGER D;  WO2018157009-A1   MODERNATX INC (MODR)   MARTINI P;  WO2018170245-A1   MODERNATX INC (MODR);  BABAOGLU K (BABA-Individual);  FLYNN J A (FLYN-Individual);  ZHANG L (ZHAN-Individual);  NICKLE D (NICK-Individual)   BABAOGLU K,  FLYNN J A,  ZHANG L,  NICKLE D,  CIARAMELLA G,  HUANG E Y;  WO2018170306-A1   MODERNATX INC (MODR)   BENENATO K E,  KUMARASINGHE E S,  CORNEBISE M;  WO2018170322-A1   MODERNATX INC (MODR)   ALMARSSON O,  CHEUNG E;  WO2018170336-A1   MODERNATX INC (MODR);  UNIV OREGON STATE (UORE);  PATEL S (PATE-Individual);  ROBINSON E (ROBI-Individual);  BROWN A (BROW-Individual)   PATEL S,  ROBINSON E,  BROWN A,  ALMARSSON O,  BENENATO K E,  SABNIS S,  SAHAY G,  NARAYANA A K;  WO2018170347-A1   MODERNATX INC (MODR)   CIARAMELLA G,  HIMANSU S,  PRESNYAK V,  BENENATO K,  KUMARASINGHE E S;  WO2018187590-A1   MODERNATX INC (MODR)   BRITO L,  BESIN G;  WO2018213789-A1   MODERNATX INC (MODR)   MOORE M J,  KOEHRER C,  JAIN R,  PRESNYAK V;  WO2018232355-A1   MODERNATX INC (MODR)   HIMANSU S,  NARAYANAN E,  CIARAMELLA G;  WO2018232357-A1   MODERNATX INC (MODR)   HOGE S,  SCHARITER J,  BOWERMAN C,  SMITH M H,  XIA Y;  WO2019035998-A1   MODERNATX INC (MODR)   GELDHOF B F;  WO2019036683-A1   MODERNATX INC (MODR)   ISSA W,  PACKER M;  WO2019036685-A1   MODERNATX INC (MODR)   ISSA W,  PACKER M;  WO2019092002-A1   VALNEVA SE (ICEL)   PITARD B,  HANSON M,  LAHMAR M,  PERUGI F,  SCHWAMBORN K,  GUEHENNEUX F;  WO2019092437-A1   UCL BUSINESS PLC (UNLO)   GRANT-SERROUKH D,  HART S L;  WO2019148101-A1   MODERNATX INC (MODR);  ESPESETH A (ESPE-Individual);  BETT A J (BETT-Individual);  CEJAS P (CEJA-Individual);  ZHANG L (ZHAN-Individual);  SHAW C (SHAW-Individual)   ESPESETH A,  BETT A J,  CEJAS P,  ZHANG L,  SHAW C,  CIARAMELLA G,  BAHL K;  WO2019232097-A1   TRANSLATE BIO INC (TRAN-Non-standard)   ZHANG Y,  KARVE S,  DEROSA F,  HEARTLEIN M;  WO2020006242-A1   MODERNATX INC (MODR);  GARNAAS M (GARN-Individual)   GARNAAS M,  ZHONG S,  BRETON B,  MCFADYEN I,  HOPSON K,  LUCZKOW V;  WO2020056370-A1   MODERNATX INC (MODR)   MARTINI P,  PRESNYAK V,  CAO J;  WO2020061284-A1   MODERNATX INC (MODR)   HENNESSY E J,  BENENATO K;  WO2020061295-A1   MODERNATX INC (MODR)   ALMARSSON O,  LIM J,  CHEUNG E,  MILTON J;  WO2020061367-A1   MODERNATX INC (MODR)   BENENATO K E,  CORNEBISE M,  HENNESSY E;  WO2020061457-A1   MODERNATX INC (MODR)   HORHOTA A,  MCLAUGHLIN C K,  CHENEY J,  GELDHOF B,  HRKACH J,  MOORE M J,  HOGE S G;  WO2020097291-A1   MODERNATX INC (MODR)   ASHBURN T,  HOPSON K,  KEATING K,  SENN J,  SWENSON C,  BRETON B,  ZHONG S,  GARNAAS M;  WO2020160397-A1   MODERNATX INC (MODR)   SMITH M,  HORHOTA A,  AUER J,  SKINNER B;  WO2020190750-A1   MODERNATX INC (MODR);  US DEPT HEALTH & HUMAN SERVICES (USSH)   LUSSO P,  ZHANG P,  NARAYANAN E,  ELBASHIR S M;  WO2020198337-A1   OHIO STATE INNOVATION FOUND (OHIS)   DONG Y,  ZENG C,  ZHAO W;  WO2020263985-A1   MODERNATX INC (MODR)   JAIN R,  REID D,  PRESNYAK V,  BICKNELL A,  KOEHRER C;  WO2021030701-A1   ACUITAS THERAPEUTICS INC (ACUI-Non-standard)   TAM Y K,  LIN P J C,  SEMPLE S,  BARBOSA C J;  WO2021050864-A1   MODERNATX INC (MODR);  JOHN S (JOHN-Individual)   JOHN S,  PANTHER L,  ZAKS T;  WO2021055811-A1   MODERNATX INC (MODR)   AMATO N J,  HUA S,  SALANDRIA K;  WO2021147025-A1   UNIV HONG KONG SHENZHEN HOSPITAL (UYHK-Non-standard);  SHENZHEN INST ADVANCED TECHNOLOGY (CAAT);  UNIV BEIJING CHEM TECHNOLOGY (UYBC);  UNIV GUANGZHOU MEDICAL FIRST AFFILIATED (UNGM)   HUANG J,  ZHANG B,  TONG Y,  ZHAO J,  DOU Y,  HU Y,  HU J,  KUWENTRAI C;  WO2021154763-A1   MODERNATX INC (MODR)   STEWART-JONES G,  NARAYANAN E,  BENNETT H,  CARFI A,  METKAR M,  PRESNYAK V;  WO2021155243-A1   MODERNATX INC (MODR)   SHAW C,  STEWARD-JONES G,  NARAYANAN E,  PRESNYAK V,  ELBASHIR S M;  WO2021155760-A1   CANSINO BIOLOGICS INC (CANS-Non-standard);  SUZHOU GENEPHARMA CO LTD (SUZH-Non-standard)   ZHU T,  LI J,  WANG H,  SHEN C,  JIANG J,  CHAO S,  QIU D;  WO2021156267-A1   CUREVAC AG (CUEV)   RAUCH S,  GROSSE H W,  PETSCH B;  WO2021159985-A1   STEMIRNA SHANGHAI BIOTECHNOLOGY CO LTD (STEM-Non-standard)   LI H,  ZHANG L,  MA X,  LI S,  YU B,  LIN A,  ZHANG J,  YAO W,  ZHANG Y,  HUANG L,  LIU N,  WU W,  LIU J,  SHEN M;  WO2021160346-A1   INST PASTEUR (INSP)   SIMON-LORIERE E,  PROT M,  MONTAGUTELLI X;  WO2021165667-A1   VAXBIO LTD (VAXB-Non-standard)   GUPTA G,  GLUECK R;  WO2021181100-A1   UNIV OXFORD INNOVATION LTD (UYOX)   GILBERT S C,  LAMBE T,  SEBASTIAN S;  WO2021188906-A1   NATURES TOOLBOX INC (NATU-Non-standard)   HUMBERT M,  KOGLIN A;  WO2021202772-A1   UNIV FLORIDA RES FOUND INC (UYFL)   SAYOUR E,  MENDEZ-GOMEZ H R,  CASTILLO CARO P A,  JONES N T,  MITCHELL D A;  WO2021204179-A1   SUZHOU ABOGEN BIOSCI CO LTD (SUZH-Non-standard)   YING B;  WO2021210686-A1   VLP THERAPEUTICS INC (VLPT-Non-standard)   UENO R,  SMITH J F,  AKAHATA W;  WO2021211688-A1   UNIV DUKE (UDUK)   HENDERSON R,  SAUNDERS K,  HAYNES B F,  ACHARYA P;  WO2021211748-A1   UNIV CALIFORNIA (REGC)   BENMOHAMED L;  WO2021213924-A1   BIONTECH RNA PHARM GMBH (BNTC)   SAHIN U,  GUELER A,  KUHN A,  MUIK A,  VOGEL A,  WALZER K,  WITZEL S,  HEIN S,  TUERECI O;  WO2021213945-A1   PFIZER INC (PFIZ);  BIONTECH SE (BNTC)   NAUTA M,  PEETERS D J,  VAN DOORSLAER T F S,  BADKAR A V,  DARVARI R,  WARNE N W,  JEAN J,  HENDRIKSE D P G,  SAHIN U,  GUELER A,  KUHN A,  MUIK A,  VOGEL A,  WALZER K,  WITZEL S,  HEIN S,  TUERECI O;  WO2021214204-A1   BIONTECH SE (BNTC)   SAHIN U,  GUELER A,  KUHN A,  MUIK A,  VOGEL A,  WALZER K,  WITZEL S,  HEIN S,  TUERECI O,  BOROS G,  MAHINY A J,  REINHOLZ J,  KARIKO K;  WO2021216729-A1   INTIMA BIOSCI INC (INTI-Non-standard)   CHOUDHRY M,  HENLEY T;  WO2021220319-A1   TAKIS SRL (TAKI-Non-standard)   AURISICCHIO L,  MARRA E,  ROSCILLI G,  PALOMBO F,  MAFFEI M,  MUZI A;  WO2021222304-A1   MODERNATX INC (MODR)   ZAKS T,  SLOBOD K,  BENNETT H;  WO2021226436-A1   TRANSLATE BIO INC (TRAN-Non-standard)   DIAS A,  TRAN K A,  ZACHARIA M,  GU X,  BOEGLIN L,  SKALESKI J A,  KARVE S,  DESORA F,  FU T,  KALNIN K,  CHIVUKULA S,  PLITNIK T,  CASIMIRO D,  DUBINS J S;  WO2021231560-A1   GREFFEX INC (GREF-Non-standard)   STAERZ U D,  PRESTON D F,  QI Y;  WO2021231929-A1   MODERNATX INC (MODR)   WHITE P;  WO2021231963-A1   MODERNATX INC (MODR)   WHITE P;  WO2021239880-A1   CUREVAC AG (CUEV)   OOSTVOGELS C,  PETSCH B,  RAUCH S,  SCHWENDT K E;  WO2022009121-A1   SPICONA INC (SPIC-Non-standard)   GLUCK R,  FAZIO A,  MONTOMOLI E,  BANZIGER K,  QUINTO C;  WO2022011092-A1   UNIV PENNSYLVANIA (UPEN)   PARDI N,  WEISSMAN D;  WO1998051278-A2   ;  WO1999014346-A2   ;  WO2002098443-A2   ;  WO2004096842-A2   BC CANCER AGENCY (BCCA)   PLUMMER F,  FELDMANN H,  JONES S,  LI Y,  BASTIEN N,  BRUNHAM R,  BROOKS-WILSON A,  HOLT R,  UPTON C,  ROPER R,  ASTELL C;  WO2006138380-A2   MASSACHUSETTS INST TECHNOLOGY (MASI)   ANDERSON D G,  ZUMBUEHL A,  LESHCHINER E S,  LANGER R S,  GOLDBERG M;  WO2007024708-A2   UNIV PENNSYLVANIA (UPEN)   KARIKO K,  WEISSMAN D;  WO2007036366-A2   UNIV MAINZ GUTENBERG JOHANNES (UMGJ)   SAHIN U,  HOLTKAMP S,  TUERECI O,  KREITER S;  WO2008016473-A2   APPLERA CORP (APLR)   KORE A R,  SHANMUGASUNDARAM M;  WO2008027942-A2   ABBOTT LAB (ABBO)   RODGERS B C,  BURCH G J;  WO2008052770-A2   CUREVAC GMBH (CUEV)   HOERR I,  VON DER MUELBE F;  WO2008157688-A2   UNIV LOUISIANA STATE & AGRIC & MECH                  COLL (LOUU)   JEMIELITY J,  GRUDZIEN-NOGALSKA E M,  KOWALSKA J,  DARZYNKIEWICZ E,  RHOADS R E;  WO2009149253-A2   UNIV WARSZAWSKI (UWAR);  UNIV LOUISIANA STATE & AGRIC & MECH                  COLL (LOUU)   DARZYNKIEWICZ E,  JEMIELITY J,  KOWALSKA J,  LUKASZEWICZ M,  RHOADS R E,  ZUBEREK J;  WO2012019168-A2   AFEYAN N B (AFEY-Individual);  BANCEL S (BANC-Individual);  SCHRUM J (SCHR-Individual);  MODERNA THERAPEUTICS INC (MODR)   AFEYAN N B,  BANCEL S,  SCHRUM J;  WO2012135805-A2   MODERNA THERAPEUTICS (MODR)   AFEYAN N B,  BANCEL S,  DE FOUGEROLLES A,  ELBASHIR S M,  SCHRUM J P,  SIECZKIEWICZ G J;  WO2013151668-A2   MODERNA THERAPEUTICS (MODR)   BANCEL S,  CHAKRABORTY T,  DE FOUGEROLLES A,  EJEBE K,  ELBASHIR S M,  ELLSWORTH J L,  GUILD J,  HATALA P,  JOHN M,  ROY A,  SCHRUM J P,  WHORISKEY S,  WOOD K M;  WO2013151672-A2   MODERNA THERAPEUTICS (MODR)   BANCEL S,  CHAKRABORTY T,  DE FOUGEROLLES A,  EJEBE K,  ELBASHIR S M,  ELLSWORTH J L,  GUILD J,  HATALA P,  JOHN M,  ROY A,  SCHRUM J P,  WHORISKEY S,  WOOD K M;  WO2013151736-A2   MODERNA THERAPEUTICS (MODR)   BANCEL S,  CHAKRABORTY T,  DE FOUGEROLLES A,  EJEBE K,  ELBASHIR S M,  ELLSWORTH J L,  GUILD J,  HATALA P,  JOHN M,  ROY A,  SCHRUM J P,  WHORISKEY S,  WOOD K M;  WO2015130584-A2   MERCK SHARP & DOHME CORP (MERI)   GINDY M,  CASIMIRO D R,  BETT A,  TER MEULEN J H;  WO2016184576-A2   CUREVAC AG (CUEV)   EBER F J,  YAZDAN PANAH B,  SEWIG S,  KETTERER T,  MUTZKE T,  ROOS T,  SONNTAG M,  WIGGENHORN M,  KOLLAND K;  WO2017049245-A2   MODERNATX INC (MODR)   BENENATO K E,  KUMARASINGHE E S,  CORNEBISE M;  WO2017049275-A2   MODERNA THERAPEUTICS INC (MODR)   BUTORA G,  FRALEY A W,  MIRACCO E J,  NELSON J,  RHODEN-SMITH A,  STANTON M;  WO2017060314-A2   BIONTECH RNA PHARM GMBH (BNTC);  UNIV MAINZ TRON TRANSLATIONALE ONKOLOGIE (UMTT)   ORLANDINI VON NIESSEN A,  FESSER S,  VALLAZZA B,  BEISSERT T,  KUHN A,  SAHIN U,  POLEGANOV M A;  WO2017070626-A2   MODERNATX INC (MODR)   CIARAMELLA G,  HIMANSU S;  WO2017191274-A2   CUREVAC AG (CUEV)   FOTIN-MLECZEK M,  HOERR I;  WO2018089851-A2   MODERNATX INC (MODR)   CIARAMELLA G;  WO2018115527-A2   CUREVAC AG (CUEV)   RAUCH S;  WO2019036670-A2   MODERNATX INC (MODR)   HOGE S,  CIARAMELLA G;  WO2019209914-A2   SEATTLE CHILDREN'S HOSPITAL RES INST (SEHS)   RAWLINGS D J,  PATTABHI S,  SCHARENBERG A M,  JACOBY K;  WO2021159040-A2   MODERNATX INC (MODR)   STEWART-JONES G;  WO2021159118-A2   RNAIMMUNE INC (RNAI-Non-standard)   TANG S,  SHEN D,  LU C,  HE Z,  HE J,  LU P Y;  WO2021159130-A2   MODERNATX INC (MODR);  US DEPT HEALTH & HUMAN SERVICES (USSH)   BENNETT H,  STEWART-JONES G,  NARAYANAN E,  CARFI A,  METKAR M,  PRESNYAK V,  GRAHAM B S,  CORBETT K S;  WO2021188969-A2   BIONTECH US INC (BNTC)   GAYNOR R B,  SRINIVASAN L,  PORAN A,  HARJANTO D,  KUKSIN C,  ROTHENBERG D A,  SROUJI J;  WO2021194826-A2   ICAHN SCHOOL MEDICINE (MOUN)   KRAMMER F,  FIRPO-BETANCOURT A,  CORDON-CARDO C,  MENDU D R,  SIMON V,  AMANAT F,  STADLBAUER D;  WO2021198706-A2   DIOSYNVAX LTD (DIOS-Non-standard);  UNIV OXFORD (UYOX)   HEENEY J L,  VISHWANATH S,  CARNELL G,  WELLS D,  FERRARI M;  WO2021202599-A2   VALIANT BIOSCI LLC (VALI-Non-standard)   JOHNSON P R;  WO2022011332-A2   ENGIMATA INC (ENGI-Non-standard)   NAYAR R,  SORAYYA A,  MOSHARRAF M","WO2021214204-A1  ZENG CHUNXI ET AL.:          ""Leveraging mRNAs sequences to express SARS-CoV-2          antigens in vivo"", BIORXIV, 5 April 2020 (2020-04-05),          XP055826383, Retrieved from the Internet          &lt;URL:https://www.biorxiv.org/content/10.1101/2020.04.01.019877v1.full.pdf&gt;          [retrieved on 20210721], DOI:          10.1101/2020.04.01.019877,relevantClaims[1,2,8-13,16,20-24,29,41,52-62,77-87,98-111,113-120,123-126,129,135-139,142-147|3-7,17-19,25-28,30-40,42-51,63-76,88-97,112,121,122,127,128,130-132],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  HYDE J.L. ET AL.:          ""A viral RNA structural element alters host recognition          of nonself RNA"", SCIENCE, vol. 343, no. 6172, 30 January          2014 (2014-01-30), US, pages 783 - 787, XP055826832,          ISSN: 0036-8075, DOI:          10.1126/science.1248465,relevantClaims[133,134],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  BOULOY M. ET AL.:          ""Both the 7-methyl and the 2'-O-methyl groups in the CAP          of mRNA strongly influence its ability to act as primer          for influenza virus RNA transcription"", PROCEEDINGS OF          THE NATIONAL ACADEMY OF SCIENCES OF THE USA, NEW YORK,          NY, US, vol. 77, no. 7, 1 July 1980 (1980-07-01), pages          3952 - 3956,          XP000607007,relevantClaims[1],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  HABJAN MATTHIAS ET          AL.: ""Sequestration by IFIT1 impairs translation of          2'O-unmethylated capped RNA"", PLOS PATHOGENS, vol. 9, no.          10, 3 October 2013 (2013-10-03), pages e1003663,          XP055826325, Retrieved from the Internet          &lt;URL:https://storage.googleapis.com/plos-corpus-prod/10.1371/journal.ppat.1003663/1/ppat.1003663.pdf?X-Goog-Algorithm=GOOG4-RSA-SHA256&X-Goog-Credential=wombat-sa@plos-prod.iam.gserviceaccount.com/20210721/auto/storage/goog4_request&X-Goog-Date=20210721T091441Z&X-Goog-Expires=86400&X-Goog-SignedHeaders=h&gt;          DOI:          10.1371/journal.ppat.1003663,relevantClaims[1],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  ANAND RAMANATHAN ET          AL.: ""mRNA capping: biological functions and          applications"", NUCLEIC ACIDS RESEARCH, vol. 44, no. 16,          17 June 2016 (2016-06-17), GB, pages 7511 - 7526,          XP055388045, ISSN: 0305-1048, DOI:          10.1093/nar/gkw551,relevantClaims[1],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            ""Helvetica Chimica Acta"", 1995, article ""A multilingual          glossary of biotechnological terms: (IUPAC          Recommendations"";            ""Molecular Cloning: A Laboratory Manual"", 1989, COLD          SPRING HARBOR LABORATORY PRESS;            JOSE ET AL., FUTURE MICROBIOL., vol. 4, 2009, pages 837 -          856;            GOULD ET AL., ANTIVIRAL RES., vol. 87, 2010, pages 111 -          124;            DECROLY E ET AL., NATURE REVIEWS, vol. 10, 2012, pages 51          - 65;            RAMANATHAN A. ET AL., NUCLEIC ACIDS RES, vol. 44, no. 16,          2016, pages 7511 - 7526;            HOLTKAMP ET AL., BLOOD, vol. 108, 2006, pages 4009 -          4017;            KOPPEL, D., J. CHEM. PHYS., vol. 57, 1972, pages 4814 -          4820;            KACZMAREK, J. C. ET AL., GENOME MEDICINE, vol. 9, 2017,          pages 60;            ""Remington's Pharmaceutical Sciences"", 1985, MACK          PUBLISHING CO.;            MASEK T ET AL., ANAL BIOCHEM, vol. 336, 2005, pages 46 -          50;            BAIERSDORFER M. ET AL., MOL THER NUCLEIC ACIDS, vol. 15,          no. 15, 2019, pages 26 - 35;            KARIKO K ET AL., MOL. THER., vol. 20, 2012, pages 948 -          953;            MAHIN AJ ET AL., METHODS MOL BIOL, vol. 1428, 2016, pages          297 - 306;            HOFFMANN ET AL., CELL, 2020CN116585464-A  CHUNXI ZENG ET AL.:          ""Leveraging mRNA Sequences and Nanoparticles to Deliver          SARS-CoV-2 Antigens In Vivo"", ADV MATER, vol. 32, no. 40,          5 April 2020 (2020-04-05), pages          2004452,relevantClaims[1-22];  JENNIFER L. HYDE ET          AL.: ""A viral RNA structural element alters host          recognition of non-self RNA"", SCIENCE, vol. 343, no.          6172, 14 February 2014 (2014-02-14), pages          783,relevantClaims[1-22]US11779659-B2            Andries, O et al., N(I)-methylpseudouridine-incorporated          mRNA outperforms pseudouridineincorporated mRNA by          providing enhanced protein expression and reduced          immunogenicity in mammalian cell lines and mice, J          Control Release, 217:337-44 (2015).;            Bouloy, M. et al., Both the 7-methyl and the 2-0-methyl          groups in the CAP of mRNA strongly influence its ability          to act as primer for influenza virus RNA transcription,          Proceedings of The National Academy of Sciences of the          USA, 77(7):3952-3956 (1980).;            Cullis, P. and Hope, M., Lipid Nanoparticle Systems for          Enabling Gene Therapies, Mol Ther, 25(7):1467-1475          (2017).;            Furuichi, Y. and Shatkin, A., Viral and cellular mRNA          capping: past and prospects, Adv Virus Res, 55:135-84          (2000).;            Furuichi, Yasuhiro, Caps on Eukaryotic mRNAs, John Wiley          & Sons, pp. 1-12 (Jul. 2014).;            Gallie, Daniel R., The cap and poly(A) tail function          synergistically to regulate mRNA translational          efficiency, Genes Dev, 5(11):2108-16 (1991).;            Gebre, M. S. et al., Optimization of Non-Coding Regions          Improves Protective Efficacy of an mRNA SARS-CoV-2          Vaccine in Nonhuman Primates, bioRxiv, 36 pages          (2021).;            Habjan, M. et al., Sequestration by IFIT1 impairs          translation of 20-unmethylated capped RNA, PLOS          Pathogens, 9(10):e1003663 (2013).;            Hassett, K. et al., Optimization of Lipid Nanoparticles          for Intramuscular Administration of mRNA Vaccines, Mol          Ther Nucleic Acids, 15:1-11 (2019).;            Huang, Q. et al., A single-dose mRNA vaccine provides a          long-term protection for hACE2 transgenic mice from          SARS-CoV-2, Nat. Comm., 12(776):1-10 (2021).;            Hyde, J. L. et al., A viral RNA structural element alters          host recognition of nonself RNA, Science,          343(6172):783-787 (2014).;            Hyde, J. L. et al., Supplementary Information, Science,          343(6172):783-787 (2014).;            International Search Report for PCT/EP2021/060508, 7          pages (dated Aug. 5, 2021).;            Ivens, I. et al., PEGylated Biopharmaceuticals: Current          Experience and Considerations for Nonclinical          Development, Toxicol Pathol., 43(7):959-83          (2015).;            Jackson, N. A. C. et al., The promise of mRNA vaccines: a          biotech and industrial perspective, NPJ Vaccines,          5(11):1-6 (2020).;            Kauffman, K. et al., Materials for non-viral          intracellular delivery of messenger RNA therapeutics, J          Control Release, 240:227-234 (2016).;            Kozma, G. T. et al., Pseudo-anaphylaxis to Polyethylene          Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and          Complement Activation in a Porcine Model of Human          Infusion Reactions, ACS Nano, 13:9315-9324          (2019).;            Kurimoto, S. et al., PEG-OligoRNA Hybridization of mRNA          for Developing Sterically Stable Lipid Nanoparticles          toward In Vivo Administration, Molecules, 24(7):1303, 16          pages (2019).;            Laczko, D. et al., A Single Immunization with          Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular          and Humoral Immune Responses against SARS-CoV-2 in Mice,          Immunity, 53(4):724-732 (2020).;            McCown, P. J. et al., Naturally occurring modified          ribonucleosides, Wires RNA, 11(e1595):1-71          (2020).;            Pardi, N. et al., Characterization of HIV-1          Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus          Macaques, Molecular Therapy: Nucleic Acids, 15:36-47          (2019).;            Pardi, N. et al., mRNA vaccinesa new era in vaccinology,          Nat Rev Drug Discov, 17(4):261-279 (2018).;            Pardi, N. et al., Nucleoside-modified mRNA immunization          elicits influenza virus hemagglutinin stalk-specific          antibodies, Nat Commun., 22;9(1):3361 (2018).;            Pardi, N. et al., Zika virus protection by a single          low-dose nucleoside-modified mRNA vaccination, Nature,          543(7644):248-251 (2017).;            Pardi, Norbert, COVID-19 Symposium: Nucleoside-modified          mRNA Vaccines Against SARS-CoV-2, Penn Medicine, 10 pages          (2020).;            Ramanathan, A. et al., mRNA capping: biological functions          and applications, Nucleic Acids Research, 44(16)          7511-7526 (2016).;            Reichmuth, A. et al., mRNA vaccine delivery using lipid          nanoparticles, Ther. Deliv., 7(5):319-334          (2016).;            Sahin, U. et al., mRNA-based therapeuticsdeveloping a new          class of drugs, Nat Rev Drug Discov., 13(10):759-80          (2014).;            Schlake, T. et al., Developing mRNA-vaccine technologies,          RNA Biol, 9(11):1319-30 (2012).;            Written Opinion for PCT/EP2021/060508, 11 pages (dated          Aug. 5, 2021).;            Xia, X., Detailed Dissection and Critical Evaluation of          the Pfizer/BioNTech and Moderna mRNA Vaccines, Vaccines,          9(734):1-19 (2021).;            Zeng, C. et al., Leveraging mRNAs sequences to express          SARS-CoV-2 antigens in vivo, bioRxiv, 16 pages (2020),          Retrieved from the Internet:          URL:https://www.biorxiv.org/content/10.1101/2020.04.01.019877vl.full.pdf.;            Zeng, C. et al., Leveraging mRNAs sequences to express          SARS-CoV-2 antigens in vivo, Supplementary Information,          bioRxiv, 13 pages (2020).;            Zhao, L. et al., Nanoparticle vaccines, Vaccine,          32(3):327-37 (2014).;            U.S. Appl. No. 17/233, 396, filed Apr. 16, 2021, Allowed,          Issue Fee paid.;            U.S. Appl. No. 17/698, 829, filed Mar. 18, 2022,          Pending.;            U.S. Appl. No. 17/699, 035, filed Mar. 18, 2022,          Pending.;            [No Author Listed], Assessment ReportComirnaty, 140 pages          Jan. 19, 2021.;            CureVac's COVID-19 vaccine (CVnCoV): Withdrawal from the          rolling review process, Oct. 12, 2021, European Medical          Agency (EMA),          ema.europa.eu/en/medicines/human/withdrawn-applications/curevacs-covid-19-vaccine-cvncov,          3 pages.;            Den Dunnon, J.T. and Antonarakis, S.E., Nomenclature for          the description of sequence variations, Human Genet.,          109(1):121-124 (2001).;            International Nonproprietary Names for Pharmaceautical          Substances (INN), WHO Drug Information, vol. 33, No. 3,          139 pages, (2019).;            Jeong, D. et al.,          Assemblies-of-putative-SARS-CoV2-spike-encoding-mRNA-sequences-for-vaccines-BNT-162b2-and-mRNA-1273,          4 pages (2021).;            Orlandini Von Niessen, A. G. et al., Improving mRNA-Based          Therapeautic Gene Delivery by Expression-Augmenting 3          UTRs Identified by Cellular Library Screening, Molecular          Therapy Original Article, 27(4):824-836 (2019).;            Sinopeg Data Sheet, 10 pages (2022).;            WHO Drug Information 2021, vol. 35, 2 [full issue], WHO          Drug Information 35(2):270-605 (2021).;            Grudezen, E. et al., Differential Inhibition of mRNA          Degradation Pathways by Novel Cap Analogs, The Journal of          Biological Chemistry, 281(4):1857-1867 (2006).;            Iadevaia, V. et al., All translation elongation factors          and the e, f, and h subunits of translation initiation          factor 3 are encoded by 5-terminal oligopyrimidine (TOP)          mRNAs, RNA, 14:1730-1736 (2008).;            Ishikawa, M. et al., Preparation of eukaryotic mRNA          having differently methylated adenosine at the 5-terminus          and the effect of the methyl group in translation,          Nucleic Acids Symposium Series, Oxford, 53:129-130          (2009).;            Koukhareva I. I. and Lebedev, A. V., Chemical Route to          the Capped RNAs, Nucloesides, Nucleotides and Nucleic          Acids, 23(10:1667-1780 (2004).;            Kuhn, A. et al., Phosphorothioate cap analogs increase          stability and translational efficiency of RNA vaccines in          immature dentritic cells and induce superior immune          responses in vivo, Gene Therapy, 17:961-971          (2010).;            Limbach, P. A. et al., Summary: the modified nucleosides          of RNA, Nucleic Acids Research, 22(12):2183-2196          (1994).;            Selisko, B. et al., Biochemical characterization of the          (nucleoside-2O)-methyltransferase activity of dengue          virus protein NS5 using purified capped RNA          oligonucleotides (7Me)GpppAC(n) and GpppAC(n), Journal of          General Virology, 91(Pt1):112-121 (2010).",105730-0-0-0 K M;  K M; 93537-0-0-0 K M; 184612-0-0-0 K M; 8349-1-0-0 K M; 184587-0-0-0 K M; 184611-0-0-0 K M; 97942-0-0-0 K M; 485836-0-0-0 K M; 478694-0-0-0 K M; 101485-0-0-0 K M; 2615841-0-0-0 K M; 114126-0-0-0 K M; 322430-0-0-0 K M;  K M; 97855-0-0-0 K M; 444-0-0-0 ; 2615841-0-0-0 CL USE,226290401 K M; 226290402 K M,,RA012P K M; RC58F9 K M; R06520 K M; RA0DG3 K M; RA01PM K M; R00148 K M; RA00C8 K M; RA00H1 K M; RA04OB K M; RA5WRV K M; RA5RK2 K M; RA00SE K M; RBEON7 K M; RA0DNM K M; RA0KDA K M; RA4HS9 K M; RBEQHU K M; RA02SP K M; R00351 ,0148-S
WO2024054769-A1,Preparing monocyte and macrophage preparation used            e.g. in immunotherapy by e.g. culturing cluster of            differentiation enriched hematopoietic stem and            progenitor cell (HSPC) in expansion culture medium on            solid phase to produce expanded HSPC,BREMPELIS K;  DELANEY C;  VON EUW E;  KREUSER S;  STOLTZMAN C,DEVERRA THERAPEUTICS INC (DEVE-Non-standard);  BREMPELIS K (BREM-Individual),2024264225,"   NOVELTY - Preparing a monocyte and/or macrophage                preparation comprises selecting many umbilical cord                blood or placental blood cells, preparing enriched                cluster of differentiation (CD)34+ hematopoietic                stem and progenitor cells (HSPCs) that are depleted                of red blood cells and T cells, culturing the CD34+                enriched HSPCs in an expansion culture medium                comprising interleukin (IL)-3, IL-6, thrombopoietin                (TPO), Flt-3 ligand (Flt-3L) and stem cell factor                (SCF) on a solid phase for a sufficient time to                produce expanded HSPCs, and culturing the expanded                HSPCs in an expansion and monocyte differentiation                culture medium comprising Flt-3L, IL-3, and                monocyte colony stimulating factor (M-CSF) and/or                granulocyte-macrophage colony stimulating factor                (GM-CSF) on a solid phase for a sufficient time to                produce expanded HSPCs and monocytes, and the cell                composition comprising 40-80 % HLA-DR+CD11b+cells                and 20-60% other myeloid cells, and the cell                population also comprising 70%                CD14+CD16+cells.    USE - The method is useful for preparing a monocyte                and/or macrophage preparation which is useful in:                immunotherapy, where the immunotherapy includes a                therapeutic agent against tumor cells, an                antimicrobial agent, autoimmune indications, or a                therapeutic in repair of injured tissue; delivery                of small molecules, plasmid DNA, oncolytic virus,                or other therapeutics (all claimed); and treating                cancer, or infectious, inflammatory, and/or                autoimmune diseases. Test details are described but                no results given.    ADVANTAGE - The method: provides improved by pre-loading                the cells with an oncolytic virus or other                immunomodulatory molecule for delivery to a solid                tumor; and offers efficiency of separation,                cytotoxicity of the methodology, ease and speed of                performance, and the necessity for sophisticated                equipment and/or technical skill.    DETAILED DESCRIPTION - Preparing a monocyte and/or macrophage                preparation comprises selecting many umbilical cord                blood or placental blood cells, preparing enriched                cluster of differentiation (CD)34+ hematopoietic                stem and progenitor cells (HSPCs) that are depleted                of red blood cells and T cells, culturing the CD34+                enriched HSPCs in an expansion culture medium                comprising interleukin (IL)-3, IL-6, thrombopoietin                (TPO), Flt-3 ligand (Flt-3L) and stem cell factor                (SCF) on a solid phase for a sufficient time to                produce expanded HSPCs, where the expanded HSPCs do                not substantially differentiate into CD11b+human                leukocyte antigen (HLA)-DR+ cells during the                expansion, and culturing the expanded HSPCs in an                expansion and monocyte differentiation culture                medium comprising Flt-3L, IL-3, and monocyte colony                stimulating factor (M-CSF) and/or                granulocyte-macrophage colony stimulating factor                (GM-CSF) on a solid phase for a sufficient time to                produce expanded HSPCs and monocytes, and the cell                composition comprising 40-80 % HLA-DR+ CD11b+cells                and 20-60% other myeloid cells, and the cell                population also comprising 70% CD14+CD16+cells, or                culturing the expanded HSPCs and monocytes in a                macrophage differentiation culture medium                comprising granulocyte-macrophage colony                stimulating factor or M-CSF and serum or a                non-animal sourced serum replacement for a                sufficient time to produce a macrophage cell                composition and/or preparation comprising 60-90 %                HLA-DR+CD11b+cells and 10-40% other myeloid cells,                and the cell population also comprising 7%                CD14+CD16-cells, 66% CD14+CD16+cells and 5%                CD14-CD16+ cells, where the macrophages can be                activated by pathogens or tumor cells. An                INDEPENDENT CLAIM is also included for a                composition comprising the monocyte and/or                macrophage composition and/or preparation produced                by above method. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E99;  B04-E07;  B04-E12;  B04-E13;  B04-F02B;  B04-F02C;  B04-F04B2;  B04-G01;  B04-H02C;  B04-H02G;  B04-H04B;  B04-H04C;  B04-H05;  B04-H07;  B04-H16;  B04-H20A;  B04-H21;  B04-L05A;  B04-N02;  B04-N12;  B11-A04A;  B11-C05;  B14-A01;  B14-A02;  B14-A04;  B14-G02D;  B14-H01;  B14-S21;  D05-H99;  D05-H08B;  D05-H19C,A61K-035/17;  A61K-039/00;  A61P-035/00,WO2024054769-A1   14 Mar 2024   A61K-035/17   202425Pages: 103   English,WO2024054769-A1    WOUS073151    30 Aug 2023,,US404486P    07 Sep 2022,WO2024054769-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2024054769-A1 -- US20180010096-A1   ;  WO2021108769-A1   DEVERRA THERAPEUTICS INC (DEVE-Non-standard)   BAI T,  CHANDRASEKARAN D,  PRIEVE M,  DELANEY C",,87032-0-0-0 K M; 86886-0-0-0 K M; 86944-0-0-0 K M; 94297-1-0-0 K M; 95154-0-0-0 K M; 97946-0-0-0 K M; 97951-0-0-0 K M; 97959-0-0-0 K M; 25-0-0-0 K M; 114126-0-0-0 K M; 114760-0-0-0 K M; 130323-0-0-0 K M; 123410-0-0-0 K M; 274553-0-0-0 K M; 1149809-0-0-0 K M; 1556529-1-0-0 K M; 1015595-0-0-0 K M; 184602-0-0-0 K M; 569339-0-0-0 K M; 1556528-1-0-0 K M; 1149810-0-0-0 K M; 1585912-1-0-0 K M; 94298-1-0-0 K M; 1556530-1-0-0 K M; 1556531-1-0-0 K M; 1556533-1-0-0 K M; 1556532-1-0-0 K M; 201562-0-0-0 K M; 109661-0-0-0 K M; 1536600-0-0-0 K M; 1870458-0-0-0 K M; 520167-0-0-0 K M; 162188-0-0-0 K M; 1281342-0-0-0 K M; 485836-0-0-0 K M; 111285-0-0-0 K M; 114367-0-0-0 K M; 97940-0-0-0 K M; 196443-0-0-0 K M; 114365-0-0-0 K M; 97961-0-0-0 K M; 97957-0-0-0 K M; 97954-0-0-0 K M; 97925-0-0-0 K M; 1149809-0-0-0 CL USE; 1556529-1-0-0 CL USE; 1015595-0-0-0 CL USE; 1556528-1-0-0 CL USE; 1149810-0-0-0 CL USE; 1585912-1-0-0 CL USE; 1556530-1-0-0 CL USE; 1556531-1-0-0 CL USE; 1556533-1-0-0 CL USE; 1556532-1-0-0 CL USE; 1536600-0-0-0 CL USE; 1870458-0-0-0 CL USE; 1281342-0-0-0 CL USE,,,RA0JLY K M; R24039 K M; RA02YD K M; RA05NO K M; RA02JJ K M; RA007V K M; R06364 K M; R16207 K M; RA04J4 K M; RA01IL K M; R00274 K M; RA0DNM K M; RA0KDA K M; RA0QMT K M; RBZ0WT K M; RA0JW7 K M; RA2528 K M; RAJEAW K M; RAS1WL K M; RAGLKB K M; RA02DV K M; RA8F98 K M; RAS1WK K M; RAJEAX K M; RASOSR K M; RA1J5S K M; RAS1WM K M; RAS1WN K M; RAS1WP K M; RAS1WO K M; RA0124 K M; RA0L0Q K M; RA5JKL K M; RARMJD K M; RB0T1G K M; RA6MMB K M; RA04OC K M; RAM5H1 K M; RA5WRV K M; RA04OD K M; RA09L5 K M; RA04OA K M; RA0IQE K M; RA03SD K M; RA09LE K M; RA04OE K M; RA03SC K M; R16255 K M; RA01ZP K M,0274-S
WO2022246781-A1;  CN117377776-A,"Nucleic acid detection system based on            electrowetting CRISPR has electrowetting chip module            comprises reagent storage area, biochemical reaction            area, fluorescent photographing area and driving system            and micro-channels between the areas",ZHANG W;  JIANG Y;  WANG J;  XI F;  LIU C;  WANG W;  CUI L;  JI Z;  GUO M;  ZHANG D;  REN H;  LAN X;  WANG O;  WANG X;  LAN Q,BGI SHENZHEN (BGIG-C);  SHENZHEN BGI LIFE SCI INST (BGIG-C),2022E8849K,"   NOVELTY - Nucleic acid detection system based on                electrowetting clustered regularly interspaced                short palindromic repeats (CRISPR) comprises an                electrowetting chip module, a CRISPR reaction                module, a signal capture module and a control and                analysis module. The electrowetting chip module                comprises a reagent storage area, a biochemical                reaction area, a fluorescent photographing area and                a driving system, and micro-channels between the                areas. The CRISPR reaction module comprises a                CRISPR reaction solution containing a fluorescent                probe, a protein reaction solution containing                Cas12a, and a gRNA reaction solution containing                gRNA. The protein reaction liquid, gRNA reaction                liquid and CRISPR reaction liquid comprise a                surfactant and an enzyme buffer solution. The                control and analysis module drives the nucleic acid                sample to be tested and the CRISPR reaction module                through the driving system to enter into the                biochemical reaction area through the                microchannel.    USE - The nucleic acid detection system is useful                for detecting nucleic acid of non-diagnostic                purpose.    ADVANTAGE - The nucleic acid detection system can achieve                high sensitivity, high throughput, simple, fast and                efficient nucleic acid detection.    DETAILED DESCRIPTION - Nucleic acid detection system based on                electrowetting clustered regularly interspaced                short palindromic repeats (CRISPR) comprises an                electrowetting chip module, a CRISPR reaction                module, a signal capture module and a control and                analysis module. The electrowetting chip module                comprises a reagent storage area, a biochemical                reaction area, a fluorescent photographing area and                a driving system, and micro-channels between the                areas. The CRISPR reaction module comprises a                CRISPR reaction solution containing a fluorescent                probe, a protein reaction solution containing                Cas12a, and a gRNA reaction solution containing                gRNA. The protein reaction liquid, gRNA reaction                liquid and CRISPR reaction liquid comprise a                surfactant and an enzyme buffer solution. The                control and analysis module drives the nucleic acid                sample to be tested and the CRISPR reaction module                through the driving system to enter into the                biochemical reaction area through the microchannel.                The nucleic acid sample to be detected and the                CRISPR reaction module are mixed in the biochemical                reaction area and generate fluorescence signal                after reaction. The fluorescent signal is captured                and collected by the signal capturing module in the                fluorescent photographing area and then is input                into the control and analysis module for analysis.                INDEPENDENT CLAIMS are also included for:    (1) detecting nucleic acid for non-diagnostic                purposes using the nucleic acid detection system                comprising (1) controlling and analyzing module                through the driving system drives the CRISPR                reaction module and the nucleic acid sample to be                tested into the electric soaking chip module, and                respectively forming liquid drop, e.g. the CRISPR                reaction liquid in the CRISPR reaction module, the                protein reaction liquid and gRNA reaction liquid                respectively form droplets, (2) mixing the liquid                drop formed by the CRISPR reaction module and the                liquid drop formed by the nucleic acid sample to be                detected, generating fluorescence signal after                reaction in the biochemical reaction area, (3)                capturing and collecting the fluorescence signal by                the signal capturing module in the fluorescence                photographing region and then analyzing by the                input control and analysis module, when the                intensity of the fluorescence signal exceeds the                negative control, judging that the target nucleic                acid exists, preferably, the (1) further comprises                (02) amplifying the nucleic acid sample to be                detected in the biochemical reaction area by the                nucleic acid amplification reaction module, thus                (1) forming liquid drops on the amplified nucleic                acid sample to be detected, more preferably, the                (02) further comprises (01) extracting the nucleic                acid from the sample to be detected in the magnetic                bead control area by the nucleic acid extraction                reaction, further preferably, in the (02), adding                nucleic acid amplification reaction module in the                same liquid drop of the nucleic acid sample to be                tested for nucleic acid amplification;    (2) an electronic device, comprising a memory                and a processor, the memory includes a computer                program stored in it, i.e. operable on a processor,                where when the processor executes the computer                program to realize the method for detecting nucleic                acid, the non-diagnostic purpose; and    (3) a computer-readable storage medium                comprising a set of instructions for detecting                nucleic acid of non-diagnostic purpose. ",,,"A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  T01 (Digital Computers)",A10-E07C;  A10-E08A;  A10-E08B;  A12-V03C2;  B04-B04D5;  B04-B04G;  B04-C03C;  B04-E01A;  B04-E01B;  B04-E05;  B04-E13;  B04-E99;  B04-F11;  B04-L01;  B05-A01B;  B05-C07;  B06-A02;  B06-A03;  B06-S;  B10-A17;  B10-B01B;  B10-B03B;  B10-C02;  B10-E04C;  B11-C07B2;  B11-C07B3;  B11-C07B7;  B11-C08E3;  B11-C08E6;  B11-C08F8;  B11-C11;  B12-K04F;  D05-H09;  D05-H18B;  D05-H19C;  D05-H99;  T01-S03,C12M-001/00;  C12Q-001/6851,WO2022246781-A1   01 Dec 2022   C12Q-001/6851   202201Pages: 47   Chinese;  CN117377776-A   09 Jan 2024   C12Q-001/6851   202407   Chinese,WO2022246781-A1    WOCN096620    28 May 2021;   CN117377776-A    CN80098529    28 May 2021,CN117377776-A PCT application Application WOCN096620;   CN117377776-A Based on Patent WO2022246781,CN80098529    28 May 2021;  WOCN096620    28 May 2021;  CN80098529    22 Nov 2023,WO2022246781-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,"WO2022246781-A1 -- CN107828874-A   UNIV SOUTHEAST (UYSE)   WANG J,  ZHANG B;  CN110387405-A   ZHEJIANG SHANCE HEQISHI BIOTECHNOLOGY CO (ZHEJ-Non-standard)   CHENG Q,  SUN W;  CN110885877-A   UNIV XIAMEN (UYXI)   LI B,  YANG C,  ZHANG R,  SUN Z,  LIN K,  GUO J,  HONG X;  CN111704994-A   UNIV EAST CHINA SCI & TECHNOLOGY (UYEC)   ZHANG L,  WANG H,  GU Z,  LIU G,  YAN B,  HUANG S,  TIAN X,  HUANG G,  LIU J,  HAN Z;  CN112029653-A   UNIV ZHEJIANG (UYZH)   YE Z,  WU C,  YING Y","WO2022246781-A1  BROUGHTON, J.P. ET          AL.: ""CRISPRCas12-based detection of SARS-CoV-2"", NAT          BIOTECHNOL, vol. 38, 16 April 2020 (2020-04-16),          XP037187541, DOI:          10.1038/s41587-020-0513-4,relevantClaims[1-10],relevantPassages[pp.          870-874];  BAO YAOFEI, QIANRU          XUE, HAIPING WU, BINGJIE ZOU, QINXIN SONG, GUOHUA ZHOU:          ""Advances in point-of-care testing for new corona virus          nucleic acid"", JOURNAL OF CHINA PHARMACEUTICAL          UNIVERSITY, NAJING, CN, vol. 51, no. 6, 31 December 2020          (2020-12-31), CN , pages 635 - 645, XP093008364, ISSN:          1000-5048, DOI:          10.11665/j.issn.1000-5048.20200601,relevantClaims[1-10],relevantPassages[pp.          635-645]",104477-1-0-0 K M; 131343-0-0-0 K M; 900-0-0-0 K M; 490-0-0-0 K M; 131086-0-1-0 K M; 3330-0-0-0 K M; 422-0-1-0 K M; 114-0-0-0 K M; 849-0-0-0 K M; 1826583-0-0-0 D K M; 90045-0-0-0 D K M; 444-0-0-0 ; 1826583-0-0-0 CL USE,,05935,R01869 K M; R08416 K M; R02044 K M; RA0GM6 K M; R00113 K M; R07968 K M; R00195 K M; R10859 K M; RA6LSL K M; R01706 K M; R00419 K M; RAXTHQ D K M; R15410 D K M; R00351 ,1869-S; 2044-S; 0113-S; 0418-S; 0195-S; 0956-S; 1706-S; 0419-S
WO2020245808-A1;  CA3142670-A1;  KR2022018036-A;  EP3980558-A1;  JP2022535584-W;  US2022307080-A1;  EP3980558-A4,"New nucleic acid molecule, or its analog            comprising first nucleic acid sequence, and second            nucleic acid sequence, useful for amplifying target            nucleic acid sequence",UNRAU P J;  ABDOLAHZADEH A,UNIV FRASER SIMON (UFSI-C);  UNIV FRASER SIMON (UFSI-C);  UNIV FRASER SIMON (UFSI-C),2020C3011E,"   NOVELTY - A nucleic acid molecule or its analog is new.                The nucleic acid molecule or its analog comprises                (a) a first nucleic acid sequence capable of                hybridizing to at least a portion of a target                nucleic acid sequence, or its reverse-complement,                and an aptamer-encoding template sequence, and (b)                a second nucleic acid sequence capable of                hybridizing to at least a portion of a target                nucleic acid sequence, or its reverse-complement,                where the 5' end of the second nucleic acid                sequence is covalently attached to the 3' end of                the first nucleic acid sequence, and the 3' end of                the second nucleic acid sequence does not                substantially hybridize to the first nucleic acid                sequence. The aptamer-encoding template sequence is                positioned at the 3' end of the first nucleic acid                sequence.    USE - The nucleic acid molecule or its analog is                useful for amplifying a target nucleic acid                sequence.    ADVANTAGE - The nucleic acid molecule or its analog                amplifies target nucleic acid sequence in a simple,                cost-effective, accurate and rapid manner with high                sensitivity.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) composition comprising a first nucleic                acid molecule;    (2) kit comprising the nucleic acid molecule,                or the composition together with instructions for                amplification of a target nucleic acid sequence;                and    (3) method for amplifying a target nucleic                acid sequence involves (i) providing a sample                suspected of containing a target nucleic acid                molecule, (ii) providing a first nucleic acid                molecule, (iii) providing a second nucleic acid                molecule capable of hybridizing to at least a                portion of the target nucleic acid sequence, or its                complement, and comprising a first RNA polymerase                promoter sequence, and (iv) performing a first                amplification reaction comprising the target                nucleic acid molecule and first primer pair to                obtain a first amplification product, where the                first amplification product comprises first                sequence of target nucleic acid sequence, and the                first and second nucleic acid molecules form a                first primer pair capable of amplifying a first                sequence of the target nucleic acid sequence. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E99;  B04-E02;  B04-E03;  B04-E05;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  C04-E99;  C04-E02;  C04-E03;  C04-E05;  C11-C07B3;  C11-C08E3;  C11-C08F8;  C12-K04D;  C12-K04F;  D05-H99;  D05-H09;  D05-H12A;  D05-H18B,C12N-015/11;  C12P-019/34;  C12Q-001/6844;  C12Q-001/6876;  C12Q-001/6853;  C12Q-001/689;  C12Q-001/70;  C12N-015/115,WO2020245808-A1   10 Dec 2020   C12Q-001/6876   202004Pages: 100   English;  CA3142670-A1   10 Dec 2020   C12Q-001/6876   202203   English;  KR2022018036-A   14 Feb 2022   C12Q-001/6876   202216   ;  EP3980558-A1   13 Apr 2022   C12Q-001/6876   202231   English;  JP2022535584-W   09 Aug 2022   C12N-015/115   202264   Japanese;  US2022307080-A1   29 Sep 2022   C12Q-001/6853   202279   English;  EP3980558-A4   19 Jul 2023   C12Q-001/6876   202360   English,WO2020245808-A1    WOIB055348    07 Jun 2020;   CA3142670-A1    CA3142670    07 Jun 2020;   KR2022018036-A    KR700631    07 Jun 2020;   EP3980558-A1    EP819192    07 Jun 2020;   JP2022535584-W    JP572506    07 Jun 2020;   US2022307080-A1    US17616841    06 Dec 2021;   EP3980558-A4    EP819192    07 Jun 2020,CA3142670-A1 PCT application Application WOIB055348;   CA3142670-A1 Based on Patent WO2020245808;   KR2022018036-A PCT application Application WOIB055348;   KR2022018036-A Based on Patent WO2020245808;   EP3980558-A1 PCT application Application WOIB055348;   EP3980558-A1 Based on Patent WO2020245808;   JP2022535584-W PCT application Application WOIB055348;   JP2022535584-W Based on Patent WO2020245808;   US2022307080-A1 PCT application Application WOIB055348;   US2022307080-A1 Provisional Application US858874P,US858874P    07 Jun 2019;  WOIB055348    07 Jun 2020;  CA3142670    03 Dec 2021;  US17616841    06 Dec 2021;  KR700631    07 Jan 2022,WO2020245808-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      EP3980558-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN      EP3980558-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  ,,"WO2020245808-A1 -- WO2018198013-A1   CENT NAT RECH SCI (CNRS);  UNIV STRASBOURG (UYSB);  UNIV FRASER SIMON (UFSI);  US DEPT HEALTH & HUMAN SERVICES (USSH)   RYCKELYNK M,  AUTOUR A,  UNRAU P,  DOLGOSHEINA E,  JENG S C Y,  PANCHAPAKESAN S S S,  ABDOLAHZADEH A,  COJOCARU R,  FERRE DAMARE A,  TRACHMAN R;  EP3980558-A4 -- KR2014029825-A   KOREA ADVANCED INST SCI & TECHNOLOGY (KOAD)   JUNG C,  PARK H G,  PARK K S;  US7723078-B2   AKZO NOBEL NV (ALKU)   DEIMAN B A L M,  FRANTZEN I M,  STRIJP A M W;  WO2018075502-A1   ARIZONA BOARD OF REGENTS (UYAZ)   GREEN A,  MA D,  TANG A;  WO2018112350-A1   ARIZONA BOARD OF REGENTS (UYAZ)   GREEN A;  WO2018198013-A1   CENT NAT RECH SCI (CNRS);  UNIV STRASBOURG (UYSB);  UNIV FRASER SIMON (UFSI);  US DEPT HEALTH & HUMAN SERVICES (USSH)   RYCKELYNK M,  AUTOUR A,  UNRAU P,  DOLGOSHEINA E,  JENG S C Y,  PANCHAPAKESAN S S S,  ABDOLAHZADEH A,  COJOCARU R,  FERRE DAMARE A,  TRACHMAN R","WO2020245808-A1  AUFDEMBRINK, LM ET          AL.: ""Highly specific, multiplexed isothermal pathogen          detection with fluorescent aptamer readout"", BIORXIV, 19          February 2020 (2020-02-19), pages 1 - 17, XP055766716,          Retrieved from the Internet          &lt;URL:https://doi.org/10.1101/2020.02.18.954719&gt;,relevantClaims[1-66],relevantPassages[.          ***whole document*** ];  AMIR ABDOLAHZADEH,          ELENA V. DOLGOSHEINA, AND PETER J. UNRAU: ""RNA detection          with high specificity and sensitivity using nested          fluorogenic Mango NASBA"", RNA, vol. 25, 24 September 2019          (2019-09-24), pages 1806 - 1813, XP055766724, ISSN:          1469-9001,relevantClaims[1-66],relevantPassages[***whole          document*** ];  DATABASE NUCLEOTIDE          13 January 2020 (2020-01-13), ZHANG Y.-Z. ET AL.: ""Wuhan          Seafood Market Pneumonia Virus Isolate Wuhan-Hu-1,          Complete Genome"", XP055766743, Database accession no.          NC_045512,relevantClaims[34],relevantPassages[***whole          document*** ];  DOLGOSHEINA EV ET          AL.: ""Fluorophore-binding RNA aptamers and their          applications"", WIRES RNA, vol. 7, 2016, pages 843 - 851,          XP055487089, ISSN: 1757-7012, DOI:          10.1002/wrna.1383,relevantClaims[1-66]EP3980558-A4  S. FUKUDA ET AL:          ""Rapid and Sensitive Detection of Norovirus Genomes in          Oysters by a Two-Step Isothermal Amplification Assay          System Combining Nucleic Acid Sequence-Based          Amplification and Reverse Transcription-Loop-Mediated          Isothermal Amplification Assays"", APPLIED AND          ENVIRONMENTAL MICROBIOLOGY, vol. 74, no. 12, 15 June 2008          (2008-06-15), US, pages 3912 - 3914, XP055418123, ISSN:          0099-2240, DOI:          10.1128/AEM.00127-08,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  ZHANG LIU LI HOU          XUE XIA GENG ZHEN LOU YONG LIANG WAN KANG LIN HAO QIN ET          AL: ""Combination of Loop-Mediated Isothermal          Amplification Assay and Nested PCR for Detection of          Borrelia burgdorferi sensu lato in Human Serum Samples"",          ?????????????, 1 January 2015 (2015-01-01), United          States, pages 312 - 315, XP055320897, Retrieved from the          Internet          &lt;URL:http://www.besjournal.com/Articles/Archive/2015/No4/201505/P020150512322006188037.pdf&gt;          DOI:          10.3967/bes2015.044,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  AMIR ABDOLAHZADEH          ET AL: ""RNA detection with high specificity and          sensitivity using nested fluorogenic Mango NASBA"", RNA,          vol. 25, 24 September 2019 (2019-09-24), pages 1806 -          1813, XP055766724, DOI:          10.1261/rna,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            See also references of WO 2020245808A1",,,,,
WO2024097397-A1,"New isolated polynucleotide encoding            ruminal-associated antigens, or fragments, variants or            variant fragments, used e.g. to reduce methane            emissions from animals e.g. ruminants, and to vaccinate            animals against ruminal-associated antigens",RAJANIEMI H;  EROSHENKO N;  KEAVENEY M;  SMITH R;  WEBSTER E;  GILL T;  JAMMEH K;  DHAR N;  BACKMAN K;  DAVILA PASILLAS D D J;  HUANG J S;  ROWE K;  LOPEZ SAUCEDA A L;  RADZINSKI N P;  QIN T,HELIX NANOTECHNOLOGIES INC (HELI-Non-standard),202448279S,"   NOVELTY - Isolated polynucleotide encoding at least one                ruminal-associated antigens, or their fragments,                variants or variant fragments, is new.    USE - The polynucleotide, polypeptide or composition                is useful for: reducing methane emissions from                animals e.g. ruminants; administering to (e.g.                vaccination of) an animal, where the animal is a                ruminant or a domestic animal (all claimed); and                vaccinating animals e.g. ruminants, against                ruminal-associated antigens. Test details are                described but no results given.    ADVANTAGE - The polynucleotide: reduces methane emissions                from the animal by at least 5%, preferably at least                90%, as compared to an otherwise comparable animal                not administered the composition or administered a                different composition; reduces a population of                microorganisms in the animal, as compared to an                otherwise comparable animal not administered the                composition or administered a different                composition, where the microorganisms is a                methanogen, optionally comprising at least one of                the clades Methanobrevibacter, Methanosphaera,                Methanobacterium, Methanosarcinales,                Methanomicrobiales, Methanothermobacter, Candidatus                Methanomethylophilus, and Thermoplasmatales,                preferably e.g. Methanobrevibacter ruminantium,                Methanobrevibacter smithii, Methanosphaera                stadtmanae, Methanosarcina mazei,                Methanobrevibacter thaueri, Methanosarcina                soligelidi, Methanothermobacter thermautotrophicus,                Methanococcus aeolicus, Methanocaldococcus                jannaschii, Methanococcus voltae, Methanococcus                vannielii, Methanococcus maripaludis, Methanopyrus                kandleri, Methanocorpusculum labreanum, and                Methanococcoides burtonii; increases a growth rate                of the animal including a daily increase in weight                of the animal by at least 5%, preferably at least                90% as compared to the growth rate of an otherwise                comparable animal not administered the composition                or administered a different composition; results in                reduced abundance of at least one microorganisms                (e.g. methanogens) in a digestive tract of the                animal, as compared to an otherwise comparable                animal not administered the composition, or                administered a different composition; can increase                the energy efficiency of animals, which in turn,                animals (e.g. ruminants) require less food,                experience an increase in muscle mass, and/or have                improved overall health, hence can lead to lower                costs for raising animals and/or increased revenue                from the sale of animals or meat obtained from such                animals; and increases digestion efficiency                (including rate of weight gain, weight to intake                relationship, or milk quality), which decreases                digestion-related disorders in animals e.g.                ruminants.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    a polypeptide encoded by the                polynucleotide;    a composition (C1) comprising at least one                polyribonucleotides, or the polypeptide;    reducing methane emissions from animals e.g.                ruminants, comprising administering the composition                (C1), to a cell, tissue or an animal; and    a composition (C2) comprising the isolated                polynucleotide, or the composition (C1). ",,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  C02 (Heterocyclic.);  ;  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-B03E;  B04-C01;  B04-E01;  B04-E02J;  B04-E03J;  B04-E99;  B04-F0100E;  B14-S03A;  B14-S11;  B14-S12;  B14-S18;  C04-B03E;  C04-C01;  C04-E02J;  C04-E03J;  C04-E99;  C04-F0100E;  C14-S11;  C14-S12;  C14-S18;  D05-H12A;  D05-H99,A61K-039/02;  A61P-031/04;  C12N-015/11;  C12N-015/85,WO2024097397-A1   10 May 2024   C12N-015/11   202448Pages: 259   English,WO2024097397-A1    WOUS036773    03 Nov 2023,,US422312P    03 Nov 2022,WO2024097397-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,,, K M; 105636-1-0-0 K M; 130661-1-0-0 K M; 200757-0-0-0 M N; 184611-0-0-0 K M; 93605-0-0-0 N; 105730-0-0-0 N; 200757-0-0-0 CL NEW USE,,,RCOQHZ K M; R07152 K M; R07151 K M; RA00GT M N; RA00H1 K M; RA00NS N; RA012P N,
WO2024058975-A1,"New phenanthrene compounds are 3C like protease            inhibitors used to treat microorganism infection or            retarding spread of microorganism, and disorders e.g.            diabetes, and obesity",SHAHEEN E;  DRANEY D;  BONNER-BROWN S,ULTRA LLC (ULTR-Non-standard),2024301164,"   NOVELTY - Phenanthrene compounds (I) are new.    USE - (I) are useful for treating microorganism                infection or retarding the spread of the                microorganism in subject (claimed); treating                disorders e.g. diabetes, diabetic complications,                dyslipidemia, obesity, and metabolic syndromes; and                skin-care preparations, cosmetic personal care                preparations, intimate hygiene preparations, and                foot care preparations.    ADVANTAGE - (I): has therapeutic or a prophylactic index                of greater than 3, preferably at least 15; kills or                slows the spread of the microorganism; improves the                stability of aqueous solution of the drug to                trigger drug release for drug delivery to improves                drug bioavailability and body fluid circulation                time to avoids drug degradation failure as well as                to improves efficacy.    DETAILED DESCRIPTION - Phenanthrene compounds of formula (I), and                their salts, are new.    R1-R4, R6, R7, R11, R12, R15, R16=1-10C alkyl,                1-10C alkylcarboxy, 1-10C hydroxyalkyl, 1-10C                alkyloxy-1-10C alkyl, 1-10C alkylamino-(1-10C)                alkyl, 1-10C aminoalkyl, aryl, 1-10C aminoalkyloxy,                1-10C amino alkylcarboxy, 1-10C                aminoalkylaminocarbonyl, 1-10C                aminoalkylcarboxamido (all optionally substituted),                H, hydroxy, 1-10C haloalkyl, 2-6C alkenyl, 2-6C                alkynyl, oxo, 1-10C azidoalkyloxy, 1-10C                cyanoalkyloxy, 1-10C guanidinoalkyl oxy, or 1-10C                guanidinoalkyl carboxy;    R5, R8, R9, R10, R13, R14=1-10C alkyl, 1-10C                aminoalkyl, aryl, 1-10C aminoalkyloxy, 1-10C                aminoalkylcarboxy, 1-10C aminoalkylaminocarbonyl                (all optionally substituted), H, hydroxy, 1-10C                hydroxyalkyl, 1-10C alkyloxy-(1-10C) alkyl, 1-10C                haloalkyl, 2-6C alkenyl, 2-6C alkynyl, oxo, 1-10C                azidoalkyloxy, 1-10C cyanoalkyloxy, 1-10C                guanidinoalkyloxy, or 1-10C                guanidinoalkylcarboxy;    L1=linking group; and    B1=biotin, desthiobiotin or biotin                mimetic.    An INDEPENDENT CLAIM is also included for                treating microorganism infection or retarding the                spread of the microorganism in subject comprising                contacting the microorganism with antimicrobial                amount of (I) or its salts, where (I) kills or                slows the spread of the microorganism.     ",,,"B01 (Steroids - including systems containing carbocyclic and/or heterocyclic rings fused onto the basic steroidal ring structure.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  C02 (Heterocyclic.);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).)",B04-E99;  B01-D02;  B04-C01;  B14-A01;  B14-A02;  B14-A04;  B14-D07C;  B14-E12;  B14-F06A;  C04-E99;  C04-C01;  C14-A01;  C14-A02;  C14-A04;  C14-D07C;  C14-E12;  C14-F06A;  D05-H99;  D08-B09A1,A61K-031/56;  A61P-031/04;  A61P-031/14;  C07J-041/00;  C07J-009/00,WO2024058975-A1   21 Mar 2024   C07J-041/00   202431Pages: 92   English,WO2024058975-A1    WOUS032261    08 Sep 2023,,US406667P    14 Sep 2022,WO2024058975-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2024058975-A1 -- US20080207574-A1   ;  US20170266206-A1   ;  US20180214472-A1   ;  US20180280550-A1   ;  WO2019211705-A1   REGIONAL CENT BIOTECHNOLOGY (REGI-Non-standard);  BAJAJ A (BAJA-Individual);  GUPTA S (GUPT-Individual);  MISHRA D (MISH-Individual);  KUMAR S (KUMA-Individual)   BAJAJ A,  GUPTA S,  MISHRA D,  KUMAR S",, N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N,230785601 N,00945; 00094,RDJV6O N; RDJV6P N; RDJV6Q N; RDJV6R N; RDJV6S N; RDJV6T N; RDJV6U N; RDJV6V N; RDJV6W N; RDJV6X N; RDJV6Y N; RDJV6Z N; RDJV70 N; RDJV71 N; RDJV72 N; RDJV73 N; RDJV74 N; RDJV75 N; RDJV76 N; RDJV77 N; RDJV78 N; RDJV79 N,
WO2024055273-A1,"New rabies immunogen nucleic acid expression            vector comprising untranslated region element, open            reading frame element encoding rabies virus            glycoprotein, polyadenylate tail element useful in            vaccine to prevent and treat rabies",XU J;  ZHANG X;  BAI S,UNIV ZHONG SHAN HOSPITAL FUDAN (UYZH-Non-standard),202430103H,"   NOVELTY - Rabies immunogen nucleic acid expression                vector comprising (a) 5'-untranslated region (UTR)                element from the 5' end to the 3' end; (b) an open                reading frame element encoding rabies virus                glycoprotein (RABV-G); (c) 3'-UTR element; (d) a                polyadenylate tail element with a total length of                more than 120 nt, which includes: multiple                adenylate strings, each adenylate string                independently containing n consecutive adenylate                strings, n is 10-80 an integer between, and the                total number of adenylates in multiple adenylate                strings is more than 100; a linker is located                between multiple adenylate strings, each of the                linkers independently contains no adenylate or only                contains 1 or 2 adenylate, is new.    USE - The vector is useful in vaccine and                preparation of products for preventing and treating                rabies (all claimed).    ADVANTAGE - The vaccine is safe and economical, has good                immune effect, and forms strong immune protection                after immunizing body.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    rabies messenger RNA (mRNA) vaccine comprising                rabies immunogen nucleic acid expression vector,                and packaging and/or delivery systems and/or                carriers for the nucleic acid expression vector;                and    preparing nucleic acid expression vector or                vaccine. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  ;  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.)",B04-B04D2;  B04-C01;  B04-C03D;  B04-E01;  B04-E08;  B04-E99;  B04-H02;  B04-H04C;  B04-N02;  B04-N06;  B14-A02B4;  B14-S11A;  B14-S11D3;  C04-C03D;  C04-E01;  C04-E08;  C04-E99;  C04-H02;  C04-N02;  C04-N06;  C14-A02B4;  C14-S11A;  C14-S11D3;  D05-H12E;  D05-H99;  A05-G01E;  A12-V01;  A12-W05,A61K-039/20;  C12N-015/47,WO2024055273-A1   21 Mar 2024   C12N-015/47   202432Pages: 49   Chinese,WO2024055273-A1    WOCN119230    16 Sep 2022,,WOCN119230    16 Sep 2022,WO2024055273-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2024055273-A1 -- CN105517569-A   CUREVAC GMBH (CUEV)   SCHNEE M,  KRAMPS T,  STITZ L,  PETSCH B;  CN110714015-A   ZHUHAI LIFANDA BIOTECHNOLOGY CO LTD (ZHUH-Non-standard)   LIU J,  PENG Y,  XIANG S,  SU X,  LIU Q,  LEI Y,  LI S;  CN114729373-A   SHENZHEN RHEGEN BIOTECHNOLOGY CO LTD (SHEN-Non-standard)   HU Y;  CN114921481-A   SHANGHAI SERUM BIOTECHNOLOGY CO LTD (SHAN-Non-standard)   FAN T,  JIN X,  HU Y,  ZHANG M;  JP08269092-A   ",,86886-0-0-0 K M; 97942-0-0-0 K M; 97946-0-0-0 K M; 97951-0-0-0 K M; 104486-0-0-0 K M; 114126-0-0-0 K M; 114365-0-0-0 K M; 96786-0-0-0 K M; 1606-0-0-0 ,230817601 K M; 230817602 K M; 230817603 K M; 230817604 K M; 230817605 K M; 230817606 K M; 230817607 K M,,R24039 K M; RA04OB K M; R06364 K M; R16207 K M; RA04J4 K M; R16492 K M; RA0DNM K M; RA0KDA K M; RA03SD K M; RA04LJ K M; R01176 ,
WO2024054825-A1,Detecting many nucleic acid sequences by            amplifying two nucleic acid sequences in amplification            reaction mixture and detecting nucleic acid            amplification product in the same optic channel with            two signal-generating oligonucleotides,COTE J,BECTON DICKINSON & CO (BECT-C),2024269907,"   NOVELTY - Detecting many nucleic acid sequences,                comprises: amplifying first and second nucleic acid                sequences in amplification reaction mixture, thus                generating first and second nucleic acid                amplification products, respectively; and detecting                in the same optic channel the amplification                products with first and second signal-generating                oligonucleotides, respectively, where the signal                generating oligonucleotides each comprise a label,                and the detecting comprises detecting the signal of                the label of the first and the second                signal-generating oligonucleotide before the                amplifying, during the amplifying and/or after the                amplifying.    USE - The method is useful for detecting many                nucleic acid sequences.    ADVANTAGE - The method: is performed in a single reaction                vessel and without thermocycling; does not comprise                using enzymes other than the reverse transcriptase                and the enzyme having a hyperthermophile polymerase                activity; and does not comprise using any enzyme                other than the enzyme having a hyperthermophile                polymerase activity.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a                kit, comprising the first forward primer and the                first reverse primer, the second forward primer and                the second reverse primer, the first                signal-generating oligonucleotide, the second                signal-generating oligonucleotide, and/or the third                signal-generating oligonucleotide, the quality                control template, the quality control primer, the                signal-generating oligonucleotide and/or the                supplemental quality control primer. ",,,"A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",A12-E13;  A12-V03C2;  A12-W11L;  B04-B03B;  B04-B03C;  B04-C02A2;  B04-C02C;  B04-C03;  B04-E01;  B04-E05;  B04-E07D;  B04-E14;  B04-E15;  B04-E16;  B04-E99;  B04-L04B;  B04-N02;  B11-C07B3;  B11-C08E3;  B11-C08F7A;  B11-C08F8;  B11-C08N1J;  B11-C08N2;  B11-C08N3;  B12-K04F;  D05-A02B;  D05-H09;  D05-H18A;  D05-H18B;  D05-H99,C12Q-001/6851,WO2024054825-A1   14 Mar 2024   C12Q-001/6851   202426Pages: 130   English,WO2024054825-A1    WOUS073521    06 Sep 2023,,US374831P    07 Sep 2022,WO2024054825-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,,,104477-1-0-0 K M; 104479-0-0-0 K M; 92818-0-0-0 K M; 92005-0-0-0 K M; 184613-0-0-0 K M; 900-0-0-0 K M; 104492-0-0-0 K M; 97486-1-0-0 K M; 95972-0-0-0 K M; 104488-0-0-0 K M; 97261-0-0-0 K M; 86886-0-0-0 K M; 91481-0-0-0 K M; 444-0-0-0 ; 107779-0-0-0 ,,42995,R01869 K M; R01870 K M; R01857 K M; RA061R K M; RA00I9 K M; R02044 K M; RA0GM6 K M; RA01EA K M; R06563 K M; RA083K K M; R24033 K M; RA04WZ K M; R01859 K M; RA016G K M; R24039 K M; R24034 K M; R00351 ; R01863 ,1869-S; 1870-S; 1857-S; 2044-S; 1859-S
WO2023037254-A1;  WO2023037254-A4,Method for treating Coronaviridae infection in            human in need involves administering bioavailable            highly permeable nanocomposite or solid dispersion or            aqueous solutions or suspensions obtained by            co-treating avermectin with host substance,DIDENKO K,DIDENKO K (DIDE-Individual),2023287222,"   NOVELTY - A method for treating an Coronaviridae                infection in a human in need involves administering                a compound (I), that is a bioavailable highly                permeable nanocomposite or bioavailable highly                permeable solid dispersion or aqueous solutions or                suspensions and obtained by co-treating avermectin                with a host substance. The avermectin is chosen                from ivermectin (a mixture of avermectins),                avermectin A1a, avermectin A1b, avermectin A2a,                avermectin A2b, avermectin B1a, avermectin B1b,                avermectin B2a, avermectin B2b or their racemate,                enantiomer, diastereomer, tautomer, polymorph,                pseudopolymorph, hydrate or solvate or ester or                prodrug. The co-treating method is chosen from e.g.                (a) grinding/milling with high energy stress                method, (b) grinding/milling, (c) media milling                method, (d) kneading method, (e) hot-melt                method/melting method/fusion method, (f) hot-melt                extrusion/hot-stage extrusion method, (g) meltrex                method, (h) melt agglomeration method, and (i)                high-pressure homogenization method.    USE - Method for treating Coronaviridae infection in                human in need.    ADVANTAGE - None given.    DETAILED DESCRIPTION - A method for treating an Coronaviridae                infection in a human in need involves administering                a compound of formula (I) (structure not                displayed), that is a bioavailable highly permeable                nanocomposite or bioavailable highly permeable                solid dispersion or aqueous solutions or                suspensions and obtained by co-treating avermectin                with a host substance. The avermectin is chosen                from ivermectin (a mixture of avermectins),                avermectin A1a, avermectin A1b, avermectin A2a,                avermectin A2b, avermectin B1a, avermectin B1b,                avermectin B2a, avermectin B2b or their racemate,                enantiomer, diastereomer, tautomer, polymorph,                pseudopolymorph, hydrate or solvate or ester or                prodrug. The co-treating method is chosen from (a)                grinding/milling with high energy stress method,                (b) grinding/milling with high energy stress and                solvent method, (c) media milling method, (d)                kneading method, (e) hot-melt method/melting                method/fusion method, (f) hot-melt                extrusion/hot-stage extrusion method, (g) meltrex                method, (h) melt agglomeration method, (i)                high-pressure homogenization method, (j) solvent                evaporation method, (k) spin-coated films method,                (l) spray-drying method, (m) supercritical fluid                (SCF) process method, (n) cryogenic techniques                method, (o) lyophilization/freeze-drying technique                method, (p) spray freezing onto cryogenic fluids                method, (q) spray freezing into cryogenic liquids                (SFL) method, (r) spray freezing into vapor over                liquid (SFV/L) method, (s) ultra-rapid freezing                method, (t) precipitation/co-precipitation method,                (u) microwave irradiation method, (v) energy input                method, and/or (w) heat/shear energy input method.                INDEPENDENT CLAIMS are included for the                following:    medical dosage form of compound (I) of                enhanced bioavailability and permeability, which                comprises a bioavailable highly permeable                nanocomposite or bioavailable highly permeable                solid dispersion or aqueous solutions or                suspensions, where the compound (I) is obtained by                co-treating avermectin with a host substance. The                avermectin is chosen from avermectins. The host                substance is chosen from (a) polymers and                oligomers, predominantly organic polymers and                oligomers, even more predominantly polysaccharides                and oligosaccharides, hemicelluloses, storage                polysaccharides, sulfated polysaccharides and                oligosaccharides, pectins, gums, and mucilages, (b)                substances that may contain in significant amounts                polysaccharides and oligosaccharides,                hemicelluloses, storage polysaccharides, sulfated                polysaccharides and oligosaccharides, pectins,                gums, mucilages, comprising (but are not limited                to) plants or algae or animal or fungi, portions of                plants or algae or animal or fungi, processed                plants or algae or animal or fungi, processed                portions of plants or algae or animal or fungi                containing in significant amounts the substances                specified in component (a), (c) synthetic polymers,                predominantly water-soluble polymers or mixtures,                (d) polyols or mixtures, (e) saccharides or                mixtures, (f) surfactants or mixtures, (g) acids or                mixtures, (h) oxides and salts based on these                oxides or mixtures, (i) copolymers of the polymers                listed in components (a) and (c), (j) methoxylated,                ethoxylated, esterificated, carboxylated,                alkoxylated, acetylated, hydroxylated, hydrated,                decarboxylated, amide, oxidized, sulfated,                aminoacid derivatives, fermented, thermally                modified, chemically modified, acid modified                derivatives of the substances in components                (a)-(i), and their esters, salts, and chemical                derivatives, and (k) combination of substances                specified components (a)-(j); and    method for preparing a medical dosage form of                compound (I) of enhanced bioavailability and                permeability. ",,,"A96 (Medical, dental, veterinary, cosmetic.);  B02 (Fused ring heterocyclics.);  C02 (Heterocyclic.)",A11-A03;  A11-B07;  A12-V01;  A12-W14;  B02-A;  B04-B01B;  B04-C02A;  B04-C02B;  B04-C02D;  B04-C02E;  B04-C03;  B05-A03B1;  B05-B01P;  B05-B02C;  B06-H;  B07-H;  B10-A07A;  B10-A07B;  B10-A09A;  B10-A22;  B10-B03B;  B10-C02;  B10-C04E1;  B10-C04E5;  B10-E04A;  B10-E04C;  B10-E04D;  B10-G02;  B14-A02B5;  B14-K01;  B15-E00;  C02-A;  C04-B01B;  C04-C02A;  C04-C02B;  C04-C02D;  C04-C02E;  C04-C03;  C05-A03B1;  C05-B01P;  C05-B02C;  C06-H;  C07-H;  C10-A07A;  C10-A07B;  C10-A09A;  C10-A22;  C10-B03B;  C10-C02;  C10-C04E1;  C10-C04E5;  C10-E04A;  C10-E04C;  C10-E04D;  C10-G02;  C14-A02B5;  C14-K01;  C15-E00,A61K-031/335;  A61K-031/424;  A61K-031/495;  A61K-039/42,WO2023037254-A1   16 Mar 2023   A61K-031/335   202326Pages: 50   English;  WO2023037254-A4   04 May 2023   A61K-031/335   202337   English,WO2023037254-A1    WOIB058395    07 Sep 2022;   WO2023037254-A4    WOIB058395    07 Sep 2022,,US241541P    08 Sep 2021,WO2023037254-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2023037254-A4:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,,,88042-0-0-0 K M; 98411-1-0-0 K M; 1117-0-0-0 K M; 88534-0-0-0 K M; 88640-0-0-0 K M; 2021-0-0-0 K M; 2068-0-0-0 K M; 2117-0-1-0 K M; 55285-2-0-0 K M; 95816-0-0-0 K M; 96279-0-0-0 K M; 96319-1-0-0 K M; 2623-0-0-0 K M; 21-0-0-0 K M; 97824-1-0-0 K M; 2853-1-0-0 K M; 99087-1-0-0 K M; 99222-0-0-0 K M; 100048-1-0-0 K M; 100051-1-0-0 K M; 101234-0-0-0 K M; 101244-0-0-0 K M; 101247-0-0-0 K M; 265-0-0-0 K M; 102639-0-0-0 K M; 103918-0-0-0 K M; 103921-0-0-0 K M; 4015-0-0-0 K M; 159573-1-0-0 K M; 107016-0-0-0 K M; 107453-1-0-0 K M; 107456-1-0-0 K M; 108692-0-0-0 K M; 109103-0-0-0 K M; 109215-0-0-0 K M; 109506-0-0-0 K M; 110654-1-0-0 K M; 408-0-0-0 K M; 129625-0-0-0 K M; 129626-0-0-0 K M; 129629-0-2-0 K M; 134125-0-0-0 K M; 490-0-0-0 K M; 135560-1-0-0 K M; 129514-0-1-0 K M; 149267-0-0-0 K M; 159573-0-0-0 K M; 686-0-0-0 K M; 196455-0-0-0 K M; 196509-7-0-0 K M;  K M; 23902-0-0-0 K M; 41621-0-0-0 K M; 849-0-0-0 K M; 949-1-0-0 K M; 511447-0-1-0 K M; 78270-0-0-0 K M; 56978-2-0-0 K M; 86729-0-0-0 K M; 86923-0-0-0 K M; 90356-0-0-0 K M; 90357-0-0-0 K M; 90359-0-0-0 K M; 90877-0-0-0 K M; 91821-0-0-0 K M; 92830-0-0-0 K M; 94618-0-0-0 K M; 96300-0-0-0 K M; 96529-0-0-0 K M; 96778-0-0-0 K M; 96796-0-0-0 K M; 97115-1-0-0 K M; 97485-1-0-0 K M; 97486-1-0-0 K M; 97487-0-0-0 K M; 100739-1-0-0 K M; 103468-0-0-0 K M; 104328-1-0-0 K M; 104346-0-0-0 K M; 104424-0-0-0 K M; 132873-1-0-0 K M; 104478-1-0-0 K M; 104479-0-0-0 K M; 104488-0-0-0 K M; 104491-0-0-0 K M; 104492-0-0-0 K M; 107307-0-0-0 K M; 107779-0-0-0 K M; 109100-1-0-0 K M; 110577-0-0-0 K M; 114270-0-0-0 K M; 114325-0-0-0 K M; 114599-0-0-0 K M; 133912-0-0-0 K M; 900-0-0-0 K M; 1062-0-0-0 K M; 238-0-0-0 ; 621-0-0-0 ; 829-0-0-0 ; 444-0-0-0 ; 7785-0-0-0 ; 10151-0-0-0 ; 90352-0-0-0 ; 90360-0-0-0 ; 135402-0-0-0 ; 8781-0-0-0 ; 1911-0-0-0 ; 133925-0-0-0 ; 96536-0-0-0 ; 92818-0-0-0 ,,42530; 42533; 06384,R21441 K M; RA06BH K M; R00950 K M; R03770 K M; R03361 K M; R00122 K M; R01147 K M; R05327 K M; R01168 K M; R03440 K M; RA013O K M; R03492 K M; R16409 K M; R00540 K M; R00822 K M; R00543 K M; R14434 K M; R00135 K M; R10352 K M; R01833 K M; RA00JW K M; R03068 K M; R00292 K M; R14113 K M; R16698 K M; R12505 K M; RAHT0Z K M; R03191 K M; R04271 K M; R00900 K M; RA29YP K M; R08754 K M; R17037 K M; RA04F7 K M; R00179 K M; R14756 K M; R00038 K M; R01694 K M; R01539 K M; R00032 K M; R23692 K M; RA0149 K M; RA02KU K M; R05220 K M; R00545 K M; RA0338 K M; R01131 K M; R01616 K M; R00173 K M; R05324 K M; RA1438 K M; RA1HEQ K M; R18623 K M; R00113 K M; RA0337 K M; R04227 K M; R10097 K M; R12638 K M; R13789 K M; R01966 K M; RACTRE K M; RA64CM K M; RAHRZY K M; R00744 K M; R10553 K M; R00419 K M; R00290 K M; R07423 K M; RA6G4V K M; R06653 K M; R00241 K M; R24070 K M; RA04J1 K M; R01852 K M; R01853 K M; RA05OE K M; R16917 K M; RA0B9L K M; R01875 K M; RA0696 K M; RA002W K M; R03275 K M; R01858 K M; RA02KY K M; R01872 K M; R03104 K M; RA024U K M; R01867 K M; R03231 K M; R03005 K M; R06563 K M; RA083K K M; R16918 K M; RA0NLR K M; R01860 K M; RA02KX K M; R17032 K M; R03882 K M; RA05UM K M; RA03FM K M; RA014C K M; R01871 K M; R01870 K M; RA04WZ K M; RA012N K M; RA01EA K M; R06725 K M; R01863 K M; RA0CQN K M; R16377 K M; RA03GS K M; R16922 K M; RA0NLS K M; RA02AR K M; R01835 K M; R06717 K M; R02044 K M; RA0GM6 K M; RA00D5 K M; R00370 ; R00338 ; R00835 ; R00351 ; R01126 ; R00460 ; R01854 ; R01855 ; R24032 ; R00444 ; R00446 ; R01866 ; R07226 ; R24037 ; R01857 ,0950-S; 1017-S; 0122-S; 1147-S; 0540-S; 0822-S; 0543-S; 0135-S; 1833-S; 0292-S; 0900-S; 0179-S; 0038-S; 1694-S; 1539-S; 0032-S; 0545-S; 1131-S; 1616-S; 0173-S; 1174-S; 0113-S; 0120-S; 1966-S; 0744-S; 0419-S; 0290-S; 0241-S; 1852-S; 1853-S; 1875-S; 1858-S; 1872-S; 1867-S; 1860-S; 1871-S; 1870-S; 1866-S; 1863-S; 1835-S; 2044-S
WO2024055272-A1,"New messenger RNA nucleic acid expression vector            expressing target protein useful e.g. for preventing            and treating diseases from viral infection, comprises            open reading frame element encoding protein of interest            and poly(A) tail elements",XU J;  ZHANG X;  BAI S,UNIV ZHONG SHAN HOSPITAL FUDAN (UYZH-Non-standard),202430153U,"   NOVELTY - Messenger RNA (mRNA) nucleic acid expression                vector expressing a target protein, comprising (a)                5'-untranslated region (UTR) element; (b) an open                reading frame element encoding the protein of                interest; (c) 3'-UTR element; and (d) poly(A) tail                elements with a total length of more than 120                nucleotides from the 5' end to the 3' end, where                the poly(A) tail elements include multiple                adenylate strings, each adenylate string                independently contains 10-80 consecutive                adenylates, and the total number of adenylates in                the multiple adenylate strings is more than 100;                and a linker is located between the multiple of                adenylate strings, each of the linkers                independently contains no adenylate or only                contains 1 or 2 adenylate, is new.    USE - The nucleic acid expression vector is useful                for preventing and/or treating diseases from: viral                infection, namely rabies virus, influenza virus,                coronavirus, Ebola virus, Zika virus, yellow fever                virus, dengue virus, cytomegalovirus, porcine                reproductive and respiratory syndrome (PRRS) virus,                porcine pestivirus, enterovirus, hepatitis B virus,                respiratory syncytial virus, herpes simplex virus,                human papillomavirus, human immunodeficiency virus,                influenza virus, coronavirus, parainfluenza virus,                measles virus, mumps virus, Nipah virus viruses or                human metapneumovirus, and cancer, e.g. squamous                cell carcinoma, basal cell carcinoma,                adenocarcinoma, hepatocellular carcinoma, renal                cell carcinoma, bladder cancer, bowel cancer,                cervical cancer, colon cancer, esophageal cancer,                head cancer, kidney cancer, liver cancer, lung                cancer, neck cancer, ovarian cancer, pancreatic                cancer, prostate cancer, gastric cancer, leukemia,                lymphoma, Burkitt's lymphoma, non-Hodgkin's                lymphoma, melanoma, myeloproliferative diseases,                sarcoma, angiosarcoma, Kaposi's sarcoma,                liposarcoma, sarcoma, peripheral                neuroepithelialoma, synovial sarcoma, glioma,                astrocytoma, oligodendroglioma, ependymoma, colloid                cytomas, neuroblastomas, ganglioneuromas,                gangliogliomas, medulloblastomas, pineal cell                tumors, meningiomas, meningiosarcomas,                neurofibromas and schwannomas, breast cancer,                uterine cancer, testicular cancer, thyroid cancer,                astrocytoma, esophageal cancer, carcinosarcoma,                Hodgkin's disease, Wilms' tumor and                teratocarcinoma, and genetic disease (e.g. single                gene disease), e.g. methylmalonic acidemia, acute                intermittent porphyria, Fabry disease, albinism,                hemophilia, phenylketonuria, galactosemia,                mucopolysaccharidoses and congenital adrenocortical                hyperplasia, and composition are useful in the                preparation of products for expressing a target                protein, for e.g., the product is mRNA vaccines,                therapeutic or preventive drugs, e.g. protein                replacement therapeutic drugs or gene editing                therapeutic drugs (all claimed), and in the field                of biopharmaceutical industry, preferably in                manufacturing genetically engineered drugs and                vaccines.    ADVANTAGE - The mRNA nucleic acid expression vector can                efficiently express target genes, avoids the hidden                dangers of insertional mutagenesis, produces mRNA                vaccine in a cell-free manner, with rapid                production, simple process, and controllable cost;                can encode multiple antigens, allowing it to target                tumor targets, different microorganisms, and                enhance immune responses against hypermutated                pathogens; has poly(A) tails to DNA plasmids which                eliminates the in vitro tailing step, reduces the                overall reaction time and loss of raw materials,                and avoids enzymatic polyadenylation using poly(A)                polymerase tail length changes; improves                intracellular mRNA stability, translation                efficiency and long-term persistence; can                efficiently express a target protein and different                target genes, whether at the in vitro cell                expression level or by delivering the mRNA via a                delivery tool; and achieves efficient translation                and stable and sustained expression when delivered                into the organism.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    composition comprising nucleic acid expression                vector, and packaging and/or a delivery system for                the nucleic acid expression vector and/or                carrier;    use of the nucleic acid expression vector                and/or the composition in the preparation of                products for expressing a target protein, for e.g.,                the product is mRNA vaccines, therapeutic or                preventive drugs, e.g. protein replacement                therapeutic drugs or gene editing therapeutic                drugs; and    preparing nucleic acid expression vector or                the composition. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-B01B;  B04-B04D2;  B04-C02X;  B04-C03D;  B04-E01B;  B04-E08;  B04-E99;  B04-H02;  B04-H04C;  B04-L04A;  B04-L05;  B04-N02;  B04-N04A;  B05-A03A1;  B14-A02;  B14-F03;  B14-F08;  B14-H01;  B14-H05;  B14-S11;  B14-S11D3;  B14-S13;  B14-S20B;  C04-B01B;  C04-B04D2;  C04-C02X;  C04-C03D;  C04-E01B;  C04-E08;  C04-E99;  C04-H02;  C04-H04C;  C04-L04A;  C04-L05;  C04-N02;  C04-N04A;  C14-A02;  C14-F03;  C14-F08;  C14-H01;  C14-H05;  C14-S11D3;  C14-S13;  C14-S20B;  D05-A02B;  D05-A02C;  D05-H12;  D05-H99,A61K-031/7105;  A61P-031/12;  A61P-035/00;  C12N-015/11;  C12N-015/67,WO2024055272-A1   21 Mar 2024   C12N-015/11   202429Pages: 38   Chinese,WO2024055272-A1    WOCN119229    16 Sep 2022,,WOCN119229    16 Sep 2022,WO2024055272-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2024055272-A1 -- CN113215178-A   CANSINO BIOLOGICS INC (CANS-Non-standard);  SUZHOU GENEPHARMA CO LTD (SUZH-Non-standard)   ZHU T,  LI J,  WANG H,  SHEN C,  JIANG J,  CHAO S,  QIU D;  CN114181962-A   CHINESE ACAD SCI BIOPHYSICS INST (CABP);  BEIJING YIBO PUHUI BIOTECHNOLOGY DEV CO (BEIJ-Non-standard)   LUO J,  YU Y,  ZHANG H,  ZHANG D,  CHENG H,  CHEN R;  CN114507675-A   ZHUHAI LIFANDA BIOTECHNOLOGY CO LTD (ZHUH-Non-standard)   FANG Z,  LI S,  LEI Y,  LIU Q,  LIU J,  PENG Y;  CN114729373-A   SHENZHEN RHEGEN BIOTECHNOLOGY CO LTD (SHEN-Non-standard)   HU Y;  WO2021102107-A1   ASKLEPIOS BIOPHARM INC (FARB);  ROBERTS M (ROBE-Individual);  IGLESIAS J M (IGLE-Individual);  TRETIAKOVA A (TRET-Individual)   ROBERTS M,  IGLESIAS J M,  TRETIAKOVA A,  OCALLAGHAN M W,  FRANCOIS A","WO2024055272-A1  TREPOTEC ZELJKA;          GEIGER JOHANNES; PLANK CHRISTIAN; ANEJA MANISH K; RUDOLPH          CARSTEN: ""Segmented poly(A) tails significantly reduce          recombination of plasmid DNA without affecting mRNA          translation efficiency or half-life"", RNA, COLD SPRING          HARBOR LABORATORY PRESS, US, vol. 25, no. 4, 31 March          2019 (2019-03-31), US , pages 507 - 518, XP009517039,          ISSN: 1355-8382, DOI:          10.1261/rna.069286.118,relevantClaims[1-14],relevantPassages[pages          507-518, see abstract, and table 1];  JUN-HONG YUAN, YANG          ZHAO-QING; MA SHAO-HUI: ""Progress in research on mRNA          vaccines"", CHINESE JOURNAL OF BIOLOGICALS, vol. 35, no.          6, 20 June 2022 (2022-06-20), pages 734 - 739,          XP093146027, DOI:          10.13200/j.cnki.cjb.003630,relevantClaims[1-14],relevantPassages[pages          734-739, see abstract]",97942-0-0-0 K M; 97946-0-0-0 K M; 97951-0-0-0 K M; 104486-0-0-0 K M; 114126-0-0-0 K M; 86886-0-0-0 K M; 96786-0-0-0 K M; 114367-0-0-0 K M; 162188-0-0-0 K M; 520167-0-0-0 K M; 204644-0-0-0 K M; 2418795-0-0-0 K M; 95638-0-0-0 K M; 173429-0-0-0 K M; 100067-0-0-0 K M; 105181-0-0-0 K M; 2418795-0-0-0 CL USE,230781201 K M,06384,RA04OB K M; R06364 K M; R16207 K M; RA04J4 K M; R16492 K M; RA0DNM K M; RA0KDA K M; R24039 K M; RA04LJ K M; RA09L5 K M; RA04OC K M; RA6MMB K M; RA031J K M; RBAAY7 K M; RA0CYH K M; R14108 K M; RA0HW8 K M; RA0LZS K M,
WO2021253119-A1;  US2023250430-A1,"New recognition moiety comprising catalytic            nucleic acid, which recognizes target nucleic acid and            cleaves the nucleic acid upon contact to produce            cleavage fragment useful in biosensor e.g. to detect            target nucleic acid in sample",BRENNAN J;  LI Y;  GU J,UNIV MCMASTER (MCST-C);  UNIV MCMASTER (MCST-C),2021E8050V,"   NOVELTY - Recognition moiety comprising a catalytic                nucleic acid, is new, where the recognition moiety                recognizes a target nucleic acid and cleaves the                target nucleic acid upon contact to produce a                cleavage fragment that acts as a primer for rolling                circle amplification (RCA) to generate                single-stranded nucleic acid molecules, and the                target nucleic acid is from severe acute                respiratory syndrome (SARS)-coronavirus                (CoV)-2.    USE - The recognition moiety is useful for in                biosensor which is used to detect target nucleic                acid in the sample, screening, diagnostics, and/or                health monitoring and the target nucleic acid                comprises RNA, is from a pathogen, virus,                preferably severe acute respiratory syndrome                (SARS)-coronavirus (CoV)-2 (all claimed) or the                biosensor is useful for detecting analyte (all                claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) a biosensor (B1) for detecting a target                nucleic acid comprising (a) a recognition moiety                comprising a catalytic nucleic acid, (b) a                polynucleotide kinase or phosphatase, and (c)                reagents for performing RCA, where the                polynucleotide kinase or phosphatase removes cyclic                phosphate from the cleavage fragment, producing a                dephosphorylated cleavage fragment that acts as a                primer for RCA to generate single-stranded nucleic                acid molecules;    (2) a biosensor system (B2) for detecting                target nucleic acid comprising the biosensor (B1),                a single-stranded oligonucleotide comprising a                first domain and a second domain, where the                single-stranded oligonucleotide is sequestered by a                partially complementary oligonucleotide prior to                RCA, a reporter moiety complementary to the first                domain of the single-stranded oligonucleotide, a                capture probe complementary to the second domain of                the single-stranded oligonucleotide, and a solid                support comprising the capture probe;    (3) detecting (M1) the presence of a target                nucleic acid in a sample, comprising contacting the                biosensor (B1) or (B2) with the sample in a                solution, allowing for production of an RCA                product, and detecting single-stranded nucleic acid                molecules generated from RCA, where detection of                the single-stranded nucleic acid molecules                indicates presence of the target nucleic acid in                the sample;    (4) detecting (M2) the presence of a target                nucleic acid in a sample, comprising (aa)                contacting the sample with a recognition moiety,                (bb) removing cyclic phosphate from the cleavage                fragment with a polynucleotide kinase or                phosphatase, (cc) performing RCA on the cleavage                fragment under conditions to generate                single-stranded nucleic acid molecules, and (dd)                detecting the single-stranded nucleic acid                molecules generated in (cc), where detection of the                single-stranded nucleic acid molecules in (dd)                indicates presence of the target nucleic acid in                the sample;    (5) detecting (M3) a viral infection in a                subject comprising testing a sample from the                subject for the presence of a target nucleic acid                using the biosensor (B1) or (B2), where presence of                a target nucleic acid indicates that the subject                has a viral infection; and    (6) detecting (M4) a viral infection in a                subject comprising testing a sample from the                subject for the presence of a target nucleic acid                using the biosensor system, where presence of a                target nucleic acid indicates that the subject has                a viral infection. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-B03C;  B04-C02D;  B04-E01;  B04-E07F;  B04-E15;  B04-E99;  B11-C07B;  B11-C08E8;  B11-C08F8;  B11-C10;  B12-K04F;  B12-K04G1B;  D05-H06A;  D05-H99,C12Q-001/6844;  C12Q-001/68;  C12Q-001/6804;  C12Q-001/6825;  C12Q-001/6876;  C12Q-001/70;  C12N-015/11;  C12N-015/113;  C12Q-001/6883,WO2021253119-A1   23 Dec 2021   C12Q-001/6844   202202Pages: 160   English;  US2023250430-A1   10 Aug 2023   C12N-015/113   202365   English,WO2021253119-A1    WOCA050818    15 Jun 2021;   US2023250430-A1    US18010878    16 Dec 2022,US2023250430-A1 Provisional Application US039518P;   US2023250430-A1 Provisional Application US169082P;   US2023250430-A1 PCT application Application WOCA050818,US039518P    16 Jun 2020;  US169082P    31 Mar 2021;  US18010878    16 Dec 2022,WO2021253119-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,"WO2021253119-A1 -- WO2018161177-A1   UNIV MCMASTER (MCST)   LI Y,  BRENNAN J,  LIU M","WO2021253119-A1  MORRISON DEVON,          ROTHENBROKER MEGHAN, LI YINGFU: ""DNAzymes: Selected for          Applications"", SMALL METHODS, WILEY - V C H VERLAG GMBH          & CO. KGAA, DE, vol. 2, no. 3, 1 March 2018          (2018-03-01), DE , pages 1700319, XP055888149, ISSN:          2366-9608, DOI:          10.1002/smtd.201700319,relevantClaims[1-65 (all          partially)];  ZHOU ZHIXUE,          BRENNAN JOHN D., LI YINGFU: ""A Multicomponent AllDNA          Biosensing System Controlled by a DNAzyme"", ANGEWANDTE          CHEMIE INTERNATIONAL EDITION, VERLAG CHEMIE| :, vol. 59,          no. 26, 22 June 2020 (2020-06-22), pages 10401 - 10405,          XP055888151, ISSN: 1433-7851, DOI:          10.1002/anie.202002019,relevantClaims[1-65 (all          partially)];  HAMADA MICHIAKI,          ONO YUKITERU, KIRYU HISANORI, SATO KENGO, KATO YUKI,          FUKUNAGA TSUKASA, MORI RYOTA, ASAI KIYOSHI: ""Rtools : a          web server for various secondary structural analyses on          single RNA sequences"", NUCLEIC ACIDS RESEARCH, OXFORD          UNIVERSITY PRESS, GB, vol. 44, no. W1, 8 July 2016          (2016-07-08), GB , pages W302 - W307, XP055888155, ISSN:          0305-1048, DOI: 10.1093/nar/gkw337,relevantClaims[1-65          (all partially)],relevantPassages[(print) 1362-4962          (web).];  ALI M. MONSUR,          WOLFE MICHAEL, TRAM KHA, GU JIMMY, FILIPE CARLOS D. M.,          LI YINGFU, BRENNAN JOHN D.: ""A DNAzymeBased Colorimetric          Paper Sensor for Helicobacter pylori"", ANGEWANDTE CHEMIE,          WILEY - V C H VERLAG GMBH & CO. KGAA, DE, vol. 131,          no. 29, 15 July 2019 (2019-07-15), DE , pages 10012 -          10016, XP055888160, ISSN: 0044-8249, DOI:          10.1002/ange.201901873,relevantClaims[1-65 (all          partially)];  BIALY ROGER M., ALI          MONSUR M., LI YINGFU, BRENNAN JOHN D.: ""ProteinMediated          Suppression of Rolling Circle Amplification for          Biosensing with an AptamerContaining DNA Primer"",          CHEMISTRY - A EUROPEAN JOURNAL, JOHN WILEY & SONS,          INC, DE, vol. 26, no. 22, 16 April 2020 (2020-04-16), DE,          pages 5085 - 5092, XP055888163, ISSN: 0947-6539, DOI:          10.1002/chem.202000245,relevantClaims[1-65 (all          partially)],relevantPassages[(print) 1521-3765          (web)];  ALHATLANI BADER Y.:          ""In silico identification of conserved cis -acting RNA          elements in the SARS-CoV-2 genome"", BIORXIV, 24 June 2020          (2020-06-24), pages 1 - 16, XP055888166, DOI:          10.1101/2020.06.23.167916,relevantClaims[1-65 (all          partially)];  PENG HANYONG, PENG          HANYONG, NEWBIGGING ASHLEY, WANG ZHIXIN, TAO JEFFREY,          DENG WENCHAN, LE, ZHANG HONGQUAN: ""DNAzyme-Mediated          Assays for Amplified Detection of Nucleic Acids and          Proteins"", ANALYTICAL CHEMISTRY, AMERICAN CHEMICAL          SOCIETY, US, vol. 90, no. 1, 2 January 2018 (2018-01-02),          US , pages 190 - 207, XP055865072, ISSN: 0003-2700, DOI:          10.1021/acs.analchem.7b04926,relevantClaims[1-65 (all          partially)],relevantPassages[(print) 1520-6882          (web)];  LIU MENG, HUI          CHRISTY Y., ZHANG QIANG, GU JIMMY, KANNAN BALAMURALI,          JAHANSHAHI-ANBUHI SANA, FILIPE CARLOS D. M., BRENNAN JOHN          D., : ""Target-Induced and Equipment-Free DNA          Amplification with a Simple Paper Device"", ANGEWANDTE          CHEMIE INTERNATIONAL EDITION, VERLAG CHEMIE| :, vol. 55,          no. 8, 18 February 2016 (2016-02-18), pages 2709 - 2713,          XP055888169, ISSN: 1433-7851, DOI:          10.1002/anie.201509389,relevantClaims[1-65 (all          partially)]",105014-0-0-0 K M,,,RA05SQ K M,
WO2023111907-A1,"New RNA polynucleotide molecule comprising open            reading frame encoding fimbrial H antigen antigenic            polypeptide, used to e.g. induce immune response            against extra-intestinal pathogenic Escherichia coli            and treat bacterial disease",CHE Y;  CHORRO L O;  DIAZ F M;  DONALD R G K;  LI J;  SILMON DE MONERRI N C;  SIMON R,PFIZER INC (PFIZ-C),202364666E,"   NOVELTY - RNA polynucleotide molecule comprising at                least one open reading frame (ORF) encoding a                fimbrial H antigen (FimH) antigenic polypeptide, is                new.    USE - The RNA molecule, composition or RNA-LNP                and/or vaccine is useful for: inducing an immune                response in a subject against extra-intestinal                pathogenic E. coli, or inducing the production of                opsonophagocytic and/or neutralizing antibodies in                a subject that are specific to extra-intestinal                pathogenic E. coli, where the subject is at risk of                developing a urinary tract infection, bacteremia,                urosepsis or sepsis, or cystitis, the subject is                less than 1 year of age, or 1-70 years of age or                older, or older, preferably 50 years of age or                older, the subject is a pregnant woman, and the                infection, disease or condition is a urinary tract                infection (all claimed); preventing, treating or                ameliorating an infection, disease or condition in                a subject, where the infection, disease or                condition is a urinary tract infection, urosepsis,                cystitis or pyelonephritis; vaccinating a subject;                and treating or preventing a bacterial disease.                Test details are described but no results                given.    ADVANTAGE - The molecule: has FimH antigens with reduced                affinity for mannoside ligands and improved                biochemical properties that result in improved                functional immunogenicity relative to wild type                FimH; and elicits an immune response including an                antibody response or a T cell response.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1)                a composition comprising the RNA molecule, where                the RNA molecule is formulated in a lipid                nanoparticle (RNA-LNP); and (2) inducing an immune                response in a subject against extra-intestinal                pathogenic Escherichia coli, or inducing the                production of opsonophagocytic and/or neutralizing                antibodies in a subject that are specific to                extra-intestinal pathogenic E. coli, comprising                administering to the subject the RNA molecule,                RNA-LNP and/or vaccine. ",,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.)",B04-B03A;  B04-B03D;  B04-C01B;  B04-C03C;  B04-E01B;  B04-E08;  B04-E99;  B04-F11;  B04-N06;  B05-B01P;  B10-B03B;  B14-A01;  B14-A02;  B14-A04;  B14-C03;  B14-N07;  B14-N10;  B14-S06;  B14-S11B;  B14-S11D3;  B14-S18;  D05-H12A;  D05-H99;  A12-V01;  A12-W14,A61K-039/108;  A61P-013/02;  A61P-031/04,WO2023111907-A1   22 Jun 2023   A61K-039/108   202361Pages: 199   English,WO2023111907-A1    WOIB062232    14 Dec 2022,,US290895P    17 Dec 2021;  US384607P    22 Nov 2022,WO2023111907-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2023111907-A1 -- US9814769-B2   UNIV QATAR (UYQA-Non-standard)   GHUNAIM H T,  ABU M M A,  POTTER A,  ALLAN B;  WO2018175783-A1   MODERNATX INC (MODR)   NARAYANAN E,  COHEN N,  CIARAMELLA G;  WO2021084429-A1   PFIZER INC (PFIZ)   ANDERSON A S,  CHEN W,  CHORRO L O,  CHU L,  DONALD R G K,  GRIFFOR M C,  GU J,  GUAN Z,  KIM J,  KODALI S,  LOMBERK S E,  LOTVIN J A,  MERCHANT N,  MORAN J K,  PAN R,  PRASAD A K,  RUPPEN M E,  SINGH S,  STEAD D R,  TAKANE K K;  WO2021123332-A1   CUREVAC AG (CUEV)   NAVARRO G,  BAUMHOF P;  WO2021144369-A1   JANSSEN PHARM INC (JANC)   FEITSMA J L,  FAE C K,  GEURTSEN J,  WEERDENBURG M E,  GRIJPSTRA J;  WO2022137078-A1   PFIZER INC (PFIZ)   CHE Y,  CHORRO L O,  DONALD R G K,  GRIFFOR M C,  SILMON DE MONERRI N C;  WO2022153166-A1   JANSSEN PHARM INC (JANC)   FEITSMA J L,  FAE C K,  GEURTSEN J,  WEERDENBBURG M E,  GRIJPSTRA J;  WO2021165928-A2   PFIZER INC (PFIZ)   DONALD R G K,  PAN R;  WO2022117595-A2   GLAXOSMITHKLINE BIOLOGICALS SA (GLAX)   ADAMO R,  COZZI R,  FANTONI A,  PHOGAT S,  ROSINI R,  SCARSELLI M,  WAHOME N;  US4578770-A   MUSASHI ENG KK (MUSA-Non-standard)   MITANI T;  US4596792-A   UNIV CALIFORNIA (REGC)   VYAS G N;  US4599230-A   SCRIPPS CLINIC & RES FOUND (SCRI)   MILICH D R,  CHISARI F V;  US4599231-A   SCRIPPS CLINIC & RES FOUND (SCRI)   MILICH D R,  CHISARI F V;  US4601903-A   US DEPT HEALTH & HUMAN SERVICE (USSH)   FRASCH C;  US4608251-A   PITMAN MOORE INC (PITM)   MIA A S;  US20040142025-A1   ;  US20070042031-A1   ;  US6733754-B2   PFIZER PROD INC (PFIZ)   DEARWESTER D A,  SWEARINGIN L A,  ROBERTS D S;  US6793923-B2   IMMUNOVACCINE TECHNOLOGIES INC (IMMU-Non-standard)   BROWN R G,  POHAJDAK W,  KIMMINS W C;  US8519110-B2   UNIV WARSZAWSKI (UYWA-Non-standard);  UNIV LOUISIANA STATE&AGRIC&MECH                  COLL (LOUU)   DARZYNKIEWICZ E,  JEMIELITY J,  KOWALSKA J,  LUKASZEWICZ M,  RHOADS R E,  ZUBEREK J;  US9737619-B2   ACUITAS THERAPEUTICS INC (ACUI-Non-standard)   ANSELL S M,  DU X;  US10166298-B2   ACUITAS THERAPEUTICS INC (ACUI-Non-standard)   ANSELL S M,  DU X;  WO2013016058-A1   MERCK SHARP & DOHME CORP (MERI)   CAMERON M,  DAVIS J R,  STANTON M G;  WO2013086373-A1   ALNYLAM PHARM INC (ALNY)   MANOHARAN M,  RAJEEV K G,  JAYARAMAN M,  AKINC A,  MATSUDA S,  MAIER M;  WO2015199952-A1   ANSELL S M (ANSE-Individual);  DU X (DUXX-Individual)   ANSELL S M,  DU X;  WO2016183501-A1   UNIV WASHINGTON SEATTLE (UNIW)   SOKURENKO E V,  KISIELA D,  THOMAS W E,  TCHESNOKOVA V L;  WO2017075531-A1   ACUITAS THERAPEUTICS INC (ACUI-Non-standard)   ANSELL S M,  DU X;  WO2020146805-A1   ACUITAS THERAPEUTICS INC (ACUI-Non-standard)   DU X;  WO2013078199-A2   CHILDRENS MEDICAL CENT (CHLD)   ROSSI D,  STEWART M,  MANDAL P;  WO2022090893-A2   PFIZER INC (PFIZ)   ANDERSON A S,  CHORRO L O,  DONALD R G K,  LYPOWY J M,  PAN R","WO2023111907-A1            HANNAN ET AL., PLOS PATHOG., vol. 6, no. 8, 12 August          2010 (2010-08-12), pages e1001042;            SCHWARTZ ET AL., INFECT IMMUN., vol. 79, no. 10, October          2011 (2011-10-01), pages 4250 - 9;            CUSUMANO CK ET AL., SCI TRANSL MED., vol. 3, no. 109,          2011, pages 109ra115;            CHEN SL ET AL., PROC NATL ACAD SCI USA., vol. 106, no.          52, 29 December 2009 (2009-12-29), pages 22439 -          44;            SCHWARTZ, D. J. ET AL., PROC NATL ACAD SCI U S A, vol.          110, 2013, pages 19089 - 19094;  LE          TRONG, I ET AL., J. STRUCT BIOL., vol. 172, no. 3,          December 2010 (2010-12-01), pages 380 - 8;            VETSCH, M. ET AL., J. MOL. BIOL., vol. 322, 2002, pages          827 - 840;            BARRITIART MM ET AL., PROC NATL ACAD SCI U S A., vol. 97,          no. 14, 5 July 2000 (2000-07-05), pages 7709 -          14;            BARNHART MM ET AL., PROC NATL ACAD SCI USA., vol. 97, no.          14, 5 July 2000 (2000-07-05), pages 7709 - 14;            SAUER MM ET AL., NAT COMMUN., vol. 7, 7 March 2016          (2016-03-07), pages 10738;            BARNHART MM ET AL., J BACTERIOL., vol. 185, no. 9, May          2003 (2003-05-01), pages 2723 - 30;            NEDDLEMANWUNSCH, J. MOL. BIOL., vol. 48, no. 443,          1970;            PEARSONLIPMAN, PROC. NATL ACAD. SCI. USA, vol. 88, no.          2444, 1988;            KORE ET AL., BIOORGANIC & MEDICINAL CHEMISTRY, vol.          21, 2013, pages 4570 - 4574;            KOPPEL, D., J. CHEM. PHYS., vol. 57, 1972, pages 4814 -          4820;  A.          R. GENNARO: ""Remington's The Science and Practice of          Pharmacy"", 2006, LIPPINCOTT, WILLIAMS &          WILKINS;            ""Remington's Pharmaceutical Sciences"", 1985, MACK          PUBLISHING CO.;            COCCHI F ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF          SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, no.          7445, 2004;            MCBRIDE CEMACHAMER CE, VIROLOGY, vol. 405, 2010, pages          139 - 48;            LISANTI MPCARAS IWDAVITZ MARODRIGUEZ-BOULAN E, JOURNAL OF          CELL BIOLOGY, vol. 109, 1989, pages 2145 - 2156;            GALIAN C ET AL., J BIOL CHEM, vol. 287, 2012, pages 16399          - 409;            MORAN PCARAS IW, J CELL BIOL, vol. 115, 1991, pages 329 -          36;            VOGEL ABKANEVSKY ICHE Y ET AL., NATURE, vol. 592, 2021,          pages 283 - 9;            MEIER SGUTHE SKIEFHABER TGRZESIEK S, J MOL BIOL, vol.          344, 2004, pages 1051 - 69;            SZIJARTO V ET AL., ANTIMICROB AGENTS CHEMOTHER, vol. 59,          2015, pages 3109 - 3116;            ALTER GMALENFANT JMALTFELD M: ""CD107a as a functional          marker for the identification of natural killer cell          activity"", J IMMUNOL METHODS, vol. 294, 2004, pages 15 -          22, XP004679751, DOI: 10.1016/j.jim.2004.08.008;            ZENOBIA CHAJISHENGALLIS G., PERIODONTOLOGY, vol. 69,          2000, pages 142 - 159", K M; 1544529-1-0-0 K M; 93537-0-0-0 K M; 93406-1-0-0 K M; 40293-1-0-0 K M; 93408-0-0-0 K M; 93440-0-0-0 K M;  K M; 755769-0-0-0 K M; 359336-0-0-0 K M;  K M; 114175-0-0-0 K M;  K M; 93538-0-0-0 K M; 1232843-1-0-0 K M; 704266-1-0-0 K M;  K M; 582153-1-0-0 K M;  K M;  K M; 2936896-1-0-0 K M; 131007-1-0-0 K M; 991375-1-0-0 K M; 155371-1-0-0 K M;  K M; 493369-1-0-0 K M; 9615-1-0-0 K M;  K M; 100880-1-0-0 K M; 92668-1-0-0 K M; 184602-0-0-0 K M;  K M; 200757-0-0-0 K M;  K M; 105730-0-0-0 M N; 444-0-0-0 ; 1544529-1-0-0 CL USE; 1232843-1-0-0 CL USE; 2936896-1-0-0 CL USE; 105730-0-0-0 CL NEW USE,229243201 K M; 229243202 K M; 229243203 K M,00212,RC58F9 K M; RARSN8 K M; R06520 K M; RA0DG3 K M; RA0GCK K M; R06521 K M; RA0KCF K M; RA1F77 K M; RA0T0J K M; R10117 K M; RCSSIP K M; RAB84W K M; RA3AH2 K M; RDG8TE K M; R21283 K M; RDG8TF K M; RA0GCJ K M; RAMZBS K M; RAA9FM K M; RDCJV4 K M; RA7WUF K M; RDCJV5 K M; RC53S9 K M; RBLLVJ K M; R07756 K M; RAG3K6 K M; R20932 K M; RASPSS K M; RDG8TH K M; RA62GA K M; RA76P6 K M; RCXD3O K M; R23688 K M; RAZG7W K M; RA02DV K M; RDG8TG K M; RA00GT K M; RBUTR3 K M; RA012P M N; R00351 ,
WO2021159020-A2;  WO2021159020-A3;  EP4100053-A2;  CN115515626-A;  US2023332253-A1;  EP4100053-A4,"Assaying for segment of coronavirus target nucleic            acid in sample, involves contacting sample to detector            nucleic acid and composition having programmable            nuclease and non-naturally occurring guide nucleic acid            and assaying signal change",TSALOGLOU M;  FASCHING C;  CHING J;  CHEN J S;  BROUGHTON J P;  DRZAL D T;  SHAPIRO S J,MAMMOTH BIOSCIENCES INC (MAMM-Non-standard);  TSALOGLOU M (TSAL-Individual);  FASCHING C (FASC-Individual);  CHING J (CHIN-Individual);  MAMMOTH BIOSCIENCES INC (MAMM-Non-standard);  MAMMOTH BIOSCIENCES INC (MAMM-Non-standard),202193395A,"   NOVELTY - Assaying for a segment of a coronavirus target                nucleic acid (TNA) in a sample, comprises (a)                contacting the sample to (i) a detector nucleic                acid and (ii) a composition comprising a                programmable nuclease and a non-naturally occurring                guide nucleic acid that hybridizes to a segment of                the target nucleic acid, where the programmable                nuclease the detector nucleic acid upon                hybridization of the non-naturally occurring guide                nucleic acid to the segment of the coronavirus                target nucleic acid and (b) assaying for a change                in a signal, where the change in the signal is                produced by cleavage of the detector nucleic                acid.    USE - The method is useful for assaying for segment                of coronavirus TNA in sample.    ADVANTAGE - The method: can used as a point of care                diagnostic or as a lab test for detecting a target                nucleic acid, thus, detecting a condition in a                subject from which the sample was taken; and used                in various sites or locations, preferably                laboratories, hospitals, in physician                offices/laboratories (POLs), in clinics, at remotes                sites, or at home; is capable of delivering results                in under an hour, thus allowing for the delivery of                antiviral therapy during the first 48 hours after                infection. The systems is capable of delivering                quick diagnoses and results, thus helping to keep                or send a patient at home, hence improves                comprehensive disease surveillance, and prevents                the spread of an infection.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) a composition comprising a non-naturally                occurring guide nucleic acid having at least 80%,                preferably at least 99% sequence identify to any                one of SEQ ID NOs: 171-177 (each comprising any one                of fully defined sequence of 41 nucleotides as                given in the specification); and    (2) a device comprising a sample interface                configured to receive a sample that comprises a                coronavirus sequence of interest, a channel in                fluid communication with the sample interface and a                detection chamber, the channel comprising one or                more movable mechanisms to separate the sample into                many droplets, where the detection chamber is                configured to receive and contact the droplets with                programmable nuclease probe disposed on a surface                of the detection chamber, where the programmable                nuclease probe comprises a guide nucleic acid                complexed with a programmable nuclease and many                sensors that determine a presence of the                coronavirus sequence of interest by detecting a                signal produced upon cleavage of a TNA region of                the sequence of interest by at least one                programmable nuclease probe. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  T01 (Digital Computers)",B04-E99;  B04-B03B;  B04-E05;  B04-E13;  B04-E15;  B04-L04A;  B04-L04B;  B04-L05A;  B04-L05A2;  B11-C08C1;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  D05-H99;  D05-A02C;  D05-H09;  D05-H18B;  D05-H19C;  T01-C07C2;  T01-J06A,C12Q-001/70;  A61K-039/12;  C12Q-001/6818;  C12Q-001/683;  C12Q-001/6897;  B01L-003/00;  B01L-007/00;  C12Q-001/6853,WO2021159020-A2   12 Aug 2021   C12Q-001/70   202170Pages: 354   English;  WO2021159020-A3   23 Sep 2021   A61K-039/12   202184   English;  EP4100053-A2   14 Dec 2022   A61K-039/12   202201   English;  CN115515626-A   23 Dec 2022   A61K-039/12   202302   Chinese;  US2023332253-A1   19 Oct 2023   C12Q-001/70   202385   English;  EP4100053-A4   20 Mar 2024   A61K-039/12   202426   English,WO2021159020-A2    WOUS016953    05 Feb 2021;   WO2021159020-A3    WOUS016953    05 Feb 2021;   EP4100053-A2    EP751118    05 Feb 2021;   CN115515626-A    CN80025696    05 Feb 2021;   US2023332253-A1    US817889    05 Aug 2022;   EP4100053-A4    EP751118    05 Feb 2021,EP4100053-A2 PCT application Application WOUS016953;   EP4100053-A2 Based on Patent WO2021159020;   CN115515626-A PCT application Application WOUS016953;   CN115515626-A Based on Patent WO2021159020;   US2023332253-A1 Cont of Application WOUS016953;   US2023332253-A1 Provisional Application US971206P;   US2023332253-A1 Provisional Application US985814P;   US2023332253-A1 Provisional Application US040473P;   US2023332253-A1 Provisional Application US113779P;   US2023332253-A1 Provisional Application US138284P,US971206P    06 Feb 2020;  US985814P    05 Mar 2020;  US040473P    17 Jun 2020;  US113779P    13 Nov 2020;  US138284P    15 Jan 2021;  WOUS016953    05 Feb 2021;  US817889    05 Aug 2022;  CN80025696    28 Sep 2022,WO2021159020-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2021159020-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP4100053-A2:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN      EP4100053-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  ,,";  WO2021159020-A3 -- US20190241954-A1   ;  WO2019148206-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ZHANG F,  GOOTENBERG J,  ABUDAYYEH O;  EP4100053-A4 -- US20190241954-A1   ;  WO2019148206-A1   BROAD INST INC (BROD);  MASSACHUSETTS INST TECHNOLOGY (MASI);  HARVARD COLLEGE (HARD)   ZHANG F,  GOOTENBERG J,  ABUDAYYEH O","WO2021159020-A3  DONG ET AL.:          ""Genomic and protein structure modeling analysis depicts          the origin and infectivity of 2019-nCoV, a new          coronavirus which caused a pneumonia outbreak in Wuhan,          China"", BIORXIV PREPRINT, 22 January 2020 (2020-01-22),          XP055859803, [retrieved on 20210707], DOI:          https://doi.org/10.1101/          2020.01.20.913368,relevantClaims[2-4,          5/(2-4)],relevantPassages[pg 3, In 33-36, pg 3, In 46-47,          pg 5, In 84-87];  DATABASE GenBank 23          January 2020 (2020-01-23), ""Wuhan seafood market          pneumonia virus isolate Wuhan -Hu-1, complete genome"",          Database accession no. MN 90894,relevantClaims[2-4,          5/(2-4)],relevantPassages[whole doc.]EP4100053-A4  DONG NING ET AL:          ""Genomic and protein structure modelling analysis depicts          the origin and infectivity of 2019-nCoV, a new          coronavirus which caused a pneumonia outbreak in Wuhan,          China"", BIORXIV, 21 January 2020 (2020-01-21),          XP055809875, Retrieved from the Internet          &lt;URL:https://www.biorxiv.org/content/10.1101/2020.01.20.913368v2.full.pdf&gt;          [retrieved on 20210602], DOI:          10.1101/2020.01.20.913368,relevantClaims[2],relevantPassages[&lt;pp&gt;3&lt;/pp&gt;&lt;line&gt;33&lt;/line&gt;&lt;linel&gt;36&lt;/linel&gt;|&lt;pp&gt;3&lt;/pp&gt;&lt;line&gt;46&lt;/line&gt;&lt;linel&gt;47&lt;/linel&gt;|&lt;pp&gt;5&lt;/pp&gt;&lt;line&gt;84&lt;/line&gt;&lt;linel&gt;87&lt;/linel&gt;|&lt;figure&gt;1B&lt;/figure&gt;]",201562-0-0-0 D K M; 218588-0-0-0 D K M; 3183009-0-0-0 K M; 3183009-0-0-0 CL USE,,,RA0124 D K M; RA0DQN D K M; RBQW40 K M,
WO2024011332-A1;  US2024108591-A1,"Increasing production of virus by cell, by            administering neddylation-activating enzyme inhibitor            to cell",DIALLO J;  WONG B;  BERGERON A;  ARULANANDAM R;  MAZNYI G V;  PRASAD J V;  CAMERON S;  STAUFFER S,OTTAWA HOSPITAL RES INST (OTTA-Non-standard);  CLEVELAND CLINIC FOUND (CLCL-C),2024073286,"   NOVELTY - Method (A) for increasing production of a                virus by a cell involves (a) administering a                neddylation-activating enzyme (NAE) inhibitor, or                its salt, solvate and/or prodrug to the cell.    USE - The method (A) is useful for increasing                production of virus by cell. The method (D) is                useful for treating disease, disorder or condition                by increasing permissiveness of cell to virus or by                gene therapy in subject. The disease, disorder or                condition is cancer or a tumor. The cancer is                lymphoblastic leukemia, myeloid leukemia,                adrenocortical carcinoma, AIDS-related cancer,                AIDS-related lymphoma, anal cancer, appendix                cancer, astrocytoma, atypical teratoid/rhabdoid                tumor, basal cell carcinoma, bile duct cancer,                bladder cancer, bone cancer, osteosarcoma,                malignant fibrous histiocytoma, brain stem glioma,                brain tumor, cerebellar astrocytoma, cerebral                astrocytoma/malignant glioma, craniopharyngioma,                ependymoblastoma, medulloblastoma, pineal                parenchymal tumors of intermediate differentiation,                supratentorial primitive neuroectodermal tumors and                pineoblastoma, visual pathway and hypothalamic                glioma, spinal cord tumors, breast cancer,                bronchial tumors, Burkitt lymphoma, carcinoid                tumor, CNS lymphoma, cervical cancer, chordoma,                chronic lymphocytic leukemia, chronic myelogenous                leukemia, chronic myeloproliferative disorders,                colon cancer, cutaneous T-cell lymphoma, embryonal                tumors, endometrial cancer, ependymoblastoma,                ependymoma, esophageal cancer, extracranial germ                cell tumor, extragonadal germ cell tumor,                extrahepatic bile duct cancer, eye cancer,                intraocular melanoma, retinoblastoma, gallbladder                cancer, gastric (stomach) cancer, gastrointestinal                carcinoid tumor, gastrointestinal stromal tumor                (GIST), gastrointestinal stromal cell tumor, germ                cell tumors, extracranial, extragonadal, ovarian,                gestational trophoblastic tumor, glioma, hairy cell                leukemia, head and neck cancer, hepatocellular                (liver) cancer, histiocytosis, Langerhans cell                cancer, Hodgkin lymphoma, hypopharyngeal cancer,                islet cell tumors, Kaposi sarcoma, kidney cancer,                laryngeal cancer, lymphocytic leukemia, hairy cell                leukemia, lip and oral cavity cancer, liver cancer,                non-small cell lung cancer, small cell lung cancer,                Hodgkin lymphoma, non-Hodgkin lymphoma, malignant                fibrous histiocytoma of bone and osteosarcoma,                medulloblastoma, medulloepithelioma, melanoma,                intraocular melanoma, Merkel cell carcinoma,                mesothelioma, metastatic squamous neck cancer,                mouth cancer, multiple endocrine neoplasia                syndrome, multiple myeloma/plasma cell neoplasm,                nasal cavity and paranasal sinus cancer,                nasopharyngeal cancer, neuroblastoma, oral cancer,                oropharyngeal cancer, ovarian cancer, pancreatic                cancer, parathyroid cancer, penile cancer,                pharyngeal cancer, pheochromocytoma, pineal                parenchymal tumors, pineoblastoma and                supratentorial primitive neuroectodermal tumors,                pituitary tumor, plasma cell neoplasm/multiple                myeloma, pleuropulmonary blastoma, primary CNS                lymphoma, prostate cancer, rectal cancer, renal                cell (kidney) cancer, renal pelvis and ureter                cancer, transitional cell cancer, respiratory tract                carcinoma, retinoblastoma, rhabdomyosarcoma,                salivary gland cancer, uterine sarcoma, skin                cancer, Merkel cell skin carcinoma, small intestine                cancer, soft tissue sarcoma, squamous cell                carcinoma, squamous neck cancer, stomach (gastric)                cancer, supratentorial primitive neuroectodermal                tumors, T-Cell lymphoma, testicular cancer, throat                cancer, thymoma and thymic carcinoma, thyroid                cancer, trophoblastic tumor, urethral cancer,                uterine cancer, endometrial cancer, uterine                sarcoma, vaginal cancer, vulvar cancer or Wilm's                tumor, preferably colon cancer, breast cancer,                rectal cancer, lung cancer, a leukemia, cervical                cancer, sarcoma, melanoma, pancreatic cancer and/or                ovarian cancer. The subject is a mammal, preferably                a human (all claimed).    ADVANTAGE - The method exhibits viral sensitizing activity                with high potency and versatility.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    a method (B) for increasing permissiveness of                a cell to a virus involves administering NAE                inhibitor, or its salt, solvate and/or prodrug to                the cell;    a method (C) for increasing permissiveness of                a cell to genetic material encoding components of a                virus involves administering NAE inhibitor, or its                salt, solvate and/or prodrug, to the cell in                combination with provision of the genetic material                encoding components of a virus to the cell;    a method (D) for treating a disease, disorder                or condition by increasing permissiveness of a cell                to a virus involves administering NAE inhibitor, or                its salt, solvate and/or prodrug, and the virus or                genetic material encoding the virus to a                subject;    a method (E) for increasing the oncolytic                activity of a virus involves administering NAE                inhibitor, or its salt, solvate and/or prodrug, and                an oncolytic virus to a subject or cell;    a method (F) for treating a disease, disorder                or condition by gene therapy involves administering                NAE inhibitor and a gene therapy vector to a                subject or cell;    a method (G) for increasing transduction of a                virus into a cell or increasing virally-encoded                transgene expression involves administering NAE                inhibitor, or its salt, solvate and/or prodrug and                the virus to the cell;    a method (H) for increasing virus growth                and/or virus spread in cells involves administering                NAE inhibitor, or its salt, solvate and/or prodrug                to the cells in combination with provision of the                virus to the cells; and    a composition comprising the NAE inhibitor, or                its salt, solvate and/or prodrug, and a virus or                genetic material encoding components of a                virus. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B02 (Fused ring heterocyclics.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  ;  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B02-P02;  B04-B03D;  B04-E01;  B04-E08;  B04-E99;  B04-F01;  B04-F0200E;  B04-F07A0E;  B04-F1100E;  B05-A03B;  B05-B01E;  B05-B01J;  B05-B01M;  B05-V;  B05-Z;  B06-H;  B07-D04C;  B07-D05;  B07-F01;  B08-D02;  B10-E02;  B11-A04A;  B14-D10;  B14-F03;  B14-H01;  B14-H05;  B14-L06;  B14-S03;  B14-S03A;  B14-S11;  B14-S18;  B14-S28;  C02-P02;  C04-B03D;  C04-E01;  C04-E08;  C04-E99;  C04-F0200E;  C04-F07A0E;  C04-F11;  C05-A03B;  C05-B01E;  C05-B01J;  C05-B01M;  C05-Z;  C06-H;  C07-D04C;  C07-D05;  C07-F01;  C08-D02;  C10-E02;  C11-A04A;  C14-D10;  C14-F03;  C14-H01;  C14-H05;  C14-L06;  C14-S03;  C14-S03A;  C14-S18;  D05-H08B;  D05-H99,C12N-015/86;  C12N-007/00;  C12N-007/01;  C12N-007/02;  A61K-031/05;  A61K-031/122;  A61P-007/02;  A61P-009/00,WO2024011332-A1   18 Jan 2024   C12N-007/00   202415Pages: 131   English;  US2024108591-A1   04 Apr 2024   A61K-031/122   202429   English,WO2024011332-A1    WOCA050955    14 Jul 2023;   US2024108591-A1    US352450    14 Jul 2023,US2024108591-A1 Provisional Application US389064P,US389064P    14 Jul 2022;  US352450    14 Jul 2023,WO2024011332-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,"WO2024011332-A1 -- WO2020058786-A1   INDIAN INST TECHNOLOGY KANPUR (IITK)   RAO J G,  MAURYA S","WO2024011332-A1  YU GUANGQING, LIU          XING, TANG JINHUA, XU CHENXI, OUYANG GANG, XIAO WUHAN:          ""Neddylation Facilitates the Antiviral Response in          Zebrafish"", FRONTIERS IN IMMUNOLOGY, FRONTIERS MEDIA,          LAUSANNE, CH, vol. 10, 25 June 2019 (2019-06-25),          Lausanne, CH , XP093130524, ISSN: 1664-3224, DOI:          10.3389/fimmu.2019.01432,relevantClaims[1, 9-12, 19,          27-36, 55, 57-63|2, 14, 16, 17, 20-24, 37, 38,          42-53],relevantPassages[*Fig. 3, 5, p. 7];  LE-TRILLING VU THUY          KHANH, MEGGER DOMINIK A., KATSCHINSKI BENJAMIN, LANDSBERG          CHRISTINE D., RUeCKBORN MEIKE U., TAO SHA, KRAWCZYK A:          ""Broad and potent antiviral activity of the NAE inhibitor          MLN4924"", SCIENTIFIC REPORTS, vol. 6, no. 1, 1 April 2016          (2016-04-01), XP055882339, DOI:          10.1038/srep19977,relevantClaims[1, 3, 4, 6, 14-20, 22,          27-29, 31,56-63],relevantPassages[*Fig. 1, 2, 3, 4, p. 2,          5];  LEE BECKY H.,          TEBALDI GIULIA, PRITCHARD SUZANNE M., NICOLA ANTHONY V.:          ""Host Cell Neddylation Facilitates Alphaherpesvirus Entry          in a Virus-Specific and Cell-Dependent Manner"",          MICROBIOLOGY SPECTRUM, AMERICAN SOCIETY FOR MICROBIOLOGY,          US, vol. 10, no. 5, 26 October 2022 (2022-10-26), US ,          XP093130541, ISSN: 2165-0497, DOI:          10.1128/spectrum.03114-22,relevantClaims[1, 3, 4, 9-12,          14, 16, 27-29, 31, 5557-63],relevantPassages[*Abstract,          Fig. 2, 4, 7, p. 8-9];  WEI WEI, GUO          HAORAN, LIU XIANJUN, ZHANG HONG, QIAN LEI, LUO KUN,          MARKHAM RICHARD B., YU XIAO-FANG: ""A First-in-Class NAE          Inhibitor, MLN4924, Blocks Lentiviral Infection in          Myeloid Cells by Disrupting Neddylation-Dependent          Vpx-Mediated SAMHD1 Degradation"", JOURNAL OF VIROLOGY,          THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 88, no.          1, 1 January 2014 (2014-01-01), US , pages 745 - 751,          XP093130544, ISSN: 0022-538X, DOI:          10.1128/JVI.02568-13,relevantClaims[1, 6,          57-63],relevantPassages[*Fig. 2A, p. 746];  SHEN RUI, LUe          DINGDING, CAO ZHIJUN, HUANG JINSHAN, ZHANG YILING, SHEN          ZHONGYUAN, TANG XUDONG: ""Involvement of the neddylation          modification system in Bombyx mori nucleopolyhedrovirus          replication"", ARCHIVES OF INSECT BIOCHEMISTRY AND          PHYSIOLOGY., ALAN R. LISS, NEW YORK, NY., US, vol. 110,          no. 4, 1 August 2022 (2022-08-01), US , XP093130545,          ISSN: 0739-4462, DOI:          10.1002/arch.21907,relevantClaims[1, 15, 18, 27, 29, 31,          57-63],relevantPassages[*Abstract, Fig. 1 and          2]",1978648-1-0-0 K M; 3517613-1-0-0 K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M; 101093-0-0-0 K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M; 1363572-1-0-0 K M;  K M;  K M;  K M; 1363573-1-0-0 K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M; 104084-1-0-0 K M;  K M; 68997-1-0-0 K M;  K M; 1978648-1-0-0 CL USE; 3517613-1-0-0 CL USE; 1363572-1-0-0 CL USE; 1363573-1-0-0 CL USE,230534001 K M; 230534002 K M; 230534003 K M,01261; 61620; 00417; 42205; 02858,RBG4AO K M; RBYHBR K M; RC396K K M; RBRFWJ K M; RDIWA1 K M; RDIWA2 K M; RDIWA3 K M; RDIWA4 K M; RDIWA5 K M; R07208 K M; RBXUJ2 K M; RD648V K M; RDIWA6 K M; RDIWA7 K M; RDIWA8 K M; RDIWA9 K M; RDIWAA K M; RDIWAB K M; RDIWAC K M; RDIWAD K M; RDIWAE K M; RDIWBF K M; RDIWAF K M; RDIWAG K M; RDIWAH K M; RDIWAI K M; RDIWAJ K M; RDIWAK K M; RDIWAL K M; RDIWAM K M; RDIWAN K M; RDIWAO K M; RDIWAP K M; RDIWAQ K M; RDIWAR K M; RDIWAS K M; RDIWAT K M; RDIWAU K M; RDIWAV K M; RDIWAW K M; RDIWAX K M; RDIWAY K M; RDIWAZ K M; RANXXR K M; RDIWB0 K M; RDIWB1 K M; RDIWB2 K M; RANXXS K M; RDIWB3 K M; RDIWB4 K M; RDIWB5 K M; RDIWB6 K M; RDIWB7 K M; RDIWB8 K M; RDIWB9 K M; RDIWBA K M; RDIWBB K M; RDIWBC K M; RDIWBD K M; RCI014 K M; RCI016 K M; R03877 K M; R09271 K M; RD3LPI K M; RAGFK9 K M; RC00PK K M,
WO2021242780-A2;  WO2021242780-A3;  AU2021282172-A1;  CA3178016-A1;  IN202247074342-A;  KR2023017215-A;  IL298192-A;  EP4157854-A2;  JP2023527786-W;  CN116368156-A;  US2023279056-A1;  HK40089067-A0,New cage protein comprising a helical bundle used            to detect troponin I in a sample,QUIJANO RUBIO A;  PARK J;  YEH H;  BAKER D;  CAO L;  COVENTRY B;  GORESHNIK I;  KOZODOY L;  STEWART L J;  QUIJANO R A;  QUIZANO R A;  YOUNG P J;  YES H;  BEJKER D;  KHAO L;  GORESINK I;  KOJO D L;  STEWART L J W,UNIV WASHINGTON SEATTLE (UNIW-C);  UNIV WASHINGTON SEATTLE (UNIW-C);  UNIV WASHINGTON SEATTLE (UNIW-C);  UNIV WASHINGTON SEATTLE (UNIW-C),2021D9279Q,"   NOVELTY - Cage protein comprising a helical bundle, is                new. The cage protein comprises a structural region                and a latch region, the latch region comprises at                least one target binding polypeptide, the cage                protein further comprises a first reporter protein                domain, the first reporter protein domain undergoes                a detectable change in reporting activity when                bound to a second split reporter protein domain,                and the structural region interacts with the latch                region to prevent solution access to the one or                more target binding polypeptide.    USE - The cage protein is useful for detecting                troponin I in a sample.    ADVANTAGE - The cage protein ensures accurate                detection.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) key protein capable of binding to the                structural region of a cage protein that does not                include the second reporter protein domain, where                binding of the key protein to the cage protein only                occurs in the presence of a target to which the                cage protein target binding polypeptide can bind,                where the key protein comprises a second reporter                protein domain, and interaction of the key protein                second reporter protein domain and the cage protein                first reporter protein domain causes a detectable                change in reporting activity from the first                reporter protein domain;    (2) biosensor, comprising (a) the cage                protein, where the cage does not include the second                reporter protein domain, and (b) the key protein,                where the key protein can only bind to the cage                protein in the presence of a target to which the                cage protein target binding polypeptide can bind,                and binding of the first reporter protein domain of                the cage protein to the second reporter protein                domain of the key protein causes a detectable                change in reporting activity from the first                reporter protein domain;    (3) detecting a target, comprising (a)                contacting the cage protein, where the cage protein                comprises the second reporter protein domain, or                the biosensor with a biological sample under                conditions to promote binding of the cage protein                target binding polypeptide to a target present in                the biological sample, causing a detectable change                in reporting activity from the first reporter                protein domain, and (b) detecting the change in                reporting activity from the first reporter protein                domain, where the change in reporting activity                identifies the sample as containing the                target;    (4) designing a biosensor, cage protein, or                key protein comprising the steps mentioned                above;    (5) nucleic acid encoding the cage protein or                key protein;    (6) expression vector, comprising the nucleic                acid operatively linked to a suitable control                element, e.g. promoter;    (7) cell, comprising the cage protein, key                protein, composition, nucleic acid, or expression                vector;    (8) composition, comprising the cage protein,                key protein, composition, nucleic acid, expression                vector, or cell and carrier;    (9) epitope, comprising amino acid sequence of                SEQ ID NO: 27384; and    (10) detecting troponin I in a sample,                comprising contacting a biological sample with the                epitope under conditions suitable to promote                binding of troponin I in the sample to the epitope                to form a binding complex, and detecting binding                complexes that demonstrate presence of troponin I                in the sample. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-B04C;  B04-C01;  B04-E02F;  B04-E03F;  B04-E08;  B04-E99;  B04-F0100E;  B04-G01;  B04-H20C;  B04-K01R0E;  B04-L03B;  B04-L03C;  B04-L05B;  B04-L05C;  B04-N03J;  B04-N04;  B04-N16;  B11-C07A;  B11-C07B;  B11-C08E8;  B12-K04G;  D05-H09;  D05-H12A;  D05-H12E;  D05-H14;  D05-H99,C07K-014/00;  C07K-019/00;  C07K-014/005;  C07K-014/47;  G01N-033/542;  G01N-033/569;  G01N-033/576;  C12N-015/11;  C12N-015/63;  C12N-015/62;  C12N-005/10;  C12N-001/19;  C12N-001/15;  C12N-001/21;  A61K-038/02;  A61K-031/7088;  A61K-048/00;  A61K-035/76;  A61K-035/12;  G01N-033/531;  G01N-033/53,WO2021242780-A2   02 Dec 2021   C07K-014/00   202103Pages: 167   English;  WO2021242780-A3   17 Feb 2022   202216   English;  AU2021282172-A1   15 Dec 2022   C07K-014/00   202201   English;  CA3178016-A1   02 Dec 2021   C07K-014/00   202308   English;  IN202247074342-A   30 Dec 2022   C07K-014/00   202311   English;  KR2023017215-A   03 Feb 2023   C07K-014/00   202318   ;  IL298192-A   01 Jan 2023   G01N-033/542   202318   English;  EP4157854-A2   05 Apr 2023   C07K-014/00   202330   English;  JP2023527786-W   30 Jun 2023   C12N-015/11   202353   Japanese;  CN116368156-A   30 Jun 2023   C07K-019/00   202363   Chinese;  US2023279056-A1   07 Sep 2023   C07K-014/00   202374   English;  HK40089067-A0   06 Oct 2023   C07K-014/00   202403   English,WO2021242780-A2    WOUS034104    25 May 2021;   WO2021242780-A3    WOUS034104    25 May 2021;   AU2021282172-A1    AU282172    25 May 2021;   CA3178016-A1    CA3178016    25 May 2021;   IN202247074342-A    IN47074342    21 Dec 2022;   KR2023017215-A    KR742798    25 May 2021;   IL298192-A    IL298192    25 May 2021;   EP4157854-A2    EP739477    25 May 2021;   JP2023527786-W    JP572292    25 May 2021;   CN116368156-A    CN80049976    25 May 2021;   US2023279056-A1    US17999524    21 Nov 2022;   HK40089067-A0    HK6077703    16 Aug 2023,AU2021282172-A1 PCT application Application WOUS034104;   AU2021282172-A1 Based on Patent WO2021242780;   CA3178016-A1 PCT application Application WOUS034104;   CA3178016-A1 Based on Patent WO2021242780;   IN202247074342-A PCT application Application WOUS034104;   IN202247074342-A Based on Patent WO2021242780;   KR2023017215-A PCT application Application WOUS034104;   KR2023017215-A Based on Patent WO2021242780;   IL298192-A Based on Patent WO2021242780;   EP4157854-A2 PCT application Application WOUS034104;   EP4157854-A2 Based on Patent WO2021242780;   JP2023527786-W PCT application Application WOUS034104;   JP2023527786-W Based on Patent WO2021242780;   CN116368156-A PCT application Application WOUS034104;   CN116368156-A Based on Patent WO2021242780;   US2023279056-A1 Provisional Application US067643P;   US2023279056-A1 Provisional Application US030836P;   US2023279056-A1 Provisional Application US051549P;   US2023279056-A1 PCT application Application WOUS034104;   HK40089067-A0 PCT application Application WOUS034104;   HK40089067-A0 Based on Patent WO2021242780;   HK40089067-A0 Previous Publ. Patent EP4157854,US030836P    27 May 2020;  US051549P    14 Jul 2020;  US067643P    19 Aug 2020;  EP739477    25 May 2021;  CA3178016    07 Nov 2022;  US17999524    21 Nov 2022;  KR742798    06 Dec 2022;  CN80049976    28 Jan 2023,WO2021242780-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2021242780-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA            EP4157854-A2:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN          ,,";  WO2021242780-A3 -- WO2015067302-A1   EPFL ECOLE POLYTECHNIQUE FEDERALE LAUSAN (EPFL)   GRISS R,  JOHNSSON K P,  SCHENA A;  WO2019241438-A2   PROMEGA CORP (PRMG)   HALL M,  ENCELL L P,  KILLORAN M,  WOOD K,  SMITH T,  KINCAID V,  KIRKLAND T,  DART M;  WO2020018935-A2   UNIV WASHINGTON SEATTLE (UNIW);  LANGAN R A (LANG-Individual);  BOYKEN S (BOYK-Individual);  BAKER D (BAKE-Individual);  NOVAK W (NOVA-Individual);  LAJOIE M J (LAJO-Individual);  QUIJANO RUBIO A (RUBI-Individual)   LANGAN R A,  BOYKEN S,  BAKER D,  NOVAK W,  LAJOIE M J,  QUIJANO RUBIO A","WO2021242780-A3  VIKTOR STEIN ET AL:          ""Synthetic protein switches: design principles and          applications"", TRENDS IN BIOTECHNOLOGY., vol. 33, no. 2,          1 February 2015 (2015-02-01), GB, pages 101 - 110,          XP055252894, ISSN: 0167-7799, DOI:          10.1016/j.tibtech.2014.11.010,relevantClaims[1-14|15-26,54-72],relevantPassages[Figure          2]",86886-0-0-0 D K M; 97055-0-0-0 D K M; 220514-0-0-0 D K M; 389866-0-0-0 D K M; 1552831-0-0-0 D K M; 93605-0-0-0 D K M; 105730-0-0-0 D K M; 375341-0-0-0 A K; 1365803-1-0-0 A K; 114817-0-0-0 A K; 184587-0-0-0 A K; 89180-0-0-0 A K; 1365803-1-0-0 CL DET,,,R24039 D K M; RA02YE D K M; RA0F7A D K M; RA3XHC D K M; RARZ0B D K M; RA00NS D K M; RA012P D K M; RA4WB8 A K; RANZLW A K; RA02JW A K; RA00C8 A K; RA026S A K,
WO2022260678-A1,"Composition used to deliver cargo to target cell            and treat therapeutic indication e.g. gastrointestinal            infection, inflammatory bowel disease, ulcerative            colitis, type I diabetes, and rheumatoid arthritis,            comprises cargo, and nanoparticle",AHMAD M;  DAY T;  HAFEZ I;  MERRITT J,DNALITE THERAPEUTICS INC (DNAL-Non-standard),2022F5090N,"   NOVELTY - Composition comprises cargo, and nanoparticle,                where the nanoparticle comprising at least one bile                salt, at least one cationic lipid, at least one                structural lipid, and at least one conjugated                lipid, and the conjugated lipid is conjugated with                a hydrophilic polymer.    USE - The composition is useful for delivering cargo                to a target cell or subject, and treating a                therapeutic indication in a subject, where the                therapeutic indication is immune-related indication                comprises a gastrointestinal indication e.g. at                least gastrointestinal infection, inflammatory                bowel disease (IBD), ulcerative colitis, and                Crohn's disease, non-gastrointestinal-specific                indication and/or a systemic indication e.g. at                least one graft versus host disease (GVHD),                systemic lupus erythematosus (SLE), type I                diabetes, rheumatoid arthritis, infection, wound,                and allergy, cancer-related indication e.g. at                least one Hodgkin's lymphoma, non-Hodgkin's                lymphoma, acute lymphoblastic leukemia, and acute                myelogenous leukemia, microvillus inclusion disease                (MVID), cystic fibrosis, hemophilia i.e. hemophilia                A, Gaucher's disease, neutropenia, and                non-alcoholic steatohepatitis (NASH). Test details                are described but no results given.    ADVANTAGE - The composition is safe, and has no                toxicity.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    composition comprising cargo, and                nanoparticle, where the nanoparticle comprises a                first cationic lipid comprising                7-(4-(dimethylamino)butyl)-7-hydroxytridecane-1,13-diyl                dioleate (CL1H6) or                7-(4-(diisopropylamino)butyl)-7-hydroxytride-cane-1,13-diyl                dioleate (CL4H6), optional second cationic lipid,                at least one bile salt, at least one structural                lipid, and at least one conjugated lipid, where the                at least one conjugated lipid is conjugated with a                hydrophilic polymer;    delivering a cargo to a target cell,                comprising contacting the target cell with the                composition;    delivering a cargo to a target cell, where the                target cell is part of a mucosal tissue, comprising                contacting the mucosal tissue with the                composition;    delivering a cargo to a subject, comprising                introducing the composition to the gastrointestinal                tract of the subject; and    treating a therapeutic indication in a                subject, comprising delivering a cargo to the                subject. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B01 (Steroids - including systems containing carbocyclic and/or heterocyclic rings fused onto the basic steroidal ring structure.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  ;  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).);  D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).)",B01-D02;  B04-B01B;  B04-C01;  B04-E01;  B04-E99;  B04-G01;  B04-H02;  B04-H04;  B04-H08;  B04-L01;  B04-N04;  B05-B01P;  B12-M11Q;  B14-A01;  B14-A02;  B14-A04;  B14-C03;  B14-C09B;  B14-E08;  B14-E10C1;  B14-F03;  B14-F08;  B14-G01;  B14-G02;  B14-H01A;  B14-H01G;  B14-K01;  B14-N12;  B14-N17;  B14-S04;  B14-S13;  B14-S18;  D05-H14;  D05-H99;  A05-H03;  A12-V01;  A12-W14,A61K-047/24;  A61K-047/28;  A61K-048/00;  A61K-009/127,WO2022260678-A1   15 Dec 2022   A61K-047/24   202304Pages: 148   English,WO2022260678-A1    WOUS037011    11 Jun 2021,,WOUS037011    11 Jun 2021,WO2022260678-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2022260678-A1 -- US20090041833-A1   ;  US20160122759-A1   ;  US20200129431-A1   ;  WO2020252375-A1   DNALITE THERAPEUTICS INC (DNAL-Non-standard)   AHMAD M,  DAY T,  HAFEZ I,  MERRITT J;  WO2019222400-A2   DNALITE THERAPEUTICS INC (DNAL-Non-standard)   AHMAD M,  DAY T P,  CALLMANN C,  ZHU X,  HAFEZ I",,86944-0-0-0 K M; 91489-0-0-0 K M; 95150-0-0-0 K M; 97940-0-0-0 K M; 97946-0-0-0 K M; 107948-0-0-0 K M; 109601-0-0-0 K M; 93605-0-0-0 K M; 105730-0-0-0 K M; 200757-0-0-0 K M; 184611-0-0-0 K M; 184587-0-0-0 K M; 184598-0-0-0 K M; 184616-0-0-0 K M; 162188-0-0-0 K M; 114126-0-0-0 K M; 4210-1-0-0 K M; 78432-1-0-0 K M; 98273-2-0-0 K M; 98273-1-0-0 K M; 108374-1-0-0 K M; 96294-1-0-0 K M; 590819-1-0-0 K M; 98273-1-4-0 K M;  K M;  K M; 1544529-1-0-0 K M; 2637103-1-0-0 K M; 3097368-1-0-0 K M;  K M; 444-0-0-0 ; 1544529-1-0-0 CL USE; 2637103-1-0-0 CL USE; 3097368-1-0-0 CL USE,,,RA02YD K M; RA05NO K M; RA09LI K M; RA0O3V K M; RA04QH K M; RA04OA K M; R06364 K M; R16207 K M; RA0J77 K M; RA05JM K M; RA00NS K M; RA012P K M; RA00GT K M; RA00H1 K M; RA00C8 K M; RA00GC K M; RA00H3 K M; RA04OC K M; RA0DNM K M; RA0KDA K M; R00486 K M; R00500 K M; R01251 K M; RA35LL K M; R08868 K M; R20447 K M; R01282 K M; RA83BC K M; RB9PNB K M; RCXMFS K M; RC1O1D K M; RARSN8 K M; RBQS5T K M; RBP23N K M; RD4IHO K M; R00351 ,0486-S; 0500-S; 1251-S; 1282-S
WO2024054823-A1,"Monitoring amplification reaction comprises            providing quality control template comprising 5' and 3'            subdomains and loop domain situated between 5' and 3'            subdomains, hybridizing, amplifying generating quality            control product, and detecting",ZHANG H;  KONG J E;  RAFIZADEH S,BECTON DICKINSON & CO (BECT-C),202426993L,"   NOVELTY - Monitoring amplification reaction, comprises:                providing a quality control template comprising a                5' subdomain, a 3' subdomain and a loop domain                situated between the 5' subdomain and the 3'                subdomain, where intramolecular nucleotide base                pairing between the 5' subdomain and the 3'                subdomain are capable of forming a paired stem                domain, and a quality control primer capable of                hybridizing to at least a portion of the 3'                subdomain of the quality control template;                subjecting the quality control template and the                quality control primer to an amplification reaction                capable of generating a first quality control                product; and detecting the first quality control                product.    USE - The method is useful for monitoring                amplification reaction.    ADVANTAGE - The method can comprise detecting the first                quality control product.    DETAILED DESCRIPTION - INDEPENDENT CLAIMs are also included                for:    kit for monitoring amplification reaction,                comprising the quality control template, the                quality control primer, the signal-generating                oligonucleotide and/or the supplemental quality                control primer; and    reaction mixture comprising the quality                control template, the signal-generating                oligonucleotide, the supplemental quality control                primer, target nucleic acid sequence, and/or                additional primers and/or probes specific to a                target nucleic acid sequence. ",,,"A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",A12-E13;  A12-V03C2;  A12-W11L;  B04-B03B;  B04-B03C;  B04-C02A2;  B04-C02C;  B04-C03;  B04-C03C;  B04-E01;  B04-E05;  B04-E07D;  B04-E14;  B04-E16;  B04-E99;  B04-L04B;  B04-N02;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  D05-A02B;  D05-H09;  D05-H18B;  D05-H99,C12Q-001/6844,WO2024054823-A1   14 Mar 2024   C12Q-001/6844   202426Pages: 112   English,WO2024054823-A1    WOUS073519    06 Sep 2023,,US374835P    07 Sep 2022,WO2024054823-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,,,86886-0-0-0 K M; 91481-0-0-0 K M; 92818-0-0-0 K M; 95972-0-0-0 K M; 97261-0-0-0 K M; 97486-1-0-0 K M; 104479-0-0-0 K M; 104492-0-0-0 K M; 201562-0-0-0 K M; 104488-0-0-0 K M; 104477-1-0-0 K M; 900-0-0-0 K M; 444-0-0-0 ; 107779-0-0-0 ,,,R24039 K M; R24034 K M; R01857 K M; R24033 K M; R01859 K M; RA016G K M; R06563 K M; RA083K K M; R01870 K M; RA01EA K M; RA0124 K M; RA04WZ K M; R01869 K M; R02044 K M; RA0GM6 K M; R00351 ; R01863 ,1857-S; 1859-S; 1870-S; 1869-S; 2044-S
WO2023066350-A1;  CN116003418-A;  HK40085637-A0;  CA3235512-A1;  AU2022370021-A1,"New substituted piperidine-2,6-dione based            compounds useful in medicine for treating tumors,            infectious diseases, autoinflammatory diseases,            inflammatory diseases, autoimmunity disease,            neurological disease, respiratory disease and            anemia",YANG X;  SUN R;  ZHAO B,GLUETACS THERAPEUTICS SHANGHAI CO LTD (GLUE-Non-standard);  BIAOXIN BIOMEDICAL TECHNOLOGY SHANGHAI (BIAO-Non-standard);  YANG X (YANG-Individual);  SUN R (SUNR-Individual);  ZHAO B (ZHAO-Individual);  GLUETACS THERAPEUTICS SHANGHAI CO LTD (GLUE-Non-standard);  GLUETACS THERAPEUTICS SHANGHAI CO LTD (GLUE-Non-standard),2023445326,"   NOVELTY - Substituted piperidine-2,6-dione based                compounds (I), are new.    USE - (I), (II), and (III) are useful in medicine                and kit or test kit for treating and preventing                tumors, infectious diseases, autoinflammatory                diseases, inflammatory diseases, autoimmunity                disease, neurological disease, respiratory disease,                anemia, hemorrhagic shock, transplant rejection,                multiple organ dysfunction syndrome (MODS), sarcoid                disease, adult respiratory distress syndrome,                congestive heart failure, myocardial infarction,                Wengwei Richter syndrome, Richter syndrome (RS),                acute liver failure, diabetes, Kennedy disease,                seborrheic alopecia, hirsutism, skin disease,                cardiovascular disease, functional Uterine                bleeding, aplastic anemia in children,                endometriosis, transplant rejection, polycystic                ovary syndrome, and thyroid disease, hemorrhagic                shock, transplant rejection, multiple organ                dysfunction syndrome (MODS), sarcoidosis, adult                respiratory distress syndrome, congestive heart                failure, myocardial infarction, Richter's syndrome                syndrome, acute liver failure and diabetes (all                claimed).    ADVANTAGE - (I), (II) and (III) are cereblon (CRBN) E3                ligase ligand compounds, have good degradation                effect to ARFL, and AR-V7 splicing, can effectively                treat or prevent diseases or diseases mediated by                cereblon protein, and diseases or conditions                associated with the degraded protein.    DETAILED DESCRIPTION - Substituted piperidine-2,6-dione based                compounds of formula (I), and their salts,                enantiomers, stereoisomers, solvates, isotopically                enriched analogs, prodrugs or polymorphs, are                new.    A=CO, CH or CD ;    R1, R2, R3 and R4=H, D, halo, optionally                deuterated 1-6C alkyl, optionally deuterated 1-6C                alkoxy, or halo 1-6C alkyl;    R5, R6, R7, and R8=R9, H, D, halo, OH,                mercapto, nitro, amino, cyano, optional deuterated                1-6C alkyl, optional deuterated 1-6C alkoxy,                halogenated 1-6C alkyl, 2-6C alkenyl, or 2-6C                alkynyl, where 1-3 of R5, R6, R7 and R8 is                R9;    R9=RU11-;    U11=a bond, N(R10) or O;    R10=H, or optionally deuterated 1-6C alkyl;                and    R=optionally substituted nitrogen-containing                heterocyclic group, where the optionally                substituted nitrogen-containing heterocyclic group                is optionally substituted nitrogen-containing                monocyclic heterocyclic group or optionally                substituted nitrogen-containing bridged                heterocyclic group, when 2-4 of R5, R6, R7 and R8                are R9, (I) is optionally partially deuterated or                fully deuterated.    Full definitions are given in the DEFINITIONS                (Full Definitions) Field. INDEPENDENT CLAIMS are                also included for:    ubstituted piperidine based compound of                formula (II) and their salts, enantiomers,                stereoisomers, solvates, isotopically enriched                analogs, prodrugs or polymorphs, and (II) does not                include                3-(4,6-difluoro-1-oxo-5-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-2-yl)piperidine-2,6-dione,                2-(2,6-dioxopiperidine-3-yl)-5-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione,                3-(4-chloro-1-oxo-5-(4-(piperidin-4-ylmethyl)piperidin-1-yl)isoindoline-2-yl)piperidine-2,6-dione,                5-(4-(azacyclobutan-3-ylmethyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione                and                2-(2,6-dioxopiperidin-3-yl)-5-(3-(piperazin-1-ylmethyl)azetidin-1-yl)isoindoline-1,3-diketone;    ubstituted ubiquitin ligase based                piperidine-2,6-dione group containing compound of                formula (PBM-R1-W1-LIN-ULM) (III); and    composition comprising substituted                piperidine-2,6-dione based compounds (I),                substituted piperidine based compound (II) and/or                substituted ubiquitin ligase based                piperidine-2,6-dione group containing compound                (III).    R11, R12, R13 and R14=H, D, halo, optionally                deuterated 1-6C alkyl, optionally deuterated 1-6C                alkoxy, or halogen substituted 1-6C alkyl;    (Rb1) =benzene ring substituted by nRb1,    Rb1=H, D, halo, OH, mercapto, nitro, amino ,                cyano, optionally deuterated 1-6C alkyl, optionally                deuterated 1-6C alkoxy, halogenated 1-6C alkyl,                2-6C alkenyl, or 2-6C alkynyl;    (Ra1) =benzene ring substituted by mRa1;    Ra1=W1-LIN-U2-Rc1-U1-;    U1 and U2=a bond, N(Rd1) or O;    Rd1=H or optionally deuterated 1-6C                alkyl;    Rc1=optionally substituted nitrogen-containing                monocyclic heterocyclic group or optionally                substituted nitrogen-containing bridged                heterocyclic group;    W1=H, optionally substituted                nitrogen-containing monocyclic heterocyclic group,                optionally substituted nitrogen-containing bridged                heterocyclic group, optionally substituted                cycloalkyl, optionally substituted heteroaryl,                optionally substituted aryl, 2-6C alkenyl, 2-6C                alkynyl, leaving group, CHO, COOH, NH , OH or                mercapto, where the compound (II) is partially                deuterated or fully deuterated;    PBM-R1-W1-=targeting moiety capable of binding                protein; and    ULM=ligand portion for binding E3 ubiquitin                ligase of formula (IIIa).         ",,,"B02 (Fused ring heterocyclics.);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).)",B05-A04A;  B06-D03;  B14-A01;  B14-A02;  B14-A04;  B14-C03;  B14-F01;  B14-F02;  B14-F03;  B14-F08;  B14-G02C;  B14-H01;  B14-J01;  B14-J05;  B14-K01;  B14-L06;  B14-N07;  B14-N11;  B14-N12;  B14-N14;  B14-N17;  B14-P02;  B14-R02;  B14-S04;  B14-S05;  D08-B,A61K-031/4035;  A61K-031/4439;  A61P-011/00;  A61P-031/00;  A61P-035/00;  A61P-037/00;  A61P-005/00;  A61P-009/00;  C07D-403/14;  A61K-031/4545;  A61K-031/4709;  A61K-031/4995;  A61K-031/501;  A61K-031/506;  A61K-031/517;  A61K-031/519;  A61K-031/551;  A61P-001/00;  A61P-001/02;  A61P-001/04;  A61P-001/16;  A61P-015/00;  A61P-017/00;  A61P-017/08;  A61P-017/14;  A61P-019/02;  A61P-019/06;  A61P-025/00;  A61P-027/04;  A61P-029/00;  A61P-003/10;  A61P-031/04;  A61P-031/06;  A61P-031/14;  A61P-031/18;  A61P-033/06;  A61P-035/02;  A61P-037/06;  A61P-005/14;  A61P-007/06;  A61P-009/04;  A61P-009/10;  C07D-401/04;  C07D-401/14;  C07D-405/14;  C07D-417/14;  C07D-471/04;  C07D-471/08;  C07D-487/04;  C07D-487/08;  C07D-495/14;  C07D-519/00,WO2023066350-A1   27 Apr 2023   C07D-403/14   202341Pages: 603   Chinese;  CN116003418-A   25 Apr 2023   C07D-487/08   202346   Chinese;  HK40085637-A0   11 Aug 2023   C07D-487/08   202395   Chinese;  CA3235512-A1   27 Apr 2023   C07D-403/14   202434   English;  AU2022370021-A1   09 May 2024   C07D-403/14   202439   English,WO2023066350-A1    WOCN126516    20 Oct 2022;   CN116003418-A    CN11289138    20 Oct 2022;   HK40085637-A0    HK4073898    31 May 2023;   CA3235512-A1    CA3235512    20 Oct 2022;   AU2022370021-A1    AU370021    20 Oct 2022,HK40085637-A0 Previous Publ. Patent CN116003418;   CA3235512-A1 PCT application Application WOCN126516;   AU2022370021-A1 PCT application Application WOCN126516;   AU2022370021-A1 Based on Patent WO2023066350,CN11231963    22 Oct 2021;  CN11289138    20 Oct 2022;  CA3235512    18 Apr 2024,WO2023066350-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA          ,,"WO2023066350-A1 -- CN110291087-A   ARVINAS INC (ARVI-Non-standard)   CREW A P,  QIAN Y,  DONG H,  WANG J,  HORNBERGER K R,  CREWS C M;  CN110506039-A   ARVINAS INC (ARVI-Non-standard)   CREW A P,  HORNBERGER K R,  SNYDER L B,  ZIMMERMANN K,  WANG J,  BERLIN M,  CREWS C M,  DONG H;  CN110612294-A   ARVINAS OPERATIONS INC (ARVI-Non-standard)   CREW A P,  BERLIN M,  DONG H,  HOMBERGER K R,  QIAN Y,  SNYDER L B,  WANG J,  ZIMMERMANN K;  CN110612297-A   ARVINAS OPERATIONS INC (ARVI-Non-standard)   QIAN Y,  CREW A P,  CREWS C M,  DONG H,  HORNBERGER K R,  WANG J;  CN110741004-A   ARVINAS INC (ARVI-Non-standard);  UNIV YALE (UYYA)   CREW A P,  HORNBERGER K R,  WANG J,  DONG H,  QIAN Y,  CREWS C M,  JAIME-FIGUEROA S;  CN112218859-A   ARVINAS OPERATIONS INC (ARVI-Non-standard);  UNIV YALE (UYYA)   CREW A P,  HORNBERGER K R,  WANG J,  DONG H,  BERLIN M,  CREWS C M;  CN112262134-A   ARVINAS INC (ARVI-Non-standard)   CREW A P,  CREWS C M,  DONG H,  HORNBERGER K R,  WANG J,  QIAN Y,  ZIMMERMANN K,  BERLIN M,  SNYDER L B;  CN112888681-A   CULLGEN SHANGHAI INC (CULL-Non-standard)   LIU J,  PLEWE M B,  WANG J,  HAN X,  CHEN L;  CN113164775-A   ARVINAS OPERATIONS INC (ARVI-Non-standard);  UNIV YALE (UYYA)   CREW A P,  HORNBERGER K R,  WANG J,  CREWS C M,  JAIME-FIGUEROA S,  DONG H,  QIAN Y,  ZIMMERMAN K;  WO2018119357-A1   ARVINAS INC (ARVI-Non-standard)   CREW A P,  SNYDER L B,  WANG J,  DONG H,  QIAN Y,  BERLIN M;  WO2019099926-A1   ARVINAS INC (ARVI-Non-standard)   CREW A P,  HORNBERGER K R,  ZIMMERMANN K,  ARAUJO E;  WO2020162725-A1   KOREA RES INST CHEM TECHNOLOGY (KRIC);  KOREA RES INST BIOSCIENCE &                  BIOTECHNOLOG (KRIB)   HWANG J Y,  HA J D,  CHO S Y,  KIM P,  YUN C S,  KIM H J,  PARK S G,  PARK B C,  KIM J H,  KIM S;  WO2021011913-A1   ARVINAS OPERATIONS INC (ARVI-Non-standard)   CREW A P,  BERLIN M,  DONG H,  ISHCHENKO A,  CACACE P D A M,  CHANDLER J T;  WO2021170109-A1   CULLGEN SHANGHAI INC (CULL-Non-standard)   LIU J,  PLEWE M B,  WANG J,  HAN X,  CHEN L,  ZHANG C;  WO2021194878-A1   ARVINAS OPERATIONS INC (ARVI-Non-standard)   SPARKS S M,  ARAUJO E,  BERLIN M,  ZHANG W,  WANG J;  WO2021194879-A1   ARVINAS OPERATIONS INC (ARVI-Non-standard)   ARAUJO E,  SPARKS S M,  BERLIN M,  ZHANG W,  WANG J;  WO2022047145-A1   ARVINAS OPERATIONS INC (ARVI-Non-standard)   HORNBERGER K R,  SNYDER L B,  WANG J;  WO2022087125-A1   ARVINAS OPERATIONS INC (ARVI-Non-standard)   BERLIN M,  CREW A,  DONG H,  HORNBERGER K,  SNYDER L,  WANG J,  ZIMMERMANN K;  WO2022098544-A1   ARVINAS OPERATIONS INC (ARVI-Non-standard)   DONG H,  SNYDER L,  WANG J;  WO2022109396-A1   FOGHORN THERAPEUTICS INC (FOGH-Non-standard)   NETHERTON M,  BRUCELLE F,  DENG J,  VOIGT J H;  WO2022133184-A1   NEWAVE PHARM INC (NEWA-Non-standard)   CHEN Y;  WO2022198112-A1   ARVINAS OPERATIONS INC (ARVI-Non-standard)   ARAUJO E,  BERLIN M,  SPARKS S M,  WANG J,  ZHANG W,  DONG H;  WO2022221673-A1   ARVINAS OPERATIONS INC (ARVI-Non-standard)   BERLIN M,  DONG H,  SHERMAN D,  SNYDER L B,  WANG J,  ZHANG W","WO2023066350-A1  DEGORCE SEBASTIEN          L., TAVANA OMID, BANKS ERICA, CRAFTER CLAIRE, GINGIPALLI          LAKSHMAIAH, KOUVCHINOV DAVID, MAO YUMENG, PACHL FIONA, :          ""Discovery of Proteolysis-Targeting Chimera Molecules          that Selectively Degrade the IRAK3 Pseudokinase"", JOURNAL          OF MEDICINAL CHEMISTRY, vol. 63, no. 18, 24 September          2020 (2020-09-24), US , pages 10460 - 10473, XP093059781,          ISSN: 0022-2623, DOI:          10.1021/acs.jmedchem.0c01125,relevantClaims[20-32, 34-38,          41-43, 49-50, 54-55, 60-62],relevantPassages[pp.          10460-10473];  HAN XIN, ZHAO          LIJIE, XIANG WEIGUO, QIN CHONG, MIAO BUKEYAN, MCEACHERN          DONNA, WANG YU, METWALLY HODA, WANG LU, MATVEKAS ALEKSAS,          WE: ""Strategies toward Discovery of Potent and Orally          Bioavailable Proteolysis Targeting Chimera Degraders of          Androgen Receptor for the Treatment of Prostate Cancer"",          JOURNAL OF MEDICINAL CHEMISTRY, vol. 64, no. 17, 9          September 2021 (2021-09-09), US , pages 12831 - 12854,          XP093059787, ISSN: 0022-2623, DOI:          10.1021/acs.jmedchem.1c00882,relevantClaims[20-32, 34-38,          41-43, 49-50, 54-55, 60-62],relevantPassages[pp.          12831-12854];  DATABASE Registry          CAS; 30 September 2021 (2021-09-30), ANONYMOUS :          ""1H-Isoindole-1,3(2H)-dio ne, 5-[2-(2-aminoeth          yl)-3-methyl-1-piperi dinyl]-2- (2,6-dioxo-3-piperidi          nyl)-"", XP093059849, Database accession no.          2703770-66-3,relevantClaims[1-3, 5-8, 51-53];  DATABASE Registry          CAS; 19 October 2021 (2021-10-19), ANONYMOUS :          ""1H-Isoindole-1,3(2H)-dio ne, 2-(2,6-dioxo-3-pi          peridinyl)-5-[4-(4- piperidinylmethyl)-1 -piperidinyl]-"",          XP093059852, Database accession no.          2714477-27-5,relevantClaims[9-15, 17-19, 51-53];  DATABASE Registry          CAS; 19 October 2021 (2021-10-19), ANONYMOUS :          ""1H-Isoindole-1,3(2H)-dio ne, 2-(2,6-dioxo-3-pi          peridinyl)-5-[4-[[1-[2- [4-[6- [5-(1-methylethoxy)-          1H-indazol-3-yl]-4-p yrimidinyl]-1-piperaz inyl]ethyl]-4-          piperidinyl]methyl]- 1-piperidinyl]-"", XP093059855,          Database accession no. 2714476-17-0,relevantClaims[20-32,          34-38, 54-55];  DATABASE Registry          CAS; 23 June 2022 (2022-06-23), ANONYMOUS :          ""Benzonitrile, 3-chloro-5- [1-[4-[[2-[4-[1-[1-[2-          (2,6-dioxo-3-piperidi nyl)- 2,3-dihydro-1,3-diox          o-1H-isoindol-5-yl]-3 -piperidinyl]-3-azetid inyl]-1-          piperazinyl]-4-pyrimi dinyl]methoxy]phen          yl]-1-methylethyl]-"", XP093059863, Database accession no.          2776896-94-5,relevantClaims[1-3, 5-8, 51-53];  DATABASE Registry          CAS; 14 October 2022 (2022-10-14), ANONYMOUS :          ""2,6-Piperidinedione, 3-[5 -[4-[(2,2-dimethyl-1-          piperazinyl)methyl]- 1-          piperidinyl]-4-fluoro1,3-dihydro-1-oxo-2          H-isoindol-2-yl]-"", XP093059866, Database accession no.          2839672-28-3,relevantClaims[9-15, 17-19, 51-53];  DATABASE Registry          CAS; 17 October 2022 (2022-10-17), ANONYMOUS ,          XP093059873, Database accession no.          2839757-07-0,relevantClaims[20-32, 34-38,          54-55]", N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N,228937801 N; 228937802 N; 228937803 N,00994; 49755; 45271; 00826; 00812; 09953; 45262; 01380,RDBYVB N; RDBYVC N; RDBYVD N; RDBYVE N; RDBYVF N; RDBYVG N; RDBYVH N; RDBYVI N; RDBYVJ N; RDBYVK N; RDBYVL N; RDBYVM N; RDBYVN N; RDBYVO N; RDBYVP N; RDBYVQ N; RDBYVR N; RDBYVS N; RDBYVT N; RDBYVU N; RDBYVV N; RDBYVW N; RDBYVX N; RDBYVY N; RDBYVZ N; RDBYW0 N; RDBYW1 N; RDBYW2 N; RDBYW3 N; RDBYW4 N; RDBYW5 N; RDBYW6 N; RDBYW7 N; RDBYW8 N; RDBYW9 N; RDBYWA N; RDBYWB N; RDBYWC N; RDBYWD N; RDBYWE N; RDBYWF N; RDBYWG N; RDBYWH N; RDBYWI N; RDBYWJ N; RDBYWK N; RDBYWL N; RDBYWM N; RDBYWN N; RDBYWO N; RDBYWP N; RDBYWQ N; RDBYWR N; RDBYWS N; RDBYWT N; RDBYWU N; RDBYWV N; RDBYWW N; RDBYWX N; RDBYWY N; RDBYWZ N; RDBYX0 N; RDBYX1 N; RDBYX2 N; RDBYX3 N; RDBYX4 N; RDBYX5 N; RDBYX6 N; RDBYX7 N; RDBYX8 N; RDBYX9 N; RDBYXA N; RDBYXB N; RDBYXC N; RDBYXD N; RDBYXE N; RDBYXF N; RDBYXG N; RDBYXH N; RDBYXI N; RDBYXJ N; RDBYXK N; RDBYXL N; RDBYXM N; RDBYXN N; RDBYXO N; RDBYXP N; RDBYXQ N; RDBYXR N; RDBYXS N; RDBYXT N; RDBYXU N; RDBYXV N; RDBYXW N; RDBYXX N; RDBYXY N,
CN114230674-A;  CN114230674-B,"New coronavirus spike protein receptor binding            domain fusion protein useful in preparing vaccine for            preventing coronavirus infection and infection-induced            diseases comprises copy of receptor binding domain            polypeptide, fragment crystallizable domain, and/or            endogenous adjuvant",ZHANG T;  WANG Z;  XU X,INST BASIC MEDICAL SCI CHINESE ACAD MEDI (MSUM-C),202249367F,"   NOVELTY - Coronavirus spike (S) protein receptor binding                domain (RBD) fusion protein comprising copy of the                RBD polypeptide, fragment crystallizable (Fc)                domain, and/or endogenous adjuvant derived from the                coronavirus S protein or S protein mutant, where                the amino acid sequence of the S protein comprises                fully defined 1273 amino acid sequence (SEQ ID                NO:1) as given in the specification, the Fc domain                is the Fc domain of human immunoglobulin G (IgG)1,                IgG2a, IgG2b, IgG3 or IgG4, the Fc domain is fused                to the C-terminus of the RBD polypeptide, the                endogenous adjuvant is RS09 adjuvant, and is fused                to the N-terminus of the RBD polypeptide and/or the                C-terminus of the Fc domain, and the RBD                polypeptide and/or the RBD polypeptide and the Fc                domain are connected by a linker, is new.    USE - The coronavirus RBD fusion protein, the                polynucleotide, the vector, or the oligomer formed                by the RBD fusion protein is useful in preparing a                vaccine for preventing coronavirus infection and                infection-induced diseases (all claimed).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:    (1) a polynucleotide encoding the RBD monomer                fusion protein;    (2) a vector, comprising the                polynucleotide;    (3) a cell, comprising the vector;    (4) an oligomer formed by the coronavirus RBD                fusion protein; and    (5) a vaccine for preventing coronavirus                infection and infection-induced diseases,                comprising the coronavirus RBD fusion protein, the                polynucleotide, the vector, the oligomer formed by                the RBD fusion protein, an adjuvant, and an                excipient or vector for a vaccine. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B14-S11D3;  B14-S11A;  B04-E99;  B04-E08;  B14-A02B5;  B04-N08;  B04-C01;  B04-N03K0E;  B04-G27G0E;  B04-G0100E;  B04-E02H;  D05-H99;  D05-H12C;  D05-H12E;  D05-H14;  D05-H07;  D05-H17C,A61K-039/215;  A61P-031/14;  C07K-014/165;  C07K-019/00;  C12N-015/62,CN114230674-A   25 Mar 2022   C07K-019/00   202242   Chinese;  CN114230674-B   26 Sep 2023   C07K-019/00   202381   Chinese,CN114230674-A    CN11444421    30 Nov 2021;   CN114230674-B    CN11444421    30 Nov 2021,CN114230674-B Previous Publ. Patent CN114230674,CN11392625    01 Dec 2020,,,"CN114230674-A -- CN111533809-A   CHINESE ACAD SCI WUHAN VIROLOGY INSTATIC (CHSC-Non-standard)   GONG R,  XIAO G,  ZHANG H,  ZHANG Z,  ZHAO S,  ZHANG X,  PAN X,  ZHAN Y,  PENG C,  GAO X;  CN114349868-A   INST BASIC MEDICAL SCI CHINESE ACAD MEDI (MSUM)   WANG Z,  ZHANG T,  ZHENG N,  XU X;  TW202246315-A   ADAGIO THERAPEUTICS INC (ADAG-Non-standard)   WALKER L,  RAPPAZZO C G,  SAKHARKAR M,  DEVEAU L,  KAKU C I;  CN114230674-B -- CN111533809-A   CHINESE ACAD SCI WUHAN VIROLOGY INSTATIC (CHSC-Non-standard)   GONG R,  XIAO G,  ZHANG H,  ZHANG Z,  ZHAO S,  ZHANG X,  PAN X,  ZHAN Y,  PENG C,  GAO X;  CN114349868-A   INST BASIC MEDICAL SCI CHINESE ACAD MEDI (MSUM)   WANG Z,  ZHANG T,  ZHENG N,  XU X;  TW202246315-A   ADAGIO THERAPEUTICS INC (ADAG-Non-standard)   WALKER L,  RAPPAZZO C G,  SAKHARKAR M,  DEVEAU L,  KAKU C I","CN114230674-A  JINGYUN YANG: ""A          vaccine targeting the RBD of the S protein of SARS-CoV-2          induces protective immunity"", 572577, vol. 586, pages          572, XP037277111, DOI:          10.1038/s41586-020-2599-8,relevantClaims[1-11];  TING ZHANG :          ""Immunogenicity of novel DNA vaccines encoding          receptor-binding domain (RBD) dimer-Fc fusing antigens          derived from different SARS-CoV-2 variants of concern"",          JOURNAL OF MEDICAL VIROLOGY, vol. 95, no. 2, pages          28563,relevantClaims[1-11];  : ""SRBD"", SRBD,          vol. 40, no. 12, pages 1645 -          1650,relevantClaims[1-11]CN114230674-B            Chang Ting, etc. Glycosylation of novel coronavirus S          protein RBD and the effect of its length on the          immunogenicity of protein vaccine; Chang Ting et al;          Glycosylation of novel coronavirus S protein RBD and the          effect of its length on the immunogenicity of protein          vaccine; Vol. 40 (Phase 12); 1645-1650;            Jingyun Yang. A vaccine targeting the RBD of the S          protein of SARS-CoV-2 induces protective immunity;Jingyun          Yang;572577;586;572577;            Ting Zhang and so on. Immunogenicity (RBD):          Immunogenicity (RBD): Immunogenicity (RBD):          Immunogenicity (RBD): Immunogenicity (RBD): Immun          dimer-Fc-derived from different SARS-CoV-2 -; Ting Zhang          and so on; Journal of medical virology; Volume 95 (Phase          2); e28563",105730-0-0-0 N; 93605-0-0-0 N; 200757-0-0-0 N; 184611-0-0-0 M K; 184616-0-0-0 M K; 184587-0-0-0 M K,,,RA012P N; RA00NS N; RA00GT N; RA00H1 M K; RA00H3 M K; RA00C8 M K,
WO2023220227-A1,"Treating disease or disorder by forming at least            one of biological sample from the subject, analyzing            for the presence of first biomarker in cell nucleus and            administering interleukin-1 receptor-associated kinase            4-modifying compound",UGOLKOV A;  MARTELL R,CURIS INC (CURS-C),2023B91327,"   NOVELTY - Treating (M1) a disease or disorder in a                subject, comprises: obtaining at least one of a                biological sample(s) from the subject; analyzing                the biological sample(s) for the presence of a                first biomarker in a cell nucleus of the biological                sample(s); and administering an interleukin-1                receptor-associated kinase 4 (IRAK4) modifying                compound comprising an IRAK4 inhibitor or an IRAK4                degrader to the subject if the presence of the                first biomarker is detected in the cell nucleus of                the biological sample(s), where the first biomarker                comprises IRAK4, nuclear factor-kappaB (NF-KB)                p-p65, NF-KB p-p50, p-IRAK1, Fms-like tyrosine                kinase 3 (FLT3), and myeloid differentiation                primary response 88 (MYD88).    USE - The methods are useful for treating a disease                or disorder in a subject, where the disease or                disorder is: a cancer e.g. brain cancer, kidney                cancer, liver cancer, stomach cancer, penile                cancer, vaginal cancer and ovarian cancer, a                hematological malignancy e.g. a non-Hodgkin's                lymphoma, a leukemia and lymphoma; and an                inflammatory disease or disorder e.g. autoimmune                disease or disorder, an ocular allergy,                conjunctivitis, vernal conjunctivitis, allergic                rhinitis, autoimmune idiopathic thrombocytopenia,                systemic lupus erythematosus, rheumatoid arthritis                and scleroderma (all claimed). Test details are                described but no results given.    ADVANTAGE - The method utilizes (I) that: has safety and                tolerability profile; is rapidly absorbed with                maximum plasma concentrations observed at 0.5-8                hours post dose; and exhibits dose-proportional                increase in exposure and has a half-life of 6                hours.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    treating (M2) a disease or disorder in a                subject, comprising obtaining at least one a                biological sample(s) from the subject, measuring a                sample expression level of a first biomarker in the                biological sample(s), comparing the sample                expression level of the first biomarker to a                reference expression level of the first biomarker,                administering an IRAK4-modifying compound                comprising the IRAK4 inhibitor or the IRAK4                degrader to the subject if the sample expression                level of the first biomarker is elevated in the                sample(s) as compared to the reference expression                level of the first biomarker; and    treating (M3) a disease or disorder in a                subject, comprising obtaining the biological                sample(s) from the subject, measuring a sample                expression level of a first biomarker in the                biological sample(s), comparing the sample                expression level of the first biomarker to a                reference expression level of the first biomarker,                analyzing the biological sample(s) for the presence                of the first biomarker in a cell nucleus of the                biological sample(s) and administering the                IRAK4-modifying compound comprising IRAK4 inhibitor                or IRAK4 degrader to the subject only if the                presence of the first biomarker is detected in the                cell nucleus of the biological sample(s) and the                sample expression level of the first biomarker is                elevated in the sample(s) as compared to the                reference expression level of the first                biomarker. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).)",B01-B01;  B02-D;  B04-A07A1;  B04-B03A;  B04-G02;  B04-G21;  B04-N16;  B05-B01A;  B05-B01J;  B06-E03;  B06-F03;  B06-H;  B07-H;  B10-B02A;  B12-M12N;  B14-C03;  B14-D06C;  B14-F03;  B14-G02A;  B14-G02D;  B14-H01E5;  B14-H01E8;  B14-H01F;  B14-H01G2;  B14-H01J1;  B14-L06;  B14-N03;  B14-N04;  B14-N17;  B14-S18;  C01-B01;  C02-D;  C04-A07A1;  C04-B03A;  C04-G02;  C04-G21;  C04-N16;  C05-B01A;  C05-B01J;  C06-E03;  C06-F03;  C06-H;  C07-H;  C10-B02A;  C12-M12N;  C14-C03;  C14-D06C;  C14-F03;  C14-G02A;  C14-G02D;  C14-H01E5;  C14-H01E8;  C14-H01F;  C14-H01G2;  C14-H01J1;  C14-L06;  C14-N03;  C14-N04;  C14-N17;  C14-S18;  D05-H11,A61K-031/4162;  A61P-031/00;  A61P-035/02;  C12Q-001/6886,WO2023220227-A1   16 Nov 2023   C12Q-001/6886   202398Pages: 164   English,WO2023220227-A1    WOUS021812    11 May 2023,,US340692P    11 May 2022,WO2023220227-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,,, K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M; 3465640-1-0-0 K M; 1485462-1-0-0 K M; 2858957-1-0-0 K M;  K M;  K M; 2602580-1-0-0 K M; 2637734-0-0-0 K M; 2627264-0-0-0 K M; 2411047-0-0-0 K M; 88573-0-0-0 K M; 128531-1-0-0 K M; 90702-0-0-0 K M; 91184-1-0-0 K M; 67298-0-0-0 K M; 8769-1-0-0 K M; 110156-1-0-0 K M; 97676-0-0-0 K M; 1506080-1-0-0 K M; 1919660-1-0-0 K M; 1198269-1-0-0 K M; 3067252-1-0-0 K M; 2922026-0-0-0 K M; 95299-1-0-0 K M; 108692-0-0-0 K M; 166620-0-0-0 K M; 88752-2-0-0 K M; 104629-1-0-0 K M; 3465640-1-0-0 CL USE; 1485462-1-0-0 CL USE; 2858957-1-0-0 CL USE; 2602580-1-0-0 CL USE; 2637734-0-0-0 CL USE; 2627264-0-0-0 CL USE; 2411047-0-0-0 CL USE; 1506080-1-0-0 CL USE; 1919660-1-0-0 CL USE; 1198269-1-0-0 CL USE; 3067252-1-0-0 CL USE; 2922026-0-0-0 CL USE,230240901 K M,01116; 01142; 01143; 01144; 07948; 07949; 01174; 01184; 01183; 47121; 01272; 07746; 11065; 13275; 00012; 00090,RBWDHP K M; RBWDHQ K M; RCKRRH K M; RBWDHR K M; RBWDHO K M; RBWDH6 K M; RBWDH5 K M; RCKRRI K M; RBWDH4 K M; RBWDH7 K M; RBWDHA K M; RCKRRJ K M; RBWDH3 K M; RBWDH2 K M; RBWDG0 K M; RCKRRK K M; RBWDG1 K M; RBWDFV K M; RCKRRL K M; RBWDFW K M; RBWDFX K M; RBWDG2 K M; RBWDFT K M; RBWDFO K M; RBWDFP K M; RBWDFU K M; RBWDFQ K M; RBWDFS K M; RBWDFN K M; RBWDFM K M; RBWDFI K M; RBWDFJ K M; RBWDFK K M; RBWDFL K M; RBWDFH K M; RBWDFG K M; RBWDFF K M; RBWDFB K M; RBWDFC K M; RCYK5D K M; RBWDFD K M; RCKRRM K M; RCKRRN K M; RBWDFE K M; RCKRRO K M; RBWDHN K M; RCKRRP K M; RCKRRR K M; RBWDHJ K M; RCKRRS K M; RBWDHK K M; RBWDHL K M; RBWDHM K M; RBWDHF K M; RBWDHG K M; RBWDHH K M; RBWDHI K M; RBWDHD K M; RBWDHE K M; RBWDFA K M; RCKRRT K M; RBWDGW K M; RBWDGX K M; RBWDGY K M; RBWDGZ K M; RBWDGS K M; RBWDGT K M; RBWDGU K M; RBWDGV K M; RBWDGN K M; RBXF0Z K M; RAU6J9 K M; RBJXNU K M; RC145R K M; RC5EKU K M; RBEE69 K M; RBKV8D K M; RBEXGI K M; RBA52F K M; RACDI6 K M; RA4ACO K M; R01215 K M; RA035K K M; R00008 K M; R02028 K M; R00125 K M; R08228 K M; RB3DP6 K M; RAZS9G K M; RAKEUW K M; RBOEUX K M; RBLABK K M; RA0CGV K M; R23692 K M; RA1VLZ K M; R00002 K M; R00067 K M,1215-S; 0008-S; 2028-S; 0125-S; 0002-S; 0067-S
US2024058425-A1,"New composition comprises CRISPR associated            protein 9 (Cas9) protein or fusion protein, where            fusion protein comprises two heterologous polypeptide            domains, and at least one guide RNA (gRNA) that targets            Cas9 protein to regulatory element of target gene, for            use in treating leukemia",REDDY T E;  CRAWFORD G E;  TER W M;  KLANN T S;  BARRERA A;  GERSBACH C A,UNIV DUKE (UDUK-C),202420237X,"   NOVELTY - Composition is new, where the composition                comprises a CRISPR associated protein 9 (Cas9)                protein or a fusion protein, where the fusion                protein comprises two heterologous polypeptide                domains, where the first polypeptide domain                comprises a Cas9 protein and the second polypeptide                domain has an activity selected from transcription                activation activity, transcription repression                activity, transcription release factor activity,                histone modification activity, nuclease activity,                nucleic acid association activity, methylase                activity, and demethylase activity. The guide RNA                (gRNA) that targets the Cas9 protein to a                regulatory element of a target gene.    USE - Composition for pharmaceutical composition is                used in treating cancer i.e. leukemia (all                claimed). The composition is further used in                targeting a novel regulatory element of a gene, and                in methods of modifying growth of a cell,                decreasing cell fitness, increasing cell fitness.                No biological data is given.    ADVANTAGE - The composition enables in targeting newly                discovered gene regulatory elements affecting cell                fitness to treat diseases, such as leukemia.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for: (1) an                isolated polynucleotide sequence, which comprises a                sequence selected from sequence 20-23 nucleobases                (SEQ ID NOs: 57-338), given in the specification;                (2) a vector encoding the composition; (3) a cell,                which comprises the composition; (4) a                pharmaceutical composition, which comprises the                composition; (5) a method of treating leukemia in a                subject, which involves targeting a regulatory                element of, or modifying the expression of a target                gene; (6) a method of modifying growth of a cell,                which involves targeting a regulatory element of,                or modifying the expression of a target gene; and                (7) a method of decreasing cell fitness, which                involves targeting a regulatory element of, or                modifying the expression of a target gene. ",,,"D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B01 (Steroids - including systems containing carbocyclic and/or heterocyclic rings fused onto the basic steroidal ring structure.)",D05-H12E;  D05-H12A;  D05-H19C;  D05-H99;  B04-E02E;  B04-E03E;  B04-E02H;  B12-Q01;  B04-L05A2E;  B04-N08;  B14-L01;  B14-S18;  B04-L05;  B04-L04;  B04-E01B;  B04-E06;  B04-C01;  B14-H01;  B04-L05A2;  B04-E13;  B04-E12;  B04-E08;  B04-E99,A61K-031/7088;  A61K-038/46;  A61P-035/02;  C12N-015/10;  C12N-015/11;  C12N-015/86;  C12N-015/90;  C12N-005/09;  C12N-009/22,US2024058425-A1   22 Feb 2024   A61K-038/46   202424   English,US2024058425-A1    US180718    08 Mar 2023,US2024058425-A1 Provisional Application US372373P;   US2024058425-A1 Provisional Application US317847P,US317847P    08 Mar 2022;  US180718    08 Mar 2023,,,,,184616-0-0-0 M K; 105730-0-0-0 M K; 184611-0-0-0 M K; 1295347-0-0-0 M K; 492314-0-0-0 M K; 934268-0-0-0 M K; 114424-0-0-0 M K; 1295347-0-0-0 CL USE,,,RA00H3 M K; RA012P M K; RA00H1 M K; RAN5IF M K; RA61KU M K; RAEXJ3 M K; RA04JD M K,
WO2022109155-A1;  EP4247971-A1;  US2023417749-A1,"Artificial biopolymer complex used to determine            presence or absence of target analyte in sample,            comprises network of polynucleotides comprising            structural units, and binders attached to network of            polynucleotides",WANG X;  YAO X;  LETOURNEAU N;  LETOUMEAU N,ATOM BIOWORKS INC (ATOM-Non-standard);  UNIV ILLINOIS FOUND (UNII-C);  ATOM BIOWORKS INC (ATOM-Non-standard);  UNIV ILLINOIS FOUND (UNII-C);  UNIV ILLINOIS FOUND (UNII-C);  ATOM BIOWORKS INC (ATOM-Non-standard),2022733836,"   NOVELTY - Artificial biopolymer complex comprises: a                network of polynucleotides comprising structural                units connected to one another via a series of arms                and junctions; and binders attached to the network                of polynucleotides. Each of the structural units                has a predetermined shape defined by at least one                strand of polynucleotides. At least a portion of                the strand of polynucleotides of each structural                unit is complementary to at least a portion of the                strand of polynucleotides of another structural                unit, and the complementary portions of the strands                of the polynucleotides are hybridized to connect                the structural units. The complementary portions of                the strands of the polynucleotides form the arms                with a predetermined length. Intersections of at                least three arms form the junctions at a                predetermined distance from one another based on                the predetermined length of the arms. The binders                bind to antigens of a target analyte.    USE - The complex is useful for: determining a                presence or absence of a target analyte in a                sample; treating subject (all claimed); and                detecting viral infections and other                diseases.    ADVANTAGE - The complex enables targeted detection with                high sensitivity and specificity, and therapy via                the introduction of toxins/therapeutics to the                target analytes or preventing entry of a pathogen                into host cells.    DETAILED DESCRIPTION - Artificial biopolymer complex comprises: a                network of polynucleotides comprising structural                units connected to one another via a series of arms                and junctions; and binders attached to the network                of polynucleotides. Each of the structural units                has a predetermined shape defined by at least one                strand of polynucleotides. At least a portion of                the strand of polynucleotides of each structural                unit is complementary to at least a portion of the                strand of polynucleotides of another structural                unit, and the complementary portions of the strands                of the polynucleotides are hybridized to connect                the structural units. The complementary portions of                the strands of the polynucleotides form the arms                with a predetermined length. Intersections of at                least three arms form the junctions at a                predetermined distance from one another based on                the predetermined length of the arms. The binders                bind to antigens of a target analyte. The binders                are attached at loci on at least one of the arms                forming the junctions, where the binders are                arranged in sets of clustered binders, each binder                of a set of clustered binders is attached to one of                the three or more arms that form a junction, and                the loci are separated by predetermined                inter-binder distances so that the binders are                positioned on the network of polynucleotides in a                predetermined three-dimensional spatial pattern                that matches a three-dimensional spatial pattern of                the antigens on the target analyte. INDEPENDENT                CLAIMS are also included for:    (1) determining (M1) a presence or absence of                a target analyte in a sample, comprising obtaining                the artificial biopolymer complex, adding the                artificial biopolymer complex to the sample,                detecting a signal from the sample, and determining                the presence or absence of the target analyte in                the sample based on the signal;    (2) determining (M2) a presence or absence of                a target analyte in a sample, comprising obtaining                the artificial biopolymer complex, adding the                artificial biopolymer complex to the sample, adding                quenchers to the sample, detecting a signal from                the sample, and determining the presence or absence                of the target analyte in the sample based on the                signal; and    (3) treating (M3) subject, comprising                obtaining the artificial biopolymer complex, and                administering the artificial biopolymer complex to                the subject to provide a treatment effect. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)",B04-C03;  B04-E99;  B11-C08;  B12-K04;  D05-H09;  D05-H99;  S03-E09F;  S03-E14H3,A61K-031/7088;  A61K-039/395;  A61K-039/42;  B82Y-015/00;  B82Y-030/00;  C12N-015/115;  C12Q-001/6816;  C12Q-001/6818;  G01N-033/544;  G01N-033/569;  G01N-033/58;  G01N-033/53;  G01N-033/543,WO2022109155-A1   27 May 2022   202249Pages: 63   English;  EP4247971-A1   27 Sep 2023   C12Q-001/6816   202379   English;  US2023417749-A1   28 Dec 2023   G01N-033/569   202402   English,WO2022109155-A1    WOUS059919    18 Nov 2021;   EP4247971-A1    EP827290    18 Nov 2021;   US2023417749-A1    US18037433    17 May 2023,EP4247971-A1 PCT application Application WOUS059919;   EP4247971-A1 Based on Patent WO2022109155;   US2023417749-A1 Provisional Application US115268P;   US2023417749-A1 PCT application Application WOUS059919,US115268P    18 Nov 2020;  US18037433    17 May 2023,WO2022109155-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP4247971-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    ,,"WO2022109155-A1 -- US20070048759-A1   ;  WO2015188053-A1   UNIV KENT STATE (UYEK);  UNIV KYOTO (KYOU)   ENDO M,  KOIRALA D P,  MAO H,  SUGIYAMA H;  WO2020086762-A1   CHAN ZUCKERBERG BIOHUB INC (CHAN-Non-standard);  UNIV LELAND STANFORD JUNIOR (STRD)   SOH H T,  WILSON B D,  HARIRI A;  WO2020197554-A1   CALIFORNIA INST OF TECHNOLOGY (CALY)   GOPINATH A,  ROTHEMUND P W K;  WO2020236711-A2   RENSSELAER POLYTECHNIC INST (RNSS)   WANG X,  KWON S,  DORDICK J S,  LINHARDT R J,  KWON P S,  CHAO J","WO2022109155-A1  KWON PAUL S ET AL:          ""Designer DNA architecture offers precise and multivalent          spatial pattern-recognition for viral sensing and          inhibition"", NATURE CHEMISTRY, NATURE PUBLISHING GROUP          UK, LONDON, vol. 12, no. 1, 25 November 2019          (2019-11-25), pages 26 - 35, XP037114908, ISSN:          1755-4330, [retrieved on 20191125], DOI:          10.1038/S41557-019-0369-8,relevantClaims[1-17,19-21,27,28,32,34,40,41|22-26,33,35-39|18,29-31,42],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  SHERRI RINKER ET          AL: ""Self-assembled DNA nanostructures for          distance-dependent multivalent ligandprotein binding"",          NATURE NANOTECHNOLOGY, vol. 3, no. 7, 22 June 2008          (2008-06-22), London, pages 418 - 422, XP055371153, ISSN:          1748-3387, DOI:          10.1038/nnano.2008.164,relevantClaims[1],relevantPassages[&lt;figure&gt;1&lt;/figure&gt;];  LI NANTAO ET AL:          ""Overcoming the limitations of COVID-19 diagnostics with          nanostructures, nucleic acid engineering, and additive          manufacturing"", CURRENT OPINION IN SOLID STATE AND          MATERIALS SCIENCE, vol. 26, no. 1, 20 November 2021          (2021-11-20), GB, pages 100966, XP055896799, ISSN:          1359-0286, DOI:          10.1016/j.cossms.2021.100966,relevantPassages[&lt;pp&gt;4-5&lt;/pp&gt;]",,,,,
WO2021236855-A1;  AU2021276410-A1;  CA3179423-A1;  EP4153244-A1;  BR112022023554-A2;  JP2023527309-W;  CN116322788-A;  US2024042015-A1;  HK40095604-A0,"New circular RNA polynucleotide comprising 3'            group I intron fragment, internal ribosome entry site,            expression sequence encoding antigens, polypeptides            useful for inducing antigen specific immune response            against SARS-CoV2",WESSELHOEFT A;  BARNES T;  GOODMAN B;  MOTZ G;  BECKER A;  HORHOTA A T;  WESSELHOEFT R A;  MERTZ G,ORNA THERAPEUTICS INC (ORNA-Non-standard);  ORNA THERAPEUTICS INC (ORNA-Non-standard);  ORNA THERAPEUTICS INC (ORNA-Non-standard);  ORNA THERAPEUTICS INC (ORNA-Non-standard),2021D5209E,"   NOVELTY - Circular RNA polynucleotide comprising (a) 3'                group I intron fragment, (b) internal Ribosome                Entry Site (IRES), (c) an expression sequence                encoding at least one antigens, adjuvants,                antigen-like or adjuvant-like polypeptides, or                fragments, and (d) 5'group I intron fragment, is                new.    USE - The circular RNA polynucleotide is useful for                producing medicament forinducing, producing, or                enhancing anantigen specific immune response in a                subjectexposed to the virus e.g. SARS-CoV2,                infected with virus, or at risk of infection by the                virus and is immunocompromised, and inducing                cross-reactivity against variety of viruses or                strains of virus in a mammal (all claimed). No                biological data given.    ADVANTAGE - The circular RNA polynucleotide has an                enhanced safety profile when compared to a                medicinal composition comprising vectors comprising                exogenous DNA encoding the same antigen; and                immunizes the subject against the virus for up to 2                years, preferably more than 2 years.    DETAILED DESCRIPTION - INDEPENDENT CLAIMSare also included for:    (1) RNA preparation comprising circular RNA                polynucleotide and linear RNA polynucleotide                comprising intron polynucleotide comprising a                monophosphorylated 5' terminus and a 3' intron                fragment, 5' intron polynucleotide comprising a                monophosphorylated 5' terminus and a 5'intron                fragment, 3' intron polynucleotide comprising a                triphosphorylated 5' terminus and a 3' intron                fragment, and 5' intron polynucleotide comprising a                triphosphorylated 5' terminus and a 3' intron                fragment, where the circular RNA polynucleotide                comprises at least 90% of the RNA                preparation;    (2) medicinal composition comprising circular                RNA polynucleotide, diluent, and salt buffer;    (3) treating subject in need comprising                administering composition comprising circular RNA                polynucleotide, nanoparticle, and targeting moiety                operably connected to the nanoparticle;    (4) vector for making a circular RNA                polynucleotide comprising 5' duplex forming region,                3' Group I intron fragment, Internal Ribosome Entry                Site (IRES), expression sequence encoding                adjuvants, antigens, adjuvant-like or antigen-like                polypeptides, or fragments, a 5' Group I intron                fragment, and a 3' duplex forming region;    (5) prokaryotic cell comprising vector;    (6) eukaryotic cell comprising circular RNA                polynucleotide;    (7) vaccine, comprising at least one circular                RNA polynucleotide having an expression sequence                encoding at least one viral antigenic polypeptide,                adjuvant or adjuvant-like polypeptide, or an                immunogenic fragment, formulated in a lipid                nanoparticle;    (8) inducing immune response in subject,                comprising administering vaccine to the subject to                produce an antigen-specific immune response in the                subject;    (9) SARS-CoV2 vaccine, comprising at least one                circular RNA polynucleotide having an expression                sequence encoding at least one SARS-CoV2 viral                antigenic polypeptide or an immunogenic fragment                formulated in a lipid nanoparticle;    (10) expression vector comprising an                engineered nucleic acid encoding at least one                circular RNA polynucleotide;    (11) circular RNA polynucleotide vaccine                comprising circular RNA polynucleotide formulated                in a lipid nanoparticle; and    (12) medicinal composition for use in                vaccination of subject, comprising circular RNA                polynucleotideencoding at least one viral antigen                or adjuvant or adjuvant-like polypeptide, or an                immunogenic fragment, where the effective dose is                sufficient to produce a 1000-10000 neutralization                titer produced by neutralizing antibody against                antigen or adjuvant or adjuvant-like polypeptide,                or an immunogenic fragment as measured in serum of                the subject at 1-72 hours post                administration. ",,,"A96 (Medical, dental, veterinary, cosmetic.);  B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  C07 (Apparatus, formulation, general. including veterinary syringes, general formulations where the active compound is not central to the invention (e.g. wettable powders) and analysis.);  ;  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",A12-V;  A12-V01;  B04-E99;  B01-D02;  B04-B01B;  B04-C01;  B04-C02;  B04-C03;  B04-E01;  B04-E08;  B04-F0100E;  B04-L01;  B04-N02;  B04-N04;  B05-B01P;  B07-A04;  B07-D09;  B10-A22;  B10-B01B;  B10-C04E2;  B10-C04E3;  B12-M11Q;  B14-A02B5;  B14-G01;  B14-S11A;  B14-S11D1;  B14-S11D2;  B14-S11D3;  B14-S18;  C04-E99;  C01-D02;  C04-B01B;  C04-C01;  C04-C02;  C04-C03;  C04-E01;  C04-F0100E;  C04-L01;  C04-N02;  C04-N04;  C05-B01P;  C07-A04;  C07-D09;  C10-A22;  C10-B01B;  C10-C04E2;  C10-C04E3;  C12-M11Q;  C14-A02B5;  C14-G01;  C14-S11A;  C14-S11D1;  C14-S11D2;  C14-S11D3;  C14-S18;  D05-H99;  D05-H12;  D05-H14,A61K-031/7088;  A61K-031/7105;  A61K-048/00;  C07K-014/725;  C12N-015/11;  C12N-015/115;  C12N-015/64;  C12N-015/85;  A61K-039/00;  A61K-039/12;  A61K-039/13;  A61K-039/145;  A61K-039/155;  A61K-039/20;  A61K-039/29;  A61K-039/39;  A61K-047/12;  A61K-047/18;  A61K-047/22;  A61K-047/28;  A61K-047/32;  A61K-047/34;  A61K-047/36;  A61K-047/42;  A61K-047/68;  A61K-009/51;  A61P-031/04;  A61P-031/12;  A61P-031/16;  A61P-031/18;  C12N-001/15;  C12N-001/19;  C12N-001/21;  C12N-015/33;  C12N-015/63;  C12N-015/87;  C12N-005/10;  A61K-039/295;  A61P-037/04,WO2021236855-A1   25 Nov 2021   A61K-048/00   202104Pages: 353   English;  AU2021276410-A1   19 Jan 2023   A61K-048/00   202306   English;  CA3179423-A1   25 Nov 2021   A61K-031/7088   202314   English;  EP4153244-A1   29 Mar 2023   A61K-048/00   202327   English;  BR112022023554-A2   11 Apr 2023   A61K-048/00   202334   ;  JP2023527309-W   28 Jun 2023   C12N-015/11   202353   Japanese;  CN116322788-A   23 Jun 2023   A61K-048/00   202364   Chinese;  US2024042015-A1   08 Feb 2024   A61K-039/295   202413   English;  HK40095604-A0   02 Feb 2024   A61K-048/00   202439   English,WO2021236855-A1    WOUS033276    19 May 2021;   AU2021276410-A1    AU276410    19 May 2021;   CA3179423-A1    CA3179423    19 May 2021;   EP4153244-A1    EP737214    19 May 2021;   BR112022023554-A2    BR11023554    19 May 2021;   JP2023527309-W    JP571116    19 May 2021;   CN116322788-A    CN80047874    19 May 2021;   US2024042015-A1    US17999378    18 Nov 2022;   HK40095604-A0    HK6083775    07 Dec 2023,AU2021276410-A1 PCT application Application WOUS033276;   AU2021276410-A1 Based on Patent WO2021236855;   CA3179423-A1 PCT application Application WOUS033276;   CA3179423-A1 Based on Patent WO2021236855;   EP4153244-A1 PCT application Application WOUS033276;   EP4153244-A1 Based on Patent WO2021236855;   BR112022023554-A2 PCT application Application WOUS033276;   JP2023527309-W PCT application Application WOUS033276;   JP2023527309-W Based on Patent WO2021236855;   CN116322788-A PCT application Application WOUS033276;   CN116322788-A Based on Patent WO2021236855;   US2024042015-A1 Provisional Application US027292P;   US2024042015-A1 PCT application Application WOUS033276;   HK40095604-A0 PCT application Application WOUS033276;   HK40095604-A0 Based on Patent WO2021236855;   HK40095604-A0 Previous Publ. Patent CN116322788,US027292P    19 May 2020;  WOUS031629    10 May 2021;  CN80047874    19 May 2021;  CA3179423    18 Nov 2022;  US17999378    18 Nov 2022;  CN80047874    04 Jan 2023,WO2021236855-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA      EP4153244-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN            ,,"WO2021236855-A1 -- US20160331828-A1   ;  US20170204422-A1   ;  US20190328769-A1   ;  US20190345503-A1   ;  WO2019118919-A1   FLAGSHIP PIONEERING INC (FLAG);  STEWART M H (STEW-Individual);  CIFUENTES-ROJAS C (CIFU-Individual);  PAEK K Y (PAEK-Individual)   STEWART M H,  PAEK K Y,  KAHVEJIAN A,  PLUGIS N M,  DE BOER A S,  WEISTEIN E G,  TROUSIL S;  WO2019213308-A1   HUTCHINSON CANCER RES CENT FRED (CANC)   STEPHAN M;  WO202020023595-A1   ;  US3832253-A   BAXTER LAB INC (BAXT);  US3854480-A   ;  US4235871-A   PAPAHADJOPOULOS D P (PAPA-Individual);  US4450150-A   LITTLE INC ARTHUR D (LITT);  US4452775-A   SYNTEX (USA) (SYNT)   KENT J S;  US4501728-A   TECHNOLOGY UNLIMITE (TECH-Non-standard)   BLAIRGEH W,  LAU J R,  GEHO W B;  US4667014-A   SYNTEX (USA) (SYNT)   NESTOR J J,  VICKERY B H;  US4737323-A   LIPOSOME TECHNOLOGY INC (LIPO-Non-standard)   MARTIN F J,  MORANO J K;  US4748034-A   SOC PROD NESTLE SA (NEST)   DERHAM O;  US4837028-A   LIPOSOME TECHNOLOGY INC (LIPO-Non-standard);  LINEAR TECHNOLOGY CORP (LIRT)   ALLEN T M,  GABIZON A;  US4897355-A   SYNTEX (USA) (SYNT)   EPPSTEIN D A,  FELGNER P L,  GADEK T R,  JONES G H,  ROMAN R B;  US5019369-A   VESTAR RES INC (VEST-Non-standard);  CITY OF HOPE NAT MEDICAL CENT (CITY)   PRESANT C A,  PROFFITT R T;  US5075109-A   UAB RES FOUNDATION (UABR);  SOUTHERN RES INST (SOUR)   TICE T T,  ELDRIDGE J H,  GILLEY R M,  STASS J K;  US5087616-A   BATTELLE MEMORIAL INST (BATT);  INTRACEL CORP (INTR-Non-standard)   MYERS A,  BICHON D;  US5171678-A   CNRS CENT NAT RECH SCI (CNRS)   BEHR J P,  LOEFFLER J P;  US5239660-A   NEC CORP (NIDE)   OOI Y;  US5334761-A   LIFE TECHNOLOGIES INC (LITC)   GEBEYEHU G,  JESSEE J A,  CICCARONE V C,  HAWLEY-NELSON P,  CHYTIL A;  US5744335-A   MIRUS CORP (MIRU-Non-standard)   HAGSTROM J,  FRITZ J,  WOLFF J A,  BUDKER V;  US5885613-A   UNIV BRITISH COLUMBIA (UYBR)   CULLIS P R,  HOLLAND J W,  MADDEN T D;  US5948902-A   SOUTH ALABAMA MEDICAL SCI FOUND (SALA-Non-standard);  ISIS PHARM INC (ISSP)   HONKANEN R E,  DEAN N M;  US6066626-A   GENZYME CORP (GENZ)   YEW N S,  ZIEGLER R J,  CHENG S H;  US2018153822-A1   TRANSLATE BIO INC (TRAN-Non-standard)   KARVE S,  DEROSA F,  BHAVSAR Z,  HEARTLEIN M;  US2018369419-A1   MODERNATX INC (MODR)   BENENATO K E,  BUTCHER W;  US2020237671-A1   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   HEARTLEIN M,  GUILD B C,  DEROSA F,  ZHANG J C;  US2021009503-A1   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   DEROSA F,  GUILD B C,  HEARTLEIN M;  US20040014194-A1   ;  US20040110709-A1   ;  US20170210697-A1   ;  US20190314284-A1   ;  US20190314524-A1   ;  US20190321489-A1   ;  US6417326-B1   UNIV BRITISH COLUMBIA (UYBR)   CULLIS P R,  CHOI L S L,  MONCK M,  BAILEY A;  US6986902-B1   INEX PHARM CORP (INEX-Non-standard);  CHEN T (CHEN-Individual);  HE Y (HEYY-Individual);  CULLIS P (CULL-Individual);  MADDEN T (MADD-Individual);  SCHERRER P (SCHE-Individual);  KIM J S (KIMJ-Individual);  TIRRELL D (TIRR-Individual);  JOSHI P (JOSH-Individual)   CHEN T,  HE Y,  CULLIS P,  MADDEN T,  SCHERRER P,  KIM J S,  TIRRELL D,  JOSHI P;  US7709226-B2   ARROWSMITH TECHNOLOGIES LLP (ARRO-Non-standard)   FOOTE J;  US10413618-B2   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   GUILD B C,  DEROSA F,  HEARTLEIN M;  WO2005121348-A1   PROTIVA BIOTHERAPEUTICS INC (PRTO)   MACLACHLAN I,  PALMER L R,  HEYES J;  WO2010042877-A1   TEKMIRA PHARM CORP (TEKM-Non-standard);  UNIV BRITISH COLUMBIA (UYBR);  LAHERTY C D (LAHE-Individual)   CHEN J,  CIUFOLINI M A,  CULLIS P R,  HOPE M J,  MADDEN T D,  MUI B,  SEMPLE S C;  WO2011075656-A1   UNIV BRITISH COLUMBIA (UYBR);  ALNYLAM PHARM INC (ALNY)   HOPE M J,  MADDEN T D,  CULLIS P,  MAIER M A,  JAYARAMAN M,  RAJEEV K G,  AKINC A,  MANOHARAN M;  WO2011127255-A1   MERCK SHARP & DOHME CORP (MERI);  UNIV PRINCETON (UPRT)   BURKE P A,  GINDY M E,  KUMAR V,  MATHRE D J,  PRUDHOMME R K,  PRUD'HOMME R K;  WO2012099755-A1   ALNYLAM PHARM INC (ALNY)   RAJEEV K G,  MANOHARAN M,  JAYARAMAN M,  MAIER M,  JAYAPRAKASH N K,  BUTLER D;  WO2012170889-A1   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   HEARTLEIN M,  GUILD B C,  DEROSA F,  ZHANG J C;  WO2012170930-A1   SHIRE HUMAN GENETIC THERAPIES INC (SHHU)   GUILD B C,  DEROSA F,  HEARTLEIN M;  WO2017112865-A1   MODERNATX INC (MODR)   BENENATO K E,  BUTCHER W;  WO2017185054-A1   INTELLIA THERAPEUTICS INC (ITLL)   BURNS S M,  MURRAY B A,  HESSE S B;  WO2018222890-A1   ARCTURUS THERAPEUTICS INC (ARCT-Non-standard)   LIMPHONG P,  PEREZ-GARCIA C G,  TACHIKAWA K,  CHIVUKULA P,  CALE A,  LEU A I,  DAVIS J;  WO2019067999-A1   INTELLIA THERAPEUTICS INC (ITLL)   STEWART M H,  VALLASTER M P,  MONTI A,  NARENDRA P K,  HO Q;  WO2019089828-A1   ACUITAS THERAPEUTICS INC (ACUI-Non-standard)   MADDEN T D,  TAM Y K C,  BARBOSA C J,  MUI B;  WO2019152557-A1   MODERNATX INC (MODR)   BESIN G,  BRITO L,  HOGE S G,  HENNESSY E,  CORNEBISE M,  BENENATO K,  SABNIS S,  DANNEMAN M W;  WO2019191780-A1   ARCTURUS THERAPEUTICS INC (ARCT-Non-standard)   CHIVUKULA P,  KARMALI P,  ESAU C,  VEGA J,  BAO Y,  MUKTHAVARM R,  MURPHY S;  WO2021076805-A1   MODERNATX INC (MODR)   HUANG E Y,  IACOVELLI J,  DE PICCIOTTO S,  TSE S,  KENNEY L;  WO2008103276-A2   MERCK & CO INC (MERI)   JADHAV V,  VARGEESE C,  SHAW L,  MORRISSEY D,  JENSEN K;  WO2010053572-A2   MASSACHUSETTS INST TECHNOLOGY (MASI)   ANDERSON D G,  LANGER R S,  LEVINS C G,  LOVE K T,  MAHON K P,  WHITEHEAD K A;  WO2013012476-A2   ARIZONA CHEM CO LLC (ARIZ)   LIN G,  HARMAN N W;  WO2017049245-A2   MODERNATX INC (MODR)   BENENATO K E,  KUMARASINGHE E S,  CORNEBISE M","WO2021236855-A1  WESSELHOEFT R          ALEXANDER ET AL: ""RNA Circularization Diminishes          Immunogenicity and Can Extend Translation DurationIn          Vivo"", MOLECULAR CELL, vol. 74, no. 3, 15 February 2019          (2019-02-15), pages 508, XP085676575, ISSN: 1097-2765,          DOI:          10.1016/J.MOLCEL.2019.02.015,relevantClaims[1,3,5-21,32,33,36-69,71-82,84-102,121-144],relevantPassages[Whole          doc., in particular p.511, col.2;p.518, col.2; p.515-516;          Fig.1A, Fig5B];  METZGAR DAVID ET          AL: ""Abrupt emergence of diverse species B adenoviruses          at US military recruit training centers"", JOURNAL OF          INFECTIOUS DISEASES, UNIVERSITY OF CHICAGO PRESS, US,          vol. 196, no. 10, 1 November 2007 (2007-11-01), pages          1465 - 1473, XP002534787, ISSN: 0022-1899, DOI:          10.1086/522970,relevantClaims[1,3,5-21,32,33,36-69,71-82,84-102,121-144],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  BAIL S ET AL: ""Tri-          to be Mono- for Bacterial mRNA Decay"", STRUCTURE,          ELSEVIER, AMSTERDAM, NL, vol. 17, no. 3, 11 March 2009          (2009-03-11), pages 317 - 319, XP026093376, ISSN:          0969-2126, [retrieved on 20090310], DOI:          10.1016/J.STR.2009.02.005,relevantClaims[22,23,26,27,30,31],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  JACEK JEMIELITY ET          AL: ""Synthetic mRNA cap analogs with a modified          triphosphate bridge - synthesis, applications and          prospects"", NEW JOURNAL OF CHEMISTRY, vol. 34, no. 5, 1          January 2010 (2010-01-01), GB, pages 829, XP055747726,          ISSN: 1144-0546, DOI:          10.1039/c0nj00041h,relevantClaims[22,23,26,27,30,31],relevantPassages[Whole          doc., in partic. p.837, col.1];            KABAT EAWU TT, ANN NY ACAD SCI, vol. 190, 1971, pages 382          - 391;            KAUFMAN ET AL., NUC. ACIDS RES., vol. 19, 1991, pages          4485 - 4490;            CHOTHIA CLESK AM, J MOL BIOL, vol. 196, 1987, pages 901 -          917;            AL-LAZIKANI B, J MOL BIOL, vol. 273, 1997, pages 927 -          948;            CHOTHIA C, J MOL BIOL, vol. 227, 1992, pages 799 -          817;            TRAMONTANO A ET AL., J MOL BIOL, vol. 215, no. 1, 1990,          pages 175 - 82;            GIEGE R ET AL., ACTA CRYSTALLOGR D BIOL CRYSTALLOGR, vol.          50, 1994, pages 339 - 350;            MCPHERSON A, EUR J BIOCHEM, vol. 189, 1990, pages 1 -          23;            CHAYEN NE, STRUCTURE, vol. 5, 1997, pages 1269 -          1274;            MCPHERSON A, J BIOL CHEM, vol. 251, 1976, pages 6300 -          6303;            MOSSER ET AL., BIOTECHNIQUES, vol. 114, 115, 1997, pages          139 - 161;            BRICOGNE G, ACTA CRYSTALLOGR D BIOL CRYSTALLOGR, vol. 49,          1993, pages 37 - 60;            ROVERSI P ET AL., ACTA CRYSTALLOGR D BIOL CRYSTALLOGR,          vol. 56, 2000, pages 1316 - 1323;            STAHLI ET AL., METHODS IN ENZYMOLOGY, vol. 9, 1983, pages          242 - 253;            KIRKLAND ET AL., J. IMMUNOL., vol. 137, 1986, pages 3614          - 3619;            MOREL, MOLEC. IMMUNOL., vol. 25, 1988, pages 7 -          15;            CHEUNG ET AL., VIROLOGY, vol. 176, 1990, pages 546 -          552;            MOLDENHAUER ET AL., SCAND. J. IMMUNOL., vol. 32, 1990,          pages 77 - 82;            GURTU ET AL., BIOCHEM. BIOPHYS. RES. COMM., vol. 229,          1996, pages 295 - 298;            KOBAYASHI ET AL., BIOTECHNIQUES, vol. 21, 1996, pages 399          - 402;            JANG, J. VIROL., vol. 63, 1989, pages 1651 -          1660;            DOBRIKOVA ET AL., PROC. NATL. ACAD. SCI., vol. 100, no.          25, 2003, pages 15125 - 15130;            RAMESH ET AL., NUCL. ACID RES, vol. 24, 1996, pages 2697          - 2700;            GARLAPATI, J BIOL. CHEM., vol. 279, no. 5, 2004, pages          3389 - 3397;            LIU, Z.CHEN, O.WALL, J.B.J. ET AL.: ""Systematic          comparison of 2A peptides for cloning multi-genes in a          polycistronic vector"", SCI REP, vol. 7, 2017, pages 2193,          XP055515282, DOI: 10.1038/s41598-017-02460-2;            EDGE, NATURE, vol. 292, 1981, pages 756;            NAMBAIR, SCIENCE, vol. 223, 1984, pages 1299;            JAY, J. BIOL CHEM., vol. 259, 1984, pages 631 1;            JAYARAMAN, PROC. NATL. ACAD. SCI. USA, vol. 88, 1991,          pages 4084 - 4088;            JONES, NATURE, vol. 54, 1986, pages 75 - 82;            RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 -          327;            VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 -          1536;            QUEEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989,          pages 10029 - 10033;            LASIC, TRENDS BIOTECHNOL., vol. 16, 1998, pages 307 -          321;            DRUMMOND, PHARMACOL. REV., vol. 51, 1999, pages 691 -          743;            LASIC ET AL., FEBS LETT., vol. 312, 1992, pages 255 -          258;  N          J CAPLEN ET AL., GENE THER., vol. 2, 1995, pages          603;  S.          LI, GENE THER., vol. 4, 1997, pages 891;            FEIGNER, PROC. NAT'L ACAD. SCI., vol. 84, 1987, pages          7413;            BEHR ET AL., PROC. NAT.'L ACAD. SCI., vol. 86, 1989,          pages 6982;            SEMPLE ET AL., NATURE BIOTECH., vol. 28, 2010, pages 172          - 176;            HEYES, J. ET AL., J CONTROLLED RELEASE, vol. 107, 2005,          pages 276 - 287;            MORRISSEY, D.V. ET AL., NAT. BIOTECHNOL., vol. 23, no. 8,          2005, pages 1003 - 1007;            GAO, BIOCHEM. BIOPHYS. RES. COMM., vol. 179, 1991, pages          280;            KLIBANOV ET AL., FEBS LETTERS, vol. 268, no. 1, 1990,          pages 235 - 237;            BLOOMFIELD, ANN REV. BIOPHYS. BIOENG., vol. 10, 1981,          pages 421 - 450;            HILLERY A M ET AL.: ""Drug Delivery and Targeting: For          Pharmacists and Pharmaceutical Scientists"", 2002, TAYLOR          & FRANCIS, INC;            ""Pharmaceutics and Pharmacy Practice"", 1982, JB.          LIPPINCOTT COMPANY, pages: 238 - 250;            ""ASHP Handbook on Injectable Dmgs"", 1986, TOISSEL, pages:          622 - 630;            SZOKA, ANN. REV. BIOPHYS. BIOENG., vol. 9, 1980, pages          467;            WADWA ET AL., J, DRUG TARGETING, vol. 3, 1995, pages          111;            WESSELHOEFT ET AL.: ""RNA Circularization Diminishes          Immunogenicity and Can Extend Translation Duration In          vivo"", MOLECULAR CELL, vol. 74, no. 3, 2019, pages 508 -          520;            WESSELHOEFT ET AL.: ""Engineering circular RNA for Potent          and Stable Translation in Eukaryotic Cells"", NATURE          COMMUNICATIONS, vol. 9, 2018, pages 2629, XP055622155,          DOI: 10.1038/s41467-018-05096-6;            BIOCONJUG CHEM, vol. 27, no. 3, 16 March 2016          (2016-03-16), pages 849 - 53;            ""Uniprot"", Database accession no. P043234;            KAOPUCK, PROC. NATL. ACAD SCI USA, vol. 60, no. 4, 1968,          pages 1275 - 81;            RITSCHEL W AKEARNS G L: ""EST: Handbook Of Basic          Pharmacokinetics Including Clinical Applications"", 1999,          AMERICAN PHARMACEUTICAL ASSOC.",6353-0-0-0 K M; 6352-0-0-0 K M; 11412-0-0-0 K M; 714924-1-1-0 K M; 349226-0-0-0 K M; 559853-0-0-0 K M; 93407-0-0-0 K M; 174010-0-0-0 K M; 93406-1-0-0 K M; 135651-0-0-0 K M; 102701-2-0-0 K M; 87667-0-0-0 K M; 105730-0-0-0 K M; 184611-0-0-0 K M; 93605-0-0-0 K M; 184616-0-0-0 K M; 256168-1-0-0 K M; 184597-0-0-0 K M; 199398-0-0-0 K M; 104374-0-0-0 K M; 280282-0-0-0 K M;  K M; 104481-0-0-0 K M; 104486-0-0-0 K M; 199390-0-0-0 K M; 104380-0-0-0 K M; 104401-0-0-0 K M; 173429-0-0-0 K M;  K M; 104381-0-0-0 K M; 104431-0-0-0 K M; 104389-0-0-0 K M; 94633-0-0-0 K M; 104427-0-0-0 K M; 104413-0-0-0 K M; 104373-0-0-0 K M; 104376-1-0-0 K M; 900-0-0-0 K M; 104366-0-0-0 K M; 114603-0-0-0 K M; 104491-0-0-0 K M; 104492-0-0-0 K M; 104494-0-0-0 K M; 1062-0-0-0 K M; 90356-0-0-0 K M; 133912-0-0-0 K M; 97485-1-0-0 K M; 133921-0-0-0 K M; 104432-0-0-0 K M; 151679-0-0-0 K M; 199467-0-0-0 K M; 114599-0-0-0 K M; 104881-0-0-0 K M; 104360-0-0-0 K M; 184619-0-0-0 K M;  K M; 91873-1-0-0 K M; 97115-1-0-0 K M; 92005-0-0-0 K M; 92818-0-0-0 K M; 104328-1-0-0 K M; 377978-0-0-0 K M; 170545-1-0-0 K M; 8349-1-0-0 K M; 191993-0-0-0 ; 490-0-0-0 ; 1956-0-0-0 ; 444-0-0-0 ; 238-0-0-0 ; 7200-0-0-0 ; 23522-0-0-0 ; 134834-0-0-0 ; 343474-0-0-0 ; 192002-0-0-0 ; 404-0-0-0 ; 7785-0-0-0 ; 192004-0-0-0 ; 192030-0-0-0 ; 381125-0-0-0 ; 135402-0-0-0 ; 107779-0-0-0 ; 829-0-0-0 ; 621-0-0-0 ; 368-0-0-0 ; 1013-0-0-0 ; 1145-0-0-0 ; 8187-0-0-0 ; 135179-0-0-0 ; 75840-0-0-0 ; 8720-0-0-0 ; 133659-0-0-0 ; 5938-0-0-0 ; 7447-0-0-0 ; 7560-0-0-0 ; 1606-0-0-0 ,226448001 K M; 226448002 K M; 226448003 K M; 226448004 K M; 226448005 K M; 226448006 K M; 226448007 K M; 226448008 K M; 226448009 K M; 226448010 K M; 226448011 K M; 226448012 K M; 226448013 K M; 226448014 K M,00262; 00357; 01649; 42995,R03721 K M; R03722 K M; R11245 K M; RALASW K M; RA3300 K M; RAAMT9 K M; R06737 K M; RA1GFX K M; RA0GCK K M; RA0MRI K M; R00954 K M; R04038 K M; RA012P K M; RA00H1 K M; RA00NS K M; RA00H3 K M; RA169K K M; RBR2F2 K M; RA14TW K M; RA0EMI K M; RA0B83 K M; RA3S13 K M; RAFJ6A K M; RA00CA K M; R16492 K M; RA0LQS K M; RA02L0 K M; RA037T K M; RA009Z K M; R14108 K M; RAFJ69 K M; RA02NX K M; RA07AE K M; RA05GF K M; RA058G K M; RA01KR K M; RA01KS K M; RA0SC3 K M; RA030X K M; R02044 K M; RA0GM6 K M; RA1EEO K M; R02038 K M; RA012N K M; RA01EA K M; RA01EC K M; RA00D5 K M; R01852 K M; R01835 K M; R06717 K M; R03005 K M; R01861 K M; RA01SI K M; RA0N3C K M; RA01R4 K M; RA02HM K M; RA02AR K M; RA02ZP K M; RA0DQF K M; RA08SW K M; RB20H6 K M; RADFV3 K M; R03231 K M; RA061R K M; R01857 K M; R03882 K M; RA3OLP K M; RA00KZ K M; R00148 K M; R24004 ; R00113 ; R00844 ; R00351 ; R00370 ; R00479 ; R00653 ; R21453 ; R24097 ; RA2YR1 ; R24019 ; R00642 ; R01126 ; R24029 ; R24055 ; R24091 ; RA3QZC ; R24032 ; R01863 ; R00835 ; R00338 ; R00708 ; R00326 ; R00964 ; R01655 ; R24015 ; R01606 ; R00815 ; R17298 ; R01295 ; R00009 ; R00448 ; R01176 ,0954-S; 2044-S; 2038-S; 1852-S; 1835-S; 1861-S; 1857-S; 0148-S
WO2022235988-A1;  AU2022271276-A1;  CA3218564-A1;  CN117651486-A;  EP4333614-A1;  JP2024518435-W,"New genetically engineered mouse comprising            germline modification comprising deletion of nucleic            acid sequence comprising heavy-chain C-region genes,            used to produce e.g. soluble heavy-chain antibody to            treat e.g. diabetes",CHEN W V,LEVERAGEN INC (LEVE-Non-standard);  LEVERAGEN INC (LEVE-Non-standard);  LEVERAGEN INC (LEVE-Non-standard);  LEVERAGEN INC (LEVE-Non-standard),2022E0801L,"   NOVELTY - Genetically engineered mouse (MO1) comprising                a germline modification comprising a deletion of a                nucleic acid sequence comprising at least one                heavy-chain C-region genes, is new, where the mouse                expresses immunoglobulin (Ig)G heavy chain antibody                and secretes the IgG heavy chain antibody into its                serum.    USE - The genetically engineered mouse is useful                for: producing a soluble heavy-chain antibody,                where the single domain antibody is a murine single                domain antibody; and producing a single domain                antibody (sdAb) identified from the engineered                non-human animal (all claimed), where the antibody                is used to treat diabetes, systemic lupus                erythematosus, multiple sclerosis, rheumatoid                arthritis, scleroderma, Crohn's disease, ulcerative                colitis, mixed connective tissue disease, Sjogren                syndrome, polymyositis, or dermatomyositis. No                biological data given.    ADVANTAGE - None given.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    genetically engineered mouse (MO2) comprising                a germline modification comprising a deletion of a                nucleic acid sequence comprising at least one                heavy-chain C-region genes, where the mouse                expresses a humanized IgG heavy chain antibody and                secretes the humanized IgG heavy chain antibody                into its serum;    an engineered non-human animal comprising a                germline genome comprising an engineered                immunoglobulin heavy chain (IgH) allele at an                endogenous IgH locus, where the engineered IgH                allele lacks an endogenous heavy-chain C region                gene, and the endogenous heavy-chain C region gene                comprises Cp, C5, Cs, Cy3, Cy2b, and/or Cj2c;    producing a genetically modified non-human                animal capable of producing a heavy-chain antibody                comprising (a) deleting an endogenous nucleic acid                sequence comprising the heavy-chain C-region genes                from an endogenous immunoglobulin heavy chain locus                in a stem cell of a non-human animal, (b)                implanting the stem cell into a blastocyst, (c)                implanting the blastocyst into a pseudo-pregnant                mouse to obtain a chimeric mouse, (d) crossing the                chimeric mouse to a wild-type mouse to produce                offspring, (e) screening the offspring for                heterozygosity, and (f) identifying a founder mouse                carrying a deletion of the heavy-chain C-region                genes, and the non-human animal is capable of                producing a heavy chain antibody or humanized heavy                chain antibody;    producing (M1) a soluble heavy-chain antibody                in the engineered non-human animal;    producing (M2) a single domain antibody (sdAb)                identified from the engineered non-human                animal;    non-human animal, where the genome of the                non-human animal comprises immunoglobulin heavy                chain (IgH) allele, comprising endogenous nucleic                acid encoding a CH2 or CH3 domain of an IgG                subclass, where the IgH allele lacks nucleic acid                encoding at least a portion of an endogenous CH1                domain of the immunoglobulin (Ig)G subclass, and                IgH allele lacks endogenous nucleic acid encoding                at least a portion of an IgM constant domain,                endogenous nucleic acid encoding at least a portion                of an IgD constant domain, endogenous nucleic acid                encoding at least a portion of an IgE constant                domain, or endogenous nucleic acid encoding at                least a portion of an IgA constant domain;                and    an antibody comprising a variable region                comprising (a) SEQ ID NO: 4, SEQ ID NO: 10, and SEQ                ID NO: 19 (each comprising any one of fully defined                sequence of 10-16 amino acids as given in the                specification) e.g.                Gly-Glu-Thr-Phe-Tyr-Asn-Gln-Gln-Phe-Lys (SEQ ID NO:                10), or (b) SEQ ID NO: 5, SEQ ID NO: 11, and SEQ ID                NO: 20 (each comprising any one of fully defined                sequence of 10-16 amino acids as given in the                specification) e.g.                Gly-Asp-Thr-Asn-Tyr-Ser-Gln-Asn-Phe-Lys (SEQ ID NO:                11). ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).)",B04-E99;  B04-G01;  B04-G08;  B04-P01B0E;  B14-C03;  B14-C09B;  B14-E08;  B14-E10C1;  B14-G02D;  B14-J05;  B14-N17;  B14-S01;  B14-S04;  B14-S14A;  C04-E99;  C04-G01;  C04-P01B0E;  C14-C03;  C14-C09B;  C14-E08;  C14-E10C1;  C14-G02D;  C14-J05;  C14-N17;  C14-S01;  C14-S04;  C14-S14A;  D05-H11;  D05-H16A;  D05-H99,A01K-067/027;  C07K-016/00;  C12N-015/09;  C12N-015/13;  A01K-067/0275;  C07K-016/10,WO2022235988-A1   10 Nov 2022   A01K-067/027   202296Pages: 198   English;  AU2022271276-A1   09 Nov 2023   A01K-067/027   202391   English;  CA3218564-A1   10 Nov 2022   202392   English;  CN117651486-A   05 Mar 2024   A01K-067/0275   202422   Chinese;  EP4333614-A1   13 Mar 2024   A01K-067/027   202422   English;  JP2024518435-W   01 May 2024   C12N-015/09   202436   Japanese,WO2022235988-A1    WOUS027946    05 May 2022;   AU2022271276-A1    AU271276    05 May 2022;   CA3218564-A1    CA3218564    05 May 2022;   CN117651486-A    CN80047822    05 May 2022;   EP4333614-A1    EP799638    05 May 2022;   JP2024518435-W    JP568507    05 May 2022,AU2022271276-A1 PCT application Application WOUS027946;   AU2022271276-A1 Based on Patent WO2022235988;   CA3218564-A1 PCT application Application WOUS027946;   CA3218564-A1 Based on Patent WO2022235988;   CN117651486-A PCT application Application WOUS027946;   CN117651486-A Based on Patent WO2022235988;   EP4333614-A1 PCT application Application WOUS027946;   EP4333614-A1 Based on Patent WO2022235988;   JP2024518435-W PCT application Application WOUS027946;   JP2024518435-W Based on Patent WO2022235988,US184384P    05 May 2021;  US184385P    05 May 2021;  CA3218564    31 Oct 2023;  CN80047822    04 Jan 2024,WO2022235988-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        EP4333614-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    ,,"WO2022235988-A1 -- US6072035-A   CIBA GEIGY AG (CIBA);  TANOX BIOSYSTEMS INC (GETH);  NOVARTIS AG (NOVS)   HARDMAN N,  KOLBINGER F,  SALDANHA J;  US20050172349-A1   ;  US20080089862-A1   ;  US20130345405-A1   ;  US20150050280-A1   ;  US20150197557-A1   ;  US20180360948-A1   ",,200757-0-0-0 N,,,RA00GT N,
EP3903811-A1;  WO2021219639-A1;  EP3903811-A4;  AU2021263889-A1;  CA3169995-A1;  EP4153217-A1;  JP2023523822-W;  US2023263889-A1;  AU2021263889-B2,"Pharmaceutical composition useful for inducing            immune response in human or animal subject suffering            from pathologic disease or disorder, preferably cancer            or viral infection, comprises autologous activated            cytotoxic cluster of differentiation 8 and            T-lymphocytes activated by dendritic cells",PAPASOTIRIOU I,RGCC HOLDINGS AG (RGCC-Non-standard);  RGCC HOLDINGS AG (RGCC-Non-standard);  RGCC HOLDINGS AG (RGCC-Non-standard);  RGCC HOLDINGS AG (RGCC-Non-standard),2021D9532W,"   NOVELTY - Pharmaceutical composition comprises                autologous activated cytotoxic cluster of                differentiation (CD)8+ T-lymphocytes (CTL),                activated by autologous primed mature dendritic                cells of the human or animal subject, where the                autologous primed mature dendritic cells presenting                an antigenic peptide, where the activated CTL are                derived from an autologous population of peripheral                blood mononuclear cells (PBMCs) isolated from                peripheral blood of the same human or animal                subject, where the activated CTL are able to                recognize the antigenic peptide, where the CTL have                been activated by autologous dendritic cells primed                with an antigenic peptide, where the dendritic                cells have been isolated from the same human or                animal subject as the CTL, where the CTL have been                activated by co-culturing cluster of                differentiation (CD)8+ T-cells derived from the                population of PBMC, with the antigen presenting                dendritic cells.    USE - The pharmaceutical composition is useful for                inducing an immune response in a human or animal                subject suffering from a pathologic disease or                disorder, (b) obtaining human or animal autologous                dendritic cells, (c) treating pathologic disease or                disorder in a human or animal subject, preferably                for cancer or viral infection, or (d) treating                cancer, preferably breast cancer in a human or                animal subject. The pathologic disease is                preferably viral infection (all claimed).    ADVANTAGE - The pharmaceutical composition supports cell                survival and expansion.    DETAILED DESCRIPTION - Pharmaceutical composition comprises                autologous activated cytotoxic cluster of                differentiation (CD)8+ T-lymphocytes (CTL),                activated by autologous primed mature dendritic                cells of the human or animal subject, where the                autologous primed mature dendritic cells presenting                an antigenic peptide, where the activated CTL are                derived from an autologous population of peripheral                blood mononuclear cells (PBMCs) isolated from                peripheral blood of the same human or animal                subject, where the activated CTL are able to                recognize the antigenic peptide, where the CTL have                been activated by autologous dendritic cells primed                with an antigenic peptide, where the dendritic                cells have been isolated from the same human or                animal subject as the CTL, where the CTL have been                activated by co-culturing cluster of                differentiation (CD)8+ T-cells derived from the                population of PBMC, with the antigen presenting                dendritic cells, where the dendritic cells before                their use in the activation of CD8+ T cells have                been cultured ex vivo and subsequently have been                primed (loaded, pulsed) with the antigenic peptide,                and have been matured in the presence of a cytokine                cocktail before their use in activation of the CD8+                T cells by co-culturing. INDEPENDENT CLAIMS are                included for the following:    (1) a method (M1) for obtaining human or                animal autologous dendritic cells;    (2) a method (M2) for producing pharmaceutical                composition for inducing an immune response in a                human or animal subject in treating pathologic                disease;    (3) a method (M3) of treating pathologic                disease or disorder in a human or animal subject,                preferably for treating cancer or viral                infection;    (4) a method (M4) of treating cancer,                preferably breast cancer in a human or animal                subject;    (5) use of pharmaceutical composition as a                medicament in treatment of a pathologic disorder of                a human or animal subject, where the composition                comprises an amount of activated cytotoxic CTLs                capable of recognizing an antigen specific for the                pathologic disorder as an active ingredient,                preferably capable of recognizing an antigenic                peptide, where the composition further comprises at                least one of the following substances: an additive,                a carrier, an excipient, and a stabilizer, where                the activated CTLs preferably have been obtained by                the method;    (6) use of activated autologous CTLs in a                pharmaceutical composition or a vaccine for                treating a pathologic disease or disorder in a                human or animal subject suffering from the                pathologic disease, preferably cancer or a viral                infection, where the activated CTLs are capable of                recognizing an antigenic peptide, following the                activation of CD8+ T-cells by autologous dendritic                cells primed with and presenting the antigenic                peptide; and    (7) pharmaceutical composition, preferably                prepared by the method, where the pharmaceutical                composition comprises (a) dosage of autologous                primed dendritic cells each presenting on their                cell surface an antigenic peptide, preferably a                tumor antigenic peptide, more preferably a MUC1                peptide, most preferably a MUC (79-87) peptide or                (b) dosage of autologous primed dendritic cells                each presenting on their cell surface and a viral                antigenic peptide, preferably an antigenic                peptide. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E99;  B04-F04B1A;  B04-F04B2A;  B04-H02A;  B04-H02D;  B04-H08;  B12-M12F;  B14-A02;  B14-G01;  B14-H01;  B14-S18;  B14-S21;  D05-H08B;  D05-H99,A61K-039/00;  A61K-039/12;  A61P-031/14;  A61P-035/00;  A61K-035/17;  A61P-015/00;  A61P-031/12;  A61P-037/04;  C07K-014/705;  C12N-005/0783,EP3903811-A1   03 Nov 2021   A61K-039/00   202100Pages: 27   English;  WO2021219639-A1   04 Nov 2021   202103   English;  EP3903811-A4   03 Nov 2021   A61K-039/00   202104   English;  AU2021263889-A1   22 Sep 2022   A61K-039/00   202277   English;  CA3169995-A1   04 Nov 2021   A61K-039/00   202290   English;  EP4153217-A1   29 Mar 2023   A61K-039/00   202326   English;  JP2023523822-W   07 Jun 2023   A61K-039/00   202346   Japanese;  US2023263889-A1   24 Aug 2023   A61K-039/00   202369   English,EP3903811-A1    EP172623    01 May 2020;   WO2021219639-A1    WOEP060987    27 Apr 2021;   EP3903811-A4    EP172623    01 May 2020;   AU2021263889-A1    AU263889    27 Apr 2021;   CA3169995-A1    CA3169995    27 Apr 2021;   EP4153217-A1    EP721110    27 Apr 2021;   JP2023523822-W    JP566388    27 Apr 2021;   US2023263889-A1    US17915767    29 Sep 2022;   AU2021263889-B2    AU263889    27 Apr 2021,AU2021263889-A1 PCT application Application WOEP060987;   AU2021263889-A1 Based on Patent WO2021219639;   CA3169995-A1 PCT application Application WOEP060987;   CA3169995-A1 Based on Patent WO2021219639;   EP4153217-A1 PCT application Application WOEP060987;   EP4153217-A1 Based on Patent WO2021219639;   JP2023523822-W PCT application Application WOEP060987;   JP2023523822-W Based on Patent WO2021219639;   US2023263889-A1 PCT application Application WOEP060987;   AU2021263889-B2 PCT application Application WOEP060987;   AU2021263889-B2 Based on Patent WO2021219639,EP172623    01 May 2020;  CA3169995    30 Aug 2022,EP3903811-A1:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  KH;  LI;  LT;  LU;  LV;  MA;  MC;  MD;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TN;  TR  WO2021219639-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW  EP3903811-A4:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR      EP4153217-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN      ,,"EP3903811-A1 -- US20100255501-A1   ;  EP1448229-A2   DANDRIT BIOTECH AS (DAND-Non-standard)   KIRKIN A,  DJANDJOUGAZIAN K,  ZEUTHEN J","EP3903811-A1  NECTARIA N          SOTIRIADOU ET AL: ""Ii-Key/HER-2/neu(776-790) hybrid          peptides induce more effective immunological responses          over the native peptide in lymphocyte cultures from          patients with HER-2/neu+ tumors"", CANCER IMMUNOLOGY,          IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 56, no. 5, 8          September 2006 (2006-09-08), pages 601 - 613,          XP019489777, ISSN:          1432-0851,relevantClaims[1,4-8,10,11,15|2,12-14,16,17,19|9],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|Materials          and          methods|Results|&lt;figure&gt;5&lt;/figure&gt;];  PENG WEI ET AL:          ""EWS/FLI-l peptide-pulsed dendritic cells induces the          antitumor immunity in a murine Ewing's sarcoma cell          model"", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER,          AMSTERDAM, NL, vol. 21, no. 2, 24 May 2014 (2014-05-24),          pages 336 - 341, XP029038740, ISSN: 1567-5769, DOI:          10.1016/J.INTIMP.2014.05.013,relevantClaims[9],relevantPassages[2.3          Peptide-binding assay|2.4 Dendritic cell generation|2.5          Induction of peptide-specific CTL];            RANIERI: ""Cytotoxic T-Cells: Methods & Protocols"",          2014, HUMANA PRESS;            SCHEIKL-GATARD T., J TRANSL MED., vol. 15, 2017, pages          154;            EISENBARTH, S.C.: ""Dendritic cell subsets in T cell          programming: location dictates function"", NAT REV          IMMUNOL, vol. 19, 2019, pages 89 - 103, XP036694900,          Retrieved from the Internet          &lt;URL:https://doi.org/10.1038/s41577-018-0088-l&gt;          DOI: 10.1038/s41577-018-0088-1;            FARHOOD, BNAJAFI, MMORTEZAEE, K.: ""CD8+ cytotoxic T          lymphocytes in cancer immunotherapy: A review"", J CELL          PHYSIOL., vol. 234, 2019, pages 8509 - 8521, Retrieved          from the Internet          &lt;URL:https://doi.org/10.1002/jcp.27782&gt;;            FRANCK J. BARRATLISHAN SU: ""A pathogenic role of          plasmacytoid dendritic cells in autoimmunity and chronic          viral infection"", J EXP MED, vol. 216, no. 9, 2 September          2019 (2019-09-02), pages 1974 - 1985, Retrieved from the          Internet          &lt;URL:https://doi.org/10.1084/jem.20181359&gt;;  HE          YLI JHECK SLUSTIGMAN SJIANG S.: ""Antigenic and          immunogenic characterization of recombinant          baculovirus-expressed severe acute respiratory syndrome          coronavirus spike protein: implication for vaccine          design"", J VIROL., vol. 80, no. 12, 2006, pages 5757 -          5767;            JEBASTIN, T.NARAYANAN, S.: ""In silico epitope          identification of unique multidrug resistance proteins          from Salmonella Typhi for vaccine development"", COMPUT.          BIOL. CHEM., vol. 78, February 2019 (2019-02-01), pages          74 - 80, ISSN: 1476-9271, Retrieved from the Internet          &lt;URL:https://doi.org/10.1016/i.compbiolchem.2018.11.020&gt;;            KRAUSE P.J.KAVATHAS P.B.RUDDLE N.H.:          ""Immunoepidemiology"", 2019, SPRINGER, article          ""Immunotherapy for Infectious Diseases, Cancer, and          Autoimmunity"";            MADDUR, M.S.LACROIX-DESMAZES, S.DIMITROV, J.D. ET AL.:          ""Natural Antibodies: from First-Line Defense Against          Pathogens to Perpetual Immune Homeostasis"", CLINIC REV          ALLERG IMMUNOL, vol. 58, 2020, pages 213 - 228,          XP037061055, Retrieved from the Internet          &lt;URL:https://doi.org/10.1007/sl2016-019-08746-9&gt;          DOI: 10.1007/s12016-019-08746-9;            MET, O.JENSEN, K.M.CHAMBERLAIN, C.A. ET AL., PRINCIPLES          OF ADOPTIVE T CELL THERAPY IN CANCER. SEMIN IMMUNOPATHOL,          vol. 41, 2019, pages 49 - 58;            ROY A. MARIUZZAPRAGATI AGNIHOTRIJOHN ORBAN: ""The          structural basis of T-cell receptor (TCR) activation: An          enduring enigma"", J. BIOL. CHEM., vol. 295, 2020, pages          914 - 925;            SANT, A.J.: ""Clinical Immunology"", 2019, article ""6 -          Overview of T-Cell Recognition: Making Pathogens Visible          to the Immune System"", pages: 93 - 106",97946-0-0-0 K M; 97954-0-0-0 K M; 97959-0-0-0 K M; 114126-0-0-0 K M,,,R06364 K M; R16207 K M; RA03SC K M; RA01IL K M; RA0DNM K M; RA0KDA K M,
WO2020191361-A2;  WO2020191361-A3;  TW202100164-A;  AU2020240135-A1;  CA3133311-A1;  AR118484-A1;  KR2022004035-A;  EP3941937-A2;  CN114080232-A;  IN202117047355-A;  SG11202109702-A1;  BR112021018694-A2;  US2022168415-A1;  JP2022526127-W;  HK40067684-A0;  SG11202109702-A;  IL286556-A;  US2023263885-A1;  MX2021011241-A1;  US11992527-B2,"Isolated extracellular vesicle for EV-drug            conjugate, for preventing or treating a disease in a            subject in need, where the disease is associated with            the antigen, comprises at least one antigen and at            least one adjuvant",MONIZ R J;  MCCONELL R E;  ROSS N;  MCCOY C;  SOOS T J;  XU K;  MCCONNELL R E;  RUSSELL M;  SOOTH T J,CODIAK BIOSCI INC (CODI-Non-standard);  CODIAK BIOSCIENCES INC (CODI-Non-standard);  CODIAK BIOSCIENCES INC (CODI-Non-standard);  CODIAK BIOSCI INC (CODI-Non-standard);  CODIAK BIOSCIENCES INC (CODI-Non-standard);  CODIAK BIOSCI INC (CODI-Non-standard);  CODIAK BIOSCI INC (CODI-Non-standard);  LONZA SALES AG (LONZ-C),202093780W,"   NOVELTY - Isolated extracellular vesicle (EV) comprises                at least one antigen and at least one                adjuvant.    USE - Isolated extracellular vesicle for EV-drug                conjugate, for preventing or treating a disease in                a subject in need, where the disease is associated                with the antigen, where the disease is a cancer,                where the cancer comprises bladder cancer, cervical                cancer, renal cell cancer, testicular cancer,                colorectal cancer, lung cancer, head and neck                cancer, ovarian, lymphoma, liver cancer,                glioblastoma, melanoma, myeloma, leukemia,                pancreatic cancer, or combinations, where the                disease is an infection and for inhibiting or                reducing metastasis of cancer in a subject.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a pharmaceutical composition, which                comprises the EV and a pharmaceutically acceptable                carrier;    (2) a cell that produces the EV;    (3) a kit, which comprises the EV and                instructions for use;    (4) a method of making EVs, which involves                culturing the cell under a suitable condition and                obtaining the EVs; and    (5) a method of inducing an immune response in                a subject in need, which involves administering the                EV to the subject. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A96 (Medical, dental, veterinary, cosmetic.)",B04-E99;  B04-F01;  B04-F12;  B04-Q;  B11-A04A;  B14-G01;  B14-H01;  B14-L01;  B14-S21;  D05-H99;  D05-H08B;  A03-A00A;  A12-V01,A61K-031/7084;  A61K-039/00;  A61K-039/39;  A61K-045/00;  A61K-047/69;  A61K-009/127;  A61P-031/00;  A61P-031/12;  A61P-033/02;  A61P-035/00;  C07K-014/705;  C12N-015/62;  A61K-039/245;  A61P-031/22;  C07K-014/005;  C07K-014/77;  C07K-016/28;  C12N-005/071;  A61K-039/12;  A61K-009/00;  A61K-009/51;  A61K-047/64;  A61K-047/68;  C12N-015/11;  A61K-039/385;  A61P-037/04;  A61K-035/12;  A61K-035/22;  A61K-047/46;  A61P-035/04;  C12N-005/10;  C12P-021/02,WO2020191361-A2   24 Sep 2020   C07K-014/705   202082Pages: 268   English;  WO2020191361-A3   29 Oct 2020   202089   English;  TW202100164-A   01 Jan 2021   A61K-031/7084   202154   Chinese;  AU2020240135-A1   14 Oct 2021   C07K-014/705   202184   English;  CA3133311-A1   24 Sep 2020   C07K-014/705   202187   English;  AR118484-A1   06 Oct 2021   C07K-014/705   202101   Spanish;  KR2022004035-A   11 Jan 2022   A61K-039/00   202207   ;  EP3941937-A2   26 Jan 2022   C07K-014/705   202212   English;  CN114080232-A   22 Feb 2022   A61K-039/00   202227   Chinese;  IN202117047355-A   11 Feb 2022   A61K-047/64   202231   English;  SG11202109702-A1   28 Oct 2021   C07K-014/705   202231   English;  BR112021018694-A2   30 Nov 2021   C07K-014/705   202235   ;  US2022168415-A1   02 Jun 2022   A61K-039/385   202246   English;  JP2022526127-W   23 May 2022   C07K-014/705   202261   Japanese;  HK40067684-A0   09 Sep 2022   C07K-014/705   202308   English;  SG11202109702-A   28 Oct 2021   C07K-014/705   202323   English;  IL286556-A   31 Oct 2021   A61K-009/00   202358   English;  US2023263885-A1   24 Aug 2023   A61K-039/385   202372   English;  MX2021011241-A1   19 Jan 2022   C07K-014/705   202397   Spanish;  US11992527-B2   28 May 2024   A61P-035/00   202444   English,WO2020191361-A2    WOUS024023    20 Mar 2020;   WO2020191361-A3    WOUS024023    20 Mar 2020;   TW202100164-A    TW109629    23 Mar 2020;   AU2020240135-A1    AU240135    20 Mar 2020;   CA3133311-A1    CA3133311    20 Mar 2020;   AR118484-A1    AR100821    25 Mar 2020;   KR2022004035-A    KR734252    20 Mar 2020;   EP3941937-A2    EP721330    20 Mar 2020;   CN114080232-A    CN80037388    20 Mar 2020;   IN202117047355-A    IN17047355    19 Oct 2021;   SG11202109702-A1    SG11009702    20 Mar 2020;   BR112021018694-A2    BR11018694    20 Mar 2020;   US2022168415-A1    US17441524    21 Sep 2021;   JP2022526127-W    JP556469    20 Mar 2020;   HK40067684-A0    HK6056736    13 Jul 2022;   SG11202109702-A    SG11009702    20 Mar 2020;   IL286556-A    IL286556    20 Mar 2020;   US2023263885-A1    US050027    26 Oct 2022;   MX2021011241-A1    MX011241    15 Sep 2021;   US11992527-B2    US050027    26 Oct 2022,AU2020240135-A1 PCT application Application WOUS024023;   AU2020240135-A1 Based on Patent WO2020191361;   CA3133311-A1 PCT application Application WOUS024023;   CA3133311-A1 Based on Patent WO2020191361;   KR2022004035-A PCT application Application WOUS024023;   KR2022004035-A Based on Patent WO2020191361;   EP3941937-A2 PCT application Application WOUS024023;   EP3941937-A2 Based on Patent WO2020191361;   CN114080232-A PCT application Application WOUS024023;   CN114080232-A Based on Patent WO2020191361;   IN202117047355-A PCT application Application WOUS024023;   IN202117047355-A Based on Patent WO2020191361;   SG11202109702-A1 PCT application Application WOUS024023;   SG11202109702-A1 Based on Patent WO2020191361;   BR112021018694-A2 PCT application Application WOUS024023;   BR112021018694-A2 Based on Patent WO2020191361;   US2022168415-A1 PCT application Application WOUS024023;   US2022168415-A1 Provisional Application US946280P;   US2022168415-A1 Provisional Application US901166P;   US2022168415-A1 Provisional Application US891048P;   US2022168415-A1 Provisional Application US840348P;   US2022168415-A1 Provisional Application US835437P;   US2022168415-A1 Provisional Application US822008P;   US2022168415-A1 Provisional Application US984146P;   JP2022526127-W PCT application Application WOUS024023;   JP2022526127-W Based on Patent WO2020191361;   HK40067684-A0 PCT application Application WOUS024023;   HK40067684-A0 Based on Patent WO2020191361;   HK40067684-A0 Previous Publ. Patent EP3941937;   SG11202109702-A PCT application Application WOUS024023;   SG11202109702-A Based on Patent WO2020191361;   IL286556-A Based on Patent WO2020191361;   US2023263885-A1 Div ex Application WOUS024023;   US2023263885-A1 Div ex Application US441524;   US2023263885-A1 Provisional Application US822008P;   US2023263885-A1 Provisional Application US835437P;   US2023263885-A1 Provisional Application US840348P;   US2023263885-A1 Provisional Application US891048P;   US2023263885-A1 Provisional Application US901166P;   US2023263885-A1 Provisional Application US946280P;   US2023263885-A1 Provisional Application US984146P;   MX2021011241-A1 PCT application Application WOUS024023;   MX2021011241-A1 Based on Patent WO2020191361;   US11992527-B2 Div ex Application WOUS024023;   US11992527-B2 Div ex Application US441524;   US11992527-B2 Provisional Application US822008P;   US11992527-B2 Provisional Application US835437P;   US11992527-B2 Provisional Application US840348P;   US11992527-B2 Provisional Application US891048P;   US11992527-B2 Provisional Application US901166P;   US11992527-B2 Provisional Application US946280P;   US11992527-B2 Provisional Application US984146P;   US11992527-B2 Previous Publ. Patent US2023263885,US822008P    21 Mar 2019;  US835437P    17 Apr 2019;  US840348P    29 Apr 2019;  US891048P    23 Aug 2019;  US901166P    16 Sep 2019;  US946280P    10 Dec 2019;  US984146P    02 Mar 2020;  EP721330    20 Mar 2020;  CA3133311    10 Sep 2021;  BR11018694    20 Sep 2021;  US17441524    21 Sep 2021;  KR734252    21 Oct 2021;  CN80037388    19 Nov 2021;  US050027    26 Oct 2022,WO2020191361-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW  WO2020191361-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA            EP3941937-A2:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  KH;  LI;  LT;  LU;  LV;  MA;  MC;  MD;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TN;  TR                          ,,";  WO2020191361-A3 -- WO2016184860-A1   UNIV TRENTO (UYTR-Non-standard)   GRANDI G,  CAFARDI V,  FANTAPPIE L,  GRIFANTINI R,  GRANDI A;  US11992527-B2 -- WO2016184860-A1   UNIV TRENTO (UYTR-Non-standard)   GRANDI G,  CAFARDI V,  FANTAPPIE L,  GRIFANTINI R,  GRANDI A","WO2020191361-A3  GNOPO YEHOU M D ET          AL: ""Designer outer membrane vesicles as immunomodulatory          systems - Reprogramming bacteria for vaccine delivery"",          ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL,          vol. 114, 10 May 2017 (2017-05-10), pages 132 - 142,          XP085157398, ISSN: 0169-409X, DOI:          10.1016/J.ADDR.2017.05.003,relevantClaims[1-9],relevantPassages[abstract,          p. 133 left-hand column first full paragraph, p. 136 the          paragraph bridging the left- to the right-hand column -          p. 137 right-hand column second full paragraph, p. 139          left-hand column last full paragraph - p. 140 the          paragraph bridging the left- to the right-hand column,          fig. 1-4];  LAURA FANTAPPIE ET          AL: ""Antibody-mediated immunity induced by engineered          Escherichia coli OMVs carrying heterologous antigens in          their lumen"", JOURNAL OF EXTRACELLULAR VESICLES, vol. 3,          no. 1, 1 January 2014 (2014-01-01), pages 24015,          XP055342003, DOI:          10.3402/jev.v3.24015,relevantClaims[1-9],relevantPassages[abstract,          p. 2 left-hand column last full paragraph - p. 3 the          paragraph bridging the left- to the right-hand column, p.          4 right-hand column third full paragraph, p. 7 the          paragraph bridging the left- to the right-hand column -          p. 10 the paragraph bridging the left- to the right-hand          column, Table II and Fig. 2-7];  KUANG TAN ET AL:          ""Outer Membrane Vesicles: Current Status and Future          Direction of These Novel Vaccine Adjuvants"", FRONTIERS IN          MICROBIOLOGY, vol. 9, 26 April 2018 (2018-04-26),          XP055716033, DOI:          10.3389/fmicb.2018.00783,relevantClaims[1-9],relevantPassages[abstract,          p. 2 right-hand column last full paragraph - p. 3 the          paragraph bridging the left- to the right-hand column, p.          8 left-hand column last full paragraph - p. 9 the          paragraph bridging the left- to the right-hand column,          Tables I and II and Fig. 1];  GRANDI ATOMASI M ET          AL: ""Synergistic protective activity of tumor-specific          epitopes engineered in bacterial outer membrane          vesicles"", FRONTIERS IN ONCOLOGY, FRONTIERS RESEARCH          FOUNDATION, CH, vol. 7, no. NOV, 7 November 2017          (2017-11-07), XP009505866, ISSN: 2234-943X, DOI:          10.3389/FONC.2017.00253,relevantClaims[1-9,86,91,92,96,114-127|87,93],relevantPassages[abstract,          p. 2 right-hand column last full paragraph, p. 3          left-hand column last full paragraph - the paragraph          bridging p. 5 to p. 6, and Fig. 1-4];  RUI CHEN ET AL:          ""Exosomes in hepatocellular carcinoma: a new horizon"",          CELL COMMUNICATION AND SIGNALING, vol. 17, no. 1, 7          January 2019 (2019-01-07), XP055716094, DOI:          10.1186/s12964-018-0315-1,relevantClaims[1-9,86,87,91-93,96,114-127],relevantPassages[abstract,          the paragraph bridging p. 7/11 to p. 8/11, p. 8/11          right-hand column first full paragraph];  KITAI YUICHI ET AL:          ""DNA-Containing Exosomes Derived from Cancer Cells          Treated with Topotecan Activate a STING- Dependent          Pathway and Reinforce Antitumor Immunity"", JOURNAL OF          IMMUNOLOGY,, vol. 198, no. 4, 15 February 2017          (2017-02-15), pages 1649 - 1659, XP002792021, DOI:          10.4049/JIMMUNOL.1601694,relevantClaims[1-9,86,87,91-93,96,114-127],relevantPassages[abstract,          p. 1650 left-hand column first full paragraph, p. 1653          the paragraph bridging the left- to the right-hand column          - p. 1654 right-hand column line 10, fig. 7];  YUKAI HE ET AL:          ""Engineering [alpha]-fetoprotein-based gene vaccines to          prevent and treat hepatocellular carcinoma: review and          future prospects"", IMMUNOTHERAPY, vol. 6, no. 6, 1 June          2014 (2014-06-01), GB, pages 725 - 736, XP055494251,          ISSN: 1750-743X, DOI:          10.2217/imt.14.46,relevantClaims[1-9,86,87,91-93,96,114-127],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  FENG MA ET AL:          ""Positive feedback regulation of type I interferon by the          interferon-stimulated gene STING"", EMBO REPORTS, vol. 16,          no. 2, 8 January 2015 (2015-01-08), GB, pages 202 - 212,          XP055716234, ISSN: 1469-221X, DOI:          10.15252/embr.201439366,relevantClaims[1-9,86,91-93,96,114-127],relevantPassages[abstract,          p. 203 left-hand column lines 28-50 and fig. 1];  HIROKO MIYABE ET          AL: ""A new adjuvant delivery system 'cyclic di-GMP/YSK05          liposome' for cancer immunotherapy"", JOURNAL OF          CONTROLLED RELEASE, vol. 184, 1 June 2014 (2014-06-01),          pages 20 - 27, XP055417407, ISSN: 0168-3659, DOI:          10.1016/j.jconrel.2014.04.004,relevantClaims[1-9,86,87,91-93,96,114-127],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  SANDEEP T. KOSHY ET          AL: ""Liposomal Delivery Enhances Immune Activation by          STING Agonists for Cancer Immunotherapy"", ADVANCED          BIOSYSTEMS, vol. 1, no. 1-2, 5 January 2017 (2017-01-05),          pages 1600013, XP055526126, ISSN: 2366-7478, DOI:          10.1002/adbi.201600013,relevantClaims[1-9,86,87,91-93,96,114-127],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  KAZUKI KATO ET AL:          ""Cyclic GMP-AMP as an Endogenous Second Messenger in          Innate Immune Signaling by Cytosolic DNA"", ANNU. REV.          BIOCHEM, vol. 86, 1 January 2017 (2017-01-01), pages 541          - 566, XP055716214, DOI:          10.1146/annurev-biochem-,relevantClaims[1-9,86,87,91-93,96,114-127],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;]US11992527-B2            Chen, R., et al., Exosomes in hepatocellular carcinoma: a          new horizon, Cell Commun Signal 17(1):1, Biomed Central,          United Kingdom (Jan. 2019).;            Fantappie, L., et al., Antibody-mediated immunity induced          by engineered &lt;xhtml:i &gt;Escherichia          coli&lt;/xhtml:i&gt;OMVs carrying heterologous          antigens in their lumen, J Extracell Vesicles 3(1), John          Wiley & Sons, United States (Aug. 2014).;            Gnopo, Y.M.D., et al., Designer outer membrane vesicles          as immunomodulatory systemsReprogramming bacteria for          vaccine delivery, Adv Drug Deliv Rev 114:132-142,          Elsevier, Netherlands (May 2017).;            Grandi, A., et al., Synergistic Protective Activity of          Tumor-Specific Epitopes Engineered in Bacterial Outer          Membrane Vesicles, Front Oncol 7:253, Frontiers Media,          S.A., Switzerland (Nov. 2017).;            He, Y., et al., Engineering -fetoprotein-based gene          vaccines to prevent and treat hepatocellular carcinoma:          review and future prospects, Immunotherapy 6(6):725-736,          Future Medicine, United Kingdom (Jun. 2014).;            International Search Report and Written Opinion for          International Application No. PCT/US2020/024023, European          Patent Office, Netherlands, mailed on Sep. 23, 2020, 31          pages.;            Kato, K., et al., Cyclic GMP-AMP as an Endogenous Second          Messenger in Innate Immune Signaling by Cytosolic DNA,          Annu Rev Biochem 86:541-566, Annual Reviews, United          States (Jun. 2017).;            Kitai, Y., et al., DNA-Containing Exosomes Derived from          Cancer Cells Treated with Topotecan Activate a          STING-Dependent Pathway and Reinforce Antitumor Immunity,          J Immunol 198(4):1649-1659, American Association of          Immunologists, United States (Feb. 2017).;            Koshy, S.T., et al., Liposomal Delivery Enhances Immune          Activation by STING Agonists for Cancer Immunotherapy,          Adv Biosyst 1(1-2):1600013, Wiley, United States (Feb.          2017).;            Ma, F., et al., Positive feedback regulation of type I          interferon by the interferon-stimulated gene STING, EMBO          Rep 16(2):202-212, Nature Portfolio, Germany (Feb.          2015).;            Miyabe, H., et al., A new adjuvant delivery system cyclic          di-GMP/YSK05 liposome for cancer immunotherapy, J Control          Release 184:20-27, Elsevier, Netherlands (Jun.          2014).;            Tan, K., et al., Outer Membrane Vesicles: Current Status          and Future Direction of These Novel Vaccine Adjuvants,          Front Microbiol 9:783, Frontiers Media S.A., Switzerland          (Apr. 2018).",200757-0-0-0 K M; 90688-1-0-0 ,,,RA00GT K M; R03233 ,
WO2022036005-A2;  WO2022036005-A3,"Detecting presence and/or amount of nucleic acid            from pathogen in biological sample comprises contacting            biological sample, amplifying nucleic acid, measuring            or analyzing and determining presence and/or amount of            nucleic acid",GAITERI J C;  MCCARTHY E;  PATTERSON A;  FANG R;  CHIANG Y;  CHIARELLO R P;  WANG T,ALVEO TECHNOLOGIES INC (ALVE-Non-standard),2022267668,"   NOVELTY - Detecting the presence and/or amount of                nucleic acid, preferably nucleic acid from a                pathogen, in a biological sample, comprises                contacting the biological sample with an assay                cartridge of detection system, amplifying the                nucleic acid by Loop-Mediated Isothermal                Amplification (LAMP) with primer set, where the                primer set comprises at least one F3 primers, at                least one B3 primers, at least one LF primers, at                least one LB primers, at least one FIP primers,                and/or at least one BIP primers,, where the primer                set is specific for genome region of the pathogen,                measuring or analyzing modulation of an electrical                signal, such as impedance or capacitance, for the                duration of the amplification with the primer set                using the detection system for detecting successful                amplification of the nucleic acid with the primer                set, and determining the presence and/or amount of                the nucleic acid in the biological sample.    USE - The method is useful for: detecting the                presence and/or amount of nucleic acid, preferably                nucleic acid from pathogen e.g. microbe, mold,                fungus, virus, bacteria, Hepatitis A Virus,                Influenza A Virus Subtype H1N1, HIV-1, Respiratory                Syncytial Virus (RSV)A, RSV B and/or Escherichia                coli, in a biological sample obtained by swabbing                from a subject, preferably human or other animal                e.g. livestock animal, plant e.g. vegetable, fruit                or legume, food, soil and/or surface e.g.                pen.    ADVANTAGE - The method: utilizes small, portable,                low-power devices, hence economical; and provides                rapid and robust sensing and identification. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E05;  B04-E99;  B05-A01B;  B11-C08E3;  B11-C08F8;  B12-K04F;  C04-E05;  C04-E99;  C05-A01B;  C11-C08E3;  C11-C08F8;  C12-K04F;  D05-H09;  D05-H18B;  D05-H99,C12Q-001/689;  C12Q-001/6825;  C12Q-001/686;  C12Q-001/70;  G01N-027/06,WO2022036005-A2   17 Feb 2022   C12Q-001/689   202220Pages: 244   English;  WO2022036005-A3   10 Mar 2022   C12Q-001/686   202221   English,WO2022036005-A2    WOUS045610    11 Aug 2021;   WO2022036005-A3    WOUS045610    11 Aug 2021,,US066040P    14 Aug 2020,WO2022036005-A2:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  WO2022036005-A3:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,;  WO2022036005-A3 -- US20150045254-A1   ;  US20190232282-A1   ,,100006-0-0-0 K U,,,RBXLO8 K U; RBXSZD K U; RBXUUF K U,
WO2023235763-A1,"Treating, or reducing subject at risk of            thrombosis with thrombocytopenia syndrome (TTS)            associated with adenoviral vector therapy comprises            administering low negative charge adenoviral vector            therapy",ABBINK P;  BAROUCH D H,VECTOR SCI INC (VECT-Non-standard);  BETH ISRAEL DEACONESS MEDICAL CENT (BEIS-C),2023C7614E,"   NOVELTY - Treating, or reducing a subject at risk of                thrombosis with thrombocytopenia syndrome (TTS)                associated with adenoviral vector therapy comprises                administering to a subject at risk of TTS low                negative charge adenoviral vector therapy.    USE - The method is useful for treating, or reducing                a subject at risk of thrombosis with TTS associated                with adenoviral vector therapy, where the subject                is a human subject, the subject is positive for                anti-PF4 antibodies, the subject is a female, the                subject is the ages of 18-70, the subject is white,                optionally further the subject is non-Hispanic, and                the subject is obese, has hypertension, is                diabetic, is on estrogen therapy (e.g. an                estrogen-based contraceptive or an estrogen-based                hormone replacement therapy), has a venous                thrombosis risk factor (e.g. cirrhosis, malignancy,                fertility treatment, or a venous catheter), has                iron deficiency anemia, and/or has hypothyroidism                (all claimed). Test details are described but no                results given.    ADVANTAGE - The method reduces the risk of TTS as compared                to administration of human or chimp adenoviral                vector therapy e.g. human adenovirus (Ad)5 vector                therapy, human Ad26 vector therapy, or chimp AdY25                (chimpanzee adenovirus (ChAd) serotype Y25                (ChAdOx1)) vector therapy.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for use                of a low negative charge adenoviral vector for                treating or reducing a subject at risk of TTS                associated with adenoviral vector therapy. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-C01A;  B04-C01B;  B04-C02E1;  B04-E08;  B04-E99;  B04-F11;  B04-G01;  B06-H;  B07-B01;  B07-D05;  B07-E01;  B07-E03;  B10-C03;  B11-C04;  B14-F03;  B14-F04;  B14-N11;  B14-N12;  B14-P01;  B14-S03A;  B14-S11;  B14-S18;  D05-H11;  D05-H99,A61K-035/761;  C07K-014/005;  C12N-015/86;  C12N-007/00,WO2023235763-A1   07 Dec 2023   A61K-035/761   202304Pages: 130   English,WO2023235763-A1    WOUS067709    31 May 2023,,US365720P    02 Jun 2022;  US401323P    26 Aug 2022,WO2023235763-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2023235763-A1 -- WO2019118480-A1   BETH ISRAEL DEACONESS MEDICAL CENT (BEIS)   BAROUCH D H,  ABBINK P,  IAMPIETRO M J,  HAVENGA M J E;  WO2014078688-A2   BETH ISRAEL DEACONESS MEDICAL CENT (BEIS);  UNIV WASHINGTON ST LOUIS (UNWL)   BAROUCH D H,  VIRGIN H,  ABBINK P","WO2023235763-A1  BILOTTA CLIO ET AL:          ""COVID-19 Vaccine-Related Thrombosis: A Systematic Review          and Exploratory Analysis"", FRONTIERS IN IMMUNOLOGY, vol.          12, 29 November 2021 (2021-11-29), XP093080002, DOI:          10.3389/fimmu.2021.729251,relevantClaims[1,2,44,45],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;|p.          10, r.c., 3rd and 4th paragraphs];  COUGHLAN LYNDA ET          AL: ""Adenovirus-based vaccines-a platform for pandemic          preparedness against emerging viral pathogens"", MOLECULAR          THERAPY, vol. 30, no. 5, 1 May 2022 (2022-05-01), US,          pages 1822 - 1849, XP093008388, ISSN: 1525-0016, DOI:          10.1016/j.ymthe.2022.01.034,relevantClaims[1,2,44,45|1-49],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;|&lt;pp&gt;1836&lt;/pp&gt;&lt;ppl&gt;1839&lt;/ppl&gt;|p.          1841: Future directions];  LEDFORD HEIDI:          ""COVID vaccines and blood clots: what researchers know so          far"", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol.          596, no. 7873, 24 August 2021 (2021-08-24), pages 479 -          481, XP037546598, ISSN: 0028-0836, [retrieved on          20210824], DOI:          10.1038/D41586-021-02291-2,relevantClaims[1,2,44,45|1-49],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;|p.          480, r.c., 4th full paragraph];  BAKER ALEXANDER T.          ET AL: ""ChAdOx1 interacts with CAR and PF4 with          implications for thrombosis with thrombocytopenia          syndrome"", SCIENCE ADVANCES, vol. 7, no. 49, 3 December          2021 (2021-12-03), XP093081811, DOI:          10.1126/sciadv.abl8213,relevantClaims[1,2,44,45|1-45],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;|p.          9 of 14, l.c., second paragraph];            PAVORD ET AL., N ENGL J MED 2021, vol. 385, 2021, pages          1680 - 1689;            ALAKUNLE, NAT REV MICROBIOL, vol. 20, no. 9, 2022, pages          507 - 508;            SINGHAL, INDIAN J. PEDIATR. DOI:          10.1007/S12098-022-04348-0, 2022;            LAI, J MICROBIOL IMMUNOL INFECT, DOI:          10.1016/J.JMII.2022.07.004, 2022;            SINGHAL, INDIAN J. PEDIATR. DOI: 10.1007/S1          2098-022-04348-0, 2022;            LAI, J MICROBIOL IMMUNOL INFECT. DOI:          10.1016/J.JMII.2022.07.004, 2022;            TITANJI, OPEN FORUM INFECT DIS, vol. 9, no. 7, 2022,          pages 310;            BENITES-ZAPATA, ANN CLIN MICROBIOL ANTIMICROB, vol. 21,          2022, pages 36;            ""GenBank"", Database accession no. AIY35100.1;            SIEVERSHIGGINS, PROTEIN SCIENCE, vol. 27, 2018, pages 135          - 145;            MOORE ET AL., SCIENCE, vol. 320, no. 5877, 2008, pages          753 - 5;            SPRANGERS ET AL., J. CLIN. MICROBIOL, vol. 41, 2003,          pages 5046 - 5052;            KOVESDIHEDLEY, VIRUSES, vol. 2, 2010, pages 1681 -          1673;            WOLD ET AL., CURR. GENE THER., vol. 13, 2013, pages 421 -          433;            JUHL ET AL., EUR J HAEMATOL., vol. 76, no. 5, 2006, pages          420 - 426;            THIELE ET AL., BLOOD, vol. 138, no. 4, 2021, pages 299 -          303;            POL ET AL., ONCOIMMUNOLOGY, vol. 5, 2016, pages          e1117740;            BAKER ET AL., CANCERS, vol. 10, 2018, pages 201;            GORADEL ET AL., J CELL PHYSIOL, vol. 1, 2018, pages          11;            PETERKUHNEL, CANCERS, vol. 12, 2020, pages 3354;            BULCHA ET AL., SIGNAL TRANSDUCTION AND TARGETED THERAPY,          vol. 6, 2021, pages 53;            MOON ET AL., VACCINES, vol. 7, 2022, pages 26;            STRAETER ET AL., NAT BIOTECHNOL, 2023, Retrieved from the          Internet          &lt;URL:https://doi.org/10.10038/s41587-023-01774-z&gt;;            NGUYEN ET AL., NAT. COMMUN., vol. 8, 2017, pages          14945;            BAKER ET AL., SCI. ADV., vol. 7, 2021, pages          eabl8213",896726-0-0-0 K M Q; 94231-0-0-0 K M Q; 96796-0-0-0 K M Q; 174388-1-0-0 K M Q; 710281-0-0-0 K M Q; 451473-0-0-0 K M Q; 684249-2-0-0 K M Q; 102820-1-0-0 K M Q; 702820-1-0-0 K M Q; 36645-0-0-0 K M Q; 87874-0-0-0 K M Q; 93507-0-0-0 K M Q; 199852-0-0-0 K M Q; 813685-1-0-0 K M Q; 91005-0-0-0 K M Q; 91332-1-0-0 K M Q; 736241-1-0-0 K M Q; 99028-1-0-0 K M Q; 896726-0-0-0 CL RCT USE; 94231-0-0-0 CL RCT USE; 96796-0-0-0 CL RCT USE; 174388-1-0-0 CL RCT USE; 710281-0-0-0 CL RCT USE; 451473-0-0-0 CL RCT USE; 684249-2-0-0 CL RCT USE; 102820-1-0-0 CL RCT USE; 702820-1-0-0 CL RCT USE; 36645-0-0-0 CL RCT USE; 87874-0-0-0 CL RCT USE; 93507-0-0-0 CL RCT USE; 199852-0-0-0 CL RCT USE; 813685-1-0-0 CL RCT USE; 91005-0-0-0 CL RCT USE; 91332-1-0-0 CL RCT USE; 736241-1-0-0 CL RCT USE; 99028-1-0-0 CL RCT USE,230304101 K M Q; 230304103 K M Q; 230304104 K M Q; 230304105 K M Q; 230304102 K M Q; 230304106 K M Q; 230304107 K M Q,01188; 07955; 01586; 01345; 03010; 00061,RAE5RQ K M Q; RA181E K M Q; R01867 K M Q; RA0J2O K M Q; RA1DKC K M Q; RAADA6 K M Q; RA9W39 K M Q; RA9Y22 K M Q; RAAQSK K M Q; RAA8IM K M Q; R00487 K M Q; R14664 K M Q; R00034 K M Q; R00159 K M Q; RA7RM2 K M Q; RACFJT K M Q; R10146 K M Q; R22347 K M Q; RAL9WD K M Q; RA0KVH K M Q,1867-S; 0487-S; 0034-S; 0159-S
WO2023109918-A1;  CN116265452-A,"New nitrogenous heterocyclic compound useful as            RIPK1 inhibitor for detecting, preventing and treating            inflammatory diseases, ischemic diseases, degenerative            diseases, tumors, cell necrosis-related diseases, and            metabolic-related diseases",DUAN W;  GENG M;  ZHANG H;  AI J;  LAN Y;  PENG X;  FANG C;  JI Y;  JIN Z;  FENG D;  DING J,CHINESE ACAD SCI SHANGHAI MATERIA MEDIC (CAMM-C);  CHINESE ACAD SCI SHANGHAI MATERIA MEDIC (CAMM-C),202364085B,"   NOVELTY - Nitrogenous heterocyclic compound (I), is                new.    USE - (I) is useful in preparation of medicine for                detecting, preventing and treating kinase-related                disease, immune, inflammatory, infection-related                disease, ischemia, reperfusion injury, degenerative                disease, tumor-related diseases, cell                necrosis-related diseases, metabolic-related                diseases, and ocular diseases (all claimed).    ADVANTAGE - (I) has excellent RIPK1 inhibitory activity,                good safety, and low toxicity and side                effects.    DETAILED DESCRIPTION - Nitrogenous heterocyclic compound of formula                (I), or its stereoisomer, enantiomer, diastereomer,                atropisomer, optical isomer, racemate, tautomer,                salt, prodrug, hydrate, solvate or isotope-labeled                compound, is new.    ring A=6-membered heteroaromatic ring;    ring E=benzene ring or 6-membered                heteroaromatic ring;    ring G=5-6 membered heteroaromatic ring or 5-6                membered heterocyclic ring;    Z1=CH substituted by at least two of                halo-atom, CDH, CD , O, S, NH, N(CH ), or N(CD                );    Y1=N or C-R1a;    R1a=H, D, halo or NR1R2;    R1 and R2=H, D, 1-8C alkyl, 1-15C alkyl C                (=O)-, 1-15C alkyl OC (=O)-, 1-15C alkyl-O-(1-8C                alkylene)-, 1-15C alkyl (O=)CO-, 2-8C alkenyl, 2-8C                alkynyl, 6-14C aryl C(=O)-, amino acid acyl, or                1-8C alkyl-C(=O)-CH=CH-, where R1 and R2 optionally                substituted by 1-5 of 6-14C aryl, (1-8C alkyl) Si-,                amino, hydroxy, halo, amino, =O, or 1-8C alkyl with                at least two of 1-8C alkyl;    Y2=N or C-R2a;    R2a=H, D, halo, 1-8C alkyl, 1-8C alkoxy,                halogenated 1-8C alkyl, halogenated 1-8C alkoxy,                3-14 membered cycloalkyl, 3-14 membered                heterocyclic group, 2-8C alkenyl, 2-8C alkynyl,                where R2a groups are optionally substituted by 1-5                of D, halo, hydroxy, amino, 1-8C alkyl, amino,                cyano, or NH C(=O)-; and    Y3=N or C-R3a.    Full definitions are given in the DEFINITIONS                (Full Definitions) Field. An INDEPENDENT CLAIM is                also included for preparation of (I).     ",,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).)",B05-A04A;  B05-B01B;  B05-B01E;  B05-B01J;  B05-B01M;  B06-H;  B14-D06C;  B14-N03;  D08-B09A1,A61K-031/55;  A61P-001/00;  C07D-401/12;  A61K-031/437;  A61K-031/438;  A61K-031/4439;  A61K-031/444;  A61K-031/4545;  A61K-031/4709;  A61K-031/4725;  A61K-031/496;  A61K-031/497;  A61K-031/501;  A61K-031/506;  A61K-031/5377;  A61K-031/675;  A61K-031/685;  A61K-031/695;  A61K-031/7056;  A61P-025/00;  A61P-027/02;  A61P-029/00;  A61P-003/00;  A61P-031/00;  A61P-035/00;  A61P-035/02;  A61P-037/02;  A61P-009/10;  C07D-401/14;  C07D-403/14;  C07D-405/14;  C07D-409/14;  C07D-413/14;  C07D-471/04;  C07D-471/10;  C07F-007/08;  C07F-009/6558;  C07H-015/26,WO2023109918-A1   22 Jun 2023   C07D-401/12   202362Pages: 76   Chinese;  CN116265452-A   20 Jun 2023   C07D-401/12   202362   Chinese,WO2023109918-A1    WOCN139380    15 Dec 2022;   CN116265452-A    CN11615954    15 Dec 2022,,CN11555302    17 Dec 2021,WO2023109918-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,"WO2023109918-A1 -- CN108191835-A   UNIV CHINA PHARM (UYCP)   WANG J,  LI Q,  WANG Z,  GU Q;  CN108431004-A   TAKEDA PHARM CO LTD (TAKE)   YOGO T,  YOSHIKAWA M,  SAITOH M,  KATOH T,  SEKI T,  NAKADA Y;  US20060241149-A1   ;  US20160024098-A1   ;  WO2016039358-A1   DAIICHI SANKYO CO LTD (DAUC)   NAGAMOCHI M,  GOTANDA K,  NOGUCHI T,  GOTO T,  SASAKI J,  TORIHATA M,  YOSHINO T,  ISOBE T,  RAMADASS V;  WO2016072402-A1   DAIICHI SANKYO CO LTD (DAUC)   NAGAMOCHI M,  GOTANDA K,  NOGUCHI T,  GOTO T,  SASAKI J,  TORIHATA M,  YOSHINO T,  ISOBE T,  RAMADASS V",, N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P,229234201 N P,01272; 00044; 00993; 42209; 02910; 01200; 01374; 01034; 01035; 01036; 01076; 01078; 01079; 01082; 01085; 01086; 01087; 01089; 01092; 01094; 01095; 01163; 01168; 01175; 01176; 01182; 01183; 01188; 01190; 01192; 01194; 01197; 01199; 01260; 01268; 01270; 01488; 01491; 01509; 01517; 01521; 01522; 01542; 01546; 01570; 01572; 01574; 01586; 01590; 01592; 01602; 01604; 01605; 01606; 01607; 01608; 01680; 01682; 01683; 07923; 07939; 07975; 07978; 08075; 08099; 08100; 09906; 09917; 09920; 09942; 10025; 10027; 10028; 10030; 10031; 10032; 11829; 11858; 11973; 11974; 11975; 11976; 12012; 40020; 40116; 40176; 40327; 40328; 40470; 40695; 40754; 41085; 41426; 41427; 41539; 41540; 41661; 41662; 41663; 42146; 42275; 42310; 42390; 42435; 42592; 44253; 44358; 44380; 45845; 46020; 46960; 46968; 46969; 46970; 47068; 47069; 47967; 48131; 48134; 48135; 48136; 48143; 48250; 48546; 48547; 50295; 50377; 50521; 50522; 50523; 50524; 50534; 50537; 50538; 50540; 50541; 50542; 50544; 50545; 50546; 50548; 50550; 50551; 52084; 52085; 53134; 53135; 55201; 55210; 55211; 56957; 59042; 59414; 59444; 59820; 61206; 61209; 62080; 62937; 64112; 64113; 64114; 64116; 64117; 69461; 70473; 74052; 74540; 74541,RDGAVX N P; RDGAVY N P; RDGAVZ N P; RDGAW0 N P; RDGAW1 N P; RDGAW2 N P; RDGAW3 N P; RDGAW4 N P; RDGAW5 N P; RDGAW6 N P; RDGAW7 N P; RDGAW8 N P; RDGAW9 N P; RDGAWA N P; RDGAWB N P; RDGAWC N P; RDGAWD N P; RDGAWE N P; RDGAWF N P; RDGAWG N P; RDGAWH N P; RDGAWI N P; RDGAWJ N P; RDGAWK N P; RDGAWL N P; RDGAWM N P; RDGAWN N P; RDGAWO N P; RDGAWP N P; RDGAWQ N P; RDGAWR N P; RDGAWS N P; RDGAWT N P; RDGAWU N P; RDGAWV N P; RDGAWW N P; RDGAWX N P; RDGAWY N P; RDGAWZ N P; RDGAX0 N P; RDGAX1 N P; RDGAX2 N P; RDGAX3 N P; RDGAX4 N P; RDGAX5 N P; RDGAX6 N P; RDGAX7 N P; RDGAX8 N P; RDGAX9 N P; RDGAXA N P; RDGAXB N P; RDGAXC N P; RDGAXD N P; RDGAXE N P; RDGAXF N P; RDGAXG N P; RDGAXH N P; RDGAXI N P; RDGAXJ N P; RDGAXK N P; RDGAXL N P; RDGAXM N P; RDGAXN N P; RDGAXO N P; RDGAXP N P; RDGAXQ N P; RDGAXR N P; RDGAXS N P; RDGAXT N P; RDGAXU N P; RDGAXV N P; RDGAXW N P; RDGAXX N P; RDGAXY N P; RDGAXZ N P; RDGAY0 N P; RDGAY1 N P; RDGAY2 N P; RDGAY3 N P; RDGAY4 N P; RDGAY5 N P; RDGAY6 N P; RDGAY7 N P; RDGAY8 N P; RDGAY9 N P; RDGAYA N P; RDGAYB N P; RDGAYC N P; RDGAYD N P; RDGAYE N P; RDGAYF N P; RDGAYG N P; RDGAYH N P; RDGAYI N P; RDGAYJ N P; RDGAYK N P; RDGAYL N P; RDGAYM N P,
WO2024108158-A1,"New antibody agent useful e.g. for preventing or            reversing mass loss, weight loss, muscle atrophy, organ            damage, senescence, kidney damage, cancer or liver            damage in human, comprises polypeptide binding to            activin-A and activin-B",JACKSON V M;  NIELSON N P,BYOMASS INC (BYOM-Non-standard);  ADIMAB LLC (ADIM-Non-standard),2024523096,"   NOVELTY - An antibody agent comprising a polypeptide                that binds to activin-A, activin-B and/or to one or                more complexes that include one or both activin-A                and activin-B comprising at least one light chain                complementarity determining region (LC CDR) and/or                at least one heavy chain complementary determining                region (HC CDR), is new.    USE - The antibody agent is useful in pharmaceutical                composition for treating subject, ameliorating a                symptom of a disorder in a subject, reducing and/or                preventing one or more side effects of a                therapeutic agent and preventing and/or reversing                mass loss, weight loss, muscle atrophy, organ                damage, senescence, kidney damage, cancer,                metastasis or liver damage in a subject, where the                mass comprises fat mass, lean mass, muscle mass,                bone mass, organ mass, or their combination, the                weight loss is involuntary, the muscle is chosen                from cardiac muscle, smooth muscle, skeletal                muscle, or their combination, the organ damage                comprises a change in function of an organ, a                reduction in size of an organ (e g. atrophy), a                change in cellularity of an organ (e.g. increased                infiltration of immune cells), a reduction in                weight of an organ, or their combination. The                subject has a condition or disorder associated with                increased activin-A and/or activin-B. The symptom                is weight loss, loss of appetite, fatigue, muscle                mass loss, fat mass loss, lean mass loss, lean mass                atrophy, bone loss, anemia, organ damage and/or                fibrosis. The liver damage is a symptom of liver                disease, where liver disease is or comprises                nonalcoholic fatty liver disease (NAFLD),                nonalcoholic steatohepatitis (NASH), cirrhosis,                hepatitis, hepatotoxicity and cancer. The one or                more side effects is or comprises muscle mass loss,                heart damage, kidney damage, liver damage, or their                combination. The liver damage comprises acute liver                injury, liver necrosis, liver fibrosis, liver                inflammation, alteration in liver function,                elevation one or more liver enzymes, changes in one                or more biomarkers of liver function, or their                combination. The kidney damage comprises acute                kidney injury, kidney fibrosis, kidney                inflammation, alteration in kidney function or                their combination. The kidney disease is or                comprises acute kidney injury, chemotherapy-induced                nephropathy, cancer-treatment-induced nephropathy,                chronic kidney disease, diabetic nephropathy,                Alport Syndrome, chronic kidney disease mineral                bone disorder, chronic kidney disease anemia,                chronic kidney disease protein energy wasting,                tubulointerstitial nephritis, focal segmental                glomerulosclerosis, immunoglobulin (Ig)A                nephropathy or autosomal dominant polycystic kidney                disease. The cancer is chosen from colorectal                cancer, colon cancer, gastric cancer, sarcoma,                lymphoma, leukemia, head and neck cancer, thymic                cancer, epithelial cancer, salivary cancer, liver                cancer, stomach cancer, thyroid cancer, lung                cancer, ovarian cancer, breast cancer, prostate                cancer, esophageal cancer, pancreatic cancer,                glioma, leukemia, lymphoma, multiple myeloma, renal                cell carcinoma, bladder cancer, cervical cancer,                choriocarcinoma, oral cancer, skin cancer,                melanoma, endometrial cancer, myleofibrosis, bone                cancer or a brain cancer. The subject is a mammal,                preferably human (all claimed).    ADVANTAGE - The antibody agent has desirable binding                kinetics, binding affinity, pharmacokinetics and/or                function, has improved characteristics compared to                a reference antibody agent and has high                specificity.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    isolated nucleic acid;    vector comprising the nucleic acid;    host cell comprising the vector;    method for preparing the antibody agent which                binds to activin-A, activin-B, and/or to one or                more complexes that include one or both activin-A                and activin-B;    composition comprising an activin A/B antibody                agent polypeptide;    pharmaceutical composition comprising activin                A/B antibody agent polypeptide or the composition,                where the pharmaceutical composition comprises an                excipient and/or carrier;    method involves contacting the pharmaceutical                composition to a cell, tissue or subject;    method for preventing and/or reversing mass                loss, weight loss, muscle atrophy, fibrosis,                senescence, liver damage, cancer, metastasis and/or                kidney damage in a subject;    method for reducing and/or preventing one or                more side effects of a therapeutic agent; and    method involves assessing a level and/or                activity of activin-A and/or activin-B in a sample                from a subject and administering an Activin-A                and/or Activin-B pharmaceutical composition to the                subject if the level of Activin-A and/or Activin-B                is higher than a comparator. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-C01;  B04-E01;  B04-E08;  B04-E99;  B04-F0100E;  B04-G01;  B04-N02;  B04-N16;  B11-C04;  B11-C07A;  B12-K04E1;  B12-K04E3;  B14-C03;  B14-F03;  B14-H01;  B14-J05;  B14-L06;  B14-N01;  B14-N10;  B14-N12;  D05-H09;  D05-H11;  D05-H12;  D05-H14;  D05-H17A1;  D05-H99,A61K-039/395;  A61P-013/00;  A61P-003/04;  A61P-005/50;  C07K-016/24,WO2024108158-A1   23 May 2024   A61K-039/395   202447Pages: 270   English,WO2024108158-A1    WOUS080341    17 Nov 2023,,US426477P    18 Nov 2022,WO2024108158-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2024108158-A1 -- US20060172347-A1   ;  US20150359850-A1   ;  US20220119514-A1   ;  WO2018098363-A2   BIOVERATIV THERAPEUTICS INC (SNFI)   PETERS R T,  LEKSA N,  PEARSE B R,  KULMAN J,  ALEMAN M,  GOODMAN A",,184587-0-0-0 N P; 86535-0-0-0 K M; 184587-0-0-0 CL NEW PRD,231080701 K M; 231080702 K M; 231080703 K M; 231080704 K M,,RA00C8 N P; RA03QY K M,
WO2023150708-A1,"Amplifying target nucleic acid sequence in sample            used for rapid detection of infection, comprises            contacting sample with acidic composition, contacting            reagent composition with acidic mixture, and amplifying            target nucleic acid sequence",ZHANG H;  KOSLOVER D J,BECTON DICKINSON & CO (BECT-C),2023841106,"   NOVELTY - Amplifying a target nucleic acid sequence in a                sample, comprises: (a) contacting a sample                comprising biological entities with an acidic                composition to generate an acidic mixture, where                the acidic composition is capable of lysing the                biological entities to release sample nucleic acids                comprised in its, and the sample nucleic acids                comprise double-stranded DNA (dsDNA) suspected of                comprising a target nucleic acid sequence, the                target nucleic acid sequence is &#8815; 100                nucleotides in length; (b) contacting a reagent                composition comprising a buffering agent with the                acidic mixture to generate a neutral mixture, where                the neutral mixture comprises the ssDNA, the                reagent composition comprises at least one                amplification reagent; and (c) amplifying the                target nucleic acid sequence in the neutral                mixture, thus generating a nucleic acid                amplification product, optionally the reagent                composition is a dried composition or a wet                composition.    USE - The method is useful for amplifying a target                nucleic acid sequence in a sample (claimed) e.g.                isothermal amplification of nucleic acids, which is                used for rapid detection of infection, disease                and/or genetic variations.    ADVANTAGE - The method: can be performed without                thermocycling, without thermal denaturation and/or                enzymatic denaturation of sample nucleic acids,                without added proteins (e.g. enzymes) to promote                strand unwinding, strand separation and/or strand                exchange, without endonuclease agents, and within a                reaction time of 10-15 minutes; is a simple and                rapid denaturation method; provides significant                value in an effective chemical lysis method i.e.                compatible with enzyme function and does not                require any nucleic acid purification steps to                remove the lysis reagents; is fast and simple                method for separating complementary strands of                dsDNA (e.g. genomic DNA) for subsequent targeting                of short sequence stretches in, e.g. amplification                reactions; and enables isothermal amplification and                real-time detection of nucleic acids without a need                for sample separation or purification for                point-of-care molecular diagnostics for direct                pathogen lysis in clinical samples.    DETAILED DESCRIPTION - Amplifying a target nucleic acid sequence in a                sample, comprises: (a) contacting a sample                comprising biological entities with an acidic                composition to generate an acidic mixture, where                the acidic composition is capable of lysing the                biological entities to release sample nucleic acids                comprised in its, the sample nucleic acids comprise                double-stranded DNA (dsDNA) suspected of comprising                a target nucleic acid sequence, the target nucleic                acid sequence is &#8815; 100 nucleotides in                length, and the acidic composition has a pH of less                than 4 and comprises (i) a monovalent salt and/or a                divalent salt, (ii) at least one surfactant, and                (iii) an acidic agent, thus denaturing the dsDNA to                generate single-stranded DNA (ssDNA); (b)                contacting a reagent composition comprising a                buffering agent with the acidic mixture to generate                a neutral mixture, where the neutral mixture                comprises the ssDNA, the reagent composition                comprises at least one amplification reagent; and                (c) amplifying the target nucleic acid sequence in                the neutral mixture, thus generating a nucleic acid                amplification product, optionally the reagent                composition is a dried composition or a wet                composition. INDEPENDENT CLAIMS are also included                for:    acidic composition for lysing biological                entities and denaturing dsDNA comprised in its,                comprising a monovalent salt at a concentration of                less than 30 mM in the acidic composition and/or a                divalent salt at a concentration of less than 15 mM                in the acidic composition, at least one surfactant,                and an acidic agent present in the acidic                composition at a concentration of less than 100 mM,                and the acidic composition has a pH less than 4;                and    kit for detecting a target nucleic acid                sequence in a sample, comprising (a) the acidic                composition, where the acidic composition is                capable of lysing biological entities to release                sample nucleic acids comprised in its, the sample                nucleic acids comprise dsDNA suspected of                comprising a target nucleic acid sequence, and the                target nucleic acid sequence is &#8815; 100                nucleotides in length, and (b1) a reagent                composition comprising a buffering agent and at                least one amplification reagent for amplifying the                target nucleic acid sequence under isothermal                amplification conditions, where the amplification                reagents comprise (1) a first primer and a second                primer, where the first primer is capable of                hybridizing to a sequence of a first strand of the                target nucleic acid sequence, and the second primer                is capable of hybridizing to a sequence of a second                strand of the target nucleic acid sequence, and (2)                an enzyme having a hyperthermophile polymerase                activity capable of generating a nucleic acid                amplification product, optionally the reagent                composition is a dried composition or a wet                composition. ",,,"A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",A12-V03C2;  A12-W11L;  B04-C02A2;  B04-C02C;  B04-C03;  B04-E01;  B04-E05;  B04-E14;  B04-E15;  B04-E16;  B04-E99;  B04-N02;  B11-C08F8;  B11-C08N2;  B12-K04F;  B12-K04G1A;  D05-H09;  D05-H18B2;  D05-H99,C12Q-001/6806;  C12Q-001/6844,WO2023150708-A1   10 Aug 2023   C12Q-001/6806   202369Pages: 106   English,WO2023150708-A1    WOUS061978    03 Feb 2023,,US307085P    05 Feb 2022,WO2023150708-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2023150708-A1 -- CN106867998-A   ZHENGZHOU AUTOBIO ENG CO LTD (ATBO)   GAO L,  LI Z,  WANG W,  YU Y,  LV M,  LI G,  FU G,  WU X,  MIAO Y;  US20080128298-A1   ;  US20200255885-A1   ;  WO2005093065-A1   ROCHE DIAGNOSTICS GMBH (HOFF);  HOFFMANN LA ROCHE & CO AG F (HOFF);  UNIV AMSTERDAM ACAD MEDICAL CENT (UYAM-Non-standard)   BELD M;  WO2010015835-A1   DIAGNOSTICS REAL WORLD LTD (DIAG-Non-standard)   CHUA Y L,  RITCHIE A V;  WO2011098085-A1   CHEMOMETEC AS (CHEM-Non-standard)   KJARULFF S,  GLENSBJERG M;  WO2021021522-A1   BECTON DICKINSON & CO (BECT)   COTE J,  FORTIN M,  BLANCHETTE V,  TREMBLAY M,  MORASSE S,  GUAY S,  SIMARD S;  WO2021204701-A1   BAYER AG (FARB)   GOLZ S,  SUMMER H,  AIGNER S,  ELLINGER-ZIEGELBAUER H,  LEINEWEBER K,  MUELLER T;  WO2022198086-A1   BECTON DICKINSON & CO (BECT)   ZHANG H,  MILLER A P,  MERMER B,  TSAI L;  WO2017176404-A1   NAT DIAGNOSTICS INC (BECT)   MILLER A P,  ZHANG H","WO2023150708-A1  DATABASE ChemoMetec          A/S [online] ChemoMetec A/S; 26 January 2021          (2021-01-26), CHEMOMETEC A/S: ""910-0010 Lysis 1 - Acidic          Lysis buffer 100 ml Contents"", XP093045327, Database          accession no. Doc.No: 992-0041          v1.1,relevantClaims[55-62],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  TOM KILLELEA ET AL:          ""PCR performance of a thermostable heterodimeric archaeal          DNA polymerase"", FRONTIERS IN MICROBIOLOGY, vol. 5, 7 May          2014 (2014-05-07), XP055468461, DOI:          10.3389/fmicb.2014.00195,relevantClaims[1-85],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  COOPER CHRISTOPHER          D.O.: ""Archaeal DNA polymerases: new frontiers in DNA          replication and repair"", EMERGING TOPICS IN LIFE          SCIENCES, vol. 2, no. 4, 14 November 2018 (2018-11-14),          pages 503 - 516, XP093044995, ISSN: 2397-8554, Retrieved          from the Internet          &lt;URL:https://portlandpress.com/emergtoplifesci/article-pdf/2/4/503/484023/etls-2018-0015c.pdf&gt;          DOI:          10.1042/ETLS20180015,relevantClaims[1-85],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            BIOPHYS J, vol. 80, no. 2, February 2001 (2001-02-01),          pages 874 - 881;            SINGLETON ET AL.: ""Dictionary of Microbiology and          Molecular Biology"", 1994, J. WILEY & SONS;            SAMBROOK ET AL.: ""Molecular Cloning, A Laboratory          Manual"", 1989, COLD SPRING HARBOR PRESS;            LENGLET ET AL., JOURNAL OF NUCLEIC ACIDS, vol. 2010,          2010, pages 17",104477-1-0-0 K M; 151725-1-0-0 K M; 151726-1-0-0 K M; 104478-1-0-0 K M; 104479-0-0-0 K M; 911704-0-0-0 K M; 154284-1-0-0 K M; 92818-0-0-0 K M; 184613-0-0-0 K M; 900-0-0-0 K M; 104492-0-0-0 K M; 95972-0-0-0 K M; 104488-0-0-0 K M; 97485-1-0-0 K M; 97261-0-0-0 K M; 86886-0-0-0 K M; 91481-0-0-0 K M; 444-0-0-0 ; 107779-0-0-0 ; 97486-1-0-0 ,,,R01869 K M; RA04X7 K M; RA12PD K M; R01871 K M; R01870 K M; RAOYW6 K M; RA0PH3 K M; R01857 K M; RA00I9 K M; R02044 K M; RA0GM6 K M; RA01EA K M; R24033 K M; RA04WZ K M; R03005 K M; R01859 K M; RA016G K M; R24039 K M; R24034 K M; R00351 ; R01863 ; R06563 ,1869-S; 1871-S; 1870-S; 1857-S; 2044-S; 1859-S
FR3142656-A1;  WO2024121037-A1,"Use of food supplement composition for oral or            nasal intake in healthy subjects comprising compound            including D-xylose, their esters, oligosaccharides            comprising D-xylose, and/or beta-D-xyloside in            physiologically acceptable medium",CHEUDJEU A,CHEUDJEU A (CHEU-Individual);  CHEUDJEU A (CHEU-Individual),202458180W,"   NOVELTY - Use of food supplement composition for oral or                nasal intake in healthy subjects comprising at                least one compound including D-xylose, their                esters, oligosaccharides comprising D-xylose,                and/or &#946; -D-xyloside in a physiologically                acceptable medium for stimulating the biosynthesis                of glycosaminoglycans, preferably at least one                heparan sulfate, dermatan sulfate and chondroitin                sulfate.    USE - The food supplement composition is useful for                oral e.g. food product, beverage, food additive or                dairy product or nasal intake in healthy subjects                for stimulating biosynthesis of glycosaminoglycans                (claimed) for treating COVID19, HIV and                diabetes.    ADVANTAGE - The food supplement reduces the side effects                e.g. laxative effects, nausea and vomiting                associated with its use. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).)",B04-A08;  B04-A10;  B04-A98;  B04-C02A1;  B04-C02E1;  B04-C02E2;  B04-C02X;  B10-A07A;  B12-M12N;  B12-M12Q;  B14-A02B1;  B14-A02B5;  B14-E11;  B14-G01B;  B14-S04;  B14-S18;  D03-H01G;  D03-H01T2B,A23L-029/30;  A23L-033/10;  A23L-033/105;  A23L-033/125;  A61K-031/7004;  A61P-003/10;  A61P-031/14;  A61P-031/18,FR3142656-A1   07 Jun 2024   A23L-033/10   202450Pages: 60   French;  WO2024121037-A1   13 Jun 2024   A23L-029/30   202450   French,FR3142656-A1    FR012766    05 Dec 2022;   WO2024121037-A1    WOEP084075    04 Dec 2023,,FR012766    05 Dec 2022,  WO2024121037-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"FR3142656-A1 -- CN107074898-A   XYLECO INC (XYLE)   MEDOFF M;  EP2206491-A1   L'OREAL SA (OREA)   LABOUREAU J,  PORTES P,  SIMONNET J T;  FR2869317-A1   L'OREAL SA (OREA)   TROUILLE S,  CAVEZZA A,  PICHAUD P;  US5104856-A   UAB RES FOUND (UABR)   ESKO J D,  LUGEMWA F N;  US20160199424-A1   ;  WO1994005678-A1   ;  WO1999024009-A1   ;  WO1999048361-A1   ;  WO2024121037-A1 -- CN107074898-A   XYLECO INC (XYLE)   MEDOFF M;  EP2206491-A1   L'OREAL SA (OREA)   LABOUREAU J,  PORTES P,  SIMONNET J T;  FR2869317-A1   L'OREAL SA (OREA)   TROUILLE S,  CAVEZZA A,  PICHAUD P;  US5104856-A   UAB RES FOUND (UABR)   ESKO J D,  LUGEMWA F N;  US20160199424-A1   ;  WO1994005678-A1   ;  WO1999024009-A1   ;  WO1999048361-A1   ","FR3142656-A1  MASSON P J ET AL:          ""The effect of the.beta.-D-xyloside naroparcil on          circulating plasma glycosaminoglycans. An explanation for          its known antithrombotic activity in the rabbit"", JOURNAL          OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR          BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 270, no. 6,          10 February 1995 (1995-02-10), pages 2662 - 2668,          XP002056036, ISSN: 0021-9258, DOI:          10.1074/JBC.270.6.2662,relevantClaims[1-4,8|5-7],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  BELLAMY F ET AL:          ""Glycosylated Derivatives of Benzophenone, Benzhydrol,          and Benzhydril as Potential Venous Antithrombotic          Agents"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN          CHEMICAL SOCIETY, US, vol. 36, no. 7, 2 April 1993          (1993-04-02), pages 898 - 903, XP002111914, ISSN:          0022-2623, DOI:          10.1021/JM00059A015,relevantClaims[1,2,8],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  ZHANG: ""A novel          cleaning process for industrial production of xylose in          pilot scale from corncob by using screw-steam-explosive          extruder"", 3 June 2014 (2014-06-03), XP093051600,          Retrieved from the Internet          &lt;URL:https://link.springer.com/article/10.1007/s00449-014-1219-0&gt;          [retrieved on          20230605],relevantClaims[5,7],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            R.R. VIVES, HEPARANES SULFATE : STRUCTURE, FONCTIONS,          REGULATION, 11 April 2020 (2020-04-11);  S.          SARRAZINW.C. LAMANNAJ.D. ESKO: ""Heparan sulfate          proteoglycans"", COLD SPRING HARB. PERSPECT. BIOL., vol.          3, 2011;  S.          SARRAZINW.C. LAMANNAJ.D. ESKO, HEPARAN SULFATE          PROTEOGLYCANS, COLD SPRING HARB. PERSPECT. BIOL;            R.R. VIVES, HEPARANES SULFATE: STRUCTURE, FONCTIONS,          REGULATION, 11 April 2020 (2020-04-11);  M.          EGEBERGR. KJEKENS.O. KOLSETT. BERGK. PRYDZ:          ""Internalization and stepwise degradation of heparan          sulfate proteoglycans in rat he-patocytes"", BIOCHIM.          BIOPHYS. ACTA, vol. 1541, 2001, pages 135 - 149;  S.          SARRAZINW.C. LAMANNAJ.D. ESKO: ""Heparan sulfate          proteoglycans"", COLD SPRING HARB. PERSPECT.          BIOL;  D.          JOLADARASHIP.V. SALIMATHN.D. CHILKUNDA: ""Diabetes results          in structural al- teration of chondroitin          sulfate/dermatan sulfate in the rat kidney: effects on          the binding to extracellular matrix components"",          GLYCOBIOLOGY, vol. 21, 2011, pages 960 - 972;            L.M. HIEBERTJ. HANA.K. MANDAL: ""Glycosaminoglycans,          hyperglycemia, and dis- ease"", ANTIOXID. REDOX SIGNAL.,          vol. 21, 2014, pages 1032 - 1043;            L.M. HIEBERT: ""Proteoglycans and diabetes"", CURR. PHARM.          DES., vol. 23, 2017, pages 1500 - 1509;  Z.          WANGK. PARKF. COMERL.C. HSIEH-WILSONC.D. SAUDEKG.W. HART:          ""Site- specifie GlcNAcylation of human erythrocyte          proteins: potential biomarker(s) for diabetes"", DIABETES,          vol. 58, 2009, pages 309 - 317;  L.          WELLSK. VOSSELLERG.W. HART: ""A role for          N-acetylglucosamine as a nutrient sensor and mediator of          insulin resistance"", CELL. MOL. LIFE SCI., vol. 60, 2003,          pages 222 - 228;  S.          MINEY. OKADAC. KAWAHARAT. TABATAY. TANAKA: ""Serum          hyaluronan con- centration as a marker of angiopathy in          patients with diabetes mellitus"", ENDOCR. J., vol. 53,          2006, pages 761 - 766;  R.          HALLGRENT. SAMUELSSONT.C. LAURENTJ. MODIG: ""Accumulation          of hyaluronan (hyaluronic acid) in the lung in adult          respiratory distress syndrome"", AM. REV. RESPIR. DIS.,          vol. 139, 1989, pages 682 - 687;  C.          GTTINGJ. KUHNK. KLEESIEK: ""Serum xylosyltransferase          activity in diabetic patients as a possible marker of          reduced proteoglycan biosynthesis"", DIABETES CARE, vol.          31, 2008, pages 2018 - 2019;  R.          KOSLOWSKIU. PFEILH. FEHRENBACHM. KASPERE. SKUTELSKYK.W.          WENZEL: ""Changes in xylosyl-transferase activity and in          proteoglycan deposition in bleo- mycin-induced lung          injury in rat"", EUR. RESPIR. J., vol. 18, 2001, pages 347          - 356;  S.          TSALAMANDRISA.S. ANTONOPOULOSE. OIKONOMOUG.A.          PAPAMIKROULISG. VOGIATZIS. PAPAIOANNOUS. DEFTEREOSD.          TOUSOULIS: ""The role of inflammation in diabetes: current          concepts and future perspectives"", EUR. CARDIOL., vol.          14, 2019, pages 50 - 59;  A.          JINNO ET AL., METHODS MOL. BIOL., vol. 1229, 2015, pages          567 - 585;  V.          CAGNO ET AL., VIRUSES, vol. 11, 2019, pages 596;  M.          BERMEJO-JAMBRINAJ. EDER ET AL., BIORXIV, 2020;            A.C. SAPHIRE ET AL., J. VIROL., vol. 75, 2001, pages 9187          - 9200;            Q.SHI ET AL., J. VIROL., vol. 87, 2013, pages 6866 -          6875;  J.          HU ET AL., FRONT. MICROBIOL, vol. 11, 2020, pages          517461;  S.          MAYAA. PLOSS, HEPATOLOGY, vol. 71, 2020, pages 380 -          382;  K.          AZARM, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK,          NY, 2020;            T.M. CLAUSEN ET AL., CELL, vol. 183, 2020, pages 1043 -          1057;  Q.          ZHANG ET AL., CELL DISCOV, vol. 6, 2020, pages          80WO2024121037-A1  MASSON P J ET AL:          ""The effect of the.beta.-D-xyloside naroparcil on          circulating plasma glycosaminoglycans. An explanation for          its known antithrombotic activity in the rabbit"", JOURNAL          OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR          BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 270, no. 6,          10 February 1995 (1995-02-10), pages 2662 - 2668,          XP002056036, ISSN: 0021-9258, DOI:          10.1074/JBC.270.6.2662,relevantClaims[1-8],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  BELLAMY F ET AL:          ""Glycosylated Derivatives of Benzophenone, Benzhydrol,          and Benzhydril as Potential Venous Antithrombotic          Agents"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN          CHEMICAL SOCIETY, US, vol. 36, no. 7, 2 April 1993          (1993-04-02), pages 898 - 903, XP002111914, ISSN:          0022-2623, DOI:          10.1021/JM00059A015,relevantClaims[1,2,4-8],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  ZHANG: ""A novel          cleaning process for industrial production of xylose in          pilot scale from corncob by using screw-steam-explosive          extruder | SpringerLink"", 3 June 2014 (2014-06-03), pages          2425 - 2436, XP093051600, Retrieved from the Internet          &lt;URL:https://link.springer.com/article/10.1007/s00449-014-1219-0&gt;          [retrieved on          20230604],relevantClaims[4,6],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            R.R. VIVES, HEPARANES SULFATE : STRUCTURE, FONCTIONS,          REGULATION, 11 April 2020 (2020-04-11);  S.          SARRAZINW.C. LAMANNAJ.D. ESKO: ""Heparan sulfate          proteoglycans"", COLD SPRING HARB. PERSPECT. BIOL., 2011,          pages 3;            R.R. VIVES, HEPARANES SULFATE, 11 April 2020          (2020-04-11);  M.          EGEBERGR. KJEKENS.O. KOLSETT. BERGK. PRYDZ:          ""Internalization and stepwise degradation of heparan          sulfate proteoglycans in rat hepatocytes"", BIOCHIM.          BIOPHYS. ACTA, vol. 1541, 2001, pages 135 - 149,          XP004330471, DOI: 10.1016/S0167-4889(01)00132-X;            R.R. VIVES, HEPARANES SULFATE: STRUCTURE, FONCTIONS,          REGULATION, 11 April 2020 (2020-04-11);  D.          JOLADARASHIP.V SALIMATHN.D. CHILKUNDA: ""Diabetes results          in structural al- teration of chondroitin          sulfate/dermatan sulfate in the rat kidney: effects on          the binding to extracellular matrix components"",          GLYCOBIOLOGY, vol. 21, 2011, pages 960 - 972;            L.M. HIEBERTJ. HANA.K. MANDAL: ""Glycosaminoglycans,          hyperglycemia, and dis- ease"", ANTIOXID. REDOX SIGNAL.,          vol. 21, 2014, pages 1032 - 1043;            L.M. HIEBERT: ""Proteoglycans and diabetes"", CURR. PHARM.          DES., vol. 23, 2017, pages 1500 - 1509;  Z.          WANGK. PARKF. COMERL.C. HSIEH-WILSONC.D. SAUDEKG.W. HART:          ""Site- specifie GlcNAcylation of human erythrocyte          proteins: potential biomarker(s) for diabetes"", DIABETES,          vol. 58, 2009, pages 309 - 317;  L.          WELLSK. VOSSELLERG.W. HART: ""A role for          N-acetylglucosamine as a nutrient sensor and mediator of          insulin resistance"", CELL. MOL. LIFE SCI., vol. 60, 2003,          pages 222 - 228;  S.          MINEY OKADAC. KAWAHARAT. TABATAY. TANAKA: ""Serum          hyaluronan con- centration as a marker of angiopathy in          patients with diabetes mellitus"", ENDOCR. J., vol. 53,          2006, pages 761 - 766;  R.          HALLGRENT. SAMUELSSONT.C. LAURENTJ. MODIG: ""Accumulation          of hyaluronan (hyaluronic acid) in the lung in adult          respiratory distress syndrome"", AM. REV. RESPIR. DIS.,          vol. 139, 1989, pages 682 - 687;  C.          GTTINGJ. KUHNK. KLEESIEK: ""Serum xylosyltransferase          activity in diabetic patients as a possible marker of          reduced proteoglycan biosynthesis"", DIABETES CARE, vol.          31, 2008, pages 2018 - 2019;  R.          KOSLOWSKIU. PFEILH. FEHRENBACHM. KASPERE. SKUTELSKYK.W.          WENZEL: ""Changes in xylosyltransferase activity and in          proteoglycan deposition in bleo-mycin-induced lung injury          in rat"", EUR. RESPIR. J., vol. 18, 2001, pages 347 -          356;  S.          TSALAMANDRISA.S. ANTONOPOULOSE. OIKONOMOUG.A.          PAPAMIKROULISG. VOGIATZIS. PAPAIOANNOUS. DEFTEREOSD.          TOUSOULIS: ""The role of inflammation in diabetes: current          concepts and future perspectives"", EUR. CARDIOL., vol.          14, 2019, pages 50 - 59;  A.          JINNO ET AL., METHODS MOL. BIOL., vol. 1229, 2015, pages          567 - 585;  V.          CAGNO ET AL., VIRUSES, vol. 11, 2019, pages 596;  M.          BERMEJO-JAMBRINAJ. EDER ET AL., BIORXIV, 2020;            A.C. SAPHIRE ET AL., J. VIROL., vol. 75, 2001, pages 9187          - 9200;            Q.SHI ET AL., J. VIROL., vol. 87, 2013, pages 6866 -          6875;  J.          HU ET AL., FRONT. MICROBIOL., vol. 11, 2020, pages          517461;  S.          MAYAA. PLOSS, HEPATOLOGY, vol. 71, 2020, pages 380 -          382;            T.M. CLAUSEN ET AL., CELL, vol. 183, 2020, pages 1043 -          1057;  Q.          ZHANG ET AL., CELL DISCOV, vol. 6, 2020, pages          80",1047340-0-0-0 K M; 90877-0-0-0 K M; 96778-0-0-0 K M; 2160045-0-0-0 K M; 755998-0-0-0 K M; 2300528-0-0-0 K M; 1542872-0-0-0 K M; 2633672-0-0-0 K M; 96795-0-0-0 K M; 129626-5-0-0 K M; 1047340-0-0-0 CL USE; 2160045-0-0-0 CL USE; 2300528-0-0-0 CL USE; 1542872-0-0-0 CL USE; 2633672-0-0-0 CL USE,231130701 K M,,RAH9IO K M; R01875 K M; RA0696 K M; RA024U K M; RB4T8S K M; RAB8B2 K M; RB7SOI K M; RARRC9 K M; RBF2EA K M; RA069A K M; R14252 K M,1875-S; 0173-S
US2024119176-A1,"Method for facilitating de-identification of e.g.            name of adrug to be administered of influenza patient            by healthcare provider in hospital, involves            obfuscating data set using fine-tuned machine-learning            model",RAJASEKHARAN A;  ARAVAMUDAN M;  MURUGADOSS K;  ARDHANARI S,NFERENCE INC (NFER-Non-standard),202437077Y,"   NOVELTY - The method involves receiving data sets. A                machine-learning model is determined from a set of                machine-learning models for entity types. The                determined machine-learning model is fine-tuned for                the entity types by creating training data sets,                training the determined machine-learning model                using the first training data set, validating the                trained machine-learning model and updating the                trained machine-learning model using the second                training data set as a function of the validation.                The second data set is obfuscated using the                fine-tuned machine-learning model.    USE - Method for facilitating de-identification of                electronic health records e.g. name of a drug to be                administered, of a patient e.g. COVID19 patients,                chronic illness patient and influenza patient, by a                healthcare provider in a hospital.    ADVANTAGE - The method enables splitting the corpus into                sentences and de-duplicating the resulting set of                sentences to improve computational efficiency. The                method enables biomedical data to be analyzed by                computational processes under the constraint of                maintaining the privacy of the individual patient                or consumer with great commercial, social and                scientific benefit to society.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view of a                federated approach for processing datasets                containing private data.    1A101Second entity    1A100First entity    1A103Third entity    1A104Fourth entity    1A105Chain of trust ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  S05 (Electrical Medical Equipment);  T01 (Digital Computers)",B11-C14;  B11-C11;  S05-G02G1;  T01-J06A1;  T01-J12C;  T01-J16C2;  T01-N02B1B,G06F-021/62;  G06N-020/00;  G16H-010/60,US2024119176-A1   11 Apr 2024   G06F-021/62   202435   English,US2024119176-A1    US381873    19 Oct 2023,US2024119176-A1 CIP of Application US908520;   US2024119176-A1 Cont of Application US192564;   US2024119176-A1 Cont of Application US975489;   US2024119176-A1 Provisional Application US012738P;   US2024119176-A1 Provisional Application US985003P;   US2024119176-A1 Provisional Application US984989P;   US2024119176-A1 Provisional Application US962146P;   US2024119176-A1 Provisional Application US865030P;   US2024119176-A1 Provisional Application US109769P;   US2024119176-A1 Provisional Application US128542P;   US2024119176-A1 CIP of Patent US11545242;   US2024119176-A1 Cont of Patent US11487902;   US2024119176-A1 Cont of Patent US11829514,US865030P    21 Jun 2019;  US381873    19 Oct 2023,,,,,,,,,
WO2024067344-A1,"New isolated anti-LIGHT antibody useful e.g. in            preparation of medicine to treat disease and condition            caused by dysregulation of LIGHT signaling pathway,            e.g. autoimmune disease and inflammatory disease",ZHANG M;  WANG G;  YU D;  CUI J,STAIDSON BEIJING BIOPHARMACEUTICALS CO (STAI-Non-standard),202435542B,"   NOVELTY - Isolated anti-LIGHT antibody comprising e.g.                heavy chain variable domain (VH) includes heavy                chain complementarity determining region (HC-CDR)                1, which includes (SEQ ID NO: 1), HC-CDR2, which                contains a fully defined sequence of 17 amino acids                (SEQ ID NO: 8 or SEQ ID NO: 9) as given in the                specification, and HC-CDR3, which contains a fully                defined sequence of 15 amino acids (SEQ ID NO: 16)                as given in the specification; and a light chain                variable domain (VL) includes light chain                complementarity determining region (LC-CDR) 1,                which includes a fully defined sequence of 11 amino                acids (SEQ ID NO: 23) as given in the                specification, LC-CDR2, which contains (SEQ ID NO:                30), and LC-CDR3, which contains (SEQ ID NO: 37),                is new.    USE - The antibody, nucleic acid molecule, vector,                host cell or medicine is useful in the preparation                of medicine for treating a disease or condition                caused by dysregulation of the LIGHT signaling                pathway, e.g. an autoimmune disease and/or an                inflammatory disease, preferably inflammatory bowel                disease (IBD), Crohn's disease, ulcerative colitis,                ankylosing spondylitis, atopic dermatitis,                rheumatoid arthritis, bronchiolitis, transplant                rejection, Allograft rejection, graft-versus-host                disease (GVHD), asthma, eosinophilic esophagitis,                acute respiratory distress syndrome (ARDS), chronic                heart failure, chronic obstructive pulmonary                disease (COPD), septic shock, fibrotic diseases,                skin fibrosis, Idiopathic pulmonary fibrosis, renal                fibrosis, chronic kidney disease, systemic                hardening, multiple sclerosis, Sjogren's syndrome,                lupus, airway inflammation, psoriasis, hepatitis,                celiac disease, primary biliary cirrhosis,                autoimmune hemolytic anemia, autoimmune neonatal                thrombocytopenia, essential thrombocytopenic                purpura, non-alcoholic fatty liver disease or                COVID19 in an individual in need (all                claimed).    ADVANTAGE - The antibody specifically recognizes LIGHT and                binds to LIGHT polypeptide; has trimer structure of                LIGHT enabling it to aggregate cell surface                receptors interacting with it, thus activating                activation of the co-stimulatory signaling pathway,                and activating T cells or intrinsic immune                cell-mediated inflammatory reactions by binding to                an HEM or LT &#946; R receptor, and improved                biological activity, retention/improvement of                antigen binding capacity and reduced                immunogenicity, and effect of enhanced                antibody-dependent cell-mediated cytotoxicity                (ADCC) and complement-dependent cytotoxic effects                (CDC); binds to the target with a higher affinity,                affinity, easier and/or longer than other target                combinations; and specifically recognizes the                antigen reacts with at least one antigens of the                antigen, which binding affinity is at least 10                times its binding affinity to other targets.    DETAILED DESCRIPTION - Isolated anti-LIGHT antibody comprising                either: heavy chain variable domain (VH) includes                heavy chain complementarity determining region                (HC-CDR) 1, which includes Gly-Tyr-Phe-Ile-Asn (SEQ                ID NO: 1), HC-CDR2, which contains a fully defined                sequence of 17 amino acids (SEQ ID NO: 8 or SEQ ID                NO: 9) as given in the specification, and HC-CDR3,                which contains a fully defined sequence of 15 amino                acids (SEQ ID NO: 16) as given in the                specification, and a light chain variable domain                (VL) includes light chain complementarity                determining region (LC-CDR) 1, which includes a                fully defined sequence of 11 amino acids (SEQ ID                NO: 23) as given in the specification, LC-CDR2,                which contains Ser-Ala-Ser-Asn-Arg-Tyr-Thr (SEQ ID                NO: 30), and LC-CDR3, which contains                Gln-Gln-Tyr-Ser-Ser-Tyr-Pro-Tyr-Thr (SEQ ID NO:                37), or heavy chain variable domain (VH) having                HC-CDR1 containing Asp-His-Ile-Met-Asn (SEQ ID NO:                6), HC-CDR2 containing a fully defined sequence of                17 amino acids (SEQ ID NO: 14) as given in the                specification, and HC-CDR3 containing                Gly-Ser-Tyr-Tyr-Trp-Asn-Ala-Met-Asp-Tyr (SEQ ID NO:                21), and light chain variable domain (VL)                containing LC-CDR1 including a fully defined                sequence of 15 amino acids (SEQ ID NO: 29) as given                in the specification or a fully defined sequence of                15 amino acids (SEQ ID NO: 83) as given in the                specification, LC-CDR2 containing                Ser-Ala-Ser-Asn-Leu-Glu-Ser (SEQ ID NO: 35), and                LC-CDR3 containing                Gln-Gln-Ser-Ile-Glu-Asp-Pro-Trp-Thr (SEQ ID NO:                43); or VH including HC-CDR1 containing                Ser-Tyr-Asn-Val-His (SEQ ID NO: 7), HC-CDR2                containing a fully defined sequence of 17 amino                acids (SEQ ID NO: 15) as given in the specification                and HC-CDR3 containing a fully defined sequence of                12 amino acids (SEQ ID NO: 22) as given in the                specification, and a light chain variable domain                (VL) including LC-CDR1 containing a fully defined                sequence of 15 amino acids (SEQ ID NO: 29) as given                in the specification, LC-CDR2 containing                Thr-Ala-Ser-Asn-Leu-Glu-Ser (SEQ ID NO: 36), and                LC-CDR3 containing                Gln-Gln-Ser-Tyr-Glu-Asp-Pro-Phe-Thr (SEQ ID NO:                44), is new. INDEPENDENT CLAIMS are also included                for:    isolated nucleic acid molecule encoding the                anti-LIGHT antibody;    vector comprising nucleic acid molecule;    isolated host cell comprising anti-LIGHT                antibody, nucleic acid molecule or vector;    preparing anti-LIGHT antibodies;    medicine composition comprising anti-LIGHT                antibody, nucleic acid molecule, vector, isolated                host cell or antibody prepared by above method and                a carrier; and    method of treating a disease or condition in a                desired individual, comprising administering                antibody, nucleic acid molecule, vector, host cell                or medicine composition to the individual. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-C01C;  B04-C01G;  B04-E02A;  B04-E03A;  B04-E08;  B04-E99;  B04-F0100E;  B04-G01;  B14-C03;  B14-C09;  B14-E08;  B14-E10A;  B14-E10C;  B14-F01B;  B14-F03;  B14-F08;  B14-G02;  B14-K01;  B14-L01;  B14-N10;  B14-N12;  B14-N17;  B14-S01;  B14-S06;  B14-S21;  D05-H11;  D05-H12A;  D05-H12E;  D05-H99,A61K-039/395;  A61P-011/00;  A61P-037/00;  C07K-016/28;  C12N-015/13,WO2024067344-A1   04 Apr 2024   C07K-016/28   202436Pages: 186   Chinese,WO2024067344-A1    WOCN120362    21 Sep 2023,,CN11184544    27 Sep 2022;  CN10861858    13 Jul 2023,WO2024067344-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"WO2024067344-A1 -- US20040096835-A1   ;  US20050129614-A1   ;  WO2008027338-A2   KIRIN PHARMA KK (KIRI-Non-standard);  LA JOLLA INST ALLERGY & IMMUNOLOGY (LJOL-Non-standard)   GRANGER S W,  KATO S,  WARE C F","WO2024067344-A1  KEXING FAN:          ""Preparation and Characterization of a Monoclonal          Antibody Against the Protein LIGHT"", HYBRIDOMA, MARY ANN          LIEBERT, INC. PUBLISHERS, US, vol. 24, no. 6, 1 December          2005 (2005-12-01), US , pages 309 - 313, XP093153432,          ISSN: 1554-0014, DOI:          10.1089/hyb.2005.24.309,relevantClaims[1-25],relevantPassages[abstract];  MENG ZHANG; LAURENT          PERRIN; PATRICIA PARDO: ""A Randomized Phase 1 Study to          Assess the Safety and Pharmacokinetics of the          Subcutaneously Injected AntiLIGHT Antibody, SAR252067"",          CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT,          WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 6, no. 3, 28          September 2016 (2016-09-28), GB , pages 292 - 301,          XP072461739, ISSN: 2160-763X, DOI:          10.1002/cpdd.295,relevantClaims[1-25],relevantPassages[abstract];  TAMADA, K. ET AL.:          ""Modulation of T-Cell-Mediated Immunity in Tumor and          Graft-Versus-Host Disease Models through the LIGHT          Co-stimulatory Pathway."", NATURE MEDICINE, vol. 6, no. 3,          31 March 2000 (2000-03-31), XP002246831, DOI:          10.1038/73136,relevantClaims[1-25],relevantPassages[abstract,          page 288 left-hand column paragraph 5];  PERLIN, D.S. ET          AL.: ""Randomized, Double-Blind, Controlled Trial of Human          Anti-LIGHT Monoclonal Antibody in COVID-19 Acute          Respiratory Distress Syndrome."", THE JOURNAL OF CLINICAL          INVESTIGATION., vol. 132, no. 3, 1 February 2022          (2022-02-01), XP093114353, DOI:          10.1172/JCI153173,relevantClaims[1-25],relevantPassages[abstract,          and page 2, right-hand column, paragraph 1]",184587-0-0-0 M N; 184587-0-0-0 CL NEW USE,,,RA00C8 M N,
CN117756870-A,"New aromatic compound useful in medicinal            composition, and preparing medicine for treating e.g.            coronavirus 19, Middle East respiratory syndrome,            severe acute respiratory syndrome, human            immunodeficiency virus, hepatitis C virus, respiratory            syncytial virus, and influenza-related virus            infections",XU Y;  CHEN Z;  YU H;  ZHAO B;  ZHANG M,SHANGHAI ABBISKO THERAPEUTICS CO LTD (SHAN-Non-standard),2024322000,"   NOVELTY - Aromatic compound i.e. substituted                1-[(2R)-oxolan-2-yl]-1,2-dihydropyrimidin-2-one                compound (I), and its stereoisomers, tautomers, or                salts, are new.    USE - (I) is useful in medicinal composition, and                preparing medicine for treating coronavirus 19                (COVID19), Middle East respiratory syndrome (MERS),                severe acute respiratory syndrome (SARS), human                immunodeficiency virus (HIV), hepatitis C virus                (HCV), Equine encephalitis virus, Pestivirus,                Flavivirus, Ebola virus, Filoviridae virus,                respiratory syncytial virus and/or                influenza-related virus infections (all claimed),                and as antiviral inhibitor.    DETAILED DESCRIPTION - Aromatic compound i.e. substituted                1-[(2R)-oxolan-2-yl]-1,2-dihydropyrimidin-2-one                compound of formula (I), and its stereoisomers,                tautomers, or salts, are new.    R1= H, 1-10C alkyl, 3-12C cycloalkyl, 3-12                membered heterocyclyl, 6-10C aryl, 5-10 membered                heteroaryl, -C (O)OR12, -C(O)R13, or                -C(O)NR14R15(are optionally substituted with                deuterium, halo, cyano, nitro, azido, 1-10C alkyl,                halo-substituted 1-10C alkyl, deuterium-substituted                1-10C alkyl, 2-10C alkenyl, 2-10C alkynyl, 3-12C                cycloalkyl, 3-12 membered heterocyclyl, 6-10C aryl,                5-10 membered heteroaryl, =O, =S, -0-8C alkyl-SF5,                -0-8C alkyl-S(O)(=N-R8)R9, -0-8C-alkyl-N=S(O)R9R10,                -0-8C-alkyl-N=SR9R10, -0-8C-alkyl-O-S(O)2R11,                -0-8C-alkyl-S(O)rR11, -0-8C-alkyl-OR12, -0-8C                alkyl-C(O)OR12, -0-8C alkyl-C(O)SR12, -0-8C                alkyl-S-C(O)R13, -0-8C alkyl-C(O)R13, -0-8C                alkyl-O-C(O)R13, -0-8C-alkyl-P(O)(R13)2,                -0-8C-alkyl-NR14R15, -0-8C-alkyl-C(=NR14)R13,                -0-8C-alkyl-N(R14)-C(=NR15)R13, -0-8C                alkyl-C(O)NR14R15, or -0-8C                alkyl-N(R14)-C(O)R13);    R2= H, deuterium, halo, cyano, nitro, azido,                1-10C alkyl, halo-substituted 1-10C alkyl,                deuterium-substituted 1-10C alkyl, 2-10C alkenyl,                2-10C alkynyl, 3-12C cycloalkyl, 3-12 membered                heterocyclyl, 6-10C aryl, 5-10 membered heteroaryl,                -0-8C alkyl-SF5, -0-8C alkyl-S(O)(=N-R8)R9,                -0-8C-alkyl-N=S(O)R9R10, -0-8C-alkyl-N=SR9R10,                -0-8C-alkyl-O-S(O)2R11, -0-8C-alkyl-S(O)rR11,                -0-8C-alkyl-OR12, -0-8C alkyl-C(O)OR12, -0-8C                alkyl-C(O)SR12, -0-8C alkyl-S-C(O)R13, -0-8C                alkyl-C(O)R13, -0-8C alkyl-O-C(O)R13,                -0-8C-alkyl-P(O)(R13)2, -0-8C-alkyl-NR14R15,                -0-8C-alkyl-C(=NR14)R13,                -0-8C-alkyl-N(R14)-C(=NR15)R13, -0-8C                alkyl-C(O)NR14R15, or -0-8C                alkyl-N(R14)-C(O)R13;    R3and R6= H, deuterium, halo, cyano, 1-10C                alkyl, halo-substituted 1-10C alkyl,                deuterium-substituted 1-10C alkyl, 2-10C alkenyl,                2-10C alkynyl, 3-12C cycloalkyl, 3-12 membered                heterocyclyl, or -O-R12;    Either R4and R5= H, deuterium, halo, cyano,                azido, 1-10C alkyl, 2-10C alkenyl, 2-10C alkynyl,                3-12C cycloalkyl, 3-12 membered heterocyclyl,                -O-S(O)2R11, -S(O)rR11, -O-R12, -S-C(O)R13,                -O-C(O)R13, or -O-P(O)(R13)2 (are optionally                substituted with deuterium, halo, cyano, nitro,                azido, 1-10C alkyl, halo-substituted 1-10C alkyl,                deuterium-substituted 1-10C alkyl, 2-10C alkenyl,                2-10C alkynyl, 3-12C cycloalkyl, 3-12 membered                heterocyclyl, 6-10C aryl, 5-10 membered heteroaryl,                =O, =S, -0-8C alkyl-SF5, -0-8C alkyl-S(O)(=N-R8)R9,                -0-8C-alkyl-N=S(O)R9R10, -0-8C-alkyl-N=SR9R10,                -0-8C-alkyl-O-S(O)2R11, -0-8C-alkyl-S(O)rR11,                -0-8C-alkyl-OR12, -0-8C alkyl-C(O)OR12, -0-8C                alkyl-C(O)SR12, -0-8C alkyl-S-C(O)R13, -0-8C                alkyl-C(O)R13, -0-8C alkyl-O-C(O)R13,                -0-8C-alkyl-P(O)(R13)2, -0-8C-alkyl-NR14R15,                -0-8C-alkyl-C(=NR14)R13,                -0-8C-alkyl-N(R14)-C(=NR15)R13, -0-8C                alkyl-C(O)NR14R15, or -0-8C alkyl-N(R14)-C(O)R13);                or    R4and R5= directly connected together with                moiety to form                ((4R,5S)-1,3-dioxolan-2-one)-4,5-diyl; and    R7= vinyl (optionally substituted with                deuterium, halo, cyano, 1-10C alkyl,                halo-substituted 1-10C alkyl, deuterium-substituted                1-10C alkyl, 3-12C cycloalkyl, 3-12 membered                heterocyclyl, 6-10C aryl, 5-10 membered heteroaryl,                -C(O)OR12, -C(O)SR12, -C(O)R13, -NR14R15,                -C(O)NR14R15, or -N(R14)-C(O)R13), 3-8C cycloalkyl                (optionally substituted with deuterium, halo,                cyano, nitro, azido, 1-10C alkyl, halo-substituted                1-10C alkyl, deuterium-substituted 1-10C alkyl,                2-10C alkenyl, 2-10C alkynyl, 3-12C cycloalkyl,                3-12 membered heterocyclyl, 6-10C aryl, 5-10                membered heteroaryl, =O, =S, -0-8C alkyl-SF5, -0-8C                alkyl-S(O)(=N-R8)R9, -0-8C-alkyl-N=S(O)R9R10,                -0-8C-alkyl-N=SR9R10, -0-8C-alkyl-O-S(O)2R11,                -0-8C-alkyl-S(O)rR11, -0-8C-alkyl-OR12, -0-8C                alkyl-C(O)OR12, -0-8C alkyl-C(O)SR12, -0-8C                alkyl-S-C(O)R13, -0-8C alkyl-C(O)R13, -0-8C                alkyl-O-C(O)R13, -0-8C-alkyl-P(O)(R13)2,                -0-8C-alkyl-NR14R15, -0-8C-alkyl-C(=NR14)R13,                -0-8C-alkyl-N(R14)-C(=NR15)R13, -0-8C                alkyl-C(O)NR14R15, or -0-8C alkyl-N(R14)-C(O)R13),                -(CH2)n-C(O)OR7a, -O-R7b, or -NR7cR7d.    Provided that: When R7is -O-R7band -NR7cR7d,                R4and R5directly connected together with moiety to                form ((4R,5S)-1,3-dioxolan-2-one)-4,5-diyl.    Full definitions are given in the DEFINITIONS                (Full Definitions) Field.    An INDEPENDENT CLAIM is also included for                medicinal composition, comprising (I) and its                stereoisomers, tautomers, or salts, and                carrier.     ",,,C02 (Heterocyclic.);  B03 (Other heterocyclics.),C05-A04A;  C04-B03D;  C14-K01D;  C14-A02;  B04-B03D;  B05-A04A;  B14-K01D;  B14-A02,A61K-031/7068;  A61P-031/12;  A61P-031/14;  A61P-031/16;  A61P-031/20;  C07H-019/067,CN117756870-A   26 Mar 2024   C07H-019/067   202443   Chinese,CN117756870-A    CN11221304    20 Sep 2023,,CN11167392    23 Sep 2022,,,,, N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N,A00493E03 N; A00493E01 N,00956,RD989F N; RD989G N,
EP4336186-A1;  WO2024056667-A1,"Detecting and/or predicting severity and/or            chronicity of systemic pulmonary disease involves            determining expression of markers such as macrophage            marker, matricellular fibrosis marker thrombospondin-2,            and/or inflammation/repair marker growth            differentiation factor in sample obtained from            patient",BOCKAMP-VILLAMIL E;  SURABATTULA R;  SCHUPPAN D;  JONIGK D;  ACKERMANN M,UNIV MAINZ GUTENBURG JOHANNES (UMGJ-C);  UNIV MAINZ GUTENBURG JOHANNES (UMGJ-C),202426292W,"   NOVELTY - Method for detecting and/or predicting                severity and/or chronicity of systemic pulmonary                disease (SPD) in a patient involves determining the                expression of markers such as macrophage marker                CD163, matricellular fibrosis marker                thrombospondin-2 (Tsp2), and/or (cardiovascular)                inflammation/repair marker growth differentiation                factor 15 (GDF-15) in a sample obtained from the                patient, where the expression of markers detects                and/or predicts the severity and/or chronicity of                SPD increases in the patient, when compared to                healthy control and/or mild to moderate SPD                control.    USE - Method for detecting and/or predicting                severity and/or chronicity of SPD such as influenza                infection, pulmonary fibrosis, idiopathic pulmonary                fibrosis, interstitial lung disease (ILD), acute                respiratory distress syndrome (ARDS), influenza A                virus infection, and coronavirus infection e.g.                coronavirus disease (COVID19) and long COVID19 in                patient (all claimed).    ADVANTAGE - The method enables prediction of severity                and/or chronicity of SPD with improved sensitivity                from 68% to 77% using reliable and non-invasive                biomarker.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:    1. a method for diagnosing the severity and/or                chronicity of SPD in a patient;    2. a method for monitoring the severity and/or                chronicity of SPD in a patient;    3. a method for predicting the efficacy of                treatment of SPD in a patient;    4. a method for identifying a compound for                preventing or treating SPD in a subject, which                involves administering candidate compounds to the                subject, and determining the expression of markers                in a sample obtained from the subject in presence                of candidate compound and comparing with the                expression of markers in a sample obtained from the                subject in absence of candidate compound and/or in                a control sample, where decrease of the expression                of markers identifies a compound for preventing or                treating SPD in the subject, where preferably the                expression of all three markers is determined, and                the expression of the marker insulin-like growth                factor binding protein 7 (IGFBP7) is                determined;    5. pharmaceutical composition, which comprises                compound for preventing or treating SPD as                identified together with carrier or diluent;                and    6. kit, preferably diagnostic or therapeutic                kit, which comprises materials for detecting and/or                predicting the severity and/or chronicity of SPD in                a patient. ",,,"D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  S03 (Scientific Instrumentation)",D05-H09;  B14-A04;  B14-A02;  B14-A01;  B12-K04G1A;  B14-K01;  B11-C08E;  B04-H06H;  B12-K04E3;  B12-K04G2G;  B04-H06L;  B04-N16;  B04-H20;  B04-K01R;  S03-E09F;  S03-E14H5,G01N-033/569;  G01N-033/68,EP4336186-A1   13 Mar 2024   G01N-033/68   202423   English;  WO2024056667-A1   21 Mar 2024   G01N-033/68   202426   English,EP4336186-A1    EP195149    12 Sep 2022;   WO2024056667-A1    WOEP075031    12 Sep 2023,,EP195149    12 Sep 2022,EP4336186-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN  WO2024056667-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CV;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  MG;  MK;  MN;  MU;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  CV;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SC;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,"EP4336186-A1 -- WO2019094777-A1   GILEAD SCI INC (GILE)   BILLIN A N,  CHUANG J,  XU R Y;  WO2019099706-A1   BETH ISRAEL DEACONESS MEDICAL CENT (BEIS);  UNIV NEBRASKA (UNEB)   LIBERMANN T A,  LAI M,  AFDHAL N H,  OTU H H,  DILLON S T;  WO2022017980-A1   HOFFMANN LA ROCHE & CO AG F (HOFF);  ROCHE DIAGNOSTICS GMBH (HOFF)   OMLAND T,  WIENHUES-THELEN U,  ZIEGLER A;  WO2022103971-A1   WISTAR INST ANATOMY & BIOLOGY (WITA)   ABDEL-MOHSEN M;  WO2022104212-A1   AMGEN INC (AMGE)   STEFANSSON K,  GUDBJARTSSON D,  ULFARSSON M,  EIRIKSDOTTIR T;  WO2022114984-A1   QATAR FOUND EDUCATION SCI &                  COMMUNITY (QATA-Non-standard);  HAMAD MEDICAL CORP (HAMA-Non-standard)   AL-EJEH F H,  MOHAMED-ALI V,  AL-NESF M A Y;  WO2012122228-A2   UNIV TEMPLE (UTEM)   MERALI S,  KELSEN S G,  BARRERO C A;  WO2024056667-A1 -- WO2019094777-A1   GILEAD SCI INC (GILE)   BILLIN A N,  CHUANG J,  XU R Y;  WO2019099706-A1   BETH ISRAEL DEACONESS MEDICAL CENT (BEIS);  UNIV NEBRASKA (UNEB)   LIBERMANN T A,  LAI M,  AFDHAL N H,  OTU H H,  DILLON S T;  WO2022017980-A1   HOFFMANN LA ROCHE & CO AG F (HOFF);  ROCHE DIAGNOSTICS GMBH (HOFF)   OMLAND T,  WIENHUES-THELEN U,  ZIEGLER A;  WO2022103971-A1   WISTAR INST ANATOMY & BIOLOGY (WITA)   ABDEL-MOHSEN M;  WO2022104212-A1   AMGEN INC (AMGE)   STEFANSSON K,  GUDBJARTSSON D,  ULFARSSON M,  EIRIKSDOTTIR T;  WO2022114984-A1   QATAR FOUND EDUCATION SCI &                  COMMUNITY (QATA-Non-standard);  HAMAD MEDICAL CORP (HAMA-Non-standard)   AL-EJEH F H,  MOHAMED-ALI V,  AL-NESF M A Y;  WO2012122228-A2   UNIV TEMPLE (UTEM)   MERALI S,  KELSEN S G,  BARRERO C A","EP4336186-A1  JONIGK DANNY ET AL:          ""Organ manifestations of COVID-19: what have we learned          so far (not only) from autopsies?"", VIRCHOWS ARCHIV,          SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 481,          no. 2, 1 April 2022 (2022-04-01), pages 139 - 159,          XP037920443, ISSN: 0945-6317, [retrieved on 20220401],          DOI:          10.1007/S00428-022-03319-2,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            MANDAL S ET AL.: ""ARC Study Group. 'Long-COVID': a          cross-sectional study of persisting symptoms, biomarker          and imaging abnormalities following hospitalisation for          COVID-19"", THORAX, vol. 76, no. 4, 10 November 2020          (2020-11-10), pages 396 - 398;            AVOUAC JCAUVET ASTEELANDT ASHIRAI YELHAI MKUWANA M ET          AL.: ""Improving risk-stratification of rheumatoid          arthritis patients for interstitial lung disease"", PLOS          ONE, vol. 15, no. 5, 2020, pages e0232978, Retrieved from          the Internet          &lt;URL:https://doi.org/10.1371/journal.pone.0232978&gt;;            AHMED DS ET AL.: ""Coping With Stress: The Mitokine GDF-15          as a Biomarker of COVID-19 Severity"", FRONT IMMUNOL, vol.          13, 16 February 2022 (2022-02-16), pages 820350,          Retrieved from the Internet          &lt;URL:https://doi.org/10.3389/fimmu.2022.820350&gt;;            MYHRE PL ET AL.: ""Growth Differentiation Factor 15          Provides Prognostic Information Superior to Established          Cardiovascular and Inflammatory Biomarkers in Unselected          Patients Hospitalized With COVID-19"", CIRCULATION, vol.          142, no. 22, December 2020 (2020-12-01), pages 2128 -          2137;            GOMEZ-RIAL J ET AL.: ""Increased Serum Levels of sCD14 and          sCD163 Indicate a Preponderant Role for Monocytes in          COVID-19 Immunopathology"", FRONT IMMUNOL, vol. 11, 23          September 2020 (2020-09-23), pages 560381;            ""UniProt"", Database accession no. Q16270;            ""Remington's Pharmaceutical Sciences"", 1991, MACK          PUBLISHING CO.;            BAUER ET AL.: ""Pharmazeutische Technologic"", 1997,          GOVI-VERLAGWO2024056667-A1  JONIGK DANNY ET AL:          ""Organ manifestations of COVID-19: what have we learned          so far (not only) from autopsies?"", VIRCHOWS ARCHIV,          SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 481,          no. 2, 1 April 2022 (2022-04-01), pages 139 - 159,          XP037920443, ISSN: 0945-6317, [retrieved on 20220401],          DOI:          10.1007/S00428-022-03319-2,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            MANDAL S ET AL.: ""ARC Study Group. 'Long-COVID': a          cross-sectional study of persisting symptoms, biomarker          and imaging abnormalities following hospitalisation for          COVID-19"", THORAX, vol. 76, no. 4, April 2021          (2021-04-01), pages 396 - 398;            AVOUAC JCAUVET ASTEELANDT ASHIRAI YELHAI MKUWANA M ET          AL.: ""Improving risk-stratification of rheumatoid          arthritis patients for interstitial lung disease"", PLOS          ONE, vol. 15, no. 5, 2020, pages e0232978, Retrieved from          the Internet          &lt;URL:https://doi.org/10.1371/joumal.pone.0232978&gt;;            AHMED DS ET AL.: ""Coping With Stress: The Mitokine GDF-15          as a Biomarker of COVID-19 Severity."", FRONT IMMUNOL.,          vol. 13, 16 February 2022 (2022-02-16), pages 820350,          Retrieved from the Internet          &lt;URL:https://doi.org/10.3389/fimmu.2022.820350&gt;;            MYHRE PL ET AL.: ""Growth Differentiation Factor 15          Provides Prognostic Information Superior to Established          Cardiovascular and Inflammatory Biomarkers in Unselected          Patients Hospitalized With COVID-19."", CIRCULATION, vol.          142, no. 22, December 2020 (2020-12-01), pages 2128 -          2137;            GOMEZ-RIAL J ET AL.: ""Increased Serum Levels of sCD14 and          sCD163 Indicate a Preponderant Role for Monocytes in          COVID-19 Immunopathology"", FRONT IMMUNOL., vol. 11, 23          September 2020 (2020-09-23), pages 560381;            ""UniProt"", Database accession no. Q16270;            ""Remington's Pharmaceutical Sciences"", 1991, MACK          PUBLISHING CO.;            BAUER ET AL.: ""Pharmazeutische Technologic"", 1997,          GOVI-VERLAG",1530746-1-0-0 A K; 330582-0-0-0 A K; 1530746-1-0-0 CL DET,,,RARI2Y A K; RA2OY4 A K,
IN202341086452-A,"Hierarchical attention network classifier based            method for separating lung areas of patient using BFC            model using medical imaging system for diagnosis of            lung infections, involves utilizing segmented results            to acquire features",MAGNETA C S,SRI ESHWAR COLLEGE ENG (SRIE-Non-standard),202408219T,"   NOVELTY - The method involves separating relevant lung                areas using a BFC model. Pre-processing phase                eliminates image external entities and image noise.                The segmented results are utilized to acquire the                features, which are obtained based on texton                features. Detecting performance is significantly                improved by segmenting the image. Once the features                have been retrieved from the segmented result.                COVID19 detection procedure is carried out using                HAN, which has been optimized using a designed                multi-objective multi-verse optimization (MRMVO)                algorithm. The efficacy of the best solution is                increased using a hybrid optimization                approach.    USE - Hierarchical attention network classifier                based method for separating lung areas of a patient                using a BFC model using a medical imaging system                i.e. chest X-ray system, for diagnosis of lung                infections.    ADVANTAGE - The automated analysis of diseases utilizing a                medical imaging system result in accurate therapy,                which aids in the management of the epidemic in the                community. A thresholding approach that efficiently                decreases processing time is applied to extract                important pixels. The pre-processing procedure is                constructed on Region of Interestremoval using                onset value, which improves the visual look to                remove unwanted and unnecessary noise. The region                of interest specifies the area of the picture that                may be relied on for the processing of the                image.    DESCRIPTION OF DRAWING(S) - The drawing shows a photograph view of a                medical imaging system. ",,,S05 (Electrical Medical Equipment);  T01 (Digital Computers),S05-G02G9;  S05-D08A;  S05-D02X;  T01-J10B1;  T01-J10B2;  T01-J16C1;  T01-J16C2;  T01-N01A2D;  T01-N01E,G06N-020/00;  G06N-003/0464;  G06N-003/08;  G06T-007/10;  G06V-010/44,IN202341086452-A   12 Jan 2024   G06N-020/00   202411   English,IN202341086452-A    IN41086452    18 Dec 2023,,IN41086452    18 Dec 2023,,,,,,,,,
IN202241032656-A,"Identifying people's sentiment involves using            TextBlob package in natural language processing, word            cloud, and collecting data through API's, where twitter            data collection is done by tweepy library, and cleaning            of data is done by regular expression from python            libraries",PATHAK D;  KRISHNA C A R;  SINGH A K;  AZAM F;  VASHISTH D,UNIV REVA (UYRE-Non-standard);  PATHAK D (PATH-Individual);  KRISHNA C A R (KRIS-Individual);  SINGH A K (SING-Individual);  AZAM F (AZAM-Individual);  VASHISTH D (VASH-Individual),202415758A,"   NOVELTY - Identifying people's sentiment involves using                TextBlob package in natural language processing                (NLP), word cloud, and collecting data through                API's, where twitter data collection is done by                tweepy library, and cleaning of the data is done by                regular expression from python libraries.    USE - Method for identifying people's                sentiment.    ADVANTAGE - The method help us to calculate the sentence's                polarity and textblob gives us polarity and                subjectivity, and get updated information about                covid19 using an Interactive Dashboard. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  P85 (Education, cryptography, adverts. (G09).);  S05 (Electrical Medical Equipment);  T01 (Digital Computers)",B12-K04;  B11-C11;  P85-A01;  S05-G02G9;  T01-J06A1;  T01-J16C3,A61K-039/00;  A61K-039/112;  A61K-039/12;  G09B-019/00;  G16H-050/80,IN202241032656-A   15 Dec 2023   A61K-039/00   202414   English,IN202241032656-A    IN41032656    08 Jun 2022,,IN41032656    08 Jun 2022,,,,,,,,,
CN117110595-A,"New molecular marker used for prognostic            diagnosis, disease classification, disease monitoring            and/or treatment monitoring of patients infected with            new coronavirus comprising hyaluronic acid",FU Y;  MAN Q;  GUO W;  YANG D;  SONG Y;  FENG Y,UNIV FUDAN ZHONGSHAN HOSPITAL (UYFU-C),2023C7163V,"   NOVELTY - Molecular marker used for prognostic                diagnosis, disease classification, disease                monitoring and/or treatment monitoring of patients                infected with new coronavirus comprising hyaluronic                acid, is new.    USE - The molecular marker is used for prognostic                diagnosis, disease classification, disease                monitoring and/or treatment monitoring of patients                infected with new coronavirus.    ADVANTAGE - The molecular marker finds for the first time                that hyaluronic acid levels have important clinical                value in predicting the prognosis of COVID19, and                provides the application of hyaluronic acid in                early warning and prognosis judgment of the                severity of COVID19 patients, where hyaluronic acid                is used as a biomarker for early identification of                high-risk patients with new coronavirus infection,                provides a basis for providing personalized                treatment plans and has clinical significance for                improving the prognosis of COVID19 patients and                hyaluronic acid is routinely used as a detection                indicator for liver cirrhosis in clinical practice,                detection method is mature, fast, simple and                convenient and has clinical application value and                good application prospects as a biomarker for                predicting the prognosis of COVID19 patients.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:    use of reagents for detecting hyaluronic acid                levels in biological samples in preparation of                products for prognostic diagnosis, disease                classification, disease monitoring and/or treatment                monitoring of patients infected with new                coronavirus, where the biological sample is a blood                sample; and    a kit for prognostic diagnosis, condition                grading, condition monitoring and/or treatment                monitoring of patients infected with new                coronavirus comprising hyaluronic acid binding                protein HABP, HABP antibody, avidin-labeled HRP,                pH9.6 carbonate buffer, pH7.4 phosphate buffer,                hyaluronic acid standard, serum protein diluent,                tetramethylbenzidine substrate solution and stop                solution which is 2M sulfuric acid solution. ",,,"J04 (Chemical/physical processes/apparatus - including catalysis, catalysts (excluding specific e.g. enzymatic or polymerisation catalysts), colloid chemistry, laboratory apparatus and methods, testing, controlling, general encapsulation, detection and sampling (excluding clinical testing) (B01J, L).);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  S03 (Scientific Instrumentation)",J04-B01;  J04-B03;  D05-H06A;  B11-C08D2;  B11-C07A5;  B11-C07A4;  B04-G01;  B04-B04D2;  B04-B04D5;  B04-C02E4;  B04-F11B2;  B12-K04G1B;  S03-E04D;  S03-E09C;  S03-E09F,G01N-021/64;  G01N-030/02;  G01N-033/53,CN117110595-A   24 Nov 2023   G01N-033/53   202404   Chinese,CN117110595-A    CN10961127    01 Aug 2023,,CN10961127    01 Aug 2023,,,,,97115-1-0-0 A K,,,R03231 A K,
EP4280132-A1;  US2023376877-A1;  IN202221028446-A,"Processor based method for business continuity            plan and safe return to workplace, involves identifying            updated value of corresponding key performance            indicator (KPI), where KPIs ARE indicative of infection            of employees and dependents predicted at aggregation            levels of offices of organization",BARAT S;  KULKARNI V;  BHIDE A M;  THOMAS P;  MULPURU D;  SAMUDRALA S;  YADAV A;  BASU A;  KRISHNA K K,TATA CONSULTANCY SERVICES LTD (TTTA-C);  TATA CONSULTANCY SERVICES LTD (TTTA-C);  TATA CONSULTANCY SERVICES LTD (TTTA-C),2023C0966T,"   NOVELTY - The method involves receiving (202) an input                data comprising epidemiological data of a                population in locations through hardware                processors. An instance of a stock and flow model                are modeled (204) for each of the locations based                on a set of employees and offices of an                organization associated with locations to obtain                instances of location specific stock and flow                models through processors. An employee-based                digital twin is created based on epidemiological                data, a demographic and health profile related                features for the employees of the organization and                the associated dependents through processors. An                updated value of a corresponding KPI comprised in                the first and second sets of KPIs is identified                based on a simulation of the employee-based digital                twin and the office-based digital twin respectively                through processors. The value of a corresponding                KPI comprised in the KPIs is indicative of                infection of employees and dependents predicted at                aggregation levels of offices of                organization.    USE - Processor based method for business continuity                plan and safe return to workplace by computing                system such as laptop computer, notebook, hand-held                device such as smartphone, tablet phone, mobile                communication device.    ADVANTAGE - The precise understanding about such                disruptions with tentative time frame helps to                refine business continuity plan (BCP) and ensure                delivery excellence. The questions that require                precise and critical evaluation when is the                appropriate time to allow their employees to work                from office. The information is generalized and                mapped to a set of archetypes of projects, cities                and offices for small projects, cities and offices,                and information helps to maintain anonymity without                compromising the analysis precision. The method                improves employee safety and customer satisfaction.                The method improves operational efficiency and                resilience as many alternatives are evaluated and                consequences are shared in advance, operational                cost for two reasons are cost effective test                environment, and validated course of action has                less chance for failure and business loss while                dealing with Covid19 related uncertainties, and                agility in change management.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    a system for business continuity plan and safe                return to workplace; and    a non-transitory machine-readable information                storage medium storing a program for business                continuity plan and safe return to workplace.    DESCRIPTION OF DRAWING(S) - The drawing shows a flow diagram illustrating                the method for business continuity plan and safe                return to workplace.    202Step for receiving the input data    204Step for modeling the instance of a stock                and flow model    206Step for calculating the location specific                susceptible to exposure rates    208Step for applying the statistical decay                function ",,,S05 (Electrical Medical Equipment);  T01 (Digital Computers);  W01 (Telephone and Data Transmission Systems),S05-G02G9;  T01-J03;  T01-J05A1;  T01-J05A2B;  T01-J05A2C;  T01-J06A1;  T01-M06A1;  T01-N01A1;  T01-N01A2E;  T01-S03;  W01-C01D3C;  W01-C01G8S,G06Q-010/0631;  G06Q-010/0635;  G16H-050/80;  G06Q-010/0639;  G06F-017/18;  G06N-005/02;  G06N-007/00;  G06Q-010/06;  G06Q-050/22,EP4280132-A1   22 Nov 2023   G06Q-010/0631   202396Pages: 43   English;  US2023376877-A1   23 Nov 2023   G06Q-010/0639   202396   English;  IN202221028446-A   24 Nov 2023   G06Q-010/06   202304   English,EP4280132-A1    EP163787    23 Mar 2023;   US2023376877-A1    US125774    24 Mar 2023;   IN202221028446-A    IN21028446    18 May 2022,,IN21028446    18 May 2022,EP4280132-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  KH;  MA;  MD;  TN      ,,EP4280132-A1 -- US20210005324-A1   ,"EP4280132-A1  BARAT SOUVIK ET AL:          ""An Agent-Based Digital Twin for Exploring Localized          Non-pharmaceutical Interventions to Control COVID-19          Pandemic"", TRANSACTIONS OF THE INDIAN NATIONAL ACADEMY OF          ENGINEERING, vol. 6, no. 2, 29 January 2021 (2021-01-29),          pages 323 - 353, XP093088501, ISSN: 2662-5415, Retrieved          from the Internet          &lt;URL:https://link.springer.com/article/10.1007/s41403-020-00197-5/fulltext.html&gt;          DOI:          10.1007/s41403-020-00197-5,relevantClaims[1-15],relevantPassages[&lt;pp&gt;326&lt;/pp&gt;&lt;ppl&gt;336&lt;/ppl&gt;&lt;figure&gt;1-5,13&lt;/figure&gt;&lt;table&gt;1-3&lt;/table&gt;];  PAN BOXU ET AL:          ""Research of Epidemic Dynamics Model Considering          Individual Movements and Urban Areas"", 2021 7TH IEEE          INTERNATIONAL CONFERENCE ON NETWORK INTELLIGENCE AND          DIGITAL CONTENT (IC-NIDC), IEEE, 17 November 2021          (2021-11-17), pages 143 - 147, XP033996101, DOI:          10.1109/IC-NIDC54101.2021.9660546,relevantClaims[1-15],relevantPassages[chapters          3.1 to 3.3];  BARAT SOUVIK ET AL:          ""A Digital Twin Based Approach For Ensuring Business          Continuity Plan And Safe Return To Workplace"", 2022          ANNUAL MODELING AND SIMULATION CONFERENCE (ANNSIM), SCS,          18 July 2022 (2022-07-18), pages 126 - 139, XP034174729,          DOI:          10.23919/ANNSIM55834.2022.9859321,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  RADULESCU ANCA ET          AL: ""Management strategies in a SEIR-type model of COVID          19 community spread"", SCIENTIFIC REPORTS, vol. 10, no. 1,          1 January 2020 (2020-01-01), pages 1 - 16, XP093088483,          Retrieved from the Internet          &lt;URL:https://www.nature.com/articles/s41598-020-77628-4.pdf&gt;          DOI:          10.1038/s41598-020-77628-4,relevantClaims[1-15],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;chapters          3.1 and 3.2]",,,,,
CN117036162-A;  CN117036162-B,"Method for realizing residual characteristic            attention fusion of super-resolution of lightweight            chest computed tomography image, involves comparing            prediction results with corresponding real labels,            calculating loss value by using loss function, and            obtaining super-resolution neural network model",LI M;  ZHANG X;  ZHAO L;  LIU S;  XUE L;  LIU K;  XU T;  YANG K,UNIV HEBEI (UYHB-C),2023C0562B,"   NOVELTY - The method involves collecting COVID19 chest                positron emission computed tomography-computed                tomography (PET-CT) image sample of an examinee                (S1). A rest slice image is provided (S2) with a                verification set and a test set. A sample with                deletion is eliminated. A sample data set is                pre-processed (S3). A neural network model is                constructed and trained (S4). An image with high                resolution is obtained. A training batch is set. A                neural network model parameter is obtained. A                sample image is input after image pre-processing in                a training set into the neural network model.                Prediction results are processed and output by                using the neural network model. Prediction results                are compared with the corresponding real labels. A                loss value is calculated by using loss function. A                super-resolution neural network model is                obtained.    USE - Method for realizing residual characteristic                attention fusion of super-resolution of lightweight                chest computed tomography (CT) image.    ADVANTAGE - The method enables utilizing and stacking a                characteristic weighting cascade group formed by                multiple characteristic weighting cascade groups in                a chain structure and gradually fusing                characteristic of each layer by a global layering                characteristic fusion strategy. The method enables                effectively fusing feature information from the                adjacent layers with different receptive fields to                obtain representative feature, generating space                attention weight by using relationship between the                space features of the global level and enhancing                feature extraction process.    DESCRIPTION OF DRAWING(S) - The drawing shows a flow chart illustrating a                method for realizing residual characteristic                attention fusion of super-resolution of lightweight                chest CT image. (Drawing includes non-English                language text).    S1Collecting COVID19 chest PET-CT image                sample of examinee    S2Providing rest slice image with                verification set and test set    S3Pre-processing sample data set    S4Constructing and training neural network                model ",,,S03 (Scientific Instrumentation);  T01 (Digital Computers),S03-E06B3A;  T01-J04A;  T01-J10B2;  T01-J10B3A;  T01-J10C4B;  T01-J10C5;  T01-J10D;  T01-J16C1,G06N-003/0464;  G06N-003/048;  G06N-003/084;  G06T-011/00;  G06T-003/40;  G06T-003/4007;  G06T-003/4046;  G06T-003/4053,CN117036162-A   10 Nov 2023   G06T-003/40   202396   Chinese;  CN117036162-B   09 Feb 2024   G06T-003/4053   202417   Chinese,CN117036162-A    CN10721302    19 Jun 2023;   CN117036162-B    CN10721302    19 Jun 2023,CN117036162-B Previous Publ. Patent CN117036162,CN10721302    19 Jun 2023,,,";  CN117036162-B -- CN111192200-A   UNIV NANJING POST & TELECOM (UNPT)   CHEN J,  ZHANG Y;  CN113222818-A   UNIV ZHEJIANG NORMAL (UYZN)   ZHENG Z,  ZHANG D,  LIU Z;  CN114266957-A   UNIV BEIJING TECHNOLOGY (UYBT)   ZHANG L,  CHE Q,  WANG S;  CN115272078-A   UNIV XIAN JIAOTONG (UYXJ)   WANG W,  MU T;  CN115496658-A   UNIV GUILIN TECHNOLOGY (UYGI)   ZHOU Z,  HAO X,  LIU X,  LU P,  XIE F;  CN115841420-A   UNIV TIANJIN (UTIJ)   DI J,  LI X,  YANG S,  HU H;  CN116091313-A   UNIV WUXI (UYWU-Non-standard)   LI F,  XU H,  QIU C;  US20200074271-A1   ;  US20200380695-A1   ;  WO2020028382-A1   SLOAN KETTERING CANCER RES INST (SLOK)   DEASY J O,  VEERARAGHAVAN H,  HU Y,  MAGERAS G,  JIANG J;  WO2022241995-A1   GUANGDONG OPT MACHINE VISION CO LTD (GOPT)   JIN L,  LU S","CN117036162-B            Song Tingqiang; Li Jixu; Zhang Xinye;. High-resolution          remote sensing image building identification based on          deep learning; Song Tingqiang; Li Jixu; Zhang Xinye;          Computer Engineering and Application (08);;  Xu          Ningning; Zheng Kai; The image super-resolution method          based on multi-loss fusion and spectrum normalization,          computer application research. (08), full text.;            Wei Xin; Zheng, Yu-fu; based on the image          super-resolution reconstruction of the total-fractional          dense connection network. Lanzhou Jiaotong University          Journal. 2019, (06), full text.;            Lei Pengcheng; Liu Pang; Tang Kang; Mr Pang Dun-lu;          layered feature fusion attention network image          super-resolution reconstruction, Chinese image graphic          report. 2020, (09), full text.;            Xiong Yarhui; Chen Dongfang; Wang Xiaofeng; Image          super-resolution reconstruction algorithm based on          multi-scale reverse projection. computer engineering.          2020, (07), full text.;  Li          Cheng; Zhang Yu; Huang, Jonghua; (04), Full          text.",,,,,
KR2023148714-A,Immunogenic composition useful in vaccine            production for the treatment of coronavirus or            influenza virus infections comprises polynucleotide            containing a 5' cap structures,SHIN J H;  KIM M;  HUN K;  LEE J;  LEE J E;  CHOI Y,SK BIOSCIENCE CO LTD (SKSK-C),2023B6616L,"   NOVELTY - Immunogenic composition comprises                polynucleotide containing a 5' cap structures                (I)-(IV).    USE - The immunogenic composition is useful in                vaccine production for the treatment of coronavirus                or influenza virus infections.    ADVANTAGE - The mRNA containing the specific 5' cap                structure has high in vitro transcription                efficiency and the composition containing it has                excellent immunogenicity, so it can be usefully                used in vaccine production.    DETAILED DESCRIPTION - Immunogenic composition comprises                polynucleotide containing a 5' cap structures of                formula (I)-(IV).    G1=rest of RNA.    INDEPENDENT CLAIMS are also included                for:    composition comprising immunogenic composition                that induces immunity against coronavirus or                influenza virus; and    method for preparing immunogenic composition                specific substituted 1H-purin-7-ium compounds of                formula (V) to (VIII) and a DNA template.                 ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-B01B;  B04-E01A;  B04-E02F;  B04-E03F;  B04-E99;  B12-M11Q1;  B14-A02B2;  B14-A02B5;  B14-G01;  B14-K01D;  B14-L01;  B14-L06;  B14-S11A;  D05-H07;  D05-H99,A61K-039/00;  A61K-039/145;  A61K-039/215;  A61P-031/14;  A61P-031/16;  C12N-015/11,KR2023148714-A   25 Oct 2023   A61K-039/215   202392Pages: 46   ,KR2023148714-A    KR077781    24 Jun 2022,,KR047750    18 Apr 2022,,,,,,,,,
JP2023120510-A,"Sound permeability improving structure for use in            counter of hospital, has resonance mechanism that            improves sound transmission performance formed on both            sides of partition element by installing perforated            plate through air layer on both sides of partition            element having insulation performance",SUGIE S;  SUZUKI H;  NITTA R,KOBAYASI INST PHYSICAL RES (KOBA-Non-standard),202391770N,"   NOVELTY - The Sound permeability improving structure has                a resonance mechanism that improves a sound                transmission performance is formed on both sides of                a plate-like transparent partition element (1) by                installing a perforated plate (2) through an air                layer (3) on both sides of the partition element                having sound insulation performance, where the                partition element is a splash prevention partition.                The perforated plates on both sides include                permanent magnets (5) that are fixed to each other                with the partition element interposed by an                attraction force of the magnets.    USE - Sound permeability improving structure for use                in counter of hospital, bank, and cashier of store,                etc., for preventing spread of infectious disease                such as COVID19.    ADVANTAGE - The permeability of sound applied to the                partition plate is improved. The degree of                dependence of resonance frequency on partition                plate is reduced. The position of the perforated                plate is adjusted easily according to the physique                of the user.    DESCRIPTION OF DRAWING(S) - The drawing shows an isometric view of the                productized partition for splash prevention.    1Plate-like transparent partition                element    2Perforated plate    3Air layer    4Support block    5Permanent magnet ",,,"P27 (Shop, household, furnishings (A47F, G, H).);  Q43 (General building constructions (E04B));  T05 (Counting, Checking, Vending, ATM and POS Systems)",P27-A02;  Q43-A01;  Q43-A99;  T05-B;  T05-L07,A47F-009/00;  E04B-002/74,JP2023120510-A   30 Aug 2023   A47F-009/00   202374Pages: 9   Japanese,JP2023120510-A    JP023428    18 Feb 2022,,JP023428    18 Feb 2022,,,,,,,,,
RU2802347-C1,METHOD OF SURGICAL TREATMENT OF RECTAL            FISTULAS,MRYKHIN G A;  GROSHILIN V S;  KUZNETSOV V D;  VARDANIAN E V;  DUBINSKII O A,FEDERAL STATE BUDGETARY EDUCATIONAL (BUDG-Non-standard),202399493R,"   NOVELTY - Through each external opening of all fistulous                tracts, a visiport Plus RPF device manufactured by                Covidien, USA is inserted, and the lumen of each                fistulous tract is cut in the longitudinal                direction under visual control. Then the ligature                is passed through the external opening of the main                fistula tract into its lumen until the ligature                exits the internal opening of the fistula. After                that, the ligature is tightened with the capture of                a portion of the anal sphincter.    USE - Medicine; surgery; coloproctology.    ADVANTAGE - Method allows to increase the efficiency of                surgical treatment, to exclude anal incontinence                and recurrence of the disease. 1 cl, 2 ex ",,,"P31 (Diagnosis, surgery (A61B).)",P31-A01;  P31-A05,A61B-001/002;  A61B-017/12,RU2802347-C1   25 Aug 2023   A61B-017/12   202379Pages: 0   Russian,RU2802347-C1    RU131335    30 Nov 2022,,RU131335    30 Nov 2022,,,,,,,,,
RU2800805-C1,METHOD OF SURGICAL TREATMENT OF RECTAL            FISTULAS,DZIUBENKO A S,DZIUBENKO A S (DZIU-Individual),202399404M,"   NOVELTY - Through each external opening of all fistulous                tracts, a visiport Plus RPF device manufactured by                Covidien, USA is inserted, and the lumen of each                fistulous tract is cut in the longitudinal                direction under visual control. Then the ligature                is passed through the external opening of the main                fistula tract into its lumen until the ligature                exits the internal opening of the fistula. After                that, the ligature is tightened with the capture of                a portion of the anal sphincter.    USE - Medicine; surgery; coloproctology.    ADVANTAGE - Method allows to increase the efficiency of                surgical treatment, to exclude anal incontinence                and recurrence of the disease. 1 cl, 2 ex ",,,"P31 (Diagnosis, surgery (A61B).)",P31-A01;  P31-A05,B65B-007/02;  B65D-035/38;  B65D-041/32;  B65D-075/58,RU2800805-C1   28 Jul 2023   B65D-075/58   202379Pages: 0   Russian,RU2800805-C1    RU103014    09 Feb 2023,,RU103014    09 Feb 2023,,,,,,,,,
KR2023084936-A;  KR2557885-B1,"New composition comprising primer and probe set            designed using a standard vector unclosing RdRp gene, E            gene and internal control gene, useful in diagnostic            kit for simultaneously detecting Corona 19 virus and            SARS virus",AHN W S;  BYUN B;  JEONG H;  LEE S H,ONES CO LTD (ONES-Non-standard),202360230V,"   NOVELTY - Composition comprising primer and probe set                designed using a standard vector unclosing RdRp                gene (ORF1ab) having (SEQ ID NOS: 1-3) (Not                defined), E gene (E) having (SEQ ID NOS: 4-6) (Not                defined), and internal control gene (RNase P)                having (SEQ ID NOS: 7-9) (Not defined), is                new.    USE - The composition is useful in diagnostic kit                for simultaneously detecting Corona 19 virus and                SARS virus (claimed).    ADVANTAGE - The composition: can quickly detects Corona 19                virus; has high specificity, sensitivity and                accuracy; and is economical.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for                diagnostic kit comprising the composition, where in                the step of mixing the composition, it is a                one-step PCR that performs real-time quantitative                PCR at once while going through the PCR process                after synthesizing DNA from RNA. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E01;  B04-E02F;  B04-E03F;  B04-E05;  B04-E08;  B04-E99;  B04-F11B;  B06-A02;  B06-A03;  B06-D01;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  D05-H06A;  D05-H09;  D05-H12D1;  D05-H18B;  D05-H99,C12Q-001/70,KR2023084936-A   13 Jun 2023   C12Q-001/70   202353Pages: 20   ;  KR2557885-B1   24 Jul 2023   C12Q-001/70   202362   ,KR2023084936-A    KR173120    06 Dec 2021;   KR2557885-B1    KR173120    06 Dec 2021,,KR173120    06 Dec 2021,,,,,248056-0-0-0 D K M; 90045-0-0-0 D K M; 1826583-0-0-0 D K M; 1826583-0-0-0 CL USE,,05935,RA104R D K M; R15410 D K M; RAXTHQ D K M,
RU2797271-C1,METHOD OF RETROPERITONEAL POSTERIOR ENDOSCOPIC            ADRENALECTOMY OF LARGE TUMORS,RYABCHENKO E V,RYABCHENKO E V (RYAB-Individual),2023709128,"   NOVELTY - Invention can be used in retroperitoneal                posterior endoscopic adrenalectomy of large tumors.                The patient is placed on the stomach with the hips                and knees bent. A 1.5 cm long transverse incision                is made under the end of the 12th rib, with the                help of the index finger a tunnel is made deep into                the retroperitoneal space, a 0.5 cm incision is                made under the control of the finger under the end                of the 11th rib and a lateral trocar with a                diameter of 5 mm is installed, so that the end of                the trocar rests against the distal phalanx of the                finger, the finger is removed. A balloon-type                trocar with a diameter of 12 mm is placed in the                first incision, sealed with a syringe, pressure is                created in the retroperitoneal space while                maintaining CO2 of 20&#8211;25 mm Hg using an                insufflator and an optical camera is introduced                into this trocar. Then, in a 1 cm incision between                the spinal column and the first trocar, a medial                trocar with a diameter of 10 mm is placed at an                angle of 45&#176; into which a manipulator is                inserted to mobilize the adrenal gland. An                electrolytic Covidien Ligasure instrument is placed                in the 5 mm lateral trocar, Gerota's fasciae are                opened, and the adrenal vein is coagulated. For                left-sided retroperitoneoscopic adrenalectomy,                using the Covidien ligasure electrocautery                instrument, the left adrenal gland is isolated                under the diaphragm, lowered medially, the adrenal                vein is found, which is coagulated, mobilizing the                lower part of the adrenal gland with the tumor,                moving away from the kidney.    USE - Medicine, surgery.    ADVANTAGE - Method allows to reduce intraoperative blood                loss, reduce the level of conversion, ensure the                prevention of postoperative complications and                reduce the rehabilitation period due to the                combination of techniques of the claimed                invention. 1 cl, 6 dwg, 2 ex ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  P31 (Diagnosis, surgery (A61B).)",B11-C04;  B14-H01;  P31-A01,A61B-017/00,RU2797271-C1   01 Jun 2023   A61B-017/00   202356Pages: 0   Russian,RU2797271-C1    RU119064    11 Jul 2022,,RU119064    11 Jul 2022,,,,,,,,,
US2023131596-A1,"Computing system for building customizable            communication platform to communicate customized            healthcare treatment plan by patient doctor to user            device, has processor identifying visual alert based on            alert tag and displaying data about request message            along with visual alert",YERMILOV I;  SOZA H R,CAREMINDR CORP (CARE-Non-standard),202344512R,"   NOVELTY - The system has a memory (610) for storing a                front-end of a software application. A processor                (620) receives a request message from a back-end of                the software application from a host server,                detects an alert tag, which is embedded within the                request message by the host server, identifies a                visual alert based on the alert tag and displays                data about the request message along with the                visual alert through a user interface of the                front-end of the software application, where the                request message comprises a HTTPmessage, and the                alert tag is embedded within a header of the                HTTPmessage. The processor identifies the visual                alert based on a mapping of the visual alert to the                alert tag included in a mapping table.    USE - Computing system for building a customizable                communication platform to communicate customized                healthcare treatment plan by a patient doctor to a                user device for treating illnesses i.e. COVID19.                Uses include but are not limited to a personal                computer, a server, a console, a personal digital                assistant (PDA), a cellular phone, a medical                machine, a tablet computing device and a                smartphone.    ADVANTAGE - The system uses a tag to indicate a level of                severity or urgency so as to alert a provider to                information that needs immediate medical action and                additional follow-up with the patient or a specific                review of patient`s medical history.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for:    (a) Method for building a customizable                communication platform to communicate customized                healthcare treatment plan by a patient doctor to a                user device;    (b) Non-transitory computer-readable medium                comprising a set of instructions for building a                customizable communication platform to communicate                customized healthcare treatment plan by a patient                doctor to a user device.    DESCRIPTION OF DRAWING(S) - The drawing shows a block diagram of a                network entity.    600Network entity    610Memory    620Processor    630Software module ",,,"S05 (Electrical Medical Equipment);  T01 (Digital Computers);  W05 (Alarms, Signalling, Telemetry and Telecontrol);  W01 (Telephone and Data Transmission Systems)",S05-G02G2;  T01-J05B4P;  T01-J12A;  T01-N01E1;  T01-N02A3C;  T01-N03;  T01-S03;  W05-A03C;  W01-C01D3C;  W01-C01G8A;  W01-C01G8S,G06F-016/22;  G16H-040/20;  H04L-067/02,US2023131596-A1   27 Apr 2023   G16H-040/20   202338   English,US2023131596-A1    US879943    03 Aug 2022,US2023131596-A1 Provisional Application US272016P,US272016P    26 Oct 2021;  US879943    03 Aug 2022,,,"US2023131596-A1 -- US20130073306-A1   ;  US20170109479-A1   ;  US20170124276-A1   ;  US20200168327-A1   ;  US20210050098-A1   ;  US10699812-B2   CERNER INNOVATION INC (CRNR)   BALA R K,  KARRA D R",,,,,,
CN115976246-A,"Kit used for detecting pathogens of lower            respiratory tract infection, comprises transcription            and amplification primers, buffer mix, diethyl            pyrocarbonate water, enzyme mix, exogenous plasmid and            positive control template",ZHU J;  JIANG G;  ZHA Y;  LI J;  ZHANG L,SHANGHAI HONGXU BIOLOGICAL MEDICAL TECHN (SHAN-Non-standard),202347188B,"   NOVELTY - Kit for rapidly detecting pathogens of lower                respiratory tract infection, comprises                transcription and amplification primers, buffer                mix, diethyl pyrocarbonate (DEPC) water, enzyme                mix, exogenous plasmid and positive control                template. The transcription and amplification                primers comprise amplified sequences of 16 kinds of                RNA viruses, 4 kinds of DNA viruses and 24 kinds of                respiratory pathogenic bacteria, a total of 44                kinds of respiratory pathogens.    USE - The kit is useful for detecting pathogens of                lower respiratory tract infection.    ADVANTAGE - The kit rapidly detects pathogens of lower                respiratory tract infection, has improved detection                specificity and detection sensitivity, reduces                false positives, and only needs existing PCR                instrument to complete amplification.    DETAILED DESCRIPTION - Kit for rapidly detecting pathogens of lower                respiratory tract infection, comprises                transcription and amplification primers, buffer                mix, diethyl pyrocarbonate (DEPC) water, enzyme                mix, exogenous plasmid and positive control                template. The transcription and amplification                primers comprise amplified sequences of 16 kinds of                RNA viruses, 4 kinds of DNA viruses and 24 kinds of                respiratory pathogenic bacteria, a total of 44                kinds of respiratory pathogens, and the primer                sequences comprise 44 pairs including OR having                base pair sequence of gcagttcccaggttgagcc (SEQ ID                NO: Not defined), OF having base pair sequence of                ggtgagcttaatacgttcatcaattg (SEQ ID NO: Not                defined), OR having base pair sequence of                tctgctattgttttcttctg (SEQ ID NO: Not defined), OF                having base pair sequence of cagacattaaagcaaatactg                (SEQ ID NO: Not defined), OR having base pair                sequence of gactcccaccgcagtttcag (SEQ ID NO: Not                defined), OF having base pair sequence of                cggatcctcaactcactcttcg (SEQ ID NO: Not defined), OR                having base pair sequence of agcagtgccccaaatcctatc                (SEQ ID NO: Not defined), OF having a base pair                sequence of gtttgccttggttgcttggt (SEQ ID NO: Not                defined), COVID19OR having a base pair sequence of                ccacgaattcgtcttgatc (SEQ ID NO: Not defined) and                COVID19OF having a base pair sequence of                caataatactgcctcttggt (SEQ ID NO: Not defined)                provided in table 3 of patent specification. An                INDEPENDENT CLAIM is included for method for                detecting lower respiratory tract infection                pathogenic bacteria, which involves (a) collecting                nasopharyngeal swabs or sputum from patients with                respiratory infections, and extracting nucleic                acid, (b) preparing reaction mix, (c) setting                nucleic acid-free water as negative control and                positive control primers and templates as positive                control, (d) setting reaction conditions according                to instructions, and (e) using fluorescence                instrument to identify each product, and according                to sample fluorescence value, negative control                fluorescence value and positive control                fluorescence value to determine the type of                respiratory pathogens. ",,,"D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.)",D05-A02B;  D05-H04;  D05-H09;  D05-H18B;  D05-H99;  B04-C03C;  B10-E03;  B05-C07;  B05-C05;  B05-C01;  B10-B03B;  B12-K04F;  B04-E01;  B04-L04A;  B04-B04D2;  B04-B03B;  B11-C07B3;  B04-B04G;  B12-K04G1C;  B04-F10;  B11-C08F8;  B11-C08E3;  B04-E05;  B04-E08;  B04-E99;  A10-E08B;  A10-E07C;  A10-E08A;  A12-W11L,C12N-015/11;  C12Q-001/686;  C12Q-001/689;  C12Q-001/6895;  C12Q-001/70;  C12R-001/01;  C12R-001/19;  C12R-001/21;  C12R-001/22;  C12R-001/32;  C12R-001/325;  C12R-001/35;  C12R-001/36;  C12R-001/37;  C12R-001/385;  C12R-001/43;  C12R-001/44;  C12R-001/445;  C12R-001/46;  C12R-001/645;  C12R-001/725,CN115976246-A   18 Apr 2023   C12Q-001/6895   202348   Chinese,CN115976246-A    CN10813591    12 Jul 2022,,CN10813591    12 Jul 2022,,,,,297125-0-0-0 M K; 104477-1-0-0 M K; 204644-0-0-0 D M K; 131086-0-1-0 M K; 87324-0-1-0 M K; 93558-1-0-0 M K; 444-0-0-0 ,,,RA20EO M K; R01869 M K; RA031J D M K; R07968 M K; R01786 M K; R04320 M K; R00351 ,1869-S; 0418-S; 1786-S
KR2023042958-A,"Dabang pocket mask for use in daily life, has mask            main body folded in three layers to minimize volume,            where size of mask wrapping paper of main body is            reduced by specific percentage",CHO D M,TAO C & C CO LTD (TAOC-Non-standard),2023348409,"   NOVELTY - The mask has a nose piece located in a center                part, where a mask main body is folded in three                layers to minimize volume. A support is designed to                be detachable in a fixed type and a non-fixed type                according to an operator convenience. The mask is                placed in a mini-wrapping bag of one-third size of                an existing wrapping paper. The size of the mask                wrapping paper of the main body is reduced by                specific percentage. The support is divided into                three parts by using the support.    USE - The dabang pocket mask is useful in daily                life.    ADVANTAGE - The mask minimizes the use of vinyl, a harmful                environmental substance, and is easy to carry in                handbag, jacket pocket, or back pocket of your                pants, so that it is possible to carry a hygienic                KF94 mask anywhere at any time, which makes it                possible to live more safely in the era of                with-COVID19.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic diagram of                dabang pocket mask. ",,,"P21 (Wearing apparel (A41, A42).);  Q32 (Container/closure types, special packaging features and transit packaging (B65D));  Q34 (Types of goods packaged/bottled/bound/labelled/unpacked (B65B, C, D))",P21-F;  P21-N;  P21-T01;  Q32-A15;  Q32-B;  Q32-D06;  Q32-T01C;  Q34-X,A41D-013/11;  B65D-033/00;  B65D-075/30;  B65D-083/08;  B65D-085/07,KR2023042958-A   30 Mar 2023   B65D-075/30   202331Pages: 5   ,KR2023042958-A    KR125859    23 Sep 2021,,KR125859    23 Sep 2021,,,,,,,,,
CN115714019-A,"System for predicting liver damage risk for            patients with normal liver function index and novel            crown primary treatment, has obtaining module that is            connected with predicting module in wireless or wired            manner, where prediction module predicts liver damage            risk parameter",CHEN J;  ZHANG F;  LI Z;  GUO T;  LIU S;  HUANG J;  BAO J;  LIU F,HANGZHOU XIXI HOSPITAL (HANG-Non-standard),202323236A,"   NOVELTY - The system comprises an obtaining module and a                prediction module, where the obtaining module is                connected with the prediction module in a wireless                or wired manner. The obtaining module is used for                obtaining a liver damage risk related variable of a                normal liver function index and novel crown primary                treatment group. The prediction module is used for                predicting a liver damage risk parameter of normal                liver function index and crown primary treatment                according to a variable that is obtained by the                obtaining module, and outputs the liver damage risk                parameter. The obtaining module comprises an                angiopoietin-like protein-3 expression level                obtaining sub-module.    USE - System for predicting liver damage risk for                the patients with a normal liver function index and                novel crown primary treatment. Can also be used for                the risk probability prediction of any clinical                diagnosis and treatment scene.    ADVANTAGE - The system provides clinical medication                guidance for patients for taking hepatotoxic                antiviral drugs, and formulates the individualized                liver function monitoring program through the risk                prediction of COVID19 liver injury.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view of a                system for predicting liver damage risk for the                patients with a normal liver function index and                novel crown primary treatment. ",,,S05 (Electrical Medical Equipment);  T01 (Digital Computers),S05-G02G2;  S05-P;  T01-C03C;  T01-J06A1,G16B-020/00;  G16B-005/00;  G16H-050/30;  G16H-050/50,CN115714019-A   24 Feb 2023   G16H-050/30   202319   Chinese,CN115714019-A    CN11141801    20 Sep 2022,,CN11141801    20 Sep 2022,,,,,,,,,
IN202311009810-A,"Derivatives of amla, preferably            1,2,3-trihydroxybenzene derivatives having            anti-coronavirus disease (COVID19) potential            activity",ROY A;  KHATANA K;  GURJAR S P,ROY A (ROYA-Individual);  KHATANA K (KHAT-Individual);  GURJAR S P (GURJ-Individual),202322719W,"   NOVELTY - Derivatives of amla, preferably                1,2,3-trihydroxybenzene derivatives (I)-(IV) having                anti-coronavirus disease (COVID19) potential                activity, are new.    USE - Derivatives of amla having anti-COVID19                potential activity. No biological data given.    ADVANTAGE - The derivatives of amla have effective                antiviral activities than commercially available                drugs of hydroxychloroquine and umifenovir, good                oral bioavailability, lower toxicity, drug                likeness, high biocompatibility and are effective                against anti-COVID19 targets according to the                hydrogen binding interactions.    DETAILED DESCRIPTION - Derivatives of amla, preferably                1,2,3-trihydroxybenzene derivatives of formulae                (I)-(IV) having anti-COVID19 potential activity,                are new.    An INDEPENDENT CLAIM is included for molecular                docking, physicochemical properties and                pharmacokinetic properties and drug likeness                assessments of the derivatives of amla.     ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  T01 (Digital Computers)",B11-C11;  B10-A07E;  B10-A07C;  B10-C03;  B07-A02B;  B14-A02B5;  B04-A10;  B04-A08G2;  T01-J13A,A61K-009/51;  G16B-015/30;  G16B-005/00;  G16C-020/30;  G16C-020/50,IN202311009810-A   17 Feb 2023   G16C-020/50   202320   English,IN202311009810-A    IN11009810    14 Feb 2023,,IN11009810    14 Feb 2023,,,,,248440-0-0-0 U K; 7650-0-0-0 M K; 47650-0-0-0 M K;  M K; 96824-1-0-0 M K,,,RA10FQ U K; R01170 M K; R13486 M K; RCZE4L M K; RB5H25 M K,1170-S
US2023029770-A1,"Method for realizing mobile navigational control            of user interface in e.g.automated teller machine, used            by employees of organizations, involves relaying key            events received from navigational control screen to            agent on transaction terminal for updating transaction            screens based on key events",POSTON J A;  LASATER Z T;  KADRY A J;  BENNETT G T;  SREERAMAN M;  AMIN A M;  MORGAN K,NCR CORP (NATC-C),202314048W,"   NOVELTY - The method (300) involves detecting (310) a                quick response (QR) code(RTM: Matrix barcode)                scanned from a transaction display of a transaction                terminal. The QR Codeis decoded, and a uniform                resource locator (URL) is obtained (320). A network                address is connected (330) with the URL. A mobile                device identifier is provided for a mobile device.                A remote-control user session is established (340)                with the transaction terminal through a server. A                navigational control screen is rendered (350) on a                display of the mobile device for operation by a                user to control transaction screens rendered by a                transaction interface on the transaction terminal                during transaction process. Key events received                from a navigational control screen are relayed                (360) to an agent on the transaction terminal                during the remote-control user session for delivery                to the transaction interface and update transaction                screens based on the key events.    USE - Method for realizing mobile navigational                control of a user interface (UI) in a transaction                terminal such as self-service terminal (SST),                automated teller machine (ATM) and cashier-assisted                point-of-sale (POS) terminal, used by high-risk                corona virus disease (COVID19) consumers and                employees of organizations.    ADVANTAGE - The method enables investing heavily in                transaction interfaces associated with transaction                terminals by organizations so as to ensure                transactions are conducted efficiently by avoiding                specialized skill being required by operators                e.g.consumers, cashiers, clerks and tellers,                operating transaction terminals by high-risk                COVID19 consumers or employees so that the                transaction interfaces render touch options in                exact same locations of displays for nearly                transactions, thus allowing a user to touch a                surface previously touched by multiple customers,                allowing customers and staffs that operate                transaction terminals to eliminate mode of virus                transaction while conducting transaction checkouts                at a retail store when virus spreads through touch                surfaces, and preventing second remote-control user                session requested from a second mobile device                connected to the transaction terminal by a remote                transaction terminal UI agent while the                remote-control user session is active with the                transaction terminal.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a mobile                device.    DESCRIPTION OF DRAWING(S) - The drawing shows a flow diagram illustrating                a method for realizing mobile navigational control                of a UI in a transaction terminal.    300Realizing mobile navigational control of                UI in transaction terminal    310Detecting QR scanned from transaction                display of transaction terminal    320Decoding QR Code and obtaining URL    330Connecting network address with URL and                providing mobile device identifier for mobile                device    340Establishing remote-control user session                with the transaction terminal through server    350Rendering navigational control screen on                display of mobile device for operation by user to                control transaction screens rendered by transaction                interface on transaction terminal during                transaction process    360Relaying key events received from                navigational control screen to agent on transaction                terminal during remote-control user session for                delivery to transaction interface and update                transaction screens based on key events ",,,"T05 (Counting, Checking, Vending, ATM and POS Systems);  T01 (Digital Computers);  W05 (Alarms, Signalling, Telemetry and Telecontrol)",T05-L01C;  T05-L01D;  T05-L02;  T05-L03C5;  T01-J12B;  T01-J21;  T01-N01A1;  T01-N02A1A;  T01-N02A3C;  W05-D05B5;  W05-D08C,G06Q-020/20;  G06Q-020/32,US2023029770-A1   02 Feb 2023   G06Q-020/32   202312   English,US2023029770-A1    US966293    14 Oct 2022,US2023029770-A1 Div ex Application US036074,US036074    29 Sep 2020;  US966293    14 Oct 2022,,,,,,,,,
KR2023014448-A,"System for diagnosing disease e.g. Sars, has            server for storing medical examination and disease            diagnosis result, where server generates and issues            health certificate according to disease diagnosis            results",JUNG S G;  KIM E S;  LIM J,MI CO BIO MED CO LTD (MIBI-Non-standard),202313762W,"   NOVELTY - The system has a terminal (10) for performing                log-in and sharing medical examination information                including a location signal, clinic reservation                information, underlying disease or medical history.                A point-of-care device (20) is provided for                diagnosing a disease by analyzing a sample taken                from a clinic. A server (30) stores reservation                information of a user, medical examination and                disease diagnosis result. The server generates and                issues a health certificate according to the                disease diagnosis results. A result determining                unit determines whether the diagnosis result is                positive or negative.    USE - Disease diagnosis system for diagnosing                infectious diseases such as Sars, Mers, COVID19,                malaria and tuberculosis.    ADVANTAGE - The user can easily select a clinic, reserve                an on-site diagnosis place, diagnose a disease                immediately after collecting a sample on a spot,                and obtain a health certificate. The system enables                the user to easily obtain the health certificate at                a desired time and place.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a                disease diagnosis method.    DESCRIPTION OF DRAWING(S) - The drawing shows a block diagram of a                disease diagnosis system (Drawing includes                non-English language text).    10Terminal    12User Terminal    14Hospital Terminal    20Point-of-care device    30Server ",,,S05 (Electrical Medical Equipment);  T01 (Digital Computers),S05-G02G1;  S05-G02G2;  S05-G02G3;  S05-G02G9;  T01-N01A1;  T01-N01A2;  T01-N01E1,G06K-019/06;  G06Q-010/02;  G16H-010/20;  G16H-010/40;  G16H-010/60;  G16H-040/20;  G16H-050/20;  G16H-050/80;  G16H-080/00,KR2023014448-A   30 Jan 2023   G16H-050/80   202321Pages: 23   ,KR2023014448-A    KR095800    21 Jul 2021,,KR095800    21 Jul 2021,,,,,,,,,
WO2023278686-A1;  CA3225747-A1;  AU2022301208-A1;  KR2024027769-A;  EP4363419-A1;  CN117980305-A;  BR112023027604-A2,"New spirocyclic pyridine-1,5-diones are            mitogen-activated proten kinase-interacting kinase 1            inhibitors used to treat or prevent e.g. neuropathic            pain, lupus, viral infection-induced pain Alzheimer's            disease, and Fragile X syndrome",PRICE T J;  SAHN J J;  SAN JAMES J;  THEODORE J P,4E THERAPEUTICS INC (FOUR-Non-standard);  4E THERAPEUTICS INC (FOUR-Non-standard);  4E THERAPEUTICS INC (FOUR-Non-standard);  4E THERAPEUTICS INC (FOUR-Non-standard);  4E THERAPEUTICS INC (FOUR-Non-standard),2023029201,"   NOVELTY - Spirocyclic pyridine-1,5-diones (I) are                new.    USE - (I) are useful for treating or preventing                disease or conditions associated with aberrant MNK                activity, and treating or preventing neuropathic                pain, lupus, viral infection-induced pain, Covid19                related acute respiratory distress syndrome,                nonalcoholic fatty liver disease, high fat diet                induced obesity, Alzheimer's disease, Fragile X                syndrome (all claimed).    ADVANTAGE - (I) have improved cellular potency,                pharmacokinetic properties, and improved oral                bioavailability e.g. area under curve, high peak                plasma concentrations (Cmax) and half life. The                pharmacokinetic property of (I) was tested in                Sprague-Dawley rats using in vivo assay. The result                showed that rats orally administered 25 mg/ml                6''-((6-aminopyrimidin-4-yl)amino)-8''-methyl-2''H-dispiro[cyclopropane-1,1'-cyclohexane-4',3''-imidazo[1,5-a]pyridine]-1'',5''-dione                exhibited mean Cmax value of 28767 ng/ml.    DETAILED DESCRIPTION - Spirocyclic pyridine-1,5-diones of formula (I)                and their hydrates, solvates, salts, prodrugs or                complexes are new.    Z1=-(-C(R4a)(R4b)-) - or                -C(R4a)=C(R4f)-;    R1, R3=H, halo, 1-6C-alkyl, 3-7C-branched                alkyl, 1-6C-haloalkyl, 3-7C-branched haloalkyl,                1-6C-hydroxyalkyl, 3-7C-branched hydroxyalkyl,                cyano, 1-6C-alkoxy, 3-7C-branched alkoxy, hydroxy,                or 3-6C-cycloalkyl (optionally substituted by 1-3                halo, 1-6C-alkyl, 1-6C-haloalkyl or                1-6C-hydroxyalkyl);    R2=pyrimidin-4-amine moiety of formula (M1),                thiazol-5-amine moiety of formula (M2),                pyridazin-4-amine moiety of formula (M3),                pyrimidin-4-ylmethanamine moiety of formula (M4),                imidazo[1,2-b]pyridazin-3-amine moiety of formula                (M5), imidazo[1,2-a]pyridin-3-amine moiety of                formula (M6), imidazo[1,2-a]pyrazin-3-amine moiety                of formula (M7), imidazo[1,2-b]pyridazine moiety of                formula (M8), imidazo[1,2-a]pyridine moiety of                formula (M9), imidazo[1,2-a]pyrazine moiety of                formula (M10), imidazo[1,2-b]pyridazin-2-amine                moiety of formula (M11),                imidazo[1,2-a]pyridin-2-amine moiety of formula                (M12), imidazo[1,2-a]pyrazin-2-amine moiety of                formula (M13), imidazo[1,2-b]pyridazine moiety of                formula (M14), imidazo[1,2-a]pyridine moiety of                formula (M15), or imidazo[1,2-a]pyrazine moiety of                formula (M16);    R4a, R4b=H, halo, 1-6C-alkyl, 3-7C-branched                alkyl, 1-6C-haloalkyl, 3-7C-branched haloalkyl,                hydroxy, 1-6C-alkoxy, 3-7C-branched alkoxy,                NHCO(1-6C-alkyl), NHCO(3-7C-branched alkyl),                NHCO(3-7C-cycloalkyl), NHSO (1-6C-alkyl), NHSO                (3-7C-branched alkyl), or NHSO                (3-7C-cycloalkyl);    R4c, R4d=H, halo, 1-6C-alkyl, 3-7C-branched                alkyl, 1-6C-haloalkyl, 3-7C-branched haloalkyl,                1-6C-hydroxyalkyl, 3-7C-branched hydroxyalkyl,                hydroxy, 1-6C-alkoxy, 3-7C-branched alkoxy,                NHCO(1-6C-alkyl), NHCO(3-7C-branched alkyl),                NHCO(3-7C-cycloalkyl), NHSO (1-6C-alkyl), NHSO                (3-7C-branched alkyl), or NHSO                (3-7C-cycloalkyl);    R4e, R4f=H, halo, 1-6C-alkyl, 3-7C-branched                alkyl, 1-6C-haloalkyl, or 3-7C-branched                haloalkyl;    R1aR1b=optionally substituted 3-7 membered                ring that optionally contains an X1 group;    X1=CF , CHCO R12, O, NH, NR8, or SO ;    m=0-2;    n=1-3;    R5=H, halo, 1-6C-alkyl, 3-7C-branched alkyl,                1-6C-haloalkyl, 3-7C-branched haloalkyl,                1-6C-alkoxy, 3-7C-branched alkoxy, or                hydroxy;    R6=H, NH , NHR6a, NHCH CH OH, NH-CH -CH -NHSO                -CH , 1-6C-alkoxy, 3-7C-branched alkoxy, or                hydroxy;    R6a=-(CO)-1-6C-alkyl, -(CO)-3-7C-branched                alkyl, -(CO)-1-6C-hydroxyalkyl,                cyclopropanecarbaldehyde moiety of formula (M17),                cyclopropanecarbaldehyde moiety of formula (M18),                morpholine moiety of formula (M19), piperazine                moiety of formula (M20),                6-azaspiro[3.3]heptane-2-carbaldehyde moiety of                formula (M21), (2R)-1-aminopropan-2-ol moiety of                formula (M22), (2S)-1-aminopropan-2-ol moiety of                formula (M23), 1-aminopropan-2-ol moiety of formula                (M24),                (1R,5S)-3-azabicyclo[3.1.0]hexane-6-carbaldehyde                moiety of formula (M25), or                (1R,5S)-3-azabicyclo[3.1.0]hexane-6-carbaldehyde                moiety of formula (M26);    q, e=1-6;    X2=H, halo, 1-5C-alkyl, 3-7C-branched alkyl,                1-5C-haloalkyl, 3-7C-branched haloalkyl, hydroxy,                1-5C-hydroxyalkyl, 3-7C-branched hydroxyalkyl,                1-5C-alkoxy. 3-7C-branched alkoxy, 1-5C-haloalkoxy,                3-7C-branched haloalkoxy, NH , NH(1-6C-alkyl),                N(1-6C-alkyl) , 1-5C-(COOH), 1-5C-(NHSO -CH                );    X3=H, halo, 1-5C-alkyl, 3-7C-branched alkyl,                1-5C-haloalkyl, 3-7C-branched haloalkyl, hydroxy,                1-5C-hydroxyalkyl, 3-7C-branched hydroxyalkyl,                1-5C-alkoxy, 3-7C-branched alkoxy, 1-5C-haloalkoxy,                3-7C-branched haloalkoxy, NH , NH(1-6C-alkyl),                N(1-6C-alkyl) , COOH, 1-5C(COOH), NHSO -CH ,                1-5C(NHSO -CH );    R7=H, halo, 1-6C-alkyl, 3-7C-branched alkyl,                1-6C-haloalkyl, 3-7C-branched haloalkyl,                1-6C-alkoxy, 3-7C-branched alkoxy, or                hydroxy;    R8=1-6C-alkyl, 1-6C-haloalkyl, 3-7C-branched                haloalkyl, 1-6C-hydroxyalkyl, 3-7C-branched                hydroxyalkyl, 1-6C-alkoxy, 3-7C-branched alkoxy,                CO(1-6C-alkyl), CO(3-7C-branched alkyl), SO                (1-6C-alkyl) or SO (3-7C branched alkyl);    R10=H, 1-6C-alkyl, 1-6C-haloalkyl,                3-7C-branched haloalkyl, 1-6C-hydroxyalkyl,                1-6C-alkoxy, 3-7C-branched alkoxy, CO(3-7C-alkyl),                CO(3-7C-branched alkyl), SO (1-6C-alkyl) or SO                (3-7C branched alkyl); and    R11, R12=H or 1-6C-alkyl.    INDEPENDENT CLAIMS are also included                for:    a composition comprising (I);    treating or preventing disease or conditions                associated with aberrant mitogen-activated proten                kinase-interacting kinases (MNK) activity,                comprising administering (I) to a subject;                and    treating or preventing neuropathic pain,                lupus, viral infection-induced pain, Covid19                related acute respiratory distress syndrome,                nonalcoholic fatty liver disease, high fat diet                induced obesity, Alzheimer's disease, Fragile X                syndrome, comprising administering (I) to a                subject; and    treating or preventing neuropathic pain,                lupus, viral infection-induced pain, Covid19                related.                                 ",,,B02 (Fused ring heterocyclics.),B06-D05;  B06-S;  B14-A02;  B14-C01;  B14-D06C;  B14-E12;  B14-G02D;  B14-J01A4;  B14-K01F;  B14-N12,A61K-031/519;  A61K-031/52;  C07D-471/04;  C07D-487/04;  A61K-031/437;  A61K-031/506;  A61P-001/16;  A61P-011/00;  A61P-025/02;  A61P-025/04;  A61P-025/28;  A61P-029/00;  A61P-003/04;  A61P-037/00,WO2023278686-A1   05 Jan 2023   C07D-471/04   202310Pages: 184   English;  CA3225747-A1   05 Jan 2023   C07D-471/04   202406   English;  AU2022301208-A1   18 Jan 2024   C07D-471/04   202408   English;  KR2024027769-A   04 Mar 2024   C07D-471/04   202421   ;  EP4363419-A1   08 May 2024   C07D-471/04   202439   English;  CN117980305-A   03 May 2024   C07D-471/04   202440   Chinese;  BR112023027604-A2   19 Mar 2024   C07D-471/04   202444   ,WO2023278686-A1    WOUS035703    30 Jun 2022;   CA3225747-A1    CA3225747    30 Jun 2022;   AU2022301208-A1    AU301208    30 Jun 2022;   KR2024027769-A    KR703331    30 Jun 2022;   EP4363419-A1    EP834211    30 Jun 2022;   CN117980305-A    CN80054706    30 Jun 2022;   BR112023027604-A2    BR11027604    30 Jun 2022,CA3225747-A1 PCT application Application WOUS035703;   AU2022301208-A1 PCT application Application WOUS035703;   AU2022301208-A1 Based on Patent WO2023278686;   KR2024027769-A PCT application Application WOUS035703;   KR2024027769-A Based on Patent WO2023278686;   EP4363419-A1 PCT application Application WOUS035703;   EP4363419-A1 Based on Patent WO2023278686;   CN117980305-A PCT application Application WOUS035703;   CN117980305-A Based on Patent WO2023278686;   BR112023027604-A2 PCT application Application WOUS035703;   BR112023027604-A2 Based on Patent WO2023278686,US217264P    30 Jun 2021;  BR11027604    27 Dec 2023;  CA3225747    28 Dec 2023;  KR703331    29 Jan 2024;  CN80054706    05 Feb 2024,WO2023278686-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IQ;  IR;  IS;  IT;  JM;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        EP4363419-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN      ,,"WO2023278686-A1 -- US20190209560-A1   ;  WO2014044691-A1   BAYER PHARMA AG (FARB)   KLAR U,  WORTMANN L,  KETTSCHAU G,  PUEHLER F,  LIENAU P,  PETERSEN K,  HAEGEBARTH A,  SUELZLE D;  WO2020155842-A1   NOVOSTAR PHARM LTD (NOVO-Non-standard)   LI B;  WO2022006331-A2   4E THERAPEUTICS INC (FOUR-Non-standard)   PRICE T J,  SAHN J J","WO2023278686-A1  DATABASE PUBCHEM          COMPOUND 2 November 2019 (2019-11-02), ANONYMOUS : ""CID          139317491"", XP093021615, retrieved from PUBCHEM Database          accession no. 139317491,relevantClaims[1-2, 6, (9-10,          12-15)/(1-2, 6)],relevantPassages[; pg. 2]", N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N;  N,228394001 N,01200; 44761; 00690; 00790; 01032; 00750; 00834; 00012; 00013; 01197; 07975; 08425; 40695,RDAC64 N; RDAC65 N; RDAC66 N; RDAC67 N; RDAC68 N; RDAC69 N; RDAC6A N; RDAC6B N; RDAC6C N; RDAC6D N; RDAC6E N; RDAC6F N; RDAC6G N; RDAC6H N; RDAC6I N; RDAC6J N; RDAC6K N; RDAC6L N; RDAC6M N; RDAC6N N; RDAC6O N; RDAC6P N; RDAC6Q N; RDAC6R N; RDAC6S N; RDAC6T N; RDAC6U N; RDAC6V N; RDAC6W N; RDAC6X N; RDAC6Y N; RDAC6Z N; RDAC70 N,
IN202211070966-A,"System for predicting student result based on            educational data mining system, which provides timely            feedback to learners and teachers as well so that            appropriate steps are taken for betterment of            learners",KAUR P;  DHANKHAR A;  SOLANKI K;  KAUR K;  DAHIYA O,UNIV LOVELY PROFESSIONAL (ULVP-C),202304322P,"   NOVELTY - The system has wide range of topics including                curriculum design, coaching, student mental health,                learning motivation and academic success. COVID19                epidemic significantly impacted the higher                education industry and changed the traditional                classroom-based teaching-learning model to one                based on online instruction. The system is intended                to imply that changes to teaching, learning,                assessment, and feedback procedures affect their                structure and nature. The system provides timely                feedback to learners and teachers as well so that                appropriate steps are taken for the betterment of                the learners.    USE - System for predicting student result based on                educational data mining system.    ADVANTAGE - The system accurately predicts the marks so                that instructor modify their approach by laying                stress on slow and weak learners. The system                classifies results into pass and fail students                which will be used by instructors for making                desired decisions, instead to making many stages of                result generation, the results regarding pass/fail                can be obtained in a single stage. The authors                concluded that this model is used for a                multidimensional data so as to usage value of data                can be enhanced and the precision of prediction can                be improved. The system works upon providing timely                feedback to learners and teachers as well so that                appropriate steps may be taken for the betterment                of the learners.    DESCRIPTION OF DRAWING(S) - The drawing shows a flow chart of the system                for predicting student result based on educational                data mining system. ",,,"P85 (Education, cryptography, adverts. (G09).);  T01 (Digital Computers);  W04 (Audio/Video Recording and Systems)",P85-A01;  P85-A07;  T01-N01A2;  T01-N01B3;  W04-W01,G06Q-050/20;  G09B-019/00;  G09B-005/00;  G09B-007/00;  G09B-007/02,IN202211070966-A   30 Dec 2022   G06Q-050/20   202305   English,IN202211070966-A    IN11070966    08 Dec 2022,,IN11070966    08 Dec 2022,,,,,,,,,
IN202211073786-A,"Performing touch less operation method for use in            lift, involves entering into lift, where two buttons            are provided on out panel of lift, and two infrared            sensors are installed for up and down",KHOSLA C;  RANI R;  SAINI B S,UNIV LOVELY PROFESSIONAL (ULVP-C),2023044188,"   NOVELTY - Performing touch less operation method                involves entering a person into an elevator. The                two buttons are provided on an out panel of the                elevator, where the buttons are up and down. The                two infrared (IR) sensors are installed, where one                of the sensors is used for up and the other for                down. The alarm is activated when someone cuts a                laser beam or like in washrooms where one moves                his/her hand in front of a tap and water starts                flowing out of the tap. The sensors are separately                labeled for clear distinction. The button is                activated depending upon which sensor is used by                the person.    USE - Method for performing touch less operation for                using a lift i.e. voice-based lift, for controlling                spread of viral diseases e.g. Covid19.    ADVANTAGE - The method provides a cost effective solution,                do not affect the existing infrastructure, it will                be added as an additional layer to the existing                system No user training required, users are already                familiar with such technology. ",,,"Q38 (Hoisting; Lifting; Hauling; Trucks (B66));  W05 (Alarms, Signalling, Telemetry and Telecontrol);  X25 (Industrial Electric Equipment)",Q38-A;  W05-A02;  X25-F04A,B66B-001/46;  B66B-013/30;  G08B-003/10;  G11B-027/34;  H04L-067/12,IN202211073786-A   30 Dec 2022   B66B-001/46   202308   English,IN202211073786-A    IN11073786    20 Dec 2022,,IN11073786    20 Dec 2022,,,,,,,,,
IN202211073842-A,"Internet of things based smart disinfectant            sprayer system used to reduce transmission of COVID19            has disinfectant sprayer comes with metal frame that            has to fitted in front of stores (vegetable and fruit            shops, medical and grocery stores)",PRASATH N D;  JERATH H;  SINGH D K,UNIV LOVELY PROFESSIONAL (ULVP-C),202304409V,"   NOVELTY - Internet of thingsbased smart disinfectant                sprayer system, comprises with disinfectant sprayer                comes with a metal frame that has to fitted in                front of the stores (vegetable shops, fruit shops,                medical store and grocery store).    USE - The system is useful for reducing transmission                of deadly diseases mainly COVID19.    ADVANTAGE - The system: reduces the transmission of deadly                diseases mainly COVID19; has better sanitization;                and helps people hold the social distance.    DESCRIPTION OF DRAWING(S) - The figure illustrates Internet of things                based smart disinfectant sprayer system. ",,,"D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).);  S05 (Electrical Medical Equipment);  T01 (Digital Computers)",D09-A01;  S05-G02G9;  T01-N01A2;  T01-N01E1;  T01-N01F,A01N-059/00;  C12N-007/00;  G06Q-050/26;  G16H-050/80;  H04L-067/12,IN202211073842-A   30 Dec 2022   G16H-050/80   202309   English,IN202211073842-A    IN11073842    20 Dec 2022,,IN11073842    20 Dec 2022,,,,,,,,,
IN202131025092-A,"Customized face mask, has central portion in which            image of part of face of person intended to cover is            printed, and attachment gear consisting of string or            any attachment which secures mask to head of user",GOGOI P;  DEY S,DEY S (DEYS-Individual),2022F5148V,"   NOVELTY - The customized face mask has a central                portion. An image of the part of the face of the                person it is intended to cover is printed which                leads to perfect camouflaging. The attachment gear                consists of a string or any attachment which                secures the mask to the head of the user. The image                of the user is printed after obtaining the image of                the face with the help of camera which takes the                photograph of the person face with a graduate,                calibrated and adjustable reference frame (2d)                around the face for accurate measurement of the                dimensions of the face.    USE - Customized face mask for covering face of                person while going out in polluted environment or                as protection against infection by microorganisms                i.e. Covid19 outbreak.    ADVANTAGE - The image is printed into the customized face                mask so that the mask camouflages with the face as                accurately as possible to provide the appearance of                a complete face, unique to each individual. The                face mask is developed which replicates the face of                the user in it. The dimensions and other attributes                of the face are preserved accurately. The                compliance in wearing masks among people is                enhanced. The accuracy of taking the photograph of                the person who is the intended user of the mask is                achieved by positioning of the camera and the                person and placing a graduated and pre-calibrated                frame at an appropriate position. The image                processing software makes adjustments in the                image's attributes after transferring the image of                person's face in the computer. The final result is                an exact replica of face which remains covered by                the mask.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view of a                customized face mask.    1DSLR camera    2Frame    2dAdjustable reference frame    2eHeight adjustment screw    2fWheels ",,,"P21 (Wearing apparel (A41, A42).);  P34 (Sterilising, syringes, electrotherapy (A61L, M, N).);  P35 (Life-saving, fire-fighting (A62).);  T01 (Digital Computers);  ",P21-F;  P21-N;  P34-A02;  P35-A03C;  P35-A03E1;  T01-J06A;  T01-J10C;  X27-A02B1A,A41D-013/11;  A61M-016/06;  A62B-018/02;  A62B-023/02;  G06T-011/00,IN202131025092-A   09 Dec 2022   A41D-013/11   202302Pages: 15   English,IN202131025092-A    IN31025092    06 Jun 2021,,IN31025092    06 Jun 2021,,,,,,,,,
PT117216-A,"Gantry-type collective protection equipment (CPE)            for disinfection of viruses, has radiation system that            is arranged for inactivation of viruses, bacteria,            fungi and other pathogens, in support of fight against            COVID19 and other respiratory and pandemic            diseases",DE FIGUEIREDO DINIS P M;  GASPAR O;  CAVAMBA BASTOS J,UNIV DA BEIRA INTERIOR (UYBE-Non-standard),2022F16385,"   NOVELTY - The gantry-type collective protection                equipment (CPE) has a radiation system that is                arranged for the inactivation of viruses, bacteria,                fungi and other pathogens, in support of the fight                against COVID19 and other respiratory and pandemic                diseases. The far UVC LED (1) is arranged for                disinfecting surfaces, clothing and objects. A                strip comprises a concave and reflective surface                (5) with a sticker on the back, which is placed on                door frame. A timer (4) controls the operating time                of the LEDs to complete a disinfection cycle and                with a sound signal that indicates end.    USE - Gantry-type collective protection equipment                (CPE) for disinfection of viruses, bacteria, fungi                and other pathogenic agents to fight against                COVID19 and other respiratory and pandemic                diseases, and installed in door frames of locations                with circulation of individuals.    ADVANTAGE - The bacteria, fungi and viruses can be                inactivated without the use of harmful chemicals or                heat.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view of the                gantry-type collective protection equipment (CPE)                for disinfection.    1Far UVC LED    2Power source    3Presence sensor    4Timer    5Concave and reflective surface ",,,"P34 (Sterilising, syringes, electrotherapy (A61L, M, N).);  X26 (Lighting)",P34-A01;  X26-H;  X26-U02,A61L-002/10;  A61L-002/24;  A61L-002/26,PT117216-A   10 Nov 2022   A61L-002/10   202348Pages: 22   ,PT117216-A    PT117216    10 May 2021,,PT117216    10 May 2021,,,,,,,,,
US2022348245-A1,"Microbial disinfectant apparatus for use in            grocery stores and malls for preventing transmission of            harmful pathogens, has attachment clips affixed to            tubular segments, and adjustment grips located at            opposed first and second ends of housing",KITT V D,KITT V D (KITT-Individual),2022D66424,"   NOVELTY - The microbial disinfectant apparatus has a                housing (1) that is made of two attachment clips,                and two tubular segments that are slidingly coupled                together. A flexible plastic material is infused in                the housing with copper and silver oxide particles.                The housing is designed to be manufactured for                multiple sizes and configurations. The attachment                clips are affixed to the tubular segments, and the                adjustment grips (8) are located at opposed first                end and the second end of the housing. The                adjustment grips include a polymeric material                infused with copper and silver oxide                particles.    USE - Microbial disinfectant apparatus for use in                grocery stores and malls for preventing the                transmission of harmful pathogens, including                COVID19 virus from one user to another when they                use grocery shopping carts or similar devices. Can                also be used on bicycle handle bars or other                commonly used objects that require a person to hold                while operating.    ADVANTAGE - The viral disinfectant apparatus can be                cleaned by utilizing sanitizer prior to use and                once removed from the cart, and the user can wipe                the apparatus for reuse. The engagement and                receiving ends of the attachment clips allows the                clips to connect in the secure position to fully                hold the apparatus to the handle. The apparatus                allows users to protect themselves against surface                viruses and germs while in public venues to ensure                the safety and health of the public.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method                of applying a microbial disinfectant apparatus for                protecting against contamination.    DESCRIPTION OF DRAWING(S) - The drawing shows a perspective view of a                microbial disinfectant apparatus.    1Housing    2First tubular segment    3Second tubular segment    8Adjustment grip    12Opposite edges ",,,"A95 (Transport - including vehicle parts, tyres and armaments.);  A97 (Miscellaneous goods not specified elsewhere - including papermaking, gramophone records, detergents, food and oil well applications.);  D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).);  P34 (Sterilising, syringes, electrotherapy (A61L, M, N).);  Q22 (Hand/foot/animal drawn vehicles (B62B-C))",A08-M02;  A12-V03C1;  A11-C03;  D09-C;  P34-M;  P34-A01;  Q22-A03,A61L-002/238;  B62B-005/06,US2022348245-A1   03 Nov 2022   B62B-005/06   202298   English,US2022348245-A1    US246881    03 May 2021,,US246881    03 May 2021,,,"US2022348245-A1 -- US5820142-A   DUER S D (DUER-Individual)   DUER S D;  US6065764-A   MOSELEY C M (MOSE-Individual)   MOSELEY C M;  US20050267233-A1   ;  US20160200341-A1   ;  US20200398883-A1   ;  US20220054680-A1   ;  US20220281504-A1   ;  US6981707-B1   DANDY A W (DAND-Individual)   DANDY A W;  US298077-S   ;  US605824-S   ;  WO2020237003-A1   NANOTOUCH MATERIALS LLC (NANO-Non-standard)   SISSON M,  HACKEMEYER D",,,,,,
US2022339166-A1,"Mitigating negative effects of gene therapy-type            COVID19, inoculations, shots, injections, other            administrations of inoculum used for preventing            Alzheimer's, blood cancer, involves administering            therapeutic core composition comprising vitamin C,            glycyrrhetinic acid, quercetin and vitamin D3",PAXTON-PIERSON S J,PAXTON-PIERSON S J (PAXT-Individual),2022D25792,"   NOVELTY - Mitigating negative effects of gene                therapy-type corona-virus-2019 (COVID19) vaccines,                inoculations, shots or injections, or other                administrations of inoculum involves administering                to human or mammal subject in need, of therapeutic                core composition comprising                therapeutically-effective amount of Vitamin C,                Glycyrrhetinic Acid, Quercetin, Vitamin D3 with                following physical or drug treatments in first 24                hours post-COVID19 vaccines, by applying stricture                or tourniquet to isolate injection area from rest                of body, in first minute after injection at time of                administering local medicaments; applying high                thermal temperature optimally in first minutes or                hours after injection, of 135&#8457; for 8                seconds, 125&#8457; to 1 minute and                120&#8457; to 8 minutes, as well as lower                temperatures above 105&#8457; for longer                durations; administering amphiprotic sclerants in                optimally about to 2 hours post injection at same                or nearby site.    USE - Method for mitigating negative effects of gene                therapy-type COVID19 vaccines, inoculations, shots                or injections, or other administrations of inoculum                used for preventing death; Guillain-barre syndrome;                acute disseminated encephalomyelitis; transverse                myelitis (polio symptoms); encephalitis; myelitis:                encephalomyelitis; meningoencephalitis; meningitis;                encephalopathy; convulsions; seizures; stroke;                narcolepsy; cataplexy; anaphylaxis, acute                myocardial infarction; myocarditis; pericarditis;                autoimmune diseases; miscarriages; demyelinating                diseases; non-anaphylactic allergic reactions;                thrombocytopenia; disseminated intravascular                coagulation; venous thromboembolism; arthritis;                arthralgia; joint pain; kawasaki disease;                multisystem inflammatory syndrome in children                (mis-c); vaccine enhanced disease; antibody                dependent enhancement; pathologic priming,                neurological diseases including spongiform                encephalopathy, early onset dementia and                Alzheimer's, solid tumors, blood cancers, and viral                infections etc.    ADVANTAGE - The method enables to prevent untoward adverse                genetic and toxic events and death in certain                persons receiving CV19 injections.    DETAILED DESCRIPTION - Mitigating negative effects of gene                therapy-type corona-virus-2019 (COVID19) vaccines,                inoculations, shots or injections, or other                administrations of inoculum involves administering                to human or mammal subject in need, of therapeutic                core composition comprising                therapeutically-effective amount of Vitamin C,                Glycyrrhetinic Acid, Quercetin, Vitamin D3 with                following physical or drug treatments in first 24                hours post-COVID19 vaccines, by applying stricture                or tourniquet to isolate injection area from rest                of body, in first minute after injection at time of                administering local medicaments; applying high                thermal temperature optimally in first minutes or                hours after injection, of 135&#8457; for 8                seconds, 125&#8457; to 1 minute and                120&#8457; to 8 minutes, as well as lower                temperatures above 105&#8457; for longer                durations; administering amphiprotic sclerants in                optimally about to 2 hours post injection at same                or nearby site, comprises 10 ml of 1% sodium                tetradecyl sulfate or 15 ml 0.5% polidocanol;                administering proteases locally in optimally at                same or nearby site to 0.05-20% bromelain;                administering detergents locally at same or nearby                site, comprises injection with soyasaponin or                sapinogen, licorice saponin or sapogenol;                administering anticoagulant compounds including                warfarin, heparin, apixaban, dabigatran, edoxaban,                enoxaparin, allicin, ajoene, S-allyl cysteine;                administering anti-syncytium triterpenoid                glycyrrhetinic acid and betulinic acid, and                composition of anti-clustered regularly interspaced                short palindromic repeats (CRISPR) AcrIIA4 protein                extracted from Listeria monocytogenes. ",,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.)",B14-A02;  B14-C01;  B14-C03;  B14-F01;  B14-F02D1;  B14-F03;  B14-F04;  B14-G02;  B14-G03;  B14-H01;  B14-J01;  B14-J07;  B14-L06;  B14-N16;  B14-N17;  B14-S01;  B15-A00;  B15-C00;  B15-E00;  B05-A01B;  B10-A09A;  B09-B;  B15-D03;  B04-C02E1;  B04-A07E;  B04-C03C;  B10-A04;  B10-B02D;  B10-A09C;  B05-A03A2;  B05-C03;  B10-B01B;  B04-A08;  B04-A10;  B04-A98;  B10-C03;  B10-B02A;  B10-B03B;  B06-H;  B01-C01;  B01-C02;  B01-B01;  B01-B02;  B01-B03;  B10-B02F;  B10-B02E;  B05-B01M;  B02-A;  B10-A09B;  B02-E;  B05-B02C;  B04-C01A;  B04-L03;  B04-L04;  B04-L02;  B10-A06;  B08-D02;  B05-C07;  B06-S;  B10-E02;  B10-G02;  B04-G01;  B04-L05;  B14-S18;  B07-H;  B10-C04;  B14-J02C;  B14-J02D;  B14-F02B1;  B14-L09,A61K-031/19;  A61K-031/353;  A61K-031/375;  A61K-031/593;  A61K-045/06,US2022339166-A1   27 Oct 2022   A61K-031/593   202291   English,US2022339166-A1    US482364    22 Sep 2021,US2022339166-A1 Provisional Application US179170P,US179170P    23 Apr 2021;  US482364    22 Sep 2021,,,,,72519-0-0-0 M K; 184618-0-0-0 M K; 96796-0-0-0 M K; 94231-0-0-0 M K; 103597-0-0-0 M K; 2068488-0-0-0 M K; 184587-0-0-0 M K; 203579-0-0-0 M K; 882-1-0-0 M K; 547252-0-0-0 M K; 107462-0-0-0 M K; 509916-0-0-0 M K; 612190-0-0-0 M K; 1337650-0-0-0 M K; 3151954-0-0-0 M K; 258007-0-0-0 M K; 321630-0-0-0 M K; 305526-0-0-0 M K; 114824-0-0-0 M K; 408848-0-0-0 M K; 90186-0-0-0 M K; 216954-0-0-0 M K; 89309-0-0-0 M K; 138286-1-0-0 M K; 94233-1-0-0 M K; 105172-0-0-0 M K; 20225-3-0-0 M K; 155189-0-1-0 M K; 130209-0-0-0 M K; 3330-0-0-0 M K; 184600-0-0-0 M K; 108771-1-0-0 M K; 12143-0-0-0 M K; 87874-0-0-0 M K; 96130-1-0-0 M K; 72366-0-0-0 M K; 7556-0-0-0 M K; 147848-0-0-0 M K; 93100-0-0-0 M K; 109140-0-0-0 M K; 70204-0-0-0 M K; 95462-0-0-0 M K; 146415-0-0-0 M K; 50639-0-0-0 M K; 95025-0-0-0 M K; 12641-0-0-0 M K; 127393-0-0-0 M K; 90016-0-0-0 M K; 67535-0-0-0 M K; 98411-1-0-0 M K; 108140-0-0-0 M K; 88182-1-0-0 M K; 109114-0-0-0 M K; 109113-0-0-0 M K; 109111-0-0-0 M K; 109110-0-0-0 M K; 4015-0-0-0 M K; 135075-0-0-0 M K; 104714-1-0-0 M K; 95854-2-0-0 M K; 36113-0-0-0 M K; 88746-1-0-0 M K; 105509-5-0-0 M K; 99712-0-0-0 M K; 21764-0-0-0 M K; 87593-0-0-0 M K; 94111-0-0-0 M K; 90899-0-0-0 M K; 105588-0-0-0 M K; 92514-0-1-0 M K; 91937-0-0-0 M K; 105615-1-0-0 M K; 85145-2-0-0 M K; 149222-1-0-0 M K; 95853-1-0-0 M K; 95106-6-0-0 M K; 90773-1-0-0 M K; 91684-2-0-0 M K; 89783-2-0-0 M K; 273004-1-0-0 M K; 101489-1-0-0 M K;  M K;  M K; 98564-1-0-0 M K;  M K; 881284-1-0-0 M K; 88327-1-0-0 M K; 96854-1-0-0 M K; 139379-1-0-0 M K; 82569-2-0-0 M K; 108335-0-0-0 M K; 102185-0-0-0 M K; 6763-0-0-0 M K; 185574-1-0-0 M K; 89192-0-0-0 M K; 95827-0-0-0 M K; 86344-1-0-0 M K; 109833-1-0-0 M K; 184599-0-0-0 M K; 195550-1-0-0 M K; 182803-1-0-0 M K; 221899-1-0-0 M K; 99051-1-0-0 M K; 161989-1-0-0 M K; 86228-1-0-0 M K; 157540-1-0-0 M K; 96319-1-0-0 M K; 88778-1-0-0 M K; 8218-1-0-0 M K; 102288-2-0-0 M K; 152390-1-0-0 M K; 103865-1-0-0 M K; 103054-0-0-0 M K; 100763-1-0-0 M K; 91319-0-0-0 M K; 100319-1-0-0 M K; 93611-0-0-0 M K; 725276-1-0-0 M K; 7903-0-0-0 M K; 98315-0-0-0 M K; 95529-1-0-0 M K; 106472-0-0-0 M K; 8313-1-0-0 M K; 76631-1-0-0 M K; 88752-1-0-0 M K; 104629-1-0-0 M K; 104616-1-0-0 M K; 109299-0-0-0 M K; 100837-1-0-0 M K; 88752-2-0-0 M K; 95307-1-0-0 M K; 95479-1-0-0 M K; 89459-1-0-0 M K; 36645-0-0-0 CL USE; 710281-0-0-0 CL USE; 451473-0-0-0 CL USE; 684249-2-0-0 CL USE; 86957-0-0-0 CL USE; 86827-0-0-0 CL USE; 86984-0-0-0 CL USE; 2068488-0-0-0 CL USE; 92112-0-0-0 CL USE; 141710-0-0-0 CL USE; 97449-0-0-0 CL USE; 89764-3-0-0 CL USE; 174423-1-0-0 CL USE; 89364-0-0-0 CL USE; 90453-0-0-0 CL USE; 15296-0-0-0 CL USE; 91216-0-0-0 CL USE; 93450-0-0-0 CL USE; 100188-0-0-0 CL USE; 99605-0-0-0 CL USE; 699916-1-0-0 CL USE; 106444-0-0-0 CL USE; 106444-2-0-0 CL USE; 911517-6-0-0 CL USE; 1337650-0-0-0 CL USE; 3151954-0-0-0 CL USE,,06384; 01391; 00137; 03549; 00976; 54107; 02572; 57428; 04757; 00998; 69392; 05595,R01844 M K; RA0137 M K; R01867 M K; RA181E M K; RA087A M K; RB2VJQ M K; RA00C8 M K; RA02HP M K; R00297 M K; RA76XE M K; RA01PS M K; RA6EY0 M K; RA8J7R M K; RANDZ5 M K; RBQ89G M K; RA17MT M K; RA2IPW M K; RA26NR M K; RA02D5 M K; RA4BMB M K; RA023U M K; RA0CHO M K; RA08C5 M K; R00035 M K; R01279 M K; R00971 M K; R00276 M K; R23238 M K; R04790 M K; R00195 M K; RA00TQ M K; R04421 M K; R04369 M K; R00034 M K; R20490 M K; R03057 M K; R01987 M K; R04845 M K; R04380 M K; R04847 M K; R03908 M K; R04393 M K; R20319 M K; R00076 M K; R02065 M K; R03008 M K; RA027G M K; R11733 M K; R00078 M K; RA06BH M K; R04427 M K; RA00N3 M K; R01693 M K; RA0CPW M K; R00990 M K; R01163 M K; R00179 M K; R22445 M K; R04686 M K; R07947 M K; R12329 M K; R01662 M K; R00282 M K; R08504 M K; R08510 M K; R06069 M K; RA0BZL M K; R09222 M K; RA03RA M K; R09596 M K; R09597 M K; RA0A96 M K; R01179 M K; R11001 M K; RA00TN M K; R13076 M K; R12870 M K; R01664 M K; R11260 M K; RB2NBN M K; RA1XA5 M K; RCSLM4 M K; RCQLVH M K; RAAMBT M K; RC4L4O M K; RAY1LR M K; R11111 M K; R01319 M K; RA5KFN M K; R10974 M K; RA03DJ M K; RA1DKG M K; R03812 M K; RA4VX6 M K; R04483 M K; R08508 M K; RANQ6B M K; R03245 M K; RA01IK M K; RA2YCC M K; RA1C6R M K; RA0GA7 M K; RA0AIC M K; RA17MV M K; RA02DL M K; RA0AIB M K; R03492 M K; RA1CVI M K; R00048 M K; R00047 M K; R11039 M K; R00184 M K; R10615 M K; RA01O7 M K; R01627 M K; R11283 M K; R11507 M K; RAAMMI M K; R00053 M K; R01723 M K; R06643 M K; R18850 M K; R00011 M K; R00068 M K; R01242 M K; R00067 M K; R00012 M K; R01071 M K; R00496 M K; R00002 M K; R06696 M K; R21762 M K; R06391 M K,1844-S; 1867-S; 0297-S; 0035-S; 1279-S; 0971-S; 0276-S; 0195-S; 0034-S; 1987-S; 0076-S; 2065-S; 0078-S; 1693-S; 0990-S; 1163-S; 0179-S; 1662-S; 0282-S; 1179-S; 1664-S; 1319-S; 0048-S; 0047-S; 1205-S; 0184-S; 1627-S; 0053-S; 1723-S; 0011-S; 0068-S; 1242-S; 0067-S; 0012-S; 1071-S; 0496-S; 0002-S
KR2022138058-A;  KR2576020-B1,"Health care mask system for use in respiratory            protection unit to prevent fine dust and bacterial            infection, has health management device and sensors            installed in mask, where signals of sensors are            transmitted to health management device",JEONG Y S,DONGSEO TECHNOLOGY HEADQUARTERS (DOGS-C),2022C9166G,"   NOVELTY - The system has health management device and                sensors installed in mask, where signals of sensors                are transmitted to health management device. A                health signal is transmitted from the device to a                smartphone by communicating with a remote server.                The system manages information for health                management by linking with a smartphone                application. A motion detection sensor is a gyro                sensor and an acceleration sensor, and a biometric                sensor is selected from breathing sensor, harmful                gas sensor, carbon dioxide sensor and a temperature                sensor. The mask is composed of a body made of                synthetic resin, which is a frame and a pad made of                cotton material.    USE - The health care mask system is useful for                respiratory protection unit to prevent fine dust                and bacterial infection.    ADVANTAGE - The infection of viruses such as Covid19 is                prevented. The immediate response to emergency                situations such as various respiratory diseases,                heart disease, and fever is enabled. The remarkable                effect of automatically sending and linking to the                registered institution server and follow-up actions                is achieved, by detecting whether you are                exercising or living in daily life with sensor data                and checking it with set data.    DESCRIPTION OF DRAWING(S) - The drawing shows a structural diagram of                operating environment of the health care mask                system (Drawing includes non-English language                text). ",,,"A96 (Medical, dental, veterinary, cosmetic.);  P31 (Diagnosis, surgery (A61B).);  P35 (Life-saving, fire-fighting (A62).);  S05 (Electrical Medical Equipment);  T01 (Digital Computers)",A03-A05;  A12-C02C;  P31-A05;  P35-A03E1;  S05-D;  S05-G02G2;  T01-J30D;  T01-N01B;  T01-N01D;  T01-N01E1,A61B-005/00;  A61B-005/01;  A61B-005/08;  A61B-005/11;  A62B-018/08;  G01D-021/02;  G16H-040/67;  G16H-050/30,KR2022138058-A   12 Oct 2022   G16H-040/67   202289Pages: 6   ;  KR2576020-B1   07 Sep 2023   G16H-040/67   202380   ,KR2022138058-A    KR043144    02 Apr 2021;   KR2576020-B1    KR043144    02 Apr 2021,,KR043144    02 Apr 2021,,,,,192545-0-0-0 ; 90356-0-0-0 ,,,R24078 ; R01852 ,
IN202211051481-A,"Computer-implemented method for providing            organizational agility for helping companies to take            advantage of artificial intelligence mechanism,            involves massively generating data through internet and            connected sensors",AARYA D D;  BOADH R;  BHAGAT R K;  RAJORIA Y K;  KUMAR D;  JENA P;  CHAUHAN A;  RATHEE A,AARYA D D (AARY-Individual);  BOADH R (BOAD-Individual);  BHAGAT R K (BHAG-Individual);  RAJORIA Y K (RAJO-Individual);  KUMAR D (KUMA-Individual);  JENA P (JENA-Individual);  CHAUHAN A (CHAU-Individual);  RATHEE A (RATH-Individual),2022C35531,"   NOVELTY - The method involves exponentially increasing                pace of environmental change at economic, social                and environmental levels during a COVID19 context.                Data is massively generated through internet and                connected sensors, where organizational agility is                the critical dynamic capability, which enables a                firm to sense environmental changes and to take                appropriate actions, and helps a company deal with                a rapidly changing environment, and areas of                artificial intelligence (AI) research include                knowledge presentations and logic, expert systems,                natural language, robotics, computer vision, neural                network and machine learning.    USE - Computer-implemented method for providing                organizational agility for helping companies to                take advantage of AI mechanism.    ADVANTAGE - The framework helps companies to take                advantage of AI mechanism or human resource                practices enablers to be agile and ultimately                ensure sustainable performance. The framework                combines human resource practices and AI mechanism                that allow the firm to sense an environment, make                better decisions and act effectively. The component                is related to a broad range of AI mechanism that                interact with a social component to increase                desired outcome, thus improving a firm's agility                level.    DESCRIPTION OF DRAWING(S) - The drawing shows a graph representing a                relationship between time and visibility of an AI                mechanism. ",,,T01 (Digital Computers);  W01 (Telephone and Data Transmission Systems),T01-J05B4P;  T01-J16C1;  T01-J16C2;  T01-J16C3;  T01-N01A2;  T01-N02B2B;  W01-A06A;  W01-B02,G06F-016/951;  G06N-003/04;  G06Q-010/06;  H04L-012/707;  H04Q-003/00,IN202211051481-A   16 Sep 2022   G06Q-010/06   202279Pages: 10   English,IN202211051481-A    IN11051481    09 Sep 2022,,IN11051481    09 Sep 2022,,,,,,,,,
IN202241047392-A,"Method for improving agility of organization to            capitalise on new opportunities, involves increasing            pace of environmental change at economic, social, and            environmental levels, especially during COVID19            context",RAJARATHNAM S;  GHOSH S;  GOSWAMI I;  SUMANGALA K;  RANA A;  PATEL P;  MALIK S;  BHANDWALKAR S S;  PANDURANG Y A;  SHARMA M;  AGRAWAL M;  SHUKLA A K,RAJARATHNAM S (RAJA-Individual);  GHOSH S (GHOS-Individual);  GOSWAMI I (GOSW-Individual);  SUMANGALA K (SUMA-Individual);  RANA A (RANA-Individual);  PATEL P (PATE-Individual);  MALIK S (MALI-Individual);  BHANDWALKAR S S (BHAN-Individual);  PANDURANG Y A (PAND-Individual);  SHARMA M (SHAR-Individual);  AGRAWAL M (AGRA-Individual);  SHUKLA A K (SHUK-Individual),2022C3537Y,"   NOVELTY - The pace of environmental change is increasing                exponentially at the economic, social, and                environmental levels, especially during the COVID19                context. The world is generating data massively                through the internet and all the connected sensors.                The Organisational agility is the critical dynamic                capability which enables the firm to sense                environmental changes and to take the appropriate                actions. The areas of artificial intelligence                research include knowledge presentations and logic,                expert systems, natural language, robotics,                computer vision, neural network and machine                learning. The robotics allow employees to                concentrate on higher-value jobs by automating                repetitive chores.    USE - Method for improving agility of organization                to capitalise on new opportunities.    ADVANTAGE - The framework helps companies to take                advantage of artificial intelligence technologies                or human resource practices enablers to be more                agile and ultimately ensure sustainable                performance. The framework combines human resource                (HR) practices and artificial intelligence (AI)                technologies that allow the firm to sense its                environment, make good decisions and act                effectively. The technical component is related to                the broad range of AI technologies that interact                with the social component, namely human resources                practices, to increase the desired outcome,                improving the firm's agility level.    DESCRIPTION OF DRAWING(S) - The drawing shows a graphical view of the                method for improving agility of                organization. ",,,T01 (Digital Computers);  W01 (Telephone and Data Transmission Systems),T01-J05B4P;  T01-J16C1;  T01-J16C2;  T01-J16C3;  T01-N01A2;  T01-N02B2B;  W01-A06A;  W01-B02,G06F-016/951;  G06N-003/04;  G06Q-010/06;  H04L-012/707;  H04Q-003/00,IN202241047392-A   16 Sep 2022   G06Q-010/06   202286Pages: 9   English,IN202241047392-A    IN41047392    19 Aug 2022,,IN41047392    19 Aug 2022,,,,,,,,,
LU102560-B1,"Radiator for use as e.g. high-speedclothes dryer            for ventilation and heating room, has L-shaped duct            supplying air to heat accumulators, and lower part            comprising fan allowing expulsion of warm and bacteria            or virus-free air",KNAUS-LOUIS R,KNAUS-LOUIS R (KNAU-Individual),2022C1788T,"   NOVELTY - The radiator has a housing (1) provided with a                first side wall (6A), a second side wall, an upper                part (8), a lower part (9), a front part (10) and a                rear part (11). The housing comprising a set of                thermal accumulators (2) positioned parallel to                each other and being separated by a suitable                distance forming a set of thermal channels (3)                allowing heat to circulate between the heat                accumulators. The housing comprises an opening (4A)                on the first side wall. The opening has an air                filter (4B) such that air passes through inside the                housing from outside the housing. An L-shaped duct                (5) supplies the air to the heat accumulators. The                lower part comprises a fan (12) allowing expulsion                of warm and bacteria or virus-free air from the                inside to the outside of the housing.    USE - Radiator for use as a high-speedclothes dryer                and an anti-Covid19 device for ventilation and                heating a room (all claimed).    ADVANTAGE - The radiator can kill bacteria and viruses,                The radiator is designed without dismantling and                building, saves energy, immediately heats floor                area if required, reduces heating cost and CO2,                performs heat, cool, dry clothes, ventilate and                store functions, reduced maintenance, improves room                ventilation and room beautification and provides                gentle night-time warm-up and rapid turbo                heat-up.    DESCRIPTION OF DRAWING(S) - The drawing shows a right side perspective                view of a radiator.    1Housing    2Thermal accumulators    3Thermal channels    4AOpening    4BAir filter    5L-shaped duct    6ASide wall    8Upper part    9Lower part    10Front part    11Rear part ",,,"Q74 (Heating, ranges, ventilating (F24))",Q74-A02A;  Q74-A02B;  Q74-T10,F24F-005/00;  F24F-008/108;  F24F-008/22;  F24H-007/04,LU102560-B1   25 Aug 2022   F24F-008/108   202282Pages: 8   German,LU102560-B1    LU102560    25 Feb 2021,,LU102560    25 Feb 2021,,,,,,,,,
IN202241045332-A,"Deep learning based early severity detection            framework for diagnosis of Covid19, by converting            Covid19 DNA sequence into RNA sequence, identifying            long non coding RNA sequence, detecting mutations and            predicting severity level",ANNEM R;  SINGARAJU J,ANNEM R (ANNE-Individual);  SINGARAJU J (SING-Individual),2022A9277E,"   NOVELTY - Deep learning based early severity detection                framework for diagnosis of Covid19 by using long                non coding RNA sequence comprises converting the                Covid19 DNA sequence into RNA sequence, identifying                the long non coding RNA sequence from Covid19 RNA                sequence, detecting the mutations in the long non                coding RNA sequence and predicting the severity                level by using its mutation rate, constructing a                deep learning model to find the severity of the                Covid19 disease and evaluating the proposed deep                learning framework with other deep learning                methods.    USE - The method is useful for deep learning based                early severity detection framework for diagnosis of                Covid19.    ADVANTAGE - The method indicates severity level of Covid19                disease in patients that is still unknown to reduce                death rate. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S05 (Electrical Medical Equipment);  T01 (Digital Computers)",B04-E07;  B04-E99;  B11-C08F7A;  B11-C11;  B12-K04F;  B12-K04G1B;  D05-H09;  D05-H18A;  D05-H99;  S05-C09;  S05-P;  T01-J06A1,C12N-015/113;  C12Q-001/6886;  G16B-030/00;  G16B-040/00;  G16H-050/20,IN202241045332-A   19 Aug 2022   C12N-015/113   202299Pages: 7   English,IN202241045332-A    IN41045332    09 Aug 2022,,IN41045332    09 Aug 2022,,,,,,,,,
CN114822869-A,"Method for extracting social media epidemic event            based on multi-task learning for use in e.g. fields of            social media, involves performing entity filling            prediction to epidemic event, and performing sentence            classification and prediction on epidemic event",XIE J,UNIV ZHEJIANG CITY COLLEGE (UZCC-C),2022A2237P,"   NOVELTY - The method involves extracting feature vectors                of text. The feature vectors are fused. Multi-task                combined training process is performed, where                multi-task comprises correlation prediction, entity                filling prediction and sentence classification                prediction. Related prediction is performed to an                epidemic event. Entity filling prediction is                performed to the epidemic event. Sentence                classification and prediction is performed on the                epidemic event. Sentence is input into a semantic                information characteristic extractor to extract                context feature vector. A character level feature                vector is extracted by using a character level                vector pre-training model.    USE - Method for extracting a social media epidemic                event based on multi-task learning for use in e.g.                fields of social media, knowledge map construction                and information-oriented artificial intelligence                development.    ADVANTAGE - The method enables obtaining multi-feature                fusion vectors by improving multi-task learning,                and adding an attention mechanism to enhance                information extraction capability of the model to                obtain accurate and effective information, so as to                utilize multi-task joint training to achieve                inter-task information sharing, task prediction,                enhanced Covid19 event extraction performance for                social media, thus ensuring achieved excellent                performance.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic block diagram                illustrating a method for extracting a social media                epidemic event based on multi-task learning.                (Drawing includes non-English language                text). ",,,S05 (Electrical Medical Equipment);  T01 (Digital Computers),S05-G02G9;  T01-J16C3;  T01-J16C1;  T01-J11A1;  T01-J06A1;  T01-J05B4P;  T01-J05B2;  T01-J04B2;  T01-F02,G06F-016/35;  G06F-040/295;  G06F-040/30;  G06N-003/04;  G16H-050/80,CN114822869-A   29 Jul 2022   G16H-050/80   202268   Chinese,CN114822869-A    CN10394552    13 Apr 2022,,CN10394552    13 Apr 2022,,,,,,,,,
IN202241039693-A,"Method for tracking firm's agility by using            artificial intelligence technologies, involves            increasing pace of environmental change exponentially            at economic, social, and environmental levels,            especially during COVID19 context",G T P;  S V;  EVANGELIN R M;  K S;  MAZHAR S S;  REHMAN A U;  TRIPATHY B;  DATTA A,G T P (GTPP-Individual);  S V (SVVV-Individual);  EVANGELIN R M (EVAN-Individual);  K S (KSSS-Individual);  MAZHAR S S (MAZH-Individual);  REHMAN A U (REHM-Individual);  TRIPATHY B (TRIP-Individual);  DATTA A (DATT-Individual),2022956153,"   NOVELTY - The pace of environmental change is increasing                exponentially at the economic, social, and                environmental levels, especially during the COVID19                context. The world is generating data massively                through the internet and all the connected sensors.                Organisational agility is the critical dynamic                capability which enables the firm to sense                environmental changes and to take the appropriate                actions. The organizational agility helps the                company deal with a rapidly changing environment.                The latter is characterized by volatility,                uncertainty, complexity, and ambiguity (VUCA).                Volatility is the pace, speed and volume of change.                The areas of artificial intelligence (AI) research                include knowledge presentations and logic, expert                systems, natural language, robotics, computer                vision, neural network and machine learning.    USE - Method for tracking firm's agility by using AI                technologies.    ADVANTAGE - The framework helps companies to take                advantage of AI technologies or human resource                practices enablers to be more agile and ultimately                ensure sustainable performance. The framework                combines human resource (HR) practices and AI                technologies that allow the firm to sense its                environment, make good decisions and act                effectively. The technical component is related to                the broad range of AI technologies that interact                with the social component, namely human resources                practices, to increase the desired outcome,                improving the firm's agility level.    DESCRIPTION OF DRAWING(S) - The drawing shows a graphical view                representing the process for tracking firm's                agility by using AI technologies. ",,,T01 (Digital Computers);  W01 (Telephone and Data Transmission Systems),T01-J05B4P;  T01-J16C1;  T01-J16C2;  T01-J16C3;  T01-N01A2;  T01-N02B2B;  W01-A06A;  W01-B02,G06F-016/951;  G06N-003/04;  G06Q-010/06;  H04L-012/707;  H04Q-003/00,IN202241039693-A   22 Jul 2022   G06Q-010/06   202266Pages: 9   English,IN202241039693-A    IN41039693    11 Jul 2022,,IN41039693    11 Jul 2022,,,,,,,,,
KR2022103262-A,"Transparent mask comprises body formed convexly in            direction opposite to face to have curve suitable for            covering nose and mouth, and edge is bent in direction            opposite to face in face contact portion in contact            with face",HO C J;  JEON B H;  KANG W,EVORAY (EVOR-Non-standard),2022940514,"   NOVELTY - Transparent mask comprises body (110) formed                convexly in a direction opposite to the face to                have a curve suitable for covering the nose and                mouth, and edge (111) is bent in the direction                opposite to the face in face contact portion. A                filter support portion (120) each protruding from                the center of the body in a direction opposite to                the face symmetrically left and right and one side                is respectively connected to the left and right of                the edge of the body by a connection part, and the                connection part (140) is bent in a direction                opposite to the face to be coupled and fixed to the                end surface of filter support part to mount filter                between the filter support part. A filter seat                portion is formed in a shape corresponding to the                end surface of the filter support portion and                filter cover (130) having more than one                through-holes formed in filter seating part and is                formed by vacuum forming transparent synthetic                resin sheet to integrally form body, filter support                part, and filter cover.    USE - The transparent mask is useful for filtering                air.    ADVANTAGE - The transparent mask covers the nose and mouth                of wearer to block dust, bacteria and viruses from                penetrating through breathing, prevents                transmission of various respiratory diseases e.g.                cold, Corona 19 virus (Covid19), novel influenza                (H1N1), and Middle East Respiratory Syndrome                (MERS), mask is easy to wear and efficient in                providing defensive measure.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for                manufacturing transparent mask.    DESCRIPTION OF DRAWING(S) - The drawing shows a perspective view of a                transparent mask.    110Body    111Edge    120Filter support portion    130Filter cover    140Connection part ",,,"A32 (Polymer fabrication - such as moulding, extrusion, forming, laminating, spinning.);  A82 (Coatings, impregnations, polishes - excluding textile finishing.);  A88 (Mechanical engineering and tools e.g. valves, gears and conveyor belts.);  G02 (Inks, paints, polishes  polymer-based paints and inks are also classified in Section A (C09D, F, G).);  P21 (Wearing apparel (A41, A42).);  P35 (Life-saving, fire-fighting (A62).)",A11-B08A;  A12-C02C;  A12-V03C1;  G02-A05;  P21-F;  P21-M;  P21-N;  P35-A03E1,A41D-013/11;  A62B-018/02;  A62B-023/02;  B29C-051/10;  B29C-051/42;  B29K-101/12;  C08L-101/00;  C09D-005/00,KR2022103262-A   22 Jul 2022   A62B-018/02   202273Pages: 14   ,KR2022103262-A    KR005648    15 Jan 2021,,KR005648    15 Jan 2021,,,,,368-0-0-0 ; 395-0-0-0 ; 129411-0-0-0 ; 1145-0-0-0 ; 621-0-0-0 ; 7200-0-0-0 ,,,R00708 ; R00817 ; R00806 ; R00964 ; R00338 ; R00479 ,
KR2022098067-A,"Producing corona virus vaccine, useful for            immunizing laying chickens through producing egg yolk            comprises infecting virus isolated with cells and            culture-proliferating it as cell maintenance medium,            recovering and centrifuging cells",HYUK J;  JOO H S;  CHOI Y,HYUK J (HYUK-Individual);  JOO H S (JOOH-Individual),202290127G,"   NOVELTY - Producing corona virus (COVID19) vaccine,                comprises (i) infecting the COVID19 virus isolated                with cells from which the cell growth medium is                removed and culture-proliferating it as a cell                maintenance medium; (ii) recovering and                centrifuging the cells at the initial stage of cell                degeneration during the passage; (iii) inactivating                the virus while isolating the coat protein of the                COVID19 virus from the recovered cells; (iv) mixing                the fluorinated COVID19 virus containing the                isolated envelope protein and an immune                enhancer.    USE - The vaccine is useful for immunizing laying                chickens through producing egg yolk as functional                food (all claimed); and for preventing virus                infection.    ADVANTAGE - The method provides vaccine that can generate                high titer antibodies by maximally increasing                antigenic force of COVID19 virus and inoculating                vaccine to laying hens by using immunity of                chickens. The vaccine can be directly ingested                after half-boiled cooking, and can be added to                various foods, beverages and applied products to                neutralize and inactivate virus.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included                for:    (1) COVID19 virus vaccine produced by the                above method; and    (2) egg yolk comprising a viral antibody from                a laying hen immunized with the vaccine. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B03 (Other heterocyclics.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  C02 (Heterocyclic.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).)",B04-B01C3;  B04-F01;  B04-G08;  B10-E04B;  B14-G01;  B14-S11A;  B14-S12;  B14-S18;  C04-B01C3;  C04-F01;  C10-E04B;  C14-G01;  C14-S11A;  C14-S12;  C14-S18;  D03-H01T2B;  D03-M;  D05-H07,A23L-015/00;  A23L-033/17;  A61K-039/00;  A61K-039/215;  A61K-039/39;  A61P-031/14;  C07K-001/12;  C07K-014/005;  C07K-016/02,KR2022098067-A   11 Jul 2022   A61K-039/215   202263Pages: 10   ,KR2022098067-A    KR190071    31 Dec 2020,,KR190071    31 Dec 2020,,,,,103242-0-0-0 K M; 131343-0-0-0 K M,,,RA0218 K M; R08416 K M,
BR202020024387-U2,"Airport baggage cart sanitizing device for disease            control, has liquid waste collection system which is            provided to prevent wetting of floor of site and wheels            of trolleys through two levels of chute, and provided            for suctioning liquid residue collected by chute",SCHMIDT K B;  DIOGENES SOARES C,MARKET CLEAN COMERCIO E SERVICOS SANITIZACAO E              HIGIENIZACAO (MARK-Non-standard),2022C9051Y,"   NOVELTY - The device has atomization chamber that is                provided with two curtains in PVC strips. In-line                arc-shaped atomization system of sanitizing                substance is formed by 4 atomizing nozzles, an air                compressor and a chemical reservoir. An optical                sensor is provided for initiating the atomization                system. A liquid waste collection system is formed                by a trough at two levels. The in-line arc-shaped                atomization system is provided to allow a thin and                uniform layer of particles of sanitizing substance                to be applied to the baggage carts in only 6                seconds. PVC strip curtains are provided to prevent                dispersion of the atomized mist. The liquid waste                collection system is provided to prevent wetting of                the floor of the site and the wheels of the                trolleys through the two levels of the chute, and                is provided for suctioning the liquid residue                collected by the chute, and storing the residue in                the reservoir through the pump.    USE - Airport baggage cart sanitizing device for                disease control (covid19).    ADVANTAGE - The self-service for sanitizing airport                baggage carts is provided, the passenger is allowed                to handle the carts more safely, the risk of                contact is reduced with contaminants during loading                and unloading.    DESCRIPTION OF DRAWING(S) - The drawing shows a perspective view of the                airport baggage cart sanitizing device.    1Sanitizing device    20Luggage cart    21Handle    22Airport baggage cart ",,,"J04 (Chemical/physical processes/apparatus - including catalysis, catalysts (excluding specific e.g. enzymatic or polymerisation catalysts), colloid chemistry, laboratory apparatus and methods, testing, controlling, general encapsulation, detection and sampling (excluding clinical testing) (B01J, L).);  A97 (Miscellaneous goods not specified elsewhere - including papermaking, gramophone records, detergents, food and oil well applications.);  D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).);  P34 (Sterilising, syringes, electrotherapy (A61L, M, N).)",J04-A05;  A04-E02E;  A12-V03C1;  D09-A01;  P34-A01;  P34-A02,A61L-002/00;  A61L-002/20;  A61L-002/22;  B01J-002/04,BR202020024387-U2   07 Jun 2022   B01J-002/04   202304Pages: 11   ,BR202020024387-U2    BR20024387    30 Nov 2020,,BR20024387    30 Nov 2020,,,,,621-0-0-0 ,,,R00338 ,
WO2022111558-A1;  CN114533677-A;  EP4251137-A1;  JP2023551056-W;  US2024016747-A1,"Solid dispersion useful in preparing drugs for            treating hyperproliferative diseases e.g. acute            monocytic leukemia, acute myelogenous leukemia, and            chronic myelogenous leukemia, comprises carriers and            active ingredients",LIN Y;  XU H;  XU F;  WU C;  GUO H;  HE X,ASCENTAGE PHARMA SUZHOU CO LTD (ASCE-Non-standard);  ASCENTAGE PHARMA GROUP CORP LTD (ASCE-Non-standard);  SUZHOU ASCENTAGE PHARMA CO LTD (SUZH-Non-standard);  ASCENTAGE PHARMA GROUP CORP LTD (ASCE-Non-standard);  ASCENTAGE PHARMA SUZHOU CO LTD (ASCE-Non-standard);  ASCENTAGE PHARMA GROUP CORP LTD (ASCE-Non-standard);  ASCENTAGE PHARMA GROUP CORP LTD (ASCE-Non-standard);  ASCENTAGE PHARMA SUZHOU CO LTD (ASCE-Non-standard),202274706A,"   NOVELTY - Solid dispersion comprises carriers and active                ingredients, and the active ingredients is                (S)-N-(4-((1,4-dioxan-2-yl)methylamino)-3-nitrophenylsulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)-4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)piperazin-1-yl)benzamide                (I), the carrier is homopolymer and copolymer of                N-vinyl lactam and/or pH-dependent cellulose                derivatives.    USE - The solid dispersion is useful in preparing                drugs for treating hyperproliferative diseases                including acute monocytic leukemia, acute                myelogenous leukemia, chronic myelogenous leukemia,                chronic lymphocytic leukemia, mixed lineage                leukemia, NUT-midline cancer, multiple myeloma,                small cell lung cancer, neuroblastoma, lymphoma,                cervical cancer, esophageal cancer, ovarian cancer,                colorectal cancer, prostate cancer and breast                cancer (all claimed). No biological data                given.    ADVANTAGE - The solid dispersion has good dissolution and                stability, and can significantly improve the                stability and bioavailability of                (S)-N-(4-((1,4-dioxan-2-yl)methylamino)-3-nitrophenylsulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)-4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)piperazin-1-yl)benzamide.    DETAILED DESCRIPTION - Solid dispersion comprises carriers and active                ingredients, and the active ingredients is                (S)-N-(4-((1,4-dioxan-2-yl)methylamino)-3-nitrophenylsulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)-4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)piperazin-1-yl)benzamide                of formula (I) and/or its salts, the carrier is                homopolymer and copolymer of N-vinyl lactam and/or                pH-dependent cellulose derivatives. INDEPENDENT                CLAIMS are also included for:    (1) preparing solid dispersion, comprising                either (A) mixing at least one (I), or its salts,                crystal forms and solvates, and other constituents                with a solvent to form a solution or suspension,                removing the solvent to obtain the solid                dispersion, (B) mixing mixing at least one (I), or                its salts, crystal forms and solvates, and other                constituents, heating and extruding to obtain the                solid dispersion, or (C) mixing at least one (I),                or its salts, crystal forms and solvates, and other                constituents, and mixing with the solvent, spray                drying to obtain the solid dispersion;    (2) preparation comprising the solid                dispersions, fillers and disintegrating agents;                and    (3) preparing preparation, comprising mixing                the constituents of the preparation. ",,,"A96 (Medical, dental, veterinary, cosmetic.);  B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B02 (Fused ring heterocyclics.)",A12-V01;  B04-C02A1;  B04-C02A2;  B04-C02B2;  B04-C03;  B05-A01B;  B05-B02A3;  B06-D05;  B07-A02B;  B10-G02;  B12-M14;  B14-H01;  B14-L06;  B14-S18,A61K-031/437;  A61K-009/20;  A61P-035/00;  A61K-031/635;  A61K-047/32;  A61K-047/38;  A61K-009/14;  A61K-009/36;  A61P-035/02;  A61K-031/496;  A61K-047/02;  A61K-047/12;  A61K-047/26;  A61K-047/34;  A61K-047/36;  A61K-047/10;  A61K-009/28,WO2022111558-A1   02 Jun 2022   A61K-009/20   202253Pages: 61   English;  CN114533677-A   27 May 2022   A61K-009/14   202253   Chinese;  EP4251137-A1   04 Oct 2023   A61K-009/20   202381   English;  JP2023551056-W   06 Dec 2023   A61K-031/496   202398   Japanese;  US2024016747-A1   18 Jan 2024   A61K-009/28   202407   English,WO2022111558-A1    WOCN132990    25 Nov 2021;   CN114533677-A    CN11409705    25 Nov 2021;   EP4251137-A1    EP897058    25 Nov 2021;   JP2023551056-W    JP532648    25 Nov 2021;   US2024016747-A1    US18038628    24 May 2023,EP4251137-A1 PCT application Application WOCN132990;   EP4251137-A1 Based on Patent WO2022111558;   JP2023551056-W PCT application Application WOCN132990;   JP2023551056-W Based on Patent WO2022111558;   US2024016747-A1 PCT application Application WOCN132990,CN11343661    25 Nov 2020;  WOCN131357    25 Nov 2020,WO2022111558-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP4251137-A1:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  KH;  LI;  LT;  LU;  LV;  MA;  MC;  MD;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TN;  TR      ,,";  CN114533677-A -- CN103167867-A   ABBOTT LAB (ABBO)   CATRON N D,  LINDLEY D J,  MILLER J,  SCHMITT E A,  TONG P;  CN103282025-A   ABBOTT LAB (ABBO)   BIRTALAN E,  HOELIG P,  LINDLEY D J,  SANZGIRI Y D,  TONG P;  CN107648185-A   CHANGZHOU AINUO XINRUI PHARM TECHNOLOGY (CHAN-Non-standard)   ZHANG X,  XIONG Z,  ZHOU T,  TU F,  XIONG L;  WO2018027097-A1   UNIV MICHIGAN (UNMI)   WANG C W,  CHEN J",,1062-0-0-0 K M; 104491-0-0-0 K M; 104488-0-0-0 K M; 114325-0-0-0 K M; 99074-0-0-0 K M; 109100-1-0-0 K M; 114599-0-0-0 K M; 104479-0-0-0 K M; 90356-0-0-0 K M; 107779-0-0-0 K M;  K M; 56978-2-0-0 K M; 3113-0-0-0 K M; 109324-0-0-0 K M; 444-0-0-0 ; 829-0-0-0 ,,00263; 00834; 01272,RA00D5 K M; RA012N K M; RA04WZ K M; R16922 K M; RA0NLS K M; RA0167 K M; RA0CQN K M; RA02AR K M; R01870 K M; R01852 K M; R01863 K M; RD778X K M; R00241 K M; R01748 K M; R01757 K M; RA00D3 K M; R00351 ; R00835 ,1870-S; 1852-S; 1863-S; 0241-S; 1748-S; 1757-S
US2022155280-A1,"System for monitoring cabin air by collecting            biological sample of passenger cabin on aircraft, has            collector for collecting particulate samples, and            outflow valve positioned in outlet flow path downstream            from collector or high efficiency particulate air            filter",GONZALEZ A C;  KRENZ M,KONINK FAB INVENTUM BV (INVE-Non-standard),2022678372,"   NOVELTY - The system (100) has a collector (102) for                collecting particulate samples positioned within an                outlet flow path (104) or a recirculation flow path                (106), where the collector includes a filter                material (112). An outflow valve (108) is                positioned in an outlet flow path downstream from                the collector or a high efficiency particulate air                (HEPA) filter positioned in a recirculation flow                path downstream from the collector, where the                collector includes the filter material. The HEPA                filter is configured and adapted to clean air                flowing through the recirculation flow path. An                adapter (114) is a frame, where the filter material                is mounted to the frame.    USE - System for monitoring cabin air by collecting                a biological sample of a passenger cabin on an                aircraft.    ADVANTAGE - The system is safe, and achieves better                monitoring, detecting, and isolating of ill                passengers specifically due to detrimental impact                on global economy to prevent spread of corona                virus-19 (COVID19) and pathogens during travel such                as air travel and rail travel due to closed                borders, movement restrictions, and testing                requirements to suitable for aircraft cabins with                well-managed airflow that inhibits transmission of                virus and that being seated onboard an aircraft is                safer than shopping in large stores.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method                for collecting particulates from cabin air.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view of a                system for monitoring aircraft air.    Cabin air monitoring system (100)    Collector (102)    Outlet flow path (104)    Recirculation flow path (106)    Outflow valve (108)    Filter material (112)    Adapter (114) ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  S03 (Scientific Instrumentation);  W06 (Aviation, Marine and Radar Systems)",B11-C08C;  B12-K04E2;  B11-C06Z;  S03-E14H9;  W06-B01C,B64D-013/08;  G01N-033/497,US2022155280-A1   19 May 2022   G01N-033/497   202250   English,US2022155280-A1    US518458    03 Nov 2021,US2022155280-A1 Provisional Application US114330P;   US2022155280-A1 Provisional Application US114339P;   US2022155280-A1 Provisional Application US114350P;   US2022155280-A1 Provisional Application US114064P;   US2022155280-A1 Provisional Application US114366P;   US2022155280-A1 Provisional Application US114157P;   US2022155280-A1 Provisional Application US114386P;   US2022155280-A1 Provisional Application US114400P,US114064P    16 Nov 2020;  US518458    03 Nov 2021,,,"US2022155280-A1 -- US20030189132-A1   ;  US20120122075-A1   ;  US20120219462-A1   ;  US20160025603-A1   ;  US20220034854-A1   ;  US20220048633-A1   ;  US20220065789-A1   ;  US10786693-B1   ORBITAL RES INC (ORBI-Non-standard);  OPPERMAN A (OPPE-Individual);  LISY F J (LISY-Individual)   OPPERMAN A,  LISY F J",,,,,,
US2022157458-A1;  US11430575-B2,"System for facilitating data driven disease test            result prediction, has computing device for comparing            aggregation of infectivity parameters to retest target            threshold and determining confidence metric as function            of comparison",HAASE W H;  MOHIUDDIN O,SPECIALTY DIAGNOSTIC SDI LAB INC (SPEC-Non-standard),202268824G,"   NOVELTY - The system comprises a computing device (104)                that receives user data (108), generates training                data (112) as a function of the user data, trains a                machine-learning model (116) as a function of the                training data and a machine-learning process,                calculates multiple infectivity parameters (120) as                a function of the user parameter and the trained                machine-learning model, compares an aggregation of                the infectivity parameters to a retest target                threshold (136), and determines a confidence metric                (144) as a function of the comparison. The training                data includes multiple entries. Each entry                correlates user parameter data to a prediction                parameter associated with an infectious disease.                The machine-learning model is trained to input the                user data and output multiple infectivity                parameters, which include a likelihood parameter                (124), a severity parameter (128), and a prevalence                parameter (132). The confidence metric informs a                testing protocol (140).    USE - System for data driven disease test result                prediction of an infectious disease, such as                Coronavirus (COVID19).    ADVANTAGE - The system provides a safe, effective, and                routine testing platform for a data driven disease                test result prediction in an effective manner. The                system utilizes a cloud computing as a model of                service delivery for enabling convenient, on-demand                network access to a shared pool of configurable                computing resources that can be rapidly provisioned                and released with minimal management effort or                interaction with a provider of the service. The                cloud computing environment is allowed to offer                infrastructure, platforms and/or software as                services for which a cloud consumer does not need                to maintain resources on a local computing                device.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method                for a data driven disease test result                prediction.    DESCRIPTION OF DRAWING(S) - The drawing shows a block diagram of a system                of a data driven test result prediction algorithm                for infectious disease.    Computing device (104)    User data (108)    Training data (112)    Machine-learning model (116)    Infectivity parameter (120)    Likelihood parameter (124)    Severity parameter (128)    Prevalence parameter (132)    Retest target threshold (136)    Testing protocol (140)    Confidence metric (144) ",,,S05 (Electrical Medical Equipment);  T01 (Digital Computers),S05-G02G9;  S05-G02G2;  S05-G02G1;  T01-N01E1;  T01-N01D3A;  T01-J04B2;  T01-E01C,G16H-010/60;  G16H-050/20;  G16H-050/30;  G16H-050/80,US2022157458-A1   19 May 2022   G16H-050/20   202244   English;  US11430575-B2   30 Aug 2022   G16H-050/20   202270   English,US2022157458-A1    US097083    13 Nov 2020;   US11430575-B2    US097083    13 Nov 2020,US11430575-B2 Previous Publ. Patent US2022157458,US097083    13 Nov 2020,,702/019000;  705/002000;  705/003000;  705/019000,";  US11430575-B2 -- US20080091471-A1   ;  US20100324936-A1   ;  US20160125158-A1   ;  US20180214088-A1   ;  US20200013488-A1   ;  US20200388347-A1   ;  US20210050116-A1   ;  US20210248268-A1   ;  US11195595-B2   SCIPHER MEDICINE CORP (SCIP-Non-standard)   GHIASSIAN S D,  MELLORS T R,  SANTOLINI M,  AMELI A,  SCHOENBRUNNER N,  AKMAEV V R,  JOHNSON K J;  US5366896-A   UNIV VIRGINIA PATENTS FOUND (UVIR)   ROBERTS J H,  FELDER R A,  SAVORY J,  MARTINEZ A,  MARGREY K S,  BOYD J C,  HOLMAN J W;  US5968731-A   UNIV CALIFORNIA (REGC)   LAYNE S P,  BEUGELSDIJK T J;  US20180286497-A1   ;  US20200081023-A1   ;  US20200124868-A1   ;  US6702988-B1   QUEST DIAGNOSTICS INVESTMENTS INC (QUDI)   SAGONA P J,  O'BRYAN D P;  US7666355-B2   NOVX SYSTEMS INC (NOVX-Non-standard)   ALAVIE T,  BECKLEY K,  HUDSON A,  LEONARD S W,  MAASKANT R,  TALEBPOUR S,  YANG W;  US8107693-B2   IRIS BIOTECHNOLOGIES INC (IRIS-Non-standard)   OSBORNE G F,  CHIN S,  MCDONALD P,  SCHNEIDER S;  US8234129-B2   BIOVERIS CORP (HOFF)   MICHON F,  MOORE S L,  FUSCO P C,  WOHLSTADTER S J,  DAVIS C Q,  COLEMAN D,  SHETTY S,  TRAPATHI V,  JOSHI K;  US8357538-B2   QIAGEN (QIAG)   GODSEY J H,  SELF B A;  US8862448-B2   THERANOS INC (THRN)   HOLMES E A,  GIBBONS I,  YOUNG D L,  MICHELSON S G;  US9958466-B2   BECTON DICKINSON & CO INC (BECT)   DALBERT C R,  KRAYER J D,  STEEL A B,  ROY D;  US10088460-B2   THERMO FISHER SCI OY (THME)   DEWITTE R,  SIIDOROV J,  NUOTIO V,  SALMINEN R,  VEHKOMAKI J,  SAUKKONEN J,  OSTMAN B,  SENTENO J M,  BRANN J E,  HERMAN J L,  ZONDERMAN J A,  OLNEY T N;  US10283217-B2   THERANOS INC (THRN)   BELHOCINE K,  GANGAKHEDKAR S,  HOLMES E,  LEE J,  LUI C,  MENZES S,  PATEL P,  RICHARDSON A,  SIVARAMAN S,  TABAKMAN S;  WO2019102282-A1   GRIFOLS DIAGNOSTIC SOLUTIONS INC (GRFO)   TRAN Q,  WUMMER J,  CODY D;  WO2017143182-A2   BECTON DICKINSON & CO (BECT)   VANSICKLER M T,  BAILEY K,  TESLUK C J,  LIVINGSTON D,  ROTUNDO S C,  LACHANCE S R,  TOUMA M J,  MCKEEN B J,  SEVIGNY G",US11430575-B2            https://fpf.org/2020/05/07/artificial-intelligence-and-the-covid-19-pandemic/.,,,,,
IN202241025410-A,"Method for screening and tracking of Covid19 infected persons face scans using deep learning algorithms, involves taking inputs from dual mode cameras such as thermal scanning and face scan images",CHINNASAMY P;  DEEPALAKSHMI P;  RAO S K;  ANUPRIYA E;  ARULANANTH T S;  SIVAKUMAR E;  KIRAN A;  USHA M,MLR TECHNOLOGY INST (MLRT-Non-standard),2022687409,   NOVELTY - The method involves taking the inputs from dual mode cameras such as thermal scanning camera input (1) as well as face scan images (5). The threshold value of thermal threshold detection (2) is given to a decision-making system (3) to check a positive label (8) and a negative label (4). A face scan detection and tracking system (6) using deep learning algorithms (7) to check the decision of input images based on the face scans inputs.    USE - Method for screening and tracking of Covid19 infected persons face scans using deep learning algorithms.    ADVANTAGE - The method enables utilizing deep learning methods to build powerful face recognition systems capable of identifying and verifying features of the infected person with high accuracy. The CNN model using collected dataset to increase the accuracy in cloud system.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic diagram of the system for screening and tracking of Covid19 infected persons face scans using deep learning algorithm.    Thermal scanning camera input (1)    Thermal threshold detection (2)    Decision-making system (3)    Negative label (4)    Face scan image (5)    Face scan detection and tracking system (6)    Deep learning algorithm (7)    Positive label (8) ,,,"S05 (Electrical Medical Equipment);  T01 (Digital Computers);  W02 (Broadcasting, Radio and Line Transmission Systems)",S05-D02X;  S05-G02G9;  T01-J06A1;  T01-J10B2A;  T01-J16C1;  W02-F01,G06K-009/00;  G06K-009/62;  G06N-003/04;  G16H-050/80;  H04N-007/18,IN202241025410-A   13 May 2022   G06K-009/00   202247Pages: 6   English,IN202241025410-A    IN41025410    30 Apr 2022,,IN41025410    30 Apr 2022,,,,,,,,,
US2022141298-A1;  WO2022098651-A1;  CA3200515-A1;  EP4241251-A1,"System for administering online examination of            e.g. student of higher education by considering events            of home schooling utilizing e.g. smartphone through            accessible online examination platform, has processor            for determining whether the user pose is indicative of            improper examination behavior",DAWICKI A M;  SHETTY A K;  DAWICKI E R,NORTHEAST MARITIME INST INC (NEMA-Non-standard);  NORTHEAST MARITIME INST INC (NEMA-Non-standard);  NORTHEAST MARITIME INST INC (NEMA-Non-standard),2022608511,"   NOVELTY - The system has a processor (1210) for                performing a pre-examination scan of an environment                of a user based on first image data of an                environment of the user received from a camera,                initiating online examination by generating a user                interface for display on an examination screen in                responsive to the pre-examination scan indicating                the environment is appropriate for test taking,                estimating multiple poses of the user based on                second image data of the user while using the user                interface, determining whether the user pose is                indicative of improper examination behavior, and                generating a warning or terminate online                examination based on the improper examination                behavior.    USE - System for administering online examination of                a user i.e. student of higher education, technical                training and education programs by considering                events utilizing a client computing device i.e.                computing device, such as a smartphone, laptop or                personal computer (PC), and a tablet device through                an accessible online examination platform. Uses                include but are not limited to events of                Coronavirus disease-19 (COVID19), scholastic                assessment test (SAT) cheating schemes,                homeschooling and professional license exam                continuity.    ADVANTAGE - The system provides the user with the                accessible online examination platform that                includes a video monitoring feature to ensure                integrity of the examination environment and/or                examination process, thus offering an integral and                efficient examination proctoring solution.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method                for administering an online examination of a                user.    DESCRIPTION OF DRAWING(S) - The drawing shows a block diagram of a system                for administering online examination of a                user.    Computer system (1200)    Processor (1210)    Memory (1220)    Non-volatile storage device (1230) ",,,T01 (Digital Computers);  W01 (Telephone and Data Transmission Systems);  W04 (Audio/Video Recording and Systems),T01-N02B2;  T01-N01B3A;  T01-J16C2;  T01-J12B;  W01-C01G8S;  W01-C01G8A;  W01-C01D3C;  W04-W05A,G06K-009/00;  G06N-020/00;  G06T-007/70;  G09B-005/08;  H04L-029/08;  G06K-009/68;  G06V-010/75,US2022141298-A1   05 May 2022   H04L-029/08   202242   English;  WO2022098651-A1   12 May 2022   G06K-009/68   202242   English;  CA3200515-A1   12 May 2022   G06K-009/68   202346   English;  EP4241251-A1   13 Sep 2023   G06V-010/75   202375   English,US2022141298-A1    US516991    02 Nov 2021;   WO2022098651-A1    WOUS057722    02 Nov 2021;   CA3200515-A1    CA3200515    02 Nov 2021;   EP4241251-A1    EP889914    02 Nov 2021,US2022141298-A1 Provisional Application US109217P;   CA3200515-A1 PCT application Application WOUS057722;   CA3200515-A1 Based on Patent WO2022098651;   EP4241251-A1 PCT application Application WOUS057722;   EP4241251-A1 Based on Patent WO2022098651,US109217P    03 Nov 2020;  US516991    02 Nov 2021;  CA3200515    03 May 2023,  WO2022098651-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP4241251-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN  ,,;  WO2022098651-A1 -- US20140222995-A1   ;  US20190197911-A1   ,,,,,,
DE202020106796-U1,"Mask adapter used as add-on module for respirator of special design, e.g. FP1 mask, provides protection against air pollutants of all kinds, including viruses of type Covid19, is provided for detection, treatment and storage of respiratory components",,BIENENHAUS GUG (BIEN-Non-standard),2022495166,"   NOVELTY - The adapter is provided as add-on module for respirator of conventional or special design, such as FP1 mask. The adapter for protection against air pollutants of all kinds, including viruses of the type Covid19, is provided for the detection, treatment and storage of respiratory components and their evaluation, as required, separately according to inhalation and exhalation or only after inhalation or exhalation, which is stored on an easily exchangeable storage medium for further treatment. The separation of inhalation and exhalation through one-way valves or similar measures separate air ducts is available in the form of hollow bodies in any shape and any material for fixed or easily replaceable connection to a conventional protective mask.    USE - Mask adapter used as add-on module for respirator of conventional or special design, such as FP1 mask and for protection against air pollutants of all kinds, such as viruses of the type Covid19.    ADVANTAGE - The reliable quality statement is hardly possible, and a uniform quality standard is excluded due to the large number of participants, different handling and evaluation from the sample name to the transmission of the result. All steps are carried out apart from the handling of the mask by the mask wearer himself, according to a uniform standard without the possibility of accidental or intentional external intervention. The gripping hand is contaminated with viruses at any time without risk or consequences. The frequent delays or limitations when capacities are exceeded, which are eliminated by continuous sampling when using the protective mask. The accumulation of viruses on the outer surface of the mask is avoided due to largely uninhibited air flow and continuous virus killing within the adapter. The cumulative measurement of components in the air in the manner of a dosimeter for radioactivity through their reactions with reagents or duct wall coatings within the respective air duct and the biochemical and digital storage of the result values is determined on an easily exchangeable storage medium. The lowest possible air resistance for inhalation and exhalation is mainly achieved through the design without the use of mechanical filtering through fleece and textiles. The easier breathing and general use of the mask result in greater acceptance of wearing the mask and greater overall safety. The exclusive and controlled inhalation and exhalation is made through the adapter while avoiding leaks between the mask and face. The source of each individual is provided in order to initiate the most important measures to destroying/killing the virus. The continuous dosimeter-type testing/measuring of radioactivity is provided using an adapter connected to the protective mask. ",,,"P35 (Life-saving, fire-fighting (A62).)",P35-A03C;  P35-A03E1,A62B-018/02;  A62B-018/08,DE202020106796-U1   07 Apr 2022   A62B-018/02   202238Pages: 7   German,DE202020106796-U1    DE20106796    25 Nov 2020,,DE20106796    25 Nov 2020,,,,,,,,,
CN114272360-A,"Traditional Chinese medicine and western medicine composition for inhibiting coronavirus and resisting virus, comprises beta-scutellarin, cephalotaxine, phillyrin, ritonavir, darunavir, raltegravir, recombinant human interferon d-2b, nimustine, oseltamivir and amantadine",MEI X,MEI X (MEIX-Individual),202251866S,"   NOVELTY - Traditional Chinese medicine and western medicine composition comprises beta-scutellarin, cephalotaxine, phillyrin, ritonavir, darunavir, raltegravir, recombinant human interferon d-2b, nimustine, oseltamivir and amantadine.    USE - Traditional Chinese medicine and western medicine composition for inhibiting coronavirus and resisting virus    ADVANTAGE - The traditional Chinese medicine and western medicine composition has inhibitory effect on topoisomerase activity, interferes with ribosome function, inhibits influenza virus neuraminidase, prevents RNA virus from penetrating host cell and has an inhibitory effect on coronavirus COVID19. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B06-E05;  B14-S18;  B04-H0500E;  B06-A01;  B06-A02;  B07-F01;  B07-D12;  B10-B02F;  B07-E04;  B09-D01;  B14-D09;  B14-D07B;  B14-A02;  D05-H17A2,A61K-031/13;  A61K-031/215;  A61K-031/34;  A61K-031/365;  A61K-031/427;  A61K-031/505;  A61K-031/513;  A61K-031/55;  A61K-031/7048;  A61K-038/21;  A61P-031/14,CN114272360-A   05 Apr 2022   A61K-038/21   202256   Chinese,CN114272360-A    CN11168235    29 Sep 2021,,CN11168235    29 Sep 2021,,,,,139379-1-0-0 M K; 90414-0-0-0 M K; 227076-1-0-0 M K; 86228-1-0-0 M K; 182803-1-0-0 M K; 1320477-0-0-0 M K; 102041-0-0-0 M K; 160569-1-0-0 M K; 87119-0-0-0 M K,,42771; 00999; 00998; 00085; 03624,RA5KFN M K; RA0SI0 M K; RA1UIQ M K; RA02DL M K; RA1C6R M K; RAN0P1 M K; R21383 M K; RA01FU M K; R01452 M K,1452-S
IN202241017796-A,"Touchless automated teller machine (ATM) machine displays ATM screen showing quick response code which is scanned using specified bank application, shows all options in mobile phone after scanning, enters transaction details and generates Dynamic PIN by Google Authenticator",MEENA M;  KUMAR P M;  KARTHIKA R;  AMBIKA M;  ANANDHI G;  SOWMYA M;  SANTHOSHKUMAR S P;  GEETHANJALI N,KUMAR P M (KUMA-Individual),202250831Y,"   NOVELTY - The ATM machine displays the ATM screen which shows Barcode and skip option. The ATM screen for physical use is displayed when skip option is entered. The quick response (QR) code shown in the ATM screen is scanned in mobile using the specified bank application. All the options in ATM are shown in the mobile phone, after scanning. The transaction details are entered through user mobile phone. The Dynamic PIN is generated by Google Authenticator (RTM: software-based authenticator by Google) and sent to the registered mobile number. The money is ejected from ATM, after all the inputs completed.    USE - Touchless ATM machine.    ADVANTAGE - The touchless actions with the ATM are achieved during the COVID19 situation to prevent the spreading of virus. Since the dynamic PIN is produced and sent the same to registered mobile number, the online robbery cases are reduced.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic diagram illustrating the operation of the touchless ATM machine. ",,,"T01 (Digital Computers);  T05 (Counting, Checking, Vending, ATM and POS Systems);  W01 (Telephone and Data Transmission Systems)",T01-N01A1;  T01-N01A2;  T01-N02B1;  T01-N03A2;  T05-L01C;  T05-L01D;  T05-L02;  T05-L03C5;  W01-C01D3C,G06Q-010/00;  G06Q-020/18;  G06Q-020/32;  G07F-019/00;  G07G-003/00,IN202241017796-A   01 Apr 2022   G07F-019/00   202235Pages: 3   English,IN202241017796-A    IN41017796    28 Mar 2022,,IN41017796    28 Mar 2022,,,,,,,,,
US2022101305-A1,"Method for mobile navigational control of            transaction terminal UIs, involves providing UI events            as HID events for HID type supported by transaction            interface to transaction terminal",POSTON J A;  LASATER Z T;  KADRY A J;  BENNETT G T;  SREERAMAN M;  AMIN A M;  MORGAN K,NCR CORP (NATC-C),202245951U,"   NOVELTY - The method involves establishing a                remote-control user session that allows control of                a transaction interface processing on a transaction                terminal by a mobile device 120 during a                transaction. The user-interface (UI) events                generated by the device are received during the                session. The UI events are provided as human                interface device (HID) events for a HID type                supported by the transaction interface to the                terminal causing the interface to update UI screens                on a display of the terminal based on the HID                events during the user session. An indirect network                connection is established to the device for the                session by a proxy device.    USE - Method for mobile navigational control of                transaction terminal user interfaces (UIs).    ADVANTAGE - The transactions are conducted efficiently and                without any specialized skill being required of the                operators, since organizations have inProcessore                user is prevented from touching a surface that was                previously touched by multiple other customers,                since transaction interfaces render touch options                in the exact same locations of the displays for                nearly all transactions. The health concerns                associated with virus transmission are likely                exasperated, since the high-risk COVID19 consumers                or employees are rightly concerned about operating                the terminals, especially since the HID events are                provided as human interface device (HID) events for                a HID type supported by the transaction interface                to the transaction terminal. The transaction                interface is enabled to update UI screens on a                display of a transaction terminal based on HID                event during the remote-control user session.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a system                for mobile navigational control of transaction                terminal user interfaces (UIs).    DESCRIPTION OF DRAWING(S) - The drawing shows a block representation of a                system for mobile navigational control of a                terminal's UI.    Mobile device (120)    Processor (121)    Non-transitory computer-readable storage                medium (122)    App (123)    Optional proxy (140) ",,,"T01 (Digital Computers);  W05 (Alarms, Signalling, Telemetry and Telecontrol)",T01-N01A1;  T01-J21;  T01-J12;  W05-D08C;  W05-D05B5,G06Q-020/20;  G06Q-020/32,US2022101305-A1   31 Mar 2022   G06Q-020/32   202229   English,US2022101305-A1    US036074    29 Sep 2020,,US036074    29 Sep 2020,,,"US2022101305-A1 -- CN108011930-A   ALIBABA GROUP HOLDING LTD (ABAB)   LI J;  JP2016533093-A   QUALCOMM INC (QCOM)   MALIK R,  TINNAKORNSRISUPHAP P,  XUE Q,  MOHANTY B P,  HAYES K N;  KR2017127649-A   LG UPLUS CORP (GLDS)   CHOI D J;  US20130179507-A1   ;  US20140244409-A1   ;  US20210318889-A1   ;  US11068879-B1   FREIRE J (FREI-Individual)   FREIRE J","US2022101305-A1  I.          Joe and Y. Lee, ""Design of remote control system for data          protection and backup in mobile devices,"" The 4th          International Conference on Interaction Sciences, 2011,          pp. 189-193. (Year: 2011)",,,,,
ES2902037-A1,"Liturgical ciborium device for administration of sacred forms without priest having to touch people with his hand in Catholic Church, has closing roulette for opening or closing lower sealing crown by turning roulette to right or left",LOPEZ MARTINEZ A;  AGUIRRE JAUREGUIALZO M,LOPEZ MARTINEZ A (MART-Individual);  AGUIRRE JAUREGUIALZO M (JAUR-Individual),202253406M,"   NOVELTY - The device has an upper cover (1) for covering the device in a watertight way. A cup (2) supports extraction mechanisms of sacred forms. A closing roulette (5) opens or closes a lower sealing crown (4) by turning the roulette to right or left. A ciborium administers sacred forms without a priest having to touch people with his hand, where the ciborium is made up of an upper cup in which six Storage cylinders are housed as a store for the sacred shapes, where moment of communion is carried out at a distance between participants greater than 1 meter.    USE - Liturgical ciborium device for administration of sacred forms without a priest having to touch people with his hand in Catholic Church in Covid19 pandemic in developing countries.    ADVANTAGE - The device avoids possible contagion between priest and faithful in the Eucharist. The device avoids contagion of other diseases.    DESCRIPTION OF DRAWING(S) - The drawing shows a a front view of liturgical ciborium device.    Upper cover (1)    Cup (2)    Exit windows (3)    Lower sealing crown (4)    Closing roulette (5) ",,,"P27 (Shop, household, furnishings (A47F, G, H).);  Q32 (Container/closure types, special packaging features and transit packaging (B65D))",P27-B03;  P27-B06;  Q32-D06,A47G-019/32;  A47G-033/00;  B65D-083/04;  B65D-083/08,ES2902037-A1   24 Mar 2022   A47G-033/00   202242Pages: 10   Spanish,ES2902037-A1    ES000136    24 Sep 2020,,ES000136    24 Sep 2020,,,,,,,,,
CH717839-A2;  CH717839-B1,"Structure for template e.g. surgical template such            as mask, has terminal that is designed to turn in            portion behind ear of user to support structure on            head, multiple rods extend between pair of posts, one            of rods is movable for cover or uncover portion of face            of user",SCHILD M,SCHILD M (SCHI-Individual),202247353G,"   NOVELTY - The structure (10) has a pair of posts (20).                Each post is designed to extend on one side of a                user's head, from a mandibular angle (100) towards                the temporal bone, and being equipped with a                terminal (21) designed to turn in portion behind                the user's ear to support the structure on the                head. Multiple rods (2, 3, 4, 5) extend between the                pair of posts. One of the rod is movable for cover                or uncover a portion of the user's face.    USE - Structure for template (claimed) e.g. surgical                template such as mask for antibacterial or                antiviral mask, and protective mask equipped with                reusable or disposable sheet for wearing in                surgical or medical field for protection against                environments potentially contaminated by                microparticles or by viral and/or bacterial                loads.    ADVANTAGE - The structure is comfortable to wear also for                extended periods of time adapted to manoeuvre the                fabric or protective material of the mask,                preserving its hygiene to support these maneuvers                in a simple and safe manner and to improve                breathing for the user. The structure allows the                mask to be worn by very time without damaging or                irritating the skin or skin without removing the                mask from the head, however being able to release                part of the face, for example, to breait or to                parse the headphone in all these cases, avoiding,                however, by resting the mask on surfaces                potentially contaminated by viruses such as                Covid19. The structure can support a tissue or a                disposable protective material removable from the                structure but be reusable unlike the tissue and                therefore be applicable to a new tissue or                protective material.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a                template.    DESCRIPTION OF DRAWING(S) - The drawing shows a perspective view of a                template structure. (Drawing includes non-English                language text)    Rod (2,3,4,5)    Structure for template (10)    Post (20)    Terminal (21)    Mandibular angle (100) ",,,"P21 (Wearing apparel (A41, A42).);  P35 (Life-saving, fire-fighting (A62).)",P21-F;  P21-N;  P35-A03C;  P35-A03E1,A41D-013/11;  A62B-018/02,CH717839-A2   15 Mar 2022   A41D-013/11   202231Pages: 11   Italian;  CH717839-B1   15 Aug 2023   A41D-013/11   202370   Italian,CH717839-A2    CH001152    15 Sep 2020;   CH717839-B1    CH001152    15 Sep 2020,,CH001152    15 Sep 2020,,,,,,,,,
WO2022044054-A1;  IN202011037535-A;  EP4204807-A1,"System for carrying out rapid detection of            pathogens comprises enclosure having front cover; head            assembly coupled with front cover, where head assembly            comprises opening; microchip placed within opening of            head assembly; and micropump",JHA S K;  KASIM D S;  SINGH H;  PANWAR S;  PANDA K;  YADAV N K;  DUTTA S;  LNU K;  SINGH T;  RAJ R;  SYED K D;  KIRTI,INDIAN INST TECHNOLOGY DELHI (IITD-C);  INDIAN INST TECHNOLOGY DELHI (IITD-C),202239779D,"   NOVELTY - The system has an enclosure having a front                cover, a head assembly is coupled with the front                cover and comprising an opening. A microchip (1000)                is placed within the opening of the head assembly,                a micropump is arranged at the microchip and                affixed at a predesignated space of over microchip.                The portion of front cover and head assembly are                movable to place microchip is within the second                opening of head assembly. The enclosure comprises a                back cover that includes an air exit window to                dissipate heat of system.    USE - System for carrying out rapid detection of                pathogens e.g. bacteria, virus and fungi.    ADVANTAGE - The system enables rapid detection of                micro-organism in real-time with high sensitivity                and specificity. The system is simple, inexpensive                and easy to scale up in a pandemic situation like                COVID19 outbreak. The microchip is placed behind                the front cover, inside the enclosure, thus                preventing the microchip from falling out of the                enclosure. The enclosure has a back cover that                includes an air exit window to dissipate heat of                the system, and a rechargeable battery placed at a                bottom cover of an enclosure, so that the system                can be used in an easy manner. The micropump is                fixed at a predesignated space over a microchip,                thus avoiding the need for gel electrophoresis, and                hence eliminating the need of sample extraction,                pre-treatment and sample preparation before mixing                chemicals in a precise manner.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a micropump for a system to carry out                rapid detection of pathogen;    (2) a microchip for a system to carry out                rapid detection of pathogen; and    (3) a method of operating a system for                carrying out rapid detection of pathogen.    DESCRIPTION OF DRAWING(S) - The drawing shows a perspective view of a                microchip of the system for carrying out rapid                detection of pathogen.    Microchip (1000)    Microchannel (1002)    Microvalve (1004)    Wax Reservoir (1006)    Microheater (1008) ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  ;  S03 (Scientific Instrumentation);  S05 (Electrical Medical Equipment);  T01 (Digital Computers)",B04-E99;  B11-C08K;  B11-C11;  B12-K04;  J04-B01;  J04-C01;  J04-F;  S03-E09F;  S03-E13;  S05-G02G1;  S05-G02G9;  T01-J06A1,G01N-001/00;  G01N-033/50;  G16H-010/40;  G16H-070/60;  B01L-003/00;  C12M-001/34;  G01N-035/00;  G01N-035/04;  G01N-035/10,WO2022044054-A1   03 Mar 2022   G01N-033/50   202224Pages: 51   English;  IN202011037535-A   30 Sep 2022   B01L-003/00   202282   English;  EP4204807-A1   05 Jul 2023   G01N-033/50   202354   English,WO2022044054-A1    WOIN050840    31 Aug 2021;   IN202011037535-A    IN11037535    31 Aug 2020;   EP4204807-A1    EP860791    31 Aug 2021,EP4204807-A1 PCT application Application WOIN050840;   EP4204807-A1 Based on Patent WO2022044054,IN11037535    31 Aug 2020,WO2022044054-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP4204807-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN  ,,"WO2022044054-A1 -- US8298763-B2   REGAN J F (REGA-Individual)   REGAN J F;  WO2007142692-A2   US SEC OF NAVY (USNA)   LIGLER F S,  STENGER D A,  ERICKSON J,  ARCHER M",,,,,,
DE102020121401-A1,"Multi-level infect card system for immediate and storage of breathing air values separated according to inhalation and exhalation on exchangeable carrier medium, has infect card evaluation unit in biochemical-immunological process",,BIENENHAUS GEMEINNUETZIGE UG (BIEN-Non-standard),2022250713,"   NOVELTY - The multi-level infect card system has an infect card evaluation unit in a biochemical-immunological process. The biochemical-immunological process is checked for harmful MO, Covid19 or other transferable harmful MOs of a comparable type are examined together with important accompanying data. The accompanying data are immediately automatically and anonymously forwarded to a central computer for further processing by infect card software. The subordinate determination of personal values has the infect card mask wearer in coordination. An infect card adapter enables the inclusion of an easily exchangeable infect card or a comparable component for the same purpose.    USE - Multi-level infect card system for first-rate, immediate, timely recording and storage of breathing air values separated according to inhalation and exhalation on an exchangeable carrier medium, such as an Infect Card stored in a biochemical-immunological process using Covid19 and comparable respiratory viruses.    ADVANTAGE - The multi-level infect card system prevents and combat a pandemic with harmful MOs, a comprehensive overview and knowledge of the current infection process are of the utmost importance to be able to act as quickly as possible on the spot.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic representation of the multi-level infect card system. ",,,S05 (Electrical Medical Equipment);  T01 (Digital Computers),S05-G02G9;  T01-J06A1,G16H-050/80,DE102020121401-A1   17 Feb 2022   G16H-050/80   202218Pages: 7   German,DE102020121401-A1    DE10121401    14 Aug 2020,,DE10121401    14 Aug 2020,,,,,,,,,
WO2022027110-A1;  IN202147033296-A,Pharmaceutical composition of tridecactide and            metenkefalin for treating and preventing complications            of local and systemic inflammatory conditions in            diseases such as severe septic condition and septic            shock caused by infectious agents,UZUNOVIC N;  SUKALO A;  GLAMOCLIJA U;  DZANANOVIC J J;  MEHIC M;  MEHMEDIKA S E;  SAVIC M,BOSNALIJEK PHARM & CHEM IND JOINT STOCK (BOSN-Non-standard),202221706E,"   NOVELTY - Pharmaceutical composition of tridecactide and                metenkefalin is useful for treating and preventing                complications of local and systemic inflammatory                conditions in diseases such as severe septic                condition and septic shock caused by infectious                agents (viruses: coronaviruses, influenza viruses                and other viruses), tissue damage caused by                non-infectious agents (burns, crush syndrome, heat                stroke), and selected chronic inflammatory                diseases, including atopic dermatitis, diabetes                mellitus, and atherosclerosis.    USE - The pharmaceutical composition of tridecactide                and metenkefalin is useful for treating and                preventing complications of local and systemic                inflammatory conditions in diseases such as severe                septic condition and septic shock caused by                infectious agents (viruses: coronaviruses,                influenza viruses and other viruses), tissue damage                caused by non-infectious agents (burns, crush                syndrome, heat stroke), and selected chronic                inflammatory diseases, including atopic dermatitis,                diabetes mellitus, and atherosclerosis (claimed).                It can also be used for treating inflammatory                conditions in COVID19 and other infectious as well                as non-infectious diseases and autoimmune                conditions associated with a cytokine storm.    ADVANTAGE - The combination of tridecactide and                methenkephalin with an immunomodulatory mechanism                of action represents a promising therapeutic option                in the treatment of sepsis. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.)",B04-E99;  B04-C01B;  B04-C01C;  B14-A02B2;  B14-C03;  B14-F07;  B14-G02D;  B14-L01;  B14-N17C;  B14-S04;  B14-S06;  B14-S18,A61K-038/33;  A61K-038/35;  A61P-031/14;  A61P-043/00;  A61B-017/22;  A61K-031/401;  A61K-038/19;  A61N-002/00;  G16H-010/60,WO2022027110-A1   10 Feb 2022   202215Pages: 23   English;  IN202147033296-A   18 Mar 2022   A61B-017/22   202200   English,WO2022027110-A1    WOBA000005    10 Sep 2020;   IN202147033296-A    IN47033296    23 Jul 2021,IN202147033296-A PCT application Application WOBA000005;   IN202147033296-A Based on Patent WO2022027110,BA003370    03 Aug 2020,WO2022027110-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW    ,,,,86493-1-0-0 K M; 94200-1-0-0 K M,,,RA1F9O K M; R07791 K M,
DE202021105877-U1,"System for detecting a Covid19 disease based on a Convolutional neural network (CNN) model and Computerized tomography (CT)/X-ray image classification, comprises a database module that collects the clinical CT/X-ray images with segmentation",,DHANDAPANI R (DHAN-Individual);  AL M A A H (ALMA-Individual);  KESAVAN S M (KESA-Individual);  RAJAKANNU A (RAJA-Individual);  VENKATESAN R (VENK-Individual),2022217961,   NOVELTY - The system (100) comprises a database module (101) that collects the clinical CT/X-ray images. A segmentation and feature extraction module (102) is provided for feature selection and partitioning of a data set. The feature concatenation module (103) is combined the features with a training and learning module (104) for the data set. An Internet of things (IoT) communication link (105) is provided for remote patient monitoring via a medical tab. A medical cloud (106) is retained in the COVID19 data for future reference. The communication module (107) for sending alerts to the patient.    USE - System for detecting a Covid19 disease based on a CNN model and CT/X-ray image classification.    ADVANTAGE - System that reduces the burden on the hospital even when the number of patients increases significantly.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view of a system for detecting a Covid19 disease based on a CNN model and CT/X-ray image classification.    System (100)    Database module (101)    Segmentation and feature extraction module (102)    Feature concatenation module (103)    Training and learning module (104)    IoT communication link (105)    Medical cloud (106)    Communication module (107) ,,,S03 (Scientific Instrumentation);  S05 (Electrical Medical Equipment);  T01 (Digital Computers),S03-E06B3;  S05-G02G3;  T01-E01B;  T01-J05B2;  T01-J05B4F;  T01-J10B2;  T01-J10B3A;  T01-N01D1B;  T01-N01E1;  T01-N01F;  T01-N02B2,G16H-050/20,DE202021105877-U1   10 Feb 2022   G16H-050/20   202216Pages: 9   German,DE202021105877-U1    DE20105877    27 Oct 2021,,DE20105877    27 Oct 2021,,,,,,,,,
KR2022000059-A,"Non-powered body temperature measurement wireless communication thermometer for checking human body temperature for preventing and spreading infectious diseases due to novel virus, has sensor for measuring body temperature, where communication chip is provided",JUNG J,SMARTECH CO LTD (SMAR-Non-standard),202201679T,"   NOVELTY - The non-powered body temperature measurement wireless communication thermometer has a sensor for measuring body temperature, and a communication chip for transmitting the body temperature value measured by the sensor to a reader. An antenna drives the communication chip, and communicates data with the reader. A radio frequency identification (RFID) tag is attached to a skin. The reader supplies power to the RFID tag. A server inputs and stores the received body temperature data into an attendance system of students or staff. A portable terminal displays a situation in which the data is abnormally high by software.    USE - Wireless communication based non-powered body temperature measurement wireless communication thermometer for checking human body temperature for preventing and spreading infectious diseases due to the novel virus COVID19.    ADVANTAGE - The thermometer measures the body temperature regardless of power consumption, and accurately measures body temperature without errors.    DESCRIPTION OF DRAWING(S) - The drawing shows a block diagram of a non-powered body temperature measurement wireless communication thermometer. (Drawing includes non-English language text). ",,,"P31 (Diagnosis, surgery (A61B).);  S05 (Electrical Medical Equipment);  T01 (Digital Computers);  T04 (Computer Peripheral Equipment);  W06 (Aviation, Marine and Radar Systems)",P31-A05;  S05-D01E;  T01-C03C;  T01-N01A2;  T01-N01B3;  T01-N01D;  T01-N01E;  T01-N03;  T04-K01C;  T04-K02B;  W06-A04B,A61B-005/00;  A61B-005/01;  G06K-019/07;  G06Q-050/26,KR2022000059-A   03 Jan 2022   A61B-005/00   202207Pages: 6   ,KR2022000059-A    KR077537    25 Jun 2020,,KR077537    25 Jun 2020,,,,,,,,,
US2021406859-A1;  US11334863-B2,"Method for touchless payment processing, involves            providing second status messages to touch less payment            status device representing changes in payment statuses            for payment based on interacting",FUGEDY J E;  MORGAN K O,NCR CORP (NATC-C),202201640G,"   NOVELTY - The method involves configuring a touchless                payment status device (130) for communicating                payment status in real time for a transaction of a                customer. A mobile device (110) operated by the                customer a code obtained from the touchless payment                status device is received. A first status message                is sent to the touchless payment status device                indicating that the customer has initiated a                payment for the transaction. The mobile device and                a payment service are interacted to process the                payment on behalf of the customer. The second                status messages are provided to the touchless                payment status device representing changes in the                payment statuses for the payment based on the                interacting. The touchless payment status device is                provided with a link or an address for receiving                the payment statuses. A touchless payment status                device identifier is obtained from the touchless                payment status device. The code comprising the link                or address and the touchless payment status device                identifier is generated.    USE - Method for processing touchless payment during                global pandemic such as COVID19.    ADVANTAGE - The method enables avoiding interaction and                touching to improve health and safety for both                customers and staffs.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a                touchless payment status device.    DESCRIPTION OF DRAWING(S) - The drawing shows a block diagram of a system                for processing touchless payment.    System for processing touchless payment                (100)    Mobile device (110)    Processors (111,121,131)    Server (120)    Transaction manager (123)    Touchless payment status device (130)    Management terminal (140) ",,,T01 (Digital Computers),T01-J05A2H,G06K-019/06;  G06Q-020/02;  G06Q-020/10;  G06Q-020/20;  G06Q-020/32;  G06Q-030/00;  G06Q-030/06;  G08B-007/00,US2021406859-A1   30 Dec 2021   G06Q-020/20   202215   English;  US11334863-B2   17 May 2022   G06Q-020/20   202241   English,US2021406859-A1    US915100    29 Jun 2020;   US11334863-B2    US915100    29 Jun 2020,US11334863-B2 Previous Publ. Patent US2021406859,US915100    29 Jun 2020,,,";  US11334863-B2 -- US20110251892-A1   ;  US20130085878-A1   ;  US20140324606-A1   ;  US10699264-B1   UP N GO (UPNG-Non-standard)   BARMAN T;  US11068867-B1   TUCKER R C (TUCK-Individual)   TUCKER R C;  US10460303-B2   DISNEY ENTERPRISES INC (DISY)   PATIL M B,  VYAS M,  KEOGH J J,  AMBROZIE M A,  EFSTATHIOU J N,  ADAMS M G",,,,,,
CN113813272-A,"Use of Forsythoside H i.e.            (E)-2-(3,4-dihydroxyphenethoxy)-4,5-dihydroxy-6-((3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-2H-pyran-3-yl            3-(3,4-dihydroxyphenyl)acrylate in preparing            anti-coronavirus product for treating infections caused            by coronavirus in e.g. human and cat",WANG L;  GAO W;  ZHAO W,UNIV CAPITAL MEDICAL (UYMD-C),2022055246,"   NOVELTY - Use of Forsythoside H i.e.                (E)-2-(3,4-dihydroxyphenethoxy)-4,5-dihydroxy-6-((3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-2H-pyran-3-yl                3-(3,4-dihydroxyphenyl)acrylate (I) in preparing                anti-coronavirus product, is claimed.    USE - (I) is useful in preparing anti-coronavirus                product for preventing/treating infections caused                by coronavirus in human, cat, dog, pig and chicken                (all claimed).    ADVANTAGE - (I): adopts molecular docking technology to                confirm inhibitory effect of Forsythoside H on 3CL                hydrolase, S protein receptor-binding domain (RBD)                and ACE2 of COVID19, and shows strong binding                ability to ACE2 through affinity experiment; and                shows inhibitory effect on coronavirus in range of                1-50 microm through experiments.    DETAILED DESCRIPTION - Use of Forsythoside H i.e.                (E)-2-(3,4-dihydroxyphenethoxy)-4,5-dihydroxy-6-((3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-2H-pyran-3-yl                3-(3,4-dihydroxyphenyl)acrylate of formula (I) in                preparing anti-coronavirus product, is                claimed. ",,,B03 (Other heterocyclics.);  C02 (Heterocyclic.),B14-A02B5;  B07-A02B;  C14-A02B5;  C07-A02B,A61K-031/7032;  A61P-031/14,CN113813272-A   21 Dec 2021   A61K-031/7032   202225   Chinese,CN113813272-A    CN11237616    09 Nov 2020,,CN11237616    09 Nov 2020,,,"CN113813272-A -- CN109908206-A   FUJIAN NANPING PEOPLES HOSPITAL (FUJI-Non-standard)   JI S,  HUANG C,  XU X,  SHI M,  XU Z,  LI X,  LIN X,  QIN W,  JIANG X,  ZHONG L;  CN113491703-A   SHANGHAI INST MATERIA MEDICA CAS (CAMM)   SU H,  KE C,  ZHAO W,  YAO S,  XU Y,  YE Y","CN113813272-A  HAI-XIA SU ET AL.:          ""Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian          preparations and bioactive ingredients"", ACTA          PHARMACOLOGICA          SINICA,relevantClaims[1-11],relevantPassages[11733]", U K,,,RC1M1F U K,
CN113813275-A,"Use of Forsythoside E i.e.            2-(3,4-dihydroxyphenethoxy)-6-((3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-2H-pyran-3,4,5-triol            in preparing anti-coronavirus product for            preventing/treating infections caused by coronavirus in            human, cat, dog, pig and chicken",WANG L;  ZHAO W;  GAO W,UNIV CAPITAL MEDICAL (UYMD-C),2022068573,"   NOVELTY - Use of Forsythoside E i.e.                2-(3,4-dihydroxyphenethoxy)-6-((3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-2H-pyran-3,4,5-triol                (I) in preparing anti-coronavirus product, is                claimed.    USE - (I) is useful in preparing anti-coronavirus                product for preventing/treating infections caused                by coronavirus in human, cat, dog, pig and chicken                (all claimed).    ADVANTAGE - (I): has inhibitory effect on 3CL hydrolase, S                protein and ACE2 of COVID19; and shows inhibitory                effect on coronavirus in range of 1-50 microm by                antiviral experiments.    DETAILED DESCRIPTION - Use of Forsythoside E i.e.                2-(3,4-dihydroxyphenethoxy)-6-((3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-2H-pyran-3,4,5-triol                of formula (I) in preparing anti-coronavirus                product, is claimed. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.)",B14-A02B5;  B14-S12,A61K-031/7032;  A61K-036/634;  A61P-011/00;  A61P-031/14,CN113813275-A   21 Dec 2021   A61K-031/7032   202216   Chinese,CN113813275-A    CN11242982    10 Nov 2020,,CN11242982    10 Nov 2020,,,"CN113813275-A -- CN101919868-A   SHANDONG LVYE NATURAL PHARM RES&DEV                  CO (SHAN-Non-standard)   WU J,  ZHU H,  JIANG W,  TIAN J,  XU B,  PENG X;  CN113491703-A   SHANGHAI INST MATERIA MEDICA CAS (CAMM)   SU H,  KE C,  ZHAO W,  YAO S,  XU Y,  YE Y","CN113813275-A  HAI-XIA SU ET AL.,:          ""Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian          preparations and bioactive ingredients"", ACTA          PHARMACOLOGICA          SINICA,relevantClaims[1-11],relevantPassages[11733];  CHENG-HAO YE ET          AL.: ""Theoretical Study of the anti-NCP Molecular          Mechanism of Traditional Chinese Medicine Lianhua-Qingwen          Formula (LQF)"", 1:BIOLOGICAL AND MEDICINAL          CHEMISTRY,relevantClaims[1-11],relevantPassages[7283.2]",200757-0-0-0 U K,,,RA00GT U K,
FR3111469-A1,"System for detecting people who test positive for a contagious disease, i.e. COVID19, comprises a current Vitale card that is replaced with a new Vitale card with a contact entry, where new specific card is created to be used in emergency",MICHEL R,MICHEL R (MICH-Individual),2021E37857,"   NOVELTY - The system comprises a current Vitale card that is replaced with a new Vitale card with a contact entry, which allows you to continue using it according to current procedures and a second contactless RFID type entry, which only gives access to an identification code of the card non-nominative for the management of an epidemic or a pandemic. A new specific card is created to be used in an emergency to process information relating to people affected or not by the epidemic or pandemic. All places open to the public for transport, public establishments, schools, shops, cultural places or activities, social activities, religious activities, sporting activities or events, places or activities activities, public or private meetings. The places are equipped with RFID readers and linked to a central file to monitor the epidemic. The carriers of the disease are listed and people who have been in contact with the positive carrier is traced before their quarantine.    USE - System for detecting people who test positive for a contagious disease, i.e. COVID19.    ADVANTAGE - The system saves time during inventorying, reduces shrinkage and improves product availability in-store. The analysis of the data makes it possible to optimize the logistics chain, and to gain in precision, in time and thus financially.    DESCRIPTION OF DRAWING(S) - The drawing shows a circuit diagram of a system for detecting people who test positive for a contagious disease. ",,,"S05 (Electrical Medical Equipment);  T01 (Digital Computers);  W06 (Aviation, Marine and Radar Systems)",S05-G02G1;  S05-G02G9;  T01-J05A2B;  T01-J05A2C;  T01-J06A1;  T01-J12C;  T01-J30D;  T01-N02B1B;  W06-A04B5C,G16H-050/80;  G16H-010/65;  G06Q-050/26;  G06F-021/35,FR3111469-A1   17 Dec 2021   G16H-050/80   202104Pages: 8   French,FR3111469-A1    FR004331    26 Apr 2021,,FR005958    08 Jun 2020,,,,,,,,,
IN202031024062-A,"Customized face mask, has attachment gear that consists of string or any attachment which secures mask to head of user",DEY S;  GOGOI P,DEY S (DEYS-Individual),2022185267,"   NOVELTY - The mask has a central portion. The image of portion of a face of a person is intended to cover is printed which leads to perfect camouflaging. An attachment gear consists of a string or any attachment which secures the mask to the head of the user. The image of the face is printed after obtaining the image with the help of a camera (1) which takes the photograph of the person face with a graduated, calibrated and adjustable reference frame (2) around the face for accurate measurement of the dimensions of face. The mask is attached to a head of a user.    USE - Customized face mask for covering face of a person while going out in a polluted environment or as a protection against infection by microorganisms such as Covid19 outbreak.    ADVANTAGE - The image is printed into the customized face mask so that the mask camouflages with the face as accurately as possible to provide the appearance of a complete face, unique to each individual. The face mask is developed which replicates the face of the user in it. The dimensions and other attributes of the face are preserved accurately. The compliance in wearing masks among people is enhanced. The accuracy of taking the photograph of the person who is the intended user of the mask is achieved by positioning of the camera and the person and placing a graduated and pre-calibrated frame at an appropriate position. The image processing software makes adjustments in the image's attributes after transferring the image of person's face in the computer. The final result is an exact replica of face which remains covered by the mask.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view of the customized face mask.    Camera (1)    Camera tripod (1a)    Frame (2)    Frame stand (2d)    Height adjustment screw (2e) ",,,"P21 (Wearing apparel (A41, A42).);  P34 (Sterilising, syringes, electrotherapy (A61L, M, N).);  P35 (Life-saving, fire-fighting (A62).);  X27 (Domestic Electric Appliances\n)",P21-F;  P21-N;  P34-A02;  P35-A03C;  P35-A03E1;  X27-A02B1A,A41D-013/11;  A61M-016/06;  A62B-018/02;  A62B-018/08;  A62B-023/02,IN202031024062-A   10 Dec 2021   A41D-013/11   202212Pages: 15   English,IN202031024062-A    IN31024062    08 Jun 2020,,IN31024062    08 Jun 2020,,,,,,,,,
WO2021240187-A1;  EP3932406-A4,Use of substituted phenylbenzamide compounds for            reducing or preventing inflammation in organ of a            mammalian subject,PAP D;  HRICZONE SZEBENI B;  VANNAY A;  VERES-SZEKELY A,SEMMELWEIS EGYETEM (SEMM-Non-standard);  PAP D (PAPD-Individual);  HRICZONE SZEBENI B (SZEB-Individual);  VANNAY A (VANN-Individual),2021D9267H,"   NOVELTY - Use of substituted phenylbenzamide compounds                (I) for reducing or preventing inflammation in                organ of a mammalian subject.    USE - (I) are useful for: reducing or preventing                inflammation in organ of a mammalian subject, where                the inflammation is acute inflammation or chronic                inflammation; reducing the expression or level of                pro-inflammatory cytokines, preferably at least a                cytokine comprising interleukin (IL)-1, preferably                IL-1 beta , IL-6, TNF- alpha , interferons (IFN)-                gamma and/or Colony Stimulating Factor 2 (CSF2),                where the inflammation is characterized by an                elevated level of the pro-inflammatory cytokine;                reducing the cytokine at the site of inflammation,                preferably reduction symptoms of inflammation; and                reducing pro-inflammatory cytokine by or peripheral                blood mononuclear cells of the subject, where the                organ is different from the brain, the subject has                a viral infection or bacterial infection                accompanied by an inflammation with elevated level                of cytokines IL-1, IL-6, TNF- alpha , IFN- gamma                and/or CSF2, preferably at least IL-1- beta and/or                IL-6, the subject has an inflammation in the lung                accompanied by elevated level of cytokines IL-1,                IL-6, TNF- alpha , IFN- gamma and/or CSF2,                preferably IL-1- beta , and/or IL-6, preferably the                subject has obstructive pulmonary disease or the                inflammation of the lung is caused by influenza,                pneumonitis or Coronavirus infection, the subject                has a renal disease, preferably inflammation after                acute renal failure accompanied by elevated level                of cytokines IL-1, IL-6, TNF- alpha , IFN- gamma                and/or CSF2, preferably IL-1- beta and/or IL-6, the                subject has a skin inflammation, accompanied by                elevated level of cytokines IL-1, preferably IL-1-                beta and/or IL-6, the subject has an inflammatory                disorder comprising inflammatory disorders of the                immune system, cardiovascular system, endocrine                system, urinary system, reproductive system,                lymphatic system, respiratory system, kidney, the                liver, the lung, the heart, pancreas, skin, joints                and the peritoneum, disorders due to viral or                bacterial infection, including influenza,                pneumonitis or Coronavirus infections i.e. COVID19                of the skin, i.e. psoriasis, of the                gastrointestinal system i.e. inflammatory bowel                disease, and the subject has an inflammatory                disorder the condition or disorder consisting of                inflammatory or allergic diseases e.g. autoimmune                diseases, systemic anaphylaxis or hypersensitivity                responses, allergic responses, and inflammatry                dermatoses e.g. dermatitis, eczema, atopic                dermatitis, allergic contact dermatitis,                scleroderma, inflammatory diseases due to wounds,                wound vasculitis, atherosclerosis, renal                ischemia-reperfusion injury, coronary heart                disease, asthma, alleric asthma, chronic                obstructive pulmonary diseases, sepsis, sepsis                induced acute kidney diseases and peritonitis (all                claimed). Test details are described but no results                given.    DETAILED DESCRIPTION - Use of substituted phenylbenzamide compounds                of formula (I) or their salts or solvates,                preferably hydrates for reducing or preventing                inflammation in organ of a mammalian subject.    R1-R3 = H, where at least one of R1-R3 is/are                different from H, straight or branched chain 1-4C                alkyl, straight or branched chain 1-8C alkylamine,                preferably 1-6C alkylamine, straight or branched                chain 1-8C alkylamide, preferably 1-6C alkylamide,                straight or branched chain 2-6C alkanoyl                (preferably acetyl), 6-10C aryl or 6-10C arylalkyl,                where any R1-R3 can be substituted by halo,                preferably one or two of R1-R3 is substituted by                1-3 halo, preferably the halogen-substituted R1-R3                is/are ethyl or methyl, where optionally the                alkylamine is substituted amine moieties of                formulae ((R8)(R7)N-CH2-CH2-) (A1) and                ((R10)(R9)N-CH2-) (A2), and/or optionally the                alkylamide is substituted amine moieties of formula                ((R12)(R11)N-C(O)-) (B1);    R7-R10 = 1-4C alkyl, preferably methyl or                ethyl; either    R11, R12 = 1-4C alkyl, preferably methyl or                ethyl or alkylamine consisting of (A1) or (A2);                or    NR11R12 = optionally with another heteroatom                form 5 or 6 membered ring;    Y1 = O or nothing; and    R5 = H, halo, straight or branched chain 1-4C                alkyl, straight or branched chain 1-8C alkylamine,                straight or branched chain 2-6C alkanoyl                (preferably acetyl), 6-10C aryl or 6-10C arylalkyl;                or    Y1 = nothing; and    R5 = monocyclic or bicyclic heterocyclic                moiety (optionally substituted with one or two 1-4C                alkyl, preferably one or two methyl); and    U1, V1, W1 = O or nothing. ",,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  B02 (Fused ring heterocyclics.);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).)",B04-E99;  B06-H;  B07-H;  B10-B03B;  B10-D03;  B14-C03;  D05-H99;  D08-B03B,A61K-031/437;  A61P-001/06;  A61P-011/00;  A61P-013/12;  A61P-029/00,WO2021240187-A1   02 Dec 2021   A61K-031/437   202102Pages: 92   English;  EP3932406-A4   05 Jan 2022   A61K-031/437   202211   English,WO2021240187-A1    WOHU050037    31 May 2021;   EP3932406-A4    EP183564    01 Jul 2020,,EP177625    29 May 2020;  EP183564    01 Jul 2020;  HU000155    16 Apr 2021,WO2021240187-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP3932406-A4:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  ,,"WO2021240187-A1 -- CN108863892-A   UNIV WENZHOU MEDICAL (WEZN);  ZHEJIANG GROST BIOTECHNOLOGY CO LTD (ZHEJ-Non-standard)   LIU Z,  ZHANG J,  QIAN J,  ZHANG Y,  ZHAO Y,  LIANG G;  KR2015130939-A   UNIV GACHON IND ACADEMIC COOP FOUND (UYAC)   SEO S Y,  KIM S H,  SHIN T Y,  JE I G,  GO Y H;  US20070037809-A1   ;  WO2006094235-A1   SIRTRIS PHARM INC (GLAX)   MILBURN M,  MILNE J,  BEMIS J,  NUNES J J,  XIE R,  NORMINGTON K D,  VU C B;  WO2006094236-A1   SIRTRIS PHARM INC (GLAX)   MILBURN M,  MILNE J,  BEMIS J,  NUNES J J,  XIE R,  NORMINGTON K D,  VU C B;  WO2016148114-A1   UNIV HOKKAIDO NAT CORP (UHOK)   SAKAITANI M,  OSE I;  WO2008029152-A2   SUMMIT CORP PLC (SUMM-Non-standard)   WYNNE G M L,  WREN S P,  LECCI C;  US20090163476-A1   ;  WO2011118812-A1   UNIV HOKKAIDO NAT CORP (UHOK)   ARIGA H","WO2021240187-A1  XIANG FEI ET AL:          ""Synthesis of Gallic Acid Analogs as Histamine and          Pro-Inflammatory Cytokine Inhibitors for Treatment of          Mast Cell-Mediated Allergic Inflammation"", MOLECULES,          vol. 22, no. 6, 29 May 2017 (2017-05-29), pages 898,          XP055758129, DOI:          10.3390/molecules22060898,relevantClaims[1,7-20],relevantPassages[&lt;table&gt;3&lt;/table&gt;&lt;compound&gt;3a&lt;/compound&gt;|&lt;pp&gt;A&lt;/pp&gt;];  LAVOIE B ET AL:          ""Gut-derived serotonin contributes to bone deficits in          colitis"", PHARMACOLOGICAL RESEARCH, ACADEMIC PRESS,          LONDON, GB, vol. 140, 17 July 2018 (2018-07-17), pages 75          - 84, XP085594548, ISSN: 1043-6618, DOI:          10.1016/J.PHRS.2018.07.018,relevantClaims[1,7-20],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            ADEGBOLA, S. O. ET AL.: ""Anti-TNF therapy in Crohn's          disease"", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,          vol. 19, no. 8, 2018, pages 2244, XP055606033, DOI:          10.3390/ijms19082244;            BAHMED, K. ET AL.: ""The effect of cysteine oxidation on          DJ-1 cytoprotective function in human alveolar type II          cells"", CELL DEATH & DISEASE, vol. 10, no. 9, 2019,          pages 1 - 14;            BALDASSANO, R. N.D. A. PICCOLI: ""Inflammatory bowel          disease in pediatric and adolescent patients"",          GASTROENTEROLOGY CLINICS OF NORTH AMERICA, vol. 28, no.          2, 1999, pages 445 - 458;            BONIFATI, V. ET AL.: ""Mutations in the DJ-1 gene          associated with autosomal recessive early-onset          parkinsonism"", SCIENCE, vol. 299, no. 5604, 2003, pages          256 - 259, XP002989501, DOI:          10.1126/science.1077209;            BRENNER, D.BLASER, H.MAK, T.: ""Regulation of tumour          necrosis factor signalling: live or let die"", NAT REV          IMMUNOL, vol. 15, 2015, pages 362 - 374, Retrieved from          the Internet          &lt;URL:https://doi.org/10.1038/nri3834&gt;;            CAI, Y. ET AL.: ""A Critical Role of the IL- I P-IL-IR          Signaling Pathway in Skin Inflammation and Psoriasis          Pathogenesis"", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol.          139, no. 1, 2019, pages 146 - 156;            CHEN, L. ET AL.: ""Inflammatory responses and          inflammation-associated diseases in organs"", ONCOTARGET,          vol. 9, no. 6, 2018, pages 7204;            CHEN, L. ET AL.: ""DJ-1 deficiency attenuates expansion of          liver progenitor cells through modulating the          inflammatory and fibrogenic niches"", CELL DEATH &          DISEASE, vol. 7, no. 6, 2016, pages e2257 -          e2257;            CHO, Y. ET AL.: ""Clinical causes of inflammation in          peritoneal dialysis patients"", INTERNATIONAL JOURNAL OF          NEPHROLOGY, 2014;            CLEMENTS, C. M. ET AL.: ""DJ-1, a cancer-and Parkinson's          disease-associated protein, stabilizes the antioxidant          transcriptional master regulator Nrf2"", PROCEEDINGS OF          THE NATIONAL ACADEMY OF SCIENCES, vol. 103, no. 41, 2006,          pages 15091 - 15096;            DANG W.: ""The controversial world of sirtuins"", DRUG          DISCOV TODAY TECHNOL., vol. 12, 2014, pages e9 -          e17;            DAVIDOVICI, B. B. ET AL.: ""Psoriasis and systemic          inflammatory diseases: potential mechanistic links          between skin disease and co-morbid conditions"", JOURNAL          OF INVESTIGATIVE DERMATOLOGY, vol. 130, no. 7, 2010,          pages 1785 - 1796;  DE          BIE, C. I. ET AL.: ""Diagnostic workup of paediatric          patients with inflammatory bowel disease in Europe:          results of a 5-year audit of the EUROKIDS registry"",          JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, vol.          54, no. 3, 2012, pages 374 - 380;  DE          SOUZA, H. S.C. FIOCCHI: ""Immunopathogenesis of IBD:          current state of the art"", NATURE REVIEWS          GASTROENTEROLOGY & HEPATOLOGY, vol. 13, no. 1, 2016,          pages 13;            DEL ZOTTO, B. ET AL.: ""TGF-I production in inflammatory          bowel disease: differing production patterns in Crohn's          disease and ulcerative colitis"", CLINICAL &          EXPERIMENTAL IMMUNOLOGY, vol. 134, no. 1, 2003, pages 120          - 126, XP055612991, DOI:          10.1046/j.1365-2249.2003.02250.x;  DI          NARZO, A. F. ET AL.: ""High-throughput identification of          the plasma proteomic signature of inflammatory bowel          disease"", JOURNAL OF CROHN'S AND COLITIS, vol. 13, no. 4,          2019, pages 462 - 471;            EICHELE, D. D.K. K. KHARBANDA: ""Dextran sodium sulfate          colitis murine model: An indispensable tool for advancing          our understanding of inflammatory bowel diseases          pathogenesis"", WORLD JOURNAL OF GASTROENTEROLOGY, vol.          23, no. 33, 2017, pages 6016;            GABAY, C.: ""Interleukin-6 and chronic inflammation"",          ARTHRITIS RESEARCH & THERAPY, vol. 8, no. 2, 2006,          pages S3;            GADOTTI, A. C.DE CASTRO DEUS, M.TELLES, J. P.WIND,          R.GOES, M.OSSOSKI, R. G. C.TUON, F. F.: ""IFN-y is an          independent risk factor associated with mortality in          patients with moderate and severe COVID-19 infection"",          VIRUS RESEARCH., vol. 289, 2020, pages 198171,          XP086289076, DOI:          10.1016/j.virusres.2020.198171;            GIROTTO, S. ET AL.: ""DJ-1 is a copper chaperone acting on          SOD1 activation"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol.          289, no. 15, 2014, pages 10887 - 10899;            GUO, S. ET AL.: ""Lipopolysaccharide causes an increase in          intestinal tight junction permeability in vitro and in          vivo by inducing enterocyte membrane expression and          localization of TLR-4 and CD 14"", THE AMERICAN JOURNAL OF          PATHOLOGY, vol. 182, no. 2, 2013, pages 375 - 387,          XP055538520;            GUZMAN, J. N. ET AL.: ""Oxidant stress evoked by          pacemaking in dopaminergic neurons is attenuated by          DJ-1"", NATURE, vol. 468, no. 7324, 2010, pages 696 -          700;            HAMILTON, J. A.: ""GM-CSF in inflammation"", THE JOURNAL OF          EXPERIMENTAL MEDICINE, vol. 217, no. 1, 2020, pages          e20190945;            HANAUER, S. B. ET AL.: ""Human anti-tumor necrosis factor          monoclonal antibody (adalimumab) in Crohn's disease: the          CLASSIC-I Trial"", GASTROENTEROLOGY, vol. 130, no. 2,          2006, pages 323 - 333, XP005284535, DOI:          10.1053/j.gastro.2005.11.030;            HIJIOKA, M. ET AL.: ""DJ-1/PARK7: a new therapeutic target          for neurodegenerative disorders"", BIOLOGICAL AND          PHARMACEUTICAL BULLETIN, vol. 40, no. 5, 2017, pages 548          - 552;            HORVATH, S. ET AL.: ""Methodological refinement of          Aldara-induced psoriasiform dermatitis model in mice"",          SCIENTIFIC REPORTS, vol. 9, no. 1, 2019, pages 1 -          8;            HUBER, JULIE L ET AL.: ""SIRT 1 -independent mechanisms of          the putative sirtuin enzyme activators SRT1720 and          SRT2183"", FUTURE MEDICINAL CHEMISTRY, vol. 2, no. 12, 7          December 2010 (2010-12-07);            IHARA, S. ET AL.: ""TGF-P in inflammatory bowel disease: a          key regulator of immune cells, epithelium, and the          intestinal microbiota"", JOURNAL OF GASTROENTEROLOGY, vol.          52, no. 7, 2017, pages 777 - 787, XP036283516, DOI:          10.1007/s00535-017-1350-1;            IRWIN, JOHN J.SHOICHET, BRIAN K., ZINC - A FREE DATABASE          OF COMMERCIALLY AVAILABLE COMPOUNDS FOR VIRTUAL SCREENING          J CHEM INF MODEL., vol. 45, no. 1, 2005, pages 177 -          182;            IVASHKIV, L. B.: ""IFNy: signalling, epigenetics and roles          in immunity, metabolism, disease and cancer          immunotherapy"", NATURE REVIEWS IMMUNOLOGY., vol. 18, no.          9, 2018, pages 545 - 558, XP036579163, DOI:          10.1038/s41577-018-0029-z;            KAISTHA, A.J. LEVINE: ""Inflammatory bowel disease: the          classic gastrointestinal autoimmune disease"", CURRENT          PROBLEMS IN PEDIATRIC AND ADOLESCENT HEALTH CARE, vol.          44, no. 11, 2014, pages 328 - 334;            LIU, W. ET AL.: ""Park7 interacts with p47 phox to direct          NADPH oxidase-dependent ROS production and protect          against sepsis"", CELL RESEARCH, vol. 25, no. 6, 2015,          pages 691 - 706;            KHASNAVIS, S.K. PAHAN: ""Sodium benzoate, a metabolite of          cinnamon and a food additive, upregulates neuroprotective          Parkinson disease protein DJ-1 in astrocytes and          neurons."", JOURNAL OF NEUROIMMUNE PHARMACOLOGY, vol. 7,          no. 2, 2012, pages 424 - 435, XP035056805, DOI:          10.1007/s11481-011-9286-3;            KIM, J.-H. ET AL.: ""DJ-1 facilitates the interaction          between STAT1 and its phosphatase, SHP-1, in brain          microglia and astrocytes: a novel anti-inflammatory          function of DJ-1"", NEUROBIOLOGY OF DISEASE, vol. 60,          2013, pages 1 - 10, XP028737945, DOI:          10.1016/j.nbd.2013.08.007;            KIM, J.-M. ET AL.: ""DJ-1 contributes to adipogenesis and          obesity-induced inflammation"", SCIENTIFIC REPORTS, vol.          4, 2014, pages 4805;            KIM, S. C.G. D. FERRY: ""Inflammatory bowel diseases in          pediatric and adolescent patients: clinical, therapeutic,          and psychosocial considerations"", GASTROENTEROLOGY, vol.          126, no. 6, 2004, pages 1550 - 1560;            KITAMURA, Y. ET AL.: ""Effects of a DJ-1-binding compound          on spatial learning and memory impairment in a mouse          model of Alzheimer's disease."", JOURNAL OF ALZHEIMER'S          DISEASE, vol. 55, no. 1, 2017, pages 67 - 72;            KITAMURA, Y. ET AL.: ""Neuroprotective effect of a new          DJ-1-binding compound against neurodegeneration in          Parkinson's disease and stroke model rats"", MOLECULAR          NEURODEGENERATION, vol. 6, no. 1, 2011, pages 48,          XP021104131, DOI: 10.1186/1750-1326-6-48;            KORN, T. ET AL.: ""IL-17 and Th17 Cells"", ANNUAL REVIEW OF          IMMUNOLOGY, vol. 27, 2009, pages 485 - 517;            LEUNG, J. ET AL.: ""IL-22-producing CD4+ cells are          depleted in actively inflamed colitis tissue"", MUCOSAL          IMMUNOLOGY, vol. 7, no. 1, 2014, pages 124 -          133;            LEVINE, Y. ET AL.: ""ESPGHAN revised Porto criteria for          the diagnosis of inflammatory bowel disease in children          and adolescents"", CHINESE JOURNAL OF PEDIATRICS, vol. 54,          no. 10, 2016, pages 728;            LIS, K. ET AL.: ""Tumor necrosis factor inhibitors-state          of knowledge"", ARCHIVES OF MEDICAL SCIENCE: AMS, vol. 10,          no. 6, 2014, pages 1175;            LUTZ, J. ET AL.: ""Anti-inflammatory treatment strategies          for ischemia/reperfusion injury in transplantation"",          JOURNAL OF INFLAMMATION, vol. 7, no. 1, 2010, pages 27,          XP021078239, DOI: 10.1186/1476-9255-7-27;            MATRICON, J. ET AL.: ""Immunopathogenesis of inflammatory          bowel disease"", SELF/NONSELF, vol. 1, no. 4, 2010, pages          299 - 309;            MEHTA, P.PORTER, J. C.MANSON, J. J.ISAACS, J. D.OPENSHAW,          P. J.MCINNES, I. B.CHAMBERS, R. C.: ""Therapeutic blockade          of granulocyte macrophage colony-stimulating factor in          COVID-19-associated hyperinflammation: challenges and          opportunities"", THE LANCET RESPIRATORY MEDICINE, vol. 8,          1 August 2020 (2020-08-01), pages 822 - 830;            MORGAN, M. J.Z.-G. LIU: ""Crosstalk of reactive oxygen          species and NF- B signaling."", CELL RESEARCH, vol. 21,          no. 1, 2011, pages 103 - 115;            MUDTER, J.M. F. NEURATH: ""11-6 signaling in inflammatory          bowel disease: pathophysiological role and clinical          relevance"", INFLAMMATORY BOWEL DISEASES, vol. 13, no. 8,          2007, pages 1016 - 1023;            NAKAE, S. ET AL.: ""Antigen-specific T cell sensitization          is impaired in IL-17-deficient mice, causing suppression          of allergic cellular and humoral responses"", IMMUNITY,          vol. 17, no. 3, 2002, pages 375 - 387;            NGKELO, A ET AL.: ""LPS induced inflammatory responses in          human peripheral blood mononuclear cells is mediated          through NOX4 and G i a dependent PI-3kinase signalling"",          JOURNAL OF INFLAMMATION, vol. 9, no. 1, 2012, pages 1,          XP021118612, DOI: 10.1186/1476-9255-9-1;            NISHINAGA, H. ET AL.: ""Expression profiles of genes in          DJ-1-knockdown and L166P DJ-1 mutant cells."",          NEUROSCIENCE LETTERS, vol. 390, no. 1, 2005, pages 54 -          59, XP005061262, DOI:          10.1016/j.neulet.2005.07.053;            NISHIYAMA, Y. ET AL.: ""Suppression of dextran sulfate          sodium-induced colitis in mice by radon inhalation"",          MEDIATORS OF INFLAMMATION, 2012;            PACHOLEC MICHELLE ET AL.: ""SRT1720, SRT2183, SRT1460, and          Resveratrol Are Not Direct Activators of SIRT1"", THE          JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 11, 2010,          pages 8340 - 8351, XP008162683, DOI:          10.1074/jbc.M109.088682;            PARK, M. D.MERAD, M.: ""Cooperation between the alveolar          epithelium and lung-resident basophils shapes alveolar          macrophages"", NATURE REVIEWS IMMUNOLOGY. NAT REV IMMUNOL,          vol. 21, 2021, pages 344, XP037470964, DOI:          10.1038/s41577-021-00561-8;            OLIVA-HEMKER, M.C. FIOCCHI: ""Etiopathogenesis of          inflammatory bowel disease: the importance of the          pediatric perspective"", INFLAMMATORY BOWEL DISEASES, vol.          8, no. 2, 2002, pages 112 - 128;            PENG, L. ET AL.: ""DJ-1 exerts anti-inflammatory effects          and regulates NLRX1-TRAF6 via SHP-1 in stroke"", JOURNAL          OF NEUROINFLAMMATION, vol. 17, no. 1, 2020, pages 1 -          13;            PERRIN, J. M. ET AL.: ""Measuring quality of life in          pediatric patients with inflammatory bowel disease:          psychometric and clinical characteristics"", JOURNAL OF          PEDIATRIC GASTROENTEROLOGY AND NUTRITION, vol. 46, no. 2,          2008, pages 164;            POGGI, A. ET AL.: ""Human gut-associated natural killer          cells in health and disease"", FRONTIERS IN IMMUNOLOGY,          vol. 10, 2019, pages 961;            QIU, B. ET AL.: ""DJ-1 promotes development of DEN-induced          hepatocellular carcinoma and proliferation of liver          cancer cells"", ONCOTARGET, vol. 8, no. 5, 2017, pages          8499;            RENDON, A.K. SCHAKEL: ""Psoriasis pathogenesis and          treatment."", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,          vol. 20, no. 6, 2019, pages 1475, XP055741528, DOI:          10.3390/ijms20061475;            SEIDERER, J. ET AL.: ""Role of the novel Th17 cytokine          IL-17F in inflammatory bowel disease (IBD): upregulated          colonic IL-17F expression in active Crohn's disease and          analysis of the IL17F p. His161Arg polymorphism in IBD"",          INFLAMMATORY BOWEL DISEASES, vol. 14, no. 4, 2008, pages          437 - 445;            SHENDELMAN, S. ET AL.: ""DJ-1 is a redox-dependent          molecular chaperone that inhibits a-synuclein aggregate          formation"", PLOS BIOLOGY, vol. 2, no. 11, 2004;            SHOUVAL, D. S. ET AL.: ""Interleukin 1(3 mediates          intestinal inflammation in mice and patients with          interleukin 10 receptor deficiency"", GASTROENTEROLOGY,          vol. 151, no. 6, 2016, pages 1100 - 1104;            TAKAHASHI-NIKI, K. ET AL.: ""DJ-1-dependent protective          activity of DJ-1-binding compound no. 23 against neuronal          cell death in MPTP-treated mouse model of Parkinson's          disease"", JOURNAL OF PHARMACOLOGICAL SCIENCES, vol. 127,          no. 3, 2015, pages 305 - 310;            TIAN, T. ET AL.: ""Pathomechanisms of oxidative stress in          inflammatory bowel disease and potential antioxidant          therapies"", OXIDATIVE MEDICINE AND CELLULAR LONGEVITY,          2017;            TURNER, D. ET AL.: ""Severe pediatric ulcerative colitis:          a prospective multicenter study of outcomes and          predictors of response"", GASTROENTEROLOGY, vol. 138, no.          7, 2010, pages 2282 - 2291, XP028191822, DOI:          10.1053/j.gastro.2010.02.047;            VASSEUR, S. ET AL.: ""Consequences of DJ-1 upregulation          following p53 loss and cell transformation"", ONCOGENE,          vol. 31, no. 5, 2012, pages 664 - 670;            VILLALBA, JOSE M.: ""A patent review of sirtuin          activators: an update"", EXPERT OPINION ON THERAPEUTIC          PATENTS, vol. 22, no. 4, 2012, pages 355 - 367,          XP002773178, DOI: 10.1517/13543776.2012.669374;            WANG, H. ET AL.: ""Anti-inflammatory effect of miltirone          on inflammatory bowel disease via TLR4/NF- B/IQGAP2          signaling pathway"", BIOMEDICINE & PHARMACOTHERAPV,          vol. 85, 2017, pages 531 - 540, XP029866910, DOI:          10.1016/j.biopha.2016.11.061;            XIONG, H. ET AL.: ""Parkin, PINK1, and DJ-1 form a          ubiquitin E3 ligase complex promoting unfolded protein          degradation"", THE JOURNAL OF CLINICAL INVESTIGATION, vol.          119, no. 3, 2009, pages 650 - 660;            XU, X. ET AL.: ""Punicalagin inhibits inflammation in          LPS-induced RAW264. 7 macrophages via the suppression of          TLR4-mediated MAPKs and NF- B activation"", INFLAMMATION,          vol. 37, no. 3, 2014, pages 956 - 965, XP055682411, DOI:          10.1007/s10753-014-9816-2;            YANG, X. ET AL.: ""High Intraperitoneal Interleukin-6          Levels Predict Peritonitis in Peritoneal Dialysis          Patients: A Prospective Cohort Study"", AMERICAN JOURNAL          OF NEPHROLOGY, vol. 47, no. 5, 2018, pages 317 -          324;            ZARBOCK, A. ET AL.: ""Sepsis-induced AKI revisited:          pathophysiology, prevention and future therapies"",          CURRENT OPINION IN CRITICAL CARE, vol. 20, no. 6, 2014,          pages 588;            ZHANG, J. ET AL.: ""Deficiency in the anti-apoptotic          protein DJ-1 promotes intestinal epithelial cell          apoptosis and aggravates inflammatory bowel disease via          p53"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 295, no. 13,          2020, pages 4237 - 4251;            ZHOU, W. ET AL.: ""The oxidation state of DJ-1 regulates          its chaperone activity toward a-synuclein"", JOURNAL OF          MOLECULAR BIOLOGY, vol. 356, no. 4, 2006, pages 1036 -          1048, XP024950732, DOI:          10.1016/j.jmb.2005.12.030",2565928-0-0-0 K U; 2565928-0-0-0 CL USE,226426501 K U,01197,RBDKVT K U,
WO2021240469-A1;  DE112021003011-A5;  US2023270369-A1;  US2023293118-A1,"Attachment for person head, has electrodes for            recording brain waves or brain potentials, where            signals from electrodes have level of            electroencephalogram signals to record group of            chemosensory-induced potentials",TRINKAUS H L;  APPLICANT I E,TRINKAUS H L (TRIN-Individual);  TRINKAUS H L (TRIN-Individual);  TRINKAUS H L (TRIN-Individual),2021D9379C,"   NOVELTY - The attachment has electrodes (E4) that are                provided for recording brain waves or brain                potentials. The electrodes lead to a control unit.                The control unit has a microprocessor. The signals                from or from the electrodes are able to record on a                time-related basis through analog to digital                converter. The unit is coupled to an actuator (Ai)                or controls the actuator, which consists of a                pressurized cartridge and is able to release a                fragrance as a stimulus in a flow in pulses (LDZi).                The signals have a level of electroencephalography                (EEG) signals to record a group of                chemosensory-induced potentials.    USE - Attachment for person head used for                generating, recording and identifying                characteristic patterns in physiological and                pathological data, and for a person head in a                clinical practice e.g. pharmaceuticals, structural                changes in the cortex as a result of masses or                inflammatory processes and changed metabolic                conditions and intoxications play a causative role                for EEG changes.    ADVANTAGE - The device represents an optimal test                environment in order to generate and record                reproducible data by means of experiments, and                controls the workflow of the experiments and                classifies the resulting data. The device creates                environmental conditions which are a prerequisite                for the successful implementation of experiments                that are used to generate test data that arise from                the reactions of test persons to the steps                specified by the procedure. It is painless and                harmless examination for the test subject that can                be repeated as often as desired. It serves as a                covidl9 early warning system.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a                measurement method for detecting change in                chemosensory, especially olfactory-related signal                partitions of EEG due to disease.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view of the                attachment for person head.    Actuator (Ai)    Electrodes (E4)    Flow in pulses (LDZi) ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  P31 (Diagnosis, surgery (A61B).);  S05 (Electrical Medical Equipment);  T01 (Digital Computers)",B11-C08B;  B11-C08K;  B11-C11;  B12-K04G2;  P31-A05;  S05-D01A2A;  T01-C08;  T01-E01A;  T01-J05A2B;  T01-J06A,A61B-005/381;  A61B-005/00;  A61B-005/24;  A61B-005/384;  A61B-005/16,WO2021240469-A1   02 Dec 2021   202101Pages: 41   German;  DE112021003011-A5   23 Mar 2023   A61B-005/381   202325   German;  US2023270369-A1   31 Aug 2023   A61B-005/381   202371   English;  US2023293118-A1   21 Sep 2023   A61B-005/00   202378   English,WO2021240469-A1    WOIB054709    28 May 2021;   DE112021003011-A5    DE11003011    28 May 2021;   US2023270369-A1    US18000101    26 Apr 2023;   US2023293118-A1    US059862    29 Nov 2022,DE112021003011-A5 PCT application Application WOIB054709;   DE112021003011-A5 Based on Patent WO2021240469;   US2023270369-A1 PCT application Application WOIB054709;   US2023293118-A1 CIP of Application WOIB054709;   US2023293118-A1 CIP of Application US000101,EP177608    29 May 2020,WO2021240469-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA        ,,"WO2021240469-A1 -- KR2020472-B1   UNIV GACHON IND ACADEMIC COOP FOUND (UYAC)   OH S H,  KANG S H,  PARK H S,  HYUN K J,  JAESEUNG K,  JEONG S M;  US6325475-B1   MICROFAB TECHNOLOGIES INC (MICR-Non-standard)   HAYES D J,  FREDERICKSON C J,  WALLACE D B","WO2021240469-A1  AMORES JUDITH ET          AL: ""Promoting relaxation using virtual reality,          olfactory interfaces and wearable EEG"", 2018 IEEE 15TH          INTERNATIONAL CONFERENCE ON WEARABLE AND IMPLANTABLE BODY          SENSOR NETWORKS (BSN), IEEE, 4 March 2018 (2018-03-04),          pages 98 - 101, XP033344020, DOI:          10.1109/BSN.2018.8329668,relevantClaims[1,2,9,22,24|3-8,10-19,25-27],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;figure&gt;1-3&lt;/figure&gt;|&lt;pp&gt;99&lt;/pp&gt;&lt;column&gt;r&lt;/column&gt;&lt;para&gt;2&lt;/para&gt;&lt;paral&gt;l&lt;/paral&gt;];            R.W. HOMAN ET AL.: ""Cerebral location of international          10-20 system electrode placement"", ELECTROENCEPHALOGRAPHY          AND CLINICAL NEUROPHYSIOLOGY, vol. 66, 1987, pages 367 -          382;  T.          HUMMEL ET AL.: ""Sniffin' Sticks: Olfactory Performance          Assessed by the Combined Testing of Odor Identification,          Odor Discrimination and Olfactory Threshold"", CHEMICAL          SENSES, vol. 22, no. 1, February 1997 (1997-02-01), pages          39 - 52, XP055535406, DOI:          10.1093/chemse/22.1.39;            HUMMEL TKLIMEK LWELGE-LUSSEN AWOLFENSBERGER GGUDZIOL          HRENNER BKOBAL G: ""Chemosensory evoked potentials for          clinical diagnosis of olfactory disorders"", HNO, vol. 48,          2000, pages 481 - 485;            HUMMEL TKOBAL G: ""Methods in chemosensory research"",          2001, CRC PRESS, article ""Olfactory event-related          potentials"", pages: 429 - 464;            PAUSE B.M.KRAUEL K.: ""Chemosensory event-related          potentials (CSERP) as a key to the psychology of odors"",          INT J PSYCHOPHYSIOL, vol. 36, 2000, pages 105 -          122;            BENSAFI MFRASNELLI JREDEN JHUMMEL T: ""The neural          representation of odor is modulated by the presence of a          trigeminal stimulus during odor encoding"", CLIN          NEUROPHYSIOL, vol. 118, 2007, pages 696 - 701,          XP005896488, DOI: 10.1016/j.clinph.2006.10.022;            GUDZIOL HSCHUBERT MHUMMEL T: ""Decreased trigeminal          sensitivity in anosmia"", ORLJ OTORHINOLARYNGOL RELAT          SPEC, vol. 63, 2001, pages 72 - 75;            HUMMEL T, KNECHT M UND KOBAL G.: ""Peripherally obtained          electrophysiological responses to olfactory stimulation          in man:electro-olfactograms exhibit a smaller degree of          desensitization compared with subjective intensity          estimates."", BRAIN RES, vol. 717, 1996, pages 160 -          164;            HUSNER AFRASNELLI JWELGE-LUSSEN AREISS GZAHNERT THUMMEL          T: ""Loss of trigeminal sensitivity reduces olfactory          function"", LARYNGOSCOPE, vol. 116, 2006, pages 1520 -          1522",,,,,
WO2021242092-A1;  AU2021278756-A1;  CA3179894-A1;  IL298429-A;  KR2023038658-A;  CN115835880-A;  EP4158012-A1;  JP2023529510-W;  US2023242896-A1;  HK40091574-A0,"ADAM Metallopeptidase With Thrombospondin Type 1            Motif 13 protein variant used as antithrombotic agent            in pharmaceutical composition, and therapy for treating            disorder having aberrant Von Willebrand Factor            activity, comprises 1-685 residues",VOORBERG J J;  GOMES GRACA N A;  ERCIG B;  GOMES G N A;  ERCID B;  ERIG B;  GOMES G;  ALEXANDRE N;  BOURBELG J J;  ELSIK B,SANQUIN IP BV (SANQ-Non-standard);  SANQUIN IP BV (SANQ-Non-standard);  SAN QUEEN IPB V (SANQ-Non-standard);  SANQUIN IP BV (SANQ-Non-standard);  SANQUIN IP BV (SANQ-Non-standard),2021D9395J,"   NOVELTY - ADAM Metallopeptidase With Thrombospondin Type                1 Motif 13 (ADAMTS13) protein variant comprises                1-685 residues of ADAMTS13, where one or more                N-linked glycosylation sites are added as compared                to wild-type ADAMTS13 and/or one or more existing                N-linked glycosylation sites are shifted as                compared to wild- type ADAMTS13 in a spacer domain                comprising amino acid residues S556 to A685 of                ADAMTS13 sequence comprising 1381 amino acid                residues.    USE - ADAM Metallopeptidase With Thrombospondin Type                1 Motif 13 (ADAMTS13) protein variant used as                antithrombotic agent in pharmaceutical composition,                therapy and manufacture of medicament for treating                a disorder characterized by aberrant Von Willebrand                Factor (VWF) activity and/or VWF processing, where                disorder is thrombotic disease, which is thrombotic                microangiopathy, thrombotic thrombocytopenic                purpura (TTP), including immune-mediated TTP                (iTTP), hemolytic-uremic syndrome (HUS), ischemic                stroke, systemic thrombosis, COVID19,                antiphospholipid syndrome, pre-eclampsia/HELLP                syndrome, sepsis or sickle cell disease (all                claimed).    ADVANTAGE - The ADAM Metallopeptidase With Thrombospondin                Type 1 Motif 13 (ADAMTS13) protein variant is used                in the treatment of HUS, in particular HUS                associated with partial AD AMTS 13 deficiency, and                treatment of ischemic stroke.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) Nucleic acid construct comprising a                nucleic acid sequence encoding an ADAMTS13 protein                variant;    (2) Pharmaceutical composition comprising an                ADAMTS13 protein variant or a nucleic acid                construct and one or more pharmaceutically                acceptable carriers, adjuvants, excipients and/or                diluents;    (3) Method for the treatment of a disorder                characterized by aberrant Von Willebrand Factor                (VWF) activity and/or VWF processing involves                administering to a subject in need a                therapeutically effective amount of an ADAMTS13                protein variant; and    (4) Method for producing an ADAMTS13 protein                variant involves introducing a nucleic acid                molecule into a host cell capable of N-linked                glycosylation, particularly an eukaryotic host                cell, and culturing the host cell under conditions                that allow expression of the ADAMTS13 protein                variant particularly where the host cell is a                mammalian cell, particularly selected from CHO                cells, NSO cells, SP2/0 cells, PERC.6 cells and                HEK293 cells. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-C01G;  B04-E08;  B04-E99;  B04-L05C1E;  B04-N0600E;  B04-N08;  B14-F01;  B14-F02;  B14-F04;  B14-S06;  D05-H12E;  D05-H17C;  D05-H99,A61K-038/48;  C12N-009/64;  A61K-038/00;  A61P-007/02;  A61P-031/04;  A61P-031/14;  A61P-007/00;  A61P-009/10;  C12N-015/12,WO2021242092-A1   02 Dec 2021   C12N-009/64   202103   English;  AU2021278756-A1   19 Jan 2023   C12N-009/64   202311   English;  CA3179894-A1   02 Dec 2021   A61K-038/48   202315   English;  IL298429-A   01 Jan 2023   C12N-009/64   202319   English;  KR2023038658-A   21 Mar 2023   C12N-009/64   202326   ;  CN115835880-A   21 Mar 2023   A61K-038/48   202329   Chinese;  EP4158012-A1   05 Apr 2023   C12N-009/64   202329   English;  JP2023529510-W   10 Jul 2023   C12N-015/12   202356   Japanese;  US2023242896-A1   03 Aug 2023   C12N-009/64   202363   English;  HK40091574-A0   08 Dec 2023   C12N-009/64   202439   English,WO2021242092-A1    WONL050325    25 May 2021;   AU2021278756-A1    AU278756    25 May 2021;   CA3179894-A1    CA3179894    25 May 2021;   IL298429-A    IL298429    25 May 2021;   KR2023038658-A    KR745100    25 May 2021;   CN115835880-A    CN80046183    25 May 2021;   EP4158012-A1    EP728126    25 May 2021;   JP2023529510-W    JP516457    25 May 2021;   US2023242896-A1    US17927474    23 Nov 2022;   HK40091574-A0    HK6079541    22 Sep 2023,AU2021278756-A1 PCT application Application WONL050325;   AU2021278756-A1 Based on Patent WO2021242092;   CA3179894-A1 PCT application Application WONL050325;   CA3179894-A1 Based on Patent WO2021242092;   IL298429-A Based on Patent WO2021242092;   KR2023038658-A PCT application Application WONL050325;   KR2023038658-A Based on Patent WO2021242092;   CN115835880-A PCT application Application WONL050325;   CN115835880-A Based on Patent WO2021242092;   EP4158012-A1 PCT application Application WONL050325;   EP4158012-A1 Based on Patent WO2021242092;   JP2023529510-W PCT application Application WONL050325;   JP2023529510-W Based on Patent WO2021242092;   US2023242896-A1 PCT application Application WONL050325;   HK40091574-A0 PCT application Application WONL050325;   HK40091574-A0 Based on Patent WO2021242092;   HK40091574-A0 Previous Publ. Patent EP4158012,EP176333    25 May 2020;  EP728126    25 May 2021;  CA3179894    23 Nov 2022;  KR745100    22 Dec 2022;  CN80046183    28 Dec 2022,WO2021242092-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW            EP4158012-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN        ,,"WO2021242092-A1 -- WO2013096793-A1   CHILDRENS HOSPITAL PHILADELPHIA (CHHP)   ZHENG X L;  EP1851319-B1   RAKUVABRIK OUE (RAKU-Soviet Institute)   SILLA T,  TAGEN I,  GEIMANEN J,  JANIKSON K,  ABROI A,  USTAV E,  USTAV M,  MANDEL T;  US9546360-A   CHILDRENS HOSPITAL PHILADELPHIA (CHHP)   ZHENG X L","WO2021242092-A1  ERCIG BOGAC ET AL:          ""N-glycan-mediated shielding of ADAMTS13 prevents binding          of pathogenic autoantibodies in immune-mediated TTP"",          BLOOD, vol. 137, no. 19, 13 May 2021 (2021-05-13), US,          pages 2694 - 2698, XP055836945, ISSN: 0006-4971,          Retrieved from the Internet          &lt;URL:https://www.sciencedirect.com/science/article/pii/S0006497121002913&gt;          [retrieved on 20210902], DOI:          10.1182/blood.2020007972,relevantClaims[1-28],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  NUNO A.G. GRACA ET          AL: ""Modifying ADAMTS13 to modulate binding of pathogenic          autoantibodies of patients with acquired thrombotic          thrombocytopenic purpura"", HAEMATOLOGICA, 21 November          2019 (2019-11-21), IT, XP055743792, ISSN: 0390-6078, DOI:          10.3324/haematol.2019.226068,relevantClaims[1-10,12-28],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  JIAN CXIAO JGONG L          ET AL.: ""Gain-of-function ADAMTS13 variants that are          resistant to autoantibodies against ADAMTS13 in patients          with acquired thrombotic thrombocytopenic purpura"",          BLOOD, vol. 119, no. 16, 2012, pages 3836 - 3843,          XP002800844,relevantClaims[1-10,12-28],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  BOGAC ERCIG ET AL:          ""Insight into 3D structure of ADAMTS13: a stepping stone          towards novel therapeutic treatment of thrombotic          thrombocytopenic Purpura."", THROMBOSIS AND HAEMOSTASIS,          vol. 118, no. 01, 1 January 2018 (2018-01-01), DE, pages          028 - 041, XP055743862, ISSN: 0340-6245, DOI:          10.1160/TH17-06-0404,relevantClaims[1-28],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;|&lt;figure&gt;1&lt;/figure&gt;|&lt;pp&gt;33&lt;/pp&gt;&lt;column&gt;r&lt;/column&gt;&lt;para&gt;1&lt;/para&gt;&lt;ppl&gt;34&lt;/ppl&gt;&lt;coll&gt;r&lt;/coll&gt;&lt;paral&gt;1&lt;/paral&gt;];  ERIC M. OSTERTAG ET          AL: ""ADAMTS13 autoantibodies cloned from patients with          acquired thrombotic thrombocytopenic purpura: 2.          Pathogenicity in an animal model"", TRANSFUSION, vol. 56,          no. 7, 4 July 2016 (2016-07-04), US, pages 1775 - 1785,          XP055329064, ISSN: 0041-1132, DOI:          10.1111/trf.13583,relevantClaims[1-28],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  W. ZHOU ET AL:          ""N-Glycans of ADAMTS13 modulate its secretion and von          Willebrand factor cleaving activity"", BLOOD, vol. 113,          no. 4, 3 November 2008 (2008-11-03), US, pages 929 - 935,          XP055616925, ISSN: 0006-4971, DOI:          10.1182/blood-2008-07-167775,relevantClaims[1-28],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  LUKEN B M ET AL:          ""The Spacer Domain of ADAMTS13 Contains a Major Binding          Site for Antibodies in Patients with Thrombotic          Thrombocytopenic Purpura"", THROMBOSIS AND HAEMOSTASIS,          SCHATTAUER GMBH, DE, vol. 93, 7 January 2005          (2005-01-07), pages 267 - 274, XP003002325, ISSN:          0340-6245,relevantClaims[1-28],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            CSHL Press; ""UniProt"", Database accession no.          Q76LX8;            AUSTIN SKSTARKE RDLAWRIE ASCOHEN HMACHIN SJMACKIE IJ:          ""The VWF/ADAMTS13 axis in the antiphospholipid syndrome:          ADAMTS13 antibodies and ADAMTS 13 dysfunction"", BR J          HAEMATOL, vol. 141, no. 4, May 2008 (2008-05-01), pages          536 - 44;            BITSADZE VBOUVIER SKHIZROEVA JCOCHERY-NOUVELLON EMERCIER          EPEREZ-MARTIN AMAKATSARIYA AGRIS JC: ""Early ADAMTS13          testing associates with pre-eclampsia occurrence in          antiphospholipid syndrome"", THROMB RES, vol. 203, 27          April 2021 (2021-04-27), pages 101 - 109;            BURBELO PD1O'HANLON TP: ""New autoantibody detection          technologies yield novel insights into autoimmune          disease"", CURR OPIN RHEUMATOL, vol. 26, no. 6, November          2014 (2014-11-01), pages 717 - 23;            CASINA VCHU WMAO J-H ET AL.: ""High-resolution epitope          mapping by HX MS reveals the pathogenic mechanism and a          possible therapy for autoimmune TTP syndrome"", PROC.          NATL. ACAD. SCI., vol. 112, no. 31, 2015, pages 9620 -          9625;            CHAUHAN AKMOTTO DGLAMB CBBERGMEIER WDOCKAL MPLAIMAUER          BSCHEIFLINGER FGINSBURG DWAGNER DD: ""Systemic          antithrombotic effects of ADAMTS13"", J EXP MED., vol.          203, no. 3, 20 March 2006 (2006-03-20), pages 767 - 76,          XP002564641, DOI: 10.1084/jem.20051732;            CHEN XCHENG XZHANG SWU D: ""ADAMTS 13: An Emerging Target          in Stroke Therapy"", FRONT NEUROL, vol. 10, 17 July 2019          (2019-07-17), pages 772;            CRAWLEY JTDE GROOT RXIANG YLUKEN BMLANE DA: ""Unraveling          the scissile bond: how ADAMTS13 recognizes and cleaves          von Willebrand factor"", BLOOD, vol. 118, no. 12, 22          September 2011 (2011-09-22), pages 3212 - 21,          XP086506667, DOI: 10.1182/blood-2011-02-306597;  DE          GROOT RLANE DACRAWLEY JTB: ""The Role of the ADAMTS13          Cysteine-Rich Domain in VWF Binding and Proteolysis"",          BLOOD, vol. 125, no. 12, 2015, pages 1968 - 75;            ERCIG BWICHAPONG KREUTELINGSPERGER CPMVANHOORELBEKE          KVOORBERG JNICOLAES GAF: ""Insights into 3D Structure of          ADAMTS13: A Stepping Stone towards Novel Therapeutic          Treatment of Thrombotic Thrombocytopenic Purpura"", THROMB          HAEMOST, vol. 118, no. 1, January 2018 (2018-01-01),          pages 28 - 41;            GRAGA AG NERCIG BVELASQUEZ PEREIRA LC ET AL.: ""Modifying          ADAMTS13 to modulate binding of pathogenic autoantibodies          of patients with acquired thrombotic thrombocytopenic          purpura"", HAEMATOLOGICA, 21 November 2019          (2019-11-21);            HIE MLGAY JGALICIER LPROVOT FPRESNE CPOULLIN PBONMARCHAND          GWYNCKEL ABENHAMOU YVANHILLE P: ""Preemptive rituximab          infusions after remission efficiently prevent relapses in          acquired thrombotic thrombocytopenic purpura"", BLOOD,          vol. 124, no. 2, 10 July 2014 (2014-07-10), pages 204 -          10;            JIAN CXIAO JGONG L ET AL.: ""Gain-of-function ADAMTS13          variants that are resistant to autoantibodies against          ADAMTS13 in patients with acquired thrombotic          thrombocytopenic purpura"", BLOOD, vol. 119, no. 16, 2012,          pages 3836 - 3843, XP002800844, DOI:          10.1182/blood-2011-12-399501;            KELWICK RDESANLIS IWHEELER GNEDWARDS DR: ""The ADAMTS (A          Disintegrin and Metalloproteinase with Thrombospondin          motifs) family"", GENOME BIOL, vol. 16, 30 May 2015          (2015-05-30), pages 113, XP021223337, DOI:          10.1186/s13059-015-0676-3;            KLAUS CPLAIMAUER BSTUDT JDDORNER FLAMMLE BMANNUCCI          PMSCHEIFLINGER F: ""Epitope mapping of ADAMTS 13          autoantibodies in acquired thrombotic thrombocytopenic          purpura"", BLOOD, vol. 103, no. 12, 15 June 2004          (2004-06-15), pages 4514 - 9, XP055063609, DOI:          10.1182/blood-2003-12-4165;            KOKAME KNOBE YKOKUBO YOKAYAMA AMIYATA T: ""FRETS-VWF73, a          first fluorogenic substrate for ADAMTS 13 assay"", BR J          HAEMATOL, vol. 129, no. 1, April 2005 (2005-04-01), pages          93 - 100, XP055052565, DOI:          10.1111/j.1365-2141.2005.05420.x;            LEEM JDUNBAR JGEORGES GSHI JDEANE CM: ""ABodyBuilder:          Automated antibody structure prediction with data-driven          accuracy estimation"", MABS, vol. 8, no. 7, 2016, pages          1259 - 1268, XP055416058, DOI:          10.1080/19420862.2016.1205773;            LEVI MSCULLY MSINGER M: ""The role of ADAMTS-13 in the          coagulopathy of sepsis"", J THROMB HAEMOST, vol. 16, no.          4, April 2018 (2018-04-01), pages 646 - 651;  DE          MAEYER BDE MEYER SFFEYS HBPAREYN IVANDEPUTTE NDECKMYN          HVANHOORELBEKE K: ""The distal carboxyterminal domains of          murine ADAMTS 13 influence proteolysis of          platelet-decorated VWF strings in vivo"", J THROMB          HAEMOST, vol. 8, no. 10, October 2010 (2010-10-01), pages          2305 - 12;            MAZEPA MAMASIAS CCHATURVEDI S: ""How targeted therapy          disrupts the treatment paradigm for acquired TTP: the          risks, benefits, and unknowns"", BLOOD, vol. 134, no. 5, 1          August 2019 (2019-08-01), pages 415 - 420;            MILLER BRMCGEE TDSWAILS JM ET AL.: ""MMPBSA.py: An          efficient program for end-state free energy          calculations"", J. CHEM. THEORY COMPUT., vol. 8, no. 9,          2012, pages 3314 - 3321;            POS WLUKEN BMKREMER HOVINGA JA ET AL.: ""VH1-69 germline          encoded antibodies directed towards ADAMTS13 in patients          with acquired thrombotic thrombocytopenic purpura"", J.          THROMB. HAEMOST., vol. 7, no. 3, 2009, pages 421 - 428,          XP055014098, DOI:          10.1111/j.1538-7836.2008.03250.x;            POS WCRAWLEY JTBFIJNHEER R ET AL.: ""An autoantibody          epitope comprising residues R660, Y661, and Y665 in the          ADAMTS13 spacer domain identifies a binding site for the          A2 domain of VWF"", BLOOD, vol. 115, no. 8, 2010, pages          1640 - 1649;            POS WSORVILLO NFIJNHEER R ET AL.: ""Residues Arg568 and          Phe592 contribute to an antigenic surface for          anti-Adamtsl3 antibodies in the spacer domain"",          HAEMATOLOGICA, vol. 96, no. 11, 2011, pages 1670 -          1677;            RAMSI MAL ALI AS: ""Thrombocytopenia-associated          multiple-organ failure (TAMOF): recognition and          management"", BMJ CASE REP, 27 August 2018          (2018-08-27);            SCULLY MKNOBL PKENTOUCHE KRICE LWINDYGA JSCHNEPPENHEIM          RKREMER HOVINGA JAKAJIWARA MFUJIMURA YMAGGIORE C:          ""Recombinant ADAMTS-13: first-inhuman pharmacokinetics          and safety in congenital thrombotic thrombocytopenic          purpura"", BLOOD, vol. 130, no. 19, 9 November 2017          (2017-11-09), pages 2055 - 2063;            SCULLY MCATALAND SRPEYVANDI FCOPPO PKNOBL PKREMER HOVINGA          JAMETJIAN ADE LA RUBIA JPAVENSKI KCALLEWAERT F: ""HERCULES          Investigators. Caplacizumab Treatment for Acquired          Thrombotic Thrombocytopenic Purpura"", N ENGL J MED, vol.          380, no. 4, 24 January 2019 (2019-01-24), pages 335 -          346;            SINS JWRSCHIMMEL MLUKEN BMNUR EZEERLEDER SSVAN TUIJN          CFJBRANDJES DPMKOPATZ WFURBANUS RTMEIJERS JCM: ""Dynamics          of von Willebrand factor reactivity in sickle cell          disease during vaso-occlusive crisis and steady state"", J          THROMB HAEMOST, vol. 15, no. 7, July 2017 (2017-07-01),          pages 1392 - 1402;            TAO ZWANG YCHOI HBERNARDO ANISHIO KSADLER JELOPEZ JADONG          JF: ""Cleavage of ultralarge multimers of von Willebrand          factor by C-terminal-truncated mutants of ADAMTS-13 under          flow"", BLOOD, vol. 106, no. 01, 2005, pages 141 - 143,          XP008126519, DOI: 10.1182/blood-2004-11-4188;            THOMAS MRDE GROOT RSCULLY MACRAWLEY JT: ""Pathogenicity of          Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic          Thrombocytopenic Purpura"", EBIOMEDICINE, vol. 2, no. 8,          11 June 2015 (2015-06-11), pages 942 - 52;            TURECEK PLPECK RCRANGARAJAN SREILLY-STITT CLAFFAN MAKAZMI          RJAMES IDUSHIANTHAN ASCHRENK GGRITSCH H: ""Recombinant          ADAMTS13 reduces abnormally up-regulated von Willebrand          factor in plasma from patients with severe COVID-19"",          THROMB RES, vol. 201, May 2021 (2021-05-01), pages 100 -          112, XP086554996, DOI:          10.1016/j.thromres.2021.02.012;            XIAO JJIN SYXUE JSORVILLO NVOORBERG JZHENG XL: ""Essential          domains of a disintegrin and metalloprotease with          thrombospondin type 1 repeats-13 metalloprotease required          for modulation of arterial thrombosis"", ARTERIOSCLER          THROMB VASE BIOL, vol. 31, no. 10, October 2011          (2011-10-01), pages 2261 - 9",155379-0-0-0 M N P; 155379-0-0-0 CL NEW PRD USE,,,RA0B7H M N P,
IN202121020779-A,"Synthesizing remdesivir with reduced and controlled particle size, desired shape and surface morphology used for treating e.g. coronavirus, by dissolving (2S)-2-ethylbutyl 2-(((4-nitrophenoxy) (phenoxy) phosphoryl) amino) propanoate, heating, performing chiral separation, filtering, and drying",SIDDHESHWAR S S;  MAHAJAN M U;  SHAIKH S B;  GHORPADE S A,SIDDHESHWAR S S (SIDD-Individual),2021F06176,"   NOVELTY - Process for synthesizing remdesivir with reduced and controlled particle size, desired shape and surface morphology, involves (i) dissolving (2S)-2-ethylbutyl 2-(((4-nitrophenoxy) (phenoxy) phosphoryl) amino) propanoate followed by addition of (2R,3R,4S.5R)-2-(4-aminopyrrolo(2,1-f) (1,2,4)triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-carbonitrile and cooling, (ii) adding solution of isobutyl magnesium chloride, heating, distilling solvent followed by washing, extracting and purifying, (iii) transferring crude remdesivir along with solvent to crystallization reactor and maintaining at low temperature, filtering and drying, (iv) performing chiral separation, filtering, and drying, (v) preparing uniform solution of remdesivir, and fluidizing, (vi) converting fluidized liquid mass into a fine spray (mist), and performing sublimation of solvent, and (vii) transferring remdesivir powder to a drying chamber under inert atmosphere to obtain dried inhalation remdesivir.    USE - The method is used for synthesizing remdesivir with reduced and controlled particle size, desired shape and surface morphology for treating patients infected with SARS, MARS, COVID19, arenaviridae, coronaviridae, filoviridae, and paramyxoviridae viruses or any other flaviviridae family viruses (all claimed).    ADVANTAGE - The dry powder inhalation device has reduced physical resistance to the flow of the powder, higher product flow-ability and suitable for delivering remdesivir with high drug and/or powder content.    DETAILED DESCRIPTION - Process for synthesizing remdesivir with reduced and controlled particle size, desired shape and surface morphology, involves (i) dissolving (2S)-2-ethylbutyl 2-(((4-nitrophenoxy) (phenoxy) phosphoryl) amino) propanoate in a solvent at ambient temperature followed by addition of (2R,3R,4S.5R)-2-(4-aminopyrrolo(2,1-f) (1,2,4)triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-carbonitrile and cooling the reaction mixture, (ii) adding solution of isobutyl magnesium chloride to the reaction mixture of step (i) followed by controlled addition of potassium carbonate, heating the mixture until completion of the reaction, distilling the solvent followed by washing, extracting and purifying to obtain crude remdesivir, (iii) transferring the solution mass of crude remdesivir of step (ii) along with solvent to crystallization reactor and maintaining at low temperature to achieve complete precipitation, filtering through centrifuge and drying under vacuum, (iv) dissolving the solid mass of step (iii) in a mixture of solvent chosen from lower branched alcohols and aromatic hydrocarbons, performing chiral separation using preparative high performance liquid chromatography (HPLC) system, recovering the solvent and filtering the solid mass through centrifuge, and drying under vacuum, (v) preparing uniform solution of remdesivir of step (iv) with concentration of 1 wt.%/vol.% in a solvent chosen from lower branched alcohols, and/or ketones, and fluidizing the liquid mass, (vi) converting the fluidized liquid mass of step (v) into a fine spray (mist) in a cryogenic air medium under inert atmosphere, and performing sublimation of the solvent to obtain ultrafine particles of remdesivir powder, and (vii) transferring the remdesivir powder of step (vi) to a drying chamber under inert atmosphere to obtain dried inhalation remdesivir in the preferable shape of elongates with particle sizes of 1-5000 nm. INDEPENDENT CLAIMS are included for the following: (1)a remdesivir in the preferable shape of elongates, having particle sizes of 1-5000 nm, a tapped density of 0.10-0.30 g.cm3; (2)a dry powder inhalation (DPI) composition comprising (i) 8.75-52.5 mg remdesivir,(ii) 5-12.5 wt.% carbohydrate (fine particles), and (iii) 35-60 wt.% carbohydrate (coarse particles), where the carbohydrates are chosen from fructose, glucose, mannitol, maltose, trehalose, cellobiose, lactose, sucrose cyclodextrin, raffinose, xylitol, and maltodextrin in the form of fine and coarse particles; (3)a process for preparing a dry powder inhaler (DPI) composition, which involves (i) uniformly mixing carbohydrates of fine and coarse forms using 3-dimensional blending followed by sifting, and (ii) uniformly mixing carbohydrate blend with the remdesivir by using 3-dimensional blending and encapsulating the blend in capsules or blister packs or reservoir packs; (4)a remdesivir pressurized metered dose inhalation (pMDI) aerosol composition comprising (i) 2.9-42.5 mg remdesivir, (ii) propellant chosen from hydrofluoroalkane (HFAs), chlorofluorocarbon (CFCs), carbon dioxide, and/or nitrogen, preferably 1,1,1,2-tetrafluoroethane (HFA134a) and/or 1,1,1,2,3,3,3-heptafluoro-n-propane (HFA227), (iii) co-solvent(s) chosen from lower branched or 1-4C linear alkyl alcohols up to 25 wt.%/wt.% of the formulation, (iv) 0.1 wt.%/wt.% surfactants chosen from sorbitan trioleate such as Span 85 (RTM: Sorbitan trioleate), lecithin, oleic acid BP/EP/USP, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (80), sorbitan mono-oleate, and/or lecithins derived from natural sources, (v) 0.5 wt.%/wt.% sodium cromoglycate BP/EP/USP as mast cell stabilizer, and (vi) 1 wt.%/wt.% excipients; (5)a process for preparing the remdesivir pressurized metered dose inhalation (pMDI) for single stage pressurized suspension filling in metered dose inhaler; (6)a dry powder inhaler (DPI) device for delivering remdesivir powder for inhalation after encapsulation directly to lungs with substantial reduction in physical resistance while inhalation comprising; (7)a nebulizer composition comprising remdesivir together with excipients; and (8)a method for treating patients infected with severe acute respiratory syndrome (SARS), mixed antagonist response syndrome (MARS), coronavirus (COVID19), arenaviridae, coronaviridae, filoviridae, and paramyxoviridae viruses or any other flaviviridae family viruses. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B02 (Fused ring heterocyclics.);  A96 (Medical, dental, veterinary, cosmetic.)",B04-B01B;  B04-B03E;  B04-C02B1;  B04-C02B4;  B04-C03C;  B05-B01P;  B07-A02;  B10-A07A;  B10-A07B;  B10-C04E3;  B12-M01B;  B14-A02B5;  B14-K01D;  A11-C01A;  A12-V01;  A12-V04C;  A12-W05,A61K-031/355;  A61K-008/67;  A61K-008/92;  A61K-008/97;  A61Q-019/00,IN202121020779-A   26 Nov 2021   A61Q-019/00   202211Pages: 69   English,IN202121020779-A    IN21020779    07 May 2021,,IN21020779    07 May 2021,,,,,2629613-1-0-0 K M P; 196509-7-0-0 K M; 159573-1-0-0 K M; 949-1-0-0 K M; 100051-1-0-0 K M; 109254-1-0-0 K M; 90353-1-0-0 K M; 56978-2-0-0 K M; 2853-1-0-0 K M; 105371-1-0-0 K M; 110654-1-0-0 K M; 107454-1-0-0 K M; 99222-0-0-0 K M; 102701-2-0-0 K M; 92005-0-0-0 K M; 100049-0-0-0 K M; 135407-0-0-0 K M; 135417-0-0-0 K M; 135402-0-0-0 ; 107779-0-0-0 ; 444-0-0-0 ,,61435; 42995,RBEZ9W K M P; RA64CM K M; R00038 K M; R00290 K M; R07423 K M; R00292 K M; R06064 K M; R06063 K M; R00241 K M; R00135 K M; R06887 K M; R00545 K M; RA0338 K M; R10262 K M; R01833 K M; RA00JW K M; R00954 K M; RA061R K M; RA01JH K M; R24059 K M; R24080 K M; R24032 ; R01863 ; R00351 ,0038-S; 0290-S; 0292-S; 0241-S; 0135-S; 0545-S; 1833-S; 0954-S; 1869-S; 1870-S
IN202011021309-A,Virus Family Detection Mobile App which enables mobile phone to detect whether the surface is contaminated with microbes comprises many microdroplets comprising single nucleic acid template and many species of primer pairs,SINGH H;  PAWAR V P;  MANGAL A;  CHORDIYA S,SINGH H (SING-Individual);  PAWAR V P (PAWA-Individual);  MANGAL A (MANG-Individual);  CHORDIYA S (CHOR-Individual),2021F0612T,"   NOVELTY - Virus Family Detection Mobile App which enables mobile phone to detect whether the surface is contaminated with microbes such as coronavirus of 120 nm/0.12 mu m, or needs decontamination, comprises many microdroplets comprising single nucleic acid template and many species of primer pairs, each species of primer pairs being specific for different target site, where each of the single nucleic acid templates in the microdroplets comprise one of the different target sites that is recognized by only single species of primer pairs, where the single species of the primer pairs binds to the target site of the single nucleic acid template in each microdroplets. The microbes undetectable with mobile phone are detected by some other instruments.    USE - The app is useful for detecting the virus, influenza or coronavirus in biological sample comprising a prepared and unprepared sample such as whole blood, lymphatic fluids, serum, plasma, sweat, tear, saliva, sputum, cerebrospinal fluids, amniotic fluids, seminal fluids, vaginal excretions, serous fluids, synovial fluids, pericardial fluids, peritoneal fluids, pleural fluids, transudates, exudates, cystic fluids, bile, urine, gastric fluids, intestinal fluids, fecal samples, fluidized tissues, fluidized organisms, biological swabs and/or biological washes.    ADVANTAGE - The app fails to predict concentration of microbes, but distinguishes between dust/wood particles/water marks and microbe, The app enable highly sensitive and quantitative analysis of biomolecules, and are suitable for point-of-care diagnosis.    DETAILED DESCRIPTION - Virus Family Detection Mobile App which enables mobile phone to detect whether the surface is contaminated with microbes such as coronavirus of 120 nm/0.12 mu m, or needs decontamination, comprises many microdroplets comprising single nucleic acid template and many species of primer pairs, each species of primer pairs being specific for different target site, where each of the single nucleic acid templates in the microdroplets comprise one of the different target sites that is recognized by only single species of primer pairs, where the single species of the primer pairs binds to the target site of the single nucleic acid template in each microdroplets. The microbes undetectable with mobile phone are detected by some other instruments. Surface decontamination is effectively done by sanitizer and or UV-C. The size of the mobile imaging platform is (23x 10x 7 cm) 0r (22x 9x 6 cm) (lengthx widthx height). With this platform, a digital enzyme assay of bovine alkaline phosphatase is successfully completed. The digital influenza virus counting based on a fluorogenic assay for neuraminidase activity of the virus is demonstrated. The lower detection efficiency is due to its relatively lower signal-to-noise ratio than that found with conventional microscopes, and unavoidable intrinsic heterogeneity of neuraminidase activity among virus particles. The digital influenza virus counting with the mobile imaging platform still showed 105 times greater sensitivity than that with a commercial rapid influenza test kit. Virus detection of clinical samples was also successfully demonstrated, suggesting the potential to realize a highly sensitive point-of-care system for influenza virus detection with smartphones and also the human beings can check whether a surface is contaminated by corona virus or virus and then take appropriate action Similarly, the dose of sanitization or UV pulse light can be fixed. INDEPENDENT CLAIMS are also included for:    (1) a method of providing a droplet in contact with a surface with a reduced concentration of a substance, the method comprising (a) providing a surface in contact with a droplet comprising a starting concentration and starting quantity of the substance and having a starting volume,(b) conducting one or more droplet operations to merge a wash droplet with the droplet provided in step (a) to yield a combined droplet, and(c) conducting one or more droplet operations to divide the combined droplet to yield a set of droplets comprising (i) droplet in contact with the surface having a decreased concentration of the substance relative to the starting concentration, and(ii) a droplet which is separated from the surface; and    (2) a method of providing droplet in contact with surface with reduced concentration of substance, the method comprising: (a) providing droplet microactuator comprising a surface in contact with a droplet comprising a starting concentration and starting quantity of the substance and having a starting volume, (b) conducting one or more droplet operations to merge a wash droplet with the droplet provided in step (a) to yield a combined droplet, and (c) conducting one or more droplet operations to divide the combined droplet to yield a set of droplets comprising: (i) droplet in contact with the surface having a decreased concentration of the substance relative to the starting concentration, and (ii) a droplet which is separated from the surface. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  J04 (Chemical/physical processes/apparatus - including catalysis, catalysts (excluding specific e.g. enzymatic or polymerisation catalysts), colloid chemistry, laboratory apparatus and methods, testing, controlling, general encapsulation, detection and sampling (excluding clinical testing) (B01J, L).);  S03 (Scientific Instrumentation);  ",B04-E01;  B04-E05;  B04-E15;  B04-F11B2;  B04-L05A;  B04-L05B;  B11-C07B2;  B11-C08B;  B11-C08E3;  B11-C08F8;  B11-C08J;  B12-K04F;  B12-K04G1B;  C04-E01;  C04-E05;  C04-E15;  C04-F11B2;  C04-L05A;  C04-L05B;  C11-C07B2;  C11-C08B;  C11-C08E3;  C11-C08F8;  C11-C08J;  C12-K04F;  C12-K04G1B;  D05-H06A;  D05-H18B;  J04-B01A2;  J04-B03;  J04-F;  S03-E04D;  S03-E09F;  S03-E14H1;  S03-E14H2;  S03-E14H3;  T01-J05B4F;  T01-J12C;  T01-J20D;  T01-N02B1B;  W01-A06E1;  W01-C01D3C;  W01-C01G8S;  W01-C01Q,G01N-021/64;  G01N-033/543;  C12Q-001/70;  C12Q-001/04;  G06F-021/56,IN202011021309-A   26 Nov 2021   G01N-021/64   202207Pages: 34   English,IN202011021309-A    IN11021309    20 May 2020,,IN11021309    20 May 2020,,,,,101849-0-0-0 A K; 86944-0-0-0 A K,,,RA0PTU A K; RA02YD A K; RA05NO A K,
WO2021232095-A1,"Remote thermography inspection system for remotely undertaking thermal imaging inspection of e.g. machinery, has remote controller that receives imaging data from image capturing device and remotely controlling operation of device and mount",ERICHSEN J,ERICHSEN ASSET PTY LTD (ERIC-Non-standard),2021D5264P,"   NOVELTY - The system (100) has a moveable mount (120) which is operably associated with an on-site operator or a vehicle for mounting a thermal image capturing device relative to a subject or structure and moving the thermal image device. A remote controller (700) is in communication with the image device and the mount for receiving imaging data from the device and for remotely controlling operation of the image and mount in real time, in which the device is a cooled infrared camera and an uncooled infrared camera. A visual image device captures visual image data of the subject or the structure (900). The mount enables movement of the thermal device about three axes relative to the mount.    USE - Thermography inspection system for remotely undertaking a thermography inspection of a subject or structure. Uses include but are not limited to an electrical inspection, a medical screening tool for detecting suspected flu or covid19 cases, a condition monitoring and fault detection of structures such as machinery and buildings.    ADVANTAGE - The system enables a thermographer to remotely control and analyze thermal images of a subject or structure in real time without the associated costs and time required to travel onsite to a remote or isolated location, thus making thermography a cost-effective unit of any service program. The system provides a quicker and more efficient inspection system.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method of remotely undertaking a thermography inspection of a subject or structure.    DESCRIPTION OF DRAWING(S) - The drawing shows the schematic diagram of the thermography inspection system.    System (100)    Moveable mount (120)    Remote controller (700)    Structure (900) ",,,"Q68 (Other engineering elements (F16M-S));  S03 (Scientific Instrumentation);  T01 (Digital Computers);  W05 (Alarms, Signalling, Telemetry and Telecontrol)",Q68-A03;  S03-A03;  T01-J06A;  T01-J07D1;  W05-D07D;  W05-D08C,G01J-005/00;  F16M-011/12,WO2021232095-A1   25 Nov 2021   G01J-005/00   202199Pages: 47   English,WO2021232095-A1    WOAU050465    19 May 2021,,AU901620    20 May 2020,WO2021232095-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,WO2021232095-A1 -- US20050103930-A1   ;  US20130335550-A1   ;  US20150043769-A1   ;  US20180136642-A1   ;  US20180196135-A1   ;  US20190168787-A1   ;  US20200057012-A1   ;  US20200116195-A1   ;  US9401977-B1   GAW D C (GAWD-Individual)   GAW D C,,,,,,
BR102020009587-A2,Two-piece facial protector has visor and            adjustable strap that are obtained simultaneously on            polymeric sheet and single cutting equipment,NOGUEIRA A J,NOGUEIRA A J (NOGU-Individual),202249540P,"   NOVELTY - The protector has a visor (2) and an                adjustable strap that are obtained simultaneously                on a polymeric sheet and single cutting equipment.                The visor is cut in a rectangular pattern with an                intermediate corner (5). The concomitant with the                cut are made pairs of parallel notches. A right                notch and a left notch are provided in the vicinity                of the upper corners of the visors. The adjustable                strap of flat design has a knurled end with slots,                a jagged end, a recess that is accompanied by a                spout forming a proximal limiter and a trapezoidal                finish that forms a distal limiter.    USE - Two-piece facial protector.    ADVANTAGE - The protector enables the production of the                EPI in large volumes and in reduced time to meet                the demand caused by the pandemic of COVID19.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic diagram of the                two-piece facial protector.    Visor (2)    Polymeric blade (4)    Intermediate corner (5) ",,,"A83 (Clothing, footwear.);  P21 (Wearing apparel (A41, A42).)",A11-A05C;  A12-C02;  P21-F;  P21-N,A41D-013/11,BR102020009587-A2   23 Nov 2021   A41D-013/11   202235Pages: 19   ,BR102020009587-A2    BR10009587    14 May 2020,,BR10009587    14 May 2020,,,,,,,,,
PH1202050133-A1,"Exposure protection microscope mounted device, has            adjustable elastic strap that has hooks on both ends is            attached to triangular metal hole that is mounted to            transparent acrylic fiber glass that provides support            and stability to device",SORIANO L R J,SORIANO L R J (SORI-Individual),202225031T,"   NOVELTY - The exposure protection microscope mounted                device (EPMMD) has a microscope used to enclose a                working area of operation, provide a safer working                environment for a surgeon and other health workers                present in an operating room. The device adds                insurance and protection without compromising view                and maneuver of the surgeon while doing the                operation. A hole of an acrylic fiber glass is                inserted in a lens of the microscope and serves as                a frame for a transparent plastic drape to provide                a spacious enclosed working area for the operation.                An adjustable elastic strap that has hooks on both                ends is attached to a triangular metal hole that is                mounted to the transparent acrylic fiber glass that                provides support and stability to the device.    USE - EPMMD.    ADVANTAGE - The EPMMD prevents impact of lives of doctors                on protocols or operations in an operating room due                to rising cases of COVID19. The EPMMD avoids                wearing of full PPE by the doctors during the                operation or accessing the eyepiece of the                microscope during an operation. ",,,"A96 (Medical, dental, veterinary, cosmetic.);  P31 (Diagnosis, surgery (A61B).);  P81 (Optics (G02).)",A04-F01A;  A12-S08B;  A12-S08D;  A12-V03D;  P31-A05;  P81-A50C;  P81-U13;  P81-U14,A61B-090/40;  G02B-021/00,PH1202050133-A1   22 Nov 2021   A61B-090/40   202218Pages: 1   English,PH1202050133-A1    PH050133    15 May 2020,,PH050133    15 May 2020,,,,,,,,,
WO2021231044-A1;  EP4149351-A1;  US2023181120-A1;  EP4149351-A4,"Machine-learning based system for detecting            coronavirus based on wearable medical sensor data and            neural network processing that bypasses feature            extraction, comprises processors configured to interact            with wearable medical sensors",HASSANTABAR S;  JHA N K,UNIV PRINCETON (UPRT-C);  UNIV PRINCETON (UPRT-C);  UNIV PRINCETON (UPRT-C),2021D07304,"   NOVELTY - The system has processors that are configured                to interact with multiple wearable medical sensors                (WMSs). The processors are configured to receive                physiological data from the WMSs and questionnaire                data from a user interface. A neural network is                trained based on raw physiological data and                questionnaire data augmented with synthetic data                and subjected to a grow-and-prune paradigm to                generate one coronavirus inference model. A                coronavirus-based decision is outputted by                inputting the received physiological data and                questionnaire data into the generated coronavirus                inference model.    USE - Machine-learning based system for coronavirus                detection based on wearable medical sensor data and                neural network processing that bypasses feature                extraction.    ADVANTAGE - The method enables pervasive health condition                tracking and disease onset detection. The method                exploits the knowledge distillation capability of                machine learning algorithms to directly extract                information from physiological signals, thus                enabling disease detection in the clinical                scenarios.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a machine-learning based method for                coronavirus detection; and    (2) a non-transitory computer-readable medium                storing computer program for coronavirus                detection.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view of the                CovidDeep framework.    Edge device (32)    Data input (34)    Model training (38)    Initial architecture (40)    Generated synthetic dataset (60) ",,,"P31 (Diagnosis, surgery (A61B).);  S05 (Electrical Medical Equipment);  T01 (Digital Computers)",P31-A05;  S05-D01;  T01-J12;  T01-N01E;  T01-S03,A61B-005/00;  A61B-005/0205;  A61B-005/0533;  G16H-010/20;  G16H-050/80;  G16H-050/20,WO2021231044-A1   18 Nov 2021   A61B-005/0205   202202Pages: 39   English;  EP4149351-A1   22 Mar 2023   A61B-005/0205   202325   English;  US2023181120-A1   15 Jun 2023   A61B-005/00   202350   English;  EP4149351-A4   05 Jun 2024   A61B-005/0205   202448   English,WO2021231044-A1    WOUS028088    20 Apr 2021;   EP4149351-A1    EP805265    20 Apr 2021;   US2023181120-A1    US17923958    08 Nov 2022;   EP4149351-A4    EP805265    20 Apr 2021,EP4149351-A1 PCT application Application WOUS028088;   EP4149351-A1 Based on Patent WO2021231044;   US2023181120-A1 Provisional Application US022997P;   US2023181120-A1 Provisional Application US053912P;   US2023181120-A1 PCT application Application WOUS028088,US022997P    11 May 2020;  US053912P    20 Jul 2020;  WOUS028088    20 Apr 2021;  US17923958    08 Nov 2022,WO2021231044-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  EP4149351-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN    EP4149351-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  ,,WO2021231044-A1 -- US20140247151-A1   ;  US20180353085-A1   ,"WO2021231044-A1  LANDI: ""Boston          startup using Al, remote monitoring to fight          coronavirus."", FIERCE HEALTHCARE, 6 March 2020          (2020-03-06), pages 1 - 4, XP055872619, Retrieved from          the Internet          &lt;URL:https://www.fiercehealthcare.com/tech/boston-startup-using-ai-remote-monitoring-to-fight-coronavirus&gt;          [retrieved on          20210616],relevantClaims[1-44],relevantPassages[, entire          document];  YIN HONGXU, MUKADAM          BILAL, DAI XIAOLIANG, JHA NIRAJ K.: ""DiabDeep: Pervasive          Diabetes Diagnosis based on Wearable Medical Sensors and          Efficient Neural Networks"", CORNELL UNIVERSITY LIBRARY/          COMPUTER SCIENCE /COMPUTER VISION AND PATTERN          RECOGNITION, 11 October 2019 (2019-10-11), pages 1139 -          1150, XP011878936, Retrieved from the Internet          &lt;URL:https://arxiv.org/abs/1910.04925&gt;          [retrieved on          20210616],relevantClaims[1-44],relevantPassages[, entire          document]",,,,,
IN202011019784-A,"Biomarker trap system utilizing convalescent            plasma to develop diagnostic kits against infectious            diseases and chronic conditions comprises convalescent            plasma from disease negative, healthy individuals is            taken as negative control in assay",CHHABRA A,UNIV AMITY (UAMI-C),2021D97922,"   NOVELTY - Biomarker trap system comprises convalescent                plasma from disease negative, healthy individuals                is taken as negative control in the assay, and a                ligand to capture the antibodies to trap total                antibody pool of the recovered patient, on a                diagnostic strip or magnetic bead.    USE - Biomarker trap system utilizing convalescent                plasma to develop diagnostic kits against                infectious diseases and chronic conditions                (claimed). Test details are described but no                results are given.    ADVANTAGE - The system ensures the accuracy of data. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  S03 (Scientific Instrumentation)",B04-B04D4;  B04-E01;  B04-E02;  B04-E03;  B04-E05;  B04-F11;  B04-G08;  B11-C07A6;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  D05-H09;  D05-H10;  D05-H18B;  S03-E09F;  S03-E14H1,A61K-039/00;  C07K-014/005;  C12Q-001/70;  G01N-033/50;  G01N-033/569,IN202011019784-A   12 Nov 2021   A61K-039/00   202104Pages: 20   English,IN202011019784-A    IN11019784    11 May 2020,,IN11019784    11 May 2020,,,,,,,,,
WO2021226513-A1;  US2023175065-A1,"Evaluating propensity or risk of subject for            having or developing an autoimmune disease or disorder            comprises detecting C4A and C4B level in the subject's            genome, where increased C4A and C4B relative            indicatesreduced propensity or risk",KAMITAKI N;  MCCARROLL S,HARVARD COLLEGE (HARD-C);  HARVARD COLLEGE (HARD-C),2021C59935,"   NOVELTY - Evaluating (M1) the propensity or risk of a                subject for having or developing an autoimmune                disease or disorder comprises detecting in a sample                obtained from the subject a dosage of C4A and C4B                in the subject's genome, where increased dosage of                C4A and C4B relative to a reference indicate that                the subject has a reduced propensity or risk for                having or developing the autoimmune disease or                disorder.    USE - The method is useful in: evaluating the                propensity or risk for having or developing an                autoimmune disease or disorder i.e. systemic lupus                erythematosus (SLE) or Sjogren's syndrome (SjS)in a                subject's sample i.e.cells, plasma or cerebral                spinal fluid; and treating an autoimmune disorder                and inflammation associated with Corona virus                infection i.e.Covid19 in a subject i.e. male or                female (claimed). No biological data given.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for    (1) treating (M2) inflammation in a subject                comprising administering C4 inhibitor to the                subject to treat the inflammation; and    (2) treating (M3) an autoimmune disorder in a                subject, comprising administering C4 agonist,                activator, or C4 supplementing agent to the                subject, to treat the autoimmune disorder. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E99;  B04-E01;  B04-E02;  B04-E03;  B04-G01;  B04-G21;  B04-G23;  B11-C08E;  B11-C11;  B12-K04F;  B12-K04G2F;  B14-A02B5;  B14-C03;  B14-G02D;  B14-L06;  B14-N17;  D05-H99;  D05-H09,C12Q-001/6883;  A61P-037/06;  C07K-016/40,WO2021226513-A1   11 Nov 2021   C12Q-001/6883   202197Pages: 117   English;  US2023175065-A1   08 Jun 2023   C12Q-001/6883   202347   English,WO2021226513-A1    WOUS031376    07 May 2021;   US2023175065-A1    US17923872    07 Nov 2022,US2023175065-A1 Provisional Application US022372P;   US2023175065-A1 PCT application Application WOUS031376,US022372P    08 May 2020;  US17923872    07 Nov 2022,WO2021226513-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    ,,,,597066-0-0-0 K M,,,RAHVEM K M,
CN113628490-A;  CN113628490-B,"Virtual simulation method of putting on and taking            off secondary protective equipment, involves removing            disposable cap, disposable inner gloves, and washing            hands, and performing virtual exercises in sequence            according to tutorials",CHEN F;  HUANG J,SUZHOU VOCATIONAL HEALTH COLLEGE (SUZV-C);  SUZHOU VOCATIONAL HEALTH COLLEGE (SUZV-C),2021D1202M,"   NOVELTY - The method involves taking off a protective                face screen according to a tutorial. A virtual                undressing tutorial prompts the learner to take off                a disposable outer glove and the learner removes                the disposable outer glove according to the                tutorial. The virtual undressing tutorial prompts                the learner to take off the disposable medical                protective clothing and waterproof shoe covers. The                learner removes the disposable medical protective                clothing and waterproof shoe covers according to                the tutorial. The virtual undressing tutorial shows                the tutorials of removing the medical protective                mask. The disposable cap, disposable inner gloves,                and washing hands are removed in sequence, and the                learner performs virtual exercises in sequence                according to the tutorials.    USE - Virtual simulation method of putting on and                taking off secondary protective equipment. Can also                be used in various places and suitable for                emergencies like COVID19    ADVANTAGE - The students in large quantities are trained                and separated from the campus learning occasion and                the method is positive practical                significance.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a virtual                simulation system for putting on and taking off                secondary protective equipment. ",,,"P85 (Education, cryptography, adverts. (G09).)",P85-A05A;  P85-A01,G09B-009/00,CN113628490-A   09 Nov 2021   G09B-009/00   202101   Chinese;  CN113628490-B   04 Aug 2023   G09B-009/00   202367   Chinese,CN113628490-A    CN10935009    16 Aug 2021;   CN113628490-B    CN10935009    16 Aug 2021,CN113628490-B Previous Publ. Patent CN113628490,CN10935009    16 Aug 2021,,,"CN113628490-A -- CN108122436-A   INST PHARM & TOXICOLOGY ACAD                  MILITARY (JSYX)   ZHONG Y,  YING Y,  LIU H,  YANG H,  LIU Y,  HUANG C;  CN111713949-A   UNIV SHANGHAI MARITIME (USHM)   CHEN P,  XU X,  YOU K,  CHEN S;  CN111739133-A   SHA R (SHAR-Individual)   SHA R;  CN111742282-A   VALKYRIE IND LTD (VALK-Non-standard)   ISAKOV I,  ATEFIPOUR K,  CLEVELY-JONES O;  CN111860422-A   UNIV NORTHWEST NORMAL (UNWN)   ZHANG Q,  GUO R,  PEI Z,  WU X,  FU F,  ZHANG H,  LU J,  ZHANG X;  CN111882942-A   ZHEJIANG LANDI ELECTRIC POWER TECHNOLOGY (ZHEJ-Non-standard)   YAO H;  CN112755418-A   UNIV BEIJING JIAOTONG (UBJI)   XI Y,  MAO J,  LIAN H,  ZHOU Z;  CN213484985-U   LIUZHOU PEOPLES HOSPITAL (LZHP)   WEI X,  LAN M,  WEI F,  WANG Y,  LIAO Y,  XIE S;  KR2007120692-A   I-OMNI CO LTD (IOMN-Non-standard)   PARK C K,  KIM S M;  RU2006100934-A   ;  US20200178632-A1   ;  CN113628490-B -- CN104432684-A   XIAN JITANG ELECTRONIC TECHNOLOGY CO LTD (XIAN-Non-standard)   ZHENG Z;  CN108122436-A   INST PHARM & TOXICOLOGY ACAD                  MILITARY (JSYX)   ZHONG Y,  YING Y,  LIU H,  YANG H,  LIU Y,  HUANG C;  CN111713949-A   UNIV SHANGHAI MARITIME (USHM)   CHEN P,  XU X,  YOU K,  CHEN S;  CN111739133-A   SHA R (SHAR-Individual)   SHA R;  CN111742282-A   VALKYRIE IND LTD (VALK-Non-standard)   ISAKOV I,  ATEFIPOUR K,  CLEVELY-JONES O;  CN111815530-A   TANG J (TANG-Individual)   TANG J;  CN111860422-A   UNIV NORTHWEST NORMAL (UNWN)   ZHANG Q,  GUO R,  PEI Z,  WU X,  FU F,  ZHANG H,  LU J,  ZHANG X;  CN111882942-A   ZHEJIANG LANDI ELECTRIC POWER TECHNOLOGY (ZHEJ-Non-standard)   YAO H;  CN112755418-A   UNIV BEIJING JIAOTONG (UBJI)   XI Y,  MAO J,  LIAN H,  ZHOU Z;  CN202908727-U   BINZHOU MEDICAL COLLEGE (BINZ-Non-standard)   SU Q,  WANG S;  CN213215490-U   XIANGYANG CENT HOSPITAL (UYRU)   WANG Y,  CHAI Y,  PENG B;  CN213484985-U   LIUZHOU PEOPLES HOSPITAL (LZHP)   WEI X,  LAN M,  WEI F,  WANG Y,  LIAO Y,  XIE S;  DE102010019837-A1   TURNAU D G (TURN-Individual)   TURNAU D G,  TURNAU K M R,  TURNAU M T,  PASSMANN A E;  KR2007120692-A   I-OMNI CO LTD (IOMN-Non-standard)   PARK C K,  KIM S M;  RU2006100934-A   ;  US20200178632-A1   ",,,,,,
WO2021205411-A1;  US2021315939-A1;  AU2021253889-A1;  CA3179925-A1;  BR112022020441-A2;  IN202217062549-A;  EP4132548-A1;  KR2023022840-A;  IL297195-A;  US2023092673-A1;  JP2023515253-W;  CN115867298-A;  VN96929-A;  MX2022012692-A1;  EP4132548-A4,"Composition useful in pharmaceutical composition            for treating acute brain injury, acute organ failure,            arthritis or acute respiratory syndrome in human,            comprises modified human amniotic fluid (HAF), and            HAF-derived nanoparticles",MITRANI M I;  MITRANI M,ORGANICELL REGENERATIVE MEDICINE INC (ORGA-Non-standard);  ORGANICELL REGENERATIVE MEDICINE INC (ORGA-Non-standard);  ORGANICELL REGENERATIVE MEDICINE INC (ORGA-Non-standard);  ORGANICELL REGENERATIVE MEDICINE INC (ORGA-Non-standard);  ORGANIZE GENERIC MEDICINE INC (ORGA-Non-standard),2021B8157A,"   NOVELTY - Composition comprises (a) a modified human                amniotic fluid (HAF), and (b) HAF-derived                nanoparticles. The nanoparticles have a diameter of                greater than 30 nm. The composition comprises at                least 1x 108 HAF-derived nanoparticles/ml.    USE - The composition is useful in pharmaceutical                composition for (i) treating a lung disease or lung                disorder in a subject, (ii) treating acute brain                injury in a subject, (iii) treating acute organ                failure in a subject, and (iv) treating arthritis                in a subject. The lung disease or lung disorder is                chosen from acute respiratory syndrome, chronic                obstructive pulmonary disease (COPD) and                bronchopulmonary dysplasia. The subject is infected                with a coronavirus, preferably a COVID19 or                SARS-associated coronavirus (SARS-CoV2). The                arthritis is osteoarthritis or rheumatoid                arthritis. The subject is human (all                claimed).    ADVANTAGE - The composition is free of cells, bacteria,                fungus, yeast, lanugo and vernix.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a                pharmaceutical composition, which comprises (a) the                composition, and (b) one or more excipient or                additive. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.)",B04-C02E4;  B04-H02;  B04-H04B;  B04-H04C;  B04-H06A;  B04-H06G;  B04-H06H;  B04-H06M;  B04-N02;  B12-M11Q;  B12-M11Q1;  B14-A02B5;  B14-C09;  B14-K01;  B14-N16,A61K-031/7105;  A61K-031/728;  A61K-035/50;  A61K-038/00;  A61K-009/127;  A61K-009/51;  A61P-011/00;  A61P-019/02;  A61P-025/00;  A61P-029/00;  A61K-045/06;  A61P-031/14;  A61P-043/00;  A61K-031/4164;  A61K-009/00;  A61K-009/08;  A61K-009/10;  A61K-009/107;  A61K-009/14;  A61K-009/16;  A61K-009/19;  A61K-009/20;  A61K-009/48;  A61K-009/70;  B82Y-005/00;  A61K-038/17;  A61K-038/18;  A61K-038/19;  A61K-038/54;  A61P-009/00;  C12N-015/11;  C12N-005/071,WO2021205411-A1   14 Oct 2021   A61K-035/50   202188Pages: 79   English;  US2021315939-A1   14 Oct 2021   A61K-035/50   202188   English;  AU2021253889-A1   17 Nov 2022   A61K-035/50   202293   English;  CA3179925-A1   14 Oct 2021   202296   English;  BR112022020441-A2   20 Dec 2022   A61K-035/50   202310   ;  IN202217062549-A   27 Jan 2023   A61K-035/50   202312   English;  EP4132548-A1   15 Feb 2023   A61K-035/50   202315   English;  KR2023022840-A   16 Feb 2023   A61K-035/50   202316   ;  IL297195-A   01 Dec 2022   A61K-035/50   202318   English;  US2023092673-A1   23 Mar 2023   A61K-035/50   202325   English;  JP2023515253-W   12 Apr 2023   A61K-035/50   202330   Japanese;  CN115867298-A   28 Mar 2023   A61K-035/50   202330   Chinese;  VN96929-A   25 Aug 2023   A61K-035/50   202395   ;  MX2022012692-A1   08 Mar 2023   A61K-035/50   202437   Spanish;  EP4132548-A4   22 May 2024   A61K-035/50   202444   English,WO2021205411-A1    WOIB052982    10 Apr 2021;   US2021315939-A1    US226587    09 Apr 2021;   AU2021253889-A1    AU253889    10 Apr 2021;   CA3179925-A1    CA3179925    10 Apr 2021;   BR112022020441-A2    BR11020441    10 Apr 2021;   IN202217062549-A    IN17062549    02 Nov 2022;   EP4132548-A1    EP784900    10 Apr 2021;   KR2023022840-A    KR739360    10 Apr 2021;   IL297195-A    IL297195    10 Apr 2021;   US2023092673-A1    US990522    18 Nov 2022;   JP2023515253-W    JP562119    10 Apr 2021;   CN115867298-A    CN80041860    10 Apr 2021;   VN96929-A    VN006884    10 Apr 2021;   MX2022012692-A1    MX012692    10 Oct 2022;   EP4132548-A4    EP784900    10 Apr 2021,US2021315939-A1 Provisional Application US008355P;   AU2021253889-A1 PCT application Application WOIB052982;   AU2021253889-A1 Based on Patent WO2021205411;   CA3179925-A1 PCT application Application WOIB052982;   CA3179925-A1 Based on Patent WO2021205411;   BR112022020441-A2 PCT application Application WOIB052982;   BR112022020441-A2 Based on Patent WO2021205411;   IN202217062549-A PCT application Application WOIB052982;   IN202217062549-A Based on Patent WO2021205411;   EP4132548-A1 PCT application Application WOIB052982;   EP4132548-A1 Based on Patent WO2021205411;   KR2023022840-A PCT application Application WOIB052982;   KR2023022840-A Based on Patent WO2021205411;   IL297195-A Based on Patent WO2021205411;   US2023092673-A1 Cont of Application US226587;   US2023092673-A1 Provisional Application US008355P;   JP2023515253-W PCT application Application WOIB052982;   JP2023515253-W Based on Patent WO2021205411;   CN115867298-A PCT application Application WOIB052982;   CN115867298-A Based on Patent WO2021205411;   VN96929-A PCT application Application WOIB052982;   VN96929-A Based on Patent WO2021205411;   MX2022012692-A1 PCT application Application WOIB052982;   MX2022012692-A1 Based on Patent WO2021205411,US008355P    10 Apr 2020;  US226587    09 Apr 2021;  WOIB052982    10 Apr 2021;  BR11020441    07 Oct 2022;  CA3179925    07 Oct 2022;  VN006884    24 Oct 2022;  KR739360    10 Nov 2022;  US990522    18 Nov 2022;  CN80041860    09 Dec 2022,WO2021205411-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA            EP4132548-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN                EP4132548-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  ,,"WO2021205411-A1 -- US20180250343-A1   ;  WO2017003954-A1   STIMLABS LLC (STIM-Non-standard)   BERG R A,  DANIEL J,  GRIFFITHS S;  WO2017165698-A1   MIMEDX GROUP INC (MIME-Non-standard)   KOOB T J,  MASSEE M;  US2023092673-A1 -- WO2013082487-A1   CHILDRENS HOSPITAL LOS ANGELES (CHNA)   WARBURTON D,  PERIN L,  GARCIA O;  EP4132548-A4 -- US20170100439-A1   ;  US20190300848-A1   ","WO2021205411-A1  C LUKE DIXON,          SAMANTHA SHELLER-MILLER, GEORGE R SAADE, STEPHEN J          FORTUNATO, ANDREW LAI, CARLOS PALMA, DOMINIC GUANZON,          RAMKUMAR ME: ""Amniotic Fluid Exosome Proteomic Profile          Exhibits Unique Pathways of Term and Preterm Labor"", vol.          159, no. 5, 1 May 2018 (2018-05-01), pages 2229 - 2240,          XP055856270, DOI:          10.1210/en.2018-00073,relevantClaims[1-29],relevantPassages[abstract;          figure 1; pages 2233-2234];  XIE JUNTAO, ZHOU          YI, GAO WENZONG, LI ZUOQING, XU ZHE, ZHOU LI: ""The          relationship between amniotic fluid miRNAs and congenital          obstructive nephropathy"", AMERICAN JOURNAL OF          TRANSLATIONAL RESEARCH, vol. 9, no. 4, 1 January 2017          (2017-01-01), US, pages 174 - 1763, XP055856274, ISSN:          1943-8141,relevantClaims[14-18],relevantPassages[abstract;          page 1762]US2021315939-A1            Bazrafshan et al. (2014) J. Surg. Res. 188: 545-552.          (Year: 214);            Antounians et al. (2019) Scientific Reports 9: 1837 (11          pages) (Year: 2019);            Balbi et al. (2017) Stem Cells Translational Medicine 6:          1340-1355. (Year: 2017);            Herretes et al. (2006) American J. Ophthamology August          2006: 271-278. (Year: 2006);            Sheller-Miller et al. (2020) Methods in Enzymology, Vol.          645: 181-194. (Year: 2020)EP4132548-A4  MANUELA ZAVATTI ET          AL: ""Comparison of the therapeutic effect of amniotic          fluid stem cells and their exosomes on          monoiodoacetate-induced animal model of osteoarthritis"",          BIOFACTORS, OXFORD UNIVERSITY PRESS, OXFORD, GB, vol. 46,          no. 1, 18 October 2019 (2019-10-18), pages 106 - 117,          XP071859949, ISSN: 0951-6433, DOI:          10.1002/BIOF.1576,relevantClaims[1-15],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;|&lt;figure&gt;7&lt;/figure&gt;];  MITRANI MARIA INES          ET AL: ""Case Report: Administration of Amniotic          Fluid-Derived Nanoparticles in Three Severely Ill          COVID-19 Patients"", FRONTIERS IN MEDICINE, vol. 8, 17          March 2021 (2021-03-17), FR, XP093149687, ISSN:          2296-858X, DOI:          10.3389/fmed.2021.583842,relevantClaims[1-15],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];            See also references of WO 2021205411A1",88640-0-0-0 K M; 1536600-0-0-0 K M; 91489-0-0-0 K M; 94297-1-0-0 K M; 96810-0-0-0 K M; 97115-1-0-0 K M; 97940-0-0-0 K M; 97942-0-0-0 K M; 97946-0-0-0 K M; 97951-0-0-0 K M; 97954-0-0-0 K M; 97959-0-0-0 K M; 97961-0-0-0 K M; 114243-0-0-0 K M; 114760-0-0-0 K M; 123286-0-0-0 K M; 1536600-0-0-0 CL USE,,,R03361 K M; RARMJD K M; RA09LI K M; RA0O3V K M; RA02JJ K M; RA0366 K M; R03231 K M; RA04OA K M; RA04OB K M; R06364 K M; R16207 K M; RA04J4 K M; RA03SC K M; RA01IL K M; RA09LE K M; RA05ZJ K M; RA0QMT K M; RA03RK K M,1017-S
WO2021206897-A1;  US2021319229-A1;  EP4133404-A1,"Video analysis system for determining physical            information from video frame, has processor that            calculates physical distance between first object and            second object and generates distance alert based on            physical distance",SUBRAMANIAN G;  CELI J,SENSORMATIC ELECTRONICS LLC (SENS-C);  SENSORMATIC ELECTRONICS LLC (SENS-C);  SENSORMATIC ELECTRONICS LLC (SENS-C),2021B6621Y,"   NOVELTY - The video analysis system (100) has a                processor that is in communication with a memory to                receive the frames from a video stream (106). A                first object and a second object within the frames                are identified. A physical distance between the                first object and the second object is calculated                using a distance determination model that uses a                first size of a first bounding box around the first                object to determine a first depth component of a                first set of coordinates for the first object and                that uses a second size of a second bounding box                around the second object to determine a second                depth component of a second set of coordinates for                the second object. A distance alert is generated                based on the physical distance.    USE - Video analysis system for determining physical                information from video frame and/or counting                objects in video stream for generating distance                alert to avoid transmission and spread of viruses                such as COVID19.    ADVANTAGE - The system provides improved accuracy and                improved efficiency to such scenarios, and may                generate distance alerts and object count alerts                based on configurable settings. The retailers are                allowing shoppers inside a store in a controlled                fashion by manually checking the occupancy status                in the store and by manually checking social                distancing constraints, so that shoppers are safe                while shopping due to health concerns to avoid                transmission and spread of viruses. The systems                that allow for determining a physical distance                between objects in one or more frames of a video                stream and generating a distance alert, and/or for                counting objects in one or more frames of a video                stream and generating an object count alert. The                system switches between separate models that are                separately trained with data collected during                daytime and nighttime hours for model selection                based on time of day, which should yield better                results than a combined model.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) a method for determining physical                information from a video frame; and    (2) a non-transitory computer-readable medium                storing program for determining physical                information from video frame.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic diagram of a                system for determining physical distances between                objects and/or counting objects in a video stream                and generating corresponding alerts.    Video analysis system (100)    Video stream (106)    Video camera (108)    Monitored area (110)    Distance alert (112) ",,,T01 (Digital Computers);  T04 (Computer Peripheral Equipment),T01-J04A;  T01-J10B2;  T01-S03;  T04-D07D3,G06K-009/00;  G06T-007/00;  G06T-007/70;  G06T-007/55,WO2021206897-A1   14 Oct 2021   G06K-009/00   202185Pages: 25   English;  US2021319229-A1   14 Oct 2021   G06K-009/00   202186   English;  EP4133404-A1   15 Feb 2023   G06K-009/00   202315   English,WO2021206897-A1    WOUS023565    23 Mar 2021;   US2021319229-A1    US207100    19 Mar 2021;   EP4133404-A1    EP718424    23 Mar 2021,US2021319229-A1 Provisional Application US007900P;   EP4133404-A1 PCT application Application WOUS023565;   EP4133404-A1 Based on Patent WO2021206897,US007900P    09 Apr 2020;  US207100    19 Mar 2021,WO2021206897-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP4133404-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN  ,,"WO2021206897-A1 -- US20180068172-A1   ;  US2021319229-A1 -- US20180068171-A1   ;  US20220124294-A1   ;  US10614294-B1   VIDEOMINING CORP (VIDE-Non-standard);  SHARMA R (SHAR-Individual);  MUMMAREDDY S (MUMM-Individual);  HERSHEY J (HERS-Individual);  MOON H (MOON-Individual)   SHARMA R,  MUMMAREDDY S,  HERSHEY J,  MOON H","WO2021206897-A1  ANONYMOUS: ""Social          Distancing really matters - V-App"", 6 April 2020          (2020-04-06), pages 1 - 4, XP055803300, Retrieved from          the Internet          &lt;URL:https://www.v-app.io/2020/04/06/social-distancing-really-matters/&gt;          [retrieved on          20210511],relevantClaims[1,2,7,8,13,14],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;];  FABRIZIO FLACCO ET          AL: ""Depth space approach to human-robot collision          avoidance"", ROBOTICS AND AUTOMATION (ICRA), 2012 IEEE          INTERNATIONAL CONFERENCE ON, IEEE, 14 May 2012          (2012-05-14), pages 338 - 345, XP032450976, ISBN:          978-1-4673-1403-9, DOI:          10.1109/ICRA.2012.6225245,relevantClaims[1-18],relevantPassages[Section          II|Section III];  MICHAEL GORKOW:          ""Track Social Distancing Using Computer Vision | by          Michael Gorkow | Medium"", 29 April 2020 (2020-04-29),          pages 1 - 6, XP055803391, Retrieved from the Internet          &lt;URL:https://medium.com/@michaelgorkow/track-social-distancing-using-computer-vision-2032d35cbcb4&gt;          [retrieved on          20210511],relevantClaims[1-18],relevantPassages[&lt;pp&gt;W&lt;/pp&gt;]US2021319229-A1            Flacco et al., A Depth Space Approach to Human-Robot          Collision Avoidance, Mar. 2012, IEEE, pages 338-345          (Year: 2012)",,,,,
IN202041012963-A,"Preparing Annona squamosa based composition useful for treating corona virus (covid19), diabetes, malaria, and pancreatic cancer comprises collecting Annona squamosa stem and bark, extracting Annomosin A and Annosquamosin, and refluxing",GUNDA S K,GUNDA S K (GUND-Individual),2021B8220A,"   NOVELTY - Preparing Annona squamosa based composition comprises collecting stem and bark of an Annona squamosa plant, chipping into small pieces, extracting Annomosin A and Annosquamosin compounds (A, B, C, D, E, F, and G) by adding a polar solvent and water to small pieces of stem and bark to obtain an ayurvedic mixture, adding preservative to prepared ayurvedic mixture, subjecting ayurvedic mixture to reflux to remove polar solvent to obtain polar solvent free ayurvedic mixture, and subjecting polar solvent free ayurvedic mixture to distillation to obtain an Annona squamosa based composition.    USE - The composition is useful for treating corona virus (covid19), HIV, diabetes, malaria, varicella, pancreatic cancer, bubonic plague, fungus, severe fever with thrombocytopenia syndrome virus, Alzheimer's disease, asthma, Mycobacterium tuberculosis, inflammation, and cardiovascular disease.    ADVANTAGE - The composition: has good diuretic, and cytotoxic effects; and does not have any side effects. ",,,"B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.)",B04-A08G2;  B04-A10H;  B04-A10J;  B09-C02;  B10-C04C;  B14-A01A;  B14-A01B1A;  B14-A03B;  B14-A04;  B14-C03;  B14-C04;  B14-F01;  B14-F02;  B14-F03;  B14-H01E6;  B14-J01A4;  B14-K01A;  B14-S04;  B14-S18;  C04-A08G2;  C04-A10H;  C04-A10J;  C09-C02;  C10-C04C;  C14-A01A;  C14-A01B1A;  C14-A03B;  C14-A04;  C14-C03;  C14-C04;  C14-F01;  C14-F02;  C14-F03;  C14-H01E6;  C14-J01A4;  C14-K01A;  C14-S04;  C14-S18,A61K-036/185;  A61K-031/365;  C22C-038/02;  C23F-017/00;  A61K-047/69,IN202041012963-A   01 Oct 2021   A61K-036/185   202191Pages: 25   English,IN202041012963-A    IN41012963    25 Mar 2020,,IN41012963    25 Mar 2020,,,,,871665-0-0-0 K M;  K M;  K M;  K M;  K M;  K M;  K M;  K M; 311-0-0-0 K M,,04804,RADMXP K M; RD45M7 K M; RD45M8 K M; RD45M9 K M; RD45MA K M; RD45MB K M; RD45MC K M; RD45MD K M; R01333 K M; RBNWXX K M,1333-S
WO2021177553-A1;  KR2021112570-A;  KR2304498-B1;  CA3152970-A1;  CN114450018-A;  US2022168375-A1;  JP2022545288-W;  HK40065317-A0;  EP4115895-A1;  MX2022002174-A1;  JP7471393-B2;  EP4115895-A4,Anti-respiratory virus composition used as            pharmaceutical composition or health functional food            for treating and preventing respiratory virus-related            diseases comprises rock pine extract,NAM J H,NAM J H (NAMJ-Individual);  NAM J H (NAMJ-Individual);  NAM J H (NAMJ-Individual),2021A3749N,"   NOVELTY - Anti-respiratory virus composition comprises                rock pine extract as an active ingredient.    USE - The anti-respiratory virus composition is                useful in pharmaceutical composition and health                functional food for preventing and treating                respiratory virus-related diseases, where the                respiratory virus is adenovirus, metapneumovirus,                rhinovirus, parainfluenza virus, influenza virus,                respiratory syncytial virus and coronavirus,                preferably coronavirus. The pharmaceutical                composition is in the form of tablets, pills,                powders, granules, capsules, suspoemulsions,                syrups, aerosols, external preparations,                suppositories or injections. The health functional                food is in the form of powder, granule, tablet,                capsule, candy, chewing gum, jelly and beverage,                preferably health functional tea (all claimed). The                food is useful as a supplement. The composition is                useful for enhancing immunity. The coronavirus is                COVID19, TGEV of pigs and porcine epidemic diarrhea                virus (PEDV). The respiratory virus includes mutant                viruses.    ADVANTAGE - The composition quickly responds to a virus                that gets mutated continuously and has no side                effects as it comprises natural components. The                composition increases the immunity when consumed                continuously. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).)",B04-A08;  B04-A10;  B04-A98;  B14-A02;  B14-G01;  B14-K01;  B14-S12;  B14-S18;  C04-A08;  C04-A10;  C04-A98;  C14-A02;  C14-G01;  C14-K01;  C14-S12;  C14-S18;  D03-D03;  D03-E09;  D03-E10A;  D03-H01J;  D03-H01T2B,A23L-033/105;  A61K-036/342;  A61K-036/41;  A61P-031/14;  A23F-003/14;  A23F-003/34;  A61K-036/315;  A61P-031/12;  A23G-003/36;  A23G-003/48;  A23G-004/06;  A23G-004/12;  A23L-002/52;  A23L-021/10;  A61K-035/644;  A61K-036/9068;  A61P-031/16;  A23F-003/00;  A61K-036/46;  A61K-045/06;  A61K-009/00;  A23L-002/38;  A61K-036/12;  A61K-036/237;  A61K-036/258;  A61K-036/284;  A61K-036/288;  A61K-036/344;  A61K-036/43;  A61K-036/48;  A61K-036/481;  A61K-036/484;  A61K-036/53;  A61K-036/537;  A61K-036/539;  A61K-036/69;  A61K-036/725;  A61K-036/752;  A61K-036/79;  A61K-036/815;  A61K-036/88;  A61K-036/894;  A61K-036/896;  A61K-036/9066;  A61P-011/00;  A61P-031/20;  A61P-043/00,WO2021177553-A1   10 Sep 2021   A61K-036/41   202180Pages: 23   ;  KR2021112570-A   15 Sep 2021   A61K-036/41   202180   ;  CA3152970-A1   10 Sep 2021   A61K-036/41   202229   English;  CN114450018-A   06 May 2022   A61K-036/41   202241   Chinese;  US2022168375-A1   02 Jun 2022   A61K-036/46   202245   English;  JP2022545288-W   26 Oct 2022   A61K-036/41   202287   Japanese;  HK40065317-A0   22 Jul 2022   A61K-036/41   202302   English;  EP4115895-A1   11 Jan 2023   A61K-036/41   202304   English;  MX2022002174-A1   22 Mar 2022   A61K-036/41   202382   Spanish;  JP7471393-B2   19 Apr 2024   A61K-036/41   202435   Japanese;  EP4115895-A4   24 Apr 2024   A23L-033/105   202436   English,WO2021177553-A1    WOKR017454    02 Dec 2020;   KR2021112570-A    KR027724    05 Mar 2020;   KR2304498-B1    KR027724    05 Mar 2020;   CA3152970-A1    CA3152970    02 Dec 2020;   CN114450018-A    CN80057132    02 Dec 2020;   US2022168375-A1    US678114    23 Feb 2022;   JP2022545288-W    JP512465    02 Dec 2020;   HK40065317-A0    HK6054329    30 May 2022;   EP4115895-A1    EP922686    02 Dec 2020;   MX2022002174-A1    MX002174    21 Feb 2022;   JP7471393-B2    JP512465    02 Dec 2020;   EP4115895-A4    EP922686    02 Dec 2020,CA3152970-A1 PCT application Application WOKR017454;   CA3152970-A1 Based on Patent WO2021177553;   CN114450018-A PCT application Application WOKR017454;   CN114450018-A Based on Patent WO2021177553;   US2022168375-A1 Cont of Application WOKR017454;   JP2022545288-W PCT application Application WOKR017454;   JP2022545288-W Based on Patent WO2021177553;   HK40065317-A0 PCT application Application WOKR017454;   HK40065317-A0 Based on Patent WO2021177553;   HK40065317-A0 Previous Publ. Patent CN114450018;   EP4115895-A1 PCT application Application WOKR017454;   EP4115895-A1 Based on Patent WO2021177553;   MX2022002174-A1 PCT application Application WOKR017454;   MX2022002174-A1 Based on Patent WO2021177553;   JP7471393-B2 PCT application Application WOKR017454;   JP7471393-B2 Previous Publ. Patent JP2022545288;   JP7471393-B2 Based on Patent WO2021177553,KR027724    05 Mar 2020;  CN80057132    02 Dec 2020;  WOKR017454    02 Dec 2020;  CN80057132    11 Feb 2022;  CA3152970    25 Feb 2022,WO2021177553-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA              EP4115895-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN      EP4115895-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  ,,"WO2021177553-A1 -- KR2014072464-A   UNIV INJE IND ACADEMIC COOP FOUND (UYIJ)   LEE D S,  LEE H S,  LEE G S,  RYE D S,  KIM S H,  KWON J H,  SUK D H;  KR2017003153-A   LEE C R (LEEC-Individual)   BOK I S,  CHUNG R L,  DAE Y H,  KIM D S;  KR2018040912-A   JEJU TECHNOPARK (JEJU-Non-standard)   YOON W J,  KIM C S,  LEE Y B,  HAM Y M,  OH D J,  YOON S A,  SONG S M,  LEE S T,  HONG I C,  HYUN H B;  KR1943475-B1   YOUNG K S (YOUN-Individual)   YOUNG K S;  CN114450018-A -- CN102665742-A   KOREA ORIENTAL MEDICINE INST (KOOR)   MA J Y,  UM Y R,  LEE J H;  CN104758362-A   ZIBO QIDINGLI PATENT INFORMATION CONSULT (ZBQD)   TIAN L;  CN105213872-A   JIE Y (JIEY-Individual)   DU Y,  JIE Y;  CN109328066-A   DONG WHA PHARM CO LTD (DONG-Non-standard)   YOON J B,  LEE H Y,  YOUM J H,  KIM K,  JEON J H,  CHANG H B,  WOO J Y,  YOON M H,  CHOI M S,  CHOI D R;  EP4115895-A4 -- CN108339017-A   AMICOGEN INC (AMIC-Non-standard)   SHIN Y,  PARK C,  KIM Y,  JIN A;  KR2017006359-A   MUN B G (MUNB-Individual)   MUN B G;  KR1608476-B1   MA O C (MAOC-Individual)   MA O C;  KR1943475-B1   YOUNG K S (YOUN-Individual)   YOUNG K S;  WO2017179931-A1   DONG WHA PHARM CO LTD (DONG-Non-standard)   YOON J B,  LEE H Y,  YOUM J H,  KIM K,  JEON J H,  CHANG H B,  WOO J Y,  YOON M H,  CHOI M S,  CHOI D R","WO2021177553-A1  PARK, JU-GWON;PARK,          JONG-CHEOL;HUR, JONG-MOON;PARK, SUNG-JONG;CHOI,          DA-RAE;SHIN, DONG-YOUNG;PARK, KY-YOUNG;CHO,          HYUN-WOOK;KIM, MOO: ""Phenolic Compounds from Orostachys          japonicus having Anti-HIV-1 Protease Activity"", NATURAL          PRODUCT SCIENCES, KOREAN SOCIETY OF PHARMACOGNOSY, SEOUL,          KR, vol. 6, no. 3, 1 September 2000 (2000-09-01), KR,          pages 117 - 121, XP053005603, ISSN:          1226-3907,relevantClaims[5,6]EP4115895-A4  PARK JU-GWON ET AL:          ""Phenolic Compounds from Orostachys japonicus having          Anti-HIV-1 Protease Activity"", NATURAL PRODUCT SCIENCES,          KOREAN SOCIETY OF PHARMACOGNOSY, SEOUL, KR, vol. 6, no.          3, 1 September 2000 (2000-09-01), pages 117 - 121,          XP053005603, ISSN:          1226-3907,relevantClaims[1-4|9,13|5-8,10-12],relevantPassages[&lt;pp&gt;A&lt;/pp&gt;];            See also references of WO 2021177553A1",200757-0-0-0 K M,,,RA00GT K M,
WO2021175296-A1;  CN113354699-A;  CN113354699-B,"Preparing remdesivir useful for treating e.g.            hepatitis C virus, coronavirus, respiratory syncytial            virus and Lassa fever virus, comprises performing            deprotection- and ring-forming reaction of            pyrrolo(2,1-f)(1,2,4)triazine compound",XIE Y;  HU T;  ZHU F;  TIAN G;  SHEN J,SHANGHAI INST MATERIA MEDICA CAS (CAMM-C);  VIGONVITA LIFE SCI CO LTD (VIGO-Non-standard);  TOPHARMAN SHANGHAI CO LTD (TOPH-Non-standard);  CHINESE ACAD SCI SHANGHAI MATERIA MEDIC (CAMM-C);  TOPHARMAN SHANGHAI CO LTD (TOPH-Non-standard);  SUZHOU WSWS BIOLOGICAL PHARM CO LTD (SUZH-Non-standard);  SHANGHAI MATERIA MEDICA CAS INST (CAMM-C),2021A4024D,"   NOVELTY - Preparing remdesivir (V), comprises either:                (a) performing deprotection reaction and a                ring-forming reaction of                pyrrolo(2,1-f)(1,2,4)triazine compound (IV); or (i)                producing pyrrolo(2,1-f)(1,2,4)triazine compound                (IV) (M2) by reacting nitrogen based compound (II)                and triazine compound (III), and performing                deprotection reaction and a ring-forming reaction                of pyrrolo(2,1-f)(1,2,4)triazine compound (IV) to                obtain intermediate of remdesivir (V).    USE - (I) are useful in medicament for treating and                preventing RNA viruses including hepatitis C virus,                coronavirus (i.e. severe acute respiratory syndrome                (SARS) and Middle East respiratory syndrome                (MERS)), respiratory syncytial virus and Lassa                fever virus.    ADVANTAGE - The method produces remdesivir with low costs,                high yield and good product purity, and can achieve                the efficient synthesis of remdesivir.    DETAILED DESCRIPTION - Preparing remdesivir of formula (V), comprises                either: (a) performing deprotection reaction and a                ring-forming reaction of                pyrrolo(2,1-f)(1,2,4)triazine compound of formula                (IV); or (i) producing                pyrrolo(2,1-f)(1,2,4)triazine compound (IV) (M2) by                reacting nitrogen based compound of formula (II)                and triazine compound of formula (III), and                performing deprotection reaction and a ring-forming                reaction of pyrrolo(2,1-f)(1,2,4)triazine compound                (IV) to obtain intermediate of remdesivir                (V).    R1 and R2 = hydroxy protecting group, or R1                and R2 groups on adjacent carbon atoms are bonded                together to form -C(R6)2-group or -CH(phenyl)-                group;    R6 = H, 1-8C alkyl, phenyl or substituted                phenyl, or two R6 and the connected C atoms are                bonded together to form optionally substituted 5-7                membered carbocyclic ring;    R3 = hydroxy protecting group;    R8 = -NHW1;    W1 = H or amino protecting group;    PG1 = H or silyl substituent;    R4 and R5 = 1-6C alkyl, 2-6C alkenyl, 2-6C                alkynyl, or 1-6C alkoxy (all are optionally                substituted by G1); or    R4+R5+N = 4- to 8-membered heterocycloalkyl                group containing 1-2 N heteroatoms and 0-1                heterosatoms of O or S; and    G1 = 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl,                1-6C alkoxy, 3-6C cycloalkyl, halo, 1-3C haloalkyl,                nitro, 6-10C aryl or benzyl.     INDEPENDENT CLAIMS are also included                for    (1) pyrrolo(2,1-f)(1,2,4)triazine compound                (IV);    (2) producing pyrrolo(2,1-f)(1,2,4)triazine                compound (IV) (M2) by the above method;    (3) nitrogen based compound (II);    (4) producing nitrogen based compound (II),                comprising (c) reacting amine based compound of                formula (R4-NH-R5) (IIa) and substituted                dihydrofuran-2(3H)-one compound of formula                (IIb);    (5) producing radcivsir, comprising using                pyrrolo(2,1-f)(1,2,4)triazine compound of formula                (IV) as intermediate to prepare radcivir; and    (6) use of the nitrogen based compound (II) or                pyrrolo(2,1-f)(1,2,4)triazine compound of formula                (IV) as intermediate for preparation of                remdesivir.    X = halo. ",,,B02 (Fused ring heterocyclics.),B04-B03D;  B06-H;  B07-H;  B14-A02B;  B14-C04;  B14-D06A;  B14-K01D;  B14-L01A2,C07H-007/06;  C07C-259/06;  C07D-295/185;  C07D-487/04;  C07F-007/18;  C07F-009/6561;  C07H-001/00,WO2021175296-A1   10 Sep 2021   C07H-007/06   202182Pages: 43   Chinese;  CN113354699-A   07 Sep 2021   C07H-007/06   202182   Chinese;  CN113354699-B   18 Jul 2023   C07H-007/06   202368   Chinese,WO2021175296-A1    WOCN079143    04 Mar 2021;   CN113354699-A    CN10241961    04 Mar 2021;   CN113354699-B    CN10241961    04 Mar 2021,CN113354699-B Previous Publ. Patent CN113354699,CN10144431    04 Mar 2020,WO2021175296-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): AL;  AT;  BE;  BG;  BW;  CH;  CY;  CZ;  DE;  DK;  EA;  EE;  ES;  FI;  FR;  GB;  GH;  GM;  GR;  HR;  HU;  IE;  IS;  IT;  KE;  LR;  LS;  LT;  LU;  LV;  MC;  MK;  MT;  MW;  MZ;  NA;  NL;  NO;  OA;  PL;  PT;  RO;  RS;  RW;  SD;  SE;  SI;  SK;  SL;  SM;  ST;  SZ;  TR;  TZ;  UG;  ZM;  ZW      ,,"WO2021175296-A1 -- CN111440176-A   UNIV JIANGSU (UYJS)   ZHU C,  XIA H;  WO2012012776-A1   GILEAD SCI INC (GILE)   MACKMAN R L,  PARRISH J P,  RAY A S,  THEODORE D A;  WO2016069826-A1   GILEAD SCI INC (GILE)   CHUN B K,  CLARKE M O N H,  DOERFFLER E,  HUI H C,  JORDAN R,  MACKMAN R L,  PARRISH J P,  RAY A S,  SIEGEL D;  CN113354699-A -- CN102596979-A   GILEAD SCI INC (GILE)   BUTLER T,  CHO A,  GRAETZ B R,  KIM C U,  METOBO S E,  SAUNDERS O L,  WALTMAN A W,  XU J,  ZHANG L;  CN107073005-A   GILEAD SCI INC (GILE)   CHUN B K,  CLARKE M O N H,  DOERFFLER E,  HUI H C,  JORDAN R,  MACKMAN R L,  PARRISH J P,  RAY A S,  SIEGEL D;  CN113214263-A   BEIJING CHEMPION TECHNOLOGY CO LTD (BEIJ-Non-standard)   GU R,  LI Y;  CN113354699-B -- CN105873938-A   SCINOPHARM TAIWAN LTD (SNPH);  SCINOPHARM SINGAPORE PTE LTD (SNPH)   ZHANG X,  MEI L;  CN106188193-A   SUZHOU VIGONVITA LIFE SCI CO LTD (SUZH-Non-standard);  TOPHARMAN SHANDONG CO LTD (TOPH-Non-standard);  SHANGHAI INST MATERIA MEDICA CAS (CAMM)   HU T,  JIANG X,  SHEN J,  TIAN G","CN113354699-A  ERWIN R. VAN          RIJSSEL ET AL.: ""Stereoselectivity in the Lewis Acid          Mediated Reduction of Ketofuranoses"", JOURNAL OF ORGANIC          CHEMISTRY,relevantClaims[10-12],relevantPassages[4553-4565]",,225846001 K P; 225846002 N P; 225846003 N P U,00956; 61435,,
CN113350497-A,"New coronary pneumonia vaccine mixed with measles            attenuated vaccine comprises measles attenuated            vaccine, and the coronary pneumonia inactivated            vaccine",YU Y,YIQI SHANGHAI INTELLIGENT TECHNOLOGY CO (YIQI-Non-standard),2021A77174,"   NOVELTY - Coronary pneumonia vaccine mixed with measles                attenuated vaccine comprises measles attenuated                vaccine, and the coronary pneumonia inactivated                vaccine, is new. The measles attenuated vaccine is                currently frequently used live measles vaccine. The                coronary pneumonia inactivated vaccine is a vaccine                made after the new coronary pneumonia virus is                inactivated.    USE - Used as coronary pneumonia vaccine mixed with                measles attenuated vaccine.    ADVANTAGE - The vaccine induce an immune response in the                human body through a live attenuated measles                vaccine antibody to the pneumonia (COVID19)                virus. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B11-C05;  B12-M10E2;  B14-A02B2;  B14-A02B5;  B14-G01;  B14-K01;  B14-S11A;  B14-S11D1;  B14-S11D2;  D05-H07,A61K-039/165;  A61K-039/215;  A61K-039/295;  A61P-031/14,CN113350497-A   07 Sep 2021   A61K-039/295   202179Pages: 3   Chinese,CN113350497-A    CN10723215    29 Jun 2021,,CN10723215    29 Jun 2021,,,,,,,,,
CN113350496-A,"New coronal pneumonia vaccine with mixed            attenuated vaccine useful for improving immune response            in human body through attenuated vaccine strain,            comprising attenuated vaccine and coronal pneumonia            inactivated vaccine",YU Y,YIQI SHANGHAI INTELLIGENT TECHNOLOGY CO (YIQI-Non-standard),2021A7604X,"   NOVELTY - Coronal pneumonia vaccine with mixed                attenuated vaccine comprising attenuated vaccines,                coronal pneumonia inactivated vaccine, where the                attenuated vaccine is a widely used live attenuated                vaccine and the coronal pneumonia inactivated                vaccine is vaccine prepared by mixing the coronal                pneumonia virus with distilled water after                inactivation, is new.    USE - The coronal pneumonia vaccine with mixed                attenuated vaccine is useful for improving immune                response in the human body through attenuated                vaccine strains.    ADVANTAGE - The vaccine: can uses coronary pneumonia                (COVID19) inactivated vaccine to allow the immune                system to recognize the method to allow the body to                produce antibodies against the coronary pneumonia                virus. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B11-C05;  B14-A02B5;  B14-G01;  B14-K01D;  B14-S11D1;  B14-S11D2;  D05-H07,A61K-039/295;  A61K-039/215;  A61K-039/165;  A61P-031/14,CN113350496-A   07 Sep 2021   A61K-039/295   202180Pages: 3   Chinese,CN113350496-A    CN10723111    29 Jun 2021,,CN10723111    29 Jun 2021,,,,,,,,,
CN113345595-A;  CN113345595-B,"Epidemic disease intervention method based on            detection and contact tracking on time series network,            involves counting proportion of recovered nodes and            dead nodes in network at steady state, and solving            critical threshold of spread of epidemic disease",WANG B;  HONG X;  HAN Y;  LI W,UNIV SHANGHAI (USHN-C),2021A5513A,"   NOVELTY - The method involves constructing (S1) a                susceptibility-latency-infection-recovery-death-hospitalization                (SEIRDH) model based on detection and contact                tracking according to the mean field theory. The                evolution rule of the timing network is established                (S2). The dynamic evolution process of the spread                of the epidemic disease is simulated (S3) according                to the evolution rules of the time series network.                The proportion of recovered nodes and dead nodes is                counted (S4) in the network at steady state. The                critical threshold of spread of epidemic disease is                solved (S5).    USE - Epidemic disease intervention method based on                detection and contact tracking on time series                network applied in time-series networks and                controlling spread of epidemic disease.    ADVANTAGE - The method considers intervention measures                such as detection and contact tracking on the                timing network such that the dynamic equation of                the SEIRDH model based on detection and contact                tracing is derived through the mean field theory,                critical threshold is theoretically solved, and the                guidance for dealing with Covid19 or other sudden                epidemic disease is provided in the future.    DESCRIPTION OF DRAWING(S) - The drawing shows the flochart illustrating                the epidemic disease intervention method based on                detection and contact tracking on time series                network. (Drawing includes non-English language                text)    Step for constructing SEIRDH model                (S1)    Step for establishing evolution rule of                timing network (S2)    Step for simulating dynamic evolution process                of spread of epidemic disease (S3)    Step for counting proportion of recovered                nodes and dead nodes in network at steady state                (S4)    Step for solving critical threshold of spread                of epidemic disease (S5) ",,,S05 (Electrical Medical Equipment);  T01 (Digital Computers),S05-G02G9;  S05-P;  T01-N01E1,G16H-050/50;  G16H-050/80,CN113345595-A   03 Sep 2021   G16H-050/80   202177Pages: 15   Chinese;  CN113345595-B   09 Jun 2023   G16H-050/80   202351   Chinese,CN113345595-A    CN10532703    17 May 2021;   CN113345595-B    CN10532703    17 May 2021,CN113345595-B Previous Publ. Patent CN113345595,CN10532703    17 May 2021,,,"CN113345595-A -- CN112529329-A   GUANGDONG ZHUJIANG CHILINK INFORMATION (GUAN-Non-standard)   TAN X,  CAO L,  QING Z;  CN112599248-A   UNIV SHANGHAI (USHN)   WANG B,  XIE Z,  HAN Y;  CN112734153-A   UNIV CHILDRENS HOSPITAL CHONGQING MEDICA (UCQM)   LIANG X,  LV G,  BI Y,  YANG K,  XIAO L,  TANG X;  US20200061026-A1   ;  CN113345595-B -- CN112133443-A   UNIV SHANGHAI (USHN)   WANG B,  ZENG H,  HAN Y",,,,,,
IN202041029265-A,"Herbal disinfectant used for pandemic condition Covid19, preferably in destroying harmful microorganisms, has e.g. giloy, Ashwagandha, neem, tulsi, Eucalyptus, Citrus, clove and cinnamon extracts along with soapnut, and natural fragrance",QAMAR S;  ALAM T;  PANWAR N;  DUBEY R;  KUMAR M;  SWARUP C,QAMAR S (QAMA-Individual);  ALAM T (ALAM-Individual);  PANWAR N (PANW-Individual);  DUBEY R (DUBE-Individual);  KUMAR M (KUMA-Individual);  SWARUP C (SWAR-Individual),2021928336,"   NOVELTY - Herbal disinfectant composition comprises: giloy extract, Ashwagandha extract, neem extract, tulsi extract, Eucalyptus extract, Citrus extract, clove extract, cinnamon extracts and soapnut in different concentration; and at least one natural fragrance, lubricant, plant-derived phytochemical, antimicrobial component or plant-derived essential oil.    USE - The herbal disinfectant composition is useful: for pandemic condition Covid19, preferably in destroying harmful microorganisms to maintain hygiene (claimed); and as hand and surface disinfectants for e.g. ware washing and cleaning hard surfaces, rinsing and sanitizing.    ADVANTAGE - The composition: is in the form of solid, which is essentially free of additives/excipients and preservatives, and provides required quantity of active constituents per dose; has reduced side effects and toxicity, and desired friability, disintegration time and hardness; has pleasant odor; is non-corrosive; removes dirt and stains completely in a simple manner; and provides instant hand wash/cleaning.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for preparing extract of herb Allium sativum used to prepare the solid formulation. ",,,"D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).);  D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).)",D08-B09A2A;  D09-E,A61K-036/81;  A61K-036/752;  A01N-065/00;  A61K-036/61;  A61K-008/97,IN202041029265-A   30 Jul 2021   A61K-036/81   202168Pages: 21   English,IN202041029265-A    IN41029265    10 Jul 2020,,IN41029265    10 Jul 2020,,,,,,,,,
IN201923051203-A,"System for intravenous infusion into patient, in which power supply source is configured for providing power to servo motor and monitor terminal such that platform is provided for mounting components of electronic sub-assembly",KAKADE A B;  KAKADE V A,RAJARAMBAPU INST TECHNOLOGY (RAJA-Non-standard),202173511B,"   NOVELTY - The system (100) has a mechanical sub-assembly, and an electronic sub-assembly. The mechanical sub-assembly has a servo motor (108) with a motor shaft, a guiding blade, and a mounting platform cum enclosure (106) for housing the servo motor. An alarm unit is provided for triggering an alarm as per pre-specified conditions. A power supply source is configured for providing power to servo motor and monitor terminal. A platform is provided for mounting components of the electronic sub-assembly. The platform is positioned on the upper end of the IV stand (101) when the IV actual flow rate is less than the pre-set IV flow rate then the microcontroller rotates the guiding blade in a direction to loosen the pinched IV pipe to allow the IV flow rate to increase and when the IV actual flow rate is greater than the pre-set IV flow rate then microcontroller rotates the guiding blade in an opposing direction to restrict the pinched IV pipe to allow the IV flow rate to decrease.    USE - System for automatically controlling flow rate of IV fluid from IV fluid reservoir suspended from IV stand, for intravenous infusion into patient.    ADVANTAGE - The automated system can stop or control the flow-rate of the IV fluid without any manual intervention. The automated and user friendly unit is provided to control the flow rate of IV fluid administered to patient as per desired set value through buttons interfaced with electronic control system. The flow rate of the IV fluid is controlled as per pre-set value by operator using feedback control system. The smartphone based application can be used to remotely control, monitor, start or stop the IV fluid being administered to the patient. The reduction in the weight of the IV fluid can be calibrated to the flow rate of the IV fluid in terms of drops being administered per minute to the patient, and can be monitored and controlled through the smartphone application. The functionality of a nurse calling system can be implemented without incurring any additional cost. The contactless and effective unit is minimum human intervention and is necessary to protect healthcare workers from possible infections in situations such as the covid19 pandemic.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for monitoring and controlling fluid flow rate of intravenous infusion in patient.    DESCRIPTION OF DRAWING(S) - The drawing shows the schematic view of the system for automatically controlling flow rate of IV fluid from IV fluid reservoir suspended from IV stand, and for intravenous infusion into patient.    System for intravenous infusion into patient (100)    IV stand (101)    IV tube locking portion (102)    Mounting platform cum enclosure (106)    Servo motor (108) ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  P34 (Sterilising, syringes, electrotherapy (A61L, M, N).);  ;  S03 (Scientific Instrumentation);  S05 (Electrical Medical Equipment);  T01 (Digital Computers);  V06 (Electromechanical Transducers and Small Machines);  W01 (Telephone and Data Transmission Systems)",B11-C04;  B11-C08;  B11-C11;  B12-K04E;  B12-M12D;  B12-M12F;  P34-A02;  P64-A99;  Q49-A;  Q49-V35;  S03-E15;  S05-J01A;  T01-J06A;  V06-M06E;  V06-M09;  V06-U10;  W01-C01C3E,A61M-005/168;  A61M-005/172;  B28C-007/02;  E21B-043/26;  G01N-035/00,IN201923051203-A   18 Jun 2021   A61M-005/168   202160Pages: 28   English,IN201923051203-A    IN23051203    11 Dec 2019,,IN23051203    11 Dec 2019,,,,,,,,,
CN112941051-A,New FENM protein mutant useful in preparation of microorganisms detection kit,SHU M,ZHEJIANG YOUNUO BIOLOGICAL TECHNOLOGY CO LTD (ZHEJ-Non-standard),202173679A,"   NOVELTY - FENM protein mutant, is new. The FENM mutant protein is obtained by fusion of a FENM protein mutant and a protein with endonuclease activity or by mutating the isoleucine site at position 143 of the flanking endonuclease to alanine.    USE - The FENM protein mutant is useful in preparation of microorganisms detection kit (claimed), preferably microorganisms are Escherichia coli, Corynebacterium glutamicum, Streptomyces coelicolor, Bacillus subtilis, conjugatedMycobacterium, influenza virus DNA fragments, COVID19 gene fragments, Severe acute respiratory syndrome (SARS) virus DNA fragments and other mixed specimens.    ADVANTAGE - The FENM protein mutant: can construct fusion protein which improves the detection specificity, recognize the targeted target sequence and then activates the bypass cleavage activity of Cas12a, is highly sensitive and specific to detect any one of the microorganisms or DNA ofEscherichia coli, Corynebacterium glutamicum, Streptomyces coelicolor, Bacillus subtilis, conjugatedMycobacterium, influenza virus DNA fragments, COVID19 gene fragments, Severe acute respiratory syndrome (SARS) virus DNA fragments and other mixed specimens without any expensive thermal cyclers; utilizes the kit which has microbial detection specificity and accuracy, and does not require instruments and experimental environments and can efficiently and accurately detect target sequences in complex environmental samples which is of great significance for clinical detection.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:    (1) fifty-four chloroplast homologue (FFC) system is a fusion protein formed by fusing the FENM protein mutant and a protein with endonuclease activity;    (2) detection kit comprises the FENM protein mutant or the FFC system; and    (3) detecting microorganisms by the detection kit, comprising (a) carrying out nucleic acid extraction of samples, reverse transcription loop-mediated isothermal amplification (RT-LAMP) amplification and FFC system reaction detection and determining result. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E02E;  B04-E03E;  B04-E05;  B04-E99;  B04-F01;  B04-F10;  B04-F11;  B04-L0800E;  B04-N08;  B11-C08E3;  B11-C08F8;  B12-K04F;  D05-H04;  D05-H06;  D05-H09;  D05-H18B;  D05-H99,C12N-009/22;  C12Q-001/04;  C12Q-001/6844;  C12Q-001/689;  C12Q-001/70;  C12R-001/15;  C12R-001/32;  C12R-001/38;  C12R-001/93;  C12R-001/94,CN112941051-A   11 Jun 2021   C12N-009/22   202163Pages: 21   Chinese,CN112941051-A    CN10211331    14 Apr 2021,,CN10211331    14 Apr 2021,,,"CN112941051-A -- CN109982560-A   SYNGENTA PARTICIPATIONS AG (SYGN);  SYNGENTA CROP PROTECTION LLC (SYGN)   KELLIHER T,  QUE Q;  CN110541022-A   UNIV FUJIAN MEDICAL MENGCHAO HEPATOBILIA (UYFU-Non-standard)   LIU J,  LIU X,  XU H,  CAI Z,  DONG X;  US20080118922-A1   ;  WO2020117553-A1   SYNGENTA CROP PROTECTION AG (SYGN);  SYNGENTA BIOTECHNOLOGY CHINA CO LTD (SYGN)   LYU J,  CHEN X,  YU K,  LIANG D,  ZHOU H,  XU J;  WO2020120711-A1   DEPIXUS (DEPI-Non-standard)   OUELLET J,  MALUENDA J","CN112941051-A  DOMBROWSKI,N. ET AL.: ""flap endonuclease 1[Archaeoglobales archaeon]"", GENBANK,relevantClaims[1-10],relevantPassages[1~2];  STOKKE,R. ET AL.: ""flap endonuclease 1[Archaeoglobus sulfaticallidus PM70-1]"", GENBANK,relevantClaims[1-10],relevantPassages[1~2];  LU,Z. ET AL.: ""flap endonuclease 1[Methanocella conradii HZ254]"", GENBANK,relevantClaims[1-10],relevantPassages[1~2];  MATSUI,E. ET AL.: ""flap endonuclease 1 [Archaeoglobus fulgidus]"", GENBANK,relevantClaims[1-10],relevantPassages[1~2];  SHU XU ET AL.: ""An alternative novel tool for DNA editing without target sequence limitation: the structure-guided nuclease"", GENOME BIOLOGY,relevantClaims[6-10|1,4,5],relevantPassages[1~12]",,,,,
CN112661985-A;  CN112661985-B,"Preparing long-acting antiviral electret            masterbatch for polypropylene non-woven fabric by            selecting high-efficiency silver-containing            disinfectant powder, tetrabutyl titanate and barium            compound, mixing in ethanol solution, and            calcining",ZHANG C;  RAN W;  LI Z,SHANGHAI JUZHI NEW MATERIAL TECHNOLOGY (SHAN-Non-standard),202151003L,"   NOVELTY - Method for preparing a long-acting antiviral                electret masterbatch for polypropylene non-woven                fabric involves (a) selecting high-efficiency                silver-containing, zinc-containing or                copper-containing inorganic powder and                chlorine-containing disinfectant powder, (b)                selecting tetrabutyl titanate and barium compound,                adding EDTA and citric acid, mixing in ethanol                solution, carbonizing, calcining, preparing                inorganic material barium titanate, and mixing the                obtained barium titanate and tourmaline powder, (c)                adding dispersant and solvent, and mixing the                composite anti-viral powder and inorganic electret                powder, and (d) adding the above two slurries to                the pre-pulverized polypropylene powder resin,                where the long-acting antiviral electret                masterbatch for polypropylene non-woven fabric                comprises 77-95 wt.% antiviral polypropylene                electret mixed resin, 2-8 wt.% stearate, 1-6 wt.%                nucleating agent, 1-6 wt.% softener, 0.3-3 wt.%                antioxidant, and 0.05-0.5 wt.% other processing                aids.    USE - The method is used for preparing a long-acting                antiviral electret masterbatch for polypropylene                non-woven fabric.    ADVANTAGE - The method ensures higher filtration                efficiency, and provides excellent antiviral                activity values greater than 99%, such as COVID19,                H1N1, and H3N2.    DETAILED DESCRIPTION - Method for preparing a long-acting antiviral                electret masterbatch for polypropylene non-woven                fabric involves (a) selecting high-efficiency                silver-containing, zinc-containing or                copper-containing inorganic powder and                chlorine-containing disinfectant powder, mixing                evenly in the liquid, and drying, crushing, and                sieving to obtain a composite antiviral powder, (b)                selecting tetrabutyl titanate and barium compound,                adding EDTA and citric acid, mixing in ethanol                solution to make a transparent sol, carbonizing at                250 degrees C, calcining at 500-700 degrees C,                preparing inorganic material barium titanate, and                mixing the obtained barium titanate and tourmaline                powder uniformly to obtain composite inorganic                electret powder, (c) adding dispersant and solvent                respectively, and mixing the composite anti-viral                powder and inorganic electret powder prepared in                steps (a) and (b), preparing high-concentration                anti-viral slurry and compound electret powder                slurry by nano-grinding machine, and controlling                their average particle size within 100 nm, (d)                adding the above two slurries to the pre-pulverized                polypropylene powder resin according to a certain                mass ratio, and volatilizing part of the solvent by                the high-speed operation of a high-speed mixer,                taking out the pre-mixed particles and putting them                in an oven for drying to obtain the anti-viral                polypropylene electret mixed resin, where the                long-acting antiviral electret masterbatch for                polypropylene non-woven fabric comprises 77-95 wt.%                antiviral polypropylene electret mixed resin, 2-8                wt.% stearate, 1-6 wt.% nucleating agent, 1-6 wt.%                softener, 0.3-3 wt.% antioxidant, and 0.05-0.5 wt.%                other processing aids. ",,,"A96 (Medical, dental, veterinary, cosmetic.);  A17 (Polymers of unsubstituted aliphatic monoolefins; including polyethylene.);  F04 (Braiding, knitting - including trimmings and non-woven fabrics (D04).)",A04-G03B;  A08-A06;  A08-M;  A08-M02;  A08-M03A;  A08-M10;  A12-S05G;  F02-C01;  F03-C02B;  F03-C07;  F03-C08,C08J-003/22;  C08K-013/02;  C08K-013/06;  C08K-003/08;  C08K-003/24;  C08K-003/38;  C08K-005/098;  C08K-005/19;  C08K-005/3492;  C08L-023/12,CN112661985-A   16 Apr 2021   C08J-003/22   202147Pages: 9   Chinese;  CN112661985-B   15 Nov 2022   C08J-003/22   202294   Chinese,CN112661985-A    CN11440891    07 Dec 2020;   CN112661985-B    CN11440891    07 Dec 2020,CN112661985-B Previous Publ. Patent CN112661985,CN11440891    07 Dec 2020,,,"CN112661985-A -- CN1670070-A   UNIV EAST CHINA SCI & TECHNOLOGY (UYEC)   QIAN Q,  WU W,  HUANG Z,  LIU M;  CN111393754-A   JIANGSU KINGFA TECHNOLOGY NEW MATERIAL (KGFA);  KINGFA SCI & TECH CO LTD (KGFA);  SHANGHAI KINGFA SIC & TECH DEV CO                  LTD (SHAN-Non-standard)   YIN C,  YANG Y,  ZHANG S,  LIU L,  YANG X,  CHEN P,  YE N,  WANG A,  JIANG X,  CHEN T,  CHENG W;  CN111423663-A   KINGFA SCI & TECH CO LTD (KGFA);  GUANGDONG JINFA TECHNOLOGY CO LTD (GUAN-Non-standard)   SU J,  YANG B,  LUO Z,  HUANG X,  YE N,  LI L,  YANG Y,  CHEN P;  CN111484678-A   KINGFA SCI & TECH CO LTD (KGFA);  GUANGDONG JINFA TECHNOLOGY CO LTD (GUAN-Non-standard)   LI L,  WANG B,  WANG D,  YANG Y,  YANG X,  CHENG W,  LIU L,  CHEN P,  YE N,  HUANG X;  CN111848885-A   SHANGHAI LANPOLY POLYMER TECHNOLOGY CO (SHAN-Non-standard)   GAO P,  ZHI F;  CN111875886-A   GUANGZHOU LUSHAN NEW MATERIALS CO LTD (GUAN-Non-standard);  GUANGZHOU LUSHAN PHOTOELECTRIC MATERIAL (GUAN-Non-standard);  JIANGSU LUSHAN NEW MATERIALS CO LTD (JIAN-Non-standard)   WANG Y,  GUO S,  TANG F,  WANG J","CN112661985-A  : ""/"",          ,relevantClaims[1-8],relevantPassages[]",1145-0-0-0 ; 3330-0-0-0 ; 849-0-0-0 ; 866-0-0-0 ; 7896-0-0-0 ; 129698-0-0-0 ; 129677-0-0-0 ,,,R00964 ; R00195 ; R00419 ; R01520 ; R05190 ; R05344 ; R05373 ,
IN202021012968-A;  WO2021191664-A1,"Preparing composition used in treating e.g. COVID19 coronavirus, involves e.g. washing and boiling complete Piper longum with water, mixing with Piper longum powder and drying, and soaking dried ginger coarse pieces, and separating water",SOLANKE R V,SOLANKE R V (SOLA-Individual),202134652G,"   NOVELTY - Preparing a composition comprises (a) using 250 g complete Piper longum, washing and boiling with water, mixing the extract with 100 g Piper longum powder, and drying the mixture to obtain a first component, (b) soaking 100 g dried ginger coarse pieces for 5-10 minutes, steaming at 100-120 degrees C under high pressure for 20-25 minutes, separating the water from the dried ginger, mixing with 100 g dried ginger powder, and drying to obtain a second component, (c) making 200-250 ml juice of fresh Phyllanthus emblica, (d) mixing the first component, second component and third component, and drying to remove moisture to obtain a mixture, and (e) adding 100 g powder of Piper nigrum in to the mixture.    USE - The method is useful for preparing the composition, which is used for treating COVID19 coronavirus and respiratory system diseases (claimed). No biological data given.    ADVANTAGE - The method provides composition, which does not have side effects, is easy to prepare and administer, and is economical.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for the composition, comprising 30-50% based on dry form weight or liquid volume of Piper longum, 20-30% dried ginger, 30-40% Phyllanthus emblica, and 5-20% Piper nigrum. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  A96 (Medical, dental, veterinary, cosmetic.);  A25 (Polyurethanes; polyethers.)",B04-A08;  B04-A09;  B04-A10;  B04-A98;  B04-D01A;  B04-F11B2;  B14-K01;  B14-S18;  A11-A03;  A12-V01,C08G-018/48;  A61K-036/00;  A61K-031/454;  A61K-031/557;  A61K-031/519,IN202021012968-A   19 Mar 2021   C08G-018/48   202134Pages: 18   English;  WO2021191664-A1   30 Sep 2021   A61K-036/00   202180   English,IN202021012968-A    IN21012968    25 Mar 2020;   WO2021191664-A1    WOIB054672    18 May 2020,IN202021012968-A PCT application Application WOIB054672,IN21012968    25 Mar 2020;  WOIB054672    18 May 2020,  WO2021191664-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA  ,,,,114315-0-0-0 K M,,,RA02A1 K M,
CN112382403-A,"Method for constructing            susceptible-exposed-infectious-removed (SEIQR)            infectious disease model based on degree of personnel            aggregation, involves dividing population into five            categories, and improving model to obtain another            model",JIN J;  CHENG S;  LIU X;  WAN J,HARBIN INST TECHNOLOGY (HAIT-C),202120273B,"   NOVELTY - The method involves dividing the population                into five categories such as susceptible population                S, latent population E, infected population I,                isolated population Q, and recovered population R.                The differential equation of the improved SEIQR-I                model is established, where St represents the                number of susceptible people on day t, Et                represents the total number of people infected on                day t but in the incubation period, Qt represents                the total number of people diagnosed on day t, and                Rt represents the total number of people cured on                the t day, Dt represents the total number of deaths                on the t day, mt represents the concentration of                people on the t day. The SEIQR-I model is improved                to obtain the SEIQR-II model.    USE - Method for constructing                susceptible-exposed-infectious-removed (SEIQR)                infectious disease model based on degree of                personnel aggregation.    ADVANTAGE - The constructed SEIQR model based on the                degree of personnel aggregation fully considers the                characteristics of the spread of the COVID19                epidemic and combines specific epidemic prevention                policies to achieve a worldwide epidemic. The                analysis of different granularities within the                scope of domestic provinces and cities, the model                prediction accuracy has reached more than 90%. The                model is modeled in stages according to the                characteristics of the epidemic spread, and the                model structure better fits the actual situation.                The change of the basic reproduction number R0                under different epidemic prevention measures is                reversed according to the model, and the                effectiveness of the epidemic prevention policy is                judged based on the change.    DESCRIPTION OF DRAWING(S) - The drawing shows the schematic view of the                SEIQR disease model. ",,,S05 (Electrical Medical Equipment);  T01 (Digital Computers),S05-G02G2;  S05-G02G9;  T01-J06A1,G16H-050/30;  G16H-050/80,CN112382403-A   19 Feb 2021   G16H-050/80   202120Pages: 6   Chinese,CN112382403-A    CN11064838    30 Sep 2020,,CN11064838    30 Sep 2020,,,"CN112382403-A -- CN101794342-A   PLA ANTI CHEM COMMAND&ENG COLLEGE (PLAA-Non-standard)   LIU F,  XU L,  LIU P,  WANG X,  CHEN H,  SHI J,  ZHOU X,  HUANG S,  GUO C,  SUN S;  CN110993119-A   TONGDUN HOLDING CO LTD (TONG-Non-standard)   MENG D,  ZHANG Y,  LI H,  LI X;  CN111430041-A   BEIJING YIYIYUN TECHNOLOGY CO LTD (BEIJ-Non-standard)   JIAO Z;  CN111445997-A   NANJING SANYANJINGLING INFORMATION TECHNOLOGY                  CO LTD (NANJ-Non-standard)   LIANG B,  WANG L,  SUN Q;  CN111524611-A   TENCENT TECHNOLOGY SHENZHEN CO LTD (TNCT)   SUN J,  ZHANG Z,  CHEN X,  LIU H,  ZHENG Y;  CN111611297-A   UNIV CENT SOUTH (UYCS)   SHI Y,  WANG D,  XU G,  YU Z,  DENG M,  CHEN Y;  CN111627563-A   CHONG P (CHON-Individual)   CHONG P,  YIN H","CN112382403-A  ;;;;;;: ""SEIQCR"",          (), no. 10,relevantClaims[1];  ;;;;: ""CCDC"", , no.          04, 15 April 2020          (2020-04-15),relevantClaims[1];  ;;;:          ""SEIR2019(COVID-19)"", (), no.          02,relevantClaims[1];  ;: ""SEIR"", , no.          06, 20 June 2020 (2020-06-20),relevantClaims[1]",,,,,
US10898169-B1;  CN114098826-A;  EP3984466-A2;  IN202144046672-A;  EP3984466-A3,Specimen collection apparatus used for testing            subject for tuberculosis has flange and removable lid            that form barrier between mesh and decanting port to            block sputum specimen from passing through it during            washing of sputum specimen,JOHNSON N E;  BOLDT K;  TORO J;  LEGOFF J,FORWARD IND INC (FORW-Non-standard);  FORWARD IND INC (FORW-Non-standard);  FORWARD IND INC (FORW-Non-standard),202109940S,"   NOVELTY - The specimen collection apparatus has a                container (2) having a top end (12), a bottom end                (10), a peripheral sidewall (16) and an opening                (14). A mesh (20), positioned within the opening                and above the bottom end of the container, supports                a sputum specimen and allows passage of wash fluid.                A flange (22) supports mash and coupling of the                mesh to peripheral sidewall. The flange has a                decanting port (24) located between the mesh and                the peripheral sidewall. A removable lid (6) seals                the opening. The flange and the removable lid form                a barrier between the mesh and the decanting port                to block the sputum specimen from passing through                it during washing of the sputum specimen.    USE - Specimen collection apparatus used for testing                subject for COVID19, tuberculosis, pneumonia and                microbial antibiotic resistance.    ADVANTAGE - Facilitates self-collection of expectorated                sputum specimens by outpatients, without need for                inpatient medical supervision. Ensures reliable,                timely and cost-effective removal of oropharyngeal                contaminants from expectorated sputum bolus                specimens by washing them in water or saline.                Improves cost-effectiveness of diagnostic sputum                testing by optimizing expectorated specimen                self-collection, transport, decontamination,                sampling and storage preservation within single                user-friendly, multifunctional                apparatus/device.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a                specimen collection method.    DESCRIPTION OF DRAWING(S) - The drawing shows the exploded perspective                view of a specimen collection apparatus.    Container (2)    Removable lid (6)    Bottom end (10)    Top end (12)    Opening (14)    Peripheral sidewall (16)    Mesh (20)    Flange (22)    Decanting port (24) ",,,"J04 (Chemical/physical processes/apparatus - including catalysis, catalysts (excluding specific e.g. enzymatic or polymerisation catalysts), colloid chemistry, laboratory apparatus and methods, testing, controlling, general encapsulation, detection and sampling (excluding clinical testing) (B01J, L).);  P31 (Diagnosis, surgery (A61B).);  S03 (Scientific Instrumentation)",J04-B01;  J04-F;  P31-A05;  P31-G;  S03-E13D;  S03-E14H,A61B-010/00;  A61B-010/02;  B01L-003/00;  G01N-001/28;  G01N-001/34;  A61J-019/04;  G01N-001/02;  A61J-019/02;  A61M-001/00;  B08B-003/02;  H01L-021/67,US10898169-B1   26 Jan 2021   A61B-010/02   202111Pages: 27   English;  CN114098826-A   01 Mar 2022   A61B-010/00   202223   Chinese;  EP3984466-A2   20 Apr 2022   A61B-010/00   202234   English;  IN202144046672-A   22 Apr 2022   H01L-021/67   202242   English;  EP3984466-A3   29 Jun 2022   A61B-010/00   202253   English,US10898169-B1    US069509    13 Oct 2020;   CN114098826-A    CN11192523    13 Oct 2021;   EP3984466-A2    EP202309    13 Oct 2021;   IN202144046672-A    IN44046672    13 Oct 2021;   EP3984466-A3    EP202309    13 Oct 2021,,US069509    13 Oct 2020,    EP3984466-A2:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  KH;  LI;  LT;  LU;  LV;  MA;  MC;  MD;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TN;  TR    EP3984466-A3:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  KH;  LI;  LT;  LU;  LV;  MA;  MC;  MD;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TN;  TR  ,,";  EP3984466-A3 -- US4771486-A   GUTIERREZ C N (GUTI-Individual)   GUTIERREZ C N,  VIGIL D;  US20100255484-A1   ;  US20200305850-A1   ;  WO2013043109-A2   SIWECKI R A (SIWE-Individual);  GISKE C G (GISK-Individual)   SIWECKI R A",,,,,,
IN202021055417-A,"Herbal disinfectant composition useful for e.g. destroying harmful microorganisms, contains neem extract, tulsi extract, Eucalyptus extract, Citrus extract, clove extract, cinnamon extract and soapnut",KUMAR S,KUMAR S (KUMA-Individual),202112558Y,"   NOVELTY - Herbal disinfectant composition comprises neem extract, tulsi extract, Eucalyptus extract, Citrus extract, clove extract, cinnamon extract and soapnut in different concentration, one or more of natural fragrance, lubricant, plant-derived phytochemicals, antimicrobial component or plant-derived essential oil, herbal ingredients chosen from vetiver, Mentha, rosemary, Ocimum, ajowan, Geranium, palmarosa, celery, Salvia, thyme, coriander, cardamom, cinnamon, clove, ginger, patchouli, fennel, lavender, lemon, lime, orange, jasmine, chamomile, nutmeg, and cumin, carbon dioxide, and one or more sweetening agents. The disinfectant is prepared using edible alcohol, alive centipede, alive pallas pit viper, alive black snake, royal jelly, notoginseng, honeysuckle, bamboo leaf, cactus and other required things in mixer.    USE - The herbal disinfectant composition is useful for destroying harmful microorganisms, killing Covid19, virus, pathogenetic bacteria, and treating skin ulcer caused by wound infection, Covid19, virus, fungi and bacteria (all claimed).    ADVANTAGE - The herbal disinfectant composition is storage stable and hygienic.    DETAILED DESCRIPTION - Herbal disinfectant composition comprises neem extract, tulsi extract, Eucalyptus extract, Citrus extract, clove extract, cinnamon extract and soapnut in different concentration, one or more of natural fragrance, lubricant, plant-derived phytochemicals, antimicrobial component or plant-derived essential oil, herbal ingredients chosen from vetiver, Mentha, rosemary, Ocimum, ajowan, Geranium, palmarosa, celery, Salvia, thyme, coriander, cardamom, cinnamon, clove, ginger, patchouli, fennel, lavender, lemon, lime, orange, jasmine, chamomile, nutmeg, and cumin, carbon dioxide, and one or more sweetening agents. The disinfectant is prepared using edible alcohol, alive centipede, alive pallas pit viper, alive black snake, royal jelly, notoginseng, honeysuckle, bamboo leaf, cactus and other required things in mixer. The composition uses alcohol to extract active matter in toxic wild animals to make medicine liquid, where the sweetening agent is chosen from 1x 10-5 g to 2x 10-1 mu g/l artificial sweetening agent and 1.46x 10-1 M natural sweetening agent. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.);  D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).)",B04-A08;  B04-A09;  B04-A10;  B04-A98;  B04-B04M1;  B04-B04M3;  B04-C02;  B04-D01;  B04-N02;  B05-C04;  B06-A03;  B10-E04;  B14-A01;  B14-A02;  B14-A04;  B14-N17B;  B14-S18;  C04-A08;  C04-A09;  C04-A10;  C04-A98;  C04-B04M1;  C04-B04M3;  C04-C02;  C04-D01;  C04-N02;  C05-C04;  C06-A03;  C10-E04;  C14-A01;  C14-A02;  C14-A04;  C14-N17B;  C14-S18;  D09-A01C,A61K-031/00,IN202021055417-A   22 Jan 2021   A61K-031/00   202114Pages: 25   English,IN202021055417-A    IN21055417    20 Dec 2020,,IN21055417    20 Dec 2020,,,,,106062-0-0-0 K M; 184614-0-0-0 K M; 200757-0-0-0 K M; 255-0-0-0 K M; 1013773-0-0-0 K M; 88117-1-0-0 K M,,03015; 66264,RA21KL K M; RA0121 K M; RA00GT K M; R01066 K M; R90202 K M; R15962 K M; RA04PC K M,1066-S
IN202031046795-A,"Automated sanitizing machine for sanitizing person without any physical touch of properties, has main portion that is provided with sanitizing process which is started automatically when person enters into sanitizing cabin",DHAR A;  DAS S;  BISWAS P;  PAL B;  SASMAL M;  RAJ A;  KHAN M A;  SAIKH S,JIS COLLEGE ENG (JISC-Non-standard),2020C6136T,"   NOVELTY - The automated sanitizing machine has a ultrasonic sensor, a Audino, a servo motor, a motor driver, and a pump. The sanitizing process is started automatically when a person enters into a sanitizing cabin. The machine is provided to stop sanitizing automatically after 10 seconds of the sanitizing process. A smart notch is fitted to the important doors of the building. A door is provided to identify the coin received by a person after sanitizing.    USE - Automated sanitizing machine for sanitizing person without any physical touch of any kind of properties.    ADVANTAGE - The sensor based smart card is provided to ensure touch less activity. The device is simple in structure, low in cost and convenient to install and dispenses with help of other optical systems. The machine is provided with proper protection from the global pandemic, COVID19 virus. The sanitizing process is provided with totally touch proof.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic diagram of the automated sanitizing machine. ",,,"P43 (Sorting, cleaning, waste disposal (B06, B07, B08, B09).)",P43-B99,B08B-003/02,IN202031046795-A   04 Dec 2020   B08B-003/02   202004Pages: 15   English,IN202031046795-A    IN31046795    27 Oct 2020,,IN31046795    27 Oct 2020,,,,,,,,,
RU2735722-C1,TECHNOLOGY OF REMOTE MEDICAL REHABILITATION OF PATIENTS WITH CORONAVIRUS INFECTION,FESIUN A D;  RACHIN A P;  GILMUTDINOVA I R;  EREMUSHKIN M A;  IAKOVLEV M I;  FISTUL I A;  ZINGERMAN B V;  LAPSHIN V V;  NOZIK A V;  KARGALSKAIA I G,NAT MEDICAL RES CENT REHABILITATION BALN (NAME-Non-standard),2020B9611R,"   NOVELTY - Invention relates to medicine, medical equipment and rehabilitation using computer technology, innovative electronic developments of distance learning and treatment systems, cloud systems and is based on use of a telemedicine platform for rehabilitation online sessions with patients suffering from or undergoing coronaviral infection in self-isolation mode, for complex improvement of the functions of their respiratory, cardiovascular, motor, digestive, and nervous systems. Remote rehabilitation is performed on a cloud telemedical platform COVIDREHAB, using a device suitable for unobstructed Internet access and video communication in real time. First, patient leaves online application on platform portal for remote rehabilitation, filling a set of questionnaires, attending physician checks completed questionnaires: health assessment, mMRC (Modified Medical Research Council), SF-36, and determines indications and contra-indications for remote rehabilitation in accordance with information received from patient. If, in the process of filling out the questionnaires, the patient indicates a symptom that is dangerous or critical for life and health, patient immediately receives notification from attending physician on in-person seeking of medical care. According to results of patient filling questionnaires and analyzing available information on patient's condition, attending physician through portal of telemedicine platform opens the patient access to set of medical recommendations in form of links to Internet resources with remote sessions with an instructor of physical therapy (PT), as well as with information materials or video lections, placed on the same portal and relating, in addition to PT, recommendations for nutrition, intestinal microflora recovery and drug-free posttraumatic recovery methods, or in accordance with the patient's condition, sends a message on the need for an in-person visit to the doctor. As rehabilitation measures, patients undergo a distance rehabilitation course for 20 days: 14 days of online sessions with a PT instructor and according to the indications with a psychologist, in a group or individually, and 6 days of self-study on video lessons. At that, as PT sessions, diaphragmatic breathing is taught to patients in online classes led by an instructor, after which they perform complex exercises of respiratory gymnastics using diaphragmatic breathing under video surveillance of instructor. In the sitting and standing positions, a complex of general strengthening exercises with respiratory exercises elements is performed, including power and aerobic exercises of increasing intensity. After each session, the patients fill the PT activity tolerance questionnaire, according to the results of which either continue this course, or the physician directs them a link to the passage of another PT complex, in accordance with their tolerability. Remote online sessions for 14 days are daily, each consisting of consecutive blocks: first 5 minutes of diaphragmatic breathing, then 40 minutes of PT, including respiratory gymnastics, then patients fill the PT activity tolerance questionnaire and send it through platform portal to attending physician, sessions with psychologist according to indications, consultation of the attending physician on dynamics of the patient's state with making a decision on continuation of the current rehabilitation complex or on the complex replacement in accordance with patient's tolerance. At end of 14th session, the patient refills the set of questionnaires used before the rehabilitation, and sends them through the platform portal to the attending physician to assess the health state dynamics, by results of which the physician directs the patient to the recommendations of the video lessons for independent rehabilitation continuation or change of PT complexes, respiratory exercises, the corresponding psychological effect, diet, wherein the duration of each video lesson with independent exercise by the patient of the corresponding exercises does not exceed 30 minutes.    USE - Medicine.    ADVANTAGE - Method provides enlarging the rehabilitation possibilities of the patients with coronavirus infection both physically and psychologically, improving functions of various human body systems within the complex unified rehabilitation program, improving quality of life of patients with the possibility of direct dynamic monitoring of their health in real time; also the method provides accelerated process of recovery after treatment, provides psychological support irrespective of the patient's location, prevention of secondary complications. 3 cl, 1 ex, 6 tbl ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  P31 (Diagnosis, surgery (A61B).);  S05 (Electrical Medical Equipment);  T01 (Digital Computers)",B11-C11;  B14-A02B5;  P31-A05;  S05-D;  S05-G02G1;  T01-J30D;  T01-N01A2;  T01-N01A3;  T01-N01B;  T01-N01D1B;  T01-N01E1;  T01-N02B1F;  T01-N02B2,A61B-005/00;  G06Q-050/00;  G16H-010/00,RU2735722-C1   06 Nov 2020   G16H-010/00   202098Pages: 0   Russian,RU2735722-C1    RU127525    18 Aug 2020,,RU127525    18 Aug 2020,,,"RU2735722-C1 -- RU2301688-C1   VASILEVA I A (VASI-Individual);  VANCHAKOVA N P (VANC-Individual);  SMIRNOV A V (SMIR-Individual);  DOBRONRAVOV V A (DOBR-Individual)   VASILEVA I A,  VANCHAKOVA N P,  SMIRNOV A V,  DOBRONRAVOV V A;  RU2700983-C2   ARES TRADING SA (MERE)   LAKE C,  PATERSON A,  EXELL S,  CHANIE E,  KOUVAS G;  US8758020-B2   BURDEA G (BURD-Individual);  ABDELBAKY M (ABDE-Individual);  RABIN B (RABI-Individual)   BURDEA G,  ABDELBAKY M,  RABIN B","RU2735722-C1  MUKAINO M. et al. Staying Active in Isolation: Telerehabilitation for Individuals With the Severe Acute Respiratory Syndrome Coronavirus 2 Infection. American journal of physical medicine & rehabilitation. - 2020. . 99. N. 6. . 478.;  .. . . // . 2019. N. 3.;  RUDEL D. et al. , . . - 2015. - N. 1.",,,,,
IN202041035233-A,"System for monitoring and controlling proximity of person to prevent virus infection, has control unit that processes signal from wearable sensor module using light proximity sensor and signal to generate alerting message to alerting module",AVANEESH A;  KODADA B B;  KARTHIK;  CHAITRALY;  KOLACHIPPU P M;  MEDHINI,AVANEESH A (AVAN-Individual);  KODADA B B (KODA-Individual);  KARTHIK (KART-Individual);  CHAITRALY (CHAI-Individual);  KOLACHIPPU P M (KOLA-Individual);  MEDHINI (MEDH-Individual),2020907762,"   NOVELTY - The system has a wearable sensor module that comprises an Light proximity sensor, used for a repeated detection of persons at surrounding the person wearing the wearable sensor module. An ultrasound sensing unit is used to detect the 180 degree position of the any person cross a predefine limit of the distance from the user. A alerting module is used to alert the user when any surrounding person comes near less than a predefine acceptable distance, obtain information after processing of the signal from the wearable sensor module. The alerting module comprises vibration sensor, configured on the body of the user to send the vibration signal to the user. The voice generator module is configured on the body of the user to get the voice alert signal. A control unit processes the signal from the wearable sensor module using the light proximity sensor and the ultrasound sensing unit, and the signal to generate alerting message to the alerting module.    USE - System for monitoring and controlling proximity of person to prevent virus infection.    ADVANTAGE - The social distance between the people is maintained to prevent the infection of virus like Covide-19.    DESCRIPTION OF DRAWING(S) - The drawing shows a block-diagram for the system to monitor and control the proximity of persons to prevent virus infection. ",,,S02 (Engineering Instrumentation);  S03 (Scientific Instrumentation),S02-A05B;  S02-A10G2;  S02-E02;  S03-E08,A61B-000/00,IN202041035233-A   04 Sep 2020   A61B-000/00   202079Pages: 24   English,IN202041035233-A    IN41035233    15 Aug 2020,,IN41035233    15 Aug 2020,,,,,,,,,
CN111620909-A;  CN111620909-B,"New pyrrolo(2,1-f)(1,2,4)triazine compound useful            in e.g. preparing antiviral medicine, including            coronavirus, filamentous virus, enterovirus, influenza            virus, parainfluenza virus, human immunodeficiency            virus and hepatitis virus",WANG G,GUANGDONG ZONK R & D CO LTD (GUAN-Non-standard),2020901839,"   NOVELTY - Pyrrolo(2,1-f)(1,2,4)triazine compound (I) are                new.    USE - (I) is useful in preparing antiviral medicine,                including coronavirus, including severe acute                respiratory syndrome virus, middle east respiratory                syndrome virus and COVID19, filamentous virus,                including Ebola virus and Marburg virus,                flavivirus, including Zika virus, enterovirus,                influenza virus, including H1N1 and H7N9,                parainfluenza virus, human immunodeficiency virus                and hepatitis viruses (all claimed).    ADVANTAGE - (I) has excellent bioavailability.    DETAILED DESCRIPTION - Pyrrolo(2,1-f)(1,2,4)triazine compound of                formula (I) are new.    X = CH2, O, NH or not exist;    R1 = 1-30C alkyl, 3-7C cycloalkyl, 1-6C                arylalkyl or aryl (all optionally substituted with                T);    T = amino, hydroxy, carboxy or halo;    R2 = H, 1-6C alkylcarbonyl, amino-substituted                1-6C alkylcarbonyl, amino-substituted 1-6C                aralkylcarbonyl, amino or halo-substituted                arylcarbonyl;    R3 = 1-30C alkyl, 1-30C alkoxyalkyl, aryl,                1-6C arylalkyl, hydroxy or halo-substituted aryl,                or hydroxy or halo-substituted 1-6C                arylalkyl;    R4 = 1-30C alkyl, 1-30C alkoxyalkyl, aryl,                1-6C arylalkyl, hydroxy or halo-substituted aryl,                or hydroxy or halo-substituted 1-6C                arylalkyl;    R5 = 1-10C alkyl, 3-7C cycloalkyl, 1-6C                arylalkyl or aryl; and    halo = F, Cl, Br or I.    An INDEPENDENT CLAIM is also included for                preparation of (I). ",,,B02 (Fused ring heterocyclics.);  C02 (Heterocyclic.),B04-B03E;  B14-A02;  B14-K01D;  B14-N12;  C04-B03E;  C14-A02;  C14-K01D;  C14-N12,A61K-031/685;  A61P-031/12;  A61P-031/14;  A61P-031/16;  A61P-031/18;  C07F-009/6561,CN111620909-A   04 Sep 2020   C07F-009/6561   202078Pages: 25   Chinese;  CN111620909-B   02 Dec 2022   C07F-009/6561   202299   Chinese,CN111620909-A    CN10503526    05 Jun 2020;   CN111620909-B    CN10503526    05 Jun 2020,CN111620909-B Previous Publ. Patent CN111620909,CN10503526    05 Jun 2020,,,"CN111620909-A -- CN108348526-A   GILEAD SCI INC (GILE)   CLARKE M O H,  FENG J Y,  JORDAN R,  MACKMAN R L,  RAY A S,  SIEGEL D;  CN110845560-A   GUANGDONG ZONK R & D CO LTD (GUAN-Non-standard)   WANG W,  LU Y,  TAN J;  CN113248508-A   ANHUI NUOQUAN PHARM CO LTD (ANHU-Non-standard)   CHEN Y,  HU Z,  HE D,  DU X,  QIAN Z,  HE Y,  XU L,  LIU Z;  CN111620909-B -- CN108348526-A   GILEAD SCI INC (GILE)   CLARKE M O H,  FENG J Y,  JORDAN R,  MACKMAN R L,  RAY A S,  SIEGEL D;  CN110845560-A   GUANGDONG ZONK R & D CO LTD (GUAN-Non-standard)   WANG W,  LU Y,  TAN J;  CN113248508-A   ANHUI NUOQUAN PHARM CO LTD (ANHU-Non-standard)   CHEN Y,  HU Z,  HE D,  DU X,  QIAN Z,  HE Y,  XU L,  LIU Z",, K S; 2903566-0-0-0 K S; 620-0-0-0 K S; 8440-0-0-0 K S; 168-0-0-0 K S; 265-0-0-0 K S; 95410-0-0-0 K S; 622-0-1-0 K U V; 406-0-0-0 K U V; 1995-0-0-0 K U V;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P;  N P; 2903566-0-0-0 CL RCT,221226101 N P,61435,RCR3TT K S; RBKW27 K S; R00873 K S; R00832 K S; R00258 K S; R00900 K S; RAKRQ5 K S; RA84IZ K U V; R01911 K U V; R14657 K U V; RCVKBQ N P; RCVKBR N P; RCVKBS N P; RCVKBT N P; RCVKBU N P; RCVKBV N P; RCVKBW N P; RCVKBX N P; RCVKBY N P; RCVKBZ N P,0873-S; 0832-S; 0258-S; 0900-S; 1911-U
AU2020101355-A4,"Swab collection equipment for use in pandemic situation, comprises collect the swab sample from human mouth or nose for the testing, the moment frontline workers are taking the swab sample standing in front of a person",HIREMATH R,HIREMATH R (HIRE-Individual),202081225A,"   NOVELTY - The swab collection equipment comprises collect the swab sample from human mouth or nose for the testing of COVID19. The moment frontline workers are taking the swab sample standing in front of a person. There are some risks for contacting the virus to the frontline workers. Frontline worker stands 1.6 meter away from the person and use this contact free swab collecting equipment that collects the swab sample. Swab collecting equipment is operated by frontline worker, this frontline worker collects the swab sample without touching the person and by maintaining social distance. Collect swab sample put in a test tube and drop the test tube in plastic zip bag.    USE - Swab collection equipment for use in pandemic situation.    ADVANTAGE - Swab collecting equipment maintains the social distance.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic diagram of the swab collection equipment. ",,,"A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.);  P31 (Diagnosis, surgery (A61B).);  S03 (Scientific Instrumentation)",A12-P02;  A12-P03;  A12-V03C2;  P31-A05;  S03-E13,A61B-010/02;  G01N-001/02,AU2020101355-A4   20 Aug 2020   A61B-010/02   202070Pages: 9   English,AU2020101355-A4    AU101355    13 Jul 2020,,AU101355    13 Jul 2020,,,,,,,,,
IN202031027653-A,"Method for detecting severe acute respiratory            syndrome (SARS) pathogenic viruses with high            sensitivity and rapidity for diagnosing SARS by using            image technology data base, involves detecting nucleic            acid amplification using such primer",MOHAN A;  YERRAM S;  YERRAMSETTY C;  VERMA K;  YADAV R K;  BHONG G L,MOHAN A (MOHA-Individual);  YERRAM S (YERR-Individual);  YERRAMSETTY C (YERR-Individual);  VERMA K (VERM-Individual);  YADAV R K (YADA-Individual);  BHONG G L (BHON-Individual),2020834691,"   NOVELTY - The method involves hybridizing an                oligonucleotide primer with any nucleotide sequence                constructed based on the nucleotide sequence of RNA                polymerase of the SARS coronavirus. The mobile                application is configured to detect the nucleic                acid amplification using such primer. The infection                is diagnosed with the SARS coronavirus through                detection of nucleic acid amplification and a kit                is configured to diagnose SARS, respectively. The                VD mobile application is configured to compare the                various image and give the 99 percentage prediction                of coronavirus status.    USE - Method for detecting severe acute respiratory                syndrome (SARS) pathogenic viruses with high                sensitivity and rapidity for diagnosing SARS by                using image technology data base.    ADVANTAGE - The method can detect all symptoms and image                data base compare and give the predictive result                immediately, predict covid19 status using cough                level, predict covid19 status Shortness of breath                or difficulty breathing, predict covid19 status                using sore throat level, predict covid19 status                using congestion or runny nose, and to predict                covid19 status Nausea or vomiting level and                number.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view of the                coronavirus. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  T01 (Digital Computers)",B04-E01;  B04-E05;  B04-F11B;  B11-C08E3;  B11-C08F8;  B11-C11;  B12-K04F;  B12-K04G1B;  B12-K04G2G;  D05-H06A;  D05-H18B;  T01-J05B4F;  T01-J12C;  T01-N02B1B,G06F-021/00,IN202031027653-A   14 Aug 2020   G06F-021/00   202072Pages: 17   English,IN202031027653-A    IN31027653    30 Jun 2020,,IN31027653    30 Jun 2020,,,,,,,,,
IN202041028746-A,"Method for disinfecting clothes, eating food, and vegetable using UV light to kill virus, involves carrying out treatment of food products by UV rays, and carrying out dewatering and drying of food products under controlled atmosphere",MISRA N K;  SAHU A K;  KRISHNAVENI B;  INGALE N;  JOSHI D,MISRA N K (MISR-Individual);  SAHU A K (SAHU-Individual);  KRISHNAVENI B (KRIS-Individual);  INGALE N (INGA-Individual);  JOSHI D (JOSH-Individual),202075304F,"   NOVELTY - The method involves treating food products by ultrasounds, UV rays. The treatment of the food products is carried out under ozone atmosphere, UV rays. The treatment of the food products is carried out by UV rays. The dewatering and drying of the food products are carried out under controlled atmosphere. The objects are disinfected over 360-degree surface with rotation and moving concept. The objects are rotated on a conveyor to illuminate entire exterior surface of the objects with a disinfecting UV-C source and the UV-C source. The UV-C light source is maintained at a preselected level of separation between the objects and the UV-C light source.    USE - Method for disinfecting clothes, eating food, vegetable, fruit, juice, groceries, and kitchen items using UV light (all claimed) to kill covid19 virus, and bacteria.    ADVANTAGE - The water consumption is reduced, outlets subjected to treatment are eliminated, and power consumption is reduced while maintaining qualitative standards of final product and ensuring a prolonged conservation under sterility conditions without employing sterilization and pasteurizing thermal processes. The noise pollution is reduced and working safety conditions are improved.    DESCRIPTION OF DRAWING(S) - The drawing shows a top view of apparatus for carrying out the food products washing and sterilization process.    Observing apparatus (1)    Loading lift (2)    Lift belt (7)    Micro filtering unit (42)    Container (43) ",,,X27 (Domestic Electric Appliances\n),X27-D10,D06F-058/20,IN202041028746-A   31 Jul 2020   D06F-058/20   202069Pages: 28   English,IN202041028746-A    IN41028746    06 Jul 2020,,IN41028746    06 Jul 2020,,,,,,,,,
IN202021027441-A,"Virus killer liquid powder used for treating skin ulcer includes tulshi extract, citrus extract, clove extract, neem extract, eucalyptus extract, cinnamon extracts and soapnut",PANDYA I Y;  KESHARI A K;  GARG R;  LAVANYA D;  SHUKLA S K;  SRIVASTAVA S,PANDYA I Y (PAND-Individual);  KESHARI A K (KESH-Individual);  GARG R (GARG-Individual);  LAVANYA D (LAVA-Individual);  SHUKLA S K (SHUK-Individual);  SRIVASTAVA S (SRIV-Individual),202075307Q,"   NOVELTY - A virus killer liquid powder in the form of herbal disinfectant composition comprises neem extract, tulshi extract, eucalyptus extract, citrus extract, clove extract, cinnamon extracts and soapnut. The composition may also include natural fragrance, lubricant, plant-derived phytochemicals, antimicrobial component and/or plant-derived essential oil. The composition can be formulated as herbal disinfectant. The disinfectant liquid and antichloristic powder is prepared by mixing edible alcohol, alive centipede, alive pallas pit viper, alive black snake, royal jelly, notoginseng, honeysuckle, bamboo leaf, cactus, and other required components. The composition uses alcohol to extract the active component in toxic wild animals to make medicine liquid with functions of strongly killing Covid19, virus, and pathogenetic bacteria.    USE - The powder in the form of herbal disinfectant composition is used for treating skin ulcer caused by wound infection, Covid19, virus, fungi and bacteria.    ADVANTAGE - The powder can destroy harmful microorganisms to maintain hygiene, and is storage stable. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).)",B04-A08;  B04-A09;  B04-A10;  B04-A98;  B04-B01C1;  B04-B04M1;  B04-B04M3;  B04-C02;  B06-A03;  B12-M11G;  B14-A01;  B14-A02;  B14-A04;  B14-N17H;  B14-S18;  D09-C04B,A61K-031/00,IN202021027441-A   31 Jul 2020   A61K-031/00   202068Pages: 23   English,IN202021027441-A    IN21027441    29 Jun 2020,,IN21027441    29 Jun 2020,,,,,184614-0-0-0 K M; 88117-1-0-0 K M,,03015; 66264,RA0121 K M; R15962 K M; RA04PC K M,
IN202041026402-A,"Covid19 protected room for disinfecting room air using machine learning system, has pre-filter that is situated ahead of blowers or fans for sterilizer, and is provided with associated UV sterilizer lamp",MADGI M;  SHAHABADKAR R;  SHAHABADKAR K R;  HARSOOR B;  JIRAGI A;  PATIL A,MADGI M (MADG-Individual);  SHAHABADKAR R (SHAH-Individual);  SHAHABADKAR K R (SHAH-Individual);  HARSOOR B (HARS-Individual);  JIRAGI A (JIRA-Individual);  PATIL A (PATI-Individual),202082339X,"   NOVELTY - The room has a housing (14) having a blower or fan (22) for blowing air, a transparent tubular unit (24) for receiving air blown by the blower or fan, and multiple UV light sources (30) arranged in a fixed pattern around the transparent tubular unit such that when the UV light sources are energized, the UV light sources project UV radiation outward to facilitate sterilizing an environment outside the housing. A room air sterilizer is mounted on the wall of the room and traps airborne particulate in a high efficiency particulate air (HEPA) filter. An UV germicidal lamp destroys any bio contamination on the trapped particulates. The sterilizer is provided with an elongated vertical housing with a return air grille near or at the lower end and a HEPA filter assembly placed at an outflow port at the upper end. A pre-filter is situated ahead of the blowers or fan for the sterilizer, and is provided with an associated UV sterilizer lamp (32).    USE - Covid19 protected room for disinfecting room air using machine learning system.    ADVANTAGE - The effective room air sterilizer is simple to install and to maintain.    DESCRIPTION OF DRAWING(S) - The drawing shows a perspective view of a disinfection unit, system and method for disinfecting both air passing through the system and disinfecting surfaces in an environment surrounding the system.    Housing (14)    Blower (22)    Transparent tubular unit (24)    UV light source (30)    UV sterilizer lamp (32) ",,,T01 (Digital Computers),T01-J16C2,G06N-020/00,IN202041026402-A   17 Jul 2020   G06N-020/00   202070Pages: 21   English,IN202041026402-A    IN41026402    23 Jun 2020,,IN41026402    23 Jun 2020,,,,,,,,,
IN202031024066-A,"System used for disinfecting Covid19 Protected Room, has three air inlets, air dispersion outlet with fan, and air intake controller that uses machine learning assembly to prefer advanced level control air flow into enclosure",MOHAN A;  SINGH P;  NIGADE M P;  D M;  PETHE R M;  SODHI R S,MOHAN A (MOHA-Individual);  SINGH P (SING-Individual);  NIGADE M P (NIGA-Individual);  D M (DMMM-Individual);  PETHE R M (PETH-Individual);  SODHI R S (SODH-Individual),202070407G,"   NOVELTY - A system (10) includes three air inlets (20), an air intake controller that uses machine learning assembly to prefer advanced level control air flow into the enclosure through the three air inlets. An air dispersion outlet (16) is provided and has a fan that draws air into the room through the three air inlets and forces air out of the room. The chemical dispersion assembly generates a disinfecting clean fog relative to the fan. The controller system controls the air intake control assembly to disperse the disinfecting clean fog into the room, and subsequently draws the disinfecting clean fog from the room and through the Covid19 killer filter assembly. The antimicrobial dispersion assembly dispenses an antimicrobial coating substance relative to the air dispersion outlet. The system controller can open the first air inlet and activate the fan to disperse the antimicrobial coating substance into the room.    USE - The system is used for disinfecting a Covid19 Protected Room.    DETAILED DESCRIPTION - A system (10) comprises three air inlets (20, 22) and an air intake controller that uses machine learning assembly to prefer advanced level control air flow into the enclosure through the three air inlets. The air flows between the exterior and interior of the enclosure through the second and third air inlets that pass through a Covid19 killer filter assembly. The room also includes an air dispersion outlet (16) having a fan (23) that draws air into the room through the three air inlets and forces air out of the room. The chemical dispersion assembly generates a disinfecting clean fog relative to the fan. The controller system (machine learning programming) controls the air intake control assembly to disperse the disinfecting clean fog into the room, and subsequently draws the disinfecting clean fog from the room and through the Covid19 killer filter assembly. The controlling programming displays the panel then user can select an air fragrancing mode of operation subsequent to selection of the air purification mode of operation. The disinfecting substance filter assembly comprises a disinfecting substance filter that neutralizes or captures disinfecting substance that passes there through and varies the surface cleaning mode of operation in response to signals sent from the user interface connected to the control system. The antimicrobial dispersion assembly dispenses an antimicrobial coating substance relative to the air dispersion outlet. The system controller can open the first air inlet and activate the fan to disperse the antimicrobial coating substance into the room.    DESCRIPTION OF DRAWING(S) - The drawing shows a perspective view of the system.    System (10)    Housing (12)    Air dispersion outlet (16)    Air dispersion assembly (18)    Air inlets (20) ",,,"D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).);  T01 (Digital Computers)",D09-A01;  T01-J12;  T01-J16C2,A01N-025/00,IN202031024066-A   17 Jul 2020   A01N-025/00   202063Pages: 24   English,IN202031024066-A    IN31024066    09 Jun 2020,,IN31024066    09 Jun 2020,,,,,,,,,
IN202041025600-A,"ADML-Covid19 protected room for disinfecting and sterilizing all types of room, food and surfaces, has air dispersion outlet that comprises fan that draws air into room through air inlets and that forces air out of room",MADANA M R;  GOSUL M;  VEMPATI S;  REDDY T K;  KUMBAKONAM M;  YERRAMANENI S;  GOWRAVARAM R,MADANA M R (MADA-Individual);  GOSUL M (GOSU-Individual);  VEMPATI S (VEMP-Individual);  REDDY T K (REDD-Individual);  KUMBAKONAM M (KUMB-Individual);  YERRAMANENI S (YERR-Individual);  GOWRAVARAM R (GOWR-Individual),202064878W,"   NOVELTY - The protected room has a UV (NU-V) source (7) that is more effective than high intensity mercury based 257nm light for destroying DNA of covid19, virus, bacteria, spores and cysts. An air disinfection unit is passed through housing from an air inlet to an air outlet opening at a predetermined air flow rate under uniform cross-sectional air flow conditions across closely spaced UV-C irradiation lamps located at a distance of between 2-4 inches. The housing has a predetermined volume selected such that airborne bacteria remain in the enclosure for a residence time of between 0.54 and 1.9seconds. The air flows between the exterior and interior of the enclosure through the second, third air inlet passes through a Corona virus killer filter assembly. An air dispersion outlet has a fan (12) that draws air into the room through the first, second air inlets and forces air out of the room.    USE - ADML-Covid19 protected room for disinfecting and sterilizing all types of room, food and surfaces contaminated with microorganisms and toxic substances to render both inactive and protecting surfaces in closed or captured environments such as large volumes such as high rise building, cruise ships and jet airliners, or small volumes such as small rooms or surgical operation areas whether in hospital operating room from external sources of microbial contamination. Can also be used for skin disinfection.    ADVANTAGE - The improved ultra violet irradiation device is provided for room air disinfection. The ultra violet irradiation device for room air disinfection is relatively simple in construction yet efficient in use. The ultra violet irradiation unit has a high disinfection rate. The ultra violet irradiation unit is adapted to be mounted in the ceilings of rooms for unobtrusive operation. The step of directing the photons comprises directing the photons to provide radiant dose energy of 62 mJ/cm2 to the substance or surface to be disinfected. The airflow then passes through a second diffuser and humidifier to ensure that the airflow is uniform across the duct and that the humidity level is controlled to some preset value. The testing determines the correct exposure limits to prevent any harmful effects that could occur when used to disinfect human skin, hands, animal surfaces such as skin, fur, and hair, and critical plastics and materials used in medical devices. The potential is provided to sterilize/disinfect medical equipment and surfaces and critical portions on an industrial assembly line prior to packaging. The apparatus is designed to make direct photons to the intended target as effectively and efficiently as possible. The apparatus makes for a cost effective process for sterilizing and disinfecting air, all types of surfaces and food during normal daily activity and prevents the previous need to restrict occupation and use of areas being treated. The process is to direct the correct spectral emission to target specific bonds in proteins and amino acids in the DNA/RNA molecule with sufficient intensity to destroy pathogens quickly and effectively. The process is significantly improved by reducing the UV dose or treatment time. The apparatus contains baffles and zone restriction devices that enhance the zone protection and minimize the positive pressure required to maintain the protected zone.    DESCRIPTION OF DRAWING(S) - The drawing shows a perspective schematic view defining the location of important components for disinfecting or sterilizing large volumes of air.    NU-V source (7)    Distance (8)    Electrostatic precipitator (9)    Humidifier (10)    Control sensors (11)    Fan (12) ",,,A85 (Electrical applications.);  T01 (Digital Computers),A12-E;  T01-J06A;  T01-J16C2,G06N-020/00,IN202041025600-A   03 Jul 2020   G06N-020/00   202059Pages: 28   English,IN202041025600-A    IN41025600    18 Jun 2020,,IN41025600    18 Jun 2020,,,,,,,,,
IN202011022186-A,"Method for sterilizing closed environment mounting fresh invigorating air generator, involves inactivating quantity of Norwalk virus in closed environment, by exposing closed environment to preset ozone concentration of for preset time",KUMAR S;  KALYANI P;  DAS S;  SODHI R S;  CHORDIYA S B;  PAWAR V P,KUMAR S (KUMA-Individual);  KALYANI P (KALY-Individual);  DAS S (DASS-Individual);  SODHI R S (SODH-Individual);  CHORDIYA S B (CHOR-Individual);  PAWAR V P (PAWA-Individual),202060607U,"   NOVELTY - The method involves placing an ozone generator into a closed environment. The ozone is generated to a predetermined ozone concentration. The humidity of the closed environment is increased. The predetermined fresh invigorating air concentration is maintained for a predetermined time. The fresh invigorating air is depleted after the expiry of period of time. The ozone generator air signals when the fresh invigorating air concentration is reduced to a predetermined thrust hold level. A thrust hold generator is provided including humidifier and timer. A quantity of Norwalk virus is inactivated in a closed environment, by exposing the closed environment to an ozone concentration of 22 to 38 ppm for 33 to 75 minutes. The fresh air breathed through AIR disinfectant Kit is filtered in side of room, care and any closed air. The preselected level is set corresponding to the minimum level of oxygen and other gas.    USE - Method for sterilizing closed environment mounting fresh invigorating air generator.    ADVANTAGE - The economical device and method for ensuring life-saving supply of fresh air to person entrapped in burning hotel room or the like, when the person is subjected to toxic smoke inhalation. The room smart fresh air system and air supply method solve problem that scavenging efficiency is low and major-minor equipment effectively links. The ventilation effect of whole room space is improved by the grading control of smart controller between new air main frame and new air- disinfectant Kit. The room smart fresh air system is featured with exempt to install various ventilation shafts and less indoor confined space. The thermal load loss and room noise are reduced since the decentralized active heat transfer device is adopted to regulate between common rooms and independent housing, and air exchange amount is carried out. The air quality in living room is improved. The external form room Smart fresh air system effectively improves indoor air environment, and air quality is far away higher than national indoor environment standard.    DETAILED DESCRIPTION - The indoor end of new air main frame is positioned at the corner that shares room. The new air- Disinfectant Kit is installed on the corner between ovaries. The airport of new air main frame and new air- Disinfectant Kit is obliquely installed. The one-level environmental feedback device and secondary environment ultra-magnifier are mainly comprised of signal transmitting and receiving module, and display module of temperature sensor, humidity sensor, dust sensor, carbon dioxide sensor (26), formaldehyde sensor, and covid19 detection sensor. The airport incline direction is provided in lower-left and bottom right. The interior wall door is provided between the ovary corners in interior wall. Interior wall door sets are arranged for guiding the movable air deflector of air-out air direction between ovaries. The first blower fan and the second blower fan are provided such that air main frame is installed by diagonal angle form. The interior wall door is provided with a door opener that is controlled by smart controller.    DESCRIPTION OF DRAWING(S) - The drawing shows a block diagram of the air-Disinfectant Kit.    Refrigerated cargo unit (10)    Refrigeration unit (12)    Controller (14)    Air exchange panel (18)    Carbon dioxide sensor (26) ",,,"D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).);  E36 (Non-metallic elements, semi-metals (Se, Te, B, Si) and their compounds (except for E35).);  J01 (Separation - including evaporation, crystallisation, solvent extraction, chromatography, dialysis, osmosis including drying gases and/or vapours, and separation of solids from gases, liquids and other solids. Isotope separation, filter materials (including molecular sieves for separation), and centrifuges (except where used for analysis) (B01D, B03, B04, B07B).);  J03 (Electrochemical processes and electrophoresis - including ozone production, brine electrolysis, water electrolysis, production of chemical compounds and non-metallic elements, but excluding batteries or other means of producing power and the treatment of metals (C25B).);  P34 (Sterilising, syringes, electrotherapy (A61L, M, N).)",D09-A01A;  D09-B01;  E10-D01D;  E11-Q03J;  E31-N05C;  J01-E02H5;  J01-G03C;  J03-A01;  P34-A01;  P34-A02,A23L-003/3409;  A61L-002/00;  A61L-002/20;  A61L-009/015;  A61L-009/16,IN202011022186-A   26 Jun 2020   A61L-002/20   202060Pages: 20   English,IN202011022186-A    IN11022186    27 May 2020,,IN11022186    27 May 2020,,,,,103087-0-0-0 K P; 255-0-0-0 A K; 34-0-0-0 A K,,,R01887 K P; R01066 A K; R00001 A K,1887-P; 1066-S; 0001-S
IN202011020603-A,"Lightweight helmet for protection against droplet infection, has transparent front cover with opening for breathing air fitted with replaceable air filter, temperature sensor and internet of things (IOT) sensor, respectively",SINGH H;  KUMAR V;  SAXENA K,SINGH H (SING-Individual);  KUMAR V (KUMA-Individual);  SAXENA K (SAXE-Individual),202060608G,"   NOVELTY - The lightweight helmet has a transparent front cover with opening for breathing air fitted with a replaceable air filter, a temperature sensor (4) and IOT sensor. The helmet is easily mountable on the head. A helmet front cover has an opening for breathing air, and the opening is fitted with air filtration medium. The opening is fitted with air filtration medium comprising a reusable three-layer cloth. The helmet front cover has the temperature sensor near the forehead and a display unit to display the temperature. The IOT enabled sensor is configured to communicate with the wrist band attached to the smart phone of the wearer and temperature sensor in the helmet.    USE - Lightweight helmet for protection against droplet infection.    ADVANTAGE - The helmet is possible to provide protection of entire head against COVID19. The helmet is capable of easily mounted on the head and is light weight, providing protection from droplet contamination by pre-symptomatic and asymptomatic COVID19 patients, reducing the transmission capability of Covid19, protecting hair, face, eyes, nose, mouth, ears, head, and upper portion including neck and shoulders, and for recoding data from sensors and communicating the same to the doctors/physicians to provide a real time data.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view of a lightweight helmet for protection against droplet infection.    Structure of lightweight helmet (1)    Mouth position (2)    Cloth (3)    Temperature sensor (4)    Device for calculating all the health parameters (5) ",,,"J01 (Separation - including evaporation, crystallisation, solvent extraction, chromatography, dialysis, osmosis including drying gases and/or vapours, and separation of solids from gases, liquids and other solids. Isotope separation, filter materials (including molecular sieves for separation), and centrifuges (except where used for analysis) (B01D, B03, B04, B07B).);  P21 (Wearing apparel (A41, A42).);  P35 (Life-saving, fire-fighting (A62).);  T01 (Digital Computers)",J01-G03;  J01-H02B;  P21-F;  P21-N;  P35-A03E1;  T01-N01F,A42B-003/04;  A42B-003/10;  A42B-003/28;  A62B-018/04;  B01D-039/16,IN202011020603-A   26 Jun 2020   A42B-003/04   202066Pages: 11   English,IN202011020603-A    IN11020603    15 May 2020,,IN11020603    15 May 2020,,,,,,,,,
IN202011018349-A,"Development of biodegradable Covid19 mask comprises reinforcing nano material and adding Tylophora indica, having antibacterial and antiviral properties",VIMAL V;  VERMA D;  SINGH T;  AGNIHOTRI A;  BHATT M;  SAVITA,VIMAL V (VIMA-Individual);  VERMA D (VERM-Individual);  SINGH T (SING-Individual);  AGNIHOTRI A (AGNI-Individual);  BHATT M (BHAT-Individual);  SAVITA (SAVI-Individual),2020606094,"   NOVELTY - Development of the biodegradable Covid19 mask comprises reinforcing the nano material and adding Tylophora indica, having antibacterial and antiviral properties.    USE - The method is useful for: developing a mask which is suitable for the restriction of the communicable disease specifically the viruses and the bacterial attack and the anti-viral textile plays an important role by acting as a physical barrier between the human and the infection leading to the direct and indirect contact, airborne droplets nuclei, and respiratory droplets, respectively (all claimed).    ADVANTAGE - The method: provides the development of the mask which is biodegradable and reusable i.e. environment friendly; makes a type of textile which is ready to restrict the attacks of the viruses and the bacteria; and designs the fabric/textile that restrict the transmission of the viral disease in an efficient manner. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  A96 (Medical, dental, veterinary, cosmetic.);  P21 (Wearing apparel (A41, A42).);  P35 (Life-saving, fire-fighting (A62).);  S05 (Electrical Medical Equipment);  T01 (Digital Computers)",B04-A08G2;  B04-A09;  B04-A10;  B11-C04;  B11-C11;  B12-M11Q;  B14-A01;  B14-A02;  B14-Z;  A12-C02;  A12-H04;  A12-V01;  A12-V03D;  A12-W14;  P21-N;  P35-A03E;  S05-G02G9;  T01-J06A1,A41D-013/11;  A61K-039/00;  A62B-023/02;  C09D-005/14;  G16H-050/80,IN202011018349-A   26 Jun 2020   A61K-039/00   202060Pages: 12   English,IN202011018349-A    IN11018349    29 Apr 2020,,IN11018349    29 Apr 2020,,,,,1399036-0-0-0 K M,,,RAOP7G K M,
IN202011016347-A,"Treating severe acute respiratory syndrome (SARS)-COV2 (COVID19) infection, comprises administering angiotensin-I-converting enzyme 2 m-RNA inhibitor desoxycorticosterone acetate",VARMA A,VARMA A (VARM-Individual),202057542F,"   NOVELTY - Treating (M1) severe acute respiratory syndrome (SARS)-COV2 (COVID19) infection in a subject experiencing acute SARS-COV2 (COVID19) infection, comprises administering angiotensin-I-converting enzyme 2 (ACE2) m-RNA inhibitor i.e. desoxycorticosterone acetate.    USE - The methods are useful: for treating SARS-COV2 infection in a subject experiencing acute SARS-COV2 infection, where the subject has SARS-COV2 infection; to alleviate or to slow progression of symptoms and signs of SARS-COV2 (COVID19) infection; to attenuate symptoms and signs of lower respiratory tract; for managing SARS-COV2 (COVID19) in the subject experiencing acute symptoms, or managing pancreatitis acute SARS COV2 (COVID19) infection (all claimed); and reducing risk of multisystem organ failure in the subject having SARS-COV2 (COVID19) infection. No biological data given.    ADVANTAGE - The method utilizes the ACE2 m-RNA inhibitor that is substantially enantiomerically pure.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for managing (M2) SARS-CoV2 (COVID19) in the subject experiencing acute symptoms, comprising administering the ACE2 m-RNA inhibitor adjunctively with at least one additional agent for managing pancreatitis acute SARS COV2 (COVID19) infection. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  B01 (Steroids - including systems containing carbocyclic and/or heterocyclic rings fused onto the basic steroidal ring structure.);  B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B01-C09;  B01-E;  B14-A02B5;  B14-C03;  B14-K01D;  B14-L06;  B14-N13;  B14-S18;  D05-H,A61K-031/522;  A61K-038/48;  A61K-045/06;  A61K-009/00;  C07D-401/12,IN202011016347-A   19 Jun 2020   A61K-038/48   202057Pages: 22   English,IN202011016347-A    IN11016347    15 Apr 2020,,IN11016347    15 Apr 2020,,,,,129573-1-0-0 K M U,,,R00105 K M U,0105-U
CN111270017-A,New primer probe combination useful for detecting            coronavirus based on digital PCR and in the preparation            of a coronavirus detection kit,ZHANG X;  HUANG S,SHENZHEN HYK GENE TECHNOLOGY CO LTD (SHEN-Non-standard),202054965K,"   NOVELTY - Primer probe combination comprises a nucleic                acid sequence of fully defined 26 nucleotides in                (SEQ ID NO: 1) and sequence of fully defined 21                nucleotides in (SEQ ID NO: 2), and sequence of                fully defined 25 nucleotides in (SEQ ID NO: 3), as                given in specification, is new.    USE - The primer probe combination is useful for                detecting coronavirus based on digital PCR and in                the preparation of a coronavirus detection kit                (claimed).    ADVANTAGE - The primer probe combination: can designs                primer pairs and probes for the ORF1ab gene region                in COVID19, which can specifically detect                coronaviruses; prepares kit, which is used together                with digital PCR technology, can absolutely                quantify samples with high detection sensitivity,                and achieves test results to eliminate the                interference of complex samples on the experimental                results, and has high accuracy.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for kit                for detecting coronavirus based on digital PCR,                comprising the primer probe combination; #using the                kit, comprising sample to be tested, mixing the                primer probe combination, enzyme and reaction                buffer, preparing droplets, then transferring the                droplets to the PCR machine for amplification, then                using a droplet analyzer to detect the amplified                droplets, analyzing data, obtaining the test result                of the sample to be tested. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E01;  B04-E05;  B04-E99;  B04-F11B;  B04-L01;  B06-A02;  B06-A03;  B06-D01;  B06-S;  B11-C07B3;  B11-C08E3;  B11-C08F8;  B12-K04F;  D05-A02;  D05-H06A;  D05-H12D1;  D05-H18B;  D05-H99,C12N-015/11;  C12Q-001/686;  C12Q-001/70,CN111270017-A   12 Jun 2020   C12Q-001/70   202053Pages: 15   Chinese,CN111270017-A    CN10259400    03 Apr 2020,,CN10259400    03 Apr 2020,,,"CN111270017-A -- CN107245532-A   INSPECTION & QUARANTINE TECHNOLOGY                  CENT (AQSI);  CHINESE ACAD INSPECTION & QUARANTINE (CAIQ);  LONGYAN ENTRY EXIT INSPECTION &                  QUARANTI (LONG-Non-standard)   CHEN X,  ZHU P,  LI Y,  WEN J;  CN107287106-A   YIXING COYOTE BIOSCIENCE CO LTD (YIXI-Non-standard)   CHEN H,  KINTSCH G,  LI C,  LI Y;  CN108950065-A   UNIV JINAN GUANGDONG (UJIN)   YE L,  CAO W,  CHEN X,  CHANG Y,  LI L,  SHI L;  CN110144422-A   WUXI CUSTOMS DISTRICT PEOPLES REPUBLIC (WUXI-Non-standard);  INST BEIJING VIRAL DISEASE CONTROL &                  PRE (CCDC)   GENG H,  ZHU N,  CAI L,  SUN Y,  XU C,  YANG Z,  WANG S,  WU H,  TAN W;  CN111057798-A   UNIV FUDAN HUASHAN HOSPITAL (UYFU)   XING Z,  GUAN M,  CAO G,  KANG Z,  XU X,  WU Z,  MA Y,  QIN H,  XU Y;  CN111273026-A   WUXI PEOPLES HOSPITAL (WXPH)   LU P,  ZOU J,  CHEN W","CN111270017-A  RENFEI LU:          ""SARS-CoV-2 detection using digital PCR for COVID-19          diagnosis, treatment monitoring and criteria for          discharge"",          MEDRXIV,relevantClaims[1-7],relevantPassages[2.23];  : """",          ,relevantClaims[1-10],relevantPassages[523-526]",90045-0-0-0 D K M; 698331-0-0-0 D K M; 484450-0-0-0 D K M;  D K M; 281290-1-0-0 D K M; 248056-0-0-0 D K M,,05935,R15410 D K M; RAA5R2 D K M; RA5VQX D K M; RCTDNT D K M; RA1P21 D K M; RA104R D K M,
IN202041016724-A,"Composition useful for e.g. detecting infectious            severe acute respiratory syndrome (SARS) Coronavirus at            user RNA, cDNA and mRNA, for screening anti-SARS            Coronavirus agent and vaccine, and reducing            SARS-Coronavirus infection",ARVIND S;  DEVIKA S;  JOSHI C;  JAIN V;  SINGH Y;  SINGH V,ARVIND S (ARVI-Individual);  DEVIKA S (DEVI-Individual);  JOSHI C (JOSH-Individual);  JAIN V (JAIN-Individual);  SINGH Y (SING-Individual);  SINGH V (SING-Individual),202051476P,"   NOVELTY - Composition, preparation method, usage method                (M1), and detection method (M2) for infectious RNA,                cDNA, and mRNA of severe acute respiratory syndrome                (SARS) Coronavirus, and replication or presence of                SARS Coronavirus in a sample, are claimed. The                method (M1) involves using composition as immunogen                or vaccines and/or to express heterologous nucleic                acids. The method (M2) involves (a) (i) detecting                presence SARS-Coronavirus guide RNA (gRNA) or sgRNA                in a sample, by reverse transcriptase PCR,                ribonuclease protection assay, and/or Northern                blot, where sgRNA comprises at least a portion of a                leader sequence, and (ii) quantitating sgRNA and/or                gRNA, or (b) (i) providing sample and cells, where                cells support replication of SARS Coronavirus in                absence of substantial cytopathic effect, (ii)                inoculating cells with sample to produce inoculated                cells, and (iii) detecting presence of                SARS-Coronavirus in inoculated cells, where cells                are chosen from HEK-293T, Huh-7, Mv1Lu, pRHMK and                pCMK.    USE - The composition is useful for detecting                infectious SARS Coronavirus, preferably covid19 at                user RNA, cDNA and mRNA, and detecting replication                or presence of SARS Coronavirus in sample, which is                useful for screening anti-SARS Coronavirus agents                and vaccines, and reducing infection with                plus-strand RNA viruses i.e. SARS-Coronavirus. The                isolated nucleic acid is useful for eliciting an                immune response in a subject (all claimed), and                treating and/or preventing SARS Coronavirus                infection in a subject.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the                following:    (1) an isolated nucleic acid, which comprises                a nucleotide sequence encoding a Nidovirus genome                or replicon RNA, where the genome or replicon RNA                comprises (i) one or more of the same mutations in                a consensus sequence (CS) present in a                transcription regulatory sequence (TRS) of a leader                sequence and in the TRS located upstream of each of                the structural genes, (ii) a wild type CS in a TRS                for open reading frame (ORFs) 3a/b, ORF4, ORF5,                ORF6, ORF7a/b, ORF8a/b and ORF9a/b, and (iii) one                or more of the same mutations in the CS of the TRS                located upstream of ORF 3a/3b, ORF 4, ORF 5, ORF6,                ORF 7a/7b, ORF 8a/b and ORF 9a/b; and    (2) a method for eliciting an immune response                in a subject involves delivering the nucleic acid                or Nidovirus particle to the subject. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)",B04-E01A;  B04-E05;  B04-E07;  B04-E99;  B04-F11B;  B04-L04B;  B11-C08E1;  B11-C08E3;  B11-C08F8;  B12-K04F;  B12-K04G1B;  B14-A02B5;  B14-K01D;  B14-S11A;  B14-S11D3;  D05-A02B;  D05-H06A;  D05-H07;  D05-H18B;  D05-H99,A61K-039/00;  A61K-039/215;  C07K-014/005;  C12N-007/00;  C12Q-001/70,IN202041016724-A   05 Jun 2020   C12Q-001/70   202052Pages: 43   English,IN202041016724-A    IN41016724    18 Apr 2020,,IN41016724    18 Apr 2020,,,,,201562-0-0-0 K U,,,RA0124 K U,
IN202041021833-A,"Disinfecting agent capable of killing coronary viruses of atypical pneumonia, comprises hydrogen peroxide, glacial acetic acid, alkylol alkylphenol ethoxylates, polyvinylpyrrolidone, EDTA, amyl diacid peroxide, oxyquinoline and water",KASALA R;  PAWAN K B;  KAWAR S;  PANDEY M K;  JAIN V;  PAWAR V P,KASALA R (KASA-Individual);  PAWAN K B (PAWA-Individual);  KAWAR S (KAWA-Individual);  PANDEY M K (PAND-Individual);  JAIN V (JAIN-Individual);  PAWAR V P (PAWA-Individual),202051473X,"   NOVELTY - Disinfecting agent capable of killing coronary viruses (Covid19) of atypical pneumonia, comprises peroxyacetic acid compound solution formed by proper proportion using matching learning programming of 1:2.7-1:8 which is diluted by pure water through the proportion of 1:200-1100 when being used, where disinfection is achieved by a soak spray (time control by machine learning programming) way and an evaporating way, and thus coronary viruses (Covid19) resulted in the atypical pneumonia are 100% killed. The disinfecting agent is preferably comprised of 26-31% hydrogen peroxide, 9-14% glacial acetic acid, 2-4% alkylol alkylphenol ethoxylates, 4-7% polyvinylpyrrolidone, 0.02-0.15% EDTA, 3-5% state amyl diacid peroxide, 0.35-0.57% oxyquinoline, and rest of pure water.    USE - The disinfecting agent is useful for suppressing and/or killing the atypical pneumonia coronavirus quality control standard as given in the specification (claimed). No biological data given.    DETAILED DESCRIPTION - Disinfecting agent capable of killing coronary viruses (Covid19) of atypical pneumonia, comprises peroxyacetic acid compound solution formed by proper proportion using matching learning programming of 1:2.7-1:8 which is diluted by pure water through the proportion of 1:200-1100 when being used, where disinfection is achieved by a soak spray (time control by machine learning programming) way and an evaporating way, and thus coronary viruses (Covid19) resulted in the atypical pneumonia are 100% killed. The disinfecting agent mainly consists of hydrogen peroxide and peracetic acid composition of either hydrogen peroxide and peracetic acid, or acetic acid and hydrogen. The oxidation coexistence equilibrium system comprises non-ionic surface active agent, cationic high molecular thickener, macromolecular complexing agent (molecular weight of greater than or equal to 4250), state amyl diacid peroxide, oxyquinoline and water. The disinfecting agent is preferably comprised of 26-31% hydrogen peroxide, 9-14% glacial acetic acid, 2-4% alkylol alkylphenol ethoxylates, 4-7% polyvinylpyrrolidone, 0.02-0.15% EDTA, 3-5% state amyl diacid peroxide, 0.35-0.57% oxyquinoline, and rest of pure water. ",,,"D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).);  ;  E13 (Heterocyclics.);  E36 (Non-metallic elements, semi-metals (Se, Te, B, Si) and their compounds (except for E35).);  A14 (Polymers of other substituted monoolefins; including PVC, PTFE.);  A21 (Epoxides; aminoplasts; phenoplasts.);  T01 (Digital Computers)",D09-A01;  D09-A01A;  E06-D02;  E10-A04B2C;  E10-B01C1;  E10-C04J2U;  E10-E04M1;  A04-D05A;  A10-E08B;  A12-E;  A12-V03C1;  A12-W04C;  A12-W12;  A12-W12A;  T01-J16C2,A01N-037/16;  C07C-409/26;  C08G-059/62;  C11D-003/48;  G06N-020/00,IN202041021833-A   05 Jun 2020   G06N-020/00   202054Pages: 16   English,IN202041021833-A    IN41021833    25 May 2020,,IN41021833    25 May 2020,,,,,1-0-0-0 K M; 196-0-0-0 K M; 209-0-0-0 K M; 97153-0-0-0 K M; 3330-0-0-0 K M; 1062-0-0-0 K M; 200958-0-0-0 K M; 14922-0-0-0 K M; 444-0-0-0 ,220159601 K M,,R00247 K M; R00453 K M; R01732 K M; R01532 K M; R00195 K M; RA00D5 K M; RA00N2 K M; R01164 K M; R00351 ,0247-S; 0453-S; 1732-S; 1532-S; 0195-S; 1164-S
AU2020100550-A4,"System for detecting virus e.g. corona virus disease (COVID19) in patient, has sensors configured to detect volatile organic compounds (VOCs) and patterns in VOC to identify pathogen and arranged as lab on chip or on small circuit board",VAN EK G,VAN EK G (VEKG-Individual);  LEDGER ASSETS PTY LTD (LEDG-Non-standard),2020559598,"   NOVELTY - The system has sensors that detect VOCs and are made of metal oxide silicon. The patterns in the VOC are detected to identify the pathogen. The electronic sensors are arranged as a lab on a chip or on a small circuit board that is connected to microprocessor that is arranged in a sealable container. The output wires from the microprocessor are plugged into a computer notebook. The cloud software is accessed where processing of the collected data takes place. The vibrator is provided to trigger to send small amounts of deposits airborne such that the VOC present in the deposit from COVID19 are sensed by the electronics array. A camera is added to the lab on a chip device, which sends back picture data. A microphone sends back sound recordings or a code is entered by an operator of the lab on a chip device. (Incomplete specification, abstract based on available information published by the patent office).    USE - System for detecting virus such as corona virus disease (COVID19) and other pathogen and bacteria in patient.    ADVANTAGE - The accuracy of detection of virus is improved until the machine learning model is very accurate.    DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view of the system for detecting virus. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  ;  S03 (Scientific Instrumentation);  T01 (Digital Computers);  V04 (Printed Circuits and Connectors);  W04 (Audio/Video Recording and Systems)",B04-F01;  B04-F10;  B04-F11;  B05-B02C;  B11-C08B;  B11-C08E8;  B11-C08J;  B11-C11;  B12-K04G1B;  D05-H04;  D05-H05;  D05-H06;  S03-E03C;  S03-E14H9;  S03-H01;  T01-J05A2G;  T01-J20D;  T01-M06A1;  T01-N01A2G;  V04-X01A;  W04-E30A3,C12Q-001/04;  G01N-027/327;  G01N-033/487;  G01N-033/497,AU2020100550-A4   28 May 2020   G01N-033/497   202052Pages: 8   English,AU2020100550-A4    AU100550    12 Apr 2020,,AU100550    12 Apr 2020,,,,,107015-0-0-0 K U,,,R01666 K U,1666-U
AU2020100553-A4,"System used to detect virus such as COVID19, other            pathogens and bacteria, comprises sensors which detects            volatile organic compounds and are made from metal            oxide silicon and patterns in VOCs are detected to            identify pathogen present",VAN EK G,VAN EK G (VEKG-Individual);  LEDGER ASSETS PTY LTD (LEDG-Non-standard),2020559596,"   NOVELTY - System comprises sensors which detects                volatile organic compounds (VOCs) and are made from                metal oxide silicon. The patterns in the VOCs are                detected to identify the pathogen present. The                system is arranged in a handheld device with a                disposable blow tube. The micro electronics                including an array of between 1 and 15 Volatile                Organic Compound (VOC) electronic sensors arranged                as a lab on a chip or on a small circuit board                connected to a microprocessor (which powers up and                controls the sensors and collects the signals and                processes the signals i.e analog to digital                conversion) arranged in a hand held device similar                to a mobile alcohol brethylser with a throw away                blow tube. The microprocessor unit connects to WIFI                or GPRS and to the Cloud based software                component.    USE - System used to detect virus such as COVID19,                other pathogens and bacteria.    ADVANTAGE - The system allows the detection of the target                Viruses such as COVID19 and bacteria better at less                or more than nominal voltage.    DESCRIPTION OF DRAWING(S) - The drawing shows schematic representation of                system used to detect virus such as COVID19, other                pathogens and bacteria. ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  ;  S03 (Scientific Instrumentation);  T01 (Digital Computers);  V04 (Printed Circuits and Connectors);  W01 (Telephone and Data Transmission Systems)",B04-F10;  B04-F11B;  B11-C08E6;  B11-C11;  B12-K04G1A;  D05-H04;  D05-H06A;  D05-H10;  S03-E14H9;  T01-C08;  T01-J20D;  V04-Q02A7;  V04-Q30M;  W01-A06C4E,C12Q-001/04;  G01N-033/487;  G01N-033/497,AU2020100553-A4   28 May 2020   G01N-033/497   202052Pages: 8   English,AU2020100553-A4    AU100553    13 Apr 2020,,AU100553    13 Apr 2020,,,,,107016-0-0-0 K M,,,R01694 K M,1694-S
KR2020001014-U,"Covid19 cover used as blindfold, has cuebang rack convex that is provided at bottom and top of cuebang and sack, and cuebang is manufactured as whole from beginning, and to function as cuebang",PARK J H,PARK J H (PARK-Individual),202043789L,"   NOVELTY - The covid19 cover has a partition portion that is used by connecting the fans sack and the cuebang, and stored by making the cuebang rack convex is provided at the bottom and top of the cuebang and the sack. The cuebang is manufactured as a whole from the beginning, and to function as the cuebang.    USE - Covid19 cover used as blindfold.    ADVANTAGE - The lower end of cover can be sized with the cue room and can be resized so that the top of the bag can be firmly attached to the top of the bag. ",,,"P24 (Hand, travelling articles, brushes (A45, A46).)",P24-A03;  P24-M,A45B-027/02,KR2020001014-U   20 May 2020   A45B-027/02   202044Pages: 3   ,KR2020001014-U    KR001491    01 May 2020,,KR001491    01 May 2020,,,,,,,,,
AU2020100453-A4,"Disinfectant Bomb (DBOMB) for use in vehicles such as police vehicle, decreases need for cleaners utilizing traditional disinfectant methods, respectively",GIUMELLI C B,GIUMELLI C (GIUM-Individual),202038975H,"   NOVELTY - The bomb provides a cheap accessible product to Australians citizens, public and private industry to mitigate the spread of virus including corona disease (COVid19). The product is configured to mitigate earlier risks within essential services and industries allowing best opportunity for business as usual functions. The device provide a readily available and financially beneficial solution to Australian industry, and also decrease the need for cleaners utilizing traditional disinfectant methods, which offers no guarantee of prevention and remove the risk of spread of disease through infection of that cleaner.    USE - Disinfectant Bomb (DBOMB) for use in vehicle such as police vehicle, ambulance, taxi, bus, trains, trams, shipping and airplane, and for use in office, hospital, private dwelling, prison, and retail venues.    ADVANTAGE - The product is possible to mitigate earlier risks by viruses within essential services and industries allowing best opportunity for business as usual functions. ",,,"B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.);  D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).);  P34 (Sterilising, syringes, electrotherapy (A61L, M, N).)",B11-B06;  D09-A01;  P34-A01,A61L-002/22;  A61L-009/14,AU2020100453-A4   30 Apr 2020   A61L-009/14   202040Pages: 6   English,AU2020100453-A4    AU100453    24 Mar 2020,,AU100453    24 Mar 2020,,,,,,,,,
US2015164602-A1;  US10022189-B2,"Apparatus for cleaning e.g. endoscopic instrument,            has fluid transmission system in communication with            chamber and fluid channel of fluid delivery unit to            circulate cleaning fluid from chamber through fluid            channel of delivery unit",BERKEY J;  CANTEY E;  DIAZ L;  FOWLER D;  GONZALEZ M J;  PETERSON D;  THOMAS B;  VASQUEZ J,STRYKER SUSTAINABILITY SOLUTIONS INC (STYC-C);  STRYKER SUSTAINABILITY SOLUTIONS INC (STYC-C),2015355754,"   NOVELTY - The apparatus (10) has a vacuum pump coupled                to vessel for depressurizing chamber. A rotatable                device (76) fixed in chamber, defines a                longitudinal axis with rotatable device having a                rack. The rotatable device having a fluid delivery                unit extends towards cavity of rack with fluid                delivery unit having an inlet and an outlet and                fluid delivery unit. A fluid transmission system in                fluid communication with chamber and fluid channel                of fluid delivery unit circulates the cleaning                fluid from chamber through fluid channel of fluid                delivery unit.    USE - Apparatus for cleaning instrument, used in                large-scale environments and/or for commercial                purposes, hospital, medical laboratory and school.                Uses include but are not limited to endoscopic                instrument and non-endoscopic instrument, trocar                such as ENDOPATH XCEL trocar (RTM: Bladeless                trocars developed by Ethicon Endo-Surgery, Inc),                ENDOPATH BASX trocar (RTM: Bladeless trocars                developed by Ethicon Endo-Surgery, Inc),                laparoscopic hand instruments such as ENSEAL G2                curved and straight tissue sealers (RTM: first                advanced energy device developed by Ethicon                Endo-Surgery, Inc), ENDO DISSECT Short and ENDO                SHEARS Short instruments (RTM: surgical dissectors                developed by Coviden Surgical), suture passer,                reamer, drill bit, saw, precision blade,                oscillating blade, arthroscopic instrument such as                DYONICS (RTM: arthroscopic drill bits and saw                blades available from Smith and Nephew), cooking                instruments such as knife, fork, spoon, measuring                instrument, household instrument, laboratory                instrument such as test tube, beaker, thermometer,                veterinary instrument.    ADVANTAGE - The apparatus effectively and efficiently                cleans the interior and/or exterior of the                instrument using a cleaning fluid. The apparatus                requires less handling of the instruments during                cleaning, which reduces breakages or damage to the                instruments as well as the individual components of                the apparatus.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a                method for cleaning an instrument with a cleaning                fluid with the instrument having an interior and an                exterior.    DESCRIPTION OF DRAWING(S) - The drawing shows a semi-schematic,                perspective view of an apparatus for cleaning                instrument.    Apparatus (10)    Instrument (12)    Hinge (32)    Rotatable device (76)    Cart (130) ",,,"P31 (Diagnosis, surgery (A61B).);  P43 (Sorting, cleaning, waste disposal (B06, B07, B08, B09).)",P31-A01;  P31-G;  P43-B01A;  P43-U13,A61B-019/00;  B08B-007/02;  B08B-009/023;  B08B-009/032;  A61B-090/70;  A61L-002/025;  B08B-011/02;  B08B-003/12;  B08B-009/00,US2015164602-A1   18 Jun 2015   A61B-019/00   201542Pages: 20   English;  US10022189-B2   17 Jul 2018   B08B-009/00   201848   English,US2015164602-A1    US572573    16 Dec 2014;   US10022189-B2    US572573    16 Dec 2014,US2015164602-A1 Provisional Application US916477P;   US10022189-B2 Provisional Application US916477P;   US10022189-B2 Previous Publ. Patent US2015164602,US916477P    16 Dec 2013;  US572573    16 Dec 2014,,134/022000,"US2015164602-A1 -- US6158450-A   PAINTER P W (PAIN-Individual)   PAINTER P W;  US6538360-B2   PUSKAS W L (PUSK-Individual)   PUSKAS W L;  US10022189-B2 -- US6158450-A   PAINTER P W (PAIN-Individual)   PAINTER P W;  US6538360-B2   PUSKAS W L (PUSK-Individual)   PUSKAS W L;  DE3416743-A   GRIESAT W (GRIE-Individual)   GRIESAT W;  DE19858344-A1   ETHICON INC (ETHI)   LIN S,  JACOBS P T,  WU S S,  CHU N S;  DE19858347-A1   ETHICON INC (ETHI)   LIN S,  JACOBS P T,  WU S S,  CHU N S;  EP302419-A   SURGIKOS INC (SURG-Non-standard);  JOHNSON & JOHNSON (JOHJ)   JACOBS P T,  BERRY R F,  SOTO R A;  EP766969-A1   PLASTICOS GALICIA SA (PLAQ)   VILLAR O;  EP835665-A2   KRAUSE I (KRAU-Individual)   KRAUSE I;  EP898971-A2   ETHICON INC (ETHI)   LIN S,  JACOBS P T;  EP923951-A2   ETHICON INC (ETHI)   LIN S,  JACOBS P T;  EP1186307-A2   ETHICON INC (ETHI)   LIN S;  EP1192954-A2   ETHICON INC (ETHI)   LIN S,  AGAMOHAMADI M;  GB2094149-A   MOTHERCARE LTD (MOTH-Non-standard)   FLEURY N;  GB2248188-A   KEYMED MED & IND EQ (OLYU)   PARKER G C,  ROSS I M;  US1540793-A   ;  US3807954-A   H P MCDONALD (MDON-Individual);  US3814901-A   LINCOLN MFG CO INC (LINC-Non-standard);  US3893843-A   ARBROOK INC (ARBR-Non-standard);  US4064886-A   RIWOPLAN MED-TECHN (RIWO-Non-standard);  US4142539-A   HOBART CORP (HOBM)   SHIH K,  BISHAI M N;  US4193818-A   AMERICAN STERILIZER CO (AMSA)   YOUNG J H,  KARLE D A,  HALLECK F E;  US4203943-A   AMERICAN STERILIZER CO (AMSA)   GILLIS J R;  US4239730-A   ELECTROLUX AB (ELEX);  US4261950-A   AMERICAN STERILIZER CO (AMSA)   BAINBRIDGE R C,  KRAHE R P;  US4278101-A   OLYMPUS OPTICAL CO LTD (OLYU)   TANAKA M,  KONOSHIMA K;  US4281674-A   OLYMPUS OPTICAL CO LTD (OLYU)   TANAKA M,  KONOSHIMA K;  US4321232-A   TEGAL CORP (TEGA-Non-standard)   BITHELL R M;  US4333773-A   FJALLSTROM B (FJAL-Individual)   FJAELLSTRO B;  US4337223-A   BEN VENUE LAB (BENV)   KAYE S;  US4380530-A   BEN VENUE LAB (BENV)   KAYE S;  US4410492-A   BEN VENUE LAB (BENV)   KAYE S;  US4489741-A   OLYMPUS OPTICAL CO LTD (OLYU)   OGASAWARA T;  US4526622-A   OLYMPUS OPTICAL CO LTD (OLYU)   TAKAMURA K,  ISHII F,  NAKAJIMA Y,  YABE H,  SASA H,  NAKAMURA T;  US4526623-A   OLYMPUS OPTICAL CO LTD (OLYU)   ISHII F,  SASA H,  YABE H,  NAKAJIMA K,  NAKAMURA T;  US4537209-A   OLYMPUS OPTICAL CO LTD (OLYU)   SASA H;  US4545956-A   SIEMENS AG (SIEI)   CISZWESKI H J,  PABST J,  WEISSER H J;  US4548197-A   OLYMPUS OPTICAL CO LTD (OLYU)   KINOSHITA K;  US4552728-A   JOHNSTON H PTY LTD (JOHN-Non-standard);  NORRIS IND LTD (NORR-Non-standard)   TAYLOR W R;  US4576650-A   OLYMPUS OPTICAL CO LTD (OLYU)   YABE H,  SASA H,  NAKAJIMA Y,  ISHII F,  TAKAMURA K,  NAKAMURA T;  US4576792-A   ELECTROLUX AB (ELEX)   MARTENSSON K I M;  US4579597-A   OLYMPUS OPTICAL CO LTD (OLYU)   SASA H,  YABE H,  NAKAJIMA Y,  ISHII F,  TAKAMURA K,  NAKAMURA T;  US4579598-A   OLYMPUS OPTICAL CO LTD (OLYU)   SASA H,  YABE H,  NAKAJIMA Y,  ISHII F,  TAKAMURA K,  NAKAMURA T;  US4590037-A   BEN VENUE LAB (BENV)   KAYE S;  US4637916-A   HENNEBERT P (HENN-Individual);  UNIV CATHOL LOUVAIN (UYLO-Non-standard);  MFRE BELGE DE GEMBLOUX (BEGE-Non-standard);  US4643876-A   SURGIKOS INC (SURG-Non-standard);  JOHNSON & JOHNSON (JOHJ)   JACOBS P T,  LIN S M;  US4710233-A   SIEMENS AG (SIEI)   HOHMANN E,  MUND K,  WEIDLICH E;  US4731222-A   INNOVATIVE MED TECH (INNO-Non-standard);  STERIS CORP (SRIS)   SCHNEIDER E T,  KRALOVIC R C;  US4744951-A   AMERICAN STERILIZER CO (AMSA)   CUMMINGS A L,  YOUNG J H,  MAKINEN R W;  US4756882-A   SURGIKOS INC (SURG-Non-standard);  JOHNSON & JOHNSON (JOHJ)   JACOBS P T,  LIN S M;  US4765963-A   MITSUBISHI DENKI KK (MITQ)   MUKOGAWA Y,  TAMURA K,  FUKUMOTO T;  US4784790-A   HENKEL KGAA (HENK)   DISCH K,  HACHMANN K,  BANSEMIR K;  US4862872-A   OLYMPUS OPTICAL CO LTD (OLYU)   YABE H,  KANNO M,  YOSHINAGA J,  YOKOI T,  OZEKI K,  NAKAMURA T,  TOJO Y,  NISHIGAKI S,  SUZUKI A;  US4863688-A   AMERICAN STERILIZER CO (AMSA)   SCHMIDT W C,  RICKLOFF J R;  US4892706-A   STERIS CORP (SRIS)   KRALOVIC R C,  SCHNEIDER E T;  US4908188-A   SCOPAS TECHNOLOGY CO INC (SCOP-Non-standard)   JEFFERIS R P,  ENGLER P V,  ROSENBLATT A A;  US4911190-A   SHELDON M W (SHEL-Individual)   SHELDON M W;  US4928917-A   WOLF H (WOLF-Individual)   WOLF H J;  US4937046-A   ANDERSEN PROD INC H W (ANDP)   ANDERSEN H W,  ANDERSON W K,  HARRISON C H;  US4943414-A   SURGIKOS INC (SURG-Non-standard);  JOHNSON & JOHNSON (JOHJ)   JACOBS P T,  BERRY R F,  SOTO R A;  US4952370-A   AMERICAN STERILIZER CO (AMSA)   CUMMINGS A L,  CHILDERS R W D;  US4956145-A   AMERICAN STERILIZER CO (AMSA)   CUMMINGS A L,  CHILDERS R W,  MIELNIK T J;  US5017241-A   GRAVER CO (GRAV-Non-standard)   RYAN L;  US5027840-A   PERLICK CORP (PERL-Non-standard)   NEZWORSKI J E;  US5035752-A   KOBE STEEL LTD (KOBM)   TANAKA K,  SATOH H,  KAWAKAMI H,  MARUKAWA N;  US5037623-A   STERIS CORP (SRIS)   SCHNEIDER E T,  KRALOVIC R C;  US5077008-A   STERIS CORP (SRIS)   KRALOVIC R C,  BADERTSCHE D C;  US5090433-A   TOSHIBA KK (TOKE)   KAMAGA R;  US5091343-A   STERIS CORP (SRIS)   SCHNEIDER E T,  SIEGEL N L,  KRALOVIC R C;  US5091345-A   JOHNSON MATTHEY PLC (JOHO)   BECKER G;  US5114596-A   GRAVER CO (GRAV-Non-standard)   LATERRA T;  US5116575-A   STERIS CORP (SRIS)   BADERTSCH D C,  KRALOVIC R C;  US5118471-A   ANDERSEN PROD INC H W (ANDP)   ANDERSEN H W,  ANDERSEN W K,  HARRISON C H;  US5120512-A   MASUDA S (MASU-Individual);  SENICHI M (SENI-Individual)   MASUDA S;  US5122344-A   MDT CORP (MDTM-Non-standard)   SCHMOEGNER J C;  US5125981-A   BELANGER INC (BELA-Non-standard)   BELANGER M J,  ASTLEY G J;  US5132084-A   SIEMENS AG (SIEI)   HARRELL D L,  MU Y;  US5145641-A   SMITHS IND PLC (SMIS)   MURRAYSHEL R;  US5176884-A   AESCULAP AG (AESC)   TASCHNER W,  WILFLE W;  US5186893-A   ABTOX INC (ABTO-Non-standard)   MOULTEN K A,  CAMPBELL B A,  CAPUTO R A;  US5190666-A   BIOCOM (BIOC-Non-standard)   BISCONTE J C;  US5209909-A   STERIS CORP (SRIS)   SIEGEL N L,  KRALOVIC R C,  SCHECKELHOFF K E;  US5217698-A   STERIS CORP (SRIS)   REBELE D J,  MARSHALL D F,  FUNG S M,  SIEGEL N L,  MINEROVIC D E,  KRALOVIC R C,  SANFORD B R,  TANNER P C,  BEISWENGER J L;  US5225160-A   STERIS CORP (SRIS)   SANFORD B R,  KRALOVIC R C;  US5227132-A   ANDERSEN PROD INC H W (ANDP)   ANDERSEN H W,  ANDERSEN W K,  HARRISON C H;  US5260021-A   ALLERGAN INC (ALLR)   ZELEZNICK L;  US5266275-A   FADDIS C G (FADD-Individual)   FADDIS C G;  US5279799-A   HAMO AG (HAMO-Non-standard)   MOSER H,  AEBI E;  US5281401-A   VAPORTEK INC (VAPO-Non-standard)   BRYSON J D;  US5288467-A   BIERMAIER H (BIER-Individual)   BIEMAIER H;  US5310524-A   MINNTECH CORP (MINN-Non-standard)   COSENTINO L C,  CAMPBELL J L;  US5348711-A   MDT CORP (MDTM-Non-standard)   JOHNSON K A,  WHITE S W;  US5350563-A   STERIS CORP (SRIS)   LINDEMAN L D H,  KRALOVIC R C,  LEVIN D Z;  US5364602-A   LEDUC S (LEDU-Individual)   LEDUC S;  US5374394-A   STERIS CORP (SRIS)   KRALOVIC R C;  US5391360-A   STERIS CORP (SRIS)   STANFORD B R,  KOCHTE W W;  US5395240-A   DENTSPLY RES & DEV CORP (DENX)   WARRIN G E,  SEPTIMUS M I,  PASCHKE R H,  PARR M P;  US5405587-A   COLGAN J R (COLG-Individual);  FERNANDEZ J M (FERN-Individual)   FERNANDEZ J M,  COLGAN J R;  US5407648-A   PARAGON GROUP PLASTICS CO INC (PARA-Non-standard)   BUSSELL T J,  ALLEN K H;  US5407685-A   STERIS CORP (SRIS)   KRALOVIC R C,  MALCHESKY P S;  US5425815-A   KEYMED MED & IND EQ (OLYU)   PARKER G C,  ROSS I M;  US5439654-A   STERIS CORP (SRIS)   KOCHTE W W;  US5441707-A   PARAGON GROUP PLASTICS CO INC (PARA-Non-standard)   LEWIS P P,  OWENS D,  SANDS D L;  US5443801-A   KEW IMPORT/EXPORT INC (KEWI-Non-standard)   LANGFORD T R;  US5445792-A   AMERICAN STERILIZER CO (AMSA)   CHILDERS R W,  UPCHURCH D C,  RICKLOFF J R;  US5492671-A   ZIMMER INC (ZIMV)   KRAFFT P;  US5492672-A   AMERICAN STERILIZER CO (AMSA)   CHILDERS R W,  RICKLOFF J R,  MIELNICK T J,  KLOBUSNIK K J;  US5494530-A   GEHRIG & CO AG F (GEHR-Non-standard)   GRAF M;  US5494637-A   OLYMPUS AMERICA INC (OLYU)   BARLOW D E;  US5505218-A   KALTENBACH & VOIGT GMBH (KALT)   STEINHAUSER P,  BODENMILLER A,  LOTT H;  US5508009-A   AMERICAN STERILIZER CO (AMSA)   CHILDERS R W,  UPCHURCH D C,  RICKLOFF J R;  US5527508-A   AMERICAN STERILIZER CO (AMSA)   CHILDER R W,  GAGNE D R;  US5529750-A   STERIS CORP (SRIS)   KOCHTE W W;  US5533539-A   SIEMENS AG (SIEI)   HRUZA D,  STETTER-ALLE R,  TRACKL K,  BEERSTECHER L,  SUTTER R;  US5534221-A   AMERICAN STERILIZER CO (AMSA)   HILLEBRENNER H W,  SHETH V B,  STACK J M,  CURTIS C T,  BUTLER K H,  SHOFF D E,  PETKO R S,  LITTLE W C,  MIELNIK T,  ZELL P;  US5540901-A   RILEY MEDICAL INC (RILE-Non-standard)   RILEY E D;  US5547456-A   STORZ GMBH & CO KARL (STOR-Non-standard)   METRAS S,  STROBL K;  US5552115-A   STERIS CORP (SRIS)   MALCHESKY P S;  US5556607-A   AMERICAN STERILIZER CO (AMSA)   CHILDERS R W,  RICKLOFF J R,  MIELNICK T J,  KLOBUSNIK K J;  US5558841-A   OLYMPUS OPTICAL CO LTD (OLYU)   YAJIMA M,  OGAWA A,  NAKANISHI N,  KINOSHITA T,  NAKAGAWA M,  NEGORO D;  US5571488-A   SIEMENS AG (SIEI)   HRUZA D,  STETTER-ALLE R,  TRACKL K,  BEERSTECHER L,  SUTTER R;  US5580530-A   JOHNSON & JOHNSON MEDICAL INC (JOHJ)   KOWATSCH R,  SOTO T,  HOWLETT C;  US5589507-A   MINNTECH CORP (MINN-Non-standard)   HALL R T,  ONSTAD B K;  US5609821-A   CHEMOXAL SA (CHEM-Non-standard)   GRIMBERG A,  DECLERCK G,  RABILLIER J,  SOUMARMON R;  US5628971-A   NORMAN G U (NORM-Individual)   NORMAN G U;  US5662866-A   STERIS CORP (SRIS)   SIEGEL N L,  SCHWARTZ L I,  KRALOVIC R C,  SWITKA J J,  SAUNDERS C M,  STANCA N E,  DALE G A,  PLANTZ J S;  US5686045-A   CARTER S D (CART-Individual)   CARTER S D;  US5711921-A   KEW IMPORT/EXPORT INC (KEWI-Non-standard)   LANGFORD T R,  DAVIS D L;  US5723090-A   SIEMENS AG (SIEI)   HRUZA D,  STETTER-ALLE R,  TRACKL K,  BEERSTECHER L,  SUTTER R;  US5732614-A   DELAWARE CAPITAL FORMATION INC (DLAW)   OSLIN G R;  US5753195-A   KEW IMPORT/EXPORT INC (KEWI-Non-standard)   LANGFORD T R,  DAVIS D L;  US5759490-A   STERIS CORP (SRIS)   MALCHESKY P S;  US5792422-A   JOHNSON & JOHNSON MEDICAL INC (JOHJ)   LIN S M,  JACOBS P T,  WU S;  US5795403-A   BIERMAIER H (BIER-Individual)   BIERMAIER H;  US5804139-A   JOHNSON & JOHNSON MEDICAL INC (JOHJ)   LIN S M,  JACOBS P T;  US5833935-A   STERIS CORP (SRIS)   MALCHESKY P S;  US5840251-A   NITTO MEDICAL CORP (NITT-Non-standard)   IWAKI Y;  US5851485-A   JOHNSON & JOHNSON MEDICAL INC (JOHJ)   LIN S M,  JACOBS P T;  US5858305-A   STERIS CORP (SRIS)   MALCHESKY P S;  US5868667-A   ETHICON INC (ETHI)   FELDMAN L A,  HUI H K,  LIN S,  JACOBS P T;  US5871692-A   STERIS CORP (SRIS)   HAIRE D M,  WOLF-BLOOM D F,  MALCHESKY P S;  US5876501-A   FORI AUTOMATION INC (FORI-Non-standard)   DOAN P G;  US5876507-A   INT BUSINESS MACHINES CORP (IBMC)   POTSKO D S,  BROWN M A,  BAJKOWSKI D J,  COLE R E;  US5882589-A   SHIPPER L (SHIP-Individual)   MARIOTTI B;  US5902413-A   PSK CONNECTORS PTY LTD (PSKC-Non-standard)   PUSZKO G B,  PUSZKO Z;  US5906802-A   LANGFORD T R (LANG-Individual)   LANGFORD T R;  US5921256-A   DEPAOLO C J (DEPA-Individual)   BARIN M N;  US5923432-A   STERIS CORP (SRIS)   KRAL J A;  US5937875-A   NYGREN R (NYGR-Individual)   NYGREN R;  US5958038-A   S3 INC (HTCC)   AGRAWAL N,  NANDA S;  US5961921-A   JOHNSON & JOHNSON MEDICAL INC (JOHJ)   JACOBS P T,  LIN S,  JACOBS J M,  ADDY T O;  US5961922-A   JOHNSON & JOHNSON MEDICAL INC (JOHJ)   WITTE M,  EULOGIO S;  US5980825-A   JOHNSON & JOHNSON MEDICAL INC (JOHJ)   ADDY T O,  JACOBS P T,  LIN S,  JACOBS J M;  US5985038-A   DAWSON L R (DAWS-Individual)   DAWSON L R;  US6001305-A   STERIS CORP (SRIS)   MUELLER W;  US6013227-A   ETHICON INC (ETHI)   LIN S,  JACOBS P T;  US6015529-A   ETHICON INC (ETHI)   LIN S,  JACOBS P T;  US6027572-A   PRINCETON TRADE & TECHNOLOGY INC (PRIN-Non-standard)   LABIB M E,  LAI C;  US6036928-A   BARNSTEAD W A (BARN-Individual)   BARNSTEAD W A;  US6041794-A   ETHICON INC (ETHI)   LIN S,  JACOBS P T,  LEONARD P,  BERHO R,  FETT D W,  SCHUBER K;  US6047431-A   OLYMPUS AMERICA INC (OLYU)   CANONICA F P;  US6066294-A   ETHICON INC (ETHI)   LIN S,  JACOBS P T;  US6068815-A   MINNTECH CORP (MINN-Non-standard)   OBERLEITNER R P,  MARXER J E,  SLY W J,  STANLEY P M,  WORSNICK G,  WEIMER K J,  MARTIN B D,  HENDERSON M B,  ONSTAD B K;  US6068825-A   KOGYO GIJUTSUINCHO (AGEN);  TSUNEMATSU S (YSUN-Individual);  US6083458-A   ETHICON INC (ETHI)   LIN S,  JACOBS P T,  WU S S,  CHU N S;  US6083485-A   UNIV BERLIN INST DIAGNOSTIKFORSCHUNG (UYBE)   LICHA K,  RIEFKE B,  SEMMLER W,  SPECK U,  HILGER C;  US6162395-A   ENVIROMEDICAL SYSTEMS INC (ENVI-Non-standard)   KOWANKO N;  US20080286178-A1   ;  US20100192978-A1   ;  US6187266-B1   ETHICON INC (ETHI)   LIN S,  JACOBS P T,  WU S S,  CHU N S;  US6203756-B1   ETHICON INC (ETHI)   LIN S,  JACOBS P T,  WU S S,  CHU N S;  US6224828-B1   ETHICON INC (ETHI)   LIN S,  JACOBS P T;  US6257254-B1   STERIS CORP (SRIS)   ROCHETTE D,  LEMAY M,  THERIAULT Y,  EMOND M,  DUCHAINE M,  PARENT G,  THIBAULT N;  US6286527-B1   MINNTECH CORP (MINN-Non-standard);  STANLEY P M (STAN-Individual)   STANLEY P M;  US6379632-B1   OLYMPUS OPTICAL CO LTD (OLYU);  OLYMPUS CORP (OLYU)   KINOSHITA T,  NAKAGAWA M;  US6423266-B1   ETHICON INC (ETHI)   CHOPERENA A M,  LIN S,  JACOBS P;  US6431187-B1   PAINTER P W (PAIN-Individual)   PAINTER P W;  US6528015-B1   ETHICON INC (ETHI)   LIN S,  JACOBS P T;  US6558620-B1   STERIS INC (SRIS)   SANFORD B R,  KRAL J A,  TVERGYAK J,  MOSS B J,  PRIEST R M,  HLEBOVY J C,  KELSCH D N,  GRESZLER A J,  MINEROVIC D E,  HOUSTON J C,  ROBINSON N A;  US6568409-B1   MCF SYSTEMS ATLANTA INC (MCFS-Non-standard)   FLECK S W;  US6582654-B1   STERIS INC (SRIS)   SANFORD B R,  KRAL J A,  TVERGYAK J,  MOSS B J,  PRIEST R M,  HLEBOVY J C,  KELSCH D N,  GRESZLER A J,  MINEROVIC D E,  HOUSTON J C,  ROBINSON N A;  US6585943-B1   STERIS INC (SRIS)   SANFORD B R,  KRAL J A,  TVERGYAK J,  MOSS B J,  PRIEST R M,  HLEBOVY J C,  KELSCH D N,  GRESZLER A J,  MINEROVIC D E,  HOUSTON J C,  ROBINSON N A;  US6596232-B1   ETHICON INC (ETHI)   LIN S,  AGAMOHAMADI M;  US6608815-B1   SPACEBRIDGE NETWORKS CORP (SPAC-Non-standard)   HUANG J,  FENGCHUN D;  US6645430-B1   ETHICON INC (ETHI)   LIN S;  US6685895-B1   ETHICON INC (ETHI)   LIN S M;  US7138087-B1   MINNTECH CORP (MINN-Non-standard)   MALKIN R K,  KIPPENHAN R C,  PETERSEN M P,  FENTON T L;  US6439248-B2   STERIS CORP (SRIS)   ROCHETTE D,  LEMAY M,  THERIAULT Y,  EMOND M,  DUCHAINE M,  PARENT G,  THIBAULT N;  US6656427-B2   LIN S (LINS-Individual);  JACOBS P T (JACO-Individual)   LIN S,  JACOBS P T;  US6797245-B2   OLYMPUS OPTICAL CO LTD (OLYU)   NAKANISHI N,  NEGORO D,  TAYA N,  HASEGAWA H,  SUZUKI E,  KUROSHIMA H;  US6814932-B2   STERIS INC (SRIS)   SANFORD B R,  KRAL J A,  TVERGYAK J,  MOSS B J,  PRIEST R M,  HLEBOVY J C,  KELSCH D N,  GRESZLER A J,  MINEROVIC D E,  HOUSTON J C,  ROBINSON N A;  US6884392-B2   MALKIN R K (MALK-Individual);  KIPPENHAN R C (KIPP-Individual);  PETERSEN M P (PETE-Individual);  FENTON T L (FENT-Individual)   MALKIN R K,  KIPPENHAN R C,  PETERSEN M P,  FENTON T L;  US7128075-B2   PUBL R (PUBL-Individual)   PUBL R;  US7353832-B2   STOCKERT D L (STOC-Individual);  EVANS T B (EVAN-Individual);  SOBECK R J (SOBE-Individual)   STOCKERT D L,  EVANS T B,  SOBECK R J;  US7608218-B2   FRYER B (FRYE-Individual);  LIN S M (LINS-Individual);  LUKASIK R (LUKA-Individual);  MORRISON T (MORR-Individual)   FRYER B,  LIN S M,  LUKASIK R,  MORRISON T;  US7625534-B2   STERIS INC (SRIS)   HORACEK J R,  SARGENT D A,  SOLOMON A M,  MAYER J J,  JETHROW C A,  LUDWIG K,  KRAL J A;  US7841104-B2   STERIS INC (SRIS)   MARTINEAU L,  PARENT G,  ROBERT M;  US7910072-B2   STERIS INC (SRIS)   JETHROW C A;  US8012425-B2   AMERICAN STERILIZER CO (AMSA)   HORACEK J R,  JETHROW C A,  KRAL J A,  LUDWIG K,  MAYER J J,  SARGENT D A,  SOLOMON A M;  WO1995022353-A1   ;  WO1997024147-A1   ;  WO2000018521-A1   ;  WO2000023118-A1   ","US2015164602-A1            Proceco, Dring after Aqueous Parts Cleaning, April 1,          2002, Proceco, date stamp, tittle, 5 paragraphs;            American Machinist, Tips on ultrasonic cleaning, Feb. 12,          2009, American Machinist, 8 paragraphsUS10022189-B2            Proceco, Dring after Aqueous Parts Cleaning, Apr. 1,          2002, Proceco, date stamp, tittle, 5          paragraphs.;            American Machinist, Tips on ultrasonic cleaning, Feb. 12,          2009, American Machinist, 8 paragraphs.;  W          AN Assenburg & Co b.v.; Technical Documentation;          Cleaning-and disinfection system for endoscopes; machine          type/Wasseenburg EDS 03; Applin/GE; Machine No.          005-(1997).;            English language abstract for DE19858344 extracted from          espacenet.com database on Apr. 21, 2015, 35 pages. Also          see English language equivalent U.S. Pat. No. 6, 645,          430.;            English language abstract and translation for WO9522353          extracted from espacenet.com database on Apr. 21, 2015,          23 pages.;            English language abstract and translation for DE3416743          extracted from espacenet.com database on Apr. 21, 2015,          41 pages.;            English language abstract for DE19858347 extracted from          espacenet.com database on Apr. 21, 2015, 35 pages. Also          see English language equivalent U.S. Pat. No. 6, 494,          964.",,,,,
WO2015066505-A1;  AU2014342065-A1;  EP3062740-A1;  US2016270894-A1;  CN105934218-A;  JP2016539764-W;  EP3062740-A4;  CN105934218-B;  AU2014342065-B2;  US10188495-B2;  US2019175323-A1;  JP2019198697-A;  US10842604-B2,"Method for implanting surgical mesh prosthesis            against targeted tissue location of surgical site,            involves adhering surgical mesh prosthesis against            surface of target tissue by adhesion strength of            positioning agent",LABRECQUE R;  SANTOS S,ATRIUM MEDICAL CORP (STIL-C);  LABRECQUE R (LABR-Individual);  SANTOS S (SANT-Individual);  SANTOS S (SANT-Individual);  ATRIUM MEDICAL CORP (STIL-C);  LABRECQUE R (LABR-Individual);  ATRIUM MEDICAL CORP (STIL-C),2015286046,"   NOVELTY - The method involves positioning surgical mesh                prosthesis (106) against surface of a target tissue                with positioning agent arranged between the                prosthesis and tissue surface. The agent has                adhesion strength adequate to maintain the                prosthesis temporarily in place or else unsupported                against the tissue in the absence of setting/curing                of agent. The prosthesis is adhered against the                surface of tissue by adhesion strength. The agent                is solution and gel that includes water and                components consist of glycerin, sodium                carboxymethylcellulose, maltrodextrin, hypromellose                and xantham gum.    USE - Method for implanting surgical mesh prosthesis                e.g. C-QUR mesh (RTM: polypropylene mesh with Omega                three gel coating manufactured by Atrium Medical                Corporation Hudson), MOSAIC mesh (RTM: Omega three                fatty acid coated polypropylene mesh manufactured                by Atrium Medical Corporation, Hudson) and Parietex                PROGRIP mesh (RTM: laparoscopic self-fixating                monofilament polyester mesh manufactured by                Tycol/Covidien) against targeted tissue location of                surgical site during surgical hernia repair.    ADVANTAGE - The positioning agent loaded surgical mesh                prosthesis is an implantable device that is removed                and replaced, or easily slid and repositioned on                the targeted tissue upon application of an external                force without traumatizing the targeted tissue. The                amount of time spent measuring and marking the                patient and mesh is minimized while enabling an                improperly positioned mesh to be repositioned                without damaging the tissue. The prosthesis is                prevented from being slid on the tissue surface                without abrading, tearing, ripping, severing,                shearing, or otherwise damaging the tissue to which                it is bonded or over which it slides by the glues                and other similar adhesives create a strong bond                with tissue during a surgical procedure. The                patient time in the operating room is reduced by                minimizing or eliminating the requirement for a                surgeon to measure and mark the patient and the                surgical mesh prosthesis to ensure that the                implanted device is centered correctly over a                hernia or other tissue defect. The prosthesis is                easily be repositioned at an optimal location over                the hernia or other tissue defect by sliding the                prosthesis along the hernia or tissue defect                without requiring lengthy measuring and marking.                The risk of long term tissue adhesions due to                inadvertent contact with the viscera is minimized                when prosthesis is removed away from the tissue at                the site of the hernia or defect and replaced into                a different position.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for an                implantable device for implanting surgical mesh                prosthesis.    DESCRIPTION OF DRAWING(S) - The drawing shows a flowchart illustrating                the method for implanting surgical mesh prosthesis                against targeted tissue location of surgical                site.    Step for receiving surgical mesh (102)    Step for applying positioning gel to first                side of mesh (104a)    Step for applying positioning gel to tissue                (104b)    Step for positioning gel to tissue and first                side of mesh (104c)    Step for positioning surgical mesh prosthesis                (106) ",,,"A96 (Medical, dental, veterinary, cosmetic.);  D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).);  P32 (Dentistry, bandages, veterinary, prosthesis (A61C, D, F).)",A12-V02;  D09-C01F;  P32-A40A;  P32-M,A61F-002/02;  A61F-002/00;  A61L-027/16;  A61L-027/28;  A61L-027/34;  A61L-027/50;  A61F-002/08;  A61F-002/30;  A61F-002/44;  A61L-031/10;  A61L-031/14;  A61L-024/00;  A61L-031/04,WO2015066505-A1   07 May 2015   A61F-002/02   201533Pages: 69   English;  AU2014342065-A1   26 May 2016   A61F-002/02   201640   English;  EP3062740-A1   07 Sep 2016   A61F-002/02   201659   English;  US2016270894-A1   22 Sep 2016   A61F-002/00   201663   English;  CN105934218-A   07 Sep 2016   A61F-002/02   201666   Chinese;  JP2016539764-W   22 Dec 2016   A61F-002/08   201702Pages: 46   Japanese;  EP3062740-A4   02 Aug 2017   A61F-002/02   201752   English;  CN105934218-B   13 Mar 2018   A61F-002/02   201822   Chinese;  AU2014342065-B2   03 Jan 2019   A61F-002/02   201903   English;  US10188495-B2   29 Jan 2019   A61F-002/00   201909   English;  US2019175323-A1   13 Jun 2019   A61F-002/00   201944   English;  JP2019198697-A   21 Nov 2019   A61F-002/08   201991Pages: 47   Japanese;  US10842604-B2   24 Nov 2020   A61F-002/00   202097   English,WO2015066505-A1    WOUS063476    31 Oct 2014;   AU2014342065-A1    AU342065    31 Oct 2014;   EP3062740-A1    EP859171    31 Oct 2014;   US2016270894-A1    US15033134    29 Apr 2016;   CN105934218-A    CN80068577    31 Oct 2014;   JP2016539764-W    JP552256    31 Oct 2014;   EP3062740-A4    EP859171    31 Oct 2014;   CN105934218-B    CN80068577    31 Oct 2014;   AU2014342065-B2    AU342065    31 Oct 2014;   US10188495-B2    US15033134    29 Apr 2016;   US2019175323-A1    US213615    07 Dec 2018;   JP2019198697-A    JP152047    22 Aug 2019;   US10842604-B2    US213615    07 Dec 2018,AU2014342065-A1 PCT application Application WOUS063476;   AU2014342065-A1 Based on Patent WO2015066505;   EP3062740-A1 PCT application Application WOUS063476;   EP3062740-A1 Based on Patent WO2015066505;   US2016270894-A1 PCT application Application WOUS063476;   US2016270894-A1 Provisional Application US898764P;   CN105934218-A PCT application Application WOUS063476;   CN105934218-A Based on Patent WO2015066505;   JP2016539764-W PCT application Application WOUS063476;   JP2016539764-W Based on Patent WO2015066505;   CN105934218-B PCT application Application WOUS063476;   CN105934218-B Based on Patent WO2015066505;   CN105934218-B Previous Publ. Patent CN105934218;   AU2014342065-B2 PCT application Application WOUS063476;   AU2014342065-B2 Based on Patent WO2015066505;   US10188495-B2 PCT application Application WOUS063476;   US10188495-B2 Provisional Application US898764P;   US10188495-B2 Based on Patent WO2015066505;   US10188495-B2 Previous Publ. Patent US2016270894;   US2019175323-A1 Provisional Application US898764P;   US2019175323-A1 Div ex Application US033134;   US2019175323-A1 Div ex Application WOUS063476;   US2019175323-A1 Div ex Patent US10188495;   JP2019198697-A Div ex Application JP552256;   US10842604-B2 Provisional Application US898764P;   US10842604-B2 Div ex Application US033134;   US10842604-B2 Div ex Application WOUS063476;   US10842604-B2 Div ex Patent US10188495;   US10842604-B2 Previous Publ. Patent US2019175323,US898764P    01 Nov 2013;  WOUS063476    31 Oct 2014;  US15033134    29 Apr 2016;  US213615    07 Dec 2018,WO2015066505-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JP;  KE;  KG;  KN;  KP;  KR;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    EP3062740-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME        EP3062740-A4:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR              ,,"WO2015066505-A1 -- US20070077271-A1   ;  US20080109017-A1   ;  US20110236460-A1   ;  US2016270894-A1 -- US20020049503-A1   ;  US20060116696-A1   ;  US20060195010-A1   ;  US20070077271-A1   ;  US20070202186-A1   ;  US20080109017-A1   ;  US20090017323-A1   ;  US20090171377-A1   ;  US20090270527-A1   ;  US20110087274-A1   ;  US20110236460-A1   ;  US20120027893-A1   ;  US20120209319-A1   ;  US20120259348-A1   ;  US20120271290-A1   ;  US20130071397-A1   ;  US20130280390-A1   ;  US20140257027-A1   ;  US20180110897-A1   ;  CN105934218-A -- CN101563116-A   FMC BIOPOLYMER AS (FMCC)   DORNISH M,  LARSEN C K,  ANDERSEN T;  US20080109017-A1   ;  US20110236460-A1   ;  WO2008097418-A2   ATRIUM MEDICAL CORP (STIL)   HERWECK S A,  FERRARO J,  MARTAKOS P,  KARWOSKI T,  HORTON A R;  CN105934218-B -- CN101563116-A   FMC BIOPOLYMER AS (FMCC)   DORNISH M,  LARSEN C K,  ANDERSEN T;  US20080109017-A1   ;  US20110236460-A1   ;  WO2008097418-A2   ATRIUM MEDICAL CORP (STIL)   HERWECK S A,  FERRARO J,  MARTAKOS P,  KARWOSKI T,  HORTON A R;  US10188495-B2 -- US20020049503-A1   ;  US20060116696-A1   ;  US20060195010-A1   ;  US20070077271-A1   ;  US20070202186-A1   ;  US20080109017-A1   ;  US20090017323-A1   ;  US20090171377-A1   ;  US20090270527-A1   ;  US20110087274-A1   ;  US20110236460-A1   ;  US20120027893-A1   ;  US20120209319-A1   ;  US20120259348-A1   ;  US20120271290-A1   ;  US20130071397-A1   ;  US20130280390-A1   ;  US20140257027-A1   ;  US20180110897-A1   ;  JP2009513182-A   FMC BIOPOLYMER AS (FMCC)   DORNISH M,  LARSEN C K,  ANDERSEN T;  JP2012095769-A   GUNZE KK (GNZE)   SUZUKI K,  HATAKEYAMA K,  SATO H,  IKADA Y;  US3328259-A   PARACHEM CORPORATION (PARG);  US5480436-A   OSTEOTECH INC (MEDT)   VAN BLITTERSWLIJK C A,  BAKKER D,  BAKKUM E A;  US5634931-A   KUGEL R D (KUGE-Individual)   KUGEL R D;  US20050054771-A1   ;  US20060078586-A1   ;  US20090005867-A1   ;  US20110038910-A1   ;  US20110276089-A1   ;  US6548081-B2   ANIKA THERAPEUTICS INC (ANIK-Non-standard)   SADOZAI K K,  KUO J,  SHERWOOD C H;  US6981944-B2   JAMIOLKOWSKI D D (JAMI-Individual);  SLATER-TOMKO A (SLAT-Individual)   JAMIOLKOWSKI D D,  SLATER-TOMKO A;  US8124127-B2   ATRIUM MEDICAL CORP (STIL)   FAUCHER K M,  TANG H,  ROGERS L,  FERRARO J,  MARTAKOS P,  HERWECK S A,  KARWOSKI T;  US10842604-B2 -- US20020049503-A1   ;  US20030100955-A1   ;  US20030124087-A1   ;  US20060116696-A1   ;  US20060195010-A1   ;  US20070077271-A1   ;  US20070202186-A1   ;  US20080109017-A1   ;  US20090017323-A1   ;  US20090171377-A1   ;  US20090270527-A1   ;  US20110087274-A1   ;  US20110236460-A1   ;  US20120027893-A1   ;  US20120209319-A1   ;  US20120259348-A1   ;  US20120271290-A1   ;  US20130071397-A1   ;  US20130280390-A1   ;  US20140112972-A1   ;  US20140257027-A1   ;  US20180110897-A1   ;  US6548081-B2   ANIKA THERAPEUTICS INC (ANIK-Non-standard)   SADOZAI K K,  KUO J,  SHERWOOD C H;  US7504386-B2   FIDIA ADVANCED BIOPOLYMERS SRL (FIDI-Non-standard)   PRESSATO D,  PAVESIO A,  CALLEGARO L;  US7582576-B2   DSM IP ASSETS BV (STAM)   SNIJDER C S,  NIELABA L J A;  US10022477-B2   SAMYANG BIOPHARMACEUTICALS CORP (SAMY)   KIM S,  KIM J,  YEO G,  YOON H;  US10188495-B2   ATRIUM MEDICAL CORP (STIL);  LABRECQUE R (LABR-Individual);  SANTOS S (SANT-Individual)   LABRECQUE R,  SANTOS S;  JP2009513182-A   FMC BIOPOLYMER AS (FMCC)   DORNISH M,  LARSEN C K,  ANDERSEN T;  JP2012095769-A   GUNZE KK (GNZE)   SUZUKI K,  HATAKEYAMA K,  SATO H,  IKADA Y;  US3328259-A   PARACHEM CORPORATION (PARG);  US5480436-A   OSTEOTECH INC (MEDT)   VAN BLITTERSWLIJK C A,  BAKKER D,  BAKKUM E A;  US5634931-A   KUGEL R D (KUGE-Individual)   KUGEL R D;  US5899909-A   MEDSCAND MEDICAL AB (MEDS-Non-standard)   ULMSTEN U;  US20050054771-A1   ;  US20060078586-A1   ;  US20090005867-A1   ;  US20110038910-A1   ;  US20110276089-A1   ;  US6981944-B2   JAMIOLKOWSKI D D (JAMI-Individual);  SLATER-TOMKO A (SLAT-Individual)   JAMIOLKOWSKI D D,  SLATER-TOMKO A;  US8124127-B2   ATRIUM MEDICAL CORP (STIL)   FAUCHER K M,  TANG H,  ROGERS L,  FERRARO J,  MARTAKOS P,  HERWECK S A,  KARWOSKI T","US10188495-B2  B.          Yelimlies et al: Carboxymethylcellulose coated on          visceral face of polypropylene mesh prevents adhesion          without impairing wound healing in incisional hernia          model in rats Hernia, vol. 7, No. 3, Sep. 1, 2003, pp.          130-133.;            Extended European Search Report for EP14859171.2          (completed Jun. 22, 2017dated Jun. 30, 2017), which          corresponds to this present application.;            International Search Report and Written Opinion dated          Feb. 11, 2015, issued for corresponding International          Application No. PCT/US2014/063476, 11 pages.;            Katkhouda, Namir, et al., Use of Fibrin Sealant for          Prosthetic Mesh Fixation in Laparoscopic Extraperitoneal          Inguinal Hernia Repair, Advances in Surgical Technique,          Annals of Surgery, 2001, vol. 233, No. 1, pp.          18-25.;            Katkhouda, Namir, et al., A new technique for          laparoscopic hernia repair using fibrin sealant, Surgical          Technology International, vol. 12, pp. 120-126, 2004,          Abstract Only (printed from website          http://europepmc.org/abstract/MED/15455316/reload=0;jsessionid=DAHpxTMPfBOoJqKWV0zx.24          on Apr. 27, 2016).;            International Case Studies, Using Adaptic Touch          Non-Adhering Silicone Dressing: Case Studies, 2013, 14          pages.;            Ladurner, R., et al., Tissue Attachment Strength and          Adhesion Formation of Intraabdominal Fixed Meshes with          Cyanoacrylat Glues, Eur. J. Med. Res., 2008, vol. 13, pp.          1-7.;            Fine, Arthur P., Laparoscopic Repair of Inguinal Hernia          Using Surgisis Mesh and Fibrin Sealant, JSLS, 2006, vol.          10, pp. 461-465.;            Melman, Lora, et al., Evaluation of Acute Fixation          Strength for Mechnical Tacking Devices and Fibrin Sealant          Versus Polypropylene Suture for Laparoscopic Ventral          Hernia Repair, Surgical Innovation, 2010, vol. 17, No. 4,          pp. 285-290.;            Fridman, Abraham, et al., Mesh Fixation Devices and          Techniques: A Review of the Literature, Bariatric Times,          Jun. 12, 2012, vol. 9, No. 6, pp. 10-12 (9 pages in          printed PDF form).;            Brugger, L., et al., Objective hypoesthesia and pain          after transabdominal preperitoneal hemioplasty: a          prospective, randomized study comparing tissue adhesive          versus spiral tacks, Surg. Endosc., Apr. 2012, vol. 26,          No. 4, pp. 1079-1085, Abstract Only (2 pages in printed          PDF form).;            Examination Report issued in counterpart Australian          Application No. 2014342065, dated Mar. 23,          2018.;            Aqualon Sodium Carboxymethylcellulose, Physical and          Chemical Properties, Hercules Incorporated, 1999,          Wilmington, Delaware.;            Lorenz, Therese, A Hypothesis for determining the maximum          viscosity of sodium carboxymethylcellulose in solutions          of divalent cations of high ionic strength (1996).          Thesis. Rochester Institute of Technology, Rochester, New          York.;            Official Action issued in counterpart JP Application No.          2016-552256, dated Jun. 11, 2018.US10842604-B2            Official Action issued in counterpart JP Application No.          2016-552256, dated Jun. 11, 2018.;            Examination Report issued in counterpart Australian          Application No. 2014342065, dated Mar. 23,          2018.;            Aqualon Sodium Carboxymethylcellulose, Physical and          Chemical Properties, Hercules Incorporated, 1999,          Wilmington, Delaware.;            Lorenz, Therese, A Hypothesis for determining the maximum          viscosity of sodium carboxymethylcellulose in solutions          of divalent cations of high ionic strength (1996).          Thesis. Rochester Institute of Technology, Rochester, New          York.;  B.          Yelimlies et al: Carboxymethylcellulose coated on          visceral face of polypropylene mesh prevents adhesion          without impairing wound healing in incisional hernia          model in rats Hernia, vol. 7, No. 3, Sep. 1, 2003, pp.          130-133.;            Extended European Search Report for EP14859171.2          (completed Jun. 22, 2017dated Jun. 30, 2017), which          corresponds to this present application.;            International Search Report and Written Opinion dated          Feb. 11, 2015, issued for corresponding International          Application No. PCT/US2014/063476, 11 pages.;            Katkhouda, Namir, et al., Use of Fibrin Sealant for          Prosthetic Mesh Fixation in Laparoscopic Extraperitoneal          Inguinal Hernia Repair, Advances in Surgical Technique,          Annals of Surgery, 2001, vol. 233, No. 1, pp.          18-25.;            Katkhouda, Namir, et al., A new technique for          laparoscopic hernia repair using fibrin sealant, Surgical          Technology International, vol. 12, pp. 120-126, 2004,          Abstract Only (printed from website          http://europepmc.org/abstract/MED/15455316/reload=0;jsessionid=DAHpxTMPfBOoJqKWV0zx.24          on Apr. 27, 2016).;            International Case Studies, Using Adaptic Touch          Non-Adhering Silicone Dressing: Case Studies, 2013, 14          pages.;            Ladurner, R., et al., Tissue Attachment Strength and          Adhesion Formation of Intraabdominal Fixed Meshes with          Cyanoacrylat Glues, Eur. J. Med. Res., 2008, vol. 13, pp.          1-7.;            Fine, Arthur P., Laparoscopic Repair of Inguinal Hernia          Using Surgisis Mesh and Fibrin Sealant, JSLS, 2006, vol.          10, pp. 461-465.;            Melman, Lora, et al., Evaluation of Acute Fixation          Strength for Mechnical Tacking Devices and Fibrin Sealant          Versus Polypropylene Suture for Laparoscopic Ventral          Hernia Repair, Surgical Innovation, 2010, vol. 17, No. 4,          pp. 285-290.;            Fridman, Abraham, et al., Mesh Fixation Devices and          Techniques: A Review of the Literature, Bariatric Times,          Jun. 12, 2012, vol. 9, No. 6, pp. 10-12 (9 pages in          printed PDF form).;            Brugger, L., et al., Objective hypoesthesia and pain          after transabdominal preperitoneal hemioplasty: a          prospective, randomized study comparing tissue adhesive          versus spiral tacks, Surg. Endosc., Apr. 2012, vol. 26,          No. 4, pp. 1079-1085, Abstract Only (2 pages in printed          PDF form).;            Japanese Office Action (with English translation) dated          Apr. 22, 2019 for related Japanese patent application No.          2016-552256, 11 pages.;            Office Action issued in EP Application No. 14859171.2          dated Mar. 10, 2020, 6 pages.;  EP          Office Action dated Jun. 25, 2019 during prosecution of          EP Patent Application No. 14859171.2, 6 pages.;  EP          Office Action dated Feb. 21, 2019 for related EP patent          application No. 14859171.2, 6 pages.;            Office Action issued in counterpart JP Application No.          2016-552256, dated Jul. 17, 2020, 7 pages.;            International Preliminary Report on Patentability issued          in counterpart International Application No.          PCT/US2014/063476 dated May 3, 2016, 7 pages.;            Office Action issued in parent U.S. Appl. No. 15/033, 134          dated Dec. 13, 2017, 13 pages.;            Anton Paar, Physica MCR, The Modular Rheometer Series, 16          pages, dated Sep. 2004.;            Ametek Sensors, Test & Calibration, LTCM Series          Motorized Test StandsLTCM Series from Chatillon,          downloaded from          http://www.ametektest.com/products/material-testers/motorized-test-stands/Itcm-series          on Sep. 13, 2017, 3 pages.;            Understanding Absolute and Kinematic Viscosity,          downloaded from          http://www.machinerylubrication.com/Articles/Print/294 on          Sep. 13, 2017, 6 pages.;            What is a Rheometer?, downloaded from          http://www.innovateus.net/print/science/what-rheometer on          Sep. 13, 2017, 3 pages.;            Definition of lubricious, downloaded from          https://www.merriam-webster.com/dictionary/lubricious on          Oct. 11, 2018, 1 page.;            Pre-Appeal Examination Report issued in counterpart          Japanese Application No. 2016-552256 dated Dec. 23, 2019,          2 pages.",1911-0-0-0 ; 1145-0-0-0 ; 133998-1-1-0 ; 133912-0-0-0 ; 97486-1-0-0 ; 92830-0-0-0 ; 107779-0-0-0 ; 110577-0-0-0 ; 91481-0-0-0 ,,,R00446 ; R00964 ; R07352 ; R06717 ; R06563 ; R03275 ; R01863 ; R16377 ; R24034 ,
US2014088583-A1;  WO2014209440-A1;  US9173707-B2,"Coaptive surgical sealing tool used for e.g. open            surgery, has spring that is formed between back            sections of arms, so as to urge back sections of arms            away from each other and electrodes that are positioned            on jaws",SINGH G,SINGH G (SING-Individual);  CITY OF HOPE (CITY-C);  CITY OF HOPE (CITY-C),2014F93591,"   NOVELTY - The surgical tool (10) has the arms (12,14)                that are pivotally attached to each other. A finger                ring (18) is positioned on the back section of each                arm. A spring (26) is formed between the back                sections of arms, so as to urge the back sections                of arms away from each other. The jaws (24) having                a length of 5 to 9 cm are positioned on the front                section of arms. The electrodes (30) are positioned                on the jaws. An irrigation port is positioned on                the first arm connected to an irrigation line                leading to irrigation fluid outlets in or adjacent                to the electrode.    USE - Coaptive surgical sealing tool for use with                radio frequency (RF)/bipolar cautery generator                including Triad-Covidean Ligasure Generator, ConMed                generator or Enseal generator for open surgery and                laparoscopic surgery.    ADVANTAGE - By incorporating the spring and the                electrodes, the tool can be provided in different                sizes for different caliber of vessels, while                sliding into the liver parenchyma without tearing                the larger blood vessels and hence the occurrence                of the tearing of larger blood vessels can be                prevented, and is safe to use for major hepatic                resection with minimal post-operative adverse                events. The design of the tool can be simplified.                The tool can be supplied at low cost. The tool can                be enabled to reduce parenchymal transection times                in excess of 50%. The occurrence of the char can be                reduced by supplying an irrigation fluid to the                cautery site. The need for frequently stopping the                procedure to clean char from the jaws can be                reduced.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a                surgical method.    DESCRIPTION OF DRAWING(S) - The drawing shows a perspective view of the                coaptive surgical sealing tool.    Surgical tool (10)    Arms (12,14)    Finger ring (18)    Jaws (24)    Spring (26)    Electrode (30) ",,,"P31 (Diagnosis, surgery (A61B).);  S05 (Electrical Medical Equipment)",S05-B,A61B-018/18;  A61B-018/00;  A61B-018/14,US2014088583-A1   27 Mar 2014   A61B-018/18   201425Pages: 8   English;  WO2014209440-A1   31 Dec 2014   A61B-018/18   201504   English;  US9173707-B2   03 Nov 2015   A61B-018/18   201573   English,US2014088583-A1    US928204    26 Jun 2013;   WO2014209440-A1    WOUS022824    10 Mar 2014;   US9173707-B2    US928204    26 Jun 2013,US2014088583-A1 Provisional Application US706603P;   US2014088583-A1 CIP of Application US842510;   US9173707-B2 Provisional Application US706603P;   US9173707-B2 CIP of Application US842510,US706603P    27 Sep 2012;  US928204    26 Jun 2013,  WO2014209440-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JP;  KE;  KG;  KN;  KP;  KR;  KZ;  LA;  LC;  LK;  LR;  LS;  LT;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW    ,,US2014088583-A1 -- US3732719-A   ;  US5300087-A   KNOEPFLER D J (KNOE-Individual)   KNOEPFLER D J;  US20030181910-A1   ;  WO2014209440-A1 -- US5300087-A   KNOEPFLER D J (KNOE-Individual)   KNOEPFLER D J;  US5395312-A   DESAI A (DESA-Individual)   DESAI A;  US20060235379-A1   ;  US20130018411-A1   ;  US9173707-B2 -- US3732719-A   ;  US4671274-A   KHARK GEN URGENT SU (KHGE-Soviet Institute);  SOROCHENKO O A (SORO-Individual);  KHARK REGIONAL CLINICAL (KHRE-Soviet Institute)   SOROCHENKO O A;  US5116332-A   LOTTICK E A (LOTT-Individual)   LOTTICK E A;  US5300087-A   KNOEPFLER D J (KNOE-Individual)   KNOEPFLER D J;  US5395312-A   DESAI A (DESA-Individual)   DESAI A;  US6010516-A   HULKA J F (HULK-Individual)   HULKA J F;  US20030181910-A1   ;  US20050159745-A1   ;  US20060235379-A1   ;  US20110004208-A1   ;  US20130018411-A1   ;  US20130296843-A1   ;  US6863669-B2   SPITZER D E (SPIT-Individual)   SPITZER D E;  US7422591-B2   PHAN H D (PHAN-Individual)   PHAN H D,"US9173707-B2            United States Patent and Trademark Office, Office Action          dated Nov. 14, 2014 for U.S. Appl. No. 13/842,510, filed          Mar. 15, 2013.;            The International Searching Authority International          Search Report and the Written Opinion for International          Application No. PCT/US2014/022824 (Jul. 1,          2014).;            Aesculap, Inc. (A B. Braun Company), Catalog_""Instruments          and Devices for Bipolar Surgery,"" Sep. 2012.;            Aragon Surgical, Inc., ""Caiman breeds confidence"",          Lektrafuse CAIMAN product brochure, 3 pages (Jan.          2010).;            United States Patent and Trademark Office, Office Action          dated Mar. 5, 2015 for U.S. Appl. No. 13/842,510, filed          Mar. 15, 2013.;            United States Patent and Trademark Office, Office Action          dated Mar. 19, 2015 for U.S. Appl. No. 14/326,736, filed          Jul. 9, 2014.",,,,,
US2012253302-A1;  WO2012138514-A1;  AU2012240512-A1;  CA2832264-A1;  EP2694005-A1;  US2014094761-A1;  AU2012240512-A2;  JP2014514068-W;  CN103764082-A;  IN201308572-P1;  RU2013148889-A;  CN105167912-A;  CN103764082-B;  AU2012240512-B2;  JP6076964-B2;  JP2017060883-A;  RU2619653-C2;  US9302034-B2;  BR112013025702-A2;  JP6346966-B2;  EP2694005-B1,"Composite gauze pad wound dressing i.e.            antimicrobial Advanced Micro Devices Foam wound            dressing, for use in negative pressure wound therapy            system, has packing member affixed to cover layer,            filling wound and supporting cover layer",CORLEY K,TYCO HEALTHCARE GROUP LP (COVI-C);  TYCO HEALTHCARE GROUP LP (COVI-C);  COVIDIEN LP (COVI-C);  COVIDIEN LP (COVI-C);  COVIDIEN LP (COVI-C);  SMITH & NEPHEW INC (SMIN-C);  SMITH & NEPHEW INC (SMIN-C);  TYCO HEALTHCARE GROUP LP (COVI-C);  TYCO HEALTHCARE GROUP LP (COVI-C);  SMITH & NEPHEW INC (SMIN-C);  SMITH & NEPHEW INC (SMIN-C),2012M84077,"   NOVELTY - The dressing (12) has a cover layer (24)                establishing a vacuum reservoir (14) over a wound                (W) in which negative pressure is maintained. A                vacuum port (30) is affixed to the cover layer to                establish fluid tight seal about an opening in the                cover layer, where the vacuum port includes a                hollow interior in fluid communication with the                opening in the cover layer and a barbed connector                to facilitate connection to a vacuum source (50). A                packing member (20) is affixed to the cover layer,                fills the wound, and supports the cover layer when                negative pressure is applied to the                reservoir.    USE - Composite gauze pad/non-woven wound dressing                i.e. Covidien (RTM: antimicrobial dressing)                Advanced Micro Devices (AMD) Foam wound dressing,                for use in negative pressure wound therapy system                for a wound patient.    ADVANTAGE - The cover layer acts as a microbial barrier to                prevent contaminants from entering the wound and as                a fluid barrier to maintain integrity of vacuum                reservoir. The dressing allows a release liner to                be adhered to adhesive at a peripheral region of                the cover layer to protect the adhesive and the                packing member prior to use of the dressing. The                dressing has a cellulose serving as stiffening                agent to provide rigidity to fingers to facilitate                handling and placement of the dressing, so that the                fingers are transitioned to a soft and pliable                configuration to promote patient comfort, thus                promoting healing by reducing probability of                infection and stimulating deposition of granulation                tissue.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a                system for facilitating subatmospheric pressure                therapy in connection with healing a wound.    DESCRIPTION OF DRAWING(S) - The drawing shows a cross-sectional view of a                negative pressure wound therapy apparatus with a                wound dressing installed over a wound.    Wound (W)    Composite wound dressing (12)    Vacuum reservoir (14)    Packing member (20)    Cover layer (24)    Vacuum port (30)    Vacuum source (50) ",,,"A96 (Medical, dental, veterinary, cosmetic.);  D22 (Sterilising, bandages, dressing and skin protection agents - including sterilising agents (other than for food), sutures, plaster casts, bioactive prostheses, contact lenses, diapers, animal litter, timber, preservatives, disinfectants, bactericidal detergents, deodorants, insect repellent compounds, moth proofers, sheep dip (A61L).);  P34 (Sterilising, syringes, electrotherapy (A61L, M, N).)",A12-S04;  A12-V03A;  D09-C04B,A61M-001/00;  A61F-013/02;  A61F-013/00;  A61M-027/00,US2012253302-A1   04 Oct 2012   A61M-001/00   201267Pages: 10   English;  WO2012138514-A1   11 Oct 2012   A61F-013/02   201267   English;  AU2012240512-A1   24 Oct 2013   A61F-013/02   201373   English;  CA2832264-A1   11 Oct 2012   A61F-013/02   201377   English;  EP2694005-A1   12 Feb 2014   A61F-013/02   201412   English;  US2014094761-A1   03 Apr 2014   A61M-001/00   201424   English;  AU2012240512-A2   29 May 2014   A61F-013/02   201435   English;  JP2014514068-W   19 Jun 2014   A61M-027/00   201440Pages: 16   Japanese;  CN103764082-A   30 Apr 2014   A61F-013/02   201442   Chinese;  IN201308572-P1   19 Dec 2014   A61F-013/02   201502   English;  CN105167912-A   23 Dec 2015   A61F-013/02   201603   English;  CN103764082-B   23 Dec 2015   A61F-013/02   201605   English;  AU2012240512-B2   08 Sep 2016   A61F-013/02   201661   English;  JP6076964-B2   08 Feb 2017   A61M-027/00   201712Pages: 13   Japanese;  JP2017060883-A   30 Mar 2017   A61M-027/00   201726Pages: 15   Japanese;  RU2619653-C2   17 May 2017   A61F-013/02   201755   Russian;  US9302034-B2   05 Apr 2016   A61M-001/00   201760   English;  BR112013025702-A2   08 Aug 2017   A61F-013/02   201775   English;  JP6346966-B2   20 Jun 2018   A61M-027/00   201842Pages: 13   Japanese;  EP2694005-B1   16 Dec 2020   A61F-013/02   202002   English,US2012253302-A1    US079298    04 Apr 2011;   WO2012138514-A1    WOUS030829    28 Mar 2012;   AU2012240512-A1    AU240512    28 Mar 2012;   CA2832264-A1    CA2832264    28 Mar 2012;   EP2694005-A1    EP715771    28 Mar 2012;   US2014094761-A1    US14110120    18 Dec 2013;   AU2012240512-A2    AU240512    28 Mar 2012;   JP2014514068-W    JP503685    28 Mar 2012;   CN103764082-A    CN80027206    28 Mar 2012;   IN201308572-P1    INDN08572    03 Oct 2013;   RU2013148889-A    RU148889    28 Mar 2012;   CN105167912-A    CN10515633    28 Mar 2012;   CN103764082-B    CN80027206    28 Mar 2012;   AU2012240512-B2    AU240512    28 Mar 2012;   JP6076964-B2    JP503685    28 Mar 2012;   JP2017060883-A    JP001634    10 Jan 2017;   RU2619653-C2    RU148889    28 Mar 2012;   US9302034-B2    US14110120    18 Dec 2013;   BR112013025702-A2    BR11025702    28 Mar 2012;   JP6346966-B2    JP001634    10 Jan 2017;   EP2694005-B1    EP715771    28 Mar 2012,AU2012240512-A1 PCT application Application WOUS030829;   AU2012240512-A1 Based on Patent WO2012138514;   CA2832264-A1 PCT application Application WOUS030829;   CA2832264-A1 Based on Patent WO2012138514;   EP2694005-A1 PCT application Application WOUS030829;   EP2694005-A1 Based on Patent WO2012138514;   US2014094761-A1 PCT application Application WOUS030829;   US2014094761-A1 CIP of Application US079298;   AU2012240512-A2 PCT application Application WOUS030829;   AU2012240512-A2 Based on Patent WO2012138514;   JP2014514068-W PCT application Application WOUS030829;   JP2014514068-W Based on Patent WO2012138514;   CN103764082-A PCT application Application WOUS030829;   CN103764082-A Based on Patent WO2012138514;   IN201308572-P1 PCT application Application WOUS030829;   IN201308572-P1 Based on Patent WO2012138514;   RU2013148889-A PCT application Application WOUS030829;   RU2013148889-A Based on Patent WO2012138514;   CN103764082-B PCT application Application WOUS030829;   CN103764082-B Based on Patent WO2012138514;   AU2012240512-B2 PCT application Application WOUS030829;   AU2012240512-B2 Based on Patent WO2012138514;   JP6076964-B2 PCT application Application WOUS030829;   JP6076964-B2 Based on Patent WO2012138514;   JP2017060883-A Div ex Application JP503685;   RU2619653-C2 PCT application Application WOUS030829;   RU2619653-C2 Based on Patent WO2012138514;   US9302034-B2 PCT application Application WOUS030829;   US9302034-B2 CIP of Application US079298;   US9302034-B2 Based on Patent WO2012138514;   BR112013025702-A2 PCT application Application WOUS030829;   BR112013025702-A2 Based on Patent WO2012138514;   JP6346966-B2 Div ex Application JP503685;   EP2694005-B1 PCT application Application WOUS030829;   EP2694005-B1 Based on Patent WO2012138514,US079298    04 Apr 2011;  CA2832264    03 Oct 2013;  US14110120    18 Dec 2013,  WO2012138514-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IS;  JP;  KE;  KG;  KM;  KN;  KP;  KR;  KZ;  LA;  LC;  LK;  LR;  LS;  LT;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW      EP2694005-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR                              EP2694005-B1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR  ,,"US2012253302-A1 -- US4422293-A   BENDIX CORP (BEND);  ALLIED CORP (ALLC)   EWALD J T;  US4665909-A   AVCOR HEALTH CARE (AVCO-Non-standard)   TRAINOR F M;  US5399418-A   ERNO RAUMFAHRTTECH GMBH (ERNO)   MUELLER-WIESNER D,  KAMPMANN L,  REIMERDES H G,  HARTMANNS J,  FISCHER W;  US20010029956-A1   ;  US20020198503-A1   ;  US20070129707-A1   ;  US20080134796-A1   ;  US20100036334-A1   ;  WO2012138514-A1 -- EP2119460-A2   TYCO HEALTHCARE GROUP LP (COVI)   VESS M;  GB2415908-A   ETHICON INC (ETHI)   LOWING P H,  DEL BONO M;  US20070027414-A1   ;  US20070161938-A1   ;  US20080009812-A1   ;  US20100286635-A1   ;  CN103764082-A -- CN101678156-A   KCI LICENSING INC (KCIL)   OLSON J S,  GINTHER D C,  SANDERS T B;  GB2415908-A   ETHICON INC (ETHI)   LOWING P H,  DEL BONO M;  US20070000129-A1   ;  US20070027414-A1   ;  US20070129707-A1   ;  CN105167912-A -- CN101453969-A   AALI A (AALI-Individual)   AALI A;  CN101678156-A   KCI LICENSING INC (KCIL)   OLSON J S,  GINTHER D C,  SANDERS T B;  US6043408-A   GENG L F (GENG-Individual)   GENG L F;  WO2002005737-A1   ;  RU2619653-C2 -- RU2244566-C2   KCI MEDICAL LTD (KCIL)   HEATON K P;  RU2261692-C2   KCI LICENSING INC (KCIL)   HUNT K W,  HEATON K P;  US20070129707-A1   ;  US9302034-B2 -- DE4111122-A1   NEHER W (NEHE-Individual)   NEHER W;  DE4306478-A1   WAGNER W (WAGN-Individual)   WAGNER W;  DE29504378-U1   ;  EP358302-A   SMITHS IND PLC (SMIS);  SMITHS IND PUBL LTD (SMIT-Non-standard)   WOOD J M;  EP853950-A1   KINETIC CONCEPTS INC (KCIL);  MEDISCUS PROD LTD (MEDI-Non-standard)   LINA C Z,  HEATON K P;  EP2848268-A1   SWAIN L D (SWAI-Individual);  MANWARING M E (MANW-Individual);  CORNET D A (CORN-Individual);  LEUNG B K (LEUN-Individual)   CORNET D A,  LEUNG B K,  MANWARING M E,  SWAIN L D;  EP1088569-A2   KCI MEDICAL LTD (KCIL)   HUNT K W,  HEATON K P;  EP1219311-A2   KINETIC CONCEPTS INC (KCIL);  MEDISCUS PROD LTD (MEDI-Non-standard)   LINA C Z,  HEATON K P;  EP2119460-A3   TYCO HEALTHCARE GROUP LP (COVI)   VESS M;  GB488232-A   ;  GB1415096-A   BLAU KG FAB KRAFTFA (BLAU-Non-standard);  GB1549756-A   SQUIBB & SONS INC E R (SQUI);  WESTABY S (WEST-Individual)   WESTABY S H,  EVERETT W G;  GB2195255-A   VACUTEC UK LTD (VACU-Non-standard);  THORN O (THOR-Individual)   THORN O,  FELD F D,  PAISNOW J,  HALLAM D;  GB2235877-A   TALLURI A (TALL-Individual)   TALLURI A;  GB2307180-A   KCI MEDICAL LTD (KCIL)   HUNT K W,  HEATON K P;  GB2329127-A   KCI MEDICAL LTD (KCIL)   HEATON K P,  HUNT K W;  GB2336546-A   KCI MEDICAL LTD (KCIL)   HEATON K P,  HUNT K W;  GB2344531-A   KCI MEDICAL LTD (KCIL)   HEATON K P,  HUNT K W;  GB2415908-A   ETHICON INC (ETHI)   LOWING P H,  DEL BONO M;  SU1762940-A1   SAMARA MED INST (SAMA-Soviet Institute)   KRIVOSHCHEKOV E P,  BOROSKII O B,  PEREVOZCHIKOV B G;  US3026874-A   ;  US3367332-A   GENE (GENE);  US3486504-A   ;  US3572340-A   ;  US3712298-A   ;  US3809086-A   SHERWOOD MEDICAL IND INC (MEDT);  US3874387-A   P P BARBIERI (BARB-Individual)   BARBIERI P P;  US3980166-A   SVENSKA FLAEKTFABRIKEN AB (SVFL);  US4063556-A   RYDER INT CORP (RYDE-Non-standard);  US4080970-A   MILLER T J (MILL-Individual)   MILLER T J;  US4112947-A   INT PAPER CO (INTO)   MAY E A;  US4112949-A   HOWMEDICA INC (HOWN)   ROSENTHAL A L,  ALPERN M,  MEISCH C E;  US4136696-A   INT PAPER CO (INTO);  BARD INC C R (BRDC)   NEHRING J R;  US4202331-A   YALE W S (YALE-Individual)   YALE W S;  US4224945-A   COHEN J (COHE-Individual)   COHEN J;  US4228798-A   DEATON D W (DEAT-Individual)   DEATON D W;  US4266545-A   MOSS J P (MOSS-Individual)   MOSS J;  US4280680-A   PAYNE B M M (PAYN-Individual);  NIEMAND C W P (NIEM-Individual);  US4382441-A   SVEDMAN P (SVED-Individual)   SVEDMAN P;  US4422293-A   BENDIX CORP (BEND);  ALLIED CORP (ALLC)   EWALD J T;  US4510802-A   SUNDSTRAND DATA CONTROL (SUNH);  US4524064-A   NIPPON OIL KK (NIOC)   NAMBU M;  US4538645-A   AMBAC IND INC (AMBA-Non-standard)   PERACH A;  US4655754-A   STRYKER CORP (STYC)   RICHMOND J W,  TICE R G,  BOOTH W M;  US4665909-A   AVCOR HEALTH CARE (AVCO-Non-standard)   TRAINOR F M;  US4700479-A   HONDA GIKEN KOGYO KK (HOND)   SAITO K,  NOJI A,  KAKUTA Y,  TAKIGAWA K;  US4710165-A   MCNEIL C B (MCNE-Individual)   MCNEIL C B,  MCEVOR T J;  US4738257-A   HOLLISTER INC (HOST)   MEYER R A,  HABIB W W,  STUPAR J A;  US4743232-A   CLINIPAD CORP (CLIN-Non-standard)   KRUGER R J;  US4870975-A   CRONK S (CRON-Individual)   CRONK S,  THOMAS M;  US4874363-A   ABELL W L (ABEL-Individual)   ABELL W L;  US4969880-A   ZAMIEROWSKI D S (ZAMI-Individual)   ZAMIEROWSKI D S;  US4990137-A   MEMORIAL HOSP CANCE (MEMO-Non-standard)   GRAHAM D;  US4997438-A   LANGMANN C C (LANG-Individual)   NIPPER J;  US5071409-A   ROSENBERG L (ROSE-Individual)   ROSENBERG L;  US5100395-A   ROSENBERG L (ROSE-Individual)   ROSENBERG L;  US5100396-A   ZAMIEROWSKI D S (ZAMI-Individual)   ZAMIEROWSKI D S;  US5106629-A   NDM ACQUISITION COR (NDMC)   CARTMELL J V,  STURTEVANT W R;  US5135485-A   COHEN L (COHE-Individual)   COHEN L,  ROSE R A;  US5141503-A   SEWELL F K (SEWE-Individual)   SEWELL F K;  US5149331-A   FERDMAN A (FERD-Individual)   FERDMAN A,  KUO J,  MILLER D,  PINSKY V,  RICHARDS W D,  SWANN D;  US5152757-A   BRIGHAM & WOMENS HO (BGHM)   ERIKSSON E;  US5160322-A   BRUNSWICK BIOMEDICAL TECHNOLOGIES INC (BRUN-Non-standard)   SCHEREMET W,  VAN BUREN M W;  US5176663-A   MOELNLYCKE AB (MOLN);  SVEDMAN P (SVED-Individual)   SVEDMAN P,  KILEBY L E;  US5178157-A   FANLO R G (FANL-Individual)   FANLO R G;  US5180375-A   FEIBUS M H (FEIB-Individual)   FEIBUS M H;  US5195977-A   LOHMANN & CO KG (LOHM)   POLLITT S;  US5261893-A   ZAMIEROWSKI D S (ZAMI-Individual)   ZAMIEROWSKI D S;  US5263922-A   PLASCO INC (PLAS-Non-standard)   SOVA D,  EISENBERG M I;  US5399418-A   ERNO RAUMFAHRTTECH GMBH (ERNO)   MUELLER-WIESNER D,  KAMPMANN L,  REIMERDES H G,  HARTMANNS J,  FISCHER W;  US5484427-A   GIBBONS D (GIBB-Individual)   GIBBONS D;  US5527293-A   KINETIC CONCEPTS INC (KCIL)   ZAMIEROWSKI D S;  US5536233-A   KHOURI BIOMEDICAL RES INC (KHOU-Non-standard)   KHOURI R K;  US5549584-A   KENDALL CO (KEND)   GROSS J R;  US5588958-A   BARD INC C R (BRDC)   FELIX A,  HALICK G V,  MURA J R,  CUNNINGHAM R W,  KOCH D;  US5624374-A   VON IDERSTEIN I F (VIDE-Individual)   VON IDERSTEIN I F;  US5636643-A   UNIV WAKE FOREST (UYWF)   ARGENTA L C,  MORYKWAS M J;  US5645081-A   UNIV WAKE FOREST (UYWF)   ARGENTA L C,  MORYKWAS M J;  US5678564-A   BRISTOL-MYERS SQUIBB CO (BRIM)   LAWRENCE W T,  STROHL C L;  US5701917-A   KHOURI BIOMEDICAL RES INC (KHOU-Non-standard)   KHOURI R K;  US5733305-A   FLEISCHMANN W (FLEI-Individual)   FLEISCHMANN W;  US5779657-A   DANESHVAR Y (DANE-Individual)   DANESHVAR Y;  US5840049-A   KINETIC CONCEPTS INC (KCIL)   TUMEY D M,  CARTMELL R L;  US5899871-A   NDM ACQUISITION CORP (NDMC);  HARTMANN AG PAUL (HARN)   CARTMELL J V,  STURTEVANT W R,  WOLF M L;  US5911222-A   BRISTOL-MYERS SQUIBB CO (BRIM)   LAWRENCE W T,  STROHL C L;  US5928174-A   GIBBINS B L (GIBB-Individual)   GIBBINS B L;  US5944703-A   RES MEDICAL PTY LTD (REME-Non-standard)   DIXON M,  STUBBER R L;  US5960837-A   DEROYAL IND INC (DERO-Non-standard)   CUDE J M;  US6010524-A   FLEISCHMANN W (FLEI-Individual)   FLEISCHMANN W;  US6071267-A   KINETIC CONCEPTS INC (KCIL)   ZAMIEROWSKI D S;  US6117111-A   FLEISCHMANN W (FLEI-Individual)   FLEISCHMANN W;  US6135116-A   KCI LICENSING INC (KCIL)   MORRIS S P,  RANDOLPH L T,  VOGEL R C,  TUMEY D M;  US6142982-A   KCI MEDICAL LTD (KCIL)   HUNT K W,  HEATON K P;  US20010020145-A1   ;  US20010029956-A1   ;  US20010031943-A1   ;  US20010043943-A1   ;  US20020016577-A1   ;  US20020108614-A1   ;  US20020143286-A1   ;  US20020151836-A1   ;  US20020161346-A1   ;  US20020198503-A1   ;  US20020198504-A1   ;  US20030078532-A1   ;  US20030093041-A1   ;  US20030181850-A1   ;  US20030208149-A1   ;  US20030212357-A1   ;  US20030212359-A1   ;  US20030219469-A1   ;  US20040006319-A1   ;  US20040030304-A1   ;  US20040039415-A1   ;  US20040064111-A1   ;  US20040064132-A1   ;  US20040093026-A1   ;  US20040113309-A1   ;  US20040122434-A1   ;  US20040167482-A1   ;  US20040193218-A1   ;  US20040241213-A1   ;  US20040243073-A1   ;  US20040249353-A1   ;  US20040260230-A1   ;  US20050004534-A1   ;  US20050010153-A1   ;  US20050020955-A1   ;  US20050070835-A1   ;  US20050070858-A1   ;  US20050085795-A1   ;  US20050090787-A1   ;  US20050101940-A1   ;  US20050107756-A1   ;  US20050131327-A1   ;  US20050137539-A1   ;  US20050147562-A1   ;  US20050177190-A1   ;  US20050182445-A1   ;  US20050222527-A1   ;  US20050222544-A1   ;  US20050261642-A1   ;  US20050261643-A1   ;  US20060015087-A1   ;  US20060025727-A1   ;  US20060029650-A1   ;  US20060039742-A1   ;  US20060041247-A1   ;  US20060079852-A1   ;  US20060100586-A1   ;  US20060100594-A1   ;  US20060116620-A1   ;  US20060149170-A1   ;  US20070005028-A1   ;  US20070014837-A1   ;  US20070016152-A1   ;  US20070021697-A1   ;  US20070027414-A1   ;  US20070032754-A1   ;  US20070032755-A1   ;  US20070032778-A1   ;  US20070055209-A1   ;  US20070078432-A1   ;  US20070129707-A1   ;  US20070161938-A1   ;  US20070167927-A1   ;  US20070179460-A1   ;  US20070185426-A1   ;  US20070219513-A1   ;  US20070225663-A1   ;  US20070233022-A1   ;  US20080009812-A1   ;  US20080011667-A1   ;  US20080071235-A1   ;  US20080082059-A1   ;  US20080103462-A1   ;  US20080132819-A1   ;  US20080134796-A1   ;  US20080167593-A1   ;  US20080183233-A1   ;  US20080200857-A1   ;  US20080200906-A1   ;  US20080208147-A1   ;  US20080234641-A1   ;  US20090012483-A1   ;  US20090054855-A1   ;  US20090306580-A1   ;  US20100036334-A1   ;  US20100256545-A1   ;  US20100286635-A1   ;  US20110028918-A1   ;  US20110054421-A1   ;  US20110213287-A1   ;  US20120253302-A1   ;  US20130138060-A1   ;  US20130144230-A1   ;  US20130204213-A1   ;  US20140094761-A1   ;  US20110172615-A2   ;  US6174306-B1   FLEISCHMANN W (FLEI-Individual)   FLEISCHMANN W;  US6203563-B1   FERNANDEZ E R (FERN-Individual)   FERNANDEZ E R;  US6261276-B1   REITSMA B J (REIT-Individual)   REITSMA B J;  US6325788-B1   MCKAY D W (MCKA-Individual)   MCKAY D W;  US6345623-B1   KCI MEDICAL LTD (KCIL)   HEATON K P,  HUNT K W;  US6348423-B1   BRISTOL-MYERS SQUIBB CO (BRIM)   GRIFFITHS B,  JACQUES E,  BISHOP S M;  US6395955-B1   PROCTER & GAMBLE CO (PROC)   ROE D C,  AHR N A,  BEWICK-SONNTAG C P,  SCHMIDT M,  GOLDMAN S A,  CHRISTISON J,  GOULAIT D J K;  US6398767-B1   FLEISCHMANN W (FLEI-Individual)   FLEISCHMANN W;  US6406447-B1   UNIV TEXAS SYSTEM (TEXA)   THRASH W J,  JONES D L;  US6420622-B1   3M INNOVATIVE PROPERTIES CO (MINN)   JOHNSTON R P,  SCHOLZ M T,  HEINECKE S B,  HENTZEN C A;  US6458109-B1   HILL-ROM INC (HILR)   HENLEY A W,  MOSES L M,  SANDERSON R L,  HOWARD J,  PRICE J H,  BESSETTE R W;  US6488643-B1   KCI LICENSING INC (KCIL)   TUMEY D M,  RANDOLPH L T;  US6500112-B1   KHOURI BIOMEDICAL RES INC (KHOU-Non-standard)   KHOURI R K;  US6520982-B1   KCI LICENSING INC (KCIL)   BOYNTON T A,  JOHNSON R W;  US6547255-B1   PAMARGAN PROD LTD (PAMA-Non-standard)   DONAWAY P,  JONES D I;  US6557704-B1   KCI LICENSING INC (KCIL)   RANDOLPH L T;  US6607495-B1   UNIV VIRGINIA PATENT FOUND (UVIR)   SKALAK T C,  COTTLER P S;  US6695823-B1   KCI LICENSING INC (KCIL)   LINA C Z,  JOHNSON R,  HEATON K;  US6767334-B1   KCI LICENSING INC (KCIL)   RANDOLPH L T;  US6994702-B1   KCI LICENSING INC (KCIL)   JOHNSON R W;  US7144390-B1   KINETIC CONCEPTS INC (KCIL)   HANNIGAN R R,  LEININGER J R,  BILTZ C I,  DILAZZARO F,  FASHEK C,  JOHNSON R W,  SCHROEDER W J;  US7169151-B1   KCI LICENSING INC (KCIL)   LYTINAS M;  US7198046-B1   UNIV WAKE FOREST (UYWF)   ARGENTA L C,  MORYKWAS M J;  US7214202-B1   KCI LICENSING INC (KCIL)   VOGEL R C,  TUMEY D M,  MORRIS S P,  RANDOLPH L T;  US7276051-B1   HILL-ROM INC (HILR)   HENLEY A W,  MOSES L M,  SANDERSON R L,  HOWARD J,  PRICE J H,  BESSETTE R W;  US7279612-B1   KCI MEDICAL LTD (KCIL)   HEATON K P,  HUNT K W;  US7316672-B1   KCI MEDICAL LTD (KCIL)   HUNT K W,  HEATON K P;  US6553998-B2   KCI MEDICAL LTD (KCIL)   HEATON K P,  HUNT K W;  US6626891-B2   POLYMEDICS NV (POLY-Non-standard)   OHMSTEDE V S;  US6648862-B2   WATSON R (WATS-Individual)   WATSON R;  US6685681-B2   LOCKWOOD J S (LOCK-Individual);  PETROSENKO R (PETR-Individual);  RISK J R (RISK-Individual)   LOCKWOOD J S,  PETROSENKO R,  RISK J R;  US6695824-B2   HOWARD P A (HOWA-Individual);  HOWARD E (HOWA-Individual)   HOWARD P A,  HOWARD E;  US6752794-B2   LOCKWOOD J S (LOCK-Individual);  PETROSENKO R (PETR-Individual);  RISK J R (RISK-Individual)   LOCKWOOD J S,  PETROSENKO R,  RISK J R;  US6755807-B2   HENLEY A W (HENL-Individual);  PETROSENKO R (PETR-Individual);  RISK J R (RISK-Individual);  SANDERSON R L (SAND-Individual)   HENLEY A W,  PETROSENKO R,  RISK J R,  SANDERSON R L;  US6764462-B2   RISK J R (RISK-Individual);  PETROSENKO R (PETR-Individual)   RISK J R,  PETROSENKO R;  US6800074-B2   HENLEY A W (HENL-Individual);  PETROSENKO R (PETR-Individual);  RISK J R (RISK-Individual);  SANDERSON R L (SAND-Individual)   HENLEY A W,  PETROSENKO R,  RISK J R,  SANDERSON R L;  US6814079-B2   KCI MEDICAL LTD (KCIL)   HEATON K P,  HUNT K W;  US6824533-B2   RISK J R (RISK-Individual);  PETROSENKO R (PETR-Individual)   RISK J R,  PETROSENKO R;  US6855135-B2   LOCKWOOD J S (LOCK-Individual);  PETROSENKO R (PETR-Individual);  RISK J R (RISK-Individual)   LOCKWOOD J S,  PETROSENKO R,  RISK J R;  US6855860-B2   RUSZCZAK Z (RUSZ-Individual);  MEHRL R (MEHR-Individual);  JECKLE J (JECK-Individual)   RUSZCZAK Z,  MEHRL R,  JECKLE J;  US6856821-B2   KCI LICENSING INC (KCIL)   JOHNSON R;  US6887228-B2   MCKAY D W (MCKA-Individual)   MCKAY D W;  US6887263-B2   RADIANT MEDICAL INC (RADI-Non-standard)   BLEAM J C,  TSAI G;  US6936037-B2   BUBB S K (BUBB-Individual);  ZAMIEROWSKI D S (ZAMI-Individual)   BUBB S K,  ZAMIEROWSKI D S;  US6942633-B2   ODLAND R M (ODLA-Individual)   ODLAND R M;  US6942634-B2   ODLAND R M (ODLA-Individual)   ODLAND R M;  US6951553-B2   BUBB S K (BUBB-Individual);  ZAMIEROWSKI D S (ZAMI-Individual)   BUBB S K,  ZAMIEROWSKI D S;  US6960181-B2   STEVENS R C (STEV-Individual)   STEVENS R C;  US6979324-B2   BYBORDI F (BYBO-Individual);  BIGGIE J J (BIGG-Individual);  BIGGIE L B (BIGG-Individual);  DAWSON J A (DAWS-Individual)   BYBORDI F,  BIGGIE J J,  BIGGIE L B,  DAWSON J A;  US7022113-B2   LOCKWOOD J S (LOCK-Individual);  PETROSENKO R (PETR-Individual);  RISK J R (RISK-Individual)   LOCKWOOD J S,  PETROSENKO R,  RISK J R;  US7037254-B2   O'CONNOR M (OCON-Individual);  COX M E (COXM-Individual)   O'CONNOR M,  COX M E;  US7052167-B2   VANDERSCHUIT C R (VAND-Individual)   VANDERSCHUIT C R;  US7070584-B2   KCI LICENSING INC (KCIL)   JOHNSON R,  TUMEY D;  US7077832-B2   FLEISCHMANN W (FLEI-Individual)   FLEISCHMANN W;  US7108683-B2   KCI LICENSING INC (KCIL)   ZAMIEROWSKI D S;  US7117869-B2   KCI MEDICAL LTD (KCIL)   HEATON K P,  HUNT K W;  US7128719-B2   LR R & D LTD (LRRD-Non-standard)   ROSENBERG L;  US7128735-B2   WESTON R S (WEST-Individual)   WESTON R S;  US7182758-B2   MCCRAW J B (MCCR-Individual)   MCCRAW J B;  US7195624-B2   HILL-ROM SERVICES INC (HILR)   LOCKWOOD J S,  PETROSENKO R;  US7216651-B2   UNIV WAKE FOREST (UYWF)   ARGENTA L C,  MORYKWAS M J;  US7273054-B2   KCI MEDICAL LTD (KCIL)   HEATON K P,  HUNT K W;  US7338482-B2   HILL-ROM SERVICES INC (HILR)   LOCKWOOD J S,  PETROSENKO R;  US7351250-B2   KCI LICENSING INC (KCIL)   ZAMIEROWSKI D S;  US7361184-B2   MICROLIN LLC (CTEC)   JOSHI A V;  US7381211-B2   KCI LICENSING INC (KCIL)   ZAMIEROWSKI D S;  US7381859-B2   KCI LICENSING INC (KCIL)   HUNT K W,  HEATON K P;  US7396345-B2   EMBRO CORP (EMBR-Non-standard)   KNIGHTON D,  FIEGEL V;  US7410495-B2   KCI LICENSING INC (KCIL)   ZAMIEROWSKI D S;  US7413570-B2   KCI LICENSING INC (KCIL)   ZAMIEROWSKI D S;  US7413571-B2   KCI LICENSING INC (KCIL)   ZAMIEROWSKI D S;  US7422576-B2   KCI LICENSING INC (KCIL)   BOYNTON T A,  JOHNSON R;  US7524315-B2   SMITH & NEPHEW PLC (SMIN)   BLOTT P L,  GREENER B,  HARTWELL E Y,  WALKER T M;  US7569742-B2   TYCO HEALTHCARE GROUP LP (COVI)   HAGGSTROM K,  TRANCHEMONTAGNE A,  LOREDANA J;  US7699823-B2   TYCO HEALTHCARE GROUP LP (COVI)   HAGGSTROM K,  FINK D,  GRUNDMEIR R;  US7708724-B2   WESTON R S (WEST-Individual)   WESTON R S;  US7838717-B2   TYCO HEALTHCARE GROUP LP (COVI)   HAGGSTROM K,  TRANCHEMONTAGNE A,  LOREDANA J;  US7846141-B2   WESTON R S (WEST-Individual)   WESTON R S;  US7964766-B2   SMITH & NEPHEW PLC (SMIN)   BLOTT P L,  GREENER B,  HARTWELL E Y,  LEE-WEBB J,  NICOLINI D;  US8062272-B2   WESTON R S (WEST-Individual)   WESTON R S;  US8207392-B2   TYCO HEALTHCARE GROUP LP (COVI)   HAGGSTROM K,  TRANCHEMONTAGNE A,  LOREDANA J;  US8257327-B2   SMITH & NEPHEW PLC (SMIN)   BLOTT P L,  GREENER B,  HARTWELL E Y,  LEE-WEBB J,  NICOLINI D,  GREEN C,  MARTIN R P;  US8409157-B2   TYCO HEALTHCARE GROUP LP (COVI)   HAGGSTROM K,  FINK D,  GRUNDMEIR R;  US8444612-B2   ;  US8777911-B2   TYCO HEALTHCARE GROUP LP (COVI)   HEAGLE D G,  CORLEY K,  WATSON K L;  US364679-S   ;  US434150-S   ;  US469175-S   ;  US469176-S   ;  US475134-S   ;  US478659-S   ;  US488558-S   ;  US544092-S   ;  US565177-S   ;  WO1980001139-A   ;  WO1980002182-A   ;  WO1984001904-A   ;  WO1989005133-A   ;  WO1990011795-A   ;  WO1992019313-A1   ;  WO1993009727-A1   ;  WO1994020041-A1   ;  WO1996005873-A1   ;  WO2000021586-A1   ;  WO2003030966-A1   HILL-ROM SERVICES INC (HILR)   BITEL A B,  LOCKWOOD J S,  PETROSENKO R,  RISK J R;  WO2003045492-A1   LOCKWOOD J S (LOCK-Individual);  PETROSENKO R (PETR-Individual);  RISK J R (RISK-Individual)   LOCKWOOD J S,  PETROSENKO R,  RISK J R;  WO2003057307-A1   HILL-ROM SERVICES INC (HILR)   LOCKWOOD J S,  PETROSENKO R;  WO2004018020-A1   HILL-ROM SERVICES INC (HILR)   PETROSENKO R,  WILKINSON K L;  WO2006015599-A1   TYTEX AS (TYTE-Non-standard)   SORENSEN B B;  WO2006105892-A1   INMEDITEC MEDIZINTECHNIK GMBH (INME-Non-standard)   BAUMANN D,  MEYER J,  ROEHRS J;  WO2008020862-A1   RICHMOND F M (RICH-Individual)   RICHMOND F M;  WO2008141228-A1   KCI LICENSING INC (KCIL)   OLSON J S,  GINTHER D C,  SANDERS T B;  WO2003101508-A2   RISK J R (RISK-Individual);  PETROSENKO R (PETR-Individual)   RISK J R,  PETROSENKO R;  WO2008048481-A2   BLUESKY MEDICAL GROUP INC (BLUE-Non-standard)   WESTON R S,  XU T;  WO2003005943-A3   LOCKWOOD J S (LOCK-Individual);  PETROSENKO R (PETR-Individual);  RISK J R (RISK-Individual)   LOCKWOOD J S,  PETROSENKO R,  RISK J R;  WO2003018098-A3   KCI LICENSING INC (KCIL)   BOYNTON T A,  SANDERS T B,  HEATON K P,  HUNT K W,  BEARD M,  TUMEY D M,  RANDOLPH L T;  WO2003057070-A3   HILL-ROM SERVICES INC (HILR)   LOCKWOOD J S,  PETROSENKO R;  WO2003057071-A3   HILL-ROM SERVICES INC (HILR)   LOCKWOOD J S,  PETROSENKO R;  WO2003086232-A3   HILL-ROM SERVICES INC (HILR)   LOCKWOOD J S,  PETROSENKO R;  WO2003092620-A3   KCI LICENSING INC (KCIL)   ZAMIEROWSKI D S;  WO2005009488-A3   SANDERS T B (SAND-Individual);  WILKES R P (WILK-Individual)   SANDERS T B,  WILKES R P;  EP2694005-B1 -- GB2415908-A   ETHICON INC (ETHI)   LOWING P H,  DEL BONO M;  US20070027414-A1   ;  US20080009812-A1   ;  US20100286635-A1   ","US9302034-B2  US          6,216,701, 04/2001, Heaton et al. (withdrawn);  US          7,186,244, 03/2007, Hunt et al. (withdrawn);            U.S. Appl. No. 13/775,964, filed Feb. 25, 2013, Haggstrom          et al.;            U.S. Appl. No. 13/866,346, filed Apr. 19, 2013, Patel et          al.;            Bagautdinov (Kazan), ""Variant of External Vacuum          Aspiration in the Treatment of Purulent Diseases of Soft          Tissues,"" UDC 616-002.36 (94-96).;            Bjorn, et al., ""Irrigation Treatment in Split-thickness          Skin Grafting of Intractable Leg Ulcers,"" Scand J Plast          Reconstr Surg 19: 211-213,1985.;            Chardack, et al., ""Experimental studies on Synthetic          Substitutes for Skin and Their Use in the Treatment of          Burns,"" vol. 155, No. 1 (128-136), 1961.;            Chariker, M. E. et al. (eds), ""Effective Management of          Incisional and Cutaneous Fistulae with Closed Suction          Wound Drainage,"" Contemporary Surgery, vol. 34, Jun.          1989, pp. 59-63.;            Fleischmann, ""Vacuum Sealing for Treatment of          Problematical Wounds"", University Surgical Clinic and          Polyclinic- Accident Surgery Department, WundForum          Spezial-IHW 94.;            Fleischmann, et al., Vacuum Sealing: Indication,          Technique and Results, Emr J Orthop Surg Tramatol (1995)          5:37-40.;            Goeran Sanden, MD., et al., ""Staphylococcal Wound          Infection in the Pig: Part II. Innoculation,          Quantification of Bacteria, and Reproducibility,"" Annals          of Plastic Surgery, vol. 23, No. 3, Sep. 1989,          (219-223).;            Gorica Zivadinovic, et al., ""Vacuum Therapy in the          Treatment of Peripheral Blood Vessels,"" Conference Papers          of the 5th Timok Medical Days, Majdanpek, 1986          (161-164).;            International Search Report for PCT/US09/047137, dated          Aug. 7, 2009.;            International Search Report for PCT/US09/036342, dated          Aug. 3, 2010.;            International Search Report and Written Opinion for          PCT/US2012/030829, mailed Jul. 26, 2012.;            Jeter, Katherine F., et al., ""Managing Draining Wounds          and Fistulae: New and Established Methods"", Chronic Wound          Care, 1990, pp. 240-246.;            Kostiuchenok, et al., ""The Vacuum Effect in the Surgical          Treatment of Purulent Wounds,"" Russian Journal: Vestnik          Khirurgii, Sep. 1986, (18-21).;            Meyer, MD., et al., ""In Surgery, Medicine and the          Specialties a Manual of its Practical Application"",          Bier's Hyperemic Treatment, Second Revised Edition, W.B.          Saunders Company, 1909.;            Mulder, GD, et al., ""Clinicians' Pocket Guide to Chronic          Wound Repair,"" Wound Healing Publications Second Edition,          1991.;            Ryosuke Fujimoro, MD., et al., ""Sponge Fixation Method          for Treatment of Early Scars,"" From the Department of          Dermatology in the Faculty Medicine, Kyoto University,          vol. 42, No. 4, Oct. 1968 (323-326).;            Stoll, ""Energetic Remedies_Cupping: Healing Within a          Vacuum,"" https:l/www.suite101.com/article.cfm/          energetic)remedies/74531, Apr. 13, 2005.;            Svedman, ""A Dressing Allowing Continuous Treatment of a          Biosurface,"" IRCS Medical Science: Biomedical Technology;          Clinical Medicine; Surgery and Transplantation, 7, 221          (1979).;            Svedman, ""A Dressing System Providing Fluid Supply and          Suction Drainage Used for Continuous or Intermittent          Irrigation,"" Annals of Plastic Surgery, vol. 17, No. 2,          Aug. 1986 (125-133).;            Svedman, ""Irrigation Treatment of Leg Ulcers,"" The          Lancet, Sep. 3, 1983 (532-534).;            Svedman, et al., ""Staphylococcal Wound Infection in the          Pig: Part I. Course,"" Annals of Plastic Surgery, vol. 23,          No. 3, Sep. 1989 (212-218).;            Teder, et al., ""Continuous Wound Irrigation in the Pig,""          Journal of Investigative Surgery, vol. 3          (399-407).;            Usupov, et al., ""Active Wound Drainage,"" Russian Journal:          Vestnik Khirugii, Apr. 1987, (42-45).;  Yu          A. Davydov, et al., ""Bacteriological and Cy1ological          Assessment of Vacuum Therapy of Purulent Wounds"", Vestnik          Khirurgii, Oct. 1988, (48-52).;  Yu          A. Davydov, et al., ""Concepts for Clinical Biological          Management of the Wound Process in the Treatment of          Purulent Wounds Using Vacuum Therapy,"" Vestnik Khirugii,          Feb. 1991, 132-135).;  Yu          A. Davydov, et al., ""Vacuum Therapy in the Treatment of          Purulent Lactation Mastitis,"" Russian Journal: Vesnik          Khirurgii, Sep. 1986, (66-70).;  Yu          A. Davydov, et al., ""Vacuum Therapy in treatment of Acute          Purulent Diseases of Soft Tissues and Purulent Wounds,""          Vestnik Khirurgii, (Surgeon's Herald), Medicine          Publishers, 1986.",90356-0-0-0 ,,,R01852 ,
US2012187179-A1;  EP2481359-A1;  CA2761474-A1;  AU2011253976-A1;  AU2011253976-B2;  US9084602-B2;  EP2481359-B1;  ES2813429-T3,Surgical stapler for stapling tissue and sealing            wound has surgical buttress that releases hemostatic            agent upon actuation of surgical stapling apparatus to            approximate pair of jaw members and exert pressure on            surgical buttress,GLEIMAN S S,GLEIMAN S S (GLEI-Individual);  TYCO HEALTHCARE GROUP LP (COVI-C);  TYCO HEALTHCARE GROUP LP (COVI-C);  TYCO HEALTHCARE GROUP LP (COVI-C);  COVIDIEN LP (COVI-C);  COVIDIEN LP (COVI-C);  COVIDIEN LP (COVI-C);  COVIDIEN LP (COVI-C),2012J61170,"   NOVELTY - The surgical stapler (10) has a jaw assembly                (16) including a pair of jaw members (20,22), and a                surgical buttress (24) positioned adjacent a tissue                contacting surface of at least one of the pair of                jaw members. The surgical buttress includes a                hemostatic agent, and releases the hemostatic agent                upon actuation of the surgical stapling apparatus                to approximate the pair of jaw members and exert a                pressure on the surgical buttress.    USE - Surgical stapler for stapling tissue and                sealing wound, e.g. Duet TRS (RTM: a brand by                Covidien company and its associates) reloads and                staplers with Tri-Staple (RTM: a revolutionary                reload design available through Covidien, which                maintain a principal place of business at 555 Long                Wharf Drive, North Haven, Conn. 06511)                technology.    ADVANTAGE - Assists in sealing the wound, and allows                tissue ingrowth, if desired, by mechanically                supporting tissues, reinforcing tissues along                staple or suture lines, and decreasing the                incidence of fluid leakage and bleeding of                tissue.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a                staple cartridge.    DESCRIPTION OF DRAWING(S) - The drawing shows the perspective view of a                surgical stapling apparatus including a surgical                buttress.    Surgical stapling apparatus (10)    Jaw assembly (16)    Jaw members (20,22)    Surgical buttress (24) ",,,"A96 (Medical, dental, veterinary, cosmetic.);  P31 (Diagnosis, surgery (A61B).)",A12-V03D,A61B-017/068;  A61B-017/00;  A61B-017/072;  A61L-031/12;  A61B-017/115;  A61L-031/16;  A61M-031/00,US2012187179-A1   26 Jul 2012   A61B-017/068   201250Pages: 15   English;  EP2481359-A1   01 Aug 2012   A61B-017/072   201250   English;  CA2761474-A1   26 Jul 2012   A61B-017/072   201256   English;  AU2011253976-A1   09 Aug 2012   A61B-017/068   201263   English;  AU2011253976-B2   22 Jan 2015   A61B-017/068   201512   English;  US9084602-B2   21 Jul 2015   A61B-017/068   201548   English;  EP2481359-B1   05 Aug 2020   A61B-017/072   202064   English;  ES2813429-T3   23 Mar 2021   A61B-017/072   202140   Spanish,US2012187179-A1    US013977    26 Jan 2011;   EP2481359-A1    EP152541    25 Jan 2012;   CA2761474-A1    CA2761474    12 Dec 2011;   AU2011253976-A1    AU253976    12 Dec 2011;   AU2011253976-B2    AU253976    12 Dec 2011;   US9084602-B2    US013977    26 Jan 2011;   EP2481359-B1    EP152541    25 Jan 2012,ES2813429-T3 EP application Application EP152541,US013977    26 Jan 2011,  EP2481359-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME          EP2481359-B1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR    ,,"US2012187179-A1 -- US4927640-A   HAESSLE AB (HASS)   DAHLINDER L E,  JOHANSSON M O,  SANDBERG J A,  SJOGREN J A;  US5281197-A   SYMBIOSIS CORP (SYMB)   SCARFONE F A,  BALES T O,  TURKEL D,  SMITH K W,  GORDON D P,  ARIAS J J,  RYAN C M;  US20020169476-A1   ;  US20070179528-A1   ;  US20100087840-A1   ;  US6358532-B2   CAP BIOTECHNOLOGY INC (CAPB-Non-standard)   STARLING L B,  STEPHAN J E;  US34742-E   EASTMAN KODAK CO (EAST)   MAIER L K,  PRIEBE E K,  LEE J S,  WOODGATE P E,  SMITH G C;  EP2481359-A1 -- EP1702570-A1   TYCO HEALTHCARE GROUP LP (COVI)   DAGOSTINO W L,  BETTUCHI M,  D'AGOSTINO W L;  EP1815804-A2   SOLTZ M A (SOLT-Individual);  PROMMERSBERGER M L (PROM-Individual);  STOPEK J (STOP-Individual)   SOLTZ M A,  PROMMERSBERGER M L,  STOPEK J;  EP2008595-A2   PROMMERSBERGER M (PROM-Individual);  NENTWICK B (NENT-Individual);  GRAVAGNA P (GRAV-Individual);  BAYON Y (BAYO-Individual);  DASSONVILLE D (DASS-Individual);  MENEGHIN A (MENE-Individual);  LECUIVRE J (LECU-Individual)   PROMMERSBERGER M,  NENTWICK B,  GRAVAGNA P,  BAYON Y,  DASSONVILLE D,  MENEGHIN A,  LECUIVRE J;  US20020028243-A1   ;  US20050149073-A1   ;  US20060173470-A1   ;  US20070123839-A1   ;  WO2012044848-A1   ETHICON ENDO-SURGERY INC (ETHI)   WOODARD J A,  SCHEIB C J,  BOUDREAUX C P,  BRUEWER D B,  SCHWEMBERGER R F,  SCHALL C J,  MORGAN J R,  SIMMS R J,  SIEBENALER D J,  SWAYZE J S,  OUWERKERK J N;  WO2006023578-A2   TYCO HEALTHCARE GROUP LP (COVI)   STOPEK J B;  WO2010075298-A2   SURMODICS PHARM INC (SURM)   BIGGS D,  BOWMAN H,  BURTON K W,  MARKLAND P,  TICE T R,  TIPTON A J;  US5915616-A   US SURGICAL CORP (USSU)   ROBERTSON J C,  VIOLA F J;  US20090001122-A1   ;  US6241139-B1   MILLIMAN K L (MILL-Individual);  VIOLA F J (VIOL-Individual);  ORBAN J (ORBA-Individual);  LEHN R F (LEHN-Individual)   MILLIMAN K L,  VIOLA F J,  ORBAN J,  LEHN R F;  US6330965-B1   US SURGICAL CORP (USSU)   MILLIMAN K L,  VIOLA F J,  ORBAN J,  LEHN R F;  US9084602-B2 -- CA2667434-A1   SCA HYGIENE PROD AB (SCAD)   HILDEBERG J,  KLINTE A,  HUSMARK U,  DAHL D;  DE19924311-A1   RAU W A (RAUW-Individual);  BERSTEIN E (BERS-Individual);  PERELMAN M (PERE-Individual);  ZIKOW A (ZIKO-Individual)   RAU W A,  BERSTEIN E,  PERELMAN M,  ZIKOW A;  EP594148-A1   US SURGICAL CORP (USSU)   TOTAKURA N,  MUTH R R;  EP667119-A1   BIO-VASCULAR INC (BIOV-Non-standard)   COOPER J,  WINEGAR-HENTGES S L,  NELSON R P,  SCHANKERELI K,  TEICH K M;  EP1256318-A1   GRANT R L (GRAN-Individual);  DALESSANDRO D A (DALE-Individual)   GRANT R L,  DALESSANDRO D A;  EP1520525-A1   DALESSANDRO D A (DALE-Individual);  LI Z (LIZZ-Individual);  SCOPELIANOS A G (SCOP-Individual)   DALESSANDRO D A,  LI Z,  SCOPELIANOS A G;  EP1702570-A1   TYCO HEALTHCARE GROUP LP (COVI)   DAGOSTINO W L,  BETTUCHI M,  D'AGOSTINO W L;  EP1825820-A1   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M J;  EP2090231-A1   ETHICON ENDO-SURGERY INC (ETHI)   HUITEMA T W,  SHELTON I;  EP2198787-A1   OLSON L (OLSO-Individual)   OLSON L;  EP2236099-A1   OLSON L (OLSO-Individual);  ARANYI E (ARAN-Individual);  MOZDZIERZ P (MOZD-Individual)   OLSON L,  ARANYI E,  MOZDZIERZ P;  EP2277458-A1   TYCO HEALTHCARE GROUP LP (COVI)   YONG M,  HEINRICH R;  EP2436348-A1   TYCO HEALTHCARE GROUP LP (COVI)   VITARIS R F,  CORLEY K M;  EP2517637-A1   TYCO HEALTHCARE GROUP LP (COVI)   HODGKINSON G N,  STEVENSON R,  WHIFFEN J;  EP2586380-A1   COVIDIEN LP (COVI)   HODGKINSON G,  POWERS W;  EP2604195-A1   COVIDIEN LP (COVI)   CARTER S,  STEVENSON R P;  EP2630922-A1   COVIDIEN LP (COVI)   HODGKINSON G;  EP1759640-A2   GRANT R L (GRAN-Individual);  ZEINER M S (ZEIN-Individual);  HUEIL G (HUEI-Individual);  WALES K (WALE-Individual);  GARNER D L (GARN-Individual)   GRANT R L,  ZEINER M S,  HUEIL G,  WALES K,  GARNER D L;  EP1815804-A2   SOLTZ M A (SOLT-Individual);  PROMMERSBERGER M L (PROM-Individual);  STOPEK J (STOP-Individual)   SOLTZ M A,  PROMMERSBERGER M L,  STOPEK J;  EP2005895-A2   MARCZYK S (MARC-Individual);  PROMMERSBERGER M (PROM-Individual);  NENTWICK B (NENT-Individual)   MARCZYK S,  PROMMERSBERGER M,  NENTWICK B;  EP2008595-A2   PROMMERSBERGER M (PROM-Individual);  NENTWICK B (NENT-Individual);  GRAVAGNA P (GRAV-Individual);  BAYON Y (BAYO-Individual);  DASSONVILLE D (DASS-Individual);  MENEGHIN A (MENE-Individual);  LECUIVRE J (LECU-Individual)   PROMMERSBERGER M,  NENTWICK B,  GRAVAGNA P,  BAYON Y,  DASSONVILLE D,  MENEGHIN A,  LECUIVRE J;  EP2177239-A2   CONFLUENT SURGICAL INC (CONF-Non-standard)   BENNETT S;  EP2179753-A2   CONFLUENT SURGICAL INC (CONF-Non-standard)   BENNETT S;  EP2236098-A2   TYCO HEALTHCARE GROUP LP (COVI)   TARINELLI D,  ARANYI E,  SIMPSON R;  EP2604197-A2   COVIDIEN LP (COVI)   HODGKINSON G,  SCIRICA P A,  CARTER S,  STEVENSON R P,  HISLOP A,  CASASANTA T;  EP2620106-A2   COVIDIEN LP (COVI)   CARTER S,  STEVENSON R P;  EP2644125-A2   ETHICON ENDO-SURGERY INC (ETHI)   SCHMID K J,  MORGAN J R,  KORVICK D L,  SHELTON I;  EP1929958-A3   FOWLER D N (FOWL-Individual)   FOWLER D N;  EP2090244-A3   ETHICON ENDO-SURGERY INC (ETHI)   HUITEMA T W,  MORGAN J R,  SHELTON I,  SWAYZE J S;  EP2090252-A3   ETHICON ENDO-SURGERY INC (ETHI)   HUITEMA T W,  SHELTON I;  EP2311386-A3   TYCO HEALTHCARE GROUP LP (COVI)   INGMANSON M D,  SHAH S,  MCNELLIS J;  EP2462880-A3   TYCO HEALTHCARE GROUP LP (COVI)   SHAH S,  SIMPSON R;  EP327022-B1   DELLON A L (DELL-Individual);  AMERICAN CYANAMID CO (AMCY)   MACKINNON S E,  DELLON A L;  EP627991-B1   DOW CHEM CO (DOWC)   SCHRENK W J;  JP07124166-A   ;  JP2000166933-A   GUNZE KK (GNZE)   YAMAUCHI K,  MATSUDA S,  IKADA Y,  ITO E;  JP2002202213-A   YASKAWA ELECTRIC CORP (YASW)   SUMIMOTO T,  HAMAMATSU H,  MIYAGAWA H;  US3054406-A   ;  US3124136-A   ;  US3364200-A   JOHNSON & JOHNSON (JOHJ);  US3666750-A   JOHNSON & JOHNSON (JOHJ);  US3937223-A   AMERICAN CYANAMID CO (AMCY);  US4347847-A   USHER F C (USHE-Individual)   USHER F C;  US4354628-A   US SURGICAL CORP (USSU)   GREEN D T;  US4452245-A   USHER F C (USHE-Individual)   USHER F C;  US4511478-A   GENENTECH SYSTEMS CORP (GETH)   NOWINSKI R C,  HOFFMAN A S;  US4605730-A   ETHICON INC (ETHI)   SHALABY S W,  JAMIOLKOWS D;  US4626253-A   JOHNSON & JOHNSON (JOHJ)   BORADNAX C H;  US4655221-A   AMERICAN CYANAMID CO (AMCY)   DEVEREUX D F;  US4663163-A   HOU K C (HOUK-Individual);  LIAO T D (LIAO-Individual)   HOU K C,  LIAO T D;  US4826945-A   UNIV JERUSALEM HEBREW (YISS);  BIOMEDICAL POLYMERS INT LTD (BIOM-Non-standard)   COHN D,  YOUNES H,  URETZKY G;  US4834090-A   MOORE J P (MOOR-Individual)   MOORE J P;  US4838884-A   AMERICAN CYANAMID CO (AMCY)   DUMICAN B L,  KAGANOV A L,  RITTER T A;  US4927640-A   HAESSLE AB (HASS)   DAHLINDER L E,  JOHANSSON M O,  SANDBERG J A,  SJOGREN J A;  US4930674-A   ABIOMED INC (ABIO)   BARAK J H;  US4938763-A   SOUTHERN RES INST (SOUR);  DUNN R L (DUNN-Individual)   DUNN R L,  ENGLISH J P,  COWSAR D R,  VANDERBILT D P;  US5002551-A   JOHNSON & JOHNSON (JOHJ);  US5014899-A   US SURGICAL CORP (USSU)   PRESTY D F,  TOMPKINS T M;  US5040715-A   US SURGICAL CORP (USSU);  GREEN D T (GREE-Individual)   GREEN D T,  BOLANOS H,  ALESI D E,  RATCLIFF K,  SHERTS C R;  US5065929-A   ETHICON INC (ETHI)   SCHULZE D R,  SHERMAN J A,  MERENESS M;  US5100992-A   YISSUM RES & DEV CO (YISS)   COHN D,  YITZCHAIEK S,  BILENKIS S;  US5160745-A   UNIV KENTUCKY RES FOUND (KENT)   DELUCA P P,  RYPACEK F;  US5201745-A   IMEDEX SA (IMED-Non-standard);  INST MERIEUX (INMR)   TAYOT J L,  MARESCAUX J,  DUMAS H,  TARDY M;  US5205459-A   ETHICON INC (ETHI)   BRINKERHOFF R J,  NOBIS R H,  WOLF H,  BILOTTI F,  FOX W,  ZEINER M S,  ALLEN E D,  SMITH R,  RECKELHOFF J,  CHURCHILL P,  GRANT R,  HILDWEIN R,  HUGHETT J D,  COLES C,  LAWRENCE W T;  US5263629-A   ETHICON INC (ETHI)   TRUMBULL H R,  KAY M E,  DURMAN B J,  AHRENS B K,  CHAMBERS J H;  US5281197-A   SYMBIOSIS CORP (SYMB)   SCARFONE F A,  BALES T O,  TURKEL D,  SMITH K W,  GORDON D P,  ARIAS J J,  RYAN C M;  US5314471-A   BAXTER INT INC (BAXT)   BRAUKER J H,  HILL R S,  MARTINSON L A,  BOGGS D R,  JOHNSON R C;  US5344454-A   BAXTER INT INC (BAXT)   HILL R S,  PAULEY R G,  CLARKE R A,  BOGGS D R,  STERNBERG S,  BRAUKER J H;  US5392979-A   US SURGICAL CORP (USSU)   GREEN D T,  RATCLIFFE K,  BOLANOS H;  US5397324-A   CARROLL B J (CARR-Individual);  GLEISCHMAN S H (GLEI-Individual)   CARROLL B J,  GLEISCHMAN S H;  US5410016-A   UNIV TEXAS SYSTEM (TEXA)   PATHAK C P,  DESAI N P,  HUBBELL J A,  HILL J L,  SAWHNEY A S;  US5425745-A   US SURGICAL CORP (USSU);  GREEN D T (GREE-Individual)   GREEN D T,  BOLANOS H,  ALESI D E,  RATCLIFF K,  SHERTS C R;  US5441193-A   US SURGICAL CORP (USSU)   GRAVENER R D;  US5441507-A   WILK P J (WILK-Individual)   WILK P J;  US5443198-A   US SURGICAL CORP (USSU)   ROBERTSON J C,  VIOLA F J;  US5468253-A   ETHICON INC (ETHI)   BEZWADA R S,  SCOPELIANOS A G;  US5484913-A   JOHNSON & JOHNSON MEDICAL INC (JOHJ)   STILWELL R L,  WHITMORE E J,  SAFERSTEIN L G;  US5503638-A   BIO-VASCULAR INC (BIOV-Non-standard)   COOPER J,  WINEGAR-HENTGES S L,  NELSON R P,  SCHANKERELI K,  TEICH K M;  US5505952-A   US SURGICAL CORP (USSU)   GRUSKIN E A,  JIANG Y;  US5514379-A   GEN HOSPITAL CORP (GEHO)   WEISSLEDER R,  BOGDANOV A;  US5527864-A   PAYNE R G (PAYN-Individual);  YASZEMSKI M J (YASZ-Individual);  MIKOS A G (MIKO-Individual);  SUGGS L J (SUGG-Individual)   SUGGS L J,  PAYNE R G,  MIKOS A G,  YASZEMSKI M J;  US5542594-A   US SURGICAL CORP (USSU)   KOYFMAN I S,  HAIN M,  MCKEAN W L;  US5549628-A   BIO-VASCULAR INC (BIOV-Non-standard)   COOPER J,  WINEGAR-HENTGES S L,  NELSON R P,  SCHANKERELI K,  TEICH K M;  US5575803-A   BIO-VASCULAR INC (BIOV-Non-standard)   COOPER J,  WINEGAR-HENTGES S L,  NELSON R P,  SCHANKERELI K,  TEICH K M;  US5580923-A   COLLAGEN CORP (CLGE)   YEUNG J E,  CHU G H,  DELUSTRO F A,  RHEE W M;  US5626863-A   UNIV TEXAS SYSTEM (TEXA)   HILL J L,  SAWHNEY A S,  PATHAK C P,  HUBBELL J A,  DESAI N P;  US5643596-A   CLARION PHARM INC (CLAQ)   PRUSS T P,  WILL J A;  US5645849-A   CLARION PHARM INC (CLAQ)   PRUSS T P,  WILL J A;  US5653756-A   BAXTER INT INC (BAXT)   HILL R S,  STERNBERG S,  CLARKE R A,  BRAUKER J H,  BOGGS D R,  PAULEY R G;  US5683809-A   HERCULES INC (HERC)   FREEMAN W J,  GUPTA R K,  HARRINGTON J H,  LEGARE R J,  SMITH T L,  WILLIAMS A W;  US5690675-A   FUSION MEDICAL TECHNOLOGIES INC (FUSI-Non-standard)   SAWYER P N,  SAWYER P M,  REICH C J;  US5702409-A   GORE & ASSOC INC W L (GORE)   RAYBURN G L,  RIFFLE R G,  WALBURN F J,  WILLIAMS B G;  US5752965-A   BIO-VASCULAR INC (BIOV-Non-standard)   FRANCIS R T,  HUGHES M E,  CLAESON A E,  COOPER J;  US5752974-A   COLLAGEN CORP (CLGE)   RHEE W M,  BERG R A,  CHU G H,  DELUSTRO F A,  JOLIVETTE D M,  MCCULLOUGH K A;  US5762256-A   US SURGICAL CORP (USSU)   MASTRI D L,  VIOLA F J,  ALESI T W,  GEISTE R J,  WILSON J E;  US5766188-A   IGAKI IRYO SEKKEI KK (IGAK-Non-standard)   IGAKI K;  US5769892-A   MITROFLOW INT INC (MITR-Non-standard)   KINGWELL B G;  US5782396-A   US SURGICAL CORP (USSU)   MASTRI D L,  VIOLA F J,  ALESI T W,  GEISTE R J,  WILSON J E;  US5799857-A   US SURGICAL CORP (USSU)   ROBERTSON J C,  VIOLA F J;  US5810855-A   GORE ENTERPRISE HOLDINGS INC (GORE)   WILLIAMS B G,  WALBURN F J,  RAYBURN G L,  RIFFLE R G;  US5814057-A   GUNZE LTD (GNZE)   OI S,  OHSHIMA H;  US5833695-A   YOON I (YOON-Individual)   YOON I;  US5843096-A   IGAKI IRYO SEKKEI KK (IGAK-Non-standard)   IGAKI K,  MORI M,  OHOI S;  US5895415-A   CHOW V (CHOW-Individual);  CHOW A Y (CHOW-Individual)   CHOW V,  CHOW A Y;  US5902312-A   FRATER D A (FRAT-Individual);  FRATER R W M (FRAT-Individual)   FRATER D A,  FRATER R W M;  US5908427-A   US SURGICAL CORP (USSU)   KOYFMAN I S,  HAIN M,  MCKEAN W L;  US5915616-A   US SURGICAL CORP (USSU)   ROBERTSON J C,  VIOLA F J;  US5931847-A   ETHICON ENDO-SURGERY INC (ETHI)   BITTNER J R,  RUDER D H,  BOWSER W G,  LAU P;  US5964774-A   US SURGICAL CORP (USSU)   KOYFMAN I S,  HAIN M,  MCKEAN W L;  US5997895-A   INTEGRA LIFESCIENCES CORP (INTE-Non-standard)   NAROTAM P K,  VAN DELLEN J,  O'FEE R P,  MCKINNEY G W,  ARCHIBALD S J,  O'GRADY J;  US6019791-A   WOOD A E (WOOD-Individual)   WOOD A E;  US6030392-A   DAKOV P (DAKO-Individual)   DAKOV P;  US6032849-A   US SURGICAL (USSU)   VIOLA F J,  ALESI T W,  GEISTE R J,  WILSON J,  MASTRI D L;  US6045560-A   US SURGICAL CORP (USSU)   HAIN M,  MCKEAN W L,  KOYFMAN I S;  US6063097-A   GUNZE LTD (GNZE)   OI S,  OHSHIMA H;  US6080169-A   TURTEL L (TURT-Individual)   TURTEL L;  US6099551-A   SHELHIGH INC (SHEL-Non-standard)   GABBAY S;  US6149667-A   HOVLAND C T (HOVL-Individual);  ABRAMS J H (ABRA-Individual)   HOVLAND C T,  ABRAMS J H;  US6152943-A   INCEPT LLC (INPT)   SAWHNEY A S,  SPIRIDIGLIOZZI J;  US6155265-A   HEMODYNAMICS INC (HEMO-Non-standard)   HAMMERSLAG J G;  US6162241-A   FOCAL INC (FOCA-Non-standard)   JARRETT P K,  SAWHNEY A,  COURY A J,  RUDOWSKY R S,  POWELL M D,  AVILA L Z,  ENSCORE D J,  GOODRICH S D,  NASON W C,  YAO F,  WEAVER D,  BARMAN S P;  US6165201-A   INCEPT LLC (INPT)   SAWHNEY A S,  CAMPBELL P K,  MELANSON D A;  US20020016626-A1   ;  US20020019187-A1   ;  US20020028243-A1   ;  US20020052622-A1   ;  US20020091397-A1   ;  US20020106409-A1   ;  US20020133236-A1   ;  US20020138152-A1   ;  US20020151911-A1   ;  US20020165559-A1   ;  US20020165562-A1   ;  US20020165563-A1   ;  US20020169476-A1   ;  US20020177859-A1   ;  US20030031697-A1   ;  US20030035786-A1   ;  US20030065345-A1   ;  US20030065346-A1   ;  US20030073663-A1   ;  US20030083676-A1   ;  US20030088256-A1   ;  US20030105510-A1   ;  US20030114866-A1   ;  US20030120284-A1   ;  US20030167064-A1   ;  US20030181927-A1   ;  US20030183671-A1   ;  US20030208231-A1   ;  US20040001879-A1   ;  US20040023842-A1   ;  US20040034377-A1   ;  US20040092960-A1   ;  US20040093029-A1   ;  US20040101546-A1   ;  US20040107006-A1   ;  US20040116945-A1   ;  US20040142621-A1   ;  US20040172048-A1   ;  US20040191277-A1   ;  US20040209059-A1   ;  US20040215214-A1   ;  US20040215219-A1   ;  US20040215221-A1   ;  US20040254590-A1   ;  US20040260315-A1   ;  US20040265371-A1   ;  US20050002981-A1   ;  US20050021026-A1   ;  US20050021053-A1   ;  US20050021085-A1   ;  US20050059996-A1   ;  US20050059997-A1   ;  US20050070929-A1   ;  US20050118435-A1   ;  US20050143756-A1   ;  US20050149073-A1   ;  US20050228446-A1   ;  US20050245965-A1   ;  US20060004407-A1   ;  US20060034930-A1   ;  US20060069337-A1   ;  US20060085034-A1   ;  US20060135992-A1   ;  US20060159733-A1   ;  US20060173470-A1   ;  US20060178683-A1   ;  US20060212050-A1   ;  US20060233869-A1   ;  US20060271104-A1   ;  US20070014862-A1   ;  US20070026031-A1   ;  US20070034669-A1   ;  US20070123817-A1   ;  US20070123839-A1   ;  US20070179528-A1   ;  US20070190110-A1   ;  US20070203509-A1   ;  US20070203510-A1   ;  US20070246505-A1   ;  US20070275073-A1   ;  US20080027365-A1   ;  US20080029570-A1   ;  US20080082126-A1   ;  US20080110959-A1   ;  US20080125812-A1   ;  US20080139694-A1   ;  US20080140115-A1   ;  US20080160051-A1   ;  US20080161831-A1   ;  US20080161832-A1   ;  US20080169327-A1   ;  US20080169328-A1   ;  US20080169329-A1   ;  US20080169330-A1   ;  US20080169331-A1   ;  US20080169332-A1   ;  US20080169333-A1   ;  US20080194805-A1   ;  US20080200949-A1   ;  US20080290134-A1   ;  US20080308608-A1   ;  US20080314960-A1   ;  US20090001121-A1   ;  US20090001122-A1   ;  US20090001123-A1   ;  US20090001124-A1   ;  US20090001125-A1   ;  US20090001126-A1   ;  US20090001128-A1   ;  US20090001130-A1   ;  US20090005808-A1   ;  US20090030452-A1   ;  US20090043334-A1   ;  US20090076510-A1   ;  US20090076528-A1   ;  US20090078739-A1   ;  US20090095791-A1   ;  US20090095792-A1   ;  US20090117070-A1   ;  US20090120994-A1   ;  US20090134200-A1   ;  US20090206125-A1   ;  US20090206126-A1   ;  US20090206139-A1   ;  US20090206141-A1   ;  US20090206142-A1   ;  US20090206143-A1   ;  US20090218384-A1   ;  US20090277947-A1   ;  US20090287230-A1   ;  US20100012704-A1   ;  US20100065606-A1   ;  US20100065607-A1   ;  US20100072254-A1   ;  US20100087840-A1   ;  US20100147921-A1   ;  US20100147922-A1   ;  US20100147923-A1   ;  US20100243707-A1   ;  US20100243708-A1   ;  US20100243711-A1   ;  US20100249805-A1   ;  US20100264195-A1   ;  US20100282815-A1   ;  US20100285088-A1   ;  US20110024476-A1   ;  US20110024481-A1   ;  US20110036894-A1   ;  US20110042442-A1   ;  US20110046650-A1   ;  US20110057016-A1   ;  US20110087279-A1   ;  US20110215132-A1   ;  US20120074199-A1   ;  US20120080336-A1   ;  US20120241499-A1   ;  US20120273547-A1   ;  US20130037596-A1   ;  US20130105548-A1   ;  US20130105553-A1   ;  US20130112732-A1   ;  US20130112733-A1   ;  US20130146641-A1   ;  US20130153633-A1   ;  US20130153634-A1   ;  US20130153635-A1   ;  US20130153636-A1   ;  US20130153638-A1   ;  US20130153639-A1   ;  US20130153640-A1   ;  US20130153641-A1   ;  US20130161374-A1   ;  US20130181031-A1   ;  US20130193186-A1   ;  US20130193190-A1   ;  US20130193191-A1   ;  US20130193192-A1   ;  US20130209659-A1   ;  US20130221062-A1   ;  US20130240600-A1   ;  US20130240601-A1   ;  US20130240602-A1   ;  US20130277411-A1   ;  US20130306707-A1   ;  US20130310873-A1   ;  US20130327807-A1   ;  US20140012317-A1   ;  US20140021242-A1   ;  US20140027490-A1   ;  US20140034704-A1   ;  US20140048580-A1   ;  US20140061280-A1   ;  US20140061281-A1   ;  US20140084042-A1   ;  US20140097224-A1   ;  US20140117066-A1   ;  US20140130330-A1   ;  US20140131418-A1   ;  US20140131419-A1   ;  US20140138423-A1   ;  US20140151431-A1   ;  US20140155916-A1   ;  US20140158742-A1   ;  US20140166721-A1   ;  US20140197224-A1   ;  US20140203061-A1   ;  US20140217147-A1   ;  US20140217148-A1   ;  US20140239046-A1   ;  US20140239047-A1   ;  US20070049953-A2   ;  US6179862-B1   INCEPT LLC (INPT)   SAWHNEY A S,  CAMPBELL P K,  MELANSON D A;  US6210439-B1   ETHNOR SA (ETHN-Non-standard)   FIRMIN F,  ARNAUD A;  US6214020-B1   BARD INC C R (BRDC)   MULHAUSER P J,  DICESARE P C;  US6241139-B1   MILLIMAN K L (MILL-Individual);  VIOLA F J (VIOL-Individual);  ORBAN J (ORBA-Individual);  LEHN R F (LEHN-Individual)   MILLIMAN K L,  VIOLA F J,  ORBAN J,  LEHN R F;  US6258107-B1   DLR DEUT ZENT LUFT & RAUMFAHRT EV (DELF)   BALAZS M,  HAGN U;  US6267772-B1   BARD INC C R (BRDC)   MULHAUSER P J,  DICESARE P C;  US6273897-B1   ETHICON INC (ETHI)   DALESSANDRO D A,  VYAKARNAM M N;  US6280453-B1   BARD ASDI INC (BARD-Non-standard)   KUGEL R D,  INMAN J D,  BIGGERS K D;  US6299631-B1   POLY-MED INC (PMED)   SHALABY S W;  US6312457-B1   BOSTON SCI CORP (BSCI)   DIMATTEO K,  RAVENSCROFT A;  US6312474-B1   BIO-VASCULAR INC (BIOV-Non-standard)   FRANCIS R T,  ZHAO Q H,  DESMITH A,  ORAY B N;  US6325810-B1   ETHICON INC (ETHI)   HAMILTON L,  BEZWADA R S,  ROLLER M B,  VYAKARNAM M N,  DALESSANDRO D A,  ROSENBLATT J S,  KATARIA R L,  SAFERSTEIN L G,  MARTIN J F;  US6376742-B1   ZDRAHALA R J (ZDRA-Individual);  ZDRAHALA I J (ZDRA-Individual)   ZDRAHALA R J,  ZDRAHALA I J;  US6454780-B1   SCIMED LIFE SYSTEMS INC (BSCI)   WALLACE M P;  US6500777-B1   JOHNSON & JOHNSON MEDICAL INC (JOHJ)   WISEMAN D M,  SAFERSTEIN L,  WOLF S;  US6514534-B1   INCEPT LLC (INPT)   SAWHNEY A S;  US6517566-B1   SURGICAL CONNECTIONS INC (SURG-Non-standard)   HOVLAND C T,  ABRAMS J H,  ROBINSON P J;  US6566406-B1   PATHAK C P (PATH-Individual)   PATHAK C P,  SAWHNEY A S,  EDELMAN P G;  US6669735-B1   PELISSIER E (PELI-Individual)   PELISSIER E;  US6673093-B1   INCEPT LLC (INPT)   SAWHNEY A S,  CAMPBELL P K,  MELANSON D A;  US6704210-B1   SHARP KK (SHAF)   TAGUCHI T;  US6746458-B1   CLOUD W G M D (CLOU-Individual)   CLOUD W G M D;  US6773458-B1   BAXTER INT INC (BAXT)   BRAUKER J H,  HILL R S,  JOHNSON R C,  MARTINSON L A,  JOHNSTON W D;  US6818018-B1   INCEPT LLC (INPT)   SAWHNEY A S;  US6927315-B1   3M INNOVATIVE PROPERTIES CO (MINN)   HEINECKE S B,  MENZIES R H,  BISBEE K M,  NORQUIST S G;  US7438209-B1   ETHICON ENDO-SURGERY INC (ETHI)   HESS C J,  WEISENBURGH W B;  US6358532-B2   CAP BIOTECHNOLOGY INC (CAPB-Non-standard)   STARLING L B,  STEPHAN J E;  US6436030-B2   REHIL O P (REHI-Individual)   REHIL O P;  US6461368-B2   FOGARTY T J (FOGA-Individual);  HERMANN G D (HERM-Individual);  WHITTEMORE J A (WHIT-Individual);  HOWELL T A (HOWE-Individual)   FOGARTY T J,  HERMANN G D,  WHITTEMORE J A,  HOWELL T A;  US6503257-B2   GRANT R L (GRAN-Individual);  PATEL S B (PATE-Individual);  MCMILLEN T A (MCMI-Individual)   GRANT R L,  PATEL S B,  MCMILLEN T A;  US6514283-B2   BOSTON SCI CORP (BSCI)   DIMATTEO K,  RAVENSCROFT A;  US6551356-B2   ETHICON INC (ETHI)   ROUSSEAU R A;  US6592597-B2   GRANT R L (GRAN-Individual);  DALESSANDRO D A (DALE-Individual)   GRANT R L,  DALESSANDRO D A;  US6605294-B2   SAWHNEY A S (SAWH-Individual)   SAWHNEY A S;  US6638285-B2   GABBAY S (GABB-Individual)   GABBAY S;  US6652594-B2   BIO-VASCULAR INC (BIOV-Non-standard)   FRANCIS R T,  ZHAO Q H,  DESMITH A,  ORAY B N;  US6656193-B2   GRANT R L (GRAN-Individual);  ZEINER M S (ZEIN-Individual);  HUEIL G (HUEI-Individual);  WALES K (WALE-Individual);  GARNER D L (GARN-Individual)   GRANT R L,  ZEINER M S,  HUEIL G,  WALES K,  GARNER D L;  US6677258-B2   DU PONT DE NEMOURS & CO E I (DUPO);  PROCTER & GAMBLE CO (PROC)   CARROLL N L,  LIM H S,  OSTAPCHENKO G J,  VAIDYA S R,  MCKENNA J M,  CURRO J J,  LAVON G D,  SPARKS R L;  US6685714-B2   ETHICON INC (ETHI)   ROUSSEAU R A;  US6703047-B2   SAWHNEY A S (SAWH-Individual);  EDELMAN P G (EDEL-Individual)   SAWHNEY A S,  EDELMAN P G;  US6723114-B2   SHALABY S W (SHAL-Individual)   SHALABY S W;  US6726706-B2   DOMINGUEZ S (DOMI-Individual)   DOMINGUEZ S;  US6736823-B2   DAROIS R E (DARO-Individual);  ELDRIDGE S N (ELDR-Individual);  LEE M J (LEEM-Individual)   DAROIS R E,  ELDRIDGE S N,  LEE M J;  US6736854-B2   VADURRO V (VADU-Individual);  DAROIS R E (DARO-Individual);  ELDRIDGE S N (ELDR-Individual);  LEE M J (LEEM-Individual)   VADURRO V,  DAROIS R E,  ELDRIDGE S N,  LEE M J;  US6800753-B2   UNIV IOWA RES FOUND (IOWA)   KUMAR V;  US6833408-B2   COHESION TECHNOLOGIES INC (COHE-Non-standard)   SEHL L C,  TROLLSAS O M,  WALLACE D G,  TOMAN D,  DELUSTRO F A,  SCHROEDER J A,  CHU G H;  US6936005-B2   ;  US6969400-B2   RHEE W M (RHEE-Individual);  DELUSTRO F A (DELU-Individual);  BERG R A (BERG-Individual)   RHEE W M,  DELUSTRO F A,  BERG R A;  US7009034-B2   PATHAK C P (PATH-Individual)   PATHAK C P,  SAWHNEY A S,  EDELMAN P G;  US7052713-B2   NYCOMED PHARMA AS (NYCO)   SCHAUFLER A;  US7128748-B2   MOORADIAN D L (MOOR-Individual);  ORAY B N (ORAY-Individual)   MOORADIAN D L,  ORAY B N;  US7147138-B2   ETHICON ENDO-SURGERY INC (ETHI)   SHELTON F E;  US7176256-B2   RHEE W M (RHEE-Individual);  DELUSTRO F A (DELU-Individual);  BERG R A (BERG-Individual)   RHEE W M,  DELUSTRO F A,  BERG R A;  US7347850-B2   SAWHNEY A S (SAWH-Individual)   SAWHNEY A S;  US7434717-B2   SHELTON F E (SHEL-Individual);  MORGAN J R (MORG-Individual)   SHELTON F E,  MORGAN J R;  US7547312-B2   BAUMAN A M (BAUM-Individual);  BROYLES S E (BROY-Individual);  CRAWLEY J M (CRAW-Individual);  DAUGHERTY J R (DAUG-Individual);  PIH N (PIHN-Individual)   BAUMAN A M,  BROYLES S E,  CRAWLEY J M,  DAUGHERTY J R,  PIH N;  US7559937-B2   TOWERTECH RES GROUP (TOWE-Non-standard)   DE LA TORRE R A,  LACONTE M P;  US7604151-B2   HESS C J (HESS-Individual);  WEISENBURGH W B (WEIS-Individual)   HESS C J,  WEISENBURGH W B;  US7665646-B2   PROMMERSBERGER M L (PROM-Individual)   PROMMERSBERGER M L;  US7717313-B2   CRISCUOLO C J (CRIS-Individual);  BETTUCHI M J (BETT-Individual)   CRISCUOLO C J,  BETTUCHI M J;  US7722642-B2   CARDVIOVASCULAR TECHNOLOGIES LLC (CARD-Non-standard)   WILLIAMSON W P,  SPENCE P A,  KELLER G A,  ROBINSON C R,  WARD T J;  US7744627-B2   TYCO HEALTHCARE GROUP LP (COVI)   ORBAN J P,  NOLAN T;  US7776060-B2   ;  US7793813-B2   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M J;  US7799026-B2   SCHECHTER D A (SCHE-Individual);  JOHNSON K D (JOHN-Individual)   SCHECHTER D A,  JOHNSON K D;  US7823592-B2   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M,  FOWLER D N,  VIOLA F J,  CRISCUOLO C J,  TARINELLI D J,  CAPELLA R,  SNIFFIN K,  HADBA A R;  US7845533-B2   MARCZYK S (MARC-Individual);  PROMMERSBERGER M (PROM-Individual);  NENTWICK B (NENT-Individual)   MARCZYK S,  PROMMERSBERGER M,  NENTWICK B;  US7845536-B2   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M,  FOWLER D N,  VIOLA F J,  CRISCUOLO C J,  TARINELLI D J,  CAPELLA R,  SNIFFIN K,  HADBA A R;  US7846149-B2   TYCO HEALTHCARE GROUP LP (COVI)   JANKOWSKI B;  US7909224-B2   TYCO HEALTHCARE GROUP LP (COVI)   PROMMERSBERGER M L;  US7950561-B2   ARANYI E (ARAN-Individual)   ARANYI E;  US7951166-B2   TYCO HEALTHCARE GROUP LP (COVI)   ORBAN J P,  NOLAN T;  US7967179-B2   OLSON L (OLSO-Individual);  ARANYI E (ARAN-Individual);  MOZDZIERZ P (MOZD-Individual)   OLSON L,  ARANYI E,  MOZDZIERZ P;  US7988027-B2   OLSON L (OLSO-Individual);  ARANYI E (ARAN-Individual);  MOZDZIERZ P (MOZD-Individual)   OLSON L,  ARANYI E,  MOZDZIERZ P;  US8011550-B2   TYCO HEALTHCARE GROUP LP (COVI)   TARINELLI D,  ARANYI E,  SIMPSON R;  US8016177-B2   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M,  NENTWICK B;  US8016178-B2   OLSON L (OLSO-Individual);  ARANYI E (ARAN-Individual);  MOZDZIERZ P (MOZD-Individual)   OLSON L,  ARANYI E,  MOZDZIERZ P;  US8028883-B2   TYCO HEALTHCARE GROUP LP (COVI)   STOPEK M L;  US8062330-B2   PROMMERSBERGER M (PROM-Individual);  NENTWICK B (NENT-Individual);  GRAVAGNA P (GRAV-Individual);  BAYON Y (BAYO-Individual);  DASSONVILLE D (DASS-Individual);  MENEGHIN A (MENE-Individual);  LECUIVRE J (LECU-Individual)   PROMMERSBERGER M,  NENTWICK B,  GRAVAGNA P,  BAYON Y,  DASSONVILLE D,  MENEGHIN A,  LECUIVRE J;  US8083119-B2   PROMMERSBERGER M L (PROM-Individual)   PROMMERSBERGER M L;  US8123766-B2   BAUMAN A M (BAUM-Individual);  BROYLES S E (BROY-Individual);  CRAWLEY J M (CRAW-Individual);  DAUGHERTY J R (DAUG-Individual);  PIH N (PIHN-Individual)   BAUMAN A M,  BROYLES S E,  CRAWLEY J M,  DAUGHERTY J R,  PIH N;  US8123767-B2   BAUMAN A M (BAUM-Individual);  BROYLES S E (BROY-Individual);  CRAWLEY J M (CRAW-Individual);  DAUGHERTY J R (DAUG-Individual);  PIH N (PIHN-Individual)   BAUMAN A M,  BROYLES S E,  CRAWLEY J M,  DAUGHERTY J R,  PIH N;  US8146791-B2   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M,  FOWLER D N,  VIOLA F J,  CRISCUOLO C J,  TARINELLI D J,  CAPELLA R,  SNIFFIN K,  HADBA A R;  US8157149-B2   TYCO HEALTHCARE GROUP LP (COVI)   OLSON L,  ARANYI E,  MOZDZIERZ P;  US8157151-B2   TYCO HEALTHCARE GROUP LP (COVI)   INGMANSON M D,  SHAH S,  MCNELLIS J;  US8167895-B2   TYCO HEALTHCARE GROUP LP (COVI)   DAGOSTINO W L,  BETTUCHI M,  D'AGOSTINO W L;  US8192460-B2   TYCO HEALTHCARE GROUP LP (COVI)   ORBAN J P,  NOLAN T;  US8210414-B2   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M,  NENTWICK B;  US8225799-B2   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M;  US8225981-B2   TYCO HEALTHCARE GROUP LP (COVI)   CRISCUOLO C J,  BETTUCHI M J;  US8231043-B2   TYCO HEALTHCARE GROUP LP (COVI)   TARINELLI D,  ARANYI E,  SIMPSON R;  US8235273-B2   TYCO HEALTHCARE GROUP LP (COVI)   OLSON L,  ARANYI E,  MOZDZIERZ P;  US8245901-B2   TYCO HEALTHCARE GROUP LP (COVI)   STOPEK M L;  US8256654-B2   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M,  NENTWICK B;  US8257391-B2   TYCO HEALTHCARE GROUP LP (COVI)   ORBAN J P,  NOLAN T;  US8276800-B2   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M;  US8286849-B2   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M J;  US8308042-B2   TYCO HEALTHCARE GROUP LP (COVI)   ARANYI E;  US8308045-B2   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M;  US8308046-B2   TYCO HEALTHCARE GROUP LP (COVI)   PROMMERSBERGER M L;  US8312885-B2   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M,  FOWLER D N,  VIOLA F J,  CRISCUOLO C J,  TARINELLI D J,  CAPELLA R,  SNIFFIN K,  HADBA A R;  US8313014-B2   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M;  US8348126-B2   TYCO HEALTHCARE GROUP LP (COVI)   OLSON L,  ARANYI E,  MOZDZIERZ P;  US8348130-B2   TYCO HEALTHCARE GROUP LP (COVI)   SHAH S,  SIMPSON R;  US8365972-B2   ARANYI E (ARAN-Individual);  MOZDZIERZ P (MOZD-Individual);  OLSON L (OLSO-Individual);  SHAH S (SHAH-Individual);  GOLEBIESKI K (GOLE-Individual);  SIMPSON R (SIMP-Individual);  GADDY A (GADD-Individual)   ARANYI E,  MOZDZIERZ P,  OLSON L,  SHAH S,  GOLEBIESKI K,  SIMPSON R,  GADDY A;  US8371491-B2   ETHICON ENDO-SURGERY INC (ETHI)   HUITEMA T W,  MORGAN J R,  SHELTON I,  SWAYZE J S;  US8371492-B2   TYCO HEALTHCARE GROUP LP (COVI)   TARINELLI D,  ARANYI E,  SIMPSON R;  US8371493-B2   TYCO HEALTHCARE GROUP LP (COVI)   TARINELLI D,  ARANYI E,  SIMPSON R;  US8393514-B2   ETHICON ENDO-SURGERY INC (ETHI)   SHELTON F E,  KNIGHT G W,  BAXTER C O,  AVIMUKTA K B;  US8408440-B2   TYCO HEALTHCARE GROUP LP (COVI)   OLSON L,  ARANYI E,  MOZDZIERZ P;  US8413871-B2   TYCO HEALTHCARE GROUP LP (COVI)   TARINELLI D,  ARANYI E,  SIMPSON R;  US8424742-B2   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M;  US8453652-B2   TYCO HEALTHCARE GROUP LP (COVI)   STOPEK M L;  US8453904-B2   GORE ENTERPRISE HOLDINGS INC (GORE)   DIPIETRO J J,  ESKAROS S,  RUSSELL M J,  WINTERLING M;  US8453909-B2   TYCO HEALTHCARE GROUP LP (COVI)   OLSON L,  ARANYI E,  MOZDZIERZ P;  US8453910-B2   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M,  NENTWICK B;  US8464925-B2   ETHICON ENDO-SURGERY INC (ETHI)   HULL J,  HABERSTICH W D,  HALL S G,  HIBNER J A,  CARTER Y F,  HWANG J J,  SHELTON F E,  SCHULTE J B,  MOLLERE R J,  DUGAN P D,  CRONIN M D,  MORGAN J R;  US8474677-B2   ETHICON ENDO-SURGERY INC (ETHI)   WOODARD J A,  SCHEIB C J,  BOUDREAUX C P,  BRUEWER D B,  SCHWEMBERGER R F,  SCHALL C J,  MORGAN J R,  SIMMS R J,  DOLL K R,  SWAYZE J S,  OUWERKERK J N;  US8479968-B2   TYCO HEALTHCARE GROUP LP (COVI)   HODGKINSON G,  CARTER S;  US8485414-B2   TYCO HEALTHCARE GROUP LP (COVI)   CRISCUOLO C J,  BETTUCHI M J;  US8496683-B2   TYCO HEALTHCARE GROUP LP (COVI)   PROMMERSBERGER M,  NENTWICK B,  GRAVAGNA P,  BAYON Y,  DASSONVILLE D,  MENEGHIN A,  LECUIVRE J;  US8511533-B2   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M,  FOWLER D N,  VIOLA F J,  CRISCUOLO C J,  TARINELLI D J,  CAPELLA R,  SNIFFIN K,  HADBA A R;  US8512402-B2   TYCO HEALTHCARE GROUP LP (COVI)   MARCZYK S,  PROMMERSBERGER M,  NENTWICK B;  US8529600-B2   ETHICON ENDO-SURGERY INC (ETHI)   WOODARD J A,  SCHEIB C J,  BOUDREAUX C P,  BRUEWER D B,  SCHWEMBERGER R F,  SCHALL C J,  MORGAN J R,  SIMMS R J,  SIEBENALER D J,  SWAYZE J S,  OUWERKERK J N;  US8540131-B2   ETHICON ENDO-SURGERY INC (ETHI)   SWAYZE J S;  US8551138-B2   TYCO HEALTHCARE GROUP LP (COVI)   ORBAN J P,  NOLAN T;  US8556918-B2   BAUMAN A M (BAUM-Individual);  BROYLES S E (BROY-Individual);  CRAWLEY J M (CRAW-Individual);  DAUGHERTY J R (DAUG-Individual);  PIH N (PIHN-Individual)   BAUMAN A M,  BROYLES S E,  CRAWLEY J M,  DAUGHERTY J R,  PIH N;  US8561873-B2   TYCO HEALTHCARE GROUP LP (COVI)   INGMANSON M D,  SHAH S,  MCNELLIS J;  US8584920-B2   TYCO HEALTHCARE GROUP LP (COVI)   HODGKINSON G;  US8590762-B2   HESS C J (HESS-Individual);  WELLS L E (WELL-Individual);  WEISENBURGH W B (WEIS-Individual)   HESS C J,  WELLS L E,  WEISENBURGH W B;  US8616430-B2   COVIDIEN LP (COVI)   P S M;  US8631989-B2   COVIDIEN LP (COVI)   ARANYI E,  MOZDZIERZ P,  OLSON L;  US8668129-B2   TYCO HEALTHCARE GROUP LP (COVI)   OLSON L;  US8684250-B2   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M,  FOWLER D N,  VIOLA F J,  CRISCUOLO C J,  TARINELLI D J,  CAPELLA R,  SNIFFIN K,  HADBA A R;  US8757466-B2   COVIDIEN LP (COVI)   OLSON L,  ARANYI E,  MOZDZIERZ P;  US8789737-B2   TYCO HEALTHCARE GROUP LP (COVI)   HODGKINSON G N,  STEVENSON R,  WHIFFEN J;  US8820606-B2   COVIDIEN LP (COVI)   HODGKINSON G;  US34742-E   EASTMAN KODAK CO (EAST)   MAIER L K,  PRIEBE E K,  LEE J S,  WOODGATE P E,  SMITH G C;  WO1990005489-A   ;  WO1994003155-A1   ;  WO1995016221-A1   ;  WO1997013463-A1   ;  WO1998017180-A1   ;  WO1999045849-A1   ;  WO2003082126-A1   MOORADIAN D L (MOOR-Individual);  ORAY B N (ORAY-Individual)   MOORADIAN D L,  ORAY B N;  WO2003094743-A1   TYCO HEALTHCARE GROUP LP (COVI)   VIOLA F J;  WO2006083748-A1   ORAY B N (ORAY-Individual);  MOORADIAN D L (MOOR-Individual)   ORAY B N,  MOORADIAN D L;  WO2008109125-A1   TYCO HEALTHCARE GROUP LP (COVI)   TARINELLI D,  ARANYI E,  SIMPSON R;  WO2012044848-A1   ETHICON ENDO-SURGERY INC (ETHI)   WOODARD J A,  SCHEIB C J,  BOUDREAUX C P,  BRUEWER D B,  SCHWEMBERGER R F,  SCHALL C J,  MORGAN J R,  SIMMS R J,  SIEBENALER D J,  SWAYZE J S,  OUWERKERK J N;  WO2003105698-A2   TYCO HEALTHCARE GROUP LP (COVI)   ORBAN J P,  NOLAN T;  WO2006023578-A2   TYCO HEALTHCARE GROUP LP (COVI)   STOPEK J B;  WO2006044490-A2   TYCO HEALTHCARE GROUP LP (COVI)   BETTUCHI M,  FOWLER D N,  VIOLA F J,  CRISCUOLO C J,  TARINELLI D J,  CAPELLA R,  SNIFFIN K,  HADBA A R;  WO2008057281-A2   TYCO HEALTHCARE GROUP LP (COVI)   STOPEK M L;  WO2010043980-A2   SOFRADIM PRODN (ADIM)   BAYON Y,  LADET S;  WO2010075298-A2   SURMODICS PHARM INC (SURM)   BIGGS D,  BOWMAN H,  BURTON K W,  MARKLAND P,  TICE T R,  TIPTON A J;  WO2011143183-A2   ETHICON ENDO-SURGERY INC (ETHI)   SCHULTE J B,  MOLLERE R J,  DUGAN P D,  CRONIN M D,  MORGAN J R,  MORGAN S K,  MCALISTER G B,  WIDENHOUSE T S V,  BALEK S J,  SCHOWALTER J P,  WITT D A,  MALAVIYA P,  SHELTON F E;  WO2003088845-A3   TYCO HEALTHCARE GROUP LP (COVI)   HEINRICH R;  WO2005079675-A3   COOK BIOTECH INC (COKC)   HILES M C,  PATEL U,  SHAH B,  MCALEXANDER C S;  EP2481359-B1 -- EP1702570-A1   TYCO HEALTHCARE GROUP LP (COVI)   DAGOSTINO W L,  BETTUCHI M,  D'AGOSTINO W L;  EP1815804-A2   SOLTZ M A (SOLT-Individual);  PROMMERSBERGER M L (PROM-Individual);  STOPEK J (STOP-Individual)   SOLTZ M A,  PROMMERSBERGER M L,  STOPEK J;  EP2008595-A3   PROMMERSBERGER M (PROM-Individual);  NENTWICK B (NENT-Individual);  GRAVAGNA P (GRAV-Individual);  BAYON Y (BAYO-Individual);  DASSONVILLE D (DASS-Individual);  MENEGHIN A (MENE-Individual);  LECUIVRE J (LECU-Individual)   PROMMERSBERGER M,  NENTWICK B,  GRAVAGNA P,  BAYON Y,  DASSONVILLE D,  MENEGHIN A,  LECUIVRE J;  US5915616-A   US SURGICAL CORP (USSU)   ROBERTSON J C,  VIOLA F J;  US20060173470-A1   ;  US20090001122-A1   ;  US6241139-B1   MILLIMAN K L (MILL-Individual);  VIOLA F J (VIOL-Individual);  ORBAN J (ORBA-Individual);  LEHN R F (LEHN-Individual)   MILLIMAN K L,  VIOLA F J,  ORBAN J,  LEHN R F;  US6330965-B1   US SURGICAL CORP (USSU)   MILLIMAN K L,  VIOLA F J,  ORBAN J,  LEHN R F;  WO2006023578-A3   TYCO HEALTHCARE GROUP LP (COVI)   STOPEK J B","US9084602-B2            International Search Report corresponding to European          Application No. EP 12 15 2229.6, completed on Feb. 23,          2012 and mailed on Mar. 1, 2012; 4 pages.;            International Search Report corresponding to European          Application No. EP 12 15 0511.9, completed on Apr. 16,          2012 and mailed on Apr. 24, 2012; 7 pages.;            International Search Report corresponding to European          Application No. EP 12 16 5609.4, completed on Jul. 5,          2012 and mailed on Jul. 13, 2012; 8 pages.;            International Search Report corresponding to European          Application No. EP 12 15 8861.0, completed on Jul. 17,          2012 and mailed on Jul. 24, 2012; 9 pages.;            International Search Report corresponding to European          Application No. EP 12 16 5878.5, completed on Jul. 24,          2012 and mailed on Aug. 6, 2012; 8 pages.;            European Search Report corresponding to European          Application No. EP 06 00 4598, completed on Jun. 22,          2006; 2 pages.;            European Search Report corresponding to European          Application No. EP 06 01 6962.0, completed on Jan. 3,          2007 and mailed on Jan. 11, 2007; 10 pages.;            International Search Report corresponding to          International Application No. PCT/US05/36740, completed          on Feb. 20, 2007 and mailed on Mar. 23, 2007; 8          pages.;            International Search Report corresponding to          International Application No. PCT/US2008/002981,          completed on Jun. 9, 2008 and mailed on Jun. 26, 2008; 2          pages.;            European Search Report corresponding to European          Application No. EP 08 25 1779, completed on Jul. 14, 2008          and mailed on Jul. 23, 2008; 5 pages.;            European Search Report corresponding to European          Application No. EP 08 25 1989.3, completed on Mar. 11,          2010 and mailed on Mar. 24, 2010; 3 pages.;            European Search Report corresponding to European          Application No. EP 05 80 4382.9, completed on Oct. 5,          2010 and mailed on Oct. 12, 2010; 3 pages.;            European Search Report corresponding to European          Application No. EP 10 25 1437.9, completed on Nov. 22,          2010 and mailed on Dec. 16, 2010; 3 pages.;            European Search Report issued in European Patent          Application No. EP 09 252 417.2 mailed on Dec. 10, 2010          (3 pages).;            European Search Report issued in European Patent          Application No. EP 09 252 421.4 mailed on Dec. 10, 2010          (3 pages).;            European Search Report corresponding to European          Application No. EP 09 25 2897.5, completed on Feb. 7,          2011 and mailed on Feb. 15, 2011; 3 pages.;            European Search Report for EP 12152541.4-1269 date of          completion is Apr. 23, 2012 (10 pages).;            Extended European Search Report corresponding to EP No.          12 19 1035.0, completed Jan. 11, 2013 and mailed Jan. 18,          2013; 7 pages.;            Extended European Search Report corresponding to EP No.          12 18 6175.1, completed Jan. 15, 2013 and mailed Jan. 23,          2013; 7 pages.;            Extended European Search Report corresponding to EP No.          12 19 1114.3, completed Jan. 23, 2013 and mailed Jan. 31,          2013; 10 pages.;            Extended European Search Report corresponding to EP No.          12 19 2224.9, completed Mar. 14, 2013 and mailed Mar. 26,          2013; 8 pages.;            Extended European Search Report corresponding to EP No.          12 19 6911.7, completed Apr. 18, 2013 and mailed Apr. 24,          2013; 8 pages.;            Extended European Search Report corresponding to EP 12 19          1035.0, completed Jan. 11, 2013 and mailed Jan. 18, 2013;          7 pages.;            Extended European Search Report corresponding to EP 12 19          6904.2; completed Mar. 28, 2013 and mailed Jul. 26, 2013;          8 pages.;            Extended European Search Report corresponding to EP 12 19          8749.9, completed May 21, 2013 and mailed May 31, 2013; 8          pages.;            Extended European Search Report corresponding to EP 07 00          5842.5, completed May 13, 2013 and mailed May 29, 2013; 7          pages.;            Extended European Search Report corresponding to EP 12 19          8776.2, completed May 16, 2013 and mailed May 27, 2013; 8          pages.;            Extended European Search Report corresponding to EP 13 15          6297.7, completed Jun. 4, 2013 and mailed Jun. 13, 2013;          7 pages.;            Extended European Search Report corresponding to EP 13 17          3985.6, completed Aug. 19, 2013 and mailed Aug. 28, 2013;          6 pages.;            Extended European Search Report corresponding to EP 13 17          3986.4, completed Aug. 20, 2013 and mailed Aug. 29, 2013;          7 pages.;            Extended European Search Report corresponding to EP 13 17          7437.4, completed Sep. 11, 2013 and mailed Sep. 19, 2013;          (6 pp).;            Extended European Search Report corresponding to EP 13 17          7441.6, completed Sep. 11, 2013 and mailed Sep. 19, 2013;          (6 pp).;            Extended European Search Report corresponding to EP 07 86          1534.1, completed Sep. 20, 2013 and mailed Sep. 30, 2013;          (5 pp).;            Extended European Search Report corresponding to EP 13 18          3876.5, completed Oct. 14, 2013 and mailed Oct. 24, 2013;          (5 pp).;            Extended European Search Report corresponding to EP 13 17          1856.1, completed Oct. 29, 2013 and mailed Nov. 7, 2013;          (8 pp).;            Extended European Search Report corresponding to EP 13 18          0373.6, completed Oct. 31, 2013 and mailed Nov. 13, 2013;          (7 pp).;            Extended European Search Report corresponding to EP 13 18          0881.8, completed Nov. 5, 2013 and mailed Nov. 14, 2013;          (6 pp).;            Extended European Search Report corresponding to EP 13 17          6895.4, completed Nov. 29, 2013 and mailed Dec. 12, 2013;          (5 pp).;            Extended European Search Report corresponding to EP 13 18          2911.1, completed Dec. 2, 2013 and mailed Dec. 16, 2013;          (8 pp).;            Extended European Search Report corresponding to EP 10 25          1795.0, completed Dec. 11, 2013 and mailed Dec. 20, 2013;          (6 pp).;            Extended European Search Report corresponding to EP 13 18          7911.6, completed Jan. 22, 2014 and mailed Jan. 31, 2014;          (8 pp).;            Extended European Search Report corresponding to EP 08 72          6500.5, completed Feb. 20, 2014 and mailed Mar. 3, 2014;          (7 pp).;            Extended European Search Report corresponding to EP 13 19          5919.9, completed Feb. 10, 2014 and mailed Mar. 3, 2014;          (7 pp).;            Extended European Search Report corresponding to EP 13 19          2123.1, completed Jan. 30, 2014 and mailed Feb. 10, 2014;          (8 pp).;            Extended European Search Report corresponding to EP 13 19          6816.6, completed Mar. 28, 2014 and mailed Apr. 9, 2014;          (9 pp).;            Extended European Search Report corresponding to EP 13 19          4995.0, completed Jun. 5, 2014 and mailed Jun. 16, 2014;          (5 pp).;            Extended European Search Report corresponding to EP 13 19          5019.8, completed Mar. 14, 2014 and mailed Mar. 24, 2014;          (7 pp).;            Extended European Search Report corresponding to EP 13 19          2111.6, completed Feb. 13, 2014 and mailed Feb. 27, 2014;          (10 pp).;            Extended European Search Report corresponding to EP 13 19          7958.5, completed Apr. 4, 2014 and mailed Apr. 15, 2014;          (8 pp).;            Extended European Search Report corresponding to EP 14 15          6342.9, completed Jul. 22, 2014 and mailed Jul. 29, 2014;          (8 pp).;            Extended European Search Report corresponding to EP 14 15          7195.0, completed Jun. 5, 2014 and mailed Jun. 18, 2014;          (9 pp).",,,,,
EP2444020-A1;  US2012101487-A1;  JP2012090983-A;  US8968289-B2;  EP2444020-B1;  JP5840453-B2;  JP2016039984-A;  JP6039780-B2,"Spacer for positioning microwave energy delivery            devices e.g. microwave ablation surgical antennas, has            compression portion that slideably engages housing            cavity, in which portion of compression housing is            positioned in cavity",CUNNINGHAM R B;  ARTS G H;  TURLEY T A;  WETZ R W;  NELSON C M,VIVANT MEDICAL INC (VIVA-C);  VIVANT MEDICAL INC (VIVA-C);  COVIDIEN LP (COVI-C);  COVIDIEN LP (COVI-C);  COVIDIEN LP (COVI-C),2012E78364,"   NOVELTY - The spacer (100) has a housing (110) including                housing main portion (111) forming a housing cavity                (114) and a multiple apertures. A compression                portion (112) slideably engages the housing cavity,                in which a portion of the compression housing is                positioned in cavity. A compression mechanism                provides a biasing force between the compression                housing and the housing main portion. The housing                device apertures are misaligned with apertures, at                one position, and multiple aligned aperture pairs                are formed to receive microwave energy delivery                device, at other position.    USE - Spacer for positioning microwave energy                delivery devices such as Evident (RTM: microwave                energy delivery device sold by Covidien) microwave                ablation Surgical Antennas for use in surgical                procedures.    ADVANTAGE - The spacer is well suited for clinicians to                position the device appropriately during surgeries.                The reliability of the device can be increased. The                accuracy of the device can be improved and the cost                involved in the manufacture of the device can be                reduced.    DESCRIPTION OF DRAWING(S) - The drawing shows a perspective view of                microwave spacer.    Spacer (100)    Housing (110)    Housing main portion (111)    Compression portion (112)    Housing cavity (114) ",,,"P31 (Diagnosis, surgery (A61B).);  P34 (Sterilising, syringes, electrotherapy (A61L, M, N).);  S05 (Electrical Medical Equipment)",S05-B;  S05-Y02,A61B-017/34;  A61B-018/18;  A61N-005/02;  A61B-019/00;  A61B-090/00;  E02D-003/12,EP2444020-A1   25 Apr 2012   A61B-018/18   201231   English;  US2012101487-A1   26 Apr 2012   A61B-018/18   201231   English;  JP2012090983-A   17 May 2012   A61B-018/18   201233Pages: 23   Japanese;  US8968289-B2   03 Mar 2015   A61B-018/18   201517   English;  EP2444020-B1   11 Mar 2015   A61B-018/18   201519   English;  JP5840453-B2   06 Jan 2016   A61B-018/18   201604Pages: 20   Japanese;  JP2016039984-A   24 Mar 2016   A61B-018/18   201623Pages: 19   English;  JP6039780-B2   07 Dec 2016   E02D-003/12   201683Pages: 19   Japanese,EP2444020-A1    EP008506    24 Oct 2011;   US2012101487-A1    US910442    22 Oct 2010;   JP2012090983-A    JP232681    24 Oct 2011;   US8968289-B2    US910442    22 Oct 2010;   EP2444020-B1    EP008506    24 Oct 2011;   JP5840453-B2    JP232681    24 Oct 2011;   JP2016039984-A    JP221179    11 Nov 2015;   JP6039780-B2    JP221179    11 Nov 2015,JP5840453-B2 Previous Publ. Patent JP2012090983;   JP2016039984-A Div ex Application JP232681;   JP6039780-B2 Div ex Application JP232681,US910442    22 Oct 2010,EP2444020-A1:      (Regional): AL;  AT;  BA;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  ME;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR        EP2444020-B1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR        ,,"EP2444020-A1 -- EP1800712-A1   ISODOSE CONTROL INTELLECTUAL PROPERTY (ISOD-Non-standard)   VAN T HOOFT E;  US20020117059-A1   ;  US20020177807-A1   ;  US6579262-B1   MICK RADIO NUCLEAR INSTR INC (MICK-Non-standard)   MICK F W,  ZABROUSKI K;  EP2444020-B1 -- EP1800712-A1   ISODOSE CONTROL INTELLECTUAL PROPERTY (ISOD-Non-standard)   VAN T HOOFT E;  US20020117059-A1   ;  US20020177807-A1   ;  US20060015161-A1   ;  US6579262-B1   MICK RADIO NUCLEAR INSTR INC (MICK-Non-standard)   MICK F W,  ZABROUSKI K;  JP5840453-B2 -- JP2011516184-A   ;  US20020177807-A1   ;  US20100268014-A1   ;  WO2009124301-A1   VISUALASE INC (MEDT)   GOWDA A,  MCNICHOLS R",,,,,,
WO2022094344-A1;  CA3197019-A1;  EP4237578-A1,"Selecting target cell comprises placing cells into            chambers, exposing subset of chambers to condition            which is exposing individual chamber with reagents, or            treating individual chamber with secondary cells, and            detecting signal or its change",TSIORIS K;  YALCIN OZKUMUR A;  YALCIN O A,ONECYTE BIOTECHNOLOGIES INC (ONEC-Non-standard);  ONECYTE BIOTECHNOLOGIES INC (ONEC-Non-standard),202258760M,"   NOVELTY - Selecting a target cell comprises: (a) placing                many cells into many chambers, where each                individual chamber of a subset of the chambers                contains one or up to 2, 3, 5, 10, 15 or 20                individual cells of the cells; (b) exposing at                least the subset of the chambers from (a) to a                condition which is exposing the individual chamber                with at least one reagent, or treating the                individual chamber with many secondary cells, or                applying a membrane to the individual chamber to                form an individual membrane-modified chamber, or                contacting the individual chamber with a capture                substrate, and/or contacting the individual chamber                with a secondary cell-immobilized capture                substrate; (c) detecting a signal or its change                from a particular chamber of the subset of the                chambers during or after the exposing in (b); and                (d) selecting the target cell in the particular                chamber from the cells at least based on a                predetermined value of the signal or its change in                (c).    USE - The method is useful for selecting a target                cell.    ADVANTAGE - The method: yields clones with a mean                productivity of within a 5-12 g/l, preferably 0.1-1                g/l; yields clones with differentiated glycan                profiles; yields clones with less than 7 percent                aggregation; achieves therapeutic benefit; and is                inexpensive.    DETAILED DESCRIPTION - Selecting a target cell comprises: (a) placing                many cells into many chambers, where each                individual chamber of a subset of the chambers                contains one or up to 2, 3, 5, 10, 15 or 20                individual cells of the cells; (b) exposing at                least the subset of the chambers from (a) to a                condition which is exposing the individual chamber                with at least one reagent, or treating the                individual chamber with many secondary cells, or                applying a membrane to the individual chamber to                form an individual membrane-modified chamber, or                contacting the individual chamber with a capture                substrate, and/or contacting the individual chamber                with a secondary cell-immobilized capture                substrate; (c) detecting a signal or its change                from a particular chamber of the subset of the                chambers during or after the exposing in (b), where                the signal or its change is indicative of (i) the                presence of a target cell in the particular                chamber, or (ii) the presence of a product produced                by the target cell in the particular chamber; and                (d) selecting the target cell in the particular                chamber from the cells at least based on a                pre-determined value of the signal or its change in                (c).    INDEPENDENT CLAIMS are also included                for:    (1) facilitating (m2) clone selection of a                cell line, from among many candidate single cells,                comprising (a1) generating, by an imaging unit,                images of each candidate single cell in an                individual chamber of many chambers, (b2)                detecting, by at least one processor analyzing the                first images for each of the candidate single                cells, at least one cell feature of each of the                candidate single cells depicted in the images, (c1)                based on the cell features, determining, by the                processors and according to a finalized single                cell-to-colony machine learning model, at least one                predicted attribute for a colony expanded from each                of the candidate single cells, and (d1) ranking the                candidate single cells according to the predicted                attributes for each of the candidate single cells,                where the finalized single cell-to-colony model                predicts attributes of a hypothetical colony based                on at least the cell features of a single                cell;    (2) developing (m3) high-throughput cell line,                comprising (a2) providing many target cells, an                array of nano-wells, at least one reagents and                instructions, (b2) loading the target cells into                the array of nano-wells so that an individual well                of the array of nano-wells contains an individual                target cell, (c2) exposing the target cells to at                least one reagents, (d2) obtaining measurements of                individual target cells and quantitative                measurements of individual articles associated with                the individual target cells, (e2) selecting a                target cell from the individual target cells to be                recovered based on predetermined values of the                measurements, where a time to reach a decision for                selecting the target cell for recovery does not                exceed 3 hours from the initialization of the                method, and the method yields clones with a mean                productivity of at least 5 g/l;    (3) isolated co-culture utilizing (m4) a                secondary cell suspension;    (4) isolated co-culture (m5) utilizing a                secondary cell immobilized-capture substrate;    (5) a system for high-throughput cell line                development, comprising (a5) an array of nano-wells                comprising individual nano-wells, where the                individual nano-wells contain at least zero target                cells, (b5) an apparatus for reversibly sealing a                capture substrate with the array of nano-wells,                (c5) a reagent module configured for supplying at                least one reagents to the array of nano-wells, (d5)                a detection module configured for performing                measurements of biomolecules secreted by the target                cell onto the capture substrate at discrete                positions indexed to the individual wells, (e5) a                cell recovery apparatus configured for recovery of                the individual cells, where values extracted from                the measurements of biomolecules and cells are                compared to predetermined criteria and used for the                selection of the individual cells to be recovered,                the system is configured to reach a decision for                selecting the target cell for recovery within 3                hours from initialization, and the system is                configured to yield clones with a mean productivity                of 5 g/l;    (6) a mechanism sealing a capture substrate to                an array of nano-wells in a sterile fashion,                comprising (a6) a top piece configured to                immobilize capture substrate, and (b6) a base                configured to immobilize an array of nano-wells,                where the base comprises at least one alignment                rods to align the top piece to the base so that the                capture substrate and the array of nano-wells are                fixed in coplanar and rotationally aligned                orientation, and the distance between the capture                substrate and the array of nano-wells can be                controllably varied along an axis perpendicular to                the coplanar planes of the capture substrate and                the array of nano-wells, thus placing the capture                substrate and the array of nano-wells in alignment                and forming a sterile, fluid tight seal;    (7) cell line development utilizing (m6) a                terminal assay for cell selection;    (8) high-throughput (m7) identification of a B                cell or antibody secreting cells (ASCs);    (9) cell line development (m8) utilizing                identification of glycosylation patterns on a                biomolecule;    (10) cell line development (m9) utilizing mass                spectrometry for identification of a biomolecule;                and    (11) selecting (m10) a target cell based on an                aggregation property of a secreted                biomolecule.    DESCRIPTION OF DRAWING(S) - The figure shows the process of clonal                selection.    Secretion profiling and subsequent analysis                (203)    Single-cells identification and recovery                (204)    Clonal growth in 96-then 24-well plate                (205)    Shake flask (206)    Bioreactor (207) ",,,"B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.);  C06 (Biotechnology - including plant genetics and veterinary vaccines.);  D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.);  A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.)",B04-N16;  B11-C07B;  B11-C08A;  B11-C08J;  B11-C10;  B11-C12;  B12-K04;  C04-N16;  C11-C07B;  C11-C08A;  C11-C08J;  C11-C10;  C11-C12;  C12-K04;  D05-H09;  D05-H14B;  A12-E06;  A12-V03C2;  A12-W11L,C12Q-001/6804;  C12Q-001/6806;  C12Q-001/6874,WO2022094344-A1   05 May 2022   C12Q-001/6804   202243Pages: 134   English;  CA3197019-A1   05 May 2022   C12Q-001/6804   202346   English;  EP4237578-A1   06 Sep 2023   C12Q-001/6804   202372   English,WO2022094344-A1    WOUS057453    29 Oct 2021;   CA3197019-A1    CA3197019    29 Oct 2021;   EP4237578-A1    EP887676    29 Oct 2021,CA3197019-A1 PCT application Application WOUS057453;   CA3197019-A1 Based on Patent WO2022094344;   EP4237578-A1 PCT application Application WOUS057453;   EP4237578-A1 Based on Patent WO2022094344,US107967P    30 Oct 2020;  US192305P    24 May 2021;  CA3197019    28 Apr 2023,WO2022094344-A1:      (National): AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  IT;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  WS;  ZA;  ZM;  ZW    (Regional): BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA    EP4237578-A1:      (Regional): AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LI;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  BA;  ME;  KH;  MA;  MD;  TN  ,,WO2022094344-A1 -- US20050070005-A1   ;  US20060094033-A1   ;  US20140248621-A1   ;  US20150291995-A1   ;  US20190366342-A1   ,,,,,,
